
<html lang="en"     class="pb-page"  data-request-id="c98b3789-14d0-4f88-8aa1-e80a360091ae"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2018.61.issue-4;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.7b00318;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="The Current State of Peptide Drug Discovery: Back to the Future?" /></meta><meta name="dc.Creator" content="Antoine  Henninot" /></meta><meta name="dc.Creator" content="James C.  Collins" /></meta><meta name="dc.Creator" content="John M.  Nuss" /></meta><meta name="dc.Description" content="Over the past decade, peptide drug discovery has experienced a revival of interest and scientific momentum, as the pharmaceutical industry has come to appreciate the role that peptide therapeutics ..." /></meta><meta name="Description" content="Over the past decade, peptide drug discovery has experienced a revival of interest and scientific momentum, as the pharmaceutical industry has come to appreciate the role that peptide therapeutics ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 11, 2017" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00318" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00318" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00318" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00318" /></link>
        
    
    

<title>The Current State of Peptide Drug Discovery: Back to the Future? | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00318" /></meta><meta property="og:title" content="The Current State of Peptide Drug Discovery: Back to the Future?" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0036.jpeg" /></meta><meta property="og:description" content="Over the past decade, peptide drug discovery has experienced a revival of interest and scientific momentum, as the pharmaceutical industry has come to appreciate the role that peptide therapeutics can play in addressing unmet medical needs and how this class of compounds can be an excellent complement or even preferable alternative to small molecule and biological therapeutics. In this Perspective, we give a concise description of the recent progress in peptide drug discovery in a holistic manner, highlighting enabling technological advances affecting nearly every aspect of this field: from lead discovery, to synthesis and optimization, to peptide drug delivery. An emphasis is placed on describing research efforts to overcome the inherent weaknesses of peptide drugs, in particular their poor pharmacokinetic properties, and how these efforts have been critical to the discovery, design, and subsequent development of novel therapeutics." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00318"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00318">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00318&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00318&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00318&amp;href=/doi/10.1021/acs.jmedchem.7b00318" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 1382-1414</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00171" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.7b00404" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">The Current State of Peptide Drug Discovery: Back to the Future?</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Antoine++Henninot">Antoine Henninot</a></span><span class="author-xref-symbol "><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James+C.++Collins">James C. Collins</a></span><span class="author-xref-symbol "><sup>â </sup></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+M.++Nuss">John M. Nuss</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0003-1213-3233" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Ferring Research Institute, 4245 Sorrento Valley Boulevard, San Diego, California 92121, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: (858)-337-0162. E-mail: <a href="/cdn-cgi/l/email-protection#92f8fce7e1e1d2fde2e2fbfef3fcbcf1fdff"><span class="__cf_email__" data-cfemail="6b01051e18182b041b1b02070a0545080406">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00318&amp;href=/doi/10.1021%2Facs.jmedchem.7b00318" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 1382â1414</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 24, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>27 February 2017</li><li><span class="item_label"><b>Published</b> online</span>11 August 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 February 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00318" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00318</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1382%26pageCount%3D33%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAntoine%2BHenninot%252C%2BJames%2BC.%2BCollins%252C%2BJohn%2BM.%2BNuss%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D4%26contentID%3Dacs.jmedchem.7b00318%26title%3DThe%2BCurrent%2BState%2Bof%2BPeptide%2BDrug%2BDiscovery%253A%2BBack%2Bto%2Bthe%2BFuture%253F%26numPages%3D33%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1414%26publicationDate%3DFebruary%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00318"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">16878</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">349</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00318" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;The Current State of Peptide Drug Discovery: Back to the Future?&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Antoine&quot;,&quot;last_name&quot;:&quot;Henninot&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;C. Collins&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;M. Nuss&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;11&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;1382-1414&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00318&quot;},&quot;abstract&quot;:&quot;Over the past decade, peptide drug discovery has experienced a revival of interest and scientific momentum, as the pharmaceutical industry has come to appreciate the role that peptide therapeutics can play in addressing unmet medical needs and how this class of compounds can be an excellent complement or even preferable alternative to small molecule and biological therapeutics. In this Perspective, we give a concise description of the recent progress in peptide drug discovery in a holistic manner, highlighting enabling technological advances affecting nearly every aspect of this field: from lead discovery, to synthesis and optimization, to peptide drug delivery. An emphasis is placed on describing research efforts to overcome the inherent weaknesses of peptide drugs, in particular their poor pharmacokinetic properties, and how these efforts have been critical to the discovery, design, and subsequent development of novel therapeutics.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00318&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00318" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00318&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00318" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00318&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00318" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00318&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00318&amp;href=/doi/10.1021/acs.jmedchem.7b00318" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00318" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00318" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00318%26sid%3Dliteratum%253Aachs%26pmid%3D28737935%26genre%3Darticle%26aulast%3DHenninot%26date%3D2018%26atitle%3DThe%2BCurrent%2BState%2Bof%2BPeptide%2BDrug%2BDiscovery%253A%2BBack%2Bto%2Bthe%2BFuture%253F%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D4%26spage%3D1382%26epage%3D1414%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291189" title="Ligation">Ligation</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a>,</li><li><a href="/action/doSearch?ConceptID=292202" title="Drug discovery">Drug discovery</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/4" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/jmcmar.2018.61.issue-4/20180222/jmcmar.2018.61.issue-4.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_null" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0036.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Over the past decade, peptide drug discovery has experienced a revival of interest and scientific momentum, as the pharmaceutical industry has come to appreciate the role that peptide therapeutics can play in addressing unmet medical needs and how this class of compounds can be an excellent complement or even preferable alternative to small molecule and biological therapeutics. In this Perspective, we give a concise description of the recent progress in peptide drug discovery in a holistic manner, highlighting enabling technological advances affecting nearly every aspect of this field: from lead discovery, to synthesis and optimization, to peptide drug delivery. An emphasis is placed on describing research efforts to overcome the inherent weaknesses of peptide drugs, in particular their poor pharmacokinetic properties, and how these efforts have been critical to the discovery, design, and subsequent development of novel therapeutics.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1 Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53841" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53841" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Peptides have profoundly impacted the development of the modern pharmaceutical industry and have contributed significantly to the advancement of biological and chemical science.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Fundamental studies in the first half of the 20th century aimed at understanding the structures and physiological role of peptide hormones such as insulin, oxytocin, gonadotropin-releasing hormone, and vasopressin have catalyzed many major advances in pharmacology, biology, and chemistry as well as other enabling technologies essential for what we now know as modern drug discovery. The investigators involved in these efforts reads like a list of the giants of 20th century science: de Vigneaud, Banting and Macleod, Schally and Guillemin, Sanger, and Merrifield, Nobel laureates all.</div><div class="NLM_p">There is no better illustration of our opening statement than the discovery and development of the 51 amino acid (aa) hormone insulin (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), which stands as one of the monumental scientific achievements of the era.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Following its initial isolation in 1921, the pace of development was remarkable, reaching patients just a year later and then becoming the first commercially available peptide drug in 1923. Considered a âmiracle drugâ, insulin was key to the growing public appreciation of the power and societal value of scientific research. This pioneering success preceded by decades the understanding of insulinâs sequence, structure and molecular pharmacology, and indeed the structure of peptides and proteins in general. In another pivotal moment for the field, human insulin was introduced in 1982 as the first recombinant drug, ultimately leading to the recent discontinuation of the original animal-derived product after a mere 86 years on the market.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Insulinâs more recent history features a litany of impressive scientific advances that have allowed diabetic patients to achieve tight glycemic control,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> yet further discussion largely falls outside the scope of this review of the discovery, design, and development of synthetic peptide drugs. However, elegant new approaches as outlined in <a class="ref internalNav" href="#sec3_4" aria-label="section 3.4">section 3.4</a> have brought insulin analogues within reach of chemical synthesis and its powerful toolkit for molecular design.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Two- and three-dimensional structures of insulin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Despite this pedigree, peptides as a class of drugs were considered by the end of the twentieth century as, frankly, a niche area. Even now, it has been our experience when discussing drug discovery with experienced âdrug huntersâ, most would never think to use a peptide to begin a drug discovery program and would always opt for small molecules or recombinant biological therapeutics (such as antibodies and fusion proteins) as their preferred therapeutic modality for addressing novel biological targets. The reasons for this loss in prominence are quite complex, yet may largely stem from the perception that the disadvantages of peptide drugs greatly outweigh the strengths (see <a class="ref internalNav" href="#sec2" aria-label="section 2">section 2</a>) and that most of the âlow hanging fruitâ in this area, i.e., work on known and well-understood hormones, had been harvested.</div><div class="NLM_p">However, the last two decades have seen a significant renaissance in peptide drug discovery; since 2000 there have been 28 new, noninsulin peptide drugs approved worldwide (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), with several achieving significant market success.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The synchronous and spectacular success of recombinant biologics has also driven reexamination of the peptide field for new opportunities due to their shared biological characteristics (vide infra) and scientific advances relevant to both areas. These achievements, viewed in the harsh light of the multidecadal exponential death spiral of research productivity termed âEroomâs Lawâ,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> have encouraged pharmaceutical companies to go âback to the futureâ and significantly increase their investments in peptide drug discovery.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Non-insulin Peptides Approved in the Years 2000â2016, Including Region of Launch</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">generic name</th><th class="colsep0 rowsep0" align="center">year of approval</th><th class="colsep0 rowsep0" align="center">therapeutic area</th><th class="colsep0 rowsep0" align="center">country of approval</th><th class="colsep0 rowsep0" align="center">generic name</th><th class="colsep0 rowsep0" align="center">year of approval</th><th class="colsep0 rowsep0" align="center">therapeutic area</th><th class="colsep0 rowsep0" align="center">country of approval</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">atosiban</td><td class="colsep0 rowsep0" align="left">2000</td><td class="colsep0 rowsep0" align="left">obstetrics</td><td class="colsep0 rowsep0" align="left">EU</td><td class="colsep0 rowsep0" align="left">mifamurtide</td><td class="colsep0 rowsep0" align="left">2009</td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">EU</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">taltirelin</td><td class="colsep0 rowsep0" align="left">2000</td><td class="colsep0 rowsep0" align="left">CNS</td><td class="colsep0 rowsep0" align="left">JP</td><td class="colsep0 rowsep0" align="left">liraglutide</td><td class="colsep0 rowsep0" align="left">2009</td><td class="colsep0 rowsep0" align="left">metabolic disease</td><td class="colsep0 rowsep0" align="left">EU</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">aviptadil</td><td class="colsep0 rowsep0" align="left">2000</td><td class="colsep0 rowsep0" align="left">urology</td><td class="colsep0 rowsep0" align="left">EU</td><td class="colsep0 rowsep0" align="left">tesamorelin</td><td class="colsep0 rowsep0" align="left">2010</td><td class="colsep0 rowsep0" align="left">antiinfective</td><td class="colsep0 rowsep0" align="left">US</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">carbetocin</td><td class="colsep0 rowsep0" align="left">2001</td><td class="colsep0 rowsep0" align="left">obstetrics</td><td class="colsep0 rowsep0" align="left">EU</td><td class="colsep0 rowsep0" align="left">lucinactant</td><td class="colsep0 rowsep0" align="left">2012</td><td class="colsep0 rowsep0" align="left">pulmonary</td><td class="colsep0 rowsep0" align="left">US</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">nesiritide</td><td class="colsep0 rowsep0" align="left">2001</td><td class="colsep0 rowsep0" align="left">cardiovascular</td><td class="colsep0 rowsep0" align="left">US</td><td class="colsep0 rowsep0" align="left">peginesatide</td><td class="colsep0 rowsep0" align="left">2012</td><td class="colsep0 rowsep0" align="left">hematology</td><td class="colsep0 rowsep0" align="left">US</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">teriparatide</td><td class="colsep0 rowsep0" align="left">2002</td><td class="colsep0 rowsep0" align="left">osteoporosis</td><td class="colsep0 rowsep0" align="left">US</td><td class="colsep0 rowsep0" align="left">pasireotide</td><td class="colsep0 rowsep0" align="left">2012</td><td class="colsep0 rowsep0" align="left">endocinology</td><td class="colsep0 rowsep0" align="left">EU</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">enfuvirtide</td><td class="colsep0 rowsep0" align="left">2003</td><td class="colsep0 rowsep0" align="left">antiinfective</td><td class="colsep0 rowsep0" align="left">US</td><td class="colsep0 rowsep0" align="left">carfilzomib</td><td class="colsep0 rowsep0" align="left">2012</td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">US</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">abarelix</td><td class="colsep0 rowsep0" align="left">2003</td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">US</td><td class="colsep0 rowsep0" align="left">linaclotide</td><td class="colsep0 rowsep0" align="left">2012</td><td class="colsep0 rowsep0" align="left">gastroenterology</td><td class="colsep0 rowsep0" align="left">US</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ziconotide</td><td class="colsep0 rowsep0" align="left">2004</td><td class="colsep0 rowsep0" align="left">pain</td><td class="colsep0 rowsep0" align="left">US</td><td class="colsep0 rowsep0" align="left">teduglutide</td><td class="colsep0 rowsep0" align="left">2012</td><td class="colsep0 rowsep0" align="left">gastroenterology</td><td class="colsep0 rowsep0" align="left">EU</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pramlintide</td><td class="colsep0 rowsep0" align="left">2005</td><td class="colsep0 rowsep0" align="left">metabolic disease</td><td class="colsep0 rowsep0" align="left">US</td><td class="colsep0 rowsep0" align="left">lixisenatide</td><td class="colsep0 rowsep0" align="left">2013</td><td class="colsep0 rowsep0" align="left">metabolic disease</td><td class="colsep0 rowsep0" align="left">EU</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">exenatide</td><td class="colsep0 rowsep0" align="left">2005</td><td class="colsep0 rowsep0" align="left">metabolic disease</td><td class="colsep0 rowsep0" align="left">US</td><td class="colsep0 rowsep0" align="left">albiglutide</td><td class="colsep0 rowsep0" align="left">2014</td><td class="colsep0 rowsep0" align="left">metabolic disease</td><td class="colsep0 rowsep0" align="left">EU</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">icatibant</td><td class="colsep0 rowsep0" align="left">2008</td><td class="colsep0 rowsep0" align="left">hematology</td><td class="colsep0 rowsep0" align="left">EU</td><td class="colsep0 rowsep0" align="left">oritavancin</td><td class="colsep0 rowsep0" align="left">2014</td><td class="colsep0 rowsep0" align="left">antiinfective</td><td class="colsep0 rowsep0" align="left">US</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">romiplostim</td><td class="colsep0 rowsep0" align="left">2008</td><td class="colsep0 rowsep0" align="left">hematology</td><td class="colsep0 rowsep0" align="left">US</td><td class="colsep0 rowsep0" align="left">dulaglutide</td><td class="colsep0 rowsep0" align="left">2014</td><td class="colsep0 rowsep0" align="left">metabolic disease</td><td class="colsep0 rowsep0" align="left">US</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">degarelix</td><td class="colsep0 rowsep0" align="left">2008</td><td class="colsep0 rowsep0" align="left">oncology</td><td class="colsep0 rowsep0" align="left">US</td><td class="colsep0 rowsep0" align="left">afamelanotide</td><td class="colsep0 rowsep0" align="left">2014</td><td class="colsep0 rowsep0" align="left">dermatology</td><td class="colsep0 rowsep0" align="left">EU</td></tr></tbody></table></div></div><div class="NLM_p">Analysis of the peptide drug market and development climate as of 2016 shows that there are >50 peptide drugs marketed worldwide (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>; this table does not include the various insulin derivatives on the market), with another ca. 170 in various stages of clinical development (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>) and >200 others at preclinical stages.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> When these figures are broken out by therapeutic area (TA), as in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>, it is apparent that two TAâs predominate, namely metabolic disease and oncology. Inclusion of insulin analogues further increases the share of the metabolic disease TA.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Peptides Approved and in Active Development by Clinical Phase as of 2015 (2016 Figures)</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase 1</td><td class="colsep0 rowsep0" align="char" char=".">55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="char" char=".">94</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phaseÂ III<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">approved</td><td class="colsep0 rowsep0" align="char" char=".">56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">total</td><td class="colsep0 rowsep0" align="char" char=".">234</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Including preregistration.</p></div></div></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Peptides approved and in active development by therapeutic area.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">World-wide sales of pharmaceuticals exceeded $1 trillion for the first time in 2014<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> and are expected to continue to rise at ca. 4% per year.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6, 7)</a> Estimates place the annual global sales of noninsulin peptide drugs in 2013 at ca. $19 billion; when combined with global sales of insulin derivatives of ca. $28 billion and assuming steady growth in recent years, the total sales of peptide drugs in 2015 can be estimated to be ca. $50 billion or about 5% of 2015 total global pharmaceutical sales.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><div class="NLM_p">While peptides make up just a fraction of global pharma sales, it is likely that as the incidence of metabolic disease and cancer in the western world continues to increase, and as advances in technology that address the inherent liabilities of peptides continue to positively impact their design and development, the demand for peptide drugs will continue to grow. With a projected annual growth rate of 9â10%, peptide drug sales are likely to exceed $70 billion in 2019 (insulins included); this growth rate is slightly higher than the rate predicted for worldwide pharmaceuticals.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><div class="NLM_p">Further examination of these data reveals an interesting aspect of the peptide market. Of the >50 commercial, noninsulin peptide drugs, a small fraction are responsible for the vast majority of the worldwide sales, as seen in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>. For example, Copaxone (glutramer), a 6.4 kDa synthetic copolymer of repeating alanine, lysine, glutamic acid, and tyrosine units used to treat multiple sclerosis, had estimated sales of $4 billion in 2015. The six glucagon-like peptide 1 (GLP-1) analogues currently on the market had combined sales of just over $4 billion in 2014, with Victoza (liraglutide) the leader at $2.4 billion. In the area of oncology, the gonadotrophin releasing hormone (GnRH) agonists Lupron (leuprolide) and Zoladex (gosarelin) together had sales of nearly $2 bn, with the somatostatin analogues octreotide and lanreotide at a comparable level. Overall, the top 6â7 selling peptide drugs are responsible for a significant fraction of worldwide sales; conversely, many of the approved agents have marginal sales (<$100 million), demonstrating once again that approval of a drug does not guarantee meaningful sales, a harsh lesson that many companies, both large pharma and small biotech, have learned.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Top-selling non-insulin peptides in 2015.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Having given the reader this historical perspective of the peptide drug field, as well as an outlook for current and future commercial prospects for the peptide market, with this review we will attempt describe the current state of the art in peptide drug discovery. In our discussion, we will focus on important recent technological advances and new approaches to the discovery and development of amino acid based therapeutics that have led to the fieldâs resurgence as well as the implications of these developments on the future of peptide drug discovery.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">2 Advantages and Disadvantages of Peptide Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55115" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55115" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Peptides, historically defined as polypeptides having 2â50 aa, play critical roles in human physiology, acting as hormones, neurotransmitters, growth factors, and antibacterial agents, inter alia, and their inherent properties define their strengths and weaknesses as drug molecules.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><table class="listgroup" border="0" width="95%" list-type="label"><tr class="li1"><td valign="top">1.</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>Peptides Are the Natural Biological Messengers for Most Endocrine Signaling Pathways.</b> Peptides are the natural ligands for many cell surface receptors such as G-protein coupled receptors (GPCRs), ion channels, and growth factor receptors, initiating signal transduction processes inside the cell. It is therefore often the case that peptides are agonists of signal transduction pathways, and most successful peptide drugs are agonists (e.g., insulin, GLP-1, GnRH, etc.). As described in <a class="ref internalNav" href="#sec3" aria-label="section 3">section 3</a>, natural peptides therefore often represent viable and validated leads for drug discovery, ultimately producing extremely potent and selective drugs.</p></td></tr><tr class="li1"><td valign="top">2.</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>Peptides Are Membrane Impermeable.</b> This is a critical property that has historically defined and circumscribed the field. The therapeutic application of peptides is restricted to extracellular and transmembrane targets, and the inability to permeate the intestinal mucosa necessitates parenteral administration via subcutaneous or intravenous injection, with the corresponding detriment to patient convenience and compliance. Peptides are also generally unable to cross the bloodâbrain barrier, which from a toxicology perspective may be a net positive but effectively precludes CNS targets. Addressing these limitations is currently a vibrant and rapidly progressing field; general and reproducible oral delivery is on the horizon (see <a class="ref internalNav" href="#sec9" aria-label="section 9">section 9</a>), and intracellular delivery has seen promising advances (see <a class="ref internalNav" href="#sec7" aria-label="section 7">section 7</a>).</p></td></tr><tr class="li1"><td valign="top">3.</td><td colspan="5" valign="top" class="paragraph"><p class="last"><b>Peptides are Biologically Unstable.</b> As the principal role of peptide hormones is to bind to and activate their cognate receptors, it is no surprise that they have evolved to very effectively serve this purpose via elaborate and highly regulated systems of checks and balances including preprohormone processing and feedback loops. Most peptides therefore necessarily have short plasma half-lives; peptides are produced in response to a biological signal, processed, and released, perform their function, and are then rapidly metabolized, i.e., the signal is turned off. Peptides are cleared primarily by proteolytic degradation and by renal filtration, generally leading to suboptimal pharmacokinetic properties which can necessitate considerable research efforts to discover analogues with sufficient plasma exposure. <a class="ref internalNav" href="#sec6" aria-label="Section 6">Section 6</a> outlines a protocol describing methods by which medicinal chemistry optimization is able to reduce or prevent proteolytic cleavage, and <a class="ref internalNav" href="#sec7" aria-label="section 7">section 7</a> describes conjugation approaches designed to reduce or eliminate renal filtration.</p></td></tr></table><div class="NLM_p">For further assessment, it is instructive to compare these stereotypical properties of peptides with their molecular competition in the drug discovery landscape. Peptides, being neither small molecule nor protein, exist at the nexus of these two classes of therapeutics but are generally classified with protein drugs because of their size, composition, distribution, and routes of administration. Small molecules have continued to dominate the worldwide drug market, with advantages including lower cost and price, oral dosing, and ease of synthesis, while their (often) inherent membrane-penetrating ability allows a much broader range of biological targets to be addressed. The proteolytic instability and rapid clearance of peptides, while an issue when considering pharmacokinetic optimization, does mean that they do not accumulate in tissues; hepatic metabolism of peptides (e.g., cytochrome P450 mediated oxidation) is generally not significant, and therefore drugâdrug interactions and nonmechanistic-based toxicology are rarely observed. These are certainly major issues with small molecule drugs. Furthermore, predicting human doses of peptides through allometric scaling is generally more straightforward than for small molecules; this can greatly facilitate early dose-range finding studies in the clinic.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Biologics, and in particular antibodies, traditionally offer considerable pharmacokinetic advantages over peptides,<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> yet peptides also have advantages here such as ease of production and lower immunogenicity. It has also been claimed by some that peptide drug discovery suffers from a lower attrition rate than small molecule discovery efforts;<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> while this may be true historically, current attrition rates may turn out to be no different than that seen with small molecules or biologics as the targets and indications addressed by modern peptide drug discovery programs are riskier than earlier efforts, which were mainly looking at older, more validated targets. Finally, peptide discovery optimization has a significant resource advantage over small molecules; the relatively simplicity and increasing automation of the required synthesis allows successful prosecution by much smaller teams of medicinal chemists, many-fold smaller than that necessary for a comparable small molecule effort.</div><div class="NLM_p">One strategic aspect of peptide drug discovery, in the experience of the authors and alluded to above, is that development of efficacious peptide agonists is often more straightforward than that of peptide antagonists. This can be explained by consideration of basic pharmacokinetic/pharmacodynamic (PK/PD) principles.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Agonists are, in general, more potent at binding to and activating their cognate receptor than are the corresponding antagonists and require lower plasma concentrations to achieve a pharmacological response. Competitive antagonists, while competing with the natural agonist for binding sites on the receptor, require high or nearly complete receptor occupancy, higher trough levels, and longer exposure to demonstrate the desired effect. Peptide agonists therefore generally require lower doses (and hence lower production volumes), lower injection volumes, and can have a more favorable dosing schedule than a peptide antagonist. Small molecules and antibodies may therefore be the preferred modalities when attempting to design and develop antagonists.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Small molecules can be dosed orally, multiple times per day, to achieve the high exposures needed for effective pharmacological antagonism. Therapeutic antibodies, though requiring parenteral injection, have pharmacokinetic advantages over peptides that allow them to be administered biweekly or monthly to achieve the requisite therapeutic exposures.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a><a class="ref internalNav" href="#sec7" aria-label="section 7">section 7</a> and <a class="ref internalNav" href="#sec9" aria-label="section 9">section 9</a> describe current approaches that are proving successful in closing this traditional gap in achievable drug exposures between peptides and antibodies.</div><div class="NLM_p">A final consideration is the cost of peptide production and the necessary HPLC purification, which, although decreasing as advances continue to be made, is still high in comparison to small molecules. Current chemical production is limited to peptides of ca. 50 aa; beyond this, the efficiency and costs of synthesis become problematic and recombinant methods become competitive.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Even now, while the majority of peptide drugs are produced synthetically using solid-phase peptide synthesis (SPPS) methods, some peptide drugs, including all of the various insulin derivatives on the market, are made using recombinant techniques. Recombinant production is especially relevant for âprotein scaffoldsâ, peptides of between 50 and 100 aa residues with stable folds that are thought to have potential for increased stability in plasma (and the GI tract) and the ability to address a wider variety of biological targets (e.g., growth factor and cytokine receptors) vis-a-vis smaller peptides. Chemical synthesis permits access to a much more diverse range of peptides because elements such as unnatural amino acids, peptidomimetic bonds, and novel cyclization methodologies can be incorporated to enhance the properties of the target peptides, for which recombinant methods are not currently viable. Looking ahead, recent technologies have focused on expanding the genetic code to produce noncanonical aa containing proteins (including the use of amber stop codon to incorporate novel aa into proteins,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> new ribosomal-based in vitro technologies<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> (vide infra), or by engineering semisynthetic organisms with expanded genetic alphabets<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a>), and the ability to utilize these methods for the large scale recombinant production of peptides and proteins having multiple non-natural aa may be imminent. This would certainly relieve some of the constraints described above and likely further spur peptide drug discovery forward. Overall, we feel there will be a convergence in recombinant and synthetic production of peptides; advanced recombinant technologies will be able to incorporate unnatural aa and macrocyclic structures, and advanced synthetic ligation methods (see <a class="ref internalNav" href="#sec3_4" aria-label="section 3.4">section 3.4</a>) will enable the economically feasible production of customized, bespoke peptides or small proteins of upward of 100 aa.</div><div class="NLM_p last">The traditional advantages and disadvantages of peptide drugs described here represent both opportunities and challenges for drug discovery teams. The prospects for the field engender an optimistic outlook, and the remainder of this perspective will describe diverse and parallel scientific advances that may soon combine to significantly mitigate these deficiencies in order to exploit the potent pharmacological activity of peptides in the clinic and beyond.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">3 Enabling Technologies in Peptide Lead Discovery</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38710" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38710" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The discovery or selection of attractive lead compounds is a critical first step in delivering a compound with a profile that will maximize success in the clinic. Historically, the selection of peptide leads for discovery programs has employed one of two general strategies, depending on the biological target of interest and what is known about its associated ligands and molecular pharmacology. The first strategy, the most common and historically productive in peptide discovery, is used when targeting a known signaling peptide, i.e., a hormone or peptide with a known receptor/target and some degree of understanding around its pharmacology. In this situation, the focus of the discovery program is on the manipulation of the parent peptideâs structure and properties (almost always via synthetic medicinal chemistry efforts) to optimize the compoundâs half-life, potency, selectivity, or other properties in order to attain the desired compound profile, as described in later sections.</div><div class="NLM_p">Alternative strategies are needed when it is not possible to optimize a cognate ligand for a biological target of interest, either because the ligand is inherently unsuitable for chemical optimization (perhaps because of instability, promiscuous biological activity, or other factors) or the endogenous ligand for the target may be unknown. This situation is not uncommon. For example, genomic studies have shown there are ca. 800 members of the G protein coupled receptor (GPCR) superfamily encoded in the human genome, making them the largest family of cell surface receptors. Their prominence is reflected in the vast number of human diseases linked to abnormal GPCR signaling, including metabolic disorders, cardiovascular diseases, mental disorders, neurodegenerative diseases, and cancer. GPCRs represent ca. 40% of the currently marketed drugs,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> and a large majority of peptide drugs address this superfamily of receptors, either as agonists or antagonists. However, even though much is known about the pharmacology and biology of this family, it is still thought that as much as 25% of the GPCRs encoded in the human genome are so-called âorphanâ receptors with unknown cognate ligands;<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> it is likely some of these receptors are peptidergic in nature and will provide new targets for peptide discovery, if a lead can be found and optimized.</div><div class="NLM_p">De novo peptide ligand discovery has traditionally been done by screening large libraries of peptides, produced either synthetically or biologically. Biological library methods include phage, ribosomal, and mRNA display and have undoubtedly become the standard for peptide discovery, with phage display playing the most prominent role to date. While there still is a role in lead discovery for high-throughput screening of synthetic peptide libraries, this subject has been reviewed extensively<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and will not be covered in this perspective.</div><div class="NLM_p">Genomic or peptidomic/proteomic approaches are also being employed to find heretofore undiscovered peptides of interest in species ranging from microorganisms to humans; these studies have also found new biological activity for known peptides.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Peptide-derived natural product research has been experiencing a revival, as evidenced by the particularly impressive advances in the discovery of nonribosomally synthesized peptide natural products.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> For the purposes of this review, we will discuss some of the more exciting examples of these technologies reported during the last 5â7 years that have enabled scientists involved in peptide drug discovery to address an ever-widening group of biological targets with peptide therapeutics.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">3.1 Naturally Occurring Peptides as Starting Points for Lead Discovery</h3><div class="NLM_p">The traditional approach to peptide drug discovery has used naturally occurring hormones and other known signaling molecules as starting points for lead discovery. Medicinal chemistry strategies to enhance the potency and pharmacokinetic profiles have been very productive at finding analogues of these signaling molecules with more drug-like properties. A particularly successful example is the discovery of analogues of the natural intestinal incretin hormone glucagon-like peptide 1 (GLP-1).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> This 37 aa peptide is involved in insulin secretion and regulation yet exhibits a very short circulating half-life that makes it an unlikely drug candidate. Considerable effort has been made to enhance the stability of this hormone while maintaining its potency and pharmacological effect. Many strategies have been employed, including stabilizing the molecule by reducing susceptibility to proteolytic cleavage by dipeptidyl peptidase-4 (DPP-IV), the protease involved in regulating the deactivation of GLP-1, and conjugating the peptide to lipophilic moieties that bind to serum albumin in order to attenuate the renal clearance of this hormone (see <a class="ref internalNav" href="#sec7" aria-label="section 7">section 7</a>). These efforts have resulted in multiple marketed products which are in the process of revolutionizing the treatment of type 2 diabetes and perhaps ultimately obesity itself.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><div class="NLM_p">Many other hormone-derived drugs been discovered and developed using a similar strategy:<ul class="NLM_list-list_type-bullet"><li><p class="inline">Octreotide (Sandostatin) is a synthetic somatostatin agonist that mimics the biological action of the natural hormone, optimized to improve potency, receptor selectivity, and pharmacokinetic profile (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>).<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Octreotide is used to treat growth hormone producing tumors in acromegaly patients and pituitary tumors secreting thyroid stimulating hormone as well as other indications.</p></li><li><p class="inline">Gonadotropin-releasing hormone (GnRH, aka LHRH), a 10 aa peptide produced in the GnRH neurons in the hypothalamus, has been a target for peptide chemists almost since its discovery (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Leuprolide is a synthetic nonapeptide GnRH receptor agonist, optimized for increased potency and half-life,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> that is used for diverse clinical applications including the treatment of hormone responsive prostate cancer, endometriosis, uterine fibroids, and precocious puberty and additionally for in vitro fertilization.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Further medicinal chemistry efforts uncovered the key modifications that resulted in potent GnRH antagonists such as degarelix,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> which has a remarkable sustained-release subcutaneous pharmacokinetic profile (see <a class="ref internalNav" href="#sec9" aria-label="section 9">section 9</a>) and is used in the treatment of hormone responsive prostate cancer and some benign gynecological conditions.</p></li><li><p class="inline">Desmopressin (1-desamino-8-<span class="smallcaps smallerCapital">d</span>-arginine vasopressin) was discovered during an extensive campaign aimed at improving the pharmacokinetic properties of the natural antidiuretic hormone arginine vasopressin while retaining its impressive potency (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). Desmopressin is used to treat diabetes insipidus, bedwetting in children, and nocturia in adults.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></p></li><li><p class="inline">Oxytocin, the first peptide hormone to be made synthetically,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> is a nonapeptide produced by the hypothalamus and is used to induce labor in case of nonprogression of parturition and for treatment of amenorrhea. The synthetic analogue carbetocin has improved pharmaceutical properties and can be prepared in a temperature-stable formulation.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> This should prove to be a huge improvement for treating mothers in parts of the developing world such as sub-Saharan Africa, where refrigeration is rare and storage of peptide drugs is problematic. Antagonists of oxytocin such as atosiban, discovered during medicinal chemistry efforts aimed at finding compounds with tocolytic activity, are used to suppress premature labor (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></p></li></ul></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures of somatostatin and octreotide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structures of GnRH, the agonist analogue leuprolide, and the antagonist analogue degarelix.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures of arginine vasopressin and the analogue desmopressin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structures of oxytocin, the agonist analogue carbetocin, and the antagonist analogue atosiban.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">3.2 Natural Product Derived Peptides as Starting Points for Drug Discovery</h3><div id="sec3_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i9" class="anchor-spacer"></div><h4 class="article-section__title" id="_i9">a Non-Ribosomally Synthesized Peptides (NRSPs)</h4><div class="NLM_p">The peptides discussed thus far in this review are all biosynthesized using the well-defined machinery of the ribosome and are thus comprised of proteinogenic amino acids. It has been known for decades that some peptide natural products produced by bacteria and fungi, such as vancomycin and cyclosporin (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>), are not synthesized at the ribosome; the amino acid constituents of these nonribosomally synthesized peptides (NRSPs) are nonstandard, and their diverse structures offer an array of structurally interesting features including an assortment of cyclization motifs, incorporation of <span class="smallcaps smallerCapital">d</span>- and <i>N</i>-methylated aa, and other unique features contributing to their unusual structures and biological properties.<a onclick="showRef(event, 'ref23 ref33'); return false;" href="javascript:void(0);" class="ref ref23 ref33">(23, 33)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structures of vancomycin and cyclosporin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The production of these peptides is controlled by clusters of genes termed nonribosomal peptide synthetases; each of these gene clusters, which operate independently of mRNA, is able to synthesize a single NRSP. Astounding progress in bacterial genetics, genomics, protein biochemistry, and mass spectrometry have delineated the principles of assembly line enzymology for the production of these NRSPs, and this field promises to become one of the most exciting areas of peptide chemistry in the years to come.</div><div class="NLM_p">The unique structures and nonstandard aa present in these NRSPs enable the molecules to overcome some of the inherent weaknesses seen with the majority of peptides. For example, the cyclic structure and <i>N</i>-methylated aa in cyclosporin combine to generate small molecule-like biological properties including enhanced membrane permeability (and an intracellular biological target), high gut stability, and significant oral bioavailability.</div><div class="NLM_p">In a series of seminal papers, Romesberg has reexamined the potential of the arylomycin family of antibiotics, a long neglected family of NRSPs that exhibited a potent but narrow spectrum of activity against Gram positive bacteria (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> By identifying that the molecular target, signal peptidase, is both unique to arylomycins and essential for viability, and via an impressive structure-based medicinal chemistry program, they have been able to transform this family of NSRPs into a broad spectrum class of antibiotics with potent activity against both Gram negative and Gram positive organisms.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34, 35)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structures of arylomycin B and the synthetic analogue arylomycin M131.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A consortium of groups has recently reported the discovery of the new NRSP antibiotic teixobactin (<a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>), a depsipeptide with significant activity against Gram positive bacteria.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Considerable excitement accompanied this report, as the putative target of this peptide, the pyrophosphate of lipid II, plays an essential role in cell membrane biosynthesis; it is hoped that this mechanism of action will result in a significantly delayed onset of resistance.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structure of teixobactin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10">b Venoms and Toxins</h4><div class="NLM_p">Peptides derived from venomous organisms have provided productive starting points for many successful drug discovery programs.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Venom peptides typically target ion channels and other membrane bound receptors. While the variety of these compounds found in nature is enormous, they generally are disulfide-rich cyclic peptides ranging in size from 12â30 residues (as seen in cone snails) to 40â80 residues (in snakes and other organisms). They can be accessed synthetically or made using recombinant methods, and the stability afforded by the disulfide bridges relative to linear peptides make these venoms extremely attractive starting points for drug discovery programs; many prominent blockbuster drugs have resulted from optimization of venom derived peptides. For example, the ACE inhibitor captopril was discovered during the optimization of a venom peptide from the Brazilian viper.<a onclick="showRef(event, 'ref33 ref39'); return false;" href="javascript:void(0);" class="ref ref33 ref39">(33, 39)</a> Similarly, the antidiabetic agent exenatide, a GLP-1 agonist, originated from Gila monster venom,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> and ziconotide, an N-type calcium channel blocker used to treat chronic neuropathic pain, derives from a venom peptide from the predatory cone snail <i>Conus magus</i>.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div><div class="NLM_p">The venoms traditionally used for drug discovery research have predominantly derived from snakes and scorpions, primarily due to the ease of collection and identification of the toxins. Recent technological advances such as next-generation sequencing (NGS) and proteomics have allowed the venoms from many heretofore neglected organisms to be accessed and studied, and this continues to be a fruitful area for new developments in peptide lead discovery.</div><div class="NLM_p">Representing the toxins is linaclotide, a cysteine-rich 14 aa bicyclic peptide, recently approved for the treatment of chronic idiopathic constipation and irritable bowel syndrome, which was derived from the <i>Escherichia coli</i> toxins STh and STp (<a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Linaclotide is an agonist of the guanyl cyclase receptor (GCCR) which regulates intestinal water and electrolyte transport and acts to increase chloride secretion and decrease intestinal fluid absorption.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Structures of <i>E. coli</i> STh toxin and the analogue linaclotide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11">c Cyclotides and Lantipeptides</h4><div class="NLM_p">Cyclotides are a family of structurally novel, plant-derived cyclic peptides with interesting biological activity and are found in a variety of plant sources that are used in traditional folk medicine.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> For example, cyclotides are prominent components of an indigenous medicinal tea used in the Democratic Republic of Congo to accelerate childbirth. That particular observation has drawn considerable interest, as it can be inferred that not only do cyclotides have pharmacological activity, but they are thermally stable and orally active. The raison dâÃªtre for these structurally intricate peptides is likely to serve as a primitive innate immune system for the host, defending the plant against a variety of challenges; to support this notion, these compounds have been found to have insecticidal activity.</div><div class="NLM_p">Cyclotides have a head-to-tail cyclized backbone and three conserved disulfide bonds, creating a cyclic cysteine knot motif as shown in <a class="ref internalNav" href="#fig12" aria-label="Figure 12">Figure 12</a> for the prototypical cyclotide kalata B1. Cyclotides are synthesized at the ribosome and are enzymatically NâC cyclized in a post-translational process. This aesthetically pleasing topology has been shown to bestow enhanced stability in plasma and gastric fluid, oral bioavailability, and a diverse range of biological activities. Additionally, the structures of cyclotides exhibit considerable topological plasticity, as changing the number and type of amino acids in the loops does little to distort the overall shape, making them particularly amenable to molecular grafting strategies. Tam and co-workers have reported a particularly interesting example of this approach, grafting a bradykinin antagonist peptide onto a cyclotide scaffold to afford orally active peptides for the treatment of inflammatory pain (<a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>).<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Two- and three-dimensional structures of cyclotide kalata B1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Grafting of active peptide sequences onto cyclotide loops.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Lanthipeptides (previously known as lantibiotics due to the use of these peptides as antimicrobials) are a class of cyclic peptides bearing a macrocyclic thioether linkage, formed by a mechanism involving dehydration of selected serine and threonine residues and subsequent intramolecular addition of the thiol of proximal cysteine residues to the newly formed Michael acceptor (<a class="ref internalNav" href="#fig14" aria-label="Figure 14">Figure 14</a>).<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Linear peptide precursors are ribosomally synthesized by Gram-positive microbes; these are then post-translationally modified enzymatically to afford the novel macrocyclic peptides. While the potent antibacterial properties of lanthipeptides such as nisin have been appreciated and exploited for decades, the current need for new antibiotics has catalyzed a renewal of interest and a flurry of recent discoveries in this class of peptides.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Mechanism of lanthionine synthesis and the structure of the lanthipeptide nisin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The basic structural feature of lantipeptides, the thioether macrocycle, has been employed by Moll and co-workers in an analogue of angiotensin.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Ang(1â7) is a heptapeptide that plays a pivotal role in the reninâangiotensin system and possesses important pharmacological activities and is the likely endogenous ligand for the Mas receptor. As with most peptides of this type, the very short half-life of Ang(1â7) limits its therapeutic potential. In an attempt to address these deficiencies, Moll used a <i>Lactococcus lactis</i> variant, equipped with the appropriate lantipeptide modification machinery, to enzymatically produce a thioether-bridged Ang(1â7) from the corresponding linear peptide (<a class="ref internalNav" href="#fig15" aria-label="Figure 15">Figure 15</a>). The resulting cyclized peptide was found to be fully resistant against purified angiotensin-converting enzyme, had significantly increased stability in plasma and tissue, and exhibited a ca. 30-fold longer plasma half-life than Ang(1â7) in rat studies. Surprisingly, the cyclized Ang(1â7) analogue <b>A</b> is also 2-fold more potent than Ang(1â7) in inducing the relaxation of precontracted rat aorta rings ex vivo. This study demonstrates the potential of lanthipeptides outside the antibiotic area and that their thioether motifs may represent a transferable tool for peptide medicinal chemistry optimization.</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Enzymatic synthesis of lanthipeptide A.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">3.3 Use of Peptidomics for the Identification of New Peptide Leads</h3><div class="NLM_p">The field of peptidomics has emerged during the past decade as an important technique for the discovery of new peptides having novel biological function.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Peptidomics combines peptide sequence identification with the profiling of peptides in various tissues and fluids and aims to systematically catalogue genetically encoded polypeptides; this is facilitated by spectacular advances in mass spectrometry and bioinformatics that permit the identification (and sequencing) of peptides present in the tissue of interest with exquisite sensitivity.</div><div class="NLM_p">Saghatelian and co-workers have developed elegant methods to describe endogenous polypeptides encoded by short or small open reading frames (smORFs) that they refer to as SEPS; SEPs were originally found in bacteria, yeast, and worms, but functional SEPs have also now been found in the human genome that may prove to be biologically significant.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> It has been estimated that >200 SEPs are encoded in the human genome, varying in length from 15 to 138 aa. As an example, a screen of a human cDNA library for the prevention of amyloid precursor protein-induced cell death led to the discovery of humanin, a 24 aa peptide encoded by a smORF on the mitochondrial genome; this represents the first peptide in a new class of mitochondrial-derived peptides (MDP).<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Humanin has also been shown to be synthesized in the cytoplasm as a 21 aa variant and has a range of interesting biological activity, including inhibiting the pro-apoptotic protein BAX and interacting with IGF-1 binding protein.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div><div class="NLM_p last">Immediate applications of peptidomics will likely be to the discovery of relevant peptide biomarkers that facilitate translational medicine, clinical studies, and even patient stratification, but this developing technology is also proving to be an engine for the discovery of new peptides and peptide drug targets.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">3.4 Display Technologies in Peptide Lead Discovery</h3><div class="NLM_p">Simultaneously with seminal discoveries in the area of peptide library synthesis and HTS methods, the first report by Smith<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> in 1985 of the ability to engineer and display peptides on the surface of bacteriophage revolutionized the discovery of bioactive peptides and proteins, and important technological developments in this area have continued unabated.<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51, 52)</a> The ability to construct and screen vast libraries of peptide, protein, and antibody motifs using recombinant technologies has facilitated the rapid identification of active peptide sequences because the phenotype (usually affinity) is directly associated with the genotype (sequence). Fueled by the critical advances made in the antibody field, where this has become the sine qua non for antibody discovery,<a onclick="showRef(event, 'ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref53 ref54">(53, 54)</a> phage display (and the related technologies mRNA and ribosomal display) have become powerful methods for the generation and optimization of peptide ligands and have been used for the discovery of peptide leads against a vast array of biological targets.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></div><div class="NLM_p">Technological advances continue to make these techniques ever more efficient and applicable to an increasing range of targets. For example, the traditional screening, or âpanningâ, protocols generally used to find peptide binders to the target of interest are being impacted by the revolution in high throughput sequencing. Using ânext generation sequencingâ protocols, more efficient screening paradigms are being developed which allow access to enormous amounts of sequence data after even a single round of panning.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> This sequence data can greatly facilitate the strategy for further screening and library synthesis during the affinity maturation stages, leading rapidly to both more potent binders and a significantly larger structureâactivity data set directly from the early panning rounds. A further advantage of reducing the number of iterations of the phage panning cycle is the prevention of a selection bias toward phage clones that more readily replicate; these âparasiticâ sequences can quickly accumulate to become a majority, seriously hindering the identification of peptides with real affinity for the target.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a></div><div class="NLM_p">By definition, the peptides produced in phage display libraries are comprised of the proteinogenic amino acids, and thus the peptide leads obtained using this technique must usually subsequently be optimized via medicinal chemistry to find compounds with the requisite pharmaceutical properties (potency, PK, solubility, etc.) required of a drug lead. Several ingenious techniques have emerged, however, that could lead to much more âdrug-likeâ peptide leads arising directly from phage libraries. For example, âon-phageâ chemical modification of libraries is an area of intense current investigation and promises to significantly expand the capabilities of peptide phage display.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> The compounds produced often have novel, conformationally restricted molecular architectures that represent unusual epitopes; in theory, this leads to improved affinity and increased stability to enzymatic degradation (though without obviating the inherent renal clearance issues). An early example of this from Heinis used a polyvalent electrophile to alkylate multiple reduced cysteine thiols in the same phage-displayed peptide, leading to the replacement of the cyclic disulfide peptide with a novel, stabilized cyclic bis-thioether peptide (<a class="ref internalNav" href="#fig16" aria-label="Figure 16">Figure 16</a>).<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> An alternative approach uses chemical modification to mimic common post-translational modifications such as glycosylation, effectively allowing the screening of a defined and characterized library of glycopeptides.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Chemical modification of phage by disulfide reduction and cysteine alkylation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Other approaches to find more pharmaceutically attractive peptides from display technology continue to be reported. Kim demonstrated in an elegant series of papers the concept of âmirror image phage displayâ. This technique uses an unnatural <span class="smallcaps smallerCapital">d</span>-peptide/protein target to select peptides from a standard <span class="smallcaps smallerCapital">l</span>-peptide phage library; the <span class="smallcaps smallerCapital">d</span>- mirror images of these active phage-displayed peptides, by symmetry, will then interact with the target protein having natural <span class="smallcaps smallerCapital">l</span>- chirality (<a class="ref internalNav" href="#fig17" aria-label="Figure 17">Figure 17</a>).<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> These <span class="smallcaps smallerCapital">d</span>-peptides are effectively guaranteed to exhibit complete plasma stability and are very attractive starting points for drug discovery programs. In the first examples of this approach, Kim found <span class="smallcaps smallerCapital">d</span>-cyclic peptides that interact with c-SRC and HIV-protease.<a onclick="showRef(event, 'ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref59 ref60">(59, 60)</a> The obvious and significant barrier to implementing this technique is the requirement for the synthesis of the <span class="smallcaps smallerCapital">d</span>-enantiomer of the target protein, an impressive scientific achievement in its own right.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> The continual improvements in synthetic methods for the production of large peptides and small proteins, outlined in <a class="ref internalNav" href="#sec3_4" aria-label="section 3.4">section 3.4</a>, may eventually allow routine access to <span class="smallcaps smallerCapital">d</span>-proteins, at which point, this screening approach may naturally supersede others to become a dominant peptide discovery tool.</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Principle of mirror image phage display.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The conceptually ideal display technology envisions a system where the chemist has an essentially unlimited toolbox of amino acid building blocks to construct display libraries, comparable to the construction of synthetic peptides, while still exploiting the power of the phenotype/genotype linkage to generate very large libraries and rapidly identify active peptides. If one could use, for example, <i>N</i>-methylated or <span class="smallcaps smallerCapital">d</span>-amino acids, or amino acids that can promote the formation of novel cyclization motifs, then display libraries could directly produce stable peptides that would immediately prove valuable for drug discovery programs, obviating the need for significant time and effort in early medicinal chemistry optimization. Several recent technological developments have shown that this goal may be close to realization.</div><div class="NLM_p">Szostak and co-workers have shown that mRNA display can be applied to the evolution, selection, and discovery of extremely large libraries (>10<sup>13</sup>) of novel, macrocyclic peptides that contain a majority of unnatural amino acids.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Using a PURE/mRNA-display system that generates the tRNAs charged with various unnatural amino acids in situ, 12 of the 20 natural amino acids were reassigned to introduce a diverse set of unnatural side chain and backbone modifications. They were able to also incorporate aa derivatives that permitted macrocyclization to introduce further conformational restriction and enhanced stability. The technology was exemplified by the discovery of nanomolar-affinity thrombin inhibitors comprising mostly unnatural amino acids that were shown to be essential for binding.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div><div class="NLM_p">Similarly, Suga has reported extensively on the use of a ribosomal display method they term the ârandom non-standard peptides integrated discoveryâ (RaPID) system, which can be used to produce large libraries of bioactive macrocyclic peptides containing noncanonical aa.<a onclick="showRef(event, 'ref17 ref64'); return false;" href="javascript:void(0);" class="ref ref17 ref64">(17, 64)</a> This highly promising technology has been demonstrated to provide hits against an increasingly wide variety of biological targets and features a critical additional element that provides an advantage over the PURE technology described above; the aminoacyl tRNAs do not have to be premade. The use of âflexibleâ tRNA acylation ribozymes, known as âflexizymesâ, facilitate the preparation of a wide array of nonproteinogenic aminoacyl tRNAs and allows ribosomal synthesis of macrocyclic peptides using an almost unlimited number of amino acids, including <span class="smallcaps smallerCapital">d</span>-aa.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> In addition to proteolytic stability, the authors claim that these unnatural peptides exhibit enhanced permeability and could potentially have sufficient bioavailability for oral dosing.</div><div class="NLM_p">With these and many other impressive advances in the application of display technologies to peptide and protein drug discovery over the past decade, it is now generally true that binders to nearly any biological target of interest can be found using phage, ribosomal, or mRNA-display methodologies, providing that the protein/receptor/enzyme target can be assayed in a relevant state.</div><div class="NLM_p">This latter caveat has traditionally excluded membrane bound targets such as GPCRs, ion channels, and single-spanning receptor tyrosine kinase (RTK) receptors despite their aforementioned prominence in the spectrum of peptide pharmacology. A number of different approaches have recently been developed to facilitate the study of transmembrane proteins and allow display screening efforts. Modified calixarenes were reported as a next-generation detergent formulation to better mimic the structure and properties of phospholipids, allowing extraction of functional membrane proteins.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Alternatively, Sligar and co-workers developed a sophisticated synthetic model of a portion of a phospholipid bilayer, termed a nanodisc, using a âdouble-beltâ of membrane scaffold proteins (MSP) to surround and stabilize the exposed hydrophobic surface.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> These nanodiscs have proven highly effective at hosting stable, soluble, and active transmembrane proteins. Finally, the transmembrane protein can be modified by precisely selected mutations for improved thermostability without impairing its pharmacology;<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> this is the basis of Heptaresâ StaR technology. These techniques allow fundamental structural investigations of GPCRs,<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> as well as enabling pharmaceutical screening efforts.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a></div><div class="NLM_p">Another major limitation of screening technologies that has to date excluded a critical part of the peptide field is the difficulty in parsing these huge libraries for receptor agonists despite the powerful pharmacology this might uncover. An inefficient two-step approach is possible, screening for competitive binders, then assaying synthesized peptide hits for agonism. The ideal technique would allow direct panning of display libraries against intact cells with a functional signaling readout, yet this approach has faced complex practical problems and challenging interpretation of the screening results. Recently, however, several groups have reported promising advances in this area that may uncover pharmacologically interesting peptide hits against whole classes of previously intractable receptor targets.</div><div class="NLM_p">Lerner and co-workers, in a series of ground-breaking papers, have described a general autocrine-based signaling system that utilizes an engineered cell line containing a membrane-tethered library of potential peptide ligands, introduced via lentivirus infection, coexpressed with the receptor of interest (<a class="ref internalNav" href="#fig18" aria-label="Figure 18">Figure 18</a>).<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Activity is reported using an artificial signal transduction system, engineered to be observed even in the presence of the endogenous signaling of the receptorâligand system. Cells having the desired phenotype are identified, sorted, and the peptides of interest identified using standard techniques. Originally used to find agonist antibodies, this system has been extended to the use of libraries of scaffold proteins, peptides, and venoms. An exciting recent report by this group described the discovery of a potent analogue of GLP-1, P5, that uniquely has a differentiated molecular pharmacology profile; it does not recruit Î²-arrestin and is a weak insulin secretogogue.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> In vivo studies in mice showed this biased agonist (see <a class="ref internalNav" href="#sec5" aria-label="section 5">section 5</a>) more effectively controls glucose levels and reduces HbA1c compared to marketed GLP-1 agonist Exendin-4 (<a class="ref internalNav" href="#fig19" aria-label="Figure 19">Figure 19</a>).</div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Principle of Lernerâs autocrine screening technology.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Comparison of the sequences of GLP-1, exenatide, and the biased agonist P5.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Yoshimoto, Kurota, and co-workers have used a similar approach for the discovery of new peptide ligands for a single membrane spanning receptor tyrosine kinase receptor, endothelial growth factor receptor (EGFR).<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> The principle is functionally identical to Lernerâs method, expression of a library of anchored peptides that can demonstrate agonism of the receptor via a fluorescence readout. The key difference is the use of a yeast cell line, which has the additional structural element of a cell wall encircling the membrane-bound screening protagonists; the peptides in this example are anchored to the inner face of the cell wall. In theory, this provides a simple solution to the potential for confounding intercell signaling, where a peptide bound to one membrane activates a receptor on an adjacent cell. This technology may have applicability to a wide variety of membrane bound receptors, including GPCRs.</div><div class="NLM_p last">These examples highlight the both the utility and versatility of display technologies for the selection of peptide binders against a broad range of biological targets. In addition, we have described some of the key technological advances in this area that have attempted to make the peptide leads discovered in display efforts much more amenable to optimization. As in vitro display technologies continue to advance, their utility in peptide drug discovery programs will no doubt increase further.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">4 New Enabling Synthetic Methods</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10831" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10831" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">That the synthesis of moderately long peptides (30â50 residues) is now considered relatively routine is a testament to decades of continual optimization, both methodological and technological. The modern infrastructure of solid-phase peptide synthesis (SPPS) would still be recognizable to chemists of earlier generations, but the accumulated knowledge and extensive chemical toolbox has dramatically expanded the scope of potential targets, both for academic research and in the higher-throughput environment of industrial drug discovery programs.</div><div class="NLM_p">The current slate of peptide synthesizers exhibit a range of capabilities; sequential or multiparallel synthesis of up to 192 peptides, at scales from 1 Î¼mol to 5 mmol, IR or microwave heating, flexible programming and preactivation chambers, and UV monitoring of the deprotection step to identify troublesome sequences. Downstream, automated HPLC purification systems are also increasing throughput at this traditional bottleneck, commonly with the addition of MS-directed sample collection. There has been a recent resurgence in peptide reverse phase (RP) flash chromatography, which may provide a cheap and high-throughput alternative, particularly for shorter peptides with good crude purity. Ideally, large multiparallel library synthesis would avoid individual chromatographic purification altogether, and interesting progress is being made in the use of reversible N-terminal capping strategies that allow the physical separation of the desired peptide;<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> refinement and incorporation of this technology into a future generation of synthesizers should prove extremely valuable.</div><div class="NLM_p">In Fmoc-SPPS, it is generally understood that the critical problem for the synthesis of long peptides is physical occlusion of the reactive N-terminus by aggregation (effectively desolvation) or the formation of secondary-structural elements on the resin. A range of approaches are now widely used for problematic sequences, in many cases routinely and preemptively. Low-substitution PEG resins such as ChemMatrix allow increased swelling and greater solvation,<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> and microwave heating offers the dual advantages of reduced aggregation and short reaction times of 5 min or less.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Solubilization can be improved using chaotropic agents and optimized solvent mixtures.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Additionally, there are three common synthetic approaches that are used to purposefully disorder the secondary structure of the growing chain:<a onclick="showRef(event, 'ref77 ref78'); return false;" href="javascript:void(0);" class="ref ref77 ref78">(77, 78)</a><ul class="NLM_list-list_type-bullet"><li><p class="inline">Pseudoprolines are cyclized Ser, Thr, and recently Cys dipeptides that have demonstrated great efficacy in destabilizing Î²-sheet formation by both masking a backbone NH and altering the overall conformation, consequently improving yield and purity (<a class="ref internalNav" href="#fig20" aria-label="Figure 20">Figure 20</a>).<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Available, cheap, and readily deprotected by the standard TFA cleavage, pseudoprolines are now often proactively incorporated every 8â10 residues where the sequence allows.</p></li><li><p class="inline">Isoacyl dipeptides, esters of Ser and Thr residues, exert a similar effect on the synthesis (<a class="ref internalNav" href="#fig20" aria-label="Figure 20">Figure 20</a>). However, the lack of any consistent advantage over pseudoprolines limits their utility, as this approach carries risks of diketopiperazine formation and Î²-elimination side reactions and requires an additional rearrangement step following cleavage.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a></p></li><li><p class="inline">Removable <i>N</i>-Î±-alkylation is an effective alternative strategy, most commonly as acid-labile Hmb- or Dmb-Gly derivatives that retain sufficient reactivity for the subsequent coupling; some dipeptides are also commercially available.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a></p></li></ul></div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Structure of isoacyl dipeptides and pseudoprolines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It is worth noting that in Boc-SPPS the TFA deprotection step effectively destroys aggregates and has proven useful for challenging sequences,<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> yet the safety-driven shift toward Fmoc-SPPS has resulted in many peptide synthesis laboratories no longer being equipped for the final HF cleavage step.</div><div class="NLM_p">The second major problem in Fmoc-SPPS of longer peptides is the accumulative formation of aspartimides by base-catalyzed cyclization of aspartic acid esters and their subsequent distribution across up to nine different side products.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Three strategies have each proven generally effective: bulky ester protecting groups such as 3-ethyl-3-pentyl (Epe),<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> buffering of the basicity of the deprotection solution using HOBt,<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Oxyma,<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> or formic acid,<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> and the use of an <i>N</i>-Î±-alkyl dipeptide for the especially susceptible Asp-Gly sequence.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a></div><div class="NLM_p">Despite these impressive advances, it is rarely practical to synthesize very large peptides and small proteins as a single chain in SPPS, and perhaps the most vibrant field of peptide synthesis research now involves the development of methods for the controlled ligation of synthesized fragments, which will comprise the majority of this section.</div><div class="NLM_p">As a logical extension from Fmoc-SPPS, the ligation of protected fragments in both solution and solid phase is possible when C-terminal racemization is controlled by the selection of Gly or Pro as the ligation site,<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> the use of a C-terminal pseudoproline residue,<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> or the careful choice of coupling conditions.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Although the selectivity of the coupling is guaranteed, the significant limitation to this method is the difficulty in handling and purifying the fully protected peptides prior to the ligation.</div><div class="NLM_p">Native chemical ligation (NCL) is the most widely used and successful fragment coupling approach and has been essential in the expansion of synthetically accessible biological space from large peptides to proteins, culminating in the recent chemical syntheses of single polypeptide chains of over 300 residues.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> NCL takes advantage of the rapid and reversible exchange of thioesters at the C-terminus to induce a highly selective proximity-directed amidation with an adjacent amine (<a class="ref internalNav" href="#fig21" aria-label="Figure 21">Figure 21</a>).<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Originally developed for ligation at cysteine, which is relatively uncommon in proteins,<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> subsequent advances have expanded the possible ligation sites through the use of both removable thiol auxiliaries<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> (<i>N</i>-alkyl glycines) and mild desulfurization conditions that convert cysteine to alanine.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> The potential of this latter approach has been further extended by the synthesis of the Î²-thiol analogues of more-common natural amino acids,<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> where the desulfurization would again result in a traceless ligation and future commercialization of these building blocks should result in widespread adoption.</div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Mechanism of native chemical ligation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Turning to the thioester ligation partner, the reactivity has been demonstrated to vary with both the steric hindrance of the C-terminal residue<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> and the nature of the chosen thiol; 4-mercaptophenylacetic acid (MPAA) is widely used.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> A number of alternative approaches have been developed to access the deprotected thioester fragment via Fmoc synthesis, four of which are highlighted here:<ul class="NLM_list-list_type-bullet"><li><p class="inline">C-Terminal hydrazides are readily synthesized and highly stable yet can be selectively and mildly nitrosated to form reactive acyl azides, which in turn are rapidly converted to thioesters with the appropriate thiol (<a class="ref internalNav" href="#fig22" aria-label="Figure 22">Figure 22</a>).<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> This widely used approach has the additional advantage of simple application in an iterative fragment condensation strategy, where each new ligation product has a C-terminal hydrazide ready for subsequent activation and coupling.</p></li><li><p class="inline">Dawsonâs second-generation <i>N</i>-acyl urea approach synthesizes the peptide fragment on a bis-aniline linker (<a class="ref internalNav" href="#fig23" aria-label="Figure 23">Figure 23</a>).<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Conversion to the urea immediately prior to cleavage again produces a reactive acyl leaving group for displacement by a thiol.</p></li><li><p class="inline">An elegant strategy takes advantage of the inherently reversible acyl transfer of Î²-thio-amines. Melnykâs bis(2-sulfanylethyl)amides (SEA), again readily prepared by SPPS using a special linker, are activated by reduction to set up this equilibrium, which can be directed at low pH toward the thioester by protonation of the amine.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Interception with an added thiol results in a stable thioester ligation partner (<a class="ref internalNav" href="#fig24" aria-label="Figure 24">Figure 24</a>).</p></li><li><p class="inline">Finally, ligations at the C-terminus of recombinant proteins have been made possible by fusion to an intein sequence. Following purification using an appropriate tag, the intein can be cleaved by addition of a thiol reagent to give the C-terminal thioester (<a class="ref internalNav" href="#fig25" aria-label="Figure 25">Figure 25</a>).<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> Another approach for recombinant expression is the genetic incorporation of Î±-hydroxy acids, creating an ester that can be displaced by hydrazine to give a ligation-compatible C-terminal hydrazide.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a></p></li></ul></div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. NCL via C-terminal hydrazides.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. NCL via C-terminal <i>N</i>-acyl ureas.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0024.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. NCL via C-terminal bis(2-sulfanylethyl)amides.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0025.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Intein-mediated protein ligation (IPL).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">These methods of initially activating the C-terminus are often also applicable to the synthesis of salicylaldehyde esters, which enable a useful serine/threonine ligation by the selective, reversible formation of oxazolidine intermediates.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> These undergo an acyl shift and subsequent hydrolysis to effect the ligation (<a class="ref internalNav" href="#fig26" aria-label="Figure 26">Figure 26</a>).</div><figure id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0026.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Mechanism of the Ser/Thr ligation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">One alternative recent method of chemical ligation has expanded the possibilities of fragment condensation approaches by uncovering a truly orthogonal and completely selective coupling reaction. Bodeâs ketoacid-hydroxylamine (KAHA) ligation uses these eponymous functionalities at the C- and N-terminus, respectively, which rapidly combine to a depsipeptide that rearranges to give the desired product (<a class="ref internalNav" href="#fig27" aria-label="Figure 27">Figure 27</a>).<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> The major limitation is currently the preferred use of oxaproline as the hydroxylamine partner, which incorporates homoserine residues into the final product; the oxazetidine analogue for serine site ligations has recently been demonstrated.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> Serial fragment condensation is possible by the use of protected precursors, and overall further refinement and commercial availability of the building blocks should make this a powerful parallel method to the NCL methods described above, particularly due to the complementary reactivity profiles of C-terminal ligation sites for these two approaches.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a></div><figure id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0027.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Mechanism of the KAHA ligation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Biochemical ligation approaches to peptide and protein synthesis represent an exciting frontier that has seen rapid advances in the past few years. The use of sortase enzymes has been mostly exploited for functional tagging of recombinant proteins due to their required five-residue âLPXTGâ recognition footprint and a relatively slow, highly reversible reaction that requires a substantial excess of one component.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a></div><div class="NLM_p">Tamâs butelase improves in many aspects, requiring only an asparagine footprint in the final product and demonstrating high rates of ligation and particularly macrocyclization, with excellence tolerance for <span class="smallcaps smallerCapital">d</span>-amino acids (<a class="ref internalNav" href="#fig28" aria-label="Figure 28">Figure 28</a>).<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Tam has recently proposed an irreversible alternative that uses a thioester motif at the ligation site, analogous to NCL approaches but accepting a broad range of nonthiol N-terminal partners.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> The most impressive enzymatic approach to date is the peptiligase family, demonstrated to have a near-perfect set of attributes for peptide and protein ligation applications: traceless combination with no recognition motif, applicability to ligation of almost every combination of primary amino acids, high efficiency in water or with organic cosolvents, no hydrolysis of internal amide bonds, and a surprisingly high synthesis/hydrolysis ratio that promotes the desired ligation.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> The acyl donors are carboxamidomethyl (CAM) esters, which are easily synthesized via conventional SPPS (<a class="ref internalNav" href="#fig29" aria-label="Figure 29">Figure 29</a>). The enzyme itself has proven amenable to industrial production and protein engineering, with two classes of product envisioned: a high-volume omniligase with maximally broad specificity and utility and the bespoke development of tight-specificity peptiligases that would allow exquisitely selective ligations of a chosen N-terminus for multifragment approaches, branched products, or even bioorthogonal applications.</div><figure id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0028.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Schematic of butelase ligation, illustrating sequence recognition and the irreversible thioester variant.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0029.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Synthesis of CAM esters as substrates for peptiligase ligation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It is of course not just peptide length that can favor recombinant production but also structural complexity. All insulin on the market is currently produced using recombinant technologies, as the disulfide-bridged heterodimeric structure has proven challenging to synthesize efficiently. Taking inspiration from the biosynthesis, a variety of recent approaches to this class of peptide have demonstrated synthetic accessibility using oxime tethering,<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> hydrolyzable depsipeptides,<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> and a chemically cleavable bis-linker tether.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> All avoid the conventional synthetic approach that requires a difficult selective dimerization of poorly soluble single strands using orthogonally protected cysteines.</div><div class="NLM_p">The commercialization of peptide drugs represents the culmination of the discovery process and the ultimate challenge for large-scale, cost-efficient production methods. A range of techniques established in the literature have been highly optimized for the synthesis of peptide active pharmaceutical ingredients, including solution-phase and ligation approaches alongside the more common solid-phase and recombinant strategies, and the challenges involved have been described in a recent review.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a></div><div class="NLM_p last">The new synthetic methods briefly described here enable peptide chemists to rapidly and efficiently drive the optimization of biologically active peptides and explore new regions of biological space. This ever-growing toolbox forms the basis of the field, a foundation for the exciting advances in peptide pharmacology and their pharmaceutical applications discussed in subsequent sections.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">5 New Paradigms in Peptide Pharmacology</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21423" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21423" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As the natural ligands for many GPCRs, peptides have been at the forefront of the considerable effort to characterize and delineate the intricately woven signaling processes mediated by these receptors. Consequently, modern GPCR pharmacology has developed far beyond simple on/off-switch notions of agonism and antagonism and the attendant assumptions of orthosteric binding, linear efficacy, and uniform receptor activation.<a onclick="showRef(event, 'ref112 ref113'); return false;" href="javascript:void(0);" class="ref ref112 ref113">(112, 113)</a></div><div class="NLM_p">One of the preeminent voices in this field, Terry Kenakin, has described seven-transmembrane (7TM) receptors as shape-shifting conformational ensembles, whose seemingly diverse signaling pathways can be holistically expressed in terms of multidirectional allosteric effects.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> To briefly summarize, all the interacting partners of a GPCR can affect its conformation and thus its binding to any other partner. These partners include traditional extracellular orthosteric ligand peptides but also other membrane receptors and a variety of intracellular signal transduction proteins. If the binding mode of a ligand to the GPCR alters the expected recruitment or activation pattern of these intracellular proteins, the resulting differential signaling is termed functional selectivity or bias.</div><div class="NLM_p">This complexity presents both challenges and opportunities in drug discovery, and new approaches and assays are continually being adopted by drug discovery scientists to not only better understand the targeted biological pathway but also to access potentially unexplored pharmacology of established GPCRs. A critical question in the peptide field is whether the pleiotropic effects of many long-established hormones, specifically where a single extracellular receptor binding event causes a multifaceted intracellular signaling response, can be divorced and isolated by careful optimization. As the receptor pharmacology is unraveled, exciting therapeutic opportunities may present themselves; can the desired effect be boosted and/or the unwanted side effects eliminated?</div><div class="NLM_p">Selected examples are presented below of peptides that were specifically developed to effect therapeutically relevant GPCR signaling outside the realm of classical orthosteric agonists and antagonists:<ul class="NLM_list-list_type-bullet"><li><p class="inline">Trevenaâs octapeptide <b>1</b> (TRV120027,<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a><a class="ref internalNav" href="#fig30" aria-label="Figure 30">Figure 30</a>a) was developed as a functionally selective ligand of the angiotensin II type 1 receptor (AT1R).<a onclick="showRef(event, 'ref113 ref115'); return false;" href="javascript:void(0);" class="ref ref113 ref115">(113, 115)</a> Classical marketed AT1R antagonists are used to block the adverse effects of the natural ligand angiotensin II (predominantly hypertension) but are thought to also prevent ionotropic effects that boost cardiac function. During acute heart failure (AHF), these become opposing therapeutic outcomes, and as such AT1R antagonists have little positive effect on AHF patients. Elucidation of the AT1R signaling pathways found that the vasoconstrictive, hypertensive pharmacology results from activation of G-proteins, whereas the ionotropic effects are mediated by Î²-arrestin signaling.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> To achieve a beneficial profile, <b>1</b> therefore both inhibits G-protein coupling and stimulates Î²-arrestin recruitment at AT1R. Despite the promise of this functional selectivity, <b>1</b> recently missed both primary and secondary end points of a phase IIb trial in AHF.</p></li><li><p class="inline">The parathyroid hormone (PTH) analogue PTH-Î²arr (<a class="ref internalNav" href="#fig30" aria-label="Figure 30">Figure 30</a>b), developed at Duke University Medical Center, is a functionally selective agonist for the Î²-arrestin signaling pathway and has been demonstrated in animal models to stimulate bone formation without the accompanying increase in bone resorption that has limited the clinical use of PTH in osteoporosis.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a></p></li><li><p class="inline">Rapastinel (<a class="ref internalNav" href="#fig30" aria-label="Figure 30">Figure 30</a>c), originally developed by Naurex, binds to an allosteric regulatory site on the <i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate (NMDA) receptor and functionally acts as a weak partial agonist of the glycine site.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> Modulation of this receptor produces a variety of profound CNS effects, and antagonists such as ketamine and PCP can have powerful antidepressant activity, albeit with a narrow therapeutic window and a range of dangerous psychotomimetic side effects. Rapastinelâs weak partial agonism has been shown to produce only the desired antidepressant (and cognitive enhancing) response, and this drug has recently completed phase II clinical development for treatment-resistant major depressive disorder. In 2016, rapastinel, now owned by Allergan, received Breakthrough Therapy designation from the FDA.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a></p></li><li><p class="inline">Pepducins, developed at Tufts Medical Center, are lipidated peptides that target the intracellular GPCR/G-protein interface, and can either activate or block the associated signaling pathway.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> Pepducin <b>2</b> (PZ-128,<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a><a class="ref internalNav" href="#fig30" aria-label="Figure 30">Figure 30</a>d) was designed to directly mimic the PAR1 receptor loop that binds to the GÎ±-protein, yielding functionally selective PAR1 inhibition.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Importantly, by not classically antagonizing the binding of thrombin to the PAR receptors, <b>2</b> has been demonstrated to prevent platelet activation and arterial thrombosis without interfering with bleeding or coagulation.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a><b>2</b> is in clinical development for patients with acute coronary syndrome (ACS) and those undergoing percutaneous coronary interventions (PCI) and has recently completed a phase I trial.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a></p></li></ul></div><figure id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0030.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. Examples of peptides exhibiting nonclassical GPCR pharmacology.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The concept of functional selectivity is gaining widespread interest in modern drug discovery programs. The biological efficacy of a GPCR ligand hit, lead, or candidate must now be seen as a multidimensional parameter, able to be both measured and optimized in a variety of functional in vitro assays. In the near future, the pioneering drug discovery efforts listed above will provide vital clinical data to begin to validate the current pharmacological signaling hypotheses and models. However, this is a nascent field; even as attempts are made to both standardize and quantify aspects of ligand bias, many questions remain. Is there a temporal difference in pathway activation? Are different signaling pathways favored in different cell types? A further decade or two of research may be required to fully understand the fundamental biology, allow confident translation to meaningful functional selectivity in vivo, and realize the clinical promise of precise control of GPCR signaling.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">6 Medicinal Chemistry Optimization of Peptides</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52607" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52607" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Successful peptide medicinal chemistry optimization requires a comprehensive multiparametric approach that ideally assesses the impact of each iteration on the key candidate properties of potency, selectivity, stability, solubility, and toxicity.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> There are a number of key differences between the optimization of peptides and small molecules:<ul class="NLM_list-list_type-bullet"><li><p class="inline">Peptide natural products or affinity-matured screening hits often present with high potency, which must then be sufficiently retained during optimization of the other critical properties.</p></li><li><p class="inline">The polymeric nature of peptides readily allows each residue to be individually optimized, with the modifications then often combining to give predictably additive results.</p></li><li><p class="inline">The ADMET properties are inherently restricted: minimal absorption, limited distribution from the plasma, an in vivo peptide metabolism that is essentially limited to proteolytic cleavage of backbone amide bonds, largely renal excretion, and consequently limited toxicological liabilities.</p></li></ul></div><div class="NLM_p">The section describes the logical sequence of steps taken in the medicinal chemistry optimization of a hit or lead peptide alongside selected examples of successful applications. One highly context-dependent factor that is also considered throughout this process, yet will not be discussed further, is ensuring intellectual property rights for the final candidate(s).</div><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">6.1 Identification of the Minimum Active Sequence</h3><div class="NLM_p last">The lead peptide is truncated by iterative removal of amino acids from the C- and N-termini to identify the core sequence critical for the desired biological properties.</div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">6.2 Positional Scanning to Determine Critical Residues</h3><div class="NLM_p last">Classically this is done as an <span class="smallcaps smallerCapital">l</span>-Ala-scan, replacing each side chain with the smallest alternative that should still retain a similar conformational profile and thus determining its importance for the biological activity. The increasing throughput of novel synthetic and purification approaches now also allows positional scanning using a defined set of amino acids that possess a wide spectrum of physical attributes (i.e., hydrophobic, basic, acidic).<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a></div></div><div id="sec6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">6.3 Protection from Degradation at the Termini</h3><div class="NLM_p last">If acceptable to the binding interactions, modification of the C- and N-termini is usually carried out to proactively prevent the degradative activity of carboxy- and aminopeptidases, respectively. The simplest analogues, C-terminal primary amide and N-terminal acetylation, often work well. If these are not tolerated, specific optimization of these residues toward unnatural analogues may prove necessary.<a onclick="showRef(event, 'ref10 ref125'); return false;" href="javascript:void(0);" class="ref ref10 ref125">(10, 125)</a></div></div><div id="sec6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">6.4 Identification of Sites of Proteolysis</h3><div class="NLM_p last">This initial exploration of the SAR, in conjunction with PK experiments, stability assays, and metabolite detection, should allow identification of the proteolytically labile amide bonds within the sequence.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a></div></div><div id="sec6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">6.5 Proteolytic Stabilization by Backbone Modification</h3><div class="NLM_p">As already discussed, proteolytic stabilization with retention of activity is one of the major challenges for the optimization of peptide natural products and screening hits. There are many common strategies available for modification of the labile amide bond(s), yet retaining the desired conformation and binding affinity can be extremely difficult:<ul class="NLM_list-list_type-bullet"><li><p class="inline"><span class="smallcaps smallerCapital">d</span>-aa are often the first resort and can be incorporated into the positional scanning libraries. A study comparing backbone modifications has determined that <span class="smallcaps smallerCapital">d</span>-aa are the most effective way to prevent chymotrypsin degradation and can confer protection remotely to nearby residues. This effect, also seen for the Î±-Me-aa strategy discussed next, could be especially useful if the labile amide bond cannot be modified without significant loss of activity.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> The retro-inverso strategy uses a reverse sequence of all <span class="smallcaps smallerCapital">d</span>-aa, which in theory should place the side chains in a similar orientation to the original <span class="smallcaps smallerCapital">l</span>-peptide;<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> this is a conceptually pleasing approach that unfortunately has rarely proven effective, likely due to the major conformational changes produced by the effective transposition of each backbone amide bond.</p></li><li><p class="inline">Î±-Me-aa occlude protease binding in a similar manner to <span class="smallcaps smallerCapital">d</span>-aa, while in theory retaining the side chain in its original spatial location.<a onclick="showRef(event, 'ref141 ref127 ref129'); return false;" href="javascript:void(0);" class="ref ref141 ref127 ref129">(141, 127, 129)</a> Quaternary aa also have restricted conformations which can prove beneficial in specific contexts, particularly for helical peptides.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Î±-Me-aa are now widely commercially available yet can pose synthetic challenges through increased steric hindrance; microwave heating and double-couplings may be required.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a></p></li><li><p class="inline"><i>N</i>-Me-aa generally offer good protease protection<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> but may also disrupt intra- or intermolecular hydrogen bonding interactions. This can modulate biological function and with judicious application also potentially decrease unwanted aggregation and improve solubility.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> An intriguing application inspired by the immunosuppressant natural product cyclosporine is the use of selective <i>N</i>-methylation to generate membrane-permeable cyclic peptides, which often also have significant oral bioavailability.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> As above, <i>N</i>-Me-aa often require more forceful coupling conditions during the synthesis.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a></p></li><li><p class="inline">Î²-aa incorporation may cause a significant conformational change in addition to the positional shift of the side chain yet has proven an effective approach when rationally introduced into Î±-helices, as exemplified by periodic incorporation in a recent parathyroid hormone inverse agonist.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a></p></li><li><p class="inline">Peptoids (poly-<i>N</i>-alkyl glycines) are a logical extension of these concepts<a onclick="showRef(event, 'ref131 ref135'); return false;" href="javascript:void(0);" class="ref ref131 ref135">(131, 135)</a> yet as a global strategy suffer from a problematic decrease in overall conformational rigidity and a corresponding entropic penalty for receptor binding. Retention of the Î±-stereocenter (e.g., alanine peptoids) has been demonstrated as a viable solution.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a></p></li><li><p class="inline">Similarly, aza-peptides can be effective in isolation in reducing proteolytic degradation but also introduce additional conformational flexibility.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a></p></li></ul></div><div class="NLM_p">A range of peptidomimetic approaches have been developed that partially or totally replace peptide backbones with non-natural oligomeric units,<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> but this is rarely attempted as part of a peptide medicinal chemistry optimization program.</div><div class="NLM_p">It is worth noting that maximizing the plasma half-life of peptide compounds, while a very common optimization goal, can of course be unnecessary in indications where the treatment is expected to be particularly acute, and a short half-life may be optimal where rapid clearance allows safer titration of the drug levels to within a narrow therapeutic window. This strategy was successfully pursued by Ferring in the development of selepressin (<a class="ref internalNav" href="#fig31" aria-label="Figure 31">Figure 31</a>), a vasopressin analogue designed to be both selective and short-acting,<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> which is currently in clinical development for the treatment of vasodilatory hypotension in septic shock.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a></div><figure id="fig31" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0031.jpeg" id="gr31" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. Structure of selepressin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig31"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22">6.6 Optimization by Side Chain Modification</h3><div class="NLM_p">The results of the positional scanning usually provide sufficient data for rational modifications of the key binding residues toward improving the affinity and selectivity of the peptide. Each natural amino acid effectively has a set of commonly used close analogues that can often be substituted in at this stage, and non-natural side chains often induce protease resistance. For example, variants of arginine include lysine, ornithine, homoarginine, citrulline, and <i>N</i>-isopropylornithine.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> Aromatic residues have a particularly broad set of available analogues including unnatural heterocycles<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> and can also benefit from the introduction of Î²-methyl groups that rigidify the conformation.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> The residues that were found to not be critically involved in the binding interaction can be rationally modified to alter the physical properties of the peptide, improving solubility or installing an unnatural amino acid that might confer increased proteolytic stability on adjacent positions.<a onclick="showRef(event, 'ref127 ref141'); return false;" href="javascript:void(0);" class="ref ref127 ref141">(127, 141)</a> Alternatively, noncritical residues provide sites for conjugation (see <a class="ref internalNav" href="#sec7" aria-label="section 7">section 7</a>) or in some cases cyclization.</div><div class="NLM_p last">An impressive recent demonstration of sequence optimization is the rational design of a triagonist by identification and combination of the active partial sequences for three individual hormones.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> The resulting single helical peptide simultaneously and equally activates the GLP-1, GIP, and glucagon receptors, resulting in superior reduction of body weight and diabetic complications in rodent models of obesity.</div></div><div id="sec6_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">6.7 Cyclization</h3><div class="NLM_p last">It is a central tenet of medicinal chemistry that restricting the conformational flexibility of a molecule to favor the orientation required to bind to the target reduces the entropic penalty of binding and can dramatically improve the affinity and selectivity.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> For peptides, cyclization also often prevents protease access to the backbone amides; these enzymes bind their substrates in a linear, extended conformation. Many natural peptides and screening hits contain one or more disulfide bridges, and this linkage can be further optimized for stability; typically, one of the sulfur atoms is replaced with a carbon atom to generate a cystathionine.<a onclick="showRef(event, 'ref46 ref143'); return false;" href="javascript:void(0);" class="ref ref46 ref143">(46, 143)</a> Disulfide positional scanning can also identify the optimal position for cyclization and conformational restraint. For helical peptides, side-chain-to-side-chain cyclization has proven highly effective at promoting and stabilizing the desired conformation. A common approach is a lactam scan,<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> coupling together the side chains of lysine and glutamic acid residues on the same face of the helix.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> Ring-closing metathesis of alkenyl side chains produces a hydrocarbon âstapleâ, and this technique has been used extensively by Aileron in the design of cell-permeable Î±-helices.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> In recent years a toolbox of chemical approaches has emerged for the one-step orthogonal stapling of cysteine residues, which offer increased throughput, diverse conformations, unnatural functionality for additional interactions, and the potential for direct modification of displayed peptides during the phage screening process.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> This latter approach has been pioneered in an industrial setting by Bicycle Therapeutics, bridging three cysteine residues to create large screening libraries of peptides with unusual fixed conformations.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Finally, Î²-turn dipeptide mimetics have proven useful for restricting the conformation of the peptide backbone and precisely mimicking the geometry of this secondary structural motif,<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> as demonstrated for a CGRP antagonist using the thioindolizine âBTDâ.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a></div></div><div id="sec6_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24">6.8 Solubility</h3><div class="NLM_p last">The latter stages of peptide optimization must involve determination of solubility and gelling properties toward achieving the desired pharmaceutical profile. Improvement of the physical properties is a largely empirical process, with some generally applicable trends: inclusion of hydrophilic and charged residues, replacement of unnecessary hydrophobic regions, and modulation of the isoelectric point to ensure sufficient charge at the desired formulation pH. A recent example demonstrated enhanced solubility of a glucagon analogue by the replacement of natural, hydrophobic, aromatic residues with 3- and 4-pyridylalanine as effective bioisosteres.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a></div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">7 Peptide Conjugates</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35677" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35677" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Many of the inherent properties of peptides make them attractive candidates for use as drug conjugates, including facile synthesis, high specificity and affinity, narrow pharmacokinetic distribution, and short half-life. The approaches that have received the most interest in drug discovery can readily be classified by strategic intent:<ul class="NLM_list-list_type-bullet"><li><p class="inline">A pharmacologically active peptide conjugated to another active molecule</p></li><li><p class="inline">An active peptide conjugated in order to modify its pharmacokinetic properties</p></li><li><p class="inline">A peptide used as a targeting agent for an active molecule</p></li><li><p class="inline">A peptide used as a trans-membrane delivery agent for an active molecule</p></li></ul></div><div class="NLM_p">In this section, the critical aspects of each of these major categories will be briefly summarized in the context of selected examples of interest.</div><div class="NLM_p">In diseases that have validated targets from multiple biological pathways, studies often find a synergistic therapeutic effect with combined administration.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> Direct conjugation of compatible active agents has advantages for clinical development; for a peptide, this compatibility generally requires the other agent to act extracellularly and have broadly similar pharmacological potency. Peptides are attractive molecular candidates for conjugation, usually providing easy synthetic access to an appropriate functional group spatially distinct from the binding pharmacophore and allowing an array of chemical conjugation strategies.</div><div class="NLM_p">Ipsenâs follow-up program to their somatostatin analogue lanreotide, used to suppress growth hormone (GH) release in acromegaly, has explored the use of small-moleculeâpeptide conjugates. Medical guidelines for these patients support both somatostatin and dopamine agonists as first-line treatments,<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> and the chimeric dual-agonist <b>3</b> (BIM-23A760,<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a><a class="ref internalNav" href="#fig32" aria-label="Figure 32">Figure 32</a>) was developed as a single polypharmacological agent.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> Structurally, <b>3</b> is a cyclic peptide containing a branching N-terminal lysine that has both amines capped with a thioether-linked ergoline-based small-molecule dopamine agonist (<a class="ref internalNav" href="#fig32" aria-label="Figure 32">Figure 32</a>). Conjugates in this series retained high affinity to somatostatin receptors-2 and -5 and dopamine receptor D2 (0.03, 42, and 15 nM, respectively, for <b>3</b>) and demonstrated robust GH suppression superior to an equimolar combination of three monospecific agonists in human ex vivo preclinical studies. However, Ipsenâs preliminary phase IIb data for <b>3</b> found only weak somatostatinergic activity in acromegaly patients, and the program was discontinued.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a></div><figure id="fig32" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0032.jpeg" id="gr32" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 32. Structure of <b>3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig32"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">CovXâs development of peptideâantibody fusion protein <b>4</b> (CVX-241<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a>) exemplifies both the first and second conjugation strategies listed above; dual pharmacology through the use of a pair of antagonist peptides targeting VEGF and Ang-2. respectively, and conjugation of both to a scaffold antibody (or CovX-Body) in order to confer increased half-life.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> In this example, the pharmacologically silent antibody acts to reduce plasma clearance by both preventing glomerular filtration (due to increased size) and preventing lysosomal degradation following nonspecific vascular endocytosis (due to the FcRn-binding recycling mechanism). A likely additional beneficial effect is reduction of enzymatic degradation of the peptides by steric occlusion of the plasma proteases. The dual targets of <b>4</b> are both established pro-angiogenic pathways in tumors, and evidence suggests simultaneous inhibition should produce an additive or synergistic effect. CovX-Bodies overcome the difficulties of site-specific conjugation to antibodies by the engineering of a single highly nucleophilic lysine in each of the Fab arms, which reacts with azetidinone-containing linkers in order to rapidly generate small-molecule and peptide conjugates in various possible combinations. Unfortunately, as with the Ipsen case above, the dual pharmacology concept did not translate into the clinic; a phase 1 trial in patients with advanced solid tumors was discontinued due to poor efficacy and an unexpectedly short half-life.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> While conceptually attractive, these polypharmacological conjugate approaches represent challenging discovery programs that must simultaneously deliver two or three diverse biological effects to achieve success.</div><div class="NLM_p">Many alternative conjugation approaches have been explored for peptide half-life extension, and the vibrant slate of GLP-1 agonists in clinical development for type 2 diabetes serves as an effective microcosm of the broader peptide field. The antibody conjugation approach has been successfully exploited here with Lillyâs dulaglutide,<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> but albumin binding is a more common and conceptually analogous strategy, similarly able to prevent glomerular filtration and take advantage of FcRn recycling.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> Albumin has a plasma half-life in humans of ca. 20 days, potentially allowing weekly-to-monthly dosing of the conjugate. GLP-1 analogues have been covalently attached to albumin through either recombinant fusion (GSKâs albiglutide)<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> or through the lone reactive cysteine-34 (Conjuchemâs CJC-1131<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a>). Alternatively, conjugation of GLP-1 analogues to an albumin-binding motif can achieve a similar pharmacokinetic effect, as the high albumin plasma concentration (600 Î¼M) results in very low levels of free conjugate even in examples with only a moderate binding affinity. These motifs can range from simple fatty acids (as in Novo Nordiskâs semaglutide)<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> to recombinant antibody domains (GSKâs exendin-AlbudAb GSK2374697<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a>). Finally, conjugation of the active peptide to a large, inert, polymeric ballast is again effective in minimizing renal clearance. PEG is the most widely used polymer across the peptide field and in marketed drugs,<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> yet its application currently divides opinions due to concerns over potential liabilities resulting from cellular accumulation and immunogenicity.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> Consequently, there is growing interest in biopolymer analogues such as XTEN<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> (including a GLP-1 agonist now known as NB-1001<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a>) or PASylation<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> (prolineâalanineâserine polymer) that have the additional advantages of recombinant production and monodispersity. Overall, conjugation approaches for half-life extension have proven highly effective in delivering drugs with both compliance-friendly dosing frequencies and continuous target coverage for enhancing efficacy. There are, however, significant optimization challenges, chiefly in retaining the pharmacological activity of the peptide while bound in vivo (covalently or not) to the macromolecule. To take maximal advantage of the multiweek plasma retention offered by these conjugation approaches, the active peptide must also be exceptionally stable to enzymatic degradation.</div><div class="NLM_p">The third distinct conjugation strategy defined above uses the availability of specific high-affinity peptides to target a molecule of interest to a specific receptor or protein in vivo. This encompasses the peptide analogues of antibodyâdrug conjugates, widely used in the oncology field to confine the powerful cytotoxicity of many small-molecule chemotherapeutics to ideally just the tumor cells, thus substantially mitigating the severe side effects that conventionally afflict these patients. Zoptarelin doxorubicin (AEterna Zentaris) uses a peptide luteinizing hormone-releasing hormone (LHRH) receptor agonist to bind, internalize, and deliver a conjugated anthracycline DNA-intercalating cytotoxic agent (<a class="ref internalNav" href="#fig33" aria-label="Figure 33">Figure 33</a>a).<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> This receptor is aberrantly present on the cell surface of a various tumor types, and the conjugate drug is currently being evaluated in a phase III trial for endometrial cancer.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> In an adjacent approach, <sup>90</sup>Y-edotreotide (Molecular Insight) is a targeted radiotherapeutic, comprising a chelate-conjugated somatostatin analogue complexed to a high-energy beta-emitting yttrium-90 atom (<a class="ref internalNav" href="#fig33" aria-label="Figure 33">Figure 33</a>b).<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> A phase I trial is underway in a variety of somatostatin-receptor-positive solid tumors.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> Peptide-targeting can also be a useful diagnostic tool, exemplified by Blaze Bioscienceâs innovative âTumor Paintâ conjugate BLZ-100,<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> which uses a scorpion chlorotoxin peptide with high affinity for tumor-specific ion channels to label these cells with a near-infrared dye.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> This conjugate is currently in phase I clinical trials to assist in the complete and precise surgical excision of various tumor types through real-time visualization.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> The specific targeting of integrins by âRGDâ peptides, a therapeutic strategy that with Merck KGaAâs cilengitide has recently stalled in the clinic,<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> is widely applied for diagnostic purposes, including PET imaging of tumor angiogenesis using conjugates containing <sup>18</sup>F or <sup>68</sup>Ga.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> Future discovery of new targeting peptides may be significantly enhanced by in vivo phage display approaches, where entire phage libraries are administered to animals or humans, and biopsies of the target tissue reveal accumulation of specific sequences of interest.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a></div><figure id="fig33" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0033.jpeg" id="gr33" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 33. Structures of (a) zoptarelin doxorubicin and (b) <sup>90</sup>Y-edotreotide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The fourth and final conjugation strategy considered here is the use of cell-penetrating peptides (CPPs) to deliver covalently bound active molecules, including large proteins and nucleic acids, to their intracellular targets.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> The majority of research in this large and active field uses amphipathic or polycationic peptides such as TAT, where the membrane translocation mechanism is poorly understood and likely occurs through multiple pathways.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> In general, these CPPs are nonspecific, require high extracellular concentrations (>5 Î¼M), and lead to the cytoplasmic delivery of only a small percentage of their cargo. Nonetheless, a growing set of CPPs have demonstrated clinical efficacy;<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> NoNO Inc.âs NA-1<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> (TAT conjugated to a peptidic inhibitor of NMDAR-pDP95 (<a class="ref internalNav" href="#fig34" aria-label="Figure 34">Figure 34</a>)) was recently found to be neuroprotective in a phase II trial of subarachnoid hemorrhage.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> Diverse CPP structures and strategies are currently under preclinical investigation, and evidence of targeted and high-yielding cytoplasmic delivery using submicromolar extracellular concentrations will be of broad interest to the drug discovery community.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a></div><figure id="fig34" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0034.jpeg" id="gr34" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 34. Structure and sequence of NA-1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig34"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The synthetic challenges in pursuing a conjugation strategy have undoubtedly been eased by the growing arsenal of bioorthogonal chemical techniques that allow controlled and efficient conjugation of unprotected peptides to their chimeric partners. Where both components are chemically synthesized, the alkeneâazide Huisgen cycloaddition remains the most reliable and valuable approach.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> Where one or both partners are recombinantly produced, there is now a remarkable toolbox of powerful methods,<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> including next-generation reagents for cysteine alkylation,<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> oxidation/oxime ligation,<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> sequence-encoded reactivity,<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> sortase<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> and ligase tags (see <a class="ref internalNav" href="#sec3_4" aria-label="section 3.4">section 3.4</a>), inteins,<a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a> and genetic encoding of unnatural functionalized amino acids.<a onclick="showRef(event, 'ref16 ref189'); return false;" href="javascript:void(0);" class="ref ref16 ref189">(16, 189)</a> These advances should accelerate the discovery, optimization, and preclinical evaluation of peptide conjugates and ultimately increase the number of bifunctional therapeutics entering clinical development.</div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">8 Predicting and Preventing Immunogenicity</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56827" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56827" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The potential for peptides and proteins to elicit an immunogenic response has historically existed as a capricious specter haunting drug development scientists, intangible to their optimization process and often materializing only in late-stage clinical trials. Production of antidrug antibodies is the most common manifestation and can significantly reduce drug efficacy and alter the PK profile.<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> As peptide drug discovery increasingly moves toward small proteins and thus into canonically immunogenic molecular space, this becomes an important criterion for the preclinical derisking of candidates. The complexity and variability of the immunization process is beyond the scope of this review, and attempts to delineate the critical structural factors have failed to provide generally applicable guidelines for the design of nonimmunogenic peptides and proteins; indeed, many axioms have subsequently been disproven or disputed:<a onclick="showRef(event, 'ref191 ref192'); return false;" href="javascript:void(0);" class="ref ref191 ref192">(191, 192)</a><ul class="NLM_list-list_type-bullet"><li><p class="inline">First, shorter peptides are not always poor immunogens. Roche and Ipsenâs projected GLP-1 blockbuster taspoglutide failed in phase III with an antibody response in almost half of patients<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> and exemplifies the apparent arbitrariness of immunogenicity by sharing almost the entirety of its structure with successful competitor GLP-1 analogues that avoided a similar outcome. Conversely, a mild antibody response did not prevent the GLP-1 species homologue exenatide from achieving market success.<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a></p></li><li><p class="inline">Second, although self-derived therapeutics are not necessarily excluded due to central immune tolerance, this theory has also shaped the GLP-1 peptide field, with Novo Nordiskâs successful development of liraglutide and semaglutide centering on the design criterion to remain as similar to native GLP-1 as possible to avoid immunogenicity.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> The critical hazard facing this strategy is the potential for antidrug antibodies that cross react with the natural ligand, potentially exacerbating the target disease or causing serious side effects.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a></p></li><li><p class="inline">From the opposing angle, there is also debate over whether unnatural peptides can be proteolytically processed and presented as antigens in the first steps of the immune response.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> Examples of all-<span class="smallcaps smallerCapital">d</span> peptides have been separately reported to be immunogenically silent and active.<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a></p></li></ul></div><div class="NLM_p last">There has however been significant innovation and success in recent years in developing and validating a hierarchy of empirical immunogenicity assays and models that have varying levels of complexity and predictive power.<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> Binding of peptide to the major histocompatibility complex (MHC) is the very first step in the process and can be determined either in vitro or increasingly in silico, providing a relatively cheap and high throughput screening tool.<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> These methods inevitably result in a high false positive rate, which the most useful current assays minimize by moving downstream to measure the subsequent CD4+ T-cell activation ex vivo in donor peripheral blood mononuclear cells, albeit with added cost and lower throughput.<a onclick="showRef(event, 'ref191 ref192'); return false;" href="javascript:void(0);" class="ref ref191 ref192">(191, 192)</a> A leading example of this technology is Antitopeâs EpiScreen, which has demonstrated a good correlation between T-cell activation and clinically observed immunogenicity<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a> and represents the current industry standard for preclinical assessment. Alternative versions of these assays use epitope mapping of larger peptides to identify the sequences that either contribute to MHC affinity or contact the T-cell receptors.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> This information greatly assists the process of deimmunization, where the candidate can ideally be optimized to retain activity with minimal immunogenicity by the judicious alteration of a few key residues. It has also been demonstrated that shielding the critical region by glycosylation<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> or PEG<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a> conjugation can prove effective at reducing immunogenicity. Looking forward, the development of low-cost, predictive in vivo models is the focus of much research, and recent advances point toward a general model using mice that have been transplanted with a fully functional human adaptive immune system.<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> The rapid progress in this area is demystifying and disarming the immunogenic response as a source of late-stage risk and should lead to increased clinical success for peptides and proteins alike.</div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">9 Peptide Formulation and Delivery</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26816" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26816" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">This final section will discuss recent advances in peptide formulation and delivery and by necessity only briefly touch on a number of large, vibrant fields of research, each of which has deservedly warranted many comprehensive reviews.<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a></div><div class="NLM_p">Parenteral administration is the canonical delivery method for therapeutic peptides, physically piercing the membrane barriers through which peptides are very poorly absorbed. However, further challenges remain, pre- and postinjection, in achieving both the desired pharmacokinetic profile and high patient compliance.</div><div class="NLM_p">One critical decision is the choice of dosage form: liquid formulation or solid powder. Both share requirements of aqueous solubility and low solution viscosity to allow the use of minimal volumes and narrow-bore âpain-freeâ needles. Liquid formulations are preferred for subcutaneously self-administered drugs, averting the need for patients to perform a reconstitution step immediately prior to injection yet have the additional obligation of multiyear solution stability. Classical formulation optimization of pH, buffer composition, and additives can in many cases achieve this goal but may be rendered unnecessary by recent technological advances in dual-chamber âmixing pensâ that combine patient-friendly reconstitution with highly stable solid powder products.<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a></div><div class="NLM_p">The majority of peptide formulation and delivery platforms have been founded with the goal of extending the circulating half-life of the therapeutic peptide, and <a class="ref internalNav" href="#sec7" aria-label="section 7">section 7</a> discussed albumin and other discrete conjugation approaches that essentially result in a long-acting plasma depot. It is important to note the fundamental difference between a true formulation approach and those examples above and below that involve conjugation to the therapeutic peptide and the concomitant creation of a new chemical entity that must face the full gauntlet of regulatory barriers. Clinical and market success has been achieved using slow-release subcutaneous polymeric depot technologies, in particular suspensions of PLGA (poly(lactic-<i>co</i>-glycolic acid)) microspheres,<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a> with Abbvieâs leuprolide formulation Lupron Depot as the prototypical example approved nearly 30 years ago. PLGA polymers offer proven safety and biocompatibility, predictable degradation, and sufficient encapsulative capacity for 3â6 month dosing frequencies. The release kinetics of PLGA depots depend heavily on the precise conditions of manufacture, composition, and cargo peptide and usually demonstrate an initial âburst phaseâ corresponding to the release of surface-absorbed or solvent-accessible peptide; in some contexts, this has been associated with adverse events.<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a> Many subsequent approaches have targeted tighter control of peptide release, including the incorporation of vitamin-E into the hydrophilic polymers to create dense hydrophobic domains that more effectively trap the peptides.<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a> Direct drugâpolymer conjugation allows the strictest control of peptide pharmacokinetics, particularly in combination with a highly predictable slow-release mechanism;<a onclick="showRef(event, 'ref207'); return false;" href="javascript:void(0);" class="ref ref207">(207)</a> ProLynxâs technology uses a tunable Î²-elimination motif to effect consistent drug release dependent only on the pH of the injection site, reaching theoretical half-lives of over a year.<a onclick="showRef(event, 'ref208'); return false;" href="javascript:void(0);" class="ref ref208">(208)</a></div><div class="NLM_p">An alternative approach to depot formation is self-assembly of the peptide itself. Ferringâs GnRH agonist degarelix demonstrates a remarkable subcutaneous half-life that was found to derive from the rapid formation and slow dissolution of fibril structures.<a onclick="showRef(event, 'ref209'); return false;" href="javascript:void(0);" class="ref ref209">(209)</a> Ipsen made a similar serendipitous discovery for somatostatin-analogue lanreotide; under specific conditions, the peptide forms helicoidal nanotubes that proved highly effective as a subcutaneous depot termed Autogel.<a onclick="showRef(event, 'ref210'); return false;" href="javascript:void(0);" class="ref ref210">(210)</a> The sustained release allowed monthly dosing, which had not proved possible with a PLGA formulation. A potentially general approach from PhaseBio has demonstrated that self-assembly can be a transferable property, conjugating an optimized elastin domain to therapeutic peptides and retaining precise control over the gelling properties. By selecting a gel-phase transition at slightly below physiological temperatures, these conjugates can be injected in solution only to immediately form gel depots in the subcutaneous space.<a onclick="showRef(event, 'ref211'); return false;" href="javascript:void(0);" class="ref ref211">(211)</a></div><div class="NLM_p">There is also growing interest in technological solutions such as implantable osmotic pumps, which offer controllable zero-order release kinetics for up to a year. These devices use an osmotic gradient to draw in water into one chamber, incrementally driving a piston to expel the drug from an adjacent reservoir of limited capacity.<a onclick="showRef(event, 'ref212'); return false;" href="javascript:void(0);" class="ref ref212">(212)</a> Similarly, a range of wearable or implanted electronic pumps are also at various stages of development. The consistency and guaranteed compliance is of course significantly offset by the inconvenience of the surgical procedures required for both the initial installation and subsequent reservoir replenishment or replacement.<a onclick="showRef(event, 'ref213'); return false;" href="javascript:void(0);" class="ref ref213">(213)</a> These technologies have therefore seen the greatest interest from the diabetes field, where long-term, precise, and reliable delivery of small doses of potent hormones is a necessity. The most advanced electronic devices in this field act as an artificial pancreas, incorporating continuous glucose monitoring of the patient to automatically direct a pair of infusion pumps to deliver the appropriate dose of either insulin or glucagon as required, thereby preventing both hyper- and hypoglycemia.<a onclick="showRef(event, 'ref214'); return false;" href="javascript:void(0);" class="ref ref214">(214)</a></div><div class="NLM_p">It is of course oral delivery of peptides that has long been sought after as a truly transformative development for the industry, allowing effective competition with small molecules and access to indications where the expected patient compliance with repeated injections is low. The combined proteolytic and absorptive physiological barriers constitute a powerful defense designed to prevent foreign proteins from entering the body, and both must be evaded to achieve systemic bioavailability.<a onclick="showRef(event, 'ref215'); return false;" href="javascript:void(0);" class="ref ref215">(215)</a> The remainder of this section explores the critical elements required through selected examples of marketed oral peptides, those in clinical development, and exciting new technological approaches.</div><div class="NLM_p">Ferringâs desmopressin, an analogue of the antidiuretic hormone vasopressin, is administered orally despite a bioavailability of just 0.1%. In this example, the low intrinsic absorption is sufficient to achieve therapeutic doses due to the very high picomolar potency.<a onclick="showRef(event, 'ref216'); return false;" href="javascript:void(0);" class="ref ref216">(216)</a> In evading the proteolytic barrier, desmopressin exemplifies some of the basic strategies also discussed in <a class="ref internalNav" href="#sec6" aria-label="section 6">section 6</a> for improving plasma stability: cyclization, modification of the termini, and conversion of a labile residue to the <span class="smallcaps smallerCapital">d</span>-enantiomer. As referenced in that section and extensively covered in a recent review,<a onclick="showRef(event, 'ref217'); return false;" href="javascript:void(0);" class="ref ref217">(217)</a> there is renewed interest in general approaches to the discovery and design of membrane-permeable (and thus orally bioavailable) cyclic peptides, using <i>N</i>-methylation and lipophilic side chains to effectively raise the log <i>P</i> to the required level. It remains to be seen whether the resulting permeable peptides will successfully acquire the desirable molecular properties of small molecule drugs without gaining the pharmacological and solubility liabilities that correlate with increased lipophilicity;<a onclick="showRef(event, 'ref218'); return false;" href="javascript:void(0);" class="ref ref218">(218)</a> a more elegant approach temporarily shields peptidic hydrophilicity via intramolecular hydrogen-bonding, yet it may be difficult to apply this as a general strategy when hydrophilic side chains or multiple backbone interactions are often critical for biological activity.<a onclick="showRef(event, 'ref219'); return false;" href="javascript:void(0);" class="ref ref219">(219)</a></div><div class="NLM_p">Of course, minimal oral bioavailability can be a desired feature for drug targets in the intestinal lumen. As previously mentioned, linaclotide is an agonist analogue of guanylin that targets GC-C in the colon, stimulating the secretion of water and thus alleviating constipation, with undetectable systemic exposure. Linaclotideâs compact structure ensures improve protease stability, rigidified by three disulfide bonds within the 14-mer sequence.<a onclick="showRef(event, 'ref220'); return false;" href="javascript:void(0);" class="ref ref220">(220)</a></div><div class="NLM_p">Looking to the current slate of peptides in clinical development,<a onclick="showRef(event, 'ref221'); return false;" href="javascript:void(0);" class="ref ref221">(221)</a> the oral formulation of Novo Nordiskâs GLP-1 analogue semaglutide exemplifies the current favored technological approach and has the potential to make a considerable impact on the peptide field. This peptide was developed as a long-acting follow-up to Novoâs current blockbuster liraglutide, addressing a known proteolytic liability and optimizing a conjugated albumin-binding fatty acid in order to achieve a plasma half-life sufficient for weekly subcutaneous administration.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> Novo then surprised the field by immediately by following up these successful diabetes trials with an oral formulation of this linear 31-mer peptide, encapsulated with Emisphereâs proprietary technology.<a onclick="showRef(event, 'ref222'); return false;" href="javascript:void(0);" class="ref ref222">(222)</a> A range of specialist companies have developed oral peptide formulations using similar combinations of enteric coatings, nonspecific protease inhibitors and, most crucially, permeation enhancers,<a onclick="showRef(event, 'ref223'); return false;" href="javascript:void(0);" class="ref ref223">(223)</a> in this case the sodium caprylate analogue SNAC. Despite concerns over epithelial damage and the effect of any long-term increase in intestinal permeability, SNAC has a very high no-observed-effect-level in rodents and primates and is already marketed for delivery of vitamin B12.<a onclick="showRef(event, 'ref224'); return false;" href="javascript:void(0);" class="ref ref224">(224)</a> Phase III trials for oral semaglutide are ongoing, and Novo have reported comparable efficacy to the weekly 1 mg subcutaneous dosing with a daily 20â40 mg oral dose and no new safety signals.<a onclick="showRef(event, 'ref225'); return false;" href="javascript:void(0);" class="ref ref225">(225)</a> Successful realization of oral semaglutideâs immense market potential over the next decade would demonstrate both the biological and economic feasibility of oral administration of long synthetic peptides and likely spur significant interest and investment in related approaches. The future of oral peptide delivery may ultimately involve cross-disciplinary technological solutions that can invoke themes of medical science fiction yet represent relatively simple engineering challenges. Raniâs ârobotic pillâ uses an in-built chemical reaction to propel an array of peptide-coated sugar microneedles through the intestinal wall and has achieved bioavailability values comparable to the analogous subcutaneous injection.<a onclick="showRef(event, 'ref226'); return false;" href="javascript:void(0);" class="ref ref226">(226)</a> Also successfully used for the delivery of insulin,<a onclick="showRef(event, 'ref227'); return false;" href="javascript:void(0);" class="ref ref227">(227)</a> oral microneedle approaches have been demonstrated to cause minimal tissue damage,<a onclick="showRef(event, 'ref227'); return false;" href="javascript:void(0);" class="ref ref227">(227)</a> and clinical success of this approach could open an interesting new frontier in peptide delivery.</div><div class="NLM_p last">A final route of interest is nasal/pulmonary delivery, which exhibits the twin advantages of a comparatively thin, porous endothelial barrier and high vascularization; the rapid absorption results in an early <i>T</i><sub>max</sub> comparable to subcutaneous delivery.<a onclick="showRef(event, 'ref228'); return false;" href="javascript:void(0);" class="ref ref228">(228)</a> Desmopressinâs bioavailability increases 20â50-fold over oral administration when delivered as a nasal spray to 3â5%.<a onclick="showRef(event, 'ref229 ref230'); return false;" href="javascript:void(0);" class="ref ref229 ref230">(229, 230)</a> The pulmonary route has proven an area of significant interest and controversy in the insulin field, where a variety of companies and technologies are vying to offer what has been a much-anticipated noninvasive alternative product.<a onclick="showRef(event, 'ref231'); return false;" href="javascript:void(0);" class="ref ref231">(231)</a> However, despite achieving bioavailability values of over 10%, the market failure of Exubera (Pfizer),<a onclick="showRef(event, 'ref232'); return false;" href="javascript:void(0);" class="ref ref232">(232)</a> and market troubles of Afrezza (Sanofi/Mannkind)<a onclick="showRef(event, 'ref233'); return false;" href="javascript:void(0);" class="ref ref233">(233)</a> for a complex blend of reasons demonstrate the difficulties in predicting success and compliance, even where the route of administration is theoretically more attractive.<a onclick="showRef(event, 'ref234'); return false;" href="javascript:void(0);" class="ref ref234">(234)</a> As with oral dosing, both patient variation in bioavailability and the impact of chronic delivery to sensitive mucosa are significant concerns.<a onclick="showRef(event, 'ref230'); return false;" href="javascript:void(0);" class="ref ref230">(230)</a></div></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">10 Summary</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00361" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00361" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The field of peptide drug discovery has never been more active nor had a more promising future, as evidenced by the vast array of new technologies that are being employed to facilitate the discovery of new peptide-based drugs, addressing a wide variety of novel biological targets in many therapeutic areas. We hope that this review has provided a perspective for the reader to appreciate the resurgence that this field has undergone during the past decade.</div><div class="NLM_p last">The ultimate measure of success in this field remains, however, the number and impact of peptide drugs approved. Drug development is a long, complicated process, with a cumulative clinical success rate of ca. 10%,<a onclick="showRef(event, 'ref235'); return false;" href="javascript:void(0);" class="ref ref235">(235)</a> yet with the dramatic increase in new peptide therapeutics entering the clinic in the past decade, we can confidently predict that the number of approved peptide drugs will increase accordingly, providing patients with innovative new treatments across a wide range of therapeutic areas.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b00318" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07334" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07334" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John M. Nuss</span> - <span class="hlFld-Affiliation affiliation">Ferring Research Institute, 4245 Sorrento Valley Boulevard, San Diego, California 92121, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1213-3233" title="Orcid link">http://orcid.org/0000-0003-1213-3233</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#0a60647f79794a657a7a63666b6424696567"><span class="__cf_email__" data-cfemail="acc6c2d9dfdfecc3dcdcc5c0cdc282cfc3c1">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Antoine Henninot</span> - <span class="hlFld-Affiliation affiliation">Ferring Research Institute, 4245 Sorrento Valley Boulevard, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James C. Collins</span> - <span class="hlFld-Affiliation affiliation">Ferring Research Institute, 4245 Sorrento Valley Boulevard, San Diego, California 92121, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>A.H. and J.C.C. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58215" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58215" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Antoine Henninot</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=BIO-d7e2165-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Antoine Henninot</b> obtained his M.Sc. at the UniversitÃ© de Lille 1 in 2011 and his Pharm.D. at the UniversitÃ© de Lille 2 in 2012. He stayed on to complete his Ph.D. (2015) in medicinal chemistry and chemical biology, under the supervision of Prof. Benoit Deprez and in collaboration with LFB Biotechnologie, working on identifying modulators of antibody post-translational modification. He joined the Chemistry department at Ferring Research Institute in San Diego as a postdoctoral researcher in 2013 before transitioning to Scientist.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="3637" class="article__inlineFigure"><h2 class="fig-label">James C. Collins</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=BIO-d7e2170-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>James C. Collins</b> obtained his M.Sc. (2006) and Ph.D. (2011) in organic and medicinal chemistry at Imperial College London under the supervision of Prof. Alan Armstrong, focusing on phosphatase inhibitors. He carried out postdoctoral research at The Scripps Research Institute in La Jolla, on macrocyclizations with Prof. Keith James, and on glycosylated vancomycin analogues with Prof. Dale Boger, before taking up his current position in the Chemistry department at Ferring Research Institute in San Diego in 2013.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="3637" class="article__inlineFigure"><h2 class="fig-label">James C. Collins</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=BIO-d7e2175-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>John M. Nuss</b> obtained his B.S. in chemistry from the University of Kansas and his Ph.D. in organic chemistry at the University of Wisconsin, working in the laboratory of Prof. Howard Zimmerman. Following an NIH postdoctoral fellowship at Stanford University with Prof. Paul Wender, he joined the faculty of UC Riverside. After moving to the pharmaceutical industry in 1994, he has led chemistry and discovery groups at Chiron, Exelixis, and Ferring Research Institute that have been responsible for the discovery of two marketed drugs, Cabozantinib (Cometriq/Cabometyx) and Cobimetinib (Cotellic) as well as more than 25 other clinical candidates. He is currently CSO of Oppilan Pharma, Encinitas, CA.</p></figure></div><div class="ack" id="ACK-d7e2180-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61677" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61677" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are grateful to Dr. Jolene Lau at Ferring Research Institute for her contributions to this article.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i34" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i34"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i35" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i35"> Abbreviations Used</h2><tr><td class="NLM_term">aa</td><td class="NLM_def"><p class="first last">amino acid</p></td></tr><tr><td class="NLM_term">Ang</td><td class="NLM_def"><p class="first last">angiotensin</p></td></tr><tr><td class="NLM_term">AT1R</td><td class="NLM_def"><p class="first last">angiotensin II type 1 receptor</p></td></tr><tr><td class="NLM_term">CPP</td><td class="NLM_def"><p class="first last">cell-penetrating peptides</p></td></tr><tr><td class="NLM_term">GLP-1</td><td class="NLM_def"><p class="first last">glucagon-like peptide 1</p></td></tr><tr><td class="NLM_term">GnRH</td><td class="NLM_def"><p class="first last">gondotrophin releasing hormone</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein coupled receptor</p></td></tr><tr><td class="NLM_term">Epe</td><td class="NLM_def"><p class="first last">3-ethyl-3-pentyl</p></td></tr><tr><td class="NLM_term">NGS</td><td class="NLM_def"><p class="first last">next-generation sequencing</p></td></tr><tr><td class="NLM_term">NRSP</td><td class="NLM_def"><p class="first last">nonribosomally synthesized peptides</p></td></tr><tr><td class="NLM_term">MHC</td><td class="NLM_def"><p class="first last">major histocompatibility complex</p></td></tr><tr><td class="NLM_term">PASylation</td><td class="NLM_def"><p class="first last">proline-alanine-serine polymer</p></td></tr><tr><td class="NLM_term">PTH</td><td class="NLM_def"><p class="first last">parathyroid hormone</p></td></tr><tr><td class="NLM_term">RP</td><td class="NLM_def"><p class="first last">reverse phase</p></td></tr><tr><td class="NLM_term">SEPs</td><td class="NLM_def"><p class="first last">smORF-encoded polypeptides</p></td></tr><tr><td class="NLM_term">smORF</td><td class="NLM_def"><p class="first last">small open reading frames</p></td></tr><tr><td class="NLM_term">SPPS</td><td class="NLM_def"><p class="first last">solid-phase peptide synthesis</p></td></tr><tr><td class="NLM_term">TCEP</td><td class="NLM_def"><p class="first last">tris(2-carboxyethyl)phosphine</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36417" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36417" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 235 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Weiland, T.; Bodanszky, M.</span> <span class="citation_source-book">The World of Peptides: A Brief History of Peptide Chemistry</span>; <span class="NLM_publisher-name">Springer Verlag</span>: <span class="NLM_publisher-loc">Berlin-Heidelberg</span>,<span class="NLM_x"> </span><span class="NLM_year">1991</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1007%2F978-3-642-75850-8" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1991&author=T.+Weiland&author=M.+Bodanszky&title=The+World+of+Peptides%3A+A+Brief+History+of+Peptide+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-75850-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-642-75850-8%26sid%3Dliteratum%253Aachs%26aulast%3DWeiland%26aufirst%3DT.%26btitle%3DThe%2520World%2520of%2520Peptides%253A%2520A%2520Brief%2520History%2520of%2520Peptide%2520Chemistry%26pub%3DSpringer%2520Verlag%26date%3D1991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kastin, A.</span> <span class="citation_source-book">Handbook of Biologically Active Peptides</span>, <span class="NLM_edition">2nd</span> ed.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">Cambridge, MA</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=A.+Kastin&title=Handbook+of+Biologically+Active+Peptides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DKastin%26aufirst%3DA.%26btitle%3DHandbook%2520of%2520Biologically%2520Active%2520Peptides%26pub%3DAcademic%2520Press%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Bliss, M.</span> <span class="citation_source-book">Discovery of Insulin</span>; <span class="NLM_publisher-name">University of Chicago Press</span>: <span class="NLM_publisher-loc">Chicago, IL</span>,<span class="NLM_x"> </span><span class="NLM_year">1982</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1982&author=M.+Bliss&title=Discovery+of+Insulin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBliss%26aufirst%3DM.%26btitle%3DDiscovery%2520of%2520Insulin%26pub%3DUniversity%2520of%2520Chicago%2520Press%26date%3D1982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span>Lilly to Discontinue Four Insulin Products. <span class="NLM_publisher-name">Eli Lilly</span>: <span class="NLM_publisher-loc">Indianapolis, IN</span>, July 6,<span class="NLM_x"> </span><span class="NLM_year">2005</span><span class="NLM_x">; </span><a href="https://investor.lilly.com/releasedetail.cfm?ReleaseID=168048" class="extLink">https://investor.lilly.com/releasedetail.cfm?ReleaseID=168048</a> (accessed January 17, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lilly+to+Discontinue+Four+Insulin+Products.+Eli+Lilly%3A+Indianapolis%2C+IN%2C+July+6%2C+2005%3B+https%3A%2F%2Finvestor.lilly.com%2Freleasedetail.cfm%3FReleaseID%3D168048+%28accessed+January+17%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DLilly%2520to%2520Discontinue%2520Four%2520Insulin%2520Products%26pub%3DEli%2520Lilly%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mathieu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benhalima, K.</span><span> </span><span class="NLM_article-title">Insulin analogues in type 1 diabetes mellitus: getting better all the time</span> <span class="citation_source-journal">Nat. Rev. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="refDoi">Â DOI: 10.1038/nrendo.2017.39</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnrendo.2017.39" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=28429780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvVCjtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=385&author=C.+Mathieuauthor=P.+Gillardauthor=K.+Benhalima&title=Insulin+analogues+in+type+1+diabetes+mellitus%3A+getting+better+all+the+time&doi=10.1038%2Fnrendo.2017.39"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin analogues in type 1 diabetes mellitus: getting better all the time</span></div><div class="casAuthors">Mathieu, Chantal; Gillard, Pieter; Benhalima, Katrien</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">385-399</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The treatment of type 1 diabetes mellitus consists of external replacement of the functions of Î² cells in an attempt to achieve blood levels of glucose as close to the normal range as possible.  This approach means that glucose sensing needs to be replaced and levels of insulin need to mimic physiol. insulin-action profiles, including basal coverage and changes around meals.  Training and educating patients are crucial for the achievement of good glycemic control, but having insulin prepns. with action profiles that provide stable basal insulin coverage and appropriate mealtime insulin peaks helps people with type 1 diabetes mellitus to live active lives without sacrificing tight glycemic control.  Insulin analogs enable patients to achieve this goal, as some have fast action profiles, and some have very slow action profiles, which gives people with type 1 diabetes mellitus the tools to achieve dynamic insulin-action profiles that enable tight glycemic control with a risk of hypoglycemia that is lower than that with human short-acting and long-acting insulins.  This Review discusses the established and novel insulin analogs that are used to treat patients with type 1 diabetes mellitus and provides insights into the future development of insulin analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7C5jVzlISF7Vg90H21EOLACvtfcHk0ljl-irBBESDvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvVCjtbk%253D&md5=648cec804f6950d6a1b80c1046d431b3</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2017.39&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2017.39%26sid%3Dliteratum%253Aachs%26aulast%3DMathieu%26aufirst%3DC.%26aulast%3DGillard%26aufirst%3DP.%26aulast%3DBenhalima%26aufirst%3DK.%26atitle%3DInsulin%2520analogues%2520in%2520type%25201%2520diabetes%2520mellitus%253A%2520getting%2520better%2520all%2520the%2520time%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2017%26volume%3D13%26spage%3D385%26doi%3D10.1038%2Fnrendo.2017.39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zaykov, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMarchi, R. D.</span><span> </span><span class="NLM_article-title">Pursuit of a perfect insulin</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">425</span><span class="NLM_x">â</span> <span class="NLM_lpage">439</span><span class="refDoi">Â DOI: 10.1038/nrd.2015.36</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnrd.2015.36" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26988411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XksVKksbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=425-439&author=A.+N.+Zaykovauthor=J.+P.+Mayerauthor=R.+D.+DiMarchi&title=Pursuit+of+a+perfect+insulin&doi=10.1038%2Fnrd.2015.36"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Pursuit of a perfect insulin</span></div><div class="casAuthors">Zaykov, Alexander N.; Mayer, John P.; DiMarchi, Richard D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">425-439</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Insulin remains indispensable in the treatment of diabetes, but its use is hampered by its narrow therapeutic index.  Although advances in peptide chem. and recombinant DNA-based macromol. synthesis have enabled the synthesis of structurally optimized insulin analogs, the growing epidemics of obesity and diabetes have emphasized the need for diabetes therapies that are more efficacious, safe and convenient.  Accordingly, a broad set of drug candidates, targeting hyperglycemia plus other disease abnormalities, is now progressing through the clinic.  The development of an insulin therapy that is responsive to glucose concn. remains an ultimate goal, with initial prototypes now reaching the proof-of-concept stage.  Simultaneously, the first alternatives to injectable delivery have progressed to registration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4KBUWswfZN7Vg90H21EOLACvtfcHk0liqd3_UbZxBbQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksVKksbs%253D&md5=1e4c4474fedd4b73d88c815e9b1a9265</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2015.36&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2015.36%26sid%3Dliteratum%253Aachs%26aulast%3DZaykov%26aufirst%3DA.%2BN.%26aulast%3DMayer%26aufirst%3DJ.%2BP.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26atitle%3DPursuit%2520of%2520a%2520perfect%2520insulin%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D425%26epage%3D439%26doi%3D10.1038%2Fnrd.2015.36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Lau, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, M. K.</span><span> </span><span class="NLM_article-title">Therapeutic peptides: Historical perspectives, current development trends, and future directions</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">in press</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=in+press&author=J.+L.+Lauauthor=M.+K.+Dunn&title=Therapeutic+peptides%3A+Historical+perspectives%2C+current+development+trends%2C+and+future+directions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLau%26aufirst%3DJ.%2BL.%26aulast%3DDunn%26aufirst%3DM.%2BK.%26atitle%3DTherapeutic%2520peptides%253A%2520Historical%2520perspectives%252C%2520current%2520development%2520trends%252C%2520and%2520future%2520directions%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3Din%2520press" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Scannell, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanckley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boldon, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warrington, B.</span><span> </span><span class="NLM_article-title">Diagnosing the decline in pharmaceutical R&D efficiency</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">â</span> <span class="NLM_lpage">200</span><span class="refDoi">Â DOI: 10.1038/nrd3681</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnrd3681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=22378269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38XivFyhtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=191-200&author=J.+W.+Scannellauthor=A.+Blanckleyauthor=H.+Boldonauthor=B.+Warrington&title=Diagnosing+the+decline+in+pharmaceutical+R%26D+efficiency&doi=10.1038%2Fnrd3681"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnosing the decline in pharmaceutical R&D efficiency</span></div><div class="casAuthors">Scannell, Jack W.; Blanckley, Alex; Boldon, Helen; Warrington, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">191-200</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The past 60 years have seen huge advances in many of the scientific, technol. and managerial factors that should tend to raise the efficiency of com. drug research and development (RD).  Yet the no. of new drugs approved per billion US dollars spent on RD has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms.  There have been many proposed solns. to the problem of declining RD efficiency.  However, their apparent lack of impact so far and the contrast between improving inputs and declining output in terms of the no. of new drugs make it sensible to ask whether the underlying problems have been correctly diagnosed.  Here, we discuss four factors that we consider to be primary causes, which we call the 'better than the Beatles' problem; the 'cautious regulator' problem; the 'throw money at it' tendency; and the 'basic research-brute force' bias.  Our aim is to provoke a more systematic anal. of the causes of the decline in RD efficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5e_81DC6r8LVg90H21EOLACvtfcHk0liqd3_UbZxBbQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivFyhtrY%253D&md5=db3e4548260e55f47a9964e8d1b216fd</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrd3681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3681%26sid%3Dliteratum%253Aachs%26aulast%3DScannell%26aufirst%3DJ.%2BW.%26aulast%3DBlanckley%26aufirst%3DA.%26aulast%3DBoldon%26aufirst%3DH.%26aulast%3DWarrington%26aufirst%3DB.%26atitle%3DDiagnosing%2520the%2520decline%2520in%2520pharmaceutical%2520R%2526D%2520efficiency%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D191%26epage%3D200%26doi%3D10.1038%2Fnrd3681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span>The CMR International Pharmaceutical R&D Factbook; <span class="NLM_publisher-name">Thomson-Reuters</span>: <span class="NLM_publisher-loc">Philadelphia</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="http://cmr.thomsonreuters.com/services/factbook/" class="extLink">http://cmr.thomsonreuters.com/services/factbook/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+CMR+International+Pharmaceutical+R%26D+Factbook%3B+Thomson-Reuters%3A+Philadelphia%2C+2015%3B+http%3A%2F%2Fcmr.thomsonreuters.com%2Fservices%2Ffactbook%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520CMR%2520International%2520Pharmaceutical%2520R%2526D%2520Factbook%26pub%3DThomson-Reuters%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span>Peptide Therapeutics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012â2018; <span class="NLM_publisher-name">Transparency Market Research</span>: <span class="NLM_publisher-loc">Albany, NY</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://www.transparencymarketresearch.com/peptide-therapeutics-market.html" class="extLink">http://www.transparencymarketresearch.com/peptide-therapeutics-market.html</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Peptide+Therapeutics+Market%3A+Global+Industry+Analysis%2C+Size%2C+Share%2C+Growth%2C+Trends+and+Forecast+2012%E2%80%932018%3B+Transparency+Market+Research%3A+Albany%2C+NY%2C+2012%3B+http%3A%2F%2Fwww.transparencymarketresearch.com%2Fpeptide-therapeutics-market.html."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DPeptide%2520Therapeutics%2520Market%253A%2520Global%2520Industry%2520Analysis%252C%2520Size%252C%2520Share%252C%2520Growth%252C%2520Trends%2520and%2520Forecast%25202012%25E2%2580%25932018%26pub%3DTransparency%2520Market%2520Research%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fosgerau, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, T.</span><span> </span><span class="NLM_article-title">Peptide therapeutics: current status and future directions</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">122</span><span class="NLM_x">â</span> <span class="NLM_lpage">128</span><span class="refDoi">Â DOI: 10.1016/j.drudis.2014.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.drudis.2014.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25450771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsl2ksLnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=122-128&author=K.+Fosgerauauthor=T.+Hoffmann&title=Peptide+therapeutics%3A+current+status+and+future+directions&doi=10.1016%2Fj.drudis.2014.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide therapeutics: current status and future directions</span></div><div class="casAuthors">Fosgerau, Keld; Hoffmann, Torsten</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">122-128</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Peptides are recognized for being highly selective and efficacious and, at the same time, relatively safe and well tolerated.  Consequently, there is an increased interest in peptides in pharmaceutical research and development (R&D), and approx. 140 peptide therapeutics are currently being evaluated in clin. trials.  Given that the low-hanging fruits in the form of obvious peptide targets have already been picked, it has now become necessary to explore new routes beyond traditional peptide design.  Examples of such approaches are multifunctional and cell penetrating peptides, as well as peptide drug conjugates.  Here, we discuss the current status, strengths, and weaknesses of peptides as medicines and the emerging new opportunities in peptide drug design and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmhpp8GnJ6JLVg90H21EOLACvtfcHk0ljLoDoqjdyPHg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsl2ksLnM&md5=f6b74aaa4e3fdb317b091b0450f3618a</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DFosgerau%26aufirst%3DK.%26aulast%3DHoffmann%26aufirst%3DT.%26atitle%3DPeptide%2520therapeutics%253A%2520current%2520status%2520and%2520future%2520directions%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26spage%3D122%26epage%3D128%26doi%3D10.1016%2Fj.drudis.2014.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Craik, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairlie, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liras, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D.</span><span> </span><span class="NLM_article-title">The future of peptide-based drugs</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">136</span><span class="NLM_x">â</span> <span class="NLM_lpage">147</span><span class="refDoi">Â DOI: 10.1111/cbdd.12055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1111%2Fcbdd.12055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23253135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1yktA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2013&pages=136-147&author=D.+J.+Craikauthor=D.+P.+Fairlieauthor=S.+Lirasauthor=D.+Price&title=The+future+of+peptide-based+drugs&doi=10.1111%2Fcbdd.12055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">The future of peptide-based drugs</span></div><div class="casAuthors">Craik, David J.; Fairlie, David P.; Liras, Spiros; Price, David</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">136-147</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The suite of currently used drugs can be divided into two categories - traditional "small mol." drugs with typical mol. wts. of <500 Da but with oral bioavailability, and much larger "biologics" typically >5000 Da that are not orally bioavailable and need to be delivered via injection.  Due to their small size, conventional small mol. drugs may suffer from reduced target selectivity that often ultimately manifests in human side-effects, whereas protein therapeutics tend to be exquisitely specific for their targets due to many more interactions with them, but this comes at a cost of low bioavailability, poor membrane permeability, and metabolic instability.  The time has now come to reinvestigate new drug leads that fit between these two mol. wt. extremes, with the goal of combining advantages of small mols. (cost, conformational restriction, membrane permeability, metabolic stability, oral bioavailability) with those of proteins (natural components, target specificity, high potency).  This article uses selected examples of peptides to highlight the importance of peptide drugs, some potential new opportunities for their exploitation, and some difficult challenges ahead in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlaEZbrPXLPbVg90H21EOLACvtfcHk0ljLoDoqjdyPHg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1yktA%253D%253D&md5=1e7e4b7e725541587fad855e6a28cadf</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12055%26sid%3Dliteratum%253Aachs%26aulast%3DCraik%26aufirst%3DD.%2BJ.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26aulast%3DLiras%26aufirst%3DS.%26aulast%3DPrice%26aufirst%3DD.%26atitle%3DThe%2520future%2520of%2520peptide-based%2520drugs%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2013%26volume%3D81%26spage%3D136%26epage%3D147%26doi%3D10.1111%2Fcbdd.12055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Dunn, B. M.</span> <span class="citation_source-book">Peptide Chemistry and Drug Design</span>; <span class="NLM_publisher-name">John Wiley & Sons</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2F9781118995303" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=B.+M.+Dunn&title=Peptide+Chemistry+and+Drug+Design"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.1002%2F9781118995303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118995303%26sid%3Dliteratum%253Aachs%26aulast%3DDunn%26aufirst%3DB.%2BM.%26btitle%3DPeptide%2520Chemistry%2520and%2520Drug%2520Design%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Di, L.</span><span> </span><span class="NLM_article-title">Strategic approaches to optimizing peptide ADME properties</span> <span class="citation_source-journal">AAPS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">â</span> <span class="NLM_lpage">143</span><span class="refDoi">Â DOI: 10.1208/s12248-014-9687-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1208%2Fs12248-014-9687-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25366889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFSnurvJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=134-143&author=L.+Di&title=Strategic+approaches+to+optimizing+peptide+ADME+properties&doi=10.1208%2Fs12248-014-9687-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Strategic Approaches to Optimizing Peptide ADME Properties</span></div><div class="casAuthors">Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">134-143</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Development of peptide drugs is challenging but also quite rewarding.  Five blockbuster peptide drugs are currently on the market, and six new peptides received first marketing approval as new mol. entities in 2012.  Although peptides only represent 2% of the drug market, the market is growing twice as quickly and might soon occupy a larger niche.  Natural peptides typically have poor absorption, distribution, metab., and excretion (ADME) properties with rapid clearance, short half-life, low permeability, and sometimes low soly.  Strategies have been developed to improve peptide drugability through enhancing permeability, reducing proteolysis and renal clearance, and prolonging half-life.  In vivo, in vitro, and in silico tools are available to evaluate ADME properties of peptides, and structural modification strategies are in place to improve peptide developability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDLDsR-Zk0OLVg90H21EOLACvtfcHk0ljLoDoqjdyPHg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFSnurvJ&md5=530597d3719d65509105096f433fee0a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1208%2Fs12248-014-9687-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-014-9687-3%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26atitle%3DStrategic%2520approaches%2520to%2520optimizing%2520peptide%2520ADME%2520properties%26jtitle%3DAAPS%2520J.%26date%3D2015%26volume%3D17%26spage%3D134%26epage%3D143%26doi%3D10.1208%2Fs12248-014-9687-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Smith, A. J.</span><span> </span><span class="NLM_article-title">New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics</span> <span class="citation_source-journal">J. Biomol. Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">â</span> <span class="NLM_lpage">453</span><span class="refDoi">Â DOI: 10.1177/1087057114562544</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1177%2F1087057114562544" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25512329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtlWjs7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=437-453&author=A.+J.+Smith&title=New+horizons+in+therapeutic+antibody+discovery%3A+opportunities+and+challenges+versus+small-molecule+therapeutics&doi=10.1177%2F1087057114562544"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics</span></div><div class="casAuthors">Smith, Alison J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">437-453</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Antibody drugs have become an increasingly significant component of the therapeutic landscape.  Their success has been driven by some of their unique properties, in particular their very high specificity and selectivity, in contrast to the offtarget liabilities of small mols. (SMs).  Antibodies can bring addnl. functionality to the table with their ability to interact with the immune system, and this can be further manipulated with advances in antibody engineering.  This review summarizes what antibody therapeutics have achieved to date and what opportunities and challenges lie ahead.  The target landscape for large mols. (LMs) vs. SMs and some of the challenges for antibody drug development are discussed.  Effective penetration of membrane barriers and intracellular targeting is one challenge, particularly across the highly resistant blood-brain barrier.  The expanding pipeline of antibody-drug conjugates offers the potential to combine SM and LM modalities in a variety of creative ways, and antibodies also offer exciting potential to build bi- and multispecific mols.  The ability to pursue more challenging targets can also be further exploited but highlights the need for earlier screening in functional cell-based assays.  I discuss how this might be addressed given the practical constraints imposed by high-throughput screening sample type and process differences in antibody primary screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAAiB0sQ4T4rVg90H21EOLACvtfcHk0lgwAn1994TtEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtlWjs7g%253D&md5=06dead2f9d85ab3c0e9cf2f5c9684708</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1177%2F1087057114562544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057114562544%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%2BJ.%26atitle%3DNew%2520horizons%2520in%2520therapeutic%2520antibody%2520discovery%253A%2520opportunities%2520and%2520challenges%2520versus%2520small-molecule%2520therapeutics%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2015%26volume%3D20%26spage%3D437%26epage%3D453%26doi%3D10.1177%2F1087057114562544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Salemi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markovic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâAmelio, R.</span><span> </span><span class="NLM_article-title">The expanding role of therapeutic antibodies</span> <span class="citation_source-journal">Int. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">202</span><span class="NLM_x">â</span> <span class="NLM_lpage">264</span><span class="refDoi">Â DOI: 10.3109/08830185.2013.863304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3109%2F08830185.2013.863304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24471447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotVersrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=202-264&author=S.+Salemiauthor=M.+Markovicauthor=G.+Martiniauthor=R.+D%E2%80%99Amelio&title=The+expanding+role+of+therapeutic+antibodies&doi=10.3109%2F08830185.2013.863304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The Expanding Role of Therapeutic Antibodies</span></div><div class="casAuthors">Salemi, Simonetta; Markovic, Milica; Martini, Gabriella; D'Amelio, Raffaele</div><div class="citationInfo"><span class="NLM_cas:title">International Reviews of Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">202-264</span>CODEN:
                <span class="NLM_cas:coden">IRIMEH</span>;
        ISSN:<span class="NLM_cas:issn">0883-0185</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Therapeutic antibodies have been used since the end of nineteenth century, but their use is progressively increased and recently, with the availability of monoclonal antibodies, they are successfully employed in a large disease spectrum, which transversally covers different fields of medicine.  Hyperimmune polyclonal immune globulin has been used against infectious diseases, in a period in which anti-microbial drugs were not yet available, and it still maintains a relevant place in prophylaxis/therapy.  Although immune globulin should be considered life-saving as replacement therapy in humoral immunodeficiencies, its place in the immune-modulating treatment is not usually first-choice, but it should be considered as support to std. approved treatments.  Despite therapeutic monoclonal antibodies have been lastly introduced in therapy, their extreme potentiality is reflected by the large no. of approved mols., addressed toward different immunol. targets and able to heavily influence the prognosis and quality of life of a wide range of different diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8jbmkoLO4jrVg90H21EOLACvtfcHk0lgwAn1994TtEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotVersrc%253D&md5=eb14f7b21fdf5ef10735cfdb90039e85</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.3109%2F08830185.2013.863304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F08830185.2013.863304%26sid%3Dliteratum%253Aachs%26aulast%3DSalemi%26aufirst%3DS.%26aulast%3DMarkovic%26aufirst%3DM.%26aulast%3DMartini%26aufirst%3DG.%26aulast%3DD%25E2%2580%2599Amelio%26aufirst%3DR.%26atitle%3DThe%2520expanding%2520role%2520of%2520therapeutic%2520antibodies%26jtitle%3DInt.%2520Rev.%2520Immunol.%26date%3D2015%26volume%3D34%26spage%3D202%26epage%3D264%26doi%3D10.3109%2F08830185.2013.863304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Kaspar, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichert, J. M.</span><span> </span><span class="NLM_article-title">Future directions for peptide therapeutics development</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">807</span><span class="NLM_x">â</span> <span class="NLM_lpage">817</span><span class="refDoi">Â DOI: 10.1016/j.drudis.2013.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.drudis.2013.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23726889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpsV2ksbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=807-817&author=A.+A.+Kasparauthor=J.+M.+Reichert&title=Future+directions+for+peptide+therapeutics+development&doi=10.1016%2Fj.drudis.2013.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Future directions for peptide therapeutics development</span></div><div class="casAuthors">Kaspar, Allan A.; Reichert, Janice M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17-18</span>),
    <span class="NLM_cas:pages">807-817</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The notable expansion of peptide therapeutics development in the late 1990s and the 2000s led to an unprecedented no. of marketing approvals in 2012 and has provided a robust pipeline that should deliver numerous approvals during the remainder of the 2010s.  To document the current status of the pipeline, we collected data for peptide therapeutics in clin. studies and regulatory review, as well as those recently approved.  In this Foundation review, we provide an overview of the pipeline, including therapeutic area and mol. targets, with a focus on glucagon-like peptide 1 receptor agonists.  Areas for potential expansion, for example constrained peptides and peptide-drug conjugates, are profiled.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwwD0F8UAjFrVg90H21EOLACvtfcHk0lgwAn1994TtEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpsV2ksbs%253D&md5=df04991ff869d0d85386254d378664cc</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DKaspar%26aufirst%3DA.%2BA.%26aulast%3DReichert%26aufirst%3DJ.%2BM.%26atitle%3DFuture%2520directions%2520for%2520peptide%2520therapeutics%2520development%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D807%26epage%3D817%26doi%3D10.1016%2Fj.drudis.2013.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Diao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meibohm, B.</span><span> </span><span class="NLM_article-title">Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">855</span><span class="NLM_x">â</span> <span class="NLM_lpage">868</span><span class="refDoi">Â DOI: 10.1007/s40262-013-0079-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1007%2Fs40262-013-0079-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23719681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVSmt77I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=855-868&author=L.+Diaoauthor=B.+Meibohm&title=Pharmacokinetics+and+pharmacokinetic-pharmacodynamic+correlations+of+therapeutic+peptides&doi=10.1007%2Fs40262-013-0079-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Correlations of Therapeutic Peptides</span></div><div class="casAuthors">Diao, Lei; Meibohm, Bernd</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">855-868</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Peptides, defined as polymers of less than 50 amino acids with a mol. wt. of less than 10 kDa, represent a fast-growing class of new therapeutics which has unique pharmacokinetic characteristics compared to large proteins or small mol. drugs.  Unmodified peptides usually undergo extensive proteolytic cleavage, resulting in short plasma half-lives.  As a result of their low permeability and susceptibility to catabolic degrdn., therapeutic peptides usually have very limited oral bioavailability and are administered either by the i.v., s.c., or i.m. route, although other routes such as nasal delivery are utilized as well.  Distribution processes are mainly driven by a combination of diffusion and to a lesser degree convective extravasation dependent on the size of the peptide, with vols. of distribution frequently not larger than the vol. of the extracellular body fluid.  Owing to the ubiquitous availability of proteases and peptidases throughout the body, proteolytic degrdn. is not limited to classic elimination organs.  Since peptides are generally freely filtered by the kidneys, glomerular filtration and subsequent renal metab. by proteolysis contribute to the elimination of many therapeutic peptides.  Although small peptides have usually limited immunogenicity, formation of anti-drug antibodies with subsequent hypersensitivity reactions has been described for some peptide therapeutics.  Numerous strategies have been applied to improve the pharmacokinetic properties of therapeutic peptides, esp. to overcome their metabolic instability, low permeability, and limited tissue residence time.  Applied techniques include amino acid substitutions, modification of the peptide terminus, inclusion of disulfide bonds, and conjugation with polymers or macromols. such as antibody fragments or albumin.  Application of model-based pharmacokinetic-pharmacodynamic correlations has been widely used for therapeutic peptides in support of drug development and dosage regimen design, esp. because their targets are often well-described endogenous regulatory pathways and processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmlFFOIFoZBrVg90H21EOLACvtfcHk0lgwAn1994TtEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVSmt77I&md5=975af68c1bbc3dda4b3dbe42b3e40181</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs40262-013-0079-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-013-0079-0%26sid%3Dliteratum%253Aachs%26aulast%3DDiao%26aufirst%3DL.%26aulast%3DMeibohm%26aufirst%3DB.%26atitle%3DPharmacokinetics%2520and%2520pharmacokinetic-pharmacodynamic%2520correlations%2520of%2520therapeutic%2520peptides%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2013%26volume%3D52%26spage%3D855%26epage%3D868%26doi%3D10.1007%2Fs40262-013-0079-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Lax, R.</span><span> </span><span class="NLM_article-title">The future of peptide development in the pharmaceutical industry</span> <span class="citation_source-journal">PharManufacturing: Int. Pept. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_fpage">10</span><span class="NLM_x">â</span> <span class="NLM_lpage">15</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=10-15&author=R.+Lax&title=The+future+of+peptide+development+in+the+pharmaceutical+industry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLax%26aufirst%3DR.%26atitle%3DThe%2520future%2520of%2520peptide%2520development%2520in%2520the%2520pharmaceutical%2520industry%26jtitle%3DPharManufacturing%253A%2520Int.%2520Pept.%2520Rev.%26date%3D2010%26spage%3D10%26epage%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Chin, J. W.</span><span> </span><span class="NLM_article-title">Expanding and reprogramming the genetic code of cells and animals</span> <span class="citation_source-journal">Annu. Rev. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">379</span><span class="NLM_x">â</span> <span class="NLM_lpage">408</span><span class="refDoi">Â DOI: 10.1146/annurev-biochem-060713-035737</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1146%2Fannurev-biochem-060713-035737" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24555827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFOhtrjK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2014&pages=379-408&author=J.+W.+Chin&title=Expanding+and+reprogramming+the+genetic+code+of+cells+and+animals&doi=10.1146%2Fannurev-biochem-060713-035737"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Expanding and reprogramming the genetic code of cells and animals</span></div><div class="casAuthors">Chin, Jason W.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">379-408</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">Genetic code expansion and reprogramming enable the site-specific incorporation of diverse designer amino acids into proteins produced in cells and animals.  Recent advances are enhancing the efficiency of unnatural amino acid incorporation by creating and evolving orthogonal ribosomes and manipulating the genome.  Increasing the no. of distinct amino acids that can be site-specifically encoded has been facilitated by the evolution of orthogonal quadruplet decoding ribosomes and the discovery of mutually orthogonal synthetase/tRNA pairs.  Rapid progress in moving genetic code expansion from bacteria to eukaryotic cells and animals (C. elegans and D. melanogaster) and the incorporation of useful unnatural amino acids has been aided by the development and application of the pyrrolysyl-tRNA (tRNA) synthetase/tRNA pair for unnatural amino acid incorporation.  Combining chemoselective reactions with encoded amino acids has facilitated the installation of posttranslational modifications, as well as rapid derivatization with diverse fluorophores for imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPEbW75CFvZLVg90H21EOLACvtfcHk0ljdn1MO21uKjQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFOhtrjK&md5=beabb2ed5bc94b9876a336bf0be25461</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1146%2Fannurev-biochem-060713-035737&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-biochem-060713-035737%26sid%3Dliteratum%253Aachs%26aulast%3DChin%26aufirst%3DJ.%2BW.%26atitle%3DExpanding%2520and%2520reprogramming%2520the%2520genetic%2520code%2520of%2520cells%2520and%2520animals%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2014%26volume%3D83%26spage%3D379%26epage%3D408%26doi%3D10.1146%2Fannurev-biochem-060713-035737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Maini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umemoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suga, H.</span><span> </span><span class="NLM_article-title">Ribosome-mediated synthesis of natural product-like peptides via cell-free translation</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">44</span><span class="NLM_x">â</span> <span class="NLM_lpage">52</span><span class="refDoi">Â DOI: 10.1016/j.cbpa.2016.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.cbpa.2016.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=27344230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFGjt73P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=44-52&author=R.+Mainiauthor=S.+Umemotoauthor=H.+Suga&title=Ribosome-mediated+synthesis+of+natural+product-like+peptides+via+cell-free+translation&doi=10.1016%2Fj.cbpa.2016.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Ribosome-mediated synthesis of natural product-like peptides via cell-free translation</span></div><div class="casAuthors">Maini, Rumit; Umemoto, Shiori; Suga, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">44-52</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Peptide natural products (PNPs) represent a unique class of compds. known for their fascinating structural motifs with important biol. activities.  Lately, PNPs have garnered a lot of interest for their application in drug discovery.  Nevertheless, lack of diversity oriented synthetic/biosynthetic platforms to generate large natural product-like libraries has limited their development as peptide therapeutics.  The promiscuity of cell-free translation has allowed for the synthesis of artificial PNPs having complex structural features.  Modified cell-free translation systems coupled with the display technologies have generated diverse natural product-like peptide libraries and led to the discovery of several biol. active mols.  Such technologies have drastically decreased the time to obtain peptide drug leads and therefore, revolutionized the field of peptide drug discovery.  In this account, we review recent developments in the synthesis of natural product-like peptides via cell-free translation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGBq1xlWp5VrVg90H21EOLACvtfcHk0ljdn1MO21uKjQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFGjt73P&md5=970458a0f34cd545e1e3aca2cc7434bc</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2016.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2016.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DMaini%26aufirst%3DR.%26aulast%3DUmemoto%26aufirst%3DS.%26aulast%3DSuga%26aufirst%3DH.%26atitle%3DRibosome-mediated%2520synthesis%2520of%2520natural%2520product-like%2520peptides%2520via%2520cell-free%2520translation%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D34%26spage%3D44%26epage%3D52%26doi%3D10.1016%2Fj.cbpa.2016.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Malyshev, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romesberg, F. E.</span><span> </span><span class="NLM_article-title">The expanded genetic alphabet</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">11930</span><span class="NLM_x">â</span> <span class="NLM_lpage">11944</span><span class="refDoi">Â DOI: 10.1002/anie.201502890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fanie.201502890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVSjtLrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=11930-11944&author=D.+A.+Malyshevauthor=F.+E.+Romesberg&title=The+expanded+genetic+alphabet&doi=10.1002%2Fanie.201502890"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">The expanded genetic alphabet</span></div><div class="casAuthors">Malyshev, Denis A.; Romesberg, Floyd E.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">11930-11944</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  All biol. information, since the last common ancestor of all life on Earth, has been encoded by a genetic alphabet consisting of only four nucleotides that form two base pairs.  Long-standing efforts to develop two synthetic nucleotides that form a third, unnatural base pair (UBP) have recently yielded three promising candidates, one based on alternative hydrogen bonding, and two based on hydrophobic and packing forces.  All three of these UBPs are replicated and transcribed with remarkable efficiency and fidelity, and the latter two thus demonstrate that hydrogen bonding is not unique in its ability to underlie the storage and retrieval of genetic information.  This Review highlights these recent developments as well as the applications enabled by the UBPs, including the expansion of the evolution process to include new functionality and the creation of semi-synthetic life that stores increased information.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxEFlLbioOhLVg90H21EOLACvtfcHk0ljdn1MO21uKjQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVSjtLrL&md5=56b77b89dbbf47428bf446e8de15ca82</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1002%2Fanie.201502890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201502890%26sid%3Dliteratum%253Aachs%26aulast%3DMalyshev%26aufirst%3DD.%2BA.%26aulast%3DRomesberg%26aufirst%3DF.%2BE.%26atitle%3DThe%2520expanded%2520genetic%2520alphabet%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D11930%26epage%3D11944%26doi%3D10.1002%2Fanie.201502890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hongdilokkul, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thirunavukarasu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romesberg, F. E.</span><span> </span><span class="NLM_article-title">The expanding world of DNA and RNA</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">â</span> <span class="NLM_lpage">87</span><span class="refDoi">Â DOI: 10.1016/j.cbpa.2016.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.cbpa.2016.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=27565457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWmtr%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=80-87&author=T.+Chenauthor=N.+Hongdilokkulauthor=Z.+Liuauthor=D.+Thirunavukarasuauthor=F.+E.+Romesberg&title=The+expanding+world+of+DNA+and+RNA&doi=10.1016%2Fj.cbpa.2016.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">The expanding world of DNA and RNA</span></div><div class="casAuthors">Chen, Tingjian; Hongdilokkul, Narupat; Liu, Zhixia; Thirunavukarasu, Deepak; Romesberg, Floyd E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">80-87</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">DNA and RNA are remarkable because they can both encode information and possess desired properties, including the ability to bind specific targets or catalyze specific reactions.  Nucleotide modifications that do not interfere with enzymic synthesis are now being used to bestow DNA or RNA with properties that further increase their utility, including phosphate and sugar modifications that increase nuclease resistance, nucleobase modifications that increase the range of activities possible, and even whole nucleobase replacement that results in selective pairing and the creation of unnatural base pairs that increase the information content.  These modifications are increasingly being applied both in vitro and in vivo, including in efforts to create semi-synthetic organisms with altered or expanded genetic alphabets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqKyb8Om4dA7Vg90H21EOLACvtfcHk0lgL2R6BHwd43w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWmtr%252FO&md5=442970017f6d14ab44454a16bcb86303</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2016.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2016.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DT.%26aulast%3DHongdilokkul%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DThirunavukarasu%26aufirst%3DD.%26aulast%3DRomesberg%26aufirst%3DF.%2BE.%26atitle%3DThe%2520expanding%2520world%2520of%2520DNA%2520and%2520RNA%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D34%26spage%3D80%26epage%3D87%26doi%3D10.1016%2Fj.cbpa.2016.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenakin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C.</span><span> </span><span class="NLM_article-title">Editorial: Orphan GPCRs as emerging drug targets</span> <span class="citation_source-journal">Front. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">295</span><span class="refDoi">Â DOI: 10.3389/fphar.2015.00295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3389%2Ffphar.2015.00295" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26696893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVGlu7zF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=295&author=Y.+Fangauthor=T.+Kenakinauthor=C.+Liu&title=Editorial%3A+Orphan+GPCRs+as+emerging+drug+targets&doi=10.3389%2Ffphar.2015.00295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">Editorial: orphan GPCRs as emerging drug targets</span></div><div class="casAuthors">Fang, Ye; Kenakin, Terry; Liu, Changlu</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">295/1-295/2</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  This article describes the human G protein coupled-receptor structure detn. and structure-based virtual screening for identifying ligands for orphan receptors and potential clin. applications of several orphan GPCRs including FFARs, H4 receptor, EIB2, GPR35, GPR55, GPR37, and GPR37L1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNxrlywN6GbLVg90H21EOLACvtfcHk0lgL2R6BHwd43w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVGlu7zF&md5=9260574bcaab25bd9dcd9f8a46745515</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2015.00295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2015.00295%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DY.%26aulast%3DKenakin%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DC.%26atitle%3DEditorial%253A%2520Orphan%2520GPCRs%2520as%2520emerging%2520drug%2520targets%26jtitle%3DFront.%2520Pharmacol.%26date%3D2015%26volume%3D6%26spage%3D295%26doi%3D10.3389%2Ffphar.2015.00295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fillmore, D.</span><span> </span><span class="NLM_article-title">It's a GPCR world</span> <span class="citation_source-journal">Mod. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">24</span><span class="NLM_x">â</span> <span class="NLM_lpage">28</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2004&pages=24-28&author=D.+Fillmore&title=It%27s+a+GPCR+world"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFillmore%26aufirst%3DD.%26atitle%3DIt%2527s%2520a%2520GPCR%2520world%26jtitle%3DMod.%2520Drug%2520Discovery%26date%3D2004%26volume%3D7%26spage%3D24%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Stockert, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devi, L. A.</span><span> </span><span class="NLM_article-title">Advancements in therapeutically targeting orphan GPCRs</span> <span class="citation_source-journal">Front. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">100</span><span class="refDoi">Â DOI: 10.3389/fphar.2015.00100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3389%2Ffphar.2015.00100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26005419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A280%3ADC%252BC2MfmvFertQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=100&author=J.+A.+Stockertauthor=L.+A.+Devi&title=Advancements+in+therapeutically+targeting+orphan+GPCRs&doi=10.3389%2Ffphar.2015.00100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20aR"><div class="casContent"><span class="casTitleNuber">20a</span><div class="casTitle"><span class="NLM_cas:atitle">Advancements in therapeutically targeting orphan GPCRs</span></div><div class="casAuthors">Stockert Jennifer A; Devi Lakshmi A</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">100</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">G-protein coupled receptors (GPCRs) are popular biological targets for drug discovery and development.  To date there are more than 140 orphan GPCRs, i.e., receptors whose endogenous ligands are unknown.  Traditionally orphan GPCRs have been difficult to study and the development of therapeutic compounds targeting these receptors has been extremely slow although these GPCRs are considered important targets based on their distribution and behavioral phenotype as revealed by animals lacking the receptor.  Recent advances in several methods used to study orphan receptors, including protein crystallography and homology modeling are likely to be useful in the identification of therapeutics targeting these receptors.  In the past 13 years, over a dozen different Class A GPCRs have been crystallized; this trend is exciting, since homology modeling of GPCRs has previously been limited by the availability of solved structures.  As the number of solved GPCR structures continues to grow so does the number of templates that can be used to generate increasingly accurate models of phylogenetically related orphan GPCRs.  The availability of solved structures along with the advances in using multiple templates to build models (in combination with molecular dynamics simulations that reveal structural information not provided by crystallographic data and methods for modeling hard-to-predict flexible loop regions) have improved the quality of GPCR homology models.  This, in turn, has improved the success rates of virtual ligand screens that use homology models to identify potential receptor binding compounds.  Experimental testing of the predicted hits and validation using traditional GPCR pharmacological approaches can be used to drive ligand-based efforts to probe orphan receptor biology as well as to define the chemotypes and chemical scaffolds important for binding.  As a result of these advances, orphan GPCRs are emerging from relative obscurity as a new class of drug targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQcSmeqGfmTqGLFM_lbR1VmfW6udTcc2eYAWd0K426KW7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfmvFertQ%253D%253D&md5=f21f3a8a7bbf9b55c875f986c9371172</span></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2015.00100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2015.00100%26sid%3Dliteratum%253Aachs%26aulast%3DStockert%26aufirst%3DJ.%2BA.%26aulast%3DDevi%26aufirst%3DL.%2BA.%26atitle%3DAdvancements%2520in%2520therapeutically%2520targeting%2520orphan%2520GPCRs%26jtitle%3DFront.%2520Pharmacol.%26date%3D2015%26volume%3D6%26spage%3D100%26doi%3D10.3389%2Ffphar.2015.00100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ngo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kufareva, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abagyan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, N. J.</span><span> </span><span class="NLM_article-title">Identifying ligands at orphan GPCRs: current status using structure-based approaches</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">173</span><span class="NLM_x">, </span> <span class="NLM_fpage">2934</span><span class="NLM_x">â</span> <span class="NLM_lpage">2951</span><span class="refDoi">Â DOI: 10.1111/bph.13452</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1111%2Fbph.13452" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26837045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1GntLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2016&pages=2934-2951&author=T.+Ngoauthor=I.+Kufarevaauthor=J.+L.+Colemanauthor=R.+M.+Grahamauthor=R.+Abagyanauthor=N.+J.+Smith&title=Identifying+ligands+at+orphan+GPCRs%3A+current+status+using+structure-based+approaches&doi=10.1111%2Fbph.13452"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20bR"><div class="casContent"><span class="casTitleNuber">20b</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying ligands at orphan GPCRs: current status using structure-based approaches</span></div><div class="casAuthors">Ngo, Tony; Kufareva, Irina; Coleman, James L. J.; Graham, Robert M.; Abagyan, Ruben; Smith, Nicola J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2934-2951</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">GPCRs are the most successful pharmaceutical targets in history.  Nevertheless, the pharmacol. of many GPCRs remains inaccessible as their endogenous or exogenous modulators have not been discovered.  Tools that explore the physiol. functions and pharmacol. potential of these 'orphan' GPCRs, whether they are endogenous and/or surrogate ligands, are therefore of paramount importance.  Rates of receptor deorphanization detd. by traditional reverse pharmacol. methods have slowed, indicating a need for the development of more sophisticated and efficient ligand screening approaches.  Here, we discuss the use of structure-based ligand discovery approaches to identify small mol. modulators for exploring the function of orphan GPCRs.  These studies have been buoyed by the growing no. of GPCR crystal structures solved in the past decade, providing a broad range of template structures for homol. modeling of orphans.  This review discusses the methods used to establish the appropriate signalling assays to test orphan receptor activity and provides current examples of structure-based methods used to identify ligands of orphan GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOIJS_m3tMZrVg90H21EOLACvtfcHk0lgL2R6BHwd43w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1GntLY%253D&md5=e23548979b85261c420240d2fa1f0bd1</span></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1111%2Fbph.13452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13452%26sid%3Dliteratum%253Aachs%26aulast%3DNgo%26aufirst%3DT.%26aulast%3DKufareva%26aufirst%3DI.%26aulast%3DColeman%26aufirst%3DJ.%2BL.%26aulast%3DGraham%26aufirst%3DR.%2BM.%26aulast%3DAbagyan%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DN.%2BJ.%26atitle%3DIdentifying%2520ligands%2520at%2520orphan%2520GPCRs%253A%2520current%2520status%2520using%2520structure-based%2520approaches%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2016%26volume%3D173%26spage%3D2934%26epage%3D2951%26doi%3D10.1111%2Fbph.13452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Tang, X.-l.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.-l.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.-y.</span><span> </span><span class="NLM_article-title">Orphan G protein-coupled receptors (GPCRs): biological functions and potential drug targets</span> <span class="citation_source-journal">Acta Pharmacol. Sin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">363</span><span class="NLM_x">â</span> <span class="NLM_lpage">371</span><span class="refDoi">Â DOI: 10.1038/aps.2011.210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Faps.2011.210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=22367282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1eru7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=363-371&author=X.-l.+Tangauthor=Y.+Wangauthor=D.-l.+Liauthor=J.+Luoauthor=M.-y.+Liu&title=Orphan+G+protein-coupled+receptors+%28GPCRs%29%3A+biological+functions+and+potential+drug+targets&doi=10.1038%2Faps.2011.210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20cR"><div class="casContent"><span class="casTitleNuber">20c</span><div class="casTitle"><span class="NLM_cas:atitle">Orphan G protein-coupled receptors (GPCRs): biological functions and potential drug targets</span></div><div class="casAuthors">Tang, Xiao-long; Wang, Ying; Li, Da-li; Luo, Jian; Liu, Ming-yao</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">363-371</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The superfamily of G protein-coupled receptors (GPCRs) includes at least 800 seven-transmembrane receptors that participate in diverse physiol. and pathol. functions.  GPCRs are the most successful targets of modern medicine, and approx. 36% of marketed pharmaceuticals target human GPCRs.  However, the endogenous ligands of more than 140 GPCRs remain unidentified, leaving the natural functions of those GPCRs in doubt.  These are the so-called orphan GPCRs, a great source of drug targets.  This review focuses on the signaling transduction pathways of the adhesion GPCR family, the LGR subfamily, and the PSGR subfamily, and their potential functions in immunol., development, and cancers.  In this review, we present the current approaches and difficulties of orphan GPCR deorphanization and characterization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv4uhC3Ymv27Vg90H21EOLACvtfcHk0liqUotXQZvpSA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1eru7s%253D&md5=c4729d885e76813567c82321a5d8d93c</span></div><a href="/servlet/linkout?suffix=cit20c&amp;dbid=16384&amp;doi=10.1038%2Faps.2011.210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2011.210%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DX.-l.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DD.-l.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DM.-y.%26atitle%3DOrphan%2520G%2520protein-coupled%2520receptors%2520%2528GPCRs%2529%253A%2520biological%2520functions%2520and%2520potential%2520drug%2520targets%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2012%26volume%3D33%26spage%3D363%26epage%3D371%26doi%3D10.1038%2Faps.2011.210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Diller, D. J.</span><span> </span><span class="NLM_article-title">The synergy between combinatorial chemistry and high-throughput screening</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">346</span><span class="NLM_x">â</span> <span class="NLM_lpage">355</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=346-355&author=D.+J.+Diller&title=The+synergy+between+combinatorial+chemistry+and+high-throughput+screening"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDiller%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520synergy%2520between%2520combinatorial%2520chemistry%2520and%2520high-throughput%2520screening%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2008%26volume%3D11%26spage%3D346%26epage%3D355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kennedy, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniels, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span> </span><span class="NLM_article-title">Application of combinatorial chemistry science on modern drug discovery</span> <span class="citation_source-journal">J. Comb. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">â</span> <span class="NLM_lpage">354</span><span class="refDoi">Â DOI: 10.1021/cc700187t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cc700187t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFShsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=345-354&author=J.+P.+Kennedyauthor=L.+Williamsauthor=T.+M.+Bridgesauthor=R.+N.+Danielsauthor=D.+Weaverauthor=C.+W.+Lindsley&title=Application+of+combinatorial+chemistry+science+on+modern+drug+discovery&doi=10.1021%2Fcc700187t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Application of Combinatorial Chemistry Science on Modern Drug Discovery</span></div><div class="casAuthors">Kennedy, J. Phillip; Williams, Lyndsey; Bridges, Thomas M.; Daniels, R. Nathan; Weaver, David; Lindsley, Craig W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Combinatorial Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">345-354</span>CODEN:
                <span class="NLM_cas:coden">JCCHFF</span>;
        ISSN:<span class="NLM_cas:issn">1520-4766</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The science that established combinatorial chem. as important new discipline in the 1980s and 1990s, has reemerged and infiltrated every subdiscipline within modern drug discovery and has profound impact.  The application of combinatorial chem. science has revolutionized high-throughput screening paradigms, chem. lead optimization, library purifn. and postpurifn. sample handling, as well as in vitro and in vivo drug metab. and pharmacokinetic assays.  Although no longer in the spotlight and heralded as the savior of the drug industry, combinatorial chem. is alive and well: actually, combinatorial chem. science is more prevalent and widespread than ever before.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_FItqaRFGt7Vg90H21EOLACvtfcHk0liqUotXQZvpSA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFShsLo%253D&md5=b97fdb2d165b9b8645d773edf48d44fa</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1021%2Fcc700187t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcc700187t%26sid%3Dliteratum%253Aachs%26aulast%3DKennedy%26aufirst%3DJ.%2BP.%26aulast%3DWilliams%26aufirst%3DL.%26aulast%3DBridges%26aufirst%3DT.%2BM.%26aulast%3DDaniels%26aufirst%3DR.%2BN.%26aulast%3DWeaver%26aufirst%3DD.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DApplication%2520of%2520combinatorial%2520chemistry%2520science%2520on%2520modern%2520drug%2520discovery%26jtitle%3DJ.%2520Comb.%2520Chem.%26date%3D2008%26volume%3D10%26spage%3D345%26epage%3D354%26doi%3D10.1021%2Fcc700187t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Bononi, F. C.; Luyt, L. G.</span><span> </span><span class="NLM_article-title">Synthesis and cell-based screening of one-bead-one-compound peptide libraries</span>. In  <span class="citation_source-book">Peptide Libraries: Methods and Protocols</span>; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">223</span><span class="NLM_x">â</span> <span class="NLM_lpage">237</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1007%2F978-1-4939-2020-4_15" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=223-237&author=F.+C.+Bononi&author=L.+G.+Luyt&title=Peptide+Libraries%3A+Methods+and+Protocols"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21c&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-2020-4_15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4939-2020-4_15%26sid%3Dliteratum%253Aachs%26aulast%3DBononi%26aufirst%3DF.%2BC.%26atitle%3DSynthesis%2520and%2520cell-based%2520screening%2520of%2520one-bead-one-compound%2520peptide%2520libraries%26btitle%3DPeptide%2520Libraries%253A%2520Methods%2520and%2520Protocols%26pub%3DSpringer%26date%3D2015%26spage%3D223%26epage%3D237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Romanova, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweedler, J. V.</span><span> </span><span class="NLM_article-title">Peptidomics for the discovery and characterization of neuropeptides and hormones</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">579</span><span class="NLM_x">â</span> <span class="NLM_lpage">586</span><span class="refDoi">Â DOI: 10.1016/j.tips.2015.05.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.tips.2015.05.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26143240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFehsLzP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=579-586&author=E.+V.+Romanovaauthor=J.+V.+Sweedler&title=Peptidomics+for+the+discovery+and+characterization+of+neuropeptides+and+hormones&doi=10.1016%2Fj.tips.2015.05.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Peptidomics for the discovery and characterization of neuropeptides and hormones</span></div><div class="casAuthors">Romanova, Elena V.; Sweedler, Jonathan V.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">579-586</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The discovery of neuropeptides as signaling mols. with paracrine or hormonal regulatory functions has led to trailblazing advances in physiol. and fostered the characterization of numerous neuropeptide-binding G protein-coupled receptors (GPCRs) as potential drug targets.  The impact on human health has been tremendous: approx. 30% of com. drugs act via the GPCR pathway.  However, about 25% of the GPCRs encoded by the mammalian genome still lack their pharmacol. identity.  Searching for the orphan GPCR endogenous ligands that are likely to be neuropeptides has proved to be a formidable task.  Here we describe the mass spectrometry (MS)-based technologies and exptl. strategies that have been successful in achieving high-throughput characterization of endogenous peptides in nervous and endocrine systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplmYoFQ4F8bLVg90H21EOLACvtfcHk0ljz_IRmivFYbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFehsLzP&md5=c04cadcd53efaf5119598f6ae5175e0e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2015.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2015.05.009%26sid%3Dliteratum%253Aachs%26aulast%3DRomanova%26aufirst%3DE.%2BV.%26aulast%3DSweedler%26aufirst%3DJ.%2BV.%26atitle%3DPeptidomics%2520for%2520the%2520discovery%2520and%2520characterization%2520of%2520neuropeptides%2520and%2520hormones%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26spage%3D579%26epage%3D586%26doi%3D10.1016%2Fj.tips.2015.05.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Calcott, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ackerley, D. F.</span><span> </span><span class="NLM_article-title">Genetic manipulation of non-ribosomal peptide synthetases to generate novel bioactive peptide products</span> <span class="citation_source-journal">Biotechnol. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">2407</span><span class="NLM_x">â</span> <span class="NLM_lpage">2416</span><span class="refDoi">Â DOI: 10.1007/s10529-014-1642-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1007%2Fs10529-014-1642-y" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2014&pages=2407-2416&author=M.+J.+Calcottauthor=D.+F.+Ackerley&title=Genetic+manipulation+of+non-ribosomal+peptide+synthetases+to+generate+novel+bioactive+peptide+products&doi=10.1007%2Fs10529-014-1642-y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=10.1007%2Fs10529-014-1642-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10529-014-1642-y%26sid%3Dliteratum%253Aachs%26aulast%3DCalcott%26aufirst%3DM.%2BJ.%26aulast%3DAckerley%26aufirst%3DD.%2BF.%26atitle%3DGenetic%2520manipulation%2520of%2520non-ribosomal%2520peptide%2520synthetases%2520to%2520generate%2520novel%2520bioactive%2520peptide%2520products%26jtitle%3DBiotechnol.%2520Lett.%26date%3D2014%26volume%3D36%26spage%3D2407%26epage%3D2416%26doi%3D10.1007%2Fs10529-014-1642-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Walsh, C. T.</span><span> </span><span class="NLM_article-title">Insights into the chemical logic and enzymatic machinery of NRPS assembly lines</span> <span class="citation_source-journal">Nat. Prod. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">â</span> <span class="NLM_lpage">135</span><span class="refDoi">Â DOI: 10.1039/C5NP00035A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1039%2FC5NP00035A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26175103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOksrzK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2016&pages=127-135&author=C.+T.+Walsh&title=Insights+into+the+chemical+logic+and+enzymatic+machinery+of+NRPS+assembly+lines&doi=10.1039%2FC5NP00035A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23bR"><div class="casContent"><span class="casTitleNuber">23b</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the chemical logic and enzymatic machinery of NRPS assembly lines</span></div><div class="casAuthors">Walsh, Christopher T.</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-135</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Appreciation that some cyclic peptide antibiotics such as gramicidin S and tyrocidine were nonribosomally synthesized has been known for 50 years.  The past two decades of research including advances in bacterial genetics, genomics, protein biochem. and mass spectrometry have codified the principles of assembly line enzymol. for hundreds of nonribosomal peptides and in parallel for thousands of polyketides.  The advances in understanding the strategies used for chain initiation, elongation and termination from these assembly lines have revitalized natural product biosynthetic communities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6hcitSzuGibVg90H21EOLACvtfcHk0ljz_IRmivFYbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOksrzK&md5=cf3a39bd3ed87abb5924ede29aeb8397</span></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=10.1039%2FC5NP00035A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5NP00035A%26sid%3Dliteratum%253Aachs%26aulast%3DWalsh%26aufirst%3DC.%2BT.%26atitle%3DInsights%2520into%2520the%2520chemical%2520logic%2520and%2520enzymatic%2520machinery%2520of%2520NRPS%2520assembly%2520lines%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2016%26volume%3D33%26spage%3D127%26epage%3D135%26doi%3D10.1039%2FC5NP00035A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Jones, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span> </span><span class="NLM_article-title">Medicinal chemistry of glucagon-like peptide receptor agonists</span> <span class="citation_source-journal">Prog. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">45</span><span class="NLM_x">â</span> <span class="NLM_lpage">96</span><span class="refDoi">Â DOI: 10.1016/B978-0-444-62652-3.00002-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2FB978-0-444-62652-3.00002-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23384666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFGrsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=45-96&author=L.+H.+Jonesauthor=D.+A.+Price&title=Medicinal+chemistry+of+glucagon-like+peptide+receptor+agonists&doi=10.1016%2FB978-0-444-62652-3.00002-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of glucagon-like peptide receptor agonists</span></div><div class="casAuthors">Jones, Lyn H.; Price, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">45-96</span>CODEN:
                <span class="NLM_cas:coden">PMDCAY</span>;
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  This article discusses the medicinal chem. of glucagon-like peptide receptor agonists.  Applications of GLP-1 ligands as imaging agents in the diagnosis of diabetes and pancreatic cancer were discussed.  Fundamental principles of GLP-1 injectable peptides medicinal chem. design and synthesis were discussed.  The potential for alternative modes of drug delivery, such as oral and inhaled administration were discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5hCxobbsxyrVg90H21EOLACvtfcHk0ljz_IRmivFYbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFGrsbY%253D&md5=b92dcf4ab78d6faeab98a32c6b25c03c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FB978-0-444-62652-3.00002-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-444-62652-3.00002-8%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26atitle%3DMedicinal%2520chemistry%2520of%2520glucagon-like%2520peptide%2520receptor%2520agonists%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D52%26spage%3D45%26epage%3D96%26doi%3D10.1016%2FB978-0-444-62652-3.00002-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Miller, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harikumar, K. G.</span><span> </span><span class="NLM_article-title">The class B G-protein-coupled GLP-1 receptor: an important target for the treatment of type-2 diabetes mellitus</span> <span class="citation_source-journal">Int. J. Obes.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">S9</span><span class="NLM_x">â</span> <span class="NLM_lpage">S13</span><span class="refDoi">Â DOI: 10.1038/ijosup.2014.4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fijosup.2014.4" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=S9-S13&author=L.+J.+Millerauthor=P.+M.+Sextonauthor=M.+Dongauthor=K.+G.+Harikumar&title=The+class+B+G-protein-coupled+GLP-1+receptor%3A+an+important+target+for+the+treatment+of+type-2+diabetes+mellitus&doi=10.1038%2Fijosup.2014.4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1038%2Fijosup.2014.4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fijosup.2014.4%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DL.%2BJ.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DDong%26aufirst%3DM.%26aulast%3DHarikumar%26aufirst%3DK.%2BG.%26atitle%3DThe%2520class%2520B%2520G-protein-coupled%2520GLP-1%2520receptor%253A%2520an%2520important%2520target%2520for%2520the%2520treatment%2520of%2520type-2%2520diabetes%2520mellitus%26jtitle%3DInt.%2520J.%2520Obes.%26date%3D2014%26volume%3D4%26spage%3DS9%26epage%3DS13%26doi%3D10.1038%2Fijosup.2014.4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit25b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Christensen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miossec, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsen, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werner, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knop, F. K.</span><span> </span><span class="NLM_article-title">The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1223</span><span class="NLM_x">â</span> <span class="NLM_lpage">1251</span><span class="refDoi">Â DOI: 10.1517/17460441.2014.942638</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1517%2F17460441.2014.942638" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25119443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KhtLzN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1223-1251&author=M.+Christensenauthor=P.+Miossecauthor=B.+D.+Larsenauthor=U.+Wernerauthor=F.+K.+Knop&title=The+design+and+discovery+of+lixisenatide+for+the+treatment+of+type+2+diabetes+mellitus&doi=10.1517%2F17460441.2014.942638"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25bR"><div class="casContent"><span class="casTitleNuber">25b</span><div class="casTitle"><span class="NLM_cas:atitle">The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus</span></div><div class="casAuthors">Christensen, Mikkel; Miossec, Patrick; Larsen, Bjarne Due; Werner, Ulrich; Knop, Filip K.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1223-1251</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: Lixisenatide is a once-daily short-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) used in the treatment of type 2 diabetes mellitus (T2DM).  It is used in combination with oral antidiabetics and/or basal insulin in patients inadequately controlled on these medications and who are undergoing diet and lifestyle modification.  GLP-1RAs glucose-dependently increase insulin secretion, decrease glucagon secretion, and slow gastric emptying, thereby improving glycemic control.  GLP-1RAs are assocd. with body wt. benefits and low rates of hypoglycemia which are welcome in patients with T2DM.  Areas covered: The authors describe the identification of GLP-1RAs as suitable targets for modification with structure-inducing probe technol. to improve stability and resistance to proteolytic degrdn.  Clin. studies have assessed lixisenatide across > 5000 patients as a monotherapy or add-on to a variety of commonly used antidiabetic medications.  These studies highlighted the effects of lixisenatide on gastric emptying, explaining its particular improvements in postprandial plasma glucose (PPG) excursions and underscoring its efficacy in combination with insulin glargine.  Lixisenatide was well tolerated, with nausea and vomiting being the most frequently reported adverse events.  Expert opinion: The once-daily administration of lixisenatide as well as its substantial sustained effect on gastric emptying and, hence, PPG excursions are all important features compared with the other GLP-1RAs.  The combination of two injectables, such as basal insulin to lower fasting plasma glucose and a GLP-1RA that curtails PPG excursions, is clin. valuable and could differentiate lixisenatide from other GLP-1RAs, esp. from those continuously acting GLP-1RAs with little effect on gastric emptying and PPG excursions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW0IfTdZVP3bVg90H21EOLACvtfcHk0lidypZ4Cqw0cQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KhtLzN&md5=aaf08b96c53617d3044e56447ca8e7f1</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1517%2F17460441.2014.942638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2014.942638%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DM.%26aulast%3DMiossec%26aufirst%3DP.%26aulast%3DLarsen%26aufirst%3DB.%2BD.%26aulast%3DWerner%26aufirst%3DU.%26aulast%3DKnop%26aufirst%3DF.%2BK.%26atitle%3DThe%2520design%2520and%2520discovery%2520of%2520lixisenatide%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%2520mellitus%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2014%26volume%3D9%26spage%3D1223%26epage%3D1251%26doi%3D10.1517%2F17460441.2014.942638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit25c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Parkes, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mace, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trautmann, M. E.</span><span> </span><span class="NLM_article-title">Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">â</span> <span class="NLM_lpage">244</span><span class="refDoi">Â DOI: 10.1517/17460441.2013.741580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1517%2F17460441.2013.741580" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=219-244&author=D.+G.+Parkesauthor=K.+F.+Maceauthor=M.+E.+Trautmann&title=Discovery+and+development+of+exenatide%3A+the+first+antidiabetic+agent+to+leverage+the+multiple+benefits+of+the+incretin+hormone%2C+GLP-1&doi=10.1517%2F17460441.2013.741580"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25c&amp;dbid=16384&amp;doi=10.1517%2F17460441.2013.741580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2013.741580%26sid%3Dliteratum%253Aachs%26aulast%3DParkes%26aufirst%3DD.%2BG.%26aulast%3DMace%26aufirst%3DK.%2BF.%26aulast%3DTrautmann%26aufirst%3DM.%2BE.%26atitle%3DDiscovery%2520and%2520development%2520of%2520exenatide%253A%2520the%2520first%2520antidiabetic%2520agent%2520to%2520leverage%2520the%2520multiple%2520benefits%2520of%2520the%2520incretin%2520hormone%252C%2520GLP-1%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2013%26volume%3D8%26spage%3D219%26epage%3D244%26doi%3D10.1517%2F17460441.2013.741580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pawlikowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melen-Mucha, G.</span><span> </span><span class="NLM_article-title">Somatostatin analogs - from new molecules to new applications</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">608</span><span class="NLM_x">â</span> <span class="NLM_lpage">613</span><span class="refDoi">Â DOI: 10.1016/j.coph.2004.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.coph.2004.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=15525552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptl2ksbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=608-613&author=M.+Pawlikowskiauthor=G.+Melen-Mucha&title=Somatostatin+analogs+-+from+new+molecules+to+new+applications&doi=10.1016%2Fj.coph.2004.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26aR"><div class="casContent"><span class="casTitleNuber">26a</span><div class="casTitle"><span class="NLM_cas:atitle">Somatostatin analogs - from new molecules to new applications</span></div><div class="casAuthors">Pawlikowski, Marek; Melen-Mucha, Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">608-613</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Somatostatin (SST) was firstly discovered as a hypothalamic hormone inhibiting GH secretion.  Despite its broad inhibitory effects on both endocrine and exocrine secretions, natural SST has limited therapeutic potential owing to its short plasma half-life.  The synthesis of the first two metabolically stabilized and more potent SST analogs (octreotide and lanreotide) established the use of SST peptide therapy.  The discovery of the five SST receptor (sst1-5) subtypes in the 1990s further enhanced the understanding of the biol. roles of SST, created new therapeutic opportunities and highlighted the limitation of 'classical' SST analogs, which act mainly via receptor subtype 2 and are unable to reproduce all actions of native SST.  To diminish these limitations, new SST analogs highly selective for particular receptor subtypes, together with so-called 'universal' analogs acting on multiple receptor subtypes, have been developed.  These compds. have shown promise in preclin. studies and might further advance the use of SST analog therapy in the future.  The development of SST analogs coupled to radioisotopes or cytotoxic drugs, which allows the selective destruction of tumor cells overexpressing sst receptors, constitutes another field of progress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi8Cim_6Y8v7Vg90H21EOLACvtfcHk0lidypZ4Cqw0cQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptl2ksbc%253D&md5=39a5ade46af0e7a6c9d308e09772ee98</span></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2004.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2004.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DPawlikowski%26aufirst%3DM.%26aulast%3DMelen-Mucha%26aufirst%3DG.%26atitle%3DSomatostatin%2520analogs%2520-%2520from%2520new%2520molecules%2520to%2520new%2520applications%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2004%26volume%3D4%26spage%3D608%26epage%3D613%26doi%3D10.1016%2Fj.coph.2004.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ben-Shlomo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melmed, S.</span><span> </span><span class="NLM_article-title">Somatostatin agonists for treatment of acromegaly</span> <span class="citation_source-journal">Mol. Cell. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">286</span><span class="NLM_x">, </span> <span class="NLM_fpage">192</span><span class="NLM_x">â</span> <span class="NLM_lpage">198</span><span class="refDoi">Â DOI: 10.1016/j.mce.2007.11.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.mce.2007.11.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=18191325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtVSmt7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2008&pages=192-198&author=A.+Ben-Shlomoauthor=S.+Melmed&title=Somatostatin+agonists+for+treatment+of+acromegaly&doi=10.1016%2Fj.mce.2007.11.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">Somatostatin agonists for treatment of acromegaly</span></div><div class="casAuthors">Ben-Shlomo, Anat; Melmed, Shlomo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">192-198</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  The discovery of somatotropin-release inhibitory factor (SRIF) in hypothalamic ext. in 1970 led to the synthesis of the first somatostatin analog octreotide, discovery of five somatostatin receptor subtypes, and development of addnl. somatostatin receptor ligands (SRL) as pharmacotherapy for acromegaly and other neuroendocrine tumors.  Long-acting formulations of SRL (octreotide LAR Depot, lanreotide SR and lanreotide autogel) assure improved patient compliance with weekly up to monthly injections, and are commonly used as primary or adjuvant treatment of acromegaly.  We review SRL currently available, emphasizing long-acting compds. and their efficacy in controlling acromegaly.  Disease control is evaluated by biochem. markers, tumor shrinkage, and disease-symptom improvement balanced against drug-related side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoML_7sWXZCHbVg90H21EOLACvtfcHk0lidypZ4Cqw0cQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtVSmt7Y%253D&md5=52d3fb101d1e4ee7cd890c5c22b8537f</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2007.11.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2007.11.024%26sid%3Dliteratum%253Aachs%26aulast%3DBen-Shlomo%26aufirst%3DA.%26aulast%3DMelmed%26aufirst%3DS.%26atitle%3DSomatostatin%2520agonists%2520for%2520treatment%2520of%2520acromegaly%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2008%26volume%3D286%26spage%3D192%26epage%3D198%26doi%3D10.1016%2Fj.mce.2007.11.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit26c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Anthony, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freda, P. U.</span><span> </span><span class="NLM_article-title">From somatostatin to octreotide LAR: evolution of a somatostatin analogue</span> <span class="citation_source-journal">Curr. Med. Res. Opin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">2989</span><span class="NLM_x">â</span> <span class="NLM_lpage">2999</span><span class="refDoi">Â DOI: 10.1185/03007990903328959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1185%2F03007990903328959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=19842996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVCrsLvE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2009&pages=2989-2999&author=L.+Anthonyauthor=P.+U.+Freda&title=From+somatostatin+to+octreotide+LAR%3A+evolution+of+a+somatostatin+analogue&doi=10.1185%2F03007990903328959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26cR"><div class="casContent"><span class="casTitleNuber">26c</span><div class="casTitle"><span class="NLM_cas:atitle">From somatostatin to octreotide LAR: evolution of a somatostatin analogue</span></div><div class="casAuthors">Anthony, Lowell; Freda, Pamela U.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medical Research and Opinion</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2989-2999</span>CODEN:
                <span class="NLM_cas:coden">CMROCX</span>;
        ISSN:<span class="NLM_cas:issn">0300-7995</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review on 20 years of clin. experience with octreotide and its impact on quality of life in patients with acromegaly and gastroenteropancreatic neuroendocrine tumors.  Topics discussed include development of octreotide, and safety and tolerability of octreotide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKqEWc7Zw8XLVg90H21EOLACvtfcHk0lgSIaOgZcZE_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVCrsLvE&md5=bccacb962c3f2c9699b872d51dc602f2</span></div><a href="/servlet/linkout?suffix=cit26c&amp;dbid=16384&amp;doi=10.1185%2F03007990903328959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1185%252F03007990903328959%26sid%3Dliteratum%253Aachs%26aulast%3DAnthony%26aufirst%3DL.%26aulast%3DFreda%26aufirst%3DP.%2BU.%26atitle%3DFrom%2520somatostatin%2520to%2520octreotide%2520LAR%253A%2520evolution%2520of%2520a%2520somatostatin%2520analogue%26jtitle%3DCurr.%2520Med.%2520Res.%2520Opin.%26date%3D2009%26volume%3D25%26spage%3D2989%26epage%3D2999%26doi%3D10.1185%2F03007990903328959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Moreau, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delavault, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumberg, J.</span><span> </span><span class="NLM_article-title">Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy</span> <span class="citation_source-journal">Clin. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1485</span><span class="NLM_x">â</span> <span class="NLM_lpage">1508</span><span class="refDoi">Â DOI: 10.1016/j.clinthera.2006.10.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.clinthera.2006.10.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=17157109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlartrzP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2006&pages=1485-1508&author=J.+P.+Moreauauthor=P.+Delavaultauthor=J.+Blumberg&title=Luteinizing+hormone-releasing+hormone+agonists+in+the+treatment+of+prostate+cancer%3A+a+review+of+their+discovery%2C+development%2C+and+place+in+therapy&doi=10.1016%2Fj.clinthera.2006.10.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy</span></div><div class="casAuthors">Moreau, Jacques-Pierre; Delavault, Patrick; Blumberg, Joelle</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1485-1508</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">A review.  Background: Early identification of the biol. activity of LH-releasing hormone (LHRH) paved the way for the synthesis of analogs with enhanced potency and biol. properties.  Early testing in animal models and humans provided insight into the potential clin. uses of these substances, and, within 10 years, LHRH-agonist therapy had become available for use in patients with advanced prostate cancer (PC).  Over time, the role of LHRH-agonist therapy has expanded to include use as part of multi-modal treatment regimens throughout the course of the disease.  Objectives: This article reviews the discovery and development of LHRH agonists and summarizes the clin. evidence for their efficacy in PC.  Methods: Relevant clin. studies were identified through searches of the English-language literature indexed on MEDLINE through May 2006.  The main search terms were prostate cancer and LHRH agonist.  Results: Results of the initial therapeutic trials of sustained-release depot formulations of LHRH agonists in patients with PC were reported in the mid-1980s, indicating that these agents were effective and well tolerated in improving clin. symptoms and producing medical castration.  Longer-term studies and subsequent meta-analyses of randomized controlled trials in patients with advanced PC found no significant differences in overall survival when single-therapy androgen suppression was achieved through the use of LHRH-agonist therapy or orchiectomy.  Randomized trials have reported significant improvements in disease-free and overall survival in patients with locally advanced or high-grade PC treated with LHRH agonists in addn. to radiotherapy.  Several prospective randomized trials have reported decreases in rates of pos. surgical margins with short-term (6 wk to 4 mo) neoadjuvant LHRH-agonist therapy in patients with stage T1 to T3a PC undergoing prostatectomy.  Definitive comparisons of immediate and delayed treatment in patients with biochem. relapse have not been reported.  However, the results of several studies suggest that immediate LHRH-agonist therapy (or orchiectomy) may improve the course of disease progression and survival.  The risks of long-term treatment (eg, osteoporosis; fracture; anabolic loss of muscle mass, with a tendency toward wt. gain) must be considered carefully in patients who are likely to receive chronic LHRH-agonist therapy.  Intermittent schedules have been developed to reduce the adverse effects assocd. with LHRH-agonist therapy; some reports support sparing effects on bone and muscle mass and relative improvements in toxicities during off-therapy periods, whereas others have documented continuing decreases in bone mineral d. (BMD), with the rate of bone loss highest during the early cycles of therapy.  Bisphosphonate therapy has been shown to increase BMD in patients with PC and may therefore be beneficial when overt symptoms of osteopenia or osteoporosis are present.  Conclusions: LHRH-agonist therapy has been the mainstay of treatment for advanced PC for >20 years.  Clin. evidence supports expanding use of these agents at an earlier stage of disease and as part of multimodal regimens that include radiotherapy.  There is a need for further study of the efficacy of adjuvant LHRH-agonist therapy along with prostatectomy, in patients with biochem. failure, in intermittent regimens, and in conjunction with cytotoxic therapies in late-stage disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryfexVq7F0orVg90H21EOLACvtfcHk0lgSIaOgZcZE_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlartrzP&md5=c4c49dc2de5d38e8645948c219cbf219</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2006.10.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2006.10.018%26sid%3Dliteratum%253Aachs%26aulast%3DMoreau%26aufirst%3DJ.%2BP.%26aulast%3DDelavault%26aufirst%3DP.%26aulast%3DBlumberg%26aufirst%3DJ.%26atitle%3DLuteinizing%2520hormone-releasing%2520hormone%2520agonists%2520in%2520the%2520treatment%2520of%2520prostate%2520cancer%253A%2520a%2520review%2520of%2520their%2520discovery%252C%2520development%252C%2520and%2520place%2520in%2520therapy%26jtitle%3DClin.%2520Ther.%26date%3D2006%26volume%3D28%26spage%3D1485%26epage%3D1508%26doi%3D10.1016%2Fj.clinthera.2006.10.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit27b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rick, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Block, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schally, A. V.</span><span> </span><span class="NLM_article-title">Agonists of luteinizing hormone-releasing hormone in prostate cancer</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2237</span><span class="NLM_x">â</span> <span class="NLM_lpage">2247</span><span class="refDoi">Â DOI: 10.1517/14656566.2013.834328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1517%2F14656566.2013.834328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23984804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1WgtbnN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=2237-2247&author=F.+G.+Rickauthor=N.+L.+Blockauthor=A.+V.+Schally&title=Agonists+of+luteinizing+hormone-releasing+hormone+in+prostate+cancer&doi=10.1517%2F14656566.2013.834328"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27bR"><div class="casContent"><span class="casTitleNuber">27b</span><div class="casTitle"><span class="NLM_cas:atitle">Agonists of luteinizing hormone-releasing hormone in prostate cancer</span></div><div class="casAuthors">Rick, Ferenc G.; Block, Norman L.; Schally, Andrew V.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2237-2247</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Androgen deprivation therapy (ADT) has been the first-line std. of care for treating patients with hormone-sensitive advanced prostate cancer (PCa) for many decades.  The agonists of LH-releasing hormone (LHRH), also called gonadotropin-releasing hormone, are still the most frequently used form of medical ADT.  Areas covered: This article reviews the available data and most recent information concerning the use of LHRH agonists in advanced PCa.  This article also reviews the discovery and development of LHRH agonists and summarizes the clin. evidence for their efficacy in PCa.  Expert opinion: The introduction and application of agonists of LHRH has modernized and improved the treatment of advanced PCa.  The life-saving benefits of LHRH agonists are well established, yet underestimated.  Despite their efficacy, agonists of LHRH have several disadvantages or drawbacks including disease flare.  The approach to ADT has been recently further refined with the development of the LHRH antagonist degarelix.  Degarelix, a highly clin. effective third-generation LHRH antagonist, is currently available in most countries for therapy of advanced PCa.  This new drug offers attractive alternatives to LHRH agonists for treatment of advanced PCa.  A therapy for castration-resistant PCa based on a targeted cytotoxic analog of LHRH, AEZS-108, is also emerging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE14ksXam2ZrVg90H21EOLACvtfcHk0lgSIaOgZcZE_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1WgtbnN&md5=9271598950ee269614ef11648349ba56</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1517%2F14656566.2013.834328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2013.834328%26sid%3Dliteratum%253Aachs%26aulast%3DRick%26aufirst%3DF.%2BG.%26aulast%3DBlock%26aufirst%3DN.%2BL.%26aulast%3DSchally%26aufirst%3DA.%2BV.%26atitle%3DAgonists%2520of%2520luteinizing%2520hormone-releasing%2520hormone%2520in%2520prostate%2520cancer%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2013%26volume%3D14%26spage%3D2237%26epage%3D2247%26doi%3D10.1517%2F14656566.2013.834328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Wilson, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vadakkadath Meethal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowen, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atwood, C. S.</span><span> </span><span class="NLM_article-title">Leuprolide acetate: a drug of diverse clinical applications</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1851</span><span class="NLM_x">â</span> <span class="NLM_lpage">1863</span><span class="refDoi">Â DOI: 10.1517/13543784.16.11.1851</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1517%2F13543784.16.11.1851" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=17970643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1aksb%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2007&pages=1851-1863&author=A.+C.+Wilsonauthor=S.+Vadakkadath+Meethalauthor=R.+L.+Bowenauthor=C.+S.+Atwood&title=Leuprolide+acetate%3A+a+drug+of+diverse+clinical+applications&doi=10.1517%2F13543784.16.11.1851"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Leuprolide acetate: A drug of diverse clinical applications</span></div><div class="casAuthors">Wilson, Andrea C.; Vadakkadath Meethal, Sivan; Bowen, Richard L.; Atwood, Craig S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1851-1863</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Leuprolide acetate is a synthetic nonapeptide that is a potent gonadotropin-releasing hormone receptor (GnRHR) agonist used for diverse clin. applications, including the treatment of prostate cancer, endometriosis, uterine fibroids, central precocious puberty and in vitro fertilization techniques.  As its basic mechanism of action, Leuprolide acetate suppresses gonadotrope secretion of LH and FSH that subsequently suppresses gonadal sex steroid prodn.  In addn., Leuprolide acetate is presently being tested for the treatment of Alzheimer's disease, polycystic ovary syndrome, functional bowel disease, short stature, premenstrual syndrome and even as an alternative for contraception.  Mounting evidence suggests that GnRH agonist suppression of serum gonadotropins may also be important in many of the clin. applications described above.  Moreover, the presence of GnRHR in a multitude of non-reproductive tissues including the recent discovery of GnRHR expression in the hippocampus and cortex of the human brain indicates that GnRH analogs such as Leuprolide acetate may also act directly via tissue GnRHRs to modulate (brain) function.  Thus, the mol. mechanisms underlying the therapeutic effect of GnRH analogs in the treatment of these diseases may be more complex than originally thought.  These observations also suggest that the potential uses of GnRH analogs in the modulation of GnRH signaling and treatment of disease has yet to be fully realized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzEd0mte-_6rVg90H21EOLACvtfcHk0lgSIaOgZcZE_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1aksb%252FI&md5=3e1f6242f7d6cbaaf9d32ccb3624f2ce</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1517%2F13543784.16.11.1851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.16.11.1851%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DA.%2BC.%26aulast%3DVadakkadath%2BMeethal%26aufirst%3DS.%26aulast%3DBowen%26aufirst%3DR.%2BL.%26aulast%3DAtwood%26aufirst%3DC.%2BS.%26atitle%3DLeuprolide%2520acetate%253A%2520a%2520drug%2520of%2520diverse%2520clinical%2520applications%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2007%26volume%3D16%26spage%3D1851%26epage%3D1863%26doi%3D10.1517%2F13543784.16.11.1851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jiang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stalewski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galyean, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dykert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schteingart, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broqua, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aebi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aubert, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semple, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinsanya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haigh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riviere, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trojnar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Junien, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivier, J. E.</span><span> </span><span class="NLM_article-title">GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">453</span><span class="NLM_x">â</span> <span class="NLM_lpage">467</span><span class="refDoi">Â DOI: 10.1021/jm0003900</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0003900" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD3cXoslKjs7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=453-467&author=G.+Jiangauthor=J.+Stalewskiauthor=R.+Galyeanauthor=J.+Dykertauthor=C.+Schteingartauthor=P.+Broquaauthor=A.+Aebiauthor=M.+L.+Aubertauthor=G.+Sempleauthor=P.+Robsonauthor=K.+Akinsanyaauthor=R.+Haighauthor=P.+Riviereauthor=J.+Trojnarauthor=J.+L.+Junienauthor=J.+E.+Rivier&title=GnRH+antagonists%3A+a+new+generation+of+long+acting+analogues+incorporating+p-ureido-phenylalanines+at+positions+5+and+6&doi=10.1021%2Fjm0003900"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29aR"><div class="casContent"><span class="casTitleNuber">29a</span><div class="casTitle"><span class="NLM_cas:atitle">GnRH Antagonists: A New Generation of Long Acting Analogues Incorporating p-Ureido-phenylalanines at Positions 5 and 6</span></div><div class="casAuthors">Jiang, Guangcheng; Stalewski, Jacek; Galyean, Robert; Dykert, John; Schteingart, Claudio; Broqua, Pierre; Aebi, Audrey; Aubert, Michel L.; Semple, Graeme; Robson, Peter; Akinsanya, Karen; Haigh, Robert; Riviere, Pierre; Trojnar, Jerzy; Junien, Jean Louis; Rivier, Jean E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">453-467</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of antagonists of gonadotropin-releasing hormone (GnRH) of the general formula Ac-D2Nal-D4Cpa-D3Pal-Ser-4Aph/4Amf(P)-D4Aph/D4Amf(Q)-Leu-ILys-Pro-DAla-NH2 was synthesized, characterized, and screened for duration of inhibition of LH release in a castrated male rat assay.  Selected analogs were tested in a reporter gene assay (IC50 and pA2) and an in vitro histamine release assay.  P and Q contain urea/carbamoyl functionalities designed to increase potential intra- and intermol. hydrogen bonding opportunities for structural stabilization and peptide/receptor interactions, resp.  These substitutions resulted in analogs with increased hydrophilicity and a lesser propensity to form gels in aq. soln. than azaline B [Ac-D2Nal-D4Cpa-D3Pal-Ser-4Aph(Atz)-D4Aph(Atz)-Leu-ILys-Pro-DAla-NH2; Atz = 3'-amino-1H-1',2',4'-triazol-5'-yl], and in some cases they resulted in a significant increase in duration of action after s.c. administration.  Ac-D2Nal-D4Cpa-D3Pal-Ser-4Aph(L-hydroorotyl)-D4Aph(carbamoyl)-Leu-ILys-Pro-DAla-NH2 (acetate salt is FE200486) (I) and eight other congeners (20, 35, 37, 39, 41, 45-47) were identified that exhibited significantly longer duration of action than acyline [Ac-D2Nal-D4Cpa-D3Pal-Ser-4Aph(Ac)-D4Aph(Ac)-Leu-ILys-Pro-DAla-NH2] (6) when administered s.c. in castrated male rats at a dose of 50 Î¼g in 100 Î¼L of phosphate buffer.  No correlation was found between retention times on a C18 reverse phase column using a triethylammonium phosphate buffer at pH 7.0 (a measure of hydrophilicity) or affinity in an in vitro human GnRH report gene assay (pA2) and duration of action.  I was selected for preclin. studies, and some of its properties were compared to those of other clin. candidates.  In the intact rat, ganirelix, abarelix, azaline B, and I inhibited plasma testosterone for 1, 1, 14, and 57 days, resp., at 2 mg/kg s.c. in 5% mannitol (injection vol. = 20 Î¼L).  Based on the information that I, 33, 35 and 37 were significantly shorter acting than acyline or azaline B after i.v. administration (100 Î¼g/rat), we surmised that the very long duration of action of the related I (for example) was likely due to unique physicochem. properties such as soly. in aq. milieu, comparatively low propensity to form gels, and ability to diffuse at high concns. in a manner similar to that described for slow release formulations of peptides.  Indeed, in rats injected s.c. with I (2 mg/kg), plasmatic concns. of I remained above 5 ng/mL until day 41, and the time after which they dropped below 3 ng/mL and plasma LH levels started rising until full recovery was reached at day 84 with levels of I hovering around 1 ng/mL.  Addnl., I was less potent at releasing histamine from isolated rat mast cells than any of the GnRH antagonists presently described in preclin. reports.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD63M9pimmB7Vg90H21EOLACvtfcHk0ljCZPfZpsPFow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXoslKjs7Y%253D&md5=f4a5d71fd83aac9d7a6b1a1b38936891</span></div><a href="/servlet/linkout?suffix=cit29a&amp;dbid=16384&amp;doi=10.1021%2Fjm0003900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0003900%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DG.%26aulast%3DStalewski%26aufirst%3DJ.%26aulast%3DGalyean%26aufirst%3DR.%26aulast%3DDykert%26aufirst%3DJ.%26aulast%3DSchteingart%26aufirst%3DC.%26aulast%3DBroqua%26aufirst%3DP.%26aulast%3DAebi%26aufirst%3DA.%26aulast%3DAubert%26aufirst%3DM.%2BL.%26aulast%3DSemple%26aufirst%3DG.%26aulast%3DRobson%26aufirst%3DP.%26aulast%3DAkinsanya%26aufirst%3DK.%26aulast%3DHaigh%26aufirst%3DR.%26aulast%3DRiviere%26aufirst%3DP.%26aulast%3DTrojnar%26aufirst%3DJ.%26aulast%3DJunien%26aufirst%3DJ.%2BL.%26aulast%3DRivier%26aufirst%3DJ.%2BE.%26atitle%3DGnRH%2520antagonists%253A%2520a%2520new%2520generation%2520of%2520long%2520acting%2520analogues%2520incorporating%2520p-ureido-phenylalanines%2520at%2520positions%25205%2520and%25206%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D453%26epage%3D467%26doi%3D10.1021%2Fjm0003900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit29b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Broqua, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riviere, P. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivier, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aubert, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Junien, J.-L.</span><span> </span><span class="NLM_article-title">Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: Degarelix</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">301</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="NLM_x">â</span> <span class="NLM_lpage">102</span><span class="refDoi">Â DOI: 10.1124/jpet.301.1.95</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1124%2Fjpet.301.1.95" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=11907162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1Kru74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=301&publication_year=2002&pages=95-102&author=P.+Broquaauthor=P.+J.+M.+Riviereauthor=P.+M.+Connauthor=J.+E.+Rivierauthor=M.+L.+Aubertauthor=J.-L.+Junien&title=Pharmacological+profile+of+a+new%2C+potent%2C+and+long-acting+gonadotropin-releasing+hormone+antagonist%3A+Degarelix&doi=10.1124%2Fjpet.301.1.95"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29bR"><div class="casContent"><span class="casTitleNuber">29b</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: Degarelix</span></div><div class="casAuthors">Broqua, Pierre; Riviere, Pierre J.-M.; Conn, P. Michael; Rivier, Jean E.; Aubert, Michel L.; Junien, Jean-Louis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">301</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">95-102</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The authors describe the pharmacol. profile in rats and monkeys of degarelix (FE200486), a member of a new class of long-acting gonadotropin-releasing hormone (GnRH) antagonists.  At single s.c. injections of 0.3 to 10 Î¼g/kg in rats, degarelix produced a dose-dependent suppression of the pituitary-gonadal axis as revealed by the decrease in plasma LH and testosterone levels.  Duration of LH suppression increased with the dose: in the rat, significant suppression of LH lasted 1, 2, and 7 days after a single s.c. injection of degarelix at 12.5, 50, or 200 Î¼g/kg, resp.  Degarelix fully suppressed plasma LH and testosterone levels in the castrated and intact rats as well as in the ovariectomized rhesus monkey for more than 40 days after a single 2-mg/kg s.c. injection.  In comparative expts., degarelix showed a longer duration of action than the recently developed GnRH antagonists abarelix, ganirelix, cetrorelix, and azaline B.  The in vivo mechanism of action of degarelix was consistent with competitive antagonism, and the prolonged action of degarelix was paralleled by continued presence of RIAable degarelix in the general circulation.  In contrast to cetrorelix and similarly to ganirelix and abarelix, degarelix had only weak histamine-releasing properties in vitro.  These results demonstrate that the unique and favorable pharmacol. properties of degarelix make it an ideal candidate for the management of sex steroid-dependent pathologies requiring long-term inhibition of the gonadotropic axis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYLP7FlkR7WbVg90H21EOLACvtfcHk0ljCZPfZpsPFow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1Kru74%253D&md5=48224902db9d7ce3d1c2c74a99869a52</span></div><a href="/servlet/linkout?suffix=cit29b&amp;dbid=16384&amp;doi=10.1124%2Fjpet.301.1.95&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.301.1.95%26sid%3Dliteratum%253Aachs%26aulast%3DBroqua%26aufirst%3DP.%26aulast%3DRiviere%26aufirst%3DP.%2BJ.%2BM.%26aulast%3DConn%26aufirst%3DP.%2BM.%26aulast%3DRivier%26aufirst%3DJ.%2BE.%26aulast%3DAubert%26aufirst%3DM.%2BL.%26aulast%3DJunien%26aufirst%3DJ.-L.%26atitle%3DPharmacological%2520profile%2520of%2520a%2520new%252C%2520potent%252C%2520and%2520long-acting%2520gonadotropin-releasing%2520hormone%2520antagonist%253A%2520Degarelix%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D301%26spage%3D95%26epage%3D102%26doi%3D10.1124%2Fjpet.301.1.95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Manning, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misicka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bankowski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoev, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chini, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durroux, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mouillac, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guillon, G.</span><span> </span><span class="NLM_article-title">Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics</span> <span class="citation_source-journal">J. Neuroendocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">609</span><span class="NLM_x">â</span> <span class="NLM_lpage">628</span><span class="refDoi">Â DOI: 10.1111/j.1365-2826.2012.02303.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1111%2Fj.1365-2826.2012.02303.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=22375852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsFKrtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2012&pages=609-628&author=M.+Manningauthor=A.+Misickaauthor=A.+Olmaauthor=K.+Bankowskiauthor=S.+Stoevauthor=B.+Chiniauthor=T.+Durrouxauthor=B.+Mouillacauthor=M.+Corbaniauthor=G.+Guillon&title=Oxytocin+and+vasopressin+agonists+and+antagonists+as+research+tools+and+potential+therapeutics&doi=10.1111%2Fj.1365-2826.2012.02303.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics</span></div><div class="casAuthors">Manning, M.; Misicka, A.; Olma, A.; Bankowski, K.; Stoev, S.; Chini, B.; Durroux, T.; Mouillac, B.; Corbani, M.; Guillon, G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroendocrinology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">609-628</span>CODEN:
                <span class="NLM_cas:coden">JOUNE2</span>;
        ISSN:<span class="NLM_cas:issn">0953-8194</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  We recently reviewed the status of peptide and nonpeptide agonists and antagonists for the V1a, V1b and V2 receptors for arginine vasopressin (AVP) and the oxytocin receptor for oxytocin (OT).  In the present review, we update the status of peptides and nonpeptides as: (i) research tools and (ii) therapeutic agents.  We also present our recent findings on the design of fluorescent ligands for V1b receptor localization and for OT receptor dimerization.  We note the exciting discoveries regarding 2 novel naturally occurring analogs of OT.  Recent reports of a selective VP V1a agonist and a selective OT agonist point to the continued therapeutic potential of peptides in this field.  To date, only 2 nonpeptides, the V2/V1a antagonist, conivaptan and the V2 antagonist tolvaptan have received Food and Drug Administration approval for clin. use.  The development of nonpeptide AVP V1a, V1b and V2 antagonists and OT agonists and antagonists has recently been abandoned by Merck, Sanofi and Pfizer.  A promising OT antagonist, Retosiban, developed at Glaxo SmithKline is currently in a Phase II clin. trial for the prevention of premature labour.  A no. of the nonpeptide ligands that were not successful in clin. trials are proving to be valuable as research tools.  Peptide agonists and antagonists continue to be very widely used as research tools in this field.  In this regard, we present receptor data on some of the most widely used peptide and nonpeptide ligands, as a guide for their use, esp. with regard to receptor selectivity and species differences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvboATX-Tv3rVg90H21EOLACvtfcHk0lj0qjJn9okGkw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsFKrtrw%253D&md5=73b26be08e84e9daf8ac9136b472e6ad</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2826.2012.02303.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2826.2012.02303.x%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DM.%26aulast%3DMisicka%26aufirst%3DA.%26aulast%3DOlma%26aufirst%3DA.%26aulast%3DBankowski%26aufirst%3DK.%26aulast%3DStoev%26aufirst%3DS.%26aulast%3DChini%26aufirst%3DB.%26aulast%3DDurroux%26aufirst%3DT.%26aulast%3DMouillac%26aufirst%3DB.%26aulast%3DCorbani%26aufirst%3DM.%26aulast%3DGuillon%26aufirst%3DG.%26atitle%3DOxytocin%2520and%2520vasopressin%2520agonists%2520and%2520antagonists%2520as%2520research%2520tools%2520and%2520potential%2520therapeutics%26jtitle%3DJ.%2520Neuroendocrinol.%26date%3D2012%26volume%3D24%26spage%3D609%26epage%3D628%26doi%3D10.1111%2Fj.1365-2826.2012.02303.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">du Vigneaud, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ressler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swan, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katsoyannis, P. G.</span><span> </span><span class="NLM_article-title">The synthesis of oxytocin</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1954</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">3115</span><span class="NLM_x">â</span> <span class="NLM_lpage">3121</span><span class="refDoi">Â DOI: 10.1021/ja01641a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja01641a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADyaG2MXjt1WhsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1954&pages=3115-3121&author=V.+du+Vigneaudauthor=C.+Resslerauthor=J.+M.+Swanauthor=C.+W.+Robertsauthor=P.+G.+Katsoyannis&title=The+synthesis+of+oxytocin&doi=10.1021%2Fja01641a004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The synthesis of oxytocin</span></div><div class="casAuthors">du Vigneaud, Vincent; Ressler, Charlotte; Swan, John M.; Roberts, Carleton W.; Katsoyannis, Panayotis G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1954</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3115-21</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">cf. preceding abstrs.  Oxytocin was synthesized by methods previously described (loc. cit.).  The cryst. flavanates prepd. from the synthetic material and natural oxytocin, m. 182-7Â° and 181-5.5Â°, resp. (m.p. depends on the rate of heating), and both had the same cryst. form.  All comparisons indicate the identity of the synthetic and natural products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4ECACTHczrLVg90H21EOLACvtfcHk0lj0qjJn9okGkw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG2MXjt1WhsA%253D%253D&md5=488bf76788489a14ea33c7f187d2ea7c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fja01641a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja01641a004%26sid%3Dliteratum%253Aachs%26aulast%3Ddu%2BVigneaud%26aufirst%3DV.%26aulast%3DRessler%26aufirst%3DC.%26aulast%3DSwan%26aufirst%3DJ.%2BM.%26aulast%3DRoberts%26aufirst%3DC.%2BW.%26aulast%3DKatsoyannis%26aufirst%3DP.%2BG.%26atitle%3DThe%2520synthesis%2520of%2520oxytocin%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1954%26volume%3D76%26spage%3D3115%26epage%3D3121%26doi%3D10.1021%2Fja01641a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span>Ferring Announces European Approval of New Room Temperature Stable Formulation of PABAL (Carbetocin); <span class="NLM_publisher-name">Ferring Pharmaceuticals</span>: <span class="NLM_publisher-loc">Saint-Prex, Switzerland</span>, April 7,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="https://www.ferring.com/en/media/press-releases/2015/pabal-new-formulation-eu-approval-7-apr-15/" class="extLink">https://www.ferring.com/en/media/press-releases/2015/pabal-new-formulation-eu-approval-7-apr-15/</a> (accessed January 17, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Ferring+Announces+European+Approval+of+New+Room+Temperature+Stable+Formulation+of+PABAL+%28Carbetocin%29%3B+Ferring+Pharmaceuticals%3A+Saint-Prex%2C+Switzerland%2C+April+7%2C+2015%3B+https%3A%2F%2Fwww.ferring.com%2Fen%2Fmedia%2Fpress-releases%2F2015%2Fpabal-new-formulation-eu-approval-7-apr-15%2F+%28accessed+January+17%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DFerring%2520Announces%2520European%2520Approval%2520of%2520New%2520Room%2520Temperature%2520Stable%2520Formulation%2520of%2520PABAL%2520%2528Carbetocin%2529%26pub%3DFerring%2520Pharmaceuticals%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Awan, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, T.</span><span> </span><span class="NLM_article-title">Biosynthesis of therapeutic natural products using synthetic biology</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x"> (</span><span class="NLM_issue">A</span><span class="NLM_x">) </span> <span class="NLM_fpage">96</span><span class="NLM_x">â</span> <span class="NLM_lpage">106</span><span class="refDoi">Â DOI: 10.1016/j.addr.2016.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.addr.2016.04.010" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2016&pages=96-106&issue=A&author=A.+R.+Awanauthor=W.+M.+Shawauthor=T.+Ellis&title=Biosynthesis+of+therapeutic+natural+products+using+synthetic+biology&doi=10.1016%2Fj.addr.2016.04.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2016.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2016.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DAwan%26aufirst%3DA.%2BR.%26aulast%3DShaw%26aufirst%3DW.%2BM.%26aulast%3DEllis%26aufirst%3DT.%26atitle%3DBiosynthesis%2520of%2520therapeutic%2520natural%2520products%2520using%2520synthetic%2520biology%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2016%26volume%3D105%26issue%3DA%26spage%3D96%26epage%3D106%26doi%3D10.1016%2Fj.addr.2016.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit33b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Marahiel, M. A.</span><span> </span><span class="NLM_article-title">Working outside the protein-synthesis rules: insights into non-ribosomal peptide synthesis</span> <span class="citation_source-journal">J. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">799</span><span class="NLM_x">â</span> <span class="NLM_lpage">807</span><span class="refDoi">Â DOI: 10.1002/psc.1183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fpsc.1183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=19827002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlOku7%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=799-807&author=M.+A.+Marahiel&title=Working+outside+the+protein-synthesis+rules%3A+insights+into+non-ribosomal+peptide+synthesis&doi=10.1002%2Fpsc.1183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33bR"><div class="casContent"><span class="casTitleNuber">33b</span><div class="casTitle"><span class="NLM_cas:atitle">Working outside the protein-synthesis rules: Insights into non-ribosomal peptide synthesis</span></div><div class="casAuthors">Marahiel, Mohamed A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">799-807</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Non-ribosomally synthesized microbial peptides show remarkable structural diversity and constitute a widespread class of the most potent antibiotics and other important pharmaceuticals that range from penicillin to the immunosuppressant cyclosporine.  They are assembled independent of the ribosome in a nucleic acid-independent way by a group of multimodular megaenzymes called non-ribosomal peptide synthetases.  These biosynthetic machineries rely not only on the 20 canonical amino acids, but also use several different building blocks, including D-configured- and Î²-amino acids, methylated, glycosylated and phosphorylated residues, heterocyclic elements and even fatty acid building blocks.  This structural diversity leads to a high d. of functional groups, which are often essential for the bioactivity.  Recent biochem. and structural studies on several non-ribosomal peptide synthetase assembly lines have substantially contributed to the understanding of the mol. mechanisms and dynamics of individual catalytic domains underlying substrate recognition and substrate shuffling among the different active sites as well as peptide bond formation and the regio- and stereoselective product release.  Copyright Â© 2009 European Peptide Society and John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnSCGxpNUutbVg90H21EOLACvtfcHk0lj0qjJn9okGkw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlOku7%252FI&md5=1534b9333ce37cf1cdd650cb1699216f</span></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=10.1002%2Fpsc.1183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.1183%26sid%3Dliteratum%253Aachs%26aulast%3DMarahiel%26aufirst%3DM.%2BA.%26atitle%3DWorking%2520outside%2520the%2520protein-synthesis%2520rules%253A%2520insights%2520into%2520non-ribosomal%2520peptide%2520synthesis%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2009%26volume%3D15%26spage%3D799%26epage%3D807%26doi%3D10.1002%2Fpsc.1183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Smith, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romesberg, F. E.</span><span> </span><span class="NLM_article-title">Mechanism of action of the arylomycin antibiotics and effects of signal peptidase I inhibition</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5054</span><span class="NLM_x">â</span> <span class="NLM_lpage">5060</span><span class="refDoi">Â DOI: 10.1128/AAC.00785-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1128%2FAAC.00785-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=22802255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKiu7vI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=5054-5060&author=P.+A.+Smithauthor=F.+E.+Romesberg&title=Mechanism+of+action+of+the+arylomycin+antibiotics+and+effects+of+signal+peptidase+I+inhibition&doi=10.1128%2FAAC.00785-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action of the arylomycin antibiotics and effects of signal peptidase I inhibition</span></div><div class="casAuthors">Smith, Peter A.; Romesberg, Floyd E.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5054-5060</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Clin. approved antibiotics inhibit only a small no. of conserved pathways that are essential for bacterial viability, and the physiol. effects of inhibiting these pathways have been studied in great detail.  Likewise, characterizing the effects of candidate antibiotics that function via novel mechanisms of action is crit. for their development, which is of increasing importance due to the ever-growing problem of resistance.  The arylomycins are a novel class of natural-product antibiotics that act via the inhibition of type I signal peptidase (SPase), which is an essential enzyme that functions as part of the general secretory pathway and is not the target of any clin. deployed antibiotic.  Correspondingly, little is known about the effects of SPase inhibition or how bacteria may respond to mitigate the assocd. secretion stress.  Using genetically sensitized Escherichia coli and Staphylococcus aureus as model organisms, the authors examine the activity of arylomycin as a function of its concn., bacterial cell d., target expression levels, and bacterial growth phase.  The results reveal that the activity of the arylomycins results from an insufficient flux of proteins through the secretion pathway and the resulting mislocalization of proteins.  Interestingly, this has profoundly different effects on E. coli and S. aureus.  Finally, the authors examine the activity of arylomycin in combination with distinct classes of antibiotics and demonstrate that SPase inhibition results in synergistic sensitivity when combined with an aminoglycoside.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruG04r4q-hUrVg90H21EOLACvtfcHk0lj0u39rREsWHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKiu7vI&md5=033578665bbd60aec3ef5222cfa8e5d3</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1128%2FAAC.00785-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00785-12%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DP.%2BA.%26aulast%3DRomesberg%26aufirst%3DF.%2BE.%26atitle%3DMechanism%2520of%2520action%2520of%2520the%2520arylomycin%2520antibiotics%2520and%2520effects%2520of%2520signal%2520peptidase%2520I%2520inhibition%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D5054%26epage%3D5060%26doi%3D10.1128%2FAAC.00785-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrios Steed, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romesberg, F.</span><span> </span><span class="NLM_article-title">Efforts toward broadening the spectrum of arylomycin antibiotic activity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5654</span><span class="NLM_x">â</span> <span class="NLM_lpage">5659</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2013.08.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.bmcl.2013.08.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24012184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVSktb7N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5654-5659&author=J.+Liuauthor=P.+A.+Smithauthor=D.+Barrios+Steedauthor=F.+Romesberg&title=Efforts+toward+broadening+the+spectrum+of+arylomycin+antibiotic+activity&doi=10.1016%2Fj.bmcl.2013.08.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Efforts toward broadening the spectrum of arylomycin antibiotic activity</span></div><div class="casAuthors">Liu, Jian; Smith, Peter A.; Steed, Danielle Barrios; Romesberg, Floyd</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5654-5659</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">New antibiotics are needed, and one source may be 'latent' antibiotics, natural products whose once broad-spectrum activity is currently limited by the evolution of resistance in nature.  We have identified a potential class of latent antibiotics, the arylomycins, which are lipopeptides with a C-terminal macrocycle that target signal peptidase and whose spectrum is limited by a resistance-conferring mutation in many bacteria.  Herein, we report the synthesis and evaluation of several arylomycin derivs., and demonstrate that both C-terminal homologation with a glycyl aldehyde and addn. of a pos. charge to the macrocycle increase the activity and spectrum of the arylomycin scaffold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppRqYx27wQcrVg90H21EOLACvtfcHk0lj0u39rREsWHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVSktb7N&md5=afc1eb200a49c359f4a37df29f6656c0</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.08.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.08.026%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DP.%2BA.%26aulast%3DBarrios%2BSteed%26aufirst%3DD.%26aulast%3DRomesberg%26aufirst%3DF.%26atitle%3DEfforts%2520toward%2520broadening%2520the%2520spectrum%2520of%2520arylomycin%2520antibiotic%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5654%26epage%3D5659%26doi%3D10.1016%2Fj.bmcl.2013.08.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Ling, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peoples, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spoering, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engels, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conlon, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaberle, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epstein, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazarides, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steadman, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felix, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fetterman, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millett, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nitti, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zullo, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, K.</span><span> </span><span class="NLM_article-title">A new antibiotic kills pathogens without detectable resistance</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">517</span><span class="NLM_x">, </span> <span class="NLM_fpage">455</span><span class="NLM_x">â</span> <span class="NLM_lpage">459</span><span class="refDoi">Â DOI: 10.1038/nature14098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnature14098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25561178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOju7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=517&publication_year=2015&pages=455-459&author=L.+L.+Lingauthor=T.+Schneiderauthor=A.+J.+Peoplesauthor=A.+L.+Spoeringauthor=I.+Engelsauthor=B.+P.+Conlonauthor=A.+Muellerauthor=T.+F.+Schaberleauthor=D.+E.+Hughesauthor=S.+Epsteinauthor=M.+Jonesauthor=L.+Lazaridesauthor=V.+A.+Steadmanauthor=D.+R.+Cohenauthor=C.+R.+Felixauthor=K.+A.+Fettermanauthor=W.+P.+Millettauthor=A.+G.+Nittiauthor=A.+M.+Zulloauthor=C.+Chenauthor=K.+Lewis&title=A+new+antibiotic+kills+pathogens+without+detectable+resistance&doi=10.1038%2Fnature14098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A new antibiotic kills pathogens without detectable resistance</span></div><div class="casAuthors">Ling, Losee L.; Schneider, Tanja; Peoples, Aaron J.; Spoering, Amy L.; Engels, Ina; Conlon, Brian P.; Mueller, Anna; Schaberle, Till F.; Hughes, Dallas E.; Epstein, Slava; Jones, Michael; Lazarides, Linos; Steadman, Victoria A.; Cohen, Douglas R.; Felix, Cintia R.; Fetterman, K. Ashley; Millett, William P.; Nitti, Anthony G.; Zullo, Ashley M.; Chen, Chao; Lewis, Kim</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">517</span>
        (<span class="NLM_cas:issue">7535</span>),
    <span class="NLM_cas:pages">455-459</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Antibiotic resistance is spreading faster than the introduction of new compds. into clin. practice, causing a public health crisis.  Most antibiotics were produced by screening soil microorganisms, but this limited resource of cultivable bacteria was overmined by the 1960s.  Synthetic approaches to produce antibiotics have been unable to replace this platform.  Uncultured bacteria make up approx. 99% of all species in external environments, and are an untapped source of new antibiotics.  We developed several methods to grow uncultured organisms by cultivation in situ or by using specific growth factors.  Here we report a new antibiotic that we term teixobactin, discovered in a screen of uncultured bacteria.  Teixobactin inhibits cell wall synthesis by binding to a highly conserved motif of lipid II (precursor of peptidoglycan) and lipid III (precursor of cell wall teichoic acid).  We did not obtain any mutants of Staphylococcus aureus or Mycobacterium tuberculosis resistant to teixobactin.  The properties of this compd. suggest a path towards developing antibiotics that are likely to avoid development of resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV0hZrSZheoLVg90H21EOLACvtfcHk0lj0u39rREsWHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOju7w%253D&md5=27e302d7d44a549a91aa52113c3b4ad8</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnature14098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14098%26sid%3Dliteratum%253Aachs%26aulast%3DLing%26aufirst%3DL.%2BL.%26aulast%3DSchneider%26aufirst%3DT.%26aulast%3DPeoples%26aufirst%3DA.%2BJ.%26aulast%3DSpoering%26aufirst%3DA.%2BL.%26aulast%3DEngels%26aufirst%3DI.%26aulast%3DConlon%26aufirst%3DB.%2BP.%26aulast%3DMueller%26aufirst%3DA.%26aulast%3DSchaberle%26aufirst%3DT.%2BF.%26aulast%3DHughes%26aufirst%3DD.%2BE.%26aulast%3DEpstein%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DM.%26aulast%3DLazarides%26aufirst%3DL.%26aulast%3DSteadman%26aufirst%3DV.%2BA.%26aulast%3DCohen%26aufirst%3DD.%2BR.%26aulast%3DFelix%26aufirst%3DC.%2BR.%26aulast%3DFetterman%26aufirst%3DK.%2BA.%26aulast%3DMillett%26aufirst%3DW.%2BP.%26aulast%3DNitti%26aufirst%3DA.%2BG.%26aulast%3DZullo%26aufirst%3DA.%2BM.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DLewis%26aufirst%3DK.%26atitle%3DA%2520new%2520antibiotic%2520kills%2520pathogens%2520without%2520detectable%2520resistance%26jtitle%3DNature%26date%3D2015%26volume%3D517%26spage%3D455%26epage%3D459%26doi%3D10.1038%2Fnature14098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Oppedijk, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breukink, E.</span><span> </span><span class="NLM_article-title">Hit âem where it hurts: the growing and structurally diverse family of peptides that target Lipid-II</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Biomembr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">1858</span><span class="NLM_x">, </span> <span class="NLM_fpage">947</span><span class="NLM_x">â</span> <span class="NLM_lpage">957</span><span class="refDoi">Â DOI: 10.1016/j.bbamem.2015.10.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.bbamem.2015.10.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26523408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKkt73F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1858&publication_year=2016&pages=947-957&author=S.+F.+Oppedijkauthor=N.+I.+Martinauthor=E.+Breukink&title=Hit+%E2%80%99em+where+it+hurts%3A+the+growing+and+structurally+diverse+family+of+peptides+that+target+Lipid-II&doi=10.1016%2Fj.bbamem.2015.10.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Hit 'em where it hurts: The growing and structurally diverse family of peptides that target lipid-II</span></div><div class="casAuthors">Oppedijk, Sabine F.; Martin, Nathaniel I.; Breukink, Eefjan</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Biomembranes</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1858</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">947-957</span>CODEN:
                <span class="NLM_cas:coden">BBBMBS</span>;
        ISSN:<span class="NLM_cas:issn">0005-2736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Understanding the mode of action of antibiotics is becoming more and more important in the time that microorganisms start to develop resistance.  One very well validated target of several classes of antibiotics is the peptidoglycan precursor lipid II.  In this review different classes of lipid II targeting antibiotics will be discussed in detail, including the lantibiotics, human invertebrate defensins and the recently discovered teixobactin.  By hitting bacteria where it hurts, at the level of lipid II, we expect to be able to develop efficient antibacterial agents in the future.  This article is part of a Special Issue entitled: Antimicrobial peptides edited by Karl Lohner and Kai Hilpert.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_3ekboMFuwLVg90H21EOLACvtfcHk0lj0u39rREsWHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKkt73F&md5=e9bca4c761fb140cc0704a397750db5e</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamem.2015.10.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamem.2015.10.024%26sid%3Dliteratum%253Aachs%26aulast%3DOppedijk%26aufirst%3DS.%2BF.%26aulast%3DMartin%26aufirst%3DN.%2BI.%26aulast%3DBreukink%26aufirst%3DE.%26atitle%3DHit%2520%25E2%2580%2599em%2520where%2520it%2520hurts%253A%2520the%2520growing%2520and%2520structurally%2520diverse%2520family%2520of%2520peptides%2520that%2520target%2520Lipid-II%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Biomembr.%26date%3D2016%26volume%3D1858%26spage%3D947%26epage%3D957%26doi%3D10.1016%2Fj.bbamem.2015.10.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">King, G. F.</span><span> </span><span class="NLM_article-title">Venoms as a platform for human drugs: translating toxins into therapeutics</span> <span class="citation_source-journal">Expert Opin. Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1469</span><span class="NLM_x">â</span> <span class="NLM_lpage">1484</span><span class="refDoi">Â DOI: 10.1517/14712598.2011.621940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1517%2F14712598.2011.621940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21939428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1ylsrjF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=1469-1484&author=G.+F.+King&title=Venoms+as+a+platform+for+human+drugs%3A+translating+toxins+into+therapeutics&doi=10.1517%2F14712598.2011.621940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Venoms as a platform for human drugs: translating toxins into therapeutics</span></div><div class="casAuthors">King, Glenn F.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1469-1484</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction:An extraordinarily diverse range of animals have evolved venoms for predation, defense, or competitor deterrence.  The major components of most venoms are peptides and proteins that are often protease-resistant due to their disulfide-rich architectures.  Some of these toxins have become valuable as pharmacol. tools and/or therapeutics due to their extremely high specificity and potency for particular mol. targets.  There are currently six FDA-approved drugs derived from venom peptides or proteins.  Areas covered:This article surveys the current pipeline of venom-derived therapeutics and critically examines the potential of peptide and protein drugs derived from venoms.  Emerging trends are identified, including an increasing industry focus on disulfide-rich venom peptides and the use of a broader array of mol. targets in order to develop venom-based therapeutics for treating a wider range of clin. conditions.  Expert opinion:Key tech. advances in combination with a renewed industry-wide focus on biologics have converged to provide a larger than ever pipeline of venom-derived therapeutics.  Disulfide-rich venom peptides obviate some of the traditional disadvantages of therapeutic peptides and some may be suitable for oral administration.  Moreover, some venom peptides can breach the blood brain barrier and translocate across cell membranes, which opens up the possibility of exploiting mol. targets not previously accessible to peptide drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoYClUIGUrZbVg90H21EOLACvtfcHk0lgkLpzF0BzunA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1ylsrjF&md5=4983d10289108fac346231191e6169f7</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1517%2F14712598.2011.621940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14712598.2011.621940%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DG.%2BF.%26atitle%3DVenoms%2520as%2520a%2520platform%2520for%2520human%2520drugs%253A%2520translating%2520toxins%2520into%2520therapeutics%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2011%26volume%3D11%26spage%3D1469%26epage%3D1484%26doi%3D10.1517%2F14712598.2011.621940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Koh, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kini, R. M.</span><span> </span><span class="NLM_article-title">From snake venom toxins to therapeutics--cardiovascular examples</span> <span class="citation_source-journal">Toxicon</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">497</span><span class="NLM_x">â</span> <span class="NLM_lpage">506</span><span class="refDoi">Â DOI: 10.1016/j.toxicon.2011.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.toxicon.2011.03.017" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2012&pages=497-506&author=C.+Y.+Kohauthor=R.+M.+Kini&title=From+snake+venom+toxins+to+therapeutics%2D%2Dcardiovascular+examples&doi=10.1016%2Fj.toxicon.2011.03.017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.toxicon.2011.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.toxicon.2011.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DKoh%26aufirst%3DC.%2BY.%26aulast%3DKini%26aufirst%3DR.%2BM.%26atitle%3DFrom%2520snake%2520venom%2520toxins%2520to%2520therapeutics--cardiovascular%2520examples%26jtitle%3DToxicon%26date%3D2012%26volume%3D59%26spage%3D497%26epage%3D506%26doi%3D10.1016%2Fj.toxicon.2011.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">McGivern, J. G.</span><span> </span><span class="NLM_article-title">Ziconotide: a review of its pharmacology and use in the treatment of pain</span> <span class="citation_source-journal">Neuropsychiatr. Dis. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">69</span><span class="NLM_x">â</span> <span class="NLM_lpage">85</span><span class="refDoi">Â DOI: 10.2147/nedt.2007.3.1.69</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.2147%2Fnedt.2007.3.1.69" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=19300539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmt12ksLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=69-85&author=J.+G.+McGivern&title=Ziconotide%3A+a+review+of+its+pharmacology+and+use+in+the+treatment+of+pain&doi=10.2147%2Fnedt.2007.3.1.69"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Ziconotide: a review of its pharmacology and use in the treatment of pain</span></div><div class="casAuthors">McGivern, Joseph G.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychiatric Disease and Treatment</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">69-85</span>CODEN:
                <span class="NLM_cas:coden">NDTEAZ</span>;
        ISSN:<span class="NLM_cas:issn">1176-6328</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press (NZ) Ltd.</span>)
        </div><div class="casAbstract">A review.  Ziconotide is a powerful analgesic drug that has a unique mechanism of action involving potent and selective block of N-type calcium channels, which control neurotransmission at many synapses.  The analgesic efficacy of ziconotide likely results from its ability to interrupt pain signaling at the level of the spinal cord.  Ziconotide is a peptidic drug and has been approved for the treatment of severe chronic pain in patients only when administered by the intrathecal route.  Importantly, prolonged administration of ziconotide does not lead to the development of addiction or tolerance.  The current review discusses the various studies that have addressed the in vitro biochem. and electrophysiol. actions of ziconotide as well as the numerous pre-clin. studies that were conducted to elucidate its antinociceptive mechanism of action in animals.  In addn., this review considers the pivotal Phase 3 (and other) clin. trials that were conducted in support of ziconotide's approval for the treatment of severe chronic pain and tries to offer some insights regarding the future discovery and development of newer analgesic drugs that would act by a similar mechanism to ziconotide but which might offer improved safety, tolerability and ease of use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHm-hL5lB7QrVg90H21EOLACvtfcHk0lgkLpzF0BzunA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmt12ksLY%253D&md5=83510a769b61bd52349d012015894f40</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.2147%2Fnedt.2007.3.1.69&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252Fnedt.2007.3.1.69%26sid%3Dliteratum%253Aachs%26aulast%3DMcGivern%26aufirst%3DJ.%2BG.%26atitle%3DZiconotide%253A%2520a%2520review%2520of%2520its%2520pharmacology%2520and%2520use%2520in%2520the%2520treatment%2520of%2520pain%26jtitle%3DNeuropsychiatr.%2520Dis.%2520Treat.%26date%3D2007%26volume%3D3%26spage%3D69%26epage%3D85%26doi%3D10.2147%2Fnedt.2007.3.1.69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Weiglmeier, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berkner, H.</span><span> </span><span class="NLM_article-title">Cure and curse: E. coli heat-stable enterotoxin and its receptor Guanylyl Cyclase C</span> <span class="citation_source-journal">Toxins</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">2213</span><span class="NLM_x">â</span> <span class="NLM_lpage">2229</span><span class="refDoi">Â DOI: 10.3390/toxins2092213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3390%2Ftoxins2092213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=22069681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFSqsrnP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=2213-2229&author=P.+R.+Weiglmeierauthor=P.+Roschauthor=H.+Berkner&title=Cure+and+curse%3A+E.+coli+heat-stable+enterotoxin+and+its+receptor+Guanylyl+Cyclase+C&doi=10.3390%2Ftoxins2092213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Cure and curse: E. coli heat-stable enterotoxin and its receptor guanylyl cyclase C</span></div><div class="casAuthors">Weiglmeier, Philipp R.; Roesch, Paul; Berkner, Hanna</div><div class="citationInfo"><span class="NLM_cas:title">Toxins</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2213-2229</span>CODEN:
                <span class="NLM_cas:coden">TOXIB7</span>;
        ISSN:<span class="NLM_cas:issn">2072-6651</span>.
    
            (<span class="NLM_cas:orgname">Molecular Diversity Preservation International</span>)
        </div><div class="casAbstract">A review.  Enterotoxigenic Escherichia coli (ETEC) assocd. diarrhea is responsible for roughly half a million deaths per yr, the majority taking place in developing countries.  The main agent responsible for these diseases is the bacterial heat-stable enterotoxin STa.  STa is secreted by ETEC and after secretion binds to the intestinal receptor guanylyl cyclase C (GC-C), thus triggering a signaling cascade that eventually leads to the release of electrolytes and water in the intestine.  Addnl., GC-C is a specific marker for colorectal carcinoma and STa is suggested to have an inhibitory effect on intestinal carcinogenesis.  To understand the conformational events involved in ligand binding to GC-C and to devise therapeutic strategies to treat both diarrheal diseases and colorectal cancer, it is paramount to obtain structural information on the receptor ligand system.  Here we summarize the currently available structural data and report on physiol. consequences of STa binding to GC-C in intestinal epithelia and colorectal carcinoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquGwHtDLUF97Vg90H21EOLACvtfcHk0lgkLpzF0BzunA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFSqsrnP&md5=81402bec18fad62a6708112ade868be5</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.3390%2Ftoxins2092213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Ftoxins2092213%26sid%3Dliteratum%253Aachs%26aulast%3DWeiglmeier%26aufirst%3DP.%2BR.%26aulast%3DRosch%26aufirst%3DP.%26aulast%3DBerkner%26aufirst%3DH.%26atitle%3DCure%2520and%2520curse%253A%2520E.%2520coli%2520heat-stable%2520enterotoxin%2520and%2520its%2520receptor%2520Guanylyl%2520Cyclase%2520C%26jtitle%3DToxins%26date%3D2010%26volume%3D2%26spage%3D2213%26epage%3D2229%26doi%3D10.3390%2Ftoxins2092213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hannig, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tchernychev, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurtz, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryant, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silos-Santiago, I.</span><span> </span><span class="NLM_article-title">Guanylate cyclase-C/cGMP: an emerging pathway in the regulation of visceral pain</span> <span class="citation_source-journal">Front. Mol. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">31</span><span class="refDoi">Â DOI: 10.3389/fnmol.2014.00031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3389%2Ffnmol.2014.00031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24795564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVaqs7fO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=31&author=G.+Hannigauthor=B.+Tchernychevauthor=C.+B.+Kurtzauthor=A.+P.+Bryantauthor=M.+G.+Currieauthor=I.+Silos-Santiago&title=Guanylate+cyclase-C%2FcGMP%3A+an+emerging+pathway+in+the+regulation+of+visceral+pain&doi=10.3389%2Ffnmol.2014.00031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42aR"><div class="casContent"><span class="casTitleNuber">42a</span><div class="casTitle"><span class="NLM_cas:atitle">Guanylate cyclase-C/cGMP: an emerging pathway in the regulation of visceral pain</span></div><div class="casAuthors">Hannig, Gerhard; Tchernychev, Boris; Kurtz, Caroline B.; Bryant, Alexander P.; Currie, Mark G.; Silos-Santiago, Inmaculada</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31/1-31/6, 6 pp.</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Activation of guanylate cyclase-C (GC-C) expressed predominantly on intestinal epithelial cells by guanylin, uroguanylin or the closely related GC-C agonist peptide, linaclotide, stimulates generation, and release of cyclic guanosine-3',5'-monophosphate (cGMP).  Evidence that the visceral analgesic effects of linaclotide are mediated by a novel, GC-C-dependent peripheral sensory mechanism was first demonstrated in animal models of visceral pain.  Subsequent studies with uroguanylin or linaclotide have confirmed the activation of a GC-C/cGMP pathway leading to increased submucosal cGMP mediated by cGMP efflux pumps, which modulates intestinal nociceptor function resulting in peripheral analgesia.  These effects can be reproduced by the addn. of exogenous cGMP and support a role for GC-C/cGMP signaling in the regulation of visceral sensation, a physiol. function that has not previously been linked to the GC-C/cGMP pathway.  Notably, targeting the GC-C/cGMP pathway for treatment of gastrointestinal pain and abdominal sensory symptoms has now been validated in the clinic.  In 2012, linaclotide was approved in the United States and European Union for the treatment of adult patients with irritable bowel syndrome with constipation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf5sDDAMWCV7Vg90H21EOLACvtfcHk0lhjwIFE02pwqg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVaqs7fO&md5=8485549bcaa6d0b9bf6d06caa78f70fc</span></div><a href="/servlet/linkout?suffix=cit42a&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2014.00031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2014.00031%26sid%3Dliteratum%253Aachs%26aulast%3DHannig%26aufirst%3DG.%26aulast%3DTchernychev%26aufirst%3DB.%26aulast%3DKurtz%26aufirst%3DC.%2BB.%26aulast%3DBryant%26aufirst%3DA.%2BP.%26aulast%3DCurrie%26aufirst%3DM.%2BG.%26aulast%3DSilos-Santiago%26aufirst%3DI.%26atitle%3DGuanylate%2520cyclase-C%252FcGMP%253A%2520an%2520emerging%2520pathway%2520in%2520the%2520regulation%2520of%2520visceral%2520pain%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2014%26volume%3D7%26spage%3D31%26doi%3D10.3389%2Ffnmol.2014.00031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit42b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rothstein, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedenberg, F. K.</span><span> </span><span class="NLM_article-title">Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2125</span><span class="NLM_x">â</span> <span class="NLM_lpage">2132</span><span class="refDoi">Â DOI: 10.1517/14656566.2013.833605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1517%2F14656566.2013.833605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24007408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyns7jL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=2125-2132&author=R.+D.+Rothsteinauthor=F.+K.+Friedenberg&title=Linaclotide%3A+a+novel+compound+for+the+treatment+of+irritable+bowel+syndrome+with+constipation&doi=10.1517%2F14656566.2013.833605"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42bR"><div class="casContent"><span class="casTitleNuber">42b</span><div class="casTitle"><span class="NLM_cas:atitle">Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation</span></div><div class="casAuthors">Rothstein, Robin D.; Friedenberg, Frank K.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2125-2132</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Irritable Bowel Syndrome with constipation (IBS-C) is assocd. with abdominal pain and infrequent spontaneous bowel movements.  Patients with Chronic Idiopathic Constipation do not have abdominal pain as a predominant symptom. represents a new class of medication approved in the USA for both of these common conditions.  Linaclotide is approved for IBS-C only in the EU.  The only other medication approved at this time for IBS-C is lubiprostone.  Areas covered: This review will cover the mechanism of action of linaclotide, and review the pivotal pre-clin. and clin. trials leading to its approval in 2012.  The indications, common side effects, and black box warnings listed for linaclotide are reviewed.  Expert opinion: Linaclotide is superior to placebo for the treatment of both IBS-C and Chronic Idiopathic Constipation.  The drug has minimal systemic bioavailability and a favorable safety profile.  For IBS-C, it is appropriate as a first-line prescription treatment.  For Chronic Idiopathic Constipation, osmotic or stimulant laxatives should be tried prior to using linaclotide due to their considerable lower cost.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2Z2gxC832MbVg90H21EOLACvtfcHk0lhjwIFE02pwqg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyns7jL&md5=a889e9cf2b6ffc4feb43885c24937b4b</span></div><a href="/servlet/linkout?suffix=cit42b&amp;dbid=16384&amp;doi=10.1517%2F14656566.2013.833605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2013.833605%26sid%3Dliteratum%253Aachs%26aulast%3DRothstein%26aufirst%3DR.%2BD.%26aulast%3DFriedenberg%26aufirst%3DF.%2BK.%26atitle%3DLinaclotide%253A%2520a%2520novel%2520compound%2520for%2520the%2520treatment%2520of%2520irritable%2520bowel%2520syndrome%2520with%2520constipation%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2013%26volume%3D14%26spage%3D2125%26epage%3D2132%26doi%3D10.1517%2F14656566.2013.833605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gould, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aboye, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camarero, J. A.</span><span> </span><span class="NLM_article-title">Cyclotides, a novel ultrastable polypeptide scaffold for drug discovery</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">4294</span><span class="NLM_x">â</span> <span class="NLM_lpage">4307</span><span class="refDoi">Â DOI: 10.2174/138161211798999438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.2174%2F138161211798999438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=22204428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFajtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=4294-4307&author=A.+Gouldauthor=Y.+Jiauthor=T.+L.+Aboyeauthor=J.+A.+Camarero&title=Cyclotides%2C+a+novel+ultrastable+polypeptide+scaffold+for+drug+discovery&doi=10.2174%2F138161211798999438"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43aR"><div class="casContent"><span class="casTitleNuber">43a</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclotides, a novel ultrastable polypeptide scaffold for drug discovery</span></div><div class="casAuthors">Gould, Andrew; Ji, Yanbin; Aboye, Teshome L.; Camarero, Julio A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">4294-4307</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cyclotides are a unique and growing family of backbone cyclized peptides that also contain a cystine knot motif built from six conserved cysteine residues.  This unique circular backbone topol. and knotted arrangement of three disulfide bonds makes them exceptionally stable to thermal, chem., and enzymic degrdn. compared to other peptides of similar size.  Aside from the conserved residues forming the cystine knot, cyclotides have been shown to have high variability in their sequences.  Consisting of over 160 known members, cyclotides have many biol. activities, ranging from anti-HIV, antimicrobial, hemolytic, and uterotonic capabilities; addnl., some cyclotides have been shown to have cell penetrating properties.  Originally discovered and isolated from plants, cyclotides can also be produced synthetically and recombinantly.  The high sequence variability, stability, and cell penetrating properties of cyclotides make them potential scaffolds to be used to graft known active peptides or engineer peptide-based drug design.  The present review reports recent findings in the biol. diversity and therapeutic potential of natural and engineered cyclotides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3vE5jX-h3mLVg90H21EOLACvtfcHk0lhjwIFE02pwqg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFajtw%253D%253D&md5=55e37d4ffa802af0af3c47ad7f87789c</span></div><a href="/servlet/linkout?suffix=cit43a&amp;dbid=16384&amp;doi=10.2174%2F138161211798999438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161211798999438%26sid%3Dliteratum%253Aachs%26aulast%3DGould%26aufirst%3DA.%26aulast%3DJi%26aufirst%3DY.%26aulast%3DAboye%26aufirst%3DT.%2BL.%26aulast%3DCamarero%26aufirst%3DJ.%2BA.%26atitle%3DCyclotides%252C%2520a%2520novel%2520ultrastable%2520polypeptide%2520scaffold%2520for%2520drug%2520discovery%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2011%26volume%3D17%26spage%3D4294%26epage%3D4307%26doi%3D10.2174%2F138161211798999438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit43b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Weidmann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craik, D. J.</span><span> </span><span class="NLM_article-title">Discovery, structure, function, and applications of cyclotides: circular proteins from plants</span> <span class="citation_source-journal">J. Exp. Bot.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">4801</span><span class="NLM_x">â</span> <span class="NLM_lpage">4812</span><span class="refDoi">Â DOI: 10.1093/jxb/erw210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1093%2Fjxb%2Ferw210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=27222514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVejs7fN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2016&pages=4801-4812&author=J.+Weidmannauthor=D.+J.+Craik&title=Discovery%2C+structure%2C+function%2C+and+applications+of+cyclotides%3A+circular+proteins+from+plants&doi=10.1093%2Fjxb%2Ferw210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43bR"><div class="casContent"><span class="casTitleNuber">43b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery, structure, function, and applications of cyclotides: circular proteins from plants</span></div><div class="casAuthors">Weidmann, Joachim; Craik, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Botany</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4801-4812</span>CODEN:
                <span class="NLM_cas:coden">JEBOA6</span>;
        ISSN:<span class="NLM_cas:issn">0022-0957</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Cyclotides are plant-derived cyclic peptides that have a head-to-tail cyclic backbone and three conserved disulfide bonds that form a cyclic cystine knot motif.  They occur in plants from the Violaceae, Rubiaceae, Cucurbitaceae, Fabaceae, and Solanaceae families, typically with 10-100 cyclotides in a given plant species, in a wide range of tissues, including flowers, leaves, stems, and roots.  Some cyclotides are expressed in large amts. (up to 1 g kg-1 wet plant wt.) and their natural function appears to be to protect plants from pests or pathogens.  This article provides a brief overview of their discovery, distribution in plants, and applications.  In particular, their exceptional stability has led to their use as peptide-based scaffolds in drug design applications.  They also have potential as natural 'ecofriendly' insecticides, and as protein engineering frameworks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBo8spGvpjBLVg90H21EOLACvtfcHk0li2IQm1SonRFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVejs7fN&md5=8c19fd65c9ed60014107edce7789b81a</span></div><a href="/servlet/linkout?suffix=cit43b&amp;dbid=16384&amp;doi=10.1093%2Fjxb%2Ferw210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjxb%252Ferw210%26sid%3Dliteratum%253Aachs%26aulast%3DWeidmann%26aufirst%3DJ.%26aulast%3DCraik%26aufirst%3DD.%2BJ.%26atitle%3DDiscovery%252C%2520structure%252C%2520function%252C%2520and%2520applications%2520of%2520cyclotides%253A%2520circular%2520proteins%2520from%2520plants%26jtitle%3DJ.%2520Exp.%2520Bot.%26date%3D2016%26volume%3D67%26spage%3D4801%26epage%3D4812%26doi%3D10.1093%2Fjxb%2Ferw210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Wong, C. T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlands, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, T. W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, G. K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, J. P.</span><span> </span><span class="NLM_article-title">Orally active peptidic bradykinin B1 receptor antagonists engineered from a cyclotide scaffold for inflammatory pain treatment</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5620</span><span class="NLM_x">â</span> <span class="NLM_lpage">5624</span><span class="refDoi">Â DOI: 10.1002/anie.201200984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fanie.201200984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtFersrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=5620-5624&author=C.+T.+T.+Wongauthor=D.+K.+Rowlandsauthor=C.-H.+Wongauthor=T.+W.+C.+Loauthor=G.+K.+T.+Nguyenauthor=H.-Y.+Liauthor=J.+P.+Tam&title=Orally+active+peptidic+bradykinin+B1+receptor+antagonists+engineered+from+a+cyclotide+scaffold+for+inflammatory+pain+treatment&doi=10.1002%2Fanie.201200984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Orally Active Peptidic Bradykinin B1 Receptor Antagonists Engineered from a Cyclotide Scaffold for Inflammatory Pain Treatment</span></div><div class="casAuthors">Wong, Clarence T. T.; Rowlands, Dewi K.; Wong, Chi-Hang; Lo, Theodore W. C.; Nguyen, Giang K. T.; Li, Hoi-Yeung; Tam, James P.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5620-5624, S5620/1-S5620/11</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The authors have successfully demonstrated that the cyclotide kalata B1 could provide a superior natural scaffold for engineering orally active peptides as potentially useful therapeutics.  The grafting of BK-antagonist peptides DALK or DAK into the kalata B1 scaffold were performed, and the stability was enhanced substantially.  Measurements of the intracellular Ca2+ level revealed that two of the designed cyclic antagonists are specific blockers for the bradykinin B1 receptor, but not for B2.  In vivo abdominal constriction assay showed significant inhibition of pain response in the animal model under i.p. administration, only the cyclic analogs were able to inhibit the writhing action, whereas the linear analogs as well as the DALK peptide itself showed poor or no inhibition, resp.  It appears that the cystine-knot constraint of the linear kb-kin also produces effect after p.o. administration, but the combination of cyclization and the cystine-knot constraint produces a stronger effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqOSACe3s0MbVg90H21EOLACvtfcHk0li2IQm1SonRFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtFersrg%253D&md5=5d82f4274df7542e49cb41df2555e573</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fanie.201200984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201200984%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DC.%2BT.%2BT.%26aulast%3DRowlands%26aufirst%3DD.%2BK.%26aulast%3DWong%26aufirst%3DC.-H.%26aulast%3DLo%26aufirst%3DT.%2BW.%2BC.%26aulast%3DNguyen%26aufirst%3DG.%2BK.%2BT.%26aulast%3DLi%26aufirst%3DH.-Y.%26aulast%3DTam%26aufirst%3DJ.%2BP.%26atitle%3DOrally%2520active%2520peptidic%2520bradykinin%2520B1%2520receptor%2520antagonists%2520engineered%2520from%2520a%2520cyclotide%2520scaffold%2520for%2520inflammatory%2520pain%2520treatment%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2012%26volume%3D51%26spage%3D5620%26epage%3D5624%26doi%3D10.1002%2Fanie.201200984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Escano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, L.</span><span> </span><span class="NLM_article-title">Multipronged approach for engineering novel peptide analogues of existing lantibiotics</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">857</span><span class="NLM_x">â</span> <span class="NLM_lpage">870</span><span class="refDoi">Â DOI: 10.1517/17460441.2015.1049527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1517%2F17460441.2015.1049527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26004576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Wnu73P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=857-870&author=J.+Escanoauthor=L.+Smith&title=Multipronged+approach+for+engineering+novel+peptide+analogues+of+existing+lantibiotics&doi=10.1517%2F17460441.2015.1049527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45aR"><div class="casContent"><span class="casTitleNuber">45a</span><div class="casTitle"><span class="NLM_cas:atitle">Multipronged approach for engineering novel peptide analogues of existing lantibiotics</span></div><div class="casAuthors">Escano, Jerome; Smith, Leif</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">857-870</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Lantibiotics are a class of ribosomally and post-translationally modified peptide antibiotics that are active against a broad spectrum of Gram-pos. bacteria.  Great efforts have been made to promote the prodn. of these antibiotics, so that they can one day be used in our antimicrobial arsenal to combat multidrug-resistant bacterial infections.  Areas covered: This review provides a synopsis of lantibiotic research aimed at furthering our understanding of the structural limitation of lantibiotics as well as identifying structural regions that can be modified to improve the bioactivity.  In vivo, in vitro and chem. synthesis of lantibiotics has been useful for engineering novel variants with enhanced activities.  These approaches have provided novel ways to further our understanding of lantibiotic function and have advanced the objective to develop lantibiotics for the treatment of infectious diseases.  Expert opinion: Synthesis of lantibiotics with enhanced activities will lead to the discovery of new promising drug candidates that will have a long lasting impact on the treatment of Gram-pos. infections.  The current body of literature for producing structural variants of lantibiotics has been more of a 'proof-of-principle' approach and the application of these methods has not yet been fully utilized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokKrEl_es0zrVg90H21EOLACvtfcHk0li2IQm1SonRFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Wnu73P&md5=07e6d35e5e405261be79c2246494629c</span></div><a href="/servlet/linkout?suffix=cit45a&amp;dbid=16384&amp;doi=10.1517%2F17460441.2015.1049527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2015.1049527%26sid%3Dliteratum%253Aachs%26aulast%3DEscano%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DL.%26atitle%3DMultipronged%2520approach%2520for%2520engineering%2520novel%2520peptide%2520analogues%2520of%2520existing%2520lantibiotics%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2015%26volume%3D10%26spage%3D857%26epage%3D870%26doi%3D10.1517%2F17460441.2015.1049527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit45b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Field, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cotter, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, R. P.</span><span> </span><span class="NLM_article-title">Bioengineering lantibiotics for therapeutic success</span> <span class="citation_source-journal">Front. Microbiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1363</span><span class="refDoi">Â DOI: 10.3389/fmicb.2015.01363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3389%2Ffmicb.2015.01363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26640466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A280%3ADC%252BC28rhtVSqtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1363&author=D.+Fieldauthor=P.+D.+Cotterauthor=C.+Hillauthor=R.+P.+Ross&title=Bioengineering+lantibiotics+for+therapeutic+success&doi=10.3389%2Ffmicb.2015.01363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45bR"><div class="casContent"><span class="casTitleNuber">45b</span><div class="casTitle"><span class="NLM_cas:atitle">Bioengineering Lantibiotics for Therapeutic Success</span></div><div class="casAuthors">Field Des; Cotter Paul D; Ross R P; Hill Colin</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in microbiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1363</span>
        ISSN:<span class="NLM_cas:issn">1664-302X</span>.
    </div><div class="casAbstract">Several examples of highly modified antimicrobial peptides have been described.  While many such peptides are non-ribosomally synthesized, ribosomally synthesized equivalents are being discovered with increased frequency.  Of the latter group, the lantibiotics continue to attract most attention.  In the present review, we discuss the implementation of in vivo and in vitro engineering systems to alter, and even enhance, the antimicrobial activity, antibacterial spectrum and physico-chemical properties, including heat stability, solubility, diffusion and protease resistance, of these compounds.  Additionally, we discuss the potential applications of these lantibiotics for use as therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQAG7TrSNZQzC6Ufuk_1xoTfW6udTcc2eZbQnhdLkI0qrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rhtVSqtA%253D%253D&md5=85c31de65a481776745c90c3cf25c518</span></div><a href="/servlet/linkout?suffix=cit45b&amp;dbid=16384&amp;doi=10.3389%2Ffmicb.2015.01363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmicb.2015.01363%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DD.%26aulast%3DCotter%26aufirst%3DP.%2BD.%26aulast%3DHill%26aufirst%3DC.%26aulast%3DRoss%26aufirst%3DR.%2BP.%26atitle%3DBioengineering%2520lantibiotics%2520for%2520therapeutic%2520success%26jtitle%3DFront.%2520Microbiol.%26date%3D2015%26volume%3D6%26spage%3D1363%26doi%3D10.3389%2Ffmicb.2015.01363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit45c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Sandiford, S. K.</span><span> </span><span class="NLM_article-title">Advances in the arsenal of tools available enabling the discovery of novel lantibiotics with therapeutic potential</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">â</span> <span class="NLM_lpage">297</span><span class="refDoi">Â DOI: 10.1517/17460441.2014.877882</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1517%2F17460441.2014.877882" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=283-297&author=S.+K.+Sandiford&title=Advances+in+the+arsenal+of+tools+available+enabling+the+discovery+of+novel+lantibiotics+with+therapeutic+potential&doi=10.1517%2F17460441.2014.877882"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45c&amp;dbid=16384&amp;doi=10.1517%2F17460441.2014.877882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2014.877882%26sid%3Dliteratum%253Aachs%26aulast%3DSandiford%26aufirst%3DS.%2BK.%26atitle%3DAdvances%2520in%2520the%2520arsenal%2520of%2520tools%2520available%2520enabling%2520the%2520discovery%2520of%2520novel%2520lantibiotics%2520with%2520therapeutic%2520potential%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2014%26volume%3D9%26spage%3D283%26epage%3D297%26doi%3D10.1517%2F17460441.2014.877882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Kluskens, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelemans, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rink, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vries, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meter-Arkema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walther, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuipers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moll, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haas, M.</span><span> </span><span class="NLM_article-title">Angiotensin-(1â7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1â7) analog</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">328</span><span class="NLM_x">, </span> <span class="NLM_fpage">849</span><span class="NLM_x">â</span> <span class="NLM_lpage">854</span><span class="refDoi">Â DOI: 10.1124/jpet.108.146431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1124%2Fjpet.108.146431" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=19038778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD1MXislalsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=328&publication_year=2009&pages=849-854&author=L.+D.+Kluskensauthor=S.+A.+Nelemansauthor=R.+Rinkauthor=L.+de+Vriesauthor=A.+Meter-Arkemaauthor=Y.+Wangauthor=T.+Waltherauthor=A.+Kuipersauthor=G.+N.+Mollauthor=M.+Haas&title=Angiotensin-%281%E2%80%937%29+with+thioether+bridge%3A+an+angiotensin-converting+enzyme-resistant%2C+potent+angiotensin-%281%E2%80%937%29+analog&doi=10.1124%2Fjpet.108.146431"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin-(1-7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analog</span></div><div class="casAuthors">Kluskens, Leon D.; Nelemans, S. Adriaan; Rink, Rick; de Vries, Louwe; Meter-Arkema, Anita; Wang, Yong; Walther, Thomas; Kuipers, Anneke; Moll, Gert N.; Haas, Marijke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">328</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">849-854</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The in vivo efficacy of many therapeutic peptides is hampered by their rapid proteolytic degrdn.  Cyclization of these therapeutic peptides is an excellent way to render them more resistant against breakdown.  Here, the authors describe the enzymic introduction of a thioether ring in angiotensin [Ang-(1-7)], a heptapeptide that plays a pivotal role in the renin-angiotensin system and possesses important therapeutic activities.  The lactic acid bacterium Lactococcus lactis, equipped with the plasmid-based nisin modification machinery, was used to produce thioether-bridged Ang-(1-7).  The resulting cyclized Ang-(1-7) is fully resistant against purified angiotensin-converting enzyme, has significantly increased stability in homogenates of different organs and in plasma derived from pig, and displays a strongly (34-fold) enhanced survival in Sprague-Dawley (SD) rats in vivo.  With respect to functional activity, cyclized Ang-(1-7) induces relaxation of precontracted SD rat aorta rings in vitro.  The magnitude of this effect is 2-fold larger than that obtained for natural Ang-(1-7).  The Ang-(1-7) receptor antagonist D-Pro7-Ang-(1-7), which completely inhibits the activity of natural Ang-(1-7), also abolishes the vasodilation by cyclized Ang-(1-7), providing evidence that cyclized Ang-(1-7) also interacts with the Ang-(1-7) receptor.  Taken together, applying a highly innovative enzymic peptide stabilization method, the authors generated a stable Ang-(1-7) analog with strongly enhanced therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJL6fTWkJn_rVg90H21EOLACvtfcHk0li_A5K3SyctTw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXislalsL8%253D&md5=21446837fe878e78712e578cfa85c060</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.146431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.146431%26sid%3Dliteratum%253Aachs%26aulast%3DKluskens%26aufirst%3DL.%2BD.%26aulast%3DNelemans%26aufirst%3DS.%2BA.%26aulast%3DRink%26aufirst%3DR.%26aulast%3Dde%2BVries%26aufirst%3DL.%26aulast%3DMeter-Arkema%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWalther%26aufirst%3DT.%26aulast%3DKuipers%26aufirst%3DA.%26aulast%3DMoll%26aufirst%3DG.%2BN.%26aulast%3DHaas%26aufirst%3DM.%26atitle%3DAngiotensin-%25281%25E2%2580%25937%2529%2520with%2520thioether%2520bridge%253A%2520an%2520angiotensin-converting%2520enzyme-resistant%252C%2520potent%2520angiotensin-%25281%25E2%2580%25937%2529%2520analog%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D328%26spage%3D849%26epage%3D854%26doi%3D10.1124%2Fjpet.108.146431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Saghatelian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Couso, J. P.</span><span> </span><span class="NLM_article-title">Discovery and characterization of smORF-encoded bioactive polypeptides</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">909</span><span class="NLM_x">â</span> <span class="NLM_lpage">916</span><span class="refDoi">Â DOI: 10.1038/nchembio.1964</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnchembio.1964" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26575237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVOgtrnI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=909-916&author=A.+Saghatelianauthor=J.+P.+Couso&title=Discovery+and+characterization+of+smORF-encoded+bioactive+polypeptides&doi=10.1038%2Fnchembio.1964"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47aR"><div class="casContent"><span class="casTitleNuber">47a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and characterization of smORF-encoded bioactive polypeptides</span></div><div class="casAuthors">Saghatelian, Alan; Couso, Juan Pablo</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">909-916</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Anal. of genomes, transcriptomes and proteomes reveals the existence of hundreds to thousands of translated, yet non-annotated, short open reading frames (small ORFs or smORFs).  The discovery of smORFs and their protein products, smORF-encoded polypeptides (SEPs), points to a fundamental gap in our knowledge of protein-coding genes.  Various studies have identified central roles for smORFs in metab., apoptosis and development.  The discovery of these bioactive SEPs emphasizes the functional potential of this unexplored class of biomols.  Here, we provide an overview of this emerging field and highlight the opportunities for chem. biol. to answer fundamental questions about these novel genes.  Such studies will provide new insights into the protein-coding potential of genomes and identify functional genes with roles in biol. and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWYcQVK4rxvbVg90H21EOLACvtfcHk0li_A5K3SyctTw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVOgtrnI&md5=de3902cf079635ff0c12d6b232cf278b</span></div><a href="/servlet/linkout?suffix=cit47a&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1964%26sid%3Dliteratum%253Aachs%26aulast%3DSaghatelian%26aufirst%3DA.%26aulast%3DCouso%26aufirst%3DJ.%2BP.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520smORF-encoded%2520bioactive%2520polypeptides%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26spage%3D909%26epage%3D916%26doi%3D10.1038%2Fnchembio.1964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit47b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saghatelian, A.</span><span> </span><span class="NLM_article-title">Identification and characterization of sORF-encoded polypeptides</span> <span class="citation_source-journal">Crit. Rev. Biochem. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">â</span> <span class="NLM_lpage">141</span><span class="refDoi">Â DOI: 10.3109/10409238.2015.1016215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3109%2F10409238.2015.1016215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25857697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1Gms7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2015&pages=134-141&author=Q.+Chuauthor=J.+Maauthor=A.+Saghatelian&title=Identification+and+characterization+of+sORF-encoded+polypeptides&doi=10.3109%2F10409238.2015.1016215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47bR"><div class="casContent"><span class="casTitleNuber">47b</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of sORF-encoded polypeptides</span></div><div class="casAuthors">Chu, Qian; Ma, Jiao; Saghatelian, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">134-141</span>CODEN:
                <span class="NLM_cas:coden">CRBBEJ</span>;
        ISSN:<span class="NLM_cas:issn">1040-9238</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Mol. biol., genomics and proteomics methods have been utilized to reveal a non-annotated class of endogenous polypeptides (small proteins and peptides) encoded by short open reading frames (sORFs), or small open reading frames (smORFs).  We refer to these polypeptides as s(m)ORF-encoded polypeptides or SEPs.  The early SEPs were identified via genetic screens, and many of the RNAs that contain s(m)ORFs were originally considered to be non-coding; however, elegant work in bacteria and flies demonstrated that these s(m)ORFs code for functional polypeptides as small as 11-amino acids in length.  The discovery of these initial SEPs led to search for these mols. using methods such as ribosome profiling and proteomics, which have revealed the existence of many SEPs, including novel human SEPs.  Unlike screens, omics methods do not necessarily link a SEP to a cellular or biol. function, but functional genomic and proteomic strategies have demonstrated that at least some of these newly discovered SEPs have biochem. and cellular functions.  Here, we provide an overview of these results and discuss the future directions in this emerging field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJ7jIaogqAxbVg90H21EOLACvtfcHk0li_A5K3SyctTw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1Gms7s%253D&md5=32681ba753595fd1eda1979b08fe39bc</span></div><a href="/servlet/linkout?suffix=cit47b&amp;dbid=16384&amp;doi=10.3109%2F10409238.2015.1016215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10409238.2015.1016215%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DSaghatelian%26aufirst%3DA.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520sORF-encoded%2520polypeptides%26jtitle%3DCrit.%2520Rev.%2520Biochem.%2520Mol.%2520Biol.%26date%3D2015%26volume%3D50%26spage%3D134%26epage%3D141%26doi%3D10.3109%2F10409238.2015.1016215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Hashimoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niikura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tajima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasukawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasumi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kouyama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doyu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sobue, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koide, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuji, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurokawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishimoto, I.</span><span> </span><span class="NLM_article-title">A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimerâs disease genes and Abeta</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">6336</span><span class="NLM_x">â</span> <span class="NLM_lpage">6341</span><span class="refDoi">Â DOI: 10.1073/pnas.101133498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1073%2Fpnas.101133498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=11371646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktVWksbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=6336-6341&author=Y.+Hashimotoauthor=T.+Niikuraauthor=H.+Tajimaauthor=T.+Yasukawaauthor=H.+Sudoauthor=Y.+Itoauthor=Y.+Kitaauthor=M.+Kawasumiauthor=K.+Kouyamaauthor=M.+Doyuauthor=G.+Sobueauthor=T.+Koideauthor=S.+Tsujiauthor=J.+Langauthor=K.+Kurokawaauthor=I.+Nishimoto&title=A+rescue+factor+abolishing+neuronal+cell+death+by+a+wide+spectrum+of+familial+Alzheimer%E2%80%99s+disease+genes+and+Abeta&doi=10.1073%2Fpnas.101133498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and AÎ²</span></div><div class="casAuthors">Hashimoto, Yuichi; Niikura, Takako; Tajima, Hirohisa; Yasukawa, Takashi; Sudo, Haruka; Ito, Yuko; Kita, Yoshiko; Kawasumi, Masaoki; Kouyama, Keisuke; Doyu, Manabu; Sobue, Gen; Koide, Takashi; Tsuji, Shoji; Lang, Jochen; Kurokawa, Kiyoshi; Nishimoto, Ikuo</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6336-6341</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Through functional expression screening, we identified a gene, designated humanin (HN) cDNA, which encodes a short polypeptide and abolishes death of neuronal cells caused by multiple different types of familial Alzheimer's disease genes and by AÎ² amyloid, without effect on death by Q79 or superoxide dismutase-1 mutants.  Transfected HN cDNA was transcribed to the corresponding polypeptide and then was secreted into the cultured medium.  The rescue action clearly depended on the primary structure of HN.  This polypeptide would serve as a mol. clue for the development of new therapeutics for Alzheimer's disease targeting neuroprotection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz_VOeH6zHjbVg90H21EOLACvtfcHk0lhpny_S3WUaqg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktVWksbk%253D&md5=effbfcb6f8a5349c1d87108f32ae6405</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1073%2Fpnas.101133498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.101133498%26sid%3Dliteratum%253Aachs%26aulast%3DHashimoto%26aufirst%3DY.%26aulast%3DNiikura%26aufirst%3DT.%26aulast%3DTajima%26aufirst%3DH.%26aulast%3DYasukawa%26aufirst%3DT.%26aulast%3DSudo%26aufirst%3DH.%26aulast%3DIto%26aufirst%3DY.%26aulast%3DKita%26aufirst%3DY.%26aulast%3DKawasumi%26aufirst%3DM.%26aulast%3DKouyama%26aufirst%3DK.%26aulast%3DDoyu%26aufirst%3DM.%26aulast%3DSobue%26aufirst%3DG.%26aulast%3DKoide%26aufirst%3DT.%26aulast%3DTsuji%26aufirst%3DS.%26aulast%3DLang%26aufirst%3DJ.%26aulast%3DKurokawa%26aufirst%3DK.%26aulast%3DNishimoto%26aufirst%3DI.%26atitle%3DA%2520rescue%2520factor%2520abolishing%2520neuronal%2520cell%2520death%2520by%2520a%2520wide%2520spectrum%2520of%2520familial%2520Alzheimer%25E2%2580%2599s%2520disease%2520genes%2520and%2520Abeta%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2001%26volume%3D98%26spage%3D6336%26epage%3D6341%26doi%3D10.1073%2Fpnas.101133498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Matsuoka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, Y.</span><span> </span><span class="NLM_article-title">Humanin and the receptors for humanin</span> <span class="citation_source-journal">Mol. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">22</span><span class="NLM_x">â</span> <span class="NLM_lpage">28</span><span class="refDoi">Â DOI: 10.1007/s12035-009-8090-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1007%2Fs12035-009-8090-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=19997871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtlalt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2010&pages=22-28&author=M.+Matsuokaauthor=Y.+Hashimoto&title=Humanin+and+the+receptors+for+humanin&doi=10.1007%2Fs12035-009-8090-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Humanin and the Receptors for Humanin</span></div><div class="casAuthors">Matsuoka, Masaaki; Hashimoto, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Neurobiology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-28</span>CODEN:
                <span class="NLM_cas:coden">MONBEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-7648</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is a prevalent dementia-causing neurodegenerative disease.  Neuronal death is closely linked to the progression of AD-assocd. dementia.  Accumulating evidence has established that a 24-amino-acid bioactive peptide, Humanin, protects neurons from AD-related neuronal death.  A series of studies using various murine AD models including familial AD gene-expressing transgenic mice have shown that Humanin is effective against AD-related neuronal dysfunction in vivo.  Most recently, it has been shown that Humanin inhibits neuronal cell death and dysfunction by binding to a novel IL-6-receptor-related receptor(s) on the cell surface involving CNTFRÎ±, WSX-1, and gp130.  These findings suggest that endogenous Humanin [or a Humanin-like substance(s)] may suppress the onset of AD-related dementia by inhibiting both AD-related neuronal cell death and dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqECH0JQ5gJs7Vg90H21EOLACvtfcHk0lhpny_S3WUaqg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtlalt7c%253D&md5=dfe2d8cc366c61489373877e8f5db015</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1007%2Fs12035-009-8090-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12035-009-8090-z%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuoka%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DY.%26atitle%3DHumanin%2520and%2520the%2520receptors%2520for%2520humanin%26jtitle%3DMol.%2520Neurobiol.%26date%3D2010%26volume%3D41%26spage%3D22%26epage%3D28%26doi%3D10.1007%2Fs12035-009-8090-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Smith, G. P.</span><span> </span><span class="NLM_article-title">Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">1315</span><span class="NLM_x">â</span> <span class="NLM_lpage">1317</span><span class="refDoi">Â DOI: 10.1126/science.4001944</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1126%2Fscience.4001944" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=4001944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A280%3ADyaL2M3hvVOquw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=1985&pages=1315-1317&author=G.+P.+Smith&title=Filamentous+fusion+phage%3A+novel+expression+vectors+that+display+cloned+antigens+on+the+virion+surface&doi=10.1126%2Fscience.4001944"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface</span></div><div class="casAuthors">Smith G P</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">4705</span>),
    <span class="NLM_cas:pages">1315-7</span>
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Foreign DNA fragments can be inserted into filamentous phage gene III to create a fusion protein with the foreign sequence in the middle.  The fusion protein is incorporated into the virion, which retains infectivity and displays the foreign amino acids in immunologically accessible form.  These "fusion phage" can be enriched more than 1000-fold over ordinary phage by affinity for antibody directed against the foreign sequence.  Fusion phage may provide a simple way of cloning a gene when an antibody against the product of that gene is available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSi6LWYDdRj7r5XHngOXiV_fW6udTcc2eY_UM5WSPhpu7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2M3hvVOquw%253D%253D&md5=cc126f0b75ba5aae24f0e12fe057ad05</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1126%2Fscience.4001944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.4001944%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DG.%2BP.%26atitle%3DFilamentous%2520fusion%2520phage%253A%2520novel%2520expression%2520vectors%2520that%2520display%2520cloned%2520antigens%2520on%2520the%2520virion%2520surface%26jtitle%3DScience%26date%3D1985%26volume%3D228%26spage%3D1315%26epage%3D1317%26doi%3D10.1126%2Fscience.4001944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Goldflam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullman, C. G.</span><span> </span><span class="NLM_article-title">Recent advances toward the discovery of drug-like peptides de novo</span> <span class="citation_source-journal">Front. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">69</span><span class="refDoi">Â DOI: 10.3389/fchem.2015.00069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3389%2Ffchem.2015.00069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26734602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A280%3ADC%252BC28rns1ejtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=69&author=M.+Goldflamauthor=C.+G.+Ullman&title=Recent+advances+toward+the+discovery+of+drug-like+peptides+de+novo&doi=10.3389%2Ffchem.2015.00069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances Toward the Discovery of Drug-Like Peptides De novo</span></div><div class="casAuthors">Goldflam Michael; Ullman Christopher G</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">69</span>
        ISSN:<span class="NLM_cas:issn">2296-2646</span>.
    </div><div class="casAbstract">Peptides are important natural molecules that possess functions as diverse as antibiotics, toxins, venoms and hormones, for example.  However, whilst these peptides have useful properties, there are many targets and pathways that are not addressed through the activities of natural peptidic compounds.  In these circumstances, directed evolution techniques, such as phage display, have been developed to sample the diverse chemical and structural repertoire of small peptides for useful means.  In this review, we consider recent concepts that relate peptide structure to drug-like attributes and how these are incorporated within display technologies to deliver peptides de novo with valuable pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSd3TNvyIUAQ2x8TEN9K18QfW6udTcc2eaoZgku5CGzHbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rns1ejtg%253D%253D&md5=57f4c0f862a0c50f97894cd6d361538c</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.3389%2Ffchem.2015.00069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffchem.2015.00069%26sid%3Dliteratum%253Aachs%26aulast%3DGoldflam%26aufirst%3DM.%26aulast%3DUllman%26aufirst%3DC.%2BG.%26atitle%3DRecent%2520advances%2520toward%2520the%2520discovery%2520of%2520drug-like%2520peptides%2520de%2520novo%26jtitle%3DFront.%2520Chem.%26date%3D2015%26volume%3D3%26spage%3D69%26doi%3D10.3389%2Ffchem.2015.00069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Omidfar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daneshpour, M.</span><span> </span><span class="NLM_article-title">Advances in phage display technology for drug discovery</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">651</span><span class="NLM_x">â</span> <span class="NLM_lpage">669</span><span class="refDoi">Â DOI: 10.1517/17460441.2015.1037738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1517%2F17460441.2015.1037738" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=651-669&author=K.+Omidfarauthor=M.+Daneshpour&title=Advances+in+phage+display+technology+for+drug+discovery&doi=10.1517%2F17460441.2015.1037738"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1517%2F17460441.2015.1037738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2015.1037738%26sid%3Dliteratum%253Aachs%26aulast%3DOmidfar%26aufirst%3DK.%26aulast%3DDaneshpour%26aufirst%3DM.%26atitle%3DAdvances%2520in%2520phage%2520display%2520technology%2520for%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2015%26volume%3D10%26spage%3D651%26epage%3D669%26doi%3D10.1517%2F17460441.2015.1037738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Frenzel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schirrmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hust, M.</span><span> </span><span class="NLM_article-title">Phage display-derived human antibodies in clinical development and therapy</span> <span class="citation_source-journal">mAbs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1177</span><span class="NLM_x">â</span> <span class="NLM_lpage">1194</span><span class="refDoi">Â DOI: 10.1080/19420862.2016.1212149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1080%2F19420862.2016.1212149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=27416017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVSlurzN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=1177-1194&author=A.+Frenzelauthor=T.+Schirrmannauthor=M.+Hust&title=Phage+display-derived+human+antibodies+in+clinical+development+and+therapy&doi=10.1080%2F19420862.2016.1212149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Phage display-derived human antibodies in clinical development and therapy</span></div><div class="casAuthors">Frenzel, Andre; Schirrmann, Thomas; Hust, Michael</div><div class="citationInfo"><span class="NLM_cas:title">mAbs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1177-1194</span>CODEN:
                <span class="NLM_cas:coden">MABSCP</span>;
        ISSN:<span class="NLM_cas:issn">1942-0870</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">Over the last 3 decades, monoclonal antibodies have become the most important class of therapeutic biologicals on the market.  Development of therapeutic antibodies was accelerated by recombinant DNA technologies, which allowed the humanization of murine monoclonal antibodies to make them more similar to those of the human body and suitable for a broad range of chronic diseases like cancer and autoimmune diseases.  In the early 1990s in vitro antibody selection technologies were developed that enabled the discovery of "fully" human antibodies with potentially superior clin. efficacy and lowest immunogenicity.  Antibody phage display is the first and most widely used of the in vitro selection technologies.  It has proven to be a robust, versatile platform technol. for the discovery of human antibodies and a powerful engineering tool to improve antibody properties.  As of the beginning of 2016, 6 human antibodies discovered or further developed by phage display were approved for therapy.  In 2002, adalimumab (Humira) became the first phage display-derived antibody granted a marketing approval.  Humira was also the first approved human antibody, and it is currently the best-selling antibody drug on the market.  Numerous phage display-derived antibodies are currently under advanced clin. investigation, and, despite the availability of other technologies such as human antibody-producing transgenic mice, phage display has not lost its importance for the discovery and engineering of therapeutic antibodies.  Here, we provide a comprehensive overview about phage display-derived antibodies that are approved for therapy or in clin. development.  A selection of these antibodies is described in more detail to demonstrate different aspects of the phage display technol. and its development over the last 25 years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXoM-jwSnZibVg90H21EOLACvtfcHk0lg3FQQwrGU6mQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVSlurzN&md5=73ec5aac5c24d1d1135f07212cde2db5</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1080%2F19420862.2016.1212149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F19420862.2016.1212149%26sid%3Dliteratum%253Aachs%26aulast%3DFrenzel%26aufirst%3DA.%26aulast%3DSchirrmann%26aufirst%3DT.%26aulast%3DHust%26aufirst%3DM.%26atitle%3DPhage%2520display-derived%2520human%2520antibodies%2520in%2520clinical%2520development%2520and%2520therapy%26jtitle%3DmAbs%26date%3D2016%26volume%3D8%26spage%3D1177%26epage%3D1194%26doi%3D10.1080%2F19420862.2016.1212149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Giustina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chanson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleinberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronstein, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemmons, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klibanski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Lely, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strasburger, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamberts, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, K. K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casanueva, F. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melmed, S.</span><span> </span><span class="NLM_article-title">Expert consensus document: A consensus on the medical treatment of acromegaly</span> <span class="citation_source-journal">Nat. Rev. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">243</span><span class="NLM_x">â</span> <span class="NLM_lpage">248</span><span class="refDoi">Â DOI: 10.1038/nrendo.2014.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnrendo.2014.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24566817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjsVGisrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=243-248&author=A.+Giustinaauthor=P.+Chansonauthor=D.+Kleinbergauthor=M.+D.+Bronsteinauthor=D.+R.+Clemmonsauthor=A.+Klibanskiauthor=A.+J.+van+der+Lelyauthor=C.+J.+Strasburgerauthor=S.+W.+Lambertsauthor=K.+K.+Y.+Hoauthor=F.+F.+Casanuevaauthor=S.+Melmed&title=Expert+consensus+document%3A+A+consensus+on+the+medical+treatment+of+acromegaly&doi=10.1038%2Fnrendo.2014.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Expert consensus document: A consensus on the medical treatment of acromegaly</span></div><div class="casAuthors">Giustina, Andrea; Chanson, Philippe; Kleinberg, David; Bronstein, Marcello D.; Clemmons, David R.; Klibanski, Anne; van der Lely, Aart J.; Strasburger, Christian J.; Lamberts, Steven W.; Ho, Ken K. Y.; Casanueva, Felipe F.; Melmed, Shlomo</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">243-248</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In March 2013, the Acromegaly Consensus Group met to revise and update guidelines for the medical treatment of acromegaly.  The meeting comprised experts skilled in the medical management of acromegaly.  The group considered treatment goals covering biochem., clin. and tumor vol. outcomes, and the place in guidelines of somatostatin receptor ligands, growth hormone receptor antagonists and dopamine agonists, and alternative modalities for treatment including combination therapy and novel treatments.  This document represents the conclusions of the workshop consensus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6rXoOAwpI7rVg90H21EOLACvtfcHk0lg3FQQwrGU6mQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjsVGisrk%253D&md5=19cb62059d8ff19b551dbebae9e5d637</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2014.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2014.21%26sid%3Dliteratum%253Aachs%26aulast%3DGiustina%26aufirst%3DA.%26aulast%3DChanson%26aufirst%3DP.%26aulast%3DKleinberg%26aufirst%3DD.%26aulast%3DBronstein%26aufirst%3DM.%2BD.%26aulast%3DClemmons%26aufirst%3DD.%2BR.%26aulast%3DKlibanski%26aufirst%3DA.%26aulast%3Dvan%2Bder%2BLely%26aufirst%3DA.%2BJ.%26aulast%3DStrasburger%26aufirst%3DC.%2BJ.%26aulast%3DLamberts%26aufirst%3DS.%2BW.%26aulast%3DHo%26aufirst%3DK.%2BK.%2BY.%26aulast%3DCasanueva%26aufirst%3DF.%2BF.%26aulast%3DMelmed%26aufirst%3DS.%26atitle%3DExpert%2520consensus%2520document%253A%2520A%2520consensus%2520on%2520the%2520medical%2520treatment%2520of%2520acromegaly%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2014%26volume%3D10%26spage%3D243%26epage%3D248%26doi%3D10.1038%2Fnrendo.2014.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Matochko, W. L.; Derda, R.</span><span> </span><span class="NLM_article-title">Next-Generation Sequencing of Phage-Displayed Peptide Libraries</span>. In  <span class="citation_source-book">Peptide Libraries: Methods and Protocols</span>; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">1248</span>, pp  <span class="NLM_fpage">249</span><span class="NLM_x">â</span> <span class="NLM_lpage">266</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&pages=249-266&author=W.+L.+Matochko&author=R.+Derda&title=Peptide+Libraries%3A+Methods+and+Protocols"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMatochko%26aufirst%3DW.%2BL.%26atitle%3DNext-Generation%2520Sequencing%2520of%2520Phage-Displayed%2520Peptide%2520Libraries%26btitle%3DPeptide%2520Libraries%253A%2520Methods%2520and%2520Protocols%26pub%3DSpringer%26date%3D2014%26volume%3D1248%26spage%3D249%26epage%3D266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Matochko, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derda, R.</span><span> </span><span class="NLM_article-title">Prospective identification of parasitic sequences in phage display screens</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1784</span><span class="NLM_x">â</span> <span class="NLM_lpage">1798</span><span class="refDoi">Â DOI: 10.1093/nar/gkt1104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1093%2Fnar%2Fgkt1104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24217917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFKks7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=1784-1798&author=W.+Matochkoauthor=S.+C.+Liauthor=S.+Tangauthor=R.+Derda&title=Prospective+identification+of+parasitic+sequences+in+phage+display+screens&doi=10.1093%2Fnar%2Fgkt1104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Prospective identification of parasitic sequences in phage display screens</span></div><div class="casAuthors">Matochko, Wadim L.; Cory Li, S.; Tang, Sindy K. Y.; Derda, Ratmir</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1784-1798</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Phage display empowered the development of proteins with new function and ligands for clin. relevant targets.  In this report, the authors use next-generation sequencing to analyze phage-displayed libraries and uncover a strong bias induced by amplification preferences of phage in bacteria.  This bias favors fast-growing sequences that collectively constitute <0.01% of the available diversity.  Specifically, a library of 109 random 7-mer peptides (Ph.D.-7) includes a few thousand sequences that grow quickly (the 'parasites'), which are the sequences that are typically identified in phage display screens published to date.  A similar collapse was obsd. in other libraries.  Using Illumina and Ion Torrent sequencing and multiple biol. replicates of amplification of Ph.D.-7 library, the authors identified a focused population of 770 'parasites'.  In all, 197 sequences from this population have been identified in literature reports that used Ph.D.-7 library.  Many of these enriched sequences have confirmed function (e.g. target binding capacity).  The bias in the literature, thus, can be viewed as a selection with two different selection pressures: (i) target-binding selection, and (ii) amplification-induced selection.  Enrichment of parasitic sequences could be minimized if amplification bias is removed.  Here, the authors demonstrate that emulsion amplification in libraries of â¼106 diverse clones prevents the biased selection of parasitic clones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCNgDSmI0C3LVg90H21EOLACvtfcHk0lg3FQQwrGU6mQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFKks7w%253D&md5=e4da42b543b6f8ee81ae5de6aa971bff</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkt1104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkt1104%26sid%3Dliteratum%253Aachs%26aulast%3DMatochko%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DS.%2BC.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DDerda%26aufirst%3DR.%26atitle%3DProspective%2520identification%2520of%2520parasitic%2520sequences%2520in%2520phage%2520display%2520screens%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2014%26volume%3D42%26spage%3D1784%26epage%3D1798%26doi%3D10.1093%2Fnar%2Fgkt1104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Heinis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winter, G.</span><span> </span><span class="NLM_article-title">Encoded libraries of chemically modified peptides</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">â</span> <span class="NLM_lpage">98</span><span class="refDoi">Â DOI: 10.1016/j.cbpa.2015.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.cbpa.2015.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25768886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFyitrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=89-98&author=C.+Heinisauthor=G.+Winter&title=Encoded+libraries+of+chemically+modified+peptides&doi=10.1016%2Fj.cbpa.2015.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Encoded libraries of chemically modified peptides</span></div><div class="casAuthors">Heinis, Christian; Winter, Greg</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89-98</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The use of powerful technologies for generating and screening DNA-encoded protein libraries has helped drive the development of proteins as pharmaceutical ligands.  However the development of peptides as pharmaceutical ligands has been more limited.  Although encoded peptide libraries are typically several orders of magnitude larger than classical chem. libraries, can be more readily screened, and can give rise to higher affinity ligands, their use as pharmaceutical ligands is limited by their intrinsic properties.  Two of the intrinsic limitations include the rotational flexibility of the peptide backbone and the limited no. (20) of natural amino acids.  However these limitations can be overcome by use of chem. modification.  For example, the libraries can be modified to introduce topol. constraints such as cyclization linkers, or to introduce new chem. entities such as small mol. ligands, fluorophores and photo-switchable compds.  This article reviews the chem. involved, the properties of the peptide ligands, and the new opportunities offered by chem. modification of DNA-encoded peptide libraries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8h4T71AlbCLVg90H21EOLACvtfcHk0ljLjP1ewVCsKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFyitrs%253D&md5=78f43d9a54a527ca116846f48f710435</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2015.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2015.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DHeinis%26aufirst%3DC.%26aulast%3DWinter%26aufirst%3DG.%26atitle%3DEncoded%2520libraries%2520of%2520chemically%2520modified%2520peptides%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D26%26spage%3D89%26epage%3D98%26doi%3D10.1016%2Fj.cbpa.2015.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Ng, S.; Tjhung, K. F.; Paschal, B. M.; Noren, C. J.; Derda, R.</span><span> </span><span class="NLM_article-title">Chemical Posttranslational Modification of Phage-Displayed Peptides</span>. In  <span class="citation_source-book">Peptide Libraries: Methods and Protocols</span>; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">1248</span>, pp  <span class="NLM_fpage">155</span><span class="NLM_x">â</span> <span class="NLM_lpage">172</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&pages=155-172&author=S.+Ng&author=K.+F.+Tjhung&author=B.+M.+Paschal&author=C.+J.+Noren&author=R.+Derda&title=Peptide+Libraries%3A+Methods+and+Protocols"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DNg%26aufirst%3DS.%26atitle%3DChemical%2520Posttranslational%2520Modification%2520of%2520Phage-Displayed%2520Peptides%26btitle%3DPeptide%2520Libraries%253A%2520Methods%2520and%2520Protocols%26pub%3DSpringer%26date%3D2014%26volume%3D1248%26spage%3D155%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Schumacher, T. N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayr, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minor, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milhollen, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgess, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, P. S.</span><span> </span><span class="NLM_article-title">Identification of D-peptide ligands through mirror-image phage display</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">271</span><span class="NLM_x">, </span> <span class="NLM_fpage">1854</span><span class="NLM_x">â</span> <span class="NLM_lpage">1857</span><span class="refDoi">Â DOI: 10.1126/science.271.5257.1854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1126%2Fscience.271.5257.1854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=8596952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADyaK28XhvFGms70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=1854-1857&author=T.+N.+M.+Schumacherauthor=L.+M.+Mayrauthor=D.+L.+Minorauthor=M.+A.+Milhollenauthor=M.+W.+Burgessauthor=P.+S.+Kim&title=Identification+of+D-peptide+ligands+through+mirror-image+phage+display&doi=10.1126%2Fscience.271.5257.1854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of D-peptide ligands through mirror-image phage display</span></div><div class="casAuthors">Schumacher, Ton N. M.; Mayr, Lorenz M.; Minor, Daniel L., Jr.; Milhollen, Michael A.; Burgess, Michael W.; Kim, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">271</span>
        (<span class="NLM_cas:issue">5257</span>),
    <span class="NLM_cas:pages">1854-7</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Genetically encoded libraries of peptides and oligonucleotides are well suited for the identification of ligands for many macromols.  A major drawback of these techniques is that the resultant ligands are subject to degrdn. by naturally occurring enzymes.  Here, a method is described that uses a biol. encoded library for the identification of D-peptide ligands, which should be resistant to proteolytic degrdn.  In this approach, a protein is synthesized in the D-amino acid configuration and used to select peptides from a phage display library expressing random L-amino acid peptides.  For reasons of sym., the mirror images of these phage-displayed peptides interact with the target protein of the natural handedness.  The value of this approach was demonstrated by the identification of a cyclic D-peptide partially overlaps the site for the physiol. ligands of this domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaSs-Xi93iBbVg90H21EOLACvtfcHk0ljLjP1ewVCsKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhvFGms70%253D&md5=dd3a5f9d87cd0dbd8b4e89cb11432831</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1126%2Fscience.271.5257.1854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.271.5257.1854%26sid%3Dliteratum%253Aachs%26aulast%3DSchumacher%26aufirst%3DT.%2BN.%2BM.%26aulast%3DMayr%26aufirst%3DL.%2BM.%26aulast%3DMinor%26aufirst%3DD.%2BL.%26aulast%3DMilhollen%26aufirst%3DM.%2BA.%26aulast%3DBurgess%26aufirst%3DM.%2BW.%26aulast%3DKim%26aufirst%3DP.%2BS.%26atitle%3DIdentification%2520of%2520D-peptide%2520ligands%2520through%2520mirror-image%2520phage%2520display%26jtitle%3DScience%26date%3D1996%26volume%3D271%26spage%3D1854%26epage%3D1857%26doi%3D10.1126%2Fscience.271.5257.1854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Eckert, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malashkevich, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, P. S.</span><span> </span><span class="NLM_article-title">Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">â</span> <span class="NLM_lpage">115</span><span class="refDoi">Â DOI: 10.1016/S0092-8674(00)80066-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2FS0092-8674%2800%2980066-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10520998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADyaK1MXmsleqsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=1999&pages=103-115&author=D.+M.+Eckertauthor=V.+N.+Malashkevichauthor=L.+H.+Hongauthor=P.+A.+Carrauthor=P.+S.+Kim&title=Inhibiting+HIV-1+entry%3A+discovery+of+D-peptide+inhibitors+that+target+the+gp41+coiled-coil+pocket&doi=10.1016%2FS0092-8674%2800%2980066-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket</span></div><div class="casAuthors">Eckert, Debra M.; Malashkevich, Vladimir N.; Hong, Lily H.; Carr, Peter A.; Kim, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">103-115</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The HIV-1 gp41 protein promotes viral entry by mediating the fusion of viral and cellular membranes.  A prominent pocket on the surface of a central trimeric coiled coil within gp41 was previously identified as a potential target for drugs that inhibit HIV-1 entry.  The authors designed a peptide, IQN17, which properly presents this pocket.  Utilizing IQN17 and mirror-image phage display, the authors identified cyclic, D-peptide inhibitors of HIV-1 infection that share a sequence motif.  A 1.5 Ã cocrystal structure of IQN17 in complex with a D-peptide, and NMR studies, show that conserved residues of these inhibitors make intimate contact with the gp41 pocket.  The authors studies validate the pocket per se as a target for drug development.  IQN17 and these D-peptide inhibitors are likely to be useful for development and identification of a new class of orally bioavailable anti-HIV drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph-j-KCy8psLVg90H21EOLACvtfcHk0ljLjP1ewVCsKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmsleqsL8%253D&md5=75bf4eb851b8a0dd82716fb57a13cc3f</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2980066-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252980066-5%26sid%3Dliteratum%253Aachs%26aulast%3DEckert%26aufirst%3DD.%2BM.%26aulast%3DMalashkevich%26aufirst%3DV.%2BN.%26aulast%3DHong%26aufirst%3DL.%2BH.%26aulast%3DCarr%26aufirst%3DP.%2BA.%26aulast%3DKim%26aufirst%3DP.%2BS.%26atitle%3DInhibiting%2520HIV-1%2520entry%253A%2520discovery%2520of%2520D-peptide%2520inhibitors%2520that%2520target%2520the%2520gp41%2520coiled-coil%2520pocket%26jtitle%3DCell%26date%3D1999%26volume%3D99%26spage%3D103%26epage%3D115%26doi%3D10.1016%2FS0092-8674%2800%2980066-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Zhao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span> </span><span class="NLM_article-title">Mirror image proteins</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span><span class="NLM_x">â</span> <span class="NLM_lpage">61</span><span class="refDoi">Â DOI: 10.1016/j.cbpa.2014.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.cbpa.2014.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25282524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1OrtrfM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=56-61&author=L.+Zhaoauthor=W.+Lu&title=Mirror+image+proteins&doi=10.1016%2Fj.cbpa.2014.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Mirror image proteins</span></div><div class="casAuthors">Zhao, Le; Lu, Wuyuan</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">56-61</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Proteins composed entirely of unnatural D-amino acids and the achiral amino acid glycine are mirror image forms of their native L-protein counterparts.  Recent advances in chem. protein synthesis afford unique and facile synthetic access to domain-sized mirror image D-proteins, enabling protein research to be conducted through 'the looking glass' and in a way previously unattainable. D-Proteins can facilitate structure detn. of their native L-forms that are difficult to crystallize (racemic X-ray crystallog.); D-proteins can serve as the bait for library screening to ultimately yield pharmacol. superior D-peptide/D-protein therapeutics (mirror-image phage display); D-proteins can also be used as a powerful mechanistic tool for probing mol. events in biol.  This review examines recent progress in the application of mirror image proteins to structural biol., drug discovery, and immunol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9u_Js4562RrVg90H21EOLACvtfcHk0ljLjP1ewVCsKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1OrtrfM&md5=163154b72bce7e96d02de46218f74c62</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2014.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2014.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DW.%26atitle%3DMirror%2520image%2520proteins%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D22%26spage%3D56%26epage%3D61%26doi%3D10.1016%2Fj.cbpa.2014.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Josephson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricardo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szostak, J. W.</span><span> </span><span class="NLM_article-title">mRNA display: from basic principles to macrocycle drug discovery</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">388</span><span class="NLM_x">â</span> <span class="NLM_lpage">399</span><span class="refDoi">Â DOI: 10.1016/j.drudis.2013.10.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.drudis.2013.10.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24157402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsleltrnI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=388-399&author=K.+Josephsonauthor=A.+Ricardoauthor=J.+W.+Szostak&title=mRNA+display%3A+from+basic+principles+to+macrocycle+drug+discovery&doi=10.1016%2Fj.drudis.2013.10.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62aR"><div class="casContent"><span class="casTitleNuber">62a</span><div class="casTitle"><span class="NLM_cas:atitle">mRNA display: from basic principles to macrocycle drug discovery</span></div><div class="casAuthors">Josephson, Kristopher; Ricardo, Alonso; Szostak, Jack W.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">388-399</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  We describe a new discovery technol. that uses mRNA-display to rapidly synthesize and screen macrocyclic peptide libraries to explore a valuable region of chem. space typified by natural products.  This technol. allows high-affinity peptidic macrocycles contg. modified backbones and unnatural side chains to be readily selected based on target binding.  Success stories covering the first examples of these libraries suggest that they could be used for the discovery of intracellular protein-protein interaction inhibitors, highly selective enzyme inhibitors or synthetic replacements for monoclonal antibodies.  The review concludes with a look to the future regarding how this technol. might be improved with respect to library design for cell permeability and bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobuL9lWFPZIbVg90H21EOLACvtfcHk0ljbn78D82hFfw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsleltrnI&md5=6676fef2ca8f0a81cc0e993ee4ec7424</span></div><a href="/servlet/linkout?suffix=cit62a&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.10.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.10.011%26sid%3Dliteratum%253Aachs%26aulast%3DJosephson%26aufirst%3DK.%26aulast%3DRicardo%26aufirst%3DA.%26aulast%3DSzostak%26aufirst%3DJ.%2BW.%26atitle%3DmRNA%2520display%253A%2520from%2520basic%2520principles%2520to%2520macrocycle%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D388%26epage%3D399%26doi%3D10.1016%2Fj.drudis.2013.10.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit62b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Josephson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, M. C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szostak, J. W.</span><span> </span><span class="NLM_article-title">Ribosomal synthesis of unnatural peptides</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">127</span><span class="NLM_x">, </span> <span class="NLM_fpage">11727</span><span class="NLM_x">â</span> <span class="NLM_lpage">11735</span><span class="refDoi">Â DOI: 10.1021/ja0515809</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja0515809" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmsFCqurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2005&pages=11727-11735&author=K.+Josephsonauthor=M.+C.+T.+Hartmanauthor=J.+W.+Szostak&title=Ribosomal+synthesis+of+unnatural+peptides&doi=10.1021%2Fja0515809"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62bR"><div class="casContent"><span class="casTitleNuber">62b</span><div class="casTitle"><span class="NLM_cas:atitle">Ribosomal Synthesis of Unnatural Peptides</span></div><div class="casAuthors">Josephson, Kristopher; Hartman, Matthew C. T.; Szostak, Jack W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">11727-11735</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Combinatorial libraries of nonbiol. polymers and drug-like peptides could in principle be synthesized from unnatural amino acids by exploiting the broad substrate specificity of the ribosome.  The ribosomal synthesis of such libraries would allow rare functional mols. to be identified using technologies developed for the in vitro selection of peptides and proteins.  Here, we use a reconstituted E. coli translation system to simultaneously reassign 35 of the 61 sense codons to 12 unnatural amino acid analogs.  This reprogrammed genetic code was used to direct the synthesis of a single peptide contg. 10 different unnatural amino acids.  This system is compatible with mRNA-display, enabling the synthesis of unnatural peptide libraries of 1014 unique members for the in vitro selection of functional unnatural mols.  We also show that the chem. space sampled by these libraries can be expanded using mutant aminoacyl-tRNA synthetases for the incorporation of addnl. unnatural amino acids or by the specific posttranslational chem. derivatization of reactive groups with small mols.  This system represents a first step toward a platform for the synthesis by enzymic tRNA aminoacylation and ribosomal translation of cyclic peptides comprised of unnatural amino acids that are similar to the nonribosomal peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdQq7-A7FhGbVg90H21EOLACvtfcHk0ljbn78D82hFfw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmsFCqurk%253D&md5=01f866a06627f9b21732210595801cc1</span></div><a href="/servlet/linkout?suffix=cit62b&amp;dbid=16384&amp;doi=10.1021%2Fja0515809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0515809%26sid%3Dliteratum%253Aachs%26aulast%3DJosephson%26aufirst%3DK.%26aulast%3DHartman%26aufirst%3DM.%2BC.%2BT.%26aulast%3DSzostak%26aufirst%3DJ.%2BW.%26atitle%3DRibosomal%2520synthesis%2520of%2520unnatural%2520peptides%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2005%26volume%3D127%26spage%3D11727%26epage%3D11735%26doi%3D10.1021%2Fja0515809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Guillen Schlippe, Y. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, M. C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Josephson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szostak, J. W.</span><span> </span><span class="NLM_article-title">In Vitro Selection of Highly Modified Cyclic Peptides That Act as Tight Binding Inhibitors</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">134</span><span class="NLM_x">, </span> <span class="NLM_fpage">10469</span><span class="NLM_x">â</span> <span class="NLM_lpage">10477</span><span class="refDoi">Â DOI: 10.1021/ja301017y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja301017y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38XktFeltbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=10469-10477&author=Y.+V.+Guillen+Schlippeauthor=M.+C.+T.+Hartmanauthor=K.+Josephsonauthor=J.+W.+Szostak&title=In+Vitro+Selection+of+Highly+Modified+Cyclic+Peptides+That+Act+as+Tight+Binding+Inhibitors&doi=10.1021%2Fja301017y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro Selection of Highly Modified Cyclic Peptides That Act as Tight Binding Inhibitors</span></div><div class="casAuthors">Guillen Schlippe, Yollete V.; Hartman, Matthew C. T.; Josephson, Kristopher; Szostak, Jack W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">10469-10477</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a great demand for the discovery of new therapeutic mols. that combine the high specificity and affinity of biol. drugs with the bioavailability and lower cost of small mols.  Small, natural-product-like peptides hold great promise in bridging this gap; however, access to libraries of these compds. has been a limitation.  Since ribosomal peptides may be subjected to in vitro selection techniques, the generation of extremely large libraries (>1013) of highly modified macrocyclic peptides may provide a powerful alternative for the generation and selection of new useful bioactive mols.  Moreover, the incorporation of many non-proteinogenic amino acids into ribosomal peptides in conjunction with macrocyclization should enhance the drug-like features of these libraries.  Here we show that mRNA-display, a technique that allows the in vitro selection of peptides, can be applied to the evolution of macrocyclic peptides that contain a majority of unnatural amino acids.  We describe the isolation and characterization of two such unnatural cyclic peptides that bind the protease thrombin with low nanomolar affinity, and we show that the unnatural residues in these peptides are essential for the obsd. high-affinity binding.  We demonstrate that the selected peptides are tight-binding inhibitors of thrombin, with Kiapp values in the low nanomolar range.  The ability to evolve highly modified macrocyclic peptides in the lab. is the first crucial step toward the facile generation of useful mol. reagents and therapeutic lead mols. that combine the advantageous features of biologics with those of small-mol. drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-KLtyEmp2hLVg90H21EOLACvtfcHk0ljbn78D82hFfw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktFeltbY%253D&md5=4bee8629fb8b3a67a816a148df28277d</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fja301017y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja301017y%26sid%3Dliteratum%253Aachs%26aulast%3DGuillen%2BSchlippe%26aufirst%3DY.%2BV.%26aulast%3DHartman%26aufirst%3DM.%2BC.%2BT.%26aulast%3DJosephson%26aufirst%3DK.%26aulast%3DSzostak%26aufirst%3DJ.%2BW.%26atitle%3DIn%2520Vitro%2520Selection%2520of%2520Highly%2520Modified%2520Cyclic%2520Peptides%2520That%2520Act%2520as%2520Tight%2520Binding%2520Inhibitors%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26spage%3D10469%26epage%3D10477%26doi%3D10.1021%2Fja301017y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Morioka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loik, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hipolito, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suga, H.</span><span> </span><span class="NLM_article-title">Selection-based discovery of macrocyclic peptides for the next generation therapeutics</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">34</span><span class="NLM_x">â</span> <span class="NLM_lpage">41</span><span class="refDoi">Â DOI: 10.1016/j.cbpa.2015.01.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.cbpa.2015.01.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25703142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFyitrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=34-41&author=T.+Moriokaauthor=N.+D.+Loikauthor=C.+J.+Hipolitoauthor=Y.+Gotoauthor=H.+Suga&title=Selection-based+discovery+of+macrocyclic+peptides+for+the+next+generation+therapeutics&doi=10.1016%2Fj.cbpa.2015.01.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64aR"><div class="casContent"><span class="casTitleNuber">64a</span><div class="casTitle"><span class="NLM_cas:atitle">Selection-based discovery of macrocyclic peptides for the next generation therapeutics</span></div><div class="casAuthors">Morioka, Tomomi; Loik, Nikita D.; Hipolito, Christopher J.; Goto, Yuki; Suga, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">34-41</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Naturally occurring macrocyclic peptides represent a unique class of compds. that exhibit various biol. activities ranging from antibiotics to immunosuppressant.  Although the discovery of such macrocyclic peptides had relied on their isolation from living organisms, recent advances in ribosomal peptide synthesis and in display techniques made it possible to use artificially generated macrocyclic peptide libraries for selection of ligands for biol. relevant proteins.  In this review, we discuss the technologies and their applications for the discovery of peptide ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri5eKuODF5srVg90H21EOLACvtfcHk0liySvtZvRIrOQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFyitrg%253D&md5=6140458ada8c98d6ff60dad07a32c5b8</span></div><a href="/servlet/linkout?suffix=cit64a&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2015.01.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2015.01.023%26sid%3Dliteratum%253Aachs%26aulast%3DMorioka%26aufirst%3DT.%26aulast%3DLoik%26aufirst%3DN.%2BD.%26aulast%3DHipolito%26aufirst%3DC.%2BJ.%26aulast%3DGoto%26aufirst%3DY.%26aulast%3DSuga%26aufirst%3DH.%26atitle%3DSelection-based%2520discovery%2520of%2520macrocyclic%2520peptides%2520for%2520the%2520next%2520generation%2520therapeutics%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D26%26spage%3D34%26epage%3D41%26doi%3D10.1016%2Fj.cbpa.2015.01.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit64b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Passioura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katoh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suga, H.</span><span> </span><span class="NLM_article-title">Selection-based discovery of drug-like macrocyclic peptides</span> <span class="citation_source-journal">Annu. Rev. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">727</span><span class="NLM_x">â</span> <span class="NLM_lpage">752</span><span class="refDoi">Â DOI: 10.1146/annurev-biochem-060713-035456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1146%2Fannurev-biochem-060713-035456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24580641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFOhtrnE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2014&pages=727-752&author=T.+Passiouraauthor=T.+Katohauthor=Y.+Gotoauthor=H.+Suga&title=Selection-based+discovery+of+drug-like+macrocyclic+peptides&doi=10.1146%2Fannurev-biochem-060713-035456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64bR"><div class="casContent"><span class="casTitleNuber">64b</span><div class="casTitle"><span class="NLM_cas:atitle">Selection-based discovery of druglike macrocyclic peptides</span></div><div class="casAuthors">Passioura, Toby; Katoh, Takayuki; Goto, Yuki; Suga, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">727-752</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  Macrocyclic peptides are an emerging class of therapeutics that can modulate protein-protein interactions.  In contrast to the heavily automated high-throughput screening systems traditionally used for the identification of chem. synthesized small-mol. drugs, peptide-based macrocycles can be synthesized by ribosomal translation and identified using in vitro selection techniques, allowing for extremely rapid (hours to days) screening of compd. libraries comprising more than 1013 different species.  Furthermore, chem. modification of translated peptides and engineering of the genetic code have greatly expanded the structural diversity of the available peptide libraries.  In this review, we discuss the use of these technologies for the identification of bioactive macrocyclic peptides, emphasizing recent developments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfAer2tXyiyrVg90H21EOLACvtfcHk0liySvtZvRIrOQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFOhtrnE&md5=34954232501b3765dbbd83d45be9508d</span></div><a href="/servlet/linkout?suffix=cit64b&amp;dbid=16384&amp;doi=10.1146%2Fannurev-biochem-060713-035456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-biochem-060713-035456%26sid%3Dliteratum%253Aachs%26aulast%3DPassioura%26aufirst%3DT.%26aulast%3DKatoh%26aufirst%3DT.%26aulast%3DGoto%26aufirst%3DY.%26aulast%3DSuga%26aufirst%3DH.%26atitle%3DSelection-based%2520discovery%2520of%2520drug-like%2520macrocyclic%2520peptides%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2014%26volume%3D83%26spage%3D727%26epage%3D752%26doi%3D10.1146%2Fannurev-biochem-060713-035456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Ohuchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suga, H.</span><span> </span><span class="NLM_article-title">The flexizyme system: a highly flexible tRNA aminoacylation tool for the translation apparatus</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">537</span><span class="NLM_x">â</span> <span class="NLM_lpage">542</span><span class="refDoi">Â DOI: 10.1016/j.cbpa.2007.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.cbpa.2007.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=17884697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtF2rsbvI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=537-542&author=M.+Ohuchiauthor=H.+Murakamiauthor=H.+Suga&title=The+flexizyme+system%3A+a+highly+flexible+tRNA+aminoacylation+tool+for+the+translation+apparatus&doi=10.1016%2Fj.cbpa.2007.08.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">The flexizyme system: a highly flexible tRNA aminoacylation tool for the translation apparatus</span></div><div class="casAuthors">Ohuchi, Masaki; Murakami, Hiroshi; Suga, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">537-542</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Flexizymes are de novo ribozymes capable of charging a wide variety of non-natural amino acids on tRNAs.  The flexizyme system enables reprogramming of the genetic code by reassigning the codons that are generally assigned to natural amino acids to non-natural residues, and thus mRNA-directed synthesis of non-natural polypeptides can be achieved.  Here, the authors comprehensively summarize the history of the flexizyme system and its subsequent development into a practical tool.  Furthermore, applications to the synthesis of novel biopolymers via genetic code reprogramming and perspectives for future applications are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjZVixZHEK1LVg90H21EOLACvtfcHk0liySvtZvRIrOQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtF2rsbvI&md5=a6bd61ea5a1afdf651eaf44c665c4ce4</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2007.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2007.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DOhuchi%26aufirst%3DM.%26aulast%3DMurakami%26aufirst%3DH.%26aulast%3DSuga%26aufirst%3DH.%26atitle%3DThe%2520flexizyme%2520system%253A%2520a%2520highly%2520flexible%2520tRNA%2520aminoacylation%2520tool%2520for%2520the%2520translation%2520apparatus%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2007%26volume%3D11%26spage%3D537%26epage%3D542%26doi%3D10.1016%2Fj.cbpa.2007.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hardy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bill, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jawhari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothnie, A.</span><span> </span><span class="NLM_article-title">Overcoming bottlenecks in the membrane protein structural biology pipeline</span> <span class="citation_source-journal">Biochem. Soc. Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">838</span><span class="NLM_x">â</span> <span class="NLM_lpage">844</span><span class="refDoi">Â DOI: 10.1042/BST20160049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1042%2FBST20160049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=27284049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28Xps1Wmt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=838-844&author=D.+Hardyauthor=R.+Billauthor=A.+Jawhariauthor=A.+Rothnie&title=Overcoming+bottlenecks+in+the+membrane+protein+structural+biology+pipeline&doi=10.1042%2FBST20160049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66aR"><div class="casContent"><span class="casTitleNuber">66a</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming bottlenecks in the membrane protein structural biology pipeline</span></div><div class="casAuthors">Hardy, David; Bill, Roslyn M.; Jawhari, Anass; Rothnie, Alice J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">838-844</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Membrane proteins account for a third of the eukaryotic proteome, but are greatly under-represented in the Protein Data Bank.  Unfortunately, recent technol. advances in X-ray crystallog. and EM cannot account for the poor soly. and stability of membrane protein samples.  A limitation of conventional detergent-based methods is that detergent mols. destabilize membrane proteins, leading to their aggregation.  The use of orthologues, mutants and fusion tags has helped improve protein stability, but at the expense of not working with the sequence of interest.  Novel detergents such as glucose neopentyl glycol (GNG), maltose neopentyl glycol (MNG) and calixarene-based detergents can improve protein stability without compromising their solubilizing properties.  Styrene maleic acid lipid particles (SMALPs) focus on retaining the native lipid bilayer of a membrane protein during purifn. and biophys. anal.  Overcoming bottlenecks in the membrane protein structural biol. pipeline, primarily by maintaining protein stability, will facilitate the elucidation of many more membrane protein structures in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK0zW9Wt0KurVg90H21EOLACvtfcHk0liySvtZvRIrOQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xps1Wmt7c%253D&md5=f10ec64f172fb2f9954c8476f5ef6473</span></div><a href="/servlet/linkout?suffix=cit66a&amp;dbid=16384&amp;doi=10.1042%2FBST20160049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20160049%26sid%3Dliteratum%253Aachs%26aulast%3DHardy%26aufirst%3DD.%26aulast%3DBill%26aufirst%3DR.%26aulast%3DJawhari%26aufirst%3DA.%26aulast%3DRothnie%26aufirst%3DA.%26atitle%3DOvercoming%2520bottlenecks%2520in%2520the%2520membrane%2520protein%2520structural%2520biology%2520pipeline%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2016%26volume%3D44%26spage%3D838%26epage%3D844%26doi%3D10.1042%2FBST20160049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit66b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Matar-Merheb, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhimi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leydier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huche, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">GaliÃ n, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desuzinges-Mandon, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ficheux, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flot, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aghajari, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Pietro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jault, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falson, P.</span><span> </span><span class="NLM_article-title">Structuring detergents for extracting and stabilizing functional membrane proteins</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e18036</span><span class="refDoi">Â DOI: 10.1371/journal.pone.0018036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1371%2Fjournal.pone.0018036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21483854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslygurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e18036&author=R.+Matar-Merhebauthor=M.+Rhimiauthor=A.+Leydierauthor=F.+Hucheauthor=C.+Gali%C3%A0nauthor=E.+Desuzinges-Mandonauthor=D.+Ficheuxauthor=D.+Flotauthor=N.+Aghajariauthor=R.+Kahnauthor=A.+Di+Pietroauthor=J.-M.+Jaultauthor=A.+W.+Colemanauthor=P.+Falson&title=Structuring+detergents+for+extracting+and+stabilizing+functional+membrane+proteins&doi=10.1371%2Fjournal.pone.0018036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66bR"><div class="casContent"><span class="casTitleNuber">66b</span><div class="casTitle"><span class="NLM_cas:atitle">Structuring detergents for extracting and stabilizing functional membrane proteins</span></div><div class="casAuthors">Matar-Merheb, Rima; Rhimi, Moez; Leydier, Antoine; Huche, Frederic; Galian, Carmen; Desuzinges-Mandon, Elodie; Ficheux, Damien; Flot, David; Aghajari, Nushin; Kahn, Richard; Di Pietro, Attilio; Jault, Jean-Michel; Coleman, Anthony W.; Falson, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e18036</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: Membrane proteins are privileged pharmaceutical targets for which the development of structure-based drug design is challenging.  One underlying reason is the fact that detergents do not stabilize membrane domains as efficiently as natural lipids in membranes, often leading to a partial to complete loss of activity/stability during protein extn. and purifn. and preventing crystn. in an active conformation.  Methodol./Principal Findings: Anionic calix[4]arene based detergents (C4Cn, n = 1-12) were designed to structure the membrane domains through hydrophobic interactions and a network of salt bridges with the basic residues found at the cytosol-membrane interface of membrane proteins.  These compds. behave as surfactants, forming micelles of 5-24 nm, with the crit. micellar concn. (CMC) being as expected sensitive to pH ranging from 0.05 to 1.5 mM.  Both by 1H NMR titrn. and Surface Tension titrn. expts., the interaction of these mols. with the basic amino acids was confirmed.  They ext. membrane proteins from different origins behaving as mild detergents, leading to partial extn. in some cases.  They also retain protein functionality, as shown for BmrA (Bacillus multidrug resistance ATP protein), a membrane multidrug-transporting ATPase, which is particularly sensitive to detergent extn.  These new detergents allow BmrA to bind daunorubicin with a Kd of 12 Î¼M, a value similar to that obsd. after purifn. using dodecyl maltoside (DDM).  They preserve the ATPase activity of BmrA (which resets the protein to its initial state after drug efflux) much more efficiently than SDS (sodium dodecyl sulfate), FC12 (Foscholine 12) or DDM.  They also maintain in a functional state the C4Cn-extd. protein upon detergent exchange with FC12.  Finally, they promote 3D-crystn. of the membrane protein.  Conclusion/Significance: These compds. seem promising to ext. in a functional state membrane proteins obeying the pos. inside rule.  In that context, they may contribute to the membrane protein crystn. field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprXt-c36z6frVg90H21EOLACvtfcHk0ljEfR1o-SYFhQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslygurw%253D&md5=fd2bdb896da7bddc0a9a314939f1a406</span></div><a href="/servlet/linkout?suffix=cit66b&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0018036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0018036%26sid%3Dliteratum%253Aachs%26aulast%3DMatar-Merheb%26aufirst%3DR.%26aulast%3DRhimi%26aufirst%3DM.%26aulast%3DLeydier%26aufirst%3DA.%26aulast%3DHuche%26aufirst%3DF.%26aulast%3DGali%25C3%25A0n%26aufirst%3DC.%26aulast%3DDesuzinges-Mandon%26aufirst%3DE.%26aulast%3DFicheux%26aufirst%3DD.%26aulast%3DFlot%26aufirst%3DD.%26aulast%3DAghajari%26aufirst%3DN.%26aulast%3DKahn%26aufirst%3DR.%26aulast%3DDi%2BPietro%26aufirst%3DA.%26aulast%3DJault%26aufirst%3DJ.-M.%26aulast%3DColeman%26aufirst%3DA.%2BW.%26aulast%3DFalson%26aufirst%3DP.%26atitle%3DStructuring%2520detergents%2520for%2520extracting%2520and%2520stabilizing%2520functional%2520membrane%2520proteins%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De18036%26doi%3D10.1371%2Fjournal.pone.0018036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bayburt, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sligar, S. G.</span><span> </span><span class="NLM_article-title">Self-assembly of single integral membrane proteins into soluble nanoscale phospholipid bilayers</span> <span class="citation_source-journal">Protein Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2476</span><span class="NLM_x">â</span> <span class="NLM_lpage">2481</span><span class="refDoi">Â DOI: 10.1110/ps.03267503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1110%2Fps.03267503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=14573860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD3sXoslelur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2003&pages=2476-2481&author=T.+H.+Bayburtauthor=S.+G.+Sligar&title=Self-assembly+of+single+integral+membrane+proteins+into+soluble+nanoscale+phospholipid+bilayers&doi=10.1110%2Fps.03267503"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67aR"><div class="casContent"><span class="casTitleNuber">67a</span><div class="casTitle"><span class="NLM_cas:atitle">Self-assembly of single integral membrane proteins into soluble nanoscale phospholipid bilayers</span></div><div class="casAuthors">Bayburt, Timothy H.; Sligar, Stephen G.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2476-2481</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">0961-8368</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">One of the biggest challenges in pharmaceutical research is obtaining integral membrane proteins in a functional, solubilized, and monodisperse state that provides a native-like environment that maintains the spectrum of in vivo activities.  Many of these integral membrane proteins are receptors, enzymes, or other macromol. assemblies that are important drug targets.  An example is the general class of proteins composed of seven-transmembrane segments (7-TM) as exemplified by the G-protein-coupled receptors.  In this article, we describe a simple system for self-assembling bacteriorhodopsin, as a model protein contg. 7-TM helixes, with phospholipids to form a nanometer-scale sol. bilayer structure encircled by a 200 amino acid scaffold protein.  The result is the single mol. incorporation of an integral membrane protein target into a sol. and monodisperse structure that allows the structural and functional tools of soln. biochem. to be applied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFexFsxcIoDLVg90H21EOLACvtfcHk0ljEfR1o-SYFhQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXoslelur8%253D&md5=74a769e484a52a430650a11b42af4610</span></div><a href="/servlet/linkout?suffix=cit67a&amp;dbid=16384&amp;doi=10.1110%2Fps.03267503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1110%252Fps.03267503%26sid%3Dliteratum%253Aachs%26aulast%3DBayburt%26aufirst%3DT.%2BH.%26aulast%3DSligar%26aufirst%3DS.%2BG.%26atitle%3DSelf-assembly%2520of%2520single%2520integral%2520membrane%2520proteins%2520into%2520soluble%2520nanoscale%2520phospholipid%2520bilayers%26jtitle%3DProtein%2520Sci.%26date%3D2003%26volume%3D12%26spage%3D2476%26epage%3D2481%26doi%3D10.1110%2Fps.03267503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit67b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bayburt, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sligar, S. G.</span><span> </span><span class="NLM_article-title">Membrane protein assembly into nanodiscs</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">584</span><span class="NLM_x">, </span> <span class="NLM_fpage">1721</span><span class="NLM_x">â</span> <span class="NLM_lpage">1727</span><span class="refDoi">Â DOI: 10.1016/j.febslet.2009.10.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.febslet.2009.10.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=19836392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFKqurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=584&publication_year=2010&pages=1721-1727&author=T.+H.+Bayburtauthor=S.+G.+Sligar&title=Membrane+protein+assembly+into+nanodiscs&doi=10.1016%2Fj.febslet.2009.10.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67bR"><div class="casContent"><span class="casTitleNuber">67b</span><div class="casTitle"><span class="NLM_cas:atitle">Membrane protein assembly into nanodisks</span></div><div class="casAuthors">Bayburt, Timothy H.; Sligar, Stephen G.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">584</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1721-1727</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Nanodisks are sol. nanoscale phospholipid bilayers which can self-assemble integral membrane proteins for biophys., enzymic or structural investigations.  This means for rendering membrane proteins sol. at the single-mol. level offers advantages over liposomes or detergent micelles in terms of size, stability, ability to add genetically modifiable features to the nanodisk structure and ready access to both sides of the phospholipid bilayer domain.  Thus, the nanodisc system provides a novel platform for understanding membrane protein function.  Here, the authors provide an overview of the nanodisk approach and document through several examples many of the applications to the study of the structure and function of integral membrane proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphr-NB4w9pNbVg90H21EOLACvtfcHk0ljEfR1o-SYFhQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFKqurw%253D&md5=1ace5001c844ff546e837251fdcb0774</span></div><a href="/servlet/linkout?suffix=cit67b&amp;dbid=16384&amp;doi=10.1016%2Fj.febslet.2009.10.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.febslet.2009.10.024%26sid%3Dliteratum%253Aachs%26aulast%3DBayburt%26aufirst%3DT.%2BH.%26aulast%3DSligar%26aufirst%3DS.%2BG.%26atitle%3DMembrane%2520protein%2520assembly%2520into%2520nanodiscs%26jtitle%3DFEBS%2520Lett.%26date%3D2010%26volume%3D584%26spage%3D1721%26epage%3D1727%26doi%3D10.1016%2Fj.febslet.2009.10.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Scott, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kummer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tremmel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">PlÃ¼ckthun, A.</span><span> </span><span class="NLM_article-title">Stabilizing membrane proteins through protein engineering</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">427</span><span class="NLM_x">â</span> <span class="NLM_lpage">435</span><span class="refDoi">Â DOI: 10.1016/j.cbpa.2013.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.cbpa.2013.04.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23639904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmslegtb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=427-435&author=D.+J.+Scottauthor=L.+Kummerauthor=D.+Tremmelauthor=A.+Pl%C3%BCckthun&title=Stabilizing+membrane+proteins+through+protein+engineering&doi=10.1016%2Fj.cbpa.2013.04.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Stabilizing membrane proteins through protein engineering</span></div><div class="casAuthors">Scott, Daniel J.; Kummer, Lutz; Tremmel, Dirk; Pluckthun, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">427-435</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Integral membrane proteins (IMPs) are crucial components of all cells but are difficult to study in vitro because they are generally unstable when removed from their native membranes using detergents.  Despite the major biomedical relevance of IMPs, less than 1% of Protein Data Bank (PDB) entries are IMP structures, reflecting the tech. gap between studies of sol. proteins compared to IMPs.  Stability can be engineered into IMPs by inserting stabilizing mutations, thereby generating proteins that can be successfully applied to biochem. and structural studies when solubilized in detergent micelles.  The identification of stabilizing mutations is not trivial, and this review will focus on the methods that have been used to identify stabilized membrane proteins, including alanine scanning and screening, directed evolution and computational design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoocb73dapL2bVg90H21EOLACvtfcHk0lhl1uHnLV3YDA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmslegtb4%253D&md5=62f707eee2a1c2995f8baf717b9776a2</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2013.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2013.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DD.%2BJ.%26aulast%3DKummer%26aufirst%3DL.%26aulast%3DTremmel%26aufirst%3DD.%26aulast%3DPl%25C3%25BCckthun%26aufirst%3DA.%26atitle%3DStabilizing%2520membrane%2520proteins%2520through%2520protein%2520engineering%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D17%26spage%3D427%26epage%3D435%26doi%3D10.1016%2Fj.cbpa.2013.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Viegas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viennet, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etzkorn, M.</span><span> </span><span class="NLM_article-title">The power, pitfalls and potential of the nanodisc system for NMR-based studies</span> <span class="citation_source-journal">Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">397</span><span class="NLM_x">, </span> <span class="NLM_fpage">1335</span><span class="NLM_x">â</span> <span class="NLM_lpage">1354</span><span class="refDoi">Â DOI: 10.1515/hsz-2016-0224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1515%2Fhsz-2016-0224" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=397&publication_year=2016&pages=1335-1354&author=A.+Viegasauthor=T.+Viennetauthor=M.+Etzkorn&title=The+power%2C+pitfalls+and+potential+of+the+nanodisc+system+for+NMR-based+studies&doi=10.1515%2Fhsz-2016-0224"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69a&amp;dbid=16384&amp;doi=10.1515%2Fhsz-2016-0224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252Fhsz-2016-0224%26sid%3Dliteratum%253Aachs%26aulast%3DViegas%26aufirst%3DA.%26aulast%3DViennet%26aufirst%3DT.%26aulast%3DEtzkorn%26aufirst%3DM.%26atitle%3DThe%2520power%252C%2520pitfalls%2520and%2520potential%2520of%2520the%2520nanodisc%2520system%2520for%2520NMR-based%2520studies%26jtitle%3DBiol.%2520Chem.%26date%3D2016%26volume%3D397%26spage%3D1335%26epage%3D1354%26doi%3D10.1515%2Fhsz-2016-0224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit69b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Dore, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Errey, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollenstein, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tehan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurrell, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Congreve, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tate, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weir, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, F. H.</span><span> </span><span class="NLM_article-title">Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1283</span><span class="NLM_x">â</span> <span class="NLM_lpage">1293</span><span class="refDoi">Â DOI: 10.1016/j.str.2011.06.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.str.2011.06.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21885291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFaru7fE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=1283-1293&author=A.+S.+Doreauthor=N.+Robertsonauthor=J.+C.+Erreyauthor=I.+Ngauthor=K.+Hollensteinauthor=B.+Tehanauthor=E.+Hurrellauthor=K.+Bennettauthor=M.+Congreveauthor=F.+Magnaniauthor=C.+G.+Tateauthor=M.+Weirauthor=F.+H.+Marshall&title=Structure+of+the+adenosine+A%282A%29+receptor+in+complex+with+ZM241385+and+the+xanthines+XAC+and+caffeine&doi=10.1016%2Fj.str.2011.06.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69bR"><div class="casContent"><span class="casTitleNuber">69b</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Adenosine A2A Receptor in Complex with ZM241385 and the Xanthines XAC and Caffeine</span></div><div class="casAuthors">Dore, Andrew S.; Robertson, Nathan; Errey, James C.; Ng, Irene; Hollenstein, Kaspar; Tehan, Ben; Hurrell, Edward; Bennett, Kirstie; Congreve, Miles; Magnani, Francesca; Tate, Christopher G.; Weir, Malcolm; Marshall, Fiona H.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1283-1293</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Methylxanthines, including caffeine and theophylline, are among the most widely consumed stimulant drugs in the world.  These effects are mediated primarily via blockade of adenosine receptors.  Xanthine analogs with improved properties have been developed as potential treatments for diseases such as Parkinson's disease.  Here we report the structures of a thermostabilized adenosine A2A receptor in complex with the xanthines xanthine amine congener and caffeine, as well as the A2A selective inverse agonist ZM241385.  The receptor is crystd. in the inactive state conformation as defined by the presence of a salt bridge known as the ionic lock.  The complete third intracellular loop, responsible for G protein coupling, is visible consisting of extended helixes 5 and 6.  The structures provide new insight into the features that define the ligand binding pocket of the adenosine receptor for ligands of diverse chemotypes as well as the cytoplasmic regions that interact with signal transduction proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWsexwFu6LD7Vg90H21EOLACvtfcHk0lhl1uHnLV3YDA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFaru7fE&md5=a25db14aa70c2b42b9c3eb98c3c16bae</span></div><a href="/servlet/linkout?suffix=cit69b&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2011.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2011.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DDore%26aufirst%3DA.%2BS.%26aulast%3DRobertson%26aufirst%3DN.%26aulast%3DErrey%26aufirst%3DJ.%2BC.%26aulast%3DNg%26aufirst%3DI.%26aulast%3DHollenstein%26aufirst%3DK.%26aulast%3DTehan%26aufirst%3DB.%26aulast%3DHurrell%26aufirst%3DE.%26aulast%3DBennett%26aufirst%3DK.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DMagnani%26aufirst%3DF.%26aulast%3DTate%26aufirst%3DC.%2BG.%26aulast%3DWeir%26aufirst%3DM.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26atitle%3DStructure%2520of%2520the%2520adenosine%2520A%25282A%2529%2520receptor%2520in%2520complex%2520with%2520ZM241385%2520and%2520the%2520xanthines%2520XAC%2520and%2520caffeine%26jtitle%3DStructure%26date%3D2011%26volume%3D19%26spage%3D1283%26epage%3D1293%26doi%3D10.1016%2Fj.str.2011.06.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Dominik, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kossiakoff, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arun, K. S.</span><span> </span><span class="NLM_article-title">Phage display selections for affinity reagents to membrane proteins in nanodiscs</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">557</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">â</span> <span class="NLM_lpage">245</span><span class="refDoi">Â DOI: 10.1016/bs.mie.2014.12.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fbs.mie.2014.12.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25950967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1KmtL%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=557&publication_year=2015&pages=219-245&author=P.+K.+Dominikauthor=A.+A.+Kossiakoffauthor=K.+S.+Arun&title=Phage+display+selections+for+affinity+reagents+to+membrane+proteins+in+nanodiscs&doi=10.1016%2Fbs.mie.2014.12.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70aR"><div class="casContent"><span class="casTitleNuber">70a</span><div class="casTitle"><span class="NLM_cas:atitle">Phage display selections for affinity reagents to membrane proteins in nanodiscs</span></div><div class="casAuthors">Dominik, Pawel K.; Kossiakoff, Anthony A.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">557</span>
        (<span class="NLM_cas:issue">Membrane Proteins--Engineering, Purification and Crystallization</span>),
    <span class="NLM_cas:pages">219-245</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Phage display selections generate high-affinity synthetic reagents that can be used as tools in structural characterization of membrane proteins.  Currently, most selection protocols are performed with membrane protein targets in detergents.  However, there are numerous tech. issues assocd. with this, primarily that detergents are poor mimics of the native lipid environment.  Here, we describe a set of protocols for phage display selection that involves reconstituting membrane proteins in nanodiscs, which are small discoidal particles consisting of lipids enclosed by membrane scaffold proteins.  The nanodisc format enabled us to expand the capabilities of competitive and subtractive phage display selection steps, and generation of high-quality synthetic reagents for membrane proteins in native-like lipid environment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_T0Gkl0d1hbVg90H21EOLACvtfcHk0lhl1uHnLV3YDA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1KmtL%252FI&md5=c962b1adb95ca8425dfd220f9aa1d1e0</span></div><a href="/servlet/linkout?suffix=cit70a&amp;dbid=16384&amp;doi=10.1016%2Fbs.mie.2014.12.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.mie.2014.12.032%26sid%3Dliteratum%253Aachs%26aulast%3DDominik%26aufirst%3DP.%2BK.%26aulast%3DKossiakoff%26aufirst%3DA.%2BA.%26aulast%3DArun%26aufirst%3DK.%2BS.%26atitle%3DPhage%2520display%2520selections%2520for%2520affinity%2520reagents%2520to%2520membrane%2520proteins%2520in%2520nanodiscs%26jtitle%3DMethods%2520Enzymol.%26date%3D2015%26volume%3D557%26spage%3D219%26epage%3D245%26doi%3D10.1016%2Fbs.mie.2014.12.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit70b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Congreve, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rich, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myszka, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figaroa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegal, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, C. K.</span><span> </span><span class="NLM_article-title">Fragment screening of stabilized G-protein-coupled receptors using biophysical methods</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">493</span><span class="NLM_x">, </span> <span class="NLM_fpage">115</span><span class="NLM_x">â</span> <span class="NLM_lpage">136</span><span class="refDoi">Â DOI: 10.1016/B978-0-12-381274-2.00005-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2FB978-0-12-381274-2.00005-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21371589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosleku7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=493&publication_year=2011&pages=115-136&author=M.+Congreveauthor=R.+L.+Richauthor=D.+G.+Myszkaauthor=F.+Figaroaauthor=G.+Siegalauthor=F.+H.+Marshallauthor=C.+K.+Lawrence&title=Fragment+screening+of+stabilized+G-protein-coupled+receptors+using+biophysical+methods&doi=10.1016%2FB978-0-12-381274-2.00005-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70bR"><div class="casContent"><span class="casTitleNuber">70b</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment screening of stabilized G-protein-coupled receptors using biophysical methods</span></div><div class="casAuthors">Congreve, Miles; Rich, Rebecca L.; Myszka, David G.; Figaroa, Francis; Siegal, Gregg; Marshall, Fiona H.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">493</span>
        (<span class="NLM_cas:issue">Fragment-Based Drug Design</span>),
    <span class="NLM_cas:pages">115-136</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Biophys. studies with G-protein-coupled receptors (GPCRs) are typically very challenging due to the poor stability of these receptors when solubilized from the cell membrane into detergent solns.  However, the stability of a GPCR can be greatly improved by introducing a no. of point mutations into the protein sequence to give a stabilized receptor or StaR.  Here, we present the utility of StaRs for biophys. studies and the screening of fragment libraries.  Two case studies are used to illustrate the methods: first, the screening of a library of fragments by surface plasmon resonance against the adenosine A2A receptor StaR, demonstrating how very small and weakly active xanthine fragments can be detected binding to the protein on chips; second, the screening and detection of fragment hits of a larger fragment library in an NMR format called TINS (target-immobilized NMR screening) against the Î²1 adrenergic StaR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQaPwGQSwwnbVg90H21EOLACvtfcHk0lgbSd1EcShg2w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosleku7c%253D&md5=e9e5e7053358ef1d0d8498669376fe9a</span></div><a href="/servlet/linkout?suffix=cit70b&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-381274-2.00005-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-381274-2.00005-4%26sid%3Dliteratum%253Aachs%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DRich%26aufirst%3DR.%2BL.%26aulast%3DMyszka%26aufirst%3DD.%2BG.%26aulast%3DFigaroa%26aufirst%3DF.%26aulast%3DSiegal%26aufirst%3DG.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26aulast%3DLawrence%26aufirst%3DC.%2BK.%26atitle%3DFragment%2520screening%2520of%2520stabilized%2520G-protein-coupled%2520receptors%2520using%2520biophysical%2520methods%26jtitle%3DMethods%2520Enzymol.%26date%3D2011%26volume%3D493%26spage%3D115%26epage%3D136%26doi%3D10.1016%2FB978-0-12-381274-2.00005-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerner, R. A.</span><span> </span><span class="NLM_article-title">A proximity based general method for identification of ligand and receptor interactions in living cells</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">454</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">â</span> <span class="NLM_lpage">255</span><span class="refDoi">Â DOI: 10.1016/j.bbrc.2014.10.085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.bbrc.2014.10.085" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=454&publication_year=2014&pages=251-255&author=H.+Zhangauthor=J.+Xieauthor=R.+A.+Lerner&title=A+proximity+based+general+method+for+identification+of+ligand+and+receptor+interactions+in+living+cells&doi=10.1016%2Fj.bbrc.2014.10.085"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71a&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2014.10.085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2014.10.085%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DLerner%26aufirst%3DR.%2BA.%26atitle%3DA%2520proximity%2520based%2520general%2520method%2520for%2520identification%2520of%2520ligand%2520and%2520receptor%2520interactions%2520in%2520living%2520cells%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2014%26volume%3D454%26spage%3D251%26epage%3D255%26doi%3D10.1016%2Fj.bbrc.2014.10.085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit71b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Peng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dharmarajan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novick, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerner, R. A.</span><span> </span><span class="NLM_article-title">A general method for insertion of functional proteins within proteins via combinatorial selection of permissive junctions</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1134</span><span class="NLM_x">â</span> <span class="NLM_lpage">1143</span><span class="refDoi">Â DOI: 10.1016/j.chembiol.2015.07.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.chembiol.2015.07.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26278185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlektrzE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=1134-1143&author=Y.+Pengauthor=W.+Zengauthor=H.+Yeauthor=K.+H.+Hanauthor=V.+Dharmarajanauthor=S.+Novickauthor=I.+A.+Wilsonauthor=P.+R.+Griffinauthor=J.+M.+Friedmanauthor=R.+A.+Lerner&title=A+general+method+for+insertion+of+functional+proteins+within+proteins+via+combinatorial+selection+of+permissive+junctions&doi=10.1016%2Fj.chembiol.2015.07.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71bR"><div class="casContent"><span class="casTitleNuber">71b</span><div class="casTitle"><span class="NLM_cas:atitle">A General Method for Insertion of Functional Proteins within Proteins via Combinatorial Selection of Permissive Junctions</span></div><div class="casAuthors">Peng, Yingjie; Zeng, Wenwen; Ye, Hui; Han, Kyung Ho; Dharmarajan, Venkatasubramanian; Novick, Scott; Wilson, Ian A.; Griffin, Patrick R.; Friedman, Jeffrey M.; Lerner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1134-1143</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A major goal of modern protein chem. is to create new proteins with different functions.  One approach is to amalgamate secondary and tertiary structures from different proteins.  This is difficult for several reasons, not the least of which is the fact that the junctions between secondary and tertiary structures are not degenerate and usually affect the function and folding of the entire complex.  Here, we offer a soln. to this problem by coupling a large combinatorial library of about 107 different N- and C-terminal junctions to a powerful system that selects for function.  Using this approach, the entire Leptin and FSH (FSH) were inserted into an antibody.  Complexes with full retention of function in vivo and in vitro, although rare, were found easily by using an autocrine selection system to search for hormonal activity.  Such large diversity systems, when coupled to robust selection systems, should enable construction of novel therapeutic proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5oCHNtWT4zbVg90H21EOLACvtfcHk0lgbSd1EcShg2w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlektrzE&md5=a28c7ab2cd9a1ca198fb303cbdabbc73</span></div><a href="/servlet/linkout?suffix=cit71b&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2015.07.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2015.07.011%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DZeng%26aufirst%3DW.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DHan%26aufirst%3DK.%2BH.%26aulast%3DDharmarajan%26aufirst%3DV.%26aulast%3DNovick%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DI.%2BA.%26aulast%3DGriffin%26aufirst%3DP.%2BR.%26aulast%3DFriedman%26aufirst%3DJ.%2BM.%26aulast%3DLerner%26aufirst%3DR.%2BA.%26atitle%3DA%2520general%2520method%2520for%2520insertion%2520of%2520functional%2520proteins%2520within%2520proteins%2520via%2520combinatorial%2520selection%2520of%2520permissive%2520junctions%26jtitle%3DChem.%2520Biol.%26date%3D2015%26volume%3D22%26spage%3D1134%26epage%3D1143%26doi%3D10.1016%2Fj.chembiol.2015.07.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit71c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Xie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yea, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerner, R. A.</span><span> </span><span class="NLM_article-title">Autocrine signaling based selection of combinatorial antibodies that transdifferentiate human stem cells</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">8099</span><span class="NLM_x">â</span> <span class="NLM_lpage">8104</span><span class="refDoi">Â DOI: 10.1073/pnas.1306263110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1073%2Fpnas.1306263110" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=8099-8104&author=J.+Xieauthor=H.+Zhangauthor=K.+Yeaauthor=R.+A.+Lerner&title=Autocrine+signaling+based+selection+of+combinatorial+antibodies+that+transdifferentiate+human+stem+cells&doi=10.1073%2Fpnas.1306263110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71c&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1306263110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1306263110%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DYea%26aufirst%3DK.%26aulast%3DLerner%26aufirst%3DR.%2BA.%26atitle%3DAutocrine%2520signaling%2520based%2520selection%2520of%2520combinatorial%2520antibodies%2520that%2520transdifferentiate%2520human%2520stem%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D8099%26epage%3D8104%26doi%3D10.1073%2Fpnas.1306263110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit71d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Possani, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yea, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerner, R. A.</span><span> </span><span class="NLM_article-title">Autocrine-based selection of drugs that target ion channels from combinatorial venom peptide libraries</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">9306</span><span class="NLM_x">â</span> <span class="NLM_lpage">9310</span><span class="refDoi">Â DOI: 10.1002/anie.201603052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fanie.201603052" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=9306-9310&author=H.+Zhangauthor=M.+Duauthor=J.+Xieauthor=X.+Liuauthor=J.+Sunauthor=W.+Wangauthor=X.+Xinauthor=L.+D.+Possaniauthor=K.+Yeaauthor=R.+A.+Lerner&title=Autocrine-based+selection+of+drugs+that+target+ion+channels+from+combinatorial+venom+peptide+libraries&doi=10.1002%2Fanie.201603052"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71d&amp;dbid=16384&amp;doi=10.1002%2Fanie.201603052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201603052%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DDu%26aufirst%3DM.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DXin%26aufirst%3DX.%26aulast%3DPossani%26aufirst%3DL.%2BD.%26aulast%3DYea%26aufirst%3DK.%26aulast%3DLerner%26aufirst%3DR.%2BA.%26atitle%3DAutocrine-based%2520selection%2520of%2520drugs%2520that%2520target%2520ion%2520channels%2520from%2520combinatorial%2520venom%2520peptide%2520libraries%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D9306%26epage%3D9310%26doi%3D10.1002%2Fanie.201603052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sturchler, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nieto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cistrone, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yea, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Stefano, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerner, R. A.</span><span> </span><span class="NLM_article-title">Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">8918</span><span class="refDoi">Â DOI: 10.1038/ncomms9918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fncomms9918" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26621478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFemtLnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=8918&author=H.+Zhangauthor=E.+Sturchlerauthor=J.+Zhuauthor=A.+Nietoauthor=P.+A.+Cistroneauthor=J.+Xieauthor=L.+Heauthor=K.+Yeaauthor=T.+Jonesauthor=R.+Turnauthor=P.+S.+Di+Stefanoauthor=P.+R.+Griffinauthor=P.+E.+Dawsonauthor=P.+H.+McDonaldauthor=R.+A.+Lerner&title=Autocrine+selection+of+a+GLP-1R+G-protein+biased+agonist+with+potent+antidiabetic+effects&doi=10.1038%2Fncomms9918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects</span></div><div class="casAuthors">Zhang, Hongkai; Sturchler, Emmanuel; Zhu, Jiang; Nieto, Ainhoa; Cistrone, Philip A.; Xie, Jia; He, LinLing; Yea, Kyungmoo; Jones, Teresa; Turn, Rachel; Di Stefano, Peter S.; Griffin, Patrick R.; Dawson, Philip E.; McDonald, Patricia H.; Lerner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8918</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonists have emerged as treatment options for type 2 diabetes mellitus (T2DM).  GLP-1R signals through G-protein-dependent, and G-protein-independent pathways by engaging the scaffold protein Î²-arrestin; preferential signalling of ligands through one or the other of these branches is known as 'ligand bias'.  Here we report the discovery of the potent and selective GLP-1R G-protein-biased agonist, P5.  We identified P5 in a high-throughput autocrine-based screening of large combinatorial peptide libraries, and show that P5 promotes G-protein signalling comparable to GLP-1 and Exendin-4, but exhibited a significantly reduced Î²-arrestin response.  Preclin. studies using different mouse models of T2DM demonstrate that P5 is a weak insulin secretagogue.  Nevertheless, chronic treatment of diabetic mice with P5 increased adipogenesis, reduced adipose tissue inflammation as well as hepatic steatosis and was more effective at correcting hyperglycemia and lowering Hb A1c levels than Exendin-4, suggesting that GLP-1R G-protein-biased agonists may provide a novel therapeutic approach to T2DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEBfb0W6bx47Vg90H21EOLACvtfcHk0ljXm6fqH_S3LQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFemtLnJ&md5=8d638fbc3fb3996f1f21779f4f8aa001</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1038%2Fncomms9918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms9918%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSturchler%26aufirst%3DE.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DNieto%26aufirst%3DA.%26aulast%3DCistrone%26aufirst%3DP.%2BA.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DYea%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DT.%26aulast%3DTurn%26aufirst%3DR.%26aulast%3DDi%2BStefano%26aufirst%3DP.%2BS.%26aulast%3DGriffin%26aufirst%3DP.%2BR.%26aulast%3DDawson%26aufirst%3DP.%2BE.%26aulast%3DMcDonald%26aufirst%3DP.%2BH.%26aulast%3DLerner%26aufirst%3DR.%2BA.%26atitle%3DAutocrine%2520selection%2520of%2520a%2520GLP-1R%2520G-protein%2520biased%2520agonist%2520with%2520potent%2520antidiabetic%2520effects%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D8918%26doi%3D10.1038%2Fncomms9918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Yoshimoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatematsu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iijima, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niimi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maturana, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanizawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuroda, S.</span><span> </span><span class="NLM_article-title">High-throughput de novo screening of receptor agonists with an automated single-cell analysis and isolation system</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">4242</span><span class="refDoi">Â DOI: 10.1038/srep04242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fsrep04242" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=4242&author=N.+Yoshimotoauthor=K.+Tatematsuauthor=M.+Iijimaauthor=T.+Niimiauthor=A.+D.+Maturanaauthor=I.+Fujiiauthor=A.+Kondoauthor=K.+Tanizawaauthor=S.+Kuroda&title=High-throughput+de+novo+screening+of+receptor+agonists+with+an+automated+single-cell+analysis+and+isolation+system&doi=10.1038%2Fsrep04242"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1038%2Fsrep04242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep04242%26sid%3Dliteratum%253Aachs%26aulast%3DYoshimoto%26aufirst%3DN.%26aulast%3DTatematsu%26aufirst%3DK.%26aulast%3DIijima%26aufirst%3DM.%26aulast%3DNiimi%26aufirst%3DT.%26aulast%3DMaturana%26aufirst%3DA.%2BD.%26aulast%3DFujii%26aufirst%3DI.%26aulast%3DKondo%26aufirst%3DA.%26aulast%3DTanizawa%26aufirst%3DK.%26aulast%3DKuroda%26aufirst%3DS.%26atitle%3DHigh-throughput%2520de%2520novo%2520screening%2520of%2520receptor%2520agonists%2520with%2520an%2520automated%2520single-cell%2520analysis%2520and%2520isolation%2520system%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D4%26spage%3D4242%26doi%3D10.1038%2Fsrep04242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Zhang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pokharel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, S.</span><span> </span><span class="NLM_article-title">Purification of synthetic peptides using a catching full-length sequence by polymerization approach</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1290</span><span class="NLM_x">â</span> <span class="NLM_lpage">1293</span><span class="refDoi">Â DOI: 10.1021/ol403426u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol403426u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=1290-1293&author=M.+Zhangauthor=D.+Pokharelauthor=S.+Fang&title=Purification+of+synthetic+peptides+using+a+catching+full-length+sequence+by+polymerization+approach&doi=10.1021%2Fol403426u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Fol403426u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol403426u%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DPokharel%26aufirst%3DD.%26aulast%3DFang%26aufirst%3DS.%26atitle%3DPurification%2520of%2520synthetic%2520peptides%2520using%2520a%2520catching%2520full-length%2520sequence%2520by%2520polymerization%2520approach%26jtitle%3DOrg.%2520Lett.%26date%3D2014%26volume%3D16%26spage%3D1290%26epage%3D1293%26doi%3D10.1021%2Fol403426u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Garcia-Martin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quintanar-Audelo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Ramos, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruz, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gravel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furic, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cote, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tulla-Puche, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albericio, F.</span><span> </span><span class="NLM_article-title">ChemMatrix, a poly(ethylene glycol)-based support for the solid-phase synthesis of complex peptides</span> <span class="citation_source-journal">J. Comb. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">â</span> <span class="NLM_lpage">220</span><span class="refDoi">Â DOI: 10.1021/cc0600019</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cc0600019" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhs1Citb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=213-220&author=F.+Garcia-Martinauthor=M.+Quintanar-Audeloauthor=Y.+Garcia-Ramosauthor=L.+J.+Cruzauthor=C.+Gravelauthor=R.+Furicauthor=S.+Coteauthor=J.+Tulla-Pucheauthor=F.+Albericio&title=ChemMatrix%2C+a+poly%28ethylene+glycol%29-based+support+for+the+solid-phase+synthesis+of+complex+peptides&doi=10.1021%2Fcc0600019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">ChemMatrix, a Poly(ethylene glycol)-Based Support for the Solid-Phase Synthesis of Complex Peptides</span></div><div class="casAuthors">Garcia-Martin, Fayna; Quintanar-Audelo, Martina; Garcia-Ramos, Yesica; Cruz, Luis J.; Gravel, Catherine; Furic, Robert; Cote, Simon; Tulla-Puche, Judit; Albericio, Fernando</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Combinatorial Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-220</span>CODEN:
                <span class="NLM_cas:coden">JCCHFF</span>;
        ISSN:<span class="NLM_cas:issn">1520-4766</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">CM (ChemMatrix) resin is a new, totally poly(ethylene glycol) (PEG)-based resin and is highly chem. stable.  It exhibits good loading and is user-friendly because of its free-flowing form upon drying.  It performs excellently for the prepn. of hydrophobic, highly structured, and poly-Arg peptides, as compared to polystyrene (PS) resins.  In the most striking example, stepwise solid-phase assembly of the highly complex Î²-amyloid (1-42) peptide resulted in a crude material of 91% purity.  In contrast, literature procedures using PS or PEG-PS-based resins for this peptide required convergent approaches, addnl. time-consuming steps, or both.  In addn. to the difficulties of its synthesis, characterization of Î²-amyloid (1-42) peptide is also a challenge, and methods for characterization by HPLC and MALDI-TOF have also been developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPx4dUMGISm7Vg90H21EOLACvtfcHk0ljXm6fqH_S3LQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhs1Citb4%253D&md5=d2040b6414ab80b8a96b47d6ce7ef0ea</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Fcc0600019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcc0600019%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Martin%26aufirst%3DF.%26aulast%3DQuintanar-Audelo%26aufirst%3DM.%26aulast%3DGarcia-Ramos%26aufirst%3DY.%26aulast%3DCruz%26aufirst%3DL.%2BJ.%26aulast%3DGravel%26aufirst%3DC.%26aulast%3DFuric%26aufirst%3DR.%26aulast%3DCote%26aufirst%3DS.%26aulast%3DTulla-Puche%26aufirst%3DJ.%26aulast%3DAlbericio%26aufirst%3DF.%26atitle%3DChemMatrix%252C%2520a%2520poly%2528ethylene%2520glycol%2529-based%2520support%2520for%2520the%2520solid-phase%2520synthesis%2520of%2520complex%2520peptides%26jtitle%3DJ.%2520Comb.%2520Chem.%26date%3D2006%26volume%3D8%26spage%3D213%26epage%3D220%26doi%3D10.1021%2Fcc0600019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Pedersen, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tofteng, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malik, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, K. J.</span><span> </span><span class="NLM_article-title">Microwave heating in solid-phase peptide synthesis</span> <span class="citation_source-journal">Chem. Soc. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1826</span><span class="NLM_x">â</span> <span class="NLM_lpage">1844</span><span class="refDoi">Â DOI: 10.1039/C1CS15214A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1039%2FC1CS15214A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=22012213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFyjsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2012&pages=1826-1844&author=S.+L.+Pedersenauthor=A.+P.+Toftengauthor=L.+Malikauthor=K.+J.+Jensen&title=Microwave+heating+in+solid-phase+peptide+synthesis&doi=10.1039%2FC1CS15214A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Microwave heating in solid-phase peptide synthesis</span></div><div class="casAuthors">Pedersen, Soren L.; Tofteng, A. Pernille; Malik, Leila; Jensen, Knud J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1826-1844</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The highly refined org. chem. in solid-phase synthesis has made it the method of choice not only to assemble peptides but also small proteins - mainly on a lab. scale but increasingly also on an industrial scale.  While conductive heating occasionally has been applied to peptide synthesis, precise microwave irradn. to heat the reaction mixt. during coupling and NÎ±-deprotection has become increasingly popular.  It has often provided dramatic redns. in synthesis times, accompanied by an increase in the crude peptide purity.  Microwave heating has been proven esp. relevant for sequences which might form Î²-sheet type structures and for sterically difficult couplings.  The beneficial effect of microwave heating appears so far to be due to the precise nature of this type of heating, rather than a peptide-specific microwave effect.  However, microwave heating as such is not a panacea for all difficulties in peptide syntheses and the conditions may need to be adjusted for the incorporation of Cys, His and Asp in peptides, and for the synthesis of, for example, phosphopeptides, glycopeptides, and N-methylated peptides.  Here, the authors provide a comprehensive overview of the advances in microwave heating for peptide synthesis, with a focus on systematic studies and general protocols, as well as important applications.  The assembly of Î²-peptides, peptoids and pseudopeptides are also evaluated in this crit. review (254 refs.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVFzfdkVUo3rVg90H21EOLACvtfcHk0ljLpa5gLkMbnQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFyjsrk%253D&md5=2bc445be062278ae85863188429ec9e8</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1039%2FC1CS15214A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC1CS15214A%26sid%3Dliteratum%253Aachs%26aulast%3DPedersen%26aufirst%3DS.%2BL.%26aulast%3DTofteng%26aufirst%3DA.%2BP.%26aulast%3DMalik%26aufirst%3DL.%26aulast%3DJensen%26aufirst%3DK.%2BJ.%26atitle%3DMicrowave%2520heating%2520in%2520solid-phase%2520peptide%2520synthesis%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2012%26volume%3D41%26spage%3D1826%26epage%3D1844%26doi%3D10.1039%2FC1CS15214A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Paradis-Bas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tulla-Puche, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albericio, F.</span><span> </span><span class="NLM_article-title">The road to the synthesis of â³difficult peptidesâ³</span> <span class="citation_source-journal">Chem. Soc. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">631</span><span class="NLM_x">â</span> <span class="NLM_lpage">654</span><span class="refDoi">Â DOI: 10.1039/C5CS00680E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1039%2FC5CS00680E" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=631-654&author=M.+Paradis-Basauthor=J.+Tulla-Pucheauthor=F.+Albericio&title=The+road+to+the+synthesis+of+%E2%80%B3difficult+peptides%E2%80%B3&doi=10.1039%2FC5CS00680E"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1039%2FC5CS00680E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5CS00680E%26sid%3Dliteratum%253Aachs%26aulast%3DParadis-Bas%26aufirst%3DM.%26aulast%3DTulla-Puche%26aufirst%3DJ.%26aulast%3DAlbericio%26aufirst%3DF.%26atitle%3DThe%2520road%2520to%2520the%2520synthesis%2520of%2520%25E2%2580%25B3difficult%2520peptides%25E2%2580%25B3%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2016%26volume%3D45%26spage%3D631%26epage%3D654%26doi%3D10.1039%2FC5CS00680E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Coin, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beyermann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bienert, M.</span><span> </span><span class="NLM_article-title">Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences</span> <span class="citation_source-journal">Nat. Protoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">3247</span><span class="NLM_x">â</span> <span class="NLM_lpage">3256</span><span class="refDoi">Â DOI: 10.1038/nprot.2007.454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnprot.2007.454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=18079725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVejtrfK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=3247-3256&author=I.+Coinauthor=M.+Beyermannauthor=M.+Bienert&title=Solid-phase+peptide+synthesis%3A+from+standard+procedures+to+the+synthesis+of+difficult+sequences&doi=10.1038%2Fnprot.2007.454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences</span></div><div class="casAuthors">Coin, Irene; Beyermann, Michael; Bienert, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3247-3256</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  This protocol for solid-phase peptide synthesis (SPPS) is based on the widely used Fmoc/tBu strategy, activation of the carboxyl groups by aminium-derived coupling reagents and use of PEG-modified polystyrene resins.  A std. protocol is described, which was successfully applied in our lab for the synthesis of the corticotropin-releasing factor (CRF), >400 CRF analogs and a countless no. of other peptides.  The 41-mer peptide CRF is obtained within â¼80 working hours.  To achieve the so-called difficult sequences, special techniques have to be applied in order to reduce aggregation of the growing peptide chain, which is the main cause of failure for peptide chem. synthesis.  Exemplary application of depsipeptide and pseudoproline units is shown for synthesizing an extremely difficult sequence, the Asn(15) analog of the WW domain FBP28, which is impossible to obtain using the std. protocol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEUh1hcec8VbVg90H21EOLACvtfcHk0ljLpa5gLkMbnQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVejtrfK&md5=7ab725d5cf80efe83e8090263d55d33f</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2007.454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2007.454%26sid%3Dliteratum%253Aachs%26aulast%3DCoin%26aufirst%3DI.%26aulast%3DBeyermann%26aufirst%3DM.%26aulast%3DBienert%26aufirst%3DM.%26atitle%3DSolid-phase%2520peptide%2520synthesis%253A%2520from%2520standard%2520procedures%2520to%2520the%2520synthesis%2520of%2520difficult%2520sequences%26jtitle%3DNat.%2520Protoc.%26date%3D2007%26volume%3D2%26spage%3D3247%26epage%3D3256%26doi%3D10.1038%2Fnprot.2007.454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wohr, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nefzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohwedder, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutter, M.</span><span> </span><span class="NLM_article-title">Pseudo-Prolines as a solubilizing, structure-disrupting protection technique in peptide synthesis</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">9218</span><span class="NLM_x">â</span> <span class="NLM_lpage">9227</span><span class="refDoi">Â DOI: 10.1021/ja961509q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja961509q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=1996&pages=9218-9227&author=T.+Wohrauthor=F.+Wahlauthor=A.+Nefziauthor=B.+Rohwedderauthor=T.+Satoauthor=X.+Sunauthor=M.+Mutter&title=Pseudo-Prolines+as+a+solubilizing%2C+structure-disrupting+protection+technique+in+peptide+synthesis&doi=10.1021%2Fja961509q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79a&amp;dbid=16384&amp;doi=10.1021%2Fja961509q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja961509q%26sid%3Dliteratum%253Aachs%26aulast%3DWohr%26aufirst%3DT.%26aulast%3DWahl%26aufirst%3DF.%26aulast%3DNefzi%26aufirst%3DA.%26aulast%3DRohwedder%26aufirst%3DB.%26aulast%3DSato%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DMutter%26aufirst%3DM.%26atitle%3DPseudo-Prolines%2520as%2520a%2520solubilizing%252C%2520structure-disrupting%2520protection%2520technique%2520in%2520peptide%2520synthesis%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1996%26volume%3D118%26spage%3D9218%26epage%3D9227%26doi%3D10.1021%2Fja961509q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit79b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Harris, P. W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowalczyk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hay, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brimble, M. A.</span><span> </span><span class="NLM_article-title">A single pseudoproline and microwave solid phase peptide synthesis facilitates an efficient synthesis of human amylin 1â37</span> <span class="citation_source-journal">Int. J. Pept. Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">â</span> <span class="NLM_lpage">155</span><span class="refDoi">Â DOI: 10.1007/s10989-012-9325-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1007%2Fs10989-012-9325-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht12ltrnE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=147-155&author=P.+W.+R.+Harrisauthor=R.+Kowalczykauthor=D.+L.+Hayauthor=M.+A.+Brimble&title=A+single+pseudoproline+and+microwave+solid+phase+peptide+synthesis+facilitates+an+efficient+synthesis+of+human+amylin+1%E2%80%9337&doi=10.1007%2Fs10989-012-9325-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79bR"><div class="casContent"><span class="casTitleNuber">79b</span><div class="casTitle"><span class="NLM_cas:atitle">A single pseudoproline and microwave solid phase peptide synthesis facilitates an efficient synthesis of human amylin 1-37</span></div><div class="casAuthors">Harris, Paul W. R.; Kowalczyk, Renata; Hay, Debbie L.; Brimble, Margaret A.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Peptide Research and Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">147-155</span>CODEN:
                <span class="NLM_cas:coden">IJPRFC</span>;
        ISSN:<span class="NLM_cas:issn">1573-3149</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A chem. synthesis of the 37 residue polypeptide human amylin using microwave enhanced solid phase peptide chem. is described.  An optimized protocol used only a single pseudoproline deriv., a CP resin and single couplings of all amino acids to deliver non-oxidized amylin in high yield.  Oxidn. of the crude peptide to form the disulfide bond was accomplished in 20 min using 2,2'-dipyridyl disulfide in DMSO giving human amylin that was fully functional in a cAMP assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_sghd75hPPbVg90H21EOLACvtfcHk0ljLpa5gLkMbnQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht12ltrnE&md5=c72fe43624f8491b2aae985c790d4d21</span></div><a href="/servlet/linkout?suffix=cit79b&amp;dbid=16384&amp;doi=10.1007%2Fs10989-012-9325-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10989-012-9325-9%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DP.%2BW.%2BR.%26aulast%3DKowalczyk%26aufirst%3DR.%26aulast%3DHay%26aufirst%3DD.%2BL.%26aulast%3DBrimble%26aufirst%3DM.%2BA.%26atitle%3DA%2520single%2520pseudoproline%2520and%2520microwave%2520solid%2520phase%2520peptide%2520synthesis%2520facilitates%2520an%2520efficient%2520synthesis%2520of%2520human%2520amylin%25201%25E2%2580%259337%26jtitle%3DInt.%2520J.%2520Pept.%2520Res.%2520Ther.%26date%3D2013%26volume%3D19%26spage%3D147%26epage%3D155%26doi%3D10.1007%2Fs10989-012-9325-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Coin, I.</span><span> </span><span class="NLM_article-title">The depsipeptide method for solid-phase synthesis of difficult peptides</span> <span class="citation_source-journal">J. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">â</span> <span class="NLM_lpage">230</span><span class="refDoi">Â DOI: 10.1002/psc.1224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fpsc.1224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=20401924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVyjsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=223-230&author=I.+Coin&title=The+depsipeptide+method+for+solid-phase+synthesis+of+difficult+peptides&doi=10.1002%2Fpsc.1224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">The depsipeptide method for solid-phase synthesis of difficult peptides</span></div><div class="casAuthors">Coin, Irene</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">223-230</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  After about one century of peptide chem., the main limitation to the accessibility of peptides and proteins via chem. synthesis is the arising of folding and aggregation phenomena.  This is true not only for sequences above a crit. length but also for several biol. relevant substrates that are relatively short yet form either highly folded structures (e.g. WW domains) or fibrils and aggregates after final deprotection (Î²-amyloid peptide).  Such so-called difficult sequences may be more easily obtained via their corresponding depsipeptides (O-acyl isopeptides), ester isomers that are often easier to assemble and purify, and are smoothly converted to the parent amides under mild conditions.  The depsipeptide method is the most recent technique to improve the outcome of difficult syntheses, applicable to sequences contg. residues of serine or threonine.  A brief overview is presented about chem. aspects of the method, the steps that have been undertaken for its optimization, and the evaluation of its efficiency.  Further applications of analogous principles to other crit. topics in peptide synthesis such as condensation of peptide segments and solid-phase synthesis of naturally occurring cyclodepsipeptides are addressed as well.  Copyright Â© 2010 European Peptide Society and John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8FWlRodL0CrVg90H21EOLACvtfcHk0lgVfTWtia1TEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVyjsbg%253D&md5=ef580fceffdfed040eb3905fcad43486</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1002%2Fpsc.1224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.1224%26sid%3Dliteratum%253Aachs%26aulast%3DCoin%26aufirst%3DI.%26atitle%3DThe%2520depsipeptide%2520method%2520for%2520solid-phase%2520synthesis%2520of%2520difficult%2520peptides%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2010%26volume%3D16%26spage%3D223%26epage%3D230%26doi%3D10.1002%2Fpsc.1224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Cardona, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberle, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barthelemy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beythien, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doerner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneeberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keyte, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, P. D.</span><span> </span><span class="NLM_article-title">Application of Dmb-dipeptides in the Fmoc SPPS of difficult and aspartimide-prone sequences</span> <span class="citation_source-journal">Int. J. Pept. Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">285</span><span class="NLM_x">â</span> <span class="NLM_lpage">292</span><span class="refDoi">Â DOI: 10.1007/s10989-008-9154-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1007%2Fs10989-008-9154-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1aisLfE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=285-292&author=V.+Cardonaauthor=I.+Eberleauthor=S.+Barthelemyauthor=J.+Beythienauthor=B.+Doernerauthor=P.+Schneebergerauthor=J.+Keyteauthor=P.+D.+White&title=Application+of+Dmb-dipeptides+in+the+Fmoc+SPPS+of+difficult+and+aspartimide-prone+sequences&doi=10.1007%2Fs10989-008-9154-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Application of DMB-dipeptides in the Fmoc SPPS of difficult and aspartimide-prone sequences</span></div><div class="casAuthors">Cardona, V.; Eberle, I.; Barthelemy, S.; Beythien, J.; Doerner, B.; Schneeberger, P.; Keyte, J.; White, P. D.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Peptide Research and Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">285-292</span>CODEN:
                <span class="NLM_cas:coden">IJPRFC</span>;
        ISSN:<span class="NLM_cas:issn">1573-3149</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Mutter's pseudoproline dipeptides and Sheppard's Hmb (Hmb = 2-hydroxy-4-methoxy-1-methylbenzene) derivs. are powerful tools for enhancing synthetic efficiency in Fmoc SPPS (Fmoc = 9-fluorenylmethoxycarbonyl, SPPS = solid phase peptide synthesis).  They work by exploiting the natural propensity of N-alkyl amino acids to disrupt the formation of the secondary structures during peptide assembly.  Their use results in better and more predictable acylation and deprotection kinetics, enhanced reaction rates, and improved yields of crude products.  However, these approaches have certain limitations: pseudoproline dipeptides can only be used for sequences contg. serine or threonine, and the coupling of the amino acid following the Hmb residue can be extremely difficult.  To alleviate some of these shortcomings, we have prepd. a range of Fmoc-Aaa-(Dmb)Gly-OH (Dmb = 2,4-dimethoxy-1-methylbenzene) dipeptides and tested their efficacy in the synthesis of a no. of challenging hydrophobic peptides.  We also compared the efficiency of N-Dmb against N-Hmb backbone protection in preventing aspartimide formation in the Fmoc SPPS of peptides contg. the Asp-Gly sequence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkMA-kRWfVc7Vg90H21EOLACvtfcHk0lgVfTWtia1TEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1aisLfE&md5=1d2e632730d47e0a835723956c9d7a6e</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1007%2Fs10989-008-9154-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10989-008-9154-z%26sid%3Dliteratum%253Aachs%26aulast%3DCardona%26aufirst%3DV.%26aulast%3DEberle%26aufirst%3DI.%26aulast%3DBarthelemy%26aufirst%3DS.%26aulast%3DBeythien%26aufirst%3DJ.%26aulast%3DDoerner%26aufirst%3DB.%26aulast%3DSchneeberger%26aufirst%3DP.%26aulast%3DKeyte%26aufirst%3DJ.%26aulast%3DWhite%26aufirst%3DP.%2BD.%26atitle%3DApplication%2520of%2520Dmb-dipeptides%2520in%2520the%2520Fmoc%2520SPPS%2520of%2520difficult%2520and%2520aspartimide-prone%2520sequences%26jtitle%3DInt.%2520J.%2520Pept.%2520Res.%2520Ther.%26date%3D2008%26volume%3D14%26spage%3D285%26epage%3D292%26doi%3D10.1007%2Fs10989-008-9154-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Behrendt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Offer, J.</span><span> </span><span class="NLM_article-title">Advances in Fmoc solid-phase peptide synthesis</span> <span class="citation_source-journal">J. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4</span><span class="NLM_x">â</span> <span class="NLM_lpage">27</span><span class="refDoi">Â DOI: 10.1002/psc.2836</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fpsc.2836" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26785684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFSnsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=4-27&author=R.+Behrendtauthor=P.+Whiteauthor=J.+Offer&title=Advances+in+Fmoc+solid-phase+peptide+synthesis&doi=10.1002%2Fpsc.2836"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in Fmoc solid-phase peptide synthesis</span></div><div class="casAuthors">Behrendt, Raymond; White, Peter; Offer, John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4-27</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Today, Fmoc SPPS is the method of choice for peptide synthesis.  Very-high-quality Fmoc building blocks are available at low cost because of the economies of scale arising from current multiton prodn. of therapeutic peptides by Fmoc SPPS.  Many modified derivs. are com. available as Fmoc building blocks, making synthetic access to a broad range of peptide derivs. straightforward.  The no. of synthetic peptides entering clin. trials has grown continuously over the last decade, and recent advances in the Fmoc SPPS technol. are a response to the growing demand from medicinal chem. and pharmacol.  Improvements are being continually reported for peptide quality, synthesis time and novel synthetic targets.  Topical peptide research has contributed to a continuous improvement and expansion of Fmoc SPPS applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNn2hqVjRZfbVg90H21EOLACvtfcHk0lj4yQrQevMCEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFSnsbo%253D&md5=ad2b68e27d36071ea520514fb02e70ba</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1002%2Fpsc.2836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.2836%26sid%3Dliteratum%253Aachs%26aulast%3DBehrendt%26aufirst%3DR.%26aulast%3DWhite%26aufirst%3DP.%26aulast%3DOffer%26aufirst%3DJ.%26atitle%3DAdvances%2520in%2520Fmoc%2520solid-phase%2520peptide%2520synthesis%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2016%26volume%3D22%26spage%3D4%26epage%3D27%26doi%3D10.1002%2Fpsc.2836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Behrendt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MartÃ­, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, P.</span><span> </span><span class="NLM_article-title">New t-butyl based aspartate protecting groups preventing aspartimide formation in Fmoc SPPS</span> <span class="citation_source-journal">J. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">680</span><span class="NLM_x">â</span> <span class="NLM_lpage">687</span><span class="refDoi">Â DOI: 10.1002/psc.2790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fpsc.2790" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26077723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpvFShsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=680-687&author=R.+Behrendtauthor=S.+Huberauthor=R.+Mart%C3%ADauthor=P.+White&title=New+t-butyl+based+aspartate+protecting+groups+preventing+aspartimide+formation+in+Fmoc+SPPS&doi=10.1002%2Fpsc.2790"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">New t-butyl based aspartate protecting groups preventing aspartimide formation in Fmoc SPPS</span></div><div class="casAuthors">Behrendt, Raymond; Huber, Simon; Marti, Roger; White, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">680-687</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Obtaining homogeneous aspartyl-contg. peptides via Fmoc/tBu chem. is often an insurmountable obstacle.  A generic soln. for this issue utilizing an optimized side-chain protection strategy that minimizes aspartimide formation would therefore be most desirable.  To this end, we developed the following new derivs.: Fmoc-Asp(OEpe)-OH (Epe = 3-ethyl-3-pentyl), Fmoc-Asp(OPhp)-OH (Php = 4-n-propyl-4-heptyl) and Fmoc-Asp(OBno)-OH (Bno = 5-n-butyl-5-nonyl).  We have compared their effectiveness against that of Fmoc-Asp(OtBu)-OH and Fmoc-Asp(OMpe)-OH in the well-established scorpion toxin II model peptide variants H-Val-Lys-Asp-Asn/Arg-Tyr-Ile-OH by treatments of the peptidyl resins with the Fmoc removal reagents contg. piperidine and DBU at both room and elevated temps.  The new derivs. proved to be extremely effective in minimizing aspartimide byproducts in each application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHNEK5O8WUpbVg90H21EOLACvtfcHk0lj4yQrQevMCEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpvFShsrg%253D&md5=a16c6807665bc6add7a02395302d426d</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1002%2Fpsc.2790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.2790%26sid%3Dliteratum%253Aachs%26aulast%3DBehrendt%26aufirst%3DR.%26aulast%3DHuber%26aufirst%3DS.%26aulast%3DMart%25C3%25AD%26aufirst%3DR.%26aulast%3DWhite%26aufirst%3DP.%26atitle%3DNew%2520t-butyl%2520based%2520aspartate%2520protecting%2520groups%2520preventing%2520aspartimide%2520formation%2520in%2520Fmoc%2520SPPS%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2015%26volume%3D21%26spage%3D680%26epage%3D687%26doi%3D10.1002%2Fpsc.2790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Michels, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dolling, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haberkorn, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mier, W.</span><span> </span><span class="NLM_article-title">Acid-mediated prevention of aspartimide formation in solid phase peptide synthesis</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">5218</span><span class="NLM_x">â</span> <span class="NLM_lpage">5221</span><span class="refDoi">Â DOI: 10.1021/ol3007925</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol3007925" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVejsrjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=5218-5221&author=T.+Michelsauthor=R.+Dollingauthor=U.+Haberkornauthor=W.+Mier&title=Acid-mediated+prevention+of+aspartimide+formation+in+solid+phase+peptide+synthesis&doi=10.1021%2Fol3007925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Acid-mediated prevention of aspartimide formation in solid phase peptide synthesis</span></div><div class="casAuthors">Michels, Tillmann; Doelling, Rudolf; Haberkorn, Uwe; Mier, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5218-5221</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aspartimide formation is one of the major obstacles that impedes the solid phase synthesis of large peptides and proteins.  Until now, no cost-effective strategy to suppress this side reaction has been developed.  Here it is demonstrated that addn. of small amts. of org. acids to the std. Fmoc cleavage agent piperidine efficiently prevents formation of aspartimide side products.  This effect is shown to be virtually independent of the acid strength.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpyen9Ony3ObVg90H21EOLACvtfcHk0lj4yQrQevMCEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVejsrjE&md5=7a0b1fdea8b46dc44c128e0c354af3ef</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1021%2Fol3007925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol3007925%26sid%3Dliteratum%253Aachs%26aulast%3DMichels%26aufirst%3DT.%26aulast%3DDolling%26aufirst%3DR.%26aulast%3DHaberkorn%26aufirst%3DU.%26aulast%3DMier%26aufirst%3DW.%26atitle%3DAcid-mediated%2520prevention%2520of%2520aspartimide%2520formation%2520in%2520solid%2520phase%2520peptide%2520synthesis%26jtitle%3DOrg.%2520Lett.%26date%3D2012%26volume%3D14%26spage%3D5218%26epage%3D5221%26doi%3D10.1021%2Fol3007925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">SubirÃ³s-Funosas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Faham, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albericio, F.</span><span> </span><span class="NLM_article-title">Use of Oxyma as pH modulatory agent to be used in the prevention of base-driven side reactions and its effect on 2-chlorotrityl chloride resin</span> <span class="citation_source-journal">Biopolymers</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">â</span> <span class="NLM_lpage">97</span><span class="refDoi">Â DOI: 10.1002/bip.21713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fbip.21713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21882170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFSjurjP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2012&pages=89-97&author=R.+Subir%C3%B3s-Funosasauthor=A.+El-Fahamauthor=F.+Albericio&title=Use+of+Oxyma+as+pH+modulatory+agent+to+be+used+in+the+prevention+of+base-driven+side+reactions+and+its+effect+on+2-chlorotrityl+chloride+resin&doi=10.1002%2Fbip.21713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Use of Oxyma as pH modulatory agent to be used in the prevention of base-driven side reactions and its effect on 2-chlorotrityl chloride resin</span></div><div class="casAuthors">Subiros-Funosas, Ramon; El-Faham, Ayman; Albericio, Fernando</div><div class="citationInfo"><span class="NLM_cas:title">Biopolymers</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">89-97</span>CODEN:
                <span class="NLM_cas:coden">BIPMAA</span>;
        ISSN:<span class="NLM_cas:issn">0006-3525</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The presence of low pKa N-hydroxylamines is beneficial in peptide chem. as they reduce some base-mediated side reactions.  Here we evaluated the applicability and buffering capacity of Et 2-cyano-2-(hydroxyimino)acetate (Oxyma) in the prevention of aspartimide/piperidide formation and Pro-based overcoupling and compared it with the performance of HOBt and HOAt.  In addn., the compatibility of these additives with the highly acid-labile 2-chlorotrityl chloride resin is examd. Â© 2011 Wiley Periodicals, Inc. Biopolymers, 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf1AbQAVUfC7Vg90H21EOLACvtfcHk0ljDXezWyk-9SQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFSjurjP&md5=73705b2ab50e4fa81dd7af619ff338e9</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1002%2Fbip.21713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbip.21713%26sid%3Dliteratum%253Aachs%26aulast%3DSubir%25C3%25B3s-Funosas%26aufirst%3DR.%26aulast%3DEl-Faham%26aufirst%3DA.%26aulast%3DAlbericio%26aufirst%3DF.%26atitle%3DUse%2520of%2520Oxyma%2520as%2520pH%2520modulatory%2520agent%2520to%2520be%2520used%2520in%2520the%2520prevention%2520of%2520base-driven%2520side%2520reactions%2520and%2520its%2520effect%2520on%25202-chlorotrityl%2520chloride%2520resin%26jtitle%3DBiopolymers%26date%3D2012%26volume%3D98%26spage%3D89%26epage%3D97%26doi%3D10.1002%2Fbip.21713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Inoue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinohara, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanabe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itoh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizoguchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuoka, S.</span><span> </span><span class="NLM_article-title">Total synthesis of the large non-ribosomal peptide polytheonamide B</span> <span class="citation_source-journal">Nat. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">280</span><span class="NLM_x">â</span> <span class="NLM_lpage">285</span><span class="refDoi">Â DOI: 10.1038/nchem.554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnchem.554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21124508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjslSgsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=280-285&author=M.+Inoueauthor=N.+Shinoharaauthor=S.+Tanabeauthor=T.+Takahashiauthor=K.+Okuraauthor=H.+Itohauthor=Y.+Mizoguchiauthor=M.+Iidaauthor=N.+Leeauthor=S.+Matsuoka&title=Total+synthesis+of+the+large+non-ribosomal+peptide+polytheonamide+B&doi=10.1038%2Fnchem.554"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Total synthesis of the large non-ribosomal peptide polytheonamide B</span></div><div class="casAuthors">Inoue, Masayuki; Shinohara, Naoki; Tanabe, Shintaro; Takahashi, Tomoaki; Okura, Ken; Itoh, Hiroaki; Mizoguchi, Yuki; Iida, Maiko; Lee, Nayoung; Matsuoka, Shigeru</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">280-285</span>CODEN:
                <span class="NLM_cas:coden">NCAHBB</span>;
        ISSN:<span class="NLM_cas:issn">1755-4330</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Polytheonamide B is by far the largest non-ribosomal peptide known at present, and displays extraordinary cytotoxicity (EC50 = 68 pg ml-1, mouse leukemia P388 cells).  Its 48 amino-acid residues include a variety of non-proteinogenic D- and L-amino acids, and the abs. stereochem. of these amino acids alternate in sequence.  These structural features induce the formation of a stable Î²-strand-type structure, giving rise to an overall tubular structure over 30 Ã in length.  In a biol. setting, this fold is believed to transport cations across the lipid bilayer through a pore, thereby acting as an ion channel.  Here, we report the first chem. construction of polytheonamide B.  Our synthesis relies on the combination of four key stages: syntheses of non-proteinogenic amino acids, a solid-phase assembly of four fragments of polytheonamide B, silver-mediated connection of the fragments and, finally, global deprotection.  The synthetic material now available will allow studies of the relationships between its conformational properties, channel functions and cytotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZj_PWLMPlULVg90H21EOLACvtfcHk0ljDXezWyk-9SQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjslSgsLo%253D&md5=f30cc2b205caf179bfb08fb7632d276a</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1038%2Fnchem.554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchem.554%26sid%3Dliteratum%253Aachs%26aulast%3DInoue%26aufirst%3DM.%26aulast%3DShinohara%26aufirst%3DN.%26aulast%3DTanabe%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DT.%26aulast%3DOkura%26aufirst%3DK.%26aulast%3DItoh%26aufirst%3DH.%26aulast%3DMizoguchi%26aufirst%3DY.%26aulast%3DIida%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DN.%26aulast%3DMatsuoka%26aufirst%3DS.%26atitle%3DTotal%2520synthesis%2520of%2520the%2520large%2520non-ribosomal%2520peptide%2520polytheonamide%2520B%26jtitle%3DNat.%2520Chem.%26date%3D2010%26volume%3D2%26spage%3D280%26epage%3D285%26doi%3D10.1038%2Fnchem.554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Heinlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VarÃ³n Silva, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">TrÃ¶ster, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unverzagt, C.</span><span> </span><span class="NLM_article-title">Fragment condensation of C-terminal pseudoproline peptides without racemization on the solid phase</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">6406</span><span class="NLM_x">â</span> <span class="NLM_lpage">6410</span><span class="refDoi">Â DOI: 10.1002/anie.201101270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fanie.201101270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFahsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=6406-6410&author=C.+Heinleinauthor=D.+Var%C3%B3n+Silvaauthor=A.+Tr%C3%B6sterauthor=J.+Schmidtauthor=A.+Grossauthor=C.+Unverzagt&title=Fragment+condensation+of+C-terminal+pseudoproline+peptides+without+racemization+on+the+solid+phase&doi=10.1002%2Fanie.201101270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment Condensation of C-Terminal Pseudoproline Peptides without Racemization on the Solid Phase</span></div><div class="casAuthors">Heinlein, Christian; Silva, Daniel Varon; Troester, Andrea; Schmidt, Jasmin; Gross, Angelina; Unverzagt, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">6406-6410</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Protected peptides featuring C-terminal pseudoprolines were synthesized on a solid support, and these versatile building blocks were used in convergent peptide-segment couplings, which proceeded without racemization even under microwave conditions.  The soly.-enhancing effect of pseudoproline residues facilitated the synthesis of complex RNase 39-mer glycopeptide thioesters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr06nUMYrPuNLVg90H21EOLACvtfcHk0lggx_t1rczelA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFahsr0%253D&md5=6f60b7d527ec7d60163d98eca188b042</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1002%2Fanie.201101270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201101270%26sid%3Dliteratum%253Aachs%26aulast%3DHeinlein%26aufirst%3DC.%26aulast%3DVar%25C3%25B3n%2BSilva%26aufirst%3DD.%26aulast%3DTr%25C3%25B6ster%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DJ.%26aulast%3DGross%26aufirst%3DA.%26aulast%3DUnverzagt%26aufirst%3DC.%26atitle%3DFragment%2520condensation%2520of%2520C-terminal%2520pseudoproline%2520peptides%2520without%2520racemization%2520on%2520the%2520solid%2520phase%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2011%26volume%3D50%26spage%3D6406%26epage%3D6410%26doi%3D10.1002%2Fanie.201101270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Hiebl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgartner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernwieser, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bodenteich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leitner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rovenszky, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alberts, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatnagar, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banyard, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baresch, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esch, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kollmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayrhofer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weihtrager, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welz, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkler, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lantos, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevenson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tubman, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Undheim, K.</span><span> </span><span class="NLM_article-title">Large-scale synthesis of hematoregulatory nonapeptide SK&F 107647 by fragment coupling</span> <span class="citation_source-journal">J. Pept. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">54</span><span class="NLM_x">â</span> <span class="NLM_lpage">65</span><span class="refDoi">Â DOI: 10.1034/j.1399-3011.1999.00089.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1034%2Fj.1399-3011.1999.00089.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10448970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADyaK1MXkslGhur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1999&pages=54-65&author=J.+Hieblauthor=H.+Baumgartnerauthor=I.+Bernwieserauthor=M.+Blankaauthor=M.+Bodenteichauthor=K.+Leitnerauthor=A.+Rioauthor=F.+Rovenszkyauthor=D.+P.+Albertsauthor=P.+K.+Bhatnagarauthor=A.+F.+Banyardauthor=K.+Bareschauthor=P.+M.+Eschauthor=H.+Kollmannauthor=G.+Mayrhoferauthor=H.+Weihtragerauthor=W.+Welzauthor=K.+Winklerauthor=T.+Chenauthor=R.+Patelauthor=I.+Lantosauthor=D.+Stevensonauthor=K.+D.+Tubmanauthor=K.+Undheim&title=Large-scale+synthesis+of+hematoregulatory+nonapeptide+SK%26F+107647+by+fragment+coupling&doi=10.1034%2Fj.1399-3011.1999.00089.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Large-scale synthesis of hematoregulatory nonapeptide SK&F 107647 by fragment coupling</span></div><div class="casAuthors">Hiebl, J.; Alberts, D. P.; Banyard, A. F.; Baresch, K.; Baumgartner, H.; Bernwieser, I.; Bhatnagar, P. K.; Blanka, M.; Bodenteich, M.; Chen, T.; Esch, P. M.; Kollmann, H.; Lantos, I.; Leitner, K.; Mayrhofer, G.; Patel, R.; Rio, A.; Rovenszky, F.; Stevenson, D.; Tubman, K. D.; Undheim, K.; Weihtrager, H.; Welz, W.; Winkler, K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-65</span>CODEN:
                <span class="NLM_cas:coden">JPERFA</span>;
        ISSN:<span class="NLM_cas:issn">1397-002X</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">Linear and convergent routes for the large-scale prepn. of the hematoregulatory nonapeptide (Glp-Glu-Asp)2-DAS-(Lys)2 (I) were investigated.  A convergent approach ("3 + 2"-route employing Boc-and benzyl ester protecting groups) was selected for the prepn. of multi-hundred-gram quantities of I.  Key steps were the prepn. and the coupling of tripeptide hydrochloride (HCl.H)2-DAS-(Lys(Z)-OBn)2 (DAS=2,7-L,L-diamino-suberic acid) and tripeptide Glp-Glu(OBn)-Asp(OBn)-OH.  Several coupling reagents were investigated in order to reduce the amt. of epimerization of this fragment coupling.  TDBTU [O-(3,4-dihydro-4-oxo-1,2,3-benzotriazin-3-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate] was identified as the condensation reagent of choice.  Using this synthetic route >97% pure final product in an overall yield of 35% calcd. on di-Boc protected 2,7-L,L-diamino-suberic acid was prepd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofKrKIFWfLT7Vg90H21EOLACvtfcHk0lggx_t1rczelA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXkslGhur0%253D&md5=304a29d0d50c0b5d47b62f162c8ce800</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1034%2Fj.1399-3011.1999.00089.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1034%252Fj.1399-3011.1999.00089.x%26sid%3Dliteratum%253Aachs%26aulast%3DHiebl%26aufirst%3DJ.%26aulast%3DBaumgartner%26aufirst%3DH.%26aulast%3DBernwieser%26aufirst%3DI.%26aulast%3DBlanka%26aufirst%3DM.%26aulast%3DBodenteich%26aufirst%3DM.%26aulast%3DLeitner%26aufirst%3DK.%26aulast%3DRio%26aufirst%3DA.%26aulast%3DRovenszky%26aufirst%3DF.%26aulast%3DAlberts%26aufirst%3DD.%2BP.%26aulast%3DBhatnagar%26aufirst%3DP.%2BK.%26aulast%3DBanyard%26aufirst%3DA.%2BF.%26aulast%3DBaresch%26aufirst%3DK.%26aulast%3DEsch%26aufirst%3DP.%2BM.%26aulast%3DKollmann%26aufirst%3DH.%26aulast%3DMayrhofer%26aufirst%3DG.%26aulast%3DWeihtrager%26aufirst%3DH.%26aulast%3DWelz%26aufirst%3DW.%26aulast%3DWinkler%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DPatel%26aufirst%3DR.%26aulast%3DLantos%26aufirst%3DI.%26aulast%3DStevenson%26aufirst%3DD.%26aulast%3DTubman%26aufirst%3DK.%2BD.%26aulast%3DUndheim%26aufirst%3DK.%26atitle%3DLarge-scale%2520synthesis%2520of%2520hematoregulatory%2520nonapeptide%2520SK%2526F%2520107647%2520by%2520fragment%2520coupling%26jtitle%3DJ.%2520Pept.%2520Res.%26date%3D1999%26volume%3D54%26spage%3D54%26epage%3D65%26doi%3D10.1034%2Fj.1399-3011.1999.00089.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Raibaut, L.; El Mahdi, O.; Melnyk, O.</span><span> </span><span class="NLM_article-title">Solid phase protein chemical synthesis</span>. In  <span class="citation_source-book">Protein Ligation and Total Synthesis II</span>; <span class="NLM_publisher-name">Springer International Publishing</span>: <span class="NLM_publisher-loc">Cham</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">103</span><span class="NLM_x">â</span> <span class="NLM_lpage">154</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=103-154&author=L.+Raibaut&author=O.+El+Mahdi&author=O.+Melnyk&title=Protein+Ligation+and+Total+Synthesis+II"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DRaibaut%26aufirst%3DL.%26atitle%3DSolid%2520phase%2520protein%2520chemical%2520synthesis%26btitle%3DProtein%2520Ligation%2520and%2520Total%2520Synthesis%2520II%26pub%3DSpringer%2520International%2520Publishing%26date%3D2015%26spage%3D103%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Johnson, E. C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, S. B. H.</span><span> </span><span class="NLM_article-title">Insights into the mechanism and catalysis of the native chemical ligation reaction</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x">, </span> <span class="NLM_fpage">6640</span><span class="NLM_x">â</span> <span class="NLM_lpage">6646</span><span class="refDoi">Â DOI: 10.1021/ja058344i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja058344i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvFyitrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2006&pages=6640-6646&author=E.+C.+B.+Johnsonauthor=S.+B.+H.+Kent&title=Insights+into+the+mechanism+and+catalysis+of+the+native+chemical+ligation+reaction&doi=10.1021%2Fja058344i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the Mechanism and Catalysis of the Native Chemical Ligation Reaction</span></div><div class="casAuthors">Johnson, Erik C. B.; Kent, Stephen B. H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6640-6646</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Native chem. ligation of unprotected peptide segments involves reaction between a peptide-Î±-thioester and a cysteine-peptide, to yield a product with a native amide bond at the ligation site.  Peptide-Î±-thioalkyl esters are commonly used because of their ease of prepn.  These thioalkyl esters are rather unreactive so the ligation reaction is catalyzed by in situ trans-thioesterification with thiol additives.  The most common thiol catalysts used to date have been either a mixt. of thiophenol/benzyl mercaptan, or the alkanethiol MESNA.  Despite the use of these thiol catalysts, ligation reactions typically take 24-48 h.  To gain insight into the mechanism of native chem. ligation and in order to find a better catalyst, we investigated the use of a no. of thiol compds.  Substituted thiophenols with pKa > 6 were found to best combine the ability to exchange rapidly and completely with thioalkyl esters, and to then act as effective leaving groups in reaction of the peptide-thioester with the thiol side chain of a cysteine-peptide.  A highly effective and practical catalyst was (4-carboxylmethyl)thiophenol (MPAA), a non-malodorous, water-sol. thiol.  Use of MPAA gave an order of magnitude faster reaction in model studies of native chem. ligation and in the synthesis of a small protein, turkey ovomucoid third domain (OMTKY3).  MPAA should find broad use in native chem. ligation and in the total synthesis of proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6aUCq6LJkP7Vg90H21EOLACvtfcHk0liX44IpUp_Awg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvFyitrc%253D&md5=ca67dc1c0f5af9efa3a421a48bb0dd0b</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Fja058344i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja058344i%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DE.%2BC.%2BB.%26aulast%3DKent%26aufirst%3DS.%2BB.%2BH.%26atitle%3DInsights%2520into%2520the%2520mechanism%2520and%2520catalysis%2520of%2520the%2520native%2520chemical%2520ligation%2520reaction%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2006%26volume%3D128%26spage%3D6640%26epage%3D6646%26doi%3D10.1021%2Fja058344i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Hormoz, S.</span><span> </span><span class="NLM_article-title">Amino acid composition of proteins reduces deleterious impact of mutations</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">2919</span><span class="refDoi">Â DOI: 10.1038/srep02919</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fsrep02919" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24108121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FnsV2hsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=2919&author=S.+Hormoz&title=Amino+acid+composition+of+proteins+reduces+deleterious+impact+of+mutations&doi=10.1038%2Fsrep02919"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Amino acid composition of proteins reduces deleterious impact of mutations</span></div><div class="casAuthors">Hormoz Sahand</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2919</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The evolutionary origin of amino acid occurrence frequencies in proteins (composition) is not yet fully understood.  We suggest that protein composition works alongside the genetic code to minimize impact of mutations on protein structure.  First, we propose a novel method for estimating thermodynamic stability of proteins whose sequence is constrained to a fixed composition.  Second, we quantify the average deleterious impact of substituting one amino acid with another.  Natural proteome compositions are special in at least two ways: 1) Natural compositions do not generate more stable proteins than the average random composition, however, they result in proteins that are less susceptible to damage from mutations. 2) Natural proteome compositions that result in more stable proteins (i.e. those of thermophiles) are also tuned to have a higher tolerance for mutations.  This is consistent with the observation that environmental factors selecting for more stable proteins also enhance the deleterious impact of mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSqIdmB720IWwqdek-gHSrIfW6udTcc2eYNd6rbUKcW8bntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FnsV2hsg%253D%253D&md5=9bff3f81488c74dd9287e46b3b27598a</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1038%2Fsrep02919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep02919%26sid%3Dliteratum%253Aachs%26aulast%3DHormoz%26aufirst%3DS.%26atitle%3DAmino%2520acid%2520composition%2520of%2520proteins%2520reduces%2520deleterious%2520impact%2520of%2520mutations%26jtitle%3DSci.%2520Rep.%26date%3D2013%26volume%3D3%26spage%3D2919%26doi%3D10.1038%2Fsrep02919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warren, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hua, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danishefsky, S. J.</span><span> </span><span class="NLM_article-title">Building complex glycopeptides: development of a cysteine-free native chemical ligation protocol</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">4116</span><span class="NLM_x">â</span> <span class="NLM_lpage">4125</span><span class="refDoi">Â DOI: 10.1002/anie.200600538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fanie.200600538" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2006&pages=4116-4125&author=B.+Wuauthor=J.+Chenauthor=J.+D.+Warrenauthor=G.+Chenauthor=Z.+Huaauthor=S.+J.+Danishefsky&title=Building+complex+glycopeptides%3A+development+of+a+cysteine-free+native+chemical+ligation+protocol&doi=10.1002%2Fanie.200600538"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92a&amp;dbid=16384&amp;doi=10.1002%2Fanie.200600538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200600538%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWarren%26aufirst%3DJ.%2BD.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DHua%26aufirst%3DZ.%26aulast%3DDanishefsky%26aufirst%3DS.%2BJ.%26atitle%3DBuilding%2520complex%2520glycopeptides%253A%2520development%2520of%2520a%2520cysteine-free%2520native%2520chemical%2520ligation%2520protocol%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2006%26volume%3D45%26spage%3D4116%26epage%3D4125%26doi%3D10.1002%2Fanie.200600538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit92b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Thapa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menon, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bingham, J.-P.</span><span> </span><span class="NLM_article-title">Native chemical ligation: a boon to peptide chemistry</span> <span class="citation_source-journal">Molecules</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">14461</span><span class="NLM_x">â</span> <span class="NLM_lpage">14483</span><span class="refDoi">Â DOI: 10.3390/molecules190914461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3390%2Fmolecules190914461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25221869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12isbvL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=14461-14483&author=P.+Thapaauthor=R.-Y.+Zhangauthor=V.+Menonauthor=J.-P.+Bingham&title=Native+chemical+ligation%3A+a+boon+to+peptide+chemistry&doi=10.3390%2Fmolecules190914461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92bR"><div class="casContent"><span class="casTitleNuber">92b</span><div class="casTitle"><span class="NLM_cas:atitle">Native chemical ligation: a boon to peptide chemistry</span></div><div class="casAuthors">Thapa, Parashar; Zhang, Rui-Yang; Menon, Vinay; Bingham, Jon-Paul</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">14461-14483, 23 pp.</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The use of chem. ligation within the realm of peptide chem. has opened various opportunities to expand the applications of peptides/proteins in biol. sciences.  Expansion and refinement of ligation chem. has made it possible for the entry of peptides into the world of viable oral therapeutic drugs through peptide backbone cyclization.  This progression has been a journey of chem. exploration and transition, leading to the dominance of native chem. ligation in the present advances of peptide/protein applications.  Here, the authors illustrate and explore the historical and current nature of peptide ligation, providing a clear indication to the possibilities and use of these novel methods to take peptides outside their typically defined boundaries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2F8ClVQ8QDLVg90H21EOLACvtfcHk0lgV0gEWBUt7Dw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12isbvL&md5=98347270b44c2577b71f160dda352a79</span></div><a href="/servlet/linkout?suffix=cit92b&amp;dbid=16384&amp;doi=10.3390%2Fmolecules190914461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules190914461%26sid%3Dliteratum%253Aachs%26aulast%3DThapa%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DR.-Y.%26aulast%3DMenon%26aufirst%3DV.%26aulast%3DBingham%26aufirst%3DJ.-P.%26atitle%3DNative%2520chemical%2520ligation%253A%2520a%2520boon%2520to%2520peptide%2520chemistry%26jtitle%3DMolecules%26date%3D2014%26volume%3D19%26spage%3D14461%26epage%3D14483%26doi%3D10.3390%2Fmolecules190914461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Rohde, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seitz, O.</span><span> </span><span class="NLM_article-title">Ligation-desulfurization: A powerful combination in the synthesis of peptides and glycopeptides</span> <span class="citation_source-journal">Biopolymers</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">551</span><span class="NLM_x">â</span> <span class="NLM_lpage">559</span><span class="refDoi">Â DOI: 10.1002/bip.21442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fbip.21442" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2010&pages=551-559&author=H.+Rohdeauthor=O.+Seitz&title=Ligation-desulfurization%3A+A+powerful+combination+in+the+synthesis+of+peptides+and+glycopeptides&doi=10.1002%2Fbip.21442"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1002%2Fbip.21442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbip.21442%26sid%3Dliteratum%253Aachs%26aulast%3DRohde%26aufirst%3DH.%26aulast%3DSeitz%26aufirst%3DO.%26atitle%3DLigation-desulfurization%253A%2520A%2520powerful%2520combination%2520in%2520the%2520synthesis%2520of%2520peptides%2520and%2520glycopeptides%26jtitle%3DBiopolymers%26date%3D2010%26volume%3D94%26spage%3D551%26epage%3D559%26doi%3D10.1002%2Fbip.21442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">Malins, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payne, R. J.</span><span> </span><span class="NLM_article-title">Recent extensions to native chemical ligation for the chemical synthesis of peptides and proteins</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">70</span><span class="NLM_x">â</span> <span class="NLM_lpage">78</span><span class="refDoi">Â DOI: 10.1016/j.cbpa.2014.09.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.cbpa.2014.09.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25285753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12nur7I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=70-78&author=L.+R.+Malinsauthor=R.+J.+Payne&title=Recent+extensions+to+native+chemical+ligation+for+the+chemical+synthesis+of+peptides+and+proteins&doi=10.1016%2Fj.cbpa.2014.09.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Recent extensions to native chemical ligation for the chemical synthesis of peptides and proteins</span></div><div class="casAuthors">Malins, Lara R.; Payne, Richard J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">70-78</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Native chem. ligation continues to play a pivotal role in the synthesis of increasingly complex peptide and protein targets twenty years after its initial report.  This opinion article will highlight a no. of recent, powerful extensions of the technol. that have expanded the scope of the reaction, accelerated ligation rates, enabled chemoselective post-ligation modifications, and streamlined the ligation of multiple peptide fragments.  These advances have facilitated the synthesis of a no. of impressive protein targets to date and hold great promise for the continued application of native chem. ligation for the detailed study of protein structure and function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNc6KMnkM7mbVg90H21EOLACvtfcHk0lgVqvgLV2Cb6Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12nur7I&md5=596adefc77f55286aca2fc413199b085</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2014.09.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2014.09.021%26sid%3Dliteratum%253Aachs%26aulast%3DMalins%26aufirst%3DL.%2BR.%26aulast%3DPayne%26aufirst%3DR.%2BJ.%26atitle%3DRecent%2520extensions%2520to%2520native%2520chemical%2520ligation%2520for%2520the%2520chemical%2520synthesis%2520of%2520peptides%2520and%2520proteins%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D22%26spage%3D70%26epage%3D78%26doi%3D10.1016%2Fj.cbpa.2014.09.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Hackeng, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, P. E.</span><span> </span><span class="NLM_article-title">Protein synthesis by native chemical ligation: Expanded scope by using straightforward methodology</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">10068</span><span class="NLM_x">â</span> <span class="NLM_lpage">10073</span><span class="refDoi">Â DOI: 10.1073/pnas.96.18.10068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1073%2Fpnas.96.18.10068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10468563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFegsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=10068-10073&author=T.+M.+Hackengauthor=J.+H.+Griffinauthor=P.+E.+Dawson&title=Protein+synthesis+by+native+chemical+ligation%3A+Expanded+scope+by+using+straightforward+methodology&doi=10.1073%2Fpnas.96.18.10068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Protein synthesis by native chemical ligation: expanded scope by using straightforward methodology</span></div><div class="casAuthors">Hackeng, Tilman M.; Griffin, John H.; Dawson, Philip E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">10068-10073</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The total chem. synthesis of proteins has great potential for increasing understanding of the mol. basis of protein function.  The introduction of native chem. ligation techniques to join unprotected peptides next to a cysteine residue has greatly facilitated the synthesis of proteins of moderate size.  Here, the authors describe a straightforward methodol. that has enabled them to rapidly analyze the compatibility of the native chem. ligation strategy for X-Cys ligation sites, where X is any of the 20 naturally occurring amino acids.  The simplified methodol. avoids the necessity of specific amino acid thioester linkers or alkylation of C-terminal thio-acid peptides.  Expts. using matrix-assisted laser-desorption ionization MS anal. of combinatorial ligations of LYRAX-C-terminal thioester peptides to the peptide CRANK show that all 20 amino acids are suitable for ligation, with Val, Ile, and Pro representing less favorable choices because of slow ligation rates.  To illustrate the method's utility, two 124-aa proteins were manually synthesized by using a three-step, four-piece ligation to yield a fully active human secretory phospholipase A2 and a catalytically inactive analog.  The combination of flexibility in design with general access because of simplified methodol. broadens the applicability and versatility of chem. protein synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2eas8MPkrprVg90H21EOLACvtfcHk0lgVqvgLV2Cb6Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFegsLw%253D&md5=edb07cac4a6b4ee133fffedc3814d285</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.18.10068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.18.10068%26sid%3Dliteratum%253Aachs%26aulast%3DHackeng%26aufirst%3DT.%2BM.%26aulast%3DGriffin%26aufirst%3DJ.%2BH.%26aulast%3DDawson%26aufirst%3DP.%2BE.%26atitle%3DProtein%2520synthesis%2520by%2520native%2520chemical%2520ligation%253A%2520Expanded%2520scope%2520by%2520using%2520straightforward%2520methodology%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26spage%3D10068%26epage%3D10073%26doi%3D10.1073%2Fpnas.96.18.10068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Zheng, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span> </span><span class="NLM_article-title">Chemical synthesis of proteins using peptide hydrazides as thioester surrogates</span> <span class="citation_source-journal">Nat. Protoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2483</span><span class="NLM_x">â</span> <span class="NLM_lpage">2495</span><span class="refDoi">Â DOI: 10.1038/nprot.2013.152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnprot.2013.152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24232250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkt1Kjsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=2483-2495&author=J.-S.+Zhengauthor=S.+Tangauthor=Y.-K.+Qiauthor=Z.-P.+Wangauthor=L.+Liu&title=Chemical+synthesis+of+proteins+using+peptide+hydrazides+as+thioester+surrogates&doi=10.1038%2Fnprot.2013.152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical synthesis of proteins using peptide hydrazides as thioester surrogates</span></div><div class="casAuthors">Zheng, Ji-Shen; Tang, Shan; Qi, Yun-Kun; Wang, Zhi-Peng; Liu, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2483-2495</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This protocol provides a detailed procedure for the chem. synthesis of proteins through native chem. ligation of peptide hydrazides.  The two crucial stages of this protocol are (i) the solid-phase synthesis of peptide hydrazides via Fmoc chem. and (ii) the native chem. ligation of peptide hydrazides through in situ NaNO2 activation and thiolysis.  This protocol may be of help in the synthesis of proteins that are not easily produced by recombinant technol. and that include acid-sensitive modifications; it also does not involve the use of hazardous HF.  The utility of the protocol is shown for the total synthesis of 140-aa-long Î±-synuclein, a protein that has an important role in the development of Parkinson's disease.  The whole synthesis of the target protein Î±-synuclein in milligram scale takes â¼30 working days.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruKtX1ELNnTbVg90H21EOLACvtfcHk0lgVqvgLV2Cb6Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkt1Kjsr4%253D&md5=31b83fce2cd55b283e5ebb9837c98aa2</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2013.152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2013.152%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DJ.-S.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DQi%26aufirst%3DY.-K.%26aulast%3DWang%26aufirst%3DZ.-P.%26aulast%3DLiu%26aufirst%3DL.%26atitle%3DChemical%2520synthesis%2520of%2520proteins%2520using%2520peptide%2520hydrazides%2520as%2520thioester%2520surrogates%26jtitle%3DNat.%2520Protoc.%26date%3D2013%26volume%3D8%26spage%3D2483%26epage%3D2495%26doi%3D10.1038%2Fnprot.2013.152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fang, G.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, H.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span> </span><span class="NLM_article-title">Protein chemical synthesis by ligation of peptide hydrazides</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">7645</span><span class="NLM_x">â</span> <span class="NLM_lpage">7649</span><span class="refDoi">Â DOI: 10.1002/anie.201100996</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fanie.201100996" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21648030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntV2rsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=7645-7649&author=G.-M.+Fangauthor=Y.-M.+Liauthor=F.+Shenauthor=Y.-C.+Huangauthor=J.-B.+Liauthor=Y.+Linauthor=H.-K.+Cuiauthor=L.+Liu&title=Protein+chemical+synthesis+by+ligation+of+peptide+hydrazides&doi=10.1002%2Fanie.201100996"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97aR"><div class="casContent"><span class="casTitleNuber">97a</span><div class="casTitle"><span class="NLM_cas:atitle">Protein Chemical Synthesis by Ligation of Peptide Hydrazides</span></div><div class="casAuthors">Fang, Ge-Min; Li, Yi-Ming; Shen, Fei; Huang, Yi-Chao; Li, Jia-Bin; Lin, Yun; Cui, Hong-Kui; Liu, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">7645-7649, S7645/1-S7645/40</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The ligation of peptide hydrazides is a new method for protein chem. synthesis that is complementary to native chem. ligation.  Peptide hydrazides may be the long-sought equiv. to a 'thioester synthon', one that is stable to the conditions of native chem. ligation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa-vzFJdvoB7Vg90H21EOLACvtfcHk0lgFXboIwP4QjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntV2rsr8%253D&md5=af3dea2524dfbb4f320b762c358cec58</span></div><a href="/servlet/linkout?suffix=cit97a&amp;dbid=16384&amp;doi=10.1002%2Fanie.201100996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201100996%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DG.-M.%26aulast%3DLi%26aufirst%3DY.-M.%26aulast%3DShen%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DY.-C.%26aulast%3DLi%26aufirst%3DJ.-B.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DCui%26aufirst%3DH.-K.%26aulast%3DLiu%26aufirst%3DL.%26atitle%3DProtein%2520chemical%2520synthesis%2520by%2520ligation%2520of%2520peptide%2520hydrazides%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2011%26volume%3D50%26spage%3D7645%26epage%3D7649%26doi%3D10.1002%2Fanie.201100996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit97b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Blanco-Canosa, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nardone, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albericio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, P. E.</span><span> </span><span class="NLM_article-title">Chemical protein synthesis using a second-generation N-acylurea linker for the preparation of peptide-thioester precursors</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">137</span><span class="NLM_x">, </span> <span class="NLM_fpage">7197</span><span class="NLM_x">â</span> <span class="NLM_lpage">7209</span><span class="refDoi">Â DOI: 10.1021/jacs.5b03504</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.5b03504" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref97/cit97b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVChsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=7197-7209&author=J.+B.+Blanco-Canosaauthor=B.+Nardoneauthor=F.+Albericioauthor=P.+E.+Dawson&title=Chemical+protein+synthesis+using+a+second-generation+N-acylurea+linker+for+the+preparation+of+peptide-thioester+precursors&doi=10.1021%2Fjacs.5b03504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97bR"><div class="casContent"><span class="casTitleNuber">97b</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical Protein Synthesis Using a Second-Generation N-Acylurea Linker for the Preparation of Peptide-Thioester Precursors</span></div><div class="casAuthors">Blanco-Canosa, Juan B.; Nardone, Brunello; Albericio, Fernando; Dawson, Philip E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7197-7209</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The broad utility of native chem. ligation (NCL) in protein synthesis has fostered a search for methods that enable the efficient synthesis of C-terminal peptide-thioesters, key intermediates in NCL.  The authors have developed an N-acylurea (Nbz) approach for the synthesis of thioester peptide precursors that efficiently undergo thiol exchange yielding thioester peptides and subsequently NCL reaction.  However, the synthesis of some glycine-rich sequences revealed limitations, such as diacylated products that can not be converted into N-acylurea peptides.  Here, the authors introduce a new N-acylurea linker bearing an o-amino(methyl)aniline (MeDbz) moiety that enables in a more robust peptide chain assembly.  The generality of the approach is illustrated by the synthesis of a pentaglycine sequence under different coupling conditions including microwave heating at coupling temps. up to 90Â°, affording the unique and desired N-acyl-N'-methylacylurea (MeNbz) product.  Further extension of the method allowed the synthesis of all 20 natural amino acids and their NCL reactions.  The kinetic anal. of the ligations using model peptides shows the MeNbz peptide rapidly converts to arylthioesters that are efficient at NCL.  Finally, the authors show that the new MeDbz linker can be applied to the synthesis of cysteine-rich proteins such the cyclotides Kalata B1 and MCoTI-II through a one cyclization/folding step in the ligation/folding buffer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi-KJFWKuka7Vg90H21EOLACvtfcHk0lgFXboIwP4QjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVChsbw%253D&md5=2f91e07ca12b1148af317aba502cf251</span></div><a href="/servlet/linkout?suffix=cit97b&amp;dbid=16384&amp;doi=10.1021%2Fjacs.5b03504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.5b03504%26sid%3Dliteratum%253Aachs%26aulast%3DBlanco-Canosa%26aufirst%3DJ.%2BB.%26aulast%3DNardone%26aufirst%3DB.%26aulast%3DAlbericio%26aufirst%3DF.%26aulast%3DDawson%26aufirst%3DP.%2BE.%26atitle%3DChemical%2520protein%2520synthesis%2520using%2520a%2520second-generation%2520N-acylurea%2520linker%2520for%2520the%2520preparation%2520of%2520peptide-thioester%2520precursors%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D7197%26epage%3D7209%26doi%3D10.1021%2Fjacs.5b03504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Boll, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drobecq, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ollivier, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanpain, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raibaut, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desmet, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vicogne, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melnyk, O.</span><span> </span><span class="NLM_article-title">One-pot chemical synthesis of small ubiquitin-like modifier protein-peptide conjugates using bis(2-sulfanylethyl)amido peptide latent thioester surrogates</span> <span class="citation_source-journal">Nat. Protoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">269</span><span class="NLM_x">â</span> <span class="NLM_lpage">292</span><span class="refDoi">Â DOI: 10.1038/nprot.2015.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnprot.2015.013" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=269-292&author=E.+Bollauthor=H.+Drobecqauthor=N.+Ollivierauthor=A.+Blanpainauthor=L.+Raibautauthor=R.+Desmetauthor=J.+Vicogneauthor=O.+Melnyk&title=One-pot+chemical+synthesis+of+small+ubiquitin-like+modifier+protein-peptide+conjugates+using+bis%282-sulfanylethyl%29amido+peptide+latent+thioester+surrogates&doi=10.1038%2Fnprot.2015.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98a&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2015.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2015.013%26sid%3Dliteratum%253Aachs%26aulast%3DBoll%26aufirst%3DE.%26aulast%3DDrobecq%26aufirst%3DH.%26aulast%3DOllivier%26aufirst%3DN.%26aulast%3DBlanpain%26aufirst%3DA.%26aulast%3DRaibaut%26aufirst%3DL.%26aulast%3DDesmet%26aufirst%3DR.%26aulast%3DVicogne%26aufirst%3DJ.%26aulast%3DMelnyk%26aufirst%3DO.%26atitle%3DOne-pot%2520chemical%2520synthesis%2520of%2520small%2520ubiquitin-like%2520modifier%2520protein-peptide%2520conjugates%2520using%2520bis%25282-sulfanylethyl%2529amido%2520peptide%2520latent%2520thioester%2520surrogates%26jtitle%3DNat.%2520Protoc.%26date%3D2015%26volume%3D10%26spage%3D269%26epage%3D292%26doi%3D10.1038%2Fnprot.2015.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit98b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ollivier, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vicogne, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vallin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drobecq, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desmet, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El Mahdi, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leclercq, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goormachtigh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fafeur, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melnyk, O.</span><span> </span><span class="NLM_article-title">A one-pot three-segment ligation strategy for protein chemical synthesis</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">â</span> <span class="NLM_lpage">213</span><span class="refDoi">Â DOI: 10.1002/anie.201105837</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fanie.201105837" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVyrurjF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=209-213&author=N.+Ollivierauthor=J.+Vicogneauthor=A.+Vallinauthor=H.+Drobecqauthor=R.+Desmetauthor=O.+El+Mahdiauthor=B.+Leclercqauthor=G.+Goormachtighauthor=V.+Fafeurauthor=O.+Melnyk&title=A+one-pot+three-segment+ligation+strategy+for+protein+chemical+synthesis&doi=10.1002%2Fanie.201105837"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98bR"><div class="casContent"><span class="casTitleNuber">98b</span><div class="casTitle"><span class="NLM_cas:atitle">A one-pot three-segment ligation strategy for protein chemical synthesis</span></div><div class="casAuthors">Ollivier, Nathalie; Vicogne, Jerome; Vallin, Aurelie; Drobecq, Herve; Desmet, Remi; El Mahdi, Ouafaa; Leclercq, Berenice; Goormachtigh, Gautier; Fafeur, Veronique; Melnyk, Oleg</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">209-213</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Herein we describe the synthesis of the K1 domain of Hepatocyte Growth Factor (HGF), which is part of HGF's high-affinity binding site for kinase phosphorylating scatter factor receptor (MET), but acts as a weak agonist.  K1 is composed of 85 amino acid residues (HGF 125-209) and is stabilized by three intrachain disulfide bridges.  K1 was assembled from HGF segments 125-148, 149-176, and 177-209 using one-pot three-segment native chem. ligation strategy.  Both ligations were performed under neutral conditions in aq. soln.  Proteomic anal. of the synthetic K1 domain using enzymic digestion and subsequent mass-spectrometry anal. of the formed peptide fragments revealed the formation of the native disulfide-bridge pattern during folding.  The structural integrity and functionality of K1 were confirmed through the study of its biol. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQC2qmJL_gbrVg90H21EOLACvtfcHk0lgGiZKjTR_vrw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVyrurjF&md5=e8326515ff4bb69d944e6f02cfab0af9</span></div><a href="/servlet/linkout?suffix=cit98b&amp;dbid=16384&amp;doi=10.1002%2Fanie.201105837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201105837%26sid%3Dliteratum%253Aachs%26aulast%3DOllivier%26aufirst%3DN.%26aulast%3DVicogne%26aufirst%3DJ.%26aulast%3DVallin%26aufirst%3DA.%26aulast%3DDrobecq%26aufirst%3DH.%26aulast%3DDesmet%26aufirst%3DR.%26aulast%3DEl%2BMahdi%26aufirst%3DO.%26aulast%3DLeclercq%26aufirst%3DB.%26aulast%3DGoormachtigh%26aufirst%3DG.%26aulast%3DFafeur%26aufirst%3DV.%26aulast%3DMelnyk%26aufirst%3DO.%26atitle%3DA%2520one-pot%2520three-segment%2520ligation%2520strategy%2520for%2520protein%2520chemical%2520synthesis%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2012%26volume%3D51%26spage%3D209%26epage%3D213%26doi%3D10.1002%2Fanie.201105837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ghosh, I.; Considine, N.; Maunus, E.; Sun, L.; Zhang, A.; Buswell, J.; Evans, T. C.; Xu, M.-Q.</span><span> </span><span class="NLM_article-title">Site-specific protein labeling by intein-mediated protein ligation</span>. In  <span class="citation_source-book">Heterologous Gene Expression in E. coli: Methods and Protocols</span>; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">Totowa, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">87</span><span class="NLM_x">â</span> <span class="NLM_lpage">107</span>;.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1007%2F978-1-61737-967-3_6" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=87-107&author=I.+Ghosh&author=N.+Considine&author=E.+Maunus&author=L.+Sun&author=A.+Zhang&author=J.+Buswell&author=T.+C.+Evans&author=M.-Q.+Xu&title=Heterologous+Gene+Expression+in+E.+coli%3A+Methods+and+Protocols"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99a&amp;dbid=16384&amp;doi=10.1007%2F978-1-61737-967-3_6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-61737-967-3_6%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DI.%26atitle%3DSite-specific%2520protein%2520labeling%2520by%2520intein-mediated%2520protein%2520ligation%26btitle%3DHeterologous%2520Gene%2520Expression%2520in%2520E.%2520coli%253A%2520Methods%2520and%2520Protocols%26pub%3DHumana%2520Press%26date%3D2011%26spage%3D87%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit99b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chu, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shabbir, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bove-Fenderson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Araman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemmens-Gruber, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, C. F. W.</span><span> </span><span class="NLM_article-title">A C-terminal membrane anchor affects the interactions of prion proteins with lipid membranes</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">30144</span><span class="NLM_x">â</span> <span class="NLM_lpage">30160</span><span class="refDoi">Â DOI: 10.1074/jbc.M114.587345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1074%2Fjbc.M114.587345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25217642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVSmtLjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=30144-30160&author=N.+K.+Chuauthor=W.+Shabbirauthor=E.+Bove-Fendersonauthor=C.+Aramanauthor=R.+Lemmens-Gruberauthor=D.+A.+Harrisauthor=C.+F.+W.+Becker&title=A+C-terminal+membrane+anchor+affects+the+interactions+of+prion+proteins+with+lipid+membranes&doi=10.1074%2Fjbc.M114.587345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99bR"><div class="casContent"><span class="casTitleNuber">99b</span><div class="casTitle"><span class="NLM_cas:atitle">A C-terminal Membrane Anchor Affects the Interactions of Prion Proteins with Lipid Membranes</span></div><div class="casAuthors">Chu, Nam K.; Shabbir, Waheed; Bove-Fenderson, Erin; Araman, Can; Lemmens-Gruber, Rosa; Harris, David A.; Becker, Christian F. W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">30144-30160</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Membrane attachment via a C-terminal glycosylphosphatidylinositol anchor is crit. for conversion of PrPC into pathogenic PrPSc.  Therefore the effects of the anchor on PrP structure and function need to be deciphered.  Three PrP variants, including full-length PrP (residues 23-231, FL_PrP), N-terminally truncated PrP (residues 90-231, T_PrP), and PrP missing its central hydrophobic region (Î105-125, ÎCR_PrP), were equipped with a C-terminal membrane anchor via a semisynthesis strategy.  Analyses of the interactions of lipidated PrPs with phospholipid membranes demonstrated that C-terminal membrane attachment induces a different binding mode of PrP to membranes, distinct from that of non-lipidated PrPs, and influences the biochem. and conformational properties of PrPs.  Addnl., fluorescence-based assays indicated pore formation by lipidated ÎCR_PrP, a variant that is known to be highly neurotoxic in transgenic mice.  This finding was supported by using patch clamp electrophysiol. measurements of cultured cells.  These results provide new evidence for the role of the membrane anchor in PrP-lipid interactions, highlighting the importance of the N-terminal and the central hydrophobic domain in these interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXJ-GlToAFC7Vg90H21EOLACvtfcHk0lhY3tN-cQB8Kg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVSmtLjE&md5=396f9fb499b5f73d444b69e9ba7e9e10</span></div><a href="/servlet/linkout?suffix=cit99b&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.587345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.587345%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DN.%2BK.%26aulast%3DShabbir%26aufirst%3DW.%26aulast%3DBove-Fenderson%26aufirst%3DE.%26aulast%3DAraman%26aufirst%3DC.%26aulast%3DLemmens-Gruber%26aufirst%3DR.%26aulast%3DHarris%26aufirst%3DD.%2BA.%26aulast%3DBecker%26aufirst%3DC.%2BF.%2BW.%26atitle%3DA%2520C-terminal%2520membrane%2520anchor%2520affects%2520the%2520interactions%2520of%2520prion%2520proteins%2520with%2520lipid%2520membranes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D30144%26epage%3D30160%26doi%3D10.1074%2Fjbc.M114.587345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Li, Y.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, M.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span> </span><span class="NLM_article-title">Ligation of expressed protein Î±-hydrazides via genetic incorporation of an Î±-hydroxy acid</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1015</span><span class="NLM_x">â</span> <span class="NLM_lpage">1022</span><span class="refDoi">Â DOI: 10.1021/cb300020s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb300020s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38XjvFKltrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1015-1022&author=Y.-M.+Liauthor=M.-Y.+Yangauthor=Y.-C.+Huangauthor=Y.-T.+Liauthor=P.+R.+Chenauthor=L.+Liu&title=Ligation+of+expressed+protein+%CE%B1-hydrazides+via+genetic+incorporation+of+an+%CE%B1-hydroxy+acid&doi=10.1021%2Fcb300020s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Ligation of Expressed Protein Î±-Hydrazides via Genetic Incorporation of an Î±-Hydroxy Acid</span></div><div class="casAuthors">Li, Yi-Ming; Yang, Mai-Yun; Huang, Yi-Chao; Li, Yi-Tong; Chen, Peng R.; Liu, Lei</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1015-1022</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Expressed protein ligation bridges the gap between synthetic peptides and recombinant proteins and thereby significantly increases the size and complexity of chem. synthesized proteins.  Although the intein-based expressed protein ligation method has been extensively used in this regard, the development of new expressed protein ligation methods may improve the flexibility and power of protein semisynthesis.  In this study a new alternative version of expressed protein ligation is developed by combining the recently developed technologies of hydrazide-based peptide ligation and genetic code expansion.  Compared to the previous intein-based expressed protein ligation method, the new method does not require the use of protein splicing technol. and generates recombinant protein Î±-hydrazides as ligation intermediates that are more chem. stable than protein Î±-thioesters.  Furthermore, the use of an evolved mutant pyrrolysyl-tRNA synthetase (PylRS), ACPK-RS, from Methanobacterium barkeri shows an improved performance for the expression of recombinant protein backbone oxoesters.  By using HdeA as a model protein the authors demonstrate that the hydrazide-based method can be used to synthesize proteins with correctly folded structures and full biol. activity.  Because the PylRS-tRNACUAPyl system is compatible with both prokaryotic and eukaryotic cells, the strategy presented here may be readily expanded to manipulate proteins produced in mammalian cells.  The new hydrazide-based method may also supplement the intein-based expressed protein ligation method by allowing for a more flexible selection of ligation site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrIsiueJfHvLVg90H21EOLACvtfcHk0lhY3tN-cQB8Kg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjvFKltrc%253D&md5=377b9d66ee179ee37251117d7dbae602</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Fcb300020s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300020s%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.-M.%26aulast%3DYang%26aufirst%3DM.-Y.%26aulast%3DHuang%26aufirst%3DY.-C.%26aulast%3DLi%26aufirst%3DY.-T.%26aulast%3DChen%26aufirst%3DP.%2BR.%26aulast%3DLiu%26aufirst%3DL.%26atitle%3DLigation%2520of%2520expressed%2520protein%2520%25CE%25B1-hydrazides%2520via%2520genetic%2520incorporation%2520of%2520an%2520%25CE%25B1-hydroxy%2520acid%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2012%26volume%3D7%26spage%3D1015%26epage%3D1022%26doi%3D10.1021%2Fcb300020s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span> </span><span class="NLM_article-title">Protein chemical synthesis by serine and threonine ligation</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">6657</span><span class="NLM_x">â</span> <span class="NLM_lpage">6662</span><span class="refDoi">Â DOI: 10.1073/pnas.1221012110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1073%2Fpnas.1221012110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23569249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXot1GhsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=6657-6662&author=Y.+Zhangauthor=C.+Xuauthor=H.+Y.+Lamauthor=C.+L.+Leeauthor=X.+Li&title=Protein+chemical+synthesis+by+serine+and+threonine+ligation&doi=10.1073%2Fpnas.1221012110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Protein chemical synthesis by serine and threonine ligation</span></div><div class="casAuthors">Zhang, Yinfeng; Xu, Ci; Lam, Hiu Yung; Lee, Chi Lung; Li, Xuechen</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6657-6662, S6657/1-S6657/40</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">An efficient method has been developed for the salicylaldehyde ester-mediated ligation of unprotected peptides at serine (Ser) or threonine (Thr) residues.  The utility of this peptide ligation approach has been demonstrated through the convergent syntheses of two therapeutic peptides, ovine-corticoliberin and Forteo, and the human erythrocyte acylphosphatase protein (â¼11 kDa).  The requisite peptide salicylaldehyde ester precursor is prepd. in an epimerization-free manner via Fmoc-based solid-phase peptide synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphXskUlr9857Vg90H21EOLACvtfcHk0liDijW_QvZ4nQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXot1GhsrY%253D&md5=ba60c71926491d7f7035921ae30f1211</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1221012110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1221012110%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DLam%26aufirst%3DH.%2BY.%26aulast%3DLee%26aufirst%3DC.%2BL.%26aulast%3DLi%26aufirst%3DX.%26atitle%3DProtein%2520chemical%2520synthesis%2520by%2520serine%2520and%2520threonine%2520ligation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D6657%26epage%3D6662%26doi%3D10.1073%2Fpnas.1221012110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Harmand, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murar, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bode, J. W.</span><span> </span><span class="NLM_article-title">Protein chemical synthesis by [alpha]-ketoacid-hydroxylamine ligation</span> <span class="citation_source-journal">Nat. Protoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1130</span><span class="NLM_x">â</span> <span class="NLM_lpage">1147</span><span class="refDoi">Â DOI: 10.1038/nprot.2016.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnprot.2016.052" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1130-1147&author=T.+J.+Harmandauthor=C.+E.+Murarauthor=J.+W.+Bode&title=Protein+chemical+synthesis+by+%5Balpha%5D-ketoacid-hydroxylamine+ligation&doi=10.1038%2Fnprot.2016.052"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2016.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2016.052%26sid%3Dliteratum%253Aachs%26aulast%3DHarmand%26aufirst%3DT.%2BJ.%26aulast%3DMurar%26aufirst%3DC.%2BE.%26aulast%3DBode%26aufirst%3DJ.%2BW.%26atitle%3DProtein%2520chemical%2520synthesis%2520by%2520%255Balpha%255D-ketoacid-hydroxylamine%2520ligation%26jtitle%3DNat.%2520Protoc.%26date%3D2016%26volume%3D11%26spage%3D1130%26epage%3D1147%26doi%3D10.1038%2Fnprot.2016.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Pusterla, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bode, J. W.</span><span> </span><span class="NLM_article-title">An oxazetidine amino acid for chemical protein synthesis by rapid, serine-forming ligations</span> <span class="citation_source-journal">Nat. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">668</span><span class="NLM_x">â</span> <span class="NLM_lpage">672</span><span class="refDoi">Â DOI: 10.1038/nchem.2282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnchem.2282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26201744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju73L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=668-672&author=I.+Pusterlaauthor=J.+W.+Bode&title=An+oxazetidine+amino+acid+for+chemical+protein+synthesis+by+rapid%2C+serine-forming+ligations&doi=10.1038%2Fnchem.2282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">An oxazetidine amino acid for chemical protein synthesis by rapid, serine-forming ligations</span></div><div class="casAuthors">Pusterla, Ivano; Bode, Jeffrey W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">668-672</span>CODEN:
                <span class="NLM_cas:coden">NCAHBB</span>;
        ISSN:<span class="NLM_cas:issn">1755-4330</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Amide-forming ligation reactions allow the chem. synthesis of proteins by the union of unprotected peptide segments, and enable the prepn. of protein derivs. not accessible by expression or bioengineering approaches.  The native chem. ligation (NCL) of thioesters and N-terminal cysteines is unquestionably the most successful approach, but is not ideal for all synthetic targets.  Here we describe the synthesis of an Fmoc-protected (Fmoc = 9-fluorenylmethoxycarbonyl) oxazetidine amino acid for use in the Î±-ketoacid-hydroxylamine (KAHA) amide ligation.  When incorporated at the N-terminus of a peptide segment, this four-membered cyclic hydroxylamine can be used for rapid serine-forming ligations with peptide Î±-ketoacids.  This ligation operates at low concn. (100 Î¼M-5 mM) and mild temps. (20-25 Â°C).  The utility of the reaction was demonstrated by the synthesis of S100A4, a 12 kDa calcium-binding protein not easily accessible by NCL or other amide-forming reactions due to its primary sequence and properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRW2vrSovYJbVg90H21EOLACvtfcHk0liDijW_QvZ4nQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju73L&md5=cd8202f8af4ae18437cf7ed51e79bb34</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1038%2Fnchem.2282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchem.2282%26sid%3Dliteratum%253Aachs%26aulast%3DPusterla%26aufirst%3DI.%26aulast%3DBode%26aufirst%3DJ.%2BW.%26atitle%3DAn%2520oxazetidine%2520amino%2520acid%2520for%2520chemical%2520protein%2520synthesis%2520by%2520rapid%252C%2520serine-forming%2520ligations%26jtitle%3DNat.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D668%26epage%3D672%26doi%3D10.1038%2Fnchem.2282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Antos, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truttmann, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ploegh, H. L.</span><span> </span><span class="NLM_article-title">Recent advances in sortase-catalyzed ligation methodology</span> <span class="citation_source-journal">Curr. Opin. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">â</span> <span class="NLM_lpage">118</span><span class="refDoi">Â DOI: 10.1016/j.sbi.2016.05.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.sbi.2016.05.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=27318815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28Xps1Wktbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2016&pages=111-118&author=J.+M.+Antosauthor=M.+C.+Truttmannauthor=H.+L.+Ploegh&title=Recent+advances+in+sortase-catalyzed+ligation+methodology&doi=10.1016%2Fj.sbi.2016.05.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104aR"><div class="casContent"><span class="casTitleNuber">104a</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in sortase-catalyzed ligation methodology</span></div><div class="casAuthors">Antos, John M.; Truttmann, Matthias C.; Ploegh, Hidde L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111-118</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The transpeptidation reaction catalyzed by bacterial sortases continues to see increasing use in the construction of novel protein derivs.  In addn. to growth in the no. of applications that rely on sortase, this field has also seen methodol. improvements that enhance reaction performance and scope.  In this opinion, we present an overview of key developments in the practise and implementation of sortase-based strategies, including applications relevant to structural biol.  Topics include the use of engineered sortases to increase reaction rates, the use of redesigned acyl donors and acceptors to mitigate reaction reversibility, and strategies for expanding the range of substrates that are compatible with a sortase-based approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp75dSSsmDxiLVg90H21EOLACvtfcHk0liYd_ZZJao1yg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xps1Wktbw%253D&md5=0ab0c724bd8673613ac3c6f520735ca5</span></div><a href="/servlet/linkout?suffix=cit104a&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2016.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2016.05.021%26sid%3Dliteratum%253Aachs%26aulast%3DAntos%26aufirst%3DJ.%2BM.%26aulast%3DTruttmann%26aufirst%3DM.%2BC.%26aulast%3DPloegh%26aufirst%3DH.%2BL.%26atitle%3DRecent%2520advances%2520in%2520sortase-catalyzed%2520ligation%2520methodology%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2016%26volume%3D38%26spage%3D111%26epage%3D118%26doi%3D10.1016%2Fj.sbi.2016.05.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit104b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Haridas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadanandan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dheepthi, N. U.</span><span> </span><span class="NLM_article-title">Sortase-based bio-organic strategies for macromolecular synthesis</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1857</span><span class="NLM_x">â</span> <span class="NLM_lpage">1867</span><span class="refDoi">Â DOI: 10.1002/cbic.201402013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fcbic.201402013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25111709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlahtLrO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1857-1867&author=V.+Haridasauthor=S.+Sadanandanauthor=N.+U.+Dheepthi&title=Sortase-based+bio-organic+strategies+for+macromolecular+synthesis&doi=10.1002%2Fcbic.201402013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104bR"><div class="casContent"><span class="casTitleNuber">104b</span><div class="casTitle"><span class="NLM_cas:atitle">Sortase-Based Bio-Organic Strategies for Macromolecular Synthesis</span></div><div class="casAuthors">Haridas, V.; Sadanandan, Sandhya; Dheepthi, N. U.</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1857-1867</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  This article discusses about the sortase-based bio-org. strategies for macromol. synthesis.  The combination of org. synthesis with SrtA-mediated ligation represents a powerful strategy for the synthesis of many natural and unnatural macromols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXexktdOjV0LVg90H21EOLACvtfcHk0liYd_ZZJao1yg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlahtLrO&md5=26df6704792c5027e5b64a4be2193a53</span></div><a href="/servlet/linkout?suffix=cit104b&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201402013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201402013%26sid%3Dliteratum%253Aachs%26aulast%3DHaridas%26aufirst%3DV.%26aulast%3DSadanandan%26aufirst%3DS.%26aulast%3DDheepthi%26aufirst%3DN.%2BU.%26atitle%3DSortase-based%2520bio-organic%2520strategies%2520for%2520macromolecular%2520synthesis%26jtitle%3DChemBioChem%26date%3D2014%26volume%3D15%26spage%3D1857%26epage%3D1867%26doi%3D10.1002%2Fcbic.201402013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Nguyen, G. K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hemu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lian, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, J. P.</span><span> </span><span class="NLM_article-title">Butelase 1 is an Asx-specific ligase enabling peptide macrocyclization and synthesis</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">732</span><span class="NLM_x">â</span> <span class="NLM_lpage">738</span><span class="refDoi">Â DOI: 10.1038/nchembio.1586</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnchembio.1586" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25038786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFygs7jL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=732-738&author=G.+K.+T.+Nguyenauthor=S.+Wangauthor=Y.+Qiuauthor=X.+Hemuauthor=Y.+Lianauthor=J.+P.+Tam&title=Butelase+1+is+an+Asx-specific+ligase+enabling+peptide+macrocyclization+and+synthesis&doi=10.1038%2Fnchembio.1586"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105aR"><div class="casContent"><span class="casTitleNuber">105a</span><div class="casTitle"><span class="NLM_cas:atitle">Butelase 1 is an Asx-specific ligase enabling peptide macrocyclization and synthesis</span></div><div class="casAuthors">Nguyen, Giang K. T.; Wang, Shujing; Qiu, Yibo; Hemu, Xinya; Lian, Yilong; Tam, James P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">732-738</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Proteases are ubiquitous in nature, whereas naturally occurring peptide ligases, enzymes catalyzing the reverse reactions of proteases, are rare occurrences.  Here we describe the discovery of butelase 1, to our knowledge the first asparagine/aspartate (Asx) peptide ligase to be reported.  This highly efficient enzyme was isolated from Clitoria ternatea, a cyclic peptide-producing medicinal plant.  Butelase 1 shares 71% sequence identity and the same catalytic triad with legumain proteases but does not hydrolyze the protease substrate of legumain.  Instead, butelase 1 cyclizes various peptides of plant and animal origin with yields greater than 95%.  With Kcat values of up to 17 s-1 and catalytic efficiencies as high as 542,000 M-1s-1, butelase 1 is the fastest peptide ligase known.  Notably, butelase 1 also displays broad specificity for the N-terminal amino acids of the peptide substrate, thus providing a new tool for C terminus-specific intermol. peptide ligations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfqnuYUbD5NLVg90H21EOLACvtfcHk0ljAwloWecppDQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFygs7jL&md5=5b990c4c323ce9404ab324c604a82dd6</span></div><a href="/servlet/linkout?suffix=cit105a&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1586%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DG.%2BK.%2BT.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DHemu%26aufirst%3DX.%26aulast%3DLian%26aufirst%3DY.%26aulast%3DTam%26aufirst%3DJ.%2BP.%26atitle%3DButelase%25201%2520is%2520an%2520Asx-specific%2520ligase%2520enabling%2520peptide%2520macrocyclization%2520and%2520synthesis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26spage%3D732%26epage%3D738%26doi%3D10.1038%2Fnchembio.1586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit105b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Nguyen, G. K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hemu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quek, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, J. P.</span><span> </span><span class="NLM_article-title">Butelase-mediated macrocyclization of D-amino-acid-containing peptides</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">12802</span><span class="NLM_x">â</span> <span class="NLM_lpage">12806</span><span class="refDoi">Â DOI: 10.1002/anie.201607188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fanie.201607188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWntbvK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=12802-12806&author=G.+K.+T.+Nguyenauthor=X.+Hemuauthor=J.-P.+Quekauthor=J.+P.+Tam&title=Butelase-mediated+macrocyclization+of+D-amino-acid-containing+peptides&doi=10.1002%2Fanie.201607188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105bR"><div class="casContent"><span class="casTitleNuber">105b</span><div class="casTitle"><span class="NLM_cas:atitle">Butelase-Mediated Macrocyclization of D-Amino-Acid-Containing Peptides</span></div><div class="casAuthors">Nguyen, Giang K. T.; Hemu, Xinya; Quek, Jun-Ping; Tam, James P.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">12802-12806</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Macrocyclic compds. have received increasing attention in recent years.  With their large surface area, they hold promise for inhibiting protein-protein interactions, a chem. space that was thought to be undruggable.  Although many chem. methods have been developed for peptide macrocyclization, enzymic methods have emerged as a promising new economical approach.  Thus far, most enzymes have been shown to act on L-peptides; their ability to cyclize D-amino-acid-contg. peptides has rarely been documented.  Herein we show that macrocycles consisting of D-amino acids, except for the Asn residue at the ligating site, were efficiently synthesized by butelase 1, an Asn/Asp-specific ligase.  Furthermore, by using a peptide-library approach, we show that butelase 1 tolerates most of the D-amino acid residues at the P1'' and P2'' positions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiA-It06RA6bVg90H21EOLACvtfcHk0ljAwloWecppDQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWntbvK&md5=e324b1662a8b4a8768b5ac0fa094fd35</span></div><a href="/servlet/linkout?suffix=cit105b&amp;dbid=16384&amp;doi=10.1002%2Fanie.201607188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201607188%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DG.%2BK.%2BT.%26aulast%3DHemu%26aufirst%3DX.%26aulast%3DQuek%26aufirst%3DJ.-P.%26aulast%3DTam%26aufirst%3DJ.%2BP.%26atitle%3DButelase-mediated%2520macrocyclization%2520of%2520D-amino-acid-containing%2520peptides%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D12802%26epage%3D12806%26doi%3D10.1002%2Fanie.201607188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">Nguyen, G. K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, J. P.</span><span> </span><span class="NLM_article-title">Site-specific N-terminal labeling of peptides and proteins using butelase 1 and thiodepsipeptide</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">15694</span><span class="NLM_x">â</span> <span class="NLM_lpage">15698</span><span class="refDoi">Â DOI: 10.1002/anie.201506810</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fanie.201506810" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVaqt7nI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=15694-15698&author=G.+K.+T.+Nguyenauthor=Y.+Caoauthor=W.+Wangauthor=C.+F.+Liuauthor=J.+P.+Tam&title=Site-specific+N-terminal+labeling+of+peptides+and+proteins+using+butelase+1+and+thiodepsipeptide&doi=10.1002%2Fanie.201506810"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Site-Specific N-Terminal Labeling of Peptides and Proteins using Butelase 1 and Thiodepsipeptide</span></div><div class="casAuthors">Nguyen, Giang K. T.; Cao, Yuan; Wang, Wei; Liu, Chuan Fa; Tam, James P.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">15694-15698</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">An efficient ligase with exquisite site-specificity is highly desirable for protein modification.  Recently, we discovered the fastest known ligase called butelase 1 from Clitoria ternatea for intramol. cyclization.  For intermol. ligation, butelase 1 requires an excess amt. of a substrate to suppress the reverse reaction, a feature similar to other ligases.  Herein, we describe the use of thiodepsipeptide substrates with a thiol as a leaving group and an unacceptable nucleophile to render the butelase-mediated ligation reactions irreversible and in high yields.  Butelase 1 also accepted depsipeptides as substrates, but unlike a thiodepsipeptide, the depsipeptide ligation was partially reversible as butelase 1 can tolerate an alc. group as a poor nucleophile.  The thiodepsipeptide method was successfully applied in N-terminal labeling of ubiquitin and green fluorescent protein (GFP) using substrates with or without a biotin group in high yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4wRlsHkeH1LVg90H21EOLACvtfcHk0ljAwloWecppDQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVaqt7nI&md5=03138f029b967fedcb0fd78ebed39c79</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1002%2Fanie.201506810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201506810%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DG.%2BK.%2BT.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DC.%2BF.%26aulast%3DTam%26aufirst%3DJ.%2BP.%26atitle%3DSite-specific%2520N-terminal%2520labeling%2520of%2520peptides%2520and%2520proteins%2520using%2520butelase%25201%2520and%2520thiodepsipeptide%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D15694%26epage%3D15698%26doi%3D10.1002%2Fanie.201506810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Toplak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuijens, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quaedflieg, P. J. L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssen, D. B.</span><span> </span><span class="NLM_article-title">Peptiligase, an enzyme for efficient chemoenzymatic peptide synthesis and cyclization in water</span> <span class="citation_source-journal">Adv. Synth. Catal.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">358</span><span class="NLM_x">, </span> <span class="NLM_fpage">2140</span><span class="NLM_x">â</span> <span class="NLM_lpage">2147</span><span class="refDoi">Â DOI: 10.1002/adsc.201600017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fadsc.201600017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XosVWhtr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2016&pages=2140-2147&author=A.+Toplakauthor=T.+Nuijensauthor=P.+J.+L.+M.+Quaedfliegauthor=B.+Wuauthor=D.+B.+Janssen&title=Peptiligase%2C+an+enzyme+for+efficient+chemoenzymatic+peptide+synthesis+and+cyclization+in+water&doi=10.1002%2Fadsc.201600017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107aR"><div class="casContent"><span class="casTitleNuber">107a</span><div class="casTitle"><span class="NLM_cas:atitle">Peptiligase, an enzyme for efficient chemoenzymatic peptide synthesis and cyclization in water</span></div><div class="casAuthors">Toplak, Ana; Nuijens, Timo; Quaedflieg, Peter J. L. M.; Wu, Bian; Janssen, Dick B.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Synthesis & Catalysis</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2140-2147</span>CODEN:
                <span class="NLM_cas:coden">ASCAF7</span>;
        ISSN:<span class="NLM_cas:issn">1615-4150</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">We describe a novel, org. cosolvent-stable and cation-independent engineered enzyme for peptide coupling reactions.  The enzyme is a variant of a stable calcium-independent mutant of subtilisin BPN', with the catalytic Ser212 mutated to Cys and Pro216 converted to Ala.  The enzyme, called peptiligase, catalyzes exceptionally efficient peptide coupling in water with a surprisingly high synthesis over hydrolysis (S/H) ratio.  The S/H ratio of the peptide ligation reaction is correlated to the length of the peptide substrate and proved to be >100 for the synthesis of a 13-mer peptide, which corresponds to >99% conversion to the ligated peptide product and <1% hydrolytic side-reaction.  Furthermore, peptiligase does not require a particular recognition motif resulting in a broadly applicable and traceless peptide ligation technol.  Peptiligase is very robust, easy to produce in Bacillus subtilis, and its purifn. is straightforward.  It shows good activity and stability in the presence of org. cosolvents and chelating or denaturing agents, enabling the ligation of poorly sol. (hydrophobic) or folded peptides.  This enzyme could be useful for the (industrial) synthesis of diverse (pharmaceutical) peptides.  In addn., peptiligase is able to efficiently catalyze head-to-tail peptide cyclization reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbrpp6FZ2rdLVg90H21EOLACvtfcHk0lh6aaTzKN79hA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosVWhtr4%253D&md5=8890d54c9d5e5f9d008d31ca075ee3b2</span></div><a href="/servlet/linkout?suffix=cit107a&amp;dbid=16384&amp;doi=10.1002%2Fadsc.201600017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadsc.201600017%26sid%3Dliteratum%253Aachs%26aulast%3DToplak%26aufirst%3DA.%26aulast%3DNuijens%26aufirst%3DT.%26aulast%3DQuaedflieg%26aufirst%3DP.%2BJ.%2BL.%2BM.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DJanssen%26aufirst%3DD.%2BB.%26atitle%3DPeptiligase%252C%2520an%2520enzyme%2520for%2520efficient%2520chemoenzymatic%2520peptide%2520synthesis%2520and%2520cyclization%2520in%2520water%26jtitle%3DAdv.%2520Synth.%2520Catal.%26date%3D2016%26volume%3D358%26spage%3D2140%26epage%3D2147%26doi%3D10.1002%2Fadsc.201600017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit107b"><span><span class="NLM_label">(b) </span>Synthesis of Long Linear and Cyclic Peptides with Omniligase: A New and Easy Ligation Methodology; Iris Biotech GmbH: <span class="NLM_publisher-loc">Marktredwitz, Germany</span>,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="http://www.enzypep.com/wp-content/uploads/2016/05/enzypep_iris_flyer_omniligase.pdf" class="extLink">http://www.enzypep.com/wp-content/uploads/2016/05/enzypep_iris_flyer_omniligase.pdf</a> (accessed January 17, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Synthesis+of+Long+Linear+and+Cyclic+Peptides+with+Omniligase%3A+A+New+and+Easy+Ligation+Methodology%3B+Iris+Biotech+GmbH%3A+Marktredwitz%2C+Germany%2C+2016%3B+http%3A%2F%2Fwww.enzypep.com%2Fwp-content%2Fuploads%2F2016%2F05%2Fenzypep_iris_flyer_omniligase.pdf+%28accessed+January+17%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26jtitle%3DSynthesis%2520of%2520Long%2520Linear%2520and%2520Cyclic%2520Peptides%2520with%2520Omniligase%253A%2520A%2520New%2520and%2520Easy%2520Ligation%2520Methodology%26jtitle%3DIris%2520Biotech%2520GmbH%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group">Sohma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, S. B. H.</span><span> </span><span class="NLM_article-title">Biomimetic synthesis of lispro Insulin via a chemically synthesized âmini-proinsulinâ prepared by oxime-forming ligation</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">16313</span><span class="NLM_x">â</span> <span class="NLM_lpage">16318</span><span class="refDoi">Â DOI: 10.1021/ja9052398</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja9052398" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1OktbjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2009&pages=16313-16318&author=Y.+Sohmaauthor=S.+B.+H.+Kent&title=Biomimetic+synthesis+of+lispro+Insulin+via+a+chemically+synthesized+%E2%80%9Cmini-proinsulin%E2%80%9D+prepared+by+oxime-forming+ligation&doi=10.1021%2Fja9052398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Biomimetic Synthesis of Lispro Insulin via a Chemically Synthesized "Mini-Proinsulin" Prepared by Oxime-Forming Ligation</span></div><div class="casAuthors">Sohma, Youhei; Kent, Stephen B. H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">16313-16318</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Here, the authors report a proof-of-principle study demonstrating the efficient folding, with concomitant formation of the correct disulfides, of an isolated polypeptide insulin precursor of defined covalent structure.  The authors used oxime-forming chem. ligation to introduce a temporary "chem. tether" to link the N-terminal residue of the insulin A chain to the C-terminal residue of the insulin B chain; the tether enabled the formation/folding of disulfides with high efficiency.  Enzymic removal of the temporary chem. tether gave mature, fully active insulin.  This chem. tethering principle could form the basis of a practical, high yield total synthesis of insulin and analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7V968UADQlrVg90H21EOLACvtfcHk0lh6aaTzKN79hA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1OktbjL&md5=5819a3a44b71c26fbe29c46fd9595257</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1021%2Fja9052398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja9052398%26sid%3Dliteratum%253Aachs%26aulast%3DSohma%26aufirst%3DY.%26aulast%3DKent%26aufirst%3DS.%2BB.%2BH.%26atitle%3DBiomimetic%2520synthesis%2520of%2520lispro%2520Insulin%2520via%2520a%2520chemically%2520synthesized%2520%25E2%2580%259Cmini-proinsulin%25E2%2580%259D%2520prepared%2520by%2520oxime-forming%2520ligation%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2009%26volume%3D131%26spage%3D16313%26epage%3D16318%26doi%3D10.1021%2Fja9052398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Sohma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hua, Q.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittaker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, S. B. H.</span><span> </span><span class="NLM_article-title">Design and folding of [GluA4(OÎ²ThrB30)]Insulin (âEster Insulinâ): A minimal proinsulin surrogate that can be chemically converted into human insulin</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">5489</span><span class="NLM_x">â</span> <span class="NLM_lpage">5493</span><span class="refDoi">Â DOI: 10.1002/anie.201001151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fanie.201001151" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=5489-5493&author=Y.+Sohmaauthor=Q.-X.+Huaauthor=J.+Whittakerauthor=M.+A.+Weissauthor=S.+B.+H.+Kent&title=Design+and+folding+of+%5BGluA4%28O%CE%B2ThrB30%29%5DInsulin+%28%E2%80%9CEster+Insulin%E2%80%9D%29%3A+A+minimal+proinsulin+surrogate+that+can+be+chemically+converted+into+human+insulin&doi=10.1002%2Fanie.201001151"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1002%2Fanie.201001151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201001151%26sid%3Dliteratum%253Aachs%26aulast%3DSohma%26aufirst%3DY.%26aulast%3DHua%26aufirst%3DQ.-X.%26aulast%3DWhittaker%26aufirst%3DJ.%26aulast%3DWeiss%26aufirst%3DM.%2BA.%26aulast%3DKent%26aufirst%3DS.%2BB.%2BH.%26atitle%3DDesign%2520and%2520folding%2520of%2520%255BGluA4%2528O%25CE%25B2ThrB30%2529%255DInsulin%2520%2528%25E2%2580%259CEster%2520Insulin%25E2%2580%259D%2529%253A%2520A%2520minimal%2520proinsulin%2520surrogate%2520that%2520can%2520be%2520chemically%2520converted%2520into%2520human%2520insulin%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2010%26volume%3D49%26spage%3D5489%26epage%3D5493%26doi%3D10.1002%2Fanie.201001151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Patil, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tailhades, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karas, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Separovic, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wade, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hossain, M. A.</span><span> </span><span class="NLM_article-title">A one-pot chemically cleavable bis-linker tether strategy for the synthesis of heterodimeric peptides</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">14552</span><span class="NLM_x">â</span> <span class="NLM_lpage">14556</span><span class="refDoi">Â DOI: 10.1002/anie.201604733</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fanie.201604733" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlegtLbL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=14552-14556&author=N.+A.+Patilauthor=J.+Tailhadesauthor=J.+A.+Karasauthor=F.+Separovicauthor=J.+D.+Wadeauthor=M.+A.+Hossain&title=A+one-pot+chemically+cleavable+bis-linker+tether+strategy+for+the+synthesis+of+heterodimeric+peptides&doi=10.1002%2Fanie.201604733"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">A One-Pot Chemically Cleavable Bis-Linker Tether Strategy for the Synthesis of Heterodimeric Peptides</span></div><div class="casAuthors">Patil, Nitin A.; Tailhades, Julien; Karas, John A.; Separovic, Frances; Wade, John D.; Hossain, Mohammed Akhter</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">14552-14556</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Heterodimeric peptides linked by disulfide bonds are attractive drug targets.  However, their chem. assembly can be tedious, time-consuming, and low yielding.  Inspired by the cellular synthesis of pro-insulin in which the two constituent peptide chains are expressed as a single-chain precursor sepd. by a connecting C-peptide, the authors have developed a novel chem. cleavable bis-linker tether which allows the convenient assembly of two peptide chains as a single "pro"-peptide on the same solid support.  Following the peptide cleavage and post-synthetic modifications, this bis-linker tether can be removed in one-step by chem. means.  This method was used to synthesize a drug delivery-cargo conjugate, TAT-PKCi peptide, and a two-disulfide bridged heterodimeric peptide, thionin (7-19)-(24-32R), a thionin analog.  To the best of their knowledge, the authors think that this is the first report of a one-pot chem. cleavable bis-linker strategy for the facile synthesis of cross-bridged two-chain peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtPNKTBxBjELVg90H21EOLACvtfcHk0lj1sp050nHNBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlegtLbL&md5=5c144c9a43865fc8a1de8efdefd83729</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1002%2Fanie.201604733&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201604733%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DN.%2BA.%26aulast%3DTailhades%26aufirst%3DJ.%26aulast%3DKaras%26aufirst%3DJ.%2BA.%26aulast%3DSeparovic%26aufirst%3DF.%26aulast%3DWade%26aufirst%3DJ.%2BD.%26aulast%3DHossain%26aufirst%3DM.%2BA.%26atitle%3DA%2520one-pot%2520chemically%2520cleavable%2520bis-linker%2520tether%2520strategy%2520for%2520the%2520synthesis%2520of%2520heterodimeric%2520peptides%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D14552%26epage%3D14556%26doi%3D10.1002%2Fanie.201604733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">Zompra, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galanis, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werbitzky, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albericio, F.</span><span> </span><span class="NLM_article-title">Manufacturing peptides as active pharmaceutical ingredients</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">â</span> <span class="NLM_lpage">377</span><span class="refDoi">Â DOI: 10.4155/fmc.09.23</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.4155%2Ffmc.09.23" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21425973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKgsrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2009&pages=361-377&author=A.+A.+Zompraauthor=A.+S.+Galanisauthor=O.+Werbitzkyauthor=F.+Albericio&title=Manufacturing+peptides+as+active+pharmaceutical+ingredients&doi=10.4155%2Ffmc.09.23"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Manufacturing peptides as active pharmaceutical ingredients</span></div><div class="casAuthors">Zompra, Alikaterini A.; Galanis, Athanassios S.; Werbitzky, Oleg; Albericio, Fernando</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">361-377</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Today, there are more than 40 peptides on the pharmaceutical world market and more than 100 in several clin. phases.  Although in the past the pharmaceutical industries had reduced their interest in peptides research, in recent decades, they have rekindled their interest in peptides as a result of contemporary novel technol. accomplishments, strategic developments, advances in the areas of formulation and enhanced drug delivery technol. of peptides.  Thus, 8 new peptide drugs that could previously were characterized as difficult to prep. on the large scale required by industry, have entered the pharmaceutical market at the new millennium.  The manufg. of most of these drugs has benefited from new technol. advances.  Traditional and most modern techniques were applied to the manuf. of these new entries.  Recent accomplishments, together with the traditional benefits of peptides (high biol. activity, high specificity and low toxicity), have led pharmaceutical companies to refocus their attention on peptide-based agents.  Therefore, several serious diseases can be treated using the potential next generation of peptide drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAf3BR3nSNGLVg90H21EOLACvtfcHk0ljXTQXeZvhSzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKgsrw%253D&md5=66f8342d8cb1f11e942aea164017857b</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.4155%2Ffmc.09.23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.09.23%26sid%3Dliteratum%253Aachs%26aulast%3DZompra%26aufirst%3DA.%2BA.%26aulast%3DGalanis%26aufirst%3DA.%2BS.%26aulast%3DWerbitzky%26aufirst%3DO.%26aulast%3DAlbericio%26aufirst%3DF.%26atitle%3DManufacturing%2520peptides%2520as%2520active%2520pharmaceutical%2520ingredients%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2009%26volume%3D1%26spage%3D361%26epage%3D377%26doi%3D10.4155%2Ffmc.09.23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Digby, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span> </span><span class="NLM_article-title">Orthosteric- and allosteric-induced ligand-directed trafficking at GPCRs</span> <span class="citation_source-journal">Curr. Opin. Drug. Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">587</span><span class="NLM_x">â</span> <span class="NLM_lpage">594</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=587-594&author=G.+J.+Digbyauthor=P.+J.+Connauthor=C.+W.+Lindsley&title=Orthosteric-+and+allosteric-induced+ligand-directed+trafficking+at+GPCRs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDigby%26aufirst%3DG.%2BJ.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DOrthosteric-%2520and%2520allosteric-induced%2520ligand-directed%2520trafficking%2520at%2520GPCRs%26jtitle%3DCurr.%2520Opin.%2520Drug.%2520Discovery%2520Dev.%26date%3D2010%26volume%3D13%26spage%3D587%26epage%3D594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit112b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kenakin, T.</span><span> </span><span class="NLM_article-title">Functional selectivity: theoretical considerations and future directions</span>. In  <span class="citation_source-book">Functional Selectivity of G Protein-Coupled Receptor Ligands</span>; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">9</span><span class="NLM_x">â</span> <span class="NLM_lpage">24</span>;.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1007%2F978-1-60327-335-0_2" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=9-24&author=T.+Kenakin&title=Functional+Selectivity+of+G+Protein-Coupled+Receptor+Ligands"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112b&amp;dbid=16384&amp;doi=10.1007%2F978-1-60327-335-0_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-60327-335-0_2%26sid%3Dliteratum%253Aachs%26aulast%3DKenakin%26aufirst%3DT.%26atitle%3DFunctional%2520selectivity%253A%2520theoretical%2520considerations%2520and%2520future%2520directions%26btitle%3DFunctional%2520Selectivity%2520of%2520G%2520Protein-Coupled%2520Receptor%2520Ligands%26pub%3DHumana%2520Press%26date%3D2009%26spage%3D9%26epage%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit112c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Kenakin, T.</span><span> </span><span class="NLM_article-title">Functional Selectivity and Biased Receptor Signaling</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">336</span><span class="NLM_x">, </span> <span class="NLM_fpage">296</span><span class="NLM_x">â</span> <span class="NLM_lpage">302</span><span class="refDoi">Â DOI: 10.1124/jpet.110.173948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1124%2Fjpet.110.173948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21030484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhslWhsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=336&publication_year=2011&pages=296-302&author=T.+Kenakin&title=Functional+Selectivity+and+Biased+Receptor+Signaling&doi=10.1124%2Fjpet.110.173948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112cR"><div class="casContent"><span class="casTitleNuber">112c</span><div class="casTitle"><span class="NLM_cas:atitle">Functional selectivity and biased receptor signaling</span></div><div class="casAuthors">Kenakin, Terry</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">336</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">296-302</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  With the emergence of information describing functional selectivity and biased agonists and antagonists has come a lack of confidence in "one size fits all" assays for detection of agonism.  Seven-transmembrane receptors are pleiotropic with respect to the signaling protein to which they couple in a cell, and many conformations of the receptor can be formed; this leads to systems where ligands can stabilize unique conformations that go on to selectively activate signaling pathways.  Thus, such "biased" ligands can produce cell-specific agonism that may require targeted assays to detect and quantify.  It also predicts that ligands can have many different efficacies for the many behaviors that the receptor can exhibit (referred to as "pluridimensional efficacy"), leading to a breakdown in the common classifications of agonist and antagonist.  This all poses unique challenges to the pharmacol. nomenclature of drugs, the detection and optimization of new drugs, and the assocn. of phenotypic clin. profiles with pharmacol. properties of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDmshypfoNALVg90H21EOLACvtfcHk0ljXTQXeZvhSzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhslWhsr0%253D&md5=83d2c05fec2f9ef9a6e97a98bc0a3616</span></div><a href="/servlet/linkout?suffix=cit112c&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.173948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.173948%26sid%3Dliteratum%253Aachs%26aulast%3DKenakin%26aufirst%3DT.%26atitle%3DFunctional%2520Selectivity%2520and%2520Biased%2520Receptor%2520Signaling%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D336%26spage%3D296%26epage%3D302%26doi%3D10.1124%2Fjpet.110.173948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit112d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Khoury, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clement, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laporte, S. A.</span><span> </span><span class="NLM_article-title">Allosteric and biased G protein-coupled receptor signaling regulation: potentials for new therapeutics</span> <span class="citation_source-journal">Front. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">68</span><span class="refDoi">Â DOI: 10.3389/fendo.2014.00068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3389%2Ffendo.2014.00068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24847311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A280%3ADC%252BC2cflvFWmtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=68&author=E.+Khouryauthor=S.+Clementauthor=S.+A.+Laporte&title=Allosteric+and+biased+G+protein-coupled+receptor+signaling+regulation%3A+potentials+for+new+therapeutics&doi=10.3389%2Ffendo.2014.00068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112dR"><div class="casContent"><span class="casTitleNuber">112d</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric and biased g protein-coupled receptor signaling regulation: potentials for new therapeutics</span></div><div class="casAuthors">Khoury Etienne; Clement Stephanie; Laporte Stephane A</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in endocrinology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">68</span>
        ISSN:<span class="NLM_cas:issn">1664-2392</span>.
    </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are seven-transmembrane proteins that participate in many aspects of the endocrine function and are important targets for drug development.  They transduce signals mainly, but not exclusively, via hetero-trimeric G proteins, leading to a diversity of intracellular signaling cascades.  Ligands binding at the hormone orthosteric sites of receptors have been classified as agonists, antagonists, and/or inverse agonists based on their ability to mainly modulate G protein signaling.  Accumulating evidence also indicates that such ligands, alone or in combination with other ones such as those acting outside the orthosteric hormone binding sites (e.g., allosteric modulators), have the ability to selectively engage subsets of signaling responses as compared to the natural endogenous ligands.  Such modes of functioning have been variously referred to as "functional selectivity" or "ligand-biased signaling." In this review, we provide an overview of the current knowledge regarding GPCR-biased signaling and their functional regulation with a focus on the evolving concept that receptor domains can also be targeted to allosterically bias signaling, and discuss the usefulness of such modes of regulation for the design of more efficient therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR9mMH7P4hI_7rIbt-tGZmxfW6udTcc2ea51PhycH7CFLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflvFWmtg%253D%253D&md5=43bb5344e99722031e19bb9896aa2cf2</span></div><a href="/servlet/linkout?suffix=cit112d&amp;dbid=16384&amp;doi=10.3389%2Ffendo.2014.00068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffendo.2014.00068%26sid%3Dliteratum%253Aachs%26aulast%3DKhoury%26aufirst%3DE.%26aulast%3DClement%26aufirst%3DS.%26aulast%3DLaporte%26aufirst%3DS.%2BA.%26atitle%3DAllosteric%2520and%2520biased%2520G%2520protein-coupled%2520receptor%2520signaling%2520regulation%253A%2520potentials%2520for%2520new%2520therapeutics%26jtitle%3DFront.%2520Endocrinol.%26date%3D2014%26volume%3D5%26spage%3D68%26doi%3D10.3389%2Ffendo.2014.00068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit112e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Luttrell, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maudsley, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohn, L. M.</span><span> </span><span class="NLM_article-title">Fulfilling the promise of â³biasedâ³ G protein-coupled receptor agonism</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">579</span><span class="NLM_x">â</span> <span class="NLM_lpage">588</span><span class="refDoi">Â DOI: 10.1124/mol.115.099630</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1124%2Fmol.115.099630" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2015&pages=579-588&author=L.+M.+Luttrellauthor=S.+Maudsleyauthor=L.+M.+Bohn&title=Fulfilling+the+promise+of+%E2%80%B3biased%E2%80%B3+G+protein-coupled+receptor+agonism&doi=10.1124%2Fmol.115.099630"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112e&amp;dbid=16384&amp;doi=10.1124%2Fmol.115.099630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.115.099630%26sid%3Dliteratum%253Aachs%26aulast%3DLuttrell%26aufirst%3DL.%2BM.%26aulast%3DMaudsley%26aufirst%3DS.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26atitle%3DFulfilling%2520the%2520promise%2520of%2520%25E2%2580%25B3biased%25E2%2580%25B3%2520G%2520protein-coupled%2520receptor%2520agonism%26jtitle%3DMol.%2520Pharmacol.%26date%3D2015%26volume%3D88%26spage%3D579%26epage%3D588%26doi%3D10.1124%2Fmol.115.099630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit112f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Wootten, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, P. M.</span><span> </span><span class="NLM_article-title">Emerging paradigms in GPCR allostery: implications for drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">630</span><span class="NLM_x">â</span> <span class="NLM_lpage">644</span><span class="refDoi">Â DOI: 10.1038/nrd4052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnrd4052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23903222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1SjtbvO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=630-644&author=D.+Woottenauthor=A.+Christopoulosauthor=P.+M.+Sexton&title=Emerging+paradigms+in+GPCR+allostery%3A+implications+for+drug+discovery&doi=10.1038%2Fnrd4052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112fR"><div class="casContent"><span class="casTitleNuber">112f</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging paradigms in GPCR allostery: implications for drug discovery</span></div><div class="casAuthors">Wootten, Denise; Christopoulos, Arthur; Sexton, Patrick M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">630-644</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Allosteric ligands bind to G protein-coupled receptors (GPCRs; also known as seven-transmembrane receptors) at sites that are distinct from the sites to which endogenous ligands bind.  The existence of allosteric ligands has enriched the ways in which the functions of GPCRs can be manipulated for potential therapeutic benefit, yet the complexity of their actions provides both challenges and opportunities for drug screening and development.  Converging avenues of research in areas such as biased signalling by allosteric ligands and the mechanisms by which allosteric ligands modulate the effects of diverse endogenous ligands have provided new insights into how interactions between allosteric ligands and GPCRs could be exploited for drug discovery.  These new findings have the potential to alter how screening for allosteric drugs is performed and may increase the chances of success in the development of allosteric modulators as clin. lead compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxRlmQUCUlsLVg90H21EOLACvtfcHk0lh1pZGzF24psw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1SjtbvO&md5=59b74e5fbd5eeb832785dd879daa7c77</span></div><a href="/servlet/linkout?suffix=cit112f&amp;dbid=16384&amp;doi=10.1038%2Fnrd4052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4052%26sid%3Dliteratum%253Aachs%26aulast%3DWootten%26aufirst%3DD.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26atitle%3DEmerging%2520paradigms%2520in%2520GPCR%2520allostery%253A%2520implications%2520for%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D630%26epage%3D644%26doi%3D10.1038%2Fnrd4052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit112g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Wootten, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koole, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, P. M.</span><span> </span><span class="NLM_article-title">Allostery and biased agonism at class B G protein-coupled receptors</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">â</span> <span class="NLM_lpage">138</span><span class="refDoi">Â DOI: 10.1021/acs.chemrev.6b00049</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.6b00049" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref112/cit112g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1yqsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2017&pages=111-138&author=D.+Woottenauthor=L.+J.+Millerauthor=C.+Kooleauthor=A.+Christopoulosauthor=P.+M.+Sexton&title=Allostery+and+biased+agonism+at+class+B+G+protein-coupled+receptors&doi=10.1021%2Facs.chemrev.6b00049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112gR"><div class="casContent"><span class="casTitleNuber">112g</span><div class="casTitle"><span class="NLM_cas:atitle">Allostery and Biased Agonism at Class B G Protein-Coupled Receptors</span></div><div class="casAuthors">Wootten, Denise; Miller, Laurence J.; Koole, Cassandra; Christopoulos, Arthur; Sexton, Patrick M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-138</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Class B G protein-coupled receptors (GPCRs) respond to paracrine or endocrine peptide hormones involved in control of bone homeostasis, glucose regulation, satiety, and gastro-intestinal function, as well as pain transmission.  These receptors are targets for existing drugs that treat osteoporosis, hypercalcemia, Paget's disease, type II diabetes, and obesity and are being actively pursued as targets for numerous other diseases.  Exploitation of class B receptors has been limited by difficulties with small mol. drug discovery and development and an under appreciation of factors governing optimal therapeutic efficacy.  Recently, there has been increasing awareness of novel attributes of GPCR function that offer new opportunity for drug development.  These include the presence of allosteric binding sites on the receptor that can be exploited as drug binding pockets and the ability of individual drugs to enrich subpopulations of receptor conformations to selectively control signaling, a phenomenon termed biased agonism.  In this review, current knowledge of biased signaling and small mol. allostery within class B GPCRs is discussed, highlighting areas that have progressed significantly over the past decade, in addn. to those that remain largely unexplored with respect to these phenomena.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqipOVZPN9YzbVg90H21EOLACvtfcHk0lj6N9G0V7SZUQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1yqsr0%253D&md5=658b38e14a6438d971cc564731d9e625</span></div><a href="/servlet/linkout?suffix=cit112g&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.6b00049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.6b00049%26sid%3Dliteratum%253Aachs%26aulast%3DWootten%26aufirst%3DD.%26aulast%3DMiller%26aufirst%3DL.%2BJ.%26aulast%3DKoole%26aufirst%3DC.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26atitle%3DAllostery%2520and%2520biased%2520agonism%2520at%2520class%2520B%2520G%2520protein-coupled%2520receptors%26jtitle%3DChem.%2520Rev.%26date%3D2017%26volume%3D117%26spage%3D111%26epage%3D138%26doi%3D10.1021%2Facs.chemrev.6b00049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group">Violin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crombie, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soergel, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lark, M. W.</span><span> </span><span class="NLM_article-title">Biased ligands at G-protein-coupled receptors: promise and progress</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">308</span><span class="NLM_x">â</span> <span class="NLM_lpage">316</span><span class="refDoi">Â DOI: 10.1016/j.tips.2014.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.tips.2014.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24878326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosl2htr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=308-316&author=J.+D.+Violinauthor=A.+L.+Crombieauthor=D.+G.+Soergelauthor=M.+W.+Lark&title=Biased+ligands+at+G-protein-coupled+receptors%3A+promise+and+progress&doi=10.1016%2Fj.tips.2014.04.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Biased ligands at G-protein-coupled receptors: promise and progress</span></div><div class="casAuthors">Violin, Jonathan D.; Crombie, Aimee L.; Soergel, David G.; Lark, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">308-316</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Drug discovery targeting G protein-coupled receptors (GPCRs) is no longer limited to seeking agonists or antagonists to stimulate or block cellular responses assocd. with a particular receptor.  GPCRs are now known to support a diversity of pharmacol. profiles, a concept broadly referred to as functional selectivity.  In particular, the concept of ligand bias, whereby a ligand stabilizes subsets of receptor conformations to engender novel pharmacol. profiles, has recently gained increasing prominence.  This review discusses how biased ligands may deliver safer, better tolerated, and more efficacious drugs, and highlights several biased ligands that are in clin. development.  Biased ligands targeting the angiotensin II type 1 receptor and the Î¼ opioid receptor illustrate the translation of the biased ligand concept from basic biol. to clin. drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBma1S1zZ0-7Vg90H21EOLACvtfcHk0lj6N9G0V7SZUQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosl2htr4%253D&md5=768953e7aa5726d1a47ecbdb068469d8</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2014.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2014.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DCrombie%26aufirst%3DA.%2BL.%26aulast%3DSoergel%26aufirst%3DD.%2BG.%26aulast%3DLark%26aufirst%3DM.%2BW.%26atitle%3DBiased%2520ligands%2520at%2520G-protein-coupled%2520receptors%253A%2520promise%2520and%2520progress%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2014%26volume%3D35%26spage%3D308%26epage%3D316%26doi%3D10.1016%2Fj.tips.2014.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group">Kenakin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, L. J.</span><span> </span><span class="NLM_article-title">Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">265</span><span class="NLM_x">â</span> <span class="NLM_lpage">304</span><span class="refDoi">Â DOI: 10.1124/pr.108.000992</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1124%2Fpr.108.000992" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=20392808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVSltbbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=265-304&author=T.+Kenakinauthor=L.+J.+Miller&title=Seven+transmembrane+receptors+as+shapeshifting+proteins%3A+the+impact+of+allosteric+modulation+and+functional+selectivity+on+new+drug+discovery&doi=10.1124%2Fpr.108.000992"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery</span></div><div class="casAuthors">Kenakin, Terry; Miller, Laurence J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">265-304</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  It is useful to consider seven transmembrane receptors (7TMRs) as disordered proteins able to allosterically respond to a no. of binding partners.  Considering 7TMRs as allosteric systems, affinity and efficacy can be thought of in terms of energy flow between a modulator, conduit (the receptor protein), and a no. of guests.  These guests can be other mols., receptors, membrane-bound proteins, or signaling proteins in the cytosol.  These vectorial flows of energy can yield std. canonical guest allostery (allosteric modification of drug effect), effects along the plane of the cell membrane (receptor oligomerization), or effects directed into the cytosol (differential signaling as functional selectivity).  This review discusses these apparently diverse pharmacol. effects in terms of mol. dynamics and protein ensemble theory, which tends to unify 7TMR behavior toward cells.  Special consideration will be given to functional selectivity (biased agonism and biased antagonism) in terms of mechanism of action and potential therapeutic application.  The explosion of technol. that has enabled observation of diverse 7TMR behavior has also shown how drugs can have multiple (pluridimensional) efficacies and how this can cause paradoxical drug classification and nomenclatures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3xCdUTrHggbVg90H21EOLACvtfcHk0ljY32lfYwviwA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVSltbbM&md5=fa2394cfb3ae2ecdde09775b50b45b8b</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1124%2Fpr.108.000992&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.108.000992%26sid%3Dliteratum%253Aachs%26aulast%3DKenakin%26aufirst%3DT.%26aulast%3DMiller%26aufirst%3DL.%2BJ.%26atitle%3DSeven%2520transmembrane%2520receptors%2520as%2520shapeshifting%2520proteins%253A%2520the%2520impact%2520of%2520allosteric%2520modulation%2520and%2520functional%2520selectivity%2520on%2520new%2520drug%2520discovery%26jtitle%3DPharmacol.%2520Rev.%26date%3D2010%26volume%3D62%26spage%3D265%26epage%3D304%26doi%3D10.1124%2Fpr.108.000992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group">Violin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeWire, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rominger, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whalen, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gowen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lark, M. W.</span><span> </span><span class="NLM_article-title">Selectively Engaging <sup>Î²</sup>-Arrestins at the Angiotensin II Type 1 Receptor Reduces Blood Pressure and Increases Cardiac Performance</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">335</span><span class="NLM_x">, </span> <span class="NLM_fpage">572</span><span class="NLM_x">â</span> <span class="NLM_lpage">579</span><span class="refDoi">Â DOI: 10.1124/jpet.110.173005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1124%2Fjpet.110.173005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=20801892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFOmsrjF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=2010&pages=572-579&author=J.+D.+Violinauthor=S.+M.+DeWireauthor=D.+Yamashitaauthor=D.+H.+Romingerauthor=L.+Nguyenauthor=K.+Schillerauthor=E.+J.+Whalenauthor=M.+Gowenauthor=M.+W.+Lark&title=Selectively+Engaging+%CE%B2-Arrestins+at+the+Angiotensin+II+Type+1+Receptor+Reduces+Blood+Pressure+and+Increases+Cardiac+Performance&doi=10.1124%2Fjpet.110.173005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Selectively engaging Î²-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance</span></div><div class="casAuthors">Violin, Jonathan D.; DeWire, Scott M.; Yamashita, Dennis; Rominger, David H.; Nguyen, Lisa; Schiller, Kevin; Whalen, Erin J.; Gowen, Maxine; Lark, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">572-579</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Biased G protein-coupled ligands engage subsets of the receptor signals normally stimulated by unbiased agonists.  However, it is unclear whether ligand bias can elicit differentiated pharmacol. in vivo.  Here, we describe the discovery of a potent, selective Î²-arrestin biased ligand of the angiotensin II type 1 receptor.  TRV 120027 (Sar-Arg-Val-Tyr-Ile-His-Pro-D-Ala-OH) competitively antagonizes angiotensin II-stimulated G protein signaling, but stimulates Î²-arrestin recruitment and activates several kinase pathways, including p42/44 mitogen-activated protein kinase, Src, and endothelial nitric-oxide synthase phosphorylation via Î²-arrestin coupling.  Consistent with Î²-arrestin efficacy, and unlike unbiased antagonists, TRV 120027 increased cardiomyocyte contractility in vitro.  In rats, TRV 120027 reduced mean arterial pressure, as did the unbiased antagonists losartan and telmisartan.  However, unlike the unbiased antagonists, which decreased cardiac performance, TRV 120027 increased cardiac performance and preserved cardiac stroke vol.  These striking differences in vivo between unbiased and Î²-arrestin biased ligands validate the use of biased ligands to selectively target specific receptor functions in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQaaai_REGvbVg90H21EOLACvtfcHk0ljY32lfYwviwA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFOmsrjF&md5=a896363e71830f706b103d8153c97f83</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.173005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.173005%26sid%3Dliteratum%253Aachs%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DDeWire%26aufirst%3DS.%2BM.%26aulast%3DYamashita%26aufirst%3DD.%26aulast%3DRominger%26aufirst%3DD.%2BH.%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DSchiller%26aufirst%3DK.%26aulast%3DWhalen%26aufirst%3DE.%2BJ.%26aulast%3DGowen%26aufirst%3DM.%26aulast%3DLark%26aufirst%3DM.%2BW.%26atitle%3DSelectively%2520Engaging%2520%25CE%25B2-Arrestins%2520at%2520the%2520Angiotensin%2520II%2520Type%25201%2520Receptor%2520Reduces%2520Blood%2520Pressure%2520and%2520Increases%2520Cardiac%2520Performance%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D335%26spage%3D572%26epage%3D579%26doi%3D10.1124%2Fjpet.110.173005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group">Gesty-Palmer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flannery, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corsino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spurney, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefkowitz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttrell, L. M.</span><span> </span><span class="NLM_article-title">A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">1ra1</span><span class="refDoi">Â DOI: 10.1126/scitranslmed.3000071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1126%2Fscitranslmed.3000071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=20368153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A280%3ADC%252BC3c3jvFSmug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2009&pages=1ra1&author=D.+Gesty-Palmerauthor=P.+Flanneryauthor=L.+Yuanauthor=L.+Corsinoauthor=R.+Spurneyauthor=R.+J.+Lefkowitzauthor=L.+M.+Luttrell&title=A+beta-arrestin-biased+agonist+of+the+parathyroid+hormone+receptor+%28PTH1R%29+promotes+bone+formation+independent+of+G+protein+activation&doi=10.1126%2Fscitranslmed.3000071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation</span></div><div class="casAuthors">Gesty-Palmer Diane; Flannery Pat; Yuan Ling; Corsino Leonor; Spurney Robert; Lefkowitz Robert J; Luttrell Louis M</div><div class="citationInfo"><span class="NLM_cas:title">Science translational medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1ra1</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">About 40% of the therapeutic agents in use today exert their effects through seven-transmembrane receptors (7TMRs).  When activated by ligands, these receptors trigger two pathways that independently transduce signals to the cell: one through heterotrimeric GTP-binding proteins (G proteins) and one through beta-arrestins; so-called biased agonists can selectively activate these distinct pathways.  Here, we investigate selective activation of these pathways through the use of a biased agonist for the type 1 parathyroid hormone (PTH)-PTH-related protein receptor (PTH1R), (D-Trp(12),Tyr(34))-PTH(7-34) (PTH-betaarr), which activates beta-arrestin but not classic G protein signaling.  In mice, PTH-betaarr induces anabolic bone formation, as does the nonselective agonist PTH(1-34), which activates both mechanisms.  In beta-arrestin2-null mice, the increase in bone mineral density evoked by PTH(1-34) is attenuated and that stimulated by PTH-betaarr is ablated.  The beta-arrestin2-dependent pathway contributes primarily to trabecular bone formation and does not stimulate bone resorption.  These results show that a biased agonist selective for the beta-arrestin pathway can elicit a response in vivo distinct from that elicited by nonselective agonists.  Ligands with these properties may form the basis for improved 7TMR-directed pharmacologic agents with enhanced therapeutic specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmuM4aCIxthdXdcedVHT5tfW6udTcc2eaoU-hDCIgOeLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c3jvFSmug%253D%253D&md5=748e4367ded72b6b7e10fd759521ba62</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3000071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3000071%26sid%3Dliteratum%253Aachs%26aulast%3DGesty-Palmer%26aufirst%3DD.%26aulast%3DFlannery%26aufirst%3DP.%26aulast%3DYuan%26aufirst%3DL.%26aulast%3DCorsino%26aufirst%3DL.%26aulast%3DSpurney%26aufirst%3DR.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DLuttrell%26aufirst%3DL.%2BM.%26atitle%3DA%2520beta-arrestin-biased%2520agonist%2520of%2520the%2520parathyroid%2520hormone%2520receptor%2520%2528PTH1R%2529%2520promotes%2520bone%2520formation%2520independent%2520of%2520G%2520protein%2520activation%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2009%26volume%3D1%26spage%3D1ra1%26doi%3D10.1126%2Fscitranslmed.3000071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Burgdorf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.-l.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balster, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leander, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanton, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroes, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moskal, J. R.</span><span> </span><span class="NLM_article-title">GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">729</span><span class="NLM_x">â</span> <span class="NLM_lpage">742</span><span class="refDoi">Â DOI: 10.1038/npp.2012.246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnpp.2012.246" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2013&pages=729-742&author=J.+Burgdorfauthor=X.-l.+Zhangauthor=K.+L.+Nicholsonauthor=R.+L.+Balsterauthor=J.+D.+Leanderauthor=P.+K.+Stantonauthor=A.+L.+Grossauthor=R.+A.+Kroesauthor=J.+R.+Moskal&title=GLYX-13%2C+a+NMDA+receptor+glycine-site+functional+partial+agonist%2C+induces+antidepressant-like+effects+without+ketamine-like+side+effects&doi=10.1038%2Fnpp.2012.246"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117a&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2012.246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2012.246%26sid%3Dliteratum%253Aachs%26aulast%3DBurgdorf%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.-l.%26aulast%3DNicholson%26aufirst%3DK.%2BL.%26aulast%3DBalster%26aufirst%3DR.%2BL.%26aulast%3DLeander%26aufirst%3DJ.%2BD.%26aulast%3DStanton%26aufirst%3DP.%2BK.%26aulast%3DGross%26aufirst%3DA.%2BL.%26aulast%3DKroes%26aufirst%3DR.%2BA.%26aulast%3DMoskal%26aufirst%3DJ.%2BR.%26atitle%3DGLYX-13%252C%2520a%2520NMDA%2520receptor%2520glycine-site%2520functional%2520partial%2520agonist%252C%2520induces%2520antidepressant-like%2520effects%2520without%2520ketamine-like%2520side%2520effects%26jtitle%3DNeuropsychopharmacology%26date%3D2013%26volume%3D38%26spage%3D729%26epage%3D742%26doi%3D10.1038%2Fnpp.2012.246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit117b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Moskal, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgdorf, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroes, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanton, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Disterhoft, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leander, J. D.</span><span> </span><span class="NLM_article-title">GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">243</span><span class="NLM_x">â</span> <span class="NLM_lpage">254</span><span class="refDoi">Â DOI: 10.1517/13543784.2014.852536</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1517%2F13543784.2014.852536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24251380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvFarsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=243-254&author=J.+R.+Moskalauthor=R.+Burchauthor=J.+S.+Burgdorfauthor=R.+A.+Kroesauthor=P.+K.+Stantonauthor=J.+F.+Disterhoftauthor=J.+D.+Leander&title=GLYX-13%2C+an+NMDA+receptor+glycine+site+functional+partial+agonist+enhances+cognition+and+produces+antidepressant+effects+without+the+psychotomimetic+side+effects+of+NMDA+receptor+antagonists&doi=10.1517%2F13543784.2014.852536"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117bR"><div class="casContent"><span class="casTitleNuber">117b</span><div class="casTitle"><span class="NLM_cas:atitle">GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists</span></div><div class="casAuthors">Moskal, Joseph R.; Burch, Ronald; Burgdorf, Jeffrey S.; Kroes, Roger A.; Stanton, Patric K.; Disterhoft, John F.; Leander, J. David</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">243-254</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The N-methyl-D-aspartate receptor-ionophore complex plays a key role in learning and memory and has efficacy in animals and humans with affective disorders.  GLYX-13 is an N-methyl-d-aspartate receptor (NMDAR) glycine-site functional partial agonist and cognitive enhancer that also shows rapid antidepressant activity without psychotomimetic side effects.  Areas covered: The authors review the mechanism of action of GLYX-13 that was investigated in preclin. studies and evaluated in clin. studies.  Specifically, the authors review its pharmacol., pharmacokinetics, and drug safety that were demonstrated in clin. studies.  Expert opinion: NMDAR full antagonists can produce rapid antidepressant effects in treatment-resistant subjects; however, they are often accompanied by psychotomimetic effects that make chronic use outside of a clin. trial inpatient setting problematic.  GLYX-13 appears to exert its antidepressant effects in the frontal cortex via NMDAR-triggered synaptic plasticity.  Understanding the mechanistic underpinning of GLYX-13's antidepressant action should provide both novel insights into the role of the glutamatergic system in depression and identify new targets for therapeutic development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1qLFmRChVArVg90H21EOLACvtfcHk0ljcvQKR0q8xNA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvFarsA%253D%253D&md5=438f7150450c25f13107b9ed359c5a75</span></div><a href="/servlet/linkout?suffix=cit117b&amp;dbid=16384&amp;doi=10.1517%2F13543784.2014.852536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2014.852536%26sid%3Dliteratum%253Aachs%26aulast%3DMoskal%26aufirst%3DJ.%2BR.%26aulast%3DBurch%26aufirst%3DR.%26aulast%3DBurgdorf%26aufirst%3DJ.%2BS.%26aulast%3DKroes%26aufirst%3DR.%2BA.%26aulast%3DStanton%26aufirst%3DP.%2BK.%26aulast%3DDisterhoft%26aufirst%3DJ.%2BF.%26aulast%3DLeander%26aufirst%3DJ.%2BD.%26atitle%3DGLYX-13%252C%2520an%2520NMDA%2520receptor%2520glycine%2520site%2520functional%2520partial%2520agonist%2520enhances%2520cognition%2520and%2520produces%2520antidepressant%2520effects%2520without%2520the%2520psychotomimetic%2520side%2520effects%2520of%2520NMDA%2520receptor%2520antagonists%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2014%26volume%3D23%26spage%3D243%26epage%3D254%26doi%3D10.1517%2F13543784.2014.852536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group">Vasilescu, A.-N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schweinfurth, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgwardt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gass, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, U. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckart, S.</span><span> </span><span class="NLM_article-title">Modulation of the activity of N-methyl-d-aspartate receptors as a novel treatment option for depression: current clinical evidence and therapeutic potential of rapastinel (GLYX-13)</span> <span class="citation_source-journal">Neuropsychiatr. Dis. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">973</span><span class="NLM_x">â</span> <span class="NLM_lpage">980</span><span class="refDoi">Â DOI: 10.2147/NDT.S119004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.2147%2FNDT.S119004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=28408831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A280%3ADC%252BC1cvnslGltQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=973-980&author=A.-N.+Vasilescuauthor=N.+Schweinfurthauthor=S.+Borgwardtauthor=P.+Gassauthor=U.+E.+Langauthor=D.+Intaauthor=S.+Eckart&title=Modulation+of+the+activity+of+N-methyl-d-aspartate+receptors+as+a+novel+treatment+option+for+depression%3A+current+clinical+evidence+and+therapeutic+potential+of+rapastinel+%28GLYX-13%29&doi=10.2147%2FNDT.S119004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of the activity of N-methyl-d-aspartate receptors as a novel treatment option for depression: current clinical evidence and therapeutic potential of rapastinel (GLYX-13)</span></div><div class="casAuthors">Vasilescu Andrei-Nicolae; Gass Peter; Inta Dragos; Schweinfurth Nina; Borgwardt Stefan; Lang Undine E; Inta Dragos; Eckart Sarah</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychiatric disease and treatment</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">973-980</span>
        ISSN:<span class="NLM_cas:issn">1176-6328</span>.
    </div><div class="casAbstract">Classical monoaminergic antidepressants show several disadvantages, such as protracted onset of therapeutic action.  Conversely, the fast and sustained antidepressant effect of the N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine raises vast interest in understanding the role of the glutamate system in mood disorders.  Indeed, numerous data support the existence of glutamatergic dysfunction in major depressive disorder (MDD).  Drawback to this short-latency therapy is its side effect profile, especially the psychotomimetic action, which seriously hampers the common and widespread clinical use of ketamine.  Therefore, there is a substantial need for alternative glutamatergic antidepressants with milder side effects.  In this article, we review evidence that implicates NMDARs in the prospective treatment of MDD with focus on rapastinel (formerly known as GLYX-13), a novel synthetic NMDAR modulator with fast antidepressant effect, which acts by enhancing NMDAR function as opposed to blocking it.  We summarize and discuss current clinical and animal studies regarding the therapeutic potential of rapastinel not only in MDD but also in other psychiatric disorders, such as obsessive-compulsive disorder and posttraumatic stress disorder.  Additionally, we discuss current data concerning the molecular mechanisms underlying the antidepressant effect of rapastinel, highlighting common aspects as well as differences to ketamine.  In 2016, rapastinel received the Breakthrough Therapy designation for the treatment of MDD from the US Food and Drug Administration, representing one of the most promising alternative antidepressants under current investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvBm8Q8B105NbHMBt0mMIXfW6udTcc2ea1kNvdVc8mA7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvnslGltQ%253D%253D&md5=e27e12ccb5d8405f33d8474bd1c75bb0</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.2147%2FNDT.S119004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FNDT.S119004%26sid%3Dliteratum%253Aachs%26aulast%3DVasilescu%26aufirst%3DA.-N.%26aulast%3DSchweinfurth%26aufirst%3DN.%26aulast%3DBorgwardt%26aufirst%3DS.%26aulast%3DGass%26aufirst%3DP.%26aulast%3DLang%26aufirst%3DU.%2BE.%26aulast%3DInta%26aufirst%3DD.%26aulast%3DEckart%26aufirst%3DS.%26atitle%3DModulation%2520of%2520the%2520activity%2520of%2520N-methyl-d-aspartate%2520receptors%2520as%2520a%2520novel%2520treatment%2520option%2520for%2520depression%253A%2520current%2520clinical%2520evidence%2520and%2520therapeutic%2520potential%2520of%2520rapastinel%2520%2528GLYX-13%2529%26jtitle%3DNeuropsychiatr.%2520Dis.%2520Treat.%26date%3D2017%26volume%3D13%26spage%3D973%26epage%3D980%26doi%3D10.2147%2FNDT.S119004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kuliopulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covic, L.</span><span> </span><span class="NLM_article-title">Blocking receptors on the inside: pepducin-based intervention of PAR signaling and thrombosis</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">â</span> <span class="NLM_lpage">262</span><span class="refDoi">Â DOI: 10.1016/j.lfs.2003.09.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.lfs.2003.09.012" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2003&pages=255-262&author=A.+Kuliopulosauthor=L.+Covic&title=Blocking+receptors+on+the+inside%3A+pepducin-based+intervention+of+PAR+signaling+and+thrombosis&doi=10.1016%2Fj.lfs.2003.09.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119a&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2003.09.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2003.09.012%26sid%3Dliteratum%253Aachs%26aulast%3DKuliopulos%26aufirst%3DA.%26aulast%3DCovic%26aufirst%3DL.%26atitle%3DBlocking%2520receptors%2520on%2520the%2520inside%253A%2520pepducin-based%2520intervention%2520of%2520PAR%2520signaling%2520and%2520thrombosis%26jtitle%3DLife%2520Sci.%26date%3D2003%26volume%3D74%26spage%3D255%26epage%3D262%26doi%3D10.1016%2Fj.lfs.2003.09.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit119b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">OâCallaghan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuliopulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covic, L.</span><span> </span><span class="NLM_article-title">Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">287</span><span class="NLM_x">, </span> <span class="NLM_fpage">12787</span><span class="NLM_x">â</span> <span class="NLM_lpage">12796</span><span class="refDoi">Â DOI: 10.1074/jbc.R112.355461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1074%2Fjbc.R112.355461" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=12787-12796&author=K.+O%E2%80%99Callaghanauthor=A.+Kuliopulosauthor=L.+Covic&title=Turning+receptors+on+and+off+with+intracellular+pepducins%3A+new+insights+into+G-protein-coupled+receptor+drug+development&doi=10.1074%2Fjbc.R112.355461"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119b&amp;dbid=16384&amp;doi=10.1074%2Fjbc.R112.355461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.R112.355461%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Callaghan%26aufirst%3DK.%26aulast%3DKuliopulos%26aufirst%3DA.%26aulast%3DCovic%26aufirst%3DL.%26atitle%3DTurning%2520receptors%2520on%2520and%2520off%2520with%2520intracellular%2520pepducins%253A%2520new%2520insights%2520into%2520G-protein-coupled%2520receptor%2520drug%2520development%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D12787%26epage%3D12796%26doi%3D10.1074%2Fjbc.R112.355461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group">Zhang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasuda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimmelstiel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâCallaghan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohm, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baleja, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covic, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuliopulos, A.</span><span> </span><span class="NLM_article-title">Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">83</span><span class="NLM_x">â</span> <span class="NLM_lpage">91</span><span class="refDoi">Â DOI: 10.1161/CIRCULATIONAHA.112.091918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1161%2FCIRCULATIONAHA.112.091918" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2012&pages=83-91&author=P.+Zhangauthor=A.+Gruberauthor=S.+Kasudaauthor=C.+Kimmelstielauthor=K.+O%E2%80%99Callaghanauthor=D.+H.+Coxauthor=A.+Bohmauthor=J.+D.+Balejaauthor=L.+Covicauthor=A.+Kuliopulos&title=Suppression+of+arterial+thrombosis+without+affecting+hemostatic+parameters+with+a+cell-penetrating+PAR1+pepducin&doi=10.1161%2FCIRCULATIONAHA.112.091918"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.112.091918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.112.091918%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DGruber%26aufirst%3DA.%26aulast%3DKasuda%26aufirst%3DS.%26aulast%3DKimmelstiel%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Callaghan%26aufirst%3DK.%26aulast%3DCox%26aufirst%3DD.%2BH.%26aulast%3DBohm%26aufirst%3DA.%26aulast%3DBaleja%26aufirst%3DJ.%2BD.%26aulast%3DCovic%26aufirst%3DL.%26aulast%3DKuliopulos%26aufirst%3DA.%26atitle%3DSuppression%2520of%2520arterial%2520thrombosis%2520without%2520affecting%2520hemostatic%2520parameters%2520with%2520a%2520cell-penetrating%2520PAR1%2520pepducin%26jtitle%3DCirculation%26date%3D2012%26volume%3D126%26spage%3D83%26epage%3D91%26doi%3D10.1161%2FCIRCULATIONAHA.112.091918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span>Clinical information can be found at: NCT01806077: Safety Study of PZ-128 in Subjects with Multiple Coronary Artery Disease Risk Factors; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="https://www.clinicaltrials.gov/" class="extLink">https://www.clinicaltrials.gov/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical+information+can+be+found+at%3A+NCT01806077%3A+Safety+Study+of+PZ-128+in+Subjects+with+Multiple+Coronary+Artery+Disease+Risk+Factors%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2016%3B+https%3A%2F%2Fwww.clinicaltrials.gov%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DNCT01806077%253A%2520Safety%2520Study%2520of%2520PZ-128%2520in%2520Subjects%2520with%2520Multiple%2520Coronary%2520Artery%2520Disease%2520Risk%2520Factors%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group">DeWire, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Violin, J. D.</span><span> </span><span class="NLM_article-title">Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology</span> <span class="citation_source-journal">Circ. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">â</span> <span class="NLM_lpage">216</span><span class="refDoi">Â DOI: 10.1161/CIRCRESAHA.110.231308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1161%2FCIRCRESAHA.110.231308" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2011&pages=205-216&author=S.+M.+DeWireauthor=J.+D.+Violin&title=Biased+ligands+for+better+cardiovascular+drugs%3A+dissecting+G-protein-coupled+receptor+pharmacology&doi=10.1161%2FCIRCRESAHA.110.231308"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.110.231308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.110.231308%26sid%3Dliteratum%253Aachs%26aulast%3DDeWire%26aufirst%3DS.%2BM.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26atitle%3DBiased%2520ligands%2520for%2520better%2520cardiovascular%2520drugs%253A%2520dissecting%2520G-protein-coupled%2520receptor%2520pharmacology%26jtitle%3DCirc.%2520Res.%26date%3D2011%26volume%3D109%26spage%3D205%26epage%3D216%26doi%3D10.1161%2FCIRCRESAHA.110.231308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group">Di, L.</span><span> </span><span class="NLM_article-title">Strategic Approaches to Optimizing Peptide ADME Properties</span> <span class="citation_source-journal">AAPS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">â</span> <span class="NLM_lpage">143</span><span class="refDoi">Â DOI: 10.1208/s12248-014-9687-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1208%2Fs12248-014-9687-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25366889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFSnurvJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=134-143&author=L.+Di&title=Strategic+Approaches+to+Optimizing+Peptide+ADME+Properties&doi=10.1208%2Fs12248-014-9687-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Strategic Approaches to Optimizing Peptide ADME Properties</span></div><div class="casAuthors">Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">134-143</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Development of peptide drugs is challenging but also quite rewarding.  Five blockbuster peptide drugs are currently on the market, and six new peptides received first marketing approval as new mol. entities in 2012.  Although peptides only represent 2% of the drug market, the market is growing twice as quickly and might soon occupy a larger niche.  Natural peptides typically have poor absorption, distribution, metab., and excretion (ADME) properties with rapid clearance, short half-life, low permeability, and sometimes low soly.  Strategies have been developed to improve peptide drugability through enhancing permeability, reducing proteolysis and renal clearance, and prolonging half-life.  In vivo, in vitro, and in silico tools are available to evaluate ADME properties of peptides, and structural modification strategies are in place to improve peptide developability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDLDsR-Zk0OLVg90H21EOLACvtfcHk0lh4WrPHq3Kudg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFSnurvJ&md5=530597d3719d65509105096f433fee0a</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1208%2Fs12248-014-9687-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-014-9687-3%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26atitle%3DStrategic%2520Approaches%2520to%2520Optimizing%2520Peptide%2520ADME%2520Properties%26jtitle%3DAAPS%2520J.%26date%3D2015%26volume%3D17%26spage%3D134%26epage%3D143%26doi%3D10.1208%2Fs12248-014-9687-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jamieson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boutard, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabatino, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubell, W. D.</span><span> </span><span class="NLM_article-title">Peptide scanning for studying structure-activity relationships in drug discovery</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">148</span><span class="NLM_x">â</span> <span class="NLM_lpage">165</span><span class="refDoi">Â DOI: 10.1111/cbdd.12042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1111%2Fcbdd.12042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23253136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1ykug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2013&pages=148-165&author=A.+G.+Jamiesonauthor=N.+Boutardauthor=D.+Sabatinoauthor=W.+D.+Lubell&title=Peptide+scanning+for+studying+structure-activity+relationships+in+drug+discovery&doi=10.1111%2Fcbdd.12042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124aR"><div class="casContent"><span class="casTitleNuber">124a</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide scanning for studying structure-activity relationships in drug discovery</span></div><div class="casAuthors">Jamieson, Andrew G.; Boutard, Nicolas; Sabatino, David; Lubell, William D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">148-165</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Peptide-based therapeutics have grown in importance over the last few decades.  Furthermore, peptides have been extensively used as lead compds. in the drug discovery process to investigate the nature of chem. space required for mol. recognition and activity at a variety of targets.  This crit. commentary reviews scanning techniques, which employ natural and non-proteinogenic amino acids to facilitate understanding of structural requirements for peptide biol. activity.  The value of sequence anal. by such methods is highlighted by examples, in which the elements for peptide affinity and activity have been elucidated and employed to prep. peptidomimetic leads for drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlnOyXem-xgLVg90H21EOLACvtfcHk0lh4WrPHq3Kudg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1ykug%253D%253D&md5=819b6f730174f5f73b0bb7cf04ca30c2</span></div><a href="/servlet/linkout?suffix=cit124a&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12042%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DA.%2BG.%26aulast%3DBoutard%26aufirst%3DN.%26aulast%3DSabatino%26aufirst%3DD.%26aulast%3DLubell%26aufirst%3DW.%2BD.%26atitle%3DPeptide%2520scanning%2520for%2520studying%2520structure-activity%2520relationships%2520in%2520drug%2520discovery%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2013%26volume%3D81%26spage%3D148%26epage%3D165%26doi%3D10.1111%2Fcbdd.12042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit124b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Eustache, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leprince, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuffery, P.</span><span> </span><span class="NLM_article-title">Progress with peptide scanning to study structure-activity relationships: the implications for drug discovery</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">771</span><span class="NLM_x">â</span> <span class="NLM_lpage">784</span><span class="refDoi">Â DOI: 10.1080/17460441.2016.1201058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1080%2F17460441.2016.1201058" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=771-784&author=S.+Eustacheauthor=J.+Leprinceauthor=P.+Tuffery&title=Progress+with+peptide+scanning+to+study+structure-activity+relationships%3A+the+implications+for+drug+discovery&doi=10.1080%2F17460441.2016.1201058"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124b&amp;dbid=16384&amp;doi=10.1080%2F17460441.2016.1201058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2016.1201058%26sid%3Dliteratum%253Aachs%26aulast%3DEustache%26aufirst%3DS.%26aulast%3DLeprince%26aufirst%3DJ.%26aulast%3DTuffery%26aufirst%3DP.%26atitle%3DProgress%2520with%2520peptide%2520scanning%2520to%2520study%2520structure-activity%2520relationships%253A%2520the%2520implications%2520for%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2016%26volume%3D11%26spage%3D771%26epage%3D784%26doi%3D10.1080%2F17460441.2016.1201058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit124c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Murray, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, Y.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aral, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stenkilsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salyers, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaida, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sickmier, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGivern, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gegg, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miranda, L. P.</span><span> </span><span class="NLM_article-title">Pharmaceutical optimization of peptide toxins for ion channel targets: potent, selective, and long-lived antagonists of Kv1.3</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">6784</span><span class="NLM_x">â</span> <span class="NLM_lpage">6802</span><span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00495</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00495" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref124/cit124c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlOjtbjK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6784-6802&author=J.+K.+Murrayauthor=Y.-X.+Qianauthor=B.+Liuauthor=R.+Elliottauthor=J.+Aralauthor=C.+Parkauthor=X.+Zhangauthor=M.+Stenkilssonauthor=K.+Salyersauthor=M.+Roseauthor=H.+Liauthor=S.+Yuauthor=K.+L.+Andrewsauthor=A.+Colomberoauthor=J.+Wernerauthor=K.+Gaidaauthor=E.+A.+Sickmierauthor=P.+Miuauthor=A.+Itanoauthor=J.+McGivernauthor=C.+V.+Geggauthor=J.+K.+Sullivanauthor=L.+P.+Miranda&title=Pharmaceutical+optimization+of+peptide+toxins+for+ion+channel+targets%3A+potent%2C+selective%2C+and+long-lived+antagonists+of+Kv1.3&doi=10.1021%2Facs.jmedchem.5b00495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124cR"><div class="casContent"><span class="casTitleNuber">124c</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmaceutical Optimization of Peptide Toxins for Ion Channel Targets: Potent, Selective, and Long-Lived Antagonists of Kv1.3</span></div><div class="casAuthors">Murray, Justin K.; Qian, Yi-Xin; Liu, Benxian; Elliott, Robin; Aral, Jennifer; Park, Cynthia; Zhang, Xuxia; Stenkilsson, Michael; Salyers, Kevin; Rose, Mark; Li, Hongyan; Yu, Steven; Andrews, Kristin L.; Colombero, Anne; Werner, Jonathan; Gaida, Kevin; Sickmier, E. Allen; Miu, Peter; Itano, Andrea; McGivern, Joseph; Gegg, Colin V.; Sullivan, John K.; Miranda, Les P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6784-6802</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To realize the medicinal potential of peptide toxins, naturally occurring disulfide-rich peptides, as ion channel antagonists, more efficient pharmaceutical optimization technologies must be developed.  The therapeutic properties of multiple cysteine toxin peptides can be rapidly and substantially improved by combining direct chem. strategies with high-throughput electrophysiol.  The authors applied whole-mol., brute-force, structure-activity analoging to ShK, a peptide toxin from the sea anemone Stichodactyla helianthus that inhibits the voltage-gated potassium ion channel Kv1.3, to effectively discover crit. structural changes for 15Ã selectivity against the closely related neuronal ion channel Kv1.1.  Subsequent site-specific polymer conjugation resulted in an exquisitely selective Kv1.3 antagonist (>1000Ã over Kv1.1) with picomolar functional activity in whole blood and a pharmacokinetic profile suitable for weekly administration in primates.  The pharmacol. potential of the optimized toxin peptide was demonstrated by potent and sustained inhibition of cytokine secretion from T cells, a therapeutic target for autoimmune diseases, in cynomolgus monkeys.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEtF-Ugp8jFbVg90H21EOLACvtfcHk0lgLf4mKerZ7mg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlOjtbjK&md5=1cfb03e783bd953480c203dc9b95af84</span></div><a href="/servlet/linkout?suffix=cit124c&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00495%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DJ.%2BK.%26aulast%3DQian%26aufirst%3DY.-X.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DElliott%26aufirst%3DR.%26aulast%3DAral%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DStenkilsson%26aufirst%3DM.%26aulast%3DSalyers%26aufirst%3DK.%26aulast%3DRose%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DColombero%26aufirst%3DA.%26aulast%3DWerner%26aufirst%3DJ.%26aulast%3DGaida%26aufirst%3DK.%26aulast%3DSickmier%26aufirst%3DE.%2BA.%26aulast%3DMiu%26aufirst%3DP.%26aulast%3DItano%26aufirst%3DA.%26aulast%3DMcGivern%26aufirst%3DJ.%26aulast%3DGegg%26aufirst%3DC.%2BV.%26aulast%3DSullivan%26aufirst%3DJ.%2BK.%26aulast%3DMiranda%26aufirst%3DL.%2BP.%26atitle%3DPharmaceutical%2520optimization%2520of%2520peptide%2520toxins%2520for%2520ion%2520channel%2520targets%253A%2520potent%252C%2520selective%252C%2520and%2520long-lived%2520antagonists%2520of%2520Kv1.3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6784%26epage%3D6802%26doi%3D10.1021%2Facs.jmedchem.5b00495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Goodwin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simerska, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toth, I.</span><span> </span><span class="NLM_article-title">Peptides as therapeutics with enhanced bioactivity</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4451</span><span class="NLM_x">â</span> <span class="NLM_lpage">4461</span><span class="refDoi">Â DOI: 10.2174/092986712803251548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.2174%2F092986712803251548" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=22830348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlens74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=4451-4461&author=D.+Goodwinauthor=P.+Simerskaauthor=I.+Toth&title=Peptides+as+therapeutics+with+enhanced+bioactivity&doi=10.2174%2F092986712803251548"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125aR"><div class="casContent"><span class="casTitleNuber">125a</span><div class="casTitle"><span class="NLM_cas:atitle">Peptides as therapeutics with enhanced bioactivity</span></div><div class="casAuthors">Goodwin, D.; Simerska, P.; Toth, I.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">4451-4461</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of techniques for efficient peptide prodn. renewed interest in peptides as therapeutics.  Numerous modifications for improving stability, transport and affinity profiles now exist.  Several new adjuvant and carrier systems have also been developed, enhancing the immunogenicity of peptides thus allowing their development as vaccines.  This review describes the established and exptl. approaches for manufg. peptide drugs and highlights the techniques currently used for improving their drug like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpComM-2TLdp7Vg90H21EOLACvtfcHk0lgLf4mKerZ7mg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlens74%253D&md5=a0cc3db7bbb1916461cc55ebc5f5746f</span></div><a href="/servlet/linkout?suffix=cit125a&amp;dbid=16384&amp;doi=10.2174%2F092986712803251548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986712803251548%26sid%3Dliteratum%253Aachs%26aulast%3DGoodwin%26aufirst%3DD.%26aulast%3DSimerska%26aufirst%3DP.%26aulast%3DToth%26aufirst%3DI.%26atitle%3DPeptides%2520as%2520therapeutics%2520with%2520enhanced%2520bioactivity%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2012%26volume%3D19%26spage%3D4451%26epage%3D4461%26doi%3D10.2174%2F092986712803251548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit125b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Varamini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansfeld, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchfield, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyse, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toth, I.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of an orally active glycosylated endomorphin-1</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">5859</span><span class="NLM_x">â</span> <span class="NLM_lpage">5867</span><span class="refDoi">Â DOI: 10.1021/jm300418d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300418d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5859-5867&author=P.+Varaminiauthor=F.+M.+Mansfeldauthor=J.+T.+Blanchfieldauthor=B.+D.+Wyseauthor=M.+T.+Smithauthor=I.+Toth&title=Synthesis+and+biological+evaluation+of+an+orally+active+glycosylated+endomorphin-1&doi=10.1021%2Fjm300418d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125b&amp;dbid=16384&amp;doi=10.1021%2Fjm300418d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300418d%26sid%3Dliteratum%253Aachs%26aulast%3DVaramini%26aufirst%3DP.%26aulast%3DMansfeld%26aufirst%3DF.%2BM.%26aulast%3DBlanchfield%26aufirst%3DJ.%2BT.%26aulast%3DWyse%26aufirst%3DB.%2BD.%26aulast%3DSmith%26aufirst%3DM.%2BT.%26aulast%3DToth%26aufirst%3DI.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520an%2520orally%2520active%2520glycosylated%2520endomorphin-1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5859%26epage%3D5867%26doi%3D10.1021%2Fjm300418d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group">Miranda, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holder, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aral, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gegg, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doellgast, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valladares, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salyers, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wild, K.</span><span> </span><span class="NLM_article-title">Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">7889</span><span class="NLM_x">â</span> <span class="NLM_lpage">7897</span><span class="refDoi">Â DOI: 10.1021/jm8009298</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8009298" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWks73F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7889-7897&author=L.+P.+Mirandaauthor=J.+R.+Holderauthor=L.+Shiauthor=B.+Bennettauthor=J.+Aralauthor=C.+V.+Geggauthor=M.+Wrightauthor=K.+Walkerauthor=G.+Doellgastauthor=R.+Rogersauthor=H.+Liauthor=V.+Valladaresauthor=K.+Salyersauthor=E.+Johnsonauthor=K.+Wild&title=Identification+of+potent%2C+selective%2C+and+metabolically+stable+peptide+antagonists+to+the+calcitonin+gene-related+peptide+%28CGRP%29+receptor&doi=10.1021%2Fjm8009298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Potent, Selective, and Metabolically Stable Peptide Antagonists to the Calcitonin Gene-Related Peptide (CGRP) Receptor</span></div><div class="casAuthors">Miranda, Les P.; Holder, Jerry Ryan; Shi, Licheng; Bennett, Brian; Aral, Jennifer; Gegg, Colin V.; Wright, Marie; Walker, Kenneth; Doellgast, George; Rogers, Rick; Li, Hongyan; Valladares, Violeta; Salyers, Kevin; Johnson, Eileen; Wild, Kenneth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7889-7897</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Calcitonin gene-related peptide (CGRP) is a 37-residue neuropeptide that can be converted to a CGRP1 receptor antagonist by the truncation of its first seven residues. CGRP(8-37), 1, has a CGRP1 receptor Ki = 3.2 nM but is rapidly degraded in human plasma (t1/2 = 20 min).  As part of an effort to identify a prolonged in vivo circulating CGRP peptide antagonist, we found that the substitution of multiple residues in the CGRP peptide increased CGRP1 receptor affinity >50-fold. Ac-Trp-[Arg24,Lys25,Asp31,Pro34,Phe35]CGRP(8-37)-NH2, 5 (Ki = 0.06 nM) had the highest CGRP1 receptor affinity.  Using complimentary in vitro and in vivo metabolic studies, we iteratively identified degrdn. sites and prepd. high affinity analogs with significantly improved plasma stability. Ac-Trp-[Cit11,18,hArg24,Lys25,2-Nal27,37,Asp31,Oic29,34,Phe35]CGRP(8-37)-NH2, 32 (Ki = 3.3 nM), had significantly increased (>100-fold) stability over 1 or 5, with a cynomolgus monkey and human in vitro plasma half-life of 38 and 68 h, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquAzoOJ-KbSbVg90H21EOLACvtfcHk0lh8isnUFMKnQA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWks73F&md5=645a1a0cf1932380134858374093a0dd</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1021%2Fjm8009298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8009298%26sid%3Dliteratum%253Aachs%26aulast%3DMiranda%26aufirst%3DL.%2BP.%26aulast%3DHolder%26aufirst%3DJ.%2BR.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DBennett%26aufirst%3DB.%26aulast%3DAral%26aufirst%3DJ.%26aulast%3DGegg%26aufirst%3DC.%2BV.%26aulast%3DWright%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DK.%26aulast%3DDoellgast%26aufirst%3DG.%26aulast%3DRogers%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DValladares%26aufirst%3DV.%26aulast%3DSalyers%26aufirst%3DK.%26aulast%3DJohnson%26aufirst%3DE.%26aulast%3DWild%26aufirst%3DK.%26atitle%3DIdentification%2520of%2520potent%252C%2520selective%252C%2520and%2520metabolically%2520stable%2520peptide%2520antagonists%2520to%2520the%2520calcitonin%2520gene-related%2520peptide%2520%2528CGRP%2529%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7889%26epage%3D7897%26doi%3D10.1021%2Fjm8009298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group">Werner, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabalteja, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, W. S.</span><span> </span><span class="NLM_article-title">Peptide backbone composition and protease susceptibility: impact of modification type, position, and tandem substitution</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">712</span><span class="NLM_x">â</span> <span class="NLM_lpage">718</span><span class="refDoi">Â DOI: 10.1002/cbic.201500312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fcbic.201500312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26205791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlGrsLnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=712-718&author=H.+M.+Wernerauthor=C.+C.+Cabaltejaauthor=W.+S.+Horne&title=Peptide+backbone+composition+and+protease+susceptibility%3A+impact+of+modification+type%2C+position%2C+and+tandem+substitution&doi=10.1002%2Fcbic.201500312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide Backbone Composition and Protease Susceptibility: Impact of Modification Type, Position, and Tandem Substitution</span></div><div class="casAuthors">Werner, Halina M.; Cabalteja, Chino C.; Horne, W. Seth</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">712-718</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The clin. utility of peptides is limited by their rapid degrdn. by endogenous proteases.  Modification of the peptide backbone can generate functional analogs with enhanced proteolytic stability.  Existing principles for the design of such oligomers have focused primarily on effective structural mimicry.  A more robust strategy would incorporate a rational approach for engineering maximal proteolytic stability with minimal unnatural residue content.  We report here the systematic comparison of the proteolytic resistance imparted by four backbone modifications commonly employed in the design of protease-stable analogs of peptides with complex folding patterns.  The degree of protection was quantified as a function of modification type, position, and tandem substitution in the context of a long, unstructured host sequence and a canonical serine protease.  These results promise to inform ongoing work to develop biostable mimics of increasingly complex peptides and proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrscNXvr8vwrVg90H21EOLACvtfcHk0lh8isnUFMKnQA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlGrsLnM&md5=aed9ab7ba11cf7c774e8dbfd04194c6a</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201500312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201500312%26sid%3Dliteratum%253Aachs%26aulast%3DWerner%26aufirst%3DH.%2BM.%26aulast%3DCabalteja%26aufirst%3DC.%2BC.%26aulast%3DHorne%26aufirst%3DW.%2BS.%26atitle%3DPeptide%2520backbone%2520composition%2520and%2520protease%2520susceptibility%253A%2520impact%2520of%2520modification%2520type%252C%2520position%252C%2520and%2520tandem%2520substitution%26jtitle%3DChemBioChem%26date%3D2016%26volume%3D17%26spage%3D712%26epage%3D718%26doi%3D10.1002%2Fcbic.201500312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Taylor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beeg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canovi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gobbi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mann, D. M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allsop, D.</span><span> </span><span class="NLM_article-title">Development of a proteolytically stable retro-inverso peptide inhibitor of Î²-amyloid oligomerization as a potential novel treatment for Alzheimerâs Disease</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">3261</span><span class="NLM_x">â</span> <span class="NLM_lpage">3272</span><span class="refDoi">Â DOI: 10.1021/bi100144m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi100144m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=3261-3272&author=M.+Taylorauthor=S.+Mooreauthor=J.+Mayesauthor=E.+Parkinauthor=M.+Beegauthor=M.+Canoviauthor=M.+Gobbiauthor=D.+M.+A.+Mannauthor=D.+Allsop&title=Development+of+a+proteolytically+stable+retro-inverso+peptide+inhibitor+of+%CE%B2-amyloid+oligomerization+as+a+potential+novel+treatment+for+Alzheimer%E2%80%99s+Disease&doi=10.1021%2Fbi100144m"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128a&amp;dbid=16384&amp;doi=10.1021%2Fbi100144m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi100144m%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DMoore%26aufirst%3DS.%26aulast%3DMayes%26aufirst%3DJ.%26aulast%3DParkin%26aufirst%3DE.%26aulast%3DBeeg%26aufirst%3DM.%26aulast%3DCanovi%26aufirst%3DM.%26aulast%3DGobbi%26aufirst%3DM.%26aulast%3DMann%26aufirst%3DD.%2BM.%2BA.%26aulast%3DAllsop%26aufirst%3DD.%26atitle%3DDevelopment%2520of%2520a%2520proteolytically%2520stable%2520retro-inverso%2520peptide%2520inhibitor%2520of%2520%25CE%25B2-amyloid%2520oligomerization%2520as%2520a%2520potential%2520novel%2520treatment%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26spage%3D3261%26epage%3D3272%26doi%3D10.1021%2Fbi100144m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit128b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wei, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span> </span><span class="NLM_article-title">Retro-inverso isomer of Angiopep-2: a stable D-peptide ligand inspires brain-targeted drug delivery</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">3261</span><span class="NLM_x">â</span> <span class="NLM_lpage">3268</span><span class="refDoi">Â DOI: 10.1021/mp500086e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp500086e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref128/cit128b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltVShsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=3261-3268&author=X.+Weiauthor=C.+Zhanauthor=X.+Chenauthor=J.+Houauthor=C.+Xieauthor=W.+Lu&title=Retro-inverso+isomer+of+Angiopep-2%3A+a+stable+D-peptide+ligand+inspires+brain-targeted+drug+delivery&doi=10.1021%2Fmp500086e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128bR"><div class="casContent"><span class="casTitleNuber">128b</span><div class="casTitle"><span class="NLM_cas:atitle">Retro-Inverso Isomer of Angiopep-2: A Stable D-Peptide Ligand Inspires Brain-Targeted Drug Delivery</span></div><div class="casAuthors">Wei, Xiaoli; Zhan, Changyou; Chen, Xishan; Hou, Jiapeng; Xie, Cao; Lu, Weiyue</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3261-3268</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The blood-brain barrier (BBB) prevents most drugs from reaching the site of central nervous system (CNS) diseases, intensively confining the therapeutic efficiency.  Angiopep-2 (here termed LAngiopep), which is a 19-mer peptide derived from human Kunitz domain, can trigger transcytosis and traverse the BBB by recognizing low d. lipoprotein-related protein 1 (LRP-1) expressed on the brain capillary endothelial cells.  Various enzymes in the blood and the BBB, however, present multiple metabolic barriers to peptide-inspired brain-targeted drug delivery.  Here we designed a retro-inverso isomer of LAngiopep, termed DAngiopep, to inspire brain-targeted drug delivery.  Both DAngiopep and LAngiopep displayed high uptake capacity in LRP-1 overexpressed cells, including bEnd.3 and U87 cells.  DAngiopep demonstrated lower uptake efficiency in both cell lines than did LAngiopep, suggestive of lower binding affinity to LRP-1 of the D-peptide.  DAngiopep was resistant to proteolysis in fresh rat blood serum, while more than 85% of LAngiopep disappeared within 2 h.  Endocytosed DAngiopep and LAngiopep were found to be colocalized with lysosomal compartments of bEnd.3 cells, indicating that susceptibility to proteolysis of LAngiopep in the BBB may further attenuate its transcytosis efficiency.  In vivo, DAngiopep modified PEG-DSPE micelles displayed high distribution in normal brain and intracranial glioblastoma.  Due to the expression of LRP-1 on the BBB and glioblastoma cells, proteolytically stable DAngiopep holds much potential for designing two-order brain tumor targeted delivery systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsGrbQqL7YD7Vg90H21EOLACvtfcHk0lh8isnUFMKnQA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltVShsbo%253D&md5=272e5a2ec73d7114ee4ca492330761e0</span></div><a href="/servlet/linkout?suffix=cit128b&amp;dbid=16384&amp;doi=10.1021%2Fmp500086e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp500086e%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DX.%26aulast%3DZhan%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DW.%26atitle%3DRetro-inverso%2520isomer%2520of%2520Angiopep-2%253A%2520a%2520stable%2520D-peptide%2520ligand%2520inspires%2520brain-targeted%2520drug%2520delivery%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2014%26volume%3D11%26spage%3D3261%26epage%3D3268%26doi%3D10.1021%2Fmp500086e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group">Yamaguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jelokhani-Niaraki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, M.</span><span> </span><span class="NLM_article-title">Effect of Î±-Î±-dialkyl amino acids on the protease resistance of peptides</span> <span class="citation_source-journal">Biosci., Biotechnol., Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">2269</span><span class="NLM_x">â</span> <span class="NLM_lpage">2272</span><span class="refDoi">Â DOI: 10.1271/bbb.67.2269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1271%2Fbbb.67.2269" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2003&pages=2269-2272&author=H.+Yamaguchiauthor=H.+Kodamaauthor=S.+Osadaauthor=F.+Katoauthor=M.+Jelokhani-Niarakiauthor=M.+Kondo&title=Effect+of+%CE%B1-%CE%B1-dialkyl+amino+acids+on+the+protease+resistance+of+peptides&doi=10.1271%2Fbbb.67.2269"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1271%2Fbbb.67.2269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1271%252Fbbb.67.2269%26sid%3Dliteratum%253Aachs%26aulast%3DYamaguchi%26aufirst%3DH.%26aulast%3DKodama%26aufirst%3DH.%26aulast%3DOsada%26aufirst%3DS.%26aulast%3DKato%26aufirst%3DF.%26aulast%3DJelokhani-Niaraki%26aufirst%3DM.%26aulast%3DKondo%26aufirst%3DM.%26atitle%3DEffect%2520of%2520%25CE%25B1-%25CE%25B1-dialkyl%2520amino%2520acids%2520on%2520the%2520protease%2520resistance%2520of%2520peptides%26jtitle%3DBiosci.%252C%2520Biotechnol.%252C%2520Biochem.%26date%3D2003%26volume%3D67%26spage%3D2269%26epage%3D2272%26doi%3D10.1271%2Fbbb.67.2269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group">Grauer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">KÃ¶nig, B.</span><span> </span><span class="NLM_article-title">Peptidomimeticsâa versatile route to biologically active compounds</span> <span class="citation_source-journal">Eur. J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">2009</span><span class="NLM_x">, </span> <span class="NLM_fpage">5099</span><span class="NLM_x">â</span> <span class="NLM_lpage">5111</span><span class="refDoi">Â DOI: 10.1002/ejoc.200900599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fejoc.200900599" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2009&publication_year=2009&pages=5099-5111&author=A.+Grauerauthor=B.+K%C3%B6nig&title=Peptidomimetics%E2%80%93a+versatile+route+to+biologically+active+compounds&doi=10.1002%2Fejoc.200900599"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1002%2Fejoc.200900599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.200900599%26sid%3Dliteratum%253Aachs%26aulast%3DGrauer%26aufirst%3DA.%26aulast%3DK%25C3%25B6nig%26aufirst%3DB.%26atitle%3DPeptidomimetics%25E2%2580%2593a%2520versatile%2520route%2520to%2520biologically%2520active%2520compounds%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2009%26volume%3D2009%26spage%3D5099%26epage%3D5111%26doi%3D10.1002%2Fejoc.200900599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group">Liskamp, R. M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rijkers, D. T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruijtzer, J. A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemmink, J.</span><span> </span><span class="NLM_article-title">Peptides and proteins as a continuing exciting source of inspiration for peptidomimetics</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1626</span><span class="NLM_x">â</span> <span class="NLM_lpage">1653</span><span class="refDoi">Â DOI: 10.1002/cbic.201000717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fcbic.201000717" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=1626-1653&author=R.+M.+J.+Liskampauthor=D.+T.+S.+Rijkersauthor=J.+A.+W.+Kruijtzerauthor=J.+Kemmink&title=Peptides+and+proteins+as+a+continuing+exciting+source+of+inspiration+for+peptidomimetics&doi=10.1002%2Fcbic.201000717"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201000717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201000717%26sid%3Dliteratum%253Aachs%26aulast%3DLiskamp%26aufirst%3DR.%2BM.%2BJ.%26aulast%3DRijkers%26aufirst%3DD.%2BT.%2BS.%26aulast%3DKruijtzer%26aufirst%3DJ.%2BA.%2BW.%26aulast%3DKemmink%26aufirst%3DJ.%26atitle%3DPeptides%2520and%2520proteins%2520as%2520a%2520continuing%2520exciting%2520source%2520of%2520inspiration%2520for%2520peptidomimetics%26jtitle%3DChemBioChem%26date%3D2011%26volume%3D12%26spage%3D1626%26epage%3D1653%26doi%3D10.1002%2Fcbic.201000717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group">Chatterjee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rechenmacher, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, H.</span><span> </span><span class="NLM_article-title">N-Methylation of peptides and proteins: an important element for modulating biological functions</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">254</span><span class="NLM_x">â</span> <span class="NLM_lpage">269</span><span class="refDoi">Â DOI: 10.1002/anie.201205674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fanie.201205674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslSku7rJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=254-269&author=J.+Chatterjeeauthor=F.+Rechenmacherauthor=H.+Kessler&title=N-Methylation+of+peptides+and+proteins%3A+an+important+element+for+modulating+biological+functions&doi=10.1002%2Fanie.201205674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">N-Methylation of Peptides and Proteins: An Important Element for Modulating Biological Functions</span></div><div class="casAuthors">Chatterjee, Jayanta; Rechenmacher, Florian; Kessler, Horst</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">254-269</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  N-Methylation is one of the simplest chem. modifications often occurring in peptides and proteins of prokaryotes and higher eukaryotes.  Over years of evolution, nature has employed N-methylation of peptides as an ingenious technique to modulate biol. function, often as a mode of survival through the prodn. of antibiotics.  This small structural change can not only mobilize large protein complexes (as in the histone methylation), but also inhibits the action of enzymes by selective recognition of protein-protein interaction surfaces.  In recent years through the advancement in synthetic approaches, the potential of N-methylation has begun to be revealed, not only in modulating biol. activity and selectivity as well as pharmacokinetic properties of peptides, but also in delivering novel drugs.  Herein, we summarize the current knowledge of the versatility of N-methylation in modulating biol., structural, and pharmacokinetic properties of peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXes6IPzFfLbVg90H21EOLACvtfcHk0lizWkgVcZgkwA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslSku7rJ&md5=3b15b08b4fe59905acdb8dd47706577c</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1002%2Fanie.201205674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201205674%26sid%3Dliteratum%253Aachs%26aulast%3DChatterjee%26aufirst%3DJ.%26aulast%3DRechenmacher%26aufirst%3DF.%26aulast%3DKessler%26aufirst%3DH.%26atitle%3DN-Methylation%2520of%2520peptides%2520and%2520proteins%253A%2520an%2520important%2520element%2520for%2520modulating%2520biological%2520functions%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D254%26epage%3D269%26doi%3D10.1002%2Fanie.201205674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group">White, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renzelman, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rand, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rezai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McEwen, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelev, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linington, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, S. S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauman, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liras, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathiowetz, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lokey, R. S.</span><span> </span><span class="NLM_article-title">On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">810</span><span class="NLM_x">â</span> <span class="NLM_lpage">817</span><span class="refDoi">Â DOI: 10.1038/nchembio.664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnchembio.664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21946276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1anurjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=810-817&author=T.+R.+Whiteauthor=C.+M.+Renzelmanauthor=A.+C.+Randauthor=T.+Rezaiauthor=C.+M.+McEwenauthor=V.+M.+Gelevauthor=R.+A.+Turnerauthor=R.+G.+Liningtonauthor=S.+S.+F.+Leungauthor=A.+S.+Kalgutkarauthor=J.+N.+Baumanauthor=Y.+Zhangauthor=S.+Lirasauthor=D.+A.+Priceauthor=A.+M.+Mathiowetzauthor=M.+P.+Jacobsonauthor=R.+S.+Lokey&title=On-resin+N-methylation+of+cyclic+peptides+for+discovery+of+orally+bioavailable+scaffolds&doi=10.1038%2Fnchembio.664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds</span></div><div class="casAuthors">White, Tina R.; Renzelman, Chad M.; Rand, Arthur C.; Rezai, Taha; McEwen, Cayla M.; Gelev, Vladimir M.; Turner, Rushia A.; Linington, Roger G.; Leung, Siegfried S. F.; Kalgutkar, Amit S.; Bauman, Jonathan N.; Zhang, Yizhong; Liras, Spiros; Price, David A.; Mathiowetz, Alan M.; Jacobson, Matthew P.; Lokey, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">810-817</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Backbone N-methylation is common among peptide natural products and has a substantial impact on both the phys. properties and the conformational states of cyclic peptides.  However, the specific impact of N-methylation on passive membrane diffusion in cyclic peptides has not been investigated systematically.  Here we report a method for the selective, on-resin N-methylation of cyclic peptides to generate compds. with drug-like membrane permeability and oral bioavailability.  The selectivity and degree of N-methylation of the cyclic peptide was dependent on backbone stereochem., suggesting that conformation dictates the regiochem. of the N-methylation reaction.  The permeabilities of the N-Me variants were corroborated by computational studies on a 1024-member virtual library of N-Me cyclic peptides.  One of the most permeable compds., a cyclic hexapeptide (mol. mass = 755 Da) with three N-Me groups, showed an oral bioavailability of 28% in rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreigsRodBtOLVg90H21EOLACvtfcHk0lizWkgVcZgkwA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1anurjL&md5=6f9f01f4ab523bb46cc0198cc8f1c34e</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.664%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DT.%2BR.%26aulast%3DRenzelman%26aufirst%3DC.%2BM.%26aulast%3DRand%26aufirst%3DA.%2BC.%26aulast%3DRezai%26aufirst%3DT.%26aulast%3DMcEwen%26aufirst%3DC.%2BM.%26aulast%3DGelev%26aufirst%3DV.%2BM.%26aulast%3DTurner%26aufirst%3DR.%2BA.%26aulast%3DLinington%26aufirst%3DR.%2BG.%26aulast%3DLeung%26aufirst%3DS.%2BS.%2BF.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DBauman%26aufirst%3DJ.%2BN.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLiras%26aufirst%3DS.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DMathiowetz%26aufirst%3DA.%2BM.%26aulast%3DJacobson%26aufirst%3DM.%2BP.%26aulast%3DLokey%26aufirst%3DR.%2BS.%26atitle%3DOn-resin%2520N-methylation%2520of%2520cyclic%2520peptides%2520for%2520discovery%2520of%2520orally%2520bioavailable%2520scaffolds%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D810%26epage%3D817%26doi%3D10.1038%2Fnchembio.664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group">Cheloha, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gellman, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardella, T. J.</span><span> </span><span class="NLM_article-title">Backbone modification of a parathyroid hormone receptor-1 antagonist/inverse agonist</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2752</span><span class="NLM_x">â</span> <span class="NLM_lpage">2762</span><span class="refDoi">Â DOI: 10.1021/acschembio.6b00404</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.6b00404" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2752-2762&author=R.+W.+Chelohaauthor=T.+Watanabeauthor=T.+Deanauthor=S.+H.+Gellmanauthor=T.+J.+Gardella&title=Backbone+modification+of+a+parathyroid+hormone+receptor-1+antagonist%2Finverse+agonist&doi=10.1021%2Facschembio.6b00404"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1021%2Facschembio.6b00404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.6b00404%26sid%3Dliteratum%253Aachs%26aulast%3DCheloha%26aufirst%3DR.%2BW.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DDean%26aufirst%3DT.%26aulast%3DGellman%26aufirst%3DS.%2BH.%26aulast%3DGardella%26aufirst%3DT.%2BJ.%26atitle%3DBackbone%2520modification%2520of%2520a%2520parathyroid%2520hormone%2520receptor-1%2520antagonist%252Finverse%2520agonist%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26spage%3D2752%26epage%3D2762%26doi%3D10.1021%2Facschembio.6b00404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Simon, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuckermann, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huebner, V. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewell, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banville, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marlowe, C. K.</span><span> </span><span class="NLM_article-title">Peptoids: a modular approach to drug discovery</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">9367</span><span class="NLM_x">â</span> <span class="NLM_lpage">9371</span><span class="refDoi">Â DOI: 10.1073/pnas.89.20.9367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1073%2Fpnas.89.20.9367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1409642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADyaK3sXhtFKhsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1992&pages=9367-9371&author=R.+J.+Simonauthor=R.+S.+Kaniaauthor=R.+N.+Zuckermannauthor=V.+D.+Huebnerauthor=D.+A.+Jewellauthor=S.+Banvilleauthor=S.+Ngauthor=L.+Wangauthor=S.+Rosenbergauthor=C.+K.+Marlowe&title=Peptoids%3A+a+modular+approach+to+drug+discovery&doi=10.1073%2Fpnas.89.20.9367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135aR"><div class="casContent"><span class="casTitleNuber">135a</span><div class="casTitle"><span class="NLM_cas:atitle">Peptoids:  a modular approach to drug discovery</span></div><div class="casAuthors">Simon, Reyna J.; Kania, Robert S.; Zuckermann, Ronald N.; Huebner, Verena D.; Jewell, David A.; Banville, Steven; Ng, Simon; Wang, Liang; Rosenberg, Steven; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9367-71</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Peptoids, oligomers of N-substituted glycines, are described as a motif for the generation of chem. diverse libraries of novel mols.  Ramachandran-type plots were calcd. and indicate a greater diversity of conformational states available for peptoids than for peptides.  The monomers incorporate t-butyl-based side-chain and 9-fluorenylmethoxy-carbonyl Î±-amine protection.  The controlled oligomerization of the peptoid monomers was performed manually and robotically with in situ activation by either benzotriazol-1-yloxytris(pyrrolidino)phosphonium hexafluorophosphate or bromotris(pyrrolidino)phosphonium hexafluorophosphate.  Other steps were identical to peptide synthesis using Î±-(9-fluorenylmethoxycarbonyl)amino acids.  A total of 15 monomers and 10 oligomers (peptoids) are described.  Preliminary data are presented on the stability of a representative oligopeptoid to enzymic hydrolysis.  Peptoid versions of peptide ligands of three biol. systems (bovine pancreatic Î±-amylase, hepatitis A virus 3C proteinase, and human immunodeficiency virus transactivator-responsive element RNA) were found with affinities comparable to those of the corresponding peptides.  The potential use of libraries of these compds. in receptor- or enzyme-based assays is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqjYjAnzlZWbVg90H21EOLACvtfcHk0lgMtejYbT8c1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhtFKhsro%253D&md5=072eed656364cd7cf06c71aa9fb001c3</span></div><a href="/servlet/linkout?suffix=cit135a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.89.20.9367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.89.20.9367%26sid%3Dliteratum%253Aachs%26aulast%3DSimon%26aufirst%3DR.%2BJ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DZuckermann%26aufirst%3DR.%2BN.%26aulast%3DHuebner%26aufirst%3DV.%2BD.%26aulast%3DJewell%26aufirst%3DD.%2BA.%26aulast%3DBanville%26aufirst%3DS.%26aulast%3DNg%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DRosenberg%26aufirst%3DS.%26aulast%3DMarlowe%26aufirst%3DC.%2BK.%26atitle%3DPeptoids%253A%2520a%2520modular%2520approach%2520to%2520drug%2520discovery%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1992%26volume%3D89%26spage%3D9367%26epage%3D9371%26doi%3D10.1073%2Fpnas.89.20.9367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit135b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kruijtzer, J. A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nijenhuis, W. A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wanders, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gispen, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liskamp, R. M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adan, R. A. H.</span><span> </span><span class="NLM_article-title">Peptoid-peptide hybrids as potent novel melanocortin receptor ligands</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">4224</span><span class="NLM_x">â</span> <span class="NLM_lpage">4230</span><span class="refDoi">Â DOI: 10.1021/jm0490033</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0490033" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref135/cit135b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD2MXksVWrsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=4224-4230&author=J.+A.+W.+Kruijtzerauthor=W.+A.+J.+Nijenhuisauthor=N.+Wandersauthor=W.+H.+Gispenauthor=R.+M.+J.+Liskampauthor=R.+A.+H.+Adan&title=Peptoid-peptide+hybrids+as+potent+novel+melanocortin+receptor+ligands&doi=10.1021%2Fjm0490033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135bR"><div class="casContent"><span class="casTitleNuber">135b</span><div class="casTitle"><span class="NLM_cas:atitle">Peptoid-Peptide Hybrids as Potent Novel Melanocortin Receptor Ligands</span></div><div class="casAuthors">Kruijtzer, John A. W.; Nijenhuis, Wouter A. J.; Wanders, Nienke; Gispen, Willem Hendrik; Liskamp, Rob M. J.; Adan, Roger A. H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4224-4230</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">All possible peptoid-peptide (peptoid = N-substituted glycine oligomers) hybrids of an MC4 receptor agonist were synthesized and investigated on cells expressing different melanocortin (MC) receptor subtypes and for rat grooming behavior.  In general, receptor selectivity remained while affinity and potency were decreased.  The length of the functional group of tryptophan was more important for MC3 and MC5 than for MC4 receptor binding.  In general, relationship between potency of the peptoid-peptide hybrids and an increase in excessive rat grooming behavior correlated well with MC4 receptor pharmacol.  Thus, using the grooming assay in rats as a bioassay for MC4 receptor activity, the authors demonstrated that these ligands display in vivo efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8KQHlH7s0RrVg90H21EOLACvtfcHk0lgMtejYbT8c1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXksVWrsb4%253D&md5=67b2fdc833ed325fd6c3ec26c0cc505c</span></div><a href="/servlet/linkout?suffix=cit135b&amp;dbid=16384&amp;doi=10.1021%2Fjm0490033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0490033%26sid%3Dliteratum%253Aachs%26aulast%3DKruijtzer%26aufirst%3DJ.%2BA.%2BW.%26aulast%3DNijenhuis%26aufirst%3DW.%2BA.%2BJ.%26aulast%3DWanders%26aufirst%3DN.%26aulast%3DGispen%26aufirst%3DW.%2BH.%26aulast%3DLiskamp%26aufirst%3DR.%2BM.%2BJ.%26aulast%3DAdan%26aufirst%3DR.%2BA.%2BH.%26atitle%3DPeptoid-peptide%2520hybrids%2520as%2520potent%2520novel%2520melanocortin%2520receptor%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D4224%26epage%3D4230%26doi%3D10.1021%2Fjm0490033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group">Gao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodadek, T.</span><span> </span><span class="NLM_article-title">Synthesis and screening of stereochemically diverse combinatorial libraries of peptide tertiary amides</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">360</span><span class="NLM_x">â</span> <span class="NLM_lpage">369</span><span class="refDoi">Â DOI: 10.1016/j.chembiol.2013.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.chembiol.2013.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23521794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksFOksrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=360-369&author=Y.+Gaoauthor=T.+Kodadek&title=Synthesis+and+screening+of+stereochemically+diverse+combinatorial+libraries+of+peptide+tertiary+amides&doi=10.1016%2Fj.chembiol.2013.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Screening of Stereochemically Diverse Combinatorial Libraries of Peptide Tertiary Amides</span></div><div class="casAuthors">Gao, Yu; Kodadek, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">360-369</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Large combinatorial libraries of N-substituted peptides would be an attractive source of protein ligands, because these compds. are known to be conformationally constrained, whereas std. peptides or peptoids are conformationally mobile.  Here, the authors report an efficient submonomer solid-phase synthetic route to these compds. and demonstrate that it can be used to create high quality libraries.  A model screening expt. and anal. of the hits indicates that the rigidity afforded by the stereocenters is crit. for high affinity binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgGLnqMrBiJbVg90H21EOLACvtfcHk0lgMtejYbT8c1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksFOksrs%253D&md5=fd771da8d27285d9d75a9915613f329d</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2013.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2013.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DY.%26aulast%3DKodadek%26aufirst%3DT.%26atitle%3DSynthesis%2520and%2520screening%2520of%2520stereochemically%2520diverse%2520combinatorial%2520libraries%2520of%2520peptide%2520tertiary%2520amides%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D360%26epage%3D369%26doi%3D10.1016%2Fj.chembiol.2013.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group">Wisniewski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galyean, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tariga, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alagarsamy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croston, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heitzmann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisniewska, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laporte, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riviere, P. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schteingart, C. D.</span><span> </span><span class="NLM_article-title">New, Potent, Selective, and Short-Acting Peptidic V1a Receptor Agonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4388</span><span class="NLM_x">â</span> <span class="NLM_lpage">4398</span><span class="refDoi">Â DOI: 10.1021/jm200278m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200278m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4388-4398&author=K.+Wisniewskiauthor=R.+Galyeanauthor=H.+Tarigaauthor=S.+Alagarsamyauthor=G.+Crostonauthor=J.+Heitzmannauthor=A.+Kohanauthor=H.+Wisniewskaauthor=R.+Laporteauthor=P.+J.+M.+Riviereauthor=C.+D.+Schteingart&title=New%2C+Potent%2C+Selective%2C+and+Short-Acting+Peptidic+V1a+Receptor+Agonists&doi=10.1021%2Fjm200278m"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1021%2Fjm200278m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200278m%26sid%3Dliteratum%253Aachs%26aulast%3DWisniewski%26aufirst%3DK.%26aulast%3DGalyean%26aufirst%3DR.%26aulast%3DTariga%26aufirst%3DH.%26aulast%3DAlagarsamy%26aufirst%3DS.%26aulast%3DCroston%26aufirst%3DG.%26aulast%3DHeitzmann%26aufirst%3DJ.%26aulast%3DKohan%26aufirst%3DA.%26aulast%3DWisniewska%26aufirst%3DH.%26aulast%3DLaporte%26aufirst%3DR.%26aulast%3DRiviere%26aufirst%3DP.%2BJ.%2BM.%26aulast%3DSchteingart%26aufirst%3DC.%2BD.%26atitle%3DNew%252C%2520Potent%252C%2520Selective%252C%2520and%2520Short-Acting%2520Peptidic%2520V1a%2520Receptor%2520Agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4388%26epage%3D4398%26doi%3D10.1021%2Fjm200278m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Laporte, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heitzmann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisniewska, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tariga, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alagarsamy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dykert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisniewski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galyean, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croston, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schteingart, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riviere, P. J. M.</span><span> </span><span class="NLM_article-title">Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">337</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">â</span> <span class="NLM_lpage">796</span><span class="refDoi">Â DOI: 10.1124/jpet.111.178848</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1124%2Fjpet.111.178848" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21411496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFeiu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=2011&pages=786-796&author=R.+Laporteauthor=A.+Kohanauthor=J.+Heitzmannauthor=H.+Wisniewskaauthor=J.+Toyauthor=E.+Laauthor=H.+Tarigaauthor=S.+Alagarsamyauthor=B.+Lyauthor=J.+Dykertauthor=S.+Qiauthor=K.+Wisniewskiauthor=R.+Galyeanauthor=G.+Crostonauthor=C.+D.+Schteingartauthor=P.+J.+M.+Riviere&title=Pharmacological+characterization+of+FE+202158%2C+a+novel%2C+potent%2C+selective%2C+and+short-acting+peptidic+vasopressin+V1a+receptor+full+agonist+for+the+treatment+of+vasodilatory+hypotension&doi=10.1124%2Fjpet.111.178848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138aR"><div class="casContent"><span class="casTitleNuber">138a</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension</span></div><div class="casAuthors">Laporte, Regent; Kohan, Arash; Heitzmann, Joshua; Wisniewska, Halina; Toy, Jeannie; La, Erin; Tariga, Hiroe; Alagarsamy, Sudarkodi; Ly, Brian; Dykert, John; Qi, Steve; Wisniewski, Kazimierz; Galyean, Robert; Croston, Glenn; Schteingart, Claudio D.; Riviere, Pierre J.-M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">337</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">786-796</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">FE 202158, ([Phe2,Ile3,Hgn4,Orn(iPr)8]vasopressin, where Hgn is homoglutamine and iPr is isopropyl), a peptidic analog of the vasoconstrictor hormone [Arg8]vasopressin (AVP), was designed to be a potent, selective, and short-acting vasopressin type 1a receptor (V1aR) agonist.  In functional reporter gene assays, FE 202158 was a potent and selective human V1aR agonist [EC50 = 2.4 nM; selectivity ratio of 1:142:1107:440 vs. human vasopressin type 1b receptor, vasopressin type 2 receptor (V2R), and oxytocin receptor, resp.] contrasting with AVP's lack of selectivity, esp. vs. the V2R (selectivity ratio of 1:18:0.2:92; human V1aR EC50 = 0.24 nM).  This activity and selectivity profile was confirmed in radioligand binding assays.  FE 202158 was a potent vasoconstrictor in the isolated rat common iliac artery ex vivo (EC50 = 3.6 nM vs. 0.8 nM for AVP) and reduced rat ear skin blood flow after i.v. infusion in vivo (ED50 = 4.0 vs. 3.4 pmol/kg/min for AVP).  The duration of its vasopressor effect by i.v. bolus in rats was as short as AVP at submaximally EDs.  FE 202158 had no V2R-mediated antidiuretic activity in rats by i.v. infusion at its ED50 for redn. of ear skin blood flow, in contrast with the pronounced antidiuretic effect of AVP.  Thus, FE 202158 seems suitable for treatment of conditions where V1aR activity is desirable but V2R activity is potentially deleterious, such as vasodilatory hypotension in septic shock.  In addn. to the desirable selectivity profile, its short-acting nature should allow dose titrn. with rapid onset and offset of action to optimize vasoconstriction efficacy and safety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXthaAxU5z9bVg90H21EOLACvtfcHk0lhUBZGDTZhwEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFeiu70%253D&md5=b824019640b4954e5e290eead08f25c6</span></div><a href="/servlet/linkout?suffix=cit138a&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.178848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.178848%26sid%3Dliteratum%253Aachs%26aulast%3DLaporte%26aufirst%3DR.%26aulast%3DKohan%26aufirst%3DA.%26aulast%3DHeitzmann%26aufirst%3DJ.%26aulast%3DWisniewska%26aufirst%3DH.%26aulast%3DToy%26aufirst%3DJ.%26aulast%3DLa%26aufirst%3DE.%26aulast%3DTariga%26aufirst%3DH.%26aulast%3DAlagarsamy%26aufirst%3DS.%26aulast%3DLy%26aufirst%3DB.%26aulast%3DDykert%26aufirst%3DJ.%26aulast%3DQi%26aufirst%3DS.%26aulast%3DWisniewski%26aufirst%3DK.%26aulast%3DGalyean%26aufirst%3DR.%26aulast%3DCroston%26aufirst%3DG.%26aulast%3DSchteingart%26aufirst%3DC.%2BD.%26aulast%3DRiviere%26aufirst%3DP.%2BJ.%2BM.%26atitle%3DPharmacological%2520characterization%2520of%2520FE%2520202158%252C%2520a%2520novel%252C%2520potent%252C%2520selective%252C%2520and%2520short-acting%2520peptidic%2520vasopressin%2520V1a%2520receptor%2520full%2520agonist%2520for%2520the%2520treatment%2520of%2520vasodilatory%2520hypotension%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D337%26spage%3D786%26epage%3D796%26doi%3D10.1124%2Fjpet.111.178848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit138b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Maybauer, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maybauer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enkhbaatar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laporte, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisniewska, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traber, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisniewski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schteingart, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riviere, P. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traber, D. L.</span><span> </span><span class="NLM_article-title">The selective V(1a) receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis</span> <span class="citation_source-journal">Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">e525</span><span class="NLM_x">â</span> <span class="NLM_lpage">e533</span><span class="refDoi">Â DOI: 10.1097/CCM.0000000000000300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1097%2FCCM.0000000000000300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24674922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpvV2ksrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=e525-e533&author=M.+O.+Maybauerauthor=D.+M.+Maybauerauthor=P.+Enkhbaatarauthor=R.+Laporteauthor=H.+Wisniewskaauthor=L.+D.+Traberauthor=C.+Linauthor=J.+Fanauthor=H.+K.+Hawkinsauthor=R.+A.+Coxauthor=K.+Wisniewskiauthor=C.+D.+Schteingartauthor=D.+W.+Landryauthor=P.+J.+M.+Riviereauthor=D.+L.+Traber&title=The+selective+V%281a%29+receptor+agonist+selepressin+%28FE+202158%29+blocks+vascular+leak+in+ovine+severe+sepsis&doi=10.1097%2FCCM.0000000000000300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138bR"><div class="casContent"><span class="casTitleNuber">138b</span><div class="casTitle"><span class="NLM_cas:atitle">The Selective Vasopressin Type 1a Receptor Agonist Selepressin (FE 202158) Blocks Vascular Leak in Ovine Severe Sepsis</span></div><div class="casAuthors">Maybauer, Marc O.; Maybauer, Dirk M.; Enkhbaatar, Perenlei; Laporte, Regent; Wisniewska, Halina; Traber, Lillian D.; Lin, Chii Dean; Fan, Juanjuan; Hawkins, Hal K.; Cox, Robert A.; Wisniewski, Kazimierz; Schteingart, Claudio D.; Landry, Donald W.; Riviere, Pierre J.-M.; Traber, Daniel L.</div><div class="citationInfo"><span class="NLM_cas:title">Critical Care Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e525-e533</span>CODEN:
                <span class="NLM_cas:coden">CCMDC7</span>;
        ISSN:<span class="NLM_cas:issn">0090-3493</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objective: To det. if the selective vasopressin type 1a receptor agonist selepressin (FE 202158) is as effective as the mixed vasopressin type 1a receptor/vasopressin V2 receptor agonist vasopressor hormone arginine vasopressin when used as a titrated first-line vasopressor therapy in an ovine model of Pseudomonas aeruginosa pneumonia-induced severe sepsis.  Design: Prospective, randomized, controlled lab. expt.  Setting: University animal research facility.  Subjects: Forty-five chronically instrumented sheep.  Interventions: Sheep were anesthetized, insufflated with cooled cotton smoke via tracheostomy, and P. aeruginosa were instilled into their airways.  They were then placed on assisted ventilation, awakened, and resuscitated with lactated Ringer's soln. titrated to maintain hematocrit Â± 3% from baseline levels.  If, despite fluid management, mean arterial pressure fell by more than 10 mm Hg from baseline level, an addnl. continuous IV infusion of arginine vasopressin or selepressin was titrated to raise and maintain mean arterial pressure within no less than 10 mm Hg from baseline level.  Effects of combination treatment of selepressin with the selective vasopressin V2 receptor agonist desmopressin were similarly investigated.  Measurements and main results: In septic sheep, MAP fell by â¼30 mm Hg, systemic vascular resistance index decreased by â¼50%, and â¼7 L of fluid were retained over 24 h; this fluid accumulation was partially reduced by arginine vasopressin and almost completely blocked by selepressin; and combined infusion of selepressin and desmopressin increased fluid accumulation to levels similar to arginine vasopressin treatment.  Conclusions: Resuscitation with the selective vasopressin type 1a receptor agonist selepressin blocked vascular leak more effectively than the mixed vasopressin type 1a receptor/vasopressin V2 receptor agonist arginine vasopressin because of its lack of agonist activity at the vasopressin V2 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAuftCmhFxS7Vg90H21EOLACvtfcHk0lhUBZGDTZhwEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpvV2ksrY%253D&md5=3a836a08eed213d23f56db6c10a4f51b</span></div><a href="/servlet/linkout?suffix=cit138b&amp;dbid=16384&amp;doi=10.1097%2FCCM.0000000000000300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCCM.0000000000000300%26sid%3Dliteratum%253Aachs%26aulast%3DMaybauer%26aufirst%3DM.%2BO.%26aulast%3DMaybauer%26aufirst%3DD.%2BM.%26aulast%3DEnkhbaatar%26aufirst%3DP.%26aulast%3DLaporte%26aufirst%3DR.%26aulast%3DWisniewska%26aufirst%3DH.%26aulast%3DTraber%26aufirst%3DL.%2BD.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DHawkins%26aufirst%3DH.%2BK.%26aulast%3DCox%26aufirst%3DR.%2BA.%26aulast%3DWisniewski%26aufirst%3DK.%26aulast%3DSchteingart%26aufirst%3DC.%2BD.%26aulast%3DLandry%26aufirst%3DD.%2BW.%26aulast%3DRiviere%26aufirst%3DP.%2BJ.%2BM.%26aulast%3DTraber%26aufirst%3DD.%2BL.%26atitle%3DThe%2520selective%2520V%25281a%2529%2520receptor%2520agonist%2520selepressin%2520%2528FE%2520202158%2529%2520blocks%2520vascular%2520leak%2520in%2520ovine%2520severe%2520sepsis%26jtitle%3DCrit.%2520Care%2520Med.%26date%3D2014%26volume%3D42%26spage%3De525%26epage%3De533%26doi%3D10.1097%2FCCM.0000000000000300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group">Frey, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viaud, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subra, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cauquil, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guichou, J.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grassy, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavanieu, A.</span><span> </span><span class="NLM_article-title">Structure-activity relationships of Bak derived peptides: Affinity and specificity modulations by amino acid replacement</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">966</span><span class="NLM_x">â</span> <span class="NLM_lpage">972</span><span class="refDoi">Â DOI: 10.1016/j.ejmech.2007.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.ejmech.2007.06.008" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2008&pages=966-972&author=V.+Freyauthor=J.+Viaudauthor=G.+Subraauthor=N.+Cauquilauthor=J.-F.+Guichouauthor=P.+Casaraauthor=G.+R.+Grassyauthor=A.+Chavanieu&title=Structure-activity+relationships+of+Bak+derived+peptides%3A+Affinity+and+specificity+modulations+by+amino+acid+replacement&doi=10.1016%2Fj.ejmech.2007.06.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2007.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2007.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DFrey%26aufirst%3DV.%26aulast%3DViaud%26aufirst%3DJ.%26aulast%3DSubra%26aufirst%3DG.%26aulast%3DCauquil%26aufirst%3DN.%26aulast%3DGuichou%26aufirst%3DJ.-F.%26aulast%3DCasara%26aufirst%3DP.%26aulast%3DGrassy%26aufirst%3DG.%2BR.%26aulast%3DChavanieu%26aufirst%3DA.%26atitle%3DStructure-activity%2520relationships%2520of%2520Bak%2520derived%2520peptides%253A%2520Affinity%2520and%2520specificity%2520modulations%2520by%2520amino%2520acid%2520replacement%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2008%26volume%3D43%26spage%3D966%26epage%3D972%26doi%3D10.1016%2Fj.ejmech.2007.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group">Haskell-Luevano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toth, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boteju, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Job, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castrucci, A. M. d. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadley, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hruby, V. J.</span><span> </span><span class="NLM_article-title">Beta-methylation of the Phe7 and Trp9 melanotropin side chain pharmacophores affects ligand-receptor interactions and prolonged biological activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">2740</span><span class="NLM_x">â</span> <span class="NLM_lpage">2749</span><span class="refDoi">Â DOI: 10.1021/jm970018t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm970018t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=2740-2749&author=C.+Haskell-Luevanoauthor=K.+Tothauthor=L.+Botejuauthor=C.+Jobauthor=A.+M.+d.+L.+Castrucciauthor=M.+E.+Hadleyauthor=V.+J.+Hruby&title=Beta-methylation+of+the+Phe7+and+Trp9+melanotropin+side+chain+pharmacophores+affects+ligand-receptor+interactions+and+prolonged+biological+activity&doi=10.1021%2Fjm970018t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Fjm970018t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm970018t%26sid%3Dliteratum%253Aachs%26aulast%3DHaskell-Luevano%26aufirst%3DC.%26aulast%3DToth%26aufirst%3DK.%26aulast%3DBoteju%26aufirst%3DL.%26aulast%3DJob%26aufirst%3DC.%26aulast%3DCastrucci%26aufirst%3DA.%2BM.%2Bd.%2BL.%26aulast%3DHadley%26aufirst%3DM.%2BE.%26aulast%3DHruby%26aufirst%3DV.%2BJ.%26atitle%3DBeta-methylation%2520of%2520the%2520Phe7%2520and%2520Trp9%2520melanotropin%2520side%2520chain%2520pharmacophores%2520affects%2520ligand-receptor%2520interactions%2520and%2520prolonged%2520biological%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D2740%26epage%3D2749%26doi%3D10.1021%2Fjm970018t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group">Sadowsky, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gellman, S. H.</span><span> </span><span class="NLM_article-title">Exploration of backbone space in foldamers containing Î±- and Î²-amino acid residues: developing protease-resistant oligomers that bind tightly to the BH3-recognition cleft of Bcl-xL</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">903</span><span class="NLM_x">â</span> <span class="NLM_lpage">916</span><span class="refDoi">Â DOI: 10.1002/cbic.200600546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fcbic.200600546" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=903-916&author=J.+D.+Sadowskyauthor=J.+K.+Murrayauthor=Y.+Tomitaauthor=S.+H.+Gellman&title=Exploration+of+backbone+space+in+foldamers+containing+%CE%B1-+and+%CE%B2-amino+acid+residues%3A+developing+protease-resistant+oligomers+that+bind+tightly+to+the+BH3-recognition+cleft+of+Bcl-xL&doi=10.1002%2Fcbic.200600546"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1002%2Fcbic.200600546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.200600546%26sid%3Dliteratum%253Aachs%26aulast%3DSadowsky%26aufirst%3DJ.%2BD.%26aulast%3DMurray%26aufirst%3DJ.%2BK.%26aulast%3DTomita%26aufirst%3DY.%26aulast%3DGellman%26aufirst%3DS.%2BH.%26atitle%3DExploration%2520of%2520backbone%2520space%2520in%2520foldamers%2520containing%2520%25CE%25B1-%2520and%2520%25CE%25B2-amino%2520acid%2520residues%253A%2520developing%2520protease-resistant%2520oligomers%2520that%2520bind%2520tightly%2520to%2520the%2520BH3-recognition%2520cleft%2520of%2520Bcl-xL%26jtitle%3DChemBioChem%26date%3D2007%26volume%3D8%26spage%3D903%26epage%3D916%26doi%3D10.1002%2Fcbic.200600546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group">Finan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottaway, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smiley, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemmensen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabenne, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habegger, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandoval, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeley, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bleicher, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uhles, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riboulet, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hertel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebokova, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conde-Knape, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konkar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelfanov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfluger, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Tilve, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMarchi, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tschop, M. H.</span><span> </span><span class="NLM_article-title">A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">â</span> <span class="NLM_lpage">36</span><span class="refDoi">Â DOI: 10.1038/nm.3761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnm.3761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25485909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCks73J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=27-36&author=B.+Finanauthor=B.+Yangauthor=N.+Ottawayauthor=D.+L.+Smileyauthor=T.+Maauthor=C.+Clemmensenauthor=J.+Chabenneauthor=L.+Zhangauthor=K.+M.+Habeggerauthor=K.+Fischerauthor=J.+E.+Campbellauthor=D.+Sandovalauthor=R.+J.+Seeleyauthor=K.+Bleicherauthor=S.+Uhlesauthor=W.+Ribouletauthor=J.+Funkauthor=C.+Hertelauthor=S.+Belliauthor=E.+Sebokovaauthor=K.+Conde-Knapeauthor=A.+Konkarauthor=D.+J.+Druckerauthor=V.+Gelfanovauthor=P.+T.+Pflugerauthor=T.+D.+Mullerauthor=D.+Perez-Tilveauthor=R.+D.+DiMarchiauthor=M.+H.+Tschop&title=A+rationally+designed+monomeric+peptide+triagonist+corrects+obesity+and+diabetes+in+rodents&doi=10.1038%2Fnm.3761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents</span></div><div class="casAuthors">Finan, Brian; Yang, Bin; Ottaway, Nickki; Smiley, David L.; Ma, Tao; Clemmensen, Christoffer; Chabenne, Joe; Zhang, Lianshan; Habegger, Kirk M.; Fischer, Katrin; Campbell, Jonathan E.; Sandoval, Darleen; Seeley, Randy J.; Bleicher, Konrad; Uhles, Sabine; Riboulet, William; Funk, Juergen; Hertel, Cornelia; Belli, Sara; Sebokova, Elena; Conde-Knape, Karin; Konkar, Anish; Drucker, Daniel J.; Gelfanov, Vasily; Pfluger, Paul T.; Mueller, Timo D.; Perez-Tilve, Diego; Di Marchi, Richard D.; Tschoep, Matthias H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-36</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We report the discovery of a new monomeric peptide that reduces body wt. and diabetic complications in rodent models of obesity by acting as an agonist at three key metabolically-related peptide hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors.  This triple agonist demonstrates supraphysiol. potency and equally aligned constituent activities at each receptor, all without cross-reactivity at other related receptors.  Such balanced unimol. triple agonism proved superior to any existing dual coagonists and best-in-class monoagonists to reduce body wt., enhance glycemic control and reverse hepatic steatosis in relevant rodent models.  Various loss-of-function models, including genetic knockout, pharmacol. blockade and selective chem. knockout, confirmed contributions of each constituent activity in vivo.  We demonstrate that these individual constituent activities harmonize to govern the overall metabolic efficacy, which predominantly results from synergistic glucagon action to increase energy expenditure, GLP-1 action to reduce caloric intake and improve glucose control, and GIP action to potentiate the incretin effect and buffer against the diabetogenic effect of inherent glucagon activity.  These preclin. studies suggest that, so far, this unimol., polypharmaceutical strategy has potential to be the most effective pharmacol. approach to reversing obesity and related metabolic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDHrGvoJsN6LVg90H21EOLACvtfcHk0lhJk4XIbseKHA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCks73J&md5=9024ca9e43d498db95332d64e9e16039</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1038%2Fnm.3761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3761%26sid%3Dliteratum%253Aachs%26aulast%3DFinan%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DOttaway%26aufirst%3DN.%26aulast%3DSmiley%26aufirst%3DD.%2BL.%26aulast%3DMa%26aufirst%3DT.%26aulast%3DClemmensen%26aufirst%3DC.%26aulast%3DChabenne%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHabegger%26aufirst%3DK.%2BM.%26aulast%3DFischer%26aufirst%3DK.%26aulast%3DCampbell%26aufirst%3DJ.%2BE.%26aulast%3DSandoval%26aufirst%3DD.%26aulast%3DSeeley%26aufirst%3DR.%2BJ.%26aulast%3DBleicher%26aufirst%3DK.%26aulast%3DUhles%26aufirst%3DS.%26aulast%3DRiboulet%26aufirst%3DW.%26aulast%3DFunk%26aufirst%3DJ.%26aulast%3DHertel%26aufirst%3DC.%26aulast%3DBelli%26aufirst%3DS.%26aulast%3DSebokova%26aufirst%3DE.%26aulast%3DConde-Knape%26aufirst%3DK.%26aulast%3DKonkar%26aufirst%3DA.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DGelfanov%26aufirst%3DV.%26aulast%3DPfluger%26aufirst%3DP.%2BT.%26aulast%3DMuller%26aufirst%3DT.%2BD.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26aulast%3DTschop%26aufirst%3DM.%2BH.%26atitle%3DA%2520rationally%2520designed%2520monomeric%2520peptide%2520triagonist%2520corrects%2520obesity%2520and%2520diabetes%2520in%2520rodents%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D27%26epage%3D36%26doi%3D10.1038%2Fnm.3761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group">Rink, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arkema-Meter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baudoin, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuipers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelemans, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akanbi, M. H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moll, G. N.</span><span> </span><span class="NLM_article-title">To protect peptide pharmaceuticals against peptidases</span> <span class="citation_source-journal">J. Pharmacol. Toxicol. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">â</span> <span class="NLM_lpage">218</span><span class="refDoi">Â DOI: 10.1016/j.vascn.2010.02.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.vascn.2010.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=20176117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVeiur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2010&pages=210-218&author=R.+Rinkauthor=A.+Arkema-Meterauthor=I.+Baudoinauthor=E.+Postauthor=A.+Kuipersauthor=S.+A.+Nelemansauthor=M.+H.+J.+Akanbiauthor=G.+N.+Moll&title=To+protect+peptide+pharmaceuticals+against+peptidases&doi=10.1016%2Fj.vascn.2010.02.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">To protect peptide pharmaceuticals against peptidases</span></div><div class="casAuthors">Rink, R.; Arkema-Meter, A.; Baudoin, I.; Post, E.; Kuipers, A.; Nelemans, S. A.; Akanbi, M. Haas Jimoh; Moll, G. N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">210-218</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The major hurdle in the application and delivery of peptide pharmaceuticals is their rapid in vivo breakdown.  We here combined two approaches to stabilize peptide pharmaceuticals, introduction of D-amino acids and cyclization, by applying an innovative enzymic method.  This method yields peptides with thioether bridges between a D-amino acid and an L-amino acid.  On the basis of guidelines concerning the flanking residues of serines/threonines and cysteines, a peptide of interest is designed with serine/threonine and cysteine at appropriate positions to allow their effective participation in cyclization.  In Lactococcus lactis the peptide of interest is directly or via a spacer genetically fused to a lantibiotic leader peptide which induces enzyme-catalyzed synthesis of a thioether-bridged peptide.  The peptide is translocated via a lantibiotic transporter, analyzed by mass spectrometry and the leader peptide is removed.  Because of its therapeutic relevance and terminal modifications we chose the decapeptide LH Release Hormone (LHRH) as a test case for thioether bridge introduction.  The N-terminal pyroglutamate protects against aminopeptidase activity; the amidated C-terminus, which occurs in 50% of all therapeutic peptides, precludes carboxypeptidase action and is essential for optimal receptor interaction.  We had Lactococcus posttranslationally introduce a thioether bridge between residues 4 and 7 of the Leu7Cys-LHRH analog QHWSYGCRPG.  The N-terminal glutamine of the thioether-bridged peptide could be converted in pyroglutamate.  The introduction of the thioether bridge proved to be compatible with subsequent chem. and enzymic amidation methods.  In this way biol. produced thioether LHRH was compared with LHRH isomers obtained by base-assisted sulfur extrusion.  Biol. produced thioether LHRH is the most stable thioether LHRH isomer with strongly enhanced proteolytic resistance compared to natural LHRH.  The data convincingly demonstrate the broad perspective of stereo- and regiospecifically generating cyclized peptide pharmaceuticals with significantly enhanced therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK7a3wOuEsV7Vg90H21EOLACvtfcHk0liouIbH9-2Cfg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVeiur4%253D&md5=ffd248fb764e21d64e69d46269e7d122</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2010.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2010.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DRink%26aufirst%3DR.%26aulast%3DArkema-Meter%26aufirst%3DA.%26aulast%3DBaudoin%26aufirst%3DI.%26aulast%3DPost%26aufirst%3DE.%26aulast%3DKuipers%26aufirst%3DA.%26aulast%3DNelemans%26aufirst%3DS.%2BA.%26aulast%3DAkanbi%26aufirst%3DM.%2BH.%2BJ.%26aulast%3DMoll%26aufirst%3DG.%2BN.%26atitle%3DTo%2520protect%2520peptide%2520pharmaceuticals%2520against%2520peptidases%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2010%26volume%3D61%26spage%3D210%26epage%3D218%26doi%3D10.1016%2Fj.vascn.2010.02.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group">Ahn, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitu, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medeiros, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swift, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trivedi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hruby, V. J.</span><span> </span><span class="NLM_article-title">A new approach to search for the bioactive conformation of glucagon: positional cyclization scanning</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">3109</span><span class="NLM_x">â</span> <span class="NLM_lpage">3116</span><span class="refDoi">Â DOI: 10.1021/jm010091q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm010091q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=3109-3116&author=J.-M.+Ahnauthor=P.+M.+Gituauthor=M.+Medeirosauthor=J.+R.+Swiftauthor=D.+Trivediauthor=V.+J.+Hruby&title=A+new+approach+to+search+for+the+bioactive+conformation+of+glucagon%3A+positional+cyclization+scanning&doi=10.1021%2Fjm010091q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Fjm010091q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010091q%26sid%3Dliteratum%253Aachs%26aulast%3DAhn%26aufirst%3DJ.-M.%26aulast%3DGitu%26aufirst%3DP.%2BM.%26aulast%3DMedeiros%26aufirst%3DM.%26aulast%3DSwift%26aufirst%3DJ.%2BR.%26aulast%3DTrivedi%26aufirst%3DD.%26aulast%3DHruby%26aufirst%3DV.%2BJ.%26atitle%3DA%2520new%2520approach%2520to%2520search%2520for%2520the%2520bioactive%2520conformation%2520of%2520glucagon%253A%2520positional%2520cyclization%2520scanning%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D3109%26epage%3D3116%26doi%3D10.1021%2Fjm010091q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group">Hoang, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derksen, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edmonds, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kok, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Limberakis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liras, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loria, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mascitti, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathiowetz, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piotrowski, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanton, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suen, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Withka, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairlie, D. P.</span><span> </span><span class="NLM_article-title">Short hydrophobic peptides with cyclic constraints are potent glucagon-like peptide-1 receptor (GLP-1R) agonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4080</span><span class="NLM_x">â</span> <span class="NLM_lpage">4085</span><span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00166</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00166" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvValur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4080-4085&author=H.+N.+Hoangauthor=K.+Songauthor=T.+A.+Hillauthor=D.+R.+Derksenauthor=D.+J.+Edmondsauthor=W.+M.+Kokauthor=C.+Limberakisauthor=S.+Lirasauthor=P.+M.+Loriaauthor=V.+Mascittiauthor=A.+M.+Mathiowetzauthor=J.+M.+Mitchellauthor=D.+W.+Piotrowskiauthor=D.+A.+Priceauthor=R.+V.+Stantonauthor=J.+Y.+Suenauthor=J.+M.+Withkaauthor=D.+A.+Griffithauthor=D.+P.+Fairlie&title=Short+hydrophobic+peptides+with+cyclic+constraints+are+potent+glucagon-like+peptide-1+receptor+%28GLP-1R%29+agonists&doi=10.1021%2Facs.jmedchem.5b00166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Short Hydrophobic Peptides with Cyclic Constraints Are Potent Glucagon-like Peptide-1 Receptor (GLP-1R) Agonists</span></div><div class="casAuthors">Hoang, Huy N.; Song, Kun; Hill, Timothy A.; Derksen, David R.; Edmonds, David J.; Kok, W. Mei; Limberakis, Chris; Liras, Spiros; Loria, Paula M.; Mascitti, Vincent; Mathiowetz, Alan M.; Mitchell, Justin M.; Piotrowski, David W.; Price, David A.; Stanton, Robert V.; Suen, Jacky Y.; Withka, Jane M.; Griffith, David A.; Fairlie, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4080-4085</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclic constraints are incorporated into an 11-residue analog of the N-terminus of glucagon-like peptide-1 (GLP-1) to investigate effects of structure on agonist activity.  Cyclization through linking side chains of residues 2 and 5 or 5 and 9 produced agonists at nM concns. in a cAMP assay.  2D NMR and CD spectra revealed an N-terminal Î²-turn and a C-terminal helix that differentially influenced affinity and agonist potency.  These structures can inform development of small mol. agonists of the GLP-1 receptor to treat type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorlSFbD2Bjx7Vg90H21EOLACvtfcHk0liouIbH9-2Cfg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvValur8%253D&md5=f0bfe3a35cb0e6fa40d5c7ed0d9996c2</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00166%26sid%3Dliteratum%253Aachs%26aulast%3DHoang%26aufirst%3DH.%2BN.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DHill%26aufirst%3DT.%2BA.%26aulast%3DDerksen%26aufirst%3DD.%2BR.%26aulast%3DEdmonds%26aufirst%3DD.%2BJ.%26aulast%3DKok%26aufirst%3DW.%2BM.%26aulast%3DLimberakis%26aufirst%3DC.%26aulast%3DLiras%26aufirst%3DS.%26aulast%3DLoria%26aufirst%3DP.%2BM.%26aulast%3DMascitti%26aufirst%3DV.%26aulast%3DMathiowetz%26aufirst%3DA.%2BM.%26aulast%3DMitchell%26aufirst%3DJ.%2BM.%26aulast%3DPiotrowski%26aufirst%3DD.%2BW.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DStanton%26aufirst%3DR.%2BV.%26aulast%3DSuen%26aufirst%3DJ.%2BY.%26aulast%3DWithka%26aufirst%3DJ.%2BM.%26aulast%3DGriffith%26aufirst%3DD.%2BA.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26atitle%3DShort%2520hydrophobic%2520peptides%2520with%2520cyclic%2520constraints%2520are%2520potent%2520glucagon-like%2520peptide-1%2520receptor%2520%2528GLP-1R%2529%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4080%26epage%3D4085%26doi%3D10.1021%2Facs.jmedchem.5b00166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bird, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madani, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Princiotto, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavathiotis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sodroski, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walensky, L. D.</span><span> </span><span class="NLM_article-title">Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">14093</span><span class="NLM_x">â</span> <span class="NLM_lpage">14098</span><span class="refDoi">Â DOI: 10.1073/pnas.1002713107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1073%2Fpnas.1002713107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=20660316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVCktrfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=14093-14098&author=G.+H.+Birdauthor=N.+Madaniauthor=A.+F.+Perryauthor=A.+M.+Princiottoauthor=J.+G.+Supkoauthor=X.+Heauthor=E.+Gavathiotisauthor=J.+G.+Sodroskiauthor=L.+D.+Walensky&title=Hydrocarbon+double-stapling+remedies+the+proteolytic+instability+of+a+lengthy+peptide+therapeutic&doi=10.1073%2Fpnas.1002713107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146aR"><div class="casContent"><span class="casTitleNuber">146a</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic</span></div><div class="casAuthors">Bird, Gregory H.; Madani, Navid; Perry, Alisa F.; Princiotto, Amy M.; Supko, Jeffrey G.; He, Xiaoying; Gavathiotis, Evripidis; Sodroski, Joseph G.; Walensky, Loren D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">14093-14098, S14093/1-S14093/8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The pharmacol. utility of lengthy peptides can be hindered by loss of bioactive structure and rapid proteolysis, which limits bioavailability.  For example, enfuvirtide (Fuzeon, T20, DP178), a 36-amino acid peptide that inhibits human immunodeficiency virus type 1 (HIV-1) infection by effectively targeting the viral fusion app., has been relegated to a salvage treatment option mostly due to poor in vivo stability and lack of oral bioavailability.  To overcome the proteolytic shortcomings of long peptides as therapeutics, the authors examd. the biophys., biol., and pharmacol. impact of inserting all-hydrocarbon staples into an HIV-1 fusion inhibitor.  The authors find that peptide double-stapling confers striking protease resistance that translates into markedly improved pharmacokinetic properties, including oral absorption.  The authors detd. that the hydrocarbon staples create a proteolytic shield by combining reinforcement of overall Î±-helical structure, which slows the kinetics of proteolysis, with complete blockade of peptide cleavage at constrained sites in the immediate vicinity of the staple.  Importantly, double-stapling also optimizes the antiviral activity of HIV-1 fusion peptides and the antiproteolytic feature extends to other therapeutic peptide templates, such as the diabetes drug exenatide (Byetta).  Thus, hydrocarbon double-stapling may unlock the therapeutic potential of natural bioactive polypeptides by transforming them into structurally fortified agents with enhanced bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqme3pVM-fEB7Vg90H21EOLACvtfcHk0lhDZYecs6LL3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVCktrfJ&md5=95edd2112b56b564864e462eeb276e11</span></div><a href="/servlet/linkout?suffix=cit146a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1002713107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1002713107%26sid%3Dliteratum%253Aachs%26aulast%3DBird%26aufirst%3DG.%2BH.%26aulast%3DMadani%26aufirst%3DN.%26aulast%3DPerry%26aufirst%3DA.%2BF.%26aulast%3DPrinciotto%26aufirst%3DA.%2BM.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DGavathiotis%26aufirst%3DE.%26aulast%3DSodroski%26aufirst%3DJ.%2BG.%26aulast%3DWalensky%26aufirst%3DL.%2BD.%26atitle%3DHydrocarbon%2520double-stapling%2520remedies%2520the%2520proteolytic%2520instability%2520of%2520a%2520lengthy%2520peptide%2520therapeutic%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D14093%26epage%3D14098%26doi%3D10.1073%2Fpnas.1002713107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit146b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chang, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graves, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerlavais, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tovar, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Packman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">To, K.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesavan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gangurde, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukherjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darlak, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elkin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filipovic, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qureshi, F. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feyfant, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horstick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Annis, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fotouhi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nash, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vassilev, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span> </span><span class="NLM_article-title">Stapled Î±-helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">E3445</span><span class="NLM_x">â</span> <span class="NLM_lpage">E3454</span><span class="refDoi">Â DOI: 10.1073/pnas.1303002110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1073%2Fpnas.1303002110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23946421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVKksLfN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=E3445-E3454&author=Y.+S.+Changauthor=B.+Gravesauthor=V.+Guerlavaisauthor=C.+Tovarauthor=K.+Packmanauthor=K.-H.+Toauthor=K.+A.+Olsonauthor=K.+Kesavanauthor=P.+Gangurdeauthor=A.+Mukherjeeauthor=T.+Bakerauthor=K.+Darlakauthor=C.+Elkinauthor=Z.+Filipovicauthor=F.+Z.+Qureshiauthor=H.+Caiauthor=P.+Berryauthor=E.+Feyfantauthor=X.+E.+Shiauthor=J.+Horstickauthor=D.+A.+Annisauthor=A.+M.+Manningauthor=N.+Fotouhiauthor=H.+Nashauthor=L.+T.+Vassilevauthor=T.+K.+Sawyer&title=Stapled+%CE%B1-helical+peptide+drug+development%3A+A+potent+dual+inhibitor+of+MDM2+and+MDMX+for+p53-dependent+cancer+therapy&doi=10.1073%2Fpnas.1303002110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146bR"><div class="casContent"><span class="casTitleNuber">146b</span><div class="casTitle"><span class="NLM_cas:atitle">Stapled Î±-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy</span></div><div class="casAuthors">Chang, Yong S.; Graves, Bradford; Guerlavais, Vincent; Tovar, Christian; Packman, Kathryn; To, Kwong-Him; Olson, Karen A.; Kesavan, Kamala; Gangurde, Pranoti; Mukherjee, Aditi; Baker, Theresa; Darlak, Krzysztof; Elkin, Carl; Filipovic, Zoran; Qureshi, Farooq Z.; Cai, Hongliang; Berry, Pamela; Feyfant, Eric; Shi, Xiangguo E.; Horstick, James; Annis, D. Allen; Manning, Anthony M.; Fotouhi, Nader; Nash, Huw; Vassilev, Lyubomir T.; Sawyer, Tomi K.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">E3445-E3454,SE3445/1-SE3445/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Stapled Î±-helical peptides have emerged as a promising new modality for a wide range of therapeutic targets.  Here, we report a potent and selective dual inhibitor of MDM2 and MDMX, ATSP-7041, which effectively activates the p53 pathway in tumors in vitro and in vivo.  Specifically, ATSP-7041 binds both MDM2 and MDMX with nanomolar affinities, shows submicromolar cellular activities in cancer cell lines in the presence of serum, and demonstrates highly specific, on-target mechanism of action.  A high resoln. (1.7-Ã) X-ray crystal structure reveals its mol. interactions with the target protein MDMX, including multiple contacts with key amino acids as well as a role for the hydrocarbon staple itself in target engagement.  Most importantly, ATSP-7041 demonstrates robust p53-dependent tumor growth suppression in MDM2/MDMX-over-expressing xenograft cancer models, with a high correlation to on-target pharmacodynamic activity, and possesses favorable pharmacokinetic and tissue distribution properties.  Overall, ATSP-7041 demonstrates in vitro and in vivo proof-of-concept that stapled peptides can be developed as therapeutically relevant inhibitors of protein-protein interaction and may offer a viable modality for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFyYiS_tqgI7Vg90H21EOLACvtfcHk0lhDZYecs6LL3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVKksLfN&md5=c7533088eb02a6c38ffb31a91fae9e2e</span></div><a href="/servlet/linkout?suffix=cit146b&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1303002110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1303002110%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DY.%2BS.%26aulast%3DGraves%26aufirst%3DB.%26aulast%3DGuerlavais%26aufirst%3DV.%26aulast%3DTovar%26aufirst%3DC.%26aulast%3DPackman%26aufirst%3DK.%26aulast%3DTo%26aufirst%3DK.-H.%26aulast%3DOlson%26aufirst%3DK.%2BA.%26aulast%3DKesavan%26aufirst%3DK.%26aulast%3DGangurde%26aufirst%3DP.%26aulast%3DMukherjee%26aufirst%3DA.%26aulast%3DBaker%26aufirst%3DT.%26aulast%3DDarlak%26aufirst%3DK.%26aulast%3DElkin%26aufirst%3DC.%26aulast%3DFilipovic%26aufirst%3DZ.%26aulast%3DQureshi%26aufirst%3DF.%2BZ.%26aulast%3DCai%26aufirst%3DH.%26aulast%3DBerry%26aufirst%3DP.%26aulast%3DFeyfant%26aufirst%3DE.%26aulast%3DShi%26aufirst%3DX.%2BE.%26aulast%3DHorstick%26aufirst%3DJ.%26aulast%3DAnnis%26aufirst%3DD.%2BA.%26aulast%3DManning%26aufirst%3DA.%2BM.%26aulast%3DFotouhi%26aufirst%3DN.%26aulast%3DNash%26aufirst%3DH.%26aulast%3DVassilev%26aufirst%3DL.%2BT.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26atitle%3DStapled%2520%25CE%25B1-helical%2520peptide%2520drug%2520development%253A%2520A%2520potent%2520dual%2520inhibitor%2520of%2520MDM2%2520and%2520MDMX%2520for%2520p53-dependent%2520cancer%2520therapy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3DE3445%26epage%3DE3454%26doi%3D10.1073%2Fpnas.1303002110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit146c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Walensky, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bird, G. H.</span><span> </span><span class="NLM_article-title">Hydrocarbon-stapled peptides: principles, practice, and progress</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">6275</span><span class="NLM_x">â</span> <span class="NLM_lpage">6288</span><span class="refDoi">Â DOI: 10.1021/jm4011675</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4011675" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref146/cit146c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislensbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6275-6288&author=L.+D.+Walenskyauthor=G.+H.+Bird&title=Hydrocarbon-stapled+peptides%3A+principles%2C+practice%2C+and+progress&doi=10.1021%2Fjm4011675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146cR"><div class="casContent"><span class="casTitleNuber">146c</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrocarbon-Stapled Peptides: Principles, Practice, and Progress</span></div><div class="casAuthors">Walensky, Loren D.; Bird, Gregory H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6275-6288</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Protein structure underlies essential biol. processes and provides a blueprint for mol. mimicry that drives drug discovery.  Although small mols. represent the lion's share of agents that target proteins for therapeutic benefit, there remains no substitute for the natural properties of proteins and their peptide subunits in the majority of biol. contexts.  The peptide Î±-helix represents a common structural motif that mediates communication between signaling proteins.  Because peptides can lose their shape when taken out of context, developing chem. interventions to stabilize their bioactive structure remains an active area of research.  The all-hydrocarbon staple has emerged as one such soln., conferring Î±-helical structure, protease resistance, cellular penetrance, and biol. activity upon successful incorporation of a series of design and application principles.  Here, we describe our more than decade-long experience in developing stapled peptides as biomedical research tools and prototype therapeutics, highlighting lessons learned, pitfalls to avoid, and keys to success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC-4FlhgczWbVg90H21EOLACvtfcHk0lhDZYecs6LL3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislensbs%253D&md5=a2d11fd1668df5707099b94d2932d352</span></div><a href="/servlet/linkout?suffix=cit146c&amp;dbid=16384&amp;doi=10.1021%2Fjm4011675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4011675%26sid%3Dliteratum%253Aachs%26aulast%3DWalensky%26aufirst%3DL.%2BD.%26aulast%3DBird%26aufirst%3DG.%2BH.%26atitle%3DHydrocarbon-stapled%2520peptides%253A%2520principles%252C%2520practice%252C%2520and%2520progress%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6275%26epage%3D6288%26doi%3D10.1021%2Fjm4011675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meinhardt, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulkarni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Low, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeGrado, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenbaum, D. C.</span><span> </span><span class="NLM_article-title">Development of Î±-helical calpain probes by mimicking a natural protein-protein interaction</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">134</span><span class="NLM_x">, </span> <span class="NLM_fpage">17704</span><span class="NLM_x">â</span> <span class="NLM_lpage">17713</span><span class="refDoi">Â DOI: 10.1021/ja307599z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja307599z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2lsrfK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=17704-17713&author=H.+Joauthor=N.+Meinhardtauthor=Y.+Wuauthor=S.+Kulkarniauthor=X.+Huauthor=K.+E.+Lowauthor=P.+L.+Daviesauthor=W.+F.+DeGradoauthor=D.+C.+Greenbaum&title=Development+of+%CE%B1-helical+calpain+probes+by+mimicking+a+natural+protein-protein+interaction&doi=10.1021%2Fja307599z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147aR"><div class="casContent"><span class="casTitleNuber">147a</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Î±-Helical Calpain Probes by Mimicking a Natural Protein-Protein Interaction</span></div><div class="casAuthors">Jo, Hyunil; Meinhardt, Nataline; Wu, Yibing; Kulkarni, Swapnil; Hu, Xiaozhen; Low, Kristin E.; Davies, Peter L.; DeGrado, William F.; Greenbaum, Doron C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">17704-17713</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A highly specific inhibitor of calpain was designed by mimicking a natural protein-protein interaction between calpain and its endogenous inhibitor calpastatin.  To enable this goal a new method of stabilizing an Î±-helix in a small peptide was established by screening 24 com. available cross-linkers for successful cysteine alkylation in a model peptide sequence.  The effects of crosslinking on the Î±-helicity of selected peptides were examd. by CD and NMR spectroscopy, and revealed structurally rigid cross-linkers to be the best at stabilizing Î±-helixes.  This strategy was applied to the design of inhibitors of calpain that are based on calpastatin, an intrinsically unstable polypeptide that becomes structured upon binding to the enzyme.  A two-turn Î±-helix that binds proximal to the active site cleft was stabilized, resulting in a potent and selective inhibitor for calpain.  The utility of this inhibitor was further expanded by developing irreversible calpain family activity-based probes (ABPs), which retained the specificity of the stabilized helical inhibitor.  It is believed that the inhibitor and ABPs will be useful for future investigation of calpains, while the crosslinking technique will enable exploration of other protein-protein interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpigseq6FFUU7Vg90H21EOLACvtfcHk0lgUlzPRbgu2JA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2lsrfK&md5=2824ee6e61d4bb0e4202696fc57f1fa0</span></div><a href="/servlet/linkout?suffix=cit147a&amp;dbid=16384&amp;doi=10.1021%2Fja307599z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja307599z%26sid%3Dliteratum%253Aachs%26aulast%3DJo%26aufirst%3DH.%26aulast%3DMeinhardt%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DKulkarni%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DLow%26aufirst%3DK.%2BE.%26aulast%3DDavies%26aufirst%3DP.%2BL.%26aulast%3DDeGrado%26aufirst%3DW.%2BF.%26aulast%3DGreenbaum%26aufirst%3DD.%2BC.%26atitle%3DDevelopment%2520of%2520%25CE%25B1-helical%2520calpain%2520probes%2520by%2520mimicking%2520a%2520natural%2520protein-protein%2520interaction%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26spage%3D17704%26epage%3D17713%26doi%3D10.1021%2Fja307599z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit147b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fairlie, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dantas de Araujo, A.</span><span> </span><span class="NLM_article-title">Stapling peptides using cysteine crosslinking</span> <span class="citation_source-journal">Biopolymers</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">843</span><span class="NLM_x">â</span> <span class="NLM_lpage">852</span><span class="refDoi">Â DOI: 10.1002/bip.22877</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fbip.22877" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=27178225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFSlsbbF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2016&pages=843-852&author=D.+P.+Fairlieauthor=A.+Dantas+de+Araujo&title=Stapling+peptides+using+cysteine+crosslinking&doi=10.1002%2Fbip.22877"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147bR"><div class="casContent"><span class="casTitleNuber">147b</span><div class="casTitle"><span class="NLM_cas:atitle">Stapling peptides using cysteine crosslinking</span></div><div class="casAuthors">Fairlie, David P.; Dantas de Araujo, Aline</div><div class="citationInfo"><span class="NLM_cas:title">Biopolymers</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">843-852</span>CODEN:
                <span class="NLM_cas:coden">BIPMAA</span>;
        ISSN:<span class="NLM_cas:issn">0006-3525</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Stapled peptides are an emerging class of cyclic peptide mols. with enhanced biophys. properties such as conformational and proteolytic stability, cellular uptake and elevated binding affinity and specificity for their biol. targets.  Among the limited no. of chemistries available for their synthesis, the cysteine-based stapling strategy has received considerable development in the last few years driven by facile access from cysteine-functionalized peptide precursors.  Here we present some recent advances in peptide and protein stapling where the side-chains of cysteine residues are covalently connected with a range of different crosslinkers affording bisthioether macrocyclic peptides of varying topol. and biophys. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS9Pa86sKxKbVg90H21EOLACvtfcHk0lgUlzPRbgu2JA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFSlsbbF&md5=760b84de40576c35ceff56e1fb86f42b</span></div><a href="/servlet/linkout?suffix=cit147b&amp;dbid=16384&amp;doi=10.1002%2Fbip.22877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbip.22877%26sid%3Dliteratum%253Aachs%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26aulast%3DDantas%2Bde%2BAraujo%26aufirst%3DA.%26atitle%3DStapling%2520peptides%2520using%2520cysteine%2520crosslinking%26jtitle%3DBiopolymers%26date%3D2016%26volume%3D106%26spage%3D843%26epage%3D852%26doi%3D10.1002%2Fbip.22877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit147c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Diderich, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertoldo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dessen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pizzitola, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Held, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huelsken, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinis, C.</span><span> </span><span class="NLM_article-title">Phage selection of chemically stabilized Î±-helical peptide ligands</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1422</span><span class="NLM_x">â</span> <span class="NLM_lpage">1427</span><span class="refDoi">Â DOI: 10.1021/acschembio.5b00963</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00963" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XjsVagtr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1422-1427&author=P.+Diderichauthor=D.+Bertoldoauthor=P.+Dessenauthor=M.+M.+Khanauthor=I.+Pizzitolaauthor=W.+Heldauthor=J.+Huelskenauthor=C.+Heinis&title=Phage+selection+of+chemically+stabilized+%CE%B1-helical+peptide+ligands&doi=10.1021%2Facschembio.5b00963"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147cR"><div class="casContent"><span class="casTitleNuber">147c</span><div class="casTitle"><span class="NLM_cas:atitle">Phage Selection of Chemically Stabilized Î±-Helical Peptide Ligands</span></div><div class="casAuthors">Diderich, Philippe; Bertoldo, Davide; Dessen, Pierre; Khan, Maola M.; Pizzitola, Irene; Held, Werner; Huelsken, Joerg; Heinis, Christian</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1422-1427</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Short Î±-helical peptides stabilized by linkages between constituent amino acids offer an attractive format for ligand development.  In recent years, a range of excellent ligands based on stabilized Î±-helixes were generated by rational design using Î±-helical peptides of natural proteins as templates.  Herein, we developed a method to engineer chem. stabilized Î±-helical ligands in a combinatorial fashion.  In brief, peptides contg. cysteines in position i and i + 4 are genetically encoded by phage display, the cysteines are modified with chem. bridges to impose Î±-helical conformations, and binders are isolated by affinity selection.  We applied the strategy to affinity mature an Î±-helical peptide binding Î²-catenin.  We succeeded in developing ligands with Kd's as low as 5.2 nM, having >200-fold improved affinity.  The strategy is generally applicable for affinity maturation of any Î±-helical peptide.  Compared to hydrocarbon stapled peptides, the herein evolved thioether-bridged peptide ligands can be synthesized more easily, as no unnatural amino acids are required and the cyclization reaction is more efficient and yields no stereoisomers.  A further advantage of the thioether-bridged peptide ligands is that they can be expressed recombinantly as fusion proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXjSfa_cgePrVg90H21EOLACvtfcHk0lgUlzPRbgu2JA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjsVagtr8%253D&md5=a25d24d4733a0d89f4797c5313ef1870</span></div><a href="/servlet/linkout?suffix=cit147c&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00963%26sid%3Dliteratum%253Aachs%26aulast%3DDiderich%26aufirst%3DP.%26aulast%3DBertoldo%26aufirst%3DD.%26aulast%3DDessen%26aufirst%3DP.%26aulast%3DKhan%26aufirst%3DM.%2BM.%26aulast%3DPizzitola%26aufirst%3DI.%26aulast%3DHeld%26aufirst%3DW.%26aulast%3DHuelsken%26aufirst%3DJ.%26aulast%3DHeinis%26aufirst%3DC.%26atitle%3DPhage%2520selection%2520of%2520chemically%2520stabilized%2520%25CE%25B1-helical%2520peptide%2520ligands%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26spage%3D1422%26epage%3D1427%26doi%3D10.1021%2Facschembio.5b00963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertoldo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angelini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pojer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinis, C.</span><span> </span><span class="NLM_article-title">Peptide ligands stabilized by small molecules</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">1602</span><span class="NLM_x">â</span> <span class="NLM_lpage">1606</span><span class="refDoi">Â DOI: 10.1002/anie.201309459</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fanie.201309459" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVyltLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=1602-1606&author=S.+Chenauthor=D.+Bertoldoauthor=A.+Angeliniauthor=F.+Pojerauthor=C.+Heinis&title=Peptide+ligands+stabilized+by+small+molecules&doi=10.1002%2Fanie.201309459"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148aR"><div class="casContent"><span class="casTitleNuber">148a</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide Ligands Stabilized by Small Molecules</span></div><div class="casAuthors">Chen, Shiyu; Bertoldo, Davide; Angelini, Alessandro; Pojer, Florence; Heinis, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1602-1606</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Bicyclic peptides generated through directed evolution by using phage display offer an attractive ligand format for the development of therapeutics.  Being nearly 100-fold smaller than antibodies, they promise advantages such as access to chem. synthesis, efficient diffusion into tissues, and needle-free application.  However, unlike antibodies, they do not have a folded structure in soln. and thus do not bind as well as antibodies.  We developed bicyclic peptides with hydrophilic chem. structures at their center to promote noncovalent intramol. interactions, thereby stabilizing the peptide conformation.  The sequences of the peptides isolated by phage display from large combinatorial libraries were strongly influenced by the type of small mol. used in the screen, thus suggesting that the peptides fold around the small mols.  X-ray structure anal. revealed that the small mols. indeed formed hydrogen bonds with the peptides.  These noncovalent interactions stabilize the peptide-protein complexes and contribute to the high binding affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0-9uyjWceNrVg90H21EOLACvtfcHk0lhV3OKCR0LGuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVyltLc%253D&md5=4bc852345c54171bd8c7143a563bba2b</span></div><a href="/servlet/linkout?suffix=cit148a&amp;dbid=16384&amp;doi=10.1002%2Fanie.201309459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201309459%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DBertoldo%26aufirst%3DD.%26aulast%3DAngelini%26aufirst%3DA.%26aulast%3DPojer%26aufirst%3DF.%26aulast%3DHeinis%26aufirst%3DC.%26atitle%3DPeptide%2520ligands%2520stabilized%2520by%2520small%2520molecules%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D1602%26epage%3D1606%26doi%3D10.1002%2Fanie.201309459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit148b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Heinis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutherford, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freund, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winter, G.</span><span> </span><span class="NLM_article-title">Phage-encoded combinatorial chemical libraries based on bicyclic peptides</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">502</span><span class="NLM_x">â</span> <span class="NLM_lpage">507</span><span class="refDoi">Â DOI: 10.1038/nchembio.184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnchembio.184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=19483697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1altbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=502-507&author=C.+Heinisauthor=T.+Rutherfordauthor=S.+Freundauthor=G.+Winter&title=Phage-encoded+combinatorial+chemical+libraries+based+on+bicyclic+peptides&doi=10.1038%2Fnchembio.184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148bR"><div class="casContent"><span class="casTitleNuber">148b</span><div class="casTitle"><span class="NLM_cas:atitle">Phage-encoded combinatorial chemical libraries based on bicyclic peptides</span></div><div class="casAuthors">Heinis, Christian; Rutherford, Trevor; Freund, Stephan; Winter, Greg</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">502-507</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we describe a phage strategy for the selection of ligands based on bicyclic or linear peptides attached covalently to an org. core.  We designed peptide repertoires with three reactive cysteine residues, each spaced apart by several random amino acid residues, and we fused the repertoires to the phage gene-3-protein.  Conjugation with tris-(bromomethyl)benzene via the reactive cysteines generated repertoires of peptide conjugates with two peptide loops anchored to a mesitylene core.  Iterative affinity selections yielded several enzyme inhibitors; after further mutagenesis and selection, we were able to chem. synthesize a lead inhibitor (PK15; Ki = 1.5 nM) specific to human plasma kallikrein that efficiently interrupted the intrinsic coagulation pathway in human plasma tested ex vivo.  This approach offers a powerful means of generating and selecting bicyclic macrocycles (or if cleaved, linear derivs. thereof) as ligands poised at the interface of small-mol. drugs and biologics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZhJRZyldisLVg90H21EOLACvtfcHk0lhV3OKCR0LGuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1altbs%253D&md5=0634460f77b185fbcf85309c6dbf93e3</span></div><a href="/servlet/linkout?suffix=cit148b&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.184%26sid%3Dliteratum%253Aachs%26aulast%3DHeinis%26aufirst%3DC.%26aulast%3DRutherford%26aufirst%3DT.%26aulast%3DFreund%26aufirst%3DS.%26aulast%3DWinter%26aufirst%3DG.%26atitle%3DPhage-encoded%2520combinatorial%2520chemical%2520libraries%2520based%2520on%2520bicyclic%2520peptides%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26spage%3D502%26epage%3D507%26doi%3D10.1038%2Fnchembio.184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Vagner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hruby, V. J.</span><span> </span><span class="NLM_article-title">Peptidomimetics, a synthetic tool of drug discovery</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">292</span><span class="NLM_x">â</span> <span class="NLM_lpage">296</span><span class="refDoi">Â DOI: 10.1016/j.cbpa.2008.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.cbpa.2008.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=18423417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnt1ersro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2008&pages=292-296&author=J.+Vagnerauthor=H.+Quauthor=V.+J.+Hruby&title=Peptidomimetics%2C+a+synthetic+tool+of+drug+discovery&doi=10.1016%2Fj.cbpa.2008.03.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149aR"><div class="casContent"><span class="casTitleNuber">149a</span><div class="casTitle"><span class="NLM_cas:atitle">Peptidomimetics, a synthetic tool of drug discovery</span></div><div class="casAuthors">Vagner, Josef; Qu, Hongchang; Hruby, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">292-296</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The demand for modified peptides with improved stability profiles and pharmacokinetic properties is driving extensive research effort in this field.  Many structural modifications of peptides guided by rational design and mol. modeling have been established to develop novel synthetic approaches.  Recent advances in the synthesis of conformationally restricted building blocks and peptide bond isosteres are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9PN_EMokFKLVg90H21EOLACvtfcHk0lhV3OKCR0LGuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnt1ersro%253D&md5=f91110417f810711b46361ba0a620745</span></div><a href="/servlet/linkout?suffix=cit149a&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2008.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2008.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DVagner%26aufirst%3DJ.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DHruby%26aufirst%3DV.%2BJ.%26atitle%3DPeptidomimetics%252C%2520a%2520synthetic%2520tool%2520of%2520drug%2520discovery%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D12%26spage%3D292%26epage%3D296%26doi%3D10.1016%2Fj.cbpa.2008.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit149b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Cluzeau, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubell, W. D.</span><span> </span><span class="NLM_article-title">Design, synthesis, and application of azabicyclo[X.Y.0]alkanone amino acids as constrained dipeptide surrogates and peptide mimics</span> <span class="citation_source-journal">Biopolymers</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">98</span><span class="NLM_x">â</span> <span class="NLM_lpage">150</span><span class="refDoi">Â DOI: 10.1002/bip.20213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fbip.20213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=15795926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktFersrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2005&pages=98-150&author=J.+Cluzeauauthor=W.+D.+Lubell&title=Design%2C+synthesis%2C+and+application+of+azabicyclo%5BX.Y.0%5Dalkanone+amino+acids+as+constrained+dipeptide+surrogates+and+peptide+mimics&doi=10.1002%2Fbip.20213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149bR"><div class="casContent"><span class="casTitleNuber">149b</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and application of azabicyclo[X.Y.O]alkanone amino acids as constrained dipeptide surrogates and peptide mimics</span></div><div class="casAuthors">Cluzeau, Jerome; Lubell, William D.</div><div class="citationInfo"><span class="NLM_cas:title">Biopolymers</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">2 and 3</span>),
    <span class="NLM_cas:pages">98-150</span>CODEN:
                <span class="NLM_cas:coden">BIPMAA</span>;
        ISSN:<span class="NLM_cas:issn">0006-3525</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Azabicyclo[X.Y.O]alkanone amino acids are challenging synthetic targets and useful tools for studying structure-activity relationships of native peptide ligands.  They have been employed to increase potency and stability in conformationally rigid enzyme inhibitors and receptor ligands.  Since last reviewed in 1997, activity in their synthesis and application has increased significantly and access is now available to a wider diversity of these peptide mimics.  This review focuses on recent syntheses of these heterocyclic amino acids and their application in the investigation of biol. active peptides and peptide mimics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6RqlEjRVDmbVg90H21EOLACvtfcHk0lhV3OKCR0LGuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktFersrY%253D&md5=49ebf2c9a45d2a83e7a69fd822f4f72a</span></div><a href="/servlet/linkout?suffix=cit149b&amp;dbid=16384&amp;doi=10.1002%2Fbip.20213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbip.20213%26sid%3Dliteratum%253Aachs%26aulast%3DCluzeau%26aufirst%3DJ.%26aulast%3DLubell%26aufirst%3DW.%2BD.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520application%2520of%2520azabicyclo%255BX.Y.0%255Dalkanone%2520amino%2520acids%2520as%2520constrained%2520dipeptide%2520surrogates%2520and%2520peptide%2520mimics%26jtitle%3DBiopolymers%26date%3D2005%26volume%3D80%26spage%3D98%26epage%3D150%26doi%3D10.1002%2Fbip.20213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group">Wisskirchen, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doyle, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gough, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, I.</span><span> </span><span class="NLM_article-title">Conformational restraints revealing bioactive Î²-bend structures for hÎ± CGRP8â37 at the CGRP2 receptor of the rat prostatic vas deferens</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">1163</span><span class="NLM_x">â</span> <span class="NLM_lpage">1170</span><span class="refDoi">Â DOI: 10.1038/sj.bjp.0702432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fsj.bjp.0702432" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10205004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADyaK1MXitFGhsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=1999&pages=1163-1170&author=F.+M.+Wisskirchenauthor=P.+M.+Doyleauthor=S.+L.+Goughauthor=C.+J.+Harrisauthor=I.+Marshall&title=Conformational+restraints+revealing+bioactive+%CE%B2-bend+structures+for+h%CE%B1+CGRP8%E2%80%9337+at+the+CGRP2+receptor+of+the+rat+prostatic+vas+deferens&doi=10.1038%2Fsj.bjp.0702432"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational restraints revealing bioactive Î²-bend structures for hÎ± CGRP8-37 at the CGRP2 receptor of the rat prostatic vas deferens</span></div><div class="casAuthors">Wisskirchen, F. M.; Doyle, P. M.; Gough, S. L.; Harris, C. J.; Marshall, I.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1163-1170</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">The main aim of this study was to identify putative Î²-bends and the role of the N- and C-terminus in the CGRP receptor antagonist hÎ± CGRP8-37, which was measured against hÎ± CGRP inhibition of twitch responses in the rat prostatic vas deferens.  With a bend-biasing residue (proline) at position 16 in hÎ± CGRP8-37 (10-5 M) an inactive compd. was produced, while alanine at the same position retained antagonist activity (apparent pKB 5.6 at 10-5 M).  Proline at position 19 within hÎ± CGRP8-37 (10-5 M) was an antagonist (apparent pKB 5.8).  Incorporation of a bend-forcing structure (beta-turn dipeptide or BTD) at either positions 19,20 or 33,34 in hÎ± CGRP8-37 (10-5 M) antagonized hÎ± CGRP responses (apparent pKB 6.0 and 6.1, resp.).  Replacement by BTD at both positions 19,20 and 33,34 within hÎ± CGRP8-37 competitively antagonized responses to hÎ± CGRP (pA2 6.2; Schild plot slope 1.0).  The hÎ± CGRP8-37 analogs (10-5 M), substituted at the N-terminus by either glycine8, or des-NH2 valine8 or proline8 were all antagonists against hÎ± CGRP (apparent pKB 6.1, 6.5 and 6.1, resp.), while hÎ± CGRP8-37 (10-5 M) substituted in three places by proline8 and glutamic acid10,14 was inactive.  Replacement of the C-terminus by alanine amide37 in hÎ± CGRP8-37 (10-5 M) failed to antagonize hÎ± CGRP responses.  Peptidase inhibitors did not alter either the agonist potency of hÎ± CGRP or the antagonist affinities of hÎ± CGRP8-37 BTD19,20 and 33,34 and hÎ± CGRP8-37 Gly8 (against hÎ± CGRP responses).  In conclusion, two Î²-bends at positions 18-21 and 32-35 are compatible with high affinity by BTD and is the first approach of modeling the bioactive structure of hÎ± CGRP8-37.  Further, the N-terminus of hÎ± CGRP8-37 is not essential for antagonism, while the C-terminus interacts directly with CGRP receptor binding sites of the rat vas deferens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5SjNK0UAAS7Vg90H21EOLACvtfcHk0livZsCqoJzrzQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXitFGhsrk%253D&md5=05b7dc0ca5ad40dee39491c9013a93b0</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0702432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0702432%26sid%3Dliteratum%253Aachs%26aulast%3DWisskirchen%26aufirst%3DF.%2BM.%26aulast%3DDoyle%26aufirst%3DP.%2BM.%26aulast%3DGough%26aufirst%3DS.%2BL.%26aulast%3DHarris%26aufirst%3DC.%2BJ.%26aulast%3DMarshall%26aufirst%3DI.%26atitle%3DConformational%2520restraints%2520revealing%2520bioactive%2520%25CE%25B2-bend%2520structures%2520for%2520h%25CE%25B1%2520CGRP8%25E2%2580%259337%2520at%2520the%2520CGRP2%2520receptor%2520of%2520the%2520rat%2520prostatic%2520vas%2520deferens%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1999%26volume%3D126%26spage%3D1163%26epage%3D1170%26doi%3D10.1038%2Fsj.bjp.0702432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yan, L. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothstein, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flora, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaughn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemens-Smith, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarty, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKnight, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nisenbaum, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, J. P.</span><span> </span><span class="NLM_article-title">Discovery of potent, cyclic calcitonin gene-related peptide receptor antagonists</span> <span class="citation_source-journal">J. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">383</span><span class="NLM_x">â</span> <span class="NLM_lpage">386</span><span class="refDoi">Â DOI: 10.1002/psc.1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fpsc.1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21412957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktlyqu7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=383-386&author=L.+Z.+Yanauthor=K.+W.+Johnsonauthor=E.+Rothsteinauthor=D.+Floraauthor=P.+Edwardsauthor=B.+Liauthor=J.+Liauthor=R.+Lynchauthor=R.+Vaughnauthor=A.+Clemens-Smithauthor=D.+McCartyauthor=C.+Chowauthor=K.+L.+McKnightauthor=J.+Luauthor=E.+S.+Nisenbaumauthor=J.+P.+Mayer&title=Discovery+of+potent%2C+cyclic+calcitonin+gene-related+peptide+receptor+antagonists&doi=10.1002%2Fpsc.1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151aR"><div class="casContent"><span class="casTitleNuber">151a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent, cyclic calcitonin gene-related peptide receptor antagonists</span></div><div class="casAuthors">Yan, Liang-Zeng; Johnson, Kirk W.; Rothstein, Emily; Flora, David; Edwards, Patrick; Li, Bao-Lin; Li, Jun-Qing; Lynch, Renee; Vaughn, Renee; Clemens-Smith, Amy; McCarty, Deborah; Chow, Charles; McKnight, Kevin L.; Lu, Ji-Rong; Nisenbaum, Eric S.; Mayer, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">383-386</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Calcitonin gene-related peptide (CGRP), a potent dilator of cerebral and dural vasculature, is known to be elevated in plasma and cerebral spinal fluid during migraine attacks.  Selective blockade of the CGRP receptor offers the promise of controlling migraine headache more effectively and without the side-effects assocd. with the use of triptans.  Our efforts to develop a novel, peptide-based CGRP antagonist focused on the C-terminal portion of the peptide which is known to bind the receptor but lack agonist properties.  Extensive SAR studies of the C-terminal CGRP (27-37) region identified a novel cyclic structure: Bz-Val-Tyr-cyclo[Cys-Thr-Asp-Val-Gly-Pro-Phe-Cys]-Phe-NH2 (23) with a kb value of 0.126 nM against the cloned human CGRP receptor.  Addnl. SAR studies directed at enhancement of potency and improvement of physicochem. properties yielded a series of analogs with kb values in the 0.05-0.10 nM range.  Copyright Â© 2011 European Peptide Society and John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7kDX4nryKprVg90H21EOLACvtfcHk0livZsCqoJzrzQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktlyqu7Y%253D&md5=ce930ff219638d47e733fce510cd8965</span></div><a href="/servlet/linkout?suffix=cit151a&amp;dbid=16384&amp;doi=10.1002%2Fpsc.1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.1358%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DL.%2BZ.%26aulast%3DJohnson%26aufirst%3DK.%2BW.%26aulast%3DRothstein%26aufirst%3DE.%26aulast%3DFlora%26aufirst%3DD.%26aulast%3DEdwards%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLynch%26aufirst%3DR.%26aulast%3DVaughn%26aufirst%3DR.%26aulast%3DClemens-Smith%26aufirst%3DA.%26aulast%3DMcCarty%26aufirst%3DD.%26aulast%3DChow%26aufirst%3DC.%26aulast%3DMcKnight%26aufirst%3DK.%2BL.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DNisenbaum%26aufirst%3DE.%2BS.%26aulast%3DMayer%26aufirst%3DJ.%2BP.%26atitle%3DDiscovery%2520of%2520potent%252C%2520cyclic%2520calcitonin%2520gene-related%2520peptide%2520receptor%2520antagonists%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2011%26volume%3D17%26spage%3D383%26epage%3D386%26doi%3D10.1002%2Fpsc.1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit151b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mroz, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Tilve, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelfanov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMarchi, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, J. P.</span><span> </span><span class="NLM_article-title">Pyridyl-alanine as a hydrophilic, aromatic element in peptide structural optimization</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">8061</span><span class="NLM_x">â</span> <span class="NLM_lpage">8067</span><span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00840</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00840" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8061-8067&author=P.+A.+Mrozauthor=D.+Perez-Tilveauthor=F.+Liuauthor=V.+Gelfanovauthor=R.+D.+DiMarchiauthor=J.+P.+Mayer&title=Pyridyl-alanine+as+a+hydrophilic%2C+aromatic+element+in+peptide+structural+optimization&doi=10.1021%2Facs.jmedchem.6b00840"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00840%26sid%3Dliteratum%253Aachs%26aulast%3DMroz%26aufirst%3DP.%2BA.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DGelfanov%26aufirst%3DV.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26aulast%3DMayer%26aufirst%3DJ.%2BP.%26atitle%3DPyridyl-alanine%2520as%2520a%2520hydrophilic%252C%2520aromatic%2520element%2520in%2520peptide%2520structural%2520optimization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8061%26epage%3D8067%26doi%3D10.1021%2Facs.jmedchem.6b00840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group">LehÃ r, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avery, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heilbut, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansen, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rickles, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Short, G. F.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staunton, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borisy, A. A.</span><span> </span><span class="NLM_article-title">Synergistic drug combinations improve therapeutic selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">659</span><span class="NLM_x">â</span> <span class="NLM_lpage">666</span><span class="refDoi">Â DOI: 10.1038/nbt.1549</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnbt.1549" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=659-666&author=J.+Leh%C3%A0rauthor=A.+S.+Kruegerauthor=W.+Averyauthor=A.+M.+Heilbutauthor=L.+M.+Johansenauthor=E.+R.+Priceauthor=R.+J.+Ricklesauthor=G.+F.+Shortauthor=J.+E.+Stauntonauthor=X.+Jinauthor=M.+S.+Leeauthor=G.+R.+Zimmermannauthor=A.+A.+Borisy&title=Synergistic+drug+combinations+improve+therapeutic+selectivity&doi=10.1038%2Fnbt.1549"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1549%26sid%3Dliteratum%253Aachs%26aulast%3DLeh%25C3%25A0r%26aufirst%3DJ.%26aulast%3DKrueger%26aufirst%3DA.%2BS.%26aulast%3DAvery%26aufirst%3DW.%26aulast%3DHeilbut%26aufirst%3DA.%2BM.%26aulast%3DJohansen%26aufirst%3DL.%2BM.%26aulast%3DPrice%26aufirst%3DE.%2BR.%26aulast%3DRickles%26aufirst%3DR.%2BJ.%26aulast%3DShort%26aufirst%3DG.%2BF.%26aulast%3DStaunton%26aufirst%3DJ.%2BE.%26aulast%3DJin%26aufirst%3DX.%26aulast%3DLee%26aufirst%3DM.%2BS.%26aulast%3DZimmermann%26aufirst%3DG.%2BR.%26aulast%3DBorisy%26aufirst%3DA.%2BA.%26atitle%3DSynergistic%2520drug%2520combinations%2520improve%2520therapeutic%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2009%26volume%3D27%26spage%3D659%26epage%3D666%26doi%3D10.1038%2Fnbt.1549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group">Jaquet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saveanu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dufour, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enjalbert, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Culler, M. D.</span><span> </span><span class="NLM_article-title">Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy</span> <span class="citation_source-journal">Eur. J. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">153</span><span class="NLM_x">, </span> <span class="NLM_fpage">135</span><span class="NLM_x">â</span> <span class="NLM_lpage">141</span><span class="refDoi">Â DOI: 10.1530/eje.1.01950</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1530%2Feje.1.01950" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=15994755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntValu74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=2005&pages=135-141&author=P.+Jaquetauthor=G.+Gunzauthor=A.+Saveanuauthor=H.+Dufourauthor=J.+Taylorauthor=J.+Dongauthor=S.+Kimauthor=J.+P.+Moreauauthor=A.+Enjalbertauthor=M.+D.+Culler&title=Efficacy+of+chimeric+molecules+directed+towards+multiple+somatostatin+and+dopamine+receptors+on+inhibition+of+GH+and+prolactin+secretion+from+GH-secreting+pituitary+adenomas+classified+as+partially+responsive+to+somatostatin+analog+therapy&doi=10.1530%2Feje.1.01950"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy</span></div><div class="casAuthors">Jaquet, P.; Gunz, G.; Saveanu, A.; Dufour, H.; Taylor, J.; Dong, J.; Kim, S.; Moreau, J.-P.; Enjalbert, A.; Culler, M. D.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Endocrinology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">135-141</span>CODEN:
                <span class="NLM_cas:coden">EJOEEP</span>;
        ISSN:<span class="NLM_cas:issn">0804-4643</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">Objective: This study compared the potency of a somatostatin receptor (sstr)2-sstr5 analog, BIM-23244, of an sstr2-dopamine D2 receptor (sstr2-DAD2) mol.  BIM-23A387 and of new somatostatin-dopamine chimeric mols. with differing, enhanced affinities for sstr2, sstr5 and DAD2, BIM-23A758, BIM-23A760 and BIM-23A761, to suppress GH and prolactin (PRL) from 18 human GH adenomas that are partially responsive to octreotide or lanreotide.  Materials and methods: The sstr2, sstr5 and DAD2 mRNA levels were detd. by RT-PCR.  The effect of drugs was tested in cell cultures at various concns.  Results: In all tumors, the sstr2, sstr5 and DAD2 mRNA levels were coexpressed (mean levelsÂ±S.E.M. 0.4Â±0.1, 5.3Â±1.9 and 2.0Â±0.4 copy/copy Î²-glucuronidase).  In 13 tumors, the maximal suppression of GH secretion produced by BIM-23A387 (30Â±3%) and BIM-23244 (28Â±3%) was greater than that produced by octreotide (23Â±3%).  In six out of 13 tumors, BIM-23A758, BIM-23A760 and BIM-23A761 produced greater maximal suppression of GH secretion than octreotide (33Â±5, 38Â±2 and 41Â±2 vs 24Â±2%).  Their EC50 values were 10, 2 and 4 pmol/l.  BIM-23A761 was more effective than BIM-23A387 in GH suppression (41Â±2 vs 32Â±4%).  The new chimeric mols. produced maximal PRL suppression greater than octreotide (62Â±8 to 74Â±5 vs 46Â±11%).  Conclusions: Novel dopamine-somatostatin chimeric mols. with differing, enhanced activity at sstr2, sstr5 and DAD2, consistently produced significantly greater suppression of GH and PRL than either octreotide or single-receptor-interacting ligands in tumors from patients classified as only partially responsive to octreotide therapy.  The higher efficacy of the chimeric compds. was, at least partially, linked to their high affinity for sstr2 (IC50 1-10 pmol/l).  The other mechanisms by which such mols. produce an enhanced inhibition of GH remain to be elucidated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmn3zwGYcxHrVg90H21EOLACvtfcHk0lh8svSMYMVfQA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntValu74%253D&md5=bbff388a99d71dab35591d870abc94d4</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1530%2Feje.1.01950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252Feje.1.01950%26sid%3Dliteratum%253Aachs%26aulast%3DJaquet%26aufirst%3DP.%26aulast%3DGunz%26aufirst%3DG.%26aulast%3DSaveanu%26aufirst%3DA.%26aulast%3DDufour%26aufirst%3DH.%26aulast%3DTaylor%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DMoreau%26aufirst%3DJ.%2BP.%26aulast%3DEnjalbert%26aufirst%3DA.%26aulast%3DCuller%26aufirst%3DM.%2BD.%26atitle%3DEfficacy%2520of%2520chimeric%2520molecules%2520directed%2520towards%2520multiple%2520somatostatin%2520and%2520dopamine%2520receptors%2520on%2520inhibition%2520of%2520GH%2520and%2520prolactin%2520secretion%2520from%2520GH-secreting%2520pituitary%2520adenomas%2520classified%2520as%2520partially%2520responsive%2520to%2520somatostatin%2520analog%2520therapy%26jtitle%3DEur.%2520J.%2520Endocrinol.%26date%3D2005%26volume%3D153%26spage%3D135%26epage%3D141%26doi%3D10.1530%2Feje.1.01950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span>Clinical information can be found at: NCT00994214: Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients with Acromegaly (TULIPIA); <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="https://www.clinicaltrials.gov/" class="extLink">https://www.clinicaltrials.gov/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical+information+can+be+found+at%3A+NCT00994214%3A+Study+to+Assess+the+Efficacy+and+Safety+of+Repeated+Administration+of+BIM+23A760+in+Patients+with+Acromegaly+%28TULIPIA%29%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2015%3B+https%3A%2F%2Fwww.clinicaltrials.gov%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DNCT00994214%253A%2520Study%2520to%2520Assess%2520the%2520Efficacy%2520and%2520Safety%2520of%2520Repeated%2520Administration%2520of%2520BIM%252023A760%2520in%2520Patients%2520with%2520Acromegaly%2520%2528TULIPIA%2529%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group">Doppalapudi, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desharnais, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shields, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Del Rosario, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oates, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ainekulu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradshaw, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodnutt, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lappe, R. W.</span><span> </span><span class="NLM_article-title">Chemical generation of bispecific antibodies</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">22611</span><span class="NLM_x">â</span> <span class="NLM_lpage">22616</span><span class="refDoi">Â DOI: 10.1073/pnas.1016478108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1073%2Fpnas.1016478108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21149738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkt1KktQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=22611-22616&author=V.+R.+Doppalapudiauthor=J.+Huangauthor=D.+Liuauthor=P.+Jinauthor=B.+Liuauthor=L.+Liauthor=J.+Desharnaisauthor=C.+Hagenauthor=N.+J.+Levinauthor=M.+J.+Shieldsauthor=M.+Parishauthor=R.+E.+Murphyauthor=J.+Del+Rosarioauthor=B.+D.+Oatesauthor=J.-Y.+Laiauthor=M.+J.+Matinauthor=Z.+Ainekuluauthor=A.+Bhatauthor=C.+W.+Bradshawauthor=G.+Woodnuttauthor=R.+A.+Lernerauthor=R.+W.+Lappe&title=Chemical+generation+of+bispecific+antibodies&doi=10.1073%2Fpnas.1016478108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical generation of bispecific antibodies</span></div><div class="casAuthors">Doppalapudi, Venkata R.; Huang, Jie; Liu, Dingguo; Jin, Ping; Liu, Bin; Li, Lingna; Desharnais, Joel; Hagen, Crystal; Levin, Nancy J.; Shields, Michael J.; Parish, Michelle; Murphy, Robert E.; Del Rosario, Joselyn; Oates, Ryan D.; Lai, Jing-Yu; Matin, Maria J.; Ainekulu, Zemeda; Bhat, Abhijit; Bradshaw, Curt W.; Woodnutt, Gary; Lerner, Richard A.; Lappe, Rodney W.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">22611-22616, S22611/1-S22611/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Bispecific antibodies (BsAbs) are regarded as promising therapeutic agents due to their ability to simultaneously bind two different antigens.  Several bispecific modalities have been developed, but their utility is limited due to problems with stability and manufg. complexity.  Here the authors report a versatile technol., based. on a scaffold antibody and pharmacophore peptide heterodimers, that enables rapid generation and chem. optimization of bispecific antibodies, which are termed bispecific CovX-Bodies.  Two different peptides are joined together using a branched azetidinone linker and fused to the scaffold antibody under mild conditions in a site-specific manner.  Whereas the pharmacophores are responsible for functional activities, the antibody scaffold imparts long half-life and Ig-like distribution.  The pharmacophores can be chem. optimized or replaced with other pharmacophores to generate optimized or unique bispecific antibodies.  As a prototype, the authors developed a bispecific antibody that binds both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2) simultaneously, inhibits their function, shows efficacy in tumor xenograft studies, and greatly augments the antitumor effects of std. chemotherapy.  This unique antiangiogenic bispecific antibody is in phase-1 clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4Ar3x3pjLJLVg90H21EOLACvtfcHk0lh8svSMYMVfQA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkt1KktQ%253D%253D&md5=007967df39ca1f43798f9e8f3c78dc66</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1016478108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1016478108%26sid%3Dliteratum%253Aachs%26aulast%3DDoppalapudi%26aufirst%3DV.%2BR.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DJin%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DDesharnais%26aufirst%3DJ.%26aulast%3DHagen%26aufirst%3DC.%26aulast%3DLevin%26aufirst%3DN.%2BJ.%26aulast%3DShields%26aufirst%3DM.%2BJ.%26aulast%3DParish%26aufirst%3DM.%26aulast%3DMurphy%26aufirst%3DR.%2BE.%26aulast%3DDel%2BRosario%26aufirst%3DJ.%26aulast%3DOates%26aufirst%3DB.%2BD.%26aulast%3DLai%26aufirst%3DJ.-Y.%26aulast%3DMatin%26aufirst%3DM.%2BJ.%26aulast%3DAinekulu%26aufirst%3DZ.%26aulast%3DBhat%26aufirst%3DA.%26aulast%3DBradshaw%26aufirst%3DC.%2BW.%26aulast%3DWoodnutt%26aufirst%3DG.%26aulast%3DLerner%26aufirst%3DR.%2BA.%26aulast%3DLappe%26aufirst%3DR.%2BW.%26atitle%3DChemical%2520generation%2520of%2520bispecific%2520antibodies%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D22611%26epage%3D22616%26doi%3D10.1073%2Fpnas.1016478108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span>Clinical information can be found at: NCT01004822: A Safety, Tolerability, And Pharmacokinetic Trial with CVX-241 in Patients with Advanced Solid Tumors; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="https://www.clinicaltrials.gov/" class="extLink">https://www.clinicaltrials.gov/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical+information+can+be+found+at%3A+NCT01004822%3A+A+Safety%2C+Tolerability%2C+And+Pharmacokinetic+Trial+with+CVX-241+in+Patients+with+Advanced+Solid+Tumors%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2015%3B+https%3A%2F%2Fwww.clinicaltrials.gov%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DNCT01004822%253A%2520A%2520Safety%252C%2520Tolerability%252C%2520And%2520Pharmacokinetic%2520Trial%2520with%2520CVX-241%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group">Jimenez-Solem, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knop, F. K.</span><span> </span><span class="NLM_article-title">Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes</span> <span class="citation_source-journal">Curr. Opin. Mol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">790</span><span class="NLM_x">â</span> <span class="NLM_lpage">797</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21154170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvVeksrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=790-797&author=E.+Jimenez-Solemauthor=M.+H.+Rasmussenauthor=M.+Christensenauthor=F.+K.+Knop&title=Dulaglutide%2C+a+long-acting+GLP-1+analog+fused+with+an+Fc+antibody+fragment+for+the+potential+treatment+of+type+2+diabetes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes</span></div><div class="casAuthors">Jimenez-Solem, Espen; Rasmussen, Mette H.; Christensen, Mikkel; Knop, Filip K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Molecular Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">790-797</span>CODEN:
                <span class="NLM_cas:coden">CUOTFO</span>;
        ISSN:<span class="NLM_cas:issn">2040-3445</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Dulaglutide (LY-2189265) is a novel, long-acting glucagon-like peptide 1 (GLP-1) analog being developed by Eli Lilly for the treatment of type 2 diabetes mellitus (T2DM).  Dulaglutide consists of GLP-l(7-37) covalently linked to an Fc fragment of human IgG4, thereby protecting the GLP-1 molety from inactivation by dipeptidyl peptidase 4.  In vitro and in vivo studies on T2DM models demonstrated glucose-dependent insulin secretion stimulation.  Pharmacokinetic studies demonstrated a t1/2 in humans of up to 90 h, making Dulaglutide an ideal candidate for once-weekly dosing.  Clin. trials suggest that Dulaglutide reduces plasma glucose, and has an insulinotropic effect increasing insulin and C-peptide levels.  Two phase II clin. trials demonstrated a dose-dependent redn. in glycated Hb (HbA1c) of up to 1.52% compared with placebo.  Side effects assocd. with Dulaglutide administration were mainly gastrointestinal.  To date, there have been no reports on the formation of antibodies against Dulaglutide, but, clearly, long-term data will be needed to asses this and other possible side effects.  The results of several phase III clin. trials are awaited for clarification of the expected effects on HbA1c and body wt.  If Dulaglutide possesses similar efficacy to other GLP-1 analogs, the once-weekly treatment will most likely be welcomed by patients with T2DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjpD7tpjLtmLVg90H21EOLACvtfcHk0lhWR0cCgtawlw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvVeksrs%253D&md5=977fe1f57be3b777d64b2652c4e4b390</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJimenez-Solem%26aufirst%3DE.%26aulast%3DRasmussen%26aufirst%3DM.%2BH.%26aulast%3DChristensen%26aufirst%3DM.%26aulast%3DKnop%26aufirst%3DF.%2BK.%26atitle%3DDulaglutide%252C%2520a%2520long-acting%2520GLP-1%2520analog%2520fused%2520with%2520an%2520Fc%2520antibody%2520fragment%2520for%2520the%2520potential%2520treatment%2520of%2520type%25202%2520diabetes%26jtitle%3DCurr.%2520Opin.%2520Mol.%2520Ther.%26date%3D2010%26volume%3D12%26spage%3D790%26epage%3D797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group">Sleep, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, L. R.</span><span> </span><span class="NLM_article-title">Albumin as a versatile platform for drug half-life extension</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Gen. Subj.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1830</span><span class="NLM_x">, </span> <span class="NLM_fpage">5526</span><span class="NLM_x">â</span> <span class="NLM_lpage">5534</span><span class="refDoi">Â DOI: 10.1016/j.bbagen.2013.04.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.bbagen.2013.04.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23639804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXot1Cjsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1830&publication_year=2013&pages=5526-5534&author=D.+Sleepauthor=J.+Cameronauthor=L.+R.+Evans&title=Albumin+as+a+versatile+platform+for+drug+half-life+extension&doi=10.1016%2Fj.bbagen.2013.04.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Albumin as a versatile platform for drug half-life extension</span></div><div class="casAuthors">Sleep, Darrell; Cameron, Jason; Evans, Leslie R.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1830</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5526-5534</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Albumin is the most abundant plasma protein, is highly sol., very stable and has an extraordinarily long circulatory half-life as a direct result of its size and interaction with the FcRn mediated recycling pathway.  In contrast, many therapeutic mols. are smaller than the renal filtration threshold and are rapidly lost from the circulation thereby limiting their therapeutic potential.  Albumin can be used in a variety of ways to increase the circulatory half-life of such mols.  This article will review the mechanisms which underpin albumin's extraordinarily long circulatory half-life and how the understanding of these processes are currently being employed to extend the circulatory half-life of drugs which can be engineered to bind to albumin, or are conjugated to, or genetically fused to, albumin.  The recent and growing understanding of the pivotal role of FcRn in maintaining the extended circulatory half-life of albumin will necessitate a greater and more thorough investigation of suitable pre-clin. model systems for assessing the pharmacokinetic profiles of drugs assocd., conjugated or fused to albumin.  Assocn., conjugation or fusion of therapeutic drugs to albumin is a well-accepted and established half-life extension technol.  The manipulation of the albumin-FcRn interaction will facilitate the modulation of the circulatory half-life of albumin-enabled drugs, leading to superior pharmacokinetics tailored to the disease state and increased patient compliance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpExYMlo75ySLVg90H21EOLACvtfcHk0lhWR0cCgtawlw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXot1Cjsr4%253D&md5=0e4c382f353eef14774c423dcb3d1963</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2013.04.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2013.04.023%26sid%3Dliteratum%253Aachs%26aulast%3DSleep%26aufirst%3DD.%26aulast%3DCameron%26aufirst%3DJ.%26aulast%3DEvans%26aufirst%3DL.%2BR.%26atitle%3DAlbumin%2520as%2520a%2520versatile%2520platform%2520for%2520drug%2520half-life%2520extension%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2013%26volume%3D1830%26spage%3D5526%26epage%3D5534%26doi%3D10.1016%2Fj.bbagen.2013.04.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group">Matthews, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Boever, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobbins, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodge, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holland, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, M. A.</span><span> </span><span class="NLM_article-title">Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">4810</span><span class="NLM_x">â</span> <span class="NLM_lpage">4817</span><span class="refDoi">Â DOI: 10.1210/jc.2008-1518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1210%2Fjc.2008-1518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=18812476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVyqtbvL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2008&pages=4810-4817&author=J.+E.+Matthewsauthor=M.+W.+Stewartauthor=E.+H.+De+Boeverauthor=R.+L.+Dobbinsauthor=R.+J.+Hodgeauthor=S.+E.+Walkerauthor=M.+C.+Hollandauthor=M.+A.+Bush&title=Pharmacodynamics%2C+pharmacokinetics%2C+safety%2C+and+tolerability+of+albiglutide%2C+a+long-acting+glucagon-like+peptide-1+mimetic%2C+in+patients+with+type+2+diabetes&doi=10.1210%2Fjc.2008-1518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes</span></div><div class="casAuthors">Matthews, Jessica E.; Stewart, Murray W.; De Boever, Erika H.; Dobbins, Robert L.; Hodge, Rebecca J.; Walker, Susan E.; Holland, M. Claire; Bush, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4810-4817</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Native glucagon-like peptide-1 increases insulin secretion, decreases glucagon secretion, and reduces appetite but is rapidly inactivated by dipeptidyl peptidase-4.  Albiglutide is a novel dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin designed to have sustained efficacy in vivo.  The objectives were to investigate pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide in type 2 diabetes subjects.  In a single-blind dose-escalation study, 54 subjects were randomized to receive placebo or 9-, 16-, or 32-mg albiglutide on days 1 and 8.  In a complementary study, 46 subjects were randomized to a single dose (16 or 64 mg) of albiglutide to the arm, leg, or abdomen.  Significant dose-dependent redns. in 24-h mean weighted glucose [area under the curve(0-24 h)] were obsd., with placebo-adjusted least squares means difference values in the 32-mg cohort of -34.8 and -56.4 mg/dL [95% confidence interval (-54.1, -15.5) and (-82.2, -30.5)] for d 2 and 9, resp.  Placebo-adjusted fasting plasma glucose decreased by -26.7 and -50.7 mg/dL [95% confidence interval (-46.3, -7.06) and (-75.4, -26.0)] on d 2 and 9, resp.  Postprandial glucose was also reduced.  No hypoglycemic episodes were detected in the albiglutide cohorts.  The frequency and severity of the most common adverse events, headache and nausea, were comparable with placebo controls.  Albiglutide half-life ranged between 6 and 7 days.  The pharmacokinetics or pharmacodynamic of albiglutide was unaffected by injection site.  Albiglutide improved fasting plasma glucose and postprandial glucose with a favorable safety profile in subjects with type 2 diabetes.  Albiglutide's long half-life may allow for once-weekly or less frequent dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIft4D7voTHbVg90H21EOLACvtfcHk0lhWR0cCgtawlw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVyqtbvL&md5=cd4b4f2ce8c2684a2a37f0c841b80c00</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1210%2Fjc.2008-1518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2008-1518%26sid%3Dliteratum%253Aachs%26aulast%3DMatthews%26aufirst%3DJ.%2BE.%26aulast%3DStewart%26aufirst%3DM.%2BW.%26aulast%3DDe%2BBoever%26aufirst%3DE.%2BH.%26aulast%3DDobbins%26aufirst%3DR.%2BL.%26aulast%3DHodge%26aufirst%3DR.%2BJ.%26aulast%3DWalker%26aufirst%3DS.%2BE.%26aulast%3DHolland%26aufirst%3DM.%2BC.%26aulast%3DBush%26aufirst%3DM.%2BA.%26atitle%3DPharmacodynamics%252C%2520pharmacokinetics%252C%2520safety%252C%2520and%2520tolerability%2520of%2520albiglutide%252C%2520a%2520long-acting%2520glucagon-like%2520peptide-1%2520mimetic%252C%2520in%2520patients%2520with%2520type%25202%2520diabetes%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2008%26volume%3D93%26spage%3D4810%26epage%3D4817%26doi%3D10.1210%2Fjc.2008-1518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group">LÃ©ger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibaudeau, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robitaille, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quraishi, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Wyk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bousquet-Gagnon, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carette, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castaigne, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridon, D. P.</span><span> </span><span class="NLM_article-title">Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7â36) analog</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">4395</span><span class="NLM_x">â</span> <span class="NLM_lpage">4398</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2004.06.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.bmcl.2004.06.066" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=4395-4398&author=R.+L%C3%A9gerauthor=K.+Thibaudeauauthor=M.+Robitailleauthor=O.+Quraishiauthor=P.+van+Wykauthor=N.+Bousquet-Gagnonauthor=J.+Caretteauthor=J.-P.+Castaigneauthor=D.+P.+Bridon&title=Identification+of+CJC-1131-albumin+bioconjugate+as+a+stable+and+bioactive+GLP-1%287%E2%80%9336%29+analog&doi=10.1016%2Fj.bmcl.2004.06.066"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.06.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.06.066%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25A9ger%26aufirst%3DR.%26aulast%3DThibaudeau%26aufirst%3DK.%26aulast%3DRobitaille%26aufirst%3DM.%26aulast%3DQuraishi%26aufirst%3DO.%26aulast%3Dvan%2BWyk%26aufirst%3DP.%26aulast%3DBousquet-Gagnon%26aufirst%3DN.%26aulast%3DCarette%26aufirst%3DJ.%26aulast%3DCastaigne%26aufirst%3DJ.-P.%26aulast%3DBridon%26aufirst%3DD.%2BP.%26atitle%3DIdentification%2520of%2520CJC-1131-albumin%2520bioconjugate%2520as%2520a%2520stable%2520and%2520bioactive%2520GLP-1%25287%25E2%2580%259336%2529%2520analog%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D4395%26epage%3D4398%26doi%3D10.1016%2Fj.bmcl.2004.06.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group">Lau, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">SchÃ¤ffer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettersson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spetzler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kofoed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madsen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudsen, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGuire, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steensgaard, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strauss, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gram, D. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudsen, S. M. l.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thygesen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reedtz-Runge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruse, T.</span><span> </span><span class="NLM_article-title">Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">7370</span><span class="NLM_x">â</span> <span class="NLM_lpage">7380</span><span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00726</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00726" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtl2qu7%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7370-7380&author=J.+Lauauthor=P.+Blochauthor=L.+Sch%C3%A4fferauthor=I.+Petterssonauthor=J.+Spetzlerauthor=J.+Kofoedauthor=K.+Madsenauthor=L.+B.+Knudsenauthor=J.+McGuireauthor=D.+B.+Steensgaardauthor=H.+M.+Straussauthor=D.+X.+Gramauthor=S.+M.+l.+Knudsenauthor=F.+S.+Nielsenauthor=P.+Thygesenauthor=S.+Reedtz-Rungeauthor=T.+Kruse&title=Discovery+of+the+once-weekly+glucagon-like+peptide-1+%28GLP-1%29+analogue+semaglutide&doi=10.1021%2Facs.jmedchem.5b00726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide</span></div><div class="casAuthors">Lau, Jesper; Bloch, Paw; Schaffer, Lauge; Pettersson, Ingrid; Spetzler, Jane; Kofoed, Jacob; Madsen, Kjeld; Knudsen, Lotte Bjerre; McGuire, James; Steensgaard, Dorte Bjerre; Strauss, Holger Martin; Gram, Dorte X.; Knudsen, Sanne Moeller; Nielsen, Flemming Seier; Thygesen, Peter; Reedtz-Runge, Steffen; Kruse, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7370-7380</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analog that binds to serum albumin in vivo and is approved for once-daily treatment of diabetes as well as obesity.  The aim of the present studies was to design a once weekly GLP-1 analog by increasing albumin affinity and secure full stability against metabolic degrdn.  The fatty acid moiety and the linking chem. to GLP-1 were the key features to secure high albumin affinity and GLP-1 receptor (GLP-1R) potency and in obtaining a prolonged exposure and action of the GLP-1 analog.  Semaglutide was selected as the optimal once weekly candidate.  Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib8, Arg34) and is derivatized at lysine 26.  The GLP-1R affinity of semaglutide (0.38 Â± 0.06 nM) was three-fold decreased compared to liraglutide, whereas the albumin affinity was increased.  The plasma half-life was 46.1 h in mini-pigs following i.v. administration, and semaglutide has an MRT of 63.6 h after s.c. dosing to mini-pigs.  Semaglutide is currently in phase 3 clin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8tFc0FzEro7Vg90H21EOLACvtfcHk0ljwGJyLgKtpBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtl2qu7%252FM&md5=0478fe17f9f4dcc0cb58919b1c55869a</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00726%26sid%3Dliteratum%253Aachs%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DBloch%26aufirst%3DP.%26aulast%3DSch%25C3%25A4ffer%26aufirst%3DL.%26aulast%3DPettersson%26aufirst%3DI.%26aulast%3DSpetzler%26aufirst%3DJ.%26aulast%3DKofoed%26aufirst%3DJ.%26aulast%3DMadsen%26aufirst%3DK.%26aulast%3DKnudsen%26aufirst%3DL.%2BB.%26aulast%3DMcGuire%26aufirst%3DJ.%26aulast%3DSteensgaard%26aufirst%3DD.%2BB.%26aulast%3DStrauss%26aufirst%3DH.%2BM.%26aulast%3DGram%26aufirst%3DD.%2BX.%26aulast%3DKnudsen%26aufirst%3DS.%2BM.%2Bl.%26aulast%3DNielsen%26aufirst%3DF.%2BS.%26aulast%3DThygesen%26aufirst%3DP.%26aulast%3DReedtz-Runge%26aufirst%3DS.%26aulast%3DKruse%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520the%2520once-weekly%2520glucagon-like%2520peptide-1%2520%2528GLP-1%2529%2520analogue%2520semaglutide%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7370%26epage%3D7380%26doi%3D10.1021%2Facs.jmedchem.5b00726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group">OâConnor-Semmes, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodge, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chism, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choudhury, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nunez, D. J.</span><span> </span><span class="NLM_article-title">GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humansâPK/PD and safety</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">704</span><span class="NLM_x">â</span> <span class="NLM_lpage">712</span><span class="refDoi">Â DOI: 10.1038/clpt.2014.187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fclpt.2014.187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25238251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslyksrrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2014&pages=704-712&author=R.+L.+O%E2%80%99Connor-Semmesauthor=J.+Linauthor=R.+J.+Hodgeauthor=S.+Andrewsauthor=J.+Chismauthor=A.+Choudhuryauthor=D.+J.+Nunez&title=GSK2374697%2C+a+novel+albumin-binding+domain+antibody+%28AlbudAb%29%2C+extends+systemic+exposure+of+exendin-4%3A+first+study+in+humans%E2%80%94PK%2FPD+and+safety&doi=10.1038%2Fclpt.2014.187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">GSK2374697, a Novel Albumin-Binding Domain Antibody (AlbudAb), Extends Systemic Exposure of Exendin-4: First Study in Humans-PK/PD and Safety</span></div><div class="casAuthors">O'Connor-Semmes, R. L.; Lin, J.; Hodge, R. J.; Andrews, S.; Chism, J.; Choudhury, A.; Nunez, D. J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">704-712</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">GSK2374697 is a genetically engineered fusion protein of a human domain antibody to exendin-4.  This mol. binds with a high affinity to human serum albumin, creating a long-duration glucagon-like peptide-1 (GLP-1) receptor agonist.  This study is the first evaluation of the albumin-binding domain antibody (AlbudAb) drug delivery platform in humans.  The aim of this randomized clin. study was to det. the pharmacokinetics, pharmacodynamics, safety, and tolerability of GSK2374697.  The pharmacokinetic profile was prolonged, with estd. half-lives ranging from 6 to 10 days.  Postprandial glucose and insulin were reduced, and gastric emptying was delayed in healthy subjects, confirming anticipated GLP-1 receptor agonist pharmacol.  The safety and tolerability were as expected for a potent GLP-1 agonist.  Gradual titrn. of doses greatly improved tolerability.  Rapid tolerance to nausea was obsd.  Study results support further investigation in type 2 diabetes and for wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO3tyn0fpBOrVg90H21EOLACvtfcHk0ljwGJyLgKtpBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslyksrrM&md5=75d6eaeb2b3300bf9471ba1237d22dd5</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2014.187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2014.187%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Connor-Semmes%26aufirst%3DR.%2BL.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DHodge%26aufirst%3DR.%2BJ.%26aulast%3DAndrews%26aufirst%3DS.%26aulast%3DChism%26aufirst%3DJ.%26aulast%3DChoudhury%26aufirst%3DA.%26aulast%3DNunez%26aufirst%3DD.%2BJ.%26atitle%3DGSK2374697%252C%2520a%2520novel%2520albumin-binding%2520domain%2520antibody%2520%2528AlbudAb%2529%252C%2520extends%2520systemic%2520exposure%2520of%2520exendin-4%253A%2520first%2520study%2520in%2520humans%25E2%2580%2594PK%252FPD%2520and%2520safety%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2014%26volume%3D96%26spage%3D704%26epage%3D712%26doi%3D10.1038%2Fclpt.2014.187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group">JevÅ¡evar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunstelj, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porekar, V. G.</span><span> </span><span class="NLM_article-title">PEGylation of therapeutic proteins</span> <span class="citation_source-journal">Biotechnol. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">â</span> <span class="NLM_lpage">128</span><span class="refDoi">Â DOI: 10.1002/biot.200900218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fbiot.200900218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=20069580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntVSlsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=113-128&author=S.+Jev%C5%A1evarauthor=M.+Kunsteljauthor=V.+G.+Porekar&title=PEGylation+of+therapeutic+proteins&doi=10.1002%2Fbiot.200900218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">PEGylation of therapeutic proteins</span></div><div class="casAuthors">Jevsevar, Simona; Kunstelj, Menci; Porekar, Vladka Gaberc</div><div class="citationInfo"><span class="NLM_cas:title">Biotechnology Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-128</span>CODEN:
                <span class="NLM_cas:coden">BJIOAM</span>;
        ISSN:<span class="NLM_cas:issn">1860-6768</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Since the first PEGylated product was approved by the Food and Drug Administration in 1990, PEGylation has been widely used as a post-prodn. modification methodol. for improving biomedical efficacy and physicochem. properties of therapeutic proteins.  Applicability and safety of this technol. have been proven by use of various PEGylated pharmaceuticals for many years.  It is expected that PEGylation, as the most established technol. for extension of drug residence in the body, will play an important role in the next generation therapeutics, such as peptides, protein nanobodies and scaffolds, which due to their diminished mol. size need half-life extension.  This review focuses on several factors important in the prodn. of PEGylated biopharmaceuticals enabling efficient prepn. of highly purified PEG-protein conjugates that have to meet stringent regulatory criteria for their use in human therapy.  Areas addressed are PEG properties, the specificity of PEGylation reactions, sepn. and large-scale purifn., the availability and anal. of PEG reagents, anal. of PEG-protein conjugates, the consistency of products and processes and approaches used for rapid screening of pharmacokinetic properties of PEG-protein conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqjWpYHBYTybVg90H21EOLACvtfcHk0ljwGJyLgKtpBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntVSlsw%253D%253D&md5=ad29019bc10b1d52ef883f9f6f3f27ce</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1002%2Fbiot.200900218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbiot.200900218%26sid%3Dliteratum%253Aachs%26aulast%3DJev%25C5%25A1evar%26aufirst%3DS.%26aulast%3DKunstelj%26aufirst%3DM.%26aulast%3DPorekar%26aufirst%3DV.%2BG.%26atitle%3DPEGylation%2520of%2520therapeutic%2520proteins%26jtitle%3DBiotechnol.%2520J.%26date%3D2010%26volume%3D5%26spage%3D113%26epage%3D128%26doi%3D10.1002%2Fbiot.200900218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group">Zhang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, H. T.</span><span> </span><span class="NLM_article-title">Discussion about several potential drawbacks of PEGylated therapeutic proteins</span> <span class="citation_source-journal">Biol. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">â</span> <span class="NLM_lpage">339</span><span class="refDoi">Â DOI: 10.1248/bpb.b13-00661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1248%2Fbpb.b13-00661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24334536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvFWlt7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2014&pages=335-339&author=F.+Zhangauthor=M.+R.+Liuauthor=H.+T.+Wan&title=Discussion+about+several+potential+drawbacks+of+PEGylated+therapeutic+proteins&doi=10.1248%2Fbpb.b13-00661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Discussion about several potential drawbacks of PEGylated therapeutic proteins</span></div><div class="casAuthors">Zhang, Fan; Liu, Mu-rong; Wan, Hai-tong</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">335-339</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">PEGylation changes the phys. and chem. properties of the biomedical mol., such as its conformation, electrostatic binding, and hydrophobicity, and results in an improvement in the pharmacokinetic behavior of the drug, while it also causes some disadvantages of which cannot be neglected.  The available data manifests that polyethylene glycol (PEG) itself shows potential risk, such as immunogenicity of the PEG and PEG-contg. vacuoles in cells obsd. with PEGylated biologicals.  Decreased activity and heterogeneity are also the neg. aspects of PEGylation.  The unfavorable impacts which are brought by the PEGylation are described here with examples of modified therapeutic proteins on the market and used in the clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwCEhui0h1OLVg90H21EOLACvtfcHk0ljaLuGhV7x5rQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvFWlt7Y%253D&md5=f8a29481f3d15e0376cec99913f1303d</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1248%2Fbpb.b13-00661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.b13-00661%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DM.%2BR.%26aulast%3DWan%26aufirst%3DH.%2BT.%26atitle%3DDiscussion%2520about%2520several%2520potential%2520drawbacks%2520of%2520PEGylated%2520therapeutic%2520proteins%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2014%26volume%3D37%26spage%3D335%26epage%3D339%26doi%3D10.1248%2Fbpb.b13-00661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group">Schellenberger, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.-w.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geething, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spink, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">To, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholle, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogin, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleland, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stemmer, W. P. C.</span><span> </span><span class="NLM_article-title">A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1186</span><span class="NLM_x">â</span> <span class="NLM_lpage">1190</span><span class="refDoi">Â DOI: 10.1038/nbt.1588</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnbt.1588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=19915550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVWlsb%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=1186-1190&author=V.+Schellenbergerauthor=C.-w.+Wangauthor=N.+C.+Geethingauthor=B.+J.+Spinkauthor=A.+Campbellauthor=W.+Toauthor=M.+D.+Scholleauthor=Y.+Yinauthor=Y.+Yaoauthor=O.+Boginauthor=J.+L.+Clelandauthor=J.+Silvermanauthor=W.+P.+C.+Stemmer&title=A+recombinant+polypeptide+extends+the+in+vivo+half-life+of+peptides+and+proteins+in+a+tunable+manner&doi=10.1038%2Fnbt.1588"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner</span></div><div class="casAuthors">Schellenberger, Volker; Wang, Chia-wei; Geething, Nathan C.; Spink, Benjamin J.; Campbell, Andrew; To, Wayne; Scholle, Michael D.; Yin, Yong; Yao, Yi; Bogin, Oren; Cleland, Jeffrey L.; Silverman, Joshua; Stemmer, Willem P. C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1186-1190</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Increasing the in vivo residence times of protein therapeutics could decrease their dosing frequencies.  We show that genetic fusion of an unstructured recombinant polypeptide of 864 amino acids, called XTEN, to a peptide or protein provides an apparently generic approach to extend plasma half-life.  Allometric scaling suggests that a fusion of XTEN to the exenatide peptide should increase exenatide half-life in humans from 2.4 h to a projected time of 139 h.  We confirmed the biol. activity of the exenatide-XTEN fusion in mice.  As extended stability might exacerbate undesirable side effects in some cases, we show that truncating the XTEN sequence can regulate plasma half-life.  XTEN lacks hydrophobic amino acid residues that often contribute to immunogenicity and complicate manuf.  Based on data on XTEN fusions to exenatide, glucagon, GFP and human growth hormone, we expect that XTEN will enable dosing of otherwise rapidly cleared protein drugs at up to monthly intervals in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXVU4baF3_cbVg90H21EOLACvtfcHk0ljaLuGhV7x5rQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVWlsb%252FK&md5=0472b2fd76a277f3021c85f864da7803</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1588%26sid%3Dliteratum%253Aachs%26aulast%3DSchellenberger%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DC.-w.%26aulast%3DGeething%26aufirst%3DN.%2BC.%26aulast%3DSpink%26aufirst%3DB.%2BJ.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DTo%26aufirst%3DW.%26aulast%3DScholle%26aufirst%3DM.%2BD.%26aulast%3DYin%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DBogin%26aufirst%3DO.%26aulast%3DCleland%26aufirst%3DJ.%2BL.%26aulast%3DSilverman%26aufirst%3DJ.%26aulast%3DStemmer%26aufirst%3DW.%2BP.%2BC.%26atitle%3DA%2520recombinant%2520polypeptide%2520extends%2520the%2520in%2520vivo%2520half-life%2520of%2520peptides%2520and%2520proteins%2520in%2520a%2520tunable%2520manner%26jtitle%3DNat.%2520Biotechnol.%26date%3D2009%26volume%3D27%26spage%3D1186%26epage%3D1190%26doi%3D10.1038%2Fnbt.1588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group">Strohl, W. R.</span><span> </span><span class="NLM_article-title">Fusion proteins for half-life extension of biologics as a strategy to make biobetters</span> <span class="citation_source-journal">BioDrugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">215</span><span class="NLM_x">â</span> <span class="NLM_lpage">239</span><span class="refDoi">Â DOI: 10.1007/s40259-015-0133-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1007%2Fs40259-015-0133-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26177629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1WrtLjN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=215-239&author=W.+R.+Strohl&title=Fusion+proteins+for+half-life+extension+of+biologics+as+a+strategy+to+make+biobetters&doi=10.1007%2Fs40259-015-0133-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters</span></div><div class="casAuthors">Strohl, William R.</div><div class="citationInfo"><span class="NLM_cas:title">BioDrugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">215-239</span>CODEN:
                <span class="NLM_cas:coden">BIDRF4</span>;
        ISSN:<span class="NLM_cas:issn">1173-8804</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">The purpose of making a "biobetter" biol. is to improve on the salient characteristics of a known biol. for which there is, minimally, clin. proof of concept or, maximally, marketed product data.  There already are several examples in which second-generation or biobetter biologics have been generated by improving the pharmacokinetic properties of an innovative drug, including Neulasta [a PEGylated, longer-half-life version of Neupogen (filgrastim)] and Aranesp [a longer-half-life version of Epogen (epoetin-Î±)].  This review describes the use of protein fusion technologies such as Fc fusion proteins, fusion to human serum albumin, fusion to carboxy-terminal peptide, and other polypeptide fusion approaches to make biobetter drugs with more desirable pharmacokinetic profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqorgYj1NyuaLVg90H21EOLACvtfcHk0ljaLuGhV7x5rQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1WrtLjN&md5=328f936b91e29c83e069db83a4d05cab</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1007%2Fs40259-015-0133-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40259-015-0133-6%26sid%3Dliteratum%253Aachs%26aulast%3DStrohl%26aufirst%3DW.%2BR.%26atitle%3DFusion%2520proteins%2520for%2520half-life%2520extension%2520of%2520biologics%2520as%2520a%2520strategy%2520to%2520make%2520biobetters%26jtitle%3DBioDrugs%26date%3D2015%26volume%3D29%26spage%3D215%26epage%3D239%26doi%3D10.1007%2Fs40259-015-0133-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group">Schlapschy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binder, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">BÃ¶rger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theobald, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wachinger, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kisling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haller, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skerra, A.</span><span> </span><span class="NLM_article-title">PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins</span> <span class="citation_source-journal">Protein Eng., Des. Sel.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">489</span><span class="NLM_x">â</span> <span class="NLM_lpage">501</span><span class="refDoi">Â DOI: 10.1093/protein/gzt023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1093%2Fprotein%2Fgzt023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23754528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSrurzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2013&pages=489-501&author=M.+Schlapschyauthor=U.+Binderauthor=C.+B%C3%B6rgerauthor=I.+Theobaldauthor=K.+Wachingerauthor=S.+Kislingauthor=D.+Hallerauthor=A.+Skerra&title=PASylation%3A+a+biological+alternative+to+PEGylation+for+extending+the+plasma+half-life+of+pharmaceutically+active+proteins&doi=10.1093%2Fprotein%2Fgzt023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins</span></div><div class="casAuthors">Schlapschy, Martin; Binder, Uli; Boerger, Claudia; Theobald, Ina; Wachinger, Klaus; Kisling, Sigrid; Haller, Dirk; Skerra, Arne</div><div class="citationInfo"><span class="NLM_cas:title">Protein Engineering, Design & Selection</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">489-501</span>CODEN:
                <span class="NLM_cas:coden">PEDSBR</span>;
        ISSN:<span class="NLM_cas:issn">1741-0126</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A major limitation of biopharmaceutical proteins is their fast clearance from circulation via kidney filtration, which strongly hampers efficacy both in animal studies and in human therapy.  We have developed conformationally disordered polypeptide chains with expanded hydrodynamic vol. comprising the small residues Pro, Ala and Ser (PAS).  PAS sequences are hydrophilic, uncharged biol. polymers with biophys. properties very similar to poly-ethylene glycol (PEG), whose chem. conjugation to drugs is an established method for plasma half-life extension.  In contrast, PAS polypeptides offer fusion to a therapeutic protein on the genetic level, permitting Escherichia coli prodn. of fully active proteins and obviating in vitro coupling or modification steps.  Furthermore, they are biodegradable, thus avoiding organ accumulation, while showing stability in serum and lacking toxicity or immunogenicity in mice.  We demonstrate that PASylation bestows typical biologics, such as interferon, growth hormone or Fab fragments, with considerably prolonged circulation and boosts bioactivity in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp794OCS5JQ9bVg90H21EOLACvtfcHk0lhIfWIsTVjK5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSrurzL&md5=745f6a35c9668e9e82c13215708fccf3</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1093%2Fprotein%2Fgzt023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fprotein%252Fgzt023%26sid%3Dliteratum%253Aachs%26aulast%3DSchlapschy%26aufirst%3DM.%26aulast%3DBinder%26aufirst%3DU.%26aulast%3DB%25C3%25B6rger%26aufirst%3DC.%26aulast%3DTheobald%26aufirst%3DI.%26aulast%3DWachinger%26aufirst%3DK.%26aulast%3DKisling%26aufirst%3DS.%26aulast%3DHaller%26aufirst%3DD.%26aulast%3DSkerra%26aufirst%3DA.%26atitle%3DPASylation%253A%2520a%2520biological%2520alternative%2520to%2520PEGylation%2520for%2520extending%2520the%2520plasma%2520half-life%2520of%2520pharmaceutically%2520active%2520proteins%26jtitle%3DProtein%2520Eng.%252C%2520Des.%2520Sel.%26date%3D2013%26volume%3D26%26spage%3D489%26epage%3D501%26doi%3D10.1093%2Fprotein%2Fgzt023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group">Bajo, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schally, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagy, A.</span><span> </span><span class="NLM_article-title">Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers</span> <span class="citation_source-journal">Clin. Cancer. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">3742</span><span class="NLM_x">â</span> <span class="NLM_lpage">3748</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=14506166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosVOksrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=3742-3748&author=A.+M.+Bajoauthor=A.+V.+Schallyauthor=G.+Halmosauthor=A.+Nagy&title=Targeted+doxorubicin-containing+luteinizing+hormone-releasing+hormone+analogue+AN-152+inhibits+the+growth+of+doxorubicin-resistant+MX-1+human+breast+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers</span></div><div class="casAuthors">Bajo, Ana M.; Schally, Andrew V.; Halmos, Gabor; Nagy, Attila</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10, Pt. 1</span>),
    <span class="NLM_cas:pages">3742-3748</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The receptors for LH-releasing hormone receptor (LHRH-R) are found in >50% of human breast cancers.  Doxorubicin (DOX) was linked to [D-Lys6]LHRH to form a cytotoxic conjugate, AN-152, which can be targeted to tumor cells expressing LHRH-R.  We evaluated the effects of AN-152 on the estrogen-independent, DOX-resistant human mammary carcinoma line MX-1, xenografted into nude mice.  Nude mice bearing MX-1 tumors were administered five i.v. injections of AN-152 or DOX at doses equiv. to 3 mg/kg DOX.  Tumor growth was followed, and changes in the expression of LHRH-R on tumors were evaluated by radioreceptor assays, reverse transcription-PCR, and Western blotting.  The effects of AN-152 on the expression of human epidermal growth factor receptor (HER)-2 were investigated.  Because LHRH-R are coupled to various G proteins, which are involved in mitogenic signaling, we detd. the outcome of treatment with AN-152 on the levels of mRNA for different G proteins.  Treatment with AN-152 significantly (P < 0.05) decreased the final tumor vol. to 978.56 Â± 176.85 mm3, compared with the control tumors, which measured 2837.38 Â± 515.38 mm3.  Tumor doubling time was likewise significantly (P < 0.05) extended by AN-152 to 12.01 Â± 1.99 days from 6.45 Â± 0.36 days for the controls.  Therapy with AN-152, but not with DOX, resulted in a significant decrease of LHRH-R levels on MX-1 tumors.  The expression of mRNAs for HER-2, HER-3, GÎ±i2, and GÎ±11 and the levels of HER-2 and HER-3 proteins were also significantly reduced by AN-152.  Cytotoxic LHRH analog AN-152 could be considered for targeted chemotherapy of DOX-resistant breast cancers expressing LHRH-R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDBP7LawW7YLVg90H21EOLACvtfcHk0lhIfWIsTVjK5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosVOksrY%253D&md5=31009f06da4f75e900b45ab18de586ad</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBajo%26aufirst%3DA.%2BM.%26aulast%3DSchally%26aufirst%3DA.%2BV.%26aulast%3DHalmos%26aufirst%3DG.%26aulast%3DNagy%26aufirst%3DA.%26atitle%3DTargeted%2520doxorubicin-containing%2520luteinizing%2520hormone-releasing%2520hormone%2520analogue%2520AN-152%2520inhibits%2520the%2520growth%2520of%2520doxorubicin-resistant%2520MX-1%2520human%2520breast%2520cancers%26jtitle%3DClin.%2520Cancer.%2520Res.%26date%3D2003%26volume%3D9%26spage%3D3742%26epage%3D3748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span>Clinical information can be found at: NCT01767155: Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer (ZoptEC); <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="https://www.clinicaltrials.gov/" class="extLink">https://www.clinicaltrials.gov/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical+information+can+be+found+at%3A+NCT01767155%3A+Zoptarelin+Doxorubicin+%28AEZS+108%29+as+Second+Line+Therapy+for+Endometrial+Cancer+%28ZoptEC%29%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2015%3B+https%3A%2F%2Fwww.clinicaltrials.gov%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DNCT01767155%253A%2520Zoptarelin%2520Doxorubicin%2520%2528AEZS%2520108%2529%2520as%2520Second%2520Line%2520Therapy%2520for%2520Endometrial%2520Cancer%2520%2528ZoptEC%2529%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Engel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emons, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schally, A. V.</span><span> </span><span class="NLM_article-title">AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">891</span><span class="NLM_x">â</span> <span class="NLM_lpage">899</span><span class="refDoi">Â DOI: 10.1517/13543784.2012.685128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1517%2F13543784.2012.685128" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=891-899&author=J.+Engelauthor=G.+Emonsauthor=J.+Pinskiauthor=A.+V.+Schally&title=AEZS-108%3A+a+targeted+cytotoxic+analog+of+LHRH+for+the+treatment+of+cancers+positive+for+LHRH+receptors&doi=10.1517%2F13543784.2012.685128"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170a&amp;dbid=16384&amp;doi=10.1517%2F13543784.2012.685128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2012.685128%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DEmons%26aufirst%3DG.%26aulast%3DPinski%26aufirst%3DJ.%26aulast%3DSchally%26aufirst%3DA.%2BV.%26atitle%3DAEZS-108%253A%2520a%2520targeted%2520cytotoxic%2520analog%2520of%2520LHRH%2520for%2520the%2520treatment%2520of%2520cancers%2520positive%2520for%2520LHRH%2520receptors%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2012%26volume%3D21%26spage%3D891%26epage%3D899%26doi%3D10.1517%2F13543784.2012.685128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit170b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bushnell, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâDorisio, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâDorisio, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Cutsem, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baulieu, J.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borson-Chazot, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anthony, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oberg, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grossman, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouterfa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kacena, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaFrance, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauwels, S. A.</span><span> </span><span class="NLM_article-title">90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1652</span><span class="NLM_x">â</span> <span class="NLM_lpage">1659</span><span class="refDoi">Â DOI: 10.1200/JCO.2009.22.8585</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1200%2FJCO.2009.22.8585" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=20194865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtVyhurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=1652-1659&author=D.+L.+Bushnellauthor=T.+M.+O%E2%80%99Dorisioauthor=M.+S.+O%E2%80%99Dorisioauthor=Y.+Mendaauthor=R.+J.+Hicksauthor=E.+Van+Cutsemauthor=J.-L.+Baulieuauthor=F.+Borson-Chazotauthor=L.+Anthonyauthor=A.+B.+Bensonauthor=K.+Obergauthor=A.+B.+Grossmanauthor=M.+Connollyauthor=H.+Bouterfaauthor=Y.+Liauthor=K.+A.+Kacenaauthor=N.+LaFranceauthor=S.+A.+Pauwels&title=90Y-Edotreotide+for+Metastatic+Carcinoid+Refractory+to+Octreotide&doi=10.1200%2FJCO.2009.22.8585"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170bR"><div class="casContent"><span class="casTitleNuber">170b</span><div class="casTitle"><span class="NLM_cas:atitle">90Y-edotreotide for metastatic carcinoid refractory to octreotide</span></div><div class="casAuthors">Bushnell, David L.; O'Dorisio, Thomas M.; O'Dorisio, M. Sue; Menda, Yusuf; Hicks, Rodney J.; van Cutsem, Eric; Baulieu, Jean-Louis; Borson-Chazot, Francoise; Anthony, Lowell; Benson, Al B.; Oberg, Kjell; Grossman, Ashley B.; Connolly, Mary; Bouterfa, Hakim; Li, Yong; Kacena, Katherine A.; La France, Norman; Pauwels, Stanislas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1652-1659</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Metastatic carcinoid is an incurable malignancy whose symptoms, such as diarrhea and flushing, can be debilitating and occasionally life-threatening.  Although symptom relief is available with octreotide, the disease eventually becomes refractory to octreotide, leaving no proven treatment options.  The goal of this study was to evaluate the clin. effect of using 90Y-edotreotide to treat symptomatic patients with carcinoid tumors.  Patients and Methods: Patients enrolled had metastatic carcinoid, at least one sign/symptom refractory to octreotide, and at least one measurable lesion.  Study treatment consisted of three cycles of 4.4 GBq (120 mCi) 90Y-edotreotide each, once every 6 wk.  Results: Ninety patients were enrolled in the study.  Using Southwest Oncol. Group tumor response criteria, 67 (74.4%) of 90 patients (95% Cl, 65.4% to 83.4%) were objectively stable or responded.  A statistically significant linear trend toward improvement was demonstrated across all 12 symptoms assessed.  Median progression-free survival was significantly greater (P = .03) for the 38 patients who had durable diarrhea improvement than the 18 patients who did not (18.2 v 7.9 mo, resp.).  Adverse events (AEs) were reported in 96.7% (87 of 90) of patients.  These AEs consisted primarily of reversible GI events (76 of 90), which could be caused in part by concomitant administration of amino acid soln. given to reduce radiation exposure to the kidneys.  There was one case each of grade 3 oliguria and grade 4 renal failure, each lasting 6 days.  Conclusion: 90Y-edotreotide treatment improved symptoms assocd. with malignant carcinoid among subjects with no treatment alternatives.  Treatment was well-tolerated and had an acceptable expected AE profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_MvgtIa4e9bVg90H21EOLACvtfcHk0lhIfWIsTVjK5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtVyhurs%253D&md5=2253b45bd72dcc75d1e0ff3ef3d58784</span></div><a href="/servlet/linkout?suffix=cit170b&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.22.8585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.22.8585%26sid%3Dliteratum%253Aachs%26aulast%3DBushnell%26aufirst%3DD.%2BL.%26aulast%3DO%25E2%2580%2599Dorisio%26aufirst%3DT.%2BM.%26aulast%3DO%25E2%2580%2599Dorisio%26aufirst%3DM.%2BS.%26aulast%3DMenda%26aufirst%3DY.%26aulast%3DHicks%26aufirst%3DR.%2BJ.%26aulast%3DVan%2BCutsem%26aufirst%3DE.%26aulast%3DBaulieu%26aufirst%3DJ.-L.%26aulast%3DBorson-Chazot%26aufirst%3DF.%26aulast%3DAnthony%26aufirst%3DL.%26aulast%3DBenson%26aufirst%3DA.%2BB.%26aulast%3DOberg%26aufirst%3DK.%26aulast%3DGrossman%26aufirst%3DA.%2BB.%26aulast%3DConnolly%26aufirst%3DM.%26aulast%3DBouterfa%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DKacena%26aufirst%3DK.%2BA.%26aulast%3DLaFrance%26aufirst%3DN.%26aulast%3DPauwels%26aufirst%3DS.%2BA.%26atitle%3D90Y-Edotreotide%2520for%2520Metastatic%2520Carcinoid%2520Refractory%2520to%2520Octreotide%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D1652%26epage%3D1659%26doi%3D10.1200%2FJCO.2009.22.8585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group">Hu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, Y.</span><span> </span><span class="NLM_article-title">Long-acting phospholipid gel of exenatide for long-term therapy of type II diabetes</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1318</span><span class="NLM_x">â</span> <span class="NLM_lpage">1326</span><span class="refDoi">Â DOI: 10.1007/s11095-016-1873-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1007%2Fs11095-016-1873-9" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2016&pages=1318-1326&author=M.+Huauthor=Y.+Zhangauthor=N.+Xiangauthor=Y.+Zhongauthor=T.+Gongauthor=Z.-R.+Zhangauthor=Y.+Fu&title=Long-acting+phospholipid+gel+of+exenatide+for+long-term+therapy+of+type+II+diabetes&doi=10.1007%2Fs11095-016-1873-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1007%2Fs11095-016-1873-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-016-1873-9%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DN.%26aulast%3DZhong%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DZ.-R.%26aulast%3DFu%26aufirst%3DY.%26atitle%3DLong-acting%2520phospholipid%2520gel%2520of%2520exenatide%2520for%2520long-term%2520therapy%2520of%2520type%2520II%2520diabetes%26jtitle%3DPharm.%2520Res.%26date%3D2016%26volume%3D33%26spage%3D1318%26epage%3D1326%26doi%3D10.1007%2Fs11095-016-1873-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group">Fidel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dernell, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiss, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroud, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molho, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knoblaugh, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meganck, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parrish-Novak, J.</span><span> </span><span class="NLM_article-title">Preclinical validation of the utility of BLZ-100 in providing fluorescence contrast for imaging spontaneous solid tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">4283</span><span class="NLM_x">â</span> <span class="NLM_lpage">4291</span><span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-15-0471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1158%2F0008-5472.CAN-15-0471" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=4283-4291&author=J.+Fidelauthor=K.+C.+Kennedyauthor=W.+S.+Dernellauthor=S.+Hansenauthor=V.+Wissauthor=M.+R.+Stroudauthor=J.+I.+Molhoauthor=S.+E.+Knoblaughauthor=J.+Meganckauthor=J.+M.+Olsonauthor=B.+Riceauthor=J.+Parrish-Novak&title=Preclinical+validation+of+the+utility+of+BLZ-100+in+providing+fluorescence+contrast+for+imaging+spontaneous+solid+tumors&doi=10.1158%2F0008-5472.CAN-15-0471"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-0471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-0471%26sid%3Dliteratum%253Aachs%26aulast%3DFidel%26aufirst%3DJ.%26aulast%3DKennedy%26aufirst%3DK.%2BC.%26aulast%3DDernell%26aufirst%3DW.%2BS.%26aulast%3DHansen%26aufirst%3DS.%26aulast%3DWiss%26aufirst%3DV.%26aulast%3DStroud%26aufirst%3DM.%2BR.%26aulast%3DMolho%26aufirst%3DJ.%2BI.%26aulast%3DKnoblaugh%26aufirst%3DS.%2BE.%26aulast%3DMeganck%26aufirst%3DJ.%26aulast%3DOlson%26aufirst%3DJ.%2BM.%26aulast%3DRice%26aufirst%3DB.%26aulast%3DParrish-Novak%26aufirst%3DJ.%26atitle%3DPreclinical%2520validation%2520of%2520the%2520utility%2520of%2520BLZ-100%2520in%2520providing%2520fluorescence%2520contrast%2520for%2520imaging%2520spontaneous%2520solid%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D4283%26epage%3D4291%26doi%3D10.1158%2F0008-5472.CAN-15-0471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span>Clinical information can be found at: NCT02234297: Safety Study of BLZ-100 in Adult Subjects with Glioma Undergoing Surgery, <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span>NCT02462629: Study of BLZ-100 in Pediatric Subjects with CNS Tumors; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="https://www.clinicaltrials.gov/" class="extLink">https://www.clinicaltrials.gov/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical+information+can+be+found+at%3A+NCT02234297%3A+Safety+Study+of+BLZ-100+in+Adult+Subjects+with+Glioma+Undergoing+Surgery%2C+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2016%3B+NCT02462629%3A+Study+of+BLZ-100+in+Pediatric+Subjects+with+CNS+Tumors%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2016%3B+https%3A%2F%2Fwww.clinicaltrials.gov%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DNCT02234297%253A%2520Safety%2520Study%2520of%2520BLZ-100%2520in%2520Adult%2520Subjects%2520with%2520Glioma%2520Undergoing%2520Surgery%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2016%26jtitle%3DNCT02462629%253A%2520Study%2520of%2520BLZ-100%2520in%2520Pediatric%2520Subjects%2520with%2520CNS%2520Tumors%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mas-Moruno, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rechenmacher, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, H.</span><span> </span><span class="NLM_article-title">Cilengitide: the first anti-angiogenic small molecule drug candidate. Design, synthesis and clinical evaluation</span> <span class="citation_source-journal">Anti-Cancer Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">753</span><span class="NLM_x">â</span> <span class="NLM_lpage">768</span><span class="refDoi">Â DOI: 10.2174/187152010794728639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.2174%2F187152010794728639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21269250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslagt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=753-768&author=C.+Mas-Morunoauthor=F.+Rechenmacherauthor=H.+Kessler&title=Cilengitide%3A+the+first+anti-angiogenic+small+molecule+drug+candidate.+Design%2C+synthesis+and+clinical+evaluation&doi=10.2174%2F187152010794728639"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174aR"><div class="casContent"><span class="casTitleNuber">174a</span><div class="casTitle"><span class="NLM_cas:atitle">Cilengitide: the first anti-angiogenic small molecule drug candidate. Design, synthesis and clinical evaluation</span></div><div class="casAuthors">Mas-Moruno, Carlos; Rechenmacher, Florian; Kessler, Horst</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">753-768</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cilengitide, a cyclic RGD pentapeptide, is currently in clin. phase III for treatment of glioblastomas and in phase II for several other tumors.  This drug is the first anti-angiogenic small mol. targeting the integrins Î±vÎ²3, Î±vÎ²5 and Î±5Î²1.  It was developed by us in the early 90s by a novel procedure, the spatial screening.  This strategy resulted in c(RGDfV), the first superactive Î±vÎ²3 inhibitor (100 to 1000 times increased activity over the linear ref. peptides), which in addn. exhibited high selectivity against the platelet receptor Î±IIbÎ²3.  This cyclic peptide was later modified by N-methylation of one peptide bond to yield an even greater antagonistic activity in c(RGDf(NMe)V).  This peptide was then dubbed Cilengitide and is currently developed as drug by the company Merck-Serono (Germany).  This article describes the chem. development of Cilengitide, the biochem. background of its activity and a short review about the present clin. trials.  The pos. anti-angiogenic effects in cancer treatment can be further increased by combination with "classical" anti-cancer therapies.  Several clin. trials in this direction are under investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZlP-_WXS6GbVg90H21EOLACvtfcHk0lhSZB0_ZQH_-w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslagt7k%253D&md5=694b4a2876be15ec767dcc82278a316c</span></div><a href="/servlet/linkout?suffix=cit174a&amp;dbid=16384&amp;doi=10.2174%2F187152010794728639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152010794728639%26sid%3Dliteratum%253Aachs%26aulast%3DMas-Moruno%26aufirst%3DC.%26aulast%3DRechenmacher%26aufirst%3DF.%26aulast%3DKessler%26aufirst%3DH.%26atitle%3DCilengitide%253A%2520the%2520first%2520anti-angiogenic%2520small%2520molecule%2520drug%2520candidate.%2520Design%252C%2520synthesis%2520and%2520clinical%2520evaluation%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2010%26volume%3D10%26spage%3D753%26epage%3D768%26doi%3D10.2174%2F187152010794728639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit174b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Stupp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegi, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorlia, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erridge, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aldape, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lhermitte, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietsch, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grujicic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinbach, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wick, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarnawski, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, D.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weyerbrock, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taphoorn, M. J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thurzo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrlinger, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kortmann, R.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adamska, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBain, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandes, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonn, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiegel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nabors, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reardon, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van den Bent, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicking, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markivskyy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weller, M.</span><span> </span><span class="NLM_article-title">Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071â22072 study): a multicentre, randomised, open-label, phase 3 trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1100</span><span class="NLM_x">â</span> <span class="NLM_lpage">1108</span><span class="refDoi">Â DOI: 10.1016/S1470-2045(14)70379-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2FS1470-2045%2814%2970379-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25163906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSmt73E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1100-1108&author=R.+Stuppauthor=M.+E.+Hegiauthor=T.+Gorliaauthor=S.+C.+Erridgeauthor=J.+Perryauthor=Y.-K.+Hongauthor=K.+D.+Aldapeauthor=B.+Lhermitteauthor=T.+Pietschauthor=D.+Grujicicauthor=J.+P.+Steinbachauthor=W.+Wickauthor=R.+Tarnawskiauthor=D.-H.+Namauthor=P.+Hauauthor=A.+Weyerbrockauthor=M.+J.+B.+Taphoornauthor=C.-C.+Shenauthor=N.+Raoauthor=L.+Thurzoauthor=U.+Herrlingerauthor=T.+Guptaauthor=R.-D.+Kortmannauthor=K.+Adamskaauthor=C.+McBainauthor=A.+A.+Brandesauthor=J.+C.+Tonnauthor=O.+Schnellauthor=T.+Wiegelauthor=C.-Y.+Kimauthor=L.+B.+Naborsauthor=D.+A.+Reardonauthor=M.+J.+van+den+Bentauthor=C.+Hickingauthor=A.+Markivskyyauthor=M.+Picardauthor=M.+Weller&title=Cilengitide+combined+with+standard+treatment+for+patients+with+newly+diagnosed+glioblastoma+with+methylated+MGMT+promoter+%28CENTRIC+EORTC+26071%E2%80%9322072+study%29%3A+a+multicentre%2C+randomised%2C+open-label%2C+phase+3+trial&doi=10.1016%2FS1470-2045%2814%2970379-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174bR"><div class="casContent"><span class="casTitleNuber">174b</span><div class="casTitle"><span class="NLM_cas:atitle">Cilengitide Combined With Standard Treatment For Patients With Newly Diagnosed Glioblastoma With Methylated Mgmt Promoter (centric Eortc 26071-22072 Study): A Multicentre, Randomised, Open-label, Phase 3 Trial</span></div><div class="casAuthors">Stupp, Roger; Hegi, Monika E.; Gorlia, Thierry; Erridge, Sara C.; Perry, James; Hong, Yong-Kil; Aldape, Kenneth D.; Lhermitte, Benoit; Pietsch, Torsten; Grujicic, Danica; Steinbach, Joachim Peter; Wick, Wolfgang; Tarnawski, Rafal; Nam, Do-Hyun; Hau, Peter; Weyerbrock, Astrid; Taphoorn, Martin J. B.; Shen, Chiung-Chyi; Rao, Nalini; Thurzo, Laszlo; Herrlinger, Ulrich; Gupta, Tejpal; Kortmann, Rolf-Dieter; Adamska, Krystyna; McBain, Catherine; Brandes, Alba A.; Tonn, Joerg Christian; Schnell, Oliver; Wiegel, Thomas; Kim, Chae-Yong; Nabors, Louis Burt; Reardon, David A.; van den Bent, Martin J.; Hicking, Christine; Markivskyy, Andriy; Picard, Martin; Weller, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1100-1108</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cilengitide is a selective Î±vÎ²3 and Î±vÎ²5 integrin inhibitor.  Data from phase 2 trials suggest that it has antitumor activity as a single agent in recurrent glioblastoma and in combination with std. temozolomide chemoradiotherapy in newly diagnosed glioblastoma (particularly in tumors with methylated MGMT promoter).  We aimed to assess cilengitide combined with temozolomide chemoradiotherapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter.  In this multicentre, open-label, phase 3 study, we investigated the efficacy of cilengitide in patients from 146 study sites in 25 countries.  Eligible patients (newly diagnosed, histol. proven supratentorial glioblastoma, methylated MGMT promoter, and age â¥18 years) were stratified for prognostic Radiation Therapy Oncol. Group recursive partitioning anal. class and geog. region and centrally randomised in a 1:1 ratio with interactive voice response system to receive temozolomide chemoradiotherapy with cilengitide 2000 mg i.v. twice weekly (cilengitide group) or temozolomide chemoradiotherapy alone (control group).  Patients and investigators were unmasked to treatment allocation.  Maintenance temozolomide was given for up to six cycles, and cilengitide was given for up to 18 mo or until disease progression or unacceptable toxic effects.  The primary endpoint was overall survival.  We analyzed survival outcomes by intention to treat.  This study is registered with ClinicalTrials.gov, no. NCT00689221.  Overall, 3471 patients were screened.  Of these patients, 3060 had tumor MGMT status tested; 926 patients had a methylated MGMT promoter, and 545 were randomly assigned to the cilengitide (n=272) or control groups (n=273) between Oct 31, 2008, and May 12, 2011.  Median overall survival was 26Â·3 mo (95% CI 23Â·8-28Â·8) in the cilengitide group and 26Â·3 mo (23Â·9-34Â·7) in the control group (hazard ratio 1Â·02, 95% CI 0Â·81-1Â·29, p=0Â·86).  None of the predefined clin. subgroups showed a benefit from cilengitide.  We noted no overall addnl. toxic effects with cilengitide treatment.  The most commonly reported adverse events of grade 3 or worse in the safety population were lymphopenia (31 [12%] in the cilengitide group vs 26 [10%] in the control group), thrombocytopenia (28 [11%] vs 46 [18%]), neutropenia (19 [7%] vs 24 [9%]), leucopenia (18 [7%] vs 20 [8%]), and convulsion (14 [5%] vs 15 [6%]).  The addn. of cilengitide to temozolomide chemoradiotherapy did not improve outcomes; cilengitide will not be further developed as an anticancer drug.  Nevertheless, integrins remain a potential treatment target for glioblastoma.Merck KGaA, Darmstadt, Germany.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWaDt0u-c9qbVg90H21EOLACvtfcHk0lj-sT0zAfJSKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSmt73E&md5=7abd568898db9f543c4db31c74faafbe</span></div><a href="/servlet/linkout?suffix=cit174b&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2814%2970379-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252814%252970379-1%26sid%3Dliteratum%253Aachs%26aulast%3DStupp%26aufirst%3DR.%26aulast%3DHegi%26aufirst%3DM.%2BE.%26aulast%3DGorlia%26aufirst%3DT.%26aulast%3DErridge%26aufirst%3DS.%2BC.%26aulast%3DPerry%26aufirst%3DJ.%26aulast%3DHong%26aufirst%3DY.-K.%26aulast%3DAldape%26aufirst%3DK.%2BD.%26aulast%3DLhermitte%26aufirst%3DB.%26aulast%3DPietsch%26aufirst%3DT.%26aulast%3DGrujicic%26aufirst%3DD.%26aulast%3DSteinbach%26aufirst%3DJ.%2BP.%26aulast%3DWick%26aufirst%3DW.%26aulast%3DTarnawski%26aufirst%3DR.%26aulast%3DNam%26aufirst%3DD.-H.%26aulast%3DHau%26aufirst%3DP.%26aulast%3DWeyerbrock%26aufirst%3DA.%26aulast%3DTaphoorn%26aufirst%3DM.%2BJ.%2BB.%26aulast%3DShen%26aufirst%3DC.-C.%26aulast%3DRao%26aufirst%3DN.%26aulast%3DThurzo%26aufirst%3DL.%26aulast%3DHerrlinger%26aufirst%3DU.%26aulast%3DGupta%26aufirst%3DT.%26aulast%3DKortmann%26aufirst%3DR.-D.%26aulast%3DAdamska%26aufirst%3DK.%26aulast%3DMcBain%26aufirst%3DC.%26aulast%3DBrandes%26aufirst%3DA.%2BA.%26aulast%3DTonn%26aufirst%3DJ.%2BC.%26aulast%3DSchnell%26aufirst%3DO.%26aulast%3DWiegel%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DC.-Y.%26aulast%3DNabors%26aufirst%3DL.%2BB.%26aulast%3DReardon%26aufirst%3DD.%2BA.%26aulast%3Dvan%2Bden%2BBent%26aufirst%3DM.%2BJ.%26aulast%3DHicking%26aufirst%3DC.%26aulast%3DMarkivskyy%26aufirst%3DA.%26aulast%3DPicard%26aufirst%3DM.%26aulast%3DWeller%26aufirst%3DM.%26atitle%3DCilengitide%2520combined%2520with%2520standard%2520treatment%2520for%2520patients%2520with%2520newly%2520diagnosed%2520glioblastoma%2520with%2520methylated%2520MGMT%2520promoter%2520%2528CENTRIC%2520EORTC%252026071%25E2%2580%259322072%2520study%2529%253A%2520a%2520multicentre%252C%2520randomised%252C%2520open-label%252C%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26spage%3D1100%26epage%3D1108%26doi%3D10.1016%2FS1470-2045%2814%2970379-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span> </span><span class="NLM_article-title">Clinical application of radiolabeled RGD peptides for PET imaging of integrin Î±vÎ²3</span> <span class="citation_source-journal">Theranostics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">78</span><span class="NLM_x">â</span> <span class="NLM_lpage">92</span><span class="refDoi">Â DOI: 10.7150/thno.13242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.7150%2Fthno.13242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26722375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XntF2nt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=78-92&author=H.+Chenauthor=G.+Niuauthor=H.+Wuauthor=X.+Chen&title=Clinical+application+of+radiolabeled+RGD+peptides+for+PET+imaging+of+integrin+%CE%B1v%CE%B23&doi=10.7150%2Fthno.13242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical application of radiolabeled RGD peptides for PET imaging of integrin Î±vÎ²3</span></div><div class="casAuthors">Chen, Haojun; Niu, Gang; Wu, Hua; Chen, Xiaoyuan</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">78-92</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Mol. imaging for non-invasive assessment of angiogenesisis is of great interest for clinicians because of the wide-spread application of anti-angiogenic cancer therapeutics.  Besides, many other interventions that involve the change of blood vessel/tumor microenvironment would also benefit from such imaging strategies.  Of the imaging techniques that target angiogenesis, radiolabeled Arg-Gly-Asp (RGD) peptides have been a major focus because of their high affinity and selectivity for integrin Î±vÎ²3--one of the most extensively examd. target of angiogenesis.  Since the level of integrin Î±vÎ²3 expression has been established as a surrogate marker of angiogenic activity, imaging Î±vÎ²3 expression can potentially be used as an early indicator of effectiveness of antiangiogenic therapy at the mol. level.  In this review, we summarize RGD-based PET tracers that have already been used in clin. trials and intercompared them in terms of radiosynthesis, dosimetry, pharmacokinetics and clin. applications.  A perspective of their future use in the clinic is also provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMF5yFaBW4RLVg90H21EOLACvtfcHk0lj-sT0zAfJSKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntF2nt7c%253D&md5=7124509bee7f3bb9b90a3a8d0ae0f82c</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.7150%2Fthno.13242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.13242%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%26aulast%3DNiu%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DClinical%2520application%2520of%2520radiolabeled%2520RGD%2520peptides%2520for%2520PET%2520imaging%2520of%2520integrin%2520%25CE%25B1v%25CE%25B23%26jtitle%3DTheranostics%26date%3D2016%26volume%3D6%26spage%3D78%26epage%3D92%26doi%3D10.7150%2Fthno.13242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group">BÃ¡bÃ­ÄkovÃ¡, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">TÃ³thovÃ¡, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celec, P.</span><span> </span><span class="NLM_article-title">In vivo phage display - A discovery tool in molecular biomedicine</span> <span class="citation_source-journal">Biotechnol. Adv.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1247</span><span class="NLM_x">â</span> <span class="NLM_lpage">1259</span><span class="refDoi">Â DOI: 10.1016/j.biotechadv.2013.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.biotechadv.2013.04.004" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1247-1259&author=J.+B%C3%A1b%C3%AD%C4%8Dkov%C3%A1author=L.+T%C3%B3thov%C3%A1author=P.+Boorauthor=P.+Celec&title=In+vivo+phage+display+-+A+discovery+tool+in+molecular+biomedicine&doi=10.1016%2Fj.biotechadv.2013.04.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1016%2Fj.biotechadv.2013.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biotechadv.2013.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25A1b%25C3%25AD%25C4%258Dkov%25C3%25A1%26aufirst%3DJ.%26aulast%3DT%25C3%25B3thov%25C3%25A1%26aufirst%3DL.%26aulast%3DBoor%26aufirst%3DP.%26aulast%3DCelec%26aufirst%3DP.%26atitle%3DIn%2520vivo%2520phage%2520display%2520-%2520A%2520discovery%2520tool%2520in%2520molecular%2520biomedicine%26jtitle%3DBiotechnol.%2520Adv.%26date%3D2013%26volume%3D31%26spage%3D1247%26epage%3D1259%26doi%3D10.1016%2Fj.biotechadv.2013.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group">Komin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hristova, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Searson, P. C.</span><span> </span><span class="NLM_article-title">Peptide-based strategies for enhanced cell uptake, transcellular transport, and circulation: Mechanisms and challenges</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">110â111</span><span class="NLM_x">, </span> <span class="NLM_fpage">52</span><span class="NLM_x">â</span> <span class="NLM_lpage">64</span><span class="refDoi">Â DOI: 10.1016/j.addr.2016.06.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.addr.2016.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=27313077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVWlu7fF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110%E2%80%93111&publication_year=2017&pages=52-64&author=A.+Kominauthor=L.+M.+Russellauthor=K.+A.+Hristovaauthor=P.+C.+Searson&title=Peptide-based+strategies+for+enhanced+cell+uptake%2C+transcellular+transport%2C+and+circulation%3A+Mechanisms+and+challenges&doi=10.1016%2Fj.addr.2016.06.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide-based strategies for enhanced cell uptake, transcellular transport, and circulation: Mechanisms and challenges</span></div><div class="casAuthors">Komin, A.; Russell, L. M.; Hristova, K. A.; Searson, P. C.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">110-111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">52-64</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Peptides are emerging as a new tool in drug and gene delivery.  Peptide-drug conjugates and peptide-modified drug delivery systems provide new opportunities to avoid macrophage recognition and subsequent phagocytosis, cross endothelial and epithelial barriers, and enter the cytoplasm of target cells.  Peptides are relatively small, low-cost, and are stable in a wide range of biol. conditions.  In this review, we summarize recent work in designing peptides to enhance penetration of biol. barriers, increase cell uptake, and avoid the immune system.  We highlight recent successes and contradictory results, and outline common emerging concepts and design rules.  The development of sequence-structure-function relationships and std. protocols for benchmarking will be a key to progress in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFDHyXD2xrQLVg90H21EOLACvtfcHk0lj-sT0zAfJSKA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVWlu7fF&md5=8d4815f6874853af7c929aa6c6f52098</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2016.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2016.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DKomin%26aufirst%3DA.%26aulast%3DRussell%26aufirst%3DL.%2BM.%26aulast%3DHristova%26aufirst%3DK.%2BA.%26aulast%3DSearson%26aufirst%3DP.%2BC.%26atitle%3DPeptide-based%2520strategies%2520for%2520enhanced%2520cell%2520uptake%252C%2520transcellular%2520transport%252C%2520and%2520circulation%253A%2520Mechanisms%2520and%2520challenges%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2017%26volume%3D110%25E2%2580%2593111%26spage%3D52%26epage%3D64%26doi%3D10.1016%2Fj.addr.2016.06.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cleal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, A. T.</span><span> </span><span class="NLM_article-title">Endocytosis, intracellular traffic and fate of cell penetrating peptide based conjugates and nanoparticles</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2878</span><span class="NLM_x">â</span> <span class="NLM_lpage">2894</span><span class="refDoi">Â DOI: 10.2174/13816128113199990297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.2174%2F13816128113199990297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23140451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovFemtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2878-2894&author=K.+Clealauthor=L.+Heauthor=P.+D.+Watsonauthor=A.+T.+Jones&title=Endocytosis%2C+intracellular+traffic+and+fate+of+cell+penetrating+peptide+based+conjugates+and+nanoparticles&doi=10.2174%2F13816128113199990297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178aR"><div class="casContent"><span class="casTitleNuber">178a</span><div class="casTitle"><span class="NLM_cas:atitle">Endocytosis, intracellular traffic and fate of cell penetrating peptide based conjugates and nanoparticles</span></div><div class="casAuthors">Cleal, Kez; He, Lin; Watson, Peter D.; Jones, Arwyn T.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2878-2894</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The insides of cells can be viewed as a treasure trove of targets for therapeutic intervention of diseases or as deposits for contrasting agents.  Increasingly the mols. that need to be delivered to the inside of cells for these purposes are macromol. and membrane impermeable.  Cell penetrating peptides (CPPs) have proven abilities to deliver a range of macromol. cargo into cells thus raising their profile as potential delivery vectors for wide-ranging applications.  There is evidence to suggest that CPPs first enter cells through endocytosis and that cytosolic delivery is mediated across endolysosomal membranes.  Their capacity to do this, over direct plasma membrane translocation, is likely to depend on the nature and size of the cargo.  Cells use a range of endocytic routes to facilitate entry from well characterized pathways regulated by clathrin to more recently discovered and less characterized pathways regulated by clathrin independent mechanisms.  These are likely to det. the intracellular fate of cell delivery vectors including those based on cell penetrating peptides.  Thus gaining accurate knowledge of their endocytic uptake and traffic is an important characterization criteria for progress in this field.  This review describes the different endocytic pathways that have been identified in mammalian cells and specific reports that have studied the uptake mechanisms and endocytic traffic of cell penetrating peptides and their assocd. cargo.  These cargoes range from short peptides to an increasing library of nanoparticles such as quantum dots, liposomes and polymeric dendrimers.  The studies highlight the effectiveness of cell penetrating peptides for delivering these entities into a diverse array of cell types using different endocytic pathways.  This is shown using microscopy based colocalization anal. with the few specific endocytic probes available, and chem. inhibitors of endocytosis that suffer from lack of specificity.  Overall, more specific probes, inhibitors and novel technologies are required for accurate characterization of cellular dynamics of cell penetrating peptide conjugates thus allowing them to reach their full potential as vectors for therapeutics and other payloads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpf1lhOrbWWrVg90H21EOLACvtfcHk0lhYUkIsgGi_Iw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovFemtbo%253D&md5=b9db84cb202a7447e6dde69e268e14a1</span></div><a href="/servlet/linkout?suffix=cit178a&amp;dbid=16384&amp;doi=10.2174%2F13816128113199990297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F13816128113199990297%26sid%3Dliteratum%253Aachs%26aulast%3DCleal%26aufirst%3DK.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DWatson%26aufirst%3DP.%2BD.%26aulast%3DJones%26aufirst%3DA.%2BT.%26atitle%3DEndocytosis%252C%2520intracellular%2520traffic%2520and%2520fate%2520of%2520cell%2520penetrating%2520peptide%2520based%2520conjugates%2520and%2520nanoparticles%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2013%26volume%3D19%26spage%3D2878%26epage%3D2894%26doi%3D10.2174%2F13816128113199990297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit178b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, F.</span><span> </span><span class="NLM_article-title">Recent progress of cell-penetrating peptides as new carriers for intracellular cargo delivery</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">174</span><span class="NLM_x">, </span> <span class="NLM_fpage">126</span><span class="NLM_x">â</span> <span class="NLM_lpage">136</span><span class="refDoi">Â DOI: 10.1016/j.jconrel.2013.11.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.jconrel.2013.11.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24291335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVymsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2014&pages=126-136&author=F.+Wangauthor=Y.+Wangauthor=X.+Zhangauthor=W.+Zhangauthor=S.+Guoauthor=F.+Jin&title=Recent+progress+of+cell-penetrating+peptides+as+new+carriers+for+intracellular+cargo+delivery&doi=10.1016%2Fj.jconrel.2013.11.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178bR"><div class="casContent"><span class="casTitleNuber">178b</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress of cell-penetrating peptides as new carriers for intracellular cargo delivery</span></div><div class="casAuthors">Wang, Feihu; Wang, Yun; Zhang, Xiao; Zhang, Wenjun; Guo, Shengrong; Jin, Fang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">126-136</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The plasma membrane as a selectively permeable barrier of living cells is essential to cell survival and function.  In many cases, however, the efficient passage of exogenous bioactive mols. through the plasma membrane remains a major hurdle for intracellular delivery of cargoes.  During the last two decades, the potential of peptides for drug delivery into cells has been highlighted by the discovery of numerous cell-penetrating peptides (CPPs).  CPPs serving as carriers can successfully intracellular transport cargoes such as siRNA, nucleic acids, proteins, small mol. therapeutic agents, quantum dots and MRI contrast agents.  This review mainly introduces recent advances of CPPs as new carriers for the development of cellular imaging, nuclear localization, pH-sensitive and thermally targeted delivery systems.  In particular, we highlight the exploiting of the synergistic effects of targeting ligands and CPPs.  What's more, the classification and cellular uptake mechanisms of CPPs are briefly discussed as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXyE_6BuPiDrVg90H21EOLACvtfcHk0lhYUkIsgGi_Iw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVymsb0%253D&md5=8ad14be5d81937ac28a279843dbb5a23</span></div><a href="/servlet/linkout?suffix=cit178b&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2013.11.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2013.11.020%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DS.%26aulast%3DJin%26aufirst%3DF.%26atitle%3DRecent%2520progress%2520of%2520cell-penetrating%2520peptides%2520as%2520new%2520carriers%2520for%2520intracellular%2520cargo%2520delivery%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2014%26volume%3D174%26spage%3D126%26epage%3D136%26doi%3D10.1016%2Fj.jconrel.2013.11.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit178c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Reissmann, S.</span><span> </span><span class="NLM_article-title">Cell penetration: scope and limitations by the application of cell-penetrating peptides</span> <span class="citation_source-journal">J. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">760</span><span class="NLM_x">â</span> <span class="NLM_lpage">784</span><span class="refDoi">Â DOI: 10.1002/psc.2672</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fpsc.2672" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25112216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlarurnL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=760-784&author=S.+Reissmann&title=Cell+penetration%3A+scope+and+limitations+by+the+application+of+cell-penetrating+peptides&doi=10.1002%2Fpsc.2672"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178cR"><div class="casContent"><span class="casTitleNuber">178c</span><div class="casTitle"><span class="NLM_cas:atitle">Cell penetration: scope and limitations by the application of cell-penetrating peptides</span></div><div class="casAuthors">Reissmann, Siegmund</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">760-784</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  The penetration of polar or badly sol. compds. through a cell membrane into live cells requires mech. support or chem. helpers.  Cell-penetrating peptides (CPPs) are very promising chem. helpers.  Because of their low cytotoxicity and final degrdn. to amino acids, they are particularly favored in in vivo studies and for clin. applications.  Clearly, the future of CPP research is bright; however, the required optimization studies for each drug require considerable individualized attention.  Thus, CPPs are not the philosopher's stone.  As of today, a large no. of such transporter peptides with very different sequences have been identified.  These have different uptake mechanisms and can transport different cargos.  Intracellular concns. of cargos can reach a low micromole range and are able to influence intracellular reactions.  Internalized ribonucleic acids such as small interfering RNA (siRNA) and mimics of RNA such as peptide nucleic acids, morpholino nucleic acids, and triesters of oligonucleotides can influence transcription and translation.  Despite the highly efficient internalization of antibodies, enzymes, and other protein factors, as well as siRNA and RNA mimics, the uptake and stabile insertion of DNA into the genome of the host cells remain substantially challenging.  This review describes a wide array of differing CPPs, cargos, cell lines, and tissues.  The application of CPPs is compared with electroporation, magnetofection, lipofection, viral vectors, dendrimers, and nanoparticles, including com. available products.  The limitations of CPPs include low cell and tissue selectivity of the first generation and the necessity for formation of fusion proteins, conjugates, or noncovalent complexes to different cargos and of cargo release from intracellular vesicles.  Furthermore, the noncovalent complexes require a strong molar excess of CPPs, and extensive experimentation is required to det. the most optimal CPP for any given cargo and cell type.  Yet to predict which CPP is optimal for any given target remains a complex question.  More recently, there have been promising developments: the enhancement of cell specificity using activatable CPPs, specific transport into cell organelles by insertion of corresponding localization sequences, and the transport of drugs through blood-brain barriers, through the conjunctiva of eyes, skin, and into nerve cells.  Proteins, siRNA, and mimics of oligonucleotides can be efficiently transported into cells and have been tested for treatment of certain diseases.  The recent state of the art in CPP research is discussed together with the overall scope, limitations, and some recommendations for future research directions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotaRZ-ATX-lbVg90H21EOLACvtfcHk0lhYUkIsgGi_Iw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlarurnL&md5=5718cfe189a30c66c776390459b62a48</span></div><a href="/servlet/linkout?suffix=cit178c&amp;dbid=16384&amp;doi=10.1002%2Fpsc.2672&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.2672%26sid%3Dliteratum%253Aachs%26aulast%3DReissmann%26aufirst%3DS.%26atitle%3DCell%2520penetration%253A%2520scope%2520and%2520limitations%2520by%2520the%2520application%2520of%2520cell-penetrating%2520peptides%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2014%26volume%3D20%26spage%3D760%26epage%3D784%26doi%3D10.1002%2Fpsc.2672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group">Johnson, R. M.; Harrison, S. D.; Maclean, D.</span><span> </span><span class="NLM_article-title">Therapeutic applications of cell-penetrating peptides</span>. In  <span class="citation_source-book">Cell-Penetrating Peptides: Methods and Protocols</span>; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">Totowa, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2010</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">535</span><span class="NLM_x">â</span> <span class="NLM_lpage">551</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=535-551&author=R.+M.+Johnson&author=S.+D.+Harrison&author=D.+Maclean&title=Cell-Penetrating+Peptides%3A+Methods+and+Protocols"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DR.%2BM.%26atitle%3DTherapeutic%2520applications%2520of%2520cell-penetrating%2520peptides%26btitle%3DCell-Penetrating%2520Peptides%253A%2520Methods%2520and%2520Protocols%26pub%3DHumana%2520Press%26date%3D2010%26spage%3D535%26epage%3D551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group">Hill, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikulis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silver, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">terBrugge, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milot, G. v.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleetwood, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDougall, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunnarsson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lum, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodd, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poublanc, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krings, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demchuk, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goyal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishop, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tymianski, M.</span><span> </span><span class="NLM_article-title">Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial</span> <span class="citation_source-journal">Lancet Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">942</span><span class="NLM_x">â</span> <span class="NLM_lpage">950</span><span class="refDoi">Â DOI: 10.1016/S1474-4422(12)70225-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2FS1474-4422%2812%2970225-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23051991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFCqtbnO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=942-950&author=M.+D.+Hillauthor=R.+H.+Martinauthor=D.+Mikulisauthor=J.+H.+Wongauthor=F.+L.+Silverauthor=K.+G.+terBruggeauthor=G.+v.+Milotauthor=W.+M.+Clarkauthor=R.+L.+MacDonaldauthor=M.+E.+Kellyauthor=M.+Boultonauthor=I.+Fleetwoodauthor=C.+McDougallauthor=T.+Gunnarssonauthor=M.+Chowauthor=C.+Lumauthor=R.+Doddauthor=J.+Poublancauthor=T.+Kringsauthor=A.+M.+Demchukauthor=M.+Goyalauthor=R.+Andersonauthor=J.+Bishopauthor=D.+Garmanauthor=M.+Tymianski&title=Safety+and+efficacy+of+NA-1+in+patients+with+iatrogenic+stroke+after+endovascular+aneurysm+repair+%28ENACT%29%3A+a+phase+2%2C+randomised%2C+double-blind%2C+placebo-controlled+trial&doi=10.1016%2FS1474-4422%2812%2970225-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial</span></div><div class="casAuthors">Hill, Michael D.; Martin, Renee H.; Mikulis, David; Wong, John H.; Silver, Frank L.; terBrugge, Karel G.; Milot, Genevieve; Clark, Wayne M.; MacDonald, R. Loch; Kelly, Michael E.; Boulton, Melford; Fleetwood, Ian; McDougall, Cameron; Gunnarsson, Thorsteinn; Chow, Michael; Lum, Cheemun; Dodd, Robert; Poublanc, Julien; Krings, Timo; Demchuk, Andrew M.; Goyal, Mayank; Anderson, Roberta; Bishop, Julie; Garman, David; Tymianski, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">942-950</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: Neuroprotection with NA-1 (Tat-NR2B9c), an inhibitor of postsynaptic d.-95 protein, has been shown in a primate model of stroke.  We assessed whether NA-1 could reduce ischemic brain damage in human beings.  Methods: For this double-blind, randomised, controlled study, we enrolled patients aged 18 years or older who had a ruptured or unruptured intracranial aneurysm amenable to endovascular repair from 14 hospitals in Canada and the USA.  We used a computer-generated randomisation sequence to allocate patients to receive an i.v. infusion of either NA-1 or saline control at the end of their endovascular procedure (1:1; stratified by site, age, and aneurysm status).  Both patients and investigators were masked to treatment allocation.  The primary outcome was safety and primary clin. outcomes were the no. and vol. of new ischemic strokes defined by MRI at 12-95 h after infusion.  We used a modified intention-to-treat (mITT) anal.  This trial is registered with ClinicalTrials.gov, no. NCT00728182.  Findings: Between Sept 16, 2008, and March 30, 2011, we randomly allocated 197 patients to treatment-12 individuals did not receive treatment because they were found to be ineligible after randomisation, so the mITT population consisted of 185 individuals, 92 in the NA-1 group and 93 in the placebo group.  Two minor adverse events were adjudged to be assocd. with NA-1; no serious adverse events were attributable to NA-1.  We recorded no difference between groups in the vol. of lesions by either diffusion-weighted MRI (adjusted p value=0Â·120) or fluid-attenuated inversion recovery MRI (adjusted p value=0Â·236).  Patients in the NA-1 group sustained fewer ischemic infarcts than did patients in the placebo group, as gauged by diffusion-weighted MRI (adjusted incidence rate ratio 0Â·53, 95% CI 0Â·38-0Â·74) and fluid-attenuated inversion recovery MRI (0Â·59, 0Â·42-0Â·83).  Interpretation: Our findings suggest that neuroprotection in human ischemic stroke is possible and that it should be investigated in larger trials.  Funding: NoNO Inc and Arbor Vita Corp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRS9lHk6iZ9rVg90H21EOLACvtfcHk0litTZPjMI3MmQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFCqtbnO&md5=1cbefddebde83dc75dbd3b5ee45bf0ac</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2812%2970225-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252812%252970225-9%26sid%3Dliteratum%253Aachs%26aulast%3DHill%26aufirst%3DM.%2BD.%26aulast%3DMartin%26aufirst%3DR.%2BH.%26aulast%3DMikulis%26aufirst%3DD.%26aulast%3DWong%26aufirst%3DJ.%2BH.%26aulast%3DSilver%26aufirst%3DF.%2BL.%26aulast%3DterBrugge%26aufirst%3DK.%2BG.%26aulast%3DMilot%26aufirst%3DG.%2Bv.%26aulast%3DClark%26aufirst%3DW.%2BM.%26aulast%3DMacDonald%26aufirst%3DR.%2BL.%26aulast%3DKelly%26aufirst%3DM.%2BE.%26aulast%3DBoulton%26aufirst%3DM.%26aulast%3DFleetwood%26aufirst%3DI.%26aulast%3DMcDougall%26aufirst%3DC.%26aulast%3DGunnarsson%26aufirst%3DT.%26aulast%3DChow%26aufirst%3DM.%26aulast%3DLum%26aufirst%3DC.%26aulast%3DDodd%26aufirst%3DR.%26aulast%3DPoublanc%26aufirst%3DJ.%26aulast%3DKrings%26aufirst%3DT.%26aulast%3DDemchuk%26aufirst%3DA.%2BM.%26aulast%3DGoyal%26aufirst%3DM.%26aulast%3DAnderson%26aufirst%3DR.%26aulast%3DBishop%26aufirst%3DJ.%26aulast%3DGarman%26aufirst%3DD.%26aulast%3DTymianski%26aufirst%3DM.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520NA-1%2520in%2520patients%2520with%2520iatrogenic%2520stroke%2520after%2520endovascular%2520aneurysm%2520repair%2520%2528ENACT%2529%253A%2520a%2520phase%25202%252C%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%2520trial%26jtitle%3DLancet%2520Neurol.%26date%3D2012%26volume%3D11%26spage%3D942%26epage%3D950%26doi%3D10.1016%2FS1474-4422%2812%2970225-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group">Dinca, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, W.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, M.</span><span> </span><span class="NLM_article-title">Intracellular delivery of proteins with cell-penetrating peptides for therapeutic uses in human disease</span> <span class="citation_source-journal">Int. J. Mol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">263</span><span class="refDoi">Â DOI: 10.3390/ijms17020263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3390%2Fijms17020263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26907261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovVGjtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=263&author=A.+Dincaauthor=W.-M.+Chienauthor=M.+Chin&title=Intracellular+delivery+of+proteins+with+cell-penetrating+peptides+for+therapeutic+uses+in+human+disease&doi=10.3390%2Fijms17020263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular delivery of proteins with cell-penetrating peptides for therapeutic uses in human disease</span></div><div class="casAuthors">Dinca, Ana; Chien, Wei-Ming; Chin, Michael T.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263/1-263/13</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Protein therapy exhibits several advantages over small mol. drugs and is increasingly being developed for the treatment of disorders ranging from single enzyme deficiencies to cancer.  Cell-penetrating peptides (CPPs), a group of small peptides capable of promoting transport of mol. cargo across the plasma membrane, have become important tools in promoting the cellular uptake of exogenously delivered proteins.  Although the mol. mechanisms of uptake are not firmly established, CPPs have been empirically shown to promote uptake of various mols., including large proteins over 100 kiloDaltons (kDa).  Recombinant proteins that include a CPP tag to promote intracellular delivery show promise as therapeutic agents with encouraging success rates in both animal and human trials.  This review highlights recent advances in protein-CPP therapy and discusses optimization strategies and potential detrimental effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7xbKredb6CLVg90H21EOLACvtfcHk0litTZPjMI3MmQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovVGjtA%253D%253D&md5=6651857828ed4f2032d0db40c76cd61d</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.3390%2Fijms17020263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms17020263%26sid%3Dliteratum%253Aachs%26aulast%3DDinca%26aufirst%3DA.%26aulast%3DChien%26aufirst%3DW.-M.%26aulast%3DChin%26aufirst%3DM.%26atitle%3DIntracellular%2520delivery%2520of%2520proteins%2520with%2520cell-penetrating%2520peptides%2520for%2520therapeutic%2520uses%2520in%2520human%2520disease%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2016%26volume%3D17%26spage%3D263%26doi%3D10.3390%2Fijms17020263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group">Presolski, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, M. G.</span><span> </span><span class="NLM_article-title">Copper-catalyzed azideâalkyne click chemistry for bioconjugation</span> <span class="citation_source-journal">Curr. Protoc. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">â</span> <span class="NLM_lpage">162</span><span class="refDoi">Â DOI: 10.1002/9780470559277.ch110148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2F9780470559277.ch110148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=22844652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A280%3ADC%252BC2srmslKltg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=153-162&author=S.+I.+Presolskiauthor=V.+P.+Hongauthor=M.+G.+Finn&title=Copper-catalyzed+azide%E2%80%93alkyne+click+chemistry+for+bioconjugation&doi=10.1002%2F9780470559277.ch110148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Copper-Catalyzed Azide-Alkyne Click Chemistry for Bioconjugation</span></div><div class="casAuthors">Presolski Stanislav I; Hong Vu Phong; Finn M G</div><div class="citationInfo"><span class="NLM_cas:title">Current protocols in chemical biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">153-162</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The copper-catalyzed azide-alkyne cycloaddition reaction is widely used for the connection of molecular entities of all sizes.  A protocol is provided here for the process with biomolecules.  Ascorbate is used as reducing agent to maintain the required cuprous oxidation state.  Since these convenient conditions produce reactive oxygen species, five equivalents of a copper-binding ligand is used with respect to metal.  The ligand both accelerates the reaction and serves as a sacrificial reductant, protecting the biomolecules from oxidation.  A procedure is also described for testing the efficiency of the reaction under desired conditions for purposes of optimization, before expensive biological reagents are used.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8A2KT2nosgEg6wdEZmT2rfW6udTcc2ebhyf1ErsEGn7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srmslKltg%253D%253D&md5=cc622ec6ed0e16170ef2e6ebd1541d0a</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1002%2F9780470559277.ch110148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F9780470559277.ch110148%26sid%3Dliteratum%253Aachs%26aulast%3DPresolski%26aufirst%3DS.%2BI.%26aulast%3DHong%26aufirst%3DV.%2BP.%26aulast%3DFinn%26aufirst%3DM.%2BG.%26atitle%3DCopper-catalyzed%2520azide%25E2%2580%2593alkyne%2520click%2520chemistry%2520for%2520bioconjugation%26jtitle%3DCurr.%2520Protoc.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D3%26spage%3D153%26epage%3D162%26doi%3D10.1002%2F9780470559277.ch110148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">McKay, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, M. G.</span><span> </span><span class="NLM_article-title">Click chemistry in complex mixtures: bioorthogonal bioconjugation</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1075</span><span class="NLM_x">â</span> <span class="NLM_lpage">1101</span><span class="refDoi">Â DOI: 10.1016/j.chembiol.2014.09.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.chembiol.2014.09.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25237856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyrur7N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=1075-1101&author=C.+S.+McKayauthor=M.+G.+Finn&title=Click+chemistry+in+complex+mixtures%3A+bioorthogonal+bioconjugation&doi=10.1016%2Fj.chembiol.2014.09.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183aR"><div class="casContent"><span class="casTitleNuber">183a</span><div class="casTitle"><span class="NLM_cas:atitle">Click Chemistry in Complex Mixtures: Bioorthogonal Bioconjugation</span></div><div class="casAuthors">McKay, Craig S.; Finn, M. G.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1075-1101</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The selective chem. modification of biol. mols. drives a good portion of modern drug development and fundamental biol. research.  While a few early examples of reactions that engage amine and thiol groups on proteins helped establish the value of such processes, the development of reactions that avoid most biol. mols. so as to achieve selectivity in desired bond-forming events has revolutionized the field.  We provide an update on recent developments in bioorthogonal chem. that highlights key advances in reaction rates, biocompatibility, and applications.  While not exhaustive, we hope this summary allows the reader to appreciate the rich continuing development of good chem. that operates in the biol. setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7SEdPeibs0LVg90H21EOLACvtfcHk0ljf1YoUiDsTLw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyrur7N&md5=64a6e5ea8a232b97fce61d1268093fe4</span></div><a href="/servlet/linkout?suffix=cit183a&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2014.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2014.09.002%26sid%3Dliteratum%253Aachs%26aulast%3DMcKay%26aufirst%3DC.%2BS.%26aulast%3DFinn%26aufirst%3DM.%2BG.%26atitle%3DClick%2520chemistry%2520in%2520complex%2520mixtures%253A%2520bioorthogonal%2520bioconjugation%26jtitle%3DChem.%2520Biol.%26date%3D2014%26volume%3D21%26spage%3D1075%26epage%3D1101%26doi%3D10.1016%2Fj.chembiol.2014.09.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit183b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Krall, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">da Cruz, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boutureira, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernardes, G. J. L.</span><span> </span><span class="NLM_article-title">Site-selective protein-modification chemistry for basic biology and drug development</span> <span class="citation_source-journal">Nat. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">â</span> <span class="NLM_lpage">113</span><span class="refDoi">Â DOI: 10.1038/nchem.2393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnchem.2393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26791892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFemsbrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=103-113&author=N.+Krallauthor=F.+P.+da+Cruzauthor=O.+Boutureiraauthor=G.+J.+L.+Bernardes&title=Site-selective+protein-modification+chemistry+for+basic+biology+and+drug+development&doi=10.1038%2Fnchem.2393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183bR"><div class="casContent"><span class="casTitleNuber">183b</span><div class="casTitle"><span class="NLM_cas:atitle">Site-selective protein-modification chemistry for basic biology and drug development</span></div><div class="casAuthors">Krall, Nikolaus; da Cruz, Filipa P.; Boutureira, Omar; Bernardes, Goncalo J. L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-113</span>CODEN:
                <span class="NLM_cas:coden">NCAHBB</span>;
        ISSN:<span class="NLM_cas:issn">1755-4330</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Nature has produced intricate machinery to covalently diversify the structure of proteins after their synthesis in the ribosome.  In an attempt to mimic nature, chemists have developed a large set of reactions that enable post-expression modification of proteins at pre-detd. sites.  These reactions are now used to selectively install particular modifications on proteins for many biol. and therapeutic applications.  For example, they provide an opportunity to install post-translational modifications on proteins to det. their exact biol. roles.  Labeling of proteins in live cells with fluorescent dyes allows protein uptake and intracellular trafficking to be tracked and also enables physiol. parameters to be measured optically.  Through the conjugation of potent cytotoxicants to antibodies, novel anti-cancer drugs with improved efficacy and reduced side effects may be obtained.  In this Perspective, we highlight the most exciting current and future applications of chem. site-selective protein modification and consider which hurdles still need to be overcome for more widespread use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCXe9yoL2S-bVg90H21EOLACvtfcHk0ljf1YoUiDsTLw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFemsbrI&md5=9a8f675a512f1286c5d88c6692d8773c</span></div><a href="/servlet/linkout?suffix=cit183b&amp;dbid=16384&amp;doi=10.1038%2Fnchem.2393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchem.2393%26sid%3Dliteratum%253Aachs%26aulast%3DKrall%26aufirst%3DN.%26aulast%3Dda%2BCruz%26aufirst%3DF.%2BP.%26aulast%3DBoutureira%26aufirst%3DO.%26aulast%3DBernardes%26aufirst%3DG.%2BJ.%2BL.%26atitle%3DSite-selective%2520protein-modification%2520chemistry%2520for%2520basic%2520biology%2520and%2520drug%2520development%26jtitle%3DNat.%2520Chem.%26date%3D2016%26volume%3D8%26spage%3D103%26epage%3D113%26doi%3D10.1038%2Fnchem.2393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit183c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Sochaj, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Å¡widerska, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otlewski, J.</span><span> </span><span class="NLM_article-title">Current methods for the synthesis of homogeneous antibody-drug conjugates</span> <span class="citation_source-journal">Biotechnol. Adv.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">775</span><span class="NLM_x">â</span> <span class="NLM_lpage">784</span><span class="refDoi">Â DOI: 10.1016/j.biotechadv.2015.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.biotechadv.2015.05.001" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=775-784&author=A.+M.+Sochajauthor=K.+W.+%C5%A1widerskaauthor=J.+Otlewski&title=Current+methods+for+the+synthesis+of+homogeneous+antibody-drug+conjugates&doi=10.1016%2Fj.biotechadv.2015.05.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit183c&amp;dbid=16384&amp;doi=10.1016%2Fj.biotechadv.2015.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biotechadv.2015.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DSochaj%26aufirst%3DA.%2BM.%26aulast%3D%25C5%25A1widerska%26aufirst%3DK.%2BW.%26aulast%3DOtlewski%26aufirst%3DJ.%26atitle%3DCurrent%2520methods%2520for%2520the%2520synthesis%2520of%2520homogeneous%2520antibody-drug%2520conjugates%26jtitle%3DBiotechnol.%2520Adv.%26date%3D2015%26volume%3D33%26spage%3D775%26epage%3D784%26doi%3D10.1016%2Fj.biotechadv.2015.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cal, P. M. S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernardes, G. J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gois, P. M. P.</span><span> </span><span class="NLM_article-title">Cysteine-selective reactions for antibody conjugation</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">10585</span><span class="NLM_x">â</span> <span class="NLM_lpage">10587</span><span class="refDoi">Â DOI: 10.1002/anie.201405702</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fanie.201405702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1ams7jF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=10585-10587&author=P.+M.+S.+D.+Calauthor=G.+J.+L.+Bernardesauthor=P.+M.+P.+Gois&title=Cysteine-selective+reactions+for+antibody+conjugation&doi=10.1002%2Fanie.201405702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184aR"><div class="casContent"><span class="casTitleNuber">184a</span><div class="casTitle"><span class="NLM_cas:atitle">Cysteine-Selective Reactions for Antibody Conjugation</span></div><div class="casAuthors">Cal, Pedro M. S. D.; Bernardes, Goncalo J. L.; Gois, Pedro M. P.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">10585-10587</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The unique targeting ability of antibodies has triggered burgeoning interest in the attachment of potent cytotoxic drugs onto these biomols. to create antibody-drug conjugates (ADCs).  A key factor in the design of therapeutically useful ADCs is the ability to create chem. defined, stable protein-drug conjugates.  The aim of this highlight is to discuss new methods for site-selective bioconjugation at native or engineered cysteines, methods which may be used to build homogeneous and stable ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMz3aKFjFe8rVg90H21EOLACvtfcHk0ljf1YoUiDsTLw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1ams7jF&md5=a9b477a09aa18c06fa325db95184e436</span></div><a href="/servlet/linkout?suffix=cit184a&amp;dbid=16384&amp;doi=10.1002%2Fanie.201405702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201405702%26sid%3Dliteratum%253Aachs%26aulast%3DCal%26aufirst%3DP.%2BM.%2BS.%2BD.%26aulast%3DBernardes%26aufirst%3DG.%2BJ.%2BL.%26aulast%3DGois%26aufirst%3DP.%2BM.%2BP.%26atitle%3DCysteine-selective%2520reactions%2520for%2520antibody%2520conjugation%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D10585%26epage%3D10587%26doi%3D10.1002%2Fanie.201405702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit184b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Vinogradova, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spokoyny, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pentelute, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, S. L.</span><span> </span><span class="NLM_article-title">Organometallic palladium reagents for cysteine bioconjugation</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">526</span><span class="NLM_x">, </span> <span class="NLM_fpage">687</span><span class="NLM_x">â</span> <span class="NLM_lpage">691</span><span class="refDoi">Â DOI: 10.1038/nature15739</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnature15739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26511579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslCnu7zK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=526&publication_year=2015&pages=687-691&author=E.+V.+Vinogradovaauthor=C.+Zhangauthor=A.+M.+Spokoynyauthor=B.+L.+Penteluteauthor=S.+L.+Buchwald&title=Organometallic+palladium+reagents+for+cysteine+bioconjugation&doi=10.1038%2Fnature15739"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184bR"><div class="casContent"><span class="casTitleNuber">184b</span><div class="casTitle"><span class="NLM_cas:atitle">Organometallic palladium reagents for cysteine bioconjugation</span></div><div class="casAuthors">Vinogradova, Ekaterina V.; Zhang, Chi; Spokoyny, Alexander M.; Pentelute, Bradley L.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">526</span>
        (<span class="NLM_cas:issue">7575</span>),
    <span class="NLM_cas:pages">687-691</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Peptides and proteins, contg. cysteine amino acid, were labeled by conjugation of the SH-group with arylpalladium 2-biphenylylphosphine hemilabile reagent, causing arylation the mercapto-group.  Reactions based on transition metals have found wide use in org. synthesis, in particular for the functionalization of small mols.  However, there are very few reports of using transition-metal-based reactions to modify complex biomols., which is due to the need for stringent reaction conditions (for example, aq. media, low temp. and mild pH) and the existence of multiple reactive functional groups found in biomols.  Here we report that palladium(II) complexes can be used for efficient and highly selective cysteine conjugation (bioconjugation) reactions that are rapid and robust under a range of bio-compatible reaction conditions.  The straightforward synthesis of the palladium reagents from diverse and easily accessible aryl halide and trifluoromethanesulfonate precursors makes the method highly practical, providing access to a large structural space for protein modification.  The resulting aryl bioconjugates are stable towards acids, bases, oxidants and external thiol nucleophiles.  The broad utility of the bioconjugation platform was further corroborated by the synthesis of new classes of stapled peptides and antibody-drug conjugates.  These palladium complexes show potential as benchtop reagents for diverse bioconjugation applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLRNU9i0UtEbVg90H21EOLACvtfcHk0liAl6-Zx_MjHg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslCnu7zK&md5=8fbb382c94600af312bb007d31b63056</span></div><a href="/servlet/linkout?suffix=cit184b&amp;dbid=16384&amp;doi=10.1038%2Fnature15739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature15739%26sid%3Dliteratum%253Aachs%26aulast%3DVinogradova%26aufirst%3DE.%2BV.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DSpokoyny%26aufirst%3DA.%2BM.%26aulast%3DPentelute%26aufirst%3DB.%2BL.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DOrganometallic%2520palladium%2520reagents%2520for%2520cysteine%2520bioconjugation%26jtitle%3DNature%26date%3D2015%26volume%3D526%26spage%3D687%26epage%3D691%26doi%3D10.1038%2Fnature15739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group">Agten, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hackeng, T. M.</span><span> </span><span class="NLM_article-title">Oxime conjugation in protein chemistry: from carbonyl incorporation to nucleophilic catalysis</span> <span class="citation_source-journal">J. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">271</span><span class="NLM_x">â</span> <span class="NLM_lpage">279</span><span class="refDoi">Â DOI: 10.1002/psc.2874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fpsc.2874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=27006095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XksFGjsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=271-279&author=S.+M.+Agtenauthor=P.+E.+Dawsonauthor=T.+M.+Hackeng&title=Oxime+conjugation+in+protein+chemistry%3A+from+carbonyl+incorporation+to+nucleophilic+catalysis&doi=10.1002%2Fpsc.2874"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Oxime conjugation in protein chemistry: from carbonyl incorporation to nucleophilic catalysis</span></div><div class="casAuthors">Agten, Stijn M.; Dawson, Philip E.; Hackeng, Tilman M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">271-279</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Use of oxime forming reactions has become a widely applied strategy for peptide and protein bioconjugation.  The efficiency of the reaction and robust stability of the oxime product led to the development of a growing list of methods to introduce the required ketone or aldehyde functionality site specifically into proteins.  Early methods focused on site-specific oxidn. of an N-terminal serine or threonine and more recently transamination methods have been developed to convert a broader set of N-terminal amino acids into a ketone or aldehyde.  More recently, site-specific modification of protein has been attained through engineering enzymes involved in posttranslational modifications to accommodate aldehyde-contg. substrates.  Similarly, a growing list of unnatural amino acids can be introduced through development of selective amino-acyl tRNA synthetase/tRNA pairs combined with codon reassignment.  In the case of glycoproteins, glycans can be selectively modified chem. or enzymically to introduce aldehyde functional groups.  Finally, the total chem. synthesis of proteins complements these biol. and chemoenzymic approaches.  Once introduced, the oxime ligation of these aldehyde and ketone groups can be catalyzed by aniline or a variety of aniline derivs. to tune the activity, pH preference, stability and soly. of the catalyst.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowHo2_J0koqrVg90H21EOLACvtfcHk0liAl6-Zx_MjHg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksFGjsrk%253D&md5=b616d6bf4a65fe8cbaa88d71dca3561b</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1002%2Fpsc.2874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.2874%26sid%3Dliteratum%253Aachs%26aulast%3DAgten%26aufirst%3DS.%2BM.%26aulast%3DDawson%26aufirst%3DP.%2BE.%26aulast%3DHackeng%26aufirst%3DT.%2BM.%26atitle%3DOxime%2520conjugation%2520in%2520protein%2520chemistry%253A%2520from%2520carbonyl%2520incorporation%2520to%2520nucleophilic%2520catalysis%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2016%26volume%3D22%26spage%3D271%26epage%3D279%26doi%3D10.1002%2Fpsc.2874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welborn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santos, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Voorhis, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pentelute, B. L.</span><span> </span><span class="NLM_article-title">Ï-Clamp-mediated cysteine conjugation</span> <span class="citation_source-journal">Nat. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">120</span><span class="NLM_x">â</span> <span class="NLM_lpage">128</span><span class="refDoi">Â DOI: 10.1038/nchem.2413</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnchem.2413" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26791894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVygurzE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=120-128&author=C.+Zhangauthor=M.+Welbornauthor=T.+Zhuauthor=N.+J.+Yangauthor=M.+S.+Santosauthor=T.+Van+Voorhisauthor=B.+L.+Pentelute&title=%CF%80-Clamp-mediated+cysteine+conjugation&doi=10.1038%2Fnchem.2413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Ï-Clamp-mediated cysteine conjugation</span></div><div class="casAuthors">Zhang, Chi; Welborn, Matthew; Zhu, Tianyu; Yang, Nicole J.; Santos, Michael S.; Van Voorhis, Troy; Pentelute, Bradley L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">120-128</span>CODEN:
                <span class="NLM_cas:coden">NCAHBB</span>;
        ISSN:<span class="NLM_cas:issn">1755-4330</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Site-selective functionalization of complex mols. is one of the most significant challenges in chem.  Typically, protecting groups or catalysts must be used to enable the selective modification of one site among many that are similarly reactive, and general strategies that selectively tune the local chem. environment around a target site are rare.  Here, the authors show a four-amino-acid sequence (Phe-Cys-Pro-Phe), which the authors call the Ï-clamp, that tunes the reactivity of its cysteine thiol for site-selective conjugation with perfluoroarom. reagents.  The authors use the Ï-clamp to selectively modify one cysteine site in proteins contg. multiple endogenous cysteine residues.  These examples include antibodies and cysteine-based enzymes that would be difficult to modify selectively using std. cysteine-based methods.  Antibodies modified using the Ï-clamp retained binding affinity to their targets, enabling the synthesis of site-specific antibody-drug conjugates for selective killing of HER2-pos. breast cancer cells.  The Ï-clamp is an unexpected approach to mediate site-selective chem. and provides new avenues to modify biomols. for research and therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN7ymIedFQd7Vg90H21EOLACvtfcHk0liAl6-Zx_MjHg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVygurzE&md5=8c3c367f6fd7c64237bd0ba3e9bd40b4</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1038%2Fnchem.2413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchem.2413%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DWelborn%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DN.%2BJ.%26aulast%3DSantos%26aufirst%3DM.%2BS.%26aulast%3DVan%2BVoorhis%26aufirst%3DT.%26aulast%3DPentelute%26aufirst%3DB.%2BL.%26atitle%3D%25CF%2580-Clamp-mediated%2520cysteine%2520conjugation%26jtitle%3DNat.%2520Chem.%26date%3D2016%26volume%3D8%26spage%3D120%26epage%3D128%26doi%3D10.1038%2Fnchem.2413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group">Theile, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blom, A. E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kundrat, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ploegh, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guimaraes, C. P.</span><span> </span><span class="NLM_article-title">Site-specific N-terminal labeling of proteins using sortase-mediated reactions</span> <span class="citation_source-journal">Nat. Protoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1800</span><span class="NLM_x">â</span> <span class="NLM_lpage">1807</span><span class="refDoi">Â DOI: 10.1038/nprot.2013.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnprot.2013.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23989674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2hurrK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1800-1807&author=C.+S.+Theileauthor=M.+D.+Witteauthor=A.+E.+M.+Blomauthor=L.+Kundratauthor=H.+L.+Ploeghauthor=C.+P.+Guimaraes&title=Site-specific+N-terminal+labeling+of+proteins+using+sortase-mediated+reactions&doi=10.1038%2Fnprot.2013.102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Site-specific N-terminal labeling of proteins using sortase-mediated reactions</span></div><div class="casAuthors">Theile, Christopher S.; Witte, Martin D.; Blom, Annet E. M.; Kundrat, Lenka; Ploegh, Hidde L.; Guimaraes, Carla P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1800-1807, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This protocol describes the use of sortase-mediated reactions to label the N terminus of any given protein of interest.  The sortase recognition sequence, LPLPXTG (for Streptococcus aureus sortase A) or LPXTA (for Staphylococcus pyogenes sortase A), can be appended to a variety of probes such as fluorophores, biotin or even to other proteins.  The protein to be labeled acts as a nucleophile by attacking the intermediate formed between the probe contg. the LPXTG/A motif and the sortase enzyme.  If sortase, the protein of interest and a suitably functionalized label are available, the reactions usually require less than 3 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy2oSU1sYbKLVg90H21EOLACvtfcHk0liAl6-Zx_MjHg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2hurrK&md5=3630095942671637c7b047ac2e69c85f</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2013.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2013.102%26sid%3Dliteratum%253Aachs%26aulast%3DTheile%26aufirst%3DC.%2BS.%26aulast%3DWitte%26aufirst%3DM.%2BD.%26aulast%3DBlom%26aufirst%3DA.%2BE.%2BM.%26aulast%3DKundrat%26aufirst%3DL.%26aulast%3DPloegh%26aufirst%3DH.%2BL.%26aulast%3DGuimaraes%26aufirst%3DC.%2BP.%26atitle%3DSite-specific%2520N-terminal%2520labeling%2520of%2520proteins%2520using%2520sortase-mediated%2520reactions%26jtitle%3DNat.%2520Protoc.%26date%3D2013%26volume%3D8%26spage%3D1800%26epage%3D1807%26doi%3D10.1038%2Fnprot.2013.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group">Wood, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camarero, J. A.</span><span> </span><span class="NLM_article-title">Intein applications: From protein purification and labeling to metabolic control methods</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">14512</span><span class="NLM_x">â</span> <span class="NLM_lpage">14519</span><span class="refDoi">Â DOI: 10.1074/jbc.R114.552653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1074%2Fjbc.R114.552653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24700459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXos1Cjurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=14512-14519&author=D.+W.+Woodauthor=J.+A.+Camarero&title=Intein+applications%3A+From+protein+purification+and+labeling+to+metabolic+control+methods&doi=10.1074%2Fjbc.R114.552653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Intein Applications: From Protein Purification and Labeling to Metabolic Control Methods</span></div><div class="casAuthors">Wood, David W.; Camarero, Julio A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">14512-14519</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review.  The discovery of inteins in the early 1990s opened the door to a wide variety of new technologies.  Early engineered inteins from various sources allowed the development of self-cleaving affinity tags and new methods for joining protein segments through expressed protein ligation.  Some applications were developed around native and engineered split inteins, which allow protein segments expressed sep. to be spliced together in vitro.  More recently, these early applications have been expanded and optimized through the discovery of highly efficient trans-splicing and trans-cleaving inteins.  These new inteins have enabled a wide variety of applications in metabolic engineering, protein labeling, biomaterials construction, protein cyclization, and protein purifn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZEPIbg2R7SbVg90H21EOLACvtfcHk0liN09oreNTGXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXos1Cjurk%253D&md5=f14b096b63bb55957d0d5fe27a33a715</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1074%2Fjbc.R114.552653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.R114.552653%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DD.%2BW.%26aulast%3DCamarero%26aufirst%3DJ.%2BA.%26atitle%3DIntein%2520applications%253A%2520From%2520protein%2520purification%2520and%2520labeling%2520to%2520metabolic%2520control%2520methods%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D14512%26epage%3D14519%26doi%3D10.1074%2Fjbc.R114.552653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kim, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Axup, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, P. G.</span><span> </span><span class="NLM_article-title">Protein conjugation with genetically encoded unnatural amino acids</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">412</span><span class="NLM_x">â</span> <span class="NLM_lpage">419</span><span class="refDoi">Â DOI: 10.1016/j.cbpa.2013.04.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.cbpa.2013.04.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23664497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVGgsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=412-419&author=C.+H.+Kimauthor=J.+Y.+Axupauthor=P.+G.+Schultz&title=Protein+conjugation+with+genetically+encoded+unnatural+amino+acids&doi=10.1016%2Fj.cbpa.2013.04.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189aR"><div class="casContent"><span class="casTitleNuber">189a</span><div class="casTitle"><span class="NLM_cas:atitle">Protein conjugation with genetically encoded unnatural amino acids</span></div><div class="casAuthors">Kim, Chan Hyuk; Axup, Jun Y.; Schultz, Peter G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">412-419</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The site-specific incorporation of unnatural amino acids with orthogonal chem. reactivity into proteins enables the synthesis of structurally defined protein conjugates.  Amino acids contg. ketone, azide, alkyne, alkene, and tetrazine side chains can be genetically encoded in response to nonsense and frameshift codons.  These bio-orthogonal chem. handles allow precise control over the site and stoichiometry of conjugation, and have enabled medicinal chem.-like optimization of the phys. and biol. properties of protein conjugates, esp. the next-generation protein therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQfHma4vcPzLVg90H21EOLACvtfcHk0liN09oreNTGXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVGgsrs%253D&md5=2fded16f212df5db3f709bdd38e87887</span></div><a href="/servlet/linkout?suffix=cit189a&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2013.04.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2013.04.017%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DC.%2BH.%26aulast%3DAxup%26aufirst%3DJ.%2BY.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26atitle%3DProtein%2520conjugation%2520with%2520genetically%2520encoded%2520unnatural%2520amino%2520acids%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D17%26spage%3D412%26epage%3D419%26doi%3D10.1016%2Fj.cbpa.2013.04.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit189b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lim, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, I.</span><span> </span><span class="NLM_article-title">Bioconjugation of therapeutic proteins and enzymes using the expanded set of genetically encoded amino acids</span> <span class="citation_source-journal">Crit. Rev. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">803</span><span class="NLM_x">â</span> <span class="NLM_lpage">815</span><span class="refDoi">Â DOI: 10.3109/07388551.2015.1048504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3109%2F07388551.2015.1048504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26036278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ehtbbL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=803-815&author=S.+I.+Limauthor=I.+Kwon&title=Bioconjugation+of+therapeutic+proteins+and+enzymes+using+the+expanded+set+of+genetically+encoded+amino+acids&doi=10.3109%2F07388551.2015.1048504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189bR"><div class="casContent"><span class="casTitleNuber">189b</span><div class="casTitle"><span class="NLM_cas:atitle">Bioconjugation of therapeutic proteins and enzymes using the expanded set of genetically encoded amino acids</span></div><div class="casAuthors">Lim, Sung In; Kwon, Inchan</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Biotechnology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">803-815</span>CODEN:
                <span class="NLM_cas:coden">CRBTE5</span>;
        ISSN:<span class="NLM_cas:issn">0738-8551</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  The last decade has witnessed striking progress in the development of bioorthogonal reactions that are strictly directed towards intended sites in biomols. while avoiding interference by a no. of phys. and chem. factors in biol. environment.  Efforts to exploit bioorthogonal reactions in protein conjugation have led to the evolution of protein translational machineries and the expansion of genetic codes that systematically incorporate a range of non-natural amino acids contg. bioorthogonal groups into recombinant proteins in a site-specific manner.  Chemoselective conjugation of proteins has begun to find valuable applications to previously inaccessible problems.  In this review, we describe bioorthogonal reactions useful for protein conjugation, and biosynthetic methods that produce proteins amenable to those reactions through an expanded genetic code.  We then provide key examples in which novel protein conjugates, generated by the genetic incorporation of a non-natural amino acid and the chemoselective reactions, address unmet needs in protein therapeutics and enzyme engineering.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonOUvKYaG7bLVg90H21EOLACvtfcHk0liN09oreNTGXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ehtbbL&md5=fca815073051ed3ee3fc403f4d5cdfb6</span></div><a href="/servlet/linkout?suffix=cit189b&amp;dbid=16384&amp;doi=10.3109%2F07388551.2015.1048504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F07388551.2015.1048504%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DS.%2BI.%26aulast%3DKwon%26aufirst%3DI.%26atitle%3DBioconjugation%2520of%2520therapeutic%2520proteins%2520and%2520enzymes%2520using%2520the%2520expanded%2520set%2520of%2520genetically%2520encoded%2520amino%2520acids%26jtitle%3DCrit.%2520Rev.%2520Biotechnol.%26date%3D2016%26volume%3D36%26spage%3D803%26epage%3D815%26doi%3D10.3109%2F07388551.2015.1048504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group">Chirmule, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jawa, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meibohm, B.</span><span> </span><span class="NLM_article-title">Immunogenicity to therapeutic proteins: Impact on PK/PD and efficacy</span> <span class="citation_source-journal">AAPS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">296</span><span class="NLM_x">â</span> <span class="NLM_lpage">302</span><span class="refDoi">Â DOI: 10.1208/s12248-012-9340-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1208%2Fs12248-012-9340-y" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=296-302&author=N.+Chirmuleauthor=V.+Jawaauthor=B.+Meibohm&title=Immunogenicity+to+therapeutic+proteins%3A+Impact+on+PK%2FPD+and+efficacy&doi=10.1208%2Fs12248-012-9340-y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1208%2Fs12248-012-9340-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-012-9340-y%26sid%3Dliteratum%253Aachs%26aulast%3DChirmule%26aufirst%3DN.%26aulast%3DJawa%26aufirst%3DV.%26aulast%3DMeibohm%26aufirst%3DB.%26atitle%3DImmunogenicity%2520to%2520therapeutic%2520proteins%253A%2520Impact%2520on%2520PK%252FPD%2520and%2520efficacy%26jtitle%3DAAPS%2520J.%26date%3D2012%26volume%3D14%26spage%3D296%26epage%3D302%26doi%3D10.1208%2Fs12248-012-9340-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group">Jawa, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cousens, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awwad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakshull, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kropshofer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Groot, A. S.</span><span> </span><span class="NLM_article-title">T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation</span> <span class="citation_source-journal">Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">149</span><span class="NLM_x">, </span> <span class="NLM_fpage">534</span><span class="NLM_x">â</span> <span class="NLM_lpage">555</span><span class="refDoi">Â DOI: 10.1016/j.clim.2013.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.clim.2013.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24263283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFeks7%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2013&pages=534-555&author=V.+Jawaauthor=L.+P.+Cousensauthor=M.+Awwadauthor=E.+Wakshullauthor=H.+Kropshoferauthor=A.+S.+De+Groot&title=T-cell+dependent+immunogenicity+of+protein+therapeutics%3A+Preclinical+assessment+and+mitigation&doi=10.1016%2Fj.clim.2013.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation</span></div><div class="casAuthors">Jawa, Vibha; Cousens, Leslie P.; Awwad, Michel; Wakshull, Eric; Kropshofer, Harald; De Groot, Anne S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Immunology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">3PB</span>),
    <span class="NLM_cas:pages">534-555</span>CODEN:
                <span class="NLM_cas:coden">CLIIFY</span>;
        ISSN:<span class="NLM_cas:issn">1521-6616</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Protein therapeutics hold a prominent and rapidly expanding place among medicinal products.  Purified blood products, recombinant cytokines, growth factors, enzyme replacement factors, monoclonal antibodies, fusion proteins, and chimeric fusion proteins are all examples of therapeutic proteins that have been developed in the past few decades and approved for use in the treatment of human disease.  Despite early belief that the fully human nature of these proteins would represent a significant advantage, adverse effects assocd. with immune responses to some biol. therapies have become a topic of some concern.  As a result, drug developers are devising strategies to assess immune responses to protein therapeutics during both the preclin. and the clin. phases of development.  While there are many factors that contribute to protein immunogenicity, T cell- (thymus-) dependent (Td) responses appear to play a crit. role in the development of antibody responses to biol. therapeutics.  A range of methodologies to predict and measure Td immune responses to protein drugs has been developed.  This review will focus on the Td contribution to immunogenicity, summarizing current approaches for the prediction and measurement of T cell-dependent immune responses to protein biologics, discussing the advantages and limitations of these technologies, and suggesting a practical approach for assessing and mitigating Td immunogenicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdjcl9PB-KorVg90H21EOLACvtfcHk0lj0eM_RacEAfA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFeks7%252FF&md5=f4f05e6e8d07d42407ca0d8b0654502f</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1016%2Fj.clim.2013.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clim.2013.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DJawa%26aufirst%3DV.%26aulast%3DCousens%26aufirst%3DL.%2BP.%26aulast%3DAwwad%26aufirst%3DM.%26aulast%3DWakshull%26aufirst%3DE.%26aulast%3DKropshofer%26aufirst%3DH.%26aulast%3DDe%2BGroot%26aufirst%3DA.%2BS.%26atitle%3DT-cell%2520dependent%2520immunogenicity%2520of%2520protein%2520therapeutics%253A%2520Preclinical%2520assessment%2520and%2520mitigation%26jtitle%3DClin.%2520Immunol.%26date%3D2013%26volume%3D149%26spage%3D534%26epage%3D555%26doi%3D10.1016%2Fj.clim.2013.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group">Baker, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lumicisi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryson, C. J.</span><span> </span><span class="NLM_article-title">Immunogenicity of protein therapeutics: The key causes, consequences and challenges</span> <span class="citation_source-journal">Self Nonself</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">â</span> <span class="NLM_lpage">322</span><span class="refDoi">Â DOI: 10.4161/self.1.4.13904</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.4161%2Fself.1.4.13904" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21487506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A280%3ADC%252BC2sbosl2ltA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=314-322&author=M.+P.+Bakerauthor=H.+M.+Reynoldsauthor=B.+Lumicisiauthor=C.+J.+Bryson&title=Immunogenicity+of+protein+therapeutics%3A+The+key+causes%2C+consequences+and+challenges&doi=10.4161%2Fself.1.4.13904"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Immunogenicity of protein therapeutics: The key causes, consequences and challenges</span></div><div class="casAuthors">Baker Matthew P; Reynolds Helen M; Lumicisi Brooke; Bryson Christine J</div><div class="citationInfo"><span class="NLM_cas:title">Self/nonself</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">314-322</span>
        ISSN:<span class="NLM_cas:issn">1938-2030</span>.
    </div><div class="casAbstract">The immunogenicity of protein therapeutics has so far proven to be difficult to predict in patients, with many biologics inducing undesirable immune responses directed towards the therapeutic resulting in reduced efficacy, anaphylaxis and occasionally life threatening autoimmunity.  The most common effect of administrating an immunogenic protein therapeutic is the development of a high affinity anti-therapeutic antibody response.  Furthermore, it is clear from clinical studies that protein therapeutics derived from endogenous human proteins are capable of stimulating undesirable immune responses in patients, and as a consequence, the prediction and reduction of immunogenicity has been the focus of intense research.  This review will outline the principle causes of the immunogenicity in protein therapeutics, and describe the development of pre-clinical models that can be used to aid in the prediction of the immunogenic potential of novel protein therapeutics prior to administration in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTP1ugBfdLNc36CEoQgWY10fW6udTcc2eZ5JFuHByAYnrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sbosl2ltA%253D%253D&md5=0fa913c65486289a38df1e06faa211b3</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.4161%2Fself.1.4.13904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fself.1.4.13904%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DM.%2BP.%26aulast%3DReynolds%26aufirst%3DH.%2BM.%26aulast%3DLumicisi%26aufirst%3DB.%26aulast%3DBryson%26aufirst%3DC.%2BJ.%26atitle%3DImmunogenicity%2520of%2520protein%2520therapeutics%253A%2520The%2520key%2520causes%252C%2520consequences%2520and%2520challenges%26jtitle%3DSelf%2520Nonself%26date%3D2010%26volume%3D1%26spage%3D314%26epage%3D322%26doi%3D10.4161%2Fself.1.4.13904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group">Rosenstock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charbonnel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolli, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boldrin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balena, R.</span><span> </span><span class="NLM_article-title">The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes</span> <span class="citation_source-journal">Diabetes Care</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">498</span><span class="NLM_x">â</span> <span class="NLM_lpage">504</span><span class="refDoi">Â DOI: 10.2337/dc12-0709</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.2337%2Fdc12-0709" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2013&pages=498-504&author=J.+Rosenstockauthor=B.+Balasauthor=B.+Charbonnelauthor=G.+B.+Bolliauthor=M.+Boldrinauthor=R.+Ratnerauthor=R.+Balena&title=The+fate+of+taspoglutide%2C+a+weekly+GLP-1+receptor+agonist%2C+versus+twice-daily+exenatide+for+type+2+diabetes&doi=10.2337%2Fdc12-0709"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.2337%2Fdc12-0709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdc12-0709%26sid%3Dliteratum%253Aachs%26aulast%3DRosenstock%26aufirst%3DJ.%26aulast%3DBalas%26aufirst%3DB.%26aulast%3DCharbonnel%26aufirst%3DB.%26aulast%3DBolli%26aufirst%3DG.%2BB.%26aulast%3DBoldrin%26aufirst%3DM.%26aulast%3DRatner%26aufirst%3DR.%26aulast%3DBalena%26aufirst%3DR.%26atitle%3DThe%2520fate%2520of%2520taspoglutide%252C%2520a%2520weekly%2520GLP-1%2520receptor%2520agonist%252C%2520versus%2520twice-daily%2520exenatide%2520for%2520type%25202%2520diabetes%26jtitle%3DDiabetes%2520Care%26date%3D2013%26volume%3D36%26spage%3D498%26epage%3D504%26doi%3D10.2337%2Fdc12-0709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Casadevall, N.</span><span> </span><span class="NLM_article-title">Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin</span> <span class="citation_source-journal">Nephrol., Dial., Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">viii37</span><span class="NLM_x">â</span> <span class="NLM_lpage">viii41</span><span class="refDoi">Â DOI: 10.1093/ndt/gfg1091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1093%2Fndt%2Fgfg1091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=14608000" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2003&pages=viii37-viii41&author=N.+Casadevall&title=Pure+red+cell+aplasia+and+anti-erythropoietin+antibodies+in+patients+treated+with+epoetin&doi=10.1093%2Fndt%2Fgfg1091"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit194a&amp;dbid=16384&amp;doi=10.1093%2Fndt%2Fgfg1091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fndt%252Fgfg1091%26sid%3Dliteratum%253Aachs%26aulast%3DCasadevall%26aufirst%3DN.%26atitle%3DPure%2520red%2520cell%2520aplasia%2520and%2520anti-erythropoietin%2520antibodies%2520in%2520patients%2520treated%2520with%2520epoetin%26jtitle%3DNephrol.%252C%2520Dial.%252C%2520Transplant.%26date%3D2003%26volume%3D18%26spage%3Dviii37%26epage%3Dviii41%26doi%3D10.1093%2Fndt%2Fgfg1091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit194b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Casadevall, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nataf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viron, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiladjian, J.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Dupont, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaud, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teyssandier, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varet, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayeux, P.</span><span> </span><span class="NLM_article-title">Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">346</span><span class="NLM_x">, </span> <span class="NLM_fpage">469</span><span class="NLM_x">â</span> <span class="NLM_lpage">475</span><span class="refDoi">Â DOI: 10.1056/NEJMoa011931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1056%2FNEJMoa011931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=11844847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtFCktr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2002&pages=469-475&author=N.+Casadevallauthor=J.+Natafauthor=B.+Vironauthor=A.+Koltaauthor=J.-J.+Kiladjianauthor=P.+Martin-Dupontauthor=P.+Michaudauthor=T.+Papoauthor=V.+Ugoauthor=I.+Teyssandierauthor=B.+Varetauthor=P.+Mayeux&title=Pure+Red-Cell+Aplasia+and+Antierythropoietin+Antibodies+in+Patients+Treated+with+Recombinant+Erythropoietin&doi=10.1056%2FNEJMoa011931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194bR"><div class="casContent"><span class="casTitleNuber">194b</span><div class="casTitle"><span class="NLM_cas:atitle">Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin</span></div><div class="casAuthors">Casadevall, Nicole; Nataf, Joelle; Viron, Beatrice; Kolta, Amir; Kiladjian, Jean-Jacques; Martin-Dupont, Philippe; Michaud, Patrick; Pap, Thomas; Ugo, Valerie; Teyssandier, Irene; Varet, Bruno; Mayeux, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">469-475</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Within a period of three years, we identified 13 patients in whom pure red-cell aplasia developed during treatment with recombinant human erythropoietin (epoetin).  We investigated whether there was an immunol. basis for the anemia in these patients.  Serum samples from the 13 patients with pure red-cell aplasia were tested for neutralizing antibodies that could inhibit erythroid-colony formation by normal bone marrow cells in vitro.  The presence of antierythropoietin antibodies was identified by means of binding assays with the use of radiolabeled intact, deglycosylated, or denatured epoetin.  Serum from all 13 patients blocked the formation of erythroid colonies by normal bone marrow cells.  The inhibition was reversed by epoetin.  Antibodies from 12 of the 13 patients bound only conformational epitopes in the protein moiety of epoetin; serum from the remaining patient bound to both conformational and linear epitopes in erythropoietin.  In all the patients, the antibody titer slowly decreased after the discontinuation of treatment with epoetin.  Neutralizing antierythropoietin antibodies and pure red-cell aplasia can develop in patients with the anemia of chronic renal failure during treatment with epoetin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaxcP6aygOU7Vg90H21EOLACvtfcHk0lhu2ey4UeJh3g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtFCktr8%253D&md5=6b5fdf9fb67db136327e78e0400885c2</span></div><a href="/servlet/linkout?suffix=cit194b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa011931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa011931%26sid%3Dliteratum%253Aachs%26aulast%3DCasadevall%26aufirst%3DN.%26aulast%3DNataf%26aufirst%3DJ.%26aulast%3DViron%26aufirst%3DB.%26aulast%3DKolta%26aufirst%3DA.%26aulast%3DKiladjian%26aufirst%3DJ.-J.%26aulast%3DMartin-Dupont%26aufirst%3DP.%26aulast%3DMichaud%26aufirst%3DP.%26aulast%3DPapo%26aufirst%3DT.%26aulast%3DUgo%26aufirst%3DV.%26aulast%3DTeyssandier%26aufirst%3DI.%26aulast%3DVaret%26aufirst%3DB.%26aulast%3DMayeux%26aufirst%3DP.%26atitle%3DPure%2520Red-Cell%2520Aplasia%2520and%2520Antierythropoietin%2520Antibodies%2520in%2520Patients%2520Treated%2520with%2520Recombinant%2520Erythropoietin%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2002%26volume%3D346%26spage%3D469%26epage%3D475%26doi%3D10.1056%2FNEJMoa011931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Van Regenmortel, M. H. V.</span><span> </span><span class="NLM_article-title">Antigenicity and immunogenicity of synthetic peptides</span> <span class="citation_source-journal">Biologicals</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">â</span> <span class="NLM_lpage">213</span><span class="refDoi">Â DOI: 10.1006/biol.2001.0308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1006%2Fbiol.2001.0308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=11851317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD38Xht1Olu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2001&pages=209-213&author=M.+H.+V.+Van+Regenmortel&title=Antigenicity+and+immunogenicity+of+synthetic+peptides&doi=10.1006%2Fbiol.2001.0308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195aR"><div class="casContent"><span class="casTitleNuber">195a</span><div class="casTitle"><span class="NLM_cas:atitle">Antigenicity and immunogenicity of synthetic peptides</span></div><div class="casAuthors">Van Regenmortel, M. H. V.</div><div class="citationInfo"><span class="NLM_cas:title">Biologicals</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3/4</span>),
    <span class="NLM_cas:pages">209-213</span>CODEN:
                <span class="NLM_cas:coden">BILSEC</span>;
        ISSN:<span class="NLM_cas:issn">1045-1056</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review.  The ability of a peptide to react specifically with the functional binding site of a complementary antibody is known as its antigenic reactivity or antigenicity.  Our understanding of peptide antigenicity has improved considerably in recent years mainly through the x-ray crystallog. anal. of peptide-monoclonal antibody complexes.  This knowledge is obtained along reductionist lines by turning the biol. question of antigen recognition into the purely chem. phenomenon of protein-peptide interactions described in terms of at. forces and non-covalent bonds.  This makes it possible to improve the degree of steric complementarity between a peptide and a single monoclonal antibody and thus to improve the peptide's antigenicity following structure-based rational design principles.  The situation is quite different with immunogenicity which is the ability of the peptide to induce an immune response in a competent host.  Whereas antigenicity can be reduced to the level of chem., such a redn. is not achievable in the case of immunogenicity which depends on many complex interactions with various elements of the host immune system.  These cellular and regulatory mechanisms cannot be controlled by adjusting the structure of the peptide in a predetd. manner.  For this reason, it is not possible to develop a synthetic peptide vaccine using mol. design principles.  (c) 2001 The International Association of Biological Standardization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSUpBhbMtKJrVg90H21EOLACvtfcHk0lhu2ey4UeJh3g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xht1Olu7g%253D&md5=c0e9d2c6985d5896024ce985420e0b6b</span></div><a href="/servlet/linkout?suffix=cit195a&amp;dbid=16384&amp;doi=10.1006%2Fbiol.2001.0308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbiol.2001.0308%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BRegenmortel%26aufirst%3DM.%2BH.%2BV.%26atitle%3DAntigenicity%2520and%2520immunogenicity%2520of%2520synthetic%2520peptides%26jtitle%3DBiologicals%26date%3D2001%26volume%3D29%26spage%3D209%26epage%3D213%26doi%3D10.1006%2Fbiol.2001.0308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit195b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Milton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milton, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, S. B.</span><span> </span><span class="NLM_article-title">Total chemical synthesis of a D-enzyme: the enantiomers of HIV-1 protease show reciprocal chiral substrate specificity</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">256</span><span class="NLM_x">, </span> <span class="NLM_fpage">1445</span><span class="NLM_x">â</span> <span class="NLM_lpage">1448</span><span class="refDoi">Â DOI: 10.1126/science.1604320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1126%2Fscience.1604320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1604320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADyaK38XltFajtbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=256&publication_year=1992&pages=1445-1448&author=R.+C.+Miltonauthor=S.+C.+Miltonauthor=S.+B.+Kent&title=Total+chemical+synthesis+of+a+D-enzyme%3A+the+enantiomers+of+HIV-1+protease+show+reciprocal+chiral+substrate+specificity&doi=10.1126%2Fscience.1604320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195bR"><div class="casContent"><span class="casTitleNuber">195b</span><div class="casTitle"><span class="NLM_cas:atitle">Total chemical synthesis of a D-enzyme:  the enantiomers of HIV-1 protease show demonstration of reciprocal chiral substrate specificity</span></div><div class="casAuthors">Milton, R. C. L.; Milton, S. C. F.; Kent, S. B. H.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">256</span>
        (<span class="NLM_cas:issue">5062</span>),
    <span class="NLM_cas:pages">1445-8</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The D and L forms of the enzyme HIV-1 protease have been prepd. by total chem. synthesis.  The two proteins had identical covalent structures.  However, the folded protein enzyme enantiomers showed reciprocal chiral specificity on peptide substrates.  I.e., each enzyme enantiomer cut only the corresponding substrate enantiomer.  Reciprocal chiral specificity was also evident in the effect of enantiomeric inhibitors.  These data imply that the folded forms of the chem. synthesized D- and L-enzyme mols. are mirror images of one another in all elements of the three-dimensional structure.  Enantiomeric proteins are expected to display reciprocal chiral specificity in all aspects of their biochem. interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_qxm_qTyi1rVg90H21EOLACvtfcHk0lhu2ey4UeJh3g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XltFajtbs%253D&md5=8f0148fa541fdaa97e043f31a99b184c</span></div><a href="/servlet/linkout?suffix=cit195b&amp;dbid=16384&amp;doi=10.1126%2Fscience.1604320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1604320%26sid%3Dliteratum%253Aachs%26aulast%3DMilton%26aufirst%3DR.%2BC.%26aulast%3DMilton%26aufirst%3DS.%2BC.%26aulast%3DKent%26aufirst%3DS.%2BB.%26atitle%3DTotal%2520chemical%2520synthesis%2520of%2520a%2520D-enzyme%253A%2520the%2520enantiomers%2520of%2520HIV-1%2520protease%2520show%2520reciprocal%2520chiral%2520substrate%2520specificity%26jtitle%3DScience%26date%3D1992%26volume%3D256%26spage%3D1445%26epage%3D1448%26doi%3D10.1126%2Fscience.1604320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Benkirane, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friede, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guichard, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briand, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Regenmortel, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, S.</span><span> </span><span class="NLM_article-title">Antigenicity and immunogenicity of modified synthetic peptides containing D-amino acid residues. Antibodies to a D-enantiomer do recognize the parent L-hexapeptide and reciprocally</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">268</span><span class="NLM_x">, </span> <span class="NLM_fpage">26279</span><span class="NLM_x">â</span> <span class="NLM_lpage">26285</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=26279-26285&author=N.+Benkiraneauthor=M.+Friedeauthor=G.+Guichardauthor=J.+P.+Briandauthor=M.+H.+Van+Regenmortelauthor=S.+Muller&title=Antigenicity+and+immunogenicity+of+modified+synthetic+peptides+containing+D-amino+acid+residues.+Antibodies+to+a+D-enantiomer+do+recognize+the+parent+L-hexapeptide+and+reciprocally"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit196a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBenkirane%26aufirst%3DN.%26aulast%3DFriede%26aufirst%3DM.%26aulast%3DGuichard%26aufirst%3DG.%26aulast%3DBriand%26aufirst%3DJ.%2BP.%26aulast%3DVan%2BRegenmortel%26aufirst%3DM.%2BH.%26aulast%3DMuller%26aufirst%3DS.%26atitle%3DAntigenicity%2520and%2520immunogenicity%2520of%2520modified%2520synthetic%2520peptides%2520containing%2520D-amino%2520acid%2520residues.%2520Antibodies%2520to%2520a%2520D-enantiomer%2520do%2520recognize%2520the%2520parent%2520L-hexapeptide%2520and%2520reciprocally%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D26279%26epage%3D26285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit196b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sela, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zisman, E.</span><span> </span><span class="NLM_article-title">Different roles of D-amino acids in immune phenomena</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">449</span><span class="NLM_x">â</span> <span class="NLM_lpage">456</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1997&pages=449-456&author=M.+Selaauthor=E.+Zisman&title=Different+roles+of+D-amino+acids+in+immune+phenomena"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit196b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSela%26aufirst%3DM.%26aulast%3DZisman%26aufirst%3DE.%26atitle%3DDifferent%2520roles%2520of%2520D-amino%2520acids%2520in%2520immune%2520phenomena%26jtitle%3DFASEB%2520J.%26date%3D1997%26volume%3D11%26spage%3D449%26epage%3D456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group">Perry, L. C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, M. P.</span><span> </span><span class="NLM_article-title">New approaches to prediction of immune responses to therapeutic proteins during preclinical development</span> <span class="citation_source-journal">Drugs R&amp;D</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">â</span> <span class="NLM_lpage">396</span><span class="refDoi">Â DOI: 10.2165/0126839-200809060-00004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.2165%2F0126839-200809060-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=18989990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsVaktQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=385-396&author=L.+C.+A.+Perryauthor=T.+D.+Jonesauthor=M.+P.+Baker&title=New+approaches+to+prediction+of+immune+responses+to+therapeutic+proteins+during+preclinical+development&doi=10.2165%2F0126839-200809060-00004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">New approaches to prediction of immune responses to therapeutic proteins during preclinical development</span></div><div class="casAuthors">Perry, Laura C. A.; Jones, Timothy D.; Baker, Matthew P.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs in R&D</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">385-396</span>CODEN:
                <span class="NLM_cas:coden">DRDDFD</span>;
        ISSN:<span class="NLM_cas:issn">1174-5886</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer Health</span>)
        </div><div class="casAbstract">A review.  Clin. studies show that immunogenicity obsd. against therapeutic proteins can limit efficacy and reduce the safety of the treatment.  It is therefore beneficial to be able to predict the immunogenicity of therapeutic proteins before they enter the clinic.  Studies using deimmunized proteins have highlighted the importance of T-cell epitopes in the generation of undesirable immunogenicity.  In silico, in vitro, ex vivo and in vivo methods have therefore been developed that focus on identification of CD4+ T-cell epitopes in the sequence of therapeutic proteins.  A case study of existing therapeutic proteins is presented to review these different approaches in order to assess their utility in predicting immunogenic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr24wFMMRGF0LVg90H21EOLACvtfcHk0ljPQngcDY-Ykw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsVaktQ%253D%253D&md5=9c4f75c046cf9a68410a1731c797030b</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.2165%2F0126839-200809060-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F0126839-200809060-00004%26sid%3Dliteratum%253Aachs%26aulast%3DPerry%26aufirst%3DL.%2BC.%2BA.%26aulast%3DJones%26aufirst%3DT.%2BD.%26aulast%3DBaker%26aufirst%3DM.%2BP.%26atitle%3DNew%2520approaches%2520to%2520prediction%2520of%2520immune%2520responses%2520to%2520therapeutic%2520proteins%2520during%2520preclinical%2520development%26jtitle%3DDrugs%2520R%2526amp%253BD%26date%3D2008%26volume%3D9%26spage%3D385%26epage%3D396%26doi%3D10.2165%2F0126839-200809060-00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span>EpiScreen Time Course T Cell Assay; <span class="NLM_publisher-name">Abenza</span>: <span class="NLM_publisher-loc">San Diego, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">; </span><a href="http://www.abzena.com/development-services/immunology/immunogenicity-assessment/episcreen-time-course-t-cell-assay/" class="extLink">http://www.abzena.com/development-services/immunology/immunogenicity-assessment/episcreen-time-course-t-cell-assay/</a> (accessed January 17, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=EpiScreen+Time+Course+T+Cell+Assay%3B+Abenza%3A+San+Diego%2C+CA%2C+2017%3B+http%3A%2F%2Fwww.abzena.com%2Fdevelopment-services%2Fimmunology%2Fimmunogenicity-assessment%2Fepiscreen-time-course-t-cell-assay%2F+%28accessed+January+17%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DEpiScreen%2520Time%2520Course%2520T%2520Cell%2520Assay%26pub%3DAbenza%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group">Baker, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, T. D.</span><span> </span><span class="NLM_article-title">Identification and removal of immunogenicity in therapeutic proteins</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">â</span> <span class="NLM_lpage">227</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2007&pages=219-227&author=M.+P.+Bakerauthor=T.+D.+Jones&title=Identification+and+removal+of+immunogenicity+in+therapeutic+proteins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DM.%2BP.%26aulast%3DJones%26aufirst%3DT.%2BD.%26atitle%3DIdentification%2520and%2520removal%2520of%2520immunogenicity%2520in%2520therapeutic%2520proteins%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2007%26volume%3D10%26spage%3D219%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group">Ho, C.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocchi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piek, T.</span><span> </span><span class="NLM_article-title">Comparison of the immunogenicity of wasp venom peptides with or without carbohydrate moieties</span> <span class="citation_source-journal">Toxicon</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">â</span> <span class="NLM_lpage">221</span><span class="refDoi">Â DOI: 10.1016/S0041-0101(97)00066-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2FS0041-0101%2897%2900066-4" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1998&pages=217-221&author=C.-L.+Hoauthor=Y.-L.+Linauthor=W.-C.+Chenauthor=R.+Rocchiauthor=T.+Piek&title=Comparison+of+the+immunogenicity+of+wasp+venom+peptides+with+or+without+carbohydrate+moieties&doi=10.1016%2FS0041-0101%2897%2900066-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1016%2FS0041-0101%2897%2900066-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0041-0101%252897%252900066-4%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DC.-L.%26aulast%3DLin%26aufirst%3DY.-L.%26aulast%3DChen%26aufirst%3DW.-C.%26aulast%3DRocchi%26aufirst%3DR.%26aulast%3DPiek%26aufirst%3DT.%26atitle%3DComparison%2520of%2520the%2520immunogenicity%2520of%2520wasp%2520venom%2520peptides%2520with%2520or%2520without%2520carbohydrate%2520moieties%26jtitle%3DToxicon%26date%3D1998%26volume%3D36%26spage%3D217%26epage%3D221%26doi%3D10.1016%2FS0041-0101%2897%2900066-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group">De Serres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillberger, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchins, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boytos, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weigl, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DePrince, R. B.</span><span> </span><span class="NLM_article-title">Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits: Evaluation of the potential for thrombopoietin neutralizing antibody production in man</span> <span class="citation_source-journal">Stem Cells</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">â</span> <span class="NLM_lpage">209</span><span class="refDoi">Â DOI: 10.1002/stem.170203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fstem.170203" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=203-209&author=M.+De+Serresauthor=B.+Ellisauthor=J.+E.+Dillbergerauthor=S.+K.+Rudolphauthor=J.+T.+Hutchinsauthor=C.+M.+Boytosauthor=D.+L.+Weiglauthor=R.+B.+DePrince&title=Immunogenicity+of+thrombopoietin+mimetic+peptide+GW395058+in+BALB%2Fc+mice+and+New+Zealand+white+rabbits%3A+Evaluation+of+the+potential+for+thrombopoietin+neutralizing+antibody+production+in+man&doi=10.1002%2Fstem.170203"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1002%2Fstem.170203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fstem.170203%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSerres%26aufirst%3DM.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DDillberger%26aufirst%3DJ.%2BE.%26aulast%3DRudolph%26aufirst%3DS.%2BK.%26aulast%3DHutchins%26aufirst%3DJ.%2BT.%26aulast%3DBoytos%26aufirst%3DC.%2BM.%26aulast%3DWeigl%26aufirst%3DD.%2BL.%26aulast%3DDePrince%26aufirst%3DR.%2BB.%26atitle%3DImmunogenicity%2520of%2520thrombopoietin%2520mimetic%2520peptide%2520GW395058%2520in%2520BALB%252Fc%2520mice%2520and%2520New%2520Zealand%2520white%2520rabbits%253A%2520Evaluation%2520of%2520the%2520potential%2520for%2520thrombopoietin%2520neutralizing%2520antibody%2520production%2520in%2520man%26jtitle%3DStem%2520Cells%26date%3D1999%26volume%3D17%26spage%3D203%26epage%3D209%26doi%3D10.1002%2Fstem.170203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group">Brinks, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiskoot, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellekens, H.</span><span> </span><span class="NLM_article-title">Immunogenicity of therapeutic proteins: The use of animal models</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">2379</span><span class="NLM_x">â</span> <span class="NLM_lpage">2385</span><span class="refDoi">Â DOI: 10.1007/s11095-011-0523-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1007%2Fs11095-011-0523-5" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2011&pages=2379-2385&author=V.+Brinksauthor=W.+Jiskootauthor=H.+Schellekens&title=Immunogenicity+of+therapeutic+proteins%3A+The+use+of+animal+models&doi=10.1007%2Fs11095-011-0523-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1007%2Fs11095-011-0523-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-011-0523-5%26sid%3Dliteratum%253Aachs%26aulast%3DBrinks%26aufirst%3DV.%26aulast%3DJiskoot%26aufirst%3DW.%26aulast%3DSchellekens%26aufirst%3DH.%26atitle%3DImmunogenicity%2520of%2520therapeutic%2520proteins%253A%2520The%2520use%2520of%2520animal%2520models%26jtitle%3DPharm.%2520Res.%26date%3D2011%26volume%3D28%26spage%3D2379%26epage%3D2385%26doi%3D10.1007%2Fs11095-011-0523-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bruno, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, C. S.</span><span> </span><span class="NLM_article-title">Basics and recent advances in peptide and protein drug delivery</span> <span class="citation_source-journal">Ther. Delivery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1443</span><span class="NLM_x">â</span> <span class="NLM_lpage">1467</span><span class="refDoi">Â DOI: 10.4155/tde.13.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.4155%2Ftde.13.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24228993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslOms7bP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1443-1467&author=B.+J.+Brunoauthor=G.+D.+Millerauthor=C.+S.+Lim&title=Basics+and+recent+advances+in+peptide+and+protein+drug+delivery&doi=10.4155%2Ftde.13.104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203aR"><div class="casContent"><span class="casTitleNuber">203a</span><div class="casTitle"><span class="NLM_cas:atitle">Basics and recent advances in peptide and protein drug delivery</span></div><div class="casAuthors">Bruno, Benjamin J.; Miller, Geoffrey D.; Lim, Carol S.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Delivery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1443-1467</span>CODEN:
                <span class="NLM_cas:coden">TDHEA7</span>;
        ISSN:<span class="NLM_cas:issn">2041-5990</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  While the peptide and protein therapeutic market has developed significantly in the past decades, delivery has limited their use.  Although oral delivery is preferred, most are currently delivered i.v. or s.c. due to degrdn. and limited absorption in the gastrointestinal tract.  Therefore, absorption enhancers, enzyme inhibitors, carrier systems and stability enhancers are being studied to facilitate oral peptide delivery.  Addnl., transdermal peptide delivery avoids the issues of the gastrointestinal tract, but also faces absorption limitations.  Due to proteases, opsonization and agglutination, free peptides are not systemically stable without modifications.  This review discusses oral and transdermal peptide drug delivery, focusing on barriers and solns. to absorption and stability issues.  Methods to increase systemic stability and site-specific delivery are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowxPeEyVr_AbVg90H21EOLACvtfcHk0ljPQngcDY-Ykw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslOms7bP&md5=89a01c120b11079cfe02f33d85248b5f</span></div><a href="/servlet/linkout?suffix=cit203a&amp;dbid=16384&amp;doi=10.4155%2Ftde.13.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ftde.13.104%26sid%3Dliteratum%253Aachs%26aulast%3DBruno%26aufirst%3DB.%2BJ.%26aulast%3DMiller%26aufirst%3DG.%2BD.%26aulast%3DLim%26aufirst%3DC.%2BS.%26atitle%3DBasics%2520and%2520recent%2520advances%2520in%2520peptide%2520and%2520protein%2520drug%2520delivery%26jtitle%3DTher.%2520Delivery%26date%3D2013%26volume%3D4%26spage%3D1443%26epage%3D1467%26doi%3D10.4155%2Ftde.13.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit203b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mitragotri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, R.</span><span> </span><span class="NLM_article-title">Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">655</span><span class="NLM_x">â</span> <span class="NLM_lpage">672</span><span class="refDoi">Â DOI: 10.1038/nrd4363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnrd4363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25103255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlWmu77J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=655-672&author=S.+Mitragotriauthor=P.+A.+Burkeauthor=R.+Langer&title=Overcoming+the+challenges+in+administering+biopharmaceuticals%3A+formulation+and+delivery+strategies&doi=10.1038%2Fnrd4363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203bR"><div class="casContent"><span class="casTitleNuber">203b</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies</span></div><div class="casAuthors">Mitragotri, Samir; Burke, Paul A.; Langer, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">655-672</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The formulation and delivery of biopharmaceutical drugs, such as monoclonal antibodies and recombinant proteins, poses substantial challenges owing to their large size and susceptibility to degrdn.  In this Review we highlight recent advances in formulation and delivery strategies - such as the use of microsphere-based controlled-release technologies, protein modification methods that make use of polyethylene glycol and other polymers, and genetic manipulation of biopharmaceutical drugs - and discuss their advantages and limitations.  We also highlight current and emerging delivery routes that provide an alternative to injection, including transdermal, oral and pulmonary delivery routes.  In addn., the potential of targeted and intracellular protein delivery is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb2Ov1x7gQYbVg90H21EOLACvtfcHk0liVoubQcKGRzQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlWmu77J&md5=c09c8b5cdbf60f13bd4c198caeada77d</span></div><a href="/servlet/linkout?suffix=cit203b&amp;dbid=16384&amp;doi=10.1038%2Fnrd4363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4363%26sid%3Dliteratum%253Aachs%26aulast%3DMitragotri%26aufirst%3DS.%26aulast%3DBurke%26aufirst%3DP.%2BA.%26aulast%3DLanger%26aufirst%3DR.%26atitle%3DOvercoming%2520the%2520challenges%2520in%2520administering%2520biopharmaceuticals%253A%2520formulation%2520and%2520delivery%2520strategies%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D655%26epage%3D672%26doi%3D10.1038%2Fnrd4363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group">Ginsberg, B. H.</span><span> </span><span class="NLM_article-title">Mixing pens and the future of diabetes drugs</span> <span class="citation_source-journal">J. Diabetes Sci. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">822</span><span class="NLM_x">â</span> <span class="NLM_lpage">823</span><span class="refDoi">Â DOI: 10.1177/1932296815585873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1177%2F1932296815585873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25944896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28Xkt1Oisbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=822-823&author=B.+H.+Ginsberg&title=Mixing+pens+and+the+future+of+diabetes+drugs&doi=10.1177%2F1932296815585873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Mixing pens and the future of diabetes drugs</span></div><div class="casAuthors">Ginsberg, Barry H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Diabetes Science and Technology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">822-823</span>CODEN:
                <span class="NLM_cas:coden">JDSTAV</span>;
        ISSN:<span class="NLM_cas:issn">1932-2968</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">With the availability of a smaller mixing pen, mass marketing of less stable medications is possible.  Bidureon is one such medication, and the properties of its pen are discussed along with the prospects for future mixing pens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX95Ins_-6R7Vg90H21EOLACvtfcHk0liVoubQcKGRzQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xkt1Oisbs%253D&md5=acba42c02ca200657e0bb219e220df5e</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1177%2F1932296815585873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1932296815585873%26sid%3Dliteratum%253Aachs%26aulast%3DGinsberg%26aufirst%3DB.%2BH.%26atitle%3DMixing%2520pens%2520and%2520the%2520future%2520of%2520diabetes%2520drugs%26jtitle%3DJ.%2520Diabetes%2520Sci.%2520Technol.%26date%3D2015%26volume%3D9%26spage%3D822%26epage%3D823%26doi%3D10.1177%2F1932296815585873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group">Makadia, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, S. J.</span><span> </span><span class="NLM_article-title">Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier</span> <span class="citation_source-journal">Polymers</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1377</span><span class="NLM_x">â</span> <span class="NLM_lpage">1397</span><span class="refDoi">Â DOI: 10.3390/polym3031377</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3390%2Fpolym3031377" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=22577513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFOis7jJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=1377-1397&author=H.+K.+Makadiaauthor=S.+J.+Siegel&title=Poly+lactic-co-glycolic+acid+%28PLGA%29+as+biodegradable+controlled+drug+delivery+carrier&doi=10.3390%2Fpolym3031377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier</span></div><div class="casAuthors">Makadia, Hirenkumar K.; Siegel, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">Polymers (Basel, Switzerland)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1377-1397</span>CODEN:
                <span class="NLM_cas:coden">POLYCK</span>;
        ISSN:<span class="NLM_cas:issn">2073-4360</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  In past two decades poly lactic-co-glycolic acid (PLGA) has been among the most attractive polymeric candidates used to fabricate devices for drug delivery and tissue engineering applications.  PLGA is biocompatible and biodegradable, exhibits a wide range of erosion times, has tunable mech. properties and most importantly, is a FDA approved polymer.  In particular, PLGA has been extensively studied for the development of devices for controlled delivery of small mol. drugs, proteins and other macromols. in com. use and in research.  This manuscript describes the various fabrication techniques for these devices and the factors affecting their degrdn. and drug release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqKSnjbA3YlrVg90H21EOLACvtfcHk0liVoubQcKGRzQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFOis7jJ&md5=dcc6e49beb083af56e0cc3213bb99f72</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.3390%2Fpolym3031377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fpolym3031377%26sid%3Dliteratum%253Aachs%26aulast%3DMakadia%26aufirst%3DH.%2BK.%26aulast%3DSiegel%26aufirst%3DS.%2BJ.%26atitle%3DPoly%2520lactic-co-glycolic%2520acid%2520%2528PLGA%2529%2520as%2520biodegradable%2520controlled%2520drug%2520delivery%2520carrier%26jtitle%3DPolymers%26date%3D2011%26volume%3D3%26spage%3D1377%26epage%3D1397%26doi%3D10.3390%2Fpolym3031377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group">Chan, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyrueix, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kravtzoff, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolas, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundstrom, K.</span><span> </span><span class="NLM_article-title">Review on MedusaÂ®: a polymer-based sustained release technology for protein and peptide drugs</span> <span class="citation_source-journal">Expert Opin. Drug Delivery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">â</span> <span class="NLM_lpage">451</span><span class="refDoi">Â DOI: 10.1517/17425247.4.4.441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1517%2F17425247.4.4.441" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=441-451&author=Y.+P.+Chanauthor=R.+Meyrueixauthor=R.+Kravtzoffauthor=F.+Nicolasauthor=K.+Lundstrom&title=Review+on+Medusa%C2%AE%3A+a+polymer-based+sustained+release+technology+for+protein+and+peptide+drugs&doi=10.1517%2F17425247.4.4.441"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1517%2F17425247.4.4.441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425247.4.4.441%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DY.%2BP.%26aulast%3DMeyrueix%26aufirst%3DR.%26aulast%3DKravtzoff%26aufirst%3DR.%26aulast%3DNicolas%26aufirst%3DF.%26aulast%3DLundstrom%26aufirst%3DK.%26atitle%3DReview%2520on%2520Medusa%25C2%25AE%253A%2520a%2520polymer-based%2520sustained%2520release%2520technology%2520for%2520protein%2520and%2520peptide%2520drugs%26jtitle%3DExpert%2520Opin.%2520Drug%2520Delivery%26date%3D2007%26volume%3D4%26spage%3D441%26epage%3D451%26doi%3D10.1517%2F17425247.4.4.441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group">Kopecek, J.</span><span> </span><span class="NLM_article-title">Polymer-drug conjugates: Origins, progress to date and future directions</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">â</span> <span class="NLM_lpage">59</span><span class="refDoi">Â DOI: 10.1016/j.addr.2012.10.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.addr.2012.10.014" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=49-59&author=J.+Kopecek&title=Polymer-drug+conjugates%3A+Origins%2C+progress+to+date+and+future+directions&doi=10.1016%2Fj.addr.2012.10.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2012.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2012.10.014%26sid%3Dliteratum%253Aachs%26aulast%3DKopecek%26aufirst%3DJ.%26atitle%3DPolymer-drug%2520conjugates%253A%2520Origins%252C%2520progress%2520to%2520date%2520and%2520future%2520directions%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2013%26volume%3D65%26spage%3D49%26epage%3D59%26doi%3D10.1016%2Fj.addr.2012.10.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Schneider, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henise, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashley, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santi, D. V.</span><span> </span><span class="NLM_article-title">Subcutaneously administered self-cleaving hydrogel octreotide conjugates provide very long-acting octreotide</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1638</span><span class="NLM_x">â</span> <span class="NLM_lpage">1644</span><span class="refDoi">Â DOI: 10.1021/acs.bioconjchem.6b00188</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.6b00188" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref208/cit208a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XptVelsbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=1638-1644&author=E.+L.+Schneiderauthor=J.+Heniseauthor=R.+Reidauthor=G.+W.+Ashleyauthor=D.+V.+Santi&title=Subcutaneously+administered+self-cleaving+hydrogel+octreotide+conjugates+provide+very+long-acting+octreotide&doi=10.1021%2Facs.bioconjchem.6b00188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208aR"><div class="casContent"><span class="casTitleNuber">208a</span><div class="casTitle"><span class="NLM_cas:atitle">Subcutaneously Administered Self-Cleaving Hydrogel-Octreotide Conjugates Provide Very Long-Acting Octreotide</span></div><div class="casAuthors">Schneider, Eric L.; Henise, Jeff; Reid, Ralph; Ashley, Gary W.; Santi, Daniel V.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1638-1644</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We developed a long-acting drug-delivery system that supports s.c. administration of the peptidic somatostatin agonist octreotide-a blockbuster drug used to treat acromegaly and neuroendocrine tumors.  The current once-a-month polymer-encapsulated octreotide, Sandostatin LAR, requires a painful intragluteal injection through a large needle by a health-care professional.  To overcome such shortcomings, Tetra-PEG hydrogel microspheres were covalently attached to the Î±-amine of D-Phe1 or the Îµ-amine of Lys5 of octreotide by a self-cleaving Î²-eliminative linker; upon s.c. injection in the rat using a small-bore needle, octreotide was slowly released.  The released drug from the Îµ-octreotide conjugate showed a remarkably long serum half-life that exceeded two months.  The Î±-octreotide conjugate had a half-life of â¼2 wk, and showed an excellent correlation of in vitro and in vivo drug release.  Pharmacokinetic models indicate these microspheres should support once-weekly to once-monthly self-administered s.c. dosing in humans.  The hydrogel-octreotide conjugate shows the favorable pharmacokinetics of Sandostatin LAR without its drawbacks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrB5E23rNfIerVg90H21EOLACvtfcHk0lhKMUgASOYoQA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptVelsbc%253D&md5=e268fe09b4ed119d78a0b4fbd7b11038</span></div><a href="/servlet/linkout?suffix=cit208a&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.6b00188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.6b00188%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DE.%2BL.%26aulast%3DHenise%26aufirst%3DJ.%26aulast%3DReid%26aufirst%3DR.%26aulast%3DAshley%26aufirst%3DG.%2BW.%26aulast%3DSanti%26aufirst%3DD.%2BV.%26atitle%3DSubcutaneously%2520administered%2520self-cleaving%2520hydrogel%2520octreotide%2520conjugates%2520provide%2520very%2520long-acting%2520octreotide%26jtitle%3DBioconjugate%2520Chem.%26date%3D2016%26volume%3D27%26spage%3D1638%26epage%3D1644%26doi%3D10.1021%2Facs.bioconjchem.6b00188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit208b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Henise, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hearn, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashley, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santi, D. V.</span><span> </span><span class="NLM_article-title">Biodegradable Tetra-PEG Hydrogels as Carriers for a Releasable Drug Delivery System</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">270</span><span class="NLM_x">â</span> <span class="NLM_lpage">278</span><span class="refDoi">Â DOI: 10.1021/bc5005476</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc5005476" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref208/cit208b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnvFGhtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=270-278&author=J.+Heniseauthor=B.+R.+Hearnauthor=G.+W.+Ashleyauthor=D.+V.+Santi&title=Biodegradable+Tetra-PEG+Hydrogels+as+Carriers+for+a+Releasable+Drug+Delivery+System&doi=10.1021%2Fbc5005476"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208bR"><div class="casContent"><span class="casTitleNuber">208b</span><div class="casTitle"><span class="NLM_cas:atitle">Biodegradable Tetra-PEG Hydrogels as Carriers for a Releasable Drug Delivery System</span></div><div class="casAuthors">Henise, Jeff; Hearn, Brian R.; Ashley, Gary W.; Santi, Daniel V.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">270-278</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have developed an approach to prep. drug-releasing Tetra-PEG hydrogels with exactly four crosslinks per monomer.  The gels contain two cleavable Î²-eliminative linkers: one for drug attachment that releases the drug at a predictable rate, and one with a longer half-life placed in each crosslink to control biodegrdn.  Thus, the system can be optimized to release the drug before significant gel degrdn. occurs.  The synthetic approach involves placing a heterobifunctional connector at each end of a four-arm PEG prepolymer; four unique end-groups of the resultant eight-arm prepolymer are used to tether a linker-drug, and the other four are used for polymn. with a second four-arm PEG.  Three different orthogonal reactions that form stable triazoles, diazines, or oximes have been used for tethering the drug to the PEG and for crosslinking the polymer.  Three formats for prepg. hydrogel-drug conjugates are described that either polymerize preformed PEG-drug conjugates or attach the drug postpolymn.  Degrdn. of drug-contg. hydrogels proceeds as expected for homogeneous tetra-PEG gels with minimal degrdn. occurring in early phases and sharp, predictable reverse gelation times.  The minimal early degrdn. allows design of gels that show almost complete drug release before significant gel-drug fragments are released.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrmt2jnIBZH7Vg90H21EOLACvtfcHk0lhKMUgASOYoQA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnvFGhtQ%253D%253D&md5=451e725bebd4c7a7ec723979a7d65f62</span></div><a href="/servlet/linkout?suffix=cit208b&amp;dbid=16384&amp;doi=10.1021%2Fbc5005476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc5005476%26sid%3Dliteratum%253Aachs%26aulast%3DHenise%26aufirst%3DJ.%26aulast%3DHearn%26aufirst%3DB.%2BR.%26aulast%3DAshley%26aufirst%3DG.%2BW.%26aulast%3DSanti%26aufirst%3DD.%2BV.%26atitle%3DBiodegradable%2520Tetra-PEG%2520Hydrogels%2520as%2520Carriers%2520for%2520a%2520Releasable%2520Drug%2520Delivery%2520System%26jtitle%3DBioconjugate%2520Chem.%26date%3D2015%26volume%3D26%26spage%3D270%26epage%3D278%26doi%3D10.1021%2Fbc5005476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group">Frampton, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyseng-Williamson, K. A.</span><span> </span><span class="NLM_article-title">Degarelix</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">1967</span><span class="NLM_x">â</span> <span class="NLM_lpage">1976</span><span class="refDoi">Â DOI: 10.2165/10484080-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.2165%2F10484080-000000000-00000" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=1967-1976&author=J.+E.+Framptonauthor=K.+A.+Lyseng-Williamson&title=Degarelix&doi=10.2165%2F10484080-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.2165%2F10484080-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F10484080-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DFrampton%26aufirst%3DJ.%2BE.%26aulast%3DLyseng-Williamson%26aufirst%3DK.%2BA.%26atitle%3DDegarelix%26jtitle%3DDrugs%26date%3D2009%26volume%3D69%26spage%3D1967%26epage%3D1976%26doi%3D10.2165%2F10484080-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group">Antonijoan, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbanoj, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordero, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peraire, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VallÃ¨s, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">CheZÃ©rif-Cheikh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torres, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bismuth, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montes, M.</span><span> </span><span class="NLM_article-title">Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers</span> <span class="citation_source-journal">J. Pharm. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">471</span><span class="NLM_x">â</span> <span class="NLM_lpage">476</span><span class="refDoi">Â DOI: 10.1211/0022357023123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1211%2F0022357023123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=15099442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkt1erurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2004&pages=471-476&author=R.+M.+Antonijoanauthor=M.+J.+Barbanojauthor=J.+A.+Corderoauthor=C.+Peraireauthor=R.+Obachauthor=J.+Vall%C3%A8sauthor=R.+CheZ%C3%A9rif-Cheikhauthor=M.+L.+Torresauthor=F.+Bismuthauthor=M.+Montes&title=Pharmacokinetics+of+a+new+Autogel+formulation+of+the+somatostatin+analogue+lanreotide+after+a+single+subcutaneous+dose+in+healthy+volunteers&doi=10.1211%2F0022357023123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers</span></div><div class="casAuthors">Antonijoan, R. M.; Barbanoj, M. J.; Cordero, J. A.; Peraire, C.; Obach, R.; Valles, J.; Cherif-Cheikh, R.; Torres, M.-L.; Bismuth, F.; Montes, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">471-476</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Press</span>)
        </div><div class="casAbstract">The pharmacokinetics/tolerability of lanreotide Autogel have been evaluated.  Healthy volunteers (n = 24) first received immediate-release lanreotide as a single s.c. injection.  After two days, 40 or 60 mg lanreotide Autogel was injected s.c.  Blood was sampled at various intervals for 56 days.  Systemic/local adverse events and changes in biol. profile/vital signs were recorded.  Lanreotide Autogel produced a prolonged-release pharmacokinetic profile: mean area under the serum concn.-time curve from time 0 to infinity (AUC) was 53.73Â±8.99 and 79.48Â±13.06 ng mL-1 day for 40 and 60 mg, resp., mean peak serum concn. (Cmax) was 4.38Â±2.91 and 5.71Â±3.52 ng mL-1, resp., median time to reach Cmax (min.-max.) was 0.50 (0.083-18.0) and 0.38 (0.083-9.01) days, resp., mean apparent elimination half-life was 21.63Â±9.42 and 22.01Â±9.87 days, resp., and relative bioavailability was 0.93Â±0.12 and 0.82Â±0.15, resp.  Thus, lanreotide Autogel exhibited linear pharmacokinetics for the doses studied.  Pharmacokinetic profiles were similar in both genders, apart from statistically significant differences in Cmax and Cmax/AUC.  The Autogel formulation of lanreotide was well tolerated, with systemic adverse events being mild/moderate.  Erythema and a painless s.c. induration were the most common local adverse events.  Lanreotide Autogel provided a prolonged dosing interval and good tolerability for treating acromegaly and carcinoid syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5qRDwhNIpxLVg90H21EOLACvtfcHk0lhKMUgASOYoQA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkt1erurk%253D&md5=50d53b840369220b33363f4b5c1ab170</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1211%2F0022357023123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1211%252F0022357023123%26sid%3Dliteratum%253Aachs%26aulast%3DAntonijoan%26aufirst%3DR.%2BM.%26aulast%3DBarbanoj%26aufirst%3DM.%2BJ.%26aulast%3DCordero%26aufirst%3DJ.%2BA.%26aulast%3DPeraire%26aufirst%3DC.%26aulast%3DObach%26aufirst%3DR.%26aulast%3DVall%25C3%25A8s%26aufirst%3DJ.%26aulast%3DCheZ%25C3%25A9rif-Cheikh%26aufirst%3DR.%26aulast%3DTorres%26aufirst%3DM.%2BL.%26aulast%3DBismuth%26aufirst%3DF.%26aulast%3DMontes%26aufirst%3DM.%26atitle%3DPharmacokinetics%2520of%2520a%2520new%2520Autogel%2520formulation%2520of%2520the%2520somatostatin%2520analogue%2520lanreotide%2520after%2520a%2520single%2520subcutaneous%2520dose%2520in%2520healthy%2520volunteers%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2004%26volume%3D56%26spage%3D471%26epage%3D476%26doi%3D10.1211%2F0022357023123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group">Amiram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luginbuhl, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feinglos, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chilkoti, A.</span><span> </span><span class="NLM_article-title">A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">172</span><span class="NLM_x">, </span> <span class="NLM_fpage">144</span><span class="NLM_x">â</span> <span class="NLM_lpage">151</span><span class="refDoi">Â DOI: 10.1016/j.jconrel.2013.07.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.jconrel.2013.07.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23928357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslOrsr7J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2013&pages=144-151&author=M.+Amiramauthor=K.+M.+Luginbuhlauthor=X.+Liauthor=M.+N.+Feinglosauthor=A.+Chilkoti&title=A+depot-forming+glucagon-like+peptide-1+fusion+protein+reduces+blood+glucose+for+five+days+with+a+single+injection&doi=10.1016%2Fj.jconrel.2013.07.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection</span></div><div class="casAuthors">Amiram, M.; Luginbuhl, K. M.; Li, X.; Feinglos, M. N.; Chilkoti, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">144-151</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Peptide drugs are an exciting class of pharmaceuticals for the treatment of a variety of diseases; however, their short half-life dictates multiple and frequent injections causing undesirable side effects.  Herein, we describe a novel peptide delivery system that seeks to combine the attractive features of prolonged circulation time with a prolonged release formulation.  This system consists of glucagon-like peptide-1, a type-2 diabetes drug fused to a thermally responsive, elastin-like-polypeptide (ELP) that undergoes a sol.-insol. phase transition between room temp. and body temp., thereby forming an injectable depot.  We synthesized a set of GLP-1-ELP fusions and verified their proteolytic stability and potency in vitro.  Significantly, a single injection of depot forming GLP-1-ELP fusions reduced blood glucose levels in mice for up to 5 days, 120 times longer than an injection of the native peptide.  These findings demonstrate the unique advantages of using ELPs to release peptide-ELP fusions from a depot combined with enhanced systemic circulation to create a tunable peptide delivery system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobECRp_3wmO7Vg90H21EOLACvtfcHk0liekOzGJkGb0g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslOrsr7J&md5=b06bf6a9e2fb8a2b759472a9eec7d60a</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2013.07.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2013.07.021%26sid%3Dliteratum%253Aachs%26aulast%3DAmiram%26aufirst%3DM.%26aulast%3DLuginbuhl%26aufirst%3DK.%2BM.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DFeinglos%26aufirst%3DM.%2BN.%26aulast%3DChilkoti%26aufirst%3DA.%26atitle%3DA%2520depot-forming%2520glucagon-like%2520peptide-1%2520fusion%2520protein%2520reduces%2520blood%2520glucose%2520for%2520five%2520days%2520with%2520a%2520single%2520injection%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2013%26volume%3D172%26spage%3D144%26epage%3D151%26doi%3D10.1016%2Fj.jconrel.2013.07.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yang, B.; Negulescu, C.; Eftimie, R. D. v. C.; Lautenbach, J. C. S.; Horwege, K.; Mercer, R.; Ford, D.; Alessi, T.</span><span> </span><span class="NLM_article-title">Stability of ITCA 650 for continuous subcutaneous delivery of exenatide at body temperature for 12 months</span>. In Diabetes Technology Meeting, November 5â7, 2009, San Francisco, CA,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=B.+Yang&author=C.+Negulescu&author=R.+D.+v.+C.+Eftimie&author=J.+C.+S.+Lautenbach&author=K.+Horwege&author=R.+Mercer&author=D.+Ford&author=T.+Alessi&title=Stability+of+ITCA+650+for+continuous+subcutaneous+delivery+of+exenatide+at+body+temperature+for+12+months"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit212a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DB.%26atitle%3DStability%2520of%2520ITCA%2520650%2520for%2520continuous%2520subcutaneous%2520delivery%2520of%2520exenatide%2520at%2520body%2520temperature%2520for%252012%2520months%26jtitle%3DDiabetes%2520Technology%2520Meeting%252C%2520November%25205%25E2%2580%25937%252C%25202009%252C%2520San%2520Francisco%252C%2520CA%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit212b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Henry, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenstock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logan, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alessi, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luskey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baron, M. A.</span><span> </span><span class="NLM_article-title">Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes</span> <span class="citation_source-journal">Diabetes Care</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">2559</span><span class="NLM_x">â</span> <span class="NLM_lpage">2565</span><span class="refDoi">Â DOI: 10.2337/dc12-2410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.2337%2Fdc12-2410" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2013&pages=2559-2565&author=R.+R.+Henryauthor=J.+Rosenstockauthor=D.+K.+Loganauthor=T.+R.+Alessiauthor=K.+Luskeyauthor=M.+A.+Baron&title=Randomized+trial+of+continuous+subcutaneous+delivery+of+exenatide+by+ITCA+650+versus+twice-daily+exenatide+injections+in+metformin-treated+type+2+diabetes&doi=10.2337%2Fdc12-2410"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit212b&amp;dbid=16384&amp;doi=10.2337%2Fdc12-2410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdc12-2410%26sid%3Dliteratum%253Aachs%26aulast%3DHenry%26aufirst%3DR.%2BR.%26aulast%3DRosenstock%26aufirst%3DJ.%26aulast%3DLogan%26aufirst%3DD.%2BK.%26aulast%3DAlessi%26aufirst%3DT.%2BR.%26aulast%3DLuskey%26aufirst%3DK.%26aulast%3DBaron%26aufirst%3DM.%2BA.%26atitle%3DRandomized%2520trial%2520of%2520continuous%2520subcutaneous%2520delivery%2520of%2520exenatide%2520by%2520ITCA%2520650%2520versus%2520twice-daily%2520exenatide%2520injections%2520in%2520metformin-treated%2520type%25202%2520diabetes%26jtitle%3DDiabetes%2520Care%26date%3D2013%26volume%3D36%26spage%3D2559%26epage%3D2565%26doi%3D10.2337%2Fdc12-2410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit212c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Henry, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenstock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alessi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luskey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baron, M. A.</span><span> </span><span class="NLM_article-title">Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes</span> <span class="citation_source-journal">J. Diabetes Complications</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">393</span><span class="NLM_x">â</span> <span class="NLM_lpage">398</span><span class="refDoi">Â DOI: 10.1016/j.jdiacomp.2013.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.jdiacomp.2013.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24631129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A280%3ADC%252BC2crktVSkuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=393-398&author=R.+R.+Henryauthor=J.+Rosenstockauthor=D.+Loganauthor=T.+Alessiauthor=K.+Luskeyauthor=M.+A.+Baron&title=Continuous+subcutaneous+delivery+of+exenatide+via+ITCA+650+leads+to+sustained+glycemic+control+and+weight+loss+for+48+weeks+in+metformin-treated+subjects+with+type+2+diabetes&doi=10.1016%2Fj.jdiacomp.2013.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit212cR"><div class="casContent"><span class="casTitleNuber">212c</span><div class="casTitle"><span class="NLM_cas:atitle">Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes</span></div><div class="casAuthors">Henry Robert R; Rosenstock Julio; Logan Douglas; Alessi Thomas; Luskey Kenneth; Baron Michelle A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of diabetes and its complications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">393-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIMS:  Evaluate the efficacy and tolerability of ITCA 650 in subjects with type 2 diabetes treated for up to 48 weeks.  METHODS:  This was a 24-week extension to a randomized, 24-week, open-label, phase 2 study in subjects with type 2 diabetes inadequately controlled with metformin.  Subjects received ITCA 650 mg (20, 40, 60 or 80 Î¼g/day).  Mean changes for HbA1c, weight, and fasting plasma glucose (FPG) were evaluated.  RESULTS:  Mean changes in HbA1c from baseline to week 48 ranged from -0.85% to -1.51%.  At week 48, â¥64% of subjects with an HbA1c â¤7% at week 24 maintained an HbA1c â¤7%.  The incidence of adverse events (AEs) was dose-related and ranged from 13.3% with 20 Î¼g/day to 37.5% with 80 Î¼g/day.  Most AEs were mild and transient; the incidence of nausea declined from 12.9% to 9.5% over the 24-week extension.  One subject on ITCA 650 80 Î¼g/day experienced mild intermittent vomiting.  Three (3.5%) subjects experienced severe AEs, but none were considered related to study drug.  CONCLUSION:  Significant changes in HbA1c, body weight, and FPG attained with ITCA 650 were maintained to 48 weeks.  The incidence of AEs was lower in the 24-week extension than in the initial 24-week treatment phase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQWIrYtplHXGMuCWE5mhx1RfW6udTcc2eY6VNviszrG6Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crktVSkuw%253D%253D&md5=cc2757106a5f572657f5541342d5626a</span></div><a href="/servlet/linkout?suffix=cit212c&amp;dbid=16384&amp;doi=10.1016%2Fj.jdiacomp.2013.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jdiacomp.2013.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DHenry%26aufirst%3DR.%2BR.%26aulast%3DRosenstock%26aufirst%3DJ.%26aulast%3DLogan%26aufirst%3DD.%26aulast%3DAlessi%26aufirst%3DT.%26aulast%3DLuskey%26aufirst%3DK.%26aulast%3DBaron%26aufirst%3DM.%2BA.%26atitle%3DContinuous%2520subcutaneous%2520delivery%2520of%2520exenatide%2520via%2520ITCA%2520650%2520leads%2520to%2520sustained%2520glycemic%2520control%2520and%2520weight%2520loss%2520for%252048%2520weeks%2520in%2520metformin-treated%2520subjects%2520with%2520type%25202%2520diabetes%26jtitle%3DJ.%2520Diabetes%2520Complications%26date%3D2014%26volume%3D28%26spage%3D393%26epage%3D398%26doi%3D10.1016%2Fj.jdiacomp.2013.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group">Schaepelynck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darmon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molines, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jannot-Lamotte, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treglia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raccah, D.</span><span> </span><span class="NLM_article-title">Advances in pump technology: insulin patch pumps, combined pumps and glucose sensors, and implanted pumps</span> <span class="citation_source-journal">Diabetes Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">S85</span><span class="NLM_x">â</span> <span class="NLM_lpage">S93</span><span class="refDoi">Â DOI: 10.1016/S1262-3636(11)70972-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2FS1262-3636%2811%2970972-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=22208717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFGitQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2011&pages=S85-S93&author=P.+Schaepelynckauthor=P.+Darmonauthor=L.+Molinesauthor=M.+F.+Jannot-Lamotteauthor=C.+Tregliaauthor=D.+Raccah&title=Advances+in+pump+technology%3A+insulin+patch+pumps%2C+combined+pumps+and+glucose+sensors%2C+and+implanted+pumps&doi=10.1016%2FS1262-3636%2811%2970972-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in pump technology: insulin patch pumps, combined pumps and glucose sensors, and implanted pumps</span></div><div class="casAuthors">Schaepelynck, P.; Darmon, P.; Molines, L.; Jannot-Lamotte, M. F.; Treglia, C.; Raccah, D.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes & Metabolism</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">Spec. Iss. 4</span>),
    <span class="NLM_cas:pages">S85-S93</span>CODEN:
                <span class="NLM_cas:coden">DIMEFW</span>;
        ISSN:<span class="NLM_cas:issn">1262-3636</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">This review discusses the most recent developments in insulin pump technol.  The benefits of the insulin pump to patients with type 1 diabetes are recognized both for its metabolic effectiveness and its pos. effects on quality of life.  The current pumps are reliable, small and light, and are becoming more and more sophisticated.  Nevertheless, there remain practical and psychol. constraints for the patient.  However, recent patch-pump advances should simplify the tech. aspects of pump treatment and enhance patient comfort.  Another advance combines the insulin pump with a glucose sensor.  Such a combination is logical for optimizing pump use and, to that end, developing an automated or closed-loop'system that permits the delivery of s.c. insulin adjusted according to measured levels of s.c. glucose.  Finally, implanted insulin pumps have proven their worth not only because of their simple use, but also for their contribution in the artificial pancreas project.  Indeed, the prompt response with i.p. administration of insulin makes it of interest for use in a closed-loop system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpigUU07f0kArVg90H21EOLACvtfcHk0linoLaMikMmYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFGitQ%253D%253D&md5=545dd974c9c8e1581d81600a4d2848db</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1016%2FS1262-3636%2811%2970972-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1262-3636%252811%252970972-7%26sid%3Dliteratum%253Aachs%26aulast%3DSchaepelynck%26aufirst%3DP.%26aulast%3DDarmon%26aufirst%3DP.%26aulast%3DMolines%26aufirst%3DL.%26aulast%3DJannot-Lamotte%26aufirst%3DM.%2BF.%26aulast%3DTreglia%26aufirst%3DC.%26aulast%3DRaccah%26aufirst%3DD.%26atitle%3DAdvances%2520in%2520pump%2520technology%253A%2520insulin%2520patch%2520pumps%252C%2520combined%2520pumps%2520and%2520glucose%2520sensors%252C%2520and%2520implanted%2520pumps%26jtitle%3DDiabetes%2520Metab.%26date%3D2011%26volume%3D37%26spage%3DS85%26epage%3DS93%26doi%3D10.1016%2FS1262-3636%2811%2970972-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group">Peyser, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dassau, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skyler, J. S.</span><span> </span><span class="NLM_article-title">The artificial pancreas: current status and future prospects in the management of diabetes</span> <span class="citation_source-journal">Ann. N. Y. Acad. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">1311</span><span class="NLM_x">, </span> <span class="NLM_fpage">102</span><span class="NLM_x">â</span> <span class="NLM_lpage">123</span><span class="refDoi">Â DOI: 10.1111/nyas.12431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1111%2Fnyas.12431" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1311&publication_year=2014&pages=102-123&author=T.+Peyserauthor=E.+Dassauauthor=M.+Bretonauthor=J.+S.+Skyler&title=The+artificial+pancreas%3A+current+status+and+future+prospects+in+the+management+of+diabetes&doi=10.1111%2Fnyas.12431"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1111%2Fnyas.12431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fnyas.12431%26sid%3Dliteratum%253Aachs%26aulast%3DPeyser%26aufirst%3DT.%26aulast%3DDassau%26aufirst%3DE.%26aulast%3DBreton%26aufirst%3DM.%26aulast%3DSkyler%26aufirst%3DJ.%2BS.%26atitle%3DThe%2520artificial%2520pancreas%253A%2520current%2520status%2520and%2520future%2520prospects%2520in%2520the%2520management%2520of%2520diabetes%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2014%26volume%3D1311%26spage%3D102%26epage%3D123%26doi%3D10.1111%2Fnyas.12431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yadav, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smart, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tajiri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basit, A. W.</span><span> </span><span class="NLM_article-title">Toward oral delivery of biopharmaceuticals: An assessment of the gastrointestinal stability of 17 peptide drugs</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">966</span><span class="NLM_x">â</span> <span class="NLM_lpage">973</span><span class="refDoi">Â DOI: 10.1021/mp500809f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp500809f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref215/cit215a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlyqsb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=966-973&author=J.+Wangauthor=V.+Yadavauthor=A.+L.+Smartauthor=S.+Tajiriauthor=A.+W.+Basit&title=Toward+oral+delivery+of+biopharmaceuticals%3A+An+assessment+of+the+gastrointestinal+stability+of+17+peptide+drugs&doi=10.1021%2Fmp500809f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit215aR"><div class="casContent"><span class="casTitleNuber">215a</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Oral Delivery of Biopharmaceuticals: An Assessment of the Gastrointestinal Stability of 17 Peptide Drugs</span></div><div class="casAuthors">Wang, Jie; Yadav, Vipul; Smart, Alice L.; Tajiri, Shinichiro; Basit, Abdul W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">966-973</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A major barrier to successful oral delivery of peptide and protein mols. is their inherent instability in the lumen of the gastrointestinal tract.  The aim of this study was to det. the stability of 17 disparate peptide drugs (insulin, calcitonin, glucagon, secretin, somatostatin, desmopressin, oxytocin, [Arg8]-vasopressin, octreotide, ciclosporin, leuprolide, nafarelin, buserelin, histrelin, [D-Ser]4-gonadorelin, deslorelin, and goserelin) in gastric and small intestinal fluids from both humans and pigs, and in simulated gastric and intestinal fluids.  In human gastric fluid, the larger peptides including somatostatin, calcitonin, secretin, glucagon, and insulin were metabolized rapidly, while the smaller peptides showed good stability.  In human small intestinal fluid, however, both small and large peptides degraded rapidly with the exception of the cyclic peptide ciclosporin and the disulfide-bridge contg. peptides octreotide and desmopressin, which showed good stability.  The stability of peptides in both simulated gastric fluid and pig gastric fluid correlated well with stability in human gastric fluid.  However, it was not possible to establish such a correlation with the small intestinal fluids because of the rapid rate of peptide degrdn.  This work has identified the mol. features in the structure of a wide range of peptides that influence their stability in the environment of the gastrointestinal tract, which in turn will allow for better selection of peptide candidates for oral delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraciXJLe-z4rVg90H21EOLACvtfcHk0linoLaMikMmYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlyqsb8%253D&md5=a29abd913a44604892e879e735818ff9</span></div><a href="/servlet/linkout?suffix=cit215a&amp;dbid=16384&amp;doi=10.1021%2Fmp500809f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp500809f%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYadav%26aufirst%3DV.%26aulast%3DSmart%26aufirst%3DA.%2BL.%26aulast%3DTajiri%26aufirst%3DS.%26aulast%3DBasit%26aufirst%3DA.%2BW.%26atitle%3DToward%2520oral%2520delivery%2520of%2520biopharmaceuticals%253A%2520An%2520assessment%2520of%2520the%2520gastrointestinal%2520stability%2520of%252017%2520peptide%2520drugs%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2015%26volume%3D12%26spage%3D966%26epage%3D973%26doi%3D10.1021%2Fmp500809f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit215b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zhou, X. H.</span><span> </span><span class="NLM_article-title">Overcoming enzymatic and absorption barriers to non-parenterally administered protein and peptide drugs</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">239</span><span class="NLM_x">â</span> <span class="NLM_lpage">252</span><span class="refDoi">Â DOI: 10.1016/0168-3659(94)90071-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2F0168-3659%2894%2990071-X" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1994&pages=239-252&author=X.+H.+Zhou&title=Overcoming+enzymatic+and+absorption+barriers+to+non-parenterally+administered+protein+and+peptide+drugs&doi=10.1016%2F0168-3659%2894%2990071-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit215b&amp;dbid=16384&amp;doi=10.1016%2F0168-3659%2894%2990071-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0168-3659%252894%252990071-X%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DX.%2BH.%26atitle%3DOvercoming%2520enzymatic%2520and%2520absorption%2520barriers%2520to%2520non-parenterally%2520administered%2520protein%2520and%2520peptide%2520drugs%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D1994%26volume%3D29%26spage%3D239%26epage%3D252%26doi%3D10.1016%2F0168-3659%2894%2990071-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit215c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Karsdal, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riis, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stern, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arbit, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christiansen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henriksen, K.</span><span> </span><span class="NLM_article-title">Lessons learned from the clinical development of oral peptides</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">720</span><span class="NLM_x">â</span> <span class="NLM_lpage">732</span><span class="refDoi">Â DOI: 10.1111/bcp.12557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1111%2Fbcp.12557" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25408230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslOnu7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2015&pages=720-732&author=M.+A.+Karsdalauthor=B.+J.+Riisauthor=N.+Mehtaauthor=W.+Sternauthor=E.+Arbitauthor=C.+Christiansenauthor=K.+Henriksen&title=Lessons+learned+from+the+clinical+development+of+oral+peptides&doi=10.1111%2Fbcp.12557"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit215cR"><div class="casContent"><span class="casTitleNuber">215c</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons learned from the clinical development of oral peptides</span></div><div class="casAuthors">Karsdal, Morten Asser; Riis, Bente Juul; Mehta, Nozer; Stern, William; Arbit, Ehud; Christiansen, Claus; Henriksen, Kim</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">720-732</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The oral delivery of peptides and proteins has been hampered by an array of obstacles.  However, several promising novel oral delivery systems have been developed.  This paper reviews the most advanced oral formulation technologies, and highlights key lessons and implications from studies undertaken to date with these oral formulations.  Special interest is given to oral salmon calcitonin (CT), glucagon-like peptide-1 (GLP-1), insulin, PYY-(3-36), recombinant human parathyroid hormone (rhPTH(1-31)-NH2) and PTH(1-34), by different technologies.  The issues addressed include (i) interaction with water, (ii) interaction with food, (iii) diurnal variation, (iv) inter- and intra-subject variability, (v) correlation between efficacy and exposure and (vi) key deliverables of different technologies.  These key lessons may aid research in the development of other oral formulations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBun32dB2rgrVg90H21EOLACvtfcHk0linoLaMikMmYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslOnu7Y%253D&md5=0f636db3549478f73bbc4ecb958e385d</span></div><a href="/servlet/linkout?suffix=cit215c&amp;dbid=16384&amp;doi=10.1111%2Fbcp.12557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.12557%26sid%3Dliteratum%253Aachs%26aulast%3DKarsdal%26aufirst%3DM.%2BA.%26aulast%3DRiis%26aufirst%3DB.%2BJ.%26aulast%3DMehta%26aufirst%3DN.%26aulast%3DStern%26aufirst%3DW.%26aulast%3DArbit%26aufirst%3DE.%26aulast%3DChristiansen%26aufirst%3DC.%26aulast%3DHenriksen%26aufirst%3DK.%26atitle%3DLessons%2520learned%2520from%2520the%2520clinical%2520development%2520of%2520oral%2520peptides%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2015%26volume%3D79%26spage%3D720%26epage%3D732%26doi%3D10.1111%2Fbcp.12557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216"><span><span class="NLM_contrib-group">Rembratt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graugaard-Jensen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senderovitz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norgaard, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Djurhuus, J. C.</span><span> </span><span class="NLM_article-title">Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55â70 years</span> <span class="citation_source-journal">Eur. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">397</span><span class="NLM_x">â</span> <span class="NLM_lpage">402</span><span class="refDoi">Â DOI: 10.1007/s00228-004-0781-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1007%2Fs00228-004-0781-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=15197520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslChsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=397-402&author=A.+Rembrattauthor=C.+Graugaard-Jensenauthor=T.+Senderovitzauthor=J.+P.+Norgaardauthor=J.+C.+Djurhuus&title=Pharmacokinetics+and+pharmacodynamics+of+desmopressin+administered+orally+versus+intravenously+at+daytime+versus+night-time+in+healthy+men+aged+55%E2%80%9370+years&doi=10.1007%2Fs00228-004-0781-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years</span></div><div class="casAuthors">Rembratt, Asa; Graugaard-Jensen, Charlotte; Senderovitz, Thomas; Norgaard, Jens Peter; Djurhuus, Jens Christian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">397-402</span>CODEN:
                <span class="NLM_cas:coden">EJCPAS</span>;
        ISSN:<span class="NLM_cas:issn">0031-6970</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">To investigate (1) the pharmacokinetic and pharmacodynamic profiles of desmopressin in men from an age group with a high incidence of nocturia; and (2) circadian variation in the pharmacokinetic parameters.  The study had an open, randomized, four-way cross-over design.  Desmopressin was administered orally (0.2 mg) and i.v. (2 Î¼g), daytime and night-time, yielding four in-hospital sessions, sepd. by at least 2 days.  Blood samples were taken before and at predetd. time points up to 12 h after dosing.  Pharmacokinetic parameters were derived using a two-compartmental model except for AUC(0 t), which was derived using non-compartmental anal.  Bioavailability was estd. using AUC(0 t) for the oral and the i.v. periods.  Urine, for measurements of vol. and osmolality, was collected in predetd. intervals before and until 12 h after dosing.  Fifteen healthy men aged 55-70 yr were included in the anal.  The concn.-time curve after 2 Î¼g i.v. desmopressin was best described using a biexponential term.  The mean (95% CI) AUC at night was 302 (272-335) pgÃh/mL and in the day was 281 (253-312) pgÃh/mL.  No statistically significant differences were detected between night and day except for terminal half-life, which was 3.1 h at night and 2.8 h in the daytime (P=0.02).  After oral desmopressin, concns. above the limit of quantification (2.5 pg/mL) were only detected in 51% of the samples.  Peak plasma concn. (Cmax) was 6.2 (5.1-7.5) pg/mL at night and 6.6 (5.5-7.9) pg/mL in the daytime.  Median time to reach Cmax (tmax) was 1.5 (range 1.0-4.1) h at night and 1.5 (range 0.5-3.0) h in the day.  The bioavailability was 0.08%.  The pharmacodynamic effects of oral and i.v. desmopressin given in the daytime were similar during the first 6 h after dosing.  The night-time dosing and daytime i.v. dose resulted in antidiuresis throughout the measuring period, while the effect of the daytime peroral dose receded after 6 h.  The pharmacokinetic profile of desmopressin is biexponential.  Terminal half-life was longer at night than in the daytime, but the difference is considered too small to be of clin. importance.  The plasma levels given by the i.v. dose resulted in a duration of action of 12 h or more.  Despite low bioavailability, the pharmacodynamic effects of oral desmopressin were similar in magnitude to those after i.v. dose at night and during the first 6 h after daytime administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-1FLSTS70pLVg90H21EOLACvtfcHk0ljtYkteUZxzcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslChsrk%253D&md5=99383d45825422d50bdb42cc04e0cf18</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1007%2Fs00228-004-0781-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00228-004-0781-9%26sid%3Dliteratum%253Aachs%26aulast%3DRembratt%26aufirst%3DA.%26aulast%3DGraugaard-Jensen%26aufirst%3DC.%26aulast%3DSenderovitz%26aufirst%3DT.%26aulast%3DNorgaard%26aufirst%3DJ.%2BP.%26aulast%3DDjurhuus%26aufirst%3DJ.%2BC.%26atitle%3DPharmacokinetics%2520and%2520pharmacodynamics%2520of%2520desmopressin%2520administered%2520orally%2520versus%2520intravenously%2520at%2520daytime%2520versus%2520night-time%2520in%2520healthy%2520men%2520aged%252055%25E2%2580%259370%2520years%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2004%26volume%3D60%26spage%3D397%26epage%3D402%26doi%3D10.1007%2Fs00228-004-0781-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit217"><span><span class="NLM_contrib-group">Nielsen, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucke, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoermer, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairlie, D. P.</span><span> </span><span class="NLM_article-title">Orally Absorbed Cyclic Peptides</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">8094</span><span class="NLM_x">â</span> <span class="NLM_lpage">8128</span><span class="refDoi">Â DOI: 10.1021/acs.chemrev.6b00838</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.6b00838" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2sXot12lurY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2017&pages=8094-8128&author=D.+S.+Nielsenauthor=N.+E.+Shepherdauthor=W.+Xuauthor=A.+J.+Luckeauthor=M.+J.+Stoermerauthor=D.+P.+Fairlie&title=Orally+Absorbed+Cyclic+Peptides&doi=10.1021%2Facs.chemrev.6b00838"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Orally Absorbed Cyclic Peptides</span></div><div class="casAuthors">Nielsen, Daniel S.; Shepherd, Nicholas E.; Xu, Weijun; Lucke, Andrew J.; Stoermer, Martin J.; Fairlie, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">8094-8128</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Peptides and proteins are not orally bioavailable in mammals, although a few peptides are intestinally absorbed in small amts.  Polypeptides are generally too large and polar to passively diffuse through lipid membranes, while most known active transport mechanisms facilitate cell uptake of only very small peptides.  Systematic evaluations of peptides with mol. wts. above 500 Da are needed to identify parameters that influence oral bioavailability.  Here we describe 125 cyclic peptides contg. four to thirty-seven amino acids that are orally absorbed by mammals.  Cyclization minimizes degrdn. in the gut, blood and tissues by removing cleavable N- and C-termini and by shielding components from metabolic enzymes.  Cyclization also folds peptides into bioactive conformations that det. exposure of polar atoms to solvation by water and lipids, and therefore should influence oral bioavailability.  Key chem. properties thought to influence oral absorption and bioavailability are analyzed, including mol. wt., octanol-water partitioning, hydrogen bond donors/acceptors, rotatable bonds and polar surface area.  The cyclic peptides violated to different degrees all of the limits traditionally considered to be important for oral bioavailability of drug-like small mols., although fewer hydrogen bond donors and reduced flexibility generally favored oral absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprHf1YVkf7ErVg90H21EOLACvtfcHk0ljtYkteUZxzcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXot12lurY%253D&md5=38af1945471e5ddffd3ae630ebbe129b</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.6b00838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.6b00838%26sid%3Dliteratum%253Aachs%26aulast%3DNielsen%26aufirst%3DD.%2BS.%26aulast%3DShepherd%26aufirst%3DN.%2BE.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DLucke%26aufirst%3DA.%2BJ.%26aulast%3DStoermer%26aufirst%3DM.%2BJ.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26atitle%3DOrally%2520Absorbed%2520Cyclic%2520Peptides%26jtitle%3DChem.%2520Rev.%26date%3D2017%26volume%3D117%26spage%3D8094%26epage%3D8128%26doi%3D10.1021%2Facs.chemrev.6b00838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref218"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref218'); return false;" data-citation="" class="refNumLink">218</a></strong><div class="NLM_citation" id="cit218a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springthorpe, B.</span><span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">â</span> <span class="NLM_lpage">890</span><span class="refDoi">Â DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit218aR"><div class="casContent"><span class="casTitleNuber">218a</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0ljtYkteUZxzcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit218a&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit218b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Arnott, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planey, S. L.</span><span> </span><span class="NLM_article-title">The influence of lipophilicity in drug discovery and design</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">863</span><span class="NLM_x">â</span> <span class="NLM_lpage">875</span><span class="refDoi">Â DOI: 10.1517/17460441.2012.714363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1517%2F17460441.2012.714363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=22992175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2lsbvJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=863-875&author=J.+A.+Arnottauthor=S.+L.+Planey&title=The+influence+of+lipophilicity+in+drug+discovery+and+design&doi=10.1517%2F17460441.2012.714363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit218bR"><div class="casContent"><span class="casTitleNuber">218b</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of lipophilicity in drug discovery and design</span></div><div class="casAuthors">Arnott, John A.; Planey, Sonia Lobo</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">863-875</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The role of lipophilicity in drug discovery and design is a crit. one.  Lipophilicity is a key physicochem. property that plays a crucial role in detg. ADMET (absorption, distribution, metab., excretion, and toxicity) properties and the overall suitability of drug candidates.  There is increasing evidence to suggest that control of physicochem. properties such as lipophilicity, within a defined optimal range, can improve compd. quality and the likelihood of therapeutic success.Areas covered: This review focuses on understanding lipophilicity, techniques used to measure lipophilicity, and summarizes the importance of lipophilicity in drug discovery and development, including a discussion of its impact on individual ADMET parameters as well as its overall influence on the drug discovery and design process, specifically within the past 15 years.Expert opinion: A current review of the literature reveals a continued reliance on the synthesis of novel structures with increased potency, rather than a focus on maintaining optimal physicochem. properties assocd. with ADMET throughout drug optimization.  Particular attention to the optimum region of lipophilicity, as well as monitoring of lipophilic efficiency indexes, may contribute significantly to the overall quality of candidate drugs at different stages of discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolWJgvv9yK87Vg90H21EOLACvtfcHk0ljmpvH30Va60w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2lsbvJ&md5=4dc5d7268216c9a59fcbd841fbf66735</span></div><a href="/servlet/linkout?suffix=cit218b&amp;dbid=16384&amp;doi=10.1517%2F17460441.2012.714363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2012.714363%26sid%3Dliteratum%253Aachs%26aulast%3DArnott%26aufirst%3DJ.%2BA.%26aulast%3DPlaney%26aufirst%3DS.%2BL.%26atitle%3DThe%2520influence%2520of%2520lipophilicity%2520in%2520drug%2520discovery%2520and%2520design%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2012%26volume%3D7%26spage%3D863%26epage%3D875%26doi%3D10.1517%2F17460441.2012.714363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref219"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref219'); return false;" data-citation="" class="refNumLink">219</a></strong><div class="NLM_citation" id="cit219a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rafi, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hearn, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vedantham, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renslo, A. R.</span><span> </span><span class="NLM_article-title">Predicting and Improving the Membrane Permeability of Peptidic Small Molecules</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">3163</span><span class="NLM_x">â</span> <span class="NLM_lpage">3169</span><span class="refDoi">Â DOI: 10.1021/jm201634q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201634q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref219/cit219a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Ogtrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3163-3169&author=S.+B.+Rafiauthor=B.+R.+Hearnauthor=P.+Vedanthamauthor=M.+P.+Jacobsonauthor=A.+R.+Renslo&title=Predicting+and+Improving+the+Membrane+Permeability+of+Peptidic+Small+Molecules&doi=10.1021%2Fjm201634q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit219aR"><div class="casContent"><span class="casTitleNuber">219a</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting and Improving the Membrane Permeability of Peptidic Small Molecules</span></div><div class="casAuthors">Rafi, Salma B.; Hearn, Brian R.; Vedantham, Punitha; Jacobson, Matthew P.; Renslo, Adam R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3163-3169</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We evaluate exptl. and computationally the membrane permeability of matched sets of peptidic small mols. bearing natural or bioisosteric unnatural amino acids.  We find that the intentional introduction of hydrogen bond acceptor-donor pairs in such mols. can improve membrane permeability while retaining or improving other favorable drug-like properties.  We employ an all-atom force field based method to calc. changes in free energy assocd. with the transfer of the peptidic mols. from water to membrane.  This computational method correctly predicts rank order exptl. permeability trends within congeneric series and is much more predictive than calcns. (e.g., clogP) that do not consider three-dimensional conformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVAMuvF4vQFrVg90H21EOLACvtfcHk0ljmpvH30Va60w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Ogtrg%253D&md5=a517000b38fb76198d38beac165d2d99</span></div><a href="/servlet/linkout?suffix=cit219a&amp;dbid=16384&amp;doi=10.1021%2Fjm201634q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201634q%26sid%3Dliteratum%253Aachs%26aulast%3DRafi%26aufirst%3DS.%2BB.%26aulast%3DHearn%26aufirst%3DB.%2BR.%26aulast%3DVedantham%26aufirst%3DP.%26aulast%3DJacobson%26aufirst%3DM.%2BP.%26aulast%3DRenslo%26aufirst%3DA.%2BR.%26atitle%3DPredicting%2520and%2520Improving%2520the%2520Membrane%2520Permeability%2520of%2520Peptidic%2520Small%2520Molecules%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3163%26epage%3D3169%26doi%3D10.1021%2Fjm201634q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit219b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rezai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bock, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalyanaraman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lokey, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, M. P.</span><span> </span><span class="NLM_article-title">Conformational Flexibility, Internal Hydrogen Bonding, and Passive Membrane Permeability: Successful in Silico Prediction of the Relative Permeabilities of Cyclic Peptides</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x">, </span> <span class="NLM_fpage">14073</span><span class="NLM_x">â</span> <span class="NLM_lpage">14080</span><span class="refDoi">Â DOI: 10.1021/ja063076p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja063076p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref219/cit219b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVCmur3I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2006&pages=14073-14080&author=T.+Rezaiauthor=J.+E.+Bockauthor=M.+V.+Zhouauthor=C.+Kalyanaramanauthor=R.+S.+Lokeyauthor=M.+P.+Jacobson&title=Conformational+Flexibility%2C+Internal+Hydrogen+Bonding%2C+and+Passive+Membrane+Permeability%3A+Successful+in+Silico+Prediction+of+the+Relative+Permeabilities+of+Cyclic+Peptides&doi=10.1021%2Fja063076p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit219bR"><div class="casContent"><span class="casTitleNuber">219b</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational Flexibility, Internal Hydrogen Bonding, and Passive Membrane Permeability: Successful in Silico Prediction of the Relative Permeabilities of Cyclic Peptides</span></div><div class="casAuthors">Rezai, Taha; Bock, Jonathan E.; Zhou, Mai V.; Kalyanaraman, Chakrapani; Lokey, R. Scott; Jacobson, Matthew P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">14073-14080</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report an atomistic phys. model for the passive membrane permeability of cyclic peptides.  The computational modeling was performed in advance of the expts. and did not involve the use of "training data".  The model explicitly treats the conformational flexibility of the peptides by extensive conformational sampling in low (membrane) and high (water) dielec. environments.  The passive membrane permeabilities of 11 cyclic peptides were obtained exptl. using a parallel artificial membrane permeability assay (PAMPA) and showed a linear correlation with the computational results with R2 = 0.96.  In general, the results support the hypothesis, already well established in the literature, that the ability to form internal hydrogen bonds is crit. for passive membrane permeability and can be the distinguishing factor among closely related compds., such as those studied here.  However, we have found that the no. of internal hydrogen bonds that can form in the membrane and the solvent-exposed polar surface area correlate more poorly with PAMPA permeability than our model, which quant. ests. the solvation free energy losses upon moving from high-dielec. water to the low-dielec. interior of a membrane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofxfL018o86rVg90H21EOLACvtfcHk0ljmpvH30Va60w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVCmur3I&md5=78d4b4082e6a72b288d4b6dac933ca35</span></div><a href="/servlet/linkout?suffix=cit219b&amp;dbid=16384&amp;doi=10.1021%2Fja063076p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja063076p%26sid%3Dliteratum%253Aachs%26aulast%3DRezai%26aufirst%3DT.%26aulast%3DBock%26aufirst%3DJ.%2BE.%26aulast%3DZhou%26aufirst%3DM.%2BV.%26aulast%3DKalyanaraman%26aufirst%3DC.%26aulast%3DLokey%26aufirst%3DR.%2BS.%26aulast%3DJacobson%26aufirst%3DM.%2BP.%26atitle%3DConformational%2520Flexibility%252C%2520Internal%2520Hydrogen%2520Bonding%252C%2520and%2520Passive%2520Membrane%2520Permeability%253A%2520Successful%2520in%2520Silico%2520Prediction%2520of%2520the%2520Relative%2520Permeabilities%2520of%2520Cyclic%2520Peptides%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2006%26volume%3D128%26spage%3D14073%26epage%3D14080%26doi%3D10.1021%2Fja063076p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit219c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Wang, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Northfield, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colless, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaousis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamernig, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohman, R.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liras, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairlie, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craik, D. J.</span><span> </span><span class="NLM_article-title">Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">17504</span><span class="NLM_x">â</span> <span class="NLM_lpage">17509</span><span class="refDoi">Â DOI: 10.1073/pnas.1417611111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1073%2Fpnas.1417611111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25416591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKmu7vE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=17504-17509&author=C.+K.+Wangauthor=S.+E.+Northfieldauthor=B.+Collessauthor=S.+Chaousisauthor=I.+Hamernigauthor=R.-J.+Lohmanauthor=D.+S.+Nielsenauthor=C.+I.+Schroederauthor=S.+Lirasauthor=D.+A.+Priceauthor=D.+P.+Fairlieauthor=D.+J.+Craik&title=Rational+design+and+synthesis+of+an+orally+bioavailable+peptide+guided+by+NMR+amide+temperature+coefficients&doi=10.1073%2Fpnas.1417611111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit219cR"><div class="casContent"><span class="casTitleNuber">219c</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients</span></div><div class="casAuthors">Wang, Conan K.; Northfield, Susan E.; Colless, Barbara; Chaousis, Stephanie; Hamernig, Ingrid; Lohman, Rink-Jan; Nielsen, Daniel S.; Schroeder, Christina I.; Liras, Spiros; Price, David A.; Fairlie, David P.; Craik, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">17504-17509</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Enhancing the oral bioavailability of peptide drug leads is a major challenge in drug design.  As such, methods to address this challenge are highly sought after by the pharmaceutical industry.  Here, we propose a strategy to identify appropriate amides for N-methylation using temp. coeffs. measured by NMR to identify exposed amides in cyclic peptides.  N-methylation effectively caps these amides, modifying the overall solvation properties of the peptides and making them more membrane permeable.  The approach for identifying sites for N-methylation is a rapid alternative to the elucidation of 3D structures of peptide drug leads, which has been a commonly used structure-guided approach in the past.  Five leucine-rich peptide scaffolds are reported with selectively designed N-methylated derivs.  In vitro membrane permeability was assessed by parallel artificial membrane permeability assay and Caco-2 assay.  The most promising N-methylated peptide was then tested in vivo.  Here we report a novel peptide (15), which displayed an oral bioavailability of 33% in a rat model, thus validating the design approach.  We show that this approach can also be used to explain the notable increase in oral bioavailability of a somatostatin analog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ1pwUl6qUw7Vg90H21EOLACvtfcHk0lhD5RkBrhoNPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKmu7vE&md5=02803e516bf514e3d941769b7bbf3607</span></div><a href="/servlet/linkout?suffix=cit219c&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1417611111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1417611111%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%2BK.%26aulast%3DNorthfield%26aufirst%3DS.%2BE.%26aulast%3DColless%26aufirst%3DB.%26aulast%3DChaousis%26aufirst%3DS.%26aulast%3DHamernig%26aufirst%3DI.%26aulast%3DLohman%26aufirst%3DR.-J.%26aulast%3DNielsen%26aufirst%3DD.%2BS.%26aulast%3DSchroeder%26aufirst%3DC.%2BI.%26aulast%3DLiras%26aufirst%3DS.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26aulast%3DCraik%26aufirst%3DD.%2BJ.%26atitle%3DRational%2520design%2520and%2520synthesis%2520of%2520an%2520orally%2520bioavailable%2520peptide%2520guided%2520by%2520NMR%2520amide%2520temperature%2520coefficients%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D17504%26epage%3D17509%26doi%3D10.1073%2Fpnas.1417611111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit219d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Ahlbach, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lexa, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bockus, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crews, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lokey, R. S.</span><span> </span><span class="NLM_article-title">Beyond cyclosporine A: conformation-dependent passive membrane permeabilities of cyclic peptide natural products</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2121</span><span class="NLM_x">â</span> <span class="NLM_lpage">2130</span><span class="refDoi">Â DOI: 10.4155/fmc.15.78</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.4155%2Ffmc.15.78" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26067057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVehs7%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=2121-2130&author=C.+L.+Ahlbachauthor=K.+W.+Lexaauthor=A.+T.+Bockusauthor=V.+Chenauthor=P.+Crewsauthor=M.+P.+Jacobsonauthor=R.+S.+Lokey&title=Beyond+cyclosporine+A%3A+conformation-dependent+passive+membrane+permeabilities+of+cyclic+peptide+natural+products&doi=10.4155%2Ffmc.15.78"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit219dR"><div class="casContent"><span class="casTitleNuber">219d</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond cyclosporine A: conformation-dependent passive membrane permeabilities of cyclic peptide natural products</span></div><div class="casAuthors">Ahlbach, Christopher L.; Lexa, Katrina W.; Bockus, Andrew T.; Chen, Valerie; Crews, Phillip; Jacobson, Matthew P.; Lokey, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2121-2130</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Many cyclic peptide natural products are larger and structurally more complex than conventional small mol. drugs.  Although some mols. in this class are known to possess favorable pharmacokinetic properties, there have been few reports on the membrane permeabilities of cyclic peptide natural products.  Here, we present the passive membrane permeabilities of 39 cyclic peptide natural products, and interpret the results using a computational permeability prediction algorithm based on their known or calcd. 3D conformations.  We found that the permeabilities of these compds., measured in a parallel artificial membrane permeability assay, spanned a wide range and demonstrated the important influence of conformation on membrane permeability.  These results will aid in the development of these compds. as a viable drug paradigm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4_Ar_CGW03bVg90H21EOLACvtfcHk0lhD5RkBrhoNPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVehs7%252FM&md5=69d8628920ebc6ad72b13162f3214f2d</span></div><a href="/servlet/linkout?suffix=cit219d&amp;dbid=16384&amp;doi=10.4155%2Ffmc.15.78&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.15.78%26sid%3Dliteratum%253Aachs%26aulast%3DAhlbach%26aufirst%3DC.%2BL.%26aulast%3DLexa%26aufirst%3DK.%2BW.%26aulast%3DBockus%26aufirst%3DA.%2BT.%26aulast%3DChen%26aufirst%3DV.%26aulast%3DCrews%26aufirst%3DP.%26aulast%3DJacobson%26aufirst%3DM.%2BP.%26aulast%3DLokey%26aufirst%3DR.%2BS.%26atitle%3DBeyond%2520cyclosporine%2520A%253A%2520conformation-dependent%2520passive%2520membrane%2520permeabilities%2520of%2520cyclic%2520peptide%2520natural%2520products%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D2121%26epage%3D2130%26doi%3D10.4155%2Ffmc.15.78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref220"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref220'); return false;" data-citation="" class="refNumLink">220</a></strong><div class="NLM_citation" id="cit220"><span><span class="NLM_contrib-group">Busby, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartolini, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryant, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannig, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solinga, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobin, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakefield, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurtz, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, M. G.</span><span> </span><span class="NLM_article-title">Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">344</span><span class="NLM_x">, </span> <span class="NLM_fpage">196</span><span class="NLM_x">â</span> <span class="NLM_lpage">206</span><span class="refDoi">Â DOI: 10.1124/jpet.112.199430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1124%2Fjpet.112.199430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23090647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1CrtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2013&pages=196-206&author=R.+W.+Busbyauthor=M.+M.+Kesslerauthor=W.+P.+Bartoliniauthor=A.+P.+Bryantauthor=G.+Hannigauthor=C.+S.+Higginsauthor=R.+M.+Solingaauthor=J.+V.+Tobinauthor=J.+D.+Wakefieldauthor=C.+B.+Kurtzauthor=M.+G.+Currie&title=Pharmacologic+properties%2C+metabolism%2C+and+disposition+of+linaclotide%2C+a+novel+therapeutic+peptide+approved+for+the+treatment+of+irritable+bowel+syndrome+with+constipation+and+chronic+idiopathic+constipation&doi=10.1124%2Fjpet.112.199430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation</span></div><div class="casAuthors">Busby, Robert W.; Kessler, Marco M.; Bartolini, Wilmin P.; Bryant, Alexander P.; Hannig, Gerhard; Higgins, Carolyn S.; Solinga, Robert M.; Tobin, Jenny V.; Wakefield, James D.; Kurtz, Caroline B.; Currie, Mark G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">196-206</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Linaclotide, a potent guanylate cyclase C agonist, is a therapeutic peptide approved in the United States for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.  We present for the first time the metab., degrdn., and disposition of linaclotide in animals and humans.  We examd. the metabolic stability of linaclotide in conditions that mimic the gastrointestinal tract and characterized the metabolite MM-419447 (CCEYCCNPACTGC), which contributes to the pharmacol. effects of linaclotide.  Systemic exposure to these active peptides is low in rats and humans, and the low systemic and portal vein concns. of linaclotide and MM-419447 obsd. in the rat confirmed both peptides are minimally absorbed after oral administration.  Linaclotide is stable in the acidic environment of the stomach and is converted to MM-419447 in the small intestine.  The disulfide bonds of both peptides are reduced in the small intestine, where they are subsequently proteolyzed and degraded.  After oral administration of linaclotide, <1% of the dose was excreted as active peptide in rat feces and a mean of 3-5% in human feces; in both cases MM-419447 was the predominant peptide recovered.  MM-419447 exhibits high-affinity binding in vitro to T84 cells, resulting in a significant, concn.-dependent accumulation of intracellular cyclic guanosine-3',5'-monophosphate (cGMP).  In rat models of gastrointestinal function, orally dosed MM-419447 significantly increased fluid secretion into small intestinal loops, increased intraluminal cGMP, and caused a dose-dependent acceleration in gastrointestinal transit.  These results demonstrate the importance of the active metabolite in contributing to linaclotide's pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0uVoDATTN-7Vg90H21EOLACvtfcHk0lhD5RkBrhoNPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1CrtQ%253D%253D&md5=dbe9f193a4cfb601e93dc3b92f3fee9f</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.199430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.199430%26sid%3Dliteratum%253Aachs%26aulast%3DBusby%26aufirst%3DR.%2BW.%26aulast%3DKessler%26aufirst%3DM.%2BM.%26aulast%3DBartolini%26aufirst%3DW.%2BP.%26aulast%3DBryant%26aufirst%3DA.%2BP.%26aulast%3DHannig%26aufirst%3DG.%26aulast%3DHiggins%26aufirst%3DC.%2BS.%26aulast%3DSolinga%26aufirst%3DR.%2BM.%26aulast%3DTobin%26aufirst%3DJ.%2BV.%26aulast%3DWakefield%26aufirst%3DJ.%2BD.%26aulast%3DKurtz%26aufirst%3DC.%2BB.%26aulast%3DCurrie%26aufirst%3DM.%2BG.%26atitle%3DPharmacologic%2520properties%252C%2520metabolism%252C%2520and%2520disposition%2520of%2520linaclotide%252C%2520a%2520novel%2520therapeutic%2520peptide%2520approved%2520for%2520the%2520treatment%2520of%2520irritable%2520bowel%2520syndrome%2520with%2520constipation%2520and%2520chronic%2520idiopathic%2520constipation%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D344%26spage%3D196%26epage%3D206%26doi%3D10.1124%2Fjpet.112.199430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref221"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref221'); return false;" data-citation="" class="refNumLink">221</a></strong><div class="NLM_citation" id="cit221"><span><span class="NLM_contrib-group">Aguirre, T. A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teijeiro-Osorio, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coulter, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alonso, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brayden, D. J.</span><span> </span><span class="NLM_article-title">Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">â</span> <span class="NLM_lpage">241</span><span class="refDoi">Â DOI: 10.1016/j.addr.2016.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.addr.2016.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26921819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1yitLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2016&pages=223-241&author=T.+A.+S.+Aguirreauthor=D.+Teijeiro-Osorioauthor=M.+Rosaauthor=I.+S.+Coulterauthor=M.+J.+Alonsoauthor=D.+J.+Brayden&title=Current+status+of+selected+oral+peptide+technologies+in+advanced+preclinical+development+and+in+clinical+trials&doi=10.1016%2Fj.addr.2016.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials</span></div><div class="casAuthors">Aguirre, T. A. S.; Teijeiro-Osorio, D.; Rosa, M.; Coulter, I. S.; Alonso, M. J.; Brayden, D. J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">Part_B</span>),
    <span class="NLM_cas:pages">223-241</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The development of oral dosage forms that allows absorption of therapeutic peptides to the systemic circulation is one of the greatest challenges for the pharmaceutical industry.  Currently, a no. of technologies including either mixts. of penetration enhancers or protease inhibitors and/or nanotechnol.-based products are under clin. development.  Typically, these formulations are presented in the form of enteric-coated tablets or capsules.  Systems undergoing preclin. investigation include further advances in nanotechnol., including intestinal microneedle patches, as well as their combination with regional delivery to the colon.  This review critically examines four selected promising oral peptide technologies at preclin. stage and the twelve that have progressed to clin. trials, as indicated in www.clinicaltrials.gov.  We examd. these technologies under the criteria of peptide selection, formulation design, system components and excipients, intestinal mechanism of action, efficacy in man, and safety issues.  The conclusion is that most of the technologies in clin. trials are incremental rather than paradigm-shifting and that even the more clin. advanced oral peptide drugs examples of oral bioavailability appear to yield oral bioavailability values of only 1-2% and are, therefore, only currently suitable for a limited range of peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNMwyZq973LLVg90H21EOLACvtfcHk0lhSM_vd38dcEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1yitLo%253D&md5=6e1b2f3b75a6c75a1a4b34cf4ec2a370</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2016.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2016.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DAguirre%26aufirst%3DT.%2BA.%2BS.%26aulast%3DTeijeiro-Osorio%26aufirst%3DD.%26aulast%3DRosa%26aufirst%3DM.%26aulast%3DCoulter%26aufirst%3DI.%2BS.%26aulast%3DAlonso%26aufirst%3DM.%2BJ.%26aulast%3DBrayden%26aufirst%3DD.%2BJ.%26atitle%3DCurrent%2520status%2520of%2520selected%2520oral%2520peptide%2520technologies%2520in%2520advanced%2520preclinical%2520development%2520and%2520in%2520clinical%2520trials%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2016%26volume%3D106%26spage%3D223%26epage%3D241%26doi%3D10.1016%2Fj.addr.2016.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref222"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref222'); return false;" data-citation="" class="refNumLink">222</a></strong><div class="NLM_citation" id="cit222"><span><span class="NLM_contrib-group">Mullard, A.</span><span> </span><span class="NLM_article-title">Oral GLP1 analogue rounds Phase II corner</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">227</span><span class="refDoi">Â DOI: 10.1038/nrd4607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnrd4607" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=227&author=A.+Mullard&title=Oral+GLP1+analogue+rounds+Phase+II+corner&doi=10.1038%2Fnrd4607"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1038%2Fnrd4607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4607%26sid%3Dliteratum%253Aachs%26aulast%3DMullard%26aufirst%3DA.%26atitle%3DOral%2520GLP1%2520analogue%2520rounds%2520Phase%2520II%2520corner%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D227%26doi%3D10.1038%2Fnrd4607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref223"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref223'); return false;" data-citation="" class="refNumLink">223</a></strong><div class="NLM_citation" id="cit223"><span><span class="NLM_contrib-group">Maher, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mrsny, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brayden, D. J.</span><span> </span><span class="NLM_article-title">Intestinal permeation enhancers for oral peptide delivery</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">277</span><span class="NLM_x">â</span> <span class="NLM_lpage">319</span><span class="refDoi">Â DOI: 10.1016/j.addr.2016.06.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.addr.2016.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=27320643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVGisbbP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2016&pages=277-319&author=S.+Maherauthor=R.+J.+Mrsnyauthor=D.+J.+Brayden&title=Intestinal+permeation+enhancers+for+oral+peptide+delivery&doi=10.1016%2Fj.addr.2016.06.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal permeation enhancers for oral peptide delivery</span></div><div class="casAuthors">Maher, Sam; Mrsny, Randall J.; Brayden, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">Part_B</span>),
    <span class="NLM_cas:pages">277-319</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Intestinal permeation enhancers (PEs) are one of the most widely tested strategies to improve oral delivery of therapeutic peptides.  This article assesses the intestinal permeation enhancement action of over 250 PEs that have been tested in intestinal delivery models.  In depth anal. of pre-clin. data is presented for PEs as components of proprietary delivery systems that have progressed to clin. trials.  Given the importance of co-presentation of sufficiently high concns. of PE and peptide at the small intestinal epithelium, there is an emphasis on studies where PEs have been formulated with poorly permeable mols. in solid dosage forms and lipoidal dispersions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnl_3hMN_terVg90H21EOLACvtfcHk0lhSM_vd38dcEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVGisbbP&md5=19fb9e5a30c6cd10009047f65d5329ad</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2016.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2016.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DMaher%26aufirst%3DS.%26aulast%3DMrsny%26aufirst%3DR.%2BJ.%26aulast%3DBrayden%26aufirst%3DD.%2BJ.%26atitle%3DIntestinal%2520permeation%2520enhancers%2520for%2520oral%2520peptide%2520delivery%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2016%26volume%3D106%26spage%3D277%26epage%3D319%26doi%3D10.1016%2Fj.addr.2016.06.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref224"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref224'); return false;" data-citation="" class="refNumLink">224</a></strong><div class="NLM_citation" id="cit224a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">McCartney, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gleeson, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brayden, D. J.</span><span> </span><span class="NLM_article-title">Safety concerns over the use of intestinal permeation enhancers: A mini-review</span> <span class="citation_source-journal">Tissue Barriers</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1176822</span><span class="refDoi">Â DOI: 10.1080/21688370.2016.1176822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1080%2F21688370.2016.1176822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=27358756" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=e1176822&author=F.+McCartneyauthor=J.+P.+Gleesonauthor=D.+J.+Brayden&title=Safety+concerns+over+the+use+of+intestinal+permeation+enhancers%3A+A+mini-review&doi=10.1080%2F21688370.2016.1176822"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit224a&amp;dbid=16384&amp;doi=10.1080%2F21688370.2016.1176822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F21688370.2016.1176822%26sid%3Dliteratum%253Aachs%26aulast%3DMcCartney%26aufirst%3DF.%26aulast%3DGleeson%26aufirst%3DJ.%2BP.%26aulast%3DBrayden%26aufirst%3DD.%2BJ.%26atitle%3DSafety%2520concerns%2520over%2520the%2520use%2520of%2520intestinal%2520permeation%2520enhancers%253A%2520A%2520mini-review%26jtitle%3DTissue%2520Barriers%26date%3D2016%26volume%3D4%26spage%3De1176822%26doi%3D10.1080%2F21688370.2016.1176822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit224b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Castelli, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riley, M. G. I.</span><span> </span><span class="NLM_article-title">Pharmacokinetics of oral cyanocobalamin formulated with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC): An open-label, randomized, single-dose, parallel-group study in healthy male subjects</span> <span class="citation_source-journal">Clin. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">934</span><span class="NLM_x">â</span> <span class="NLM_lpage">945</span><span class="refDoi">Â DOI: 10.1016/j.clinthera.2011.05.088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.clinthera.2011.05.088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21722960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptVygsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2011&pages=934-945&author=M.+C.+Castelliauthor=D.+F.+Wongauthor=K.+Friedmanauthor=M.+G.+I.+Riley&title=Pharmacokinetics+of+oral+cyanocobalamin+formulated+with+sodium+N-%5B8-%282-hydroxybenzoyl%29amino%5Dcaprylate+%28SNAC%29%3A+An+open-label%2C+randomized%2C+single-dose%2C+parallel-group+study+in+healthy+male+subjects&doi=10.1016%2Fj.clinthera.2011.05.088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit224bR"><div class="casContent"><span class="casTitleNuber">224b</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of Oral Cyanocobalamin Formulated With Sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC): An Open-Label, Randomized, Single-Dose, Parallel-Group Study in Healthy Male Subjects</span></div><div class="casAuthors">Castelli, M. Cristina; Wong, Diane F.; Friedman, Kristen; Riley, M. Gary I.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">934-945</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Vitamin B12 (cobalamin) deficiency may be caused by inadequate dietary intake of B12 or by conditions that result in malabsorption of the vitamin.  Cryst. vitamin B12, usually in the form of cyanocobalamin, is administered parenterally (ie, i.m.) or orally for treating deficiency states.  I.m. administration is widely accepted as a treatment method.  Oral B12 supplementation is also used, but it is considered to be less reliable.  This study was conducted to compare the pharmacokinetics and tolerability of 2 oral formulations of cyanocobalamin-a marketed cyanocobalamin tablet (immediate-release B12 5 mg) and cyanocobalamin formulated with a proprietary carrier, sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC)-to establish the feasibility of using an absorption enhancer with B12 to improve uptake of the vitamin.  This was the first clin. study conducted with the cyanocobalamin/SNAC coformulation.  An open-label, randomized, single-dose, parallel-group study was conducted in healthy male subjects.  Subjects were randomly assigned to 1 of 4 treatment groups: treatment A subjects (n = 4) received 2 tablets of 5-mg cyanocobalamin formulated with 100-mg SNAC as part of a dose range-finding arm included to det. a dose to provide a measurable concn. of vitamin B12 at all time points when tested with the available vitamin B12 assay; treatment B subjects (n = 6) received 1 tablet of 5-mg cyanocobalamin formulated with 100-mg SNAC; treatment C subjects (n = 6) received 1 com. available 5-mg cyanocobalamin tablet; and treatment D subjects (n = 4) received com. available 1-mg cyanocobalamin IV.  Treatment A was completed 3 wk before treatments B, C, and D were studied.  Human serum B12 was analyzed by chemiluminescence assay method.  Validation procedures established that samples could be dild. up to 100 times without any effects on accuracy and precision.  The pharmacokinetic properties of vitamin B12 were characterized by noncompartmental anal.  Vitamin B12 abs. bioavailability ests. were calcd. between the oral (A, B, and C) and IV (D) treatments using non-baseline-adjusted vitamin B12 concns. as well as baseline-adjusted vitamin B12 concns., with or without body wt. adjustments.  Tolerability was evaluated through review or monitoring of medical history, phys. examn. findings, concomitant medications, vital signs, lab. tests (hematol., serum chem., and urinalysis values), electrocardiog., adverse events, and serious adverse events.  Twenty healthy male subjects, aged 20 to 45 years, participated in this study.  Based on data from treatment A, a 5-mg cyanocobalamin dose was selected for use with treatments B and C. The oral cyanocobalamin formulation contg. SNAC had greater mean abs. bioavailability than the com. oral formulation (5.09% vs 2.16%, resp.), calcd. on AUC0-last values uncorrected for baseline, wt., or body mass index.  It also had a reduced Tmax compared with the com. formulation (0.5 h vs 6.83 h, resp.).  The Ke was similar between treatments (0.028 1/h vs 0.025 1/h).  Comparable results were achieved using cor. values.  The cyanocobalamin/SNAC formulation was well tolerated, and there were no reported adverse events.  An oral formulation of 5-mg cyanocobalamin contg. 100-mg SNAC, an absorption enhancer, provided significantly improved bioavailability and a significant decrease in Tmax for B12 in a small study of normal healthy subjects compared with a com. available 5-mg cyanocobalamin oral formulation.  Both oral formulations and com. 1-mg cyanocobalamin IV were well tolerated.  ClinicalTrials.gov identifier: NCT01311739.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBbGPXAxLHQrVg90H21EOLACvtfcHk0lhSM_vd38dcEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptVygsLw%253D&md5=a3bfd8f032bd54e560440a3019a7d161</span></div><a href="/servlet/linkout?suffix=cit224b&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2011.05.088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2011.05.088%26sid%3Dliteratum%253Aachs%26aulast%3DCastelli%26aufirst%3DM.%2BC.%26aulast%3DWong%26aufirst%3DD.%2BF.%26aulast%3DFriedman%26aufirst%3DK.%26aulast%3DRiley%26aufirst%3DM.%2BG.%2BI.%26atitle%3DPharmacokinetics%2520of%2520oral%2520cyanocobalamin%2520formulated%2520with%2520sodium%2520N-%255B8-%25282-hydroxybenzoyl%2529amino%255Dcaprylate%2520%2528SNAC%2529%253A%2520An%2520open-label%252C%2520randomized%252C%2520single-dose%252C%2520parallel-group%2520study%2520in%2520healthy%2520male%2520subjects%26jtitle%3DClin.%2520Ther.%26date%3D2011%26volume%3D33%26spage%3D934%26epage%3D945%26doi%3D10.1016%2Fj.clinthera.2011.05.088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref225"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref225'); return false;" data-citation="" class="refNumLink">225</a></strong><div class="NLM_citation" id="cit225"><span><span class="NLM_contrib-group">Jabbour, S.; Pieber, R.; Rosenstock, J.</span><span> </span><span class="NLM_article-title">OR15â3: Robust dose-dependent glucose lowering and body weight reductions with the novel oral formulation of semaglutide in patients with early type 2 diabetes</span>. ENDO Endocrine Societyâs 98th Annual Meeting and Expo April 1â4, 2016, Boston, MA,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+Jabbour&author=R.+Pieber&author=J.+Rosenstock&title=OR15%E2%80%933%3A+Robust+dose-dependent+glucose+lowering+and+body+weight+reductions+with+the+novel+oral+formulation+of+semaglutide+in+patients+with+early+type+2+diabetes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DJabbour%26aufirst%3DS.%26atitle%3DOR15%25E2%2580%25933%253A%2520Robust%2520dose-dependent%2520glucose%2520lowering%2520and%2520body%2520weight%2520reductions%2520with%2520the%2520novel%2520oral%2520formulation%2520of%2520semaglutide%2520in%2520patients%2520with%2520early%2520type%25202%2520diabetes%26jtitle%3DENDO%2520Endocrine%2520Society%25E2%2580%2599s%252098th%2520Annual%2520Meeting%2520and%2520Expo%2520April%25201%25E2%2580%25934%252C%25202016%252C%2520Boston%252C%2520MA%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref226"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref226'); return false;" data-citation="" class="refNumLink">226</a></strong><div class="NLM_citation" id="cit226"><span>Pre-clinical Data on Insulin and Adalimumab (Humira); <span class="NLM_publisher-name">Rani Therapeutics</span>: <span class="NLM_publisher-loc">San Jose, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">; </span><a href="http://www.ranitherapeutics.com/assets/rani_pre-clinical_data.pdf" class="extLink">http://www.ranitherapeutics.com/assets/rani_pre-clinical_data.pdf</a> (accessed January 17 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pre-clinical+Data+on+Insulin+and+Adalimumab+%28Humira%29%3B+Rani+Therapeutics%3A+San+Jose%2C+CA%2C+2017%3B+http%3A%2F%2Fwww.ranitherapeutics.com%2Fassets%2Frani_pre-clinical_data.pdf+%28accessed+January+17+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DPre-clinical%2520Data%2520on%2520Insulin%2520and%2520Adalimumab%2520%2528Humira%2529%26pub%3DRani%2520Therapeutics%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref227"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref227'); return false;" data-citation="" class="refNumLink">227</a></strong><div class="NLM_citation" id="cit227"><span><span class="NLM_contrib-group">Traverso, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoellhammer, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauwers, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polat, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blankschtein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, R.</span><span> </span><span class="NLM_article-title">Microneedles for drug delivery via the gastrointestinal tract</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">362</span><span class="NLM_x">â</span> <span class="NLM_lpage">367</span><span class="refDoi">Â DOI: 10.1002/jps.24182</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fjps.24182" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25250829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVyntL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2015&pages=362-367&author=G.+Traversoauthor=C.+M.+Schoellhammerauthor=A.+Schroederauthor=R.+Maaauthor=G.+Y.+Lauwersauthor=B.+E.+Polatauthor=D.+G.+Andersonauthor=D.+Blankschteinauthor=R.+Langer&title=Microneedles+for+drug+delivery+via+the+gastrointestinal+tract&doi=10.1002%2Fjps.24182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Microneedles for Drug Delivery via the Gastrointestinal Tract</span></div><div class="casAuthors">Traverso, Giovanni; Schoellhammer, Carl M.; Schroeder, Avi; Maa, Ruby; Lauwers, Gregory Y.; Polat, Baris E.; Anderson, Daniel G.; Blankschtein, Daniel; Langer, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">362-367</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Both patients and physicians prefer the oral route of drug delivery.  The gastrointestinal (GI) tract, though, limits the bioavailability of certain therapeutics because of its protease and bacteria-rich environment as well as general pH variability from pH 1 to 7.  These extreme environments make oral delivery particularly challenging for the biol. class of therapeutics.  Here, we demonstrate proof-of-concept expts. in swine that microneedle-based delivery has the capacity for improved bioavailability of a biol. active macromol.  Moreover, we show that microneedle-contg. devices can be passed and excreted from the GI tract safely.  These findings strongly support the success of implementation of microneedle technol. for use in the GI tract. Â© 2014 Wiley Periodicals, Inc. and the American Pharmacists Assocn. J Pharm Sci 104:362-367, 2015.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMhdiZaPej2rVg90H21EOLACvtfcHk0lgTdCgE7ecjyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVyntL4%253D&md5=1381e40c98af31d4fb689c6c03a08cff</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1002%2Fjps.24182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.24182%26sid%3Dliteratum%253Aachs%26aulast%3DTraverso%26aufirst%3DG.%26aulast%3DSchoellhammer%26aufirst%3DC.%2BM.%26aulast%3DSchroeder%26aufirst%3DA.%26aulast%3DMaa%26aufirst%3DR.%26aulast%3DLauwers%26aufirst%3DG.%2BY.%26aulast%3DPolat%26aufirst%3DB.%2BE.%26aulast%3DAnderson%26aufirst%3DD.%2BG.%26aulast%3DBlankschtein%26aufirst%3DD.%26aulast%3DLanger%26aufirst%3DR.%26atitle%3DMicroneedles%2520for%2520drug%2520delivery%2520via%2520the%2520gastrointestinal%2520tract%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2015%26volume%3D104%26spage%3D362%26epage%3D367%26doi%3D10.1002%2Fjps.24182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref228"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref228'); return false;" data-citation="" class="refNumLink">228</a></strong><div class="NLM_citation" id="cit228"><span><span class="NLM_contrib-group">Turker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onur, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozer, Y.</span><span> </span><span class="NLM_article-title">Nasal route and drug delivery systems</span> <span class="citation_source-journal">Pharm. World Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">137</span><span class="NLM_x">â</span> <span class="NLM_lpage">142</span><span class="refDoi">Â DOI: 10.1023/B:PHAR.0000026823.82950.ff</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1023%2FB%3APHAR.0000026823.82950.ff" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=15230360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A280%3ADC%252BD2czivVKhuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2004&pages=137-142&author=S.+Turkerauthor=E.+Onurauthor=Y.+Ozer&title=Nasal+route+and+drug+delivery+systems&doi=10.1023%2FB%3APHAR.0000026823.82950.ff"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Nasal route and drug delivery systems</span></div><div class="casAuthors">Turker Selcan; Onur Erten; Ozer Yekta</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacy world & science : PWS</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">137-42</span>
        ISSN:<span class="NLM_cas:issn">0928-1231</span>.
    </div><div class="casAbstract">Nasal drug administration has been used as an alternative route for the systemic availability of drugs restricted to intravenous administration.  This is due to the large surface area, porous endothelial membrane, high total blood flow, the avoidance of first-pass metabolism, and ready accessibility.  The nasal administration of drugs, including numerous compound, peptide and protein drugs, for systemic medication has been widely investigated in recent years.  Drugs are cleared rapidly from the nasal cavity after intranasal administration, resulting in rapid systemic drug absorption.  Several approaches are here discussed for increasing the residence time of drug formulations in the nasal cavity, resulting in improved nasal drug absorption.  The article highlights the importance and advantages of the drug delivery systems applied via the nasal route, which have bioadhesive properties.  Bioadhesive, or more appropriately, mucoadhesive systems have been prepared for both oral and peroral administration in the past.  The nasal mucosa presents an ideal site for bioadhesive drug delivery systems.  In this review we discuss the effects of microspheres and other bioadhesive drug delivery systems on nasal drug absorption.  Drug delivery systems, such as microspheres, liposomes and gels have been demonstrated to have good bioadhesive characteristics and that swell easily when in contact with the nasal mucosa.  These drug delivery systems have the ability to control the rate of drug clearance from the nasal cavity as well as protect the drug from enzymatic degradation in nasal secretions.  The mechanisms and effectiveness of these drug delivery systems are described in order to guide the development of specific and effective therapies for the future development of peptide preparations and other drugs that otherwise should be administered parenterally.  As a consequence, bioavailability and residence time of the drugs that are administered via the nasal route can be increased by bioadhesive drug delivery systems.  Although the majority of this work involving the use of microspheres, liposomes and gels is limited to the delivery of macromolecules (e.g., insulin and growth hormone), the general principles involved could be applied to other drug candidates.  It must be emphasized that many drugs can be absorbed well if the contact time between formulation and the nasal mucosa is optimized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTFPMMW718vtMKL0FlyGHDofW6udTcc2eZvwqMSKjFWpbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2czivVKhuw%253D%253D&md5=8402f7717a50782df9331f6716fdb350</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1023%2FB%3APHAR.0000026823.82950.ff&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FB%253APHAR.0000026823.82950.ff%26sid%3Dliteratum%253Aachs%26aulast%3DTurker%26aufirst%3DS.%26aulast%3DOnur%26aufirst%3DE.%26aulast%3DOzer%26aufirst%3DY.%26atitle%3DNasal%2520route%2520and%2520drug%2520delivery%2520systems%26jtitle%3DPharm.%2520World%2520Sci.%26date%3D2004%26volume%3D26%26spage%3D137%26epage%3D142%26doi%3D10.1023%2FB%3APHAR.0000026823.82950.ff" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref229"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref229'); return false;" data-citation="" class="refNumLink">229</a></strong><div class="NLM_citation" id="cit229"><span><span class="NLM_contrib-group">Thwala, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preat, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Csaba, N. S.</span><span> </span><span class="NLM_article-title">Emerging delivery platforms for mucosal administration of biopharmaceuticals: a critical update on nasal, pulmonary and oral routes</span> <span class="citation_source-journal">Expert Opin. Drug Delivery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">â</span> <span class="NLM_lpage">36</span><span class="refDoi">Â DOI: 10.1080/17425247.2016.1206074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1080%2F17425247.2016.1206074" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=23-36&author=L.+N.+Thwalaauthor=V.+Preatauthor=N.+S.+Csaba&title=Emerging+delivery+platforms+for+mucosal+administration+of+biopharmaceuticals%3A+a+critical+update+on+nasal%2C+pulmonary+and+oral+routes&doi=10.1080%2F17425247.2016.1206074"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1080%2F17425247.2016.1206074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17425247.2016.1206074%26sid%3Dliteratum%253Aachs%26aulast%3DThwala%26aufirst%3DL.%2BN.%26aulast%3DPreat%26aufirst%3DV.%26aulast%3DCsaba%26aufirst%3DN.%2BS.%26atitle%3DEmerging%2520delivery%2520platforms%2520for%2520mucosal%2520administration%2520of%2520biopharmaceuticals%253A%2520a%2520critical%2520update%2520on%2520nasal%252C%2520pulmonary%2520and%2520oral%2520routes%26jtitle%3DExpert%2520Opin.%2520Drug%2520Delivery%26date%3D2017%26volume%3D14%26spage%3D23%26epage%3D36%26doi%3D10.1080%2F17425247.2016.1206074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref230"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref230'); return false;" data-citation="" class="refNumLink">230</a></strong><div class="NLM_citation" id="cit230"><span><span class="NLM_contrib-group">Ozsoy, Y. L. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gungor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cevher, E.</span><span> </span><span class="NLM_article-title">Nasal delivery of high molecular weight drugs</span> <span class="citation_source-journal">Molecules</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">3754</span><span class="NLM_x">â</span> <span class="NLM_lpage">3779</span><span class="refDoi">Â DOI: 10.3390/molecules14093754</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3390%2Fmolecules14093754" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=19783956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1egsbzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=3754-3779&author=Y.+L.+Z.+Ozsoyauthor=S.+Gungorauthor=E.+Cevher&title=Nasal+delivery+of+high+molecular+weight+drugs&doi=10.3390%2Fmolecules14093754"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">Nasal delivery of high molecular weight drugs</span></div><div class="casAuthors">Ozsoy, Yildiz; Gungor, Sevgi; Cevher, Erdal</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3754-3779</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">Molecular Diversity Preservation International</span>)
        </div><div class="casAbstract">A review.  Nasal drug delivery may be used for either local or systemic effects.  Low mol. wt. drugs with are rapidly absorbed through nasal mucosa.  The main reasons for this are the high permeability, fairly wide absorption area, porous and thin endothelial basement membrane of the nasal epithelium.  Despite the many advantages of the nasal route, limitations such as the high mol. wt. (HMW) of drugs may impede drug absorption through the nasal mucosa.  Recent studies have focused particularly on the nasal application of HMW therapeutic agents such as peptide-protein drugs and vaccines intended for systemic effects.  Due to their hydrophilic structure, the nasal bioavailability of peptide and protein drugs is normally less than 1%.  Besides their weak mucosal membrane permeability and enzymic degrdn. in nasal mucosa, these drugs are rapidly cleared from the nasal cavity after administration because of mucociliary clearance.  There are many approaches for increasing the residence time of drug formulations in the nasal cavity resulting in enhanced drug absorption.  In this review article, nasal route and transport mechanisms across the nasal mucosa will be briefly presented.  In the second part, current studies regarding the nasal application of macromol. drugs and vaccines with nano- and micro-particulate carrier systems will be summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWSOHRGWj0HrVg90H21EOLACvtfcHk0ljT5GtRGXmBQg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1egsbzL&md5=b13f278926081cf6506bae4df275f607</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.3390%2Fmolecules14093754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules14093754%26sid%3Dliteratum%253Aachs%26aulast%3DOzsoy%26aufirst%3DY.%2BL.%2BZ.%26aulast%3DGungor%26aufirst%3DS.%26aulast%3DCevher%26aufirst%3DE.%26atitle%3DNasal%2520delivery%2520of%2520high%2520molecular%2520weight%2520drugs%26jtitle%3DMolecules%26date%3D2009%26volume%3D14%26spage%3D3754%26epage%3D3779%26doi%3D10.3390%2Fmolecules14093754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref231"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref231'); return false;" data-citation="" class="refNumLink">231</a></strong><div class="NLM_citation" id="cit231"><span><span class="NLM_contrib-group">Black, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummins, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Royle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philip, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waugh, N.</span><span> </span><span class="NLM_article-title">The clinical and cost effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation</span> <span class="citation_source-journal">Health Technol. Assess.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">126</span><span class="refDoi">Â DOI: 10.3310/hta11330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3310%2Fhta11330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=17767897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A280%3ADC%252BD2srhslamtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=1-126&author=C.+Blackauthor=E.+Cumminsauthor=P.+Royleauthor=S.+Philipauthor=N.+Waugh&title=The+clinical+and+cost+effectiveness+of+inhaled+insulin+in+diabetes+mellitus%3A+a+systematic+review+and+economic+evaluation&doi=10.3310%2Fhta11330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation</span></div><div class="casAuthors">Black C; Cummins E; Royle P; Philip S; Waugh N</div><div class="citationInfo"><span class="NLM_cas:title">Health technology assessment (Winchester, England)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">1-126</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  To review the clinical effectiveness and cost-effectiveness of a new technology, the inhaled insulin, Exubera (Pfizer and Sanofi-Aventis, in collaboration with Nektar Therapeutics), a short-acting insulin.  DATA SOURCES:  Electronic databases were searched up to November 2005.  REVIEW METHODS:  A systematic literature review was conducted and economic modelling carried out.  An industry model was used for modelling.  RESULTS:  Nine trials of inhaled insulins were found, but only seven used the Exubera form of inhaled insulin.  The other two used inhaled insulins that have not yet been licensed.  There were five trials in type 1 and two in type 2 diabetes.  Inhaled insulin is clinically effective, and is as good as short-acting soluble insulin in controlling blood glucose, plus it works slightly more quickly.  None of the published trials compared it with short-acting analogues.  Most patients in the trials were on combinations of short-acting, and either long- or intermediate-acting insulin, and both were changed, making it more difficult to assess the effects of only the change from soluble to inhaled insulin.  Patient preference was the only significant difference between inhaled and soluble insulin in the trials.  Most patients preferred inhaled to injected short-acting insulin, and this has some effect on quality of life measures.  However, the control groups mostly used syringes and needles, rather than pens.  As pens are more convenient, their use might have narrowed the patient satisfaction difference.  There were no trials of inhaled insulin against continuous subcutaneous insulin infusion (CSII).  No serious adverse experiences of inhaled insulin in the lung have been seen to date, but it is too soon yet to judge long-term effects.  The manufacturer's model appears to be a high-quality one, although the results depend more on the assumptions fed into the model than on the model itself.  The key assumptions are the size of the gain in quality of life utility from inhaling rather than injecting insulin, the effect of having an inhaled option on the willingness to start insulin among people with poor diabetic control on oral drugs, and the effect on glycaemic control.  We consider that these assumptions make the cost-effectiveness appear better than it really would be.  The manufacturer's submission assumed utility gains of 0.036-0.075 in patients with type 1 diabetes, and 0.027-0.067 in those with type 2, based on an unpublished utility elicitation study sponsored by the manufacturer.  We thought that these gains were optimistic and that gains of 0.02 or less were more likely, on average.  However, patients with particular problems with injection sites might have more to gain, although they might also be a group with much to gain from CSII.  A key factor is the cost of inhaled insulin.  Much more insulin has to be given by inhaler than by injection, and so the cost of inhaled insulin is much higher than injected.  The extra cost depends on dosage but ranges from around 600 pounds to over 1000 pounds per patient per year.  CONCLUSIONS:  The inhaled insulin, Exubera, appears to be as effective, but no better than injected short-acting insulin.  The additional cost is so much more that it is unlikely to be cost-effective.  The long-term safety is uncertain.  Additional research is recommended into the safety, efficacy and cost-effectiveness of inhaled insulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQcZKcAPknDOPtos8R3JUhXfW6udTcc2eY6tB7IEehDO7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2srhslamtQ%253D%253D&md5=dbec6e42e0bb804f6fd8bdb7dac0594a</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.3310%2Fhta11330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3310%252Fhta11330%26sid%3Dliteratum%253Aachs%26aulast%3DBlack%26aufirst%3DC.%26aulast%3DCummins%26aufirst%3DE.%26aulast%3DRoyle%26aufirst%3DP.%26aulast%3DPhilip%26aufirst%3DS.%26aulast%3DWaugh%26aufirst%3DN.%26atitle%3DThe%2520clinical%2520and%2520cost%2520effectiveness%2520of%2520inhaled%2520insulin%2520in%2520diabetes%2520mellitus%253A%2520a%2520systematic%2520review%2520and%2520economic%2520evaluation%26jtitle%3DHealth%2520Technol.%2520Assess.%26date%3D2007%26volume%3D11%26spage%3D1%26epage%3D126%26doi%3D10.3310%2Fhta11330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref232"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref232'); return false;" data-citation="" class="refNumLink">232</a></strong><div class="NLM_citation" id="cit232"><span><span class="NLM_contrib-group">Hollander, P. A.</span><span> </span><span class="NLM_article-title">Evolution of a pulmonary insulin delivery system (Exubera) for patients with diabetes</span> <span class="citation_source-journal">MedGenMed</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">45</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2007&pages=45&author=P.+A.+Hollander&title=Evolution+of+a+pulmonary+insulin+delivery+system+%28Exubera%29+for+patients+with+diabetes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHollander%26aufirst%3DP.%2BA.%26atitle%3DEvolution%2520of%2520a%2520pulmonary%2520insulin%2520delivery%2520system%2520%2528Exubera%2529%2520for%2520patients%2520with%2520diabetes%26jtitle%3DMedGenMed%26date%3D2007%26volume%3D9%26spage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref233"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref233'); return false;" data-citation="" class="refNumLink">233</a></strong><div class="NLM_citation" id="cit233"><span><span class="NLM_contrib-group">Heinemann, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baughman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boss, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hompesch, M.</span><span> </span><span class="NLM_article-title">Pharmacokinetic and pharmacodynamic properties of a novel inhaled insulin</span> <span class="citation_source-journal">J. Diabetes Sci. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">148</span><span class="NLM_x">â</span> <span class="NLM_lpage">156</span><span class="refDoi">Â DOI: 10.1177/1932296816658055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1177%2F1932296816658055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=27378794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVOgt7fN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=148-156&author=L.+Heinemannauthor=R.+Baughmanauthor=A.+Bossauthor=M.+Hompesch&title=Pharmacokinetic+and+pharmacodynamic+properties+of+a+novel+inhaled+insulin&doi=10.1177%2F1932296816658055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic and pharmacodynamic properties of a novel inhaled insulin</span></div><div class="casAuthors">Heinemann, Lutz; Baughman, Robert; Boss, Anders; Hompesch, Marcus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Diabetes Science and Technology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">148-156</span>CODEN:
                <span class="NLM_cas:coden">JDSTAV</span>;
        ISSN:<span class="NLM_cas:issn">1932-2968</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Advances in insulin treatment options over recent decades have markedly improved the management of diabetes.  Despite this, glycemic control remains suboptimal in many people with diabetes.  Although postprandial glucose control has been improved with the development of s.c. injected rapid-acting insulin analogs, currently available insulins are not able to fully mimic the physiol. time-action profile of endogenously secreted insulin after a meal.  The delayed onset of metabolic action and prolonged period of effect induce the risk of postprandial hyperglycemia and late postprandial hypoglycemia.  A no. of alternative routes of insulin administration have been investigated over time in an attempt to overcome the limitations assocd. with s.c. administration and to provide an improved time-action insulin profile more closely simulating physiol. prandial insulin release.  Among these, pulmonary insulin delivery has shown the most promise.  Technosphere Inhaled Insulin (TI) is a rapid-acting inhaled human insulin recently approved by the FDA for prandial insulin therapy.  In this article we discuss the pharmacokinetic and pharmacodynamic properties of TI, and, based on key studies performed during its clin. development, the implications for improved postprandial glucose control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWzEom0UsOibVg90H21EOLACvtfcHk0ljT5GtRGXmBQg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVOgt7fN&md5=6e3482cecbad3052fe0a29d381c755f8</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1177%2F1932296816658055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1932296816658055%26sid%3Dliteratum%253Aachs%26aulast%3DHeinemann%26aufirst%3DL.%26aulast%3DBaughman%26aufirst%3DR.%26aulast%3DBoss%26aufirst%3DA.%26aulast%3DHompesch%26aufirst%3DM.%26atitle%3DPharmacokinetic%2520and%2520pharmacodynamic%2520properties%2520of%2520a%2520novel%2520inhaled%2520insulin%26jtitle%3DJ.%2520Diabetes%2520Sci.%2520Technol.%26date%3D2017%26volume%3D11%26spage%3D148%26epage%3D156%26doi%3D10.1177%2F1932296816658055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref234"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref234'); return false;" data-citation="" class="refNumLink">234</a></strong><div class="NLM_citation" id="cit234"><span>Inhalable Insulin: A Losing Battle?; <span class="NLM_publisher-name">Pharmaceutical-technology.com</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">; </span><a href="http://www.pharmaceutical-technology.com/features/featureinhalable-insulin-a-losing-battle-4872250/" class="extLink">http://www.pharmaceutical-technology.com/features/featureinhalable-insulin-a-losing-battle-4872250/</a> (accessed January 17 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Inhalable+Insulin%3A+A+Losing+Battle%3F%3B+Pharmaceutical-technology.com%3A+New+York%2C+2017%3B+http%3A%2F%2Fwww.pharmaceutical-technology.com%2Ffeatures%2Ffeatureinhalable-insulin-a-losing-battle-4872250%2F+%28accessed+January+17+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DInhalable%2520Insulin%253A%2520A%2520Losing%2520Battle%253F%26pub%3DPharmaceutical-technology.com%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref235"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref235'); return false;" data-citation="" class="refNumLink">235</a></strong><div class="NLM_citation" id="cit235"><span><span class="NLM_contrib-group">Smietana, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siatkowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">M?ller, M.</span><span> </span><span class="NLM_article-title">Trends in clinical success rates</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">379</span><span class="NLM_x">â</span> <span class="NLM_lpage">380</span><span class="refDoi">Â DOI: 10.1038/nrd.2016.85</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnrd.2016.85" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=27199245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28Xot1Smurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=379-380&author=K.+Smietanaauthor=M.+Siatkowskiauthor=M.+M%3Fller&title=Trends+in+clinical+success+rates&doi=10.1038%2Fnrd.2016.85"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">Trends in clinical success rates</span></div><div class="casAuthors">Smietana, Katarzyna; Siatkowski, Marcin; Moeller, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">379-380</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This anal. of the industry's clin.-stage portfolio in the past two decades reveals several trends, including a recent improvement in success rates in late-stage trials, an increase in overall portfolio size and higher success rates for biologics and partnered projects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQX2Lw9DBOLbVg90H21EOLACvtfcHk0lhSBsB4Oyj3pA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xot1Smurg%253D&md5=2654eccd09eda5f587d19af95b6b42b9</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.85&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.85%26sid%3Dliteratum%253Aachs%26aulast%3DSmietana%26aufirst%3DK.%26aulast%3DSiatkowski%26aufirst%3DM.%26aulast%3DM%253Fller%26aufirst%3DM.%26atitle%3DTrends%2520in%2520clinical%2520success%2520rates%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D379%26epage%3D380%26doi%3D10.1038%2Fnrd.2016.85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4a','cit4b'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9a','cit9b','cit9c'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18a','cit18b'],'ref19':['cit19a','cit19b'],'ref20':['cit20a','cit20b','cit20c'],'ref21':['cit21a','cit21b','cit21c'],'ref22':['cit22'],'ref23':['cit23a','cit23b'],'ref24':['cit24'],'ref25':['cit25a','cit25b','cit25c'],'ref26':['cit26a','cit26b','cit26c'],'ref27':['cit27a','cit27b'],'ref28':['cit28'],'ref29':['cit29a','cit29b'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33a','cit33b'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42a','cit42b'],'ref43':['cit43a','cit43b'],'ref44':['cit44'],'ref45':['cit45a','cit45b','cit45c'],'ref46':['cit46'],'ref47':['cit47a','cit47b'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62a','cit62b'],'ref63':['cit63'],'ref64':['cit64a','cit64b'],'ref65':['cit65'],'ref66':['cit66a','cit66b'],'ref67':['cit67a','cit67b'],'ref68':['cit68'],'ref69':['cit69a','cit69b'],'ref70':['cit70a','cit70b'],'ref71':['cit71a','cit71b','cit71c','cit71d'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79a','cit79b'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92a','cit92b'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97a','cit97b'],'ref98':['cit98a','cit98b'],'ref99':['cit99a','cit99b'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104a','cit104b'],'ref105':['cit105a','cit105b'],'ref106':['cit106'],'ref107':['cit107a','cit107b'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112a','cit112b','cit112c','cit112d','cit112e','cit112f','cit112g'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117a','cit117b'],'ref118':['cit118'],'ref119':['cit119a','cit119b'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124a','cit124b','cit124c'],'ref125':['cit125a','cit125b'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128a','cit128b'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135a','cit135b'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138a','cit138b'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146a','cit146b','cit146c'],'ref147':['cit147a','cit147b','cit147c'],'ref148':['cit148a','cit148b'],'ref149':['cit149a','cit149b'],'ref150':['cit150'],'ref151':['cit151a','cit151b'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170a','cit170b'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174a','cit174b'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178a','cit178b','cit178c'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183a','cit183b','cit183c'],'ref184':['cit184a','cit184b'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189a','cit189b'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194a','cit194b'],'ref195':['cit195a','cit195b'],'ref196':['cit196a','cit196b'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203a','cit203b'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208a','cit208b'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212a','cit212b','cit212c'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215a','cit215b','cit215c'],'ref216':['cit216'],'ref217':['cit217'],'ref218':['cit218a','cit218b'],'ref219':['cit219a','cit219b','cit219c','cit219d'],'ref220':['cit220'],'ref221':['cit221'],'ref222':['cit222'],'ref223':['cit223'],'ref224':['cit224a','cit224b'],'ref225':['cit225'],'ref226':['cit226'],'ref227':['cit227'],'ref228':['cit228'],'ref229':['cit229'],'ref230':['cit230'],'ref231':['cit231'],'ref232':['cit232'],'ref233':['cit233'],'ref234':['cit234'],'ref235':['cit235']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 349 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Michael O. Frederick, Raymond A. Boyse, Timothy M. Braden, Joel R. Calvin, Bradley M. Campbell, Shujauddin M. Changi, Stephanie R. Coffin, Carmel Condon, Olivia Gowran, Jennifer McClary Groh, Stephen R. Groskreutz, Zachary D. Harms, Ashley A. Humenik, Neil J. Kallman, Nicholas D. Klitzing, Michael E. Kopach, Juliana K. Kretsinger, Gordon R. Lambertus, Jeffrey T. Lampert, Laura M. Maguire, Humphrey A. Moynihan, Nessa S. Mullane, John D. Murphy, Marie E. OâMahony, Rachel N. Richey, Kevin D. Seibert, Richard D. Spencer, Mark A. Strege, Nil Tandogan, Frank L. Torres Torres, Sergey V. Tsukanov, <span class="NLM_string-name hlFld-ContribAuthor">Han Xia</span>. </span><span class="cited-content_cbyCitation_article-title">Kilogram-Scale GMP Manufacture of Tirzepatide Using a Hybrid SPPS/LPPS Approach with Continuous Manufacturing. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2021,</strong> <em>25 </em>
                                    (7)
                                     , 1628-1636. <a href="https://doi.org/10.1021/acs.oprd.1c00108" title="DOI URL">https://doi.org/10.1021/acs.oprd.1c00108</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.1c00108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.1c00108%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DKilogram-Scale%252BGMP%252BManufacture%252Bof%252BTirzepatide%252BUsing%252Ba%252BHybrid%252BSPPS%25252FLPPS%252BApproach%252Bwith%252BContinuous%252BManufacturing%26aulast%3DFrederick%26aufirst%3DMichael%2BO.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D26032021%26date%3D17062021%26volume%3D25%26issue%3D7%26spage%3D1628%26epage%3D1636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">JosÃ© A. C. Delgado, JosÃ© T. M. Correia, Emanuele F. Pissinati, <span class="NLM_string-name hlFld-ContribAuthor">MÃ¡rcio W. PaixÃ£o</span>. </span><span class="cited-content_cbyCitation_article-title">Biocompatible Photoinduced Alkylation of Dehydroalanine for the Synthesis of Unnatural Î±-Amino Acids. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2021,</strong> <em>23 </em>
                                    (13)
                                     , 5251-5255. <a href="https://doi.org/10.1021/acs.orglett.1c01781" title="DOI URL">https://doi.org/10.1021/acs.orglett.1c01781</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.1c01781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.1c01781%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DBiocompatible%252BPhotoinduced%252BAlkylation%252Bof%252BDehydroalanine%252Bfor%252Bthe%252BSynthesis%252Bof%252BUnnatural%252B%2525CE%2525B1-Amino%252BAcids%26aulast%3DDelgado%26aufirst%3DJos%25C3%25A9%2BA.%2BC.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D27052021%26date%3D21062021%26volume%3D23%26issue%3D13%26spage%3D5251%26epage%3D5255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Koichi Kamiya, Hiroaki Itoh, <span class="NLM_string-name hlFld-ContribAuthor">Masayuki Inoue</span>. </span><span class="cited-content_cbyCitation_article-title">Generation and Biological Evaluation of Degraded Derivatives of the Three E/Z-Isomers of Yakuâamide B. </span><span class="cited-content_cbyCitation_journal-name">Journal of Natural Products</span><span> <strong>2021,</strong> <em>84 </em>
                                    (6)
                                     , 1854-1859. <a href="https://doi.org/10.1021/acs.jnatprod.1c00339" title="DOI URL">https://doi.org/10.1021/acs.jnatprod.1c00339</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jnatprod.1c00339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jnatprod.1c00339%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Natural%2520Products%26atitle%3DGeneration%252Band%252BBiological%252BEvaluation%252Bof%252BDegraded%252BDerivatives%252Bof%252Bthe%252BThree%252BE%25252FZ-Isomers%252Bof%252BYaku%2525E2%252580%252599amide%252BB%26aulast%3DKamiya%26aufirst%3DKoichi%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D10042021%26date%3D03062021%26volume%3D84%26issue%3D6%26spage%3D1854%26epage%3D1859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhuo Chen, Meijie Zhu, Mengwei Cai, Lulu Xu, <span class="NLM_string-name hlFld-ContribAuthor">Yiyi Weng</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium-Catalyzed C(sp3)âH Arylation and Alkynylation of Peptides Directed by Aspartic Acid (Asp). </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2021,</strong> <em>11 </em>
                                    (12)
                                     , 7401-7410. <a href="https://doi.org/10.1021/acscatal.1c01417" title="DOI URL">https://doi.org/10.1021/acscatal.1c01417</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.1c01417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.1c01417%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DPalladium-Catalyzed%252BC%252528sp3%252529%2525E2%252580%252593H%252BArylation%252Band%252BAlkynylation%252Bof%252BPeptides%252BDirected%252Bby%252BAspartic%252BAcid%252B%252528Asp%252529%26aulast%3DChen%26aufirst%3DZhuo%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D29032021%26date%3D24052021%26date%3D07062021%26volume%3D11%26issue%3D12%26spage%3D7401%26epage%3D7410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Damir Bojadzic, Oscar Alcazar, Jinshui Chen, Sung-Ting Chuang, Jose M. Condor Capcha, Lina A. Shehadeh, <span class="NLM_string-name hlFld-ContribAuthor">Peter Buchwald</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 ProteinâProtein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2021,</strong> <em>7 </em>
                                    (6)
                                     , 1519-1534. <a href="https://doi.org/10.1021/acsinfecdis.1c00070" title="DOI URL">https://doi.org/10.1021/acsinfecdis.1c00070</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.1c00070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.1c00070%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DSmall-Molecule%252BInhibitors%252Bof%252Bthe%252BCoronavirus%252BSpike%25253A%252BACE2%252BProtein%2525E2%252580%252593Protein%252BInteraction%252Bas%252BBlockers%252Bof%252BViral%252BAttachment%252Band%252BEntry%252Bfor%252BSARS-CoV-2%26aulast%3DBojadzic%26aufirst%3DDamir%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D08022021%26date%3D12052021%26volume%3D7%26issue%3D6%26spage%3D1519%26epage%3D1534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Peng Zhou, Qian Liu, Ting Wu, Qingqing Miao, Shuyong Shang, Heyi Wang, Zheng Chen, Shaozhou Wang, <span class="NLM_string-name hlFld-ContribAuthor">Heyan Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Systematic Comparison and Comprehensive Evaluation of 80 Amino Acid Descriptors in Peptide QSAR Modeling. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2021,</strong> <em>61 </em>
                                    (4)
                                     , 1718-1731. <a href="https://doi.org/10.1021/acs.jcim.0c01370" title="DOI URL">https://doi.org/10.1021/acs.jcim.0c01370</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.0c01370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.0c01370%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DSystematic%252BComparison%252Band%252BComprehensive%252BEvaluation%252Bof%252B80%252BAmino%252BAcid%252BDescriptors%252Bin%252BPeptide%252BQSAR%252BModeling%26aulast%3DZhou%26aufirst%3DPeng%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D26112020%26date%3D12032021%26volume%3D61%26issue%3D4%26spage%3D1718%26epage%3D1731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sara Mohajeri, <span class="NLM_string-name hlFld-ContribAuthor">Brian G Amsden</span>. </span><span class="cited-content_cbyCitation_article-title">In Vivo Degradation Mechanism and Biocompatibility of a Biodegradable Aliphatic Polycarbonate: Poly(Trimethylene Carbonate-co-5-Hydroxy Trimethylene Carbonate). </span><span class="cited-content_cbyCitation_journal-name">ACS Applied Bio Materials</span><span> <strong>2021,</strong> <em>4 </em>
                                    (4)
                                     , 3686-3696. <a href="https://doi.org/10.1021/acsabm.1c00160" title="DOI URL">https://doi.org/10.1021/acsabm.1c00160</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsabm.1c00160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsabm.1c00160%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Applied%2520Bio%2520Materials%26atitle%3DIn%252BVivo%252BDegradation%252BMechanism%252Band%252BBiocompatibility%252Bof%252Ba%252BBiodegradable%252BAliphatic%252BPolycarbonate%25253A%252BPoly%252528Trimethylene%252BCarbonate-co-5-Hydroxy%252BTrimethylene%252BCarbonate%252529%26aulast%3DMohajeri%26aufirst%3DSara%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D08022021%26date%3D22032021%26date%3D30032021%26volume%3D4%26issue%3D4%26spage%3D3686%26epage%3D3696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Beatriz G. de la
Torre, Shaveer Ramkisson, Fernando Albericio, <span class="NLM_string-name hlFld-ContribAuthor">John Lopez</span>. </span><span class="cited-content_cbyCitation_article-title">Refractive Index: The Ultimate Tool for Real-Time Monitoring of Solid-Phase Peptide Synthesis. Greening the Process. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2021,</strong> <em>25 </em>
                                    (4)
                                     , 1047-1053. <a href="https://doi.org/10.1021/acs.oprd.1c00051" title="DOI URL">https://doi.org/10.1021/acs.oprd.1c00051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.1c00051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.1c00051%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DRefractive%252BIndex%25253A%252BThe%252BUltimate%252BTool%252Bfor%252BReal-Time%252BMonitoring%252Bof%252BSolid-Phase%252BPeptide%252BSynthesis.%252BGreening%252Bthe%252BProcess%26aulast%3Dde%2Bla%2BTorre%26aufirst%3DBeatriz%2BG.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D11022021%26date%3D18032021%26volume%3D25%26issue%3D4%26spage%3D1047%26epage%3D1053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Shu Liu, Chuangxu Cai, Zengbing Bai, Wangjian Sheng, Jiantao Tan, <span class="NLM_string-name hlFld-ContribAuthor">Huan Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Late-Stage Macrocyclization of Bioactive Peptides with Internal Oxazole Motifs via Palladium-Catalyzed CâH Olefination. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2021,</strong> <em>23 </em>
                                    (8)
                                     , 2933-2937. <a href="https://doi.org/10.1021/acs.orglett.1c00580" title="DOI URL">https://doi.org/10.1021/acs.orglett.1c00580</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.1c00580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.1c00580%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DLate-Stage%252BMacrocyclization%252Bof%252BBioactive%252BPeptides%252Bwith%252BInternal%252BOxazole%252BMotifs%252Bvia%252BPalladium-Catalyzed%252BC%2525E2%252580%252593H%252BOlefination%26aulast%3DLiu%26aufirst%3DShu%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D17022021%26date%3D05042021%26volume%3D23%26issue%3D8%26spage%3D2933%26epage%3D2937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jingjing Sun, Changying Song, Dongying Ma, Shigang Shen, <span class="NLM_string-name hlFld-ContribAuthor">Shuying Huo</span>. </span><span class="cited-content_cbyCitation_article-title">Expanding the Toolbox for Peptide Disulfide Bond Formation via l-Methionine Selenoxide Oxidation. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>86 </em>
                                    (5)
                                     , 4035-4044. <a href="https://doi.org/10.1021/acs.joc.0c02877" title="DOI URL">https://doi.org/10.1021/acs.joc.0c02877</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c02877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c02877%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DExpanding%252Bthe%252BToolbox%252Bfor%252BPeptide%252BDisulfide%252BBond%252BFormation%252Bvia%252Bl-Methionine%252BSelenoxide%252BOxidation%26aulast%3DSun%26aufirst%3DJingjing%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D03122020%26date%3D23022021%26volume%3D86%26issue%3D5%26spage%3D4035%26epage%3D4044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bradley B. Stocks, Gregory H. Bird, Loren D. Walensky, <span class="NLM_string-name hlFld-ContribAuthor">Jeremy E. Melanson</span>. </span><span class="cited-content_cbyCitation_article-title">Characterizing Native and Hydrocarbon-Stapled Enfuvirtide Conformations with Ion Mobility Mass Spectrometry and HydrogenâDeuterium Exchange. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Society for Mass Spectrometry</span><span> <strong>2021,</strong> <em>32 </em>
                                    (3)
                                     , 753-761. <a href="https://doi.org/10.1021/jasms.0c00453" title="DOI URL">https://doi.org/10.1021/jasms.0c00453</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jasms.0c00453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjasms.0c00453%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Society%2520for%2520Mass%2520Spectrometry%26atitle%3DCharacterizing%252BNative%252Band%252BHydrocarbon-Stapled%252BEnfuvirtide%252BConformations%252Bwith%252BIon%252BMobility%252BMass%252BSpectrometry%252Band%252BHydrogen%2525E2%252580%252593Deuterium%252BExchange%26aulast%3DStocks%26aufirst%3DBradley%2BB.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D2021%26date%3D09122020%26date%3D25012021%26date%3D25012021%26date%3D03022021%26volume%3D32%26issue%3D3%26spage%3D753%26epage%3D761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yves Yeboue, Marion Jean, Gilles Subra, Jean Martinez, FrÃ©dÃ©ric Lamaty, <span class="NLM_string-name hlFld-ContribAuthor">Thomas-Xavier MÃ©tro</span>. </span><span class="cited-content_cbyCitation_article-title">Epimerization-Free C-Term Activation of Peptide Fragments by Ball Milling. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2021,</strong> <em>23 </em>
                                    (3)
                                     , 631-635. <a href="https://doi.org/10.1021/acs.orglett.0c03209" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c03209</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c03209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c03209%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DEpimerization-Free%252BC-Term%252BActivation%252Bof%252BPeptide%252BFragments%252Bby%252BBall%252BMilling%26aulast%3DYeboue%26aufirst%3DYves%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D24092020%26date%3D04012021%26volume%3D23%26issue%3D3%26spage%3D631%26epage%3D635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ying Zhang, Daniel Carney, Antoine Henninot, <span class="NLM_string-name hlFld-ContribAuthor">Karthik Srinivasan</span>. </span><span class="cited-content_cbyCitation_article-title">Novel High-Throughput Strategy for the Aqueous Solubility Assessment of Peptides and Proteins Exhibiting a Propensity for Gelation: Application to the Discovery of Novel Antibacterial Teixobactin Analogues. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2021,</strong> <em>18 </em>
                                    (1)
                                     , 469-474. <a href="https://doi.org/10.1021/acs.molpharmaceut.0c00990" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.0c00990</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.0c00990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.0c00990%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DNovel%252BHigh-Throughput%252BStrategy%252Bfor%252Bthe%252BAqueous%252BSolubility%252BAssessment%252Bof%252BPeptides%252Band%252BProteins%252BExhibiting%252Ba%252BPropensity%252Bfor%252BGelation%25253A%252BApplication%252Bto%252Bthe%252BDiscovery%252Bof%252BNovel%252BAntibacterial%252BTeixobactin%252BAnalogues%26aulast%3DZhang%26aufirst%3DYing%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03102020%26date%3D03122020%26date%3D11112020%26date%3D08122020%26volume%3D18%26issue%3D1%26spage%3D469%26epage%3D474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Olivier B. C. Monty, Nicholas Simmons, Srinivas Chamakuri, Martin M. Matzuk, <span class="NLM_string-name hlFld-ContribAuthor">Damian W. Young</span>. </span><span class="cited-content_cbyCitation_article-title">Solution-Phase Fmoc-Based Peptide Synthesis for DNA-Encoded Chemical Libraries: Reaction Conditions, Protecting Group Strategies, and Pitfalls. </span><span class="cited-content_cbyCitation_journal-name">ACS Combinatorial Science</span><span> <strong>2020,</strong> <em>22 </em>
                                    (12)
                                     , 833-843. <a href="https://doi.org/10.1021/acscombsci.0c00144" title="DOI URL">https://doi.org/10.1021/acscombsci.0c00144</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscombsci.0c00144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscombsci.0c00144%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Combinatorial%2520Science%26atitle%3DSolution-Phase%252BFmoc-Based%252BPeptide%252BSynthesis%252Bfor%252BDNA-Encoded%252BChemical%252BLibraries%25253A%252BReaction%252BConditions%25252C%252BProtecting%252BGroup%252BStrategies%25252C%252Band%252BPitfalls%26aulast%3DMonty%26aufirst%3DOlivier%2BB.%2BC.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D16072020%26date%3D30092020%26date%3D19102020%26volume%3D22%26issue%3D12%26spage%3D833%26epage%3D843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Jianping Wu</span>. </span><span class="cited-content_cbyCitation_article-title">A Novel Angiotensin Converting Enzyme 2 (ACE2) Activating Peptide: A Reflection of 10 Years of Research on a Small Peptide Ile-Arg-Trp (IRW). </span><span class="cited-content_cbyCitation_journal-name">Journal of Agricultural and Food Chemistry</span><span> <strong>2020,</strong> <em>68 </em>
                                    (49)
                                     , 14402-14408. <a href="https://doi.org/10.1021/acs.jafc.0c05544" title="DOI URL">https://doi.org/10.1021/acs.jafc.0c05544</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jafc.0c05544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jafc.0c05544%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Agricultural%2520and%2520Food%2520Chemistry%26atitle%3DA%252BNovel%252BAngiotensin%252BConverting%252BEnzyme%252B2%252B%252528ACE2%252529%252BActivating%252BPeptide%25253A%252BA%252BReflection%252Bof%252B10%252BYears%252Bof%252BResearch%252Bon%252Ba%252BSmall%252BPeptide%252BIle-Arg-Trp%252B%252528IRW%252529%26aulast%3DWu%26aufirst%3DJianping%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D29082020%26date%3D17112020%26date%3D10112020%26date%3D29112020%26volume%3D68%26issue%3D49%26spage%3D14402%26epage%3D14408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Stephen E. Miller, Kohei Tsuji, Rachel P.M. Abrams, Terrence R. Burke, Jr., <span class="NLM_string-name hlFld-ContribAuthor">Joel P. Schneider</span>. </span><span class="cited-content_cbyCitation_article-title">Uncoupling the Folding-Function Paradigm of Lytic Peptides to Deliver Impermeable Inhibitors of Intracellular ProteinâProtein Interactions. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2020,</strong> <em>142 </em>
                                    (47)
                                     , 19950-19955. <a href="https://doi.org/10.1021/jacs.0c07921" title="DOI URL">https://doi.org/10.1021/jacs.0c07921</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.0c07921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.0c07921%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DUncoupling%252Bthe%252BFolding-Function%252BParadigm%252Bof%252BLytic%252BPeptides%252Bto%252BDeliver%252BImpermeable%252BInhibitors%252Bof%252BIntracellular%252BProtein%2525E2%252580%252593Protein%252BInteractions%26aulast%3DMiller%26aufirst%3DStephen%2BE.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D22072020%26date%3D11112020%26volume%3D142%26issue%3D47%26spage%3D19950%26epage%3D19955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Rajneet Kaur Saini, Deepti Goyal, <span class="NLM_string-name hlFld-ContribAuthor">Bhupesh Goyal</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Human Islet Amyloid Polypeptide Aggregation and Toxicity in Type 2 Diabetes: An Overview of Peptide-Based Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Toxicology</span><span> <strong>2020,</strong> <em>33 </em>
                                    (11)
                                     , 2719-2738. <a href="https://doi.org/10.1021/acs.chemrestox.0c00416" title="DOI URL">https://doi.org/10.1021/acs.chemrestox.0c00416</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrestox.0c00416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrestox.0c00416%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Toxicology%26atitle%3DTargeting%252BHuman%252BIslet%252BAmyloid%252BPolypeptide%252BAggregation%252Band%252BToxicity%252Bin%252BType%252B2%252BDiabetes%25253A%252BAn%252BOverview%252Bof%252BPeptide-Based%252BInhibitors%26aulast%3DSaini%26aufirst%3DRajneet%2BKaur%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D28092020%26date%3D30102020%26volume%3D33%26issue%3D11%26spage%3D2719%26epage%3D2738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Shikha Kumari, Angelica V. Carmona, Amit K. Tiwari, <span class="NLM_string-name hlFld-ContribAuthor">Paul C. Trippier</span>. </span><span class="cited-content_cbyCitation_article-title">Amide Bond Bioisosteres: Strategies, Synthesis, and Successes. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (21)
                                     , 12290-12358. <a href="https://doi.org/10.1021/acs.jmedchem.0c00530" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00530</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00530%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAmide%252BBond%252BBioisosteres%25253A%252BStrategies%25252C%252BSynthesis%25252C%252Band%252BSuccesses%26aulast%3DKumari%26aufirst%3DShikha%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D31032020%26date%3D04082020%26date%3D20072020%26volume%3D63%26issue%3D21%26spage%3D12290%26epage%3D12358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chuan Dai, Fang Wang, Dandan Zhang, Lei Xu, Xuefeng Xia, <span class="NLM_string-name hlFld-ContribAuthor">Jinqiang Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Biological Evaluation of N-Aminoimidazolidin-2-one-Containing Angiotensin-(1â7) Peptidomimetics. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (21)
                                     , 8475-8479. <a href="https://doi.org/10.1021/acs.orglett.0c03070" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c03070</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c03070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c03070%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BN-Aminoimidazolidin-2-one-Containing%252BAngiotensin-%2525281%2525E2%252580%2525937%252529%252BPeptidomimetics%26aulast%3DDai%26aufirst%3DChuan%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D14092020%26date%3D26102020%26volume%3D22%26issue%3D21%26spage%3D8475%26epage%3D8479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Masayoshi Koshizuka, Kazuishi Makino, <span class="NLM_string-name hlFld-ContribAuthor">Naoyuki Shimada</span>. </span><span class="cited-content_cbyCitation_article-title">Diboronic Acid Anhydride-Catalyzed Direct Peptide Bond Formation Enabled by Hydroxy-Directed Dehydrative Condensation. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (21)
                                     , 8658-8664. <a href="https://doi.org/10.1021/acs.orglett.0c03252" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c03252</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c03252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c03252%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DDiboronic%252BAcid%252BAnhydride-Catalyzed%252BDirect%252BPeptide%252BBond%252BFormation%252BEnabled%252Bby%252BHydroxy-Directed%252BDehydrative%252BCondensation%26aulast%3DKoshizuka%26aufirst%3DMasayoshi%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D28092020%26date%3D12102020%26volume%3D22%26issue%3D21%26spage%3D8658%26epage%3D8664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Haruaki Kurasaki, Akihiro Nagaya, Yutaka Kobayashi, Ayumu Matsuda, Masatoshi Matsumoto, Koki Morimoto, Tomonori Taguri, Hisayuki Takeuchi, Michiharu Handa, Douglas R. Cary, Naoki Nishizawa, <span class="NLM_string-name hlFld-ContribAuthor">Keiichi Masuya</span>. </span><span class="cited-content_cbyCitation_article-title">Isostearyl Mixed Anhydrides for the Preparation of N-Methylated Peptides Using C-Terminally Unprotected N-Methylamino Acids. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (20)
                                     , 8039-8043. <a href="https://doi.org/10.1021/acs.orglett.0c02984" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c02984</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c02984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c02984%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DIsostearyl%252BMixed%252BAnhydrides%252Bfor%252Bthe%252BPreparation%252Bof%252BN-Methylated%252BPeptides%252BUsing%252BC-Terminally%252BUnprotected%252BN-Methylamino%252BAcids%26aulast%3DKurasaki%26aufirst%3DHaruaki%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D07092020%26date%3D02102020%26volume%3D22%26issue%3D20%26spage%3D8039%26epage%3D8043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sam Giannakoulias, Sumant R. Shringari, Chunxiao Liu, Hoang Anh T. Phan, Taylor M. Barrett, John J. Ferrie, <span class="NLM_string-name hlFld-ContribAuthor">E. James Petersson</span>. </span><span class="cited-content_cbyCitation_article-title">Rosetta Machine Learning Models Accurately Classify Positional Effects of Thioamides on Proteolysis. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Physical Chemistry B</span><span> <strong>2020,</strong> <em>124 </em>
                                    (37)
                                     , 8032-8041. <a href="https://doi.org/10.1021/acs.jpcb.0c05981" title="DOI URL">https://doi.org/10.1021/acs.jpcb.0c05981</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jpcb.0c05981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jpcb.0c05981%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Physical%2520Chemistry%2520B%26atitle%3DRosetta%252BMachine%252BLearning%252BModels%252BAccurately%252BClassify%252BPositional%252BEffects%252Bof%252BThioamides%252Bon%252BProteolysis%26aulast%3DGiannakoulias%26aufirst%3DSam%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D30062020%26date%3D07082020%26date%3D01092020%26volume%3D124%26issue%3D37%26spage%3D8032%26epage%3D8041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Christin Pohl, Matja Zalar, Inas El Bialy, Sowmya Indrakumar, GÃ¼nther H. J. Peters, Wolfgang Friess, Alexander P. Golovanov, Werner W. Streicher, Allan Noergaard, <span class="NLM_string-name hlFld-ContribAuthor">Pernille Harris</span>. </span><span class="cited-content_cbyCitation_article-title">The Effect of Point Mutations on the Biophysical Properties of an Antimicrobial Peptide: Development of a Screening Protocol for Peptide Stability Screening. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2020,</strong> <em>17 </em>
                                    (9)
                                     , 3298-3313. <a href="https://doi.org/10.1021/acs.molpharmaceut.0c00406" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.0c00406</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.0c00406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.0c00406%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DThe%252BEffect%252Bof%252BPoint%252BMutations%252Bon%252Bthe%252BBiophysical%252BProperties%252Bof%252Ban%252BAntimicrobial%252BPeptide%25253A%252BDevelopment%252Bof%252Ba%252BScreening%252BProtocol%252Bfor%252BPeptide%252BStability%252BScreening%26aulast%3DPohl%26aufirst%3DChristin%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D15042020%26date%3D01072020%26date%3D01072020%26date%3D07082020%26date%3D01072020%26volume%3D17%26issue%3D9%26spage%3D3298%26epage%3D3313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Victor K. Outlaw, Dale F. Kreitler, Debora Stelitano, Matteo Porotto, Anne Moscona, <span class="NLM_string-name hlFld-ContribAuthor">Samuel H. Gellman</span>. </span><span class="cited-content_cbyCitation_article-title">Effects of Single Î±-to-Î² Residue Replacements on Recognition of an Extended Segment in a Viral Fusion Protein. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2020,</strong> <em>6 </em>
                                    (8)
                                     , 2017-2022. <a href="https://doi.org/10.1021/acsinfecdis.0c00385" title="DOI URL">https://doi.org/10.1021/acsinfecdis.0c00385</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.0c00385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.0c00385%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DEffects%252Bof%252BSingle%252B%2525CE%2525B1-to-%2525CE%2525B2%252BResidue%252BReplacements%252Bon%252BRecognition%252Bof%252Ban%252BExtended%252BSegment%252Bin%252Ba%252BViral%252BFusion%252BProtein%26aulast%3DOutlaw%26aufirst%3DVictor%2BK.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D04062020%26date%3D27072020%26date%3D21072020%26volume%3D6%26issue%3D8%26spage%3D2017%26epage%3D2022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marion Erny, Marika Lundqvist, Jon H. Rasmussen, Olivier Ludemann-Hombourger, FrÃ©dÃ©ric Bihel, <span class="NLM_string-name hlFld-ContribAuthor">Jan Pawlas</span>. </span><span class="cited-content_cbyCitation_article-title">Minimizing HCN in DIC/Oxyma-Mediated Amide Bond-Forming Reactions. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2020,</strong> <em>24 </em>
                                    (7)
                                     , 1341-1349. <a href="https://doi.org/10.1021/acs.oprd.0c00227" title="DOI URL">https://doi.org/10.1021/acs.oprd.0c00227</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.0c00227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.0c00227%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DMinimizing%252BHCN%252Bin%252BDIC%25252FOxyma-Mediated%252BAmide%252BBond-Forming%252BReactions%26aulast%3DErny%26aufirst%3DMarion%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D14052020%26date%3D22062020%26date%3D15062020%26volume%3D24%26issue%3D7%26spage%3D1341%26epage%3D1349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yi-de He, Ke-wei Zheng, Cui-jiao Wen, Xin-min Li, Jia-yuan Gong, Yu-hua Hao, Yong Zhao, <span class="NLM_string-name hlFld-ContribAuthor">Zheng Tan</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Targeting of Guanine-Vacancy-Bearing G-Quadruplexes by G-Quartet Complementation and Stabilization with a GuanineâPeptide Conjugate. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2020,</strong> <em>142 </em>
                                    (26)
                                     , 11394-11403. <a href="https://doi.org/10.1021/jacs.0c00774" title="DOI URL">https://doi.org/10.1021/jacs.0c00774</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.0c00774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.0c00774%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DSelective%252BTargeting%252Bof%252BGuanine-Vacancy-Bearing%252BG-Quadruplexes%252Bby%252BG-Quartet%252BComplementation%252Band%252BStabilization%252Bwith%252Ba%252BGuanine%2525E2%252580%252593Peptide%252BConjugate%26aulast%3DHe%26aufirst%3DYi-de%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D20012020%26date%3D18062020%26date%3D03062020%26volume%3D142%26issue%3D26%26spage%3D11394%26epage%3D11403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Henok Asfaw Sahile, Maria Santos MartÃ­nez-MartÃ­nez, Melissa Dillenberger, Katja Becker, <span class="NLM_string-name hlFld-ContribAuthor">Peter Imming</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Evaluation of Antimycobacterial and Antiplasmodial Activities of Hirsutellide A and Its Analogues. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2020,</strong> <em>5 </em>
                                    (24)
                                     , 14451-14460. <a href="https://doi.org/10.1021/acsomega.0c01065" title="DOI URL">https://doi.org/10.1021/acsomega.0c01065</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.0c01065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.0c01065%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DSynthesis%252Band%252BEvaluation%252Bof%252BAntimycobacterial%252Band%252BAntiplasmodial%252BActivities%252Bof%252BHirsutellide%252BA%252Band%252BIts%252BAnalogues%26aulast%3DSahile%26aufirst%3DHenok%2BAsfaw%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D09032020%26date%3D08052020%26date%3D09062020%26volume%3D5%26issue%3D24%26spage%3D14451%26epage%3D14460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bhupesh Goyal, <span class="NLM_string-name hlFld-ContribAuthor">Deepti Goyal</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy. </span><span class="cited-content_cbyCitation_journal-name">ACS Combinatorial Science</span><span> <strong>2020,</strong> <em>22 </em>
                                    (6)
                                     , 297-305. <a href="https://doi.org/10.1021/acscombsci.0c00058" title="DOI URL">https://doi.org/10.1021/acscombsci.0c00058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscombsci.0c00058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscombsci.0c00058%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Combinatorial%2520Science%26atitle%3DTargeting%252Bthe%252BDimerization%252Bof%252Bthe%252BMain%252BProtease%252Bof%252BCoronaviruses%25253A%252BA%252BPotential%252BBroad-Spectrum%252BTherapeutic%252BStrategy%26aulast%3DGoyal%26aufirst%3DBhupesh%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D18042020%26date%3D13052020%26date%3D27052020%26date%3D13052020%26volume%3D22%26issue%3D6%26spage%3D297%26epage%3D305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Huanyu Tao, Yanjun Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Sheng-You Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Improving ProteinâPeptide Docking Results via Pose-Clustering and Rescoring with a Combined Knowledge-Based and MMâGBSA Scoring Function. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (4)
                                     , 2377-2387. <a href="https://doi.org/10.1021/acs.jcim.0c00058" title="DOI URL">https://doi.org/10.1021/acs.jcim.0c00058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.0c00058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.0c00058%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DImproving%252BProtein%2525E2%252580%252593Peptide%252BDocking%252BResults%252Bvia%252BPose-Clustering%252Band%252BRescoring%252Bwith%252Ba%252BCombined%252BKnowledge-Based%252Band%252BMM%2525E2%252580%252593GBSA%252BScoring%252BFunction%26aulast%3DTao%26aufirst%3DHuanyu%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D19012020%26date%3D16042020%26date%3D08042020%26volume%3D60%26issue%3D4%26spage%3D2377%26epage%3D2387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yue Zhang, Jun-Kuan Li, Fa-Guang Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Jun-An Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Catalytic Asymmetric Access to Noncanonical Chiral Î±-Amino Acids from Cyclic Iminoglyoxylates and Enamides. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (8)
                                     , 5580-5589. <a href="https://doi.org/10.1021/acs.joc.0c00436" title="DOI URL">https://doi.org/10.1021/acs.joc.0c00436</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c00436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c00436%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DCatalytic%252BAsymmetric%252BAccess%252Bto%252BNoncanonical%252BChiral%252B%2525CE%2525B1-Amino%252BAcids%252Bfrom%252BCyclic%252BIminoglyoxylates%252Band%252BEnamides%26aulast%3DZhang%26aufirst%3DYue%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D19022020%26date%3D06042020%26date%3D30032020%26volume%3D85%26issue%3D8%26spage%3D5580%26epage%3D5589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lee E. Eiden, Ki Ann Goosens, Kenneth A. Jacobson, Lorenzo Leggio, <span class="NLM_string-name hlFld-ContribAuthor">Limei Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Peptide-Liganded G Protein-Coupled Receptors as Neurotherapeutics. </span><span class="cited-content_cbyCitation_journal-name">ACS Pharmacology & Translational Science</span><span> <strong>2020,</strong> <em>3 </em>
                                    (2)
                                     , 190-202. <a href="https://doi.org/10.1021/acsptsci.0c00017" title="DOI URL">https://doi.org/10.1021/acsptsci.0c00017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsptsci.0c00017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsptsci.0c00017%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Pharmacology%2520%2526%2520Translational%2520Science%26atitle%3DPeptide-Liganded%252BG%252BProtein-Coupled%252BReceptors%252Bas%252BNeurotherapeutics%26aulast%3DEiden%26aufirst%3DLee%2BE.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D10022020%26date%3D25032020%26date%3D18032020%26volume%3D3%26issue%3D2%26spage%3D190%26epage%3D202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Breanna L. Zerfas, Marianne E. Maresh, <span class="NLM_string-name hlFld-ContribAuthor">Darci J. Trader</span>. </span><span class="cited-content_cbyCitation_article-title">The Immunoproteasome: An Emerging Target in Cancer and Autoimmune and Neurological Disorders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (5)
                                     , 1841-1858. <a href="https://doi.org/10.1021/acs.jmedchem.9b01226" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01226</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01226%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BImmunoproteasome%25253A%252BAn%252BEmerging%252BTarget%252Bin%252BCancer%252Band%252BAutoimmune%252Band%252BNeurological%252BDisorders%26aulast%3DZerfas%26aufirst%3DBreanna%2BL.%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D29072019%26date%3D21112019%26date%3D31102019%26volume%3D63%26issue%3D5%26spage%3D1841%26epage%3D1858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Pilar VÃ¡squez, Felipe Vidal, Josefa Torres, VerÃ³nica A. JimÃ©nez, <span class="NLM_string-name hlFld-ContribAuthor">Leonardo GuzmÃ¡n</span>. </span><span class="cited-content_cbyCitation_article-title">Rational Design and In Vitro Evaluation of Novel Peptides Binding to Neuroligin-1 for Synaptic Targeting. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (2)
                                     , 995-1004. <a href="https://doi.org/10.1021/acs.jcim.9b01003" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b01003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b01003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b01003%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DRational%252BDesign%252Band%252BIn%252BVitro%252BEvaluation%252Bof%252BNovel%252BPeptides%252BBinding%252Bto%252BNeuroligin-1%252Bfor%252BSynaptic%252BTargeting%26aulast%3DV%25C3%25A1squez%26aufirst%3DPilar%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D30102019%26date%3D07012020%26date%3D26122019%26volume%3D60%26issue%3D2%26spage%3D995%26epage%3D1004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Todd T. Romoff, Bernardo G. Ignacio, Noel Mansour, Andrew B. Palmer, Christopher J. Creighton, Hidenori Abe, Hiroki Moriwaki, Jianlin Han, Hiroyuki Konno, <span class="NLM_string-name hlFld-ContribAuthor">Vadim A. Soloshonok</span>. </span><span class="cited-content_cbyCitation_article-title">Large-Scale Synthesis of the Glycine Schiff Base Ni(II) Complex Derived from (S)- and (R)-N-(2-Benzoyl-4-chlorophenyl)-1-[(3,4-dichlorophenyl)methyl]-2-pyrrolidinecarboxamide. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2020,</strong> <em>24 </em>
                                    (2)
                                     , 294-300. <a href="https://doi.org/10.1021/acs.oprd.9b00399" title="DOI URL">https://doi.org/10.1021/acs.oprd.9b00399</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.9b00399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.9b00399%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DLarge-Scale%252BSynthesis%252Bof%252Bthe%252BGlycine%252BSchiff%252BBase%252BNi%252528II%252529%252BComplex%252BDerived%252Bfrom%252B%252528S%252529-%252Band%252B%252528R%252529-N-%2525282-Benzoyl-4-chlorophenyl%252529-1-%25255B%2525283%25252C4-dichlorophenyl%252529methyl%25255D-2-pyrrolidinecarboxamide%26aulast%3DRomoff%26aufirst%3DTodd%2BT.%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D19092019%26date%3D16012020%26volume%3D24%26issue%3D2%26spage%3D294%26epage%3D300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Daniel Joaquin, Michael A. Lee, David W. Kastner, Jatinder Singh, Shardon T. Morrill, Gracie Damstedt, <span class="NLM_string-name hlFld-ContribAuthor">Steven L. Castle</span>. </span><span class="cited-content_cbyCitation_article-title">Impact of Dehydroamino Acids on the Structure and Stability of Incipient 310-Helical Peptides. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (3)
                                     , 1601-1613. <a href="https://doi.org/10.1021/acs.joc.9b02747" title="DOI URL">https://doi.org/10.1021/acs.joc.9b02747</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.9b02747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.9b02747%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DImpact%252Bof%252BDehydroamino%252BAcids%252Bon%252Bthe%252BStructure%252Band%252BStability%252Bof%252BIncipient%252B310-Helical%252BPeptides%26aulast%3DJoaquin%26aufirst%3DDaniel%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D10102019%26date%3D25112019%26date%3D15112019%26volume%3D85%26issue%3D3%26spage%3D1601%26epage%3D1613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Alice Capecchi, Alain Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Jean-Louis Reymond</span>. </span><span class="cited-content_cbyCitation_article-title">Populating Chemical Space with Peptides Using a Genetic Algorithm. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (1)
                                     , 121-132. <a href="https://doi.org/10.1021/acs.jcim.9b01014" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b01014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b01014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b01014%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DPopulating%252BChemical%252BSpace%252Bwith%252BPeptides%252BUsing%252Ba%252BGenetic%252BAlgorithm%26aulast%3DCapecchi%26aufirst%3DAlice%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D01112019%26date%3D07012020%26date%3D23122019%26volume%3D60%26issue%3D1%26spage%3D121%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Line A. Ryberg, Pernille SÃ¸nderby, Jens T. Bukrinski, Pernille Harris, <span class="NLM_string-name hlFld-ContribAuthor">GÃ¼nther H. J. Peters</span>. </span><span class="cited-content_cbyCitation_article-title">Investigations of AlbuminâInsulin Detemir Complexes Using Molecular Dynamics Simulations and Free Energy Calculations. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2020,</strong> <em>17 </em>
                                    (1)
                                     , 132-144. <a href="https://doi.org/10.1021/acs.molpharmaceut.9b00839" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.9b00839</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.9b00839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.9b00839%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DInvestigations%252Bof%252BAlbumin%2525E2%252580%252593Insulin%252BDetemir%252BComplexes%252BUsing%252BMolecular%252BDynamics%252BSimulations%252Band%252BFree%252BEnergy%252BCalculations%26aulast%3DRyberg%26aufirst%3DLine%2BA.%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D06082019%26date%3D02122019%26date%3D31102019%26date%3D16122019%26date%3D02122019%26volume%3D17%26issue%3D1%26spage%3D132%26epage%3D144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Fidel
E. Morales Vicente, Melaine GonzÃ¡lez-Garcia, Erbio Diaz Pico, Elena Moreno-Castillo, Hilda E. Garay, Pablo E. Rosi, Asiel Mena Jimenez, Jose A. Campos-Delgado, Daniel G. Rivera, Glay Chinea, Rosemeire C. L.
R. Pietro, Steffen Stenger, Barbara Spellerberg, Dennis Kubiczek, Nicholas Bodenberger, Steffen Dietz, Frank Rosenau, MÃ¡rcio Weber PaixÃ£o, Ludger StÃ¤ndker, <span class="NLM_string-name hlFld-ContribAuthor">Anselmo J. Otero-GonzÃ¡lez</span>. </span><span class="cited-content_cbyCitation_article-title">Design of a Helical-Stabilized, Cyclic, and Nontoxic Analogue of the Peptide Cm-p5 with Improved Antifungal Activity. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2019,</strong> <em>4 </em>
                                    (21)
                                     , 19081-19095. <a href="https://doi.org/10.1021/acsomega.9b02201" title="DOI URL">https://doi.org/10.1021/acsomega.9b02201</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.9b02201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.9b02201%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DDesign%252Bof%252Ba%252BHelical-Stabilized%25252C%252BCyclic%25252C%252Band%252BNontoxic%252BAnalogue%252Bof%252Bthe%252BPeptide%252BCm-p5%252Bwith%252BImproved%252BAntifungal%252BActivity%26aulast%3DVicente%26aufirst%3DFidel%2BE.%2BMorales%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D24072019%26date%3D04102019%26date%3D05112019%26volume%3D4%26issue%3D21%26spage%3D19081%26epage%3D19095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yohei Okada, Rico Takasawa, Daisuke Kubo, Natsumi Iwanaga, Shuji Fujita, Kosuke Suzuki, Hideaki Suzuki, Hidehiro Kamiya, <span class="NLM_string-name hlFld-ContribAuthor">Kazuhiro Chiba</span>. </span><span class="cited-content_cbyCitation_article-title">Improved Tag-Assisted Liquid-Phase Peptide Synthesis: Application to the Synthesis of the Bradykinin Receptor Antagonist Icatibant Acetate. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2019,</strong> <em>23 </em>
                                    (11)
                                     , 2576-2581. <a href="https://doi.org/10.1021/acs.oprd.9b00397" title="DOI URL">https://doi.org/10.1021/acs.oprd.9b00397</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.9b00397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.9b00397%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DImproved%252BTag-Assisted%252BLiquid-Phase%252BPeptide%252BSynthesis%25253A%252BApplication%252Bto%252Bthe%252BSynthesis%252Bof%252Bthe%252BBradykinin%252BReceptor%252BAntagonist%252BIcatibant%252BAcetate%26aulast%3DOkada%26aufirst%3DYohei%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D16092019%26date%3D25102019%26date%3D21102019%26volume%3D23%26issue%3D11%26spage%3D2576%26epage%3D2581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaoping Chen, Farong Ye, Xiaosheng Luo, Xueyi Liu, Jie Zhao, Siyao Wang, Qingqing Zhou, Gong Chen, <span class="NLM_string-name hlFld-ContribAuthor">Ping Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Histidine-Specific Peptide Modification via Visible-Light-Promoted CâH Alkylation. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2019,</strong> <em>141 </em>
                                    (45)
                                     , 18230-18237. <a href="https://doi.org/10.1021/jacs.9b09127" title="DOI URL">https://doi.org/10.1021/jacs.9b09127</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.9b09127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.9b09127%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DHistidine-Specific%252BPeptide%252BModification%252Bvia%252BVisible-Light-Promoted%252BC%2525E2%252580%252593H%252BAlkylation%26aulast%3DChen%26aufirst%3DXiaoping%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D23082019%26date%3D01112019%26date%3D21102019%26volume%3D141%26issue%3D45%26spage%3D18230%26epage%3D18237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yumi Hayashi, Tomoyasu Hirose, Masato Iwatsuki, Satoshi OÌmura, <span class="NLM_string-name hlFld-ContribAuthor">Toshiaki Sunazuka</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of the Antimalarial Peptide Aldehyde, a Precursor of Kozupeptin A, Utilizing a Designed Hydrophobic Anchor Molecule. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (20)
                                     , 8229-8233. <a href="https://doi.org/10.1021/acs.orglett.9b02966" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b02966</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b02966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b02966%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSynthesis%252Bof%252Bthe%252BAntimalarial%252BPeptide%252BAldehyde%25252C%252Ba%252BPrecursor%252Bof%252BKozupeptin%252BA%25252C%252BUtilizing%252Ba%252BDesigned%252BHydrophobic%252BAnchor%252BMolecule%26aulast%3DHayashi%26aufirst%3DYumi%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D20082019%26date%3D16092019%26volume%3D21%26issue%3D20%26spage%3D8229%26epage%3D8233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Rachael Dickman, Serena A. Mitchell, Angelo M. Figueiredo, D. Flemming Hansen, <span class="NLM_string-name hlFld-ContribAuthor">Alethea B. Tabor</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Recognition of Lipid II by Lantibiotics: Synthesis and Conformational Studies of Analogues of Nisin and Mutacin Rings A and B. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>
                                    (18)
                                     , 11493-11512. <a href="https://doi.org/10.1021/acs.joc.9b01253" title="DOI URL">https://doi.org/10.1021/acs.joc.9b01253</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.9b01253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.9b01253%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DMolecular%252BRecognition%252Bof%252BLipid%252BII%252Bby%252BLantibiotics%25253A%252BSynthesis%252Band%252BConformational%252BStudies%252Bof%252BAnalogues%252Bof%252BNisin%252Band%252BMutacin%252BRings%252BA%252Band%252BB%26aulast%3DDickman%26aufirst%3DRachael%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D21052019%26date%3D29082019%26volume%3D84%26issue%3D18%26spage%3D11493%26epage%3D11512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Salvatore Pacifico, Valentina Albanese, Davide Illuminati, Anna Fantinati, Erika Marzola, Federica Ferrari, Joaquim Azevedo Neto, Chiara Sturaro, Chiara Ruzza, Girolamo CalÃ², Delia Preti, <span class="NLM_string-name hlFld-ContribAuthor">Remo Guerrini</span>. </span><span class="cited-content_cbyCitation_article-title">Tetrabranched Hetero-Conjugated Peptides as Bifunctional Agonists of the NOP and Mu Opioid Receptors. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2019,</strong> <em>30 </em>
                                    (9)
                                     , 2444-2451. <a href="https://doi.org/10.1021/acs.bioconjchem.9b00519" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.9b00519</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.9b00519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.9b00519%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DTetrabranched%252BHetero-Conjugated%252BPeptides%252Bas%252BBifunctional%252BAgonists%252Bof%252Bthe%252BNOP%252Band%252BMu%252BOpioid%252BReceptors%26aulast%3DPacifico%26aufirst%3DSalvatore%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D30072019%26date%3D27082019%26date%3D04092019%26date%3D28082019%26volume%3D30%26issue%3D9%26spage%3D2444%26epage%3D2451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Thomas DenÃ¨fle, Elodie Pramil, Luis GÃ³mez-Morales, Mikail D. Levasseur, Eva LardÃ©, Clara Newton, Kenny Herry, Linda Herbi, Yann Lamotte, Estelle Odile, Nicolas Ancellin, Pascal Grondin, Ana-Carolina Martinez-Torres, Fabrice Viviani, HÃ©lÃ¨ne Merle-Beral, Olivier Lequin, Santos A. Susin, <span class="NLM_string-name hlFld-ContribAuthor">Philippe Karoyan</span>. </span><span class="cited-content_cbyCitation_article-title">Homotrimerization Approach in the Design of Thrombospondin-1 Mimetic Peptides with Improved Potency in Triggering Regulated Cell Death of Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (17)
                                     , 7656-7668. <a href="https://doi.org/10.1021/acs.jmedchem.9b00024" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00024%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHomotrimerization%252BApproach%252Bin%252Bthe%252BDesign%252Bof%252BThrombospondin-1%252BMimetic%252BPeptides%252Bwith%252BImproved%252BPotency%252Bin%252BTriggering%252BRegulated%252BCell%252BDeath%252Bof%252BCancer%252BCells%26aulast%3DDen%25C3%25A8fle%26aufirst%3DThomas%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D05012019%26date%3D26082019%26date%3D12082019%26volume%3D62%26issue%3D17%26spage%3D7656%26epage%3D7668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Paul M. Levine, Aaron T. Balana, Emmanuel Sturchler, Cassandra Koole, Hiroshi Noda, Barbara Zarzycka, Eileen J. Daley, Tin T. Truong, Vsevolod Katritch, Thomas J. Gardella, Denise Wootten, Patrick M. Sexton, Patricia McDonald, <span class="NLM_string-name hlFld-ContribAuthor">Matthew R. Pratt</span>. </span><span class="cited-content_cbyCitation_article-title">O-GlcNAc Engineering of GPCR Peptide-Agonists Improves Their Stability and in Vivo Activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2019,</strong> <em>141 </em>
                                    (36)
                                     , 14210-14219. <a href="https://doi.org/10.1021/jacs.9b05365" title="DOI URL">https://doi.org/10.1021/jacs.9b05365</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.9b05365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.9b05365%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DO-GlcNAc%252BEngineering%252Bof%252BGPCR%252BPeptide-Agonists%252BImproves%252BTheir%252BStability%252Band%252Bin%252BVivo%252BActivity%26aulast%3DLevine%26aufirst%3DPaul%2BM.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D19052019%26date%3D28082019%26date%3D16082019%26volume%3D141%26issue%3D36%26spage%3D14210%26epage%3D14219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Francesco Merlino, Stefano Tomassi, Ali M. Yousif, Anna Messere, Luciana Marinelli, Paolo Grieco, Ettore Novellino, Sandro Cosconati, <span class="NLM_string-name hlFld-ContribAuthor">Salvatore Di Maro</span>. </span><span class="cited-content_cbyCitation_article-title">Boosting Fmoc Solid-Phase Peptide Synthesis by Ultrasonication. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (16)
                                     , 6378-6382. <a href="https://doi.org/10.1021/acs.orglett.9b02283" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b02283</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b02283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b02283%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DBoosting%252BFmoc%252BSolid-Phase%252BPeptide%252BSynthesis%252Bby%252BUltrasonication%26aulast%3DMerlino%26aufirst%3DFrancesco%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D02072019%26date%3D30072019%26volume%3D21%26issue%3D16%26spage%3D6378%26epage%3D6382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Haibo Mei, Jianlin Han, Ryosuke Takeda, Tsubasa Sakamoto, Toshio Miwa, Yutaka Minamitsuji, Hiroki Moriwaki, Hidenori Abe, <span class="NLM_string-name hlFld-ContribAuthor">Vadim A. Soloshonok</span>. </span><span class="cited-content_cbyCitation_article-title">Practical Method for Preparation of (S)-2-Amino-5,5,5-trifluoropentanoic Acid via Dynamic Kinetic Resolution. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2019,</strong> <em>4 </em>
                                    (7)
                                     , 11844-11851. <a href="https://doi.org/10.1021/acsomega.9b01537" title="DOI URL">https://doi.org/10.1021/acsomega.9b01537</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.9b01537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.9b01537%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DPractical%252BMethod%252Bfor%252BPreparation%252Bof%252B%252528S%252529-2-Amino-5%25252C5%25252C5-trifluoropentanoic%252BAcid%252Bvia%252BDynamic%252BKinetic%252BResolution%26aulast%3DMei%26aufirst%3DHaibo%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D26052019%26date%3D25062019%26volume%3D4%26issue%3D7%26spage%3D11844%26epage%3D11851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Amira
H. Dardir, Nilay Hazari, Scott J. Miller, <span class="NLM_string-name hlFld-ContribAuthor">Christopher R. Shugrue</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium-Catalyzed SuzukiâMiyaura Reactions of Aspartic Acid Derived Phenyl Esters. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (14)
                                     , 5762-5766. <a href="https://doi.org/10.1021/acs.orglett.9b02214" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b02214</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b02214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b02214%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DPalladium-Catalyzed%252BSuzuki%2525E2%252580%252593Miyaura%252BReactions%252Bof%252BAspartic%252BAcid%252BDerived%252BPhenyl%252BEsters%26aulast%3DDardir%26aufirst%3DAmira%2BH.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D26062019%26date%3D10072019%26volume%3D21%26issue%3D14%26spage%3D5762%26epage%3D5766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Alexandr Nasedkin, Silvina Cerveny, <span class="NLM_string-name hlFld-ContribAuthor">Jan Swenson</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Insights into Dipole Relaxation Processes in WaterâLysine Mixtures. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Physical Chemistry B</span><span> <strong>2019,</strong> <em>123 </em>
                                    (28)
                                     , 6056-6064. <a href="https://doi.org/10.1021/acs.jpcb.9b01928" title="DOI URL">https://doi.org/10.1021/acs.jpcb.9b01928</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jpcb.9b01928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jpcb.9b01928%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Physical%2520Chemistry%2520B%26atitle%3DMolecular%252BInsights%252Binto%252BDipole%252BRelaxation%252BProcesses%252Bin%252BWater%2525E2%252580%252593Lysine%252BMixtures%26aulast%3DNasedkin%26aufirst%3DAlexandr%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D28022019%26date%3D18062019%26date%3D03072019%26date%3D21062019%26volume%3D123%26issue%3D28%26spage%3D6056%26epage%3D6064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Alan Hibbitts, Aoife M. OâConnor, Joanna McCarthy, Ãanna B. Forde, Gary Hessman, Caitriona M. OâDriscoll, Sally-Ann Cryan, <span class="NLM_string-name hlFld-ContribAuthor">Marc Devocelle</span>. </span><span class="cited-content_cbyCitation_article-title">Poly(ethylene glycol)-Based Peptidomimetic âPEGtideâ of Oligo-Arginine Allows for Efficient siRNA Transfection and Gene Inhibition. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2019,</strong> <em>4 </em>
                                    (6)
                                     , 10078-10088. <a href="https://doi.org/10.1021/acsomega.9b00265" title="DOI URL">https://doi.org/10.1021/acsomega.9b00265</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.9b00265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.9b00265%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DPoly%252528ethylene%252Bglycol%252529-Based%252BPeptidomimetic%252B%2525E2%252580%25259CPEGtide%2525E2%252580%25259D%252Bof%252BOligo-Arginine%252BAllows%252Bfor%252BEfficient%252BsiRNA%252BTransfection%252Band%252BGene%252BInhibition%26aulast%3DHibbitts%26aufirst%3DAlan%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D30012019%26date%3D29052019%26volume%3D4%26issue%3D6%26spage%3D10078%26epage%3D10088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Rui-Hua Liu, Yi-Heng He, Wei Yu, Bo Zhou, <span class="NLM_string-name hlFld-ContribAuthor">Bing Han</span>. </span><span class="cited-content_cbyCitation_article-title">Silver-Catalyzed Site-Selective Ring-Opening and CâC Bond Functionalization of Cyclic Amines: Access to Distal Aminoalkyl-Substituted Quinones. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (12)
                                     , 4590-4594. <a href="https://doi.org/10.1021/acs.orglett.9b01496" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b01496</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b01496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b01496%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSilver-Catalyzed%252BSite-Selective%252BRing-Opening%252Band%252BC%2525E2%252580%252593C%252BBond%252BFunctionalization%252Bof%252BCyclic%252BAmines%25253A%252BAccess%252Bto%252BDistal%252BAminoalkyl-Substituted%252BQuinones%26aulast%3DLiu%26aufirst%3DRui-Hua%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D29042019%26date%3D11062019%26volume%3D21%26issue%3D12%26spage%3D4590%26epage%3D4594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Albert Isidro-Llobet, Martin N. Kenworthy, Subha Mukherjee, Michael E. Kopach, Katarzyna Wegner, Fabrice Gallou, Austin G. Smith, <span class="NLM_string-name hlFld-ContribAuthor">Frank Roschangar</span>. </span><span class="cited-content_cbyCitation_article-title">Sustainability Challenges in Peptide Synthesis and Purification: From R&D to Production. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>
                                    (8)
                                     , 4615-4628. <a href="https://doi.org/10.1021/acs.joc.8b03001" title="DOI URL">https://doi.org/10.1021/acs.joc.8b03001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b03001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b03001%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSustainability%252BChallenges%252Bin%252BPeptide%252BSynthesis%252Band%252BPurification%25253A%252BFrom%252BR%252526D%252Bto%252BProduction%26aulast%3DIsidro-Llobet%26aufirst%3DAlbert%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D24112018%26date%3D22032019%26volume%3D84%26issue%3D8%26spage%3D4615%26epage%3D4628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Haibo Mei, Takahiro Hiramatsu, Ryosuke Takeda, Hiroki Moriwaki, Hidenori Abe, Jianlin Han, <span class="NLM_string-name hlFld-ContribAuthor">Vadim A. Soloshonok</span>. </span><span class="cited-content_cbyCitation_article-title">Expedient Asymmetric Synthesis of (S)-2-Amino-4,4,4-trifluorobutanoic Acid via Alkylation of Chiral Nucleophilic Glycine Equivalent. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2019,</strong> <em>23 </em>
                                    (4)
                                     , 629-634. <a href="https://doi.org/10.1021/acs.oprd.8b00404" title="DOI URL">https://doi.org/10.1021/acs.oprd.8b00404</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.8b00404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.8b00404%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DExpedient%252BAsymmetric%252BSynthesis%252Bof%252B%252528S%252529-2-Amino-4%25252C4%25252C4-trifluorobutanoic%252BAcid%252Bvia%252BAlkylation%252Bof%252BChiral%252BNucleophilic%252BGlycine%252BEquivalent%26aulast%3DMei%26aufirst%3DHaibo%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D29112018%26date%3D16012019%26volume%3D23%26issue%3D4%26spage%3D629%26epage%3D634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Motohiro Takahashi, Hiroki Moriwaki, Toshio Miwa, Brittanie Hoang, Peng Wang, <span class="NLM_string-name hlFld-ContribAuthor">Vadim A. Soloshonok</span>. </span><span class="cited-content_cbyCitation_article-title">Large Scale Synthesis of Chiral (3Z,5Z)-2,7-Dihydro-1H-azepine-Derived Hamari Ligand for General Asymmetric Synthesis of Tailor-Made Amino Acids. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2019,</strong> <em>23 </em>
                                    (4)
                                     , 619-628. <a href="https://doi.org/10.1021/acs.oprd.8b00406" title="DOI URL">https://doi.org/10.1021/acs.oprd.8b00406</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.8b00406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.8b00406%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DLarge%252BScale%252BSynthesis%252Bof%252BChiral%252B%2525283Z%25252C5Z%252529-2%25252C7-Dihydro-1H-azepine-Derived%252BHamari%252BLigand%252Bfor%252BGeneral%252BAsymmetric%252BSynthesis%252Bof%252BTailor-Made%252BAmino%252BAcids%26aulast%3DTakahashi%26aufirst%3DMotohiro%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D29112018%26date%3D18012019%26volume%3D23%26issue%3D4%26spage%3D619%26epage%3D628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Srinivasaraghavan Kannan, Pietro G. A. Aronica, Yaw Sing Tan, <span class="NLM_string-name hlFld-ContribAuthor">Chandra S. Verma</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibiting S100B(Î²Î²) for Activating Wild-Type p53: Design of Stapled Peptides. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2019,</strong> <em>4 </em>
                                    (3)
                                     , 5335-5344. <a href="https://doi.org/10.1021/acsomega.9b00097" title="DOI URL">https://doi.org/10.1021/acsomega.9b00097</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.9b00097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.9b00097%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DInhibiting%252BS100B%252528%2525CE%2525B2%2525CE%2525B2%252529%252Bfor%252BActivating%252BWild-Type%252Bp53%25253A%252BDesign%252Bof%252BStapled%252BPeptides%26aulast%3DKannan%26aufirst%3DSrinivasaraghavan%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D11012019%26date%3D04032019%26volume%3D4%26issue%3D3%26spage%3D5335%26epage%3D5344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Haruki Inada, Masatoshi Shibuya, <span class="NLM_string-name hlFld-ContribAuthor">Yoshihiko Yamamoto</span>. </span><span class="cited-content_cbyCitation_article-title">Direct Synthesis of Free Î±-Amino Acids by Telescoping Three-Step Process from 1,2-Diols. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (3)
                                     , 709-713. <a href="https://doi.org/10.1021/acs.orglett.8b03910" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b03910</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b03910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b03910%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DDirect%252BSynthesis%252Bof%252BFree%252B%2525CE%2525B1-Amino%252BAcids%252Bby%252BTelescoping%252BThree-Step%252BProcess%252Bfrom%252B1%25252C2-Diols%26aulast%3DInada%26aufirst%3DHaruki%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D07122018%26date%3D15012019%26volume%3D21%26issue%3D3%26spage%3D709%26epage%3D713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Oleg Babii, Sergii Afonin, Aleksandr Yu. Ishchenko, Tim Schober, Anatoliy O. Negelia, Ganna M. Tolstanova, Liudmyla V. Garmanchuk, Liudmyla I. Ostapchenko, Igor V. Komarov, <span class="NLM_string-name hlFld-ContribAuthor">Anne S. Ulrich</span>. </span><span class="cited-content_cbyCitation_article-title">StructureâActivity Relationships of Photoswitchable Diarylethene-Based Î²-Hairpin Peptides as Membranolytic Antimicrobial and Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (23)
                                     , 10793-10813. <a href="https://doi.org/10.1021/acs.jmedchem.8b01428" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01428</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01428%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure%2525E2%252580%252593Activity%252BRelationships%252Bof%252BPhotoswitchable%252BDiarylethene-Based%252B%2525CE%2525B2-Hairpin%252BPeptides%252Bas%252BMembranolytic%252BAntimicrobial%252Band%252BAnticancer%252BAgents%26aulast%3DBabii%26aufirst%3DOleg%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D13092018%26date%3D04122018%26date%3D19112018%26volume%3D61%26issue%3D23%26spage%3D10793%26epage%3D10813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Henry Cox, Hai Xu, Thomas A. Waigh, <span class="NLM_string-name hlFld-ContribAuthor">Jian R. Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Single-Molecule Study of Peptide Gel Dynamics Reveals States of Prestress. </span><span class="cited-content_cbyCitation_journal-name">Langmuir</span><span> <strong>2018,</strong> <em>34 </em>
                                    (48)
                                     , 14678-14689. <a href="https://doi.org/10.1021/acs.langmuir.8b03334" title="DOI URL">https://doi.org/10.1021/acs.langmuir.8b03334</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.langmuir.8b03334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.langmuir.8b03334%26sid%3Dliteratum%253Aachs%26jtitle%3DLangmuir%26atitle%3DSingle-Molecule%252BStudy%252Bof%252BPeptide%252BGel%252BDynamics%252BReveals%252BStates%252Bof%252BPrestress%26aulast%3DCox%26aufirst%3DHenry%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D02102018%26date%3D06112018%26date%3D21112018%26date%3D08112018%26volume%3D34%26issue%3D48%26spage%3D14678%26epage%3D14689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Qiang Wei, Yao Ma, Li Li, Qingfei Liu, Zijie Liu, <span class="NLM_string-name hlFld-ContribAuthor">Gang Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Quaternary Î±-Fluorinated Î±-Amino Acid Derivatives via Coordinating Cu(II) Catalytic Î±-C(sp3)âH Direct Fluorination. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (22)
                                     , 7100-7103. <a href="https://doi.org/10.1021/acs.orglett.8b03044" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b03044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b03044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b03044%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSynthesis%252Bof%252BQuaternary%252B%2525CE%2525B1-Fluorinated%252B%2525CE%2525B1-Amino%252BAcid%252BDerivatives%252Bvia%252BCoordinating%252BCu%252528II%252529%252BCatalytic%252B%2525CE%2525B1-C%252528sp3%252529%2525E2%252580%252593H%252BDirect%252BFluorination%26aulast%3DWei%26aufirst%3DQiang%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D24092018%26date%3D26102018%26volume%3D20%26issue%3D22%26spage%3D7100%26epage%3D7103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tao Wang, Jian Fan, Xiao-Xu Chen, Rui Zhao, Yang Xu, Donald Bierer, Lei Liu, Yi-Ming Li, Jing Shi, <span class="NLM_string-name hlFld-ContribAuthor">Ge-Min Fang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Peptide Disulfide-Bond Mimics by Using Fully Orthogonally Protected Diaminodiacids. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (19)
                                     , 6074-6078. <a href="https://doi.org/10.1021/acs.orglett.8b02459" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b02459</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b02459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b02459%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSynthesis%252Bof%252BPeptide%252BDisulfide-Bond%252BMimics%252Bby%252BUsing%252BFully%252BOrthogonally%252BProtected%252BDiaminodiacids%26aulast%3DWang%26aufirst%3DTao%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D02082018%26date%3D14092018%26volume%3D20%26issue%3D19%26spage%3D6074%26epage%3D6078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kai Kitamura, Hiroaki Itoh, Kaori Sakurai, Shingo Dan, <span class="NLM_string-name hlFld-ContribAuthor">Masayuki Inoue</span>. </span><span class="cited-content_cbyCitation_article-title">Target Identification of Yakuâamide B and Its Two Distinct Activities against Mitochondrial FoF1-ATP Synthase. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2018,</strong> <em>140 </em>
                                    (38)
                                     , 12189-12199. <a href="https://doi.org/10.1021/jacs.8b07339" title="DOI URL">https://doi.org/10.1021/jacs.8b07339</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.8b07339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.8b07339%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DTarget%252BIdentification%252Bof%252BYaku%2525E2%252580%252599amide%252BB%252Band%252BIts%252BTwo%252BDistinct%252BActivities%252Bagainst%252BMitochondrial%252BFoF1-ATP%252BSynthase%26aulast%3DKitamura%26aufirst%3DKai%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D12072018%26date%3D12092018%26date%3D29082018%26volume%3D140%26issue%3D38%26spage%3D12189%26epage%3D12199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ryosuke Takeda, Aki Kawashima, Junya Yamamoto, Tatsunori Sato, Hiroki Moriwaki, Kunisuke Izawa, Hidenori Abe, <span class="NLM_string-name hlFld-ContribAuthor">Vadim A. Soloshonok</span>. </span><span class="cited-content_cbyCitation_article-title">Tandem AlkylationâSecond-Order Asymmetric Transformation Protocol for the Preparation of Phenylalanine-Type Tailor-Made Î±-Amino Acids. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2018,</strong> <em>3 </em>
                                    (8)
                                     , 9729-9737. <a href="https://doi.org/10.1021/acsomega.8b01424" title="DOI URL">https://doi.org/10.1021/acsomega.8b01424</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.8b01424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.8b01424%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DTandem%252BAlkylation%2525E2%252580%252593Second-Order%252BAsymmetric%252BTransformation%252BProtocol%252Bfor%252Bthe%252BPreparation%252Bof%252BPhenylalanine-Type%252BTailor-Made%252B%2525CE%2525B1-Amino%252BAcids%26aulast%3DTakeda%26aufirst%3DRyosuke%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D22062018%26date%3D08082018%26volume%3D3%26issue%3D8%26spage%3D9729%26epage%3D9737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Adi Schumacher-Klinger, Joseph Fanous, Shira Merzbach, Michael WeinmÃ¼ller, Florian Reichart, Andreas F. B. RÃ¤der, Agata Gitlin-Domagalska, Chaim Gilon, Horst Kessler, <span class="NLM_string-name hlFld-ContribAuthor">Amnon Hoffman</span>. </span><span class="cited-content_cbyCitation_article-title">Enhancing Oral Bioavailability of Cyclic RGD Hexa-peptides by the Lipophilic Prodrug Charge Masking Approach: Redirection of Peptide Intestinal Permeability from a Paracellular to Transcellular Pathway. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2018,</strong> <em>15 </em>
                                    (8)
                                     , 3468-3477. <a href="https://doi.org/10.1021/acs.molpharmaceut.8b00466" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.8b00466</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.8b00466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.8b00466%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DEnhancing%252BOral%252BBioavailability%252Bof%252BCyclic%252BRGD%252BHexa-peptides%252Bby%252Bthe%252BLipophilic%252BProdrug%252BCharge%252BMasking%252BApproach%25253A%252BRedirection%252Bof%252BPeptide%252BIntestinal%252BPermeability%252Bfrom%252Ba%252BParacellular%252Bto%252BTranscellular%252BPathway%26aulast%3DSchumacher-Klinger%26aufirst%3DAdi%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D03052018%26date%3D05072018%26date%3D03062018%26date%3D25072018%26date%3D05072018%26volume%3D15%26issue%3D8%26spage%3D3468%26epage%3D3477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Justine N. deGruyter</span>. </span><span class="cited-content_cbyCitation_article-title">Functionalized Peptides: Ideal Targets for Collaborative Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry</span><span> <strong>2018,</strong> <em>57 </em>
                                    (19)
                                     , 2745-2746. <a href="https://doi.org/10.1021/acs.biochem.8b00298" title="DOI URL">https://doi.org/10.1021/acs.biochem.8b00298</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.biochem.8b00298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.biochem.8b00298%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemistry%26atitle%3DFunctionalized%252BPeptides%25253A%252BIdeal%252BTargets%252Bfor%252BCollaborative%252BChemistry%26aulast%3DdeGruyter%26aufirst%3DJustine%2BN.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D09032018%26date%3D27042018%26volume%3D57%26issue%3D19%26spage%3D2745%26epage%3D2746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Suvankar Das, Gurupada Bairy, <span class="NLM_string-name hlFld-ContribAuthor">Ranjan Jana</span>. </span><span class="cited-content_cbyCitation_article-title">Ligand-Promoted Î³-C(sp3)âH Arylation and Unsymmetrical Diarylation to Access Unnatural Amino Acid Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (9)
                                     , 2667-2671. <a href="https://doi.org/10.1021/acs.orglett.8b00874" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b00874</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b00874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b00874%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DLigand-Promoted%252B%2525CE%2525B3-C%252528sp3%252529%2525E2%252580%252593H%252BArylation%252Band%252BUnsymmetrical%252BDiarylation%252Bto%252BAccess%252BUnnatural%252BAmino%252BAcid%252BDerivatives%26aulast%3DDas%26aufirst%3DSuvankar%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D17032018%26date%3D23042018%26volume%3D20%26issue%3D9%26spage%3D2667%26epage%3D2671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sarah K.  Madden</span>, <span class="hlFld-ContribAuthor ">Aline Dantas  de Araujo</span>, <span class="hlFld-ContribAuthor ">Mara  Gerhardt</span>, <span class="hlFld-ContribAuthor ">David P.  Fairlie</span>, <span class="hlFld-ContribAuthor ">Jody M.  Mason</span>. </span><span class="cited-content_cbyCitation_article-title">Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer</span><span> <strong>2021,</strong> <em>20 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12943-020-01291-6" title="DOI URL">https://doi.org/10.1186/s12943-020-01291-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12943-020-01291-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12943-020-01291-6%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%26atitle%3DTaking%252Bthe%252BMyc%252Bout%252Bof%252Bcancer%25253A%252Btoward%252Btherapeutic%252Bstrategies%252Bto%252Bdirectly%252Binhibit%252Bc-Myc%26aulast%3DMadden%26aufirst%3DSarah%2BK.%26date%3D2021%26date%3D2021%26volume%3D20%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bach-Ngan  Nguyen</span>, <span class="hlFld-ContribAuthor ">Florian  Tieves</span>, <span class="hlFld-ContribAuthor ">Thomas  Rohr</span>, <span class="hlFld-ContribAuthor ">Hilke  Wobst</span>, <span class="hlFld-ContribAuthor ">Felix S.  SchÃ¶pf</span>, <span class="hlFld-ContribAuthor ">JÃ³se D. Montoya  Solano</span>, <span class="hlFld-ContribAuthor ">Julia  Schneider</span>, <span class="hlFld-ContribAuthor ">Janpeter  Stock</span>, <span class="hlFld-ContribAuthor ">Andreas  Uhde</span>, <span class="hlFld-ContribAuthor ">Thomas  Kalthoff</span>, <span class="hlFld-ContribAuthor ">Karl Erich  Jaeger</span>, <span class="hlFld-ContribAuthor ">Lutz  Schmitt</span>, <span class="hlFld-ContribAuthor ">Christian  Schwarz</span>. </span><span class="cited-content_cbyCitation_article-title">Numaswitch: an efficient high-titer expression platform to produce peptides and small proteins. </span><span class="cited-content_cbyCitation_journal-name">AMB Express</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13568-021-01204-w" title="DOI URL">https://doi.org/10.1186/s13568-021-01204-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13568-021-01204-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13568-021-01204-w%26sid%3Dliteratum%253Aachs%26jtitle%3DAMB%2520Express%26atitle%3DNumaswitch%25253A%252Ban%252Befficient%252Bhigh-titer%252Bexpression%252Bplatform%252Bto%252Bproduce%252Bpeptides%252Band%252Bsmall%252Bproteins%26aulast%3DNguyen%26aufirst%3DBach-Ngan%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ewerton Cristhian Lima  de Oliveira</span>, <span class="hlFld-ContribAuthor ">KauÃª  Santana</span>, <span class="hlFld-ContribAuthor ">Luiz  Josino</span>, <span class="hlFld-ContribAuthor ">Anderson Henrique  Lima e Lima</span>, <span class="hlFld-ContribAuthor ">Claudomiro  de Souza de Sales JÃºnior</span>. </span><span class="cited-content_cbyCitation_article-title">Predicting cell-penetrating peptides using machine learning algorithms and navigating in their chemical space. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-021-87134-w" title="DOI URL">https://doi.org/10.1038/s41598-021-87134-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-021-87134-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-021-87134-w%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DPredicting%252Bcell-penetrating%252Bpeptides%252Busing%252Bmachine%252Blearning%252Balgorithms%252Band%252Bnavigating%252Bin%252Btheir%252Bchemical%252Bspace%26aulast%3Dde%2BOliveira%26aufirst%3DEwerton%2BCristhian%2BLima%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Parisa  Hosseinzadeh</span>, <span class="hlFld-ContribAuthor ">Paris R.  Watson</span>, <span class="hlFld-ContribAuthor ">Timothy W.  Craven</span>, <span class="hlFld-ContribAuthor ">Xinting  Li</span>, <span class="hlFld-ContribAuthor ">Stephen  Rettie</span>, <span class="hlFld-ContribAuthor ">FÃ¡tima  Pardo-Avila</span>, <span class="hlFld-ContribAuthor ">Asim K.  Bera</span>, <span class="hlFld-ContribAuthor ">Vikram Khipple  Mulligan</span>, <span class="hlFld-ContribAuthor ">Peilong  Lu</span>, <span class="hlFld-ContribAuthor ">Alexander S.  Ford</span>, <span class="hlFld-ContribAuthor ">Brian D.  Weitzner</span>, <span class="hlFld-ContribAuthor ">Lance J.  Stewart</span>, <span class="hlFld-ContribAuthor ">Adam P.  Moyer</span>, <span class="hlFld-ContribAuthor ">Maddalena  Di Piazza</span>, <span class="hlFld-ContribAuthor ">Joshua G.  Whalen</span>, <span class="hlFld-ContribAuthor ">Per  Greisen</span>, <span class="hlFld-ContribAuthor ">David W.  Christianson</span>, <span class="hlFld-ContribAuthor ">David  Baker</span>. </span><span class="cited-content_cbyCitation_article-title">Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2021,</strong> <em>12 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41467-021-23609-8" title="DOI URL">https://doi.org/10.1038/s41467-021-23609-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41467-021-23609-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41467-021-23609-8%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DAnchor%252Bextension%25253A%252Ba%252Bstructure-guided%252Bapproach%252Bto%252Bdesign%252Bcyclic%252Bpeptides%252Btargeting%252Benzyme%252Bactive%252Bsites%26aulast%3DHosseinzadeh%26aufirst%3DParisa%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lucia  De Rosa</span>, <span class="hlFld-ContribAuthor ">Domenica  Capasso</span>, <span class="hlFld-ContribAuthor ">Donatella  Diana</span>, <span class="hlFld-ContribAuthor ">Rachele  Stefania</span>, <span class="hlFld-ContribAuthor ">Rossella  Di Stasi</span>, <span class="hlFld-ContribAuthor ">Roberto  Fattorusso</span>, <span class="hlFld-ContribAuthor ">Luca Domenico  D'Andrea</span>. </span><span class="cited-content_cbyCitation_article-title">Metabolic and conformational stabilization of a VEGF-mimetic beta-hairpin peptide by click-chemistry. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>222 </em>, 113575. <a href="https://doi.org/10.1016/j.ejmech.2021.113575" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113575</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113575%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMetabolic%252Band%252Bconformational%252Bstabilization%252Bof%252Ba%252BVEGF-mimetic%252Bbeta-hairpin%252Bpeptide%252Bby%252Bclick-chemistry%26aulast%3DDe%2BRosa%26aufirst%3DLucia%26date%3D2021%26volume%3D222%26spage%3D113575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Faisal  Zarif</span>, <span class="hlFld-ContribAuthor ">Mohd Ishtiaq  Anasir</span>, <span class="hlFld-ContribAuthor ">Jia Xuen  Koh</span>, <span class="hlFld-ContribAuthor ">Miaw-Fang  Chew</span>, <span class="hlFld-ContribAuthor ">Chit Laa  Poh</span>. </span><span class="cited-content_cbyCitation_article-title">Stability and antiviral activity of SP40 peptide in human serum. </span><span class="cited-content_cbyCitation_journal-name">Virus Research</span><span> <strong>2021,</strong> <em>303 </em>, 198456. <a href="https://doi.org/10.1016/j.virusres.2021.198456" title="DOI URL">https://doi.org/10.1016/j.virusres.2021.198456</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.virusres.2021.198456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.virusres.2021.198456%26sid%3Dliteratum%253Aachs%26jtitle%3DVirus%2520Research%26atitle%3DStability%252Band%252Bantiviral%252Bactivity%252Bof%252BSP40%252Bpeptide%252Bin%252Bhuman%252Bserum%26aulast%3DZarif%26aufirst%3DFaisal%26date%3D2021%26volume%3D303%26spage%3D198456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raheleh  Tooyserkani</span>, <span class="hlFld-ContribAuthor ">Mohammad Javad  Rasaee</span>, <span class="hlFld-ContribAuthor ">Mojgan  Bandehpour</span>, <span class="hlFld-ContribAuthor ">Dennis  W. P. M. LÃ¶wik</span>. </span><span class="cited-content_cbyCitation_article-title">Novel anti-PD-L1 peptide selected from combinatorial phage library inhibits tumor cell growth and restores T-cell activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Drug Targeting</span><span> <strong>2021,</strong> <em>29 </em>
                                    (7)
                                     , 771-782. <a href="https://doi.org/10.1080/1061186X.2021.1879087" title="DOI URL">https://doi.org/10.1080/1061186X.2021.1879087</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/1061186X.2021.1879087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F1061186X.2021.1879087%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Drug%2520Targeting%26atitle%3DNovel%252Banti-PD-L1%252Bpeptide%252Bselected%252Bfrom%252Bcombinatorial%252Bphage%252Blibrary%252Binhibits%252Btumor%252Bcell%252Bgrowth%252Band%252Brestores%252BT-cell%252Bactivity%26aulast%3DTooyserkani%26aufirst%3DRaheleh%26date%3D2021%26date%3D2021%26volume%3D29%26issue%3D7%26spage%3D771%26epage%3D782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fuzhuo  Li</span>, <span class="hlFld-ContribAuthor ">LiâCheng  Yang</span>, <span class="hlFld-ContribAuthor ">Jingyang  Zhang</span>, <span class="hlFld-ContribAuthor ">Jason S.  Chen</span>, <span class="hlFld-ContribAuthor ">Hans  Renata</span>. </span><span class="cited-content_cbyCitation_article-title">Stereoselective Synthesis of Î²âBranched Aromatic Î±âAmino Acids by Biocatalytic Dynamic Kinetic Resolution**. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2021,</strong> <em>133 </em>
                                    (32)
                                     , 17821-17826. <a href="https://doi.org/10.1002/ange.202105656" title="DOI URL">https://doi.org/10.1002/ange.202105656</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202105656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202105656%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DStereoselective%252BSynthesis%252Bof%252B%2525CE%2525B2%2525E2%252580%252590Branched%252BAromatic%252B%2525CE%2525B1%2525E2%252580%252590Amino%252BAcids%252Bby%252BBiocatalytic%252BDynamic%252BKinetic%252BResolution%252A%252A%26aulast%3DLi%26aufirst%3DFuzhuo%26date%3D2021%26date%3D2021%26volume%3D133%26issue%3D32%26spage%3D17821%26epage%3D17826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ping  Zeng</span>, <span class="hlFld-ContribAuthor ">Lanhua  Yi</span>, <span class="hlFld-ContribAuthor ">Qipeng  Cheng</span>, <span class="hlFld-ContribAuthor ">Jun  Liu</span>, <span class="hlFld-ContribAuthor ">Sheng  Chen</span>, <span class="hlFld-ContribAuthor ">Kin-Fai  Chan</span>, <span class="hlFld-ContribAuthor ">Kwok-Yin  Wong</span>. </span><span class="cited-content_cbyCitation_article-title">An ornithine-rich dodecapeptide with improved proteolytic stability selectively kills gram-negative food-borne pathogens and its action mode on Escherichia coli O157:H7. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Food Microbiology</span><span> <strong>2021,</strong> <em>352 </em>, 109281. <a href="https://doi.org/10.1016/j.ijfoodmicro.2021.109281" title="DOI URL">https://doi.org/10.1016/j.ijfoodmicro.2021.109281</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijfoodmicro.2021.109281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijfoodmicro.2021.109281%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Food%2520Microbiology%26atitle%3DAn%252Bornithine-rich%252Bdodecapeptide%252Bwith%252Bimproved%252Bproteolytic%252Bstability%252Bselectively%252Bkills%252Bgram-negative%252Bfood-borne%252Bpathogens%252Band%252Bits%252Baction%252Bmode%252Bon%252BEscherichia%252Bcoli%252BO157%25253AH7%26aulast%3DZeng%26aufirst%3DPing%26date%3D2021%26volume%3D352%26spage%3D109281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhi  Luo</span>, <span class="hlFld-ContribAuthor ">Nevena  PaunoviÄ</span>, <span class="hlFld-ContribAuthor ">Jean-Christophe  Leroux</span>. </span><span class="cited-content_cbyCitation_article-title">Physical methods for enhancing drug absorption from the gastrointestinal tract. </span><span class="cited-content_cbyCitation_journal-name">Advanced Drug Delivery Reviews</span><span> <strong>2021,</strong> <em>175 </em>, 113814. <a href="https://doi.org/10.1016/j.addr.2021.05.024" title="DOI URL">https://doi.org/10.1016/j.addr.2021.05.024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.addr.2021.05.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.addr.2021.05.024%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Drug%2520Delivery%2520Reviews%26atitle%3DPhysical%252Bmethods%252Bfor%252Benhancing%252Bdrug%252Babsorption%252Bfrom%252Bthe%252Bgastrointestinal%252Btract%26aulast%3DLuo%26aufirst%3DZhi%26date%3D2021%26volume%3D175%26spage%3D113814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jan  Pawlas</span>, <span class="hlFld-ContribAuthor ">Jon H.  Rasmussen</span>. </span><span class="cited-content_cbyCitation_article-title">Circular Aqueous Fmoc/tâBu SolidâPhase Peptide Synthesis. </span><span class="cited-content_cbyCitation_journal-name">ChemSusChem</span><span> <strong>2021,</strong> <em>120 </em><a href="https://doi.org/10.1002/cssc.202101028" title="DOI URL">https://doi.org/10.1002/cssc.202101028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cssc.202101028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcssc.202101028%26sid%3Dliteratum%253Aachs%26jtitle%3DChemSusChem%26atitle%3DCircular%252BAqueous%252BFmoc%25252Ft%2525E2%252580%252590Bu%252BSolid%2525E2%252580%252590Phase%252BPeptide%252BSynthesis%26aulast%3DPawlas%26aufirst%3DJan%26date%3D2021%26date%3D2021%26volume%3D120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Apurva  Panjla</span>, <span class="hlFld-ContribAuthor ">Irfan  Qayoom</span>, <span class="hlFld-ContribAuthor ">Ashok  Kumar</span>, <span class="hlFld-ContribAuthor ">Sandeep  Verma</span>. </span><span class="cited-content_cbyCitation_article-title">Anionic diketopiperazine induces osteogenic differentiation and supports osteogenesis in a 3D cryogel microenvironment. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2021,</strong> <em>57 </em>
                                    (60)
                                     , 7422-7425. <a href="https://doi.org/10.1039/D1CC01985F" title="DOI URL">https://doi.org/10.1039/D1CC01985F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1CC01985F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1CC01985F%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DAnionic%252Bdiketopiperazine%252Binduces%252Bosteogenic%252Bdifferentiation%252Band%252Bsupports%252Bosteogenesis%252Bin%252Ba%252B3D%252Bcryogel%252Bmicroenvironment%26aulast%3DPanjla%26aufirst%3DApurva%26date%3D2021%26date%3D2021%26volume%3D57%26issue%3D60%26spage%3D7422%26epage%3D7425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aoi  Takeuchi</span>, <span class="hlFld-ContribAuthor ">Hiroaki  Itoh</span>, <span class="hlFld-ContribAuthor ">Masayuki  Inoue</span>. </span><span class="cited-content_cbyCitation_article-title">18
              O/
              16
              OâEncoding Strategy for Microscale Stereochemical Determination of Peptidic Natural Products. </span><span class="cited-content_cbyCitation_journal-name">Chemistry â An Asian Journal</span><span> <strong>2021,</strong> <em>83 </em><a href="https://doi.org/10.1002/asia.202100674" title="DOI URL">https://doi.org/10.1002/asia.202100674</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/asia.202100674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fasia.202100674%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520An%2520Asian%2520Journal%26atitle%3D18%252BO%25252F%252B16%252BO%2525E2%252580%252590Encoding%252BStrategy%252Bfor%252BMicroscale%252BStereochemical%252BDetermination%252Bof%252BPeptidic%252BNatural%252BProducts%26aulast%3DTakeuchi%26aufirst%3DAoi%26date%3D2021%26date%3D2021%26volume%3D83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyun  Zhao</span>, <span class="hlFld-ContribAuthor ">Bai  Li</span>, <span class="hlFld-ContribAuthor ">Jingyao  Xu</span>, <span class="hlFld-ContribAuthor ">Qinglin  Tang</span>, <span class="hlFld-ContribAuthor ">Zhengjun  Cai</span>, <span class="hlFld-ContribAuthor ">Xianxing  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">VisibleâLightâDriven Redox Neutral Direct CâH Amination of Glycine Derivatives and Peptides with
              N
              âAcyloxyphthalimides. </span><span class="cited-content_cbyCitation_journal-name">Chemistry â A European Journal</span><span> <strong>2021,</strong> <em>4 </em><a href="https://doi.org/10.1002/chem.202101982" title="DOI URL">https://doi.org/10.1002/chem.202101982</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.202101982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.202101982%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DVisible%2525E2%252580%252590Light%2525E2%252580%252590Driven%252BRedox%252BNeutral%252BDirect%252BC%2525E2%252588%252592H%252BAmination%252Bof%252BGlycine%252BDerivatives%252Band%252BPeptides%252Bwith%252BN%252B%2525E2%252580%252590Acyloxyphthalimides%26aulast%3DZhao%26aufirst%3DXiaoyun%26date%3D2021%26date%3D2021%26volume%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Roshanak  Hariri</span>, <span class="hlFld-ContribAuthor ">Mina  Saeedi</span>, <span class="hlFld-ContribAuthor ">Tahmineh  Akbarzadeh</span>. </span><span class="cited-content_cbyCitation_article-title">Naturally occurring and synthetic peptides: Efficient tyrosinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Peptide Science</span><span> <strong>2021,</strong> <em>27 </em>
                                    (7)
                                     <a href="https://doi.org/10.1002/psc.3329" title="DOI URL">https://doi.org/10.1002/psc.3329</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/psc.3329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fpsc.3329%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Peptide%2520Science%26atitle%3DNaturally%252Boccurring%252Band%252Bsynthetic%252Bpeptides%25253A%252BEfficient%252Btyrosinase%252Binhibitors%26aulast%3DHariri%26aufirst%3DRoshanak%26date%3D2021%26date%3D2021%26volume%3D27%26issue%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xue  Zhou</span>, <span class="hlFld-ContribAuthor ">Quentin R.  Smith</span>, <span class="hlFld-ContribAuthor ">Xinli  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Brain penetrating peptides and peptideâdrug conjugates to overcome the bloodâbrain barrier and target
              CNS
              diseases. </span><span class="cited-content_cbyCitation_journal-name">WIREs Nanomedicine and Nanobiotechnology</span><span> <strong>2021,</strong> <em>13 </em>
                                    (4)
                                     <a href="https://doi.org/10.1002/wnan.1695" title="DOI URL">https://doi.org/10.1002/wnan.1695</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/wnan.1695&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fwnan.1695%26sid%3Dliteratum%253Aachs%26jtitle%3DWIREs%2520Nanomedicine%2520and%2520Nanobiotechnology%26atitle%3DBrain%252Bpenetrating%252Bpeptides%252Band%252Bpeptide%2525E2%252580%252593drug%252Bconjugates%252Bto%252Bovercome%252Bthe%252Bblood%2525E2%252580%252593brain%252Bbarrier%252Band%252Btarget%252BCNS%252Bdiseases%26aulast%3DZhou%26aufirst%3DXue%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ange  Ilangala Booka</span>, <span class="hlFld-ContribAuthor ">Anna  Lechanteur</span>, <span class="hlFld-ContribAuthor ">Marianne  Fillet</span>, <span class="hlFld-ContribAuthor ">GÃ©raldine  Piel</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic peptides for chemotherapy: trends and challenges for advanced delivery systems. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmaceutics and Biopharmaceutics</span><span> <strong>2021,</strong> <em>45 </em><a href="https://doi.org/10.1016/j.ejpb.2021.07.010" title="DOI URL">https://doi.org/10.1016/j.ejpb.2021.07.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejpb.2021.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejpb.2021.07.010%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmaceutics%2520and%2520Biopharmaceutics%26atitle%3DTherapeutic%252Bpeptides%252Bfor%252Bchemotherapy%25253A%252Btrends%252Band%252Bchallenges%252Bfor%252Badvanced%252Bdelivery%252Bsystems%26aulast%3DIlangala%2BBooka%26aufirst%3DAnge%26date%3D2021%26volume%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fuzhuo  Li</span>, <span class="hlFld-ContribAuthor ">LiâCheng  Yang</span>, <span class="hlFld-ContribAuthor ">Jingyang  Zhang</span>, <span class="hlFld-ContribAuthor ">Jason S.  Chen</span>, <span class="hlFld-ContribAuthor ">Hans  Renata</span>. </span><span class="cited-content_cbyCitation_article-title">Stereoselective Synthesis of Î²âBranched Aromatic Î±âAmino Acids by Biocatalytic Dynamic Kinetic Resolution**. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2021,</strong> <em>1 </em><a href="https://doi.org/10.1002/anie.202105656" title="DOI URL">https://doi.org/10.1002/anie.202105656</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202105656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202105656%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DStereoselective%252BSynthesis%252Bof%252B%2525CE%2525B2%2525E2%252580%252590Branched%252BAromatic%252B%2525CE%2525B1%2525E2%252580%252590Amino%252BAcids%252Bby%252BBiocatalytic%252BDynamic%252BKinetic%252BResolution%252A%252A%26aulast%3DLi%26aufirst%3DFuzhuo%26date%3D2021%26date%3D2021%26volume%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vaezeh  Fathi Vavsari</span>, <span class="hlFld-ContribAuthor ">Saeed  Balalaie</span>. </span><span class="cited-content_cbyCitation_article-title">An overview on the two recent decadesâ study of peptides synthesis and biological activities in Iran. </span><span class="cited-content_cbyCitation_journal-name">Journal of the Iranian Chemical Society</span><span> <strong>2021,</strong> <em>1 </em><a href="https://doi.org/10.1007/s13738-021-02312-x" title="DOI URL">https://doi.org/10.1007/s13738-021-02312-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s13738-021-02312-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs13738-021-02312-x%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520Iranian%2520Chemical%2520Society%26atitle%3DAn%252Boverview%252Bon%252Bthe%252Btwo%252Brecent%252Bdecades%2525E2%252580%252599%252Bstudy%252Bof%252Bpeptides%252Bsynthesis%252Band%252Bbiological%252Bactivities%252Bin%252BIran%26aulast%3DFathi%2BVavsari%26aufirst%3DVaezeh%26date%3D2021%26date%3D2021%26volume%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arkaitz  Correa</span>. </span><span class="cited-content_cbyCitation_article-title">MetalâCatalyzed C(sp
              2
              )âH Functionalization Processes of Phenylalanineâ and TyrosineâContaining Peptides. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Inorganic Chemistry</span><span> <strong>2021,</strong> <em>54 </em><a href="https://doi.org/10.1002/ejic.202100374" title="DOI URL">https://doi.org/10.1002/ejic.202100374</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejic.202100374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejic.202100374%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Inorganic%2520Chemistry%26atitle%3DMetal%2525E2%252580%252590Catalyzed%252BC%252528sp%252B2%252B%252529%2525E2%252588%252592H%252BFunctionalization%252BProcesses%252Bof%252BPhenylalanine%2525E2%252580%252590%252Band%252BTyrosine%2525E2%252580%252590Containing%252BPeptides%26aulast%3DCorrea%26aufirst%3DArkaitz%26date%3D2021%26date%3D2021%26volume%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ping  Zeng</span>, <span class="hlFld-ContribAuthor ">Lanhua  Yi</span>, <span class="hlFld-ContribAuthor ">Jiangtao  Xu</span>, <span class="hlFld-ContribAuthor ">Wei  Gao</span>, <span class="hlFld-ContribAuthor ">Chen  Xu</span>, <span class="hlFld-ContribAuthor ">Sheng  Chen</span>, <span class="hlFld-ContribAuthor ">Kin-Fai  Chan</span>, <span class="hlFld-ContribAuthor ">Kwok-Yin  Wong</span>. </span><span class="cited-content_cbyCitation_article-title">Investigation of antibiofilm activity, antibacterial activity, and mechanistic studies of an amphiphilic peptide against Acinetobacter baumannii. </span><span class="cited-content_cbyCitation_journal-name">Biochimica et Biophysica Acta (BBA) - Biomembranes</span><span> <strong>2021,</strong> <em>1863 </em>
                                    (6)
                                     , 183600. <a href="https://doi.org/10.1016/j.bbamem.2021.183600" title="DOI URL">https://doi.org/10.1016/j.bbamem.2021.183600</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbamem.2021.183600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbamem.2021.183600%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimica%2520et%2520Biophysica%2520Acta%2520%2528BBA%2529%2520-%2520Biomembranes%26atitle%3DInvestigation%252Bof%252Bantibiofilm%252Bactivity%25252C%252Bantibacterial%252Bactivity%25252C%252Band%252Bmechanistic%252Bstudies%252Bof%252Ban%252Bamphiphilic%252Bpeptide%252Bagainst%252BAcinetobacter%252Bbaumannii%26aulast%3DZeng%26aufirst%3DPing%26date%3D2021%26volume%3D1863%26issue%3D6%26spage%3D183600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">C. S.  Brian Chia</span>. </span><span class="cited-content_cbyCitation_article-title">A Review on the Metabolism of 25 Peptide Drugs. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Peptide Research and Therapeutics</span><span> <strong>2021,</strong> <em>27 </em>
                                    (2)
                                     , 1397-1418. <a href="https://doi.org/10.1007/s10989-021-10177-0" title="DOI URL">https://doi.org/10.1007/s10989-021-10177-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10989-021-10177-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10989-021-10177-0%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Peptide%2520Research%2520and%2520Therapeutics%26atitle%3DA%252BReview%252Bon%252Bthe%252BMetabolism%252Bof%252B25%252BPeptide%252BDrugs%26aulast%3DBrian%2BChia%26aufirst%3DC.%2BS.%26date%3D2021%26date%3D2021%26volume%3D27%26issue%3D2%26spage%3D1397%26epage%3D1418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stephen J  Barigye</span>, <span class="hlFld-ContribAuthor ">JosÃ© M  GarcÃ­a de la Vega</span>, <span class="hlFld-ContribAuthor ">Yunierkis  Perez-Castillo</span>, <span class="hlFld-ContribAuthor ">Juan A  Castillo-Garit</span>. </span><span class="cited-content_cbyCitation_article-title">Evolutionary algorithm-based generation of optimum peptide sequences with dengue virus inhibitory activity. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2021,</strong> <em>13 </em>
                                    (11)
                                     , 993-1000. <a href="https://doi.org/10.4155/fmc-2020-0372" title="DOI URL">https://doi.org/10.4155/fmc-2020-0372</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2020-0372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2020-0372%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DEvolutionary%252Balgorithm-based%252Bgeneration%252Bof%252Boptimum%252Bpeptide%252Bsequences%252Bwith%252Bdengue%252Bvirus%252Binhibitory%252Bactivity%26aulast%3DBarigye%26aufirst%3DStephen%2BJ%26date%3D2021%26volume%3D13%26issue%3D11%26spage%3D993%26epage%3D1000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mateusz  Zalewski</span>, <span class="hlFld-ContribAuthor ">Sebastian  Kmiecik</span>, <span class="hlFld-ContribAuthor ">MichaÅ  KoliÅski</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Dynamics Scoring of ProteinâPeptide Models Derived from Coarse-Grained Docking. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (11)
                                     , 3293. <a href="https://doi.org/10.3390/molecules26113293" title="DOI URL">https://doi.org/10.3390/molecules26113293</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26113293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26113293%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DMolecular%252BDynamics%252BScoring%252Bof%252BProtein%2525E2%252580%252593Peptide%252BModels%252BDerived%252Bfrom%252BCoarse-Grained%252BDocking%26aulast%3DZalewski%26aufirst%3DMateusz%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D11%26spage%3D3293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hans  Renata</span>, <span class="hlFld-ContribAuthor ">Emily  Shimizu</span>, <span class="hlFld-ContribAuthor ">Christian R.  Zwick</span>. </span><span class="cited-content_cbyCitation_article-title">Regiodivergent biocatalytic hydroxylation of l-Glutamine facilitated by characterization of Non-Heme dioxygenases from Non-Ribosomal peptide biosyntheses. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2021,</strong> <em>90 </em>, 132190. <a href="https://doi.org/10.1016/j.tet.2021.132190" title="DOI URL">https://doi.org/10.1016/j.tet.2021.132190</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2021.132190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2021.132190%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DRegiodivergent%252Bbiocatalytic%252Bhydroxylation%252Bof%252Bl-Glutamine%252Bfacilitated%252Bby%252Bcharacterization%252Bof%252BNon-Heme%252Bdioxygenases%252Bfrom%252BNon-Ribosomal%252Bpeptide%252Bbiosyntheses%26aulast%3DRenata%26aufirst%3DHans%26date%3D2021%26volume%3D90%26spage%3D132190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vera  DâAloisio</span>, <span class="hlFld-ContribAuthor ">Paolo  Dognini</span>, <span class="hlFld-ContribAuthor ">Gillian A.  Hutcheon</span>, <span class="hlFld-ContribAuthor ">Christopher R.  Coxon</span>. </span><span class="cited-content_cbyCitation_article-title">PepTherDia: database and structural composition analysis of approved peptide therapeutics and diagnostics. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2021,</strong> <em>26 </em>
                                    (6)
                                     , 1409-1419. <a href="https://doi.org/10.1016/j.drudis.2021.02.019" title="DOI URL">https://doi.org/10.1016/j.drudis.2021.02.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2021.02.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2021.02.019%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DPepTherDia%25253A%252Bdatabase%252Band%252Bstructural%252Bcomposition%252Banalysis%252Bof%252Bapproved%252Bpeptide%252Btherapeutics%252Band%252Bdiagnostics%26aulast%3DD%25E2%2580%2599Aloisio%26aufirst%3DVera%26date%3D2021%26volume%3D26%26issue%3D6%26spage%3D1409%26epage%3D1419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Diego A.  MoyÃ¡</span>, <span class="hlFld-ContribAuthor ">Michael A.  Lee</span>, <span class="hlFld-ContribAuthor ">Joseph C.  Chanthakhoun</span>, <span class="hlFld-ContribAuthor ">Austin K.  LeSueur</span>, <span class="hlFld-ContribAuthor ">Daniel  Joaquin</span>, <span class="hlFld-ContribAuthor ">Jaden D.  Barfuss</span>, <span class="hlFld-ContribAuthor ">Steven L.  Castle</span>. </span><span class="cited-content_cbyCitation_article-title">Towards a streamlined synthesis of peptides containing Î±,Î²-dehydroamino acids. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2021,</strong> <em>74 </em>, 153175. <a href="https://doi.org/10.1016/j.tetlet.2021.153175" title="DOI URL">https://doi.org/10.1016/j.tetlet.2021.153175</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2021.153175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2021.153175%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DTowards%252Ba%252Bstreamlined%252Bsynthesis%252Bof%252Bpeptides%252Bcontaining%252B%2525CE%2525B1%25252C%2525CE%2525B2-dehydroamino%252Bacids%26aulast%3DMoy%25C3%25A1%26aufirst%3DDiego%2BA.%26date%3D2021%26volume%3D74%26spage%3D153175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">JooâYoung  Kim</span>, <span class="hlFld-ContribAuthor ">Jae Yun  Lee</span>, <span class="hlFld-ContribAuthor ">Ha Yeon  Park</span>, <span class="hlFld-ContribAuthor ">Hyunji  Kim</span>, <span class="hlFld-ContribAuthor ">Jeon Hyeong  Kang</span>, <span class="hlFld-ContribAuthor ">Hyun Jin  Kim</span>, <span class="hlFld-ContribAuthor ">WooâJin  Jeong</span>. </span><span class="cited-content_cbyCitation_article-title">Combination of peptides with biological, organic, and inorganic materials for synergistically enhanced diagnostics and therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Peptide Science</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.1002/pep2.24233" title="DOI URL">https://doi.org/10.1002/pep2.24233</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/pep2.24233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fpep2.24233%26sid%3Dliteratum%253Aachs%26jtitle%3DPeptide%2520Science%26atitle%3DCombination%252Bof%252Bpeptides%252Bwith%252Bbiological%25252C%252Borganic%25252C%252Band%252Binorganic%252Bmaterials%252Bfor%252Bsynergistically%252Benhanced%252Bdiagnostics%252Band%252Btherapeutics%26aulast%3DKim%26aufirst%3DJoo%25E2%2580%2590Young%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aleksandra E  Badaczewska-Dawid</span>, <span class="hlFld-ContribAuthor ">Sebastian  Kmiecik</span>, <span class="hlFld-ContribAuthor ">MichaÅ  KoliÅski</span>. </span><span class="cited-content_cbyCitation_article-title">Docking of peptides to GPCRs using a combination of CABS-dock with FlexPepDock refinement. </span><span class="cited-content_cbyCitation_journal-name">Briefings in Bioinformatics</span><span> <strong>2021,</strong> <em>22 </em>
                                    (3)
                                     <a href="https://doi.org/10.1093/bib/bbaa109" title="DOI URL">https://doi.org/10.1093/bib/bbaa109</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/bib/bbaa109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fbib%2Fbbaa109%26sid%3Dliteratum%253Aachs%26jtitle%3DBriefings%2520in%2520Bioinformatics%26atitle%3DDocking%252Bof%252Bpeptides%252Bto%252BGPCRs%252Busing%252Ba%252Bcombination%252Bof%252BCABS-dock%252Bwith%252BFlexPepDock%252Brefinement%26aulast%3DBadaczewska-Dawid%26aufirst%3DAleksandra%2BE%26date%3D2021%26date%3D2020%26volume%3D22%26issue%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thanawat  Suwatthanarak</span>, <span class="hlFld-ContribAuthor ">Masayoshi  Tanaka</span>, <span class="hlFld-ContribAuthor ">Yoshitaka  Miyamoto</span>, <span class="hlFld-ContribAuthor ">Kenji  Miyado</span>, <span class="hlFld-ContribAuthor ">Mina  Okochi</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of cancer-cell migration by tetraspanin CD9-binding peptide. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2021,</strong> <em>57 </em>
                                    (40)
                                     , 4906-4909. <a href="https://doi.org/10.1039/D1CC01295A" title="DOI URL">https://doi.org/10.1039/D1CC01295A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1CC01295A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1CC01295A%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DInhibition%252Bof%252Bcancer-cell%252Bmigration%252Bby%252Btetraspanin%252BCD9-binding%252Bpeptide%26aulast%3DSuwatthanarak%26aufirst%3DThanawat%26date%3D2021%26date%3D2021%26volume%3D57%26issue%3D40%26spage%3D4906%26epage%3D4909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Heather C.  Hayes</span>, <span class="hlFld-ContribAuthor ">Louis Y. P.  Luk</span>, <span class="hlFld-ContribAuthor ">Yu-Hsuan  Tsai</span>. </span><span class="cited-content_cbyCitation_article-title">Approaches for peptide and protein cyclisation. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2021,</strong> <em>19 </em>
                                    (18)
                                     , 3983-4001. <a href="https://doi.org/10.1039/D1OB00411E" title="DOI URL">https://doi.org/10.1039/D1OB00411E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1OB00411E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1OB00411E%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DApproaches%252Bfor%252Bpeptide%252Band%252Bprotein%252Bcyclisation%26aulast%3DHayes%26aufirst%3DHeather%2BC.%26date%3D2021%26date%3D2021%26volume%3D19%26issue%3D18%26spage%3D3983%26epage%3D4001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vincent  Martin</span>, <span class="hlFld-ContribAuthor ">Sandip  Jadhav</span>, <span class="hlFld-ContribAuthor ">Peter H. G.  Egelund</span>, <span class="hlFld-ContribAuthor ">Raphael  Liffert</span>, <span class="hlFld-ContribAuthor ">Henrik  Johansson Castro</span>, <span class="hlFld-ContribAuthor ">Tobias  KrÃ¼ger</span>, <span class="hlFld-ContribAuthor ">Kim F.  Haselmann</span>, <span class="hlFld-ContribAuthor ">Sebastian  Thordal Le Quement</span>, <span class="hlFld-ContribAuthor ">Fernando  Albericio</span>, <span class="hlFld-ContribAuthor ">Frank  Dettner</span>, <span class="hlFld-ContribAuthor ">Carolin  Lechner</span>, <span class="hlFld-ContribAuthor ">Ralph  SchÃ¶nleber</span>, <span class="hlFld-ContribAuthor ">Daniel Sejer  Pedersen</span>. </span><span class="cited-content_cbyCitation_article-title">Harnessing polarity and viscosity to identify green binary solvent mixtures as viable alternatives to DMF in solid-phase peptide synthesis. </span><span class="cited-content_cbyCitation_journal-name">Green Chemistry</span><span> <strong>2021,</strong> <em>23 </em>
                                    (9)
                                     , 3295-3311. <a href="https://doi.org/10.1039/D1GC00603G" title="DOI URL">https://doi.org/10.1039/D1GC00603G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1GC00603G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1GC00603G%26sid%3Dliteratum%253Aachs%26jtitle%3DGreen%2520Chemistry%26atitle%3DHarnessing%252Bpolarity%252Band%252Bviscosity%252Bto%252Bidentify%252Bgreen%252Bbinary%252Bsolvent%252Bmixtures%252Bas%252Bviable%252Balternatives%252Bto%252BDMF%252Bin%252Bsolid-phase%252Bpeptide%252Bsynthesis%26aulast%3DMartin%26aufirst%3DVincent%26date%3D2021%26date%3D2021%26volume%3D23%26issue%3D9%26spage%3D3295%26epage%3D3311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Diego  La Mendola</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Arena</span>, <span class="hlFld-ContribAuthor ">Adriana  Pietropaolo</span>, <span class="hlFld-ContribAuthor ">Cristina  Satriano</span>, <span class="hlFld-ContribAuthor ">Enrico  Rizzarelli</span>. </span><span class="cited-content_cbyCitation_article-title">Metal ion coordination in peptide fragments of neurotrophins: A crucial step for understanding the role and signaling of these proteins in the brain. </span><span class="cited-content_cbyCitation_journal-name">Coordination Chemistry Reviews</span><span> <strong>2021,</strong> <em>435 </em>, 213790. <a href="https://doi.org/10.1016/j.ccr.2021.213790" title="DOI URL">https://doi.org/10.1016/j.ccr.2021.213790</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ccr.2021.213790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ccr.2021.213790%26sid%3Dliteratum%253Aachs%26jtitle%3DCoordination%2520Chemistry%2520Reviews%26atitle%3DMetal%252Bion%252Bcoordination%252Bin%252Bpeptide%252Bfragments%252Bof%252Bneurotrophins%25253A%252BA%252Bcrucial%252Bstep%252Bfor%252Bunderstanding%252Bthe%252Brole%252Band%252Bsignaling%252Bof%252Bthese%252Bproteins%252Bin%252Bthe%252Bbrain%26aulast%3DLa%2BMendola%26aufirst%3DDiego%26date%3D2021%26volume%3D435%26spage%3D213790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sindija  Lapcinska</span>, <span class="hlFld-ContribAuthor ">Pavel  Arsenyan</span>. </span><span class="cited-content_cbyCitation_article-title">Straightforward Functionalization of Sulfur-Containing Peptides via 5- and 6-endo-dig Cyclization Reactions. </span><span class="cited-content_cbyCitation_journal-name">Synthesis</span><span> <strong>2021,</strong> <em>53 </em>
                                    (10)
                                     , 1805-1820. <a href="https://doi.org/10.1055/a-1343-5607" title="DOI URL">https://doi.org/10.1055/a-1343-5607</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1055/a-1343-5607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1055%2Fa-1343-5607%26sid%3Dliteratum%253Aachs%26jtitle%3DSynthesis%26atitle%3DStraightforward%252BFunctionalization%252Bof%252BSulfur-Containing%252BPeptides%252Bvia%252B5-%252Band%252B6-endo-dig%252BCyclization%252BReactions%26aulast%3DLapcinska%26aufirst%3DSindija%26date%3D2021%26date%3D2020%26volume%3D53%26issue%3D10%26spage%3D1805%26epage%3D1820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tomohiro  Hattori</span>, <span class="hlFld-ContribAuthor ">Wataru  Muramatsu</span>, <span class="hlFld-ContribAuthor ">Hisashi  Yamamoto</span>. </span><span class="cited-content_cbyCitation_article-title">Substrate-Controlled Amide Bond Formation: Innovation of Peptide Synthesis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Synthetic Organic Chemistry, Japan</span><span> <strong>2021,</strong> <em>79 </em>
                                    (5)
                                     , 382-390. <a href="https://doi.org/10.5059/yukigoseikyokaishi.79.382" title="DOI URL">https://doi.org/10.5059/yukigoseikyokaishi.79.382</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5059/yukigoseikyokaishi.79.382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5059%2Fyukigoseikyokaishi.79.382%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Synthetic%2520Organic%2520Chemistry%252C%2520Japan%26atitle%3DSubstrate-Controlled%252BAmide%252BBond%252BFormation%25253A%252BInnovation%252Bof%252BPeptide%252BSynthesis%26aulast%3DHattori%26aufirst%3DTomohiro%26date%3D2021%26volume%3D79%26issue%3D5%26spage%3D382%26epage%3D390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div><a href="#" data-source="/pb/widgets/cited-by?doi=10.1021%2Facs.jmedchem.7b00318&amp;widgetId=9cf770f4-a9a2-46e0-bd29-3da15bcf4ae0&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-4%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00318%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text&amp;citedByCount=349&amp;pagesCount=4&amp;pageNumber=2" title="Load more citations" class="button_primary float-right cited-by__see-more mb-5"><i aria-hidden="âtrueâ" class="icon-angle-double-down"></i><span>Load more citations</span></a></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_null" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0036.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Two- and three-dimensional structures of insulin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Peptides approved and in active development by therapeutic area.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Top-selling non-insulin peptides in 2015.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures of somatostatin and octreotide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structures of GnRH, the agonist analogue leuprolide, and the antagonist analogue degarelix.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures of arginine vasopressin and the analogue desmopressin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structures of oxytocin, the agonist analogue carbetocin, and the antagonist analogue atosiban.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structures of vancomycin and cyclosporin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structures of arylomycin B and the synthetic analogue arylomycin M131.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structure of teixobactin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Structures of <i>E. coli</i> STh toxin and the analogue linaclotide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Two- and three-dimensional structures of cyclotide kalata B1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Grafting of active peptide sequences onto cyclotide loops.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Mechanism of lanthionine synthesis and the structure of the lanthipeptide nisin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Enzymatic synthesis of lanthipeptide A.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Chemical modification of phage by disulfide reduction and cysteine alkylation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Principle of mirror image phage display.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Principle of Lernerâs autocrine screening technology.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Comparison of the sequences of GLP-1, exenatide, and the biased agonist P5.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Structure of isoacyl dipeptides and pseudoprolines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Mechanism of native chemical ligation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. NCL via C-terminal hydrazides.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. NCL via C-terminal <i>N</i>-acyl ureas.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0024.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. NCL via C-terminal bis(2-sulfanylethyl)amides.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0025.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Intein-mediated protein ligation (IPL).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0026.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Mechanism of the Ser/Thr ligation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0027.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Mechanism of the KAHA ligation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0028.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Schematic of butelase ligation, illustrating sequence recognition and the irreversible thioester variant.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0029.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Synthesis of CAM esters as substrates for peptiligase ligation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0030.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. Examples of peptides exhibiting nonclassical GPCR pharmacology.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig31" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0031.jpeg" id="rightTab-gr31" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. Structure of selepressin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig31"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig32" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0032.jpeg" id="rightTab-gr32" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 32. Structure of <b>3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig32"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig33" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0033.jpeg" id="rightTab-gr33" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 33. Structures of (a) zoptarelin doxorubicin and (b) <sup>90</sup>Y-edotreotide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig34" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/medium/jm-2017-00318y_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0034.jpeg" id="rightTab-gr34" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 34. Structure and sequence of NA-1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b00318/20180215/images/large/jm-2017-00318y_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00318&amp;id=fig34"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03623" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03623" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 235 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Weiland, T.; Bodanszky, M.</span> <span class="citation_source-book">The World of Peptides: A Brief History of Peptide Chemistry</span>; <span class="NLM_publisher-name">Springer Verlag</span>: <span class="NLM_publisher-loc">Berlin-Heidelberg</span>,<span class="NLM_x"> </span><span class="NLM_year">1991</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1007%2F978-3-642-75850-8" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1991&author=T.+Weiland&author=M.+Bodanszky&title=The+World+of+Peptides%3A+A+Brief+History+of+Peptide+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-75850-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-642-75850-8%26sid%3Dliteratum%253Aachs%26aulast%3DWeiland%26aufirst%3DT.%26btitle%3DThe%2520World%2520of%2520Peptides%253A%2520A%2520Brief%2520History%2520of%2520Peptide%2520Chemistry%26pub%3DSpringer%2520Verlag%26date%3D1991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kastin, A.</span> <span class="citation_source-book">Handbook of Biologically Active Peptides</span>, <span class="NLM_edition">2nd</span> ed.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">Cambridge, MA</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=A.+Kastin&title=Handbook+of+Biologically+Active+Peptides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DKastin%26aufirst%3DA.%26btitle%3DHandbook%2520of%2520Biologically%2520Active%2520Peptides%26pub%3DAcademic%2520Press%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Bliss, M.</span> <span class="citation_source-book">Discovery of Insulin</span>; <span class="NLM_publisher-name">University of Chicago Press</span>: <span class="NLM_publisher-loc">Chicago, IL</span>,<span class="NLM_x"> </span><span class="NLM_year">1982</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1982&author=M.+Bliss&title=Discovery+of+Insulin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBliss%26aufirst%3DM.%26btitle%3DDiscovery%2520of%2520Insulin%26pub%3DUniversity%2520of%2520Chicago%2520Press%26date%3D1982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span>Lilly to Discontinue Four Insulin Products. <span class="NLM_publisher-name">Eli Lilly</span>: <span class="NLM_publisher-loc">Indianapolis, IN</span>, July 6,<span class="NLM_x"> </span><span class="NLM_year">2005</span><span class="NLM_x">; </span><a href="https://investor.lilly.com/releasedetail.cfm?ReleaseID=168048" class="extLink">https://investor.lilly.com/releasedetail.cfm?ReleaseID=168048</a> (accessed January 17, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lilly+to+Discontinue+Four+Insulin+Products.+Eli+Lilly%3A+Indianapolis%2C+IN%2C+July+6%2C+2005%3B+https%3A%2F%2Finvestor.lilly.com%2Freleasedetail.cfm%3FReleaseID%3D168048+%28accessed+January+17%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DLilly%2520to%2520Discontinue%2520Four%2520Insulin%2520Products%26pub%3DEli%2520Lilly%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mathieu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benhalima, K.</span><span> </span><span class="NLM_article-title">Insulin analogues in type 1 diabetes mellitus: getting better all the time</span> <span class="citation_source-journal">Nat. Rev. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="refDoi">Â DOI: 10.1038/nrendo.2017.39</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnrendo.2017.39" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=28429780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvVCjtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=385&author=C.+Mathieuauthor=P.+Gillardauthor=K.+Benhalima&title=Insulin+analogues+in+type+1+diabetes+mellitus%3A+getting+better+all+the+time&doi=10.1038%2Fnrendo.2017.39"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin analogues in type 1 diabetes mellitus: getting better all the time</span></div><div class="casAuthors">Mathieu, Chantal; Gillard, Pieter; Benhalima, Katrien</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">385-399</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The treatment of type 1 diabetes mellitus consists of external replacement of the functions of Î² cells in an attempt to achieve blood levels of glucose as close to the normal range as possible.  This approach means that glucose sensing needs to be replaced and levels of insulin need to mimic physiol. insulin-action profiles, including basal coverage and changes around meals.  Training and educating patients are crucial for the achievement of good glycemic control, but having insulin prepns. with action profiles that provide stable basal insulin coverage and appropriate mealtime insulin peaks helps people with type 1 diabetes mellitus to live active lives without sacrificing tight glycemic control.  Insulin analogs enable patients to achieve this goal, as some have fast action profiles, and some have very slow action profiles, which gives people with type 1 diabetes mellitus the tools to achieve dynamic insulin-action profiles that enable tight glycemic control with a risk of hypoglycemia that is lower than that with human short-acting and long-acting insulins.  This Review discusses the established and novel insulin analogs that are used to treat patients with type 1 diabetes mellitus and provides insights into the future development of insulin analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7C5jVzlISF7Vg90H21EOLACvtfcHk0lhb3VBKBUZ4wQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvVCjtbk%253D&md5=648cec804f6950d6a1b80c1046d431b3</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2017.39&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2017.39%26sid%3Dliteratum%253Aachs%26aulast%3DMathieu%26aufirst%3DC.%26aulast%3DGillard%26aufirst%3DP.%26aulast%3DBenhalima%26aufirst%3DK.%26atitle%3DInsulin%2520analogues%2520in%2520type%25201%2520diabetes%2520mellitus%253A%2520getting%2520better%2520all%2520the%2520time%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2017%26volume%3D13%26spage%3D385%26doi%3D10.1038%2Fnrendo.2017.39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zaykov, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMarchi, R. D.</span><span> </span><span class="NLM_article-title">Pursuit of a perfect insulin</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">425</span><span class="NLM_x">â</span> <span class="NLM_lpage">439</span><span class="refDoi">Â DOI: 10.1038/nrd.2015.36</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnrd.2015.36" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26988411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XksVKksbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=425-439&author=A.+N.+Zaykovauthor=J.+P.+Mayerauthor=R.+D.+DiMarchi&title=Pursuit+of+a+perfect+insulin&doi=10.1038%2Fnrd.2015.36"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Pursuit of a perfect insulin</span></div><div class="casAuthors">Zaykov, Alexander N.; Mayer, John P.; DiMarchi, Richard D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">425-439</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Insulin remains indispensable in the treatment of diabetes, but its use is hampered by its narrow therapeutic index.  Although advances in peptide chem. and recombinant DNA-based macromol. synthesis have enabled the synthesis of structurally optimized insulin analogs, the growing epidemics of obesity and diabetes have emphasized the need for diabetes therapies that are more efficacious, safe and convenient.  Accordingly, a broad set of drug candidates, targeting hyperglycemia plus other disease abnormalities, is now progressing through the clinic.  The development of an insulin therapy that is responsive to glucose concn. remains an ultimate goal, with initial prototypes now reaching the proof-of-concept stage.  Simultaneously, the first alternatives to injectable delivery have progressed to registration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4KBUWswfZN7Vg90H21EOLACvtfcHk0liPQXECw78crA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksVKksbs%253D&md5=1e4c4474fedd4b73d88c815e9b1a9265</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2015.36&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2015.36%26sid%3Dliteratum%253Aachs%26aulast%3DZaykov%26aufirst%3DA.%2BN.%26aulast%3DMayer%26aufirst%3DJ.%2BP.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26atitle%3DPursuit%2520of%2520a%2520perfect%2520insulin%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D425%26epage%3D439%26doi%3D10.1038%2Fnrd.2015.36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Lau, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, M. K.</span><span> </span><span class="NLM_article-title">Therapeutic peptides: Historical perspectives, current development trends, and future directions</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">in press</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=in+press&author=J.+L.+Lauauthor=M.+K.+Dunn&title=Therapeutic+peptides%3A+Historical+perspectives%2C+current+development+trends%2C+and+future+directions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLau%26aufirst%3DJ.%2BL.%26aulast%3DDunn%26aufirst%3DM.%2BK.%26atitle%3DTherapeutic%2520peptides%253A%2520Historical%2520perspectives%252C%2520current%2520development%2520trends%252C%2520and%2520future%2520directions%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3Din%2520press" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Scannell, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanckley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boldon, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warrington, B.</span><span> </span><span class="NLM_article-title">Diagnosing the decline in pharmaceutical R&D efficiency</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">â</span> <span class="NLM_lpage">200</span><span class="refDoi">Â DOI: 10.1038/nrd3681</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnrd3681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=22378269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38XivFyhtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=191-200&author=J.+W.+Scannellauthor=A.+Blanckleyauthor=H.+Boldonauthor=B.+Warrington&title=Diagnosing+the+decline+in+pharmaceutical+R%26D+efficiency&doi=10.1038%2Fnrd3681"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnosing the decline in pharmaceutical R&D efficiency</span></div><div class="casAuthors">Scannell, Jack W.; Blanckley, Alex; Boldon, Helen; Warrington, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">191-200</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The past 60 years have seen huge advances in many of the scientific, technol. and managerial factors that should tend to raise the efficiency of com. drug research and development (RD).  Yet the no. of new drugs approved per billion US dollars spent on RD has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms.  There have been many proposed solns. to the problem of declining RD efficiency.  However, their apparent lack of impact so far and the contrast between improving inputs and declining output in terms of the no. of new drugs make it sensible to ask whether the underlying problems have been correctly diagnosed.  Here, we discuss four factors that we consider to be primary causes, which we call the 'better than the Beatles' problem; the 'cautious regulator' problem; the 'throw money at it' tendency; and the 'basic research-brute force' bias.  Our aim is to provoke a more systematic anal. of the causes of the decline in RD efficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5e_81DC6r8LVg90H21EOLACvtfcHk0liPQXECw78crA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivFyhtrY%253D&md5=db3e4548260e55f47a9964e8d1b216fd</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrd3681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3681%26sid%3Dliteratum%253Aachs%26aulast%3DScannell%26aufirst%3DJ.%2BW.%26aulast%3DBlanckley%26aufirst%3DA.%26aulast%3DBoldon%26aufirst%3DH.%26aulast%3DWarrington%26aufirst%3DB.%26atitle%3DDiagnosing%2520the%2520decline%2520in%2520pharmaceutical%2520R%2526D%2520efficiency%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D191%26epage%3D200%26doi%3D10.1038%2Fnrd3681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span>The CMR International Pharmaceutical R&D Factbook; <span class="NLM_publisher-name">Thomson-Reuters</span>: <span class="NLM_publisher-loc">Philadelphia</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="http://cmr.thomsonreuters.com/services/factbook/" class="extLink">http://cmr.thomsonreuters.com/services/factbook/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+CMR+International+Pharmaceutical+R%26D+Factbook%3B+Thomson-Reuters%3A+Philadelphia%2C+2015%3B+http%3A%2F%2Fcmr.thomsonreuters.com%2Fservices%2Ffactbook%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520CMR%2520International%2520Pharmaceutical%2520R%2526D%2520Factbook%26pub%3DThomson-Reuters%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span>Peptide Therapeutics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012â2018; <span class="NLM_publisher-name">Transparency Market Research</span>: <span class="NLM_publisher-loc">Albany, NY</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://www.transparencymarketresearch.com/peptide-therapeutics-market.html" class="extLink">http://www.transparencymarketresearch.com/peptide-therapeutics-market.html</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Peptide+Therapeutics+Market%3A+Global+Industry+Analysis%2C+Size%2C+Share%2C+Growth%2C+Trends+and+Forecast+2012%E2%80%932018%3B+Transparency+Market+Research%3A+Albany%2C+NY%2C+2012%3B+http%3A%2F%2Fwww.transparencymarketresearch.com%2Fpeptide-therapeutics-market.html."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DPeptide%2520Therapeutics%2520Market%253A%2520Global%2520Industry%2520Analysis%252C%2520Size%252C%2520Share%252C%2520Growth%252C%2520Trends%2520and%2520Forecast%25202012%25E2%2580%25932018%26pub%3DTransparency%2520Market%2520Research%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fosgerau, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, T.</span><span> </span><span class="NLM_article-title">Peptide therapeutics: current status and future directions</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">122</span><span class="NLM_x">â</span> <span class="NLM_lpage">128</span><span class="refDoi">Â DOI: 10.1016/j.drudis.2014.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.drudis.2014.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25450771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsl2ksLnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=122-128&author=K.+Fosgerauauthor=T.+Hoffmann&title=Peptide+therapeutics%3A+current+status+and+future+directions&doi=10.1016%2Fj.drudis.2014.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide therapeutics: current status and future directions</span></div><div class="casAuthors">Fosgerau, Keld; Hoffmann, Torsten</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">122-128</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Peptides are recognized for being highly selective and efficacious and, at the same time, relatively safe and well tolerated.  Consequently, there is an increased interest in peptides in pharmaceutical research and development (R&D), and approx. 140 peptide therapeutics are currently being evaluated in clin. trials.  Given that the low-hanging fruits in the form of obvious peptide targets have already been picked, it has now become necessary to explore new routes beyond traditional peptide design.  Examples of such approaches are multifunctional and cell penetrating peptides, as well as peptide drug conjugates.  Here, we discuss the current status, strengths, and weaknesses of peptides as medicines and the emerging new opportunities in peptide drug design and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmhpp8GnJ6JLVg90H21EOLACvtfcHk0lgUv0w4p5d7Yg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsl2ksLnM&md5=f6b74aaa4e3fdb317b091b0450f3618a</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DFosgerau%26aufirst%3DK.%26aulast%3DHoffmann%26aufirst%3DT.%26atitle%3DPeptide%2520therapeutics%253A%2520current%2520status%2520and%2520future%2520directions%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26spage%3D122%26epage%3D128%26doi%3D10.1016%2Fj.drudis.2014.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Craik, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairlie, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liras, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D.</span><span> </span><span class="NLM_article-title">The future of peptide-based drugs</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">136</span><span class="NLM_x">â</span> <span class="NLM_lpage">147</span><span class="refDoi">Â DOI: 10.1111/cbdd.12055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1111%2Fcbdd.12055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23253135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1yktA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2013&pages=136-147&author=D.+J.+Craikauthor=D.+P.+Fairlieauthor=S.+Lirasauthor=D.+Price&title=The+future+of+peptide-based+drugs&doi=10.1111%2Fcbdd.12055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">The future of peptide-based drugs</span></div><div class="casAuthors">Craik, David J.; Fairlie, David P.; Liras, Spiros; Price, David</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">136-147</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The suite of currently used drugs can be divided into two categories - traditional "small mol." drugs with typical mol. wts. of <500 Da but with oral bioavailability, and much larger "biologics" typically >5000 Da that are not orally bioavailable and need to be delivered via injection.  Due to their small size, conventional small mol. drugs may suffer from reduced target selectivity that often ultimately manifests in human side-effects, whereas protein therapeutics tend to be exquisitely specific for their targets due to many more interactions with them, but this comes at a cost of low bioavailability, poor membrane permeability, and metabolic instability.  The time has now come to reinvestigate new drug leads that fit between these two mol. wt. extremes, with the goal of combining advantages of small mols. (cost, conformational restriction, membrane permeability, metabolic stability, oral bioavailability) with those of proteins (natural components, target specificity, high potency).  This article uses selected examples of peptides to highlight the importance of peptide drugs, some potential new opportunities for their exploitation, and some difficult challenges ahead in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlaEZbrPXLPbVg90H21EOLACvtfcHk0lgUv0w4p5d7Yg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1yktA%253D%253D&md5=1e7e4b7e725541587fad855e6a28cadf</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12055%26sid%3Dliteratum%253Aachs%26aulast%3DCraik%26aufirst%3DD.%2BJ.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26aulast%3DLiras%26aufirst%3DS.%26aulast%3DPrice%26aufirst%3DD.%26atitle%3DThe%2520future%2520of%2520peptide-based%2520drugs%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2013%26volume%3D81%26spage%3D136%26epage%3D147%26doi%3D10.1111%2Fcbdd.12055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Dunn, B. M.</span> <span class="citation_source-book">Peptide Chemistry and Drug Design</span>; <span class="NLM_publisher-name">John Wiley & Sons</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2F9781118995303" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=B.+M.+Dunn&title=Peptide+Chemistry+and+Drug+Design"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.1002%2F9781118995303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118995303%26sid%3Dliteratum%253Aachs%26aulast%3DDunn%26aufirst%3DB.%2BM.%26btitle%3DPeptide%2520Chemistry%2520and%2520Drug%2520Design%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Di, L.</span><span> </span><span class="NLM_article-title">Strategic approaches to optimizing peptide ADME properties</span> <span class="citation_source-journal">AAPS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">â</span> <span class="NLM_lpage">143</span><span class="refDoi">Â DOI: 10.1208/s12248-014-9687-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1208%2Fs12248-014-9687-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25366889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFSnurvJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=134-143&author=L.+Di&title=Strategic+approaches+to+optimizing+peptide+ADME+properties&doi=10.1208%2Fs12248-014-9687-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Strategic Approaches to Optimizing Peptide ADME Properties</span></div><div class="casAuthors">Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">134-143</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Development of peptide drugs is challenging but also quite rewarding.  Five blockbuster peptide drugs are currently on the market, and six new peptides received first marketing approval as new mol. entities in 2012.  Although peptides only represent 2% of the drug market, the market is growing twice as quickly and might soon occupy a larger niche.  Natural peptides typically have poor absorption, distribution, metab., and excretion (ADME) properties with rapid clearance, short half-life, low permeability, and sometimes low soly.  Strategies have been developed to improve peptide drugability through enhancing permeability, reducing proteolysis and renal clearance, and prolonging half-life.  In vivo, in vitro, and in silico tools are available to evaluate ADME properties of peptides, and structural modification strategies are in place to improve peptide developability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDLDsR-Zk0OLVg90H21EOLACvtfcHk0ljNihpkQKCzaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFSnurvJ&md5=530597d3719d65509105096f433fee0a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1208%2Fs12248-014-9687-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-014-9687-3%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26atitle%3DStrategic%2520approaches%2520to%2520optimizing%2520peptide%2520ADME%2520properties%26jtitle%3DAAPS%2520J.%26date%3D2015%26volume%3D17%26spage%3D134%26epage%3D143%26doi%3D10.1208%2Fs12248-014-9687-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Smith, A. J.</span><span> </span><span class="NLM_article-title">New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics</span> <span class="citation_source-journal">J. Biomol. Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">â</span> <span class="NLM_lpage">453</span><span class="refDoi">Â DOI: 10.1177/1087057114562544</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1177%2F1087057114562544" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25512329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtlWjs7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=437-453&author=A.+J.+Smith&title=New+horizons+in+therapeutic+antibody+discovery%3A+opportunities+and+challenges+versus+small-molecule+therapeutics&doi=10.1177%2F1087057114562544"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics</span></div><div class="casAuthors">Smith, Alison J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">437-453</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Antibody drugs have become an increasingly significant component of the therapeutic landscape.  Their success has been driven by some of their unique properties, in particular their very high specificity and selectivity, in contrast to the offtarget liabilities of small mols. (SMs).  Antibodies can bring addnl. functionality to the table with their ability to interact with the immune system, and this can be further manipulated with advances in antibody engineering.  This review summarizes what antibody therapeutics have achieved to date and what opportunities and challenges lie ahead.  The target landscape for large mols. (LMs) vs. SMs and some of the challenges for antibody drug development are discussed.  Effective penetration of membrane barriers and intracellular targeting is one challenge, particularly across the highly resistant blood-brain barrier.  The expanding pipeline of antibody-drug conjugates offers the potential to combine SM and LM modalities in a variety of creative ways, and antibodies also offer exciting potential to build bi- and multispecific mols.  The ability to pursue more challenging targets can also be further exploited but highlights the need for earlier screening in functional cell-based assays.  I discuss how this might be addressed given the practical constraints imposed by high-throughput screening sample type and process differences in antibody primary screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAAiB0sQ4T4rVg90H21EOLACvtfcHk0ljNihpkQKCzaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtlWjs7g%253D&md5=06dead2f9d85ab3c0e9cf2f5c9684708</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1177%2F1087057114562544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057114562544%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%2BJ.%26atitle%3DNew%2520horizons%2520in%2520therapeutic%2520antibody%2520discovery%253A%2520opportunities%2520and%2520challenges%2520versus%2520small-molecule%2520therapeutics%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2015%26volume%3D20%26spage%3D437%26epage%3D453%26doi%3D10.1177%2F1087057114562544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Salemi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markovic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâAmelio, R.</span><span> </span><span class="NLM_article-title">The expanding role of therapeutic antibodies</span> <span class="citation_source-journal">Int. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">202</span><span class="NLM_x">â</span> <span class="NLM_lpage">264</span><span class="refDoi">Â DOI: 10.3109/08830185.2013.863304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3109%2F08830185.2013.863304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24471447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotVersrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=202-264&author=S.+Salemiauthor=M.+Markovicauthor=G.+Martiniauthor=R.+D%E2%80%99Amelio&title=The+expanding+role+of+therapeutic+antibodies&doi=10.3109%2F08830185.2013.863304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The Expanding Role of Therapeutic Antibodies</span></div><div class="casAuthors">Salemi, Simonetta; Markovic, Milica; Martini, Gabriella; D'Amelio, Raffaele</div><div class="citationInfo"><span class="NLM_cas:title">International Reviews of Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">202-264</span>CODEN:
                <span class="NLM_cas:coden">IRIMEH</span>;
        ISSN:<span class="NLM_cas:issn">0883-0185</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Therapeutic antibodies have been used since the end of nineteenth century, but their use is progressively increased and recently, with the availability of monoclonal antibodies, they are successfully employed in a large disease spectrum, which transversally covers different fields of medicine.  Hyperimmune polyclonal immune globulin has been used against infectious diseases, in a period in which anti-microbial drugs were not yet available, and it still maintains a relevant place in prophylaxis/therapy.  Although immune globulin should be considered life-saving as replacement therapy in humoral immunodeficiencies, its place in the immune-modulating treatment is not usually first-choice, but it should be considered as support to std. approved treatments.  Despite therapeutic monoclonal antibodies have been lastly introduced in therapy, their extreme potentiality is reflected by the large no. of approved mols., addressed toward different immunol. targets and able to heavily influence the prognosis and quality of life of a wide range of different diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8jbmkoLO4jrVg90H21EOLACvtfcHk0ljNihpkQKCzaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotVersrc%253D&md5=eb14f7b21fdf5ef10735cfdb90039e85</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.3109%2F08830185.2013.863304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F08830185.2013.863304%26sid%3Dliteratum%253Aachs%26aulast%3DSalemi%26aufirst%3DS.%26aulast%3DMarkovic%26aufirst%3DM.%26aulast%3DMartini%26aufirst%3DG.%26aulast%3DD%25E2%2580%2599Amelio%26aufirst%3DR.%26atitle%3DThe%2520expanding%2520role%2520of%2520therapeutic%2520antibodies%26jtitle%3DInt.%2520Rev.%2520Immunol.%26date%3D2015%26volume%3D34%26spage%3D202%26epage%3D264%26doi%3D10.3109%2F08830185.2013.863304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Kaspar, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichert, J. M.</span><span> </span><span class="NLM_article-title">Future directions for peptide therapeutics development</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">807</span><span class="NLM_x">â</span> <span class="NLM_lpage">817</span><span class="refDoi">Â DOI: 10.1016/j.drudis.2013.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.drudis.2013.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23726889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpsV2ksbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=807-817&author=A.+A.+Kasparauthor=J.+M.+Reichert&title=Future+directions+for+peptide+therapeutics+development&doi=10.1016%2Fj.drudis.2013.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Future directions for peptide therapeutics development</span></div><div class="casAuthors">Kaspar, Allan A.; Reichert, Janice M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17-18</span>),
    <span class="NLM_cas:pages">807-817</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The notable expansion of peptide therapeutics development in the late 1990s and the 2000s led to an unprecedented no. of marketing approvals in 2012 and has provided a robust pipeline that should deliver numerous approvals during the remainder of the 2010s.  To document the current status of the pipeline, we collected data for peptide therapeutics in clin. studies and regulatory review, as well as those recently approved.  In this Foundation review, we provide an overview of the pipeline, including therapeutic area and mol. targets, with a focus on glucagon-like peptide 1 receptor agonists.  Areas for potential expansion, for example constrained peptides and peptide-drug conjugates, are profiled.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwwD0F8UAjFrVg90H21EOLACvtfcHk0ljNihpkQKCzaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpsV2ksbs%253D&md5=df04991ff869d0d85386254d378664cc</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DKaspar%26aufirst%3DA.%2BA.%26aulast%3DReichert%26aufirst%3DJ.%2BM.%26atitle%3DFuture%2520directions%2520for%2520peptide%2520therapeutics%2520development%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D807%26epage%3D817%26doi%3D10.1016%2Fj.drudis.2013.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Diao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meibohm, B.</span><span> </span><span class="NLM_article-title">Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">855</span><span class="NLM_x">â</span> <span class="NLM_lpage">868</span><span class="refDoi">Â DOI: 10.1007/s40262-013-0079-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1007%2Fs40262-013-0079-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23719681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVSmt77I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=855-868&author=L.+Diaoauthor=B.+Meibohm&title=Pharmacokinetics+and+pharmacokinetic-pharmacodynamic+correlations+of+therapeutic+peptides&doi=10.1007%2Fs40262-013-0079-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Correlations of Therapeutic Peptides</span></div><div class="casAuthors">Diao, Lei; Meibohm, Bernd</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">855-868</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Peptides, defined as polymers of less than 50 amino acids with a mol. wt. of less than 10 kDa, represent a fast-growing class of new therapeutics which has unique pharmacokinetic characteristics compared to large proteins or small mol. drugs.  Unmodified peptides usually undergo extensive proteolytic cleavage, resulting in short plasma half-lives.  As a result of their low permeability and susceptibility to catabolic degrdn., therapeutic peptides usually have very limited oral bioavailability and are administered either by the i.v., s.c., or i.m. route, although other routes such as nasal delivery are utilized as well.  Distribution processes are mainly driven by a combination of diffusion and to a lesser degree convective extravasation dependent on the size of the peptide, with vols. of distribution frequently not larger than the vol. of the extracellular body fluid.  Owing to the ubiquitous availability of proteases and peptidases throughout the body, proteolytic degrdn. is not limited to classic elimination organs.  Since peptides are generally freely filtered by the kidneys, glomerular filtration and subsequent renal metab. by proteolysis contribute to the elimination of many therapeutic peptides.  Although small peptides have usually limited immunogenicity, formation of anti-drug antibodies with subsequent hypersensitivity reactions has been described for some peptide therapeutics.  Numerous strategies have been applied to improve the pharmacokinetic properties of therapeutic peptides, esp. to overcome their metabolic instability, low permeability, and limited tissue residence time.  Applied techniques include amino acid substitutions, modification of the peptide terminus, inclusion of disulfide bonds, and conjugation with polymers or macromols. such as antibody fragments or albumin.  Application of model-based pharmacokinetic-pharmacodynamic correlations has been widely used for therapeutic peptides in support of drug development and dosage regimen design, esp. because their targets are often well-described endogenous regulatory pathways and processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmlFFOIFoZBrVg90H21EOLACvtfcHk0liMvC-ImwBAsA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVSmt77I&md5=975af68c1bbc3dda4b3dbe42b3e40181</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs40262-013-0079-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-013-0079-0%26sid%3Dliteratum%253Aachs%26aulast%3DDiao%26aufirst%3DL.%26aulast%3DMeibohm%26aufirst%3DB.%26atitle%3DPharmacokinetics%2520and%2520pharmacokinetic-pharmacodynamic%2520correlations%2520of%2520therapeutic%2520peptides%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2013%26volume%3D52%26spage%3D855%26epage%3D868%26doi%3D10.1007%2Fs40262-013-0079-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Lax, R.</span><span> </span><span class="NLM_article-title">The future of peptide development in the pharmaceutical industry</span> <span class="citation_source-journal">PharManufacturing: Int. Pept. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_fpage">10</span><span class="NLM_x">â</span> <span class="NLM_lpage">15</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=10-15&author=R.+Lax&title=The+future+of+peptide+development+in+the+pharmaceutical+industry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLax%26aufirst%3DR.%26atitle%3DThe%2520future%2520of%2520peptide%2520development%2520in%2520the%2520pharmaceutical%2520industry%26jtitle%3DPharManufacturing%253A%2520Int.%2520Pept.%2520Rev.%26date%3D2010%26spage%3D10%26epage%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Chin, J. W.</span><span> </span><span class="NLM_article-title">Expanding and reprogramming the genetic code of cells and animals</span> <span class="citation_source-journal">Annu. Rev. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">379</span><span class="NLM_x">â</span> <span class="NLM_lpage">408</span><span class="refDoi">Â DOI: 10.1146/annurev-biochem-060713-035737</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1146%2Fannurev-biochem-060713-035737" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24555827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFOhtrjK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2014&pages=379-408&author=J.+W.+Chin&title=Expanding+and+reprogramming+the+genetic+code+of+cells+and+animals&doi=10.1146%2Fannurev-biochem-060713-035737"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Expanding and reprogramming the genetic code of cells and animals</span></div><div class="casAuthors">Chin, Jason W.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">379-408</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">Genetic code expansion and reprogramming enable the site-specific incorporation of diverse designer amino acids into proteins produced in cells and animals.  Recent advances are enhancing the efficiency of unnatural amino acid incorporation by creating and evolving orthogonal ribosomes and manipulating the genome.  Increasing the no. of distinct amino acids that can be site-specifically encoded has been facilitated by the evolution of orthogonal quadruplet decoding ribosomes and the discovery of mutually orthogonal synthetase/tRNA pairs.  Rapid progress in moving genetic code expansion from bacteria to eukaryotic cells and animals (C. elegans and D. melanogaster) and the incorporation of useful unnatural amino acids has been aided by the development and application of the pyrrolysyl-tRNA (tRNA) synthetase/tRNA pair for unnatural amino acid incorporation.  Combining chemoselective reactions with encoded amino acids has facilitated the installation of posttranslational modifications, as well as rapid derivatization with diverse fluorophores for imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPEbW75CFvZLVg90H21EOLACvtfcHk0liMvC-ImwBAsA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFOhtrjK&md5=beabb2ed5bc94b9876a336bf0be25461</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1146%2Fannurev-biochem-060713-035737&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-biochem-060713-035737%26sid%3Dliteratum%253Aachs%26aulast%3DChin%26aufirst%3DJ.%2BW.%26atitle%3DExpanding%2520and%2520reprogramming%2520the%2520genetic%2520code%2520of%2520cells%2520and%2520animals%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2014%26volume%3D83%26spage%3D379%26epage%3D408%26doi%3D10.1146%2Fannurev-biochem-060713-035737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Maini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umemoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suga, H.</span><span> </span><span class="NLM_article-title">Ribosome-mediated synthesis of natural product-like peptides via cell-free translation</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">44</span><span class="NLM_x">â</span> <span class="NLM_lpage">52</span><span class="refDoi">Â DOI: 10.1016/j.cbpa.2016.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.cbpa.2016.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=27344230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFGjt73P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=44-52&author=R.+Mainiauthor=S.+Umemotoauthor=H.+Suga&title=Ribosome-mediated+synthesis+of+natural+product-like+peptides+via+cell-free+translation&doi=10.1016%2Fj.cbpa.2016.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Ribosome-mediated synthesis of natural product-like peptides via cell-free translation</span></div><div class="casAuthors">Maini, Rumit; Umemoto, Shiori; Suga, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">44-52</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Peptide natural products (PNPs) represent a unique class of compds. known for their fascinating structural motifs with important biol. activities.  Lately, PNPs have garnered a lot of interest for their application in drug discovery.  Nevertheless, lack of diversity oriented synthetic/biosynthetic platforms to generate large natural product-like libraries has limited their development as peptide therapeutics.  The promiscuity of cell-free translation has allowed for the synthesis of artificial PNPs having complex structural features.  Modified cell-free translation systems coupled with the display technologies have generated diverse natural product-like peptide libraries and led to the discovery of several biol. active mols.  Such technologies have drastically decreased the time to obtain peptide drug leads and therefore, revolutionized the field of peptide drug discovery.  In this account, we review recent developments in the synthesis of natural product-like peptides via cell-free translation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGBq1xlWp5VrVg90H21EOLACvtfcHk0liMvC-ImwBAsA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFGjt73P&md5=970458a0f34cd545e1e3aca2cc7434bc</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2016.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2016.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DMaini%26aufirst%3DR.%26aulast%3DUmemoto%26aufirst%3DS.%26aulast%3DSuga%26aufirst%3DH.%26atitle%3DRibosome-mediated%2520synthesis%2520of%2520natural%2520product-like%2520peptides%2520via%2520cell-free%2520translation%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D34%26spage%3D44%26epage%3D52%26doi%3D10.1016%2Fj.cbpa.2016.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Malyshev, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romesberg, F. E.</span><span> </span><span class="NLM_article-title">The expanded genetic alphabet</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">11930</span><span class="NLM_x">â</span> <span class="NLM_lpage">11944</span><span class="refDoi">Â DOI: 10.1002/anie.201502890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fanie.201502890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVSjtLrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=11930-11944&author=D.+A.+Malyshevauthor=F.+E.+Romesberg&title=The+expanded+genetic+alphabet&doi=10.1002%2Fanie.201502890"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">The expanded genetic alphabet</span></div><div class="casAuthors">Malyshev, Denis A.; Romesberg, Floyd E.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">11930-11944</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  All biol. information, since the last common ancestor of all life on Earth, has been encoded by a genetic alphabet consisting of only four nucleotides that form two base pairs.  Long-standing efforts to develop two synthetic nucleotides that form a third, unnatural base pair (UBP) have recently yielded three promising candidates, one based on alternative hydrogen bonding, and two based on hydrophobic and packing forces.  All three of these UBPs are replicated and transcribed with remarkable efficiency and fidelity, and the latter two thus demonstrate that hydrogen bonding is not unique in its ability to underlie the storage and retrieval of genetic information.  This Review highlights these recent developments as well as the applications enabled by the UBPs, including the expansion of the evolution process to include new functionality and the creation of semi-synthetic life that stores increased information.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxEFlLbioOhLVg90H21EOLACvtfcHk0lh7KPcZzo1JHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVSjtLrL&md5=56b77b89dbbf47428bf446e8de15ca82</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1002%2Fanie.201502890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201502890%26sid%3Dliteratum%253Aachs%26aulast%3DMalyshev%26aufirst%3DD.%2BA.%26aulast%3DRomesberg%26aufirst%3DF.%2BE.%26atitle%3DThe%2520expanded%2520genetic%2520alphabet%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D11930%26epage%3D11944%26doi%3D10.1002%2Fanie.201502890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hongdilokkul, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thirunavukarasu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romesberg, F. E.</span><span> </span><span class="NLM_article-title">The expanding world of DNA and RNA</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">â</span> <span class="NLM_lpage">87</span><span class="refDoi">Â DOI: 10.1016/j.cbpa.2016.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.cbpa.2016.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=27565457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWmtr%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=80-87&author=T.+Chenauthor=N.+Hongdilokkulauthor=Z.+Liuauthor=D.+Thirunavukarasuauthor=F.+E.+Romesberg&title=The+expanding+world+of+DNA+and+RNA&doi=10.1016%2Fj.cbpa.2016.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">The expanding world of DNA and RNA</span></div><div class="casAuthors">Chen, Tingjian; Hongdilokkul, Narupat; Liu, Zhixia; Thirunavukarasu, Deepak; Romesberg, Floyd E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">80-87</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">DNA and RNA are remarkable because they can both encode information and possess desired properties, including the ability to bind specific targets or catalyze specific reactions.  Nucleotide modifications that do not interfere with enzymic synthesis are now being used to bestow DNA or RNA with properties that further increase their utility, including phosphate and sugar modifications that increase nuclease resistance, nucleobase modifications that increase the range of activities possible, and even whole nucleobase replacement that results in selective pairing and the creation of unnatural base pairs that increase the information content.  These modifications are increasingly being applied both in vitro and in vivo, including in efforts to create semi-synthetic organisms with altered or expanded genetic alphabets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqKyb8Om4dA7Vg90H21EOLACvtfcHk0lh7KPcZzo1JHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWmtr%252FO&md5=442970017f6d14ab44454a16bcb86303</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2016.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2016.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DT.%26aulast%3DHongdilokkul%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DThirunavukarasu%26aufirst%3DD.%26aulast%3DRomesberg%26aufirst%3DF.%2BE.%26atitle%3DThe%2520expanding%2520world%2520of%2520DNA%2520and%2520RNA%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D34%26spage%3D80%26epage%3D87%26doi%3D10.1016%2Fj.cbpa.2016.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenakin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C.</span><span> </span><span class="NLM_article-title">Editorial: Orphan GPCRs as emerging drug targets</span> <span class="citation_source-journal">Front. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">295</span><span class="refDoi">Â DOI: 10.3389/fphar.2015.00295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3389%2Ffphar.2015.00295" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26696893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVGlu7zF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=295&author=Y.+Fangauthor=T.+Kenakinauthor=C.+Liu&title=Editorial%3A+Orphan+GPCRs+as+emerging+drug+targets&doi=10.3389%2Ffphar.2015.00295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">Editorial: orphan GPCRs as emerging drug targets</span></div><div class="casAuthors">Fang, Ye; Kenakin, Terry; Liu, Changlu</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">295/1-295/2</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  This article describes the human G protein coupled-receptor structure detn. and structure-based virtual screening for identifying ligands for orphan receptors and potential clin. applications of several orphan GPCRs including FFARs, H4 receptor, EIB2, GPR35, GPR55, GPR37, and GPR37L1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNxrlywN6GbLVg90H21EOLACvtfcHk0lh7KPcZzo1JHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVGlu7zF&md5=9260574bcaab25bd9dcd9f8a46745515</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2015.00295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2015.00295%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DY.%26aulast%3DKenakin%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DC.%26atitle%3DEditorial%253A%2520Orphan%2520GPCRs%2520as%2520emerging%2520drug%2520targets%26jtitle%3DFront.%2520Pharmacol.%26date%3D2015%26volume%3D6%26spage%3D295%26doi%3D10.3389%2Ffphar.2015.00295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fillmore, D.</span><span> </span><span class="NLM_article-title">It's a GPCR world</span> <span class="citation_source-journal">Mod. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">24</span><span class="NLM_x">â</span> <span class="NLM_lpage">28</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2004&pages=24-28&author=D.+Fillmore&title=It%27s+a+GPCR+world"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFillmore%26aufirst%3DD.%26atitle%3DIt%2527s%2520a%2520GPCR%2520world%26jtitle%3DMod.%2520Drug%2520Discovery%26date%3D2004%26volume%3D7%26spage%3D24%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Stockert, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devi, L. A.</span><span> </span><span class="NLM_article-title">Advancements in therapeutically targeting orphan GPCRs</span> <span class="citation_source-journal">Front. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">100</span><span class="refDoi">Â DOI: 10.3389/fphar.2015.00100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3389%2Ffphar.2015.00100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26005419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A280%3ADC%252BC2MfmvFertQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=100&author=J.+A.+Stockertauthor=L.+A.+Devi&title=Advancements+in+therapeutically+targeting+orphan+GPCRs&doi=10.3389%2Ffphar.2015.00100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20aR"><div class="casContent"><span class="casTitleNuber">20a</span><div class="casTitle"><span class="NLM_cas:atitle">Advancements in therapeutically targeting orphan GPCRs</span></div><div class="casAuthors">Stockert Jennifer A; Devi Lakshmi A</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">100</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">G-protein coupled receptors (GPCRs) are popular biological targets for drug discovery and development.  To date there are more than 140 orphan GPCRs, i.e., receptors whose endogenous ligands are unknown.  Traditionally orphan GPCRs have been difficult to study and the development of therapeutic compounds targeting these receptors has been extremely slow although these GPCRs are considered important targets based on their distribution and behavioral phenotype as revealed by animals lacking the receptor.  Recent advances in several methods used to study orphan receptors, including protein crystallography and homology modeling are likely to be useful in the identification of therapeutics targeting these receptors.  In the past 13 years, over a dozen different Class A GPCRs have been crystallized; this trend is exciting, since homology modeling of GPCRs has previously been limited by the availability of solved structures.  As the number of solved GPCR structures continues to grow so does the number of templates that can be used to generate increasingly accurate models of phylogenetically related orphan GPCRs.  The availability of solved structures along with the advances in using multiple templates to build models (in combination with molecular dynamics simulations that reveal structural information not provided by crystallographic data and methods for modeling hard-to-predict flexible loop regions) have improved the quality of GPCR homology models.  This, in turn, has improved the success rates of virtual ligand screens that use homology models to identify potential receptor binding compounds.  Experimental testing of the predicted hits and validation using traditional GPCR pharmacological approaches can be used to drive ligand-based efforts to probe orphan receptor biology as well as to define the chemotypes and chemical scaffolds important for binding.  As a result of these advances, orphan GPCRs are emerging from relative obscurity as a new class of drug targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQcSmeqGfmTqGLFM_lbR1VmfW6udTcc2eYAYu6M9PTCC7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfmvFertQ%253D%253D&md5=f21f3a8a7bbf9b55c875f986c9371172</span></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2015.00100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2015.00100%26sid%3Dliteratum%253Aachs%26aulast%3DStockert%26aufirst%3DJ.%2BA.%26aulast%3DDevi%26aufirst%3DL.%2BA.%26atitle%3DAdvancements%2520in%2520therapeutically%2520targeting%2520orphan%2520GPCRs%26jtitle%3DFront.%2520Pharmacol.%26date%3D2015%26volume%3D6%26spage%3D100%26doi%3D10.3389%2Ffphar.2015.00100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ngo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kufareva, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abagyan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, N. J.</span><span> </span><span class="NLM_article-title">Identifying ligands at orphan GPCRs: current status using structure-based approaches</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">173</span><span class="NLM_x">, </span> <span class="NLM_fpage">2934</span><span class="NLM_x">â</span> <span class="NLM_lpage">2951</span><span class="refDoi">Â DOI: 10.1111/bph.13452</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1111%2Fbph.13452" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26837045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1GntLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2016&pages=2934-2951&author=T.+Ngoauthor=I.+Kufarevaauthor=J.+L.+Colemanauthor=R.+M.+Grahamauthor=R.+Abagyanauthor=N.+J.+Smith&title=Identifying+ligands+at+orphan+GPCRs%3A+current+status+using+structure-based+approaches&doi=10.1111%2Fbph.13452"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20bR"><div class="casContent"><span class="casTitleNuber">20b</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying ligands at orphan GPCRs: current status using structure-based approaches</span></div><div class="casAuthors">Ngo, Tony; Kufareva, Irina; Coleman, James L. J.; Graham, Robert M.; Abagyan, Ruben; Smith, Nicola J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2934-2951</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">GPCRs are the most successful pharmaceutical targets in history.  Nevertheless, the pharmacol. of many GPCRs remains inaccessible as their endogenous or exogenous modulators have not been discovered.  Tools that explore the physiol. functions and pharmacol. potential of these 'orphan' GPCRs, whether they are endogenous and/or surrogate ligands, are therefore of paramount importance.  Rates of receptor deorphanization detd. by traditional reverse pharmacol. methods have slowed, indicating a need for the development of more sophisticated and efficient ligand screening approaches.  Here, we discuss the use of structure-based ligand discovery approaches to identify small mol. modulators for exploring the function of orphan GPCRs.  These studies have been buoyed by the growing no. of GPCR crystal structures solved in the past decade, providing a broad range of template structures for homol. modeling of orphans.  This review discusses the methods used to establish the appropriate signalling assays to test orphan receptor activity and provides current examples of structure-based methods used to identify ligands of orphan GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOIJS_m3tMZrVg90H21EOLACvtfcHk0lg-SMQvWImdRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1GntLY%253D&md5=e23548979b85261c420240d2fa1f0bd1</span></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1111%2Fbph.13452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13452%26sid%3Dliteratum%253Aachs%26aulast%3DNgo%26aufirst%3DT.%26aulast%3DKufareva%26aufirst%3DI.%26aulast%3DColeman%26aufirst%3DJ.%2BL.%26aulast%3DGraham%26aufirst%3DR.%2BM.%26aulast%3DAbagyan%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DN.%2BJ.%26atitle%3DIdentifying%2520ligands%2520at%2520orphan%2520GPCRs%253A%2520current%2520status%2520using%2520structure-based%2520approaches%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2016%26volume%3D173%26spage%3D2934%26epage%3D2951%26doi%3D10.1111%2Fbph.13452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Tang, X.-l.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.-l.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.-y.</span><span> </span><span class="NLM_article-title">Orphan G protein-coupled receptors (GPCRs): biological functions and potential drug targets</span> <span class="citation_source-journal">Acta Pharmacol. Sin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">363</span><span class="NLM_x">â</span> <span class="NLM_lpage">371</span><span class="refDoi">Â DOI: 10.1038/aps.2011.210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Faps.2011.210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=22367282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1eru7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=363-371&author=X.-l.+Tangauthor=Y.+Wangauthor=D.-l.+Liauthor=J.+Luoauthor=M.-y.+Liu&title=Orphan+G+protein-coupled+receptors+%28GPCRs%29%3A+biological+functions+and+potential+drug+targets&doi=10.1038%2Faps.2011.210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20cR"><div class="casContent"><span class="casTitleNuber">20c</span><div class="casTitle"><span class="NLM_cas:atitle">Orphan G protein-coupled receptors (GPCRs): biological functions and potential drug targets</span></div><div class="casAuthors">Tang, Xiao-long; Wang, Ying; Li, Da-li; Luo, Jian; Liu, Ming-yao</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">363-371</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The superfamily of G protein-coupled receptors (GPCRs) includes at least 800 seven-transmembrane receptors that participate in diverse physiol. and pathol. functions.  GPCRs are the most successful targets of modern medicine, and approx. 36% of marketed pharmaceuticals target human GPCRs.  However, the endogenous ligands of more than 140 GPCRs remain unidentified, leaving the natural functions of those GPCRs in doubt.  These are the so-called orphan GPCRs, a great source of drug targets.  This review focuses on the signaling transduction pathways of the adhesion GPCR family, the LGR subfamily, and the PSGR subfamily, and their potential functions in immunol., development, and cancers.  In this review, we present the current approaches and difficulties of orphan GPCR deorphanization and characterization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv4uhC3Ymv27Vg90H21EOLACvtfcHk0lg-SMQvWImdRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1eru7s%253D&md5=c4729d885e76813567c82321a5d8d93c</span></div><a href="/servlet/linkout?suffix=cit20c&amp;dbid=16384&amp;doi=10.1038%2Faps.2011.210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2011.210%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DX.-l.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DD.-l.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DM.-y.%26atitle%3DOrphan%2520G%2520protein-coupled%2520receptors%2520%2528GPCRs%2529%253A%2520biological%2520functions%2520and%2520potential%2520drug%2520targets%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2012%26volume%3D33%26spage%3D363%26epage%3D371%26doi%3D10.1038%2Faps.2011.210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Diller, D. J.</span><span> </span><span class="NLM_article-title">The synergy between combinatorial chemistry and high-throughput screening</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">346</span><span class="NLM_x">â</span> <span class="NLM_lpage">355</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=346-355&author=D.+J.+Diller&title=The+synergy+between+combinatorial+chemistry+and+high-throughput+screening"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDiller%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520synergy%2520between%2520combinatorial%2520chemistry%2520and%2520high-throughput%2520screening%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2008%26volume%3D11%26spage%3D346%26epage%3D355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kennedy, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniels, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span> </span><span class="NLM_article-title">Application of combinatorial chemistry science on modern drug discovery</span> <span class="citation_source-journal">J. Comb. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">â</span> <span class="NLM_lpage">354</span><span class="refDoi">Â DOI: 10.1021/cc700187t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cc700187t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFShsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=345-354&author=J.+P.+Kennedyauthor=L.+Williamsauthor=T.+M.+Bridgesauthor=R.+N.+Danielsauthor=D.+Weaverauthor=C.+W.+Lindsley&title=Application+of+combinatorial+chemistry+science+on+modern+drug+discovery&doi=10.1021%2Fcc700187t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Application of Combinatorial Chemistry Science on Modern Drug Discovery</span></div><div class="casAuthors">Kennedy, J. Phillip; Williams, Lyndsey; Bridges, Thomas M.; Daniels, R. Nathan; Weaver, David; Lindsley, Craig W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Combinatorial Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">345-354</span>CODEN:
                <span class="NLM_cas:coden">JCCHFF</span>;
        ISSN:<span class="NLM_cas:issn">1520-4766</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The science that established combinatorial chem. as important new discipline in the 1980s and 1990s, has reemerged and infiltrated every subdiscipline within modern drug discovery and has profound impact.  The application of combinatorial chem. science has revolutionized high-throughput screening paradigms, chem. lead optimization, library purifn. and postpurifn. sample handling, as well as in vitro and in vivo drug metab. and pharmacokinetic assays.  Although no longer in the spotlight and heralded as the savior of the drug industry, combinatorial chem. is alive and well: actually, combinatorial chem. science is more prevalent and widespread than ever before.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_FItqaRFGt7Vg90H21EOLACvtfcHk0lg-SMQvWImdRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFShsLo%253D&md5=b97fdb2d165b9b8645d773edf48d44fa</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1021%2Fcc700187t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcc700187t%26sid%3Dliteratum%253Aachs%26aulast%3DKennedy%26aufirst%3DJ.%2BP.%26aulast%3DWilliams%26aufirst%3DL.%26aulast%3DBridges%26aufirst%3DT.%2BM.%26aulast%3DDaniels%26aufirst%3DR.%2BN.%26aulast%3DWeaver%26aufirst%3DD.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DApplication%2520of%2520combinatorial%2520chemistry%2520science%2520on%2520modern%2520drug%2520discovery%26jtitle%3DJ.%2520Comb.%2520Chem.%26date%3D2008%26volume%3D10%26spage%3D345%26epage%3D354%26doi%3D10.1021%2Fcc700187t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Bononi, F. C.; Luyt, L. G.</span><span> </span><span class="NLM_article-title">Synthesis and cell-based screening of one-bead-one-compound peptide libraries</span>. In  <span class="citation_source-book">Peptide Libraries: Methods and Protocols</span>; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">223</span><span class="NLM_x">â</span> <span class="NLM_lpage">237</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1007%2F978-1-4939-2020-4_15" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=223-237&author=F.+C.+Bononi&author=L.+G.+Luyt&title=Peptide+Libraries%3A+Methods+and+Protocols"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21c&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-2020-4_15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4939-2020-4_15%26sid%3Dliteratum%253Aachs%26aulast%3DBononi%26aufirst%3DF.%2BC.%26atitle%3DSynthesis%2520and%2520cell-based%2520screening%2520of%2520one-bead-one-compound%2520peptide%2520libraries%26btitle%3DPeptide%2520Libraries%253A%2520Methods%2520and%2520Protocols%26pub%3DSpringer%26date%3D2015%26spage%3D223%26epage%3D237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Romanova, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweedler, J. V.</span><span> </span><span class="NLM_article-title">Peptidomics for the discovery and characterization of neuropeptides and hormones</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">579</span><span class="NLM_x">â</span> <span class="NLM_lpage">586</span><span class="refDoi">Â DOI: 10.1016/j.tips.2015.05.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.tips.2015.05.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26143240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFehsLzP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=579-586&author=E.+V.+Romanovaauthor=J.+V.+Sweedler&title=Peptidomics+for+the+discovery+and+characterization+of+neuropeptides+and+hormones&doi=10.1016%2Fj.tips.2015.05.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Peptidomics for the discovery and characterization of neuropeptides and hormones</span></div><div class="casAuthors">Romanova, Elena V.; Sweedler, Jonathan V.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">579-586</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The discovery of neuropeptides as signaling mols. with paracrine or hormonal regulatory functions has led to trailblazing advances in physiol. and fostered the characterization of numerous neuropeptide-binding G protein-coupled receptors (GPCRs) as potential drug targets.  The impact on human health has been tremendous: approx. 30% of com. drugs act via the GPCR pathway.  However, about 25% of the GPCRs encoded by the mammalian genome still lack their pharmacol. identity.  Searching for the orphan GPCR endogenous ligands that are likely to be neuropeptides has proved to be a formidable task.  Here we describe the mass spectrometry (MS)-based technologies and exptl. strategies that have been successful in achieving high-throughput characterization of endogenous peptides in nervous and endocrine systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplmYoFQ4F8bLVg90H21EOLACvtfcHk0liQLMdyg8dceQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFehsLzP&md5=c04cadcd53efaf5119598f6ae5175e0e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2015.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2015.05.009%26sid%3Dliteratum%253Aachs%26aulast%3DRomanova%26aufirst%3DE.%2BV.%26aulast%3DSweedler%26aufirst%3DJ.%2BV.%26atitle%3DPeptidomics%2520for%2520the%2520discovery%2520and%2520characterization%2520of%2520neuropeptides%2520and%2520hormones%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26spage%3D579%26epage%3D586%26doi%3D10.1016%2Fj.tips.2015.05.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Calcott, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ackerley, D. F.</span><span> </span><span class="NLM_article-title">Genetic manipulation of non-ribosomal peptide synthetases to generate novel bioactive peptide products</span> <span class="citation_source-journal">Biotechnol. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">2407</span><span class="NLM_x">â</span> <span class="NLM_lpage">2416</span><span class="refDoi">Â DOI: 10.1007/s10529-014-1642-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1007%2Fs10529-014-1642-y" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2014&pages=2407-2416&author=M.+J.+Calcottauthor=D.+F.+Ackerley&title=Genetic+manipulation+of+non-ribosomal+peptide+synthetases+to+generate+novel+bioactive+peptide+products&doi=10.1007%2Fs10529-014-1642-y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=10.1007%2Fs10529-014-1642-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10529-014-1642-y%26sid%3Dliteratum%253Aachs%26aulast%3DCalcott%26aufirst%3DM.%2BJ.%26aulast%3DAckerley%26aufirst%3DD.%2BF.%26atitle%3DGenetic%2520manipulation%2520of%2520non-ribosomal%2520peptide%2520synthetases%2520to%2520generate%2520novel%2520bioactive%2520peptide%2520products%26jtitle%3DBiotechnol.%2520Lett.%26date%3D2014%26volume%3D36%26spage%3D2407%26epage%3D2416%26doi%3D10.1007%2Fs10529-014-1642-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Walsh, C. T.</span><span> </span><span class="NLM_article-title">Insights into the chemical logic and enzymatic machinery of NRPS assembly lines</span> <span class="citation_source-journal">Nat. Prod. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">â</span> <span class="NLM_lpage">135</span><span class="refDoi">Â DOI: 10.1039/C5NP00035A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1039%2FC5NP00035A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26175103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOksrzK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2016&pages=127-135&author=C.+T.+Walsh&title=Insights+into+the+chemical+logic+and+enzymatic+machinery+of+NRPS+assembly+lines&doi=10.1039%2FC5NP00035A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23bR"><div class="casContent"><span class="casTitleNuber">23b</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the chemical logic and enzymatic machinery of NRPS assembly lines</span></div><div class="casAuthors">Walsh, Christopher T.</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-135</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Appreciation that some cyclic peptide antibiotics such as gramicidin S and tyrocidine were nonribosomally synthesized has been known for 50 years.  The past two decades of research including advances in bacterial genetics, genomics, protein biochem. and mass spectrometry have codified the principles of assembly line enzymol. for hundreds of nonribosomal peptides and in parallel for thousands of polyketides.  The advances in understanding the strategies used for chain initiation, elongation and termination from these assembly lines have revitalized natural product biosynthetic communities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6hcitSzuGibVg90H21EOLACvtfcHk0liQLMdyg8dceQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOksrzK&md5=cf3a39bd3ed87abb5924ede29aeb8397</span></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=10.1039%2FC5NP00035A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5NP00035A%26sid%3Dliteratum%253Aachs%26aulast%3DWalsh%26aufirst%3DC.%2BT.%26atitle%3DInsights%2520into%2520the%2520chemical%2520logic%2520and%2520enzymatic%2520machinery%2520of%2520NRPS%2520assembly%2520lines%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2016%26volume%3D33%26spage%3D127%26epage%3D135%26doi%3D10.1039%2FC5NP00035A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Jones, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span> </span><span class="NLM_article-title">Medicinal chemistry of glucagon-like peptide receptor agonists</span> <span class="citation_source-journal">Prog. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">45</span><span class="NLM_x">â</span> <span class="NLM_lpage">96</span><span class="refDoi">Â DOI: 10.1016/B978-0-444-62652-3.00002-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2FB978-0-444-62652-3.00002-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23384666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFGrsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=45-96&author=L.+H.+Jonesauthor=D.+A.+Price&title=Medicinal+chemistry+of+glucagon-like+peptide+receptor+agonists&doi=10.1016%2FB978-0-444-62652-3.00002-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of glucagon-like peptide receptor agonists</span></div><div class="casAuthors">Jones, Lyn H.; Price, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">45-96</span>CODEN:
                <span class="NLM_cas:coden">PMDCAY</span>;
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  This article discusses the medicinal chem. of glucagon-like peptide receptor agonists.  Applications of GLP-1 ligands as imaging agents in the diagnosis of diabetes and pancreatic cancer were discussed.  Fundamental principles of GLP-1 injectable peptides medicinal chem. design and synthesis were discussed.  The potential for alternative modes of drug delivery, such as oral and inhaled administration were discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5hCxobbsxyrVg90H21EOLACvtfcHk0liQLMdyg8dceQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFGrsbY%253D&md5=b92dcf4ab78d6faeab98a32c6b25c03c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FB978-0-444-62652-3.00002-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-444-62652-3.00002-8%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26atitle%3DMedicinal%2520chemistry%2520of%2520glucagon-like%2520peptide%2520receptor%2520agonists%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D52%26spage%3D45%26epage%3D96%26doi%3D10.1016%2FB978-0-444-62652-3.00002-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Miller, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harikumar, K. G.</span><span> </span><span class="NLM_article-title">The class B G-protein-coupled GLP-1 receptor: an important target for the treatment of type-2 diabetes mellitus</span> <span class="citation_source-journal">Int. J. Obes.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">S9</span><span class="NLM_x">â</span> <span class="NLM_lpage">S13</span><span class="refDoi">Â DOI: 10.1038/ijosup.2014.4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fijosup.2014.4" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=S9-S13&author=L.+J.+Millerauthor=P.+M.+Sextonauthor=M.+Dongauthor=K.+G.+Harikumar&title=The+class+B+G-protein-coupled+GLP-1+receptor%3A+an+important+target+for+the+treatment+of+type-2+diabetes+mellitus&doi=10.1038%2Fijosup.2014.4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1038%2Fijosup.2014.4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fijosup.2014.4%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DL.%2BJ.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DDong%26aufirst%3DM.%26aulast%3DHarikumar%26aufirst%3DK.%2BG.%26atitle%3DThe%2520class%2520B%2520G-protein-coupled%2520GLP-1%2520receptor%253A%2520an%2520important%2520target%2520for%2520the%2520treatment%2520of%2520type-2%2520diabetes%2520mellitus%26jtitle%3DInt.%2520J.%2520Obes.%26date%3D2014%26volume%3D4%26spage%3DS9%26epage%3DS13%26doi%3D10.1038%2Fijosup.2014.4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit25b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Christensen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miossec, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsen, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werner, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knop, F. K.</span><span> </span><span class="NLM_article-title">The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1223</span><span class="NLM_x">â</span> <span class="NLM_lpage">1251</span><span class="refDoi">Â DOI: 10.1517/17460441.2014.942638</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1517%2F17460441.2014.942638" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25119443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KhtLzN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1223-1251&author=M.+Christensenauthor=P.+Miossecauthor=B.+D.+Larsenauthor=U.+Wernerauthor=F.+K.+Knop&title=The+design+and+discovery+of+lixisenatide+for+the+treatment+of+type+2+diabetes+mellitus&doi=10.1517%2F17460441.2014.942638"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25bR"><div class="casContent"><span class="casTitleNuber">25b</span><div class="casTitle"><span class="NLM_cas:atitle">The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus</span></div><div class="casAuthors">Christensen, Mikkel; Miossec, Patrick; Larsen, Bjarne Due; Werner, Ulrich; Knop, Filip K.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1223-1251</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: Lixisenatide is a once-daily short-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) used in the treatment of type 2 diabetes mellitus (T2DM).  It is used in combination with oral antidiabetics and/or basal insulin in patients inadequately controlled on these medications and who are undergoing diet and lifestyle modification.  GLP-1RAs glucose-dependently increase insulin secretion, decrease glucagon secretion, and slow gastric emptying, thereby improving glycemic control.  GLP-1RAs are assocd. with body wt. benefits and low rates of hypoglycemia which are welcome in patients with T2DM.  Areas covered: The authors describe the identification of GLP-1RAs as suitable targets for modification with structure-inducing probe technol. to improve stability and resistance to proteolytic degrdn.  Clin. studies have assessed lixisenatide across > 5000 patients as a monotherapy or add-on to a variety of commonly used antidiabetic medications.  These studies highlighted the effects of lixisenatide on gastric emptying, explaining its particular improvements in postprandial plasma glucose (PPG) excursions and underscoring its efficacy in combination with insulin glargine.  Lixisenatide was well tolerated, with nausea and vomiting being the most frequently reported adverse events.  Expert opinion: The once-daily administration of lixisenatide as well as its substantial sustained effect on gastric emptying and, hence, PPG excursions are all important features compared with the other GLP-1RAs.  The combination of two injectables, such as basal insulin to lower fasting plasma glucose and a GLP-1RA that curtails PPG excursions, is clin. valuable and could differentiate lixisenatide from other GLP-1RAs, esp. from those continuously acting GLP-1RAs with little effect on gastric emptying and PPG excursions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW0IfTdZVP3bVg90H21EOLACvtfcHk0lgsleQf_HAVAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KhtLzN&md5=aaf08b96c53617d3044e56447ca8e7f1</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1517%2F17460441.2014.942638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2014.942638%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DM.%26aulast%3DMiossec%26aufirst%3DP.%26aulast%3DLarsen%26aufirst%3DB.%2BD.%26aulast%3DWerner%26aufirst%3DU.%26aulast%3DKnop%26aufirst%3DF.%2BK.%26atitle%3DThe%2520design%2520and%2520discovery%2520of%2520lixisenatide%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%2520mellitus%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2014%26volume%3D9%26spage%3D1223%26epage%3D1251%26doi%3D10.1517%2F17460441.2014.942638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit25c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Parkes, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mace, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trautmann, M. E.</span><span> </span><span class="NLM_article-title">Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">â</span> <span class="NLM_lpage">244</span><span class="refDoi">Â DOI: 10.1517/17460441.2013.741580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1517%2F17460441.2013.741580" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=219-244&author=D.+G.+Parkesauthor=K.+F.+Maceauthor=M.+E.+Trautmann&title=Discovery+and+development+of+exenatide%3A+the+first+antidiabetic+agent+to+leverage+the+multiple+benefits+of+the+incretin+hormone%2C+GLP-1&doi=10.1517%2F17460441.2013.741580"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25c&amp;dbid=16384&amp;doi=10.1517%2F17460441.2013.741580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2013.741580%26sid%3Dliteratum%253Aachs%26aulast%3DParkes%26aufirst%3DD.%2BG.%26aulast%3DMace%26aufirst%3DK.%2BF.%26aulast%3DTrautmann%26aufirst%3DM.%2BE.%26atitle%3DDiscovery%2520and%2520development%2520of%2520exenatide%253A%2520the%2520first%2520antidiabetic%2520agent%2520to%2520leverage%2520the%2520multiple%2520benefits%2520of%2520the%2520incretin%2520hormone%252C%2520GLP-1%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2013%26volume%3D8%26spage%3D219%26epage%3D244%26doi%3D10.1517%2F17460441.2013.741580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pawlikowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melen-Mucha, G.</span><span> </span><span class="NLM_article-title">Somatostatin analogs - from new molecules to new applications</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">608</span><span class="NLM_x">â</span> <span class="NLM_lpage">613</span><span class="refDoi">Â DOI: 10.1016/j.coph.2004.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.coph.2004.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=15525552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptl2ksbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=608-613&author=M.+Pawlikowskiauthor=G.+Melen-Mucha&title=Somatostatin+analogs+-+from+new+molecules+to+new+applications&doi=10.1016%2Fj.coph.2004.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26aR"><div class="casContent"><span class="casTitleNuber">26a</span><div class="casTitle"><span class="NLM_cas:atitle">Somatostatin analogs - from new molecules to new applications</span></div><div class="casAuthors">Pawlikowski, Marek; Melen-Mucha, Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">608-613</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Somatostatin (SST) was firstly discovered as a hypothalamic hormone inhibiting GH secretion.  Despite its broad inhibitory effects on both endocrine and exocrine secretions, natural SST has limited therapeutic potential owing to its short plasma half-life.  The synthesis of the first two metabolically stabilized and more potent SST analogs (octreotide and lanreotide) established the use of SST peptide therapy.  The discovery of the five SST receptor (sst1-5) subtypes in the 1990s further enhanced the understanding of the biol. roles of SST, created new therapeutic opportunities and highlighted the limitation of 'classical' SST analogs, which act mainly via receptor subtype 2 and are unable to reproduce all actions of native SST.  To diminish these limitations, new SST analogs highly selective for particular receptor subtypes, together with so-called 'universal' analogs acting on multiple receptor subtypes, have been developed.  These compds. have shown promise in preclin. studies and might further advance the use of SST analog therapy in the future.  The development of SST analogs coupled to radioisotopes or cytotoxic drugs, which allows the selective destruction of tumor cells overexpressing sst receptors, constitutes another field of progress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi8Cim_6Y8v7Vg90H21EOLACvtfcHk0lgsleQf_HAVAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptl2ksbc%253D&md5=39a5ade46af0e7a6c9d308e09772ee98</span></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2004.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2004.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DPawlikowski%26aufirst%3DM.%26aulast%3DMelen-Mucha%26aufirst%3DG.%26atitle%3DSomatostatin%2520analogs%2520-%2520from%2520new%2520molecules%2520to%2520new%2520applications%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2004%26volume%3D4%26spage%3D608%26epage%3D613%26doi%3D10.1016%2Fj.coph.2004.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ben-Shlomo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melmed, S.</span><span> </span><span class="NLM_article-title">Somatostatin agonists for treatment of acromegaly</span> <span class="citation_source-journal">Mol. Cell. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">286</span><span class="NLM_x">, </span> <span class="NLM_fpage">192</span><span class="NLM_x">â</span> <span class="NLM_lpage">198</span><span class="refDoi">Â DOI: 10.1016/j.mce.2007.11.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.mce.2007.11.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=18191325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtVSmt7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2008&pages=192-198&author=A.+Ben-Shlomoauthor=S.+Melmed&title=Somatostatin+agonists+for+treatment+of+acromegaly&doi=10.1016%2Fj.mce.2007.11.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">Somatostatin agonists for treatment of acromegaly</span></div><div class="casAuthors">Ben-Shlomo, Anat; Melmed, Shlomo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">192-198</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  The discovery of somatotropin-release inhibitory factor (SRIF) in hypothalamic ext. in 1970 led to the synthesis of the first somatostatin analog octreotide, discovery of five somatostatin receptor subtypes, and development of addnl. somatostatin receptor ligands (SRL) as pharmacotherapy for acromegaly and other neuroendocrine tumors.  Long-acting formulations of SRL (octreotide LAR Depot, lanreotide SR and lanreotide autogel) assure improved patient compliance with weekly up to monthly injections, and are commonly used as primary or adjuvant treatment of acromegaly.  We review SRL currently available, emphasizing long-acting compds. and their efficacy in controlling acromegaly.  Disease control is evaluated by biochem. markers, tumor shrinkage, and disease-symptom improvement balanced against drug-related side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoML_7sWXZCHbVg90H21EOLACvtfcHk0lgsleQf_HAVAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtVSmt7Y%253D&md5=52d3fb101d1e4ee7cd890c5c22b8537f</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2007.11.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2007.11.024%26sid%3Dliteratum%253Aachs%26aulast%3DBen-Shlomo%26aufirst%3DA.%26aulast%3DMelmed%26aufirst%3DS.%26atitle%3DSomatostatin%2520agonists%2520for%2520treatment%2520of%2520acromegaly%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2008%26volume%3D286%26spage%3D192%26epage%3D198%26doi%3D10.1016%2Fj.mce.2007.11.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit26c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Anthony, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freda, P. U.</span><span> </span><span class="NLM_article-title">From somatostatin to octreotide LAR: evolution of a somatostatin analogue</span> <span class="citation_source-journal">Curr. Med. Res. Opin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">2989</span><span class="NLM_x">â</span> <span class="NLM_lpage">2999</span><span class="refDoi">Â DOI: 10.1185/03007990903328959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1185%2F03007990903328959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=19842996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVCrsLvE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2009&pages=2989-2999&author=L.+Anthonyauthor=P.+U.+Freda&title=From+somatostatin+to+octreotide+LAR%3A+evolution+of+a+somatostatin+analogue&doi=10.1185%2F03007990903328959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26cR"><div class="casContent"><span class="casTitleNuber">26c</span><div class="casTitle"><span class="NLM_cas:atitle">From somatostatin to octreotide LAR: evolution of a somatostatin analogue</span></div><div class="casAuthors">Anthony, Lowell; Freda, Pamela U.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medical Research and Opinion</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2989-2999</span>CODEN:
                <span class="NLM_cas:coden">CMROCX</span>;
        ISSN:<span class="NLM_cas:issn">0300-7995</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review on 20 years of clin. experience with octreotide and its impact on quality of life in patients with acromegaly and gastroenteropancreatic neuroendocrine tumors.  Topics discussed include development of octreotide, and safety and tolerability of octreotide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKqEWc7Zw8XLVg90H21EOLACvtfcHk0lgzZislhn5Uzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVCrsLvE&md5=bccacb962c3f2c9699b872d51dc602f2</span></div><a href="/servlet/linkout?suffix=cit26c&amp;dbid=16384&amp;doi=10.1185%2F03007990903328959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1185%252F03007990903328959%26sid%3Dliteratum%253Aachs%26aulast%3DAnthony%26aufirst%3DL.%26aulast%3DFreda%26aufirst%3DP.%2BU.%26atitle%3DFrom%2520somatostatin%2520to%2520octreotide%2520LAR%253A%2520evolution%2520of%2520a%2520somatostatin%2520analogue%26jtitle%3DCurr.%2520Med.%2520Res.%2520Opin.%26date%3D2009%26volume%3D25%26spage%3D2989%26epage%3D2999%26doi%3D10.1185%2F03007990903328959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Moreau, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delavault, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumberg, J.</span><span> </span><span class="NLM_article-title">Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy</span> <span class="citation_source-journal">Clin. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1485</span><span class="NLM_x">â</span> <span class="NLM_lpage">1508</span><span class="refDoi">Â DOI: 10.1016/j.clinthera.2006.10.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.clinthera.2006.10.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=17157109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlartrzP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2006&pages=1485-1508&author=J.+P.+Moreauauthor=P.+Delavaultauthor=J.+Blumberg&title=Luteinizing+hormone-releasing+hormone+agonists+in+the+treatment+of+prostate+cancer%3A+a+review+of+their+discovery%2C+development%2C+and+place+in+therapy&doi=10.1016%2Fj.clinthera.2006.10.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy</span></div><div class="casAuthors">Moreau, Jacques-Pierre; Delavault, Patrick; Blumberg, Joelle</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1485-1508</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">A review.  Background: Early identification of the biol. activity of LH-releasing hormone (LHRH) paved the way for the synthesis of analogs with enhanced potency and biol. properties.  Early testing in animal models and humans provided insight into the potential clin. uses of these substances, and, within 10 years, LHRH-agonist therapy had become available for use in patients with advanced prostate cancer (PC).  Over time, the role of LHRH-agonist therapy has expanded to include use as part of multi-modal treatment regimens throughout the course of the disease.  Objectives: This article reviews the discovery and development of LHRH agonists and summarizes the clin. evidence for their efficacy in PC.  Methods: Relevant clin. studies were identified through searches of the English-language literature indexed on MEDLINE through May 2006.  The main search terms were prostate cancer and LHRH agonist.  Results: Results of the initial therapeutic trials of sustained-release depot formulations of LHRH agonists in patients with PC were reported in the mid-1980s, indicating that these agents were effective and well tolerated in improving clin. symptoms and producing medical castration.  Longer-term studies and subsequent meta-analyses of randomized controlled trials in patients with advanced PC found no significant differences in overall survival when single-therapy androgen suppression was achieved through the use of LHRH-agonist therapy or orchiectomy.  Randomized trials have reported significant improvements in disease-free and overall survival in patients with locally advanced or high-grade PC treated with LHRH agonists in addn. to radiotherapy.  Several prospective randomized trials have reported decreases in rates of pos. surgical margins with short-term (6 wk to 4 mo) neoadjuvant LHRH-agonist therapy in patients with stage T1 to T3a PC undergoing prostatectomy.  Definitive comparisons of immediate and delayed treatment in patients with biochem. relapse have not been reported.  However, the results of several studies suggest that immediate LHRH-agonist therapy (or orchiectomy) may improve the course of disease progression and survival.  The risks of long-term treatment (eg, osteoporosis; fracture; anabolic loss of muscle mass, with a tendency toward wt. gain) must be considered carefully in patients who are likely to receive chronic LHRH-agonist therapy.  Intermittent schedules have been developed to reduce the adverse effects assocd. with LHRH-agonist therapy; some reports support sparing effects on bone and muscle mass and relative improvements in toxicities during off-therapy periods, whereas others have documented continuing decreases in bone mineral d. (BMD), with the rate of bone loss highest during the early cycles of therapy.  Bisphosphonate therapy has been shown to increase BMD in patients with PC and may therefore be beneficial when overt symptoms of osteopenia or osteoporosis are present.  Conclusions: LHRH-agonist therapy has been the mainstay of treatment for advanced PC for >20 years.  Clin. evidence supports expanding use of these agents at an earlier stage of disease and as part of multimodal regimens that include radiotherapy.  There is a need for further study of the efficacy of adjuvant LHRH-agonist therapy along with prostatectomy, in patients with biochem. failure, in intermittent regimens, and in conjunction with cytotoxic therapies in late-stage disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryfexVq7F0orVg90H21EOLACvtfcHk0lgzZislhn5Uzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlartrzP&md5=c4c49dc2de5d38e8645948c219cbf219</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2006.10.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2006.10.018%26sid%3Dliteratum%253Aachs%26aulast%3DMoreau%26aufirst%3DJ.%2BP.%26aulast%3DDelavault%26aufirst%3DP.%26aulast%3DBlumberg%26aufirst%3DJ.%26atitle%3DLuteinizing%2520hormone-releasing%2520hormone%2520agonists%2520in%2520the%2520treatment%2520of%2520prostate%2520cancer%253A%2520a%2520review%2520of%2520their%2520discovery%252C%2520development%252C%2520and%2520place%2520in%2520therapy%26jtitle%3DClin.%2520Ther.%26date%3D2006%26volume%3D28%26spage%3D1485%26epage%3D1508%26doi%3D10.1016%2Fj.clinthera.2006.10.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit27b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rick, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Block, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schally, A. V.</span><span> </span><span class="NLM_article-title">Agonists of luteinizing hormone-releasing hormone in prostate cancer</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2237</span><span class="NLM_x">â</span> <span class="NLM_lpage">2247</span><span class="refDoi">Â DOI: 10.1517/14656566.2013.834328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1517%2F14656566.2013.834328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23984804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1WgtbnN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=2237-2247&author=F.+G.+Rickauthor=N.+L.+Blockauthor=A.+V.+Schally&title=Agonists+of+luteinizing+hormone-releasing+hormone+in+prostate+cancer&doi=10.1517%2F14656566.2013.834328"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27bR"><div class="casContent"><span class="casTitleNuber">27b</span><div class="casTitle"><span class="NLM_cas:atitle">Agonists of luteinizing hormone-releasing hormone in prostate cancer</span></div><div class="casAuthors">Rick, Ferenc G.; Block, Norman L.; Schally, Andrew V.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2237-2247</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Androgen deprivation therapy (ADT) has been the first-line std. of care for treating patients with hormone-sensitive advanced prostate cancer (PCa) for many decades.  The agonists of LH-releasing hormone (LHRH), also called gonadotropin-releasing hormone, are still the most frequently used form of medical ADT.  Areas covered: This article reviews the available data and most recent information concerning the use of LHRH agonists in advanced PCa.  This article also reviews the discovery and development of LHRH agonists and summarizes the clin. evidence for their efficacy in PCa.  Expert opinion: The introduction and application of agonists of LHRH has modernized and improved the treatment of advanced PCa.  The life-saving benefits of LHRH agonists are well established, yet underestimated.  Despite their efficacy, agonists of LHRH have several disadvantages or drawbacks including disease flare.  The approach to ADT has been recently further refined with the development of the LHRH antagonist degarelix.  Degarelix, a highly clin. effective third-generation LHRH antagonist, is currently available in most countries for therapy of advanced PCa.  This new drug offers attractive alternatives to LHRH agonists for treatment of advanced PCa.  A therapy for castration-resistant PCa based on a targeted cytotoxic analog of LHRH, AEZS-108, is also emerging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE14ksXam2ZrVg90H21EOLACvtfcHk0lgzZislhn5Uzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1WgtbnN&md5=9271598950ee269614ef11648349ba56</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1517%2F14656566.2013.834328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2013.834328%26sid%3Dliteratum%253Aachs%26aulast%3DRick%26aufirst%3DF.%2BG.%26aulast%3DBlock%26aufirst%3DN.%2BL.%26aulast%3DSchally%26aufirst%3DA.%2BV.%26atitle%3DAgonists%2520of%2520luteinizing%2520hormone-releasing%2520hormone%2520in%2520prostate%2520cancer%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2013%26volume%3D14%26spage%3D2237%26epage%3D2247%26doi%3D10.1517%2F14656566.2013.834328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Wilson, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vadakkadath Meethal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowen, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atwood, C. S.</span><span> </span><span class="NLM_article-title">Leuprolide acetate: a drug of diverse clinical applications</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1851</span><span class="NLM_x">â</span> <span class="NLM_lpage">1863</span><span class="refDoi">Â DOI: 10.1517/13543784.16.11.1851</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1517%2F13543784.16.11.1851" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=17970643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1aksb%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2007&pages=1851-1863&author=A.+C.+Wilsonauthor=S.+Vadakkadath+Meethalauthor=R.+L.+Bowenauthor=C.+S.+Atwood&title=Leuprolide+acetate%3A+a+drug+of+diverse+clinical+applications&doi=10.1517%2F13543784.16.11.1851"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Leuprolide acetate: A drug of diverse clinical applications</span></div><div class="casAuthors">Wilson, Andrea C.; Vadakkadath Meethal, Sivan; Bowen, Richard L.; Atwood, Craig S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1851-1863</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Leuprolide acetate is a synthetic nonapeptide that is a potent gonadotropin-releasing hormone receptor (GnRHR) agonist used for diverse clin. applications, including the treatment of prostate cancer, endometriosis, uterine fibroids, central precocious puberty and in vitro fertilization techniques.  As its basic mechanism of action, Leuprolide acetate suppresses gonadotrope secretion of LH and FSH that subsequently suppresses gonadal sex steroid prodn.  In addn., Leuprolide acetate is presently being tested for the treatment of Alzheimer's disease, polycystic ovary syndrome, functional bowel disease, short stature, premenstrual syndrome and even as an alternative for contraception.  Mounting evidence suggests that GnRH agonist suppression of serum gonadotropins may also be important in many of the clin. applications described above.  Moreover, the presence of GnRHR in a multitude of non-reproductive tissues including the recent discovery of GnRHR expression in the hippocampus and cortex of the human brain indicates that GnRH analogs such as Leuprolide acetate may also act directly via tissue GnRHRs to modulate (brain) function.  Thus, the mol. mechanisms underlying the therapeutic effect of GnRH analogs in the treatment of these diseases may be more complex than originally thought.  These observations also suggest that the potential uses of GnRH analogs in the modulation of GnRH signaling and treatment of disease has yet to be fully realized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzEd0mte-_6rVg90H21EOLACvtfcHk0liIWnLg_wNJbQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1aksb%252FI&md5=3e1f6242f7d6cbaaf9d32ccb3624f2ce</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1517%2F13543784.16.11.1851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.16.11.1851%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DA.%2BC.%26aulast%3DVadakkadath%2BMeethal%26aufirst%3DS.%26aulast%3DBowen%26aufirst%3DR.%2BL.%26aulast%3DAtwood%26aufirst%3DC.%2BS.%26atitle%3DLeuprolide%2520acetate%253A%2520a%2520drug%2520of%2520diverse%2520clinical%2520applications%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2007%26volume%3D16%26spage%3D1851%26epage%3D1863%26doi%3D10.1517%2F13543784.16.11.1851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jiang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stalewski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galyean, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dykert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schteingart, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broqua, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aebi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aubert, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semple, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinsanya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haigh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riviere, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trojnar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Junien, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivier, J. E.</span><span> </span><span class="NLM_article-title">GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">453</span><span class="NLM_x">â</span> <span class="NLM_lpage">467</span><span class="refDoi">Â DOI: 10.1021/jm0003900</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0003900" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD3cXoslKjs7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=453-467&author=G.+Jiangauthor=J.+Stalewskiauthor=R.+Galyeanauthor=J.+Dykertauthor=C.+Schteingartauthor=P.+Broquaauthor=A.+Aebiauthor=M.+L.+Aubertauthor=G.+Sempleauthor=P.+Robsonauthor=K.+Akinsanyaauthor=R.+Haighauthor=P.+Riviereauthor=J.+Trojnarauthor=J.+L.+Junienauthor=J.+E.+Rivier&title=GnRH+antagonists%3A+a+new+generation+of+long+acting+analogues+incorporating+p-ureido-phenylalanines+at+positions+5+and+6&doi=10.1021%2Fjm0003900"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29aR"><div class="casContent"><span class="casTitleNuber">29a</span><div class="casTitle"><span class="NLM_cas:atitle">GnRH Antagonists: A New Generation of Long Acting Analogues Incorporating p-Ureido-phenylalanines at Positions 5 and 6</span></div><div class="casAuthors">Jiang, Guangcheng; Stalewski, Jacek; Galyean, Robert; Dykert, John; Schteingart, Claudio; Broqua, Pierre; Aebi, Audrey; Aubert, Michel L.; Semple, Graeme; Robson, Peter; Akinsanya, Karen; Haigh, Robert; Riviere, Pierre; Trojnar, Jerzy; Junien, Jean Louis; Rivier, Jean E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">453-467</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of antagonists of gonadotropin-releasing hormone (GnRH) of the general formula Ac-D2Nal-D4Cpa-D3Pal-Ser-4Aph/4Amf(P)-D4Aph/D4Amf(Q)-Leu-ILys-Pro-DAla-NH2 was synthesized, characterized, and screened for duration of inhibition of LH release in a castrated male rat assay.  Selected analogs were tested in a reporter gene assay (IC50 and pA2) and an in vitro histamine release assay.  P and Q contain urea/carbamoyl functionalities designed to increase potential intra- and intermol. hydrogen bonding opportunities for structural stabilization and peptide/receptor interactions, resp.  These substitutions resulted in analogs with increased hydrophilicity and a lesser propensity to form gels in aq. soln. than azaline B [Ac-D2Nal-D4Cpa-D3Pal-Ser-4Aph(Atz)-D4Aph(Atz)-Leu-ILys-Pro-DAla-NH2; Atz = 3'-amino-1H-1',2',4'-triazol-5'-yl], and in some cases they resulted in a significant increase in duration of action after s.c. administration.  Ac-D2Nal-D4Cpa-D3Pal-Ser-4Aph(L-hydroorotyl)-D4Aph(carbamoyl)-Leu-ILys-Pro-DAla-NH2 (acetate salt is FE200486) (I) and eight other congeners (20, 35, 37, 39, 41, 45-47) were identified that exhibited significantly longer duration of action than acyline [Ac-D2Nal-D4Cpa-D3Pal-Ser-4Aph(Ac)-D4Aph(Ac)-Leu-ILys-Pro-DAla-NH2] (6) when administered s.c. in castrated male rats at a dose of 50 Î¼g in 100 Î¼L of phosphate buffer.  No correlation was found between retention times on a C18 reverse phase column using a triethylammonium phosphate buffer at pH 7.0 (a measure of hydrophilicity) or affinity in an in vitro human GnRH report gene assay (pA2) and duration of action.  I was selected for preclin. studies, and some of its properties were compared to those of other clin. candidates.  In the intact rat, ganirelix, abarelix, azaline B, and I inhibited plasma testosterone for 1, 1, 14, and 57 days, resp., at 2 mg/kg s.c. in 5% mannitol (injection vol. = 20 Î¼L).  Based on the information that I, 33, 35 and 37 were significantly shorter acting than acyline or azaline B after i.v. administration (100 Î¼g/rat), we surmised that the very long duration of action of the related I (for example) was likely due to unique physicochem. properties such as soly. in aq. milieu, comparatively low propensity to form gels, and ability to diffuse at high concns. in a manner similar to that described for slow release formulations of peptides.  Indeed, in rats injected s.c. with I (2 mg/kg), plasmatic concns. of I remained above 5 ng/mL until day 41, and the time after which they dropped below 3 ng/mL and plasma LH levels started rising until full recovery was reached at day 84 with levels of I hovering around 1 ng/mL.  Addnl., I was less potent at releasing histamine from isolated rat mast cells than any of the GnRH antagonists presently described in preclin. reports.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD63M9pimmB7Vg90H21EOLACvtfcHk0liIWnLg_wNJbQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXoslKjs7Y%253D&md5=f4a5d71fd83aac9d7a6b1a1b38936891</span></div><a href="/servlet/linkout?suffix=cit29a&amp;dbid=16384&amp;doi=10.1021%2Fjm0003900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0003900%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DG.%26aulast%3DStalewski%26aufirst%3DJ.%26aulast%3DGalyean%26aufirst%3DR.%26aulast%3DDykert%26aufirst%3DJ.%26aulast%3DSchteingart%26aufirst%3DC.%26aulast%3DBroqua%26aufirst%3DP.%26aulast%3DAebi%26aufirst%3DA.%26aulast%3DAubert%26aufirst%3DM.%2BL.%26aulast%3DSemple%26aufirst%3DG.%26aulast%3DRobson%26aufirst%3DP.%26aulast%3DAkinsanya%26aufirst%3DK.%26aulast%3DHaigh%26aufirst%3DR.%26aulast%3DRiviere%26aufirst%3DP.%26aulast%3DTrojnar%26aufirst%3DJ.%26aulast%3DJunien%26aufirst%3DJ.%2BL.%26aulast%3DRivier%26aufirst%3DJ.%2BE.%26atitle%3DGnRH%2520antagonists%253A%2520a%2520new%2520generation%2520of%2520long%2520acting%2520analogues%2520incorporating%2520p-ureido-phenylalanines%2520at%2520positions%25205%2520and%25206%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D453%26epage%3D467%26doi%3D10.1021%2Fjm0003900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit29b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Broqua, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riviere, P. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivier, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aubert, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Junien, J.-L.</span><span> </span><span class="NLM_article-title">Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: Degarelix</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">301</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="NLM_x">â</span> <span class="NLM_lpage">102</span><span class="refDoi">Â DOI: 10.1124/jpet.301.1.95</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1124%2Fjpet.301.1.95" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=11907162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1Kru74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=301&publication_year=2002&pages=95-102&author=P.+Broquaauthor=P.+J.+M.+Riviereauthor=P.+M.+Connauthor=J.+E.+Rivierauthor=M.+L.+Aubertauthor=J.-L.+Junien&title=Pharmacological+profile+of+a+new%2C+potent%2C+and+long-acting+gonadotropin-releasing+hormone+antagonist%3A+Degarelix&doi=10.1124%2Fjpet.301.1.95"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29bR"><div class="casContent"><span class="casTitleNuber">29b</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: Degarelix</span></div><div class="casAuthors">Broqua, Pierre; Riviere, Pierre J.-M.; Conn, P. Michael; Rivier, Jean E.; Aubert, Michel L.; Junien, Jean-Louis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">301</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">95-102</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The authors describe the pharmacol. profile in rats and monkeys of degarelix (FE200486), a member of a new class of long-acting gonadotropin-releasing hormone (GnRH) antagonists.  At single s.c. injections of 0.3 to 10 Î¼g/kg in rats, degarelix produced a dose-dependent suppression of the pituitary-gonadal axis as revealed by the decrease in plasma LH and testosterone levels.  Duration of LH suppression increased with the dose: in the rat, significant suppression of LH lasted 1, 2, and 7 days after a single s.c. injection of degarelix at 12.5, 50, or 200 Î¼g/kg, resp.  Degarelix fully suppressed plasma LH and testosterone levels in the castrated and intact rats as well as in the ovariectomized rhesus monkey for more than 40 days after a single 2-mg/kg s.c. injection.  In comparative expts., degarelix showed a longer duration of action than the recently developed GnRH antagonists abarelix, ganirelix, cetrorelix, and azaline B.  The in vivo mechanism of action of degarelix was consistent with competitive antagonism, and the prolonged action of degarelix was paralleled by continued presence of RIAable degarelix in the general circulation.  In contrast to cetrorelix and similarly to ganirelix and abarelix, degarelix had only weak histamine-releasing properties in vitro.  These results demonstrate that the unique and favorable pharmacol. properties of degarelix make it an ideal candidate for the management of sex steroid-dependent pathologies requiring long-term inhibition of the gonadotropic axis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYLP7FlkR7WbVg90H21EOLACvtfcHk0liIWnLg_wNJbQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1Kru74%253D&md5=48224902db9d7ce3d1c2c74a99869a52</span></div><a href="/servlet/linkout?suffix=cit29b&amp;dbid=16384&amp;doi=10.1124%2Fjpet.301.1.95&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.301.1.95%26sid%3Dliteratum%253Aachs%26aulast%3DBroqua%26aufirst%3DP.%26aulast%3DRiviere%26aufirst%3DP.%2BJ.%2BM.%26aulast%3DConn%26aufirst%3DP.%2BM.%26aulast%3DRivier%26aufirst%3DJ.%2BE.%26aulast%3DAubert%26aufirst%3DM.%2BL.%26aulast%3DJunien%26aufirst%3DJ.-L.%26atitle%3DPharmacological%2520profile%2520of%2520a%2520new%252C%2520potent%252C%2520and%2520long-acting%2520gonadotropin-releasing%2520hormone%2520antagonist%253A%2520Degarelix%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D301%26spage%3D95%26epage%3D102%26doi%3D10.1124%2Fjpet.301.1.95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Manning, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misicka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bankowski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoev, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chini, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durroux, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mouillac, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guillon, G.</span><span> </span><span class="NLM_article-title">Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics</span> <span class="citation_source-journal">J. Neuroendocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">609</span><span class="NLM_x">â</span> <span class="NLM_lpage">628</span><span class="refDoi">Â DOI: 10.1111/j.1365-2826.2012.02303.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1111%2Fj.1365-2826.2012.02303.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=22375852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsFKrtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2012&pages=609-628&author=M.+Manningauthor=A.+Misickaauthor=A.+Olmaauthor=K.+Bankowskiauthor=S.+Stoevauthor=B.+Chiniauthor=T.+Durrouxauthor=B.+Mouillacauthor=M.+Corbaniauthor=G.+Guillon&title=Oxytocin+and+vasopressin+agonists+and+antagonists+as+research+tools+and+potential+therapeutics&doi=10.1111%2Fj.1365-2826.2012.02303.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics</span></div><div class="casAuthors">Manning, M.; Misicka, A.; Olma, A.; Bankowski, K.; Stoev, S.; Chini, B.; Durroux, T.; Mouillac, B.; Corbani, M.; Guillon, G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroendocrinology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">609-628</span>CODEN:
                <span class="NLM_cas:coden">JOUNE2</span>;
        ISSN:<span class="NLM_cas:issn">0953-8194</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  We recently reviewed the status of peptide and nonpeptide agonists and antagonists for the V1a, V1b and V2 receptors for arginine vasopressin (AVP) and the oxytocin receptor for oxytocin (OT).  In the present review, we update the status of peptides and nonpeptides as: (i) research tools and (ii) therapeutic agents.  We also present our recent findings on the design of fluorescent ligands for V1b receptor localization and for OT receptor dimerization.  We note the exciting discoveries regarding 2 novel naturally occurring analogs of OT.  Recent reports of a selective VP V1a agonist and a selective OT agonist point to the continued therapeutic potential of peptides in this field.  To date, only 2 nonpeptides, the V2/V1a antagonist, conivaptan and the V2 antagonist tolvaptan have received Food and Drug Administration approval for clin. use.  The development of nonpeptide AVP V1a, V1b and V2 antagonists and OT agonists and antagonists has recently been abandoned by Merck, Sanofi and Pfizer.  A promising OT antagonist, Retosiban, developed at Glaxo SmithKline is currently in a Phase II clin. trial for the prevention of premature labour.  A no. of the nonpeptide ligands that were not successful in clin. trials are proving to be valuable as research tools.  Peptide agonists and antagonists continue to be very widely used as research tools in this field.  In this regard, we present receptor data on some of the most widely used peptide and nonpeptide ligands, as a guide for their use, esp. with regard to receptor selectivity and species differences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvboATX-Tv3rVg90H21EOLACvtfcHk0lhwTrHekhW9Qg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsFKrtrw%253D&md5=73b26be08e84e9daf8ac9136b472e6ad</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2826.2012.02303.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2826.2012.02303.x%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DM.%26aulast%3DMisicka%26aufirst%3DA.%26aulast%3DOlma%26aufirst%3DA.%26aulast%3DBankowski%26aufirst%3DK.%26aulast%3DStoev%26aufirst%3DS.%26aulast%3DChini%26aufirst%3DB.%26aulast%3DDurroux%26aufirst%3DT.%26aulast%3DMouillac%26aufirst%3DB.%26aulast%3DCorbani%26aufirst%3DM.%26aulast%3DGuillon%26aufirst%3DG.%26atitle%3DOxytocin%2520and%2520vasopressin%2520agonists%2520and%2520antagonists%2520as%2520research%2520tools%2520and%2520potential%2520therapeutics%26jtitle%3DJ.%2520Neuroendocrinol.%26date%3D2012%26volume%3D24%26spage%3D609%26epage%3D628%26doi%3D10.1111%2Fj.1365-2826.2012.02303.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">du Vigneaud, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ressler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swan, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katsoyannis, P. G.</span><span> </span><span class="NLM_article-title">The synthesis of oxytocin</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1954</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">3115</span><span class="NLM_x">â</span> <span class="NLM_lpage">3121</span><span class="refDoi">Â DOI: 10.1021/ja01641a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja01641a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADyaG2MXjt1WhsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1954&pages=3115-3121&author=V.+du+Vigneaudauthor=C.+Resslerauthor=J.+M.+Swanauthor=C.+W.+Robertsauthor=P.+G.+Katsoyannis&title=The+synthesis+of+oxytocin&doi=10.1021%2Fja01641a004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The synthesis of oxytocin</span></div><div class="casAuthors">du Vigneaud, Vincent; Ressler, Charlotte; Swan, John M.; Roberts, Carleton W.; Katsoyannis, Panayotis G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1954</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3115-21</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">cf. preceding abstrs.  Oxytocin was synthesized by methods previously described (loc. cit.).  The cryst. flavanates prepd. from the synthetic material and natural oxytocin, m. 182-7Â° and 181-5.5Â°, resp. (m.p. depends on the rate of heating), and both had the same cryst. form.  All comparisons indicate the identity of the synthetic and natural products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4ECACTHczrLVg90H21EOLACvtfcHk0lhwTrHekhW9Qg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG2MXjt1WhsA%253D%253D&md5=488bf76788489a14ea33c7f187d2ea7c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fja01641a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja01641a004%26sid%3Dliteratum%253Aachs%26aulast%3Ddu%2BVigneaud%26aufirst%3DV.%26aulast%3DRessler%26aufirst%3DC.%26aulast%3DSwan%26aufirst%3DJ.%2BM.%26aulast%3DRoberts%26aufirst%3DC.%2BW.%26aulast%3DKatsoyannis%26aufirst%3DP.%2BG.%26atitle%3DThe%2520synthesis%2520of%2520oxytocin%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1954%26volume%3D76%26spage%3D3115%26epage%3D3121%26doi%3D10.1021%2Fja01641a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span>Ferring Announces European Approval of New Room Temperature Stable Formulation of PABAL (Carbetocin); <span class="NLM_publisher-name">Ferring Pharmaceuticals</span>: <span class="NLM_publisher-loc">Saint-Prex, Switzerland</span>, April 7,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="https://www.ferring.com/en/media/press-releases/2015/pabal-new-formulation-eu-approval-7-apr-15/" class="extLink">https://www.ferring.com/en/media/press-releases/2015/pabal-new-formulation-eu-approval-7-apr-15/</a> (accessed January 17, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Ferring+Announces+European+Approval+of+New+Room+Temperature+Stable+Formulation+of+PABAL+%28Carbetocin%29%3B+Ferring+Pharmaceuticals%3A+Saint-Prex%2C+Switzerland%2C+April+7%2C+2015%3B+https%3A%2F%2Fwww.ferring.com%2Fen%2Fmedia%2Fpress-releases%2F2015%2Fpabal-new-formulation-eu-approval-7-apr-15%2F+%28accessed+January+17%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DFerring%2520Announces%2520European%2520Approval%2520of%2520New%2520Room%2520Temperature%2520Stable%2520Formulation%2520of%2520PABAL%2520%2528Carbetocin%2529%26pub%3DFerring%2520Pharmaceuticals%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Awan, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, T.</span><span> </span><span class="NLM_article-title">Biosynthesis of therapeutic natural products using synthetic biology</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x"> (</span><span class="NLM_issue">A</span><span class="NLM_x">) </span> <span class="NLM_fpage">96</span><span class="NLM_x">â</span> <span class="NLM_lpage">106</span><span class="refDoi">Â DOI: 10.1016/j.addr.2016.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.addr.2016.04.010" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2016&pages=96-106&issue=A&author=A.+R.+Awanauthor=W.+M.+Shawauthor=T.+Ellis&title=Biosynthesis+of+therapeutic+natural+products+using+synthetic+biology&doi=10.1016%2Fj.addr.2016.04.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2016.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2016.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DAwan%26aufirst%3DA.%2BR.%26aulast%3DShaw%26aufirst%3DW.%2BM.%26aulast%3DEllis%26aufirst%3DT.%26atitle%3DBiosynthesis%2520of%2520therapeutic%2520natural%2520products%2520using%2520synthetic%2520biology%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2016%26volume%3D105%26issue%3DA%26spage%3D96%26epage%3D106%26doi%3D10.1016%2Fj.addr.2016.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit33b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Marahiel, M. A.</span><span> </span><span class="NLM_article-title">Working outside the protein-synthesis rules: insights into non-ribosomal peptide synthesis</span> <span class="citation_source-journal">J. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">799</span><span class="NLM_x">â</span> <span class="NLM_lpage">807</span><span class="refDoi">Â DOI: 10.1002/psc.1183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fpsc.1183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=19827002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlOku7%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=799-807&author=M.+A.+Marahiel&title=Working+outside+the+protein-synthesis+rules%3A+insights+into+non-ribosomal+peptide+synthesis&doi=10.1002%2Fpsc.1183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33bR"><div class="casContent"><span class="casTitleNuber">33b</span><div class="casTitle"><span class="NLM_cas:atitle">Working outside the protein-synthesis rules: Insights into non-ribosomal peptide synthesis</span></div><div class="casAuthors">Marahiel, Mohamed A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">799-807</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Non-ribosomally synthesized microbial peptides show remarkable structural diversity and constitute a widespread class of the most potent antibiotics and other important pharmaceuticals that range from penicillin to the immunosuppressant cyclosporine.  They are assembled independent of the ribosome in a nucleic acid-independent way by a group of multimodular megaenzymes called non-ribosomal peptide synthetases.  These biosynthetic machineries rely not only on the 20 canonical amino acids, but also use several different building blocks, including D-configured- and Î²-amino acids, methylated, glycosylated and phosphorylated residues, heterocyclic elements and even fatty acid building blocks.  This structural diversity leads to a high d. of functional groups, which are often essential for the bioactivity.  Recent biochem. and structural studies on several non-ribosomal peptide synthetase assembly lines have substantially contributed to the understanding of the mol. mechanisms and dynamics of individual catalytic domains underlying substrate recognition and substrate shuffling among the different active sites as well as peptide bond formation and the regio- and stereoselective product release.  Copyright Â© 2009 European Peptide Society and John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnSCGxpNUutbVg90H21EOLACvtfcHk0lhwTrHekhW9Qg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlOku7%252FI&md5=1534b9333ce37cf1cdd650cb1699216f</span></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=10.1002%2Fpsc.1183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.1183%26sid%3Dliteratum%253Aachs%26aulast%3DMarahiel%26aufirst%3DM.%2BA.%26atitle%3DWorking%2520outside%2520the%2520protein-synthesis%2520rules%253A%2520insights%2520into%2520non-ribosomal%2520peptide%2520synthesis%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2009%26volume%3D15%26spage%3D799%26epage%3D807%26doi%3D10.1002%2Fpsc.1183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Smith, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romesberg, F. E.</span><span> </span><span class="NLM_article-title">Mechanism of action of the arylomycin antibiotics and effects of signal peptidase I inhibition</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5054</span><span class="NLM_x">â</span> <span class="NLM_lpage">5060</span><span class="refDoi">Â DOI: 10.1128/AAC.00785-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1128%2FAAC.00785-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=22802255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKiu7vI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=5054-5060&author=P.+A.+Smithauthor=F.+E.+Romesberg&title=Mechanism+of+action+of+the+arylomycin+antibiotics+and+effects+of+signal+peptidase+I+inhibition&doi=10.1128%2FAAC.00785-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action of the arylomycin antibiotics and effects of signal peptidase I inhibition</span></div><div class="casAuthors">Smith, Peter A.; Romesberg, Floyd E.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5054-5060</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Clin. approved antibiotics inhibit only a small no. of conserved pathways that are essential for bacterial viability, and the physiol. effects of inhibiting these pathways have been studied in great detail.  Likewise, characterizing the effects of candidate antibiotics that function via novel mechanisms of action is crit. for their development, which is of increasing importance due to the ever-growing problem of resistance.  The arylomycins are a novel class of natural-product antibiotics that act via the inhibition of type I signal peptidase (SPase), which is an essential enzyme that functions as part of the general secretory pathway and is not the target of any clin. deployed antibiotic.  Correspondingly, little is known about the effects of SPase inhibition or how bacteria may respond to mitigate the assocd. secretion stress.  Using genetically sensitized Escherichia coli and Staphylococcus aureus as model organisms, the authors examine the activity of arylomycin as a function of its concn., bacterial cell d., target expression levels, and bacterial growth phase.  The results reveal that the activity of the arylomycins results from an insufficient flux of proteins through the secretion pathway and the resulting mislocalization of proteins.  Interestingly, this has profoundly different effects on E. coli and S. aureus.  Finally, the authors examine the activity of arylomycin in combination with distinct classes of antibiotics and demonstrate that SPase inhibition results in synergistic sensitivity when combined with an aminoglycoside.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruG04r4q-hUrVg90H21EOLACvtfcHk0lgyJN3ZD6ihpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKiu7vI&md5=033578665bbd60aec3ef5222cfa8e5d3</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1128%2FAAC.00785-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00785-12%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DP.%2BA.%26aulast%3DRomesberg%26aufirst%3DF.%2BE.%26atitle%3DMechanism%2520of%2520action%2520of%2520the%2520arylomycin%2520antibiotics%2520and%2520effects%2520of%2520signal%2520peptidase%2520I%2520inhibition%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D5054%26epage%3D5060%26doi%3D10.1128%2FAAC.00785-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrios Steed, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romesberg, F.</span><span> </span><span class="NLM_article-title">Efforts toward broadening the spectrum of arylomycin antibiotic activity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5654</span><span class="NLM_x">â</span> <span class="NLM_lpage">5659</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2013.08.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.bmcl.2013.08.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24012184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVSktb7N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5654-5659&author=J.+Liuauthor=P.+A.+Smithauthor=D.+Barrios+Steedauthor=F.+Romesberg&title=Efforts+toward+broadening+the+spectrum+of+arylomycin+antibiotic+activity&doi=10.1016%2Fj.bmcl.2013.08.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Efforts toward broadening the spectrum of arylomycin antibiotic activity</span></div><div class="casAuthors">Liu, Jian; Smith, Peter A.; Steed, Danielle Barrios; Romesberg, Floyd</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5654-5659</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">New antibiotics are needed, and one source may be 'latent' antibiotics, natural products whose once broad-spectrum activity is currently limited by the evolution of resistance in nature.  We have identified a potential class of latent antibiotics, the arylomycins, which are lipopeptides with a C-terminal macrocycle that target signal peptidase and whose spectrum is limited by a resistance-conferring mutation in many bacteria.  Herein, we report the synthesis and evaluation of several arylomycin derivs., and demonstrate that both C-terminal homologation with a glycyl aldehyde and addn. of a pos. charge to the macrocycle increase the activity and spectrum of the arylomycin scaffold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppRqYx27wQcrVg90H21EOLACvtfcHk0lgyJN3ZD6ihpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVSktb7N&md5=afc1eb200a49c359f4a37df29f6656c0</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.08.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.08.026%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DP.%2BA.%26aulast%3DBarrios%2BSteed%26aufirst%3DD.%26aulast%3DRomesberg%26aufirst%3DF.%26atitle%3DEfforts%2520toward%2520broadening%2520the%2520spectrum%2520of%2520arylomycin%2520antibiotic%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5654%26epage%3D5659%26doi%3D10.1016%2Fj.bmcl.2013.08.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Ling, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peoples, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spoering, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engels, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conlon, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaberle, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epstein, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazarides, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steadman, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felix, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fetterman, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millett, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nitti, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zullo, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, K.</span><span> </span><span class="NLM_article-title">A new antibiotic kills pathogens without detectable resistance</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">517</span><span class="NLM_x">, </span> <span class="NLM_fpage">455</span><span class="NLM_x">â</span> <span class="NLM_lpage">459</span><span class="refDoi">Â DOI: 10.1038/nature14098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnature14098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25561178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOju7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=517&publication_year=2015&pages=455-459&author=L.+L.+Lingauthor=T.+Schneiderauthor=A.+J.+Peoplesauthor=A.+L.+Spoeringauthor=I.+Engelsauthor=B.+P.+Conlonauthor=A.+Muellerauthor=T.+F.+Schaberleauthor=D.+E.+Hughesauthor=S.+Epsteinauthor=M.+Jonesauthor=L.+Lazaridesauthor=V.+A.+Steadmanauthor=D.+R.+Cohenauthor=C.+R.+Felixauthor=K.+A.+Fettermanauthor=W.+P.+Millettauthor=A.+G.+Nittiauthor=A.+M.+Zulloauthor=C.+Chenauthor=K.+Lewis&title=A+new+antibiotic+kills+pathogens+without+detectable+resistance&doi=10.1038%2Fnature14098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A new antibiotic kills pathogens without detectable resistance</span></div><div class="casAuthors">Ling, Losee L.; Schneider, Tanja; Peoples, Aaron J.; Spoering, Amy L.; Engels, Ina; Conlon, Brian P.; Mueller, Anna; Schaberle, Till F.; Hughes, Dallas E.; Epstein, Slava; Jones, Michael; Lazarides, Linos; Steadman, Victoria A.; Cohen, Douglas R.; Felix, Cintia R.; Fetterman, K. Ashley; Millett, William P.; Nitti, Anthony G.; Zullo, Ashley M.; Chen, Chao; Lewis, Kim</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">517</span>
        (<span class="NLM_cas:issue">7535</span>),
    <span class="NLM_cas:pages">455-459</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Antibiotic resistance is spreading faster than the introduction of new compds. into clin. practice, causing a public health crisis.  Most antibiotics were produced by screening soil microorganisms, but this limited resource of cultivable bacteria was overmined by the 1960s.  Synthetic approaches to produce antibiotics have been unable to replace this platform.  Uncultured bacteria make up approx. 99% of all species in external environments, and are an untapped source of new antibiotics.  We developed several methods to grow uncultured organisms by cultivation in situ or by using specific growth factors.  Here we report a new antibiotic that we term teixobactin, discovered in a screen of uncultured bacteria.  Teixobactin inhibits cell wall synthesis by binding to a highly conserved motif of lipid II (precursor of peptidoglycan) and lipid III (precursor of cell wall teichoic acid).  We did not obtain any mutants of Staphylococcus aureus or Mycobacterium tuberculosis resistant to teixobactin.  The properties of this compd. suggest a path towards developing antibiotics that are likely to avoid development of resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV0hZrSZheoLVg90H21EOLACvtfcHk0lgyJN3ZD6ihpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOju7w%253D&md5=27e302d7d44a549a91aa52113c3b4ad8</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnature14098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14098%26sid%3Dliteratum%253Aachs%26aulast%3DLing%26aufirst%3DL.%2BL.%26aulast%3DSchneider%26aufirst%3DT.%26aulast%3DPeoples%26aufirst%3DA.%2BJ.%26aulast%3DSpoering%26aufirst%3DA.%2BL.%26aulast%3DEngels%26aufirst%3DI.%26aulast%3DConlon%26aufirst%3DB.%2BP.%26aulast%3DMueller%26aufirst%3DA.%26aulast%3DSchaberle%26aufirst%3DT.%2BF.%26aulast%3DHughes%26aufirst%3DD.%2BE.%26aulast%3DEpstein%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DM.%26aulast%3DLazarides%26aufirst%3DL.%26aulast%3DSteadman%26aufirst%3DV.%2BA.%26aulast%3DCohen%26aufirst%3DD.%2BR.%26aulast%3DFelix%26aufirst%3DC.%2BR.%26aulast%3DFetterman%26aufirst%3DK.%2BA.%26aulast%3DMillett%26aufirst%3DW.%2BP.%26aulast%3DNitti%26aufirst%3DA.%2BG.%26aulast%3DZullo%26aufirst%3DA.%2BM.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DLewis%26aufirst%3DK.%26atitle%3DA%2520new%2520antibiotic%2520kills%2520pathogens%2520without%2520detectable%2520resistance%26jtitle%3DNature%26date%3D2015%26volume%3D517%26spage%3D455%26epage%3D459%26doi%3D10.1038%2Fnature14098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Oppedijk, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breukink, E.</span><span> </span><span class="NLM_article-title">Hit âem where it hurts: the growing and structurally diverse family of peptides that target Lipid-II</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Biomembr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">1858</span><span class="NLM_x">, </span> <span class="NLM_fpage">947</span><span class="NLM_x">â</span> <span class="NLM_lpage">957</span><span class="refDoi">Â DOI: 10.1016/j.bbamem.2015.10.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.bbamem.2015.10.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26523408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKkt73F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1858&publication_year=2016&pages=947-957&author=S.+F.+Oppedijkauthor=N.+I.+Martinauthor=E.+Breukink&title=Hit+%E2%80%99em+where+it+hurts%3A+the+growing+and+structurally+diverse+family+of+peptides+that+target+Lipid-II&doi=10.1016%2Fj.bbamem.2015.10.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Hit 'em where it hurts: The growing and structurally diverse family of peptides that target lipid-II</span></div><div class="casAuthors">Oppedijk, Sabine F.; Martin, Nathaniel I.; Breukink, Eefjan</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Biomembranes</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1858</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">947-957</span>CODEN:
                <span class="NLM_cas:coden">BBBMBS</span>;
        ISSN:<span class="NLM_cas:issn">0005-2736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Understanding the mode of action of antibiotics is becoming more and more important in the time that microorganisms start to develop resistance.  One very well validated target of several classes of antibiotics is the peptidoglycan precursor lipid II.  In this review different classes of lipid II targeting antibiotics will be discussed in detail, including the lantibiotics, human invertebrate defensins and the recently discovered teixobactin.  By hitting bacteria where it hurts, at the level of lipid II, we expect to be able to develop efficient antibacterial agents in the future.  This article is part of a Special Issue entitled: Antimicrobial peptides edited by Karl Lohner and Kai Hilpert.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_3ekboMFuwLVg90H21EOLACvtfcHk0lixNSQqQhzIbQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKkt73F&md5=e9bca4c761fb140cc0704a397750db5e</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamem.2015.10.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamem.2015.10.024%26sid%3Dliteratum%253Aachs%26aulast%3DOppedijk%26aufirst%3DS.%2BF.%26aulast%3DMartin%26aufirst%3DN.%2BI.%26aulast%3DBreukink%26aufirst%3DE.%26atitle%3DHit%2520%25E2%2580%2599em%2520where%2520it%2520hurts%253A%2520the%2520growing%2520and%2520structurally%2520diverse%2520family%2520of%2520peptides%2520that%2520target%2520Lipid-II%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Biomembr.%26date%3D2016%26volume%3D1858%26spage%3D947%26epage%3D957%26doi%3D10.1016%2Fj.bbamem.2015.10.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">King, G. F.</span><span> </span><span class="NLM_article-title">Venoms as a platform for human drugs: translating toxins into therapeutics</span> <span class="citation_source-journal">Expert Opin. Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1469</span><span class="NLM_x">â</span> <span class="NLM_lpage">1484</span><span class="refDoi">Â DOI: 10.1517/14712598.2011.621940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1517%2F14712598.2011.621940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21939428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1ylsrjF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=1469-1484&author=G.+F.+King&title=Venoms+as+a+platform+for+human+drugs%3A+translating+toxins+into+therapeutics&doi=10.1517%2F14712598.2011.621940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Venoms as a platform for human drugs: translating toxins into therapeutics</span></div><div class="casAuthors">King, Glenn F.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1469-1484</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction:An extraordinarily diverse range of animals have evolved venoms for predation, defense, or competitor deterrence.  The major components of most venoms are peptides and proteins that are often protease-resistant due to their disulfide-rich architectures.  Some of these toxins have become valuable as pharmacol. tools and/or therapeutics due to their extremely high specificity and potency for particular mol. targets.  There are currently six FDA-approved drugs derived from venom peptides or proteins.  Areas covered:This article surveys the current pipeline of venom-derived therapeutics and critically examines the potential of peptide and protein drugs derived from venoms.  Emerging trends are identified, including an increasing industry focus on disulfide-rich venom peptides and the use of a broader array of mol. targets in order to develop venom-based therapeutics for treating a wider range of clin. conditions.  Expert opinion:Key tech. advances in combination with a renewed industry-wide focus on biologics have converged to provide a larger than ever pipeline of venom-derived therapeutics.  Disulfide-rich venom peptides obviate some of the traditional disadvantages of therapeutic peptides and some may be suitable for oral administration.  Moreover, some venom peptides can breach the blood brain barrier and translocate across cell membranes, which opens up the possibility of exploiting mol. targets not previously accessible to peptide drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoYClUIGUrZbVg90H21EOLACvtfcHk0lixNSQqQhzIbQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1ylsrjF&md5=4983d10289108fac346231191e6169f7</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1517%2F14712598.2011.621940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14712598.2011.621940%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DG.%2BF.%26atitle%3DVenoms%2520as%2520a%2520platform%2520for%2520human%2520drugs%253A%2520translating%2520toxins%2520into%2520therapeutics%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2011%26volume%3D11%26spage%3D1469%26epage%3D1484%26doi%3D10.1517%2F14712598.2011.621940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Koh, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kini, R. M.</span><span> </span><span class="NLM_article-title">From snake venom toxins to therapeutics--cardiovascular examples</span> <span class="citation_source-journal">Toxicon</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">497</span><span class="NLM_x">â</span> <span class="NLM_lpage">506</span><span class="refDoi">Â DOI: 10.1016/j.toxicon.2011.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.toxicon.2011.03.017" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2012&pages=497-506&author=C.+Y.+Kohauthor=R.+M.+Kini&title=From+snake+venom+toxins+to+therapeutics%2D%2Dcardiovascular+examples&doi=10.1016%2Fj.toxicon.2011.03.017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.toxicon.2011.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.toxicon.2011.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DKoh%26aufirst%3DC.%2BY.%26aulast%3DKini%26aufirst%3DR.%2BM.%26atitle%3DFrom%2520snake%2520venom%2520toxins%2520to%2520therapeutics--cardiovascular%2520examples%26jtitle%3DToxicon%26date%3D2012%26volume%3D59%26spage%3D497%26epage%3D506%26doi%3D10.1016%2Fj.toxicon.2011.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">McGivern, J. G.</span><span> </span><span class="NLM_article-title">Ziconotide: a review of its pharmacology and use in the treatment of pain</span> <span class="citation_source-journal">Neuropsychiatr. Dis. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">69</span><span class="NLM_x">â</span> <span class="NLM_lpage">85</span><span class="refDoi">Â DOI: 10.2147/nedt.2007.3.1.69</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.2147%2Fnedt.2007.3.1.69" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=19300539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmt12ksLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=69-85&author=J.+G.+McGivern&title=Ziconotide%3A+a+review+of+its+pharmacology+and+use+in+the+treatment+of+pain&doi=10.2147%2Fnedt.2007.3.1.69"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Ziconotide: a review of its pharmacology and use in the treatment of pain</span></div><div class="casAuthors">McGivern, Joseph G.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychiatric Disease and Treatment</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">69-85</span>CODEN:
                <span class="NLM_cas:coden">NDTEAZ</span>;
        ISSN:<span class="NLM_cas:issn">1176-6328</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press (NZ) Ltd.</span>)
        </div><div class="casAbstract">A review.  Ziconotide is a powerful analgesic drug that has a unique mechanism of action involving potent and selective block of N-type calcium channels, which control neurotransmission at many synapses.  The analgesic efficacy of ziconotide likely results from its ability to interrupt pain signaling at the level of the spinal cord.  Ziconotide is a peptidic drug and has been approved for the treatment of severe chronic pain in patients only when administered by the intrathecal route.  Importantly, prolonged administration of ziconotide does not lead to the development of addiction or tolerance.  The current review discusses the various studies that have addressed the in vitro biochem. and electrophysiol. actions of ziconotide as well as the numerous pre-clin. studies that were conducted to elucidate its antinociceptive mechanism of action in animals.  In addn., this review considers the pivotal Phase 3 (and other) clin. trials that were conducted in support of ziconotide's approval for the treatment of severe chronic pain and tries to offer some insights regarding the future discovery and development of newer analgesic drugs that would act by a similar mechanism to ziconotide but which might offer improved safety, tolerability and ease of use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHm-hL5lB7QrVg90H21EOLACvtfcHk0lixNSQqQhzIbQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmt12ksLY%253D&md5=83510a769b61bd52349d012015894f40</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.2147%2Fnedt.2007.3.1.69&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252Fnedt.2007.3.1.69%26sid%3Dliteratum%253Aachs%26aulast%3DMcGivern%26aufirst%3DJ.%2BG.%26atitle%3DZiconotide%253A%2520a%2520review%2520of%2520its%2520pharmacology%2520and%2520use%2520in%2520the%2520treatment%2520of%2520pain%26jtitle%3DNeuropsychiatr.%2520Dis.%2520Treat.%26date%3D2007%26volume%3D3%26spage%3D69%26epage%3D85%26doi%3D10.2147%2Fnedt.2007.3.1.69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Weiglmeier, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berkner, H.</span><span> </span><span class="NLM_article-title">Cure and curse: E. coli heat-stable enterotoxin and its receptor Guanylyl Cyclase C</span> <span class="citation_source-journal">Toxins</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">2213</span><span class="NLM_x">â</span> <span class="NLM_lpage">2229</span><span class="refDoi">Â DOI: 10.3390/toxins2092213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3390%2Ftoxins2092213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=22069681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFSqsrnP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=2213-2229&author=P.+R.+Weiglmeierauthor=P.+Roschauthor=H.+Berkner&title=Cure+and+curse%3A+E.+coli+heat-stable+enterotoxin+and+its+receptor+Guanylyl+Cyclase+C&doi=10.3390%2Ftoxins2092213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Cure and curse: E. coli heat-stable enterotoxin and its receptor guanylyl cyclase C</span></div><div class="casAuthors">Weiglmeier, Philipp R.; Roesch, Paul; Berkner, Hanna</div><div class="citationInfo"><span class="NLM_cas:title">Toxins</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2213-2229</span>CODEN:
                <span class="NLM_cas:coden">TOXIB7</span>;
        ISSN:<span class="NLM_cas:issn">2072-6651</span>.
    
            (<span class="NLM_cas:orgname">Molecular Diversity Preservation International</span>)
        </div><div class="casAbstract">A review.  Enterotoxigenic Escherichia coli (ETEC) assocd. diarrhea is responsible for roughly half a million deaths per yr, the majority taking place in developing countries.  The main agent responsible for these diseases is the bacterial heat-stable enterotoxin STa.  STa is secreted by ETEC and after secretion binds to the intestinal receptor guanylyl cyclase C (GC-C), thus triggering a signaling cascade that eventually leads to the release of electrolytes and water in the intestine.  Addnl., GC-C is a specific marker for colorectal carcinoma and STa is suggested to have an inhibitory effect on intestinal carcinogenesis.  To understand the conformational events involved in ligand binding to GC-C and to devise therapeutic strategies to treat both diarrheal diseases and colorectal cancer, it is paramount to obtain structural information on the receptor ligand system.  Here we summarize the currently available structural data and report on physiol. consequences of STa binding to GC-C in intestinal epithelia and colorectal carcinoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquGwHtDLUF97Vg90H21EOLACvtfcHk0lixNSQqQhzIbQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFSqsrnP&md5=81402bec18fad62a6708112ade868be5</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.3390%2Ftoxins2092213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Ftoxins2092213%26sid%3Dliteratum%253Aachs%26aulast%3DWeiglmeier%26aufirst%3DP.%2BR.%26aulast%3DRosch%26aufirst%3DP.%26aulast%3DBerkner%26aufirst%3DH.%26atitle%3DCure%2520and%2520curse%253A%2520E.%2520coli%2520heat-stable%2520enterotoxin%2520and%2520its%2520receptor%2520Guanylyl%2520Cyclase%2520C%26jtitle%3DToxins%26date%3D2010%26volume%3D2%26spage%3D2213%26epage%3D2229%26doi%3D10.3390%2Ftoxins2092213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hannig, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tchernychev, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurtz, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryant, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silos-Santiago, I.</span><span> </span><span class="NLM_article-title">Guanylate cyclase-C/cGMP: an emerging pathway in the regulation of visceral pain</span> <span class="citation_source-journal">Front. Mol. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">31</span><span class="refDoi">Â DOI: 10.3389/fnmol.2014.00031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3389%2Ffnmol.2014.00031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24795564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVaqs7fO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=31&author=G.+Hannigauthor=B.+Tchernychevauthor=C.+B.+Kurtzauthor=A.+P.+Bryantauthor=M.+G.+Currieauthor=I.+Silos-Santiago&title=Guanylate+cyclase-C%2FcGMP%3A+an+emerging+pathway+in+the+regulation+of+visceral+pain&doi=10.3389%2Ffnmol.2014.00031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42aR"><div class="casContent"><span class="casTitleNuber">42a</span><div class="casTitle"><span class="NLM_cas:atitle">Guanylate cyclase-C/cGMP: an emerging pathway in the regulation of visceral pain</span></div><div class="casAuthors">Hannig, Gerhard; Tchernychev, Boris; Kurtz, Caroline B.; Bryant, Alexander P.; Currie, Mark G.; Silos-Santiago, Inmaculada</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31/1-31/6, 6 pp.</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Activation of guanylate cyclase-C (GC-C) expressed predominantly on intestinal epithelial cells by guanylin, uroguanylin or the closely related GC-C agonist peptide, linaclotide, stimulates generation, and release of cyclic guanosine-3',5'-monophosphate (cGMP).  Evidence that the visceral analgesic effects of linaclotide are mediated by a novel, GC-C-dependent peripheral sensory mechanism was first demonstrated in animal models of visceral pain.  Subsequent studies with uroguanylin or linaclotide have confirmed the activation of a GC-C/cGMP pathway leading to increased submucosal cGMP mediated by cGMP efflux pumps, which modulates intestinal nociceptor function resulting in peripheral analgesia.  These effects can be reproduced by the addn. of exogenous cGMP and support a role for GC-C/cGMP signaling in the regulation of visceral sensation, a physiol. function that has not previously been linked to the GC-C/cGMP pathway.  Notably, targeting the GC-C/cGMP pathway for treatment of gastrointestinal pain and abdominal sensory symptoms has now been validated in the clinic.  In 2012, linaclotide was approved in the United States and European Union for the treatment of adult patients with irritable bowel syndrome with constipation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf5sDDAMWCV7Vg90H21EOLACvtfcHk0lhkiYXpgeZ3sw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVaqs7fO&md5=8485549bcaa6d0b9bf6d06caa78f70fc</span></div><a href="/servlet/linkout?suffix=cit42a&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2014.00031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2014.00031%26sid%3Dliteratum%253Aachs%26aulast%3DHannig%26aufirst%3DG.%26aulast%3DTchernychev%26aufirst%3DB.%26aulast%3DKurtz%26aufirst%3DC.%2BB.%26aulast%3DBryant%26aufirst%3DA.%2BP.%26aulast%3DCurrie%26aufirst%3DM.%2BG.%26aulast%3DSilos-Santiago%26aufirst%3DI.%26atitle%3DGuanylate%2520cyclase-C%252FcGMP%253A%2520an%2520emerging%2520pathway%2520in%2520the%2520regulation%2520of%2520visceral%2520pain%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2014%26volume%3D7%26spage%3D31%26doi%3D10.3389%2Ffnmol.2014.00031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit42b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rothstein, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedenberg, F. K.</span><span> </span><span class="NLM_article-title">Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2125</span><span class="NLM_x">â</span> <span class="NLM_lpage">2132</span><span class="refDoi">Â DOI: 10.1517/14656566.2013.833605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1517%2F14656566.2013.833605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24007408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyns7jL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=2125-2132&author=R.+D.+Rothsteinauthor=F.+K.+Friedenberg&title=Linaclotide%3A+a+novel+compound+for+the+treatment+of+irritable+bowel+syndrome+with+constipation&doi=10.1517%2F14656566.2013.833605"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42bR"><div class="casContent"><span class="casTitleNuber">42b</span><div class="casTitle"><span class="NLM_cas:atitle">Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation</span></div><div class="casAuthors">Rothstein, Robin D.; Friedenberg, Frank K.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2125-2132</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Irritable Bowel Syndrome with constipation (IBS-C) is assocd. with abdominal pain and infrequent spontaneous bowel movements.  Patients with Chronic Idiopathic Constipation do not have abdominal pain as a predominant symptom. represents a new class of medication approved in the USA for both of these common conditions.  Linaclotide is approved for IBS-C only in the EU.  The only other medication approved at this time for IBS-C is lubiprostone.  Areas covered: This review will cover the mechanism of action of linaclotide, and review the pivotal pre-clin. and clin. trials leading to its approval in 2012.  The indications, common side effects, and black box warnings listed for linaclotide are reviewed.  Expert opinion: Linaclotide is superior to placebo for the treatment of both IBS-C and Chronic Idiopathic Constipation.  The drug has minimal systemic bioavailability and a favorable safety profile.  For IBS-C, it is appropriate as a first-line prescription treatment.  For Chronic Idiopathic Constipation, osmotic or stimulant laxatives should be tried prior to using linaclotide due to their considerable lower cost.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2Z2gxC832MbVg90H21EOLACvtfcHk0lhkiYXpgeZ3sw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyns7jL&md5=a889e9cf2b6ffc4feb43885c24937b4b</span></div><a href="/servlet/linkout?suffix=cit42b&amp;dbid=16384&amp;doi=10.1517%2F14656566.2013.833605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2013.833605%26sid%3Dliteratum%253Aachs%26aulast%3DRothstein%26aufirst%3DR.%2BD.%26aulast%3DFriedenberg%26aufirst%3DF.%2BK.%26atitle%3DLinaclotide%253A%2520a%2520novel%2520compound%2520for%2520the%2520treatment%2520of%2520irritable%2520bowel%2520syndrome%2520with%2520constipation%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2013%26volume%3D14%26spage%3D2125%26epage%3D2132%26doi%3D10.1517%2F14656566.2013.833605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gould, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aboye, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camarero, J. A.</span><span> </span><span class="NLM_article-title">Cyclotides, a novel ultrastable polypeptide scaffold for drug discovery</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">4294</span><span class="NLM_x">â</span> <span class="NLM_lpage">4307</span><span class="refDoi">Â DOI: 10.2174/138161211798999438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.2174%2F138161211798999438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=22204428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFajtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=4294-4307&author=A.+Gouldauthor=Y.+Jiauthor=T.+L.+Aboyeauthor=J.+A.+Camarero&title=Cyclotides%2C+a+novel+ultrastable+polypeptide+scaffold+for+drug+discovery&doi=10.2174%2F138161211798999438"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43aR"><div class="casContent"><span class="casTitleNuber">43a</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclotides, a novel ultrastable polypeptide scaffold for drug discovery</span></div><div class="casAuthors">Gould, Andrew; Ji, Yanbin; Aboye, Teshome L.; Camarero, Julio A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">4294-4307</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cyclotides are a unique and growing family of backbone cyclized peptides that also contain a cystine knot motif built from six conserved cysteine residues.  This unique circular backbone topol. and knotted arrangement of three disulfide bonds makes them exceptionally stable to thermal, chem., and enzymic degrdn. compared to other peptides of similar size.  Aside from the conserved residues forming the cystine knot, cyclotides have been shown to have high variability in their sequences.  Consisting of over 160 known members, cyclotides have many biol. activities, ranging from anti-HIV, antimicrobial, hemolytic, and uterotonic capabilities; addnl., some cyclotides have been shown to have cell penetrating properties.  Originally discovered and isolated from plants, cyclotides can also be produced synthetically and recombinantly.  The high sequence variability, stability, and cell penetrating properties of cyclotides make them potential scaffolds to be used to graft known active peptides or engineer peptide-based drug design.  The present review reports recent findings in the biol. diversity and therapeutic potential of natural and engineered cyclotides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3vE5jX-h3mLVg90H21EOLACvtfcHk0lhkiYXpgeZ3sw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFajtw%253D%253D&md5=55e37d4ffa802af0af3c47ad7f87789c</span></div><a href="/servlet/linkout?suffix=cit43a&amp;dbid=16384&amp;doi=10.2174%2F138161211798999438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161211798999438%26sid%3Dliteratum%253Aachs%26aulast%3DGould%26aufirst%3DA.%26aulast%3DJi%26aufirst%3DY.%26aulast%3DAboye%26aufirst%3DT.%2BL.%26aulast%3DCamarero%26aufirst%3DJ.%2BA.%26atitle%3DCyclotides%252C%2520a%2520novel%2520ultrastable%2520polypeptide%2520scaffold%2520for%2520drug%2520discovery%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2011%26volume%3D17%26spage%3D4294%26epage%3D4307%26doi%3D10.2174%2F138161211798999438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit43b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Weidmann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craik, D. J.</span><span> </span><span class="NLM_article-title">Discovery, structure, function, and applications of cyclotides: circular proteins from plants</span> <span class="citation_source-journal">J. Exp. Bot.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">4801</span><span class="NLM_x">â</span> <span class="NLM_lpage">4812</span><span class="refDoi">Â DOI: 10.1093/jxb/erw210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1093%2Fjxb%2Ferw210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=27222514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVejs7fN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2016&pages=4801-4812&author=J.+Weidmannauthor=D.+J.+Craik&title=Discovery%2C+structure%2C+function%2C+and+applications+of+cyclotides%3A+circular+proteins+from+plants&doi=10.1093%2Fjxb%2Ferw210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43bR"><div class="casContent"><span class="casTitleNuber">43b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery, structure, function, and applications of cyclotides: circular proteins from plants</span></div><div class="casAuthors">Weidmann, Joachim; Craik, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Botany</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4801-4812</span>CODEN:
                <span class="NLM_cas:coden">JEBOA6</span>;
        ISSN:<span class="NLM_cas:issn">0022-0957</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Cyclotides are plant-derived cyclic peptides that have a head-to-tail cyclic backbone and three conserved disulfide bonds that form a cyclic cystine knot motif.  They occur in plants from the Violaceae, Rubiaceae, Cucurbitaceae, Fabaceae, and Solanaceae families, typically with 10-100 cyclotides in a given plant species, in a wide range of tissues, including flowers, leaves, stems, and roots.  Some cyclotides are expressed in large amts. (up to 1 g kg-1 wet plant wt.) and their natural function appears to be to protect plants from pests or pathogens.  This article provides a brief overview of their discovery, distribution in plants, and applications.  In particular, their exceptional stability has led to their use as peptide-based scaffolds in drug design applications.  They also have potential as natural 'ecofriendly' insecticides, and as protein engineering frameworks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBo8spGvpjBLVg90H21EOLACvtfcHk0lhkiYXpgeZ3sw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVejs7fN&md5=8c19fd65c9ed60014107edce7789b81a</span></div><a href="/servlet/linkout?suffix=cit43b&amp;dbid=16384&amp;doi=10.1093%2Fjxb%2Ferw210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjxb%252Ferw210%26sid%3Dliteratum%253Aachs%26aulast%3DWeidmann%26aufirst%3DJ.%26aulast%3DCraik%26aufirst%3DD.%2BJ.%26atitle%3DDiscovery%252C%2520structure%252C%2520function%252C%2520and%2520applications%2520of%2520cyclotides%253A%2520circular%2520proteins%2520from%2520plants%26jtitle%3DJ.%2520Exp.%2520Bot.%26date%3D2016%26volume%3D67%26spage%3D4801%26epage%3D4812%26doi%3D10.1093%2Fjxb%2Ferw210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Wong, C. T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlands, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, T. W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, G. K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, J. P.</span><span> </span><span class="NLM_article-title">Orally active peptidic bradykinin B1 receptor antagonists engineered from a cyclotide scaffold for inflammatory pain treatment</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5620</span><span class="NLM_x">â</span> <span class="NLM_lpage">5624</span><span class="refDoi">Â DOI: 10.1002/anie.201200984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fanie.201200984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtFersrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=5620-5624&author=C.+T.+T.+Wongauthor=D.+K.+Rowlandsauthor=C.-H.+Wongauthor=T.+W.+C.+Loauthor=G.+K.+T.+Nguyenauthor=H.-Y.+Liauthor=J.+P.+Tam&title=Orally+active+peptidic+bradykinin+B1+receptor+antagonists+engineered+from+a+cyclotide+scaffold+for+inflammatory+pain+treatment&doi=10.1002%2Fanie.201200984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Orally Active Peptidic Bradykinin B1 Receptor Antagonists Engineered from a Cyclotide Scaffold for Inflammatory Pain Treatment</span></div><div class="casAuthors">Wong, Clarence T. T.; Rowlands, Dewi K.; Wong, Chi-Hang; Lo, Theodore W. C.; Nguyen, Giang K. T.; Li, Hoi-Yeung; Tam, James P.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5620-5624, S5620/1-S5620/11</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The authors have successfully demonstrated that the cyclotide kalata B1 could provide a superior natural scaffold for engineering orally active peptides as potentially useful therapeutics.  The grafting of BK-antagonist peptides DALK or DAK into the kalata B1 scaffold were performed, and the stability was enhanced substantially.  Measurements of the intracellular Ca2+ level revealed that two of the designed cyclic antagonists are specific blockers for the bradykinin B1 receptor, but not for B2.  In vivo abdominal constriction assay showed significant inhibition of pain response in the animal model under i.p. administration, only the cyclic analogs were able to inhibit the writhing action, whereas the linear analogs as well as the DALK peptide itself showed poor or no inhibition, resp.  It appears that the cystine-knot constraint of the linear kb-kin also produces effect after p.o. administration, but the combination of cyclization and the cystine-knot constraint produces a stronger effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqOSACe3s0MbVg90H21EOLACvtfcHk0lgvAFF70LwLwA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtFersrg%253D&md5=5d82f4274df7542e49cb41df2555e573</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fanie.201200984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201200984%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DC.%2BT.%2BT.%26aulast%3DRowlands%26aufirst%3DD.%2BK.%26aulast%3DWong%26aufirst%3DC.-H.%26aulast%3DLo%26aufirst%3DT.%2BW.%2BC.%26aulast%3DNguyen%26aufirst%3DG.%2BK.%2BT.%26aulast%3DLi%26aufirst%3DH.-Y.%26aulast%3DTam%26aufirst%3DJ.%2BP.%26atitle%3DOrally%2520active%2520peptidic%2520bradykinin%2520B1%2520receptor%2520antagonists%2520engineered%2520from%2520a%2520cyclotide%2520scaffold%2520for%2520inflammatory%2520pain%2520treatment%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2012%26volume%3D51%26spage%3D5620%26epage%3D5624%26doi%3D10.1002%2Fanie.201200984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Escano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, L.</span><span> </span><span class="NLM_article-title">Multipronged approach for engineering novel peptide analogues of existing lantibiotics</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">857</span><span class="NLM_x">â</span> <span class="NLM_lpage">870</span><span class="refDoi">Â DOI: 10.1517/17460441.2015.1049527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1517%2F17460441.2015.1049527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26004576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Wnu73P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=857-870&author=J.+Escanoauthor=L.+Smith&title=Multipronged+approach+for+engineering+novel+peptide+analogues+of+existing+lantibiotics&doi=10.1517%2F17460441.2015.1049527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45aR"><div class="casContent"><span class="casTitleNuber">45a</span><div class="casTitle"><span class="NLM_cas:atitle">Multipronged approach for engineering novel peptide analogues of existing lantibiotics</span></div><div class="casAuthors">Escano, Jerome; Smith, Leif</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">857-870</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Lantibiotics are a class of ribosomally and post-translationally modified peptide antibiotics that are active against a broad spectrum of Gram-pos. bacteria.  Great efforts have been made to promote the prodn. of these antibiotics, so that they can one day be used in our antimicrobial arsenal to combat multidrug-resistant bacterial infections.  Areas covered: This review provides a synopsis of lantibiotic research aimed at furthering our understanding of the structural limitation of lantibiotics as well as identifying structural regions that can be modified to improve the bioactivity.  In vivo, in vitro and chem. synthesis of lantibiotics has been useful for engineering novel variants with enhanced activities.  These approaches have provided novel ways to further our understanding of lantibiotic function and have advanced the objective to develop lantibiotics for the treatment of infectious diseases.  Expert opinion: Synthesis of lantibiotics with enhanced activities will lead to the discovery of new promising drug candidates that will have a long lasting impact on the treatment of Gram-pos. infections.  The current body of literature for producing structural variants of lantibiotics has been more of a 'proof-of-principle' approach and the application of these methods has not yet been fully utilized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokKrEl_es0zrVg90H21EOLACvtfcHk0lgvAFF70LwLwA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Wnu73P&md5=07e6d35e5e405261be79c2246494629c</span></div><a href="/servlet/linkout?suffix=cit45a&amp;dbid=16384&amp;doi=10.1517%2F17460441.2015.1049527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2015.1049527%26sid%3Dliteratum%253Aachs%26aulast%3DEscano%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DL.%26atitle%3DMultipronged%2520approach%2520for%2520engineering%2520novel%2520peptide%2520analogues%2520of%2520existing%2520lantibiotics%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2015%26volume%3D10%26spage%3D857%26epage%3D870%26doi%3D10.1517%2F17460441.2015.1049527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit45b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Field, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cotter, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, R. P.</span><span> </span><span class="NLM_article-title">Bioengineering lantibiotics for therapeutic success</span> <span class="citation_source-journal">Front. Microbiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1363</span><span class="refDoi">Â DOI: 10.3389/fmicb.2015.01363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3389%2Ffmicb.2015.01363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26640466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A280%3ADC%252BC28rhtVSqtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1363&author=D.+Fieldauthor=P.+D.+Cotterauthor=C.+Hillauthor=R.+P.+Ross&title=Bioengineering+lantibiotics+for+therapeutic+success&doi=10.3389%2Ffmicb.2015.01363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45bR"><div class="casContent"><span class="casTitleNuber">45b</span><div class="casTitle"><span class="NLM_cas:atitle">Bioengineering Lantibiotics for Therapeutic Success</span></div><div class="casAuthors">Field Des; Cotter Paul D; Ross R P; Hill Colin</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in microbiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1363</span>
        ISSN:<span class="NLM_cas:issn">1664-302X</span>.
    </div><div class="casAbstract">Several examples of highly modified antimicrobial peptides have been described.  While many such peptides are non-ribosomally synthesized, ribosomally synthesized equivalents are being discovered with increased frequency.  Of the latter group, the lantibiotics continue to attract most attention.  In the present review, we discuss the implementation of in vivo and in vitro engineering systems to alter, and even enhance, the antimicrobial activity, antibacterial spectrum and physico-chemical properties, including heat stability, solubility, diffusion and protease resistance, of these compounds.  Additionally, we discuss the potential applications of these lantibiotics for use as therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQAG7TrSNZQzC6Ufuk_1xoTfW6udTcc2eb_p2XW1Sq5-Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rhtVSqtA%253D%253D&md5=85c31de65a481776745c90c3cf25c518</span></div><a href="/servlet/linkout?suffix=cit45b&amp;dbid=16384&amp;doi=10.3389%2Ffmicb.2015.01363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmicb.2015.01363%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DD.%26aulast%3DCotter%26aufirst%3DP.%2BD.%26aulast%3DHill%26aufirst%3DC.%26aulast%3DRoss%26aufirst%3DR.%2BP.%26atitle%3DBioengineering%2520lantibiotics%2520for%2520therapeutic%2520success%26jtitle%3DFront.%2520Microbiol.%26date%3D2015%26volume%3D6%26spage%3D1363%26doi%3D10.3389%2Ffmicb.2015.01363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit45c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Sandiford, S. K.</span><span> </span><span class="NLM_article-title">Advances in the arsenal of tools available enabling the discovery of novel lantibiotics with therapeutic potential</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">â</span> <span class="NLM_lpage">297</span><span class="refDoi">Â DOI: 10.1517/17460441.2014.877882</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1517%2F17460441.2014.877882" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=283-297&author=S.+K.+Sandiford&title=Advances+in+the+arsenal+of+tools+available+enabling+the+discovery+of+novel+lantibiotics+with+therapeutic+potential&doi=10.1517%2F17460441.2014.877882"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45c&amp;dbid=16384&amp;doi=10.1517%2F17460441.2014.877882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2014.877882%26sid%3Dliteratum%253Aachs%26aulast%3DSandiford%26aufirst%3DS.%2BK.%26atitle%3DAdvances%2520in%2520the%2520arsenal%2520of%2520tools%2520available%2520enabling%2520the%2520discovery%2520of%2520novel%2520lantibiotics%2520with%2520therapeutic%2520potential%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2014%26volume%3D9%26spage%3D283%26epage%3D297%26doi%3D10.1517%2F17460441.2014.877882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Kluskens, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelemans, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rink, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vries, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meter-Arkema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walther, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuipers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moll, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haas, M.</span><span> </span><span class="NLM_article-title">Angiotensin-(1â7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1â7) analog</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">328</span><span class="NLM_x">, </span> <span class="NLM_fpage">849</span><span class="NLM_x">â</span> <span class="NLM_lpage">854</span><span class="refDoi">Â DOI: 10.1124/jpet.108.146431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1124%2Fjpet.108.146431" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=19038778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD1MXislalsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=328&publication_year=2009&pages=849-854&author=L.+D.+Kluskensauthor=S.+A.+Nelemansauthor=R.+Rinkauthor=L.+de+Vriesauthor=A.+Meter-Arkemaauthor=Y.+Wangauthor=T.+Waltherauthor=A.+Kuipersauthor=G.+N.+Mollauthor=M.+Haas&title=Angiotensin-%281%E2%80%937%29+with+thioether+bridge%3A+an+angiotensin-converting+enzyme-resistant%2C+potent+angiotensin-%281%E2%80%937%29+analog&doi=10.1124%2Fjpet.108.146431"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin-(1-7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analog</span></div><div class="casAuthors">Kluskens, Leon D.; Nelemans, S. Adriaan; Rink, Rick; de Vries, Louwe; Meter-Arkema, Anita; Wang, Yong; Walther, Thomas; Kuipers, Anneke; Moll, Gert N.; Haas, Marijke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">328</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">849-854</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The in vivo efficacy of many therapeutic peptides is hampered by their rapid proteolytic degrdn.  Cyclization of these therapeutic peptides is an excellent way to render them more resistant against breakdown.  Here, the authors describe the enzymic introduction of a thioether ring in angiotensin [Ang-(1-7)], a heptapeptide that plays a pivotal role in the renin-angiotensin system and possesses important therapeutic activities.  The lactic acid bacterium Lactococcus lactis, equipped with the plasmid-based nisin modification machinery, was used to produce thioether-bridged Ang-(1-7).  The resulting cyclized Ang-(1-7) is fully resistant against purified angiotensin-converting enzyme, has significantly increased stability in homogenates of different organs and in plasma derived from pig, and displays a strongly (34-fold) enhanced survival in Sprague-Dawley (SD) rats in vivo.  With respect to functional activity, cyclized Ang-(1-7) induces relaxation of precontracted SD rat aorta rings in vitro.  The magnitude of this effect is 2-fold larger than that obtained for natural Ang-(1-7).  The Ang-(1-7) receptor antagonist D-Pro7-Ang-(1-7), which completely inhibits the activity of natural Ang-(1-7), also abolishes the vasodilation by cyclized Ang-(1-7), providing evidence that cyclized Ang-(1-7) also interacts with the Ang-(1-7) receptor.  Taken together, applying a highly innovative enzymic peptide stabilization method, the authors generated a stable Ang-(1-7) analog with strongly enhanced therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJL6fTWkJn_rVg90H21EOLACvtfcHk0ljqDAgFGNbRqA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXislalsL8%253D&md5=21446837fe878e78712e578cfa85c060</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.146431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.146431%26sid%3Dliteratum%253Aachs%26aulast%3DKluskens%26aufirst%3DL.%2BD.%26aulast%3DNelemans%26aufirst%3DS.%2BA.%26aulast%3DRink%26aufirst%3DR.%26aulast%3Dde%2BVries%26aufirst%3DL.%26aulast%3DMeter-Arkema%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWalther%26aufirst%3DT.%26aulast%3DKuipers%26aufirst%3DA.%26aulast%3DMoll%26aufirst%3DG.%2BN.%26aulast%3DHaas%26aufirst%3DM.%26atitle%3DAngiotensin-%25281%25E2%2580%25937%2529%2520with%2520thioether%2520bridge%253A%2520an%2520angiotensin-converting%2520enzyme-resistant%252C%2520potent%2520angiotensin-%25281%25E2%2580%25937%2529%2520analog%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D328%26spage%3D849%26epage%3D854%26doi%3D10.1124%2Fjpet.108.146431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Saghatelian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Couso, J. P.</span><span> </span><span class="NLM_article-title">Discovery and characterization of smORF-encoded bioactive polypeptides</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">909</span><span class="NLM_x">â</span> <span class="NLM_lpage">916</span><span class="refDoi">Â DOI: 10.1038/nchembio.1964</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnchembio.1964" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26575237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVOgtrnI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=909-916&author=A.+Saghatelianauthor=J.+P.+Couso&title=Discovery+and+characterization+of+smORF-encoded+bioactive+polypeptides&doi=10.1038%2Fnchembio.1964"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47aR"><div class="casContent"><span class="casTitleNuber">47a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and characterization of smORF-encoded bioactive polypeptides</span></div><div class="casAuthors">Saghatelian, Alan; Couso, Juan Pablo</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">909-916</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Anal. of genomes, transcriptomes and proteomes reveals the existence of hundreds to thousands of translated, yet non-annotated, short open reading frames (small ORFs or smORFs).  The discovery of smORFs and their protein products, smORF-encoded polypeptides (SEPs), points to a fundamental gap in our knowledge of protein-coding genes.  Various studies have identified central roles for smORFs in metab., apoptosis and development.  The discovery of these bioactive SEPs emphasizes the functional potential of this unexplored class of biomols.  Here, we provide an overview of this emerging field and highlight the opportunities for chem. biol. to answer fundamental questions about these novel genes.  Such studies will provide new insights into the protein-coding potential of genomes and identify functional genes with roles in biol. and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWYcQVK4rxvbVg90H21EOLACvtfcHk0ljqDAgFGNbRqA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVOgtrnI&md5=de3902cf079635ff0c12d6b232cf278b</span></div><a href="/servlet/linkout?suffix=cit47a&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1964%26sid%3Dliteratum%253Aachs%26aulast%3DSaghatelian%26aufirst%3DA.%26aulast%3DCouso%26aufirst%3DJ.%2BP.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520smORF-encoded%2520bioactive%2520polypeptides%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26spage%3D909%26epage%3D916%26doi%3D10.1038%2Fnchembio.1964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit47b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saghatelian, A.</span><span> </span><span class="NLM_article-title">Identification and characterization of sORF-encoded polypeptides</span> <span class="citation_source-journal">Crit. Rev. Biochem. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">â</span> <span class="NLM_lpage">141</span><span class="refDoi">Â DOI: 10.3109/10409238.2015.1016215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3109%2F10409238.2015.1016215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25857697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1Gms7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2015&pages=134-141&author=Q.+Chuauthor=J.+Maauthor=A.+Saghatelian&title=Identification+and+characterization+of+sORF-encoded+polypeptides&doi=10.3109%2F10409238.2015.1016215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47bR"><div class="casContent"><span class="casTitleNuber">47b</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of sORF-encoded polypeptides</span></div><div class="casAuthors">Chu, Qian; Ma, Jiao; Saghatelian, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">134-141</span>CODEN:
                <span class="NLM_cas:coden">CRBBEJ</span>;
        ISSN:<span class="NLM_cas:issn">1040-9238</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Mol. biol., genomics and proteomics methods have been utilized to reveal a non-annotated class of endogenous polypeptides (small proteins and peptides) encoded by short open reading frames (sORFs), or small open reading frames (smORFs).  We refer to these polypeptides as s(m)ORF-encoded polypeptides or SEPs.  The early SEPs were identified via genetic screens, and many of the RNAs that contain s(m)ORFs were originally considered to be non-coding; however, elegant work in bacteria and flies demonstrated that these s(m)ORFs code for functional polypeptides as small as 11-amino acids in length.  The discovery of these initial SEPs led to search for these mols. using methods such as ribosome profiling and proteomics, which have revealed the existence of many SEPs, including novel human SEPs.  Unlike screens, omics methods do not necessarily link a SEP to a cellular or biol. function, but functional genomic and proteomic strategies have demonstrated that at least some of these newly discovered SEPs have biochem. and cellular functions.  Here, we provide an overview of these results and discuss the future directions in this emerging field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJ7jIaogqAxbVg90H21EOLACvtfcHk0ljqDAgFGNbRqA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1Gms7s%253D&md5=32681ba753595fd1eda1979b08fe39bc</span></div><a href="/servlet/linkout?suffix=cit47b&amp;dbid=16384&amp;doi=10.3109%2F10409238.2015.1016215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10409238.2015.1016215%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DSaghatelian%26aufirst%3DA.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520sORF-encoded%2520polypeptides%26jtitle%3DCrit.%2520Rev.%2520Biochem.%2520Mol.%2520Biol.%26date%3D2015%26volume%3D50%26spage%3D134%26epage%3D141%26doi%3D10.3109%2F10409238.2015.1016215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Hashimoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niikura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tajima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasukawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasumi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kouyama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doyu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sobue, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koide, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuji, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurokawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishimoto, I.</span><span> </span><span class="NLM_article-title">A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimerâs disease genes and Abeta</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">6336</span><span class="NLM_x">â</span> <span class="NLM_lpage">6341</span><span class="refDoi">Â DOI: 10.1073/pnas.101133498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1073%2Fpnas.101133498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=11371646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktVWksbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=6336-6341&author=Y.+Hashimotoauthor=T.+Niikuraauthor=H.+Tajimaauthor=T.+Yasukawaauthor=H.+Sudoauthor=Y.+Itoauthor=Y.+Kitaauthor=M.+Kawasumiauthor=K.+Kouyamaauthor=M.+Doyuauthor=G.+Sobueauthor=T.+Koideauthor=S.+Tsujiauthor=J.+Langauthor=K.+Kurokawaauthor=I.+Nishimoto&title=A+rescue+factor+abolishing+neuronal+cell+death+by+a+wide+spectrum+of+familial+Alzheimer%E2%80%99s+disease+genes+and+Abeta&doi=10.1073%2Fpnas.101133498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and AÎ²</span></div><div class="casAuthors">Hashimoto, Yuichi; Niikura, Takako; Tajima, Hirohisa; Yasukawa, Takashi; Sudo, Haruka; Ito, Yuko; Kita, Yoshiko; Kawasumi, Masaoki; Kouyama, Keisuke; Doyu, Manabu; Sobue, Gen; Koide, Takashi; Tsuji, Shoji; Lang, Jochen; Kurokawa, Kiyoshi; Nishimoto, Ikuo</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6336-6341</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Through functional expression screening, we identified a gene, designated humanin (HN) cDNA, which encodes a short polypeptide and abolishes death of neuronal cells caused by multiple different types of familial Alzheimer's disease genes and by AÎ² amyloid, without effect on death by Q79 or superoxide dismutase-1 mutants.  Transfected HN cDNA was transcribed to the corresponding polypeptide and then was secreted into the cultured medium.  The rescue action clearly depended on the primary structure of HN.  This polypeptide would serve as a mol. clue for the development of new therapeutics for Alzheimer's disease targeting neuroprotection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz_VOeH6zHjbVg90H21EOLACvtfcHk0lj_lXDtESTVXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktVWksbk%253D&md5=effbfcb6f8a5349c1d87108f32ae6405</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1073%2Fpnas.101133498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.101133498%26sid%3Dliteratum%253Aachs%26aulast%3DHashimoto%26aufirst%3DY.%26aulast%3DNiikura%26aufirst%3DT.%26aulast%3DTajima%26aufirst%3DH.%26aulast%3DYasukawa%26aufirst%3DT.%26aulast%3DSudo%26aufirst%3DH.%26aulast%3DIto%26aufirst%3DY.%26aulast%3DKita%26aufirst%3DY.%26aulast%3DKawasumi%26aufirst%3DM.%26aulast%3DKouyama%26aufirst%3DK.%26aulast%3DDoyu%26aufirst%3DM.%26aulast%3DSobue%26aufirst%3DG.%26aulast%3DKoide%26aufirst%3DT.%26aulast%3DTsuji%26aufirst%3DS.%26aulast%3DLang%26aufirst%3DJ.%26aulast%3DKurokawa%26aufirst%3DK.%26aulast%3DNishimoto%26aufirst%3DI.%26atitle%3DA%2520rescue%2520factor%2520abolishing%2520neuronal%2520cell%2520death%2520by%2520a%2520wide%2520spectrum%2520of%2520familial%2520Alzheimer%25E2%2580%2599s%2520disease%2520genes%2520and%2520Abeta%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2001%26volume%3D98%26spage%3D6336%26epage%3D6341%26doi%3D10.1073%2Fpnas.101133498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Matsuoka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, Y.</span><span> </span><span class="NLM_article-title">Humanin and the receptors for humanin</span> <span class="citation_source-journal">Mol. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">22</span><span class="NLM_x">â</span> <span class="NLM_lpage">28</span><span class="refDoi">Â DOI: 10.1007/s12035-009-8090-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1007%2Fs12035-009-8090-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=19997871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtlalt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2010&pages=22-28&author=M.+Matsuokaauthor=Y.+Hashimoto&title=Humanin+and+the+receptors+for+humanin&doi=10.1007%2Fs12035-009-8090-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Humanin and the Receptors for Humanin</span></div><div class="casAuthors">Matsuoka, Masaaki; Hashimoto, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Neurobiology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-28</span>CODEN:
                <span class="NLM_cas:coden">MONBEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-7648</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is a prevalent dementia-causing neurodegenerative disease.  Neuronal death is closely linked to the progression of AD-assocd. dementia.  Accumulating evidence has established that a 24-amino-acid bioactive peptide, Humanin, protects neurons from AD-related neuronal death.  A series of studies using various murine AD models including familial AD gene-expressing transgenic mice have shown that Humanin is effective against AD-related neuronal dysfunction in vivo.  Most recently, it has been shown that Humanin inhibits neuronal cell death and dysfunction by binding to a novel IL-6-receptor-related receptor(s) on the cell surface involving CNTFRÎ±, WSX-1, and gp130.  These findings suggest that endogenous Humanin [or a Humanin-like substance(s)] may suppress the onset of AD-related dementia by inhibiting both AD-related neuronal cell death and dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqECH0JQ5gJs7Vg90H21EOLACvtfcHk0lj_lXDtESTVXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtlalt7c%253D&md5=dfe2d8cc366c61489373877e8f5db015</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1007%2Fs12035-009-8090-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12035-009-8090-z%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuoka%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DY.%26atitle%3DHumanin%2520and%2520the%2520receptors%2520for%2520humanin%26jtitle%3DMol.%2520Neurobiol.%26date%3D2010%26volume%3D41%26spage%3D22%26epage%3D28%26doi%3D10.1007%2Fs12035-009-8090-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Smith, G. P.</span><span> </span><span class="NLM_article-title">Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">1315</span><span class="NLM_x">â</span> <span class="NLM_lpage">1317</span><span class="refDoi">Â DOI: 10.1126/science.4001944</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1126%2Fscience.4001944" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=4001944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A280%3ADyaL2M3hvVOquw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=1985&pages=1315-1317&author=G.+P.+Smith&title=Filamentous+fusion+phage%3A+novel+expression+vectors+that+display+cloned+antigens+on+the+virion+surface&doi=10.1126%2Fscience.4001944"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface</span></div><div class="casAuthors">Smith G P</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">4705</span>),
    <span class="NLM_cas:pages">1315-7</span>
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Foreign DNA fragments can be inserted into filamentous phage gene III to create a fusion protein with the foreign sequence in the middle.  The fusion protein is incorporated into the virion, which retains infectivity and displays the foreign amino acids in immunologically accessible form.  These "fusion phage" can be enriched more than 1000-fold over ordinary phage by affinity for antibody directed against the foreign sequence.  Fusion phage may provide a simple way of cloning a gene when an antibody against the product of that gene is available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSi6LWYDdRj7r5XHngOXiV_fW6udTcc2ebynQnQcpdl37ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2M3hvVOquw%253D%253D&md5=cc126f0b75ba5aae24f0e12fe057ad05</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1126%2Fscience.4001944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.4001944%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DG.%2BP.%26atitle%3DFilamentous%2520fusion%2520phage%253A%2520novel%2520expression%2520vectors%2520that%2520display%2520cloned%2520antigens%2520on%2520the%2520virion%2520surface%26jtitle%3DScience%26date%3D1985%26volume%3D228%26spage%3D1315%26epage%3D1317%26doi%3D10.1126%2Fscience.4001944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Goldflam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullman, C. G.</span><span> </span><span class="NLM_article-title">Recent advances toward the discovery of drug-like peptides de novo</span> <span class="citation_source-journal">Front. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">69</span><span class="refDoi">Â DOI: 10.3389/fchem.2015.00069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3389%2Ffchem.2015.00069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26734602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A280%3ADC%252BC28rns1ejtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=69&author=M.+Goldflamauthor=C.+G.+Ullman&title=Recent+advances+toward+the+discovery+of+drug-like+peptides+de+novo&doi=10.3389%2Ffchem.2015.00069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances Toward the Discovery of Drug-Like Peptides De novo</span></div><div class="casAuthors">Goldflam Michael; Ullman Christopher G</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">69</span>
        ISSN:<span class="NLM_cas:issn">2296-2646</span>.
    </div><div class="casAbstract">Peptides are important natural molecules that possess functions as diverse as antibiotics, toxins, venoms and hormones, for example.  However, whilst these peptides have useful properties, there are many targets and pathways that are not addressed through the activities of natural peptidic compounds.  In these circumstances, directed evolution techniques, such as phage display, have been developed to sample the diverse chemical and structural repertoire of small peptides for useful means.  In this review, we consider recent concepts that relate peptide structure to drug-like attributes and how these are incorporated within display technologies to deliver peptides de novo with valuable pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSd3TNvyIUAQ2x8TEN9K18QfW6udTcc2ebeunaUV_r8VLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rns1ejtg%253D%253D&md5=57f4c0f862a0c50f97894cd6d361538c</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.3389%2Ffchem.2015.00069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffchem.2015.00069%26sid%3Dliteratum%253Aachs%26aulast%3DGoldflam%26aufirst%3DM.%26aulast%3DUllman%26aufirst%3DC.%2BG.%26atitle%3DRecent%2520advances%2520toward%2520the%2520discovery%2520of%2520drug-like%2520peptides%2520de%2520novo%26jtitle%3DFront.%2520Chem.%26date%3D2015%26volume%3D3%26spage%3D69%26doi%3D10.3389%2Ffchem.2015.00069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Omidfar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daneshpour, M.</span><span> </span><span class="NLM_article-title">Advances in phage display technology for drug discovery</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">651</span><span class="NLM_x">â</span> <span class="NLM_lpage">669</span><span class="refDoi">Â DOI: 10.1517/17460441.2015.1037738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1517%2F17460441.2015.1037738" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=651-669&author=K.+Omidfarauthor=M.+Daneshpour&title=Advances+in+phage+display+technology+for+drug+discovery&doi=10.1517%2F17460441.2015.1037738"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1517%2F17460441.2015.1037738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2015.1037738%26sid%3Dliteratum%253Aachs%26aulast%3DOmidfar%26aufirst%3DK.%26aulast%3DDaneshpour%26aufirst%3DM.%26atitle%3DAdvances%2520in%2520phage%2520display%2520technology%2520for%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2015%26volume%3D10%26spage%3D651%26epage%3D669%26doi%3D10.1517%2F17460441.2015.1037738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Frenzel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schirrmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hust, M.</span><span> </span><span class="NLM_article-title">Phage display-derived human antibodies in clinical development and therapy</span> <span class="citation_source-journal">mAbs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1177</span><span class="NLM_x">â</span> <span class="NLM_lpage">1194</span><span class="refDoi">Â DOI: 10.1080/19420862.2016.1212149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1080%2F19420862.2016.1212149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=27416017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVSlurzN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=1177-1194&author=A.+Frenzelauthor=T.+Schirrmannauthor=M.+Hust&title=Phage+display-derived+human+antibodies+in+clinical+development+and+therapy&doi=10.1080%2F19420862.2016.1212149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Phage display-derived human antibodies in clinical development and therapy</span></div><div class="casAuthors">Frenzel, Andre; Schirrmann, Thomas; Hust, Michael</div><div class="citationInfo"><span class="NLM_cas:title">mAbs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1177-1194</span>CODEN:
                <span class="NLM_cas:coden">MABSCP</span>;
        ISSN:<span class="NLM_cas:issn">1942-0870</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">Over the last 3 decades, monoclonal antibodies have become the most important class of therapeutic biologicals on the market.  Development of therapeutic antibodies was accelerated by recombinant DNA technologies, which allowed the humanization of murine monoclonal antibodies to make them more similar to those of the human body and suitable for a broad range of chronic diseases like cancer and autoimmune diseases.  In the early 1990s in vitro antibody selection technologies were developed that enabled the discovery of "fully" human antibodies with potentially superior clin. efficacy and lowest immunogenicity.  Antibody phage display is the first and most widely used of the in vitro selection technologies.  It has proven to be a robust, versatile platform technol. for the discovery of human antibodies and a powerful engineering tool to improve antibody properties.  As of the beginning of 2016, 6 human antibodies discovered or further developed by phage display were approved for therapy.  In 2002, adalimumab (Humira) became the first phage display-derived antibody granted a marketing approval.  Humira was also the first approved human antibody, and it is currently the best-selling antibody drug on the market.  Numerous phage display-derived antibodies are currently under advanced clin. investigation, and, despite the availability of other technologies such as human antibody-producing transgenic mice, phage display has not lost its importance for the discovery and engineering of therapeutic antibodies.  Here, we provide a comprehensive overview about phage display-derived antibodies that are approved for therapy or in clin. development.  A selection of these antibodies is described in more detail to demonstrate different aspects of the phage display technol. and its development over the last 25 years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXoM-jwSnZibVg90H21EOLACvtfcHk0lhBkyIIgBUc3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVSlurzN&md5=73ec5aac5c24d1d1135f07212cde2db5</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1080%2F19420862.2016.1212149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F19420862.2016.1212149%26sid%3Dliteratum%253Aachs%26aulast%3DFrenzel%26aufirst%3DA.%26aulast%3DSchirrmann%26aufirst%3DT.%26aulast%3DHust%26aufirst%3DM.%26atitle%3DPhage%2520display-derived%2520human%2520antibodies%2520in%2520clinical%2520development%2520and%2520therapy%26jtitle%3DmAbs%26date%3D2016%26volume%3D8%26spage%3D1177%26epage%3D1194%26doi%3D10.1080%2F19420862.2016.1212149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Giustina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chanson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleinberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronstein, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemmons, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klibanski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Lely, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strasburger, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamberts, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, K. K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casanueva, F. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melmed, S.</span><span> </span><span class="NLM_article-title">Expert consensus document: A consensus on the medical treatment of acromegaly</span> <span class="citation_source-journal">Nat. Rev. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">243</span><span class="NLM_x">â</span> <span class="NLM_lpage">248</span><span class="refDoi">Â DOI: 10.1038/nrendo.2014.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnrendo.2014.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24566817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjsVGisrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=243-248&author=A.+Giustinaauthor=P.+Chansonauthor=D.+Kleinbergauthor=M.+D.+Bronsteinauthor=D.+R.+Clemmonsauthor=A.+Klibanskiauthor=A.+J.+van+der+Lelyauthor=C.+J.+Strasburgerauthor=S.+W.+Lambertsauthor=K.+K.+Y.+Hoauthor=F.+F.+Casanuevaauthor=S.+Melmed&title=Expert+consensus+document%3A+A+consensus+on+the+medical+treatment+of+acromegaly&doi=10.1038%2Fnrendo.2014.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Expert consensus document: A consensus on the medical treatment of acromegaly</span></div><div class="casAuthors">Giustina, Andrea; Chanson, Philippe; Kleinberg, David; Bronstein, Marcello D.; Clemmons, David R.; Klibanski, Anne; van der Lely, Aart J.; Strasburger, Christian J.; Lamberts, Steven W.; Ho, Ken K. Y.; Casanueva, Felipe F.; Melmed, Shlomo</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">243-248</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In March 2013, the Acromegaly Consensus Group met to revise and update guidelines for the medical treatment of acromegaly.  The meeting comprised experts skilled in the medical management of acromegaly.  The group considered treatment goals covering biochem., clin. and tumor vol. outcomes, and the place in guidelines of somatostatin receptor ligands, growth hormone receptor antagonists and dopamine agonists, and alternative modalities for treatment including combination therapy and novel treatments.  This document represents the conclusions of the workshop consensus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6rXoOAwpI7rVg90H21EOLACvtfcHk0lhBkyIIgBUc3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjsVGisrk%253D&md5=19cb62059d8ff19b551dbebae9e5d637</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2014.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2014.21%26sid%3Dliteratum%253Aachs%26aulast%3DGiustina%26aufirst%3DA.%26aulast%3DChanson%26aufirst%3DP.%26aulast%3DKleinberg%26aufirst%3DD.%26aulast%3DBronstein%26aufirst%3DM.%2BD.%26aulast%3DClemmons%26aufirst%3DD.%2BR.%26aulast%3DKlibanski%26aufirst%3DA.%26aulast%3Dvan%2Bder%2BLely%26aufirst%3DA.%2BJ.%26aulast%3DStrasburger%26aufirst%3DC.%2BJ.%26aulast%3DLamberts%26aufirst%3DS.%2BW.%26aulast%3DHo%26aufirst%3DK.%2BK.%2BY.%26aulast%3DCasanueva%26aufirst%3DF.%2BF.%26aulast%3DMelmed%26aufirst%3DS.%26atitle%3DExpert%2520consensus%2520document%253A%2520A%2520consensus%2520on%2520the%2520medical%2520treatment%2520of%2520acromegaly%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2014%26volume%3D10%26spage%3D243%26epage%3D248%26doi%3D10.1038%2Fnrendo.2014.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Matochko, W. L.; Derda, R.</span><span> </span><span class="NLM_article-title">Next-Generation Sequencing of Phage-Displayed Peptide Libraries</span>. In  <span class="citation_source-book">Peptide Libraries: Methods and Protocols</span>; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">1248</span>, pp  <span class="NLM_fpage">249</span><span class="NLM_x">â</span> <span class="NLM_lpage">266</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&pages=249-266&author=W.+L.+Matochko&author=R.+Derda&title=Peptide+Libraries%3A+Methods+and+Protocols"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMatochko%26aufirst%3DW.%2BL.%26atitle%3DNext-Generation%2520Sequencing%2520of%2520Phage-Displayed%2520Peptide%2520Libraries%26btitle%3DPeptide%2520Libraries%253A%2520Methods%2520and%2520Protocols%26pub%3DSpringer%26date%3D2014%26volume%3D1248%26spage%3D249%26epage%3D266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Matochko, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derda, R.</span><span> </span><span class="NLM_article-title">Prospective identification of parasitic sequences in phage display screens</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1784</span><span class="NLM_x">â</span> <span class="NLM_lpage">1798</span><span class="refDoi">Â DOI: 10.1093/nar/gkt1104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1093%2Fnar%2Fgkt1104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24217917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFKks7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=1784-1798&author=W.+Matochkoauthor=S.+C.+Liauthor=S.+Tangauthor=R.+Derda&title=Prospective+identification+of+parasitic+sequences+in+phage+display+screens&doi=10.1093%2Fnar%2Fgkt1104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Prospective identification of parasitic sequences in phage display screens</span></div><div class="casAuthors">Matochko, Wadim L.; Cory Li, S.; Tang, Sindy K. Y.; Derda, Ratmir</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1784-1798</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Phage display empowered the development of proteins with new function and ligands for clin. relevant targets.  In this report, the authors use next-generation sequencing to analyze phage-displayed libraries and uncover a strong bias induced by amplification preferences of phage in bacteria.  This bias favors fast-growing sequences that collectively constitute <0.01% of the available diversity.  Specifically, a library of 109 random 7-mer peptides (Ph.D.-7) includes a few thousand sequences that grow quickly (the 'parasites'), which are the sequences that are typically identified in phage display screens published to date.  A similar collapse was obsd. in other libraries.  Using Illumina and Ion Torrent sequencing and multiple biol. replicates of amplification of Ph.D.-7 library, the authors identified a focused population of 770 'parasites'.  In all, 197 sequences from this population have been identified in literature reports that used Ph.D.-7 library.  Many of these enriched sequences have confirmed function (e.g. target binding capacity).  The bias in the literature, thus, can be viewed as a selection with two different selection pressures: (i) target-binding selection, and (ii) amplification-induced selection.  Enrichment of parasitic sequences could be minimized if amplification bias is removed.  Here, the authors demonstrate that emulsion amplification in libraries of â¼106 diverse clones prevents the biased selection of parasitic clones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCNgDSmI0C3LVg90H21EOLACvtfcHk0ljZrKtvDW4Q2w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFKks7w%253D&md5=e4da42b543b6f8ee81ae5de6aa971bff</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkt1104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkt1104%26sid%3Dliteratum%253Aachs%26aulast%3DMatochko%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DS.%2BC.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DDerda%26aufirst%3DR.%26atitle%3DProspective%2520identification%2520of%2520parasitic%2520sequences%2520in%2520phage%2520display%2520screens%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2014%26volume%3D42%26spage%3D1784%26epage%3D1798%26doi%3D10.1093%2Fnar%2Fgkt1104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Heinis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winter, G.</span><span> </span><span class="NLM_article-title">Encoded libraries of chemically modified peptides</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">â</span> <span class="NLM_lpage">98</span><span class="refDoi">Â DOI: 10.1016/j.cbpa.2015.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.cbpa.2015.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25768886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFyitrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=89-98&author=C.+Heinisauthor=G.+Winter&title=Encoded+libraries+of+chemically+modified+peptides&doi=10.1016%2Fj.cbpa.2015.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Encoded libraries of chemically modified peptides</span></div><div class="casAuthors">Heinis, Christian; Winter, Greg</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89-98</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The use of powerful technologies for generating and screening DNA-encoded protein libraries has helped drive the development of proteins as pharmaceutical ligands.  However the development of peptides as pharmaceutical ligands has been more limited.  Although encoded peptide libraries are typically several orders of magnitude larger than classical chem. libraries, can be more readily screened, and can give rise to higher affinity ligands, their use as pharmaceutical ligands is limited by their intrinsic properties.  Two of the intrinsic limitations include the rotational flexibility of the peptide backbone and the limited no. (20) of natural amino acids.  However these limitations can be overcome by use of chem. modification.  For example, the libraries can be modified to introduce topol. constraints such as cyclization linkers, or to introduce new chem. entities such as small mol. ligands, fluorophores and photo-switchable compds.  This article reviews the chem. involved, the properties of the peptide ligands, and the new opportunities offered by chem. modification of DNA-encoded peptide libraries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8h4T71AlbCLVg90H21EOLACvtfcHk0ljZrKtvDW4Q2w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFyitrs%253D&md5=78f43d9a54a527ca116846f48f710435</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2015.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2015.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DHeinis%26aufirst%3DC.%26aulast%3DWinter%26aufirst%3DG.%26atitle%3DEncoded%2520libraries%2520of%2520chemically%2520modified%2520peptides%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D26%26spage%3D89%26epage%3D98%26doi%3D10.1016%2Fj.cbpa.2015.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Ng, S.; Tjhung, K. F.; Paschal, B. M.; Noren, C. J.; Derda, R.</span><span> </span><span class="NLM_article-title">Chemical Posttranslational Modification of Phage-Displayed Peptides</span>. In  <span class="citation_source-book">Peptide Libraries: Methods and Protocols</span>; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">1248</span>, pp  <span class="NLM_fpage">155</span><span class="NLM_x">â</span> <span class="NLM_lpage">172</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&pages=155-172&author=S.+Ng&author=K.+F.+Tjhung&author=B.+M.+Paschal&author=C.+J.+Noren&author=R.+Derda&title=Peptide+Libraries%3A+Methods+and+Protocols"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DNg%26aufirst%3DS.%26atitle%3DChemical%2520Posttranslational%2520Modification%2520of%2520Phage-Displayed%2520Peptides%26btitle%3DPeptide%2520Libraries%253A%2520Methods%2520and%2520Protocols%26pub%3DSpringer%26date%3D2014%26volume%3D1248%26spage%3D155%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Schumacher, T. N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayr, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minor, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milhollen, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgess, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, P. S.</span><span> </span><span class="NLM_article-title">Identification of D-peptide ligands through mirror-image phage display</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">271</span><span class="NLM_x">, </span> <span class="NLM_fpage">1854</span><span class="NLM_x">â</span> <span class="NLM_lpage">1857</span><span class="refDoi">Â DOI: 10.1126/science.271.5257.1854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1126%2Fscience.271.5257.1854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=8596952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADyaK28XhvFGms70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=1854-1857&author=T.+N.+M.+Schumacherauthor=L.+M.+Mayrauthor=D.+L.+Minorauthor=M.+A.+Milhollenauthor=M.+W.+Burgessauthor=P.+S.+Kim&title=Identification+of+D-peptide+ligands+through+mirror-image+phage+display&doi=10.1126%2Fscience.271.5257.1854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of D-peptide ligands through mirror-image phage display</span></div><div class="casAuthors">Schumacher, Ton N. M.; Mayr, Lorenz M.; Minor, Daniel L., Jr.; Milhollen, Michael A.; Burgess, Michael W.; Kim, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">271</span>
        (<span class="NLM_cas:issue">5257</span>),
    <span class="NLM_cas:pages">1854-7</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Genetically encoded libraries of peptides and oligonucleotides are well suited for the identification of ligands for many macromols.  A major drawback of these techniques is that the resultant ligands are subject to degrdn. by naturally occurring enzymes.  Here, a method is described that uses a biol. encoded library for the identification of D-peptide ligands, which should be resistant to proteolytic degrdn.  In this approach, a protein is synthesized in the D-amino acid configuration and used to select peptides from a phage display library expressing random L-amino acid peptides.  For reasons of sym., the mirror images of these phage-displayed peptides interact with the target protein of the natural handedness.  The value of this approach was demonstrated by the identification of a cyclic D-peptide partially overlaps the site for the physiol. ligands of this domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaSs-Xi93iBbVg90H21EOLACvtfcHk0ljZrKtvDW4Q2w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhvFGms70%253D&md5=dd3a5f9d87cd0dbd8b4e89cb11432831</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1126%2Fscience.271.5257.1854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.271.5257.1854%26sid%3Dliteratum%253Aachs%26aulast%3DSchumacher%26aufirst%3DT.%2BN.%2BM.%26aulast%3DMayr%26aufirst%3DL.%2BM.%26aulast%3DMinor%26aufirst%3DD.%2BL.%26aulast%3DMilhollen%26aufirst%3DM.%2BA.%26aulast%3DBurgess%26aufirst%3DM.%2BW.%26aulast%3DKim%26aufirst%3DP.%2BS.%26atitle%3DIdentification%2520of%2520D-peptide%2520ligands%2520through%2520mirror-image%2520phage%2520display%26jtitle%3DScience%26date%3D1996%26volume%3D271%26spage%3D1854%26epage%3D1857%26doi%3D10.1126%2Fscience.271.5257.1854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Eckert, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malashkevich, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, P. S.</span><span> </span><span class="NLM_article-title">Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">â</span> <span class="NLM_lpage">115</span><span class="refDoi">Â DOI: 10.1016/S0092-8674(00)80066-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2FS0092-8674%2800%2980066-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10520998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADyaK1MXmsleqsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=1999&pages=103-115&author=D.+M.+Eckertauthor=V.+N.+Malashkevichauthor=L.+H.+Hongauthor=P.+A.+Carrauthor=P.+S.+Kim&title=Inhibiting+HIV-1+entry%3A+discovery+of+D-peptide+inhibitors+that+target+the+gp41+coiled-coil+pocket&doi=10.1016%2FS0092-8674%2800%2980066-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket</span></div><div class="casAuthors">Eckert, Debra M.; Malashkevich, Vladimir N.; Hong, Lily H.; Carr, Peter A.; Kim, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">103-115</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The HIV-1 gp41 protein promotes viral entry by mediating the fusion of viral and cellular membranes.  A prominent pocket on the surface of a central trimeric coiled coil within gp41 was previously identified as a potential target for drugs that inhibit HIV-1 entry.  The authors designed a peptide, IQN17, which properly presents this pocket.  Utilizing IQN17 and mirror-image phage display, the authors identified cyclic, D-peptide inhibitors of HIV-1 infection that share a sequence motif.  A 1.5 Ã cocrystal structure of IQN17 in complex with a D-peptide, and NMR studies, show that conserved residues of these inhibitors make intimate contact with the gp41 pocket.  The authors studies validate the pocket per se as a target for drug development.  IQN17 and these D-peptide inhibitors are likely to be useful for development and identification of a new class of orally bioavailable anti-HIV drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph-j-KCy8psLVg90H21EOLACvtfcHk0ljO_IHb8qCxXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmsleqsL8%253D&md5=75bf4eb851b8a0dd82716fb57a13cc3f</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2980066-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252980066-5%26sid%3Dliteratum%253Aachs%26aulast%3DEckert%26aufirst%3DD.%2BM.%26aulast%3DMalashkevich%26aufirst%3DV.%2BN.%26aulast%3DHong%26aufirst%3DL.%2BH.%26aulast%3DCarr%26aufirst%3DP.%2BA.%26aulast%3DKim%26aufirst%3DP.%2BS.%26atitle%3DInhibiting%2520HIV-1%2520entry%253A%2520discovery%2520of%2520D-peptide%2520inhibitors%2520that%2520target%2520the%2520gp41%2520coiled-coil%2520pocket%26jtitle%3DCell%26date%3D1999%26volume%3D99%26spage%3D103%26epage%3D115%26doi%3D10.1016%2FS0092-8674%2800%2980066-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Zhao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span> </span><span class="NLM_article-title">Mirror image proteins</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span><span class="NLM_x">â</span> <span class="NLM_lpage">61</span><span class="refDoi">Â DOI: 10.1016/j.cbpa.2014.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.cbpa.2014.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25282524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1OrtrfM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=56-61&author=L.+Zhaoauthor=W.+Lu&title=Mirror+image+proteins&doi=10.1016%2Fj.cbpa.2014.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Mirror image proteins</span></div><div class="casAuthors">Zhao, Le; Lu, Wuyuan</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">56-61</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Proteins composed entirely of unnatural D-amino acids and the achiral amino acid glycine are mirror image forms of their native L-protein counterparts.  Recent advances in chem. protein synthesis afford unique and facile synthetic access to domain-sized mirror image D-proteins, enabling protein research to be conducted through 'the looking glass' and in a way previously unattainable. D-Proteins can facilitate structure detn. of their native L-forms that are difficult to crystallize (racemic X-ray crystallog.); D-proteins can serve as the bait for library screening to ultimately yield pharmacol. superior D-peptide/D-protein therapeutics (mirror-image phage display); D-proteins can also be used as a powerful mechanistic tool for probing mol. events in biol.  This review examines recent progress in the application of mirror image proteins to structural biol., drug discovery, and immunol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9u_Js4562RrVg90H21EOLACvtfcHk0ljO_IHb8qCxXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1OrtrfM&md5=163154b72bce7e96d02de46218f74c62</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2014.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2014.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DW.%26atitle%3DMirror%2520image%2520proteins%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D22%26spage%3D56%26epage%3D61%26doi%3D10.1016%2Fj.cbpa.2014.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Josephson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricardo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szostak, J. W.</span><span> </span><span class="NLM_article-title">mRNA display: from basic principles to macrocycle drug discovery</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">388</span><span class="NLM_x">â</span> <span class="NLM_lpage">399</span><span class="refDoi">Â DOI: 10.1016/j.drudis.2013.10.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.drudis.2013.10.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24157402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsleltrnI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=388-399&author=K.+Josephsonauthor=A.+Ricardoauthor=J.+W.+Szostak&title=mRNA+display%3A+from+basic+principles+to+macrocycle+drug+discovery&doi=10.1016%2Fj.drudis.2013.10.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62aR"><div class="casContent"><span class="casTitleNuber">62a</span><div class="casTitle"><span class="NLM_cas:atitle">mRNA display: from basic principles to macrocycle drug discovery</span></div><div class="casAuthors">Josephson, Kristopher; Ricardo, Alonso; Szostak, Jack W.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">388-399</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  We describe a new discovery technol. that uses mRNA-display to rapidly synthesize and screen macrocyclic peptide libraries to explore a valuable region of chem. space typified by natural products.  This technol. allows high-affinity peptidic macrocycles contg. modified backbones and unnatural side chains to be readily selected based on target binding.  Success stories covering the first examples of these libraries suggest that they could be used for the discovery of intracellular protein-protein interaction inhibitors, highly selective enzyme inhibitors or synthetic replacements for monoclonal antibodies.  The review concludes with a look to the future regarding how this technol. might be improved with respect to library design for cell permeability and bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobuL9lWFPZIbVg90H21EOLACvtfcHk0ljO_IHb8qCxXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsleltrnI&md5=6676fef2ca8f0a81cc0e993ee4ec7424</span></div><a href="/servlet/linkout?suffix=cit62a&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.10.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.10.011%26sid%3Dliteratum%253Aachs%26aulast%3DJosephson%26aufirst%3DK.%26aulast%3DRicardo%26aufirst%3DA.%26aulast%3DSzostak%26aufirst%3DJ.%2BW.%26atitle%3DmRNA%2520display%253A%2520from%2520basic%2520principles%2520to%2520macrocycle%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D388%26epage%3D399%26doi%3D10.1016%2Fj.drudis.2013.10.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit62b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Josephson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, M. C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szostak, J. W.</span><span> </span><span class="NLM_article-title">Ribosomal synthesis of unnatural peptides</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">127</span><span class="NLM_x">, </span> <span class="NLM_fpage">11727</span><span class="NLM_x">â</span> <span class="NLM_lpage">11735</span><span class="refDoi">Â DOI: 10.1021/ja0515809</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja0515809" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmsFCqurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2005&pages=11727-11735&author=K.+Josephsonauthor=M.+C.+T.+Hartmanauthor=J.+W.+Szostak&title=Ribosomal+synthesis+of+unnatural+peptides&doi=10.1021%2Fja0515809"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62bR"><div class="casContent"><span class="casTitleNuber">62b</span><div class="casTitle"><span class="NLM_cas:atitle">Ribosomal Synthesis of Unnatural Peptides</span></div><div class="casAuthors">Josephson, Kristopher; Hartman, Matthew C. T.; Szostak, Jack W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">11727-11735</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Combinatorial libraries of nonbiol. polymers and drug-like peptides could in principle be synthesized from unnatural amino acids by exploiting the broad substrate specificity of the ribosome.  The ribosomal synthesis of such libraries would allow rare functional mols. to be identified using technologies developed for the in vitro selection of peptides and proteins.  Here, we use a reconstituted E. coli translation system to simultaneously reassign 35 of the 61 sense codons to 12 unnatural amino acid analogs.  This reprogrammed genetic code was used to direct the synthesis of a single peptide contg. 10 different unnatural amino acids.  This system is compatible with mRNA-display, enabling the synthesis of unnatural peptide libraries of 1014 unique members for the in vitro selection of functional unnatural mols.  We also show that the chem. space sampled by these libraries can be expanded using mutant aminoacyl-tRNA synthetases for the incorporation of addnl. unnatural amino acids or by the specific posttranslational chem. derivatization of reactive groups with small mols.  This system represents a first step toward a platform for the synthesis by enzymic tRNA aminoacylation and ribosomal translation of cyclic peptides comprised of unnatural amino acids that are similar to the nonribosomal peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdQq7-A7FhGbVg90H21EOLACvtfcHk0ljwcUvov6nWeg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmsFCqurk%253D&md5=01f866a06627f9b21732210595801cc1</span></div><a href="/servlet/linkout?suffix=cit62b&amp;dbid=16384&amp;doi=10.1021%2Fja0515809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0515809%26sid%3Dliteratum%253Aachs%26aulast%3DJosephson%26aufirst%3DK.%26aulast%3DHartman%26aufirst%3DM.%2BC.%2BT.%26aulast%3DSzostak%26aufirst%3DJ.%2BW.%26atitle%3DRibosomal%2520synthesis%2520of%2520unnatural%2520peptides%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2005%26volume%3D127%26spage%3D11727%26epage%3D11735%26doi%3D10.1021%2Fja0515809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Guillen Schlippe, Y. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, M. C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Josephson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szostak, J. W.</span><span> </span><span class="NLM_article-title">In Vitro Selection of Highly Modified Cyclic Peptides That Act as Tight Binding Inhibitors</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">134</span><span class="NLM_x">, </span> <span class="NLM_fpage">10469</span><span class="NLM_x">â</span> <span class="NLM_lpage">10477</span><span class="refDoi">Â DOI: 10.1021/ja301017y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja301017y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38XktFeltbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=10469-10477&author=Y.+V.+Guillen+Schlippeauthor=M.+C.+T.+Hartmanauthor=K.+Josephsonauthor=J.+W.+Szostak&title=In+Vitro+Selection+of+Highly+Modified+Cyclic+Peptides+That+Act+as+Tight+Binding+Inhibitors&doi=10.1021%2Fja301017y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro Selection of Highly Modified Cyclic Peptides That Act as Tight Binding Inhibitors</span></div><div class="casAuthors">Guillen Schlippe, Yollete V.; Hartman, Matthew C. T.; Josephson, Kristopher; Szostak, Jack W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">10469-10477</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a great demand for the discovery of new therapeutic mols. that combine the high specificity and affinity of biol. drugs with the bioavailability and lower cost of small mols.  Small, natural-product-like peptides hold great promise in bridging this gap; however, access to libraries of these compds. has been a limitation.  Since ribosomal peptides may be subjected to in vitro selection techniques, the generation of extremely large libraries (>1013) of highly modified macrocyclic peptides may provide a powerful alternative for the generation and selection of new useful bioactive mols.  Moreover, the incorporation of many non-proteinogenic amino acids into ribosomal peptides in conjunction with macrocyclization should enhance the drug-like features of these libraries.  Here we show that mRNA-display, a technique that allows the in vitro selection of peptides, can be applied to the evolution of macrocyclic peptides that contain a majority of unnatural amino acids.  We describe the isolation and characterization of two such unnatural cyclic peptides that bind the protease thrombin with low nanomolar affinity, and we show that the unnatural residues in these peptides are essential for the obsd. high-affinity binding.  We demonstrate that the selected peptides are tight-binding inhibitors of thrombin, with Kiapp values in the low nanomolar range.  The ability to evolve highly modified macrocyclic peptides in the lab. is the first crucial step toward the facile generation of useful mol. reagents and therapeutic lead mols. that combine the advantageous features of biologics with those of small-mol. drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-KLtyEmp2hLVg90H21EOLACvtfcHk0ljwcUvov6nWeg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktFeltbY%253D&md5=4bee8629fb8b3a67a816a148df28277d</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fja301017y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja301017y%26sid%3Dliteratum%253Aachs%26aulast%3DGuillen%2BSchlippe%26aufirst%3DY.%2BV.%26aulast%3DHartman%26aufirst%3DM.%2BC.%2BT.%26aulast%3DJosephson%26aufirst%3DK.%26aulast%3DSzostak%26aufirst%3DJ.%2BW.%26atitle%3DIn%2520Vitro%2520Selection%2520of%2520Highly%2520Modified%2520Cyclic%2520Peptides%2520That%2520Act%2520as%2520Tight%2520Binding%2520Inhibitors%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26spage%3D10469%26epage%3D10477%26doi%3D10.1021%2Fja301017y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Morioka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loik, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hipolito, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suga, H.</span><span> </span><span class="NLM_article-title">Selection-based discovery of macrocyclic peptides for the next generation therapeutics</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">34</span><span class="NLM_x">â</span> <span class="NLM_lpage">41</span><span class="refDoi">Â DOI: 10.1016/j.cbpa.2015.01.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.cbpa.2015.01.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25703142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFyitrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=34-41&author=T.+Moriokaauthor=N.+D.+Loikauthor=C.+J.+Hipolitoauthor=Y.+Gotoauthor=H.+Suga&title=Selection-based+discovery+of+macrocyclic+peptides+for+the+next+generation+therapeutics&doi=10.1016%2Fj.cbpa.2015.01.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64aR"><div class="casContent"><span class="casTitleNuber">64a</span><div class="casTitle"><span class="NLM_cas:atitle">Selection-based discovery of macrocyclic peptides for the next generation therapeutics</span></div><div class="casAuthors">Morioka, Tomomi; Loik, Nikita D.; Hipolito, Christopher J.; Goto, Yuki; Suga, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">34-41</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Naturally occurring macrocyclic peptides represent a unique class of compds. that exhibit various biol. activities ranging from antibiotics to immunosuppressant.  Although the discovery of such macrocyclic peptides had relied on their isolation from living organisms, recent advances in ribosomal peptide synthesis and in display techniques made it possible to use artificially generated macrocyclic peptide libraries for selection of ligands for biol. relevant proteins.  In this review, we discuss the technologies and their applications for the discovery of peptide ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri5eKuODF5srVg90H21EOLACvtfcHk0ljwcUvov6nWeg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFyitrg%253D&md5=6140458ada8c98d6ff60dad07a32c5b8</span></div><a href="/servlet/linkout?suffix=cit64a&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2015.01.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2015.01.023%26sid%3Dliteratum%253Aachs%26aulast%3DMorioka%26aufirst%3DT.%26aulast%3DLoik%26aufirst%3DN.%2BD.%26aulast%3DHipolito%26aufirst%3DC.%2BJ.%26aulast%3DGoto%26aufirst%3DY.%26aulast%3DSuga%26aufirst%3DH.%26atitle%3DSelection-based%2520discovery%2520of%2520macrocyclic%2520peptides%2520for%2520the%2520next%2520generation%2520therapeutics%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D26%26spage%3D34%26epage%3D41%26doi%3D10.1016%2Fj.cbpa.2015.01.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit64b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Passioura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katoh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suga, H.</span><span> </span><span class="NLM_article-title">Selection-based discovery of drug-like macrocyclic peptides</span> <span class="citation_source-journal">Annu. Rev. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">727</span><span class="NLM_x">â</span> <span class="NLM_lpage">752</span><span class="refDoi">Â DOI: 10.1146/annurev-biochem-060713-035456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1146%2Fannurev-biochem-060713-035456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24580641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFOhtrnE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2014&pages=727-752&author=T.+Passiouraauthor=T.+Katohauthor=Y.+Gotoauthor=H.+Suga&title=Selection-based+discovery+of+drug-like+macrocyclic+peptides&doi=10.1146%2Fannurev-biochem-060713-035456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64bR"><div class="casContent"><span class="casTitleNuber">64b</span><div class="casTitle"><span class="NLM_cas:atitle">Selection-based discovery of druglike macrocyclic peptides</span></div><div class="casAuthors">Passioura, Toby; Katoh, Takayuki; Goto, Yuki; Suga, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">727-752</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  Macrocyclic peptides are an emerging class of therapeutics that can modulate protein-protein interactions.  In contrast to the heavily automated high-throughput screening systems traditionally used for the identification of chem. synthesized small-mol. drugs, peptide-based macrocycles can be synthesized by ribosomal translation and identified using in vitro selection techniques, allowing for extremely rapid (hours to days) screening of compd. libraries comprising more than 1013 different species.  Furthermore, chem. modification of translated peptides and engineering of the genetic code have greatly expanded the structural diversity of the available peptide libraries.  In this review, we discuss the use of these technologies for the identification of bioactive macrocyclic peptides, emphasizing recent developments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfAer2tXyiyrVg90H21EOLACvtfcHk0ljwcUvov6nWeg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFOhtrnE&md5=34954232501b3765dbbd83d45be9508d</span></div><a href="/servlet/linkout?suffix=cit64b&amp;dbid=16384&amp;doi=10.1146%2Fannurev-biochem-060713-035456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-biochem-060713-035456%26sid%3Dliteratum%253Aachs%26aulast%3DPassioura%26aufirst%3DT.%26aulast%3DKatoh%26aufirst%3DT.%26aulast%3DGoto%26aufirst%3DY.%26aulast%3DSuga%26aufirst%3DH.%26atitle%3DSelection-based%2520discovery%2520of%2520drug-like%2520macrocyclic%2520peptides%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2014%26volume%3D83%26spage%3D727%26epage%3D752%26doi%3D10.1146%2Fannurev-biochem-060713-035456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Ohuchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suga, H.</span><span> </span><span class="NLM_article-title">The flexizyme system: a highly flexible tRNA aminoacylation tool for the translation apparatus</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">537</span><span class="NLM_x">â</span> <span class="NLM_lpage">542</span><span class="refDoi">Â DOI: 10.1016/j.cbpa.2007.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.cbpa.2007.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=17884697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtF2rsbvI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=537-542&author=M.+Ohuchiauthor=H.+Murakamiauthor=H.+Suga&title=The+flexizyme+system%3A+a+highly+flexible+tRNA+aminoacylation+tool+for+the+translation+apparatus&doi=10.1016%2Fj.cbpa.2007.08.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">The flexizyme system: a highly flexible tRNA aminoacylation tool for the translation apparatus</span></div><div class="casAuthors">Ohuchi, Masaki; Murakami, Hiroshi; Suga, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">537-542</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Flexizymes are de novo ribozymes capable of charging a wide variety of non-natural amino acids on tRNAs.  The flexizyme system enables reprogramming of the genetic code by reassigning the codons that are generally assigned to natural amino acids to non-natural residues, and thus mRNA-directed synthesis of non-natural polypeptides can be achieved.  Here, the authors comprehensively summarize the history of the flexizyme system and its subsequent development into a practical tool.  Furthermore, applications to the synthesis of novel biopolymers via genetic code reprogramming and perspectives for future applications are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjZVixZHEK1LVg90H21EOLACvtfcHk0lh-sDDIh184FA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtF2rsbvI&md5=a6bd61ea5a1afdf651eaf44c665c4ce4</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2007.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2007.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DOhuchi%26aufirst%3DM.%26aulast%3DMurakami%26aufirst%3DH.%26aulast%3DSuga%26aufirst%3DH.%26atitle%3DThe%2520flexizyme%2520system%253A%2520a%2520highly%2520flexible%2520tRNA%2520aminoacylation%2520tool%2520for%2520the%2520translation%2520apparatus%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2007%26volume%3D11%26spage%3D537%26epage%3D542%26doi%3D10.1016%2Fj.cbpa.2007.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hardy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bill, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jawhari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothnie, A.</span><span> </span><span class="NLM_article-title">Overcoming bottlenecks in the membrane protein structural biology pipeline</span> <span class="citation_source-journal">Biochem. Soc. Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">838</span><span class="NLM_x">â</span> <span class="NLM_lpage">844</span><span class="refDoi">Â DOI: 10.1042/BST20160049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1042%2FBST20160049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=27284049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28Xps1Wmt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=838-844&author=D.+Hardyauthor=R.+Billauthor=A.+Jawhariauthor=A.+Rothnie&title=Overcoming+bottlenecks+in+the+membrane+protein+structural+biology+pipeline&doi=10.1042%2FBST20160049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66aR"><div class="casContent"><span class="casTitleNuber">66a</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming bottlenecks in the membrane protein structural biology pipeline</span></div><div class="casAuthors">Hardy, David; Bill, Roslyn M.; Jawhari, Anass; Rothnie, Alice J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">838-844</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Membrane proteins account for a third of the eukaryotic proteome, but are greatly under-represented in the Protein Data Bank.  Unfortunately, recent technol. advances in X-ray crystallog. and EM cannot account for the poor soly. and stability of membrane protein samples.  A limitation of conventional detergent-based methods is that detergent mols. destabilize membrane proteins, leading to their aggregation.  The use of orthologues, mutants and fusion tags has helped improve protein stability, but at the expense of not working with the sequence of interest.  Novel detergents such as glucose neopentyl glycol (GNG), maltose neopentyl glycol (MNG) and calixarene-based detergents can improve protein stability without compromising their solubilizing properties.  Styrene maleic acid lipid particles (SMALPs) focus on retaining the native lipid bilayer of a membrane protein during purifn. and biophys. anal.  Overcoming bottlenecks in the membrane protein structural biol. pipeline, primarily by maintaining protein stability, will facilitate the elucidation of many more membrane protein structures in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK0zW9Wt0KurVg90H21EOLACvtfcHk0lh-sDDIh184FA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xps1Wmt7c%253D&md5=f10ec64f172fb2f9954c8476f5ef6473</span></div><a href="/servlet/linkout?suffix=cit66a&amp;dbid=16384&amp;doi=10.1042%2FBST20160049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20160049%26sid%3Dliteratum%253Aachs%26aulast%3DHardy%26aufirst%3DD.%26aulast%3DBill%26aufirst%3DR.%26aulast%3DJawhari%26aufirst%3DA.%26aulast%3DRothnie%26aufirst%3DA.%26atitle%3DOvercoming%2520bottlenecks%2520in%2520the%2520membrane%2520protein%2520structural%2520biology%2520pipeline%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2016%26volume%3D44%26spage%3D838%26epage%3D844%26doi%3D10.1042%2FBST20160049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit66b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Matar-Merheb, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhimi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leydier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huche, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">GaliÃ n, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desuzinges-Mandon, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ficheux, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flot, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aghajari, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Pietro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jault, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falson, P.</span><span> </span><span class="NLM_article-title">Structuring detergents for extracting and stabilizing functional membrane proteins</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e18036</span><span class="refDoi">Â DOI: 10.1371/journal.pone.0018036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1371%2Fjournal.pone.0018036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21483854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslygurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e18036&author=R.+Matar-Merhebauthor=M.+Rhimiauthor=A.+Leydierauthor=F.+Hucheauthor=C.+Gali%C3%A0nauthor=E.+Desuzinges-Mandonauthor=D.+Ficheuxauthor=D.+Flotauthor=N.+Aghajariauthor=R.+Kahnauthor=A.+Di+Pietroauthor=J.-M.+Jaultauthor=A.+W.+Colemanauthor=P.+Falson&title=Structuring+detergents+for+extracting+and+stabilizing+functional+membrane+proteins&doi=10.1371%2Fjournal.pone.0018036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66bR"><div class="casContent"><span class="casTitleNuber">66b</span><div class="casTitle"><span class="NLM_cas:atitle">Structuring detergents for extracting and stabilizing functional membrane proteins</span></div><div class="casAuthors">Matar-Merheb, Rima; Rhimi, Moez; Leydier, Antoine; Huche, Frederic; Galian, Carmen; Desuzinges-Mandon, Elodie; Ficheux, Damien; Flot, David; Aghajari, Nushin; Kahn, Richard; Di Pietro, Attilio; Jault, Jean-Michel; Coleman, Anthony W.; Falson, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e18036</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: Membrane proteins are privileged pharmaceutical targets for which the development of structure-based drug design is challenging.  One underlying reason is the fact that detergents do not stabilize membrane domains as efficiently as natural lipids in membranes, often leading to a partial to complete loss of activity/stability during protein extn. and purifn. and preventing crystn. in an active conformation.  Methodol./Principal Findings: Anionic calix[4]arene based detergents (C4Cn, n = 1-12) were designed to structure the membrane domains through hydrophobic interactions and a network of salt bridges with the basic residues found at the cytosol-membrane interface of membrane proteins.  These compds. behave as surfactants, forming micelles of 5-24 nm, with the crit. micellar concn. (CMC) being as expected sensitive to pH ranging from 0.05 to 1.5 mM.  Both by 1H NMR titrn. and Surface Tension titrn. expts., the interaction of these mols. with the basic amino acids was confirmed.  They ext. membrane proteins from different origins behaving as mild detergents, leading to partial extn. in some cases.  They also retain protein functionality, as shown for BmrA (Bacillus multidrug resistance ATP protein), a membrane multidrug-transporting ATPase, which is particularly sensitive to detergent extn.  These new detergents allow BmrA to bind daunorubicin with a Kd of 12 Î¼M, a value similar to that obsd. after purifn. using dodecyl maltoside (DDM).  They preserve the ATPase activity of BmrA (which resets the protein to its initial state after drug efflux) much more efficiently than SDS (sodium dodecyl sulfate), FC12 (Foscholine 12) or DDM.  They also maintain in a functional state the C4Cn-extd. protein upon detergent exchange with FC12.  Finally, they promote 3D-crystn. of the membrane protein.  Conclusion/Significance: These compds. seem promising to ext. in a functional state membrane proteins obeying the pos. inside rule.  In that context, they may contribute to the membrane protein crystn. field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprXt-c36z6frVg90H21EOLACvtfcHk0lh-sDDIh184FA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslygurw%253D&md5=fd2bdb896da7bddc0a9a314939f1a406</span></div><a href="/servlet/linkout?suffix=cit66b&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0018036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0018036%26sid%3Dliteratum%253Aachs%26aulast%3DMatar-Merheb%26aufirst%3DR.%26aulast%3DRhimi%26aufirst%3DM.%26aulast%3DLeydier%26aufirst%3DA.%26aulast%3DHuche%26aufirst%3DF.%26aulast%3DGali%25C3%25A0n%26aufirst%3DC.%26aulast%3DDesuzinges-Mandon%26aufirst%3DE.%26aulast%3DFicheux%26aufirst%3DD.%26aulast%3DFlot%26aufirst%3DD.%26aulast%3DAghajari%26aufirst%3DN.%26aulast%3DKahn%26aufirst%3DR.%26aulast%3DDi%2BPietro%26aufirst%3DA.%26aulast%3DJault%26aufirst%3DJ.-M.%26aulast%3DColeman%26aufirst%3DA.%2BW.%26aulast%3DFalson%26aufirst%3DP.%26atitle%3DStructuring%2520detergents%2520for%2520extracting%2520and%2520stabilizing%2520functional%2520membrane%2520proteins%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De18036%26doi%3D10.1371%2Fjournal.pone.0018036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bayburt, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sligar, S. G.</span><span> </span><span class="NLM_article-title">Self-assembly of single integral membrane proteins into soluble nanoscale phospholipid bilayers</span> <span class="citation_source-journal">Protein Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2476</span><span class="NLM_x">â</span> <span class="NLM_lpage">2481</span><span class="refDoi">Â DOI: 10.1110/ps.03267503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1110%2Fps.03267503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=14573860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD3sXoslelur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2003&pages=2476-2481&author=T.+H.+Bayburtauthor=S.+G.+Sligar&title=Self-assembly+of+single+integral+membrane+proteins+into+soluble+nanoscale+phospholipid+bilayers&doi=10.1110%2Fps.03267503"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67aR"><div class="casContent"><span class="casTitleNuber">67a</span><div class="casTitle"><span class="NLM_cas:atitle">Self-assembly of single integral membrane proteins into soluble nanoscale phospholipid bilayers</span></div><div class="casAuthors">Bayburt, Timothy H.; Sligar, Stephen G.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2476-2481</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">0961-8368</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">One of the biggest challenges in pharmaceutical research is obtaining integral membrane proteins in a functional, solubilized, and monodisperse state that provides a native-like environment that maintains the spectrum of in vivo activities.  Many of these integral membrane proteins are receptors, enzymes, or other macromol. assemblies that are important drug targets.  An example is the general class of proteins composed of seven-transmembrane segments (7-TM) as exemplified by the G-protein-coupled receptors.  In this article, we describe a simple system for self-assembling bacteriorhodopsin, as a model protein contg. 7-TM helixes, with phospholipids to form a nanometer-scale sol. bilayer structure encircled by a 200 amino acid scaffold protein.  The result is the single mol. incorporation of an integral membrane protein target into a sol. and monodisperse structure that allows the structural and functional tools of soln. biochem. to be applied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFexFsxcIoDLVg90H21EOLACvtfcHk0liHSmvHNedr_w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXoslelur8%253D&md5=74a769e484a52a430650a11b42af4610</span></div><a href="/servlet/linkout?suffix=cit67a&amp;dbid=16384&amp;doi=10.1110%2Fps.03267503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1110%252Fps.03267503%26sid%3Dliteratum%253Aachs%26aulast%3DBayburt%26aufirst%3DT.%2BH.%26aulast%3DSligar%26aufirst%3DS.%2BG.%26atitle%3DSelf-assembly%2520of%2520single%2520integral%2520membrane%2520proteins%2520into%2520soluble%2520nanoscale%2520phospholipid%2520bilayers%26jtitle%3DProtein%2520Sci.%26date%3D2003%26volume%3D12%26spage%3D2476%26epage%3D2481%26doi%3D10.1110%2Fps.03267503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit67b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bayburt, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sligar, S. G.</span><span> </span><span class="NLM_article-title">Membrane protein assembly into nanodiscs</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">584</span><span class="NLM_x">, </span> <span class="NLM_fpage">1721</span><span class="NLM_x">â</span> <span class="NLM_lpage">1727</span><span class="refDoi">Â DOI: 10.1016/j.febslet.2009.10.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.febslet.2009.10.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=19836392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFKqurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=584&publication_year=2010&pages=1721-1727&author=T.+H.+Bayburtauthor=S.+G.+Sligar&title=Membrane+protein+assembly+into+nanodiscs&doi=10.1016%2Fj.febslet.2009.10.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67bR"><div class="casContent"><span class="casTitleNuber">67b</span><div class="casTitle"><span class="NLM_cas:atitle">Membrane protein assembly into nanodisks</span></div><div class="casAuthors">Bayburt, Timothy H.; Sligar, Stephen G.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">584</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1721-1727</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Nanodisks are sol. nanoscale phospholipid bilayers which can self-assemble integral membrane proteins for biophys., enzymic or structural investigations.  This means for rendering membrane proteins sol. at the single-mol. level offers advantages over liposomes or detergent micelles in terms of size, stability, ability to add genetically modifiable features to the nanodisk structure and ready access to both sides of the phospholipid bilayer domain.  Thus, the nanodisc system provides a novel platform for understanding membrane protein function.  Here, the authors provide an overview of the nanodisk approach and document through several examples many of the applications to the study of the structure and function of integral membrane proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphr-NB4w9pNbVg90H21EOLACvtfcHk0liHSmvHNedr_w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFKqurw%253D&md5=1ace5001c844ff546e837251fdcb0774</span></div><a href="/servlet/linkout?suffix=cit67b&amp;dbid=16384&amp;doi=10.1016%2Fj.febslet.2009.10.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.febslet.2009.10.024%26sid%3Dliteratum%253Aachs%26aulast%3DBayburt%26aufirst%3DT.%2BH.%26aulast%3DSligar%26aufirst%3DS.%2BG.%26atitle%3DMembrane%2520protein%2520assembly%2520into%2520nanodiscs%26jtitle%3DFEBS%2520Lett.%26date%3D2010%26volume%3D584%26spage%3D1721%26epage%3D1727%26doi%3D10.1016%2Fj.febslet.2009.10.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Scott, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kummer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tremmel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">PlÃ¼ckthun, A.</span><span> </span><span class="NLM_article-title">Stabilizing membrane proteins through protein engineering</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">427</span><span class="NLM_x">â</span> <span class="NLM_lpage">435</span><span class="refDoi">Â DOI: 10.1016/j.cbpa.2013.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.cbpa.2013.04.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23639904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmslegtb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=427-435&author=D.+J.+Scottauthor=L.+Kummerauthor=D.+Tremmelauthor=A.+Pl%C3%BCckthun&title=Stabilizing+membrane+proteins+through+protein+engineering&doi=10.1016%2Fj.cbpa.2013.04.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Stabilizing membrane proteins through protein engineering</span></div><div class="casAuthors">Scott, Daniel J.; Kummer, Lutz; Tremmel, Dirk; Pluckthun, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">427-435</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Integral membrane proteins (IMPs) are crucial components of all cells but are difficult to study in vitro because they are generally unstable when removed from their native membranes using detergents.  Despite the major biomedical relevance of IMPs, less than 1% of Protein Data Bank (PDB) entries are IMP structures, reflecting the tech. gap between studies of sol. proteins compared to IMPs.  Stability can be engineered into IMPs by inserting stabilizing mutations, thereby generating proteins that can be successfully applied to biochem. and structural studies when solubilized in detergent micelles.  The identification of stabilizing mutations is not trivial, and this review will focus on the methods that have been used to identify stabilized membrane proteins, including alanine scanning and screening, directed evolution and computational design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoocb73dapL2bVg90H21EOLACvtfcHk0liHSmvHNedr_w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmslegtb4%253D&md5=62f707eee2a1c2995f8baf717b9776a2</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2013.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2013.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DD.%2BJ.%26aulast%3DKummer%26aufirst%3DL.%26aulast%3DTremmel%26aufirst%3DD.%26aulast%3DPl%25C3%25BCckthun%26aufirst%3DA.%26atitle%3DStabilizing%2520membrane%2520proteins%2520through%2520protein%2520engineering%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D17%26spage%3D427%26epage%3D435%26doi%3D10.1016%2Fj.cbpa.2013.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Viegas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viennet, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etzkorn, M.</span><span> </span><span class="NLM_article-title">The power, pitfalls and potential of the nanodisc system for NMR-based studies</span> <span class="citation_source-journal">Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">397</span><span class="NLM_x">, </span> <span class="NLM_fpage">1335</span><span class="NLM_x">â</span> <span class="NLM_lpage">1354</span><span class="refDoi">Â DOI: 10.1515/hsz-2016-0224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1515%2Fhsz-2016-0224" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=397&publication_year=2016&pages=1335-1354&author=A.+Viegasauthor=T.+Viennetauthor=M.+Etzkorn&title=The+power%2C+pitfalls+and+potential+of+the+nanodisc+system+for+NMR-based+studies&doi=10.1515%2Fhsz-2016-0224"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69a&amp;dbid=16384&amp;doi=10.1515%2Fhsz-2016-0224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252Fhsz-2016-0224%26sid%3Dliteratum%253Aachs%26aulast%3DViegas%26aufirst%3DA.%26aulast%3DViennet%26aufirst%3DT.%26aulast%3DEtzkorn%26aufirst%3DM.%26atitle%3DThe%2520power%252C%2520pitfalls%2520and%2520potential%2520of%2520the%2520nanodisc%2520system%2520for%2520NMR-based%2520studies%26jtitle%3DBiol.%2520Chem.%26date%3D2016%26volume%3D397%26spage%3D1335%26epage%3D1354%26doi%3D10.1515%2Fhsz-2016-0224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit69b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Dore, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Errey, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollenstein, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tehan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurrell, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Congreve, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tate, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weir, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, F. H.</span><span> </span><span class="NLM_article-title">Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1283</span><span class="NLM_x">â</span> <span class="NLM_lpage">1293</span><span class="refDoi">Â DOI: 10.1016/j.str.2011.06.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.str.2011.06.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21885291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFaru7fE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=1283-1293&author=A.+S.+Doreauthor=N.+Robertsonauthor=J.+C.+Erreyauthor=I.+Ngauthor=K.+Hollensteinauthor=B.+Tehanauthor=E.+Hurrellauthor=K.+Bennettauthor=M.+Congreveauthor=F.+Magnaniauthor=C.+G.+Tateauthor=M.+Weirauthor=F.+H.+Marshall&title=Structure+of+the+adenosine+A%282A%29+receptor+in+complex+with+ZM241385+and+the+xanthines+XAC+and+caffeine&doi=10.1016%2Fj.str.2011.06.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69bR"><div class="casContent"><span class="casTitleNuber">69b</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Adenosine A2A Receptor in Complex with ZM241385 and the Xanthines XAC and Caffeine</span></div><div class="casAuthors">Dore, Andrew S.; Robertson, Nathan; Errey, James C.; Ng, Irene; Hollenstein, Kaspar; Tehan, Ben; Hurrell, Edward; Bennett, Kirstie; Congreve, Miles; Magnani, Francesca; Tate, Christopher G.; Weir, Malcolm; Marshall, Fiona H.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1283-1293</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Methylxanthines, including caffeine and theophylline, are among the most widely consumed stimulant drugs in the world.  These effects are mediated primarily via blockade of adenosine receptors.  Xanthine analogs with improved properties have been developed as potential treatments for diseases such as Parkinson's disease.  Here we report the structures of a thermostabilized adenosine A2A receptor in complex with the xanthines xanthine amine congener and caffeine, as well as the A2A selective inverse agonist ZM241385.  The receptor is crystd. in the inactive state conformation as defined by the presence of a salt bridge known as the ionic lock.  The complete third intracellular loop, responsible for G protein coupling, is visible consisting of extended helixes 5 and 6.  The structures provide new insight into the features that define the ligand binding pocket of the adenosine receptor for ligands of diverse chemotypes as well as the cytoplasmic regions that interact with signal transduction proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWsexwFu6LD7Vg90H21EOLACvtfcHk0liLU1PRoWULog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFaru7fE&md5=a25db14aa70c2b42b9c3eb98c3c16bae</span></div><a href="/servlet/linkout?suffix=cit69b&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2011.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2011.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DDore%26aufirst%3DA.%2BS.%26aulast%3DRobertson%26aufirst%3DN.%26aulast%3DErrey%26aufirst%3DJ.%2BC.%26aulast%3DNg%26aufirst%3DI.%26aulast%3DHollenstein%26aufirst%3DK.%26aulast%3DTehan%26aufirst%3DB.%26aulast%3DHurrell%26aufirst%3DE.%26aulast%3DBennett%26aufirst%3DK.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DMagnani%26aufirst%3DF.%26aulast%3DTate%26aufirst%3DC.%2BG.%26aulast%3DWeir%26aufirst%3DM.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26atitle%3DStructure%2520of%2520the%2520adenosine%2520A%25282A%2529%2520receptor%2520in%2520complex%2520with%2520ZM241385%2520and%2520the%2520xanthines%2520XAC%2520and%2520caffeine%26jtitle%3DStructure%26date%3D2011%26volume%3D19%26spage%3D1283%26epage%3D1293%26doi%3D10.1016%2Fj.str.2011.06.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Dominik, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kossiakoff, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arun, K. S.</span><span> </span><span class="NLM_article-title">Phage display selections for affinity reagents to membrane proteins in nanodiscs</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">557</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">â</span> <span class="NLM_lpage">245</span><span class="refDoi">Â DOI: 10.1016/bs.mie.2014.12.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fbs.mie.2014.12.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25950967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1KmtL%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=557&publication_year=2015&pages=219-245&author=P.+K.+Dominikauthor=A.+A.+Kossiakoffauthor=K.+S.+Arun&title=Phage+display+selections+for+affinity+reagents+to+membrane+proteins+in+nanodiscs&doi=10.1016%2Fbs.mie.2014.12.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70aR"><div class="casContent"><span class="casTitleNuber">70a</span><div class="casTitle"><span class="NLM_cas:atitle">Phage display selections for affinity reagents to membrane proteins in nanodiscs</span></div><div class="casAuthors">Dominik, Pawel K.; Kossiakoff, Anthony A.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">557</span>
        (<span class="NLM_cas:issue">Membrane Proteins--Engineering, Purification and Crystallization</span>),
    <span class="NLM_cas:pages">219-245</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Phage display selections generate high-affinity synthetic reagents that can be used as tools in structural characterization of membrane proteins.  Currently, most selection protocols are performed with membrane protein targets in detergents.  However, there are numerous tech. issues assocd. with this, primarily that detergents are poor mimics of the native lipid environment.  Here, we describe a set of protocols for phage display selection that involves reconstituting membrane proteins in nanodiscs, which are small discoidal particles consisting of lipids enclosed by membrane scaffold proteins.  The nanodisc format enabled us to expand the capabilities of competitive and subtractive phage display selection steps, and generation of high-quality synthetic reagents for membrane proteins in native-like lipid environment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_T0Gkl0d1hbVg90H21EOLACvtfcHk0liLU1PRoWULog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1KmtL%252FI&md5=c962b1adb95ca8425dfd220f9aa1d1e0</span></div><a href="/servlet/linkout?suffix=cit70a&amp;dbid=16384&amp;doi=10.1016%2Fbs.mie.2014.12.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.mie.2014.12.032%26sid%3Dliteratum%253Aachs%26aulast%3DDominik%26aufirst%3DP.%2BK.%26aulast%3DKossiakoff%26aufirst%3DA.%2BA.%26aulast%3DArun%26aufirst%3DK.%2BS.%26atitle%3DPhage%2520display%2520selections%2520for%2520affinity%2520reagents%2520to%2520membrane%2520proteins%2520in%2520nanodiscs%26jtitle%3DMethods%2520Enzymol.%26date%3D2015%26volume%3D557%26spage%3D219%26epage%3D245%26doi%3D10.1016%2Fbs.mie.2014.12.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit70b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Congreve, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rich, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myszka, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figaroa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegal, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, C. K.</span><span> </span><span class="NLM_article-title">Fragment screening of stabilized G-protein-coupled receptors using biophysical methods</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">493</span><span class="NLM_x">, </span> <span class="NLM_fpage">115</span><span class="NLM_x">â</span> <span class="NLM_lpage">136</span><span class="refDoi">Â DOI: 10.1016/B978-0-12-381274-2.00005-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2FB978-0-12-381274-2.00005-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21371589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosleku7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=493&publication_year=2011&pages=115-136&author=M.+Congreveauthor=R.+L.+Richauthor=D.+G.+Myszkaauthor=F.+Figaroaauthor=G.+Siegalauthor=F.+H.+Marshallauthor=C.+K.+Lawrence&title=Fragment+screening+of+stabilized+G-protein-coupled+receptors+using+biophysical+methods&doi=10.1016%2FB978-0-12-381274-2.00005-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70bR"><div class="casContent"><span class="casTitleNuber">70b</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment screening of stabilized G-protein-coupled receptors using biophysical methods</span></div><div class="casAuthors">Congreve, Miles; Rich, Rebecca L.; Myszka, David G.; Figaroa, Francis; Siegal, Gregg; Marshall, Fiona H.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">493</span>
        (<span class="NLM_cas:issue">Fragment-Based Drug Design</span>),
    <span class="NLM_cas:pages">115-136</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Biophys. studies with G-protein-coupled receptors (GPCRs) are typically very challenging due to the poor stability of these receptors when solubilized from the cell membrane into detergent solns.  However, the stability of a GPCR can be greatly improved by introducing a no. of point mutations into the protein sequence to give a stabilized receptor or StaR.  Here, we present the utility of StaRs for biophys. studies and the screening of fragment libraries.  Two case studies are used to illustrate the methods: first, the screening of a library of fragments by surface plasmon resonance against the adenosine A2A receptor StaR, demonstrating how very small and weakly active xanthine fragments can be detected binding to the protein on chips; second, the screening and detection of fragment hits of a larger fragment library in an NMR format called TINS (target-immobilized NMR screening) against the Î²1 adrenergic StaR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQaPwGQSwwnbVg90H21EOLACvtfcHk0liLU1PRoWULog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosleku7c%253D&md5=e9e5e7053358ef1d0d8498669376fe9a</span></div><a href="/servlet/linkout?suffix=cit70b&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-381274-2.00005-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-381274-2.00005-4%26sid%3Dliteratum%253Aachs%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DRich%26aufirst%3DR.%2BL.%26aulast%3DMyszka%26aufirst%3DD.%2BG.%26aulast%3DFigaroa%26aufirst%3DF.%26aulast%3DSiegal%26aufirst%3DG.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26aulast%3DLawrence%26aufirst%3DC.%2BK.%26atitle%3DFragment%2520screening%2520of%2520stabilized%2520G-protein-coupled%2520receptors%2520using%2520biophysical%2520methods%26jtitle%3DMethods%2520Enzymol.%26date%3D2011%26volume%3D493%26spage%3D115%26epage%3D136%26doi%3D10.1016%2FB978-0-12-381274-2.00005-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerner, R. A.</span><span> </span><span class="NLM_article-title">A proximity based general method for identification of ligand and receptor interactions in living cells</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">454</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">â</span> <span class="NLM_lpage">255</span><span class="refDoi">Â DOI: 10.1016/j.bbrc.2014.10.085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.bbrc.2014.10.085" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=454&publication_year=2014&pages=251-255&author=H.+Zhangauthor=J.+Xieauthor=R.+A.+Lerner&title=A+proximity+based+general+method+for+identification+of+ligand+and+receptor+interactions+in+living+cells&doi=10.1016%2Fj.bbrc.2014.10.085"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71a&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2014.10.085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2014.10.085%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DLerner%26aufirst%3DR.%2BA.%26atitle%3DA%2520proximity%2520based%2520general%2520method%2520for%2520identification%2520of%2520ligand%2520and%2520receptor%2520interactions%2520in%2520living%2520cells%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2014%26volume%3D454%26spage%3D251%26epage%3D255%26doi%3D10.1016%2Fj.bbrc.2014.10.085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit71b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Peng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dharmarajan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novick, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerner, R. A.</span><span> </span><span class="NLM_article-title">A general method for insertion of functional proteins within proteins via combinatorial selection of permissive junctions</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1134</span><span class="NLM_x">â</span> <span class="NLM_lpage">1143</span><span class="refDoi">Â DOI: 10.1016/j.chembiol.2015.07.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.chembiol.2015.07.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26278185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlektrzE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=1134-1143&author=Y.+Pengauthor=W.+Zengauthor=H.+Yeauthor=K.+H.+Hanauthor=V.+Dharmarajanauthor=S.+Novickauthor=I.+A.+Wilsonauthor=P.+R.+Griffinauthor=J.+M.+Friedmanauthor=R.+A.+Lerner&title=A+general+method+for+insertion+of+functional+proteins+within+proteins+via+combinatorial+selection+of+permissive+junctions&doi=10.1016%2Fj.chembiol.2015.07.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71bR"><div class="casContent"><span class="casTitleNuber">71b</span><div class="casTitle"><span class="NLM_cas:atitle">A General Method for Insertion of Functional Proteins within Proteins via Combinatorial Selection of Permissive Junctions</span></div><div class="casAuthors">Peng, Yingjie; Zeng, Wenwen; Ye, Hui; Han, Kyung Ho; Dharmarajan, Venkatasubramanian; Novick, Scott; Wilson, Ian A.; Griffin, Patrick R.; Friedman, Jeffrey M.; Lerner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1134-1143</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A major goal of modern protein chem. is to create new proteins with different functions.  One approach is to amalgamate secondary and tertiary structures from different proteins.  This is difficult for several reasons, not the least of which is the fact that the junctions between secondary and tertiary structures are not degenerate and usually affect the function and folding of the entire complex.  Here, we offer a soln. to this problem by coupling a large combinatorial library of about 107 different N- and C-terminal junctions to a powerful system that selects for function.  Using this approach, the entire Leptin and FSH (FSH) were inserted into an antibody.  Complexes with full retention of function in vivo and in vitro, although rare, were found easily by using an autocrine selection system to search for hormonal activity.  Such large diversity systems, when coupled to robust selection systems, should enable construction of novel therapeutic proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5oCHNtWT4zbVg90H21EOLACvtfcHk0lgZaibejK-Lyg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlektrzE&md5=a28c7ab2cd9a1ca198fb303cbdabbc73</span></div><a href="/servlet/linkout?suffix=cit71b&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2015.07.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2015.07.011%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DZeng%26aufirst%3DW.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DHan%26aufirst%3DK.%2BH.%26aulast%3DDharmarajan%26aufirst%3DV.%26aulast%3DNovick%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DI.%2BA.%26aulast%3DGriffin%26aufirst%3DP.%2BR.%26aulast%3DFriedman%26aufirst%3DJ.%2BM.%26aulast%3DLerner%26aufirst%3DR.%2BA.%26atitle%3DA%2520general%2520method%2520for%2520insertion%2520of%2520functional%2520proteins%2520within%2520proteins%2520via%2520combinatorial%2520selection%2520of%2520permissive%2520junctions%26jtitle%3DChem.%2520Biol.%26date%3D2015%26volume%3D22%26spage%3D1134%26epage%3D1143%26doi%3D10.1016%2Fj.chembiol.2015.07.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit71c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Xie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yea, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerner, R. A.</span><span> </span><span class="NLM_article-title">Autocrine signaling based selection of combinatorial antibodies that transdifferentiate human stem cells</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">8099</span><span class="NLM_x">â</span> <span class="NLM_lpage">8104</span><span class="refDoi">Â DOI: 10.1073/pnas.1306263110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1073%2Fpnas.1306263110" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=8099-8104&author=J.+Xieauthor=H.+Zhangauthor=K.+Yeaauthor=R.+A.+Lerner&title=Autocrine+signaling+based+selection+of+combinatorial+antibodies+that+transdifferentiate+human+stem+cells&doi=10.1073%2Fpnas.1306263110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71c&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1306263110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1306263110%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DYea%26aufirst%3DK.%26aulast%3DLerner%26aufirst%3DR.%2BA.%26atitle%3DAutocrine%2520signaling%2520based%2520selection%2520of%2520combinatorial%2520antibodies%2520that%2520transdifferentiate%2520human%2520stem%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D8099%26epage%3D8104%26doi%3D10.1073%2Fpnas.1306263110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit71d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Possani, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yea, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerner, R. A.</span><span> </span><span class="NLM_article-title">Autocrine-based selection of drugs that target ion channels from combinatorial venom peptide libraries</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">9306</span><span class="NLM_x">â</span> <span class="NLM_lpage">9310</span><span class="refDoi">Â DOI: 10.1002/anie.201603052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fanie.201603052" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=9306-9310&author=H.+Zhangauthor=M.+Duauthor=J.+Xieauthor=X.+Liuauthor=J.+Sunauthor=W.+Wangauthor=X.+Xinauthor=L.+D.+Possaniauthor=K.+Yeaauthor=R.+A.+Lerner&title=Autocrine-based+selection+of+drugs+that+target+ion+channels+from+combinatorial+venom+peptide+libraries&doi=10.1002%2Fanie.201603052"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71d&amp;dbid=16384&amp;doi=10.1002%2Fanie.201603052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201603052%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DDu%26aufirst%3DM.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DXin%26aufirst%3DX.%26aulast%3DPossani%26aufirst%3DL.%2BD.%26aulast%3DYea%26aufirst%3DK.%26aulast%3DLerner%26aufirst%3DR.%2BA.%26atitle%3DAutocrine-based%2520selection%2520of%2520drugs%2520that%2520target%2520ion%2520channels%2520from%2520combinatorial%2520venom%2520peptide%2520libraries%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D9306%26epage%3D9310%26doi%3D10.1002%2Fanie.201603052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sturchler, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nieto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cistrone, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yea, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Stefano, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerner, R. A.</span><span> </span><span class="NLM_article-title">Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">8918</span><span class="refDoi">Â DOI: 10.1038/ncomms9918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fncomms9918" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26621478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFemtLnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=8918&author=H.+Zhangauthor=E.+Sturchlerauthor=J.+Zhuauthor=A.+Nietoauthor=P.+A.+Cistroneauthor=J.+Xieauthor=L.+Heauthor=K.+Yeaauthor=T.+Jonesauthor=R.+Turnauthor=P.+S.+Di+Stefanoauthor=P.+R.+Griffinauthor=P.+E.+Dawsonauthor=P.+H.+McDonaldauthor=R.+A.+Lerner&title=Autocrine+selection+of+a+GLP-1R+G-protein+biased+agonist+with+potent+antidiabetic+effects&doi=10.1038%2Fncomms9918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects</span></div><div class="casAuthors">Zhang, Hongkai; Sturchler, Emmanuel; Zhu, Jiang; Nieto, Ainhoa; Cistrone, Philip A.; Xie, Jia; He, LinLing; Yea, Kyungmoo; Jones, Teresa; Turn, Rachel; Di Stefano, Peter S.; Griffin, Patrick R.; Dawson, Philip E.; McDonald, Patricia H.; Lerner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8918</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonists have emerged as treatment options for type 2 diabetes mellitus (T2DM).  GLP-1R signals through G-protein-dependent, and G-protein-independent pathways by engaging the scaffold protein Î²-arrestin; preferential signalling of ligands through one or the other of these branches is known as 'ligand bias'.  Here we report the discovery of the potent and selective GLP-1R G-protein-biased agonist, P5.  We identified P5 in a high-throughput autocrine-based screening of large combinatorial peptide libraries, and show that P5 promotes G-protein signalling comparable to GLP-1 and Exendin-4, but exhibited a significantly reduced Î²-arrestin response.  Preclin. studies using different mouse models of T2DM demonstrate that P5 is a weak insulin secretagogue.  Nevertheless, chronic treatment of diabetic mice with P5 increased adipogenesis, reduced adipose tissue inflammation as well as hepatic steatosis and was more effective at correcting hyperglycemia and lowering Hb A1c levels than Exendin-4, suggesting that GLP-1R G-protein-biased agonists may provide a novel therapeutic approach to T2DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEBfb0W6bx47Vg90H21EOLACvtfcHk0lgZaibejK-Lyg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFemtLnJ&md5=8d638fbc3fb3996f1f21779f4f8aa001</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1038%2Fncomms9918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms9918%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DSturchler%26aufirst%3DE.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DNieto%26aufirst%3DA.%26aulast%3DCistrone%26aufirst%3DP.%2BA.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DYea%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DT.%26aulast%3DTurn%26aufirst%3DR.%26aulast%3DDi%2BStefano%26aufirst%3DP.%2BS.%26aulast%3DGriffin%26aufirst%3DP.%2BR.%26aulast%3DDawson%26aufirst%3DP.%2BE.%26aulast%3DMcDonald%26aufirst%3DP.%2BH.%26aulast%3DLerner%26aufirst%3DR.%2BA.%26atitle%3DAutocrine%2520selection%2520of%2520a%2520GLP-1R%2520G-protein%2520biased%2520agonist%2520with%2520potent%2520antidiabetic%2520effects%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D8918%26doi%3D10.1038%2Fncomms9918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Yoshimoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatematsu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iijima, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niimi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maturana, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanizawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuroda, S.</span><span> </span><span class="NLM_article-title">High-throughput de novo screening of receptor agonists with an automated single-cell analysis and isolation system</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">4242</span><span class="refDoi">Â DOI: 10.1038/srep04242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fsrep04242" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=4242&author=N.+Yoshimotoauthor=K.+Tatematsuauthor=M.+Iijimaauthor=T.+Niimiauthor=A.+D.+Maturanaauthor=I.+Fujiiauthor=A.+Kondoauthor=K.+Tanizawaauthor=S.+Kuroda&title=High-throughput+de+novo+screening+of+receptor+agonists+with+an+automated+single-cell+analysis+and+isolation+system&doi=10.1038%2Fsrep04242"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1038%2Fsrep04242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep04242%26sid%3Dliteratum%253Aachs%26aulast%3DYoshimoto%26aufirst%3DN.%26aulast%3DTatematsu%26aufirst%3DK.%26aulast%3DIijima%26aufirst%3DM.%26aulast%3DNiimi%26aufirst%3DT.%26aulast%3DMaturana%26aufirst%3DA.%2BD.%26aulast%3DFujii%26aufirst%3DI.%26aulast%3DKondo%26aufirst%3DA.%26aulast%3DTanizawa%26aufirst%3DK.%26aulast%3DKuroda%26aufirst%3DS.%26atitle%3DHigh-throughput%2520de%2520novo%2520screening%2520of%2520receptor%2520agonists%2520with%2520an%2520automated%2520single-cell%2520analysis%2520and%2520isolation%2520system%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D4%26spage%3D4242%26doi%3D10.1038%2Fsrep04242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Zhang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pokharel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, S.</span><span> </span><span class="NLM_article-title">Purification of synthetic peptides using a catching full-length sequence by polymerization approach</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1290</span><span class="NLM_x">â</span> <span class="NLM_lpage">1293</span><span class="refDoi">Â DOI: 10.1021/ol403426u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol403426u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=1290-1293&author=M.+Zhangauthor=D.+Pokharelauthor=S.+Fang&title=Purification+of+synthetic+peptides+using+a+catching+full-length+sequence+by+polymerization+approach&doi=10.1021%2Fol403426u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Fol403426u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol403426u%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DPokharel%26aufirst%3DD.%26aulast%3DFang%26aufirst%3DS.%26atitle%3DPurification%2520of%2520synthetic%2520peptides%2520using%2520a%2520catching%2520full-length%2520sequence%2520by%2520polymerization%2520approach%26jtitle%3DOrg.%2520Lett.%26date%3D2014%26volume%3D16%26spage%3D1290%26epage%3D1293%26doi%3D10.1021%2Fol403426u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Garcia-Martin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quintanar-Audelo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Ramos, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruz, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gravel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furic, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cote, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tulla-Puche, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albericio, F.</span><span> </span><span class="NLM_article-title">ChemMatrix, a poly(ethylene glycol)-based support for the solid-phase synthesis of complex peptides</span> <span class="citation_source-journal">J. Comb. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">â</span> <span class="NLM_lpage">220</span><span class="refDoi">Â DOI: 10.1021/cc0600019</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cc0600019" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhs1Citb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=213-220&author=F.+Garcia-Martinauthor=M.+Quintanar-Audeloauthor=Y.+Garcia-Ramosauthor=L.+J.+Cruzauthor=C.+Gravelauthor=R.+Furicauthor=S.+Coteauthor=J.+Tulla-Pucheauthor=F.+Albericio&title=ChemMatrix%2C+a+poly%28ethylene+glycol%29-based+support+for+the+solid-phase+synthesis+of+complex+peptides&doi=10.1021%2Fcc0600019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">ChemMatrix, a Poly(ethylene glycol)-Based Support for the Solid-Phase Synthesis of Complex Peptides</span></div><div class="casAuthors">Garcia-Martin, Fayna; Quintanar-Audelo, Martina; Garcia-Ramos, Yesica; Cruz, Luis J.; Gravel, Catherine; Furic, Robert; Cote, Simon; Tulla-Puche, Judit; Albericio, Fernando</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Combinatorial Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-220</span>CODEN:
                <span class="NLM_cas:coden">JCCHFF</span>;
        ISSN:<span class="NLM_cas:issn">1520-4766</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">CM (ChemMatrix) resin is a new, totally poly(ethylene glycol) (PEG)-based resin and is highly chem. stable.  It exhibits good loading and is user-friendly because of its free-flowing form upon drying.  It performs excellently for the prepn. of hydrophobic, highly structured, and poly-Arg peptides, as compared to polystyrene (PS) resins.  In the most striking example, stepwise solid-phase assembly of the highly complex Î²-amyloid (1-42) peptide resulted in a crude material of 91% purity.  In contrast, literature procedures using PS or PEG-PS-based resins for this peptide required convergent approaches, addnl. time-consuming steps, or both.  In addn. to the difficulties of its synthesis, characterization of Î²-amyloid (1-42) peptide is also a challenge, and methods for characterization by HPLC and MALDI-TOF have also been developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPx4dUMGISm7Vg90H21EOLACvtfcHk0lhjPg3bCNGBLQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhs1Citb4%253D&md5=d2040b6414ab80b8a96b47d6ce7ef0ea</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Fcc0600019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcc0600019%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Martin%26aufirst%3DF.%26aulast%3DQuintanar-Audelo%26aufirst%3DM.%26aulast%3DGarcia-Ramos%26aufirst%3DY.%26aulast%3DCruz%26aufirst%3DL.%2BJ.%26aulast%3DGravel%26aufirst%3DC.%26aulast%3DFuric%26aufirst%3DR.%26aulast%3DCote%26aufirst%3DS.%26aulast%3DTulla-Puche%26aufirst%3DJ.%26aulast%3DAlbericio%26aufirst%3DF.%26atitle%3DChemMatrix%252C%2520a%2520poly%2528ethylene%2520glycol%2529-based%2520support%2520for%2520the%2520solid-phase%2520synthesis%2520of%2520complex%2520peptides%26jtitle%3DJ.%2520Comb.%2520Chem.%26date%3D2006%26volume%3D8%26spage%3D213%26epage%3D220%26doi%3D10.1021%2Fcc0600019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Pedersen, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tofteng, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malik, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, K. J.</span><span> </span><span class="NLM_article-title">Microwave heating in solid-phase peptide synthesis</span> <span class="citation_source-journal">Chem. Soc. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1826</span><span class="NLM_x">â</span> <span class="NLM_lpage">1844</span><span class="refDoi">Â DOI: 10.1039/C1CS15214A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1039%2FC1CS15214A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=22012213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFyjsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2012&pages=1826-1844&author=S.+L.+Pedersenauthor=A.+P.+Toftengauthor=L.+Malikauthor=K.+J.+Jensen&title=Microwave+heating+in+solid-phase+peptide+synthesis&doi=10.1039%2FC1CS15214A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Microwave heating in solid-phase peptide synthesis</span></div><div class="casAuthors">Pedersen, Soren L.; Tofteng, A. Pernille; Malik, Leila; Jensen, Knud J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1826-1844</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The highly refined org. chem. in solid-phase synthesis has made it the method of choice not only to assemble peptides but also small proteins - mainly on a lab. scale but increasingly also on an industrial scale.  While conductive heating occasionally has been applied to peptide synthesis, precise microwave irradn. to heat the reaction mixt. during coupling and NÎ±-deprotection has become increasingly popular.  It has often provided dramatic redns. in synthesis times, accompanied by an increase in the crude peptide purity.  Microwave heating has been proven esp. relevant for sequences which might form Î²-sheet type structures and for sterically difficult couplings.  The beneficial effect of microwave heating appears so far to be due to the precise nature of this type of heating, rather than a peptide-specific microwave effect.  However, microwave heating as such is not a panacea for all difficulties in peptide syntheses and the conditions may need to be adjusted for the incorporation of Cys, His and Asp in peptides, and for the synthesis of, for example, phosphopeptides, glycopeptides, and N-methylated peptides.  Here, the authors provide a comprehensive overview of the advances in microwave heating for peptide synthesis, with a focus on systematic studies and general protocols, as well as important applications.  The assembly of Î²-peptides, peptoids and pseudopeptides are also evaluated in this crit. review (254 refs.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVFzfdkVUo3rVg90H21EOLACvtfcHk0lhjPg3bCNGBLQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFyjsrk%253D&md5=2bc445be062278ae85863188429ec9e8</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1039%2FC1CS15214A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC1CS15214A%26sid%3Dliteratum%253Aachs%26aulast%3DPedersen%26aufirst%3DS.%2BL.%26aulast%3DTofteng%26aufirst%3DA.%2BP.%26aulast%3DMalik%26aufirst%3DL.%26aulast%3DJensen%26aufirst%3DK.%2BJ.%26atitle%3DMicrowave%2520heating%2520in%2520solid-phase%2520peptide%2520synthesis%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2012%26volume%3D41%26spage%3D1826%26epage%3D1844%26doi%3D10.1039%2FC1CS15214A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Paradis-Bas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tulla-Puche, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albericio, F.</span><span> </span><span class="NLM_article-title">The road to the synthesis of â³difficult peptidesâ³</span> <span class="citation_source-journal">Chem. Soc. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">631</span><span class="NLM_x">â</span> <span class="NLM_lpage">654</span><span class="refDoi">Â DOI: 10.1039/C5CS00680E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1039%2FC5CS00680E" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=631-654&author=M.+Paradis-Basauthor=J.+Tulla-Pucheauthor=F.+Albericio&title=The+road+to+the+synthesis+of+%E2%80%B3difficult+peptides%E2%80%B3&doi=10.1039%2FC5CS00680E"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1039%2FC5CS00680E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5CS00680E%26sid%3Dliteratum%253Aachs%26aulast%3DParadis-Bas%26aufirst%3DM.%26aulast%3DTulla-Puche%26aufirst%3DJ.%26aulast%3DAlbericio%26aufirst%3DF.%26atitle%3DThe%2520road%2520to%2520the%2520synthesis%2520of%2520%25E2%2580%25B3difficult%2520peptides%25E2%2580%25B3%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2016%26volume%3D45%26spage%3D631%26epage%3D654%26doi%3D10.1039%2FC5CS00680E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Coin, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beyermann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bienert, M.</span><span> </span><span class="NLM_article-title">Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences</span> <span class="citation_source-journal">Nat. Protoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">3247</span><span class="NLM_x">â</span> <span class="NLM_lpage">3256</span><span class="refDoi">Â DOI: 10.1038/nprot.2007.454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnprot.2007.454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=18079725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVejtrfK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=3247-3256&author=I.+Coinauthor=M.+Beyermannauthor=M.+Bienert&title=Solid-phase+peptide+synthesis%3A+from+standard+procedures+to+the+synthesis+of+difficult+sequences&doi=10.1038%2Fnprot.2007.454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences</span></div><div class="casAuthors">Coin, Irene; Beyermann, Michael; Bienert, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3247-3256</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  This protocol for solid-phase peptide synthesis (SPPS) is based on the widely used Fmoc/tBu strategy, activation of the carboxyl groups by aminium-derived coupling reagents and use of PEG-modified polystyrene resins.  A std. protocol is described, which was successfully applied in our lab for the synthesis of the corticotropin-releasing factor (CRF), >400 CRF analogs and a countless no. of other peptides.  The 41-mer peptide CRF is obtained within â¼80 working hours.  To achieve the so-called difficult sequences, special techniques have to be applied in order to reduce aggregation of the growing peptide chain, which is the main cause of failure for peptide chem. synthesis.  Exemplary application of depsipeptide and pseudoproline units is shown for synthesizing an extremely difficult sequence, the Asn(15) analog of the WW domain FBP28, which is impossible to obtain using the std. protocol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEUh1hcec8VbVg90H21EOLACvtfcHk0lholVsQADW83A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVejtrfK&md5=7ab725d5cf80efe83e8090263d55d33f</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2007.454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2007.454%26sid%3Dliteratum%253Aachs%26aulast%3DCoin%26aufirst%3DI.%26aulast%3DBeyermann%26aufirst%3DM.%26aulast%3DBienert%26aufirst%3DM.%26atitle%3DSolid-phase%2520peptide%2520synthesis%253A%2520from%2520standard%2520procedures%2520to%2520the%2520synthesis%2520of%2520difficult%2520sequences%26jtitle%3DNat.%2520Protoc.%26date%3D2007%26volume%3D2%26spage%3D3247%26epage%3D3256%26doi%3D10.1038%2Fnprot.2007.454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wohr, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nefzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohwedder, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutter, M.</span><span> </span><span class="NLM_article-title">Pseudo-Prolines as a solubilizing, structure-disrupting protection technique in peptide synthesis</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">9218</span><span class="NLM_x">â</span> <span class="NLM_lpage">9227</span><span class="refDoi">Â DOI: 10.1021/ja961509q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja961509q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=1996&pages=9218-9227&author=T.+Wohrauthor=F.+Wahlauthor=A.+Nefziauthor=B.+Rohwedderauthor=T.+Satoauthor=X.+Sunauthor=M.+Mutter&title=Pseudo-Prolines+as+a+solubilizing%2C+structure-disrupting+protection+technique+in+peptide+synthesis&doi=10.1021%2Fja961509q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79a&amp;dbid=16384&amp;doi=10.1021%2Fja961509q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja961509q%26sid%3Dliteratum%253Aachs%26aulast%3DWohr%26aufirst%3DT.%26aulast%3DWahl%26aufirst%3DF.%26aulast%3DNefzi%26aufirst%3DA.%26aulast%3DRohwedder%26aufirst%3DB.%26aulast%3DSato%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DMutter%26aufirst%3DM.%26atitle%3DPseudo-Prolines%2520as%2520a%2520solubilizing%252C%2520structure-disrupting%2520protection%2520technique%2520in%2520peptide%2520synthesis%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1996%26volume%3D118%26spage%3D9218%26epage%3D9227%26doi%3D10.1021%2Fja961509q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit79b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Harris, P. W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowalczyk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hay, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brimble, M. A.</span><span> </span><span class="NLM_article-title">A single pseudoproline and microwave solid phase peptide synthesis facilitates an efficient synthesis of human amylin 1â37</span> <span class="citation_source-journal">Int. J. Pept. Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">â</span> <span class="NLM_lpage">155</span><span class="refDoi">Â DOI: 10.1007/s10989-012-9325-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1007%2Fs10989-012-9325-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht12ltrnE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=147-155&author=P.+W.+R.+Harrisauthor=R.+Kowalczykauthor=D.+L.+Hayauthor=M.+A.+Brimble&title=A+single+pseudoproline+and+microwave+solid+phase+peptide+synthesis+facilitates+an+efficient+synthesis+of+human+amylin+1%E2%80%9337&doi=10.1007%2Fs10989-012-9325-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79bR"><div class="casContent"><span class="casTitleNuber">79b</span><div class="casTitle"><span class="NLM_cas:atitle">A single pseudoproline and microwave solid phase peptide synthesis facilitates an efficient synthesis of human amylin 1-37</span></div><div class="casAuthors">Harris, Paul W. R.; Kowalczyk, Renata; Hay, Debbie L.; Brimble, Margaret A.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Peptide Research and Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">147-155</span>CODEN:
                <span class="NLM_cas:coden">IJPRFC</span>;
        ISSN:<span class="NLM_cas:issn">1573-3149</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A chem. synthesis of the 37 residue polypeptide human amylin using microwave enhanced solid phase peptide chem. is described.  An optimized protocol used only a single pseudoproline deriv., a CP resin and single couplings of all amino acids to deliver non-oxidized amylin in high yield.  Oxidn. of the crude peptide to form the disulfide bond was accomplished in 20 min using 2,2'-dipyridyl disulfide in DMSO giving human amylin that was fully functional in a cAMP assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_sghd75hPPbVg90H21EOLACvtfcHk0lholVsQADW83A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht12ltrnE&md5=c72fe43624f8491b2aae985c790d4d21</span></div><a href="/servlet/linkout?suffix=cit79b&amp;dbid=16384&amp;doi=10.1007%2Fs10989-012-9325-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10989-012-9325-9%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DP.%2BW.%2BR.%26aulast%3DKowalczyk%26aufirst%3DR.%26aulast%3DHay%26aufirst%3DD.%2BL.%26aulast%3DBrimble%26aufirst%3DM.%2BA.%26atitle%3DA%2520single%2520pseudoproline%2520and%2520microwave%2520solid%2520phase%2520peptide%2520synthesis%2520facilitates%2520an%2520efficient%2520synthesis%2520of%2520human%2520amylin%25201%25E2%2580%259337%26jtitle%3DInt.%2520J.%2520Pept.%2520Res.%2520Ther.%26date%3D2013%26volume%3D19%26spage%3D147%26epage%3D155%26doi%3D10.1007%2Fs10989-012-9325-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Coin, I.</span><span> </span><span class="NLM_article-title">The depsipeptide method for solid-phase synthesis of difficult peptides</span> <span class="citation_source-journal">J. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">â</span> <span class="NLM_lpage">230</span><span class="refDoi">Â DOI: 10.1002/psc.1224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fpsc.1224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=20401924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVyjsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=223-230&author=I.+Coin&title=The+depsipeptide+method+for+solid-phase+synthesis+of+difficult+peptides&doi=10.1002%2Fpsc.1224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">The depsipeptide method for solid-phase synthesis of difficult peptides</span></div><div class="casAuthors">Coin, Irene</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">223-230</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  After about one century of peptide chem., the main limitation to the accessibility of peptides and proteins via chem. synthesis is the arising of folding and aggregation phenomena.  This is true not only for sequences above a crit. length but also for several biol. relevant substrates that are relatively short yet form either highly folded structures (e.g. WW domains) or fibrils and aggregates after final deprotection (Î²-amyloid peptide).  Such so-called difficult sequences may be more easily obtained via their corresponding depsipeptides (O-acyl isopeptides), ester isomers that are often easier to assemble and purify, and are smoothly converted to the parent amides under mild conditions.  The depsipeptide method is the most recent technique to improve the outcome of difficult syntheses, applicable to sequences contg. residues of serine or threonine.  A brief overview is presented about chem. aspects of the method, the steps that have been undertaken for its optimization, and the evaluation of its efficiency.  Further applications of analogous principles to other crit. topics in peptide synthesis such as condensation of peptide segments and solid-phase synthesis of naturally occurring cyclodepsipeptides are addressed as well.  Copyright Â© 2010 European Peptide Society and John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8FWlRodL0CrVg90H21EOLACvtfcHk0lholVsQADW83A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVyjsbg%253D&md5=ef580fceffdfed040eb3905fcad43486</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1002%2Fpsc.1224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.1224%26sid%3Dliteratum%253Aachs%26aulast%3DCoin%26aufirst%3DI.%26atitle%3DThe%2520depsipeptide%2520method%2520for%2520solid-phase%2520synthesis%2520of%2520difficult%2520peptides%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2010%26volume%3D16%26spage%3D223%26epage%3D230%26doi%3D10.1002%2Fpsc.1224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Cardona, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberle, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barthelemy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beythien, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doerner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneeberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keyte, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, P. D.</span><span> </span><span class="NLM_article-title">Application of Dmb-dipeptides in the Fmoc SPPS of difficult and aspartimide-prone sequences</span> <span class="citation_source-journal">Int. J. Pept. Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">285</span><span class="NLM_x">â</span> <span class="NLM_lpage">292</span><span class="refDoi">Â DOI: 10.1007/s10989-008-9154-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1007%2Fs10989-008-9154-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1aisLfE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=285-292&author=V.+Cardonaauthor=I.+Eberleauthor=S.+Barthelemyauthor=J.+Beythienauthor=B.+Doernerauthor=P.+Schneebergerauthor=J.+Keyteauthor=P.+D.+White&title=Application+of+Dmb-dipeptides+in+the+Fmoc+SPPS+of+difficult+and+aspartimide-prone+sequences&doi=10.1007%2Fs10989-008-9154-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Application of DMB-dipeptides in the Fmoc SPPS of difficult and aspartimide-prone sequences</span></div><div class="casAuthors">Cardona, V.; Eberle, I.; Barthelemy, S.; Beythien, J.; Doerner, B.; Schneeberger, P.; Keyte, J.; White, P. D.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Peptide Research and Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">285-292</span>CODEN:
                <span class="NLM_cas:coden">IJPRFC</span>;
        ISSN:<span class="NLM_cas:issn">1573-3149</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Mutter's pseudoproline dipeptides and Sheppard's Hmb (Hmb = 2-hydroxy-4-methoxy-1-methylbenzene) derivs. are powerful tools for enhancing synthetic efficiency in Fmoc SPPS (Fmoc = 9-fluorenylmethoxycarbonyl, SPPS = solid phase peptide synthesis).  They work by exploiting the natural propensity of N-alkyl amino acids to disrupt the formation of the secondary structures during peptide assembly.  Their use results in better and more predictable acylation and deprotection kinetics, enhanced reaction rates, and improved yields of crude products.  However, these approaches have certain limitations: pseudoproline dipeptides can only be used for sequences contg. serine or threonine, and the coupling of the amino acid following the Hmb residue can be extremely difficult.  To alleviate some of these shortcomings, we have prepd. a range of Fmoc-Aaa-(Dmb)Gly-OH (Dmb = 2,4-dimethoxy-1-methylbenzene) dipeptides and tested their efficacy in the synthesis of a no. of challenging hydrophobic peptides.  We also compared the efficiency of N-Dmb against N-Hmb backbone protection in preventing aspartimide formation in the Fmoc SPPS of peptides contg. the Asp-Gly sequence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkMA-kRWfVc7Vg90H21EOLACvtfcHk0lholVsQADW83A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1aisLfE&md5=1d2e632730d47e0a835723956c9d7a6e</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1007%2Fs10989-008-9154-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10989-008-9154-z%26sid%3Dliteratum%253Aachs%26aulast%3DCardona%26aufirst%3DV.%26aulast%3DEberle%26aufirst%3DI.%26aulast%3DBarthelemy%26aufirst%3DS.%26aulast%3DBeythien%26aufirst%3DJ.%26aulast%3DDoerner%26aufirst%3DB.%26aulast%3DSchneeberger%26aufirst%3DP.%26aulast%3DKeyte%26aufirst%3DJ.%26aulast%3DWhite%26aufirst%3DP.%2BD.%26atitle%3DApplication%2520of%2520Dmb-dipeptides%2520in%2520the%2520Fmoc%2520SPPS%2520of%2520difficult%2520and%2520aspartimide-prone%2520sequences%26jtitle%3DInt.%2520J.%2520Pept.%2520Res.%2520Ther.%26date%3D2008%26volume%3D14%26spage%3D285%26epage%3D292%26doi%3D10.1007%2Fs10989-008-9154-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Behrendt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Offer, J.</span><span> </span><span class="NLM_article-title">Advances in Fmoc solid-phase peptide synthesis</span> <span class="citation_source-journal">J. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4</span><span class="NLM_x">â</span> <span class="NLM_lpage">27</span><span class="refDoi">Â DOI: 10.1002/psc.2836</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fpsc.2836" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26785684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFSnsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=4-27&author=R.+Behrendtauthor=P.+Whiteauthor=J.+Offer&title=Advances+in+Fmoc+solid-phase+peptide+synthesis&doi=10.1002%2Fpsc.2836"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in Fmoc solid-phase peptide synthesis</span></div><div class="casAuthors">Behrendt, Raymond; White, Peter; Offer, John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4-27</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Today, Fmoc SPPS is the method of choice for peptide synthesis.  Very-high-quality Fmoc building blocks are available at low cost because of the economies of scale arising from current multiton prodn. of therapeutic peptides by Fmoc SPPS.  Many modified derivs. are com. available as Fmoc building blocks, making synthetic access to a broad range of peptide derivs. straightforward.  The no. of synthetic peptides entering clin. trials has grown continuously over the last decade, and recent advances in the Fmoc SPPS technol. are a response to the growing demand from medicinal chem. and pharmacol.  Improvements are being continually reported for peptide quality, synthesis time and novel synthetic targets.  Topical peptide research has contributed to a continuous improvement and expansion of Fmoc SPPS applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNn2hqVjRZfbVg90H21EOLACvtfcHk0li6pbGPRNy_Gg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFSnsbo%253D&md5=ad2b68e27d36071ea520514fb02e70ba</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1002%2Fpsc.2836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.2836%26sid%3Dliteratum%253Aachs%26aulast%3DBehrendt%26aufirst%3DR.%26aulast%3DWhite%26aufirst%3DP.%26aulast%3DOffer%26aufirst%3DJ.%26atitle%3DAdvances%2520in%2520Fmoc%2520solid-phase%2520peptide%2520synthesis%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2016%26volume%3D22%26spage%3D4%26epage%3D27%26doi%3D10.1002%2Fpsc.2836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Behrendt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MartÃ­, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, P.</span><span> </span><span class="NLM_article-title">New t-butyl based aspartate protecting groups preventing aspartimide formation in Fmoc SPPS</span> <span class="citation_source-journal">J. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">680</span><span class="NLM_x">â</span> <span class="NLM_lpage">687</span><span class="refDoi">Â DOI: 10.1002/psc.2790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fpsc.2790" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26077723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpvFShsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=680-687&author=R.+Behrendtauthor=S.+Huberauthor=R.+Mart%C3%ADauthor=P.+White&title=New+t-butyl+based+aspartate+protecting+groups+preventing+aspartimide+formation+in+Fmoc+SPPS&doi=10.1002%2Fpsc.2790"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">New t-butyl based aspartate protecting groups preventing aspartimide formation in Fmoc SPPS</span></div><div class="casAuthors">Behrendt, Raymond; Huber, Simon; Marti, Roger; White, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">680-687</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Obtaining homogeneous aspartyl-contg. peptides via Fmoc/tBu chem. is often an insurmountable obstacle.  A generic soln. for this issue utilizing an optimized side-chain protection strategy that minimizes aspartimide formation would therefore be most desirable.  To this end, we developed the following new derivs.: Fmoc-Asp(OEpe)-OH (Epe = 3-ethyl-3-pentyl), Fmoc-Asp(OPhp)-OH (Php = 4-n-propyl-4-heptyl) and Fmoc-Asp(OBno)-OH (Bno = 5-n-butyl-5-nonyl).  We have compared their effectiveness against that of Fmoc-Asp(OtBu)-OH and Fmoc-Asp(OMpe)-OH in the well-established scorpion toxin II model peptide variants H-Val-Lys-Asp-Asn/Arg-Tyr-Ile-OH by treatments of the peptidyl resins with the Fmoc removal reagents contg. piperidine and DBU at both room and elevated temps.  The new derivs. proved to be extremely effective in minimizing aspartimide byproducts in each application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHNEK5O8WUpbVg90H21EOLACvtfcHk0li6pbGPRNy_Gg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpvFShsrg%253D&md5=a16c6807665bc6add7a02395302d426d</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1002%2Fpsc.2790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.2790%26sid%3Dliteratum%253Aachs%26aulast%3DBehrendt%26aufirst%3DR.%26aulast%3DHuber%26aufirst%3DS.%26aulast%3DMart%25C3%25AD%26aufirst%3DR.%26aulast%3DWhite%26aufirst%3DP.%26atitle%3DNew%2520t-butyl%2520based%2520aspartate%2520protecting%2520groups%2520preventing%2520aspartimide%2520formation%2520in%2520Fmoc%2520SPPS%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2015%26volume%3D21%26spage%3D680%26epage%3D687%26doi%3D10.1002%2Fpsc.2790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Michels, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dolling, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haberkorn, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mier, W.</span><span> </span><span class="NLM_article-title">Acid-mediated prevention of aspartimide formation in solid phase peptide synthesis</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">5218</span><span class="NLM_x">â</span> <span class="NLM_lpage">5221</span><span class="refDoi">Â DOI: 10.1021/ol3007925</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol3007925" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVejsrjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=5218-5221&author=T.+Michelsauthor=R.+Dollingauthor=U.+Haberkornauthor=W.+Mier&title=Acid-mediated+prevention+of+aspartimide+formation+in+solid+phase+peptide+synthesis&doi=10.1021%2Fol3007925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Acid-mediated prevention of aspartimide formation in solid phase peptide synthesis</span></div><div class="casAuthors">Michels, Tillmann; Doelling, Rudolf; Haberkorn, Uwe; Mier, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5218-5221</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aspartimide formation is one of the major obstacles that impedes the solid phase synthesis of large peptides and proteins.  Until now, no cost-effective strategy to suppress this side reaction has been developed.  Here it is demonstrated that addn. of small amts. of org. acids to the std. Fmoc cleavage agent piperidine efficiently prevents formation of aspartimide side products.  This effect is shown to be virtually independent of the acid strength.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpyen9Ony3ObVg90H21EOLACvtfcHk0li6pbGPRNy_Gg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVejsrjE&md5=7a0b1fdea8b46dc44c128e0c354af3ef</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1021%2Fol3007925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol3007925%26sid%3Dliteratum%253Aachs%26aulast%3DMichels%26aufirst%3DT.%26aulast%3DDolling%26aufirst%3DR.%26aulast%3DHaberkorn%26aufirst%3DU.%26aulast%3DMier%26aufirst%3DW.%26atitle%3DAcid-mediated%2520prevention%2520of%2520aspartimide%2520formation%2520in%2520solid%2520phase%2520peptide%2520synthesis%26jtitle%3DOrg.%2520Lett.%26date%3D2012%26volume%3D14%26spage%3D5218%26epage%3D5221%26doi%3D10.1021%2Fol3007925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">SubirÃ³s-Funosas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Faham, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albericio, F.</span><span> </span><span class="NLM_article-title">Use of Oxyma as pH modulatory agent to be used in the prevention of base-driven side reactions and its effect on 2-chlorotrityl chloride resin</span> <span class="citation_source-journal">Biopolymers</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">â</span> <span class="NLM_lpage">97</span><span class="refDoi">Â DOI: 10.1002/bip.21713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fbip.21713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21882170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFSjurjP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2012&pages=89-97&author=R.+Subir%C3%B3s-Funosasauthor=A.+El-Fahamauthor=F.+Albericio&title=Use+of+Oxyma+as+pH+modulatory+agent+to+be+used+in+the+prevention+of+base-driven+side+reactions+and+its+effect+on+2-chlorotrityl+chloride+resin&doi=10.1002%2Fbip.21713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Use of Oxyma as pH modulatory agent to be used in the prevention of base-driven side reactions and its effect on 2-chlorotrityl chloride resin</span></div><div class="casAuthors">Subiros-Funosas, Ramon; El-Faham, Ayman; Albericio, Fernando</div><div class="citationInfo"><span class="NLM_cas:title">Biopolymers</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">89-97</span>CODEN:
                <span class="NLM_cas:coden">BIPMAA</span>;
        ISSN:<span class="NLM_cas:issn">0006-3525</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The presence of low pKa N-hydroxylamines is beneficial in peptide chem. as they reduce some base-mediated side reactions.  Here we evaluated the applicability and buffering capacity of Et 2-cyano-2-(hydroxyimino)acetate (Oxyma) in the prevention of aspartimide/piperidide formation and Pro-based overcoupling and compared it with the performance of HOBt and HOAt.  In addn., the compatibility of these additives with the highly acid-labile 2-chlorotrityl chloride resin is examd. Â© 2011 Wiley Periodicals, Inc. Biopolymers, 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf1AbQAVUfC7Vg90H21EOLACvtfcHk0liCgfgq5k1q0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFSjurjP&md5=73705b2ab50e4fa81dd7af619ff338e9</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1002%2Fbip.21713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbip.21713%26sid%3Dliteratum%253Aachs%26aulast%3DSubir%25C3%25B3s-Funosas%26aufirst%3DR.%26aulast%3DEl-Faham%26aufirst%3DA.%26aulast%3DAlbericio%26aufirst%3DF.%26atitle%3DUse%2520of%2520Oxyma%2520as%2520pH%2520modulatory%2520agent%2520to%2520be%2520used%2520in%2520the%2520prevention%2520of%2520base-driven%2520side%2520reactions%2520and%2520its%2520effect%2520on%25202-chlorotrityl%2520chloride%2520resin%26jtitle%3DBiopolymers%26date%3D2012%26volume%3D98%26spage%3D89%26epage%3D97%26doi%3D10.1002%2Fbip.21713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Inoue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinohara, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanabe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itoh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizoguchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuoka, S.</span><span> </span><span class="NLM_article-title">Total synthesis of the large non-ribosomal peptide polytheonamide B</span> <span class="citation_source-journal">Nat. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">280</span><span class="NLM_x">â</span> <span class="NLM_lpage">285</span><span class="refDoi">Â DOI: 10.1038/nchem.554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnchem.554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21124508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjslSgsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=280-285&author=M.+Inoueauthor=N.+Shinoharaauthor=S.+Tanabeauthor=T.+Takahashiauthor=K.+Okuraauthor=H.+Itohauthor=Y.+Mizoguchiauthor=M.+Iidaauthor=N.+Leeauthor=S.+Matsuoka&title=Total+synthesis+of+the+large+non-ribosomal+peptide+polytheonamide+B&doi=10.1038%2Fnchem.554"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Total synthesis of the large non-ribosomal peptide polytheonamide B</span></div><div class="casAuthors">Inoue, Masayuki; Shinohara, Naoki; Tanabe, Shintaro; Takahashi, Tomoaki; Okura, Ken; Itoh, Hiroaki; Mizoguchi, Yuki; Iida, Maiko; Lee, Nayoung; Matsuoka, Shigeru</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">280-285</span>CODEN:
                <span class="NLM_cas:coden">NCAHBB</span>;
        ISSN:<span class="NLM_cas:issn">1755-4330</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Polytheonamide B is by far the largest non-ribosomal peptide known at present, and displays extraordinary cytotoxicity (EC50 = 68 pg ml-1, mouse leukemia P388 cells).  Its 48 amino-acid residues include a variety of non-proteinogenic D- and L-amino acids, and the abs. stereochem. of these amino acids alternate in sequence.  These structural features induce the formation of a stable Î²-strand-type structure, giving rise to an overall tubular structure over 30 Ã in length.  In a biol. setting, this fold is believed to transport cations across the lipid bilayer through a pore, thereby acting as an ion channel.  Here, we report the first chem. construction of polytheonamide B.  Our synthesis relies on the combination of four key stages: syntheses of non-proteinogenic amino acids, a solid-phase assembly of four fragments of polytheonamide B, silver-mediated connection of the fragments and, finally, global deprotection.  The synthetic material now available will allow studies of the relationships between its conformational properties, channel functions and cytotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZj_PWLMPlULVg90H21EOLACvtfcHk0liCgfgq5k1q0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjslSgsLo%253D&md5=f30cc2b205caf179bfb08fb7632d276a</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1038%2Fnchem.554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchem.554%26sid%3Dliteratum%253Aachs%26aulast%3DInoue%26aufirst%3DM.%26aulast%3DShinohara%26aufirst%3DN.%26aulast%3DTanabe%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DT.%26aulast%3DOkura%26aufirst%3DK.%26aulast%3DItoh%26aufirst%3DH.%26aulast%3DMizoguchi%26aufirst%3DY.%26aulast%3DIida%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DN.%26aulast%3DMatsuoka%26aufirst%3DS.%26atitle%3DTotal%2520synthesis%2520of%2520the%2520large%2520non-ribosomal%2520peptide%2520polytheonamide%2520B%26jtitle%3DNat.%2520Chem.%26date%3D2010%26volume%3D2%26spage%3D280%26epage%3D285%26doi%3D10.1038%2Fnchem.554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Heinlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VarÃ³n Silva, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">TrÃ¶ster, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unverzagt, C.</span><span> </span><span class="NLM_article-title">Fragment condensation of C-terminal pseudoproline peptides without racemization on the solid phase</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">6406</span><span class="NLM_x">â</span> <span class="NLM_lpage">6410</span><span class="refDoi">Â DOI: 10.1002/anie.201101270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fanie.201101270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFahsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=6406-6410&author=C.+Heinleinauthor=D.+Var%C3%B3n+Silvaauthor=A.+Tr%C3%B6sterauthor=J.+Schmidtauthor=A.+Grossauthor=C.+Unverzagt&title=Fragment+condensation+of+C-terminal+pseudoproline+peptides+without+racemization+on+the+solid+phase&doi=10.1002%2Fanie.201101270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment Condensation of C-Terminal Pseudoproline Peptides without Racemization on the Solid Phase</span></div><div class="casAuthors">Heinlein, Christian; Silva, Daniel Varon; Troester, Andrea; Schmidt, Jasmin; Gross, Angelina; Unverzagt, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">6406-6410</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Protected peptides featuring C-terminal pseudoprolines were synthesized on a solid support, and these versatile building blocks were used in convergent peptide-segment couplings, which proceeded without racemization even under microwave conditions.  The soly.-enhancing effect of pseudoproline residues facilitated the synthesis of complex RNase 39-mer glycopeptide thioesters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr06nUMYrPuNLVg90H21EOLACvtfcHk0liCgfgq5k1q0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFahsr0%253D&md5=6f60b7d527ec7d60163d98eca188b042</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1002%2Fanie.201101270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201101270%26sid%3Dliteratum%253Aachs%26aulast%3DHeinlein%26aufirst%3DC.%26aulast%3DVar%25C3%25B3n%2BSilva%26aufirst%3DD.%26aulast%3DTr%25C3%25B6ster%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DJ.%26aulast%3DGross%26aufirst%3DA.%26aulast%3DUnverzagt%26aufirst%3DC.%26atitle%3DFragment%2520condensation%2520of%2520C-terminal%2520pseudoproline%2520peptides%2520without%2520racemization%2520on%2520the%2520solid%2520phase%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2011%26volume%3D50%26spage%3D6406%26epage%3D6410%26doi%3D10.1002%2Fanie.201101270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Hiebl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgartner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernwieser, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bodenteich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leitner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rovenszky, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alberts, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatnagar, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banyard, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baresch, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esch, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kollmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayrhofer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weihtrager, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welz, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkler, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lantos, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevenson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tubman, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Undheim, K.</span><span> </span><span class="NLM_article-title">Large-scale synthesis of hematoregulatory nonapeptide SK&F 107647 by fragment coupling</span> <span class="citation_source-journal">J. Pept. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">54</span><span class="NLM_x">â</span> <span class="NLM_lpage">65</span><span class="refDoi">Â DOI: 10.1034/j.1399-3011.1999.00089.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1034%2Fj.1399-3011.1999.00089.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10448970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADyaK1MXkslGhur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1999&pages=54-65&author=J.+Hieblauthor=H.+Baumgartnerauthor=I.+Bernwieserauthor=M.+Blankaauthor=M.+Bodenteichauthor=K.+Leitnerauthor=A.+Rioauthor=F.+Rovenszkyauthor=D.+P.+Albertsauthor=P.+K.+Bhatnagarauthor=A.+F.+Banyardauthor=K.+Bareschauthor=P.+M.+Eschauthor=H.+Kollmannauthor=G.+Mayrhoferauthor=H.+Weihtragerauthor=W.+Welzauthor=K.+Winklerauthor=T.+Chenauthor=R.+Patelauthor=I.+Lantosauthor=D.+Stevensonauthor=K.+D.+Tubmanauthor=K.+Undheim&title=Large-scale+synthesis+of+hematoregulatory+nonapeptide+SK%26F+107647+by+fragment+coupling&doi=10.1034%2Fj.1399-3011.1999.00089.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Large-scale synthesis of hematoregulatory nonapeptide SK&F 107647 by fragment coupling</span></div><div class="casAuthors">Hiebl, J.; Alberts, D. P.; Banyard, A. F.; Baresch, K.; Baumgartner, H.; Bernwieser, I.; Bhatnagar, P. K.; Blanka, M.; Bodenteich, M.; Chen, T.; Esch, P. M.; Kollmann, H.; Lantos, I.; Leitner, K.; Mayrhofer, G.; Patel, R.; Rio, A.; Rovenszky, F.; Stevenson, D.; Tubman, K. D.; Undheim, K.; Weihtrager, H.; Welz, W.; Winkler, K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-65</span>CODEN:
                <span class="NLM_cas:coden">JPERFA</span>;
        ISSN:<span class="NLM_cas:issn">1397-002X</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">Linear and convergent routes for the large-scale prepn. of the hematoregulatory nonapeptide (Glp-Glu-Asp)2-DAS-(Lys)2 (I) were investigated.  A convergent approach ("3 + 2"-route employing Boc-and benzyl ester protecting groups) was selected for the prepn. of multi-hundred-gram quantities of I.  Key steps were the prepn. and the coupling of tripeptide hydrochloride (HCl.H)2-DAS-(Lys(Z)-OBn)2 (DAS=2,7-L,L-diamino-suberic acid) and tripeptide Glp-Glu(OBn)-Asp(OBn)-OH.  Several coupling reagents were investigated in order to reduce the amt. of epimerization of this fragment coupling.  TDBTU [O-(3,4-dihydro-4-oxo-1,2,3-benzotriazin-3-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate] was identified as the condensation reagent of choice.  Using this synthetic route >97% pure final product in an overall yield of 35% calcd. on di-Boc protected 2,7-L,L-diamino-suberic acid was prepd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofKrKIFWfLT7Vg90H21EOLACvtfcHk0liQ5AxiIF7w7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXkslGhur0%253D&md5=304a29d0d50c0b5d47b62f162c8ce800</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1034%2Fj.1399-3011.1999.00089.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1034%252Fj.1399-3011.1999.00089.x%26sid%3Dliteratum%253Aachs%26aulast%3DHiebl%26aufirst%3DJ.%26aulast%3DBaumgartner%26aufirst%3DH.%26aulast%3DBernwieser%26aufirst%3DI.%26aulast%3DBlanka%26aufirst%3DM.%26aulast%3DBodenteich%26aufirst%3DM.%26aulast%3DLeitner%26aufirst%3DK.%26aulast%3DRio%26aufirst%3DA.%26aulast%3DRovenszky%26aufirst%3DF.%26aulast%3DAlberts%26aufirst%3DD.%2BP.%26aulast%3DBhatnagar%26aufirst%3DP.%2BK.%26aulast%3DBanyard%26aufirst%3DA.%2BF.%26aulast%3DBaresch%26aufirst%3DK.%26aulast%3DEsch%26aufirst%3DP.%2BM.%26aulast%3DKollmann%26aufirst%3DH.%26aulast%3DMayrhofer%26aufirst%3DG.%26aulast%3DWeihtrager%26aufirst%3DH.%26aulast%3DWelz%26aufirst%3DW.%26aulast%3DWinkler%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DPatel%26aufirst%3DR.%26aulast%3DLantos%26aufirst%3DI.%26aulast%3DStevenson%26aufirst%3DD.%26aulast%3DTubman%26aufirst%3DK.%2BD.%26aulast%3DUndheim%26aufirst%3DK.%26atitle%3DLarge-scale%2520synthesis%2520of%2520hematoregulatory%2520nonapeptide%2520SK%2526F%2520107647%2520by%2520fragment%2520coupling%26jtitle%3DJ.%2520Pept.%2520Res.%26date%3D1999%26volume%3D54%26spage%3D54%26epage%3D65%26doi%3D10.1034%2Fj.1399-3011.1999.00089.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Raibaut, L.; El Mahdi, O.; Melnyk, O.</span><span> </span><span class="NLM_article-title">Solid phase protein chemical synthesis</span>. In  <span class="citation_source-book">Protein Ligation and Total Synthesis II</span>; <span class="NLM_publisher-name">Springer International Publishing</span>: <span class="NLM_publisher-loc">Cham</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">103</span><span class="NLM_x">â</span> <span class="NLM_lpage">154</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=103-154&author=L.+Raibaut&author=O.+El+Mahdi&author=O.+Melnyk&title=Protein+Ligation+and+Total+Synthesis+II"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DRaibaut%26aufirst%3DL.%26atitle%3DSolid%2520phase%2520protein%2520chemical%2520synthesis%26btitle%3DProtein%2520Ligation%2520and%2520Total%2520Synthesis%2520II%26pub%3DSpringer%2520International%2520Publishing%26date%3D2015%26spage%3D103%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Johnson, E. C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, S. B. H.</span><span> </span><span class="NLM_article-title">Insights into the mechanism and catalysis of the native chemical ligation reaction</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x">, </span> <span class="NLM_fpage">6640</span><span class="NLM_x">â</span> <span class="NLM_lpage">6646</span><span class="refDoi">Â DOI: 10.1021/ja058344i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja058344i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvFyitrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2006&pages=6640-6646&author=E.+C.+B.+Johnsonauthor=S.+B.+H.+Kent&title=Insights+into+the+mechanism+and+catalysis+of+the+native+chemical+ligation+reaction&doi=10.1021%2Fja058344i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the Mechanism and Catalysis of the Native Chemical Ligation Reaction</span></div><div class="casAuthors">Johnson, Erik C. B.; Kent, Stephen B. H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6640-6646</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Native chem. ligation of unprotected peptide segments involves reaction between a peptide-Î±-thioester and a cysteine-peptide, to yield a product with a native amide bond at the ligation site.  Peptide-Î±-thioalkyl esters are commonly used because of their ease of prepn.  These thioalkyl esters are rather unreactive so the ligation reaction is catalyzed by in situ trans-thioesterification with thiol additives.  The most common thiol catalysts used to date have been either a mixt. of thiophenol/benzyl mercaptan, or the alkanethiol MESNA.  Despite the use of these thiol catalysts, ligation reactions typically take 24-48 h.  To gain insight into the mechanism of native chem. ligation and in order to find a better catalyst, we investigated the use of a no. of thiol compds.  Substituted thiophenols with pKa > 6 were found to best combine the ability to exchange rapidly and completely with thioalkyl esters, and to then act as effective leaving groups in reaction of the peptide-thioester with the thiol side chain of a cysteine-peptide.  A highly effective and practical catalyst was (4-carboxylmethyl)thiophenol (MPAA), a non-malodorous, water-sol. thiol.  Use of MPAA gave an order of magnitude faster reaction in model studies of native chem. ligation and in the synthesis of a small protein, turkey ovomucoid third domain (OMTKY3).  MPAA should find broad use in native chem. ligation and in the total synthesis of proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6aUCq6LJkP7Vg90H21EOLACvtfcHk0liQ5AxiIF7w7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvFyitrc%253D&md5=ca67dc1c0f5af9efa3a421a48bb0dd0b</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Fja058344i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja058344i%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DE.%2BC.%2BB.%26aulast%3DKent%26aufirst%3DS.%2BB.%2BH.%26atitle%3DInsights%2520into%2520the%2520mechanism%2520and%2520catalysis%2520of%2520the%2520native%2520chemical%2520ligation%2520reaction%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2006%26volume%3D128%26spage%3D6640%26epage%3D6646%26doi%3D10.1021%2Fja058344i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Hormoz, S.</span><span> </span><span class="NLM_article-title">Amino acid composition of proteins reduces deleterious impact of mutations</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">2919</span><span class="refDoi">Â DOI: 10.1038/srep02919</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fsrep02919" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24108121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FnsV2hsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=2919&author=S.+Hormoz&title=Amino+acid+composition+of+proteins+reduces+deleterious+impact+of+mutations&doi=10.1038%2Fsrep02919"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Amino acid composition of proteins reduces deleterious impact of mutations</span></div><div class="casAuthors">Hormoz Sahand</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2919</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The evolutionary origin of amino acid occurrence frequencies in proteins (composition) is not yet fully understood.  We suggest that protein composition works alongside the genetic code to minimize impact of mutations on protein structure.  First, we propose a novel method for estimating thermodynamic stability of proteins whose sequence is constrained to a fixed composition.  Second, we quantify the average deleterious impact of substituting one amino acid with another.  Natural proteome compositions are special in at least two ways: 1) Natural compositions do not generate more stable proteins than the average random composition, however, they result in proteins that are less susceptible to damage from mutations. 2) Natural proteome compositions that result in more stable proteins (i.e. those of thermophiles) are also tuned to have a higher tolerance for mutations.  This is consistent with the observation that environmental factors selecting for more stable proteins also enhance the deleterious impact of mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSqIdmB720IWwqdek-gHSrIfW6udTcc2ebESQu4PTEmc7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FnsV2hsg%253D%253D&md5=9bff3f81488c74dd9287e46b3b27598a</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1038%2Fsrep02919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep02919%26sid%3Dliteratum%253Aachs%26aulast%3DHormoz%26aufirst%3DS.%26atitle%3DAmino%2520acid%2520composition%2520of%2520proteins%2520reduces%2520deleterious%2520impact%2520of%2520mutations%26jtitle%3DSci.%2520Rep.%26date%3D2013%26volume%3D3%26spage%3D2919%26doi%3D10.1038%2Fsrep02919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warren, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hua, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danishefsky, S. J.</span><span> </span><span class="NLM_article-title">Building complex glycopeptides: development of a cysteine-free native chemical ligation protocol</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">4116</span><span class="NLM_x">â</span> <span class="NLM_lpage">4125</span><span class="refDoi">Â DOI: 10.1002/anie.200600538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fanie.200600538" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2006&pages=4116-4125&author=B.+Wuauthor=J.+Chenauthor=J.+D.+Warrenauthor=G.+Chenauthor=Z.+Huaauthor=S.+J.+Danishefsky&title=Building+complex+glycopeptides%3A+development+of+a+cysteine-free+native+chemical+ligation+protocol&doi=10.1002%2Fanie.200600538"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92a&amp;dbid=16384&amp;doi=10.1002%2Fanie.200600538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200600538%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWarren%26aufirst%3DJ.%2BD.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DHua%26aufirst%3DZ.%26aulast%3DDanishefsky%26aufirst%3DS.%2BJ.%26atitle%3DBuilding%2520complex%2520glycopeptides%253A%2520development%2520of%2520a%2520cysteine-free%2520native%2520chemical%2520ligation%2520protocol%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2006%26volume%3D45%26spage%3D4116%26epage%3D4125%26doi%3D10.1002%2Fanie.200600538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit92b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Thapa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menon, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bingham, J.-P.</span><span> </span><span class="NLM_article-title">Native chemical ligation: a boon to peptide chemistry</span> <span class="citation_source-journal">Molecules</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">14461</span><span class="NLM_x">â</span> <span class="NLM_lpage">14483</span><span class="refDoi">Â DOI: 10.3390/molecules190914461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3390%2Fmolecules190914461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25221869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12isbvL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=14461-14483&author=P.+Thapaauthor=R.-Y.+Zhangauthor=V.+Menonauthor=J.-P.+Bingham&title=Native+chemical+ligation%3A+a+boon+to+peptide+chemistry&doi=10.3390%2Fmolecules190914461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92bR"><div class="casContent"><span class="casTitleNuber">92b</span><div class="casTitle"><span class="NLM_cas:atitle">Native chemical ligation: a boon to peptide chemistry</span></div><div class="casAuthors">Thapa, Parashar; Zhang, Rui-Yang; Menon, Vinay; Bingham, Jon-Paul</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">14461-14483, 23 pp.</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The use of chem. ligation within the realm of peptide chem. has opened various opportunities to expand the applications of peptides/proteins in biol. sciences.  Expansion and refinement of ligation chem. has made it possible for the entry of peptides into the world of viable oral therapeutic drugs through peptide backbone cyclization.  This progression has been a journey of chem. exploration and transition, leading to the dominance of native chem. ligation in the present advances of peptide/protein applications.  Here, the authors illustrate and explore the historical and current nature of peptide ligation, providing a clear indication to the possibilities and use of these novel methods to take peptides outside their typically defined boundaries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2F8ClVQ8QDLVg90H21EOLACvtfcHk0libmMlG7hGuuw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12isbvL&md5=98347270b44c2577b71f160dda352a79</span></div><a href="/servlet/linkout?suffix=cit92b&amp;dbid=16384&amp;doi=10.3390%2Fmolecules190914461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules190914461%26sid%3Dliteratum%253Aachs%26aulast%3DThapa%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DR.-Y.%26aulast%3DMenon%26aufirst%3DV.%26aulast%3DBingham%26aufirst%3DJ.-P.%26atitle%3DNative%2520chemical%2520ligation%253A%2520a%2520boon%2520to%2520peptide%2520chemistry%26jtitle%3DMolecules%26date%3D2014%26volume%3D19%26spage%3D14461%26epage%3D14483%26doi%3D10.3390%2Fmolecules190914461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Rohde, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seitz, O.</span><span> </span><span class="NLM_article-title">Ligation-desulfurization: A powerful combination in the synthesis of peptides and glycopeptides</span> <span class="citation_source-journal">Biopolymers</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">551</span><span class="NLM_x">â</span> <span class="NLM_lpage">559</span><span class="refDoi">Â DOI: 10.1002/bip.21442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fbip.21442" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2010&pages=551-559&author=H.+Rohdeauthor=O.+Seitz&title=Ligation-desulfurization%3A+A+powerful+combination+in+the+synthesis+of+peptides+and+glycopeptides&doi=10.1002%2Fbip.21442"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1002%2Fbip.21442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbip.21442%26sid%3Dliteratum%253Aachs%26aulast%3DRohde%26aufirst%3DH.%26aulast%3DSeitz%26aufirst%3DO.%26atitle%3DLigation-desulfurization%253A%2520A%2520powerful%2520combination%2520in%2520the%2520synthesis%2520of%2520peptides%2520and%2520glycopeptides%26jtitle%3DBiopolymers%26date%3D2010%26volume%3D94%26spage%3D551%26epage%3D559%26doi%3D10.1002%2Fbip.21442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">Malins, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payne, R. J.</span><span> </span><span class="NLM_article-title">Recent extensions to native chemical ligation for the chemical synthesis of peptides and proteins</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">70</span><span class="NLM_x">â</span> <span class="NLM_lpage">78</span><span class="refDoi">Â DOI: 10.1016/j.cbpa.2014.09.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.cbpa.2014.09.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25285753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12nur7I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=70-78&author=L.+R.+Malinsauthor=R.+J.+Payne&title=Recent+extensions+to+native+chemical+ligation+for+the+chemical+synthesis+of+peptides+and+proteins&doi=10.1016%2Fj.cbpa.2014.09.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Recent extensions to native chemical ligation for the chemical synthesis of peptides and proteins</span></div><div class="casAuthors">Malins, Lara R.; Payne, Richard J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">70-78</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Native chem. ligation continues to play a pivotal role in the synthesis of increasingly complex peptide and protein targets twenty years after its initial report.  This opinion article will highlight a no. of recent, powerful extensions of the technol. that have expanded the scope of the reaction, accelerated ligation rates, enabled chemoselective post-ligation modifications, and streamlined the ligation of multiple peptide fragments.  These advances have facilitated the synthesis of a no. of impressive protein targets to date and hold great promise for the continued application of native chem. ligation for the detailed study of protein structure and function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNc6KMnkM7mbVg90H21EOLACvtfcHk0libmMlG7hGuuw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12nur7I&md5=596adefc77f55286aca2fc413199b085</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2014.09.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2014.09.021%26sid%3Dliteratum%253Aachs%26aulast%3DMalins%26aufirst%3DL.%2BR.%26aulast%3DPayne%26aufirst%3DR.%2BJ.%26atitle%3DRecent%2520extensions%2520to%2520native%2520chemical%2520ligation%2520for%2520the%2520chemical%2520synthesis%2520of%2520peptides%2520and%2520proteins%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D22%26spage%3D70%26epage%3D78%26doi%3D10.1016%2Fj.cbpa.2014.09.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Hackeng, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, P. E.</span><span> </span><span class="NLM_article-title">Protein synthesis by native chemical ligation: Expanded scope by using straightforward methodology</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">10068</span><span class="NLM_x">â</span> <span class="NLM_lpage">10073</span><span class="refDoi">Â DOI: 10.1073/pnas.96.18.10068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1073%2Fpnas.96.18.10068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10468563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFegsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=10068-10073&author=T.+M.+Hackengauthor=J.+H.+Griffinauthor=P.+E.+Dawson&title=Protein+synthesis+by+native+chemical+ligation%3A+Expanded+scope+by+using+straightforward+methodology&doi=10.1073%2Fpnas.96.18.10068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Protein synthesis by native chemical ligation: expanded scope by using straightforward methodology</span></div><div class="casAuthors">Hackeng, Tilman M.; Griffin, John H.; Dawson, Philip E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">10068-10073</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The total chem. synthesis of proteins has great potential for increasing understanding of the mol. basis of protein function.  The introduction of native chem. ligation techniques to join unprotected peptides next to a cysteine residue has greatly facilitated the synthesis of proteins of moderate size.  Here, the authors describe a straightforward methodol. that has enabled them to rapidly analyze the compatibility of the native chem. ligation strategy for X-Cys ligation sites, where X is any of the 20 naturally occurring amino acids.  The simplified methodol. avoids the necessity of specific amino acid thioester linkers or alkylation of C-terminal thio-acid peptides.  Expts. using matrix-assisted laser-desorption ionization MS anal. of combinatorial ligations of LYRAX-C-terminal thioester peptides to the peptide CRANK show that all 20 amino acids are suitable for ligation, with Val, Ile, and Pro representing less favorable choices because of slow ligation rates.  To illustrate the method's utility, two 124-aa proteins were manually synthesized by using a three-step, four-piece ligation to yield a fully active human secretory phospholipase A2 and a catalytically inactive analog.  The combination of flexibility in design with general access because of simplified methodol. broadens the applicability and versatility of chem. protein synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2eas8MPkrprVg90H21EOLACvtfcHk0libmMlG7hGuuw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFegsLw%253D&md5=edb07cac4a6b4ee133fffedc3814d285</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.18.10068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.18.10068%26sid%3Dliteratum%253Aachs%26aulast%3DHackeng%26aufirst%3DT.%2BM.%26aulast%3DGriffin%26aufirst%3DJ.%2BH.%26aulast%3DDawson%26aufirst%3DP.%2BE.%26atitle%3DProtein%2520synthesis%2520by%2520native%2520chemical%2520ligation%253A%2520Expanded%2520scope%2520by%2520using%2520straightforward%2520methodology%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26spage%3D10068%26epage%3D10073%26doi%3D10.1073%2Fpnas.96.18.10068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Zheng, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span> </span><span class="NLM_article-title">Chemical synthesis of proteins using peptide hydrazides as thioester surrogates</span> <span class="citation_source-journal">Nat. Protoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2483</span><span class="NLM_x">â</span> <span class="NLM_lpage">2495</span><span class="refDoi">Â DOI: 10.1038/nprot.2013.152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnprot.2013.152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24232250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkt1Kjsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=2483-2495&author=J.-S.+Zhengauthor=S.+Tangauthor=Y.-K.+Qiauthor=Z.-P.+Wangauthor=L.+Liu&title=Chemical+synthesis+of+proteins+using+peptide+hydrazides+as+thioester+surrogates&doi=10.1038%2Fnprot.2013.152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical synthesis of proteins using peptide hydrazides as thioester surrogates</span></div><div class="casAuthors">Zheng, Ji-Shen; Tang, Shan; Qi, Yun-Kun; Wang, Zhi-Peng; Liu, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2483-2495</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This protocol provides a detailed procedure for the chem. synthesis of proteins through native chem. ligation of peptide hydrazides.  The two crucial stages of this protocol are (i) the solid-phase synthesis of peptide hydrazides via Fmoc chem. and (ii) the native chem. ligation of peptide hydrazides through in situ NaNO2 activation and thiolysis.  This protocol may be of help in the synthesis of proteins that are not easily produced by recombinant technol. and that include acid-sensitive modifications; it also does not involve the use of hazardous HF.  The utility of the protocol is shown for the total synthesis of 140-aa-long Î±-synuclein, a protein that has an important role in the development of Parkinson's disease.  The whole synthesis of the target protein Î±-synuclein in milligram scale takes â¼30 working days.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruKtX1ELNnTbVg90H21EOLACvtfcHk0liGBhXa32i_Rg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkt1Kjsr4%253D&md5=31b83fce2cd55b283e5ebb9837c98aa2</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2013.152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2013.152%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DJ.-S.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DQi%26aufirst%3DY.-K.%26aulast%3DWang%26aufirst%3DZ.-P.%26aulast%3DLiu%26aufirst%3DL.%26atitle%3DChemical%2520synthesis%2520of%2520proteins%2520using%2520peptide%2520hydrazides%2520as%2520thioester%2520surrogates%26jtitle%3DNat.%2520Protoc.%26date%3D2013%26volume%3D8%26spage%3D2483%26epage%3D2495%26doi%3D10.1038%2Fnprot.2013.152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fang, G.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, H.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span> </span><span class="NLM_article-title">Protein chemical synthesis by ligation of peptide hydrazides</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">7645</span><span class="NLM_x">â</span> <span class="NLM_lpage">7649</span><span class="refDoi">Â DOI: 10.1002/anie.201100996</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fanie.201100996" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21648030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntV2rsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=7645-7649&author=G.-M.+Fangauthor=Y.-M.+Liauthor=F.+Shenauthor=Y.-C.+Huangauthor=J.-B.+Liauthor=Y.+Linauthor=H.-K.+Cuiauthor=L.+Liu&title=Protein+chemical+synthesis+by+ligation+of+peptide+hydrazides&doi=10.1002%2Fanie.201100996"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97aR"><div class="casContent"><span class="casTitleNuber">97a</span><div class="casTitle"><span class="NLM_cas:atitle">Protein Chemical Synthesis by Ligation of Peptide Hydrazides</span></div><div class="casAuthors">Fang, Ge-Min; Li, Yi-Ming; Shen, Fei; Huang, Yi-Chao; Li, Jia-Bin; Lin, Yun; Cui, Hong-Kui; Liu, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">7645-7649, S7645/1-S7645/40</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The ligation of peptide hydrazides is a new method for protein chem. synthesis that is complementary to native chem. ligation.  Peptide hydrazides may be the long-sought equiv. to a 'thioester synthon', one that is stable to the conditions of native chem. ligation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa-vzFJdvoB7Vg90H21EOLACvtfcHk0liGBhXa32i_Rg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntV2rsr8%253D&md5=af3dea2524dfbb4f320b762c358cec58</span></div><a href="/servlet/linkout?suffix=cit97a&amp;dbid=16384&amp;doi=10.1002%2Fanie.201100996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201100996%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DG.-M.%26aulast%3DLi%26aufirst%3DY.-M.%26aulast%3DShen%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DY.-C.%26aulast%3DLi%26aufirst%3DJ.-B.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DCui%26aufirst%3DH.-K.%26aulast%3DLiu%26aufirst%3DL.%26atitle%3DProtein%2520chemical%2520synthesis%2520by%2520ligation%2520of%2520peptide%2520hydrazides%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2011%26volume%3D50%26spage%3D7645%26epage%3D7649%26doi%3D10.1002%2Fanie.201100996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit97b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Blanco-Canosa, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nardone, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albericio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, P. E.</span><span> </span><span class="NLM_article-title">Chemical protein synthesis using a second-generation N-acylurea linker for the preparation of peptide-thioester precursors</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">137</span><span class="NLM_x">, </span> <span class="NLM_fpage">7197</span><span class="NLM_x">â</span> <span class="NLM_lpage">7209</span><span class="refDoi">Â DOI: 10.1021/jacs.5b03504</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.5b03504" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref97/cit97b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVChsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=7197-7209&author=J.+B.+Blanco-Canosaauthor=B.+Nardoneauthor=F.+Albericioauthor=P.+E.+Dawson&title=Chemical+protein+synthesis+using+a+second-generation+N-acylurea+linker+for+the+preparation+of+peptide-thioester+precursors&doi=10.1021%2Fjacs.5b03504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97bR"><div class="casContent"><span class="casTitleNuber">97b</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical Protein Synthesis Using a Second-Generation N-Acylurea Linker for the Preparation of Peptide-Thioester Precursors</span></div><div class="casAuthors">Blanco-Canosa, Juan B.; Nardone, Brunello; Albericio, Fernando; Dawson, Philip E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7197-7209</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The broad utility of native chem. ligation (NCL) in protein synthesis has fostered a search for methods that enable the efficient synthesis of C-terminal peptide-thioesters, key intermediates in NCL.  The authors have developed an N-acylurea (Nbz) approach for the synthesis of thioester peptide precursors that efficiently undergo thiol exchange yielding thioester peptides and subsequently NCL reaction.  However, the synthesis of some glycine-rich sequences revealed limitations, such as diacylated products that can not be converted into N-acylurea peptides.  Here, the authors introduce a new N-acylurea linker bearing an o-amino(methyl)aniline (MeDbz) moiety that enables in a more robust peptide chain assembly.  The generality of the approach is illustrated by the synthesis of a pentaglycine sequence under different coupling conditions including microwave heating at coupling temps. up to 90Â°, affording the unique and desired N-acyl-N'-methylacylurea (MeNbz) product.  Further extension of the method allowed the synthesis of all 20 natural amino acids and their NCL reactions.  The kinetic anal. of the ligations using model peptides shows the MeNbz peptide rapidly converts to arylthioesters that are efficient at NCL.  Finally, the authors show that the new MeDbz linker can be applied to the synthesis of cysteine-rich proteins such the cyclotides Kalata B1 and MCoTI-II through a one cyclization/folding step in the ligation/folding buffer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi-KJFWKuka7Vg90H21EOLACvtfcHk0liGBhXa32i_Rg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVChsbw%253D&md5=2f91e07ca12b1148af317aba502cf251</span></div><a href="/servlet/linkout?suffix=cit97b&amp;dbid=16384&amp;doi=10.1021%2Fjacs.5b03504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.5b03504%26sid%3Dliteratum%253Aachs%26aulast%3DBlanco-Canosa%26aufirst%3DJ.%2BB.%26aulast%3DNardone%26aufirst%3DB.%26aulast%3DAlbericio%26aufirst%3DF.%26aulast%3DDawson%26aufirst%3DP.%2BE.%26atitle%3DChemical%2520protein%2520synthesis%2520using%2520a%2520second-generation%2520N-acylurea%2520linker%2520for%2520the%2520preparation%2520of%2520peptide-thioester%2520precursors%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D7197%26epage%3D7209%26doi%3D10.1021%2Fjacs.5b03504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Boll, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drobecq, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ollivier, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanpain, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raibaut, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desmet, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vicogne, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melnyk, O.</span><span> </span><span class="NLM_article-title">One-pot chemical synthesis of small ubiquitin-like modifier protein-peptide conjugates using bis(2-sulfanylethyl)amido peptide latent thioester surrogates</span> <span class="citation_source-journal">Nat. Protoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">269</span><span class="NLM_x">â</span> <span class="NLM_lpage">292</span><span class="refDoi">Â DOI: 10.1038/nprot.2015.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnprot.2015.013" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=269-292&author=E.+Bollauthor=H.+Drobecqauthor=N.+Ollivierauthor=A.+Blanpainauthor=L.+Raibautauthor=R.+Desmetauthor=J.+Vicogneauthor=O.+Melnyk&title=One-pot+chemical+synthesis+of+small+ubiquitin-like+modifier+protein-peptide+conjugates+using+bis%282-sulfanylethyl%29amido+peptide+latent+thioester+surrogates&doi=10.1038%2Fnprot.2015.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98a&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2015.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2015.013%26sid%3Dliteratum%253Aachs%26aulast%3DBoll%26aufirst%3DE.%26aulast%3DDrobecq%26aufirst%3DH.%26aulast%3DOllivier%26aufirst%3DN.%26aulast%3DBlanpain%26aufirst%3DA.%26aulast%3DRaibaut%26aufirst%3DL.%26aulast%3DDesmet%26aufirst%3DR.%26aulast%3DVicogne%26aufirst%3DJ.%26aulast%3DMelnyk%26aufirst%3DO.%26atitle%3DOne-pot%2520chemical%2520synthesis%2520of%2520small%2520ubiquitin-like%2520modifier%2520protein-peptide%2520conjugates%2520using%2520bis%25282-sulfanylethyl%2529amido%2520peptide%2520latent%2520thioester%2520surrogates%26jtitle%3DNat.%2520Protoc.%26date%3D2015%26volume%3D10%26spage%3D269%26epage%3D292%26doi%3D10.1038%2Fnprot.2015.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit98b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ollivier, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vicogne, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vallin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drobecq, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desmet, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El Mahdi, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leclercq, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goormachtigh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fafeur, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melnyk, O.</span><span> </span><span class="NLM_article-title">A one-pot three-segment ligation strategy for protein chemical synthesis</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">â</span> <span class="NLM_lpage">213</span><span class="refDoi">Â DOI: 10.1002/anie.201105837</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fanie.201105837" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVyrurjF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=209-213&author=N.+Ollivierauthor=J.+Vicogneauthor=A.+Vallinauthor=H.+Drobecqauthor=R.+Desmetauthor=O.+El+Mahdiauthor=B.+Leclercqauthor=G.+Goormachtighauthor=V.+Fafeurauthor=O.+Melnyk&title=A+one-pot+three-segment+ligation+strategy+for+protein+chemical+synthesis&doi=10.1002%2Fanie.201105837"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98bR"><div class="casContent"><span class="casTitleNuber">98b</span><div class="casTitle"><span class="NLM_cas:atitle">A one-pot three-segment ligation strategy for protein chemical synthesis</span></div><div class="casAuthors">Ollivier, Nathalie; Vicogne, Jerome; Vallin, Aurelie; Drobecq, Herve; Desmet, Remi; El Mahdi, Ouafaa; Leclercq, Berenice; Goormachtigh, Gautier; Fafeur, Veronique; Melnyk, Oleg</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">209-213</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Herein we describe the synthesis of the K1 domain of Hepatocyte Growth Factor (HGF), which is part of HGF's high-affinity binding site for kinase phosphorylating scatter factor receptor (MET), but acts as a weak agonist.  K1 is composed of 85 amino acid residues (HGF 125-209) and is stabilized by three intrachain disulfide bridges.  K1 was assembled from HGF segments 125-148, 149-176, and 177-209 using one-pot three-segment native chem. ligation strategy.  Both ligations were performed under neutral conditions in aq. soln.  Proteomic anal. of the synthetic K1 domain using enzymic digestion and subsequent mass-spectrometry anal. of the formed peptide fragments revealed the formation of the native disulfide-bridge pattern during folding.  The structural integrity and functionality of K1 were confirmed through the study of its biol. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQC2qmJL_gbrVg90H21EOLACvtfcHk0lgpcNseJ-m7_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVyrurjF&md5=e8326515ff4bb69d944e6f02cfab0af9</span></div><a href="/servlet/linkout?suffix=cit98b&amp;dbid=16384&amp;doi=10.1002%2Fanie.201105837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201105837%26sid%3Dliteratum%253Aachs%26aulast%3DOllivier%26aufirst%3DN.%26aulast%3DVicogne%26aufirst%3DJ.%26aulast%3DVallin%26aufirst%3DA.%26aulast%3DDrobecq%26aufirst%3DH.%26aulast%3DDesmet%26aufirst%3DR.%26aulast%3DEl%2BMahdi%26aufirst%3DO.%26aulast%3DLeclercq%26aufirst%3DB.%26aulast%3DGoormachtigh%26aufirst%3DG.%26aulast%3DFafeur%26aufirst%3DV.%26aulast%3DMelnyk%26aufirst%3DO.%26atitle%3DA%2520one-pot%2520three-segment%2520ligation%2520strategy%2520for%2520protein%2520chemical%2520synthesis%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2012%26volume%3D51%26spage%3D209%26epage%3D213%26doi%3D10.1002%2Fanie.201105837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ghosh, I.; Considine, N.; Maunus, E.; Sun, L.; Zhang, A.; Buswell, J.; Evans, T. C.; Xu, M.-Q.</span><span> </span><span class="NLM_article-title">Site-specific protein labeling by intein-mediated protein ligation</span>. In  <span class="citation_source-book">Heterologous Gene Expression in E. coli: Methods and Protocols</span>; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">Totowa, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">87</span><span class="NLM_x">â</span> <span class="NLM_lpage">107</span>;.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1007%2F978-1-61737-967-3_6" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=87-107&author=I.+Ghosh&author=N.+Considine&author=E.+Maunus&author=L.+Sun&author=A.+Zhang&author=J.+Buswell&author=T.+C.+Evans&author=M.-Q.+Xu&title=Heterologous+Gene+Expression+in+E.+coli%3A+Methods+and+Protocols"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99a&amp;dbid=16384&amp;doi=10.1007%2F978-1-61737-967-3_6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-61737-967-3_6%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DI.%26atitle%3DSite-specific%2520protein%2520labeling%2520by%2520intein-mediated%2520protein%2520ligation%26btitle%3DHeterologous%2520Gene%2520Expression%2520in%2520E.%2520coli%253A%2520Methods%2520and%2520Protocols%26pub%3DHumana%2520Press%26date%3D2011%26spage%3D87%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit99b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chu, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shabbir, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bove-Fenderson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Araman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemmens-Gruber, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, C. F. W.</span><span> </span><span class="NLM_article-title">A C-terminal membrane anchor affects the interactions of prion proteins with lipid membranes</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">30144</span><span class="NLM_x">â</span> <span class="NLM_lpage">30160</span><span class="refDoi">Â DOI: 10.1074/jbc.M114.587345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1074%2Fjbc.M114.587345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25217642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVSmtLjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=30144-30160&author=N.+K.+Chuauthor=W.+Shabbirauthor=E.+Bove-Fendersonauthor=C.+Aramanauthor=R.+Lemmens-Gruberauthor=D.+A.+Harrisauthor=C.+F.+W.+Becker&title=A+C-terminal+membrane+anchor+affects+the+interactions+of+prion+proteins+with+lipid+membranes&doi=10.1074%2Fjbc.M114.587345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99bR"><div class="casContent"><span class="casTitleNuber">99b</span><div class="casTitle"><span class="NLM_cas:atitle">A C-terminal Membrane Anchor Affects the Interactions of Prion Proteins with Lipid Membranes</span></div><div class="casAuthors">Chu, Nam K.; Shabbir, Waheed; Bove-Fenderson, Erin; Araman, Can; Lemmens-Gruber, Rosa; Harris, David A.; Becker, Christian F. W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">30144-30160</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Membrane attachment via a C-terminal glycosylphosphatidylinositol anchor is crit. for conversion of PrPC into pathogenic PrPSc.  Therefore the effects of the anchor on PrP structure and function need to be deciphered.  Three PrP variants, including full-length PrP (residues 23-231, FL_PrP), N-terminally truncated PrP (residues 90-231, T_PrP), and PrP missing its central hydrophobic region (Î105-125, ÎCR_PrP), were equipped with a C-terminal membrane anchor via a semisynthesis strategy.  Analyses of the interactions of lipidated PrPs with phospholipid membranes demonstrated that C-terminal membrane attachment induces a different binding mode of PrP to membranes, distinct from that of non-lipidated PrPs, and influences the biochem. and conformational properties of PrPs.  Addnl., fluorescence-based assays indicated pore formation by lipidated ÎCR_PrP, a variant that is known to be highly neurotoxic in transgenic mice.  This finding was supported by using patch clamp electrophysiol. measurements of cultured cells.  These results provide new evidence for the role of the membrane anchor in PrP-lipid interactions, highlighting the importance of the N-terminal and the central hydrophobic domain in these interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXJ-GlToAFC7Vg90H21EOLACvtfcHk0lgpcNseJ-m7_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVSmtLjE&md5=396f9fb499b5f73d444b69e9ba7e9e10</span></div><a href="/servlet/linkout?suffix=cit99b&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.587345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.587345%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DN.%2BK.%26aulast%3DShabbir%26aufirst%3DW.%26aulast%3DBove-Fenderson%26aufirst%3DE.%26aulast%3DAraman%26aufirst%3DC.%26aulast%3DLemmens-Gruber%26aufirst%3DR.%26aulast%3DHarris%26aufirst%3DD.%2BA.%26aulast%3DBecker%26aufirst%3DC.%2BF.%2BW.%26atitle%3DA%2520C-terminal%2520membrane%2520anchor%2520affects%2520the%2520interactions%2520of%2520prion%2520proteins%2520with%2520lipid%2520membranes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D30144%26epage%3D30160%26doi%3D10.1074%2Fjbc.M114.587345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Li, Y.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, M.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span> </span><span class="NLM_article-title">Ligation of expressed protein Î±-hydrazides via genetic incorporation of an Î±-hydroxy acid</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1015</span><span class="NLM_x">â</span> <span class="NLM_lpage">1022</span><span class="refDoi">Â DOI: 10.1021/cb300020s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb300020s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38XjvFKltrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1015-1022&author=Y.-M.+Liauthor=M.-Y.+Yangauthor=Y.-C.+Huangauthor=Y.-T.+Liauthor=P.+R.+Chenauthor=L.+Liu&title=Ligation+of+expressed+protein+%CE%B1-hydrazides+via+genetic+incorporation+of+an+%CE%B1-hydroxy+acid&doi=10.1021%2Fcb300020s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Ligation of Expressed Protein Î±-Hydrazides via Genetic Incorporation of an Î±-Hydroxy Acid</span></div><div class="casAuthors">Li, Yi-Ming; Yang, Mai-Yun; Huang, Yi-Chao; Li, Yi-Tong; Chen, Peng R.; Liu, Lei</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1015-1022</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Expressed protein ligation bridges the gap between synthetic peptides and recombinant proteins and thereby significantly increases the size and complexity of chem. synthesized proteins.  Although the intein-based expressed protein ligation method has been extensively used in this regard, the development of new expressed protein ligation methods may improve the flexibility and power of protein semisynthesis.  In this study a new alternative version of expressed protein ligation is developed by combining the recently developed technologies of hydrazide-based peptide ligation and genetic code expansion.  Compared to the previous intein-based expressed protein ligation method, the new method does not require the use of protein splicing technol. and generates recombinant protein Î±-hydrazides as ligation intermediates that are more chem. stable than protein Î±-thioesters.  Furthermore, the use of an evolved mutant pyrrolysyl-tRNA synthetase (PylRS), ACPK-RS, from Methanobacterium barkeri shows an improved performance for the expression of recombinant protein backbone oxoesters.  By using HdeA as a model protein the authors demonstrate that the hydrazide-based method can be used to synthesize proteins with correctly folded structures and full biol. activity.  Because the PylRS-tRNACUAPyl system is compatible with both prokaryotic and eukaryotic cells, the strategy presented here may be readily expanded to manipulate proteins produced in mammalian cells.  The new hydrazide-based method may also supplement the intein-based expressed protein ligation method by allowing for a more flexible selection of ligation site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrIsiueJfHvLVg90H21EOLACvtfcHk0lgpcNseJ-m7_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjvFKltrc%253D&md5=377b9d66ee179ee37251117d7dbae602</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Fcb300020s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300020s%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.-M.%26aulast%3DYang%26aufirst%3DM.-Y.%26aulast%3DHuang%26aufirst%3DY.-C.%26aulast%3DLi%26aufirst%3DY.-T.%26aulast%3DChen%26aufirst%3DP.%2BR.%26aulast%3DLiu%26aufirst%3DL.%26atitle%3DLigation%2520of%2520expressed%2520protein%2520%25CE%25B1-hydrazides%2520via%2520genetic%2520incorporation%2520of%2520an%2520%25CE%25B1-hydroxy%2520acid%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2012%26volume%3D7%26spage%3D1015%26epage%3D1022%26doi%3D10.1021%2Fcb300020s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span> </span><span class="NLM_article-title">Protein chemical synthesis by serine and threonine ligation</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">6657</span><span class="NLM_x">â</span> <span class="NLM_lpage">6662</span><span class="refDoi">Â DOI: 10.1073/pnas.1221012110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1073%2Fpnas.1221012110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23569249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXot1GhsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=6657-6662&author=Y.+Zhangauthor=C.+Xuauthor=H.+Y.+Lamauthor=C.+L.+Leeauthor=X.+Li&title=Protein+chemical+synthesis+by+serine+and+threonine+ligation&doi=10.1073%2Fpnas.1221012110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Protein chemical synthesis by serine and threonine ligation</span></div><div class="casAuthors">Zhang, Yinfeng; Xu, Ci; Lam, Hiu Yung; Lee, Chi Lung; Li, Xuechen</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6657-6662, S6657/1-S6657/40</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">An efficient method has been developed for the salicylaldehyde ester-mediated ligation of unprotected peptides at serine (Ser) or threonine (Thr) residues.  The utility of this peptide ligation approach has been demonstrated through the convergent syntheses of two therapeutic peptides, ovine-corticoliberin and Forteo, and the human erythrocyte acylphosphatase protein (â¼11 kDa).  The requisite peptide salicylaldehyde ester precursor is prepd. in an epimerization-free manner via Fmoc-based solid-phase peptide synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphXskUlr9857Vg90H21EOLACvtfcHk0lgYdwZrI9LQXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXot1GhsrY%253D&md5=ba60c71926491d7f7035921ae30f1211</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1221012110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1221012110%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DLam%26aufirst%3DH.%2BY.%26aulast%3DLee%26aufirst%3DC.%2BL.%26aulast%3DLi%26aufirst%3DX.%26atitle%3DProtein%2520chemical%2520synthesis%2520by%2520serine%2520and%2520threonine%2520ligation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D6657%26epage%3D6662%26doi%3D10.1073%2Fpnas.1221012110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Harmand, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murar, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bode, J. W.</span><span> </span><span class="NLM_article-title">Protein chemical synthesis by [alpha]-ketoacid-hydroxylamine ligation</span> <span class="citation_source-journal">Nat. Protoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1130</span><span class="NLM_x">â</span> <span class="NLM_lpage">1147</span><span class="refDoi">Â DOI: 10.1038/nprot.2016.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnprot.2016.052" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1130-1147&author=T.+J.+Harmandauthor=C.+E.+Murarauthor=J.+W.+Bode&title=Protein+chemical+synthesis+by+%5Balpha%5D-ketoacid-hydroxylamine+ligation&doi=10.1038%2Fnprot.2016.052"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2016.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2016.052%26sid%3Dliteratum%253Aachs%26aulast%3DHarmand%26aufirst%3DT.%2BJ.%26aulast%3DMurar%26aufirst%3DC.%2BE.%26aulast%3DBode%26aufirst%3DJ.%2BW.%26atitle%3DProtein%2520chemical%2520synthesis%2520by%2520%255Balpha%255D-ketoacid-hydroxylamine%2520ligation%26jtitle%3DNat.%2520Protoc.%26date%3D2016%26volume%3D11%26spage%3D1130%26epage%3D1147%26doi%3D10.1038%2Fnprot.2016.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Pusterla, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bode, J. W.</span><span> </span><span class="NLM_article-title">An oxazetidine amino acid for chemical protein synthesis by rapid, serine-forming ligations</span> <span class="citation_source-journal">Nat. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">668</span><span class="NLM_x">â</span> <span class="NLM_lpage">672</span><span class="refDoi">Â DOI: 10.1038/nchem.2282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnchem.2282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26201744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju73L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=668-672&author=I.+Pusterlaauthor=J.+W.+Bode&title=An+oxazetidine+amino+acid+for+chemical+protein+synthesis+by+rapid%2C+serine-forming+ligations&doi=10.1038%2Fnchem.2282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">An oxazetidine amino acid for chemical protein synthesis by rapid, serine-forming ligations</span></div><div class="casAuthors">Pusterla, Ivano; Bode, Jeffrey W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">668-672</span>CODEN:
                <span class="NLM_cas:coden">NCAHBB</span>;
        ISSN:<span class="NLM_cas:issn">1755-4330</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Amide-forming ligation reactions allow the chem. synthesis of proteins by the union of unprotected peptide segments, and enable the prepn. of protein derivs. not accessible by expression or bioengineering approaches.  The native chem. ligation (NCL) of thioesters and N-terminal cysteines is unquestionably the most successful approach, but is not ideal for all synthetic targets.  Here we describe the synthesis of an Fmoc-protected (Fmoc = 9-fluorenylmethoxycarbonyl) oxazetidine amino acid for use in the Î±-ketoacid-hydroxylamine (KAHA) amide ligation.  When incorporated at the N-terminus of a peptide segment, this four-membered cyclic hydroxylamine can be used for rapid serine-forming ligations with peptide Î±-ketoacids.  This ligation operates at low concn. (100 Î¼M-5 mM) and mild temps. (20-25 Â°C).  The utility of the reaction was demonstrated by the synthesis of S100A4, a 12 kDa calcium-binding protein not easily accessible by NCL or other amide-forming reactions due to its primary sequence and properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRW2vrSovYJbVg90H21EOLACvtfcHk0lgYdwZrI9LQXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju73L&md5=cd8202f8af4ae18437cf7ed51e79bb34</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1038%2Fnchem.2282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchem.2282%26sid%3Dliteratum%253Aachs%26aulast%3DPusterla%26aufirst%3DI.%26aulast%3DBode%26aufirst%3DJ.%2BW.%26atitle%3DAn%2520oxazetidine%2520amino%2520acid%2520for%2520chemical%2520protein%2520synthesis%2520by%2520rapid%252C%2520serine-forming%2520ligations%26jtitle%3DNat.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D668%26epage%3D672%26doi%3D10.1038%2Fnchem.2282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Antos, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truttmann, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ploegh, H. L.</span><span> </span><span class="NLM_article-title">Recent advances in sortase-catalyzed ligation methodology</span> <span class="citation_source-journal">Curr. Opin. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">â</span> <span class="NLM_lpage">118</span><span class="refDoi">Â DOI: 10.1016/j.sbi.2016.05.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.sbi.2016.05.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=27318815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28Xps1Wktbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2016&pages=111-118&author=J.+M.+Antosauthor=M.+C.+Truttmannauthor=H.+L.+Ploegh&title=Recent+advances+in+sortase-catalyzed+ligation+methodology&doi=10.1016%2Fj.sbi.2016.05.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104aR"><div class="casContent"><span class="casTitleNuber">104a</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in sortase-catalyzed ligation methodology</span></div><div class="casAuthors">Antos, John M.; Truttmann, Matthias C.; Ploegh, Hidde L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111-118</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The transpeptidation reaction catalyzed by bacterial sortases continues to see increasing use in the construction of novel protein derivs.  In addn. to growth in the no. of applications that rely on sortase, this field has also seen methodol. improvements that enhance reaction performance and scope.  In this opinion, we present an overview of key developments in the practise and implementation of sortase-based strategies, including applications relevant to structural biol.  Topics include the use of engineered sortases to increase reaction rates, the use of redesigned acyl donors and acceptors to mitigate reaction reversibility, and strategies for expanding the range of substrates that are compatible with a sortase-based approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp75dSSsmDxiLVg90H21EOLACvtfcHk0lgYdwZrI9LQXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xps1Wktbw%253D&md5=0ab0c724bd8673613ac3c6f520735ca5</span></div><a href="/servlet/linkout?suffix=cit104a&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2016.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2016.05.021%26sid%3Dliteratum%253Aachs%26aulast%3DAntos%26aufirst%3DJ.%2BM.%26aulast%3DTruttmann%26aufirst%3DM.%2BC.%26aulast%3DPloegh%26aufirst%3DH.%2BL.%26atitle%3DRecent%2520advances%2520in%2520sortase-catalyzed%2520ligation%2520methodology%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2016%26volume%3D38%26spage%3D111%26epage%3D118%26doi%3D10.1016%2Fj.sbi.2016.05.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit104b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Haridas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadanandan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dheepthi, N. U.</span><span> </span><span class="NLM_article-title">Sortase-based bio-organic strategies for macromolecular synthesis</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1857</span><span class="NLM_x">â</span> <span class="NLM_lpage">1867</span><span class="refDoi">Â DOI: 10.1002/cbic.201402013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fcbic.201402013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25111709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlahtLrO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1857-1867&author=V.+Haridasauthor=S.+Sadanandanauthor=N.+U.+Dheepthi&title=Sortase-based+bio-organic+strategies+for+macromolecular+synthesis&doi=10.1002%2Fcbic.201402013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104bR"><div class="casContent"><span class="casTitleNuber">104b</span><div class="casTitle"><span class="NLM_cas:atitle">Sortase-Based Bio-Organic Strategies for Macromolecular Synthesis</span></div><div class="casAuthors">Haridas, V.; Sadanandan, Sandhya; Dheepthi, N. U.</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1857-1867</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  This article discusses about the sortase-based bio-org. strategies for macromol. synthesis.  The combination of org. synthesis with SrtA-mediated ligation represents a powerful strategy for the synthesis of many natural and unnatural macromols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXexktdOjV0LVg90H21EOLACvtfcHk0lghyEuyNY1zgA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlahtLrO&md5=26df6704792c5027e5b64a4be2193a53</span></div><a href="/servlet/linkout?suffix=cit104b&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201402013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201402013%26sid%3Dliteratum%253Aachs%26aulast%3DHaridas%26aufirst%3DV.%26aulast%3DSadanandan%26aufirst%3DS.%26aulast%3DDheepthi%26aufirst%3DN.%2BU.%26atitle%3DSortase-based%2520bio-organic%2520strategies%2520for%2520macromolecular%2520synthesis%26jtitle%3DChemBioChem%26date%3D2014%26volume%3D15%26spage%3D1857%26epage%3D1867%26doi%3D10.1002%2Fcbic.201402013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Nguyen, G. K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hemu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lian, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, J. P.</span><span> </span><span class="NLM_article-title">Butelase 1 is an Asx-specific ligase enabling peptide macrocyclization and synthesis</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">732</span><span class="NLM_x">â</span> <span class="NLM_lpage">738</span><span class="refDoi">Â DOI: 10.1038/nchembio.1586</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnchembio.1586" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25038786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFygs7jL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=732-738&author=G.+K.+T.+Nguyenauthor=S.+Wangauthor=Y.+Qiuauthor=X.+Hemuauthor=Y.+Lianauthor=J.+P.+Tam&title=Butelase+1+is+an+Asx-specific+ligase+enabling+peptide+macrocyclization+and+synthesis&doi=10.1038%2Fnchembio.1586"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105aR"><div class="casContent"><span class="casTitleNuber">105a</span><div class="casTitle"><span class="NLM_cas:atitle">Butelase 1 is an Asx-specific ligase enabling peptide macrocyclization and synthesis</span></div><div class="casAuthors">Nguyen, Giang K. T.; Wang, Shujing; Qiu, Yibo; Hemu, Xinya; Lian, Yilong; Tam, James P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">732-738</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Proteases are ubiquitous in nature, whereas naturally occurring peptide ligases, enzymes catalyzing the reverse reactions of proteases, are rare occurrences.  Here we describe the discovery of butelase 1, to our knowledge the first asparagine/aspartate (Asx) peptide ligase to be reported.  This highly efficient enzyme was isolated from Clitoria ternatea, a cyclic peptide-producing medicinal plant.  Butelase 1 shares 71% sequence identity and the same catalytic triad with legumain proteases but does not hydrolyze the protease substrate of legumain.  Instead, butelase 1 cyclizes various peptides of plant and animal origin with yields greater than 95%.  With Kcat values of up to 17 s-1 and catalytic efficiencies as high as 542,000 M-1s-1, butelase 1 is the fastest peptide ligase known.  Notably, butelase 1 also displays broad specificity for the N-terminal amino acids of the peptide substrate, thus providing a new tool for C terminus-specific intermol. peptide ligations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfqnuYUbD5NLVg90H21EOLACvtfcHk0lghyEuyNY1zgA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFygs7jL&md5=5b990c4c323ce9404ab324c604a82dd6</span></div><a href="/servlet/linkout?suffix=cit105a&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1586%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DG.%2BK.%2BT.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DHemu%26aufirst%3DX.%26aulast%3DLian%26aufirst%3DY.%26aulast%3DTam%26aufirst%3DJ.%2BP.%26atitle%3DButelase%25201%2520is%2520an%2520Asx-specific%2520ligase%2520enabling%2520peptide%2520macrocyclization%2520and%2520synthesis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26spage%3D732%26epage%3D738%26doi%3D10.1038%2Fnchembio.1586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit105b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Nguyen, G. K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hemu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quek, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, J. P.</span><span> </span><span class="NLM_article-title">Butelase-mediated macrocyclization of D-amino-acid-containing peptides</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">12802</span><span class="NLM_x">â</span> <span class="NLM_lpage">12806</span><span class="refDoi">Â DOI: 10.1002/anie.201607188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fanie.201607188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWntbvK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=12802-12806&author=G.+K.+T.+Nguyenauthor=X.+Hemuauthor=J.-P.+Quekauthor=J.+P.+Tam&title=Butelase-mediated+macrocyclization+of+D-amino-acid-containing+peptides&doi=10.1002%2Fanie.201607188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105bR"><div class="casContent"><span class="casTitleNuber">105b</span><div class="casTitle"><span class="NLM_cas:atitle">Butelase-Mediated Macrocyclization of D-Amino-Acid-Containing Peptides</span></div><div class="casAuthors">Nguyen, Giang K. T.; Hemu, Xinya; Quek, Jun-Ping; Tam, James P.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">12802-12806</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Macrocyclic compds. have received increasing attention in recent years.  With their large surface area, they hold promise for inhibiting protein-protein interactions, a chem. space that was thought to be undruggable.  Although many chem. methods have been developed for peptide macrocyclization, enzymic methods have emerged as a promising new economical approach.  Thus far, most enzymes have been shown to act on L-peptides; their ability to cyclize D-amino-acid-contg. peptides has rarely been documented.  Herein we show that macrocycles consisting of D-amino acids, except for the Asn residue at the ligating site, were efficiently synthesized by butelase 1, an Asn/Asp-specific ligase.  Furthermore, by using a peptide-library approach, we show that butelase 1 tolerates most of the D-amino acid residues at the P1'' and P2'' positions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiA-It06RA6bVg90H21EOLACvtfcHk0lghyEuyNY1zgA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWntbvK&md5=e324b1662a8b4a8768b5ac0fa094fd35</span></div><a href="/servlet/linkout?suffix=cit105b&amp;dbid=16384&amp;doi=10.1002%2Fanie.201607188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201607188%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DG.%2BK.%2BT.%26aulast%3DHemu%26aufirst%3DX.%26aulast%3DQuek%26aufirst%3DJ.-P.%26aulast%3DTam%26aufirst%3DJ.%2BP.%26atitle%3DButelase-mediated%2520macrocyclization%2520of%2520D-amino-acid-containing%2520peptides%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D12802%26epage%3D12806%26doi%3D10.1002%2Fanie.201607188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">Nguyen, G. K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, J. P.</span><span> </span><span class="NLM_article-title">Site-specific N-terminal labeling of peptides and proteins using butelase 1 and thiodepsipeptide</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">15694</span><span class="NLM_x">â</span> <span class="NLM_lpage">15698</span><span class="refDoi">Â DOI: 10.1002/anie.201506810</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fanie.201506810" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVaqt7nI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=15694-15698&author=G.+K.+T.+Nguyenauthor=Y.+Caoauthor=W.+Wangauthor=C.+F.+Liuauthor=J.+P.+Tam&title=Site-specific+N-terminal+labeling+of+peptides+and+proteins+using+butelase+1+and+thiodepsipeptide&doi=10.1002%2Fanie.201506810"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Site-Specific N-Terminal Labeling of Peptides and Proteins using Butelase 1 and Thiodepsipeptide</span></div><div class="casAuthors">Nguyen, Giang K. T.; Cao, Yuan; Wang, Wei; Liu, Chuan Fa; Tam, James P.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">15694-15698</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">An efficient ligase with exquisite site-specificity is highly desirable for protein modification.  Recently, we discovered the fastest known ligase called butelase 1 from Clitoria ternatea for intramol. cyclization.  For intermol. ligation, butelase 1 requires an excess amt. of a substrate to suppress the reverse reaction, a feature similar to other ligases.  Herein, we describe the use of thiodepsipeptide substrates with a thiol as a leaving group and an unacceptable nucleophile to render the butelase-mediated ligation reactions irreversible and in high yields.  Butelase 1 also accepted depsipeptides as substrates, but unlike a thiodepsipeptide, the depsipeptide ligation was partially reversible as butelase 1 can tolerate an alc. group as a poor nucleophile.  The thiodepsipeptide method was successfully applied in N-terminal labeling of ubiquitin and green fluorescent protein (GFP) using substrates with or without a biotin group in high yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4wRlsHkeH1LVg90H21EOLACvtfcHk0liDAvQPAaUVmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVaqt7nI&md5=03138f029b967fedcb0fd78ebed39c79</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1002%2Fanie.201506810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201506810%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DG.%2BK.%2BT.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DC.%2BF.%26aulast%3DTam%26aufirst%3DJ.%2BP.%26atitle%3DSite-specific%2520N-terminal%2520labeling%2520of%2520peptides%2520and%2520proteins%2520using%2520butelase%25201%2520and%2520thiodepsipeptide%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D15694%26epage%3D15698%26doi%3D10.1002%2Fanie.201506810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Toplak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuijens, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quaedflieg, P. J. L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssen, D. B.</span><span> </span><span class="NLM_article-title">Peptiligase, an enzyme for efficient chemoenzymatic peptide synthesis and cyclization in water</span> <span class="citation_source-journal">Adv. Synth. Catal.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">358</span><span class="NLM_x">, </span> <span class="NLM_fpage">2140</span><span class="NLM_x">â</span> <span class="NLM_lpage">2147</span><span class="refDoi">Â DOI: 10.1002/adsc.201600017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fadsc.201600017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XosVWhtr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2016&pages=2140-2147&author=A.+Toplakauthor=T.+Nuijensauthor=P.+J.+L.+M.+Quaedfliegauthor=B.+Wuauthor=D.+B.+Janssen&title=Peptiligase%2C+an+enzyme+for+efficient+chemoenzymatic+peptide+synthesis+and+cyclization+in+water&doi=10.1002%2Fadsc.201600017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107aR"><div class="casContent"><span class="casTitleNuber">107a</span><div class="casTitle"><span class="NLM_cas:atitle">Peptiligase, an enzyme for efficient chemoenzymatic peptide synthesis and cyclization in water</span></div><div class="casAuthors">Toplak, Ana; Nuijens, Timo; Quaedflieg, Peter J. L. M.; Wu, Bian; Janssen, Dick B.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Synthesis & Catalysis</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2140-2147</span>CODEN:
                <span class="NLM_cas:coden">ASCAF7</span>;
        ISSN:<span class="NLM_cas:issn">1615-4150</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">We describe a novel, org. cosolvent-stable and cation-independent engineered enzyme for peptide coupling reactions.  The enzyme is a variant of a stable calcium-independent mutant of subtilisin BPN', with the catalytic Ser212 mutated to Cys and Pro216 converted to Ala.  The enzyme, called peptiligase, catalyzes exceptionally efficient peptide coupling in water with a surprisingly high synthesis over hydrolysis (S/H) ratio.  The S/H ratio of the peptide ligation reaction is correlated to the length of the peptide substrate and proved to be >100 for the synthesis of a 13-mer peptide, which corresponds to >99% conversion to the ligated peptide product and <1% hydrolytic side-reaction.  Furthermore, peptiligase does not require a particular recognition motif resulting in a broadly applicable and traceless peptide ligation technol.  Peptiligase is very robust, easy to produce in Bacillus subtilis, and its purifn. is straightforward.  It shows good activity and stability in the presence of org. cosolvents and chelating or denaturing agents, enabling the ligation of poorly sol. (hydrophobic) or folded peptides.  This enzyme could be useful for the (industrial) synthesis of diverse (pharmaceutical) peptides.  In addn., peptiligase is able to efficiently catalyze head-to-tail peptide cyclization reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbrpp6FZ2rdLVg90H21EOLACvtfcHk0liDAvQPAaUVmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosVWhtr4%253D&md5=8890d54c9d5e5f9d008d31ca075ee3b2</span></div><a href="/servlet/linkout?suffix=cit107a&amp;dbid=16384&amp;doi=10.1002%2Fadsc.201600017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadsc.201600017%26sid%3Dliteratum%253Aachs%26aulast%3DToplak%26aufirst%3DA.%26aulast%3DNuijens%26aufirst%3DT.%26aulast%3DQuaedflieg%26aufirst%3DP.%2BJ.%2BL.%2BM.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DJanssen%26aufirst%3DD.%2BB.%26atitle%3DPeptiligase%252C%2520an%2520enzyme%2520for%2520efficient%2520chemoenzymatic%2520peptide%2520synthesis%2520and%2520cyclization%2520in%2520water%26jtitle%3DAdv.%2520Synth.%2520Catal.%26date%3D2016%26volume%3D358%26spage%3D2140%26epage%3D2147%26doi%3D10.1002%2Fadsc.201600017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit107b"><span><span class="NLM_label">(b) </span>Synthesis of Long Linear and Cyclic Peptides with Omniligase: A New and Easy Ligation Methodology; Iris Biotech GmbH: <span class="NLM_publisher-loc">Marktredwitz, Germany</span>,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="http://www.enzypep.com/wp-content/uploads/2016/05/enzypep_iris_flyer_omniligase.pdf" class="extLink">http://www.enzypep.com/wp-content/uploads/2016/05/enzypep_iris_flyer_omniligase.pdf</a> (accessed January 17, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Synthesis+of+Long+Linear+and+Cyclic+Peptides+with+Omniligase%3A+A+New+and+Easy+Ligation+Methodology%3B+Iris+Biotech+GmbH%3A+Marktredwitz%2C+Germany%2C+2016%3B+http%3A%2F%2Fwww.enzypep.com%2Fwp-content%2Fuploads%2F2016%2F05%2Fenzypep_iris_flyer_omniligase.pdf+%28accessed+January+17%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26jtitle%3DSynthesis%2520of%2520Long%2520Linear%2520and%2520Cyclic%2520Peptides%2520with%2520Omniligase%253A%2520A%2520New%2520and%2520Easy%2520Ligation%2520Methodology%26jtitle%3DIris%2520Biotech%2520GmbH%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group">Sohma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, S. B. H.</span><span> </span><span class="NLM_article-title">Biomimetic synthesis of lispro Insulin via a chemically synthesized âmini-proinsulinâ prepared by oxime-forming ligation</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">16313</span><span class="NLM_x">â</span> <span class="NLM_lpage">16318</span><span class="refDoi">Â DOI: 10.1021/ja9052398</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja9052398" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1OktbjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2009&pages=16313-16318&author=Y.+Sohmaauthor=S.+B.+H.+Kent&title=Biomimetic+synthesis+of+lispro+Insulin+via+a+chemically+synthesized+%E2%80%9Cmini-proinsulin%E2%80%9D+prepared+by+oxime-forming+ligation&doi=10.1021%2Fja9052398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Biomimetic Synthesis of Lispro Insulin via a Chemically Synthesized "Mini-Proinsulin" Prepared by Oxime-Forming Ligation</span></div><div class="casAuthors">Sohma, Youhei; Kent, Stephen B. H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">16313-16318</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Here, the authors report a proof-of-principle study demonstrating the efficient folding, with concomitant formation of the correct disulfides, of an isolated polypeptide insulin precursor of defined covalent structure.  The authors used oxime-forming chem. ligation to introduce a temporary "chem. tether" to link the N-terminal residue of the insulin A chain to the C-terminal residue of the insulin B chain; the tether enabled the formation/folding of disulfides with high efficiency.  Enzymic removal of the temporary chem. tether gave mature, fully active insulin.  This chem. tethering principle could form the basis of a practical, high yield total synthesis of insulin and analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7V968UADQlrVg90H21EOLACvtfcHk0liDAvQPAaUVmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1OktbjL&md5=5819a3a44b71c26fbe29c46fd9595257</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1021%2Fja9052398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja9052398%26sid%3Dliteratum%253Aachs%26aulast%3DSohma%26aufirst%3DY.%26aulast%3DKent%26aufirst%3DS.%2BB.%2BH.%26atitle%3DBiomimetic%2520synthesis%2520of%2520lispro%2520Insulin%2520via%2520a%2520chemically%2520synthesized%2520%25E2%2580%259Cmini-proinsulin%25E2%2580%259D%2520prepared%2520by%2520oxime-forming%2520ligation%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2009%26volume%3D131%26spage%3D16313%26epage%3D16318%26doi%3D10.1021%2Fja9052398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Sohma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hua, Q.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittaker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, S. B. H.</span><span> </span><span class="NLM_article-title">Design and folding of [GluA4(OÎ²ThrB30)]Insulin (âEster Insulinâ): A minimal proinsulin surrogate that can be chemically converted into human insulin</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">5489</span><span class="NLM_x">â</span> <span class="NLM_lpage">5493</span><span class="refDoi">Â DOI: 10.1002/anie.201001151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fanie.201001151" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=5489-5493&author=Y.+Sohmaauthor=Q.-X.+Huaauthor=J.+Whittakerauthor=M.+A.+Weissauthor=S.+B.+H.+Kent&title=Design+and+folding+of+%5BGluA4%28O%CE%B2ThrB30%29%5DInsulin+%28%E2%80%9CEster+Insulin%E2%80%9D%29%3A+A+minimal+proinsulin+surrogate+that+can+be+chemically+converted+into+human+insulin&doi=10.1002%2Fanie.201001151"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1002%2Fanie.201001151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201001151%26sid%3Dliteratum%253Aachs%26aulast%3DSohma%26aufirst%3DY.%26aulast%3DHua%26aufirst%3DQ.-X.%26aulast%3DWhittaker%26aufirst%3DJ.%26aulast%3DWeiss%26aufirst%3DM.%2BA.%26aulast%3DKent%26aufirst%3DS.%2BB.%2BH.%26atitle%3DDesign%2520and%2520folding%2520of%2520%255BGluA4%2528O%25CE%25B2ThrB30%2529%255DInsulin%2520%2528%25E2%2580%259CEster%2520Insulin%25E2%2580%259D%2529%253A%2520A%2520minimal%2520proinsulin%2520surrogate%2520that%2520can%2520be%2520chemically%2520converted%2520into%2520human%2520insulin%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2010%26volume%3D49%26spage%3D5489%26epage%3D5493%26doi%3D10.1002%2Fanie.201001151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Patil, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tailhades, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karas, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Separovic, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wade, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hossain, M. A.</span><span> </span><span class="NLM_article-title">A one-pot chemically cleavable bis-linker tether strategy for the synthesis of heterodimeric peptides</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">14552</span><span class="NLM_x">â</span> <span class="NLM_lpage">14556</span><span class="refDoi">Â DOI: 10.1002/anie.201604733</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fanie.201604733" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlegtLbL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=14552-14556&author=N.+A.+Patilauthor=J.+Tailhadesauthor=J.+A.+Karasauthor=F.+Separovicauthor=J.+D.+Wadeauthor=M.+A.+Hossain&title=A+one-pot+chemically+cleavable+bis-linker+tether+strategy+for+the+synthesis+of+heterodimeric+peptides&doi=10.1002%2Fanie.201604733"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">A One-Pot Chemically Cleavable Bis-Linker Tether Strategy for the Synthesis of Heterodimeric Peptides</span></div><div class="casAuthors">Patil, Nitin A.; Tailhades, Julien; Karas, John A.; Separovic, Frances; Wade, John D.; Hossain, Mohammed Akhter</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">14552-14556</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Heterodimeric peptides linked by disulfide bonds are attractive drug targets.  However, their chem. assembly can be tedious, time-consuming, and low yielding.  Inspired by the cellular synthesis of pro-insulin in which the two constituent peptide chains are expressed as a single-chain precursor sepd. by a connecting C-peptide, the authors have developed a novel chem. cleavable bis-linker tether which allows the convenient assembly of two peptide chains as a single "pro"-peptide on the same solid support.  Following the peptide cleavage and post-synthetic modifications, this bis-linker tether can be removed in one-step by chem. means.  This method was used to synthesize a drug delivery-cargo conjugate, TAT-PKCi peptide, and a two-disulfide bridged heterodimeric peptide, thionin (7-19)-(24-32R), a thionin analog.  To the best of their knowledge, the authors think that this is the first report of a one-pot chem. cleavable bis-linker strategy for the facile synthesis of cross-bridged two-chain peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtPNKTBxBjELVg90H21EOLACvtfcHk0liiBZfK-NlW1g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlegtLbL&md5=5c144c9a43865fc8a1de8efdefd83729</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1002%2Fanie.201604733&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201604733%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DN.%2BA.%26aulast%3DTailhades%26aufirst%3DJ.%26aulast%3DKaras%26aufirst%3DJ.%2BA.%26aulast%3DSeparovic%26aufirst%3DF.%26aulast%3DWade%26aufirst%3DJ.%2BD.%26aulast%3DHossain%26aufirst%3DM.%2BA.%26atitle%3DA%2520one-pot%2520chemically%2520cleavable%2520bis-linker%2520tether%2520strategy%2520for%2520the%2520synthesis%2520of%2520heterodimeric%2520peptides%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D14552%26epage%3D14556%26doi%3D10.1002%2Fanie.201604733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">Zompra, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galanis, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werbitzky, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albericio, F.</span><span> </span><span class="NLM_article-title">Manufacturing peptides as active pharmaceutical ingredients</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">â</span> <span class="NLM_lpage">377</span><span class="refDoi">Â DOI: 10.4155/fmc.09.23</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.4155%2Ffmc.09.23" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21425973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKgsrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2009&pages=361-377&author=A.+A.+Zompraauthor=A.+S.+Galanisauthor=O.+Werbitzkyauthor=F.+Albericio&title=Manufacturing+peptides+as+active+pharmaceutical+ingredients&doi=10.4155%2Ffmc.09.23"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Manufacturing peptides as active pharmaceutical ingredients</span></div><div class="casAuthors">Zompra, Alikaterini A.; Galanis, Athanassios S.; Werbitzky, Oleg; Albericio, Fernando</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">361-377</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Today, there are more than 40 peptides on the pharmaceutical world market and more than 100 in several clin. phases.  Although in the past the pharmaceutical industries had reduced their interest in peptides research, in recent decades, they have rekindled their interest in peptides as a result of contemporary novel technol. accomplishments, strategic developments, advances in the areas of formulation and enhanced drug delivery technol. of peptides.  Thus, 8 new peptide drugs that could previously were characterized as difficult to prep. on the large scale required by industry, have entered the pharmaceutical market at the new millennium.  The manufg. of most of these drugs has benefited from new technol. advances.  Traditional and most modern techniques were applied to the manuf. of these new entries.  Recent accomplishments, together with the traditional benefits of peptides (high biol. activity, high specificity and low toxicity), have led pharmaceutical companies to refocus their attention on peptide-based agents.  Therefore, several serious diseases can be treated using the potential next generation of peptide drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAf3BR3nSNGLVg90H21EOLACvtfcHk0liiBZfK-NlW1g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKgsrw%253D&md5=66f8342d8cb1f11e942aea164017857b</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.4155%2Ffmc.09.23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.09.23%26sid%3Dliteratum%253Aachs%26aulast%3DZompra%26aufirst%3DA.%2BA.%26aulast%3DGalanis%26aufirst%3DA.%2BS.%26aulast%3DWerbitzky%26aufirst%3DO.%26aulast%3DAlbericio%26aufirst%3DF.%26atitle%3DManufacturing%2520peptides%2520as%2520active%2520pharmaceutical%2520ingredients%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2009%26volume%3D1%26spage%3D361%26epage%3D377%26doi%3D10.4155%2Ffmc.09.23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Digby, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span> </span><span class="NLM_article-title">Orthosteric- and allosteric-induced ligand-directed trafficking at GPCRs</span> <span class="citation_source-journal">Curr. Opin. Drug. Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">587</span><span class="NLM_x">â</span> <span class="NLM_lpage">594</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=587-594&author=G.+J.+Digbyauthor=P.+J.+Connauthor=C.+W.+Lindsley&title=Orthosteric-+and+allosteric-induced+ligand-directed+trafficking+at+GPCRs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDigby%26aufirst%3DG.%2BJ.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DOrthosteric-%2520and%2520allosteric-induced%2520ligand-directed%2520trafficking%2520at%2520GPCRs%26jtitle%3DCurr.%2520Opin.%2520Drug.%2520Discovery%2520Dev.%26date%3D2010%26volume%3D13%26spage%3D587%26epage%3D594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit112b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kenakin, T.</span><span> </span><span class="NLM_article-title">Functional selectivity: theoretical considerations and future directions</span>. In  <span class="citation_source-book">Functional Selectivity of G Protein-Coupled Receptor Ligands</span>; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">9</span><span class="NLM_x">â</span> <span class="NLM_lpage">24</span>;.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1007%2F978-1-60327-335-0_2" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=9-24&author=T.+Kenakin&title=Functional+Selectivity+of+G+Protein-Coupled+Receptor+Ligands"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112b&amp;dbid=16384&amp;doi=10.1007%2F978-1-60327-335-0_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-60327-335-0_2%26sid%3Dliteratum%253Aachs%26aulast%3DKenakin%26aufirst%3DT.%26atitle%3DFunctional%2520selectivity%253A%2520theoretical%2520considerations%2520and%2520future%2520directions%26btitle%3DFunctional%2520Selectivity%2520of%2520G%2520Protein-Coupled%2520Receptor%2520Ligands%26pub%3DHumana%2520Press%26date%3D2009%26spage%3D9%26epage%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit112c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Kenakin, T.</span><span> </span><span class="NLM_article-title">Functional Selectivity and Biased Receptor Signaling</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">336</span><span class="NLM_x">, </span> <span class="NLM_fpage">296</span><span class="NLM_x">â</span> <span class="NLM_lpage">302</span><span class="refDoi">Â DOI: 10.1124/jpet.110.173948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1124%2Fjpet.110.173948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21030484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhslWhsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=336&publication_year=2011&pages=296-302&author=T.+Kenakin&title=Functional+Selectivity+and+Biased+Receptor+Signaling&doi=10.1124%2Fjpet.110.173948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112cR"><div class="casContent"><span class="casTitleNuber">112c</span><div class="casTitle"><span class="NLM_cas:atitle">Functional selectivity and biased receptor signaling</span></div><div class="casAuthors">Kenakin, Terry</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">336</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">296-302</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  With the emergence of information describing functional selectivity and biased agonists and antagonists has come a lack of confidence in "one size fits all" assays for detection of agonism.  Seven-transmembrane receptors are pleiotropic with respect to the signaling protein to which they couple in a cell, and many conformations of the receptor can be formed; this leads to systems where ligands can stabilize unique conformations that go on to selectively activate signaling pathways.  Thus, such "biased" ligands can produce cell-specific agonism that may require targeted assays to detect and quantify.  It also predicts that ligands can have many different efficacies for the many behaviors that the receptor can exhibit (referred to as "pluridimensional efficacy"), leading to a breakdown in the common classifications of agonist and antagonist.  This all poses unique challenges to the pharmacol. nomenclature of drugs, the detection and optimization of new drugs, and the assocn. of phenotypic clin. profiles with pharmacol. properties of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDmshypfoNALVg90H21EOLACvtfcHk0liiBZfK-NlW1g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhslWhsr0%253D&md5=83d2c05fec2f9ef9a6e97a98bc0a3616</span></div><a href="/servlet/linkout?suffix=cit112c&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.173948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.173948%26sid%3Dliteratum%253Aachs%26aulast%3DKenakin%26aufirst%3DT.%26atitle%3DFunctional%2520Selectivity%2520and%2520Biased%2520Receptor%2520Signaling%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D336%26spage%3D296%26epage%3D302%26doi%3D10.1124%2Fjpet.110.173948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit112d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Khoury, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clement, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laporte, S. A.</span><span> </span><span class="NLM_article-title">Allosteric and biased G protein-coupled receptor signaling regulation: potentials for new therapeutics</span> <span class="citation_source-journal">Front. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">68</span><span class="refDoi">Â DOI: 10.3389/fendo.2014.00068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3389%2Ffendo.2014.00068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24847311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A280%3ADC%252BC2cflvFWmtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=68&author=E.+Khouryauthor=S.+Clementauthor=S.+A.+Laporte&title=Allosteric+and+biased+G+protein-coupled+receptor+signaling+regulation%3A+potentials+for+new+therapeutics&doi=10.3389%2Ffendo.2014.00068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112dR"><div class="casContent"><span class="casTitleNuber">112d</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric and biased g protein-coupled receptor signaling regulation: potentials for new therapeutics</span></div><div class="casAuthors">Khoury Etienne; Clement Stephanie; Laporte Stephane A</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in endocrinology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">68</span>
        ISSN:<span class="NLM_cas:issn">1664-2392</span>.
    </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are seven-transmembrane proteins that participate in many aspects of the endocrine function and are important targets for drug development.  They transduce signals mainly, but not exclusively, via hetero-trimeric G proteins, leading to a diversity of intracellular signaling cascades.  Ligands binding at the hormone orthosteric sites of receptors have been classified as agonists, antagonists, and/or inverse agonists based on their ability to mainly modulate G protein signaling.  Accumulating evidence also indicates that such ligands, alone or in combination with other ones such as those acting outside the orthosteric hormone binding sites (e.g., allosteric modulators), have the ability to selectively engage subsets of signaling responses as compared to the natural endogenous ligands.  Such modes of functioning have been variously referred to as "functional selectivity" or "ligand-biased signaling." In this review, we provide an overview of the current knowledge regarding GPCR-biased signaling and their functional regulation with a focus on the evolving concept that receptor domains can also be targeted to allosterically bias signaling, and discuss the usefulness of such modes of regulation for the design of more efficient therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR9mMH7P4hI_7rIbt-tGZmxfW6udTcc2eaeQ5t7lx2E67ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflvFWmtg%253D%253D&md5=43bb5344e99722031e19bb9896aa2cf2</span></div><a href="/servlet/linkout?suffix=cit112d&amp;dbid=16384&amp;doi=10.3389%2Ffendo.2014.00068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffendo.2014.00068%26sid%3Dliteratum%253Aachs%26aulast%3DKhoury%26aufirst%3DE.%26aulast%3DClement%26aufirst%3DS.%26aulast%3DLaporte%26aufirst%3DS.%2BA.%26atitle%3DAllosteric%2520and%2520biased%2520G%2520protein-coupled%2520receptor%2520signaling%2520regulation%253A%2520potentials%2520for%2520new%2520therapeutics%26jtitle%3DFront.%2520Endocrinol.%26date%3D2014%26volume%3D5%26spage%3D68%26doi%3D10.3389%2Ffendo.2014.00068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit112e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Luttrell, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maudsley, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohn, L. M.</span><span> </span><span class="NLM_article-title">Fulfilling the promise of â³biasedâ³ G protein-coupled receptor agonism</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">579</span><span class="NLM_x">â</span> <span class="NLM_lpage">588</span><span class="refDoi">Â DOI: 10.1124/mol.115.099630</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1124%2Fmol.115.099630" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2015&pages=579-588&author=L.+M.+Luttrellauthor=S.+Maudsleyauthor=L.+M.+Bohn&title=Fulfilling+the+promise+of+%E2%80%B3biased%E2%80%B3+G+protein-coupled+receptor+agonism&doi=10.1124%2Fmol.115.099630"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112e&amp;dbid=16384&amp;doi=10.1124%2Fmol.115.099630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.115.099630%26sid%3Dliteratum%253Aachs%26aulast%3DLuttrell%26aufirst%3DL.%2BM.%26aulast%3DMaudsley%26aufirst%3DS.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26atitle%3DFulfilling%2520the%2520promise%2520of%2520%25E2%2580%25B3biased%25E2%2580%25B3%2520G%2520protein-coupled%2520receptor%2520agonism%26jtitle%3DMol.%2520Pharmacol.%26date%3D2015%26volume%3D88%26spage%3D579%26epage%3D588%26doi%3D10.1124%2Fmol.115.099630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit112f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Wootten, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, P. M.</span><span> </span><span class="NLM_article-title">Emerging paradigms in GPCR allostery: implications for drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">630</span><span class="NLM_x">â</span> <span class="NLM_lpage">644</span><span class="refDoi">Â DOI: 10.1038/nrd4052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnrd4052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23903222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1SjtbvO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=630-644&author=D.+Woottenauthor=A.+Christopoulosauthor=P.+M.+Sexton&title=Emerging+paradigms+in+GPCR+allostery%3A+implications+for+drug+discovery&doi=10.1038%2Fnrd4052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112fR"><div class="casContent"><span class="casTitleNuber">112f</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging paradigms in GPCR allostery: implications for drug discovery</span></div><div class="casAuthors">Wootten, Denise; Christopoulos, Arthur; Sexton, Patrick M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">630-644</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Allosteric ligands bind to G protein-coupled receptors (GPCRs; also known as seven-transmembrane receptors) at sites that are distinct from the sites to which endogenous ligands bind.  The existence of allosteric ligands has enriched the ways in which the functions of GPCRs can be manipulated for potential therapeutic benefit, yet the complexity of their actions provides both challenges and opportunities for drug screening and development.  Converging avenues of research in areas such as biased signalling by allosteric ligands and the mechanisms by which allosteric ligands modulate the effects of diverse endogenous ligands have provided new insights into how interactions between allosteric ligands and GPCRs could be exploited for drug discovery.  These new findings have the potential to alter how screening for allosteric drugs is performed and may increase the chances of success in the development of allosteric modulators as clin. lead compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxRlmQUCUlsLVg90H21EOLACvtfcHk0lg_rv6ARyrYeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1SjtbvO&md5=59b74e5fbd5eeb832785dd879daa7c77</span></div><a href="/servlet/linkout?suffix=cit112f&amp;dbid=16384&amp;doi=10.1038%2Fnrd4052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4052%26sid%3Dliteratum%253Aachs%26aulast%3DWootten%26aufirst%3DD.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26atitle%3DEmerging%2520paradigms%2520in%2520GPCR%2520allostery%253A%2520implications%2520for%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D630%26epage%3D644%26doi%3D10.1038%2Fnrd4052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit112g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Wootten, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koole, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, P. M.</span><span> </span><span class="NLM_article-title">Allostery and biased agonism at class B G protein-coupled receptors</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">â</span> <span class="NLM_lpage">138</span><span class="refDoi">Â DOI: 10.1021/acs.chemrev.6b00049</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.6b00049" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref112/cit112g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1yqsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2017&pages=111-138&author=D.+Woottenauthor=L.+J.+Millerauthor=C.+Kooleauthor=A.+Christopoulosauthor=P.+M.+Sexton&title=Allostery+and+biased+agonism+at+class+B+G+protein-coupled+receptors&doi=10.1021%2Facs.chemrev.6b00049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112gR"><div class="casContent"><span class="casTitleNuber">112g</span><div class="casTitle"><span class="NLM_cas:atitle">Allostery and Biased Agonism at Class B G Protein-Coupled Receptors</span></div><div class="casAuthors">Wootten, Denise; Miller, Laurence J.; Koole, Cassandra; Christopoulos, Arthur; Sexton, Patrick M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-138</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Class B G protein-coupled receptors (GPCRs) respond to paracrine or endocrine peptide hormones involved in control of bone homeostasis, glucose regulation, satiety, and gastro-intestinal function, as well as pain transmission.  These receptors are targets for existing drugs that treat osteoporosis, hypercalcemia, Paget's disease, type II diabetes, and obesity and are being actively pursued as targets for numerous other diseases.  Exploitation of class B receptors has been limited by difficulties with small mol. drug discovery and development and an under appreciation of factors governing optimal therapeutic efficacy.  Recently, there has been increasing awareness of novel attributes of GPCR function that offer new opportunity for drug development.  These include the presence of allosteric binding sites on the receptor that can be exploited as drug binding pockets and the ability of individual drugs to enrich subpopulations of receptor conformations to selectively control signaling, a phenomenon termed biased agonism.  In this review, current knowledge of biased signaling and small mol. allostery within class B GPCRs is discussed, highlighting areas that have progressed significantly over the past decade, in addn. to those that remain largely unexplored with respect to these phenomena.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqipOVZPN9YzbVg90H21EOLACvtfcHk0lg_rv6ARyrYeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1yqsr0%253D&md5=658b38e14a6438d971cc564731d9e625</span></div><a href="/servlet/linkout?suffix=cit112g&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.6b00049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.6b00049%26sid%3Dliteratum%253Aachs%26aulast%3DWootten%26aufirst%3DD.%26aulast%3DMiller%26aufirst%3DL.%2BJ.%26aulast%3DKoole%26aufirst%3DC.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26atitle%3DAllostery%2520and%2520biased%2520agonism%2520at%2520class%2520B%2520G%2520protein-coupled%2520receptors%26jtitle%3DChem.%2520Rev.%26date%3D2017%26volume%3D117%26spage%3D111%26epage%3D138%26doi%3D10.1021%2Facs.chemrev.6b00049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group">Violin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crombie, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soergel, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lark, M. W.</span><span> </span><span class="NLM_article-title">Biased ligands at G-protein-coupled receptors: promise and progress</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">308</span><span class="NLM_x">â</span> <span class="NLM_lpage">316</span><span class="refDoi">Â DOI: 10.1016/j.tips.2014.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.tips.2014.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24878326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosl2htr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=308-316&author=J.+D.+Violinauthor=A.+L.+Crombieauthor=D.+G.+Soergelauthor=M.+W.+Lark&title=Biased+ligands+at+G-protein-coupled+receptors%3A+promise+and+progress&doi=10.1016%2Fj.tips.2014.04.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Biased ligands at G-protein-coupled receptors: promise and progress</span></div><div class="casAuthors">Violin, Jonathan D.; Crombie, Aimee L.; Soergel, David G.; Lark, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">308-316</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Drug discovery targeting G protein-coupled receptors (GPCRs) is no longer limited to seeking agonists or antagonists to stimulate or block cellular responses assocd. with a particular receptor.  GPCRs are now known to support a diversity of pharmacol. profiles, a concept broadly referred to as functional selectivity.  In particular, the concept of ligand bias, whereby a ligand stabilizes subsets of receptor conformations to engender novel pharmacol. profiles, has recently gained increasing prominence.  This review discusses how biased ligands may deliver safer, better tolerated, and more efficacious drugs, and highlights several biased ligands that are in clin. development.  Biased ligands targeting the angiotensin II type 1 receptor and the Î¼ opioid receptor illustrate the translation of the biased ligand concept from basic biol. to clin. drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBma1S1zZ0-7Vg90H21EOLACvtfcHk0lhHK23Y56Anbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosl2htr4%253D&md5=768953e7aa5726d1a47ecbdb068469d8</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2014.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2014.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DCrombie%26aufirst%3DA.%2BL.%26aulast%3DSoergel%26aufirst%3DD.%2BG.%26aulast%3DLark%26aufirst%3DM.%2BW.%26atitle%3DBiased%2520ligands%2520at%2520G-protein-coupled%2520receptors%253A%2520promise%2520and%2520progress%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2014%26volume%3D35%26spage%3D308%26epage%3D316%26doi%3D10.1016%2Fj.tips.2014.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group">Kenakin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, L. J.</span><span> </span><span class="NLM_article-title">Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">265</span><span class="NLM_x">â</span> <span class="NLM_lpage">304</span><span class="refDoi">Â DOI: 10.1124/pr.108.000992</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1124%2Fpr.108.000992" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=20392808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVSltbbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=265-304&author=T.+Kenakinauthor=L.+J.+Miller&title=Seven+transmembrane+receptors+as+shapeshifting+proteins%3A+the+impact+of+allosteric+modulation+and+functional+selectivity+on+new+drug+discovery&doi=10.1124%2Fpr.108.000992"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery</span></div><div class="casAuthors">Kenakin, Terry; Miller, Laurence J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">265-304</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  It is useful to consider seven transmembrane receptors (7TMRs) as disordered proteins able to allosterically respond to a no. of binding partners.  Considering 7TMRs as allosteric systems, affinity and efficacy can be thought of in terms of energy flow between a modulator, conduit (the receptor protein), and a no. of guests.  These guests can be other mols., receptors, membrane-bound proteins, or signaling proteins in the cytosol.  These vectorial flows of energy can yield std. canonical guest allostery (allosteric modification of drug effect), effects along the plane of the cell membrane (receptor oligomerization), or effects directed into the cytosol (differential signaling as functional selectivity).  This review discusses these apparently diverse pharmacol. effects in terms of mol. dynamics and protein ensemble theory, which tends to unify 7TMR behavior toward cells.  Special consideration will be given to functional selectivity (biased agonism and biased antagonism) in terms of mechanism of action and potential therapeutic application.  The explosion of technol. that has enabled observation of diverse 7TMR behavior has also shown how drugs can have multiple (pluridimensional) efficacies and how this can cause paradoxical drug classification and nomenclatures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3xCdUTrHggbVg90H21EOLACvtfcHk0lhHK23Y56Anbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVSltbbM&md5=fa2394cfb3ae2ecdde09775b50b45b8b</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1124%2Fpr.108.000992&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.108.000992%26sid%3Dliteratum%253Aachs%26aulast%3DKenakin%26aufirst%3DT.%26aulast%3DMiller%26aufirst%3DL.%2BJ.%26atitle%3DSeven%2520transmembrane%2520receptors%2520as%2520shapeshifting%2520proteins%253A%2520the%2520impact%2520of%2520allosteric%2520modulation%2520and%2520functional%2520selectivity%2520on%2520new%2520drug%2520discovery%26jtitle%3DPharmacol.%2520Rev.%26date%3D2010%26volume%3D62%26spage%3D265%26epage%3D304%26doi%3D10.1124%2Fpr.108.000992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group">Violin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeWire, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rominger, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whalen, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gowen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lark, M. W.</span><span> </span><span class="NLM_article-title">Selectively Engaging <sup>Î²</sup>-Arrestins at the Angiotensin II Type 1 Receptor Reduces Blood Pressure and Increases Cardiac Performance</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">335</span><span class="NLM_x">, </span> <span class="NLM_fpage">572</span><span class="NLM_x">â</span> <span class="NLM_lpage">579</span><span class="refDoi">Â DOI: 10.1124/jpet.110.173005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1124%2Fjpet.110.173005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=20801892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFOmsrjF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=2010&pages=572-579&author=J.+D.+Violinauthor=S.+M.+DeWireauthor=D.+Yamashitaauthor=D.+H.+Romingerauthor=L.+Nguyenauthor=K.+Schillerauthor=E.+J.+Whalenauthor=M.+Gowenauthor=M.+W.+Lark&title=Selectively+Engaging+%CE%B2-Arrestins+at+the+Angiotensin+II+Type+1+Receptor+Reduces+Blood+Pressure+and+Increases+Cardiac+Performance&doi=10.1124%2Fjpet.110.173005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Selectively engaging Î²-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance</span></div><div class="casAuthors">Violin, Jonathan D.; DeWire, Scott M.; Yamashita, Dennis; Rominger, David H.; Nguyen, Lisa; Schiller, Kevin; Whalen, Erin J.; Gowen, Maxine; Lark, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">572-579</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Biased G protein-coupled ligands engage subsets of the receptor signals normally stimulated by unbiased agonists.  However, it is unclear whether ligand bias can elicit differentiated pharmacol. in vivo.  Here, we describe the discovery of a potent, selective Î²-arrestin biased ligand of the angiotensin II type 1 receptor.  TRV 120027 (Sar-Arg-Val-Tyr-Ile-His-Pro-D-Ala-OH) competitively antagonizes angiotensin II-stimulated G protein signaling, but stimulates Î²-arrestin recruitment and activates several kinase pathways, including p42/44 mitogen-activated protein kinase, Src, and endothelial nitric-oxide synthase phosphorylation via Î²-arrestin coupling.  Consistent with Î²-arrestin efficacy, and unlike unbiased antagonists, TRV 120027 increased cardiomyocyte contractility in vitro.  In rats, TRV 120027 reduced mean arterial pressure, as did the unbiased antagonists losartan and telmisartan.  However, unlike the unbiased antagonists, which decreased cardiac performance, TRV 120027 increased cardiac performance and preserved cardiac stroke vol.  These striking differences in vivo between unbiased and Î²-arrestin biased ligands validate the use of biased ligands to selectively target specific receptor functions in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQaaai_REGvbVg90H21EOLACvtfcHk0lhHK23Y56Anbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFOmsrjF&md5=a896363e71830f706b103d8153c97f83</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.173005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.173005%26sid%3Dliteratum%253Aachs%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DDeWire%26aufirst%3DS.%2BM.%26aulast%3DYamashita%26aufirst%3DD.%26aulast%3DRominger%26aufirst%3DD.%2BH.%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DSchiller%26aufirst%3DK.%26aulast%3DWhalen%26aufirst%3DE.%2BJ.%26aulast%3DGowen%26aufirst%3DM.%26aulast%3DLark%26aufirst%3DM.%2BW.%26atitle%3DSelectively%2520Engaging%2520%25CE%25B2-Arrestins%2520at%2520the%2520Angiotensin%2520II%2520Type%25201%2520Receptor%2520Reduces%2520Blood%2520Pressure%2520and%2520Increases%2520Cardiac%2520Performance%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D335%26spage%3D572%26epage%3D579%26doi%3D10.1124%2Fjpet.110.173005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group">Gesty-Palmer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flannery, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corsino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spurney, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefkowitz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttrell, L. M.</span><span> </span><span class="NLM_article-title">A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">1ra1</span><span class="refDoi">Â DOI: 10.1126/scitranslmed.3000071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1126%2Fscitranslmed.3000071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=20368153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A280%3ADC%252BC3c3jvFSmug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2009&pages=1ra1&author=D.+Gesty-Palmerauthor=P.+Flanneryauthor=L.+Yuanauthor=L.+Corsinoauthor=R.+Spurneyauthor=R.+J.+Lefkowitzauthor=L.+M.+Luttrell&title=A+beta-arrestin-biased+agonist+of+the+parathyroid+hormone+receptor+%28PTH1R%29+promotes+bone+formation+independent+of+G+protein+activation&doi=10.1126%2Fscitranslmed.3000071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation</span></div><div class="casAuthors">Gesty-Palmer Diane; Flannery Pat; Yuan Ling; Corsino Leonor; Spurney Robert; Lefkowitz Robert J; Luttrell Louis M</div><div class="citationInfo"><span class="NLM_cas:title">Science translational medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1ra1</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">About 40% of the therapeutic agents in use today exert their effects through seven-transmembrane receptors (7TMRs).  When activated by ligands, these receptors trigger two pathways that independently transduce signals to the cell: one through heterotrimeric GTP-binding proteins (G proteins) and one through beta-arrestins; so-called biased agonists can selectively activate these distinct pathways.  Here, we investigate selective activation of these pathways through the use of a biased agonist for the type 1 parathyroid hormone (PTH)-PTH-related protein receptor (PTH1R), (D-Trp(12),Tyr(34))-PTH(7-34) (PTH-betaarr), which activates beta-arrestin but not classic G protein signaling.  In mice, PTH-betaarr induces anabolic bone formation, as does the nonselective agonist PTH(1-34), which activates both mechanisms.  In beta-arrestin2-null mice, the increase in bone mineral density evoked by PTH(1-34) is attenuated and that stimulated by PTH-betaarr is ablated.  The beta-arrestin2-dependent pathway contributes primarily to trabecular bone formation and does not stimulate bone resorption.  These results show that a biased agonist selective for the beta-arrestin pathway can elicit a response in vivo distinct from that elicited by nonselective agonists.  Ligands with these properties may form the basis for improved 7TMR-directed pharmacologic agents with enhanced therapeutic specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmuM4aCIxthdXdcedVHT5tfW6udTcc2eZKWxAlQplIrLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c3jvFSmug%253D%253D&md5=748e4367ded72b6b7e10fd759521ba62</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3000071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3000071%26sid%3Dliteratum%253Aachs%26aulast%3DGesty-Palmer%26aufirst%3DD.%26aulast%3DFlannery%26aufirst%3DP.%26aulast%3DYuan%26aufirst%3DL.%26aulast%3DCorsino%26aufirst%3DL.%26aulast%3DSpurney%26aufirst%3DR.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DLuttrell%26aufirst%3DL.%2BM.%26atitle%3DA%2520beta-arrestin-biased%2520agonist%2520of%2520the%2520parathyroid%2520hormone%2520receptor%2520%2528PTH1R%2529%2520promotes%2520bone%2520formation%2520independent%2520of%2520G%2520protein%2520activation%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2009%26volume%3D1%26spage%3D1ra1%26doi%3D10.1126%2Fscitranslmed.3000071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Burgdorf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.-l.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balster, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leander, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanton, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroes, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moskal, J. R.</span><span> </span><span class="NLM_article-title">GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">729</span><span class="NLM_x">â</span> <span class="NLM_lpage">742</span><span class="refDoi">Â DOI: 10.1038/npp.2012.246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnpp.2012.246" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2013&pages=729-742&author=J.+Burgdorfauthor=X.-l.+Zhangauthor=K.+L.+Nicholsonauthor=R.+L.+Balsterauthor=J.+D.+Leanderauthor=P.+K.+Stantonauthor=A.+L.+Grossauthor=R.+A.+Kroesauthor=J.+R.+Moskal&title=GLYX-13%2C+a+NMDA+receptor+glycine-site+functional+partial+agonist%2C+induces+antidepressant-like+effects+without+ketamine-like+side+effects&doi=10.1038%2Fnpp.2012.246"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117a&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2012.246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2012.246%26sid%3Dliteratum%253Aachs%26aulast%3DBurgdorf%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.-l.%26aulast%3DNicholson%26aufirst%3DK.%2BL.%26aulast%3DBalster%26aufirst%3DR.%2BL.%26aulast%3DLeander%26aufirst%3DJ.%2BD.%26aulast%3DStanton%26aufirst%3DP.%2BK.%26aulast%3DGross%26aufirst%3DA.%2BL.%26aulast%3DKroes%26aufirst%3DR.%2BA.%26aulast%3DMoskal%26aufirst%3DJ.%2BR.%26atitle%3DGLYX-13%252C%2520a%2520NMDA%2520receptor%2520glycine-site%2520functional%2520partial%2520agonist%252C%2520induces%2520antidepressant-like%2520effects%2520without%2520ketamine-like%2520side%2520effects%26jtitle%3DNeuropsychopharmacology%26date%3D2013%26volume%3D38%26spage%3D729%26epage%3D742%26doi%3D10.1038%2Fnpp.2012.246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit117b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Moskal, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgdorf, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroes, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanton, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Disterhoft, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leander, J. D.</span><span> </span><span class="NLM_article-title">GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">243</span><span class="NLM_x">â</span> <span class="NLM_lpage">254</span><span class="refDoi">Â DOI: 10.1517/13543784.2014.852536</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1517%2F13543784.2014.852536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24251380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvFarsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=243-254&author=J.+R.+Moskalauthor=R.+Burchauthor=J.+S.+Burgdorfauthor=R.+A.+Kroesauthor=P.+K.+Stantonauthor=J.+F.+Disterhoftauthor=J.+D.+Leander&title=GLYX-13%2C+an+NMDA+receptor+glycine+site+functional+partial+agonist+enhances+cognition+and+produces+antidepressant+effects+without+the+psychotomimetic+side+effects+of+NMDA+receptor+antagonists&doi=10.1517%2F13543784.2014.852536"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117bR"><div class="casContent"><span class="casTitleNuber">117b</span><div class="casTitle"><span class="NLM_cas:atitle">GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists</span></div><div class="casAuthors">Moskal, Joseph R.; Burch, Ronald; Burgdorf, Jeffrey S.; Kroes, Roger A.; Stanton, Patric K.; Disterhoft, John F.; Leander, J. David</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">243-254</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The N-methyl-D-aspartate receptor-ionophore complex plays a key role in learning and memory and has efficacy in animals and humans with affective disorders.  GLYX-13 is an N-methyl-d-aspartate receptor (NMDAR) glycine-site functional partial agonist and cognitive enhancer that also shows rapid antidepressant activity without psychotomimetic side effects.  Areas covered: The authors review the mechanism of action of GLYX-13 that was investigated in preclin. studies and evaluated in clin. studies.  Specifically, the authors review its pharmacol., pharmacokinetics, and drug safety that were demonstrated in clin. studies.  Expert opinion: NMDAR full antagonists can produce rapid antidepressant effects in treatment-resistant subjects; however, they are often accompanied by psychotomimetic effects that make chronic use outside of a clin. trial inpatient setting problematic.  GLYX-13 appears to exert its antidepressant effects in the frontal cortex via NMDAR-triggered synaptic plasticity.  Understanding the mechanistic underpinning of GLYX-13's antidepressant action should provide both novel insights into the role of the glutamatergic system in depression and identify new targets for therapeutic development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1qLFmRChVArVg90H21EOLACvtfcHk0lgnnGAc77kIXw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvFarsA%253D%253D&md5=438f7150450c25f13107b9ed359c5a75</span></div><a href="/servlet/linkout?suffix=cit117b&amp;dbid=16384&amp;doi=10.1517%2F13543784.2014.852536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2014.852536%26sid%3Dliteratum%253Aachs%26aulast%3DMoskal%26aufirst%3DJ.%2BR.%26aulast%3DBurch%26aufirst%3DR.%26aulast%3DBurgdorf%26aufirst%3DJ.%2BS.%26aulast%3DKroes%26aufirst%3DR.%2BA.%26aulast%3DStanton%26aufirst%3DP.%2BK.%26aulast%3DDisterhoft%26aufirst%3DJ.%2BF.%26aulast%3DLeander%26aufirst%3DJ.%2BD.%26atitle%3DGLYX-13%252C%2520an%2520NMDA%2520receptor%2520glycine%2520site%2520functional%2520partial%2520agonist%2520enhances%2520cognition%2520and%2520produces%2520antidepressant%2520effects%2520without%2520the%2520psychotomimetic%2520side%2520effects%2520of%2520NMDA%2520receptor%2520antagonists%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2014%26volume%3D23%26spage%3D243%26epage%3D254%26doi%3D10.1517%2F13543784.2014.852536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group">Vasilescu, A.-N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schweinfurth, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgwardt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gass, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, U. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckart, S.</span><span> </span><span class="NLM_article-title">Modulation of the activity of N-methyl-d-aspartate receptors as a novel treatment option for depression: current clinical evidence and therapeutic potential of rapastinel (GLYX-13)</span> <span class="citation_source-journal">Neuropsychiatr. Dis. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">973</span><span class="NLM_x">â</span> <span class="NLM_lpage">980</span><span class="refDoi">Â DOI: 10.2147/NDT.S119004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.2147%2FNDT.S119004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=28408831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A280%3ADC%252BC1cvnslGltQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=973-980&author=A.-N.+Vasilescuauthor=N.+Schweinfurthauthor=S.+Borgwardtauthor=P.+Gassauthor=U.+E.+Langauthor=D.+Intaauthor=S.+Eckart&title=Modulation+of+the+activity+of+N-methyl-d-aspartate+receptors+as+a+novel+treatment+option+for+depression%3A+current+clinical+evidence+and+therapeutic+potential+of+rapastinel+%28GLYX-13%29&doi=10.2147%2FNDT.S119004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of the activity of N-methyl-d-aspartate receptors as a novel treatment option for depression: current clinical evidence and therapeutic potential of rapastinel (GLYX-13)</span></div><div class="casAuthors">Vasilescu Andrei-Nicolae; Gass Peter; Inta Dragos; Schweinfurth Nina; Borgwardt Stefan; Lang Undine E; Inta Dragos; Eckart Sarah</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychiatric disease and treatment</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">973-980</span>
        ISSN:<span class="NLM_cas:issn">1176-6328</span>.
    </div><div class="casAbstract">Classical monoaminergic antidepressants show several disadvantages, such as protracted onset of therapeutic action.  Conversely, the fast and sustained antidepressant effect of the N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine raises vast interest in understanding the role of the glutamate system in mood disorders.  Indeed, numerous data support the existence of glutamatergic dysfunction in major depressive disorder (MDD).  Drawback to this short-latency therapy is its side effect profile, especially the psychotomimetic action, which seriously hampers the common and widespread clinical use of ketamine.  Therefore, there is a substantial need for alternative glutamatergic antidepressants with milder side effects.  In this article, we review evidence that implicates NMDARs in the prospective treatment of MDD with focus on rapastinel (formerly known as GLYX-13), a novel synthetic NMDAR modulator with fast antidepressant effect, which acts by enhancing NMDAR function as opposed to blocking it.  We summarize and discuss current clinical and animal studies regarding the therapeutic potential of rapastinel not only in MDD but also in other psychiatric disorders, such as obsessive-compulsive disorder and posttraumatic stress disorder.  Additionally, we discuss current data concerning the molecular mechanisms underlying the antidepressant effect of rapastinel, highlighting common aspects as well as differences to ketamine.  In 2016, rapastinel received the Breakthrough Therapy designation for the treatment of MDD from the US Food and Drug Administration, representing one of the most promising alternative antidepressants under current investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvBm8Q8B105NbHMBt0mMIXfW6udTcc2eZKWxAlQplIrLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvnslGltQ%253D%253D&md5=e27e12ccb5d8405f33d8474bd1c75bb0</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.2147%2FNDT.S119004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FNDT.S119004%26sid%3Dliteratum%253Aachs%26aulast%3DVasilescu%26aufirst%3DA.-N.%26aulast%3DSchweinfurth%26aufirst%3DN.%26aulast%3DBorgwardt%26aufirst%3DS.%26aulast%3DGass%26aufirst%3DP.%26aulast%3DLang%26aufirst%3DU.%2BE.%26aulast%3DInta%26aufirst%3DD.%26aulast%3DEckart%26aufirst%3DS.%26atitle%3DModulation%2520of%2520the%2520activity%2520of%2520N-methyl-d-aspartate%2520receptors%2520as%2520a%2520novel%2520treatment%2520option%2520for%2520depression%253A%2520current%2520clinical%2520evidence%2520and%2520therapeutic%2520potential%2520of%2520rapastinel%2520%2528GLYX-13%2529%26jtitle%3DNeuropsychiatr.%2520Dis.%2520Treat.%26date%3D2017%26volume%3D13%26spage%3D973%26epage%3D980%26doi%3D10.2147%2FNDT.S119004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kuliopulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covic, L.</span><span> </span><span class="NLM_article-title">Blocking receptors on the inside: pepducin-based intervention of PAR signaling and thrombosis</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">â</span> <span class="NLM_lpage">262</span><span class="refDoi">Â DOI: 10.1016/j.lfs.2003.09.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.lfs.2003.09.012" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2003&pages=255-262&author=A.+Kuliopulosauthor=L.+Covic&title=Blocking+receptors+on+the+inside%3A+pepducin-based+intervention+of+PAR+signaling+and+thrombosis&doi=10.1016%2Fj.lfs.2003.09.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119a&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2003.09.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2003.09.012%26sid%3Dliteratum%253Aachs%26aulast%3DKuliopulos%26aufirst%3DA.%26aulast%3DCovic%26aufirst%3DL.%26atitle%3DBlocking%2520receptors%2520on%2520the%2520inside%253A%2520pepducin-based%2520intervention%2520of%2520PAR%2520signaling%2520and%2520thrombosis%26jtitle%3DLife%2520Sci.%26date%3D2003%26volume%3D74%26spage%3D255%26epage%3D262%26doi%3D10.1016%2Fj.lfs.2003.09.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit119b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">OâCallaghan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuliopulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covic, L.</span><span> </span><span class="NLM_article-title">Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">287</span><span class="NLM_x">, </span> <span class="NLM_fpage">12787</span><span class="NLM_x">â</span> <span class="NLM_lpage">12796</span><span class="refDoi">Â DOI: 10.1074/jbc.R112.355461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1074%2Fjbc.R112.355461" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=12787-12796&author=K.+O%E2%80%99Callaghanauthor=A.+Kuliopulosauthor=L.+Covic&title=Turning+receptors+on+and+off+with+intracellular+pepducins%3A+new+insights+into+G-protein-coupled+receptor+drug+development&doi=10.1074%2Fjbc.R112.355461"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119b&amp;dbid=16384&amp;doi=10.1074%2Fjbc.R112.355461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.R112.355461%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Callaghan%26aufirst%3DK.%26aulast%3DKuliopulos%26aufirst%3DA.%26aulast%3DCovic%26aufirst%3DL.%26atitle%3DTurning%2520receptors%2520on%2520and%2520off%2520with%2520intracellular%2520pepducins%253A%2520new%2520insights%2520into%2520G-protein-coupled%2520receptor%2520drug%2520development%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D12787%26epage%3D12796%26doi%3D10.1074%2Fjbc.R112.355461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group">Zhang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasuda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimmelstiel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâCallaghan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohm, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baleja, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covic, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuliopulos, A.</span><span> </span><span class="NLM_article-title">Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">83</span><span class="NLM_x">â</span> <span class="NLM_lpage">91</span><span class="refDoi">Â DOI: 10.1161/CIRCULATIONAHA.112.091918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1161%2FCIRCULATIONAHA.112.091918" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2012&pages=83-91&author=P.+Zhangauthor=A.+Gruberauthor=S.+Kasudaauthor=C.+Kimmelstielauthor=K.+O%E2%80%99Callaghanauthor=D.+H.+Coxauthor=A.+Bohmauthor=J.+D.+Balejaauthor=L.+Covicauthor=A.+Kuliopulos&title=Suppression+of+arterial+thrombosis+without+affecting+hemostatic+parameters+with+a+cell-penetrating+PAR1+pepducin&doi=10.1161%2FCIRCULATIONAHA.112.091918"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.112.091918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.112.091918%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DGruber%26aufirst%3DA.%26aulast%3DKasuda%26aufirst%3DS.%26aulast%3DKimmelstiel%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Callaghan%26aufirst%3DK.%26aulast%3DCox%26aufirst%3DD.%2BH.%26aulast%3DBohm%26aufirst%3DA.%26aulast%3DBaleja%26aufirst%3DJ.%2BD.%26aulast%3DCovic%26aufirst%3DL.%26aulast%3DKuliopulos%26aufirst%3DA.%26atitle%3DSuppression%2520of%2520arterial%2520thrombosis%2520without%2520affecting%2520hemostatic%2520parameters%2520with%2520a%2520cell-penetrating%2520PAR1%2520pepducin%26jtitle%3DCirculation%26date%3D2012%26volume%3D126%26spage%3D83%26epage%3D91%26doi%3D10.1161%2FCIRCULATIONAHA.112.091918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span>Clinical information can be found at: NCT01806077: Safety Study of PZ-128 in Subjects with Multiple Coronary Artery Disease Risk Factors; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="https://www.clinicaltrials.gov/" class="extLink">https://www.clinicaltrials.gov/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical+information+can+be+found+at%3A+NCT01806077%3A+Safety+Study+of+PZ-128+in+Subjects+with+Multiple+Coronary+Artery+Disease+Risk+Factors%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2016%3B+https%3A%2F%2Fwww.clinicaltrials.gov%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DNCT01806077%253A%2520Safety%2520Study%2520of%2520PZ-128%2520in%2520Subjects%2520with%2520Multiple%2520Coronary%2520Artery%2520Disease%2520Risk%2520Factors%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group">DeWire, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Violin, J. D.</span><span> </span><span class="NLM_article-title">Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology</span> <span class="citation_source-journal">Circ. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">â</span> <span class="NLM_lpage">216</span><span class="refDoi">Â DOI: 10.1161/CIRCRESAHA.110.231308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1161%2FCIRCRESAHA.110.231308" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2011&pages=205-216&author=S.+M.+DeWireauthor=J.+D.+Violin&title=Biased+ligands+for+better+cardiovascular+drugs%3A+dissecting+G-protein-coupled+receptor+pharmacology&doi=10.1161%2FCIRCRESAHA.110.231308"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.110.231308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.110.231308%26sid%3Dliteratum%253Aachs%26aulast%3DDeWire%26aufirst%3DS.%2BM.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26atitle%3DBiased%2520ligands%2520for%2520better%2520cardiovascular%2520drugs%253A%2520dissecting%2520G-protein-coupled%2520receptor%2520pharmacology%26jtitle%3DCirc.%2520Res.%26date%3D2011%26volume%3D109%26spage%3D205%26epage%3D216%26doi%3D10.1161%2FCIRCRESAHA.110.231308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group">Di, L.</span><span> </span><span class="NLM_article-title">Strategic Approaches to Optimizing Peptide ADME Properties</span> <span class="citation_source-journal">AAPS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">â</span> <span class="NLM_lpage">143</span><span class="refDoi">Â DOI: 10.1208/s12248-014-9687-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1208%2Fs12248-014-9687-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25366889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFSnurvJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=134-143&author=L.+Di&title=Strategic+Approaches+to+Optimizing+Peptide+ADME+Properties&doi=10.1208%2Fs12248-014-9687-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Strategic Approaches to Optimizing Peptide ADME Properties</span></div><div class="casAuthors">Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">134-143</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Development of peptide drugs is challenging but also quite rewarding.  Five blockbuster peptide drugs are currently on the market, and six new peptides received first marketing approval as new mol. entities in 2012.  Although peptides only represent 2% of the drug market, the market is growing twice as quickly and might soon occupy a larger niche.  Natural peptides typically have poor absorption, distribution, metab., and excretion (ADME) properties with rapid clearance, short half-life, low permeability, and sometimes low soly.  Strategies have been developed to improve peptide drugability through enhancing permeability, reducing proteolysis and renal clearance, and prolonging half-life.  In vivo, in vitro, and in silico tools are available to evaluate ADME properties of peptides, and structural modification strategies are in place to improve peptide developability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDLDsR-Zk0OLVg90H21EOLACvtfcHk0lgJTMtvL0E0Bg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFSnurvJ&md5=530597d3719d65509105096f433fee0a</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1208%2Fs12248-014-9687-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-014-9687-3%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26atitle%3DStrategic%2520Approaches%2520to%2520Optimizing%2520Peptide%2520ADME%2520Properties%26jtitle%3DAAPS%2520J.%26date%3D2015%26volume%3D17%26spage%3D134%26epage%3D143%26doi%3D10.1208%2Fs12248-014-9687-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jamieson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boutard, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabatino, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubell, W. D.</span><span> </span><span class="NLM_article-title">Peptide scanning for studying structure-activity relationships in drug discovery</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">148</span><span class="NLM_x">â</span> <span class="NLM_lpage">165</span><span class="refDoi">Â DOI: 10.1111/cbdd.12042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1111%2Fcbdd.12042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23253136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1ykug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2013&pages=148-165&author=A.+G.+Jamiesonauthor=N.+Boutardauthor=D.+Sabatinoauthor=W.+D.+Lubell&title=Peptide+scanning+for+studying+structure-activity+relationships+in+drug+discovery&doi=10.1111%2Fcbdd.12042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124aR"><div class="casContent"><span class="casTitleNuber">124a</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide scanning for studying structure-activity relationships in drug discovery</span></div><div class="casAuthors">Jamieson, Andrew G.; Boutard, Nicolas; Sabatino, David; Lubell, William D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">148-165</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Peptide-based therapeutics have grown in importance over the last few decades.  Furthermore, peptides have been extensively used as lead compds. in the drug discovery process to investigate the nature of chem. space required for mol. recognition and activity at a variety of targets.  This crit. commentary reviews scanning techniques, which employ natural and non-proteinogenic amino acids to facilitate understanding of structural requirements for peptide biol. activity.  The value of sequence anal. by such methods is highlighted by examples, in which the elements for peptide affinity and activity have been elucidated and employed to prep. peptidomimetic leads for drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlnOyXem-xgLVg90H21EOLACvtfcHk0lhRgQQEoz0yGA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1ykug%253D%253D&md5=819b6f730174f5f73b0bb7cf04ca30c2</span></div><a href="/servlet/linkout?suffix=cit124a&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12042%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DA.%2BG.%26aulast%3DBoutard%26aufirst%3DN.%26aulast%3DSabatino%26aufirst%3DD.%26aulast%3DLubell%26aufirst%3DW.%2BD.%26atitle%3DPeptide%2520scanning%2520for%2520studying%2520structure-activity%2520relationships%2520in%2520drug%2520discovery%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2013%26volume%3D81%26spage%3D148%26epage%3D165%26doi%3D10.1111%2Fcbdd.12042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit124b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Eustache, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leprince, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuffery, P.</span><span> </span><span class="NLM_article-title">Progress with peptide scanning to study structure-activity relationships: the implications for drug discovery</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">771</span><span class="NLM_x">â</span> <span class="NLM_lpage">784</span><span class="refDoi">Â DOI: 10.1080/17460441.2016.1201058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1080%2F17460441.2016.1201058" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=771-784&author=S.+Eustacheauthor=J.+Leprinceauthor=P.+Tuffery&title=Progress+with+peptide+scanning+to+study+structure-activity+relationships%3A+the+implications+for+drug+discovery&doi=10.1080%2F17460441.2016.1201058"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124b&amp;dbid=16384&amp;doi=10.1080%2F17460441.2016.1201058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2016.1201058%26sid%3Dliteratum%253Aachs%26aulast%3DEustache%26aufirst%3DS.%26aulast%3DLeprince%26aufirst%3DJ.%26aulast%3DTuffery%26aufirst%3DP.%26atitle%3DProgress%2520with%2520peptide%2520scanning%2520to%2520study%2520structure-activity%2520relationships%253A%2520the%2520implications%2520for%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2016%26volume%3D11%26spage%3D771%26epage%3D784%26doi%3D10.1080%2F17460441.2016.1201058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit124c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Murray, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, Y.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aral, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stenkilsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salyers, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaida, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sickmier, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGivern, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gegg, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miranda, L. P.</span><span> </span><span class="NLM_article-title">Pharmaceutical optimization of peptide toxins for ion channel targets: potent, selective, and long-lived antagonists of Kv1.3</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">6784</span><span class="NLM_x">â</span> <span class="NLM_lpage">6802</span><span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00495</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00495" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref124/cit124c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlOjtbjK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6784-6802&author=J.+K.+Murrayauthor=Y.-X.+Qianauthor=B.+Liuauthor=R.+Elliottauthor=J.+Aralauthor=C.+Parkauthor=X.+Zhangauthor=M.+Stenkilssonauthor=K.+Salyersauthor=M.+Roseauthor=H.+Liauthor=S.+Yuauthor=K.+L.+Andrewsauthor=A.+Colomberoauthor=J.+Wernerauthor=K.+Gaidaauthor=E.+A.+Sickmierauthor=P.+Miuauthor=A.+Itanoauthor=J.+McGivernauthor=C.+V.+Geggauthor=J.+K.+Sullivanauthor=L.+P.+Miranda&title=Pharmaceutical+optimization+of+peptide+toxins+for+ion+channel+targets%3A+potent%2C+selective%2C+and+long-lived+antagonists+of+Kv1.3&doi=10.1021%2Facs.jmedchem.5b00495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124cR"><div class="casContent"><span class="casTitleNuber">124c</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmaceutical Optimization of Peptide Toxins for Ion Channel Targets: Potent, Selective, and Long-Lived Antagonists of Kv1.3</span></div><div class="casAuthors">Murray, Justin K.; Qian, Yi-Xin; Liu, Benxian; Elliott, Robin; Aral, Jennifer; Park, Cynthia; Zhang, Xuxia; Stenkilsson, Michael; Salyers, Kevin; Rose, Mark; Li, Hongyan; Yu, Steven; Andrews, Kristin L.; Colombero, Anne; Werner, Jonathan; Gaida, Kevin; Sickmier, E. Allen; Miu, Peter; Itano, Andrea; McGivern, Joseph; Gegg, Colin V.; Sullivan, John K.; Miranda, Les P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6784-6802</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To realize the medicinal potential of peptide toxins, naturally occurring disulfide-rich peptides, as ion channel antagonists, more efficient pharmaceutical optimization technologies must be developed.  The therapeutic properties of multiple cysteine toxin peptides can be rapidly and substantially improved by combining direct chem. strategies with high-throughput electrophysiol.  The authors applied whole-mol., brute-force, structure-activity analoging to ShK, a peptide toxin from the sea anemone Stichodactyla helianthus that inhibits the voltage-gated potassium ion channel Kv1.3, to effectively discover crit. structural changes for 15Ã selectivity against the closely related neuronal ion channel Kv1.1.  Subsequent site-specific polymer conjugation resulted in an exquisitely selective Kv1.3 antagonist (>1000Ã over Kv1.1) with picomolar functional activity in whole blood and a pharmacokinetic profile suitable for weekly administration in primates.  The pharmacol. potential of the optimized toxin peptide was demonstrated by potent and sustained inhibition of cytokine secretion from T cells, a therapeutic target for autoimmune diseases, in cynomolgus monkeys.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEtF-Ugp8jFbVg90H21EOLACvtfcHk0lhRgQQEoz0yGA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlOjtbjK&md5=1cfb03e783bd953480c203dc9b95af84</span></div><a href="/servlet/linkout?suffix=cit124c&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00495%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DJ.%2BK.%26aulast%3DQian%26aufirst%3DY.-X.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DElliott%26aufirst%3DR.%26aulast%3DAral%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DStenkilsson%26aufirst%3DM.%26aulast%3DSalyers%26aufirst%3DK.%26aulast%3DRose%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DColombero%26aufirst%3DA.%26aulast%3DWerner%26aufirst%3DJ.%26aulast%3DGaida%26aufirst%3DK.%26aulast%3DSickmier%26aufirst%3DE.%2BA.%26aulast%3DMiu%26aufirst%3DP.%26aulast%3DItano%26aufirst%3DA.%26aulast%3DMcGivern%26aufirst%3DJ.%26aulast%3DGegg%26aufirst%3DC.%2BV.%26aulast%3DSullivan%26aufirst%3DJ.%2BK.%26aulast%3DMiranda%26aufirst%3DL.%2BP.%26atitle%3DPharmaceutical%2520optimization%2520of%2520peptide%2520toxins%2520for%2520ion%2520channel%2520targets%253A%2520potent%252C%2520selective%252C%2520and%2520long-lived%2520antagonists%2520of%2520Kv1.3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6784%26epage%3D6802%26doi%3D10.1021%2Facs.jmedchem.5b00495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Goodwin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simerska, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toth, I.</span><span> </span><span class="NLM_article-title">Peptides as therapeutics with enhanced bioactivity</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4451</span><span class="NLM_x">â</span> <span class="NLM_lpage">4461</span><span class="refDoi">Â DOI: 10.2174/092986712803251548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.2174%2F092986712803251548" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=22830348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlens74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=4451-4461&author=D.+Goodwinauthor=P.+Simerskaauthor=I.+Toth&title=Peptides+as+therapeutics+with+enhanced+bioactivity&doi=10.2174%2F092986712803251548"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125aR"><div class="casContent"><span class="casTitleNuber">125a</span><div class="casTitle"><span class="NLM_cas:atitle">Peptides as therapeutics with enhanced bioactivity</span></div><div class="casAuthors">Goodwin, D.; Simerska, P.; Toth, I.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">4451-4461</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of techniques for efficient peptide prodn. renewed interest in peptides as therapeutics.  Numerous modifications for improving stability, transport and affinity profiles now exist.  Several new adjuvant and carrier systems have also been developed, enhancing the immunogenicity of peptides thus allowing their development as vaccines.  This review describes the established and exptl. approaches for manufg. peptide drugs and highlights the techniques currently used for improving their drug like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpComM-2TLdp7Vg90H21EOLACvtfcHk0lhRgQQEoz0yGA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlens74%253D&md5=a0cc3db7bbb1916461cc55ebc5f5746f</span></div><a href="/servlet/linkout?suffix=cit125a&amp;dbid=16384&amp;doi=10.2174%2F092986712803251548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986712803251548%26sid%3Dliteratum%253Aachs%26aulast%3DGoodwin%26aufirst%3DD.%26aulast%3DSimerska%26aufirst%3DP.%26aulast%3DToth%26aufirst%3DI.%26atitle%3DPeptides%2520as%2520therapeutics%2520with%2520enhanced%2520bioactivity%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2012%26volume%3D19%26spage%3D4451%26epage%3D4461%26doi%3D10.2174%2F092986712803251548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit125b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Varamini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansfeld, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchfield, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyse, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toth, I.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of an orally active glycosylated endomorphin-1</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">5859</span><span class="NLM_x">â</span> <span class="NLM_lpage">5867</span><span class="refDoi">Â DOI: 10.1021/jm300418d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300418d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5859-5867&author=P.+Varaminiauthor=F.+M.+Mansfeldauthor=J.+T.+Blanchfieldauthor=B.+D.+Wyseauthor=M.+T.+Smithauthor=I.+Toth&title=Synthesis+and+biological+evaluation+of+an+orally+active+glycosylated+endomorphin-1&doi=10.1021%2Fjm300418d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125b&amp;dbid=16384&amp;doi=10.1021%2Fjm300418d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300418d%26sid%3Dliteratum%253Aachs%26aulast%3DVaramini%26aufirst%3DP.%26aulast%3DMansfeld%26aufirst%3DF.%2BM.%26aulast%3DBlanchfield%26aufirst%3DJ.%2BT.%26aulast%3DWyse%26aufirst%3DB.%2BD.%26aulast%3DSmith%26aufirst%3DM.%2BT.%26aulast%3DToth%26aufirst%3DI.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520an%2520orally%2520active%2520glycosylated%2520endomorphin-1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5859%26epage%3D5867%26doi%3D10.1021%2Fjm300418d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group">Miranda, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holder, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aral, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gegg, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doellgast, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valladares, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salyers, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wild, K.</span><span> </span><span class="NLM_article-title">Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">7889</span><span class="NLM_x">â</span> <span class="NLM_lpage">7897</span><span class="refDoi">Â DOI: 10.1021/jm8009298</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8009298" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWks73F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7889-7897&author=L.+P.+Mirandaauthor=J.+R.+Holderauthor=L.+Shiauthor=B.+Bennettauthor=J.+Aralauthor=C.+V.+Geggauthor=M.+Wrightauthor=K.+Walkerauthor=G.+Doellgastauthor=R.+Rogersauthor=H.+Liauthor=V.+Valladaresauthor=K.+Salyersauthor=E.+Johnsonauthor=K.+Wild&title=Identification+of+potent%2C+selective%2C+and+metabolically+stable+peptide+antagonists+to+the+calcitonin+gene-related+peptide+%28CGRP%29+receptor&doi=10.1021%2Fjm8009298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Potent, Selective, and Metabolically Stable Peptide Antagonists to the Calcitonin Gene-Related Peptide (CGRP) Receptor</span></div><div class="casAuthors">Miranda, Les P.; Holder, Jerry Ryan; Shi, Licheng; Bennett, Brian; Aral, Jennifer; Gegg, Colin V.; Wright, Marie; Walker, Kenneth; Doellgast, George; Rogers, Rick; Li, Hongyan; Valladares, Violeta; Salyers, Kevin; Johnson, Eileen; Wild, Kenneth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7889-7897</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Calcitonin gene-related peptide (CGRP) is a 37-residue neuropeptide that can be converted to a CGRP1 receptor antagonist by the truncation of its first seven residues. CGRP(8-37), 1, has a CGRP1 receptor Ki = 3.2 nM but is rapidly degraded in human plasma (t1/2 = 20 min).  As part of an effort to identify a prolonged in vivo circulating CGRP peptide antagonist, we found that the substitution of multiple residues in the CGRP peptide increased CGRP1 receptor affinity >50-fold. Ac-Trp-[Arg24,Lys25,Asp31,Pro34,Phe35]CGRP(8-37)-NH2, 5 (Ki = 0.06 nM) had the highest CGRP1 receptor affinity.  Using complimentary in vitro and in vivo metabolic studies, we iteratively identified degrdn. sites and prepd. high affinity analogs with significantly improved plasma stability. Ac-Trp-[Cit11,18,hArg24,Lys25,2-Nal27,37,Asp31,Oic29,34,Phe35]CGRP(8-37)-NH2, 32 (Ki = 3.3 nM), had significantly increased (>100-fold) stability over 1 or 5, with a cynomolgus monkey and human in vitro plasma half-life of 38 and 68 h, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquAzoOJ-KbSbVg90H21EOLACvtfcHk0lhEKWMfUwJCqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWks73F&md5=645a1a0cf1932380134858374093a0dd</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1021%2Fjm8009298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8009298%26sid%3Dliteratum%253Aachs%26aulast%3DMiranda%26aufirst%3DL.%2BP.%26aulast%3DHolder%26aufirst%3DJ.%2BR.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DBennett%26aufirst%3DB.%26aulast%3DAral%26aufirst%3DJ.%26aulast%3DGegg%26aufirst%3DC.%2BV.%26aulast%3DWright%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DK.%26aulast%3DDoellgast%26aufirst%3DG.%26aulast%3DRogers%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DValladares%26aufirst%3DV.%26aulast%3DSalyers%26aufirst%3DK.%26aulast%3DJohnson%26aufirst%3DE.%26aulast%3DWild%26aufirst%3DK.%26atitle%3DIdentification%2520of%2520potent%252C%2520selective%252C%2520and%2520metabolically%2520stable%2520peptide%2520antagonists%2520to%2520the%2520calcitonin%2520gene-related%2520peptide%2520%2528CGRP%2529%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7889%26epage%3D7897%26doi%3D10.1021%2Fjm8009298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group">Werner, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabalteja, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, W. S.</span><span> </span><span class="NLM_article-title">Peptide backbone composition and protease susceptibility: impact of modification type, position, and tandem substitution</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">712</span><span class="NLM_x">â</span> <span class="NLM_lpage">718</span><span class="refDoi">Â DOI: 10.1002/cbic.201500312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fcbic.201500312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26205791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlGrsLnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=712-718&author=H.+M.+Wernerauthor=C.+C.+Cabaltejaauthor=W.+S.+Horne&title=Peptide+backbone+composition+and+protease+susceptibility%3A+impact+of+modification+type%2C+position%2C+and+tandem+substitution&doi=10.1002%2Fcbic.201500312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide Backbone Composition and Protease Susceptibility: Impact of Modification Type, Position, and Tandem Substitution</span></div><div class="casAuthors">Werner, Halina M.; Cabalteja, Chino C.; Horne, W. Seth</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">712-718</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The clin. utility of peptides is limited by their rapid degrdn. by endogenous proteases.  Modification of the peptide backbone can generate functional analogs with enhanced proteolytic stability.  Existing principles for the design of such oligomers have focused primarily on effective structural mimicry.  A more robust strategy would incorporate a rational approach for engineering maximal proteolytic stability with minimal unnatural residue content.  We report here the systematic comparison of the proteolytic resistance imparted by four backbone modifications commonly employed in the design of protease-stable analogs of peptides with complex folding patterns.  The degree of protection was quantified as a function of modification type, position, and tandem substitution in the context of a long, unstructured host sequence and a canonical serine protease.  These results promise to inform ongoing work to develop biostable mimics of increasingly complex peptides and proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrscNXvr8vwrVg90H21EOLACvtfcHk0lhEKWMfUwJCqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlGrsLnM&md5=aed9ab7ba11cf7c774e8dbfd04194c6a</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201500312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201500312%26sid%3Dliteratum%253Aachs%26aulast%3DWerner%26aufirst%3DH.%2BM.%26aulast%3DCabalteja%26aufirst%3DC.%2BC.%26aulast%3DHorne%26aufirst%3DW.%2BS.%26atitle%3DPeptide%2520backbone%2520composition%2520and%2520protease%2520susceptibility%253A%2520impact%2520of%2520modification%2520type%252C%2520position%252C%2520and%2520tandem%2520substitution%26jtitle%3DChemBioChem%26date%3D2016%26volume%3D17%26spage%3D712%26epage%3D718%26doi%3D10.1002%2Fcbic.201500312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Taylor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beeg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canovi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gobbi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mann, D. M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allsop, D.</span><span> </span><span class="NLM_article-title">Development of a proteolytically stable retro-inverso peptide inhibitor of Î²-amyloid oligomerization as a potential novel treatment for Alzheimerâs Disease</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">3261</span><span class="NLM_x">â</span> <span class="NLM_lpage">3272</span><span class="refDoi">Â DOI: 10.1021/bi100144m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi100144m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=3261-3272&author=M.+Taylorauthor=S.+Mooreauthor=J.+Mayesauthor=E.+Parkinauthor=M.+Beegauthor=M.+Canoviauthor=M.+Gobbiauthor=D.+M.+A.+Mannauthor=D.+Allsop&title=Development+of+a+proteolytically+stable+retro-inverso+peptide+inhibitor+of+%CE%B2-amyloid+oligomerization+as+a+potential+novel+treatment+for+Alzheimer%E2%80%99s+Disease&doi=10.1021%2Fbi100144m"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128a&amp;dbid=16384&amp;doi=10.1021%2Fbi100144m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi100144m%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DMoore%26aufirst%3DS.%26aulast%3DMayes%26aufirst%3DJ.%26aulast%3DParkin%26aufirst%3DE.%26aulast%3DBeeg%26aufirst%3DM.%26aulast%3DCanovi%26aufirst%3DM.%26aulast%3DGobbi%26aufirst%3DM.%26aulast%3DMann%26aufirst%3DD.%2BM.%2BA.%26aulast%3DAllsop%26aufirst%3DD.%26atitle%3DDevelopment%2520of%2520a%2520proteolytically%2520stable%2520retro-inverso%2520peptide%2520inhibitor%2520of%2520%25CE%25B2-amyloid%2520oligomerization%2520as%2520a%2520potential%2520novel%2520treatment%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26spage%3D3261%26epage%3D3272%26doi%3D10.1021%2Fbi100144m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit128b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wei, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span> </span><span class="NLM_article-title">Retro-inverso isomer of Angiopep-2: a stable D-peptide ligand inspires brain-targeted drug delivery</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">3261</span><span class="NLM_x">â</span> <span class="NLM_lpage">3268</span><span class="refDoi">Â DOI: 10.1021/mp500086e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp500086e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref128/cit128b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltVShsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=3261-3268&author=X.+Weiauthor=C.+Zhanauthor=X.+Chenauthor=J.+Houauthor=C.+Xieauthor=W.+Lu&title=Retro-inverso+isomer+of+Angiopep-2%3A+a+stable+D-peptide+ligand+inspires+brain-targeted+drug+delivery&doi=10.1021%2Fmp500086e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128bR"><div class="casContent"><span class="casTitleNuber">128b</span><div class="casTitle"><span class="NLM_cas:atitle">Retro-Inverso Isomer of Angiopep-2: A Stable D-Peptide Ligand Inspires Brain-Targeted Drug Delivery</span></div><div class="casAuthors">Wei, Xiaoli; Zhan, Changyou; Chen, Xishan; Hou, Jiapeng; Xie, Cao; Lu, Weiyue</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3261-3268</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The blood-brain barrier (BBB) prevents most drugs from reaching the site of central nervous system (CNS) diseases, intensively confining the therapeutic efficiency.  Angiopep-2 (here termed LAngiopep), which is a 19-mer peptide derived from human Kunitz domain, can trigger transcytosis and traverse the BBB by recognizing low d. lipoprotein-related protein 1 (LRP-1) expressed on the brain capillary endothelial cells.  Various enzymes in the blood and the BBB, however, present multiple metabolic barriers to peptide-inspired brain-targeted drug delivery.  Here we designed a retro-inverso isomer of LAngiopep, termed DAngiopep, to inspire brain-targeted drug delivery.  Both DAngiopep and LAngiopep displayed high uptake capacity in LRP-1 overexpressed cells, including bEnd.3 and U87 cells.  DAngiopep demonstrated lower uptake efficiency in both cell lines than did LAngiopep, suggestive of lower binding affinity to LRP-1 of the D-peptide.  DAngiopep was resistant to proteolysis in fresh rat blood serum, while more than 85% of LAngiopep disappeared within 2 h.  Endocytosed DAngiopep and LAngiopep were found to be colocalized with lysosomal compartments of bEnd.3 cells, indicating that susceptibility to proteolysis of LAngiopep in the BBB may further attenuate its transcytosis efficiency.  In vivo, DAngiopep modified PEG-DSPE micelles displayed high distribution in normal brain and intracranial glioblastoma.  Due to the expression of LRP-1 on the BBB and glioblastoma cells, proteolytically stable DAngiopep holds much potential for designing two-order brain tumor targeted delivery systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsGrbQqL7YD7Vg90H21EOLACvtfcHk0lhx0Q4myvzeUA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltVShsbo%253D&md5=272e5a2ec73d7114ee4ca492330761e0</span></div><a href="/servlet/linkout?suffix=cit128b&amp;dbid=16384&amp;doi=10.1021%2Fmp500086e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp500086e%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DX.%26aulast%3DZhan%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DW.%26atitle%3DRetro-inverso%2520isomer%2520of%2520Angiopep-2%253A%2520a%2520stable%2520D-peptide%2520ligand%2520inspires%2520brain-targeted%2520drug%2520delivery%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2014%26volume%3D11%26spage%3D3261%26epage%3D3268%26doi%3D10.1021%2Fmp500086e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group">Yamaguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jelokhani-Niaraki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, M.</span><span> </span><span class="NLM_article-title">Effect of Î±-Î±-dialkyl amino acids on the protease resistance of peptides</span> <span class="citation_source-journal">Biosci., Biotechnol., Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">2269</span><span class="NLM_x">â</span> <span class="NLM_lpage">2272</span><span class="refDoi">Â DOI: 10.1271/bbb.67.2269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1271%2Fbbb.67.2269" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2003&pages=2269-2272&author=H.+Yamaguchiauthor=H.+Kodamaauthor=S.+Osadaauthor=F.+Katoauthor=M.+Jelokhani-Niarakiauthor=M.+Kondo&title=Effect+of+%CE%B1-%CE%B1-dialkyl+amino+acids+on+the+protease+resistance+of+peptides&doi=10.1271%2Fbbb.67.2269"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1271%2Fbbb.67.2269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1271%252Fbbb.67.2269%26sid%3Dliteratum%253Aachs%26aulast%3DYamaguchi%26aufirst%3DH.%26aulast%3DKodama%26aufirst%3DH.%26aulast%3DOsada%26aufirst%3DS.%26aulast%3DKato%26aufirst%3DF.%26aulast%3DJelokhani-Niaraki%26aufirst%3DM.%26aulast%3DKondo%26aufirst%3DM.%26atitle%3DEffect%2520of%2520%25CE%25B1-%25CE%25B1-dialkyl%2520amino%2520acids%2520on%2520the%2520protease%2520resistance%2520of%2520peptides%26jtitle%3DBiosci.%252C%2520Biotechnol.%252C%2520Biochem.%26date%3D2003%26volume%3D67%26spage%3D2269%26epage%3D2272%26doi%3D10.1271%2Fbbb.67.2269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group">Grauer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">KÃ¶nig, B.</span><span> </span><span class="NLM_article-title">Peptidomimeticsâa versatile route to biologically active compounds</span> <span class="citation_source-journal">Eur. J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">2009</span><span class="NLM_x">, </span> <span class="NLM_fpage">5099</span><span class="NLM_x">â</span> <span class="NLM_lpage">5111</span><span class="refDoi">Â DOI: 10.1002/ejoc.200900599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fejoc.200900599" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2009&publication_year=2009&pages=5099-5111&author=A.+Grauerauthor=B.+K%C3%B6nig&title=Peptidomimetics%E2%80%93a+versatile+route+to+biologically+active+compounds&doi=10.1002%2Fejoc.200900599"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1002%2Fejoc.200900599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.200900599%26sid%3Dliteratum%253Aachs%26aulast%3DGrauer%26aufirst%3DA.%26aulast%3DK%25C3%25B6nig%26aufirst%3DB.%26atitle%3DPeptidomimetics%25E2%2580%2593a%2520versatile%2520route%2520to%2520biologically%2520active%2520compounds%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2009%26volume%3D2009%26spage%3D5099%26epage%3D5111%26doi%3D10.1002%2Fejoc.200900599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group">Liskamp, R. M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rijkers, D. T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruijtzer, J. A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemmink, J.</span><span> </span><span class="NLM_article-title">Peptides and proteins as a continuing exciting source of inspiration for peptidomimetics</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1626</span><span class="NLM_x">â</span> <span class="NLM_lpage">1653</span><span class="refDoi">Â DOI: 10.1002/cbic.201000717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fcbic.201000717" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=1626-1653&author=R.+M.+J.+Liskampauthor=D.+T.+S.+Rijkersauthor=J.+A.+W.+Kruijtzerauthor=J.+Kemmink&title=Peptides+and+proteins+as+a+continuing+exciting+source+of+inspiration+for+peptidomimetics&doi=10.1002%2Fcbic.201000717"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201000717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201000717%26sid%3Dliteratum%253Aachs%26aulast%3DLiskamp%26aufirst%3DR.%2BM.%2BJ.%26aulast%3DRijkers%26aufirst%3DD.%2BT.%2BS.%26aulast%3DKruijtzer%26aufirst%3DJ.%2BA.%2BW.%26aulast%3DKemmink%26aufirst%3DJ.%26atitle%3DPeptides%2520and%2520proteins%2520as%2520a%2520continuing%2520exciting%2520source%2520of%2520inspiration%2520for%2520peptidomimetics%26jtitle%3DChemBioChem%26date%3D2011%26volume%3D12%26spage%3D1626%26epage%3D1653%26doi%3D10.1002%2Fcbic.201000717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group">Chatterjee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rechenmacher, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, H.</span><span> </span><span class="NLM_article-title">N-Methylation of peptides and proteins: an important element for modulating biological functions</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">254</span><span class="NLM_x">â</span> <span class="NLM_lpage">269</span><span class="refDoi">Â DOI: 10.1002/anie.201205674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fanie.201205674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslSku7rJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=254-269&author=J.+Chatterjeeauthor=F.+Rechenmacherauthor=H.+Kessler&title=N-Methylation+of+peptides+and+proteins%3A+an+important+element+for+modulating+biological+functions&doi=10.1002%2Fanie.201205674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">N-Methylation of Peptides and Proteins: An Important Element for Modulating Biological Functions</span></div><div class="casAuthors">Chatterjee, Jayanta; Rechenmacher, Florian; Kessler, Horst</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">254-269</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  N-Methylation is one of the simplest chem. modifications often occurring in peptides and proteins of prokaryotes and higher eukaryotes.  Over years of evolution, nature has employed N-methylation of peptides as an ingenious technique to modulate biol. function, often as a mode of survival through the prodn. of antibiotics.  This small structural change can not only mobilize large protein complexes (as in the histone methylation), but also inhibits the action of enzymes by selective recognition of protein-protein interaction surfaces.  In recent years through the advancement in synthetic approaches, the potential of N-methylation has begun to be revealed, not only in modulating biol. activity and selectivity as well as pharmacokinetic properties of peptides, but also in delivering novel drugs.  Herein, we summarize the current knowledge of the versatility of N-methylation in modulating biol., structural, and pharmacokinetic properties of peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXes6IPzFfLbVg90H21EOLACvtfcHk0lhx0Q4myvzeUA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslSku7rJ&md5=3b15b08b4fe59905acdb8dd47706577c</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1002%2Fanie.201205674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201205674%26sid%3Dliteratum%253Aachs%26aulast%3DChatterjee%26aufirst%3DJ.%26aulast%3DRechenmacher%26aufirst%3DF.%26aulast%3DKessler%26aufirst%3DH.%26atitle%3DN-Methylation%2520of%2520peptides%2520and%2520proteins%253A%2520an%2520important%2520element%2520for%2520modulating%2520biological%2520functions%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D254%26epage%3D269%26doi%3D10.1002%2Fanie.201205674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group">White, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renzelman, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rand, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rezai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McEwen, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelev, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linington, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, S. S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauman, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liras, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathiowetz, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lokey, R. S.</span><span> </span><span class="NLM_article-title">On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">810</span><span class="NLM_x">â</span> <span class="NLM_lpage">817</span><span class="refDoi">Â DOI: 10.1038/nchembio.664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnchembio.664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21946276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1anurjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=810-817&author=T.+R.+Whiteauthor=C.+M.+Renzelmanauthor=A.+C.+Randauthor=T.+Rezaiauthor=C.+M.+McEwenauthor=V.+M.+Gelevauthor=R.+A.+Turnerauthor=R.+G.+Liningtonauthor=S.+S.+F.+Leungauthor=A.+S.+Kalgutkarauthor=J.+N.+Baumanauthor=Y.+Zhangauthor=S.+Lirasauthor=D.+A.+Priceauthor=A.+M.+Mathiowetzauthor=M.+P.+Jacobsonauthor=R.+S.+Lokey&title=On-resin+N-methylation+of+cyclic+peptides+for+discovery+of+orally+bioavailable+scaffolds&doi=10.1038%2Fnchembio.664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds</span></div><div class="casAuthors">White, Tina R.; Renzelman, Chad M.; Rand, Arthur C.; Rezai, Taha; McEwen, Cayla M.; Gelev, Vladimir M.; Turner, Rushia A.; Linington, Roger G.; Leung, Siegfried S. F.; Kalgutkar, Amit S.; Bauman, Jonathan N.; Zhang, Yizhong; Liras, Spiros; Price, David A.; Mathiowetz, Alan M.; Jacobson, Matthew P.; Lokey, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">810-817</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Backbone N-methylation is common among peptide natural products and has a substantial impact on both the phys. properties and the conformational states of cyclic peptides.  However, the specific impact of N-methylation on passive membrane diffusion in cyclic peptides has not been investigated systematically.  Here we report a method for the selective, on-resin N-methylation of cyclic peptides to generate compds. with drug-like membrane permeability and oral bioavailability.  The selectivity and degree of N-methylation of the cyclic peptide was dependent on backbone stereochem., suggesting that conformation dictates the regiochem. of the N-methylation reaction.  The permeabilities of the N-Me variants were corroborated by computational studies on a 1024-member virtual library of N-Me cyclic peptides.  One of the most permeable compds., a cyclic hexapeptide (mol. mass = 755 Da) with three N-Me groups, showed an oral bioavailability of 28% in rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreigsRodBtOLVg90H21EOLACvtfcHk0lg9uweHeNZgQQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1anurjL&md5=6f9f01f4ab523bb46cc0198cc8f1c34e</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.664%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DT.%2BR.%26aulast%3DRenzelman%26aufirst%3DC.%2BM.%26aulast%3DRand%26aufirst%3DA.%2BC.%26aulast%3DRezai%26aufirst%3DT.%26aulast%3DMcEwen%26aufirst%3DC.%2BM.%26aulast%3DGelev%26aufirst%3DV.%2BM.%26aulast%3DTurner%26aufirst%3DR.%2BA.%26aulast%3DLinington%26aufirst%3DR.%2BG.%26aulast%3DLeung%26aufirst%3DS.%2BS.%2BF.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DBauman%26aufirst%3DJ.%2BN.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLiras%26aufirst%3DS.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DMathiowetz%26aufirst%3DA.%2BM.%26aulast%3DJacobson%26aufirst%3DM.%2BP.%26aulast%3DLokey%26aufirst%3DR.%2BS.%26atitle%3DOn-resin%2520N-methylation%2520of%2520cyclic%2520peptides%2520for%2520discovery%2520of%2520orally%2520bioavailable%2520scaffolds%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D810%26epage%3D817%26doi%3D10.1038%2Fnchembio.664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group">Cheloha, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gellman, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardella, T. J.</span><span> </span><span class="NLM_article-title">Backbone modification of a parathyroid hormone receptor-1 antagonist/inverse agonist</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2752</span><span class="NLM_x">â</span> <span class="NLM_lpage">2762</span><span class="refDoi">Â DOI: 10.1021/acschembio.6b00404</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.6b00404" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2752-2762&author=R.+W.+Chelohaauthor=T.+Watanabeauthor=T.+Deanauthor=S.+H.+Gellmanauthor=T.+J.+Gardella&title=Backbone+modification+of+a+parathyroid+hormone+receptor-1+antagonist%2Finverse+agonist&doi=10.1021%2Facschembio.6b00404"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1021%2Facschembio.6b00404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.6b00404%26sid%3Dliteratum%253Aachs%26aulast%3DCheloha%26aufirst%3DR.%2BW.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DDean%26aufirst%3DT.%26aulast%3DGellman%26aufirst%3DS.%2BH.%26aulast%3DGardella%26aufirst%3DT.%2BJ.%26atitle%3DBackbone%2520modification%2520of%2520a%2520parathyroid%2520hormone%2520receptor-1%2520antagonist%252Finverse%2520agonist%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26spage%3D2752%26epage%3D2762%26doi%3D10.1021%2Facschembio.6b00404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Simon, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuckermann, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huebner, V. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewell, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banville, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marlowe, C. K.</span><span> </span><span class="NLM_article-title">Peptoids: a modular approach to drug discovery</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">9367</span><span class="NLM_x">â</span> <span class="NLM_lpage">9371</span><span class="refDoi">Â DOI: 10.1073/pnas.89.20.9367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1073%2Fpnas.89.20.9367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1409642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADyaK3sXhtFKhsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1992&pages=9367-9371&author=R.+J.+Simonauthor=R.+S.+Kaniaauthor=R.+N.+Zuckermannauthor=V.+D.+Huebnerauthor=D.+A.+Jewellauthor=S.+Banvilleauthor=S.+Ngauthor=L.+Wangauthor=S.+Rosenbergauthor=C.+K.+Marlowe&title=Peptoids%3A+a+modular+approach+to+drug+discovery&doi=10.1073%2Fpnas.89.20.9367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135aR"><div class="casContent"><span class="casTitleNuber">135a</span><div class="casTitle"><span class="NLM_cas:atitle">Peptoids:  a modular approach to drug discovery</span></div><div class="casAuthors">Simon, Reyna J.; Kania, Robert S.; Zuckermann, Ronald N.; Huebner, Verena D.; Jewell, David A.; Banville, Steven; Ng, Simon; Wang, Liang; Rosenberg, Steven; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9367-71</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Peptoids, oligomers of N-substituted glycines, are described as a motif for the generation of chem. diverse libraries of novel mols.  Ramachandran-type plots were calcd. and indicate a greater diversity of conformational states available for peptoids than for peptides.  The monomers incorporate t-butyl-based side-chain and 9-fluorenylmethoxy-carbonyl Î±-amine protection.  The controlled oligomerization of the peptoid monomers was performed manually and robotically with in situ activation by either benzotriazol-1-yloxytris(pyrrolidino)phosphonium hexafluorophosphate or bromotris(pyrrolidino)phosphonium hexafluorophosphate.  Other steps were identical to peptide synthesis using Î±-(9-fluorenylmethoxycarbonyl)amino acids.  A total of 15 monomers and 10 oligomers (peptoids) are described.  Preliminary data are presented on the stability of a representative oligopeptoid to enzymic hydrolysis.  Peptoid versions of peptide ligands of three biol. systems (bovine pancreatic Î±-amylase, hepatitis A virus 3C proteinase, and human immunodeficiency virus transactivator-responsive element RNA) were found with affinities comparable to those of the corresponding peptides.  The potential use of libraries of these compds. in receptor- or enzyme-based assays is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqjYjAnzlZWbVg90H21EOLACvtfcHk0lg9uweHeNZgQQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhtFKhsro%253D&md5=072eed656364cd7cf06c71aa9fb001c3</span></div><a href="/servlet/linkout?suffix=cit135a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.89.20.9367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.89.20.9367%26sid%3Dliteratum%253Aachs%26aulast%3DSimon%26aufirst%3DR.%2BJ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DZuckermann%26aufirst%3DR.%2BN.%26aulast%3DHuebner%26aufirst%3DV.%2BD.%26aulast%3DJewell%26aufirst%3DD.%2BA.%26aulast%3DBanville%26aufirst%3DS.%26aulast%3DNg%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DRosenberg%26aufirst%3DS.%26aulast%3DMarlowe%26aufirst%3DC.%2BK.%26atitle%3DPeptoids%253A%2520a%2520modular%2520approach%2520to%2520drug%2520discovery%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1992%26volume%3D89%26spage%3D9367%26epage%3D9371%26doi%3D10.1073%2Fpnas.89.20.9367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit135b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kruijtzer, J. A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nijenhuis, W. A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wanders, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gispen, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liskamp, R. M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adan, R. A. H.</span><span> </span><span class="NLM_article-title">Peptoid-peptide hybrids as potent novel melanocortin receptor ligands</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">4224</span><span class="NLM_x">â</span> <span class="NLM_lpage">4230</span><span class="refDoi">Â DOI: 10.1021/jm0490033</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0490033" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref135/cit135b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD2MXksVWrsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=4224-4230&author=J.+A.+W.+Kruijtzerauthor=W.+A.+J.+Nijenhuisauthor=N.+Wandersauthor=W.+H.+Gispenauthor=R.+M.+J.+Liskampauthor=R.+A.+H.+Adan&title=Peptoid-peptide+hybrids+as+potent+novel+melanocortin+receptor+ligands&doi=10.1021%2Fjm0490033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135bR"><div class="casContent"><span class="casTitleNuber">135b</span><div class="casTitle"><span class="NLM_cas:atitle">Peptoid-Peptide Hybrids as Potent Novel Melanocortin Receptor Ligands</span></div><div class="casAuthors">Kruijtzer, John A. W.; Nijenhuis, Wouter A. J.; Wanders, Nienke; Gispen, Willem Hendrik; Liskamp, Rob M. J.; Adan, Roger A. H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4224-4230</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">All possible peptoid-peptide (peptoid = N-substituted glycine oligomers) hybrids of an MC4 receptor agonist were synthesized and investigated on cells expressing different melanocortin (MC) receptor subtypes and for rat grooming behavior.  In general, receptor selectivity remained while affinity and potency were decreased.  The length of the functional group of tryptophan was more important for MC3 and MC5 than for MC4 receptor binding.  In general, relationship between potency of the peptoid-peptide hybrids and an increase in excessive rat grooming behavior correlated well with MC4 receptor pharmacol.  Thus, using the grooming assay in rats as a bioassay for MC4 receptor activity, the authors demonstrated that these ligands display in vivo efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8KQHlH7s0RrVg90H21EOLACvtfcHk0lg3jYZ7mup9GA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXksVWrsb4%253D&md5=67b2fdc833ed325fd6c3ec26c0cc505c</span></div><a href="/servlet/linkout?suffix=cit135b&amp;dbid=16384&amp;doi=10.1021%2Fjm0490033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0490033%26sid%3Dliteratum%253Aachs%26aulast%3DKruijtzer%26aufirst%3DJ.%2BA.%2BW.%26aulast%3DNijenhuis%26aufirst%3DW.%2BA.%2BJ.%26aulast%3DWanders%26aufirst%3DN.%26aulast%3DGispen%26aufirst%3DW.%2BH.%26aulast%3DLiskamp%26aufirst%3DR.%2BM.%2BJ.%26aulast%3DAdan%26aufirst%3DR.%2BA.%2BH.%26atitle%3DPeptoid-peptide%2520hybrids%2520as%2520potent%2520novel%2520melanocortin%2520receptor%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D4224%26epage%3D4230%26doi%3D10.1021%2Fjm0490033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group">Gao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodadek, T.</span><span> </span><span class="NLM_article-title">Synthesis and screening of stereochemically diverse combinatorial libraries of peptide tertiary amides</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">360</span><span class="NLM_x">â</span> <span class="NLM_lpage">369</span><span class="refDoi">Â DOI: 10.1016/j.chembiol.2013.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.chembiol.2013.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23521794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksFOksrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=360-369&author=Y.+Gaoauthor=T.+Kodadek&title=Synthesis+and+screening+of+stereochemically+diverse+combinatorial+libraries+of+peptide+tertiary+amides&doi=10.1016%2Fj.chembiol.2013.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Screening of Stereochemically Diverse Combinatorial Libraries of Peptide Tertiary Amides</span></div><div class="casAuthors">Gao, Yu; Kodadek, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">360-369</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Large combinatorial libraries of N-substituted peptides would be an attractive source of protein ligands, because these compds. are known to be conformationally constrained, whereas std. peptides or peptoids are conformationally mobile.  Here, the authors report an efficient submonomer solid-phase synthetic route to these compds. and demonstrate that it can be used to create high quality libraries.  A model screening expt. and anal. of the hits indicates that the rigidity afforded by the stereocenters is crit. for high affinity binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgGLnqMrBiJbVg90H21EOLACvtfcHk0lg3jYZ7mup9GA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksFOksrs%253D&md5=fd771da8d27285d9d75a9915613f329d</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2013.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2013.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DY.%26aulast%3DKodadek%26aufirst%3DT.%26atitle%3DSynthesis%2520and%2520screening%2520of%2520stereochemically%2520diverse%2520combinatorial%2520libraries%2520of%2520peptide%2520tertiary%2520amides%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D360%26epage%3D369%26doi%3D10.1016%2Fj.chembiol.2013.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group">Wisniewski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galyean, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tariga, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alagarsamy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croston, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heitzmann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisniewska, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laporte, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riviere, P. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schteingart, C. D.</span><span> </span><span class="NLM_article-title">New, Potent, Selective, and Short-Acting Peptidic V1a Receptor Agonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4388</span><span class="NLM_x">â</span> <span class="NLM_lpage">4398</span><span class="refDoi">Â DOI: 10.1021/jm200278m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200278m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4388-4398&author=K.+Wisniewskiauthor=R.+Galyeanauthor=H.+Tarigaauthor=S.+Alagarsamyauthor=G.+Crostonauthor=J.+Heitzmannauthor=A.+Kohanauthor=H.+Wisniewskaauthor=R.+Laporteauthor=P.+J.+M.+Riviereauthor=C.+D.+Schteingart&title=New%2C+Potent%2C+Selective%2C+and+Short-Acting+Peptidic+V1a+Receptor+Agonists&doi=10.1021%2Fjm200278m"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1021%2Fjm200278m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200278m%26sid%3Dliteratum%253Aachs%26aulast%3DWisniewski%26aufirst%3DK.%26aulast%3DGalyean%26aufirst%3DR.%26aulast%3DTariga%26aufirst%3DH.%26aulast%3DAlagarsamy%26aufirst%3DS.%26aulast%3DCroston%26aufirst%3DG.%26aulast%3DHeitzmann%26aufirst%3DJ.%26aulast%3DKohan%26aufirst%3DA.%26aulast%3DWisniewska%26aufirst%3DH.%26aulast%3DLaporte%26aufirst%3DR.%26aulast%3DRiviere%26aufirst%3DP.%2BJ.%2BM.%26aulast%3DSchteingart%26aufirst%3DC.%2BD.%26atitle%3DNew%252C%2520Potent%252C%2520Selective%252C%2520and%2520Short-Acting%2520Peptidic%2520V1a%2520Receptor%2520Agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4388%26epage%3D4398%26doi%3D10.1021%2Fjm200278m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Laporte, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heitzmann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisniewska, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tariga, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alagarsamy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dykert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisniewski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galyean, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croston, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schteingart, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riviere, P. J. M.</span><span> </span><span class="NLM_article-title">Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">337</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">â</span> <span class="NLM_lpage">796</span><span class="refDoi">Â DOI: 10.1124/jpet.111.178848</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1124%2Fjpet.111.178848" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21411496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFeiu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=2011&pages=786-796&author=R.+Laporteauthor=A.+Kohanauthor=J.+Heitzmannauthor=H.+Wisniewskaauthor=J.+Toyauthor=E.+Laauthor=H.+Tarigaauthor=S.+Alagarsamyauthor=B.+Lyauthor=J.+Dykertauthor=S.+Qiauthor=K.+Wisniewskiauthor=R.+Galyeanauthor=G.+Crostonauthor=C.+D.+Schteingartauthor=P.+J.+M.+Riviere&title=Pharmacological+characterization+of+FE+202158%2C+a+novel%2C+potent%2C+selective%2C+and+short-acting+peptidic+vasopressin+V1a+receptor+full+agonist+for+the+treatment+of+vasodilatory+hypotension&doi=10.1124%2Fjpet.111.178848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138aR"><div class="casContent"><span class="casTitleNuber">138a</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension</span></div><div class="casAuthors">Laporte, Regent; Kohan, Arash; Heitzmann, Joshua; Wisniewska, Halina; Toy, Jeannie; La, Erin; Tariga, Hiroe; Alagarsamy, Sudarkodi; Ly, Brian; Dykert, John; Qi, Steve; Wisniewski, Kazimierz; Galyean, Robert; Croston, Glenn; Schteingart, Claudio D.; Riviere, Pierre J.-M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">337</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">786-796</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">FE 202158, ([Phe2,Ile3,Hgn4,Orn(iPr)8]vasopressin, where Hgn is homoglutamine and iPr is isopropyl), a peptidic analog of the vasoconstrictor hormone [Arg8]vasopressin (AVP), was designed to be a potent, selective, and short-acting vasopressin type 1a receptor (V1aR) agonist.  In functional reporter gene assays, FE 202158 was a potent and selective human V1aR agonist [EC50 = 2.4 nM; selectivity ratio of 1:142:1107:440 vs. human vasopressin type 1b receptor, vasopressin type 2 receptor (V2R), and oxytocin receptor, resp.] contrasting with AVP's lack of selectivity, esp. vs. the V2R (selectivity ratio of 1:18:0.2:92; human V1aR EC50 = 0.24 nM).  This activity and selectivity profile was confirmed in radioligand binding assays.  FE 202158 was a potent vasoconstrictor in the isolated rat common iliac artery ex vivo (EC50 = 3.6 nM vs. 0.8 nM for AVP) and reduced rat ear skin blood flow after i.v. infusion in vivo (ED50 = 4.0 vs. 3.4 pmol/kg/min for AVP).  The duration of its vasopressor effect by i.v. bolus in rats was as short as AVP at submaximally EDs.  FE 202158 had no V2R-mediated antidiuretic activity in rats by i.v. infusion at its ED50 for redn. of ear skin blood flow, in contrast with the pronounced antidiuretic effect of AVP.  Thus, FE 202158 seems suitable for treatment of conditions where V1aR activity is desirable but V2R activity is potentially deleterious, such as vasodilatory hypotension in septic shock.  In addn. to the desirable selectivity profile, its short-acting nature should allow dose titrn. with rapid onset and offset of action to optimize vasoconstriction efficacy and safety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXthaAxU5z9bVg90H21EOLACvtfcHk0lg3jYZ7mup9GA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFeiu70%253D&md5=b824019640b4954e5e290eead08f25c6</span></div><a href="/servlet/linkout?suffix=cit138a&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.178848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.178848%26sid%3Dliteratum%253Aachs%26aulast%3DLaporte%26aufirst%3DR.%26aulast%3DKohan%26aufirst%3DA.%26aulast%3DHeitzmann%26aufirst%3DJ.%26aulast%3DWisniewska%26aufirst%3DH.%26aulast%3DToy%26aufirst%3DJ.%26aulast%3DLa%26aufirst%3DE.%26aulast%3DTariga%26aufirst%3DH.%26aulast%3DAlagarsamy%26aufirst%3DS.%26aulast%3DLy%26aufirst%3DB.%26aulast%3DDykert%26aufirst%3DJ.%26aulast%3DQi%26aufirst%3DS.%26aulast%3DWisniewski%26aufirst%3DK.%26aulast%3DGalyean%26aufirst%3DR.%26aulast%3DCroston%26aufirst%3DG.%26aulast%3DSchteingart%26aufirst%3DC.%2BD.%26aulast%3DRiviere%26aufirst%3DP.%2BJ.%2BM.%26atitle%3DPharmacological%2520characterization%2520of%2520FE%2520202158%252C%2520a%2520novel%252C%2520potent%252C%2520selective%252C%2520and%2520short-acting%2520peptidic%2520vasopressin%2520V1a%2520receptor%2520full%2520agonist%2520for%2520the%2520treatment%2520of%2520vasodilatory%2520hypotension%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D337%26spage%3D786%26epage%3D796%26doi%3D10.1124%2Fjpet.111.178848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit138b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Maybauer, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maybauer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enkhbaatar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laporte, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisniewska, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traber, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisniewski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schteingart, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riviere, P. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traber, D. L.</span><span> </span><span class="NLM_article-title">The selective V(1a) receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis</span> <span class="citation_source-journal">Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">e525</span><span class="NLM_x">â</span> <span class="NLM_lpage">e533</span><span class="refDoi">Â DOI: 10.1097/CCM.0000000000000300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1097%2FCCM.0000000000000300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24674922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpvV2ksrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=e525-e533&author=M.+O.+Maybauerauthor=D.+M.+Maybauerauthor=P.+Enkhbaatarauthor=R.+Laporteauthor=H.+Wisniewskaauthor=L.+D.+Traberauthor=C.+Linauthor=J.+Fanauthor=H.+K.+Hawkinsauthor=R.+A.+Coxauthor=K.+Wisniewskiauthor=C.+D.+Schteingartauthor=D.+W.+Landryauthor=P.+J.+M.+Riviereauthor=D.+L.+Traber&title=The+selective+V%281a%29+receptor+agonist+selepressin+%28FE+202158%29+blocks+vascular+leak+in+ovine+severe+sepsis&doi=10.1097%2FCCM.0000000000000300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138bR"><div class="casContent"><span class="casTitleNuber">138b</span><div class="casTitle"><span class="NLM_cas:atitle">The Selective Vasopressin Type 1a Receptor Agonist Selepressin (FE 202158) Blocks Vascular Leak in Ovine Severe Sepsis</span></div><div class="casAuthors">Maybauer, Marc O.; Maybauer, Dirk M.; Enkhbaatar, Perenlei; Laporte, Regent; Wisniewska, Halina; Traber, Lillian D.; Lin, Chii Dean; Fan, Juanjuan; Hawkins, Hal K.; Cox, Robert A.; Wisniewski, Kazimierz; Schteingart, Claudio D.; Landry, Donald W.; Riviere, Pierre J.-M.; Traber, Daniel L.</div><div class="citationInfo"><span class="NLM_cas:title">Critical Care Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e525-e533</span>CODEN:
                <span class="NLM_cas:coden">CCMDC7</span>;
        ISSN:<span class="NLM_cas:issn">0090-3493</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objective: To det. if the selective vasopressin type 1a receptor agonist selepressin (FE 202158) is as effective as the mixed vasopressin type 1a receptor/vasopressin V2 receptor agonist vasopressor hormone arginine vasopressin when used as a titrated first-line vasopressor therapy in an ovine model of Pseudomonas aeruginosa pneumonia-induced severe sepsis.  Design: Prospective, randomized, controlled lab. expt.  Setting: University animal research facility.  Subjects: Forty-five chronically instrumented sheep.  Interventions: Sheep were anesthetized, insufflated with cooled cotton smoke via tracheostomy, and P. aeruginosa were instilled into their airways.  They were then placed on assisted ventilation, awakened, and resuscitated with lactated Ringer's soln. titrated to maintain hematocrit Â± 3% from baseline levels.  If, despite fluid management, mean arterial pressure fell by more than 10 mm Hg from baseline level, an addnl. continuous IV infusion of arginine vasopressin or selepressin was titrated to raise and maintain mean arterial pressure within no less than 10 mm Hg from baseline level.  Effects of combination treatment of selepressin with the selective vasopressin V2 receptor agonist desmopressin were similarly investigated.  Measurements and main results: In septic sheep, MAP fell by â¼30 mm Hg, systemic vascular resistance index decreased by â¼50%, and â¼7 L of fluid were retained over 24 h; this fluid accumulation was partially reduced by arginine vasopressin and almost completely blocked by selepressin; and combined infusion of selepressin and desmopressin increased fluid accumulation to levels similar to arginine vasopressin treatment.  Conclusions: Resuscitation with the selective vasopressin type 1a receptor agonist selepressin blocked vascular leak more effectively than the mixed vasopressin type 1a receptor/vasopressin V2 receptor agonist arginine vasopressin because of its lack of agonist activity at the vasopressin V2 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAuftCmhFxS7Vg90H21EOLACvtfcHk0li6jlGOLI4ulQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpvV2ksrY%253D&md5=3a836a08eed213d23f56db6c10a4f51b</span></div><a href="/servlet/linkout?suffix=cit138b&amp;dbid=16384&amp;doi=10.1097%2FCCM.0000000000000300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCCM.0000000000000300%26sid%3Dliteratum%253Aachs%26aulast%3DMaybauer%26aufirst%3DM.%2BO.%26aulast%3DMaybauer%26aufirst%3DD.%2BM.%26aulast%3DEnkhbaatar%26aufirst%3DP.%26aulast%3DLaporte%26aufirst%3DR.%26aulast%3DWisniewska%26aufirst%3DH.%26aulast%3DTraber%26aufirst%3DL.%2BD.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DHawkins%26aufirst%3DH.%2BK.%26aulast%3DCox%26aufirst%3DR.%2BA.%26aulast%3DWisniewski%26aufirst%3DK.%26aulast%3DSchteingart%26aufirst%3DC.%2BD.%26aulast%3DLandry%26aufirst%3DD.%2BW.%26aulast%3DRiviere%26aufirst%3DP.%2BJ.%2BM.%26aulast%3DTraber%26aufirst%3DD.%2BL.%26atitle%3DThe%2520selective%2520V%25281a%2529%2520receptor%2520agonist%2520selepressin%2520%2528FE%2520202158%2529%2520blocks%2520vascular%2520leak%2520in%2520ovine%2520severe%2520sepsis%26jtitle%3DCrit.%2520Care%2520Med.%26date%3D2014%26volume%3D42%26spage%3De525%26epage%3De533%26doi%3D10.1097%2FCCM.0000000000000300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group">Frey, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viaud, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subra, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cauquil, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guichou, J.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grassy, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavanieu, A.</span><span> </span><span class="NLM_article-title">Structure-activity relationships of Bak derived peptides: Affinity and specificity modulations by amino acid replacement</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">966</span><span class="NLM_x">â</span> <span class="NLM_lpage">972</span><span class="refDoi">Â DOI: 10.1016/j.ejmech.2007.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.ejmech.2007.06.008" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2008&pages=966-972&author=V.+Freyauthor=J.+Viaudauthor=G.+Subraauthor=N.+Cauquilauthor=J.-F.+Guichouauthor=P.+Casaraauthor=G.+R.+Grassyauthor=A.+Chavanieu&title=Structure-activity+relationships+of+Bak+derived+peptides%3A+Affinity+and+specificity+modulations+by+amino+acid+replacement&doi=10.1016%2Fj.ejmech.2007.06.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2007.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2007.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DFrey%26aufirst%3DV.%26aulast%3DViaud%26aufirst%3DJ.%26aulast%3DSubra%26aufirst%3DG.%26aulast%3DCauquil%26aufirst%3DN.%26aulast%3DGuichou%26aufirst%3DJ.-F.%26aulast%3DCasara%26aufirst%3DP.%26aulast%3DGrassy%26aufirst%3DG.%2BR.%26aulast%3DChavanieu%26aufirst%3DA.%26atitle%3DStructure-activity%2520relationships%2520of%2520Bak%2520derived%2520peptides%253A%2520Affinity%2520and%2520specificity%2520modulations%2520by%2520amino%2520acid%2520replacement%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2008%26volume%3D43%26spage%3D966%26epage%3D972%26doi%3D10.1016%2Fj.ejmech.2007.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group">Haskell-Luevano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toth, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boteju, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Job, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castrucci, A. M. d. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadley, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hruby, V. J.</span><span> </span><span class="NLM_article-title">Beta-methylation of the Phe7 and Trp9 melanotropin side chain pharmacophores affects ligand-receptor interactions and prolonged biological activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">2740</span><span class="NLM_x">â</span> <span class="NLM_lpage">2749</span><span class="refDoi">Â DOI: 10.1021/jm970018t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm970018t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=2740-2749&author=C.+Haskell-Luevanoauthor=K.+Tothauthor=L.+Botejuauthor=C.+Jobauthor=A.+M.+d.+L.+Castrucciauthor=M.+E.+Hadleyauthor=V.+J.+Hruby&title=Beta-methylation+of+the+Phe7+and+Trp9+melanotropin+side+chain+pharmacophores+affects+ligand-receptor+interactions+and+prolonged+biological+activity&doi=10.1021%2Fjm970018t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Fjm970018t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm970018t%26sid%3Dliteratum%253Aachs%26aulast%3DHaskell-Luevano%26aufirst%3DC.%26aulast%3DToth%26aufirst%3DK.%26aulast%3DBoteju%26aufirst%3DL.%26aulast%3DJob%26aufirst%3DC.%26aulast%3DCastrucci%26aufirst%3DA.%2BM.%2Bd.%2BL.%26aulast%3DHadley%26aufirst%3DM.%2BE.%26aulast%3DHruby%26aufirst%3DV.%2BJ.%26atitle%3DBeta-methylation%2520of%2520the%2520Phe7%2520and%2520Trp9%2520melanotropin%2520side%2520chain%2520pharmacophores%2520affects%2520ligand-receptor%2520interactions%2520and%2520prolonged%2520biological%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D2740%26epage%3D2749%26doi%3D10.1021%2Fjm970018t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group">Sadowsky, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gellman, S. H.</span><span> </span><span class="NLM_article-title">Exploration of backbone space in foldamers containing Î±- and Î²-amino acid residues: developing protease-resistant oligomers that bind tightly to the BH3-recognition cleft of Bcl-xL</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">903</span><span class="NLM_x">â</span> <span class="NLM_lpage">916</span><span class="refDoi">Â DOI: 10.1002/cbic.200600546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fcbic.200600546" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=903-916&author=J.+D.+Sadowskyauthor=J.+K.+Murrayauthor=Y.+Tomitaauthor=S.+H.+Gellman&title=Exploration+of+backbone+space+in+foldamers+containing+%CE%B1-+and+%CE%B2-amino+acid+residues%3A+developing+protease-resistant+oligomers+that+bind+tightly+to+the+BH3-recognition+cleft+of+Bcl-xL&doi=10.1002%2Fcbic.200600546"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1002%2Fcbic.200600546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.200600546%26sid%3Dliteratum%253Aachs%26aulast%3DSadowsky%26aufirst%3DJ.%2BD.%26aulast%3DMurray%26aufirst%3DJ.%2BK.%26aulast%3DTomita%26aufirst%3DY.%26aulast%3DGellman%26aufirst%3DS.%2BH.%26atitle%3DExploration%2520of%2520backbone%2520space%2520in%2520foldamers%2520containing%2520%25CE%25B1-%2520and%2520%25CE%25B2-amino%2520acid%2520residues%253A%2520developing%2520protease-resistant%2520oligomers%2520that%2520bind%2520tightly%2520to%2520the%2520BH3-recognition%2520cleft%2520of%2520Bcl-xL%26jtitle%3DChemBioChem%26date%3D2007%26volume%3D8%26spage%3D903%26epage%3D916%26doi%3D10.1002%2Fcbic.200600546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group">Finan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottaway, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smiley, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemmensen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabenne, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habegger, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandoval, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeley, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bleicher, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uhles, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riboulet, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hertel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebokova, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conde-Knape, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konkar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drucker, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelfanov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfluger, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Tilve, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMarchi, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tschop, M. H.</span><span> </span><span class="NLM_article-title">A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">â</span> <span class="NLM_lpage">36</span><span class="refDoi">Â DOI: 10.1038/nm.3761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnm.3761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25485909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCks73J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=27-36&author=B.+Finanauthor=B.+Yangauthor=N.+Ottawayauthor=D.+L.+Smileyauthor=T.+Maauthor=C.+Clemmensenauthor=J.+Chabenneauthor=L.+Zhangauthor=K.+M.+Habeggerauthor=K.+Fischerauthor=J.+E.+Campbellauthor=D.+Sandovalauthor=R.+J.+Seeleyauthor=K.+Bleicherauthor=S.+Uhlesauthor=W.+Ribouletauthor=J.+Funkauthor=C.+Hertelauthor=S.+Belliauthor=E.+Sebokovaauthor=K.+Conde-Knapeauthor=A.+Konkarauthor=D.+J.+Druckerauthor=V.+Gelfanovauthor=P.+T.+Pflugerauthor=T.+D.+Mullerauthor=D.+Perez-Tilveauthor=R.+D.+DiMarchiauthor=M.+H.+Tschop&title=A+rationally+designed+monomeric+peptide+triagonist+corrects+obesity+and+diabetes+in+rodents&doi=10.1038%2Fnm.3761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents</span></div><div class="casAuthors">Finan, Brian; Yang, Bin; Ottaway, Nickki; Smiley, David L.; Ma, Tao; Clemmensen, Christoffer; Chabenne, Joe; Zhang, Lianshan; Habegger, Kirk M.; Fischer, Katrin; Campbell, Jonathan E.; Sandoval, Darleen; Seeley, Randy J.; Bleicher, Konrad; Uhles, Sabine; Riboulet, William; Funk, Juergen; Hertel, Cornelia; Belli, Sara; Sebokova, Elena; Conde-Knape, Karin; Konkar, Anish; Drucker, Daniel J.; Gelfanov, Vasily; Pfluger, Paul T.; Mueller, Timo D.; Perez-Tilve, Diego; Di Marchi, Richard D.; Tschoep, Matthias H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-36</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We report the discovery of a new monomeric peptide that reduces body wt. and diabetic complications in rodent models of obesity by acting as an agonist at three key metabolically-related peptide hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors.  This triple agonist demonstrates supraphysiol. potency and equally aligned constituent activities at each receptor, all without cross-reactivity at other related receptors.  Such balanced unimol. triple agonism proved superior to any existing dual coagonists and best-in-class monoagonists to reduce body wt., enhance glycemic control and reverse hepatic steatosis in relevant rodent models.  Various loss-of-function models, including genetic knockout, pharmacol. blockade and selective chem. knockout, confirmed contributions of each constituent activity in vivo.  We demonstrate that these individual constituent activities harmonize to govern the overall metabolic efficacy, which predominantly results from synergistic glucagon action to increase energy expenditure, GLP-1 action to reduce caloric intake and improve glucose control, and GIP action to potentiate the incretin effect and buffer against the diabetogenic effect of inherent glucagon activity.  These preclin. studies suggest that, so far, this unimol., polypharmaceutical strategy has potential to be the most effective pharmacol. approach to reversing obesity and related metabolic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDHrGvoJsN6LVg90H21EOLACvtfcHk0livyMuAboMo4w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCks73J&md5=9024ca9e43d498db95332d64e9e16039</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1038%2Fnm.3761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3761%26sid%3Dliteratum%253Aachs%26aulast%3DFinan%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DOttaway%26aufirst%3DN.%26aulast%3DSmiley%26aufirst%3DD.%2BL.%26aulast%3DMa%26aufirst%3DT.%26aulast%3DClemmensen%26aufirst%3DC.%26aulast%3DChabenne%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHabegger%26aufirst%3DK.%2BM.%26aulast%3DFischer%26aufirst%3DK.%26aulast%3DCampbell%26aufirst%3DJ.%2BE.%26aulast%3DSandoval%26aufirst%3DD.%26aulast%3DSeeley%26aufirst%3DR.%2BJ.%26aulast%3DBleicher%26aufirst%3DK.%26aulast%3DUhles%26aufirst%3DS.%26aulast%3DRiboulet%26aufirst%3DW.%26aulast%3DFunk%26aufirst%3DJ.%26aulast%3DHertel%26aufirst%3DC.%26aulast%3DBelli%26aufirst%3DS.%26aulast%3DSebokova%26aufirst%3DE.%26aulast%3DConde-Knape%26aufirst%3DK.%26aulast%3DKonkar%26aufirst%3DA.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DGelfanov%26aufirst%3DV.%26aulast%3DPfluger%26aufirst%3DP.%2BT.%26aulast%3DMuller%26aufirst%3DT.%2BD.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26aulast%3DTschop%26aufirst%3DM.%2BH.%26atitle%3DA%2520rationally%2520designed%2520monomeric%2520peptide%2520triagonist%2520corrects%2520obesity%2520and%2520diabetes%2520in%2520rodents%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D27%26epage%3D36%26doi%3D10.1038%2Fnm.3761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group">Rink, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arkema-Meter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baudoin, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuipers, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelemans, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akanbi, M. H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moll, G. N.</span><span> </span><span class="NLM_article-title">To protect peptide pharmaceuticals against peptidases</span> <span class="citation_source-journal">J. Pharmacol. Toxicol. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">â</span> <span class="NLM_lpage">218</span><span class="refDoi">Â DOI: 10.1016/j.vascn.2010.02.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.vascn.2010.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=20176117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVeiur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2010&pages=210-218&author=R.+Rinkauthor=A.+Arkema-Meterauthor=I.+Baudoinauthor=E.+Postauthor=A.+Kuipersauthor=S.+A.+Nelemansauthor=M.+H.+J.+Akanbiauthor=G.+N.+Moll&title=To+protect+peptide+pharmaceuticals+against+peptidases&doi=10.1016%2Fj.vascn.2010.02.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">To protect peptide pharmaceuticals against peptidases</span></div><div class="casAuthors">Rink, R.; Arkema-Meter, A.; Baudoin, I.; Post, E.; Kuipers, A.; Nelemans, S. A.; Akanbi, M. Haas Jimoh; Moll, G. N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">210-218</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The major hurdle in the application and delivery of peptide pharmaceuticals is their rapid in vivo breakdown.  We here combined two approaches to stabilize peptide pharmaceuticals, introduction of D-amino acids and cyclization, by applying an innovative enzymic method.  This method yields peptides with thioether bridges between a D-amino acid and an L-amino acid.  On the basis of guidelines concerning the flanking residues of serines/threonines and cysteines, a peptide of interest is designed with serine/threonine and cysteine at appropriate positions to allow their effective participation in cyclization.  In Lactococcus lactis the peptide of interest is directly or via a spacer genetically fused to a lantibiotic leader peptide which induces enzyme-catalyzed synthesis of a thioether-bridged peptide.  The peptide is translocated via a lantibiotic transporter, analyzed by mass spectrometry and the leader peptide is removed.  Because of its therapeutic relevance and terminal modifications we chose the decapeptide LH Release Hormone (LHRH) as a test case for thioether bridge introduction.  The N-terminal pyroglutamate protects against aminopeptidase activity; the amidated C-terminus, which occurs in 50% of all therapeutic peptides, precludes carboxypeptidase action and is essential for optimal receptor interaction.  We had Lactococcus posttranslationally introduce a thioether bridge between residues 4 and 7 of the Leu7Cys-LHRH analog QHWSYGCRPG.  The N-terminal glutamine of the thioether-bridged peptide could be converted in pyroglutamate.  The introduction of the thioether bridge proved to be compatible with subsequent chem. and enzymic amidation methods.  In this way biol. produced thioether LHRH was compared with LHRH isomers obtained by base-assisted sulfur extrusion.  Biol. produced thioether LHRH is the most stable thioether LHRH isomer with strongly enhanced proteolytic resistance compared to natural LHRH.  The data convincingly demonstrate the broad perspective of stereo- and regiospecifically generating cyclized peptide pharmaceuticals with significantly enhanced therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK7a3wOuEsV7Vg90H21EOLACvtfcHk0livyMuAboMo4w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVeiur4%253D&md5=ffd248fb764e21d64e69d46269e7d122</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2010.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2010.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DRink%26aufirst%3DR.%26aulast%3DArkema-Meter%26aufirst%3DA.%26aulast%3DBaudoin%26aufirst%3DI.%26aulast%3DPost%26aufirst%3DE.%26aulast%3DKuipers%26aufirst%3DA.%26aulast%3DNelemans%26aufirst%3DS.%2BA.%26aulast%3DAkanbi%26aufirst%3DM.%2BH.%2BJ.%26aulast%3DMoll%26aufirst%3DG.%2BN.%26atitle%3DTo%2520protect%2520peptide%2520pharmaceuticals%2520against%2520peptidases%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2010%26volume%3D61%26spage%3D210%26epage%3D218%26doi%3D10.1016%2Fj.vascn.2010.02.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group">Ahn, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitu, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medeiros, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swift, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trivedi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hruby, V. J.</span><span> </span><span class="NLM_article-title">A new approach to search for the bioactive conformation of glucagon: positional cyclization scanning</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">3109</span><span class="NLM_x">â</span> <span class="NLM_lpage">3116</span><span class="refDoi">Â DOI: 10.1021/jm010091q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm010091q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=3109-3116&author=J.-M.+Ahnauthor=P.+M.+Gituauthor=M.+Medeirosauthor=J.+R.+Swiftauthor=D.+Trivediauthor=V.+J.+Hruby&title=A+new+approach+to+search+for+the+bioactive+conformation+of+glucagon%3A+positional+cyclization+scanning&doi=10.1021%2Fjm010091q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Fjm010091q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010091q%26sid%3Dliteratum%253Aachs%26aulast%3DAhn%26aufirst%3DJ.-M.%26aulast%3DGitu%26aufirst%3DP.%2BM.%26aulast%3DMedeiros%26aufirst%3DM.%26aulast%3DSwift%26aufirst%3DJ.%2BR.%26aulast%3DTrivedi%26aufirst%3DD.%26aulast%3DHruby%26aufirst%3DV.%2BJ.%26atitle%3DA%2520new%2520approach%2520to%2520search%2520for%2520the%2520bioactive%2520conformation%2520of%2520glucagon%253A%2520positional%2520cyclization%2520scanning%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D3109%26epage%3D3116%26doi%3D10.1021%2Fjm010091q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group">Hoang, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derksen, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edmonds, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kok, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Limberakis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liras, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loria, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mascitti, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathiowetz, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piotrowski, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanton, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suen, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Withka, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairlie, D. P.</span><span> </span><span class="NLM_article-title">Short hydrophobic peptides with cyclic constraints are potent glucagon-like peptide-1 receptor (GLP-1R) agonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">4080</span><span class="NLM_x">â</span> <span class="NLM_lpage">4085</span><span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00166</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00166" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvValur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4080-4085&author=H.+N.+Hoangauthor=K.+Songauthor=T.+A.+Hillauthor=D.+R.+Derksenauthor=D.+J.+Edmondsauthor=W.+M.+Kokauthor=C.+Limberakisauthor=S.+Lirasauthor=P.+M.+Loriaauthor=V.+Mascittiauthor=A.+M.+Mathiowetzauthor=J.+M.+Mitchellauthor=D.+W.+Piotrowskiauthor=D.+A.+Priceauthor=R.+V.+Stantonauthor=J.+Y.+Suenauthor=J.+M.+Withkaauthor=D.+A.+Griffithauthor=D.+P.+Fairlie&title=Short+hydrophobic+peptides+with+cyclic+constraints+are+potent+glucagon-like+peptide-1+receptor+%28GLP-1R%29+agonists&doi=10.1021%2Facs.jmedchem.5b00166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Short Hydrophobic Peptides with Cyclic Constraints Are Potent Glucagon-like Peptide-1 Receptor (GLP-1R) Agonists</span></div><div class="casAuthors">Hoang, Huy N.; Song, Kun; Hill, Timothy A.; Derksen, David R.; Edmonds, David J.; Kok, W. Mei; Limberakis, Chris; Liras, Spiros; Loria, Paula M.; Mascitti, Vincent; Mathiowetz, Alan M.; Mitchell, Justin M.; Piotrowski, David W.; Price, David A.; Stanton, Robert V.; Suen, Jacky Y.; Withka, Jane M.; Griffith, David A.; Fairlie, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4080-4085</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclic constraints are incorporated into an 11-residue analog of the N-terminus of glucagon-like peptide-1 (GLP-1) to investigate effects of structure on agonist activity.  Cyclization through linking side chains of residues 2 and 5 or 5 and 9 produced agonists at nM concns. in a cAMP assay.  2D NMR and CD spectra revealed an N-terminal Î²-turn and a C-terminal helix that differentially influenced affinity and agonist potency.  These structures can inform development of small mol. agonists of the GLP-1 receptor to treat type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorlSFbD2Bjx7Vg90H21EOLACvtfcHk0li7YXx9akAWIg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvValur8%253D&md5=f0bfe3a35cb0e6fa40d5c7ed0d9996c2</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00166%26sid%3Dliteratum%253Aachs%26aulast%3DHoang%26aufirst%3DH.%2BN.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DHill%26aufirst%3DT.%2BA.%26aulast%3DDerksen%26aufirst%3DD.%2BR.%26aulast%3DEdmonds%26aufirst%3DD.%2BJ.%26aulast%3DKok%26aufirst%3DW.%2BM.%26aulast%3DLimberakis%26aufirst%3DC.%26aulast%3DLiras%26aufirst%3DS.%26aulast%3DLoria%26aufirst%3DP.%2BM.%26aulast%3DMascitti%26aufirst%3DV.%26aulast%3DMathiowetz%26aufirst%3DA.%2BM.%26aulast%3DMitchell%26aufirst%3DJ.%2BM.%26aulast%3DPiotrowski%26aufirst%3DD.%2BW.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DStanton%26aufirst%3DR.%2BV.%26aulast%3DSuen%26aufirst%3DJ.%2BY.%26aulast%3DWithka%26aufirst%3DJ.%2BM.%26aulast%3DGriffith%26aufirst%3DD.%2BA.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26atitle%3DShort%2520hydrophobic%2520peptides%2520with%2520cyclic%2520constraints%2520are%2520potent%2520glucagon-like%2520peptide-1%2520receptor%2520%2528GLP-1R%2529%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4080%26epage%3D4085%26doi%3D10.1021%2Facs.jmedchem.5b00166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bird, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madani, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Princiotto, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavathiotis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sodroski, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walensky, L. D.</span><span> </span><span class="NLM_article-title">Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">14093</span><span class="NLM_x">â</span> <span class="NLM_lpage">14098</span><span class="refDoi">Â DOI: 10.1073/pnas.1002713107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1073%2Fpnas.1002713107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=20660316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVCktrfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=14093-14098&author=G.+H.+Birdauthor=N.+Madaniauthor=A.+F.+Perryauthor=A.+M.+Princiottoauthor=J.+G.+Supkoauthor=X.+Heauthor=E.+Gavathiotisauthor=J.+G.+Sodroskiauthor=L.+D.+Walensky&title=Hydrocarbon+double-stapling+remedies+the+proteolytic+instability+of+a+lengthy+peptide+therapeutic&doi=10.1073%2Fpnas.1002713107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146aR"><div class="casContent"><span class="casTitleNuber">146a</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic</span></div><div class="casAuthors">Bird, Gregory H.; Madani, Navid; Perry, Alisa F.; Princiotto, Amy M.; Supko, Jeffrey G.; He, Xiaoying; Gavathiotis, Evripidis; Sodroski, Joseph G.; Walensky, Loren D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">14093-14098, S14093/1-S14093/8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The pharmacol. utility of lengthy peptides can be hindered by loss of bioactive structure and rapid proteolysis, which limits bioavailability.  For example, enfuvirtide (Fuzeon, T20, DP178), a 36-amino acid peptide that inhibits human immunodeficiency virus type 1 (HIV-1) infection by effectively targeting the viral fusion app., has been relegated to a salvage treatment option mostly due to poor in vivo stability and lack of oral bioavailability.  To overcome the proteolytic shortcomings of long peptides as therapeutics, the authors examd. the biophys., biol., and pharmacol. impact of inserting all-hydrocarbon staples into an HIV-1 fusion inhibitor.  The authors find that peptide double-stapling confers striking protease resistance that translates into markedly improved pharmacokinetic properties, including oral absorption.  The authors detd. that the hydrocarbon staples create a proteolytic shield by combining reinforcement of overall Î±-helical structure, which slows the kinetics of proteolysis, with complete blockade of peptide cleavage at constrained sites in the immediate vicinity of the staple.  Importantly, double-stapling also optimizes the antiviral activity of HIV-1 fusion peptides and the antiproteolytic feature extends to other therapeutic peptide templates, such as the diabetes drug exenatide (Byetta).  Thus, hydrocarbon double-stapling may unlock the therapeutic potential of natural bioactive polypeptides by transforming them into structurally fortified agents with enhanced bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqme3pVM-fEB7Vg90H21EOLACvtfcHk0li7YXx9akAWIg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVCktrfJ&md5=95edd2112b56b564864e462eeb276e11</span></div><a href="/servlet/linkout?suffix=cit146a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1002713107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1002713107%26sid%3Dliteratum%253Aachs%26aulast%3DBird%26aufirst%3DG.%2BH.%26aulast%3DMadani%26aufirst%3DN.%26aulast%3DPerry%26aufirst%3DA.%2BF.%26aulast%3DPrinciotto%26aufirst%3DA.%2BM.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DGavathiotis%26aufirst%3DE.%26aulast%3DSodroski%26aufirst%3DJ.%2BG.%26aulast%3DWalensky%26aufirst%3DL.%2BD.%26atitle%3DHydrocarbon%2520double-stapling%2520remedies%2520the%2520proteolytic%2520instability%2520of%2520a%2520lengthy%2520peptide%2520therapeutic%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D14093%26epage%3D14098%26doi%3D10.1073%2Fpnas.1002713107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit146b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chang, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graves, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerlavais, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tovar, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Packman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">To, K.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesavan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gangurde, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukherjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darlak, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elkin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filipovic, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qureshi, F. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feyfant, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horstick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Annis, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fotouhi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nash, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vassilev, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span> </span><span class="NLM_article-title">Stapled Î±-helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">E3445</span><span class="NLM_x">â</span> <span class="NLM_lpage">E3454</span><span class="refDoi">Â DOI: 10.1073/pnas.1303002110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1073%2Fpnas.1303002110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23946421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVKksLfN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=E3445-E3454&author=Y.+S.+Changauthor=B.+Gravesauthor=V.+Guerlavaisauthor=C.+Tovarauthor=K.+Packmanauthor=K.-H.+Toauthor=K.+A.+Olsonauthor=K.+Kesavanauthor=P.+Gangurdeauthor=A.+Mukherjeeauthor=T.+Bakerauthor=K.+Darlakauthor=C.+Elkinauthor=Z.+Filipovicauthor=F.+Z.+Qureshiauthor=H.+Caiauthor=P.+Berryauthor=E.+Feyfantauthor=X.+E.+Shiauthor=J.+Horstickauthor=D.+A.+Annisauthor=A.+M.+Manningauthor=N.+Fotouhiauthor=H.+Nashauthor=L.+T.+Vassilevauthor=T.+K.+Sawyer&title=Stapled+%CE%B1-helical+peptide+drug+development%3A+A+potent+dual+inhibitor+of+MDM2+and+MDMX+for+p53-dependent+cancer+therapy&doi=10.1073%2Fpnas.1303002110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146bR"><div class="casContent"><span class="casTitleNuber">146b</span><div class="casTitle"><span class="NLM_cas:atitle">Stapled Î±-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy</span></div><div class="casAuthors">Chang, Yong S.; Graves, Bradford; Guerlavais, Vincent; Tovar, Christian; Packman, Kathryn; To, Kwong-Him; Olson, Karen A.; Kesavan, Kamala; Gangurde, Pranoti; Mukherjee, Aditi; Baker, Theresa; Darlak, Krzysztof; Elkin, Carl; Filipovic, Zoran; Qureshi, Farooq Z.; Cai, Hongliang; Berry, Pamela; Feyfant, Eric; Shi, Xiangguo E.; Horstick, James; Annis, D. Allen; Manning, Anthony M.; Fotouhi, Nader; Nash, Huw; Vassilev, Lyubomir T.; Sawyer, Tomi K.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">E3445-E3454,SE3445/1-SE3445/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Stapled Î±-helical peptides have emerged as a promising new modality for a wide range of therapeutic targets.  Here, we report a potent and selective dual inhibitor of MDM2 and MDMX, ATSP-7041, which effectively activates the p53 pathway in tumors in vitro and in vivo.  Specifically, ATSP-7041 binds both MDM2 and MDMX with nanomolar affinities, shows submicromolar cellular activities in cancer cell lines in the presence of serum, and demonstrates highly specific, on-target mechanism of action.  A high resoln. (1.7-Ã) X-ray crystal structure reveals its mol. interactions with the target protein MDMX, including multiple contacts with key amino acids as well as a role for the hydrocarbon staple itself in target engagement.  Most importantly, ATSP-7041 demonstrates robust p53-dependent tumor growth suppression in MDM2/MDMX-over-expressing xenograft cancer models, with a high correlation to on-target pharmacodynamic activity, and possesses favorable pharmacokinetic and tissue distribution properties.  Overall, ATSP-7041 demonstrates in vitro and in vivo proof-of-concept that stapled peptides can be developed as therapeutically relevant inhibitors of protein-protein interaction and may offer a viable modality for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFyYiS_tqgI7Vg90H21EOLACvtfcHk0li7YXx9akAWIg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVKksLfN&md5=c7533088eb02a6c38ffb31a91fae9e2e</span></div><a href="/servlet/linkout?suffix=cit146b&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1303002110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1303002110%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DY.%2BS.%26aulast%3DGraves%26aufirst%3DB.%26aulast%3DGuerlavais%26aufirst%3DV.%26aulast%3DTovar%26aufirst%3DC.%26aulast%3DPackman%26aufirst%3DK.%26aulast%3DTo%26aufirst%3DK.-H.%26aulast%3DOlson%26aufirst%3DK.%2BA.%26aulast%3DKesavan%26aufirst%3DK.%26aulast%3DGangurde%26aufirst%3DP.%26aulast%3DMukherjee%26aufirst%3DA.%26aulast%3DBaker%26aufirst%3DT.%26aulast%3DDarlak%26aufirst%3DK.%26aulast%3DElkin%26aufirst%3DC.%26aulast%3DFilipovic%26aufirst%3DZ.%26aulast%3DQureshi%26aufirst%3DF.%2BZ.%26aulast%3DCai%26aufirst%3DH.%26aulast%3DBerry%26aufirst%3DP.%26aulast%3DFeyfant%26aufirst%3DE.%26aulast%3DShi%26aufirst%3DX.%2BE.%26aulast%3DHorstick%26aufirst%3DJ.%26aulast%3DAnnis%26aufirst%3DD.%2BA.%26aulast%3DManning%26aufirst%3DA.%2BM.%26aulast%3DFotouhi%26aufirst%3DN.%26aulast%3DNash%26aufirst%3DH.%26aulast%3DVassilev%26aufirst%3DL.%2BT.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26atitle%3DStapled%2520%25CE%25B1-helical%2520peptide%2520drug%2520development%253A%2520A%2520potent%2520dual%2520inhibitor%2520of%2520MDM2%2520and%2520MDMX%2520for%2520p53-dependent%2520cancer%2520therapy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3DE3445%26epage%3DE3454%26doi%3D10.1073%2Fpnas.1303002110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit146c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Walensky, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bird, G. H.</span><span> </span><span class="NLM_article-title">Hydrocarbon-stapled peptides: principles, practice, and progress</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">6275</span><span class="NLM_x">â</span> <span class="NLM_lpage">6288</span><span class="refDoi">Â DOI: 10.1021/jm4011675</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4011675" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref146/cit146c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislensbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6275-6288&author=L.+D.+Walenskyauthor=G.+H.+Bird&title=Hydrocarbon-stapled+peptides%3A+principles%2C+practice%2C+and+progress&doi=10.1021%2Fjm4011675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146cR"><div class="casContent"><span class="casTitleNuber">146c</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrocarbon-Stapled Peptides: Principles, Practice, and Progress</span></div><div class="casAuthors">Walensky, Loren D.; Bird, Gregory H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6275-6288</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Protein structure underlies essential biol. processes and provides a blueprint for mol. mimicry that drives drug discovery.  Although small mols. represent the lion's share of agents that target proteins for therapeutic benefit, there remains no substitute for the natural properties of proteins and their peptide subunits in the majority of biol. contexts.  The peptide Î±-helix represents a common structural motif that mediates communication between signaling proteins.  Because peptides can lose their shape when taken out of context, developing chem. interventions to stabilize their bioactive structure remains an active area of research.  The all-hydrocarbon staple has emerged as one such soln., conferring Î±-helical structure, protease resistance, cellular penetrance, and biol. activity upon successful incorporation of a series of design and application principles.  Here, we describe our more than decade-long experience in developing stapled peptides as biomedical research tools and prototype therapeutics, highlighting lessons learned, pitfalls to avoid, and keys to success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC-4FlhgczWbVg90H21EOLACvtfcHk0lhDitDgPsGn8A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislensbs%253D&md5=a2d11fd1668df5707099b94d2932d352</span></div><a href="/servlet/linkout?suffix=cit146c&amp;dbid=16384&amp;doi=10.1021%2Fjm4011675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4011675%26sid%3Dliteratum%253Aachs%26aulast%3DWalensky%26aufirst%3DL.%2BD.%26aulast%3DBird%26aufirst%3DG.%2BH.%26atitle%3DHydrocarbon-stapled%2520peptides%253A%2520principles%252C%2520practice%252C%2520and%2520progress%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6275%26epage%3D6288%26doi%3D10.1021%2Fjm4011675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meinhardt, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulkarni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Low, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeGrado, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenbaum, D. C.</span><span> </span><span class="NLM_article-title">Development of Î±-helical calpain probes by mimicking a natural protein-protein interaction</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">134</span><span class="NLM_x">, </span> <span class="NLM_fpage">17704</span><span class="NLM_x">â</span> <span class="NLM_lpage">17713</span><span class="refDoi">Â DOI: 10.1021/ja307599z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja307599z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2lsrfK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=17704-17713&author=H.+Joauthor=N.+Meinhardtauthor=Y.+Wuauthor=S.+Kulkarniauthor=X.+Huauthor=K.+E.+Lowauthor=P.+L.+Daviesauthor=W.+F.+DeGradoauthor=D.+C.+Greenbaum&title=Development+of+%CE%B1-helical+calpain+probes+by+mimicking+a+natural+protein-protein+interaction&doi=10.1021%2Fja307599z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147aR"><div class="casContent"><span class="casTitleNuber">147a</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Î±-Helical Calpain Probes by Mimicking a Natural Protein-Protein Interaction</span></div><div class="casAuthors">Jo, Hyunil; Meinhardt, Nataline; Wu, Yibing; Kulkarni, Swapnil; Hu, Xiaozhen; Low, Kristin E.; Davies, Peter L.; DeGrado, William F.; Greenbaum, Doron C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">17704-17713</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A highly specific inhibitor of calpain was designed by mimicking a natural protein-protein interaction between calpain and its endogenous inhibitor calpastatin.  To enable this goal a new method of stabilizing an Î±-helix in a small peptide was established by screening 24 com. available cross-linkers for successful cysteine alkylation in a model peptide sequence.  The effects of crosslinking on the Î±-helicity of selected peptides were examd. by CD and NMR spectroscopy, and revealed structurally rigid cross-linkers to be the best at stabilizing Î±-helixes.  This strategy was applied to the design of inhibitors of calpain that are based on calpastatin, an intrinsically unstable polypeptide that becomes structured upon binding to the enzyme.  A two-turn Î±-helix that binds proximal to the active site cleft was stabilized, resulting in a potent and selective inhibitor for calpain.  The utility of this inhibitor was further expanded by developing irreversible calpain family activity-based probes (ABPs), which retained the specificity of the stabilized helical inhibitor.  It is believed that the inhibitor and ABPs will be useful for future investigation of calpains, while the crosslinking technique will enable exploration of other protein-protein interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpigseq6FFUU7Vg90H21EOLACvtfcHk0lhDitDgPsGn8A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2lsrfK&md5=2824ee6e61d4bb0e4202696fc57f1fa0</span></div><a href="/servlet/linkout?suffix=cit147a&amp;dbid=16384&amp;doi=10.1021%2Fja307599z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja307599z%26sid%3Dliteratum%253Aachs%26aulast%3DJo%26aufirst%3DH.%26aulast%3DMeinhardt%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DKulkarni%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DLow%26aufirst%3DK.%2BE.%26aulast%3DDavies%26aufirst%3DP.%2BL.%26aulast%3DDeGrado%26aufirst%3DW.%2BF.%26aulast%3DGreenbaum%26aufirst%3DD.%2BC.%26atitle%3DDevelopment%2520of%2520%25CE%25B1-helical%2520calpain%2520probes%2520by%2520mimicking%2520a%2520natural%2520protein-protein%2520interaction%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26spage%3D17704%26epage%3D17713%26doi%3D10.1021%2Fja307599z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit147b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fairlie, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dantas de Araujo, A.</span><span> </span><span class="NLM_article-title">Stapling peptides using cysteine crosslinking</span> <span class="citation_source-journal">Biopolymers</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">843</span><span class="NLM_x">â</span> <span class="NLM_lpage">852</span><span class="refDoi">Â DOI: 10.1002/bip.22877</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fbip.22877" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=27178225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFSlsbbF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2016&pages=843-852&author=D.+P.+Fairlieauthor=A.+Dantas+de+Araujo&title=Stapling+peptides+using+cysteine+crosslinking&doi=10.1002%2Fbip.22877"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147bR"><div class="casContent"><span class="casTitleNuber">147b</span><div class="casTitle"><span class="NLM_cas:atitle">Stapling peptides using cysteine crosslinking</span></div><div class="casAuthors">Fairlie, David P.; Dantas de Araujo, Aline</div><div class="citationInfo"><span class="NLM_cas:title">Biopolymers</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">843-852</span>CODEN:
                <span class="NLM_cas:coden">BIPMAA</span>;
        ISSN:<span class="NLM_cas:issn">0006-3525</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Stapled peptides are an emerging class of cyclic peptide mols. with enhanced biophys. properties such as conformational and proteolytic stability, cellular uptake and elevated binding affinity and specificity for their biol. targets.  Among the limited no. of chemistries available for their synthesis, the cysteine-based stapling strategy has received considerable development in the last few years driven by facile access from cysteine-functionalized peptide precursors.  Here we present some recent advances in peptide and protein stapling where the side-chains of cysteine residues are covalently connected with a range of different crosslinkers affording bisthioether macrocyclic peptides of varying topol. and biophys. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS9Pa86sKxKbVg90H21EOLACvtfcHk0lhDitDgPsGn8A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFSlsbbF&md5=760b84de40576c35ceff56e1fb86f42b</span></div><a href="/servlet/linkout?suffix=cit147b&amp;dbid=16384&amp;doi=10.1002%2Fbip.22877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbip.22877%26sid%3Dliteratum%253Aachs%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26aulast%3DDantas%2Bde%2BAraujo%26aufirst%3DA.%26atitle%3DStapling%2520peptides%2520using%2520cysteine%2520crosslinking%26jtitle%3DBiopolymers%26date%3D2016%26volume%3D106%26spage%3D843%26epage%3D852%26doi%3D10.1002%2Fbip.22877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit147c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Diderich, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertoldo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dessen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pizzitola, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Held, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huelsken, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinis, C.</span><span> </span><span class="NLM_article-title">Phage selection of chemically stabilized Î±-helical peptide ligands</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1422</span><span class="NLM_x">â</span> <span class="NLM_lpage">1427</span><span class="refDoi">Â DOI: 10.1021/acschembio.5b00963</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00963" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XjsVagtr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1422-1427&author=P.+Diderichauthor=D.+Bertoldoauthor=P.+Dessenauthor=M.+M.+Khanauthor=I.+Pizzitolaauthor=W.+Heldauthor=J.+Huelskenauthor=C.+Heinis&title=Phage+selection+of+chemically+stabilized+%CE%B1-helical+peptide+ligands&doi=10.1021%2Facschembio.5b00963"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147cR"><div class="casContent"><span class="casTitleNuber">147c</span><div class="casTitle"><span class="NLM_cas:atitle">Phage Selection of Chemically Stabilized Î±-Helical Peptide Ligands</span></div><div class="casAuthors">Diderich, Philippe; Bertoldo, Davide; Dessen, Pierre; Khan, Maola M.; Pizzitola, Irene; Held, Werner; Huelsken, Joerg; Heinis, Christian</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1422-1427</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Short Î±-helical peptides stabilized by linkages between constituent amino acids offer an attractive format for ligand development.  In recent years, a range of excellent ligands based on stabilized Î±-helixes were generated by rational design using Î±-helical peptides of natural proteins as templates.  Herein, we developed a method to engineer chem. stabilized Î±-helical ligands in a combinatorial fashion.  In brief, peptides contg. cysteines in position i and i + 4 are genetically encoded by phage display, the cysteines are modified with chem. bridges to impose Î±-helical conformations, and binders are isolated by affinity selection.  We applied the strategy to affinity mature an Î±-helical peptide binding Î²-catenin.  We succeeded in developing ligands with Kd's as low as 5.2 nM, having >200-fold improved affinity.  The strategy is generally applicable for affinity maturation of any Î±-helical peptide.  Compared to hydrocarbon stapled peptides, the herein evolved thioether-bridged peptide ligands can be synthesized more easily, as no unnatural amino acids are required and the cyclization reaction is more efficient and yields no stereoisomers.  A further advantage of the thioether-bridged peptide ligands is that they can be expressed recombinantly as fusion proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXjSfa_cgePrVg90H21EOLACvtfcHk0lhGCTSdF-W-BA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjsVagtr8%253D&md5=a25d24d4733a0d89f4797c5313ef1870</span></div><a href="/servlet/linkout?suffix=cit147c&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00963%26sid%3Dliteratum%253Aachs%26aulast%3DDiderich%26aufirst%3DP.%26aulast%3DBertoldo%26aufirst%3DD.%26aulast%3DDessen%26aufirst%3DP.%26aulast%3DKhan%26aufirst%3DM.%2BM.%26aulast%3DPizzitola%26aufirst%3DI.%26aulast%3DHeld%26aufirst%3DW.%26aulast%3DHuelsken%26aufirst%3DJ.%26aulast%3DHeinis%26aufirst%3DC.%26atitle%3DPhage%2520selection%2520of%2520chemically%2520stabilized%2520%25CE%25B1-helical%2520peptide%2520ligands%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26spage%3D1422%26epage%3D1427%26doi%3D10.1021%2Facschembio.5b00963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertoldo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angelini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pojer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinis, C.</span><span> </span><span class="NLM_article-title">Peptide ligands stabilized by small molecules</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">1602</span><span class="NLM_x">â</span> <span class="NLM_lpage">1606</span><span class="refDoi">Â DOI: 10.1002/anie.201309459</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fanie.201309459" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVyltLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=1602-1606&author=S.+Chenauthor=D.+Bertoldoauthor=A.+Angeliniauthor=F.+Pojerauthor=C.+Heinis&title=Peptide+ligands+stabilized+by+small+molecules&doi=10.1002%2Fanie.201309459"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148aR"><div class="casContent"><span class="casTitleNuber">148a</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide Ligands Stabilized by Small Molecules</span></div><div class="casAuthors">Chen, Shiyu; Bertoldo, Davide; Angelini, Alessandro; Pojer, Florence; Heinis, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1602-1606</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Bicyclic peptides generated through directed evolution by using phage display offer an attractive ligand format for the development of therapeutics.  Being nearly 100-fold smaller than antibodies, they promise advantages such as access to chem. synthesis, efficient diffusion into tissues, and needle-free application.  However, unlike antibodies, they do not have a folded structure in soln. and thus do not bind as well as antibodies.  We developed bicyclic peptides with hydrophilic chem. structures at their center to promote noncovalent intramol. interactions, thereby stabilizing the peptide conformation.  The sequences of the peptides isolated by phage display from large combinatorial libraries were strongly influenced by the type of small mol. used in the screen, thus suggesting that the peptides fold around the small mols.  X-ray structure anal. revealed that the small mols. indeed formed hydrogen bonds with the peptides.  These noncovalent interactions stabilize the peptide-protein complexes and contribute to the high binding affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0-9uyjWceNrVg90H21EOLACvtfcHk0lhGCTSdF-W-BA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVyltLc%253D&md5=4bc852345c54171bd8c7143a563bba2b</span></div><a href="/servlet/linkout?suffix=cit148a&amp;dbid=16384&amp;doi=10.1002%2Fanie.201309459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201309459%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DBertoldo%26aufirst%3DD.%26aulast%3DAngelini%26aufirst%3DA.%26aulast%3DPojer%26aufirst%3DF.%26aulast%3DHeinis%26aufirst%3DC.%26atitle%3DPeptide%2520ligands%2520stabilized%2520by%2520small%2520molecules%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D1602%26epage%3D1606%26doi%3D10.1002%2Fanie.201309459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit148b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Heinis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutherford, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freund, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winter, G.</span><span> </span><span class="NLM_article-title">Phage-encoded combinatorial chemical libraries based on bicyclic peptides</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">502</span><span class="NLM_x">â</span> <span class="NLM_lpage">507</span><span class="refDoi">Â DOI: 10.1038/nchembio.184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnchembio.184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=19483697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1altbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=502-507&author=C.+Heinisauthor=T.+Rutherfordauthor=S.+Freundauthor=G.+Winter&title=Phage-encoded+combinatorial+chemical+libraries+based+on+bicyclic+peptides&doi=10.1038%2Fnchembio.184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148bR"><div class="casContent"><span class="casTitleNuber">148b</span><div class="casTitle"><span class="NLM_cas:atitle">Phage-encoded combinatorial chemical libraries based on bicyclic peptides</span></div><div class="casAuthors">Heinis, Christian; Rutherford, Trevor; Freund, Stephan; Winter, Greg</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">502-507</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we describe a phage strategy for the selection of ligands based on bicyclic or linear peptides attached covalently to an org. core.  We designed peptide repertoires with three reactive cysteine residues, each spaced apart by several random amino acid residues, and we fused the repertoires to the phage gene-3-protein.  Conjugation with tris-(bromomethyl)benzene via the reactive cysteines generated repertoires of peptide conjugates with two peptide loops anchored to a mesitylene core.  Iterative affinity selections yielded several enzyme inhibitors; after further mutagenesis and selection, we were able to chem. synthesize a lead inhibitor (PK15; Ki = 1.5 nM) specific to human plasma kallikrein that efficiently interrupted the intrinsic coagulation pathway in human plasma tested ex vivo.  This approach offers a powerful means of generating and selecting bicyclic macrocycles (or if cleaved, linear derivs. thereof) as ligands poised at the interface of small-mol. drugs and biologics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZhJRZyldisLVg90H21EOLACvtfcHk0lhGCTSdF-W-BA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1altbs%253D&md5=0634460f77b185fbcf85309c6dbf93e3</span></div><a href="/servlet/linkout?suffix=cit148b&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.184%26sid%3Dliteratum%253Aachs%26aulast%3DHeinis%26aufirst%3DC.%26aulast%3DRutherford%26aufirst%3DT.%26aulast%3DFreund%26aufirst%3DS.%26aulast%3DWinter%26aufirst%3DG.%26atitle%3DPhage-encoded%2520combinatorial%2520chemical%2520libraries%2520based%2520on%2520bicyclic%2520peptides%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26spage%3D502%26epage%3D507%26doi%3D10.1038%2Fnchembio.184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Vagner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hruby, V. J.</span><span> </span><span class="NLM_article-title">Peptidomimetics, a synthetic tool of drug discovery</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">292</span><span class="NLM_x">â</span> <span class="NLM_lpage">296</span><span class="refDoi">Â DOI: 10.1016/j.cbpa.2008.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.cbpa.2008.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=18423417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnt1ersro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2008&pages=292-296&author=J.+Vagnerauthor=H.+Quauthor=V.+J.+Hruby&title=Peptidomimetics%2C+a+synthetic+tool+of+drug+discovery&doi=10.1016%2Fj.cbpa.2008.03.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149aR"><div class="casContent"><span class="casTitleNuber">149a</span><div class="casTitle"><span class="NLM_cas:atitle">Peptidomimetics, a synthetic tool of drug discovery</span></div><div class="casAuthors">Vagner, Josef; Qu, Hongchang; Hruby, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">292-296</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The demand for modified peptides with improved stability profiles and pharmacokinetic properties is driving extensive research effort in this field.  Many structural modifications of peptides guided by rational design and mol. modeling have been established to develop novel synthetic approaches.  Recent advances in the synthesis of conformationally restricted building blocks and peptide bond isosteres are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9PN_EMokFKLVg90H21EOLACvtfcHk0lhGCTSdF-W-BA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnt1ersro%253D&md5=f91110417f810711b46361ba0a620745</span></div><a href="/servlet/linkout?suffix=cit149a&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2008.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2008.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DVagner%26aufirst%3DJ.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DHruby%26aufirst%3DV.%2BJ.%26atitle%3DPeptidomimetics%252C%2520a%2520synthetic%2520tool%2520of%2520drug%2520discovery%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2008%26volume%3D12%26spage%3D292%26epage%3D296%26doi%3D10.1016%2Fj.cbpa.2008.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit149b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Cluzeau, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubell, W. D.</span><span> </span><span class="NLM_article-title">Design, synthesis, and application of azabicyclo[X.Y.0]alkanone amino acids as constrained dipeptide surrogates and peptide mimics</span> <span class="citation_source-journal">Biopolymers</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">98</span><span class="NLM_x">â</span> <span class="NLM_lpage">150</span><span class="refDoi">Â DOI: 10.1002/bip.20213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fbip.20213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=15795926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktFersrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2005&pages=98-150&author=J.+Cluzeauauthor=W.+D.+Lubell&title=Design%2C+synthesis%2C+and+application+of+azabicyclo%5BX.Y.0%5Dalkanone+amino+acids+as+constrained+dipeptide+surrogates+and+peptide+mimics&doi=10.1002%2Fbip.20213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149bR"><div class="casContent"><span class="casTitleNuber">149b</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and application of azabicyclo[X.Y.O]alkanone amino acids as constrained dipeptide surrogates and peptide mimics</span></div><div class="casAuthors">Cluzeau, Jerome; Lubell, William D.</div><div class="citationInfo"><span class="NLM_cas:title">Biopolymers</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">2 and 3</span>),
    <span class="NLM_cas:pages">98-150</span>CODEN:
                <span class="NLM_cas:coden">BIPMAA</span>;
        ISSN:<span class="NLM_cas:issn">0006-3525</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Azabicyclo[X.Y.O]alkanone amino acids are challenging synthetic targets and useful tools for studying structure-activity relationships of native peptide ligands.  They have been employed to increase potency and stability in conformationally rigid enzyme inhibitors and receptor ligands.  Since last reviewed in 1997, activity in their synthesis and application has increased significantly and access is now available to a wider diversity of these peptide mimics.  This review focuses on recent syntheses of these heterocyclic amino acids and their application in the investigation of biol. active peptides and peptide mimics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6RqlEjRVDmbVg90H21EOLACvtfcHk0lhQXnj8wqdYgQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktFersrY%253D&md5=49ebf2c9a45d2a83e7a69fd822f4f72a</span></div><a href="/servlet/linkout?suffix=cit149b&amp;dbid=16384&amp;doi=10.1002%2Fbip.20213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbip.20213%26sid%3Dliteratum%253Aachs%26aulast%3DCluzeau%26aufirst%3DJ.%26aulast%3DLubell%26aufirst%3DW.%2BD.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520application%2520of%2520azabicyclo%255BX.Y.0%255Dalkanone%2520amino%2520acids%2520as%2520constrained%2520dipeptide%2520surrogates%2520and%2520peptide%2520mimics%26jtitle%3DBiopolymers%26date%3D2005%26volume%3D80%26spage%3D98%26epage%3D150%26doi%3D10.1002%2Fbip.20213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group">Wisskirchen, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doyle, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gough, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, I.</span><span> </span><span class="NLM_article-title">Conformational restraints revealing bioactive Î²-bend structures for hÎ± CGRP8â37 at the CGRP2 receptor of the rat prostatic vas deferens</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">1163</span><span class="NLM_x">â</span> <span class="NLM_lpage">1170</span><span class="refDoi">Â DOI: 10.1038/sj.bjp.0702432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fsj.bjp.0702432" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10205004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADyaK1MXitFGhsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=1999&pages=1163-1170&author=F.+M.+Wisskirchenauthor=P.+M.+Doyleauthor=S.+L.+Goughauthor=C.+J.+Harrisauthor=I.+Marshall&title=Conformational+restraints+revealing+bioactive+%CE%B2-bend+structures+for+h%CE%B1+CGRP8%E2%80%9337+at+the+CGRP2+receptor+of+the+rat+prostatic+vas+deferens&doi=10.1038%2Fsj.bjp.0702432"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational restraints revealing bioactive Î²-bend structures for hÎ± CGRP8-37 at the CGRP2 receptor of the rat prostatic vas deferens</span></div><div class="casAuthors">Wisskirchen, F. M.; Doyle, P. M.; Gough, S. L.; Harris, C. J.; Marshall, I.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1163-1170</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">The main aim of this study was to identify putative Î²-bends and the role of the N- and C-terminus in the CGRP receptor antagonist hÎ± CGRP8-37, which was measured against hÎ± CGRP inhibition of twitch responses in the rat prostatic vas deferens.  With a bend-biasing residue (proline) at position 16 in hÎ± CGRP8-37 (10-5 M) an inactive compd. was produced, while alanine at the same position retained antagonist activity (apparent pKB 5.6 at 10-5 M).  Proline at position 19 within hÎ± CGRP8-37 (10-5 M) was an antagonist (apparent pKB 5.8).  Incorporation of a bend-forcing structure (beta-turn dipeptide or BTD) at either positions 19,20 or 33,34 in hÎ± CGRP8-37 (10-5 M) antagonized hÎ± CGRP responses (apparent pKB 6.0 and 6.1, resp.).  Replacement by BTD at both positions 19,20 and 33,34 within hÎ± CGRP8-37 competitively antagonized responses to hÎ± CGRP (pA2 6.2; Schild plot slope 1.0).  The hÎ± CGRP8-37 analogs (10-5 M), substituted at the N-terminus by either glycine8, or des-NH2 valine8 or proline8 were all antagonists against hÎ± CGRP (apparent pKB 6.1, 6.5 and 6.1, resp.), while hÎ± CGRP8-37 (10-5 M) substituted in three places by proline8 and glutamic acid10,14 was inactive.  Replacement of the C-terminus by alanine amide37 in hÎ± CGRP8-37 (10-5 M) failed to antagonize hÎ± CGRP responses.  Peptidase inhibitors did not alter either the agonist potency of hÎ± CGRP or the antagonist affinities of hÎ± CGRP8-37 BTD19,20 and 33,34 and hÎ± CGRP8-37 Gly8 (against hÎ± CGRP responses).  In conclusion, two Î²-bends at positions 18-21 and 32-35 are compatible with high affinity by BTD and is the first approach of modeling the bioactive structure of hÎ± CGRP8-37.  Further, the N-terminus of hÎ± CGRP8-37 is not essential for antagonism, while the C-terminus interacts directly with CGRP receptor binding sites of the rat vas deferens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5SjNK0UAAS7Vg90H21EOLACvtfcHk0lhQXnj8wqdYgQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXitFGhsrk%253D&md5=05b7dc0ca5ad40dee39491c9013a93b0</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0702432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0702432%26sid%3Dliteratum%253Aachs%26aulast%3DWisskirchen%26aufirst%3DF.%2BM.%26aulast%3DDoyle%26aufirst%3DP.%2BM.%26aulast%3DGough%26aufirst%3DS.%2BL.%26aulast%3DHarris%26aufirst%3DC.%2BJ.%26aulast%3DMarshall%26aufirst%3DI.%26atitle%3DConformational%2520restraints%2520revealing%2520bioactive%2520%25CE%25B2-bend%2520structures%2520for%2520h%25CE%25B1%2520CGRP8%25E2%2580%259337%2520at%2520the%2520CGRP2%2520receptor%2520of%2520the%2520rat%2520prostatic%2520vas%2520deferens%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1999%26volume%3D126%26spage%3D1163%26epage%3D1170%26doi%3D10.1038%2Fsj.bjp.0702432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yan, L. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothstein, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flora, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaughn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemens-Smith, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarty, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKnight, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nisenbaum, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, J. P.</span><span> </span><span class="NLM_article-title">Discovery of potent, cyclic calcitonin gene-related peptide receptor antagonists</span> <span class="citation_source-journal">J. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">383</span><span class="NLM_x">â</span> <span class="NLM_lpage">386</span><span class="refDoi">Â DOI: 10.1002/psc.1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fpsc.1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21412957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktlyqu7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=383-386&author=L.+Z.+Yanauthor=K.+W.+Johnsonauthor=E.+Rothsteinauthor=D.+Floraauthor=P.+Edwardsauthor=B.+Liauthor=J.+Liauthor=R.+Lynchauthor=R.+Vaughnauthor=A.+Clemens-Smithauthor=D.+McCartyauthor=C.+Chowauthor=K.+L.+McKnightauthor=J.+Luauthor=E.+S.+Nisenbaumauthor=J.+P.+Mayer&title=Discovery+of+potent%2C+cyclic+calcitonin+gene-related+peptide+receptor+antagonists&doi=10.1002%2Fpsc.1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151aR"><div class="casContent"><span class="casTitleNuber">151a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent, cyclic calcitonin gene-related peptide receptor antagonists</span></div><div class="casAuthors">Yan, Liang-Zeng; Johnson, Kirk W.; Rothstein, Emily; Flora, David; Edwards, Patrick; Li, Bao-Lin; Li, Jun-Qing; Lynch, Renee; Vaughn, Renee; Clemens-Smith, Amy; McCarty, Deborah; Chow, Charles; McKnight, Kevin L.; Lu, Ji-Rong; Nisenbaum, Eric S.; Mayer, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">383-386</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Calcitonin gene-related peptide (CGRP), a potent dilator of cerebral and dural vasculature, is known to be elevated in plasma and cerebral spinal fluid during migraine attacks.  Selective blockade of the CGRP receptor offers the promise of controlling migraine headache more effectively and without the side-effects assocd. with the use of triptans.  Our efforts to develop a novel, peptide-based CGRP antagonist focused on the C-terminal portion of the peptide which is known to bind the receptor but lack agonist properties.  Extensive SAR studies of the C-terminal CGRP (27-37) region identified a novel cyclic structure: Bz-Val-Tyr-cyclo[Cys-Thr-Asp-Val-Gly-Pro-Phe-Cys]-Phe-NH2 (23) with a kb value of 0.126 nM against the cloned human CGRP receptor.  Addnl. SAR studies directed at enhancement of potency and improvement of physicochem. properties yielded a series of analogs with kb values in the 0.05-0.10 nM range.  Copyright Â© 2011 European Peptide Society and John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7kDX4nryKprVg90H21EOLACvtfcHk0lhQXnj8wqdYgQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktlyqu7Y%253D&md5=ce930ff219638d47e733fce510cd8965</span></div><a href="/servlet/linkout?suffix=cit151a&amp;dbid=16384&amp;doi=10.1002%2Fpsc.1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.1358%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DL.%2BZ.%26aulast%3DJohnson%26aufirst%3DK.%2BW.%26aulast%3DRothstein%26aufirst%3DE.%26aulast%3DFlora%26aufirst%3DD.%26aulast%3DEdwards%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLynch%26aufirst%3DR.%26aulast%3DVaughn%26aufirst%3DR.%26aulast%3DClemens-Smith%26aufirst%3DA.%26aulast%3DMcCarty%26aufirst%3DD.%26aulast%3DChow%26aufirst%3DC.%26aulast%3DMcKnight%26aufirst%3DK.%2BL.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DNisenbaum%26aufirst%3DE.%2BS.%26aulast%3DMayer%26aufirst%3DJ.%2BP.%26atitle%3DDiscovery%2520of%2520potent%252C%2520cyclic%2520calcitonin%2520gene-related%2520peptide%2520receptor%2520antagonists%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2011%26volume%3D17%26spage%3D383%26epage%3D386%26doi%3D10.1002%2Fpsc.1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit151b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mroz, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Tilve, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelfanov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMarchi, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, J. P.</span><span> </span><span class="NLM_article-title">Pyridyl-alanine as a hydrophilic, aromatic element in peptide structural optimization</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">8061</span><span class="NLM_x">â</span> <span class="NLM_lpage">8067</span><span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00840</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00840" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8061-8067&author=P.+A.+Mrozauthor=D.+Perez-Tilveauthor=F.+Liuauthor=V.+Gelfanovauthor=R.+D.+DiMarchiauthor=J.+P.+Mayer&title=Pyridyl-alanine+as+a+hydrophilic%2C+aromatic+element+in+peptide+structural+optimization&doi=10.1021%2Facs.jmedchem.6b00840"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00840%26sid%3Dliteratum%253Aachs%26aulast%3DMroz%26aufirst%3DP.%2BA.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DGelfanov%26aufirst%3DV.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26aulast%3DMayer%26aufirst%3DJ.%2BP.%26atitle%3DPyridyl-alanine%2520as%2520a%2520hydrophilic%252C%2520aromatic%2520element%2520in%2520peptide%2520structural%2520optimization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8061%26epage%3D8067%26doi%3D10.1021%2Facs.jmedchem.6b00840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group">LehÃ r, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avery, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heilbut, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansen, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rickles, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Short, G. F.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staunton, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borisy, A. A.</span><span> </span><span class="NLM_article-title">Synergistic drug combinations improve therapeutic selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">659</span><span class="NLM_x">â</span> <span class="NLM_lpage">666</span><span class="refDoi">Â DOI: 10.1038/nbt.1549</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnbt.1549" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=659-666&author=J.+Leh%C3%A0rauthor=A.+S.+Kruegerauthor=W.+Averyauthor=A.+M.+Heilbutauthor=L.+M.+Johansenauthor=E.+R.+Priceauthor=R.+J.+Ricklesauthor=G.+F.+Shortauthor=J.+E.+Stauntonauthor=X.+Jinauthor=M.+S.+Leeauthor=G.+R.+Zimmermannauthor=A.+A.+Borisy&title=Synergistic+drug+combinations+improve+therapeutic+selectivity&doi=10.1038%2Fnbt.1549"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1549%26sid%3Dliteratum%253Aachs%26aulast%3DLeh%25C3%25A0r%26aufirst%3DJ.%26aulast%3DKrueger%26aufirst%3DA.%2BS.%26aulast%3DAvery%26aufirst%3DW.%26aulast%3DHeilbut%26aufirst%3DA.%2BM.%26aulast%3DJohansen%26aufirst%3DL.%2BM.%26aulast%3DPrice%26aufirst%3DE.%2BR.%26aulast%3DRickles%26aufirst%3DR.%2BJ.%26aulast%3DShort%26aufirst%3DG.%2BF.%26aulast%3DStaunton%26aufirst%3DJ.%2BE.%26aulast%3DJin%26aufirst%3DX.%26aulast%3DLee%26aufirst%3DM.%2BS.%26aulast%3DZimmermann%26aufirst%3DG.%2BR.%26aulast%3DBorisy%26aufirst%3DA.%2BA.%26atitle%3DSynergistic%2520drug%2520combinations%2520improve%2520therapeutic%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2009%26volume%3D27%26spage%3D659%26epage%3D666%26doi%3D10.1038%2Fnbt.1549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group">Jaquet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saveanu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dufour, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enjalbert, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Culler, M. D.</span><span> </span><span class="NLM_article-title">Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy</span> <span class="citation_source-journal">Eur. J. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">153</span><span class="NLM_x">, </span> <span class="NLM_fpage">135</span><span class="NLM_x">â</span> <span class="NLM_lpage">141</span><span class="refDoi">Â DOI: 10.1530/eje.1.01950</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1530%2Feje.1.01950" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=15994755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntValu74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=2005&pages=135-141&author=P.+Jaquetauthor=G.+Gunzauthor=A.+Saveanuauthor=H.+Dufourauthor=J.+Taylorauthor=J.+Dongauthor=S.+Kimauthor=J.+P.+Moreauauthor=A.+Enjalbertauthor=M.+D.+Culler&title=Efficacy+of+chimeric+molecules+directed+towards+multiple+somatostatin+and+dopamine+receptors+on+inhibition+of+GH+and+prolactin+secretion+from+GH-secreting+pituitary+adenomas+classified+as+partially+responsive+to+somatostatin+analog+therapy&doi=10.1530%2Feje.1.01950"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy</span></div><div class="casAuthors">Jaquet, P.; Gunz, G.; Saveanu, A.; Dufour, H.; Taylor, J.; Dong, J.; Kim, S.; Moreau, J.-P.; Enjalbert, A.; Culler, M. D.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Endocrinology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">135-141</span>CODEN:
                <span class="NLM_cas:coden">EJOEEP</span>;
        ISSN:<span class="NLM_cas:issn">0804-4643</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">Objective: This study compared the potency of a somatostatin receptor (sstr)2-sstr5 analog, BIM-23244, of an sstr2-dopamine D2 receptor (sstr2-DAD2) mol.  BIM-23A387 and of new somatostatin-dopamine chimeric mols. with differing, enhanced affinities for sstr2, sstr5 and DAD2, BIM-23A758, BIM-23A760 and BIM-23A761, to suppress GH and prolactin (PRL) from 18 human GH adenomas that are partially responsive to octreotide or lanreotide.  Materials and methods: The sstr2, sstr5 and DAD2 mRNA levels were detd. by RT-PCR.  The effect of drugs was tested in cell cultures at various concns.  Results: In all tumors, the sstr2, sstr5 and DAD2 mRNA levels were coexpressed (mean levelsÂ±S.E.M. 0.4Â±0.1, 5.3Â±1.9 and 2.0Â±0.4 copy/copy Î²-glucuronidase).  In 13 tumors, the maximal suppression of GH secretion produced by BIM-23A387 (30Â±3%) and BIM-23244 (28Â±3%) was greater than that produced by octreotide (23Â±3%).  In six out of 13 tumors, BIM-23A758, BIM-23A760 and BIM-23A761 produced greater maximal suppression of GH secretion than octreotide (33Â±5, 38Â±2 and 41Â±2 vs 24Â±2%).  Their EC50 values were 10, 2 and 4 pmol/l.  BIM-23A761 was more effective than BIM-23A387 in GH suppression (41Â±2 vs 32Â±4%).  The new chimeric mols. produced maximal PRL suppression greater than octreotide (62Â±8 to 74Â±5 vs 46Â±11%).  Conclusions: Novel dopamine-somatostatin chimeric mols. with differing, enhanced activity at sstr2, sstr5 and DAD2, consistently produced significantly greater suppression of GH and PRL than either octreotide or single-receptor-interacting ligands in tumors from patients classified as only partially responsive to octreotide therapy.  The higher efficacy of the chimeric compds. was, at least partially, linked to their high affinity for sstr2 (IC50 1-10 pmol/l).  The other mechanisms by which such mols. produce an enhanced inhibition of GH remain to be elucidated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmn3zwGYcxHrVg90H21EOLACvtfcHk0lg4WzzuxOUv2A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntValu74%253D&md5=bbff388a99d71dab35591d870abc94d4</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1530%2Feje.1.01950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252Feje.1.01950%26sid%3Dliteratum%253Aachs%26aulast%3DJaquet%26aufirst%3DP.%26aulast%3DGunz%26aufirst%3DG.%26aulast%3DSaveanu%26aufirst%3DA.%26aulast%3DDufour%26aufirst%3DH.%26aulast%3DTaylor%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DMoreau%26aufirst%3DJ.%2BP.%26aulast%3DEnjalbert%26aufirst%3DA.%26aulast%3DCuller%26aufirst%3DM.%2BD.%26atitle%3DEfficacy%2520of%2520chimeric%2520molecules%2520directed%2520towards%2520multiple%2520somatostatin%2520and%2520dopamine%2520receptors%2520on%2520inhibition%2520of%2520GH%2520and%2520prolactin%2520secretion%2520from%2520GH-secreting%2520pituitary%2520adenomas%2520classified%2520as%2520partially%2520responsive%2520to%2520somatostatin%2520analog%2520therapy%26jtitle%3DEur.%2520J.%2520Endocrinol.%26date%3D2005%26volume%3D153%26spage%3D135%26epage%3D141%26doi%3D10.1530%2Feje.1.01950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span>Clinical information can be found at: NCT00994214: Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients with Acromegaly (TULIPIA); <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="https://www.clinicaltrials.gov/" class="extLink">https://www.clinicaltrials.gov/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical+information+can+be+found+at%3A+NCT00994214%3A+Study+to+Assess+the+Efficacy+and+Safety+of+Repeated+Administration+of+BIM+23A760+in+Patients+with+Acromegaly+%28TULIPIA%29%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2015%3B+https%3A%2F%2Fwww.clinicaltrials.gov%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DNCT00994214%253A%2520Study%2520to%2520Assess%2520the%2520Efficacy%2520and%2520Safety%2520of%2520Repeated%2520Administration%2520of%2520BIM%252023A760%2520in%2520Patients%2520with%2520Acromegaly%2520%2528TULIPIA%2529%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group">Doppalapudi, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desharnais, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shields, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Del Rosario, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oates, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ainekulu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradshaw, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodnutt, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lappe, R. W.</span><span> </span><span class="NLM_article-title">Chemical generation of bispecific antibodies</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">22611</span><span class="NLM_x">â</span> <span class="NLM_lpage">22616</span><span class="refDoi">Â DOI: 10.1073/pnas.1016478108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1073%2Fpnas.1016478108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21149738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkt1KktQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=22611-22616&author=V.+R.+Doppalapudiauthor=J.+Huangauthor=D.+Liuauthor=P.+Jinauthor=B.+Liuauthor=L.+Liauthor=J.+Desharnaisauthor=C.+Hagenauthor=N.+J.+Levinauthor=M.+J.+Shieldsauthor=M.+Parishauthor=R.+E.+Murphyauthor=J.+Del+Rosarioauthor=B.+D.+Oatesauthor=J.-Y.+Laiauthor=M.+J.+Matinauthor=Z.+Ainekuluauthor=A.+Bhatauthor=C.+W.+Bradshawauthor=G.+Woodnuttauthor=R.+A.+Lernerauthor=R.+W.+Lappe&title=Chemical+generation+of+bispecific+antibodies&doi=10.1073%2Fpnas.1016478108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical generation of bispecific antibodies</span></div><div class="casAuthors">Doppalapudi, Venkata R.; Huang, Jie; Liu, Dingguo; Jin, Ping; Liu, Bin; Li, Lingna; Desharnais, Joel; Hagen, Crystal; Levin, Nancy J.; Shields, Michael J.; Parish, Michelle; Murphy, Robert E.; Del Rosario, Joselyn; Oates, Ryan D.; Lai, Jing-Yu; Matin, Maria J.; Ainekulu, Zemeda; Bhat, Abhijit; Bradshaw, Curt W.; Woodnutt, Gary; Lerner, Richard A.; Lappe, Rodney W.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">22611-22616, S22611/1-S22611/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Bispecific antibodies (BsAbs) are regarded as promising therapeutic agents due to their ability to simultaneously bind two different antigens.  Several bispecific modalities have been developed, but their utility is limited due to problems with stability and manufg. complexity.  Here the authors report a versatile technol., based. on a scaffold antibody and pharmacophore peptide heterodimers, that enables rapid generation and chem. optimization of bispecific antibodies, which are termed bispecific CovX-Bodies.  Two different peptides are joined together using a branched azetidinone linker and fused to the scaffold antibody under mild conditions in a site-specific manner.  Whereas the pharmacophores are responsible for functional activities, the antibody scaffold imparts long half-life and Ig-like distribution.  The pharmacophores can be chem. optimized or replaced with other pharmacophores to generate optimized or unique bispecific antibodies.  As a prototype, the authors developed a bispecific antibody that binds both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2) simultaneously, inhibits their function, shows efficacy in tumor xenograft studies, and greatly augments the antitumor effects of std. chemotherapy.  This unique antiangiogenic bispecific antibody is in phase-1 clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4Ar3x3pjLJLVg90H21EOLACvtfcHk0ljs8AKm5nzKyQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkt1KktQ%253D%253D&md5=007967df39ca1f43798f9e8f3c78dc66</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1016478108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1016478108%26sid%3Dliteratum%253Aachs%26aulast%3DDoppalapudi%26aufirst%3DV.%2BR.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DJin%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DDesharnais%26aufirst%3DJ.%26aulast%3DHagen%26aufirst%3DC.%26aulast%3DLevin%26aufirst%3DN.%2BJ.%26aulast%3DShields%26aufirst%3DM.%2BJ.%26aulast%3DParish%26aufirst%3DM.%26aulast%3DMurphy%26aufirst%3DR.%2BE.%26aulast%3DDel%2BRosario%26aufirst%3DJ.%26aulast%3DOates%26aufirst%3DB.%2BD.%26aulast%3DLai%26aufirst%3DJ.-Y.%26aulast%3DMatin%26aufirst%3DM.%2BJ.%26aulast%3DAinekulu%26aufirst%3DZ.%26aulast%3DBhat%26aufirst%3DA.%26aulast%3DBradshaw%26aufirst%3DC.%2BW.%26aulast%3DWoodnutt%26aufirst%3DG.%26aulast%3DLerner%26aufirst%3DR.%2BA.%26aulast%3DLappe%26aufirst%3DR.%2BW.%26atitle%3DChemical%2520generation%2520of%2520bispecific%2520antibodies%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D22611%26epage%3D22616%26doi%3D10.1073%2Fpnas.1016478108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span>Clinical information can be found at: NCT01004822: A Safety, Tolerability, And Pharmacokinetic Trial with CVX-241 in Patients with Advanced Solid Tumors; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="https://www.clinicaltrials.gov/" class="extLink">https://www.clinicaltrials.gov/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical+information+can+be+found+at%3A+NCT01004822%3A+A+Safety%2C+Tolerability%2C+And+Pharmacokinetic+Trial+with+CVX-241+in+Patients+with+Advanced+Solid+Tumors%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2015%3B+https%3A%2F%2Fwww.clinicaltrials.gov%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DNCT01004822%253A%2520A%2520Safety%252C%2520Tolerability%252C%2520And%2520Pharmacokinetic%2520Trial%2520with%2520CVX-241%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group">Jimenez-Solem, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knop, F. K.</span><span> </span><span class="NLM_article-title">Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes</span> <span class="citation_source-journal">Curr. Opin. Mol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">790</span><span class="NLM_x">â</span> <span class="NLM_lpage">797</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21154170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvVeksrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=790-797&author=E.+Jimenez-Solemauthor=M.+H.+Rasmussenauthor=M.+Christensenauthor=F.+K.+Knop&title=Dulaglutide%2C+a+long-acting+GLP-1+analog+fused+with+an+Fc+antibody+fragment+for+the+potential+treatment+of+type+2+diabetes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes</span></div><div class="casAuthors">Jimenez-Solem, Espen; Rasmussen, Mette H.; Christensen, Mikkel; Knop, Filip K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Molecular Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">790-797</span>CODEN:
                <span class="NLM_cas:coden">CUOTFO</span>;
        ISSN:<span class="NLM_cas:issn">2040-3445</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Dulaglutide (LY-2189265) is a novel, long-acting glucagon-like peptide 1 (GLP-1) analog being developed by Eli Lilly for the treatment of type 2 diabetes mellitus (T2DM).  Dulaglutide consists of GLP-l(7-37) covalently linked to an Fc fragment of human IgG4, thereby protecting the GLP-1 molety from inactivation by dipeptidyl peptidase 4.  In vitro and in vivo studies on T2DM models demonstrated glucose-dependent insulin secretion stimulation.  Pharmacokinetic studies demonstrated a t1/2 in humans of up to 90 h, making Dulaglutide an ideal candidate for once-weekly dosing.  Clin. trials suggest that Dulaglutide reduces plasma glucose, and has an insulinotropic effect increasing insulin and C-peptide levels.  Two phase II clin. trials demonstrated a dose-dependent redn. in glycated Hb (HbA1c) of up to 1.52% compared with placebo.  Side effects assocd. with Dulaglutide administration were mainly gastrointestinal.  To date, there have been no reports on the formation of antibodies against Dulaglutide, but, clearly, long-term data will be needed to asses this and other possible side effects.  The results of several phase III clin. trials are awaited for clarification of the expected effects on HbA1c and body wt.  If Dulaglutide possesses similar efficacy to other GLP-1 analogs, the once-weekly treatment will most likely be welcomed by patients with T2DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjpD7tpjLtmLVg90H21EOLACvtfcHk0ljs8AKm5nzKyQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvVeksrs%253D&md5=977fe1f57be3b777d64b2652c4e4b390</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJimenez-Solem%26aufirst%3DE.%26aulast%3DRasmussen%26aufirst%3DM.%2BH.%26aulast%3DChristensen%26aufirst%3DM.%26aulast%3DKnop%26aufirst%3DF.%2BK.%26atitle%3DDulaglutide%252C%2520a%2520long-acting%2520GLP-1%2520analog%2520fused%2520with%2520an%2520Fc%2520antibody%2520fragment%2520for%2520the%2520potential%2520treatment%2520of%2520type%25202%2520diabetes%26jtitle%3DCurr.%2520Opin.%2520Mol.%2520Ther.%26date%3D2010%26volume%3D12%26spage%3D790%26epage%3D797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group">Sleep, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, L. R.</span><span> </span><span class="NLM_article-title">Albumin as a versatile platform for drug half-life extension</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Gen. Subj.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1830</span><span class="NLM_x">, </span> <span class="NLM_fpage">5526</span><span class="NLM_x">â</span> <span class="NLM_lpage">5534</span><span class="refDoi">Â DOI: 10.1016/j.bbagen.2013.04.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.bbagen.2013.04.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23639804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXot1Cjsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1830&publication_year=2013&pages=5526-5534&author=D.+Sleepauthor=J.+Cameronauthor=L.+R.+Evans&title=Albumin+as+a+versatile+platform+for+drug+half-life+extension&doi=10.1016%2Fj.bbagen.2013.04.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Albumin as a versatile platform for drug half-life extension</span></div><div class="casAuthors">Sleep, Darrell; Cameron, Jason; Evans, Leslie R.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1830</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5526-5534</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Albumin is the most abundant plasma protein, is highly sol., very stable and has an extraordinarily long circulatory half-life as a direct result of its size and interaction with the FcRn mediated recycling pathway.  In contrast, many therapeutic mols. are smaller than the renal filtration threshold and are rapidly lost from the circulation thereby limiting their therapeutic potential.  Albumin can be used in a variety of ways to increase the circulatory half-life of such mols.  This article will review the mechanisms which underpin albumin's extraordinarily long circulatory half-life and how the understanding of these processes are currently being employed to extend the circulatory half-life of drugs which can be engineered to bind to albumin, or are conjugated to, or genetically fused to, albumin.  The recent and growing understanding of the pivotal role of FcRn in maintaining the extended circulatory half-life of albumin will necessitate a greater and more thorough investigation of suitable pre-clin. model systems for assessing the pharmacokinetic profiles of drugs assocd., conjugated or fused to albumin.  Assocn., conjugation or fusion of therapeutic drugs to albumin is a well-accepted and established half-life extension technol.  The manipulation of the albumin-FcRn interaction will facilitate the modulation of the circulatory half-life of albumin-enabled drugs, leading to superior pharmacokinetics tailored to the disease state and increased patient compliance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpExYMlo75ySLVg90H21EOLACvtfcHk0ljs8AKm5nzKyQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXot1Cjsr4%253D&md5=0e4c382f353eef14774c423dcb3d1963</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2013.04.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2013.04.023%26sid%3Dliteratum%253Aachs%26aulast%3DSleep%26aufirst%3DD.%26aulast%3DCameron%26aufirst%3DJ.%26aulast%3DEvans%26aufirst%3DL.%2BR.%26atitle%3DAlbumin%2520as%2520a%2520versatile%2520platform%2520for%2520drug%2520half-life%2520extension%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2013%26volume%3D1830%26spage%3D5526%26epage%3D5534%26doi%3D10.1016%2Fj.bbagen.2013.04.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group">Matthews, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Boever, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobbins, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodge, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holland, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, M. A.</span><span> </span><span class="NLM_article-title">Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">4810</span><span class="NLM_x">â</span> <span class="NLM_lpage">4817</span><span class="refDoi">Â DOI: 10.1210/jc.2008-1518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1210%2Fjc.2008-1518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=18812476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVyqtbvL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2008&pages=4810-4817&author=J.+E.+Matthewsauthor=M.+W.+Stewartauthor=E.+H.+De+Boeverauthor=R.+L.+Dobbinsauthor=R.+J.+Hodgeauthor=S.+E.+Walkerauthor=M.+C.+Hollandauthor=M.+A.+Bush&title=Pharmacodynamics%2C+pharmacokinetics%2C+safety%2C+and+tolerability+of+albiglutide%2C+a+long-acting+glucagon-like+peptide-1+mimetic%2C+in+patients+with+type+2+diabetes&doi=10.1210%2Fjc.2008-1518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes</span></div><div class="casAuthors">Matthews, Jessica E.; Stewart, Murray W.; De Boever, Erika H.; Dobbins, Robert L.; Hodge, Rebecca J.; Walker, Susan E.; Holland, M. Claire; Bush, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4810-4817</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Native glucagon-like peptide-1 increases insulin secretion, decreases glucagon secretion, and reduces appetite but is rapidly inactivated by dipeptidyl peptidase-4.  Albiglutide is a novel dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin designed to have sustained efficacy in vivo.  The objectives were to investigate pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide in type 2 diabetes subjects.  In a single-blind dose-escalation study, 54 subjects were randomized to receive placebo or 9-, 16-, or 32-mg albiglutide on days 1 and 8.  In a complementary study, 46 subjects were randomized to a single dose (16 or 64 mg) of albiglutide to the arm, leg, or abdomen.  Significant dose-dependent redns. in 24-h mean weighted glucose [area under the curve(0-24 h)] were obsd., with placebo-adjusted least squares means difference values in the 32-mg cohort of -34.8 and -56.4 mg/dL [95% confidence interval (-54.1, -15.5) and (-82.2, -30.5)] for d 2 and 9, resp.  Placebo-adjusted fasting plasma glucose decreased by -26.7 and -50.7 mg/dL [95% confidence interval (-46.3, -7.06) and (-75.4, -26.0)] on d 2 and 9, resp.  Postprandial glucose was also reduced.  No hypoglycemic episodes were detected in the albiglutide cohorts.  The frequency and severity of the most common adverse events, headache and nausea, were comparable with placebo controls.  Albiglutide half-life ranged between 6 and 7 days.  The pharmacokinetics or pharmacodynamic of albiglutide was unaffected by injection site.  Albiglutide improved fasting plasma glucose and postprandial glucose with a favorable safety profile in subjects with type 2 diabetes.  Albiglutide's long half-life may allow for once-weekly or less frequent dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIft4D7voTHbVg90H21EOLACvtfcHk0lh01CTwvHAJEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVyqtbvL&md5=cd4b4f2ce8c2684a2a37f0c841b80c00</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1210%2Fjc.2008-1518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2008-1518%26sid%3Dliteratum%253Aachs%26aulast%3DMatthews%26aufirst%3DJ.%2BE.%26aulast%3DStewart%26aufirst%3DM.%2BW.%26aulast%3DDe%2BBoever%26aufirst%3DE.%2BH.%26aulast%3DDobbins%26aufirst%3DR.%2BL.%26aulast%3DHodge%26aufirst%3DR.%2BJ.%26aulast%3DWalker%26aufirst%3DS.%2BE.%26aulast%3DHolland%26aufirst%3DM.%2BC.%26aulast%3DBush%26aufirst%3DM.%2BA.%26atitle%3DPharmacodynamics%252C%2520pharmacokinetics%252C%2520safety%252C%2520and%2520tolerability%2520of%2520albiglutide%252C%2520a%2520long-acting%2520glucagon-like%2520peptide-1%2520mimetic%252C%2520in%2520patients%2520with%2520type%25202%2520diabetes%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2008%26volume%3D93%26spage%3D4810%26epage%3D4817%26doi%3D10.1210%2Fjc.2008-1518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group">LÃ©ger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibaudeau, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robitaille, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quraishi, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Wyk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bousquet-Gagnon, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carette, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castaigne, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridon, D. P.</span><span> </span><span class="NLM_article-title">Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7â36) analog</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">4395</span><span class="NLM_x">â</span> <span class="NLM_lpage">4398</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2004.06.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.bmcl.2004.06.066" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=4395-4398&author=R.+L%C3%A9gerauthor=K.+Thibaudeauauthor=M.+Robitailleauthor=O.+Quraishiauthor=P.+van+Wykauthor=N.+Bousquet-Gagnonauthor=J.+Caretteauthor=J.-P.+Castaigneauthor=D.+P.+Bridon&title=Identification+of+CJC-1131-albumin+bioconjugate+as+a+stable+and+bioactive+GLP-1%287%E2%80%9336%29+analog&doi=10.1016%2Fj.bmcl.2004.06.066"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.06.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.06.066%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25A9ger%26aufirst%3DR.%26aulast%3DThibaudeau%26aufirst%3DK.%26aulast%3DRobitaille%26aufirst%3DM.%26aulast%3DQuraishi%26aufirst%3DO.%26aulast%3Dvan%2BWyk%26aufirst%3DP.%26aulast%3DBousquet-Gagnon%26aufirst%3DN.%26aulast%3DCarette%26aufirst%3DJ.%26aulast%3DCastaigne%26aufirst%3DJ.-P.%26aulast%3DBridon%26aufirst%3DD.%2BP.%26atitle%3DIdentification%2520of%2520CJC-1131-albumin%2520bioconjugate%2520as%2520a%2520stable%2520and%2520bioactive%2520GLP-1%25287%25E2%2580%259336%2529%2520analog%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D4395%26epage%3D4398%26doi%3D10.1016%2Fj.bmcl.2004.06.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group">Lau, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">SchÃ¤ffer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettersson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spetzler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kofoed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madsen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudsen, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGuire, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steensgaard, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strauss, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gram, D. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudsen, S. M. l.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thygesen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reedtz-Runge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruse, T.</span><span> </span><span class="NLM_article-title">Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">7370</span><span class="NLM_x">â</span> <span class="NLM_lpage">7380</span><span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00726</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00726" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtl2qu7%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7370-7380&author=J.+Lauauthor=P.+Blochauthor=L.+Sch%C3%A4fferauthor=I.+Petterssonauthor=J.+Spetzlerauthor=J.+Kofoedauthor=K.+Madsenauthor=L.+B.+Knudsenauthor=J.+McGuireauthor=D.+B.+Steensgaardauthor=H.+M.+Straussauthor=D.+X.+Gramauthor=S.+M.+l.+Knudsenauthor=F.+S.+Nielsenauthor=P.+Thygesenauthor=S.+Reedtz-Rungeauthor=T.+Kruse&title=Discovery+of+the+once-weekly+glucagon-like+peptide-1+%28GLP-1%29+analogue+semaglutide&doi=10.1021%2Facs.jmedchem.5b00726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide</span></div><div class="casAuthors">Lau, Jesper; Bloch, Paw; Schaffer, Lauge; Pettersson, Ingrid; Spetzler, Jane; Kofoed, Jacob; Madsen, Kjeld; Knudsen, Lotte Bjerre; McGuire, James; Steensgaard, Dorte Bjerre; Strauss, Holger Martin; Gram, Dorte X.; Knudsen, Sanne Moeller; Nielsen, Flemming Seier; Thygesen, Peter; Reedtz-Runge, Steffen; Kruse, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7370-7380</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analog that binds to serum albumin in vivo and is approved for once-daily treatment of diabetes as well as obesity.  The aim of the present studies was to design a once weekly GLP-1 analog by increasing albumin affinity and secure full stability against metabolic degrdn.  The fatty acid moiety and the linking chem. to GLP-1 were the key features to secure high albumin affinity and GLP-1 receptor (GLP-1R) potency and in obtaining a prolonged exposure and action of the GLP-1 analog.  Semaglutide was selected as the optimal once weekly candidate.  Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib8, Arg34) and is derivatized at lysine 26.  The GLP-1R affinity of semaglutide (0.38 Â± 0.06 nM) was three-fold decreased compared to liraglutide, whereas the albumin affinity was increased.  The plasma half-life was 46.1 h in mini-pigs following i.v. administration, and semaglutide has an MRT of 63.6 h after s.c. dosing to mini-pigs.  Semaglutide is currently in phase 3 clin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8tFc0FzEro7Vg90H21EOLACvtfcHk0lh01CTwvHAJEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtl2qu7%252FM&md5=0478fe17f9f4dcc0cb58919b1c55869a</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00726%26sid%3Dliteratum%253Aachs%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DBloch%26aufirst%3DP.%26aulast%3DSch%25C3%25A4ffer%26aufirst%3DL.%26aulast%3DPettersson%26aufirst%3DI.%26aulast%3DSpetzler%26aufirst%3DJ.%26aulast%3DKofoed%26aufirst%3DJ.%26aulast%3DMadsen%26aufirst%3DK.%26aulast%3DKnudsen%26aufirst%3DL.%2BB.%26aulast%3DMcGuire%26aufirst%3DJ.%26aulast%3DSteensgaard%26aufirst%3DD.%2BB.%26aulast%3DStrauss%26aufirst%3DH.%2BM.%26aulast%3DGram%26aufirst%3DD.%2BX.%26aulast%3DKnudsen%26aufirst%3DS.%2BM.%2Bl.%26aulast%3DNielsen%26aufirst%3DF.%2BS.%26aulast%3DThygesen%26aufirst%3DP.%26aulast%3DReedtz-Runge%26aufirst%3DS.%26aulast%3DKruse%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520the%2520once-weekly%2520glucagon-like%2520peptide-1%2520%2528GLP-1%2529%2520analogue%2520semaglutide%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7370%26epage%3D7380%26doi%3D10.1021%2Facs.jmedchem.5b00726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group">OâConnor-Semmes, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodge, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chism, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choudhury, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nunez, D. J.</span><span> </span><span class="NLM_article-title">GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humansâPK/PD and safety</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">704</span><span class="NLM_x">â</span> <span class="NLM_lpage">712</span><span class="refDoi">Â DOI: 10.1038/clpt.2014.187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fclpt.2014.187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25238251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslyksrrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2014&pages=704-712&author=R.+L.+O%E2%80%99Connor-Semmesauthor=J.+Linauthor=R.+J.+Hodgeauthor=S.+Andrewsauthor=J.+Chismauthor=A.+Choudhuryauthor=D.+J.+Nunez&title=GSK2374697%2C+a+novel+albumin-binding+domain+antibody+%28AlbudAb%29%2C+extends+systemic+exposure+of+exendin-4%3A+first+study+in+humans%E2%80%94PK%2FPD+and+safety&doi=10.1038%2Fclpt.2014.187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">GSK2374697, a Novel Albumin-Binding Domain Antibody (AlbudAb), Extends Systemic Exposure of Exendin-4: First Study in Humans-PK/PD and Safety</span></div><div class="casAuthors">O'Connor-Semmes, R. L.; Lin, J.; Hodge, R. J.; Andrews, S.; Chism, J.; Choudhury, A.; Nunez, D. J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">704-712</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">GSK2374697 is a genetically engineered fusion protein of a human domain antibody to exendin-4.  This mol. binds with a high affinity to human serum albumin, creating a long-duration glucagon-like peptide-1 (GLP-1) receptor agonist.  This study is the first evaluation of the albumin-binding domain antibody (AlbudAb) drug delivery platform in humans.  The aim of this randomized clin. study was to det. the pharmacokinetics, pharmacodynamics, safety, and tolerability of GSK2374697.  The pharmacokinetic profile was prolonged, with estd. half-lives ranging from 6 to 10 days.  Postprandial glucose and insulin were reduced, and gastric emptying was delayed in healthy subjects, confirming anticipated GLP-1 receptor agonist pharmacol.  The safety and tolerability were as expected for a potent GLP-1 agonist.  Gradual titrn. of doses greatly improved tolerability.  Rapid tolerance to nausea was obsd.  Study results support further investigation in type 2 diabetes and for wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO3tyn0fpBOrVg90H21EOLACvtfcHk0liehRKlzYU7eQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslyksrrM&md5=75d6eaeb2b3300bf9471ba1237d22dd5</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2014.187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2014.187%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Connor-Semmes%26aufirst%3DR.%2BL.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DHodge%26aufirst%3DR.%2BJ.%26aulast%3DAndrews%26aufirst%3DS.%26aulast%3DChism%26aufirst%3DJ.%26aulast%3DChoudhury%26aufirst%3DA.%26aulast%3DNunez%26aufirst%3DD.%2BJ.%26atitle%3DGSK2374697%252C%2520a%2520novel%2520albumin-binding%2520domain%2520antibody%2520%2528AlbudAb%2529%252C%2520extends%2520systemic%2520exposure%2520of%2520exendin-4%253A%2520first%2520study%2520in%2520humans%25E2%2580%2594PK%252FPD%2520and%2520safety%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2014%26volume%3D96%26spage%3D704%26epage%3D712%26doi%3D10.1038%2Fclpt.2014.187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group">JevÅ¡evar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunstelj, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porekar, V. G.</span><span> </span><span class="NLM_article-title">PEGylation of therapeutic proteins</span> <span class="citation_source-journal">Biotechnol. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">â</span> <span class="NLM_lpage">128</span><span class="refDoi">Â DOI: 10.1002/biot.200900218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fbiot.200900218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=20069580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntVSlsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=113-128&author=S.+Jev%C5%A1evarauthor=M.+Kunsteljauthor=V.+G.+Porekar&title=PEGylation+of+therapeutic+proteins&doi=10.1002%2Fbiot.200900218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">PEGylation of therapeutic proteins</span></div><div class="casAuthors">Jevsevar, Simona; Kunstelj, Menci; Porekar, Vladka Gaberc</div><div class="citationInfo"><span class="NLM_cas:title">Biotechnology Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-128</span>CODEN:
                <span class="NLM_cas:coden">BJIOAM</span>;
        ISSN:<span class="NLM_cas:issn">1860-6768</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Since the first PEGylated product was approved by the Food and Drug Administration in 1990, PEGylation has been widely used as a post-prodn. modification methodol. for improving biomedical efficacy and physicochem. properties of therapeutic proteins.  Applicability and safety of this technol. have been proven by use of various PEGylated pharmaceuticals for many years.  It is expected that PEGylation, as the most established technol. for extension of drug residence in the body, will play an important role in the next generation therapeutics, such as peptides, protein nanobodies and scaffolds, which due to their diminished mol. size need half-life extension.  This review focuses on several factors important in the prodn. of PEGylated biopharmaceuticals enabling efficient prepn. of highly purified PEG-protein conjugates that have to meet stringent regulatory criteria for their use in human therapy.  Areas addressed are PEG properties, the specificity of PEGylation reactions, sepn. and large-scale purifn., the availability and anal. of PEG reagents, anal. of PEG-protein conjugates, the consistency of products and processes and approaches used for rapid screening of pharmacokinetic properties of PEG-protein conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqjWpYHBYTybVg90H21EOLACvtfcHk0liehRKlzYU7eQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntVSlsw%253D%253D&md5=ad29019bc10b1d52ef883f9f6f3f27ce</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1002%2Fbiot.200900218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbiot.200900218%26sid%3Dliteratum%253Aachs%26aulast%3DJev%25C5%25A1evar%26aufirst%3DS.%26aulast%3DKunstelj%26aufirst%3DM.%26aulast%3DPorekar%26aufirst%3DV.%2BG.%26atitle%3DPEGylation%2520of%2520therapeutic%2520proteins%26jtitle%3DBiotechnol.%2520J.%26date%3D2010%26volume%3D5%26spage%3D113%26epage%3D128%26doi%3D10.1002%2Fbiot.200900218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group">Zhang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, H. T.</span><span> </span><span class="NLM_article-title">Discussion about several potential drawbacks of PEGylated therapeutic proteins</span> <span class="citation_source-journal">Biol. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">â</span> <span class="NLM_lpage">339</span><span class="refDoi">Â DOI: 10.1248/bpb.b13-00661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1248%2Fbpb.b13-00661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24334536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvFWlt7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2014&pages=335-339&author=F.+Zhangauthor=M.+R.+Liuauthor=H.+T.+Wan&title=Discussion+about+several+potential+drawbacks+of+PEGylated+therapeutic+proteins&doi=10.1248%2Fbpb.b13-00661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Discussion about several potential drawbacks of PEGylated therapeutic proteins</span></div><div class="casAuthors">Zhang, Fan; Liu, Mu-rong; Wan, Hai-tong</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">335-339</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">PEGylation changes the phys. and chem. properties of the biomedical mol., such as its conformation, electrostatic binding, and hydrophobicity, and results in an improvement in the pharmacokinetic behavior of the drug, while it also causes some disadvantages of which cannot be neglected.  The available data manifests that polyethylene glycol (PEG) itself shows potential risk, such as immunogenicity of the PEG and PEG-contg. vacuoles in cells obsd. with PEGylated biologicals.  Decreased activity and heterogeneity are also the neg. aspects of PEGylation.  The unfavorable impacts which are brought by the PEGylation are described here with examples of modified therapeutic proteins on the market and used in the clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwCEhui0h1OLVg90H21EOLACvtfcHk0liehRKlzYU7eQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvFWlt7Y%253D&md5=f8a29481f3d15e0376cec99913f1303d</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1248%2Fbpb.b13-00661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.b13-00661%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DM.%2BR.%26aulast%3DWan%26aufirst%3DH.%2BT.%26atitle%3DDiscussion%2520about%2520several%2520potential%2520drawbacks%2520of%2520PEGylated%2520therapeutic%2520proteins%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2014%26volume%3D37%26spage%3D335%26epage%3D339%26doi%3D10.1248%2Fbpb.b13-00661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group">Schellenberger, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.-w.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geething, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spink, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">To, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholle, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogin, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cleland, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stemmer, W. P. C.</span><span> </span><span class="NLM_article-title">A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1186</span><span class="NLM_x">â</span> <span class="NLM_lpage">1190</span><span class="refDoi">Â DOI: 10.1038/nbt.1588</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnbt.1588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=19915550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVWlsb%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=1186-1190&author=V.+Schellenbergerauthor=C.-w.+Wangauthor=N.+C.+Geethingauthor=B.+J.+Spinkauthor=A.+Campbellauthor=W.+Toauthor=M.+D.+Scholleauthor=Y.+Yinauthor=Y.+Yaoauthor=O.+Boginauthor=J.+L.+Clelandauthor=J.+Silvermanauthor=W.+P.+C.+Stemmer&title=A+recombinant+polypeptide+extends+the+in+vivo+half-life+of+peptides+and+proteins+in+a+tunable+manner&doi=10.1038%2Fnbt.1588"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner</span></div><div class="casAuthors">Schellenberger, Volker; Wang, Chia-wei; Geething, Nathan C.; Spink, Benjamin J.; Campbell, Andrew; To, Wayne; Scholle, Michael D.; Yin, Yong; Yao, Yi; Bogin, Oren; Cleland, Jeffrey L.; Silverman, Joshua; Stemmer, Willem P. C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1186-1190</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Increasing the in vivo residence times of protein therapeutics could decrease their dosing frequencies.  We show that genetic fusion of an unstructured recombinant polypeptide of 864 amino acids, called XTEN, to a peptide or protein provides an apparently generic approach to extend plasma half-life.  Allometric scaling suggests that a fusion of XTEN to the exenatide peptide should increase exenatide half-life in humans from 2.4 h to a projected time of 139 h.  We confirmed the biol. activity of the exenatide-XTEN fusion in mice.  As extended stability might exacerbate undesirable side effects in some cases, we show that truncating the XTEN sequence can regulate plasma half-life.  XTEN lacks hydrophobic amino acid residues that often contribute to immunogenicity and complicate manuf.  Based on data on XTEN fusions to exenatide, glucagon, GFP and human growth hormone, we expect that XTEN will enable dosing of otherwise rapidly cleared protein drugs at up to monthly intervals in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXVU4baF3_cbVg90H21EOLACvtfcHk0liehRKlzYU7eQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVWlsb%252FK&md5=0472b2fd76a277f3021c85f864da7803</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1588%26sid%3Dliteratum%253Aachs%26aulast%3DSchellenberger%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DC.-w.%26aulast%3DGeething%26aufirst%3DN.%2BC.%26aulast%3DSpink%26aufirst%3DB.%2BJ.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DTo%26aufirst%3DW.%26aulast%3DScholle%26aufirst%3DM.%2BD.%26aulast%3DYin%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DBogin%26aufirst%3DO.%26aulast%3DCleland%26aufirst%3DJ.%2BL.%26aulast%3DSilverman%26aufirst%3DJ.%26aulast%3DStemmer%26aufirst%3DW.%2BP.%2BC.%26atitle%3DA%2520recombinant%2520polypeptide%2520extends%2520the%2520in%2520vivo%2520half-life%2520of%2520peptides%2520and%2520proteins%2520in%2520a%2520tunable%2520manner%26jtitle%3DNat.%2520Biotechnol.%26date%3D2009%26volume%3D27%26spage%3D1186%26epage%3D1190%26doi%3D10.1038%2Fnbt.1588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group">Strohl, W. R.</span><span> </span><span class="NLM_article-title">Fusion proteins for half-life extension of biologics as a strategy to make biobetters</span> <span class="citation_source-journal">BioDrugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">215</span><span class="NLM_x">â</span> <span class="NLM_lpage">239</span><span class="refDoi">Â DOI: 10.1007/s40259-015-0133-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1007%2Fs40259-015-0133-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26177629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1WrtLjN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=215-239&author=W.+R.+Strohl&title=Fusion+proteins+for+half-life+extension+of+biologics+as+a+strategy+to+make+biobetters&doi=10.1007%2Fs40259-015-0133-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters</span></div><div class="casAuthors">Strohl, William R.</div><div class="citationInfo"><span class="NLM_cas:title">BioDrugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">215-239</span>CODEN:
                <span class="NLM_cas:coden">BIDRF4</span>;
        ISSN:<span class="NLM_cas:issn">1173-8804</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">The purpose of making a "biobetter" biol. is to improve on the salient characteristics of a known biol. for which there is, minimally, clin. proof of concept or, maximally, marketed product data.  There already are several examples in which second-generation or biobetter biologics have been generated by improving the pharmacokinetic properties of an innovative drug, including Neulasta [a PEGylated, longer-half-life version of Neupogen (filgrastim)] and Aranesp [a longer-half-life version of Epogen (epoetin-Î±)].  This review describes the use of protein fusion technologies such as Fc fusion proteins, fusion to human serum albumin, fusion to carboxy-terminal peptide, and other polypeptide fusion approaches to make biobetter drugs with more desirable pharmacokinetic profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqorgYj1NyuaLVg90H21EOLACvtfcHk0lgtYue-PbH39A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1WrtLjN&md5=328f936b91e29c83e069db83a4d05cab</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1007%2Fs40259-015-0133-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40259-015-0133-6%26sid%3Dliteratum%253Aachs%26aulast%3DStrohl%26aufirst%3DW.%2BR.%26atitle%3DFusion%2520proteins%2520for%2520half-life%2520extension%2520of%2520biologics%2520as%2520a%2520strategy%2520to%2520make%2520biobetters%26jtitle%3DBioDrugs%26date%3D2015%26volume%3D29%26spage%3D215%26epage%3D239%26doi%3D10.1007%2Fs40259-015-0133-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group">Schlapschy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binder, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">BÃ¶rger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theobald, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wachinger, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kisling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haller, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skerra, A.</span><span> </span><span class="NLM_article-title">PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins</span> <span class="citation_source-journal">Protein Eng., Des. Sel.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">489</span><span class="NLM_x">â</span> <span class="NLM_lpage">501</span><span class="refDoi">Â DOI: 10.1093/protein/gzt023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1093%2Fprotein%2Fgzt023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23754528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSrurzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2013&pages=489-501&author=M.+Schlapschyauthor=U.+Binderauthor=C.+B%C3%B6rgerauthor=I.+Theobaldauthor=K.+Wachingerauthor=S.+Kislingauthor=D.+Hallerauthor=A.+Skerra&title=PASylation%3A+a+biological+alternative+to+PEGylation+for+extending+the+plasma+half-life+of+pharmaceutically+active+proteins&doi=10.1093%2Fprotein%2Fgzt023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins</span></div><div class="casAuthors">Schlapschy, Martin; Binder, Uli; Boerger, Claudia; Theobald, Ina; Wachinger, Klaus; Kisling, Sigrid; Haller, Dirk; Skerra, Arne</div><div class="citationInfo"><span class="NLM_cas:title">Protein Engineering, Design & Selection</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">489-501</span>CODEN:
                <span class="NLM_cas:coden">PEDSBR</span>;
        ISSN:<span class="NLM_cas:issn">1741-0126</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A major limitation of biopharmaceutical proteins is their fast clearance from circulation via kidney filtration, which strongly hampers efficacy both in animal studies and in human therapy.  We have developed conformationally disordered polypeptide chains with expanded hydrodynamic vol. comprising the small residues Pro, Ala and Ser (PAS).  PAS sequences are hydrophilic, uncharged biol. polymers with biophys. properties very similar to poly-ethylene glycol (PEG), whose chem. conjugation to drugs is an established method for plasma half-life extension.  In contrast, PAS polypeptides offer fusion to a therapeutic protein on the genetic level, permitting Escherichia coli prodn. of fully active proteins and obviating in vitro coupling or modification steps.  Furthermore, they are biodegradable, thus avoiding organ accumulation, while showing stability in serum and lacking toxicity or immunogenicity in mice.  We demonstrate that PASylation bestows typical biologics, such as interferon, growth hormone or Fab fragments, with considerably prolonged circulation and boosts bioactivity in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp794OCS5JQ9bVg90H21EOLACvtfcHk0lgtYue-PbH39A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSrurzL&md5=745f6a35c9668e9e82c13215708fccf3</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1093%2Fprotein%2Fgzt023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fprotein%252Fgzt023%26sid%3Dliteratum%253Aachs%26aulast%3DSchlapschy%26aufirst%3DM.%26aulast%3DBinder%26aufirst%3DU.%26aulast%3DB%25C3%25B6rger%26aufirst%3DC.%26aulast%3DTheobald%26aufirst%3DI.%26aulast%3DWachinger%26aufirst%3DK.%26aulast%3DKisling%26aufirst%3DS.%26aulast%3DHaller%26aufirst%3DD.%26aulast%3DSkerra%26aufirst%3DA.%26atitle%3DPASylation%253A%2520a%2520biological%2520alternative%2520to%2520PEGylation%2520for%2520extending%2520the%2520plasma%2520half-life%2520of%2520pharmaceutically%2520active%2520proteins%26jtitle%3DProtein%2520Eng.%252C%2520Des.%2520Sel.%26date%3D2013%26volume%3D26%26spage%3D489%26epage%3D501%26doi%3D10.1093%2Fprotein%2Fgzt023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group">Bajo, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schally, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagy, A.</span><span> </span><span class="NLM_article-title">Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers</span> <span class="citation_source-journal">Clin. Cancer. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">3742</span><span class="NLM_x">â</span> <span class="NLM_lpage">3748</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=14506166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosVOksrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=3742-3748&author=A.+M.+Bajoauthor=A.+V.+Schallyauthor=G.+Halmosauthor=A.+Nagy&title=Targeted+doxorubicin-containing+luteinizing+hormone-releasing+hormone+analogue+AN-152+inhibits+the+growth+of+doxorubicin-resistant+MX-1+human+breast+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers</span></div><div class="casAuthors">Bajo, Ana M.; Schally, Andrew V.; Halmos, Gabor; Nagy, Attila</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10, Pt. 1</span>),
    <span class="NLM_cas:pages">3742-3748</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The receptors for LH-releasing hormone receptor (LHRH-R) are found in >50% of human breast cancers.  Doxorubicin (DOX) was linked to [D-Lys6]LHRH to form a cytotoxic conjugate, AN-152, which can be targeted to tumor cells expressing LHRH-R.  We evaluated the effects of AN-152 on the estrogen-independent, DOX-resistant human mammary carcinoma line MX-1, xenografted into nude mice.  Nude mice bearing MX-1 tumors were administered five i.v. injections of AN-152 or DOX at doses equiv. to 3 mg/kg DOX.  Tumor growth was followed, and changes in the expression of LHRH-R on tumors were evaluated by radioreceptor assays, reverse transcription-PCR, and Western blotting.  The effects of AN-152 on the expression of human epidermal growth factor receptor (HER)-2 were investigated.  Because LHRH-R are coupled to various G proteins, which are involved in mitogenic signaling, we detd. the outcome of treatment with AN-152 on the levels of mRNA for different G proteins.  Treatment with AN-152 significantly (P < 0.05) decreased the final tumor vol. to 978.56 Â± 176.85 mm3, compared with the control tumors, which measured 2837.38 Â± 515.38 mm3.  Tumor doubling time was likewise significantly (P < 0.05) extended by AN-152 to 12.01 Â± 1.99 days from 6.45 Â± 0.36 days for the controls.  Therapy with AN-152, but not with DOX, resulted in a significant decrease of LHRH-R levels on MX-1 tumors.  The expression of mRNAs for HER-2, HER-3, GÎ±i2, and GÎ±11 and the levels of HER-2 and HER-3 proteins were also significantly reduced by AN-152.  Cytotoxic LHRH analog AN-152 could be considered for targeted chemotherapy of DOX-resistant breast cancers expressing LHRH-R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDBP7LawW7YLVg90H21EOLACvtfcHk0lgtYue-PbH39A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosVOksrY%253D&md5=31009f06da4f75e900b45ab18de586ad</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBajo%26aufirst%3DA.%2BM.%26aulast%3DSchally%26aufirst%3DA.%2BV.%26aulast%3DHalmos%26aufirst%3DG.%26aulast%3DNagy%26aufirst%3DA.%26atitle%3DTargeted%2520doxorubicin-containing%2520luteinizing%2520hormone-releasing%2520hormone%2520analogue%2520AN-152%2520inhibits%2520the%2520growth%2520of%2520doxorubicin-resistant%2520MX-1%2520human%2520breast%2520cancers%26jtitle%3DClin.%2520Cancer.%2520Res.%26date%3D2003%26volume%3D9%26spage%3D3742%26epage%3D3748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span>Clinical information can be found at: NCT01767155: Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer (ZoptEC); <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="https://www.clinicaltrials.gov/" class="extLink">https://www.clinicaltrials.gov/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical+information+can+be+found+at%3A+NCT01767155%3A+Zoptarelin+Doxorubicin+%28AEZS+108%29+as+Second+Line+Therapy+for+Endometrial+Cancer+%28ZoptEC%29%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2015%3B+https%3A%2F%2Fwww.clinicaltrials.gov%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DNCT01767155%253A%2520Zoptarelin%2520Doxorubicin%2520%2528AEZS%2520108%2529%2520as%2520Second%2520Line%2520Therapy%2520for%2520Endometrial%2520Cancer%2520%2528ZoptEC%2529%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Engel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emons, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schally, A. V.</span><span> </span><span class="NLM_article-title">AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">891</span><span class="NLM_x">â</span> <span class="NLM_lpage">899</span><span class="refDoi">Â DOI: 10.1517/13543784.2012.685128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1517%2F13543784.2012.685128" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=891-899&author=J.+Engelauthor=G.+Emonsauthor=J.+Pinskiauthor=A.+V.+Schally&title=AEZS-108%3A+a+targeted+cytotoxic+analog+of+LHRH+for+the+treatment+of+cancers+positive+for+LHRH+receptors&doi=10.1517%2F13543784.2012.685128"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170a&amp;dbid=16384&amp;doi=10.1517%2F13543784.2012.685128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2012.685128%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DEmons%26aufirst%3DG.%26aulast%3DPinski%26aufirst%3DJ.%26aulast%3DSchally%26aufirst%3DA.%2BV.%26atitle%3DAEZS-108%253A%2520a%2520targeted%2520cytotoxic%2520analog%2520of%2520LHRH%2520for%2520the%2520treatment%2520of%2520cancers%2520positive%2520for%2520LHRH%2520receptors%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2012%26volume%3D21%26spage%3D891%26epage%3D899%26doi%3D10.1517%2F13543784.2012.685128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit170b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bushnell, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâDorisio, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâDorisio, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Cutsem, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baulieu, J.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borson-Chazot, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anthony, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oberg, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grossman, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouterfa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kacena, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaFrance, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauwels, S. A.</span><span> </span><span class="NLM_article-title">90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1652</span><span class="NLM_x">â</span> <span class="NLM_lpage">1659</span><span class="refDoi">Â DOI: 10.1200/JCO.2009.22.8585</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1200%2FJCO.2009.22.8585" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=20194865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtVyhurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=1652-1659&author=D.+L.+Bushnellauthor=T.+M.+O%E2%80%99Dorisioauthor=M.+S.+O%E2%80%99Dorisioauthor=Y.+Mendaauthor=R.+J.+Hicksauthor=E.+Van+Cutsemauthor=J.-L.+Baulieuauthor=F.+Borson-Chazotauthor=L.+Anthonyauthor=A.+B.+Bensonauthor=K.+Obergauthor=A.+B.+Grossmanauthor=M.+Connollyauthor=H.+Bouterfaauthor=Y.+Liauthor=K.+A.+Kacenaauthor=N.+LaFranceauthor=S.+A.+Pauwels&title=90Y-Edotreotide+for+Metastatic+Carcinoid+Refractory+to+Octreotide&doi=10.1200%2FJCO.2009.22.8585"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170bR"><div class="casContent"><span class="casTitleNuber">170b</span><div class="casTitle"><span class="NLM_cas:atitle">90Y-edotreotide for metastatic carcinoid refractory to octreotide</span></div><div class="casAuthors">Bushnell, David L.; O'Dorisio, Thomas M.; O'Dorisio, M. Sue; Menda, Yusuf; Hicks, Rodney J.; van Cutsem, Eric; Baulieu, Jean-Louis; Borson-Chazot, Francoise; Anthony, Lowell; Benson, Al B.; Oberg, Kjell; Grossman, Ashley B.; Connolly, Mary; Bouterfa, Hakim; Li, Yong; Kacena, Katherine A.; La France, Norman; Pauwels, Stanislas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1652-1659</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Metastatic carcinoid is an incurable malignancy whose symptoms, such as diarrhea and flushing, can be debilitating and occasionally life-threatening.  Although symptom relief is available with octreotide, the disease eventually becomes refractory to octreotide, leaving no proven treatment options.  The goal of this study was to evaluate the clin. effect of using 90Y-edotreotide to treat symptomatic patients with carcinoid tumors.  Patients and Methods: Patients enrolled had metastatic carcinoid, at least one sign/symptom refractory to octreotide, and at least one measurable lesion.  Study treatment consisted of three cycles of 4.4 GBq (120 mCi) 90Y-edotreotide each, once every 6 wk.  Results: Ninety patients were enrolled in the study.  Using Southwest Oncol. Group tumor response criteria, 67 (74.4%) of 90 patients (95% Cl, 65.4% to 83.4%) were objectively stable or responded.  A statistically significant linear trend toward improvement was demonstrated across all 12 symptoms assessed.  Median progression-free survival was significantly greater (P = .03) for the 38 patients who had durable diarrhea improvement than the 18 patients who did not (18.2 v 7.9 mo, resp.).  Adverse events (AEs) were reported in 96.7% (87 of 90) of patients.  These AEs consisted primarily of reversible GI events (76 of 90), which could be caused in part by concomitant administration of amino acid soln. given to reduce radiation exposure to the kidneys.  There was one case each of grade 3 oliguria and grade 4 renal failure, each lasting 6 days.  Conclusion: 90Y-edotreotide treatment improved symptoms assocd. with malignant carcinoid among subjects with no treatment alternatives.  Treatment was well-tolerated and had an acceptable expected AE profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_MvgtIa4e9bVg90H21EOLACvtfcHk0ljQyo_G_0eXZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtVyhurs%253D&md5=2253b45bd72dcc75d1e0ff3ef3d58784</span></div><a href="/servlet/linkout?suffix=cit170b&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.22.8585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.22.8585%26sid%3Dliteratum%253Aachs%26aulast%3DBushnell%26aufirst%3DD.%2BL.%26aulast%3DO%25E2%2580%2599Dorisio%26aufirst%3DT.%2BM.%26aulast%3DO%25E2%2580%2599Dorisio%26aufirst%3DM.%2BS.%26aulast%3DMenda%26aufirst%3DY.%26aulast%3DHicks%26aufirst%3DR.%2BJ.%26aulast%3DVan%2BCutsem%26aufirst%3DE.%26aulast%3DBaulieu%26aufirst%3DJ.-L.%26aulast%3DBorson-Chazot%26aufirst%3DF.%26aulast%3DAnthony%26aufirst%3DL.%26aulast%3DBenson%26aufirst%3DA.%2BB.%26aulast%3DOberg%26aufirst%3DK.%26aulast%3DGrossman%26aufirst%3DA.%2BB.%26aulast%3DConnolly%26aufirst%3DM.%26aulast%3DBouterfa%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DKacena%26aufirst%3DK.%2BA.%26aulast%3DLaFrance%26aufirst%3DN.%26aulast%3DPauwels%26aufirst%3DS.%2BA.%26atitle%3D90Y-Edotreotide%2520for%2520Metastatic%2520Carcinoid%2520Refractory%2520to%2520Octreotide%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D1652%26epage%3D1659%26doi%3D10.1200%2FJCO.2009.22.8585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group">Hu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, Y.</span><span> </span><span class="NLM_article-title">Long-acting phospholipid gel of exenatide for long-term therapy of type II diabetes</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1318</span><span class="NLM_x">â</span> <span class="NLM_lpage">1326</span><span class="refDoi">Â DOI: 10.1007/s11095-016-1873-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1007%2Fs11095-016-1873-9" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2016&pages=1318-1326&author=M.+Huauthor=Y.+Zhangauthor=N.+Xiangauthor=Y.+Zhongauthor=T.+Gongauthor=Z.-R.+Zhangauthor=Y.+Fu&title=Long-acting+phospholipid+gel+of+exenatide+for+long-term+therapy+of+type+II+diabetes&doi=10.1007%2Fs11095-016-1873-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1007%2Fs11095-016-1873-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-016-1873-9%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DN.%26aulast%3DZhong%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DZ.-R.%26aulast%3DFu%26aufirst%3DY.%26atitle%3DLong-acting%2520phospholipid%2520gel%2520of%2520exenatide%2520for%2520long-term%2520therapy%2520of%2520type%2520II%2520diabetes%26jtitle%3DPharm.%2520Res.%26date%3D2016%26volume%3D33%26spage%3D1318%26epage%3D1326%26doi%3D10.1007%2Fs11095-016-1873-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group">Fidel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dernell, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiss, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroud, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molho, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knoblaugh, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meganck, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parrish-Novak, J.</span><span> </span><span class="NLM_article-title">Preclinical validation of the utility of BLZ-100 in providing fluorescence contrast for imaging spontaneous solid tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">4283</span><span class="NLM_x">â</span> <span class="NLM_lpage">4291</span><span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-15-0471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1158%2F0008-5472.CAN-15-0471" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=4283-4291&author=J.+Fidelauthor=K.+C.+Kennedyauthor=W.+S.+Dernellauthor=S.+Hansenauthor=V.+Wissauthor=M.+R.+Stroudauthor=J.+I.+Molhoauthor=S.+E.+Knoblaughauthor=J.+Meganckauthor=J.+M.+Olsonauthor=B.+Riceauthor=J.+Parrish-Novak&title=Preclinical+validation+of+the+utility+of+BLZ-100+in+providing+fluorescence+contrast+for+imaging+spontaneous+solid+tumors&doi=10.1158%2F0008-5472.CAN-15-0471"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-0471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-0471%26sid%3Dliteratum%253Aachs%26aulast%3DFidel%26aufirst%3DJ.%26aulast%3DKennedy%26aufirst%3DK.%2BC.%26aulast%3DDernell%26aufirst%3DW.%2BS.%26aulast%3DHansen%26aufirst%3DS.%26aulast%3DWiss%26aufirst%3DV.%26aulast%3DStroud%26aufirst%3DM.%2BR.%26aulast%3DMolho%26aufirst%3DJ.%2BI.%26aulast%3DKnoblaugh%26aufirst%3DS.%2BE.%26aulast%3DMeganck%26aufirst%3DJ.%26aulast%3DOlson%26aufirst%3DJ.%2BM.%26aulast%3DRice%26aufirst%3DB.%26aulast%3DParrish-Novak%26aufirst%3DJ.%26atitle%3DPreclinical%2520validation%2520of%2520the%2520utility%2520of%2520BLZ-100%2520in%2520providing%2520fluorescence%2520contrast%2520for%2520imaging%2520spontaneous%2520solid%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D4283%26epage%3D4291%26doi%3D10.1158%2F0008-5472.CAN-15-0471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span>Clinical information can be found at: NCT02234297: Safety Study of BLZ-100 in Adult Subjects with Glioma Undergoing Surgery, <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span>NCT02462629: Study of BLZ-100 in Pediatric Subjects with CNS Tumors; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="https://www.clinicaltrials.gov/" class="extLink">https://www.clinicaltrials.gov/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical+information+can+be+found+at%3A+NCT02234297%3A+Safety+Study+of+BLZ-100+in+Adult+Subjects+with+Glioma+Undergoing+Surgery%2C+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2016%3B+NCT02462629%3A+Study+of+BLZ-100+in+Pediatric+Subjects+with+CNS+Tumors%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2016%3B+https%3A%2F%2Fwww.clinicaltrials.gov%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DNCT02234297%253A%2520Safety%2520Study%2520of%2520BLZ-100%2520in%2520Adult%2520Subjects%2520with%2520Glioma%2520Undergoing%2520Surgery%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2016%26jtitle%3DNCT02462629%253A%2520Study%2520of%2520BLZ-100%2520in%2520Pediatric%2520Subjects%2520with%2520CNS%2520Tumors%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mas-Moruno, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rechenmacher, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, H.</span><span> </span><span class="NLM_article-title">Cilengitide: the first anti-angiogenic small molecule drug candidate. Design, synthesis and clinical evaluation</span> <span class="citation_source-journal">Anti-Cancer Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">753</span><span class="NLM_x">â</span> <span class="NLM_lpage">768</span><span class="refDoi">Â DOI: 10.2174/187152010794728639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.2174%2F187152010794728639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21269250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslagt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=753-768&author=C.+Mas-Morunoauthor=F.+Rechenmacherauthor=H.+Kessler&title=Cilengitide%3A+the+first+anti-angiogenic+small+molecule+drug+candidate.+Design%2C+synthesis+and+clinical+evaluation&doi=10.2174%2F187152010794728639"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174aR"><div class="casContent"><span class="casTitleNuber">174a</span><div class="casTitle"><span class="NLM_cas:atitle">Cilengitide: the first anti-angiogenic small molecule drug candidate. Design, synthesis and clinical evaluation</span></div><div class="casAuthors">Mas-Moruno, Carlos; Rechenmacher, Florian; Kessler, Horst</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">753-768</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cilengitide, a cyclic RGD pentapeptide, is currently in clin. phase III for treatment of glioblastomas and in phase II for several other tumors.  This drug is the first anti-angiogenic small mol. targeting the integrins Î±vÎ²3, Î±vÎ²5 and Î±5Î²1.  It was developed by us in the early 90s by a novel procedure, the spatial screening.  This strategy resulted in c(RGDfV), the first superactive Î±vÎ²3 inhibitor (100 to 1000 times increased activity over the linear ref. peptides), which in addn. exhibited high selectivity against the platelet receptor Î±IIbÎ²3.  This cyclic peptide was later modified by N-methylation of one peptide bond to yield an even greater antagonistic activity in c(RGDf(NMe)V).  This peptide was then dubbed Cilengitide and is currently developed as drug by the company Merck-Serono (Germany).  This article describes the chem. development of Cilengitide, the biochem. background of its activity and a short review about the present clin. trials.  The pos. anti-angiogenic effects in cancer treatment can be further increased by combination with "classical" anti-cancer therapies.  Several clin. trials in this direction are under investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZlP-_WXS6GbVg90H21EOLACvtfcHk0lhprPhTRJYU7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslagt7k%253D&md5=694b4a2876be15ec767dcc82278a316c</span></div><a href="/servlet/linkout?suffix=cit174a&amp;dbid=16384&amp;doi=10.2174%2F187152010794728639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152010794728639%26sid%3Dliteratum%253Aachs%26aulast%3DMas-Moruno%26aufirst%3DC.%26aulast%3DRechenmacher%26aufirst%3DF.%26aulast%3DKessler%26aufirst%3DH.%26atitle%3DCilengitide%253A%2520the%2520first%2520anti-angiogenic%2520small%2520molecule%2520drug%2520candidate.%2520Design%252C%2520synthesis%2520and%2520clinical%2520evaluation%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2010%26volume%3D10%26spage%3D753%26epage%3D768%26doi%3D10.2174%2F187152010794728639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit174b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Stupp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegi, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorlia, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erridge, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aldape, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lhermitte, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietsch, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grujicic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinbach, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wick, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarnawski, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, D.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weyerbrock, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taphoorn, M. J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thurzo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrlinger, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kortmann, R.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adamska, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBain, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandes, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonn, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiegel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nabors, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reardon, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van den Bent, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicking, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markivskyy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weller, M.</span><span> </span><span class="NLM_article-title">Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071â22072 study): a multicentre, randomised, open-label, phase 3 trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1100</span><span class="NLM_x">â</span> <span class="NLM_lpage">1108</span><span class="refDoi">Â DOI: 10.1016/S1470-2045(14)70379-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2FS1470-2045%2814%2970379-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25163906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSmt73E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1100-1108&author=R.+Stuppauthor=M.+E.+Hegiauthor=T.+Gorliaauthor=S.+C.+Erridgeauthor=J.+Perryauthor=Y.-K.+Hongauthor=K.+D.+Aldapeauthor=B.+Lhermitteauthor=T.+Pietschauthor=D.+Grujicicauthor=J.+P.+Steinbachauthor=W.+Wickauthor=R.+Tarnawskiauthor=D.-H.+Namauthor=P.+Hauauthor=A.+Weyerbrockauthor=M.+J.+B.+Taphoornauthor=C.-C.+Shenauthor=N.+Raoauthor=L.+Thurzoauthor=U.+Herrlingerauthor=T.+Guptaauthor=R.-D.+Kortmannauthor=K.+Adamskaauthor=C.+McBainauthor=A.+A.+Brandesauthor=J.+C.+Tonnauthor=O.+Schnellauthor=T.+Wiegelauthor=C.-Y.+Kimauthor=L.+B.+Naborsauthor=D.+A.+Reardonauthor=M.+J.+van+den+Bentauthor=C.+Hickingauthor=A.+Markivskyyauthor=M.+Picardauthor=M.+Weller&title=Cilengitide+combined+with+standard+treatment+for+patients+with+newly+diagnosed+glioblastoma+with+methylated+MGMT+promoter+%28CENTRIC+EORTC+26071%E2%80%9322072+study%29%3A+a+multicentre%2C+randomised%2C+open-label%2C+phase+3+trial&doi=10.1016%2FS1470-2045%2814%2970379-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174bR"><div class="casContent"><span class="casTitleNuber">174b</span><div class="casTitle"><span class="NLM_cas:atitle">Cilengitide Combined With Standard Treatment For Patients With Newly Diagnosed Glioblastoma With Methylated Mgmt Promoter (centric Eortc 26071-22072 Study): A Multicentre, Randomised, Open-label, Phase 3 Trial</span></div><div class="casAuthors">Stupp, Roger; Hegi, Monika E.; Gorlia, Thierry; Erridge, Sara C.; Perry, James; Hong, Yong-Kil; Aldape, Kenneth D.; Lhermitte, Benoit; Pietsch, Torsten; Grujicic, Danica; Steinbach, Joachim Peter; Wick, Wolfgang; Tarnawski, Rafal; Nam, Do-Hyun; Hau, Peter; Weyerbrock, Astrid; Taphoorn, Martin J. B.; Shen, Chiung-Chyi; Rao, Nalini; Thurzo, Laszlo; Herrlinger, Ulrich; Gupta, Tejpal; Kortmann, Rolf-Dieter; Adamska, Krystyna; McBain, Catherine; Brandes, Alba A.; Tonn, Joerg Christian; Schnell, Oliver; Wiegel, Thomas; Kim, Chae-Yong; Nabors, Louis Burt; Reardon, David A.; van den Bent, Martin J.; Hicking, Christine; Markivskyy, Andriy; Picard, Martin; Weller, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1100-1108</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cilengitide is a selective Î±vÎ²3 and Î±vÎ²5 integrin inhibitor.  Data from phase 2 trials suggest that it has antitumor activity as a single agent in recurrent glioblastoma and in combination with std. temozolomide chemoradiotherapy in newly diagnosed glioblastoma (particularly in tumors with methylated MGMT promoter).  We aimed to assess cilengitide combined with temozolomide chemoradiotherapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter.  In this multicentre, open-label, phase 3 study, we investigated the efficacy of cilengitide in patients from 146 study sites in 25 countries.  Eligible patients (newly diagnosed, histol. proven supratentorial glioblastoma, methylated MGMT promoter, and age â¥18 years) were stratified for prognostic Radiation Therapy Oncol. Group recursive partitioning anal. class and geog. region and centrally randomised in a 1:1 ratio with interactive voice response system to receive temozolomide chemoradiotherapy with cilengitide 2000 mg i.v. twice weekly (cilengitide group) or temozolomide chemoradiotherapy alone (control group).  Patients and investigators were unmasked to treatment allocation.  Maintenance temozolomide was given for up to six cycles, and cilengitide was given for up to 18 mo or until disease progression or unacceptable toxic effects.  The primary endpoint was overall survival.  We analyzed survival outcomes by intention to treat.  This study is registered with ClinicalTrials.gov, no. NCT00689221.  Overall, 3471 patients were screened.  Of these patients, 3060 had tumor MGMT status tested; 926 patients had a methylated MGMT promoter, and 545 were randomly assigned to the cilengitide (n=272) or control groups (n=273) between Oct 31, 2008, and May 12, 2011.  Median overall survival was 26Â·3 mo (95% CI 23Â·8-28Â·8) in the cilengitide group and 26Â·3 mo (23Â·9-34Â·7) in the control group (hazard ratio 1Â·02, 95% CI 0Â·81-1Â·29, p=0Â·86).  None of the predefined clin. subgroups showed a benefit from cilengitide.  We noted no overall addnl. toxic effects with cilengitide treatment.  The most commonly reported adverse events of grade 3 or worse in the safety population were lymphopenia (31 [12%] in the cilengitide group vs 26 [10%] in the control group), thrombocytopenia (28 [11%] vs 46 [18%]), neutropenia (19 [7%] vs 24 [9%]), leucopenia (18 [7%] vs 20 [8%]), and convulsion (14 [5%] vs 15 [6%]).  The addn. of cilengitide to temozolomide chemoradiotherapy did not improve outcomes; cilengitide will not be further developed as an anticancer drug.  Nevertheless, integrins remain a potential treatment target for glioblastoma.Merck KGaA, Darmstadt, Germany.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWaDt0u-c9qbVg90H21EOLACvtfcHk0lhprPhTRJYU7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSmt73E&md5=7abd568898db9f543c4db31c74faafbe</span></div><a href="/servlet/linkout?suffix=cit174b&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2814%2970379-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252814%252970379-1%26sid%3Dliteratum%253Aachs%26aulast%3DStupp%26aufirst%3DR.%26aulast%3DHegi%26aufirst%3DM.%2BE.%26aulast%3DGorlia%26aufirst%3DT.%26aulast%3DErridge%26aufirst%3DS.%2BC.%26aulast%3DPerry%26aufirst%3DJ.%26aulast%3DHong%26aufirst%3DY.-K.%26aulast%3DAldape%26aufirst%3DK.%2BD.%26aulast%3DLhermitte%26aufirst%3DB.%26aulast%3DPietsch%26aufirst%3DT.%26aulast%3DGrujicic%26aufirst%3DD.%26aulast%3DSteinbach%26aufirst%3DJ.%2BP.%26aulast%3DWick%26aufirst%3DW.%26aulast%3DTarnawski%26aufirst%3DR.%26aulast%3DNam%26aufirst%3DD.-H.%26aulast%3DHau%26aufirst%3DP.%26aulast%3DWeyerbrock%26aufirst%3DA.%26aulast%3DTaphoorn%26aufirst%3DM.%2BJ.%2BB.%26aulast%3DShen%26aufirst%3DC.-C.%26aulast%3DRao%26aufirst%3DN.%26aulast%3DThurzo%26aufirst%3DL.%26aulast%3DHerrlinger%26aufirst%3DU.%26aulast%3DGupta%26aufirst%3DT.%26aulast%3DKortmann%26aufirst%3DR.-D.%26aulast%3DAdamska%26aufirst%3DK.%26aulast%3DMcBain%26aufirst%3DC.%26aulast%3DBrandes%26aufirst%3DA.%2BA.%26aulast%3DTonn%26aufirst%3DJ.%2BC.%26aulast%3DSchnell%26aufirst%3DO.%26aulast%3DWiegel%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DC.-Y.%26aulast%3DNabors%26aufirst%3DL.%2BB.%26aulast%3DReardon%26aufirst%3DD.%2BA.%26aulast%3Dvan%2Bden%2BBent%26aufirst%3DM.%2BJ.%26aulast%3DHicking%26aufirst%3DC.%26aulast%3DMarkivskyy%26aufirst%3DA.%26aulast%3DPicard%26aufirst%3DM.%26aulast%3DWeller%26aufirst%3DM.%26atitle%3DCilengitide%2520combined%2520with%2520standard%2520treatment%2520for%2520patients%2520with%2520newly%2520diagnosed%2520glioblastoma%2520with%2520methylated%2520MGMT%2520promoter%2520%2528CENTRIC%2520EORTC%252026071%25E2%2580%259322072%2520study%2529%253A%2520a%2520multicentre%252C%2520randomised%252C%2520open-label%252C%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26spage%3D1100%26epage%3D1108%26doi%3D10.1016%2FS1470-2045%2814%2970379-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span> </span><span class="NLM_article-title">Clinical application of radiolabeled RGD peptides for PET imaging of integrin Î±vÎ²3</span> <span class="citation_source-journal">Theranostics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">78</span><span class="NLM_x">â</span> <span class="NLM_lpage">92</span><span class="refDoi">Â DOI: 10.7150/thno.13242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.7150%2Fthno.13242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26722375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XntF2nt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=78-92&author=H.+Chenauthor=G.+Niuauthor=H.+Wuauthor=X.+Chen&title=Clinical+application+of+radiolabeled+RGD+peptides+for+PET+imaging+of+integrin+%CE%B1v%CE%B23&doi=10.7150%2Fthno.13242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical application of radiolabeled RGD peptides for PET imaging of integrin Î±vÎ²3</span></div><div class="casAuthors">Chen, Haojun; Niu, Gang; Wu, Hua; Chen, Xiaoyuan</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">78-92</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Mol. imaging for non-invasive assessment of angiogenesisis is of great interest for clinicians because of the wide-spread application of anti-angiogenic cancer therapeutics.  Besides, many other interventions that involve the change of blood vessel/tumor microenvironment would also benefit from such imaging strategies.  Of the imaging techniques that target angiogenesis, radiolabeled Arg-Gly-Asp (RGD) peptides have been a major focus because of their high affinity and selectivity for integrin Î±vÎ²3--one of the most extensively examd. target of angiogenesis.  Since the level of integrin Î±vÎ²3 expression has been established as a surrogate marker of angiogenic activity, imaging Î±vÎ²3 expression can potentially be used as an early indicator of effectiveness of antiangiogenic therapy at the mol. level.  In this review, we summarize RGD-based PET tracers that have already been used in clin. trials and intercompared them in terms of radiosynthesis, dosimetry, pharmacokinetics and clin. applications.  A perspective of their future use in the clinic is also provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMF5yFaBW4RLVg90H21EOLACvtfcHk0lhprPhTRJYU7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntF2nt7c%253D&md5=7124509bee7f3bb9b90a3a8d0ae0f82c</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.7150%2Fthno.13242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.13242%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%26aulast%3DNiu%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DClinical%2520application%2520of%2520radiolabeled%2520RGD%2520peptides%2520for%2520PET%2520imaging%2520of%2520integrin%2520%25CE%25B1v%25CE%25B23%26jtitle%3DTheranostics%26date%3D2016%26volume%3D6%26spage%3D78%26epage%3D92%26doi%3D10.7150%2Fthno.13242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group">BÃ¡bÃ­ÄkovÃ¡, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">TÃ³thovÃ¡, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celec, P.</span><span> </span><span class="NLM_article-title">In vivo phage display - A discovery tool in molecular biomedicine</span> <span class="citation_source-journal">Biotechnol. Adv.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1247</span><span class="NLM_x">â</span> <span class="NLM_lpage">1259</span><span class="refDoi">Â DOI: 10.1016/j.biotechadv.2013.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.biotechadv.2013.04.004" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1247-1259&author=J.+B%C3%A1b%C3%AD%C4%8Dkov%C3%A1author=L.+T%C3%B3thov%C3%A1author=P.+Boorauthor=P.+Celec&title=In+vivo+phage+display+-+A+discovery+tool+in+molecular+biomedicine&doi=10.1016%2Fj.biotechadv.2013.04.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1016%2Fj.biotechadv.2013.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biotechadv.2013.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25A1b%25C3%25AD%25C4%258Dkov%25C3%25A1%26aufirst%3DJ.%26aulast%3DT%25C3%25B3thov%25C3%25A1%26aufirst%3DL.%26aulast%3DBoor%26aufirst%3DP.%26aulast%3DCelec%26aufirst%3DP.%26atitle%3DIn%2520vivo%2520phage%2520display%2520-%2520A%2520discovery%2520tool%2520in%2520molecular%2520biomedicine%26jtitle%3DBiotechnol.%2520Adv.%26date%3D2013%26volume%3D31%26spage%3D1247%26epage%3D1259%26doi%3D10.1016%2Fj.biotechadv.2013.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group">Komin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hristova, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Searson, P. C.</span><span> </span><span class="NLM_article-title">Peptide-based strategies for enhanced cell uptake, transcellular transport, and circulation: Mechanisms and challenges</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">110â111</span><span class="NLM_x">, </span> <span class="NLM_fpage">52</span><span class="NLM_x">â</span> <span class="NLM_lpage">64</span><span class="refDoi">Â DOI: 10.1016/j.addr.2016.06.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.addr.2016.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=27313077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVWlu7fF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110%E2%80%93111&publication_year=2017&pages=52-64&author=A.+Kominauthor=L.+M.+Russellauthor=K.+A.+Hristovaauthor=P.+C.+Searson&title=Peptide-based+strategies+for+enhanced+cell+uptake%2C+transcellular+transport%2C+and+circulation%3A+Mechanisms+and+challenges&doi=10.1016%2Fj.addr.2016.06.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide-based strategies for enhanced cell uptake, transcellular transport, and circulation: Mechanisms and challenges</span></div><div class="casAuthors">Komin, A.; Russell, L. M.; Hristova, K. A.; Searson, P. C.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">110-111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">52-64</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Peptides are emerging as a new tool in drug and gene delivery.  Peptide-drug conjugates and peptide-modified drug delivery systems provide new opportunities to avoid macrophage recognition and subsequent phagocytosis, cross endothelial and epithelial barriers, and enter the cytoplasm of target cells.  Peptides are relatively small, low-cost, and are stable in a wide range of biol. conditions.  In this review, we summarize recent work in designing peptides to enhance penetration of biol. barriers, increase cell uptake, and avoid the immune system.  We highlight recent successes and contradictory results, and outline common emerging concepts and design rules.  The development of sequence-structure-function relationships and std. protocols for benchmarking will be a key to progress in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFDHyXD2xrQLVg90H21EOLACvtfcHk0lgCTidOeQTiVA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVWlu7fF&md5=8d4815f6874853af7c929aa6c6f52098</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2016.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2016.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DKomin%26aufirst%3DA.%26aulast%3DRussell%26aufirst%3DL.%2BM.%26aulast%3DHristova%26aufirst%3DK.%2BA.%26aulast%3DSearson%26aufirst%3DP.%2BC.%26atitle%3DPeptide-based%2520strategies%2520for%2520enhanced%2520cell%2520uptake%252C%2520transcellular%2520transport%252C%2520and%2520circulation%253A%2520Mechanisms%2520and%2520challenges%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2017%26volume%3D110%25E2%2580%2593111%26spage%3D52%26epage%3D64%26doi%3D10.1016%2Fj.addr.2016.06.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cleal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, A. T.</span><span> </span><span class="NLM_article-title">Endocytosis, intracellular traffic and fate of cell penetrating peptide based conjugates and nanoparticles</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2878</span><span class="NLM_x">â</span> <span class="NLM_lpage">2894</span><span class="refDoi">Â DOI: 10.2174/13816128113199990297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.2174%2F13816128113199990297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23140451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovFemtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2878-2894&author=K.+Clealauthor=L.+Heauthor=P.+D.+Watsonauthor=A.+T.+Jones&title=Endocytosis%2C+intracellular+traffic+and+fate+of+cell+penetrating+peptide+based+conjugates+and+nanoparticles&doi=10.2174%2F13816128113199990297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178aR"><div class="casContent"><span class="casTitleNuber">178a</span><div class="casTitle"><span class="NLM_cas:atitle">Endocytosis, intracellular traffic and fate of cell penetrating peptide based conjugates and nanoparticles</span></div><div class="casAuthors">Cleal, Kez; He, Lin; Watson, Peter D.; Jones, Arwyn T.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2878-2894</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The insides of cells can be viewed as a treasure trove of targets for therapeutic intervention of diseases or as deposits for contrasting agents.  Increasingly the mols. that need to be delivered to the inside of cells for these purposes are macromol. and membrane impermeable.  Cell penetrating peptides (CPPs) have proven abilities to deliver a range of macromol. cargo into cells thus raising their profile as potential delivery vectors for wide-ranging applications.  There is evidence to suggest that CPPs first enter cells through endocytosis and that cytosolic delivery is mediated across endolysosomal membranes.  Their capacity to do this, over direct plasma membrane translocation, is likely to depend on the nature and size of the cargo.  Cells use a range of endocytic routes to facilitate entry from well characterized pathways regulated by clathrin to more recently discovered and less characterized pathways regulated by clathrin independent mechanisms.  These are likely to det. the intracellular fate of cell delivery vectors including those based on cell penetrating peptides.  Thus gaining accurate knowledge of their endocytic uptake and traffic is an important characterization criteria for progress in this field.  This review describes the different endocytic pathways that have been identified in mammalian cells and specific reports that have studied the uptake mechanisms and endocytic traffic of cell penetrating peptides and their assocd. cargo.  These cargoes range from short peptides to an increasing library of nanoparticles such as quantum dots, liposomes and polymeric dendrimers.  The studies highlight the effectiveness of cell penetrating peptides for delivering these entities into a diverse array of cell types using different endocytic pathways.  This is shown using microscopy based colocalization anal. with the few specific endocytic probes available, and chem. inhibitors of endocytosis that suffer from lack of specificity.  Overall, more specific probes, inhibitors and novel technologies are required for accurate characterization of cellular dynamics of cell penetrating peptide conjugates thus allowing them to reach their full potential as vectors for therapeutics and other payloads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpf1lhOrbWWrVg90H21EOLACvtfcHk0lgCTidOeQTiVA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovFemtbo%253D&md5=b9db84cb202a7447e6dde69e268e14a1</span></div><a href="/servlet/linkout?suffix=cit178a&amp;dbid=16384&amp;doi=10.2174%2F13816128113199990297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F13816128113199990297%26sid%3Dliteratum%253Aachs%26aulast%3DCleal%26aufirst%3DK.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DWatson%26aufirst%3DP.%2BD.%26aulast%3DJones%26aufirst%3DA.%2BT.%26atitle%3DEndocytosis%252C%2520intracellular%2520traffic%2520and%2520fate%2520of%2520cell%2520penetrating%2520peptide%2520based%2520conjugates%2520and%2520nanoparticles%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2013%26volume%3D19%26spage%3D2878%26epage%3D2894%26doi%3D10.2174%2F13816128113199990297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit178b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, F.</span><span> </span><span class="NLM_article-title">Recent progress of cell-penetrating peptides as new carriers for intracellular cargo delivery</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">174</span><span class="NLM_x">, </span> <span class="NLM_fpage">126</span><span class="NLM_x">â</span> <span class="NLM_lpage">136</span><span class="refDoi">Â DOI: 10.1016/j.jconrel.2013.11.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.jconrel.2013.11.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24291335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVymsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2014&pages=126-136&author=F.+Wangauthor=Y.+Wangauthor=X.+Zhangauthor=W.+Zhangauthor=S.+Guoauthor=F.+Jin&title=Recent+progress+of+cell-penetrating+peptides+as+new+carriers+for+intracellular+cargo+delivery&doi=10.1016%2Fj.jconrel.2013.11.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178bR"><div class="casContent"><span class="casTitleNuber">178b</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress of cell-penetrating peptides as new carriers for intracellular cargo delivery</span></div><div class="casAuthors">Wang, Feihu; Wang, Yun; Zhang, Xiao; Zhang, Wenjun; Guo, Shengrong; Jin, Fang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">126-136</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The plasma membrane as a selectively permeable barrier of living cells is essential to cell survival and function.  In many cases, however, the efficient passage of exogenous bioactive mols. through the plasma membrane remains a major hurdle for intracellular delivery of cargoes.  During the last two decades, the potential of peptides for drug delivery into cells has been highlighted by the discovery of numerous cell-penetrating peptides (CPPs).  CPPs serving as carriers can successfully intracellular transport cargoes such as siRNA, nucleic acids, proteins, small mol. therapeutic agents, quantum dots and MRI contrast agents.  This review mainly introduces recent advances of CPPs as new carriers for the development of cellular imaging, nuclear localization, pH-sensitive and thermally targeted delivery systems.  In particular, we highlight the exploiting of the synergistic effects of targeting ligands and CPPs.  What's more, the classification and cellular uptake mechanisms of CPPs are briefly discussed as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXyE_6BuPiDrVg90H21EOLACvtfcHk0lgCTidOeQTiVA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVymsb0%253D&md5=8ad14be5d81937ac28a279843dbb5a23</span></div><a href="/servlet/linkout?suffix=cit178b&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2013.11.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2013.11.020%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DS.%26aulast%3DJin%26aufirst%3DF.%26atitle%3DRecent%2520progress%2520of%2520cell-penetrating%2520peptides%2520as%2520new%2520carriers%2520for%2520intracellular%2520cargo%2520delivery%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2014%26volume%3D174%26spage%3D126%26epage%3D136%26doi%3D10.1016%2Fj.jconrel.2013.11.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit178c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Reissmann, S.</span><span> </span><span class="NLM_article-title">Cell penetration: scope and limitations by the application of cell-penetrating peptides</span> <span class="citation_source-journal">J. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">760</span><span class="NLM_x">â</span> <span class="NLM_lpage">784</span><span class="refDoi">Â DOI: 10.1002/psc.2672</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fpsc.2672" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25112216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlarurnL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=760-784&author=S.+Reissmann&title=Cell+penetration%3A+scope+and+limitations+by+the+application+of+cell-penetrating+peptides&doi=10.1002%2Fpsc.2672"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178cR"><div class="casContent"><span class="casTitleNuber">178c</span><div class="casTitle"><span class="NLM_cas:atitle">Cell penetration: scope and limitations by the application of cell-penetrating peptides</span></div><div class="casAuthors">Reissmann, Siegmund</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">760-784</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  The penetration of polar or badly sol. compds. through a cell membrane into live cells requires mech. support or chem. helpers.  Cell-penetrating peptides (CPPs) are very promising chem. helpers.  Because of their low cytotoxicity and final degrdn. to amino acids, they are particularly favored in in vivo studies and for clin. applications.  Clearly, the future of CPP research is bright; however, the required optimization studies for each drug require considerable individualized attention.  Thus, CPPs are not the philosopher's stone.  As of today, a large no. of such transporter peptides with very different sequences have been identified.  These have different uptake mechanisms and can transport different cargos.  Intracellular concns. of cargos can reach a low micromole range and are able to influence intracellular reactions.  Internalized ribonucleic acids such as small interfering RNA (siRNA) and mimics of RNA such as peptide nucleic acids, morpholino nucleic acids, and triesters of oligonucleotides can influence transcription and translation.  Despite the highly efficient internalization of antibodies, enzymes, and other protein factors, as well as siRNA and RNA mimics, the uptake and stabile insertion of DNA into the genome of the host cells remain substantially challenging.  This review describes a wide array of differing CPPs, cargos, cell lines, and tissues.  The application of CPPs is compared with electroporation, magnetofection, lipofection, viral vectors, dendrimers, and nanoparticles, including com. available products.  The limitations of CPPs include low cell and tissue selectivity of the first generation and the necessity for formation of fusion proteins, conjugates, or noncovalent complexes to different cargos and of cargo release from intracellular vesicles.  Furthermore, the noncovalent complexes require a strong molar excess of CPPs, and extensive experimentation is required to det. the most optimal CPP for any given cargo and cell type.  Yet to predict which CPP is optimal for any given target remains a complex question.  More recently, there have been promising developments: the enhancement of cell specificity using activatable CPPs, specific transport into cell organelles by insertion of corresponding localization sequences, and the transport of drugs through blood-brain barriers, through the conjunctiva of eyes, skin, and into nerve cells.  Proteins, siRNA, and mimics of oligonucleotides can be efficiently transported into cells and have been tested for treatment of certain diseases.  The recent state of the art in CPP research is discussed together with the overall scope, limitations, and some recommendations for future research directions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotaRZ-ATX-lbVg90H21EOLACvtfcHk0lhEesscoBjMmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlarurnL&md5=5718cfe189a30c66c776390459b62a48</span></div><a href="/servlet/linkout?suffix=cit178c&amp;dbid=16384&amp;doi=10.1002%2Fpsc.2672&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.2672%26sid%3Dliteratum%253Aachs%26aulast%3DReissmann%26aufirst%3DS.%26atitle%3DCell%2520penetration%253A%2520scope%2520and%2520limitations%2520by%2520the%2520application%2520of%2520cell-penetrating%2520peptides%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2014%26volume%3D20%26spage%3D760%26epage%3D784%26doi%3D10.1002%2Fpsc.2672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group">Johnson, R. M.; Harrison, S. D.; Maclean, D.</span><span> </span><span class="NLM_article-title">Therapeutic applications of cell-penetrating peptides</span>. In  <span class="citation_source-book">Cell-Penetrating Peptides: Methods and Protocols</span>; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">Totowa, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2010</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">535</span><span class="NLM_x">â</span> <span class="NLM_lpage">551</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=535-551&author=R.+M.+Johnson&author=S.+D.+Harrison&author=D.+Maclean&title=Cell-Penetrating+Peptides%3A+Methods+and+Protocols"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DR.%2BM.%26atitle%3DTherapeutic%2520applications%2520of%2520cell-penetrating%2520peptides%26btitle%3DCell-Penetrating%2520Peptides%253A%2520Methods%2520and%2520Protocols%26pub%3DHumana%2520Press%26date%3D2010%26spage%3D535%26epage%3D551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group">Hill, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikulis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silver, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">terBrugge, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milot, G. v.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleetwood, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDougall, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunnarsson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lum, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodd, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poublanc, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krings, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demchuk, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goyal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishop, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tymianski, M.</span><span> </span><span class="NLM_article-title">Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial</span> <span class="citation_source-journal">Lancet Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">942</span><span class="NLM_x">â</span> <span class="NLM_lpage">950</span><span class="refDoi">Â DOI: 10.1016/S1474-4422(12)70225-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2FS1474-4422%2812%2970225-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23051991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFCqtbnO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=942-950&author=M.+D.+Hillauthor=R.+H.+Martinauthor=D.+Mikulisauthor=J.+H.+Wongauthor=F.+L.+Silverauthor=K.+G.+terBruggeauthor=G.+v.+Milotauthor=W.+M.+Clarkauthor=R.+L.+MacDonaldauthor=M.+E.+Kellyauthor=M.+Boultonauthor=I.+Fleetwoodauthor=C.+McDougallauthor=T.+Gunnarssonauthor=M.+Chowauthor=C.+Lumauthor=R.+Doddauthor=J.+Poublancauthor=T.+Kringsauthor=A.+M.+Demchukauthor=M.+Goyalauthor=R.+Andersonauthor=J.+Bishopauthor=D.+Garmanauthor=M.+Tymianski&title=Safety+and+efficacy+of+NA-1+in+patients+with+iatrogenic+stroke+after+endovascular+aneurysm+repair+%28ENACT%29%3A+a+phase+2%2C+randomised%2C+double-blind%2C+placebo-controlled+trial&doi=10.1016%2FS1474-4422%2812%2970225-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial</span></div><div class="casAuthors">Hill, Michael D.; Martin, Renee H.; Mikulis, David; Wong, John H.; Silver, Frank L.; terBrugge, Karel G.; Milot, Genevieve; Clark, Wayne M.; MacDonald, R. Loch; Kelly, Michael E.; Boulton, Melford; Fleetwood, Ian; McDougall, Cameron; Gunnarsson, Thorsteinn; Chow, Michael; Lum, Cheemun; Dodd, Robert; Poublanc, Julien; Krings, Timo; Demchuk, Andrew M.; Goyal, Mayank; Anderson, Roberta; Bishop, Julie; Garman, David; Tymianski, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">942-950</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: Neuroprotection with NA-1 (Tat-NR2B9c), an inhibitor of postsynaptic d.-95 protein, has been shown in a primate model of stroke.  We assessed whether NA-1 could reduce ischemic brain damage in human beings.  Methods: For this double-blind, randomised, controlled study, we enrolled patients aged 18 years or older who had a ruptured or unruptured intracranial aneurysm amenable to endovascular repair from 14 hospitals in Canada and the USA.  We used a computer-generated randomisation sequence to allocate patients to receive an i.v. infusion of either NA-1 or saline control at the end of their endovascular procedure (1:1; stratified by site, age, and aneurysm status).  Both patients and investigators were masked to treatment allocation.  The primary outcome was safety and primary clin. outcomes were the no. and vol. of new ischemic strokes defined by MRI at 12-95 h after infusion.  We used a modified intention-to-treat (mITT) anal.  This trial is registered with ClinicalTrials.gov, no. NCT00728182.  Findings: Between Sept 16, 2008, and March 30, 2011, we randomly allocated 197 patients to treatment-12 individuals did not receive treatment because they were found to be ineligible after randomisation, so the mITT population consisted of 185 individuals, 92 in the NA-1 group and 93 in the placebo group.  Two minor adverse events were adjudged to be assocd. with NA-1; no serious adverse events were attributable to NA-1.  We recorded no difference between groups in the vol. of lesions by either diffusion-weighted MRI (adjusted p value=0Â·120) or fluid-attenuated inversion recovery MRI (adjusted p value=0Â·236).  Patients in the NA-1 group sustained fewer ischemic infarcts than did patients in the placebo group, as gauged by diffusion-weighted MRI (adjusted incidence rate ratio 0Â·53, 95% CI 0Â·38-0Â·74) and fluid-attenuated inversion recovery MRI (0Â·59, 0Â·42-0Â·83).  Interpretation: Our findings suggest that neuroprotection in human ischemic stroke is possible and that it should be investigated in larger trials.  Funding: NoNO Inc and Arbor Vita Corp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRS9lHk6iZ9rVg90H21EOLACvtfcHk0lhEesscoBjMmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFCqtbnO&md5=1cbefddebde83dc75dbd3b5ee45bf0ac</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2812%2970225-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252812%252970225-9%26sid%3Dliteratum%253Aachs%26aulast%3DHill%26aufirst%3DM.%2BD.%26aulast%3DMartin%26aufirst%3DR.%2BH.%26aulast%3DMikulis%26aufirst%3DD.%26aulast%3DWong%26aufirst%3DJ.%2BH.%26aulast%3DSilver%26aufirst%3DF.%2BL.%26aulast%3DterBrugge%26aufirst%3DK.%2BG.%26aulast%3DMilot%26aufirst%3DG.%2Bv.%26aulast%3DClark%26aufirst%3DW.%2BM.%26aulast%3DMacDonald%26aufirst%3DR.%2BL.%26aulast%3DKelly%26aufirst%3DM.%2BE.%26aulast%3DBoulton%26aufirst%3DM.%26aulast%3DFleetwood%26aufirst%3DI.%26aulast%3DMcDougall%26aufirst%3DC.%26aulast%3DGunnarsson%26aufirst%3DT.%26aulast%3DChow%26aufirst%3DM.%26aulast%3DLum%26aufirst%3DC.%26aulast%3DDodd%26aufirst%3DR.%26aulast%3DPoublanc%26aufirst%3DJ.%26aulast%3DKrings%26aufirst%3DT.%26aulast%3DDemchuk%26aufirst%3DA.%2BM.%26aulast%3DGoyal%26aufirst%3DM.%26aulast%3DAnderson%26aufirst%3DR.%26aulast%3DBishop%26aufirst%3DJ.%26aulast%3DGarman%26aufirst%3DD.%26aulast%3DTymianski%26aufirst%3DM.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520NA-1%2520in%2520patients%2520with%2520iatrogenic%2520stroke%2520after%2520endovascular%2520aneurysm%2520repair%2520%2528ENACT%2529%253A%2520a%2520phase%25202%252C%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%2520trial%26jtitle%3DLancet%2520Neurol.%26date%3D2012%26volume%3D11%26spage%3D942%26epage%3D950%26doi%3D10.1016%2FS1474-4422%2812%2970225-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group">Dinca, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, W.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, M.</span><span> </span><span class="NLM_article-title">Intracellular delivery of proteins with cell-penetrating peptides for therapeutic uses in human disease</span> <span class="citation_source-journal">Int. J. Mol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">263</span><span class="refDoi">Â DOI: 10.3390/ijms17020263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3390%2Fijms17020263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26907261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovVGjtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=263&author=A.+Dincaauthor=W.-M.+Chienauthor=M.+Chin&title=Intracellular+delivery+of+proteins+with+cell-penetrating+peptides+for+therapeutic+uses+in+human+disease&doi=10.3390%2Fijms17020263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular delivery of proteins with cell-penetrating peptides for therapeutic uses in human disease</span></div><div class="casAuthors">Dinca, Ana; Chien, Wei-Ming; Chin, Michael T.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263/1-263/13</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Protein therapy exhibits several advantages over small mol. drugs and is increasingly being developed for the treatment of disorders ranging from single enzyme deficiencies to cancer.  Cell-penetrating peptides (CPPs), a group of small peptides capable of promoting transport of mol. cargo across the plasma membrane, have become important tools in promoting the cellular uptake of exogenously delivered proteins.  Although the mol. mechanisms of uptake are not firmly established, CPPs have been empirically shown to promote uptake of various mols., including large proteins over 100 kiloDaltons (kDa).  Recombinant proteins that include a CPP tag to promote intracellular delivery show promise as therapeutic agents with encouraging success rates in both animal and human trials.  This review highlights recent advances in protein-CPP therapy and discusses optimization strategies and potential detrimental effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7xbKredb6CLVg90H21EOLACvtfcHk0lheR1LcLIPw5A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovVGjtA%253D%253D&md5=6651857828ed4f2032d0db40c76cd61d</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.3390%2Fijms17020263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms17020263%26sid%3Dliteratum%253Aachs%26aulast%3DDinca%26aufirst%3DA.%26aulast%3DChien%26aufirst%3DW.-M.%26aulast%3DChin%26aufirst%3DM.%26atitle%3DIntracellular%2520delivery%2520of%2520proteins%2520with%2520cell-penetrating%2520peptides%2520for%2520therapeutic%2520uses%2520in%2520human%2520disease%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2016%26volume%3D17%26spage%3D263%26doi%3D10.3390%2Fijms17020263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group">Presolski, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, M. G.</span><span> </span><span class="NLM_article-title">Copper-catalyzed azideâalkyne click chemistry for bioconjugation</span> <span class="citation_source-journal">Curr. Protoc. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">â</span> <span class="NLM_lpage">162</span><span class="refDoi">Â DOI: 10.1002/9780470559277.ch110148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2F9780470559277.ch110148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=22844652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A280%3ADC%252BC2srmslKltg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=153-162&author=S.+I.+Presolskiauthor=V.+P.+Hongauthor=M.+G.+Finn&title=Copper-catalyzed+azide%E2%80%93alkyne+click+chemistry+for+bioconjugation&doi=10.1002%2F9780470559277.ch110148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Copper-Catalyzed Azide-Alkyne Click Chemistry for Bioconjugation</span></div><div class="casAuthors">Presolski Stanislav I; Hong Vu Phong; Finn M G</div><div class="citationInfo"><span class="NLM_cas:title">Current protocols in chemical biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">153-162</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The copper-catalyzed azide-alkyne cycloaddition reaction is widely used for the connection of molecular entities of all sizes.  A protocol is provided here for the process with biomolecules.  Ascorbate is used as reducing agent to maintain the required cuprous oxidation state.  Since these convenient conditions produce reactive oxygen species, five equivalents of a copper-binding ligand is used with respect to metal.  The ligand both accelerates the reaction and serves as a sacrificial reductant, protecting the biomolecules from oxidation.  A procedure is also described for testing the efficiency of the reaction under desired conditions for purposes of optimization, before expensive biological reagents are used.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8A2KT2nosgEg6wdEZmT2rfW6udTcc2eY6Uf-qMC6Dhbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srmslKltg%253D%253D&md5=cc622ec6ed0e16170ef2e6ebd1541d0a</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1002%2F9780470559277.ch110148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F9780470559277.ch110148%26sid%3Dliteratum%253Aachs%26aulast%3DPresolski%26aufirst%3DS.%2BI.%26aulast%3DHong%26aufirst%3DV.%2BP.%26aulast%3DFinn%26aufirst%3DM.%2BG.%26atitle%3DCopper-catalyzed%2520azide%25E2%2580%2593alkyne%2520click%2520chemistry%2520for%2520bioconjugation%26jtitle%3DCurr.%2520Protoc.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D3%26spage%3D153%26epage%3D162%26doi%3D10.1002%2F9780470559277.ch110148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">McKay, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, M. G.</span><span> </span><span class="NLM_article-title">Click chemistry in complex mixtures: bioorthogonal bioconjugation</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1075</span><span class="NLM_x">â</span> <span class="NLM_lpage">1101</span><span class="refDoi">Â DOI: 10.1016/j.chembiol.2014.09.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.chembiol.2014.09.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25237856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyrur7N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=1075-1101&author=C.+S.+McKayauthor=M.+G.+Finn&title=Click+chemistry+in+complex+mixtures%3A+bioorthogonal+bioconjugation&doi=10.1016%2Fj.chembiol.2014.09.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183aR"><div class="casContent"><span class="casTitleNuber">183a</span><div class="casTitle"><span class="NLM_cas:atitle">Click Chemistry in Complex Mixtures: Bioorthogonal Bioconjugation</span></div><div class="casAuthors">McKay, Craig S.; Finn, M. G.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1075-1101</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The selective chem. modification of biol. mols. drives a good portion of modern drug development and fundamental biol. research.  While a few early examples of reactions that engage amine and thiol groups on proteins helped establish the value of such processes, the development of reactions that avoid most biol. mols. so as to achieve selectivity in desired bond-forming events has revolutionized the field.  We provide an update on recent developments in bioorthogonal chem. that highlights key advances in reaction rates, biocompatibility, and applications.  While not exhaustive, we hope this summary allows the reader to appreciate the rich continuing development of good chem. that operates in the biol. setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7SEdPeibs0LVg90H21EOLACvtfcHk0lheR1LcLIPw5A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyrur7N&md5=64a6e5ea8a232b97fce61d1268093fe4</span></div><a href="/servlet/linkout?suffix=cit183a&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2014.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2014.09.002%26sid%3Dliteratum%253Aachs%26aulast%3DMcKay%26aufirst%3DC.%2BS.%26aulast%3DFinn%26aufirst%3DM.%2BG.%26atitle%3DClick%2520chemistry%2520in%2520complex%2520mixtures%253A%2520bioorthogonal%2520bioconjugation%26jtitle%3DChem.%2520Biol.%26date%3D2014%26volume%3D21%26spage%3D1075%26epage%3D1101%26doi%3D10.1016%2Fj.chembiol.2014.09.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit183b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Krall, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">da Cruz, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boutureira, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernardes, G. J. L.</span><span> </span><span class="NLM_article-title">Site-selective protein-modification chemistry for basic biology and drug development</span> <span class="citation_source-journal">Nat. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">â</span> <span class="NLM_lpage">113</span><span class="refDoi">Â DOI: 10.1038/nchem.2393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnchem.2393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26791892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFemsbrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=103-113&author=N.+Krallauthor=F.+P.+da+Cruzauthor=O.+Boutureiraauthor=G.+J.+L.+Bernardes&title=Site-selective+protein-modification+chemistry+for+basic+biology+and+drug+development&doi=10.1038%2Fnchem.2393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183bR"><div class="casContent"><span class="casTitleNuber">183b</span><div class="casTitle"><span class="NLM_cas:atitle">Site-selective protein-modification chemistry for basic biology and drug development</span></div><div class="casAuthors">Krall, Nikolaus; da Cruz, Filipa P.; Boutureira, Omar; Bernardes, Goncalo J. L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-113</span>CODEN:
                <span class="NLM_cas:coden">NCAHBB</span>;
        ISSN:<span class="NLM_cas:issn">1755-4330</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Nature has produced intricate machinery to covalently diversify the structure of proteins after their synthesis in the ribosome.  In an attempt to mimic nature, chemists have developed a large set of reactions that enable post-expression modification of proteins at pre-detd. sites.  These reactions are now used to selectively install particular modifications on proteins for many biol. and therapeutic applications.  For example, they provide an opportunity to install post-translational modifications on proteins to det. their exact biol. roles.  Labeling of proteins in live cells with fluorescent dyes allows protein uptake and intracellular trafficking to be tracked and also enables physiol. parameters to be measured optically.  Through the conjugation of potent cytotoxicants to antibodies, novel anti-cancer drugs with improved efficacy and reduced side effects may be obtained.  In this Perspective, we highlight the most exciting current and future applications of chem. site-selective protein modification and consider which hurdles still need to be overcome for more widespread use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCXe9yoL2S-bVg90H21EOLACvtfcHk0livQvz6Gd7CVQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFemsbrI&md5=9a8f675a512f1286c5d88c6692d8773c</span></div><a href="/servlet/linkout?suffix=cit183b&amp;dbid=16384&amp;doi=10.1038%2Fnchem.2393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchem.2393%26sid%3Dliteratum%253Aachs%26aulast%3DKrall%26aufirst%3DN.%26aulast%3Dda%2BCruz%26aufirst%3DF.%2BP.%26aulast%3DBoutureira%26aufirst%3DO.%26aulast%3DBernardes%26aufirst%3DG.%2BJ.%2BL.%26atitle%3DSite-selective%2520protein-modification%2520chemistry%2520for%2520basic%2520biology%2520and%2520drug%2520development%26jtitle%3DNat.%2520Chem.%26date%3D2016%26volume%3D8%26spage%3D103%26epage%3D113%26doi%3D10.1038%2Fnchem.2393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit183c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Sochaj, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Å¡widerska, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otlewski, J.</span><span> </span><span class="NLM_article-title">Current methods for the synthesis of homogeneous antibody-drug conjugates</span> <span class="citation_source-journal">Biotechnol. Adv.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">775</span><span class="NLM_x">â</span> <span class="NLM_lpage">784</span><span class="refDoi">Â DOI: 10.1016/j.biotechadv.2015.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.biotechadv.2015.05.001" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=775-784&author=A.+M.+Sochajauthor=K.+W.+%C5%A1widerskaauthor=J.+Otlewski&title=Current+methods+for+the+synthesis+of+homogeneous+antibody-drug+conjugates&doi=10.1016%2Fj.biotechadv.2015.05.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit183c&amp;dbid=16384&amp;doi=10.1016%2Fj.biotechadv.2015.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biotechadv.2015.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DSochaj%26aufirst%3DA.%2BM.%26aulast%3D%25C5%25A1widerska%26aufirst%3DK.%2BW.%26aulast%3DOtlewski%26aufirst%3DJ.%26atitle%3DCurrent%2520methods%2520for%2520the%2520synthesis%2520of%2520homogeneous%2520antibody-drug%2520conjugates%26jtitle%3DBiotechnol.%2520Adv.%26date%3D2015%26volume%3D33%26spage%3D775%26epage%3D784%26doi%3D10.1016%2Fj.biotechadv.2015.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cal, P. M. S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernardes, G. J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gois, P. M. P.</span><span> </span><span class="NLM_article-title">Cysteine-selective reactions for antibody conjugation</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">10585</span><span class="NLM_x">â</span> <span class="NLM_lpage">10587</span><span class="refDoi">Â DOI: 10.1002/anie.201405702</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fanie.201405702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1ams7jF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=10585-10587&author=P.+M.+S.+D.+Calauthor=G.+J.+L.+Bernardesauthor=P.+M.+P.+Gois&title=Cysteine-selective+reactions+for+antibody+conjugation&doi=10.1002%2Fanie.201405702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184aR"><div class="casContent"><span class="casTitleNuber">184a</span><div class="casTitle"><span class="NLM_cas:atitle">Cysteine-Selective Reactions for Antibody Conjugation</span></div><div class="casAuthors">Cal, Pedro M. S. D.; Bernardes, Goncalo J. L.; Gois, Pedro M. P.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">10585-10587</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The unique targeting ability of antibodies has triggered burgeoning interest in the attachment of potent cytotoxic drugs onto these biomols. to create antibody-drug conjugates (ADCs).  A key factor in the design of therapeutically useful ADCs is the ability to create chem. defined, stable protein-drug conjugates.  The aim of this highlight is to discuss new methods for site-selective bioconjugation at native or engineered cysteines, methods which may be used to build homogeneous and stable ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMz3aKFjFe8rVg90H21EOLACvtfcHk0livQvz6Gd7CVQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1ams7jF&md5=a9b477a09aa18c06fa325db95184e436</span></div><a href="/servlet/linkout?suffix=cit184a&amp;dbid=16384&amp;doi=10.1002%2Fanie.201405702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201405702%26sid%3Dliteratum%253Aachs%26aulast%3DCal%26aufirst%3DP.%2BM.%2BS.%2BD.%26aulast%3DBernardes%26aufirst%3DG.%2BJ.%2BL.%26aulast%3DGois%26aufirst%3DP.%2BM.%2BP.%26atitle%3DCysteine-selective%2520reactions%2520for%2520antibody%2520conjugation%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D10585%26epage%3D10587%26doi%3D10.1002%2Fanie.201405702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit184b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Vinogradova, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spokoyny, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pentelute, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, S. L.</span><span> </span><span class="NLM_article-title">Organometallic palladium reagents for cysteine bioconjugation</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">526</span><span class="NLM_x">, </span> <span class="NLM_fpage">687</span><span class="NLM_x">â</span> <span class="NLM_lpage">691</span><span class="refDoi">Â DOI: 10.1038/nature15739</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnature15739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26511579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslCnu7zK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=526&publication_year=2015&pages=687-691&author=E.+V.+Vinogradovaauthor=C.+Zhangauthor=A.+M.+Spokoynyauthor=B.+L.+Penteluteauthor=S.+L.+Buchwald&title=Organometallic+palladium+reagents+for+cysteine+bioconjugation&doi=10.1038%2Fnature15739"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184bR"><div class="casContent"><span class="casTitleNuber">184b</span><div class="casTitle"><span class="NLM_cas:atitle">Organometallic palladium reagents for cysteine bioconjugation</span></div><div class="casAuthors">Vinogradova, Ekaterina V.; Zhang, Chi; Spokoyny, Alexander M.; Pentelute, Bradley L.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">526</span>
        (<span class="NLM_cas:issue">7575</span>),
    <span class="NLM_cas:pages">687-691</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Peptides and proteins, contg. cysteine amino acid, were labeled by conjugation of the SH-group with arylpalladium 2-biphenylylphosphine hemilabile reagent, causing arylation the mercapto-group.  Reactions based on transition metals have found wide use in org. synthesis, in particular for the functionalization of small mols.  However, there are very few reports of using transition-metal-based reactions to modify complex biomols., which is due to the need for stringent reaction conditions (for example, aq. media, low temp. and mild pH) and the existence of multiple reactive functional groups found in biomols.  Here we report that palladium(II) complexes can be used for efficient and highly selective cysteine conjugation (bioconjugation) reactions that are rapid and robust under a range of bio-compatible reaction conditions.  The straightforward synthesis of the palladium reagents from diverse and easily accessible aryl halide and trifluoromethanesulfonate precursors makes the method highly practical, providing access to a large structural space for protein modification.  The resulting aryl bioconjugates are stable towards acids, bases, oxidants and external thiol nucleophiles.  The broad utility of the bioconjugation platform was further corroborated by the synthesis of new classes of stapled peptides and antibody-drug conjugates.  These palladium complexes show potential as benchtop reagents for diverse bioconjugation applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLRNU9i0UtEbVg90H21EOLACvtfcHk0livQvz6Gd7CVQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslCnu7zK&md5=8fbb382c94600af312bb007d31b63056</span></div><a href="/servlet/linkout?suffix=cit184b&amp;dbid=16384&amp;doi=10.1038%2Fnature15739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature15739%26sid%3Dliteratum%253Aachs%26aulast%3DVinogradova%26aufirst%3DE.%2BV.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DSpokoyny%26aufirst%3DA.%2BM.%26aulast%3DPentelute%26aufirst%3DB.%2BL.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DOrganometallic%2520palladium%2520reagents%2520for%2520cysteine%2520bioconjugation%26jtitle%3DNature%26date%3D2015%26volume%3D526%26spage%3D687%26epage%3D691%26doi%3D10.1038%2Fnature15739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group">Agten, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hackeng, T. M.</span><span> </span><span class="NLM_article-title">Oxime conjugation in protein chemistry: from carbonyl incorporation to nucleophilic catalysis</span> <span class="citation_source-journal">J. Pept. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">271</span><span class="NLM_x">â</span> <span class="NLM_lpage">279</span><span class="refDoi">Â DOI: 10.1002/psc.2874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fpsc.2874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=27006095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XksFGjsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=271-279&author=S.+M.+Agtenauthor=P.+E.+Dawsonauthor=T.+M.+Hackeng&title=Oxime+conjugation+in+protein+chemistry%3A+from+carbonyl+incorporation+to+nucleophilic+catalysis&doi=10.1002%2Fpsc.2874"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Oxime conjugation in protein chemistry: from carbonyl incorporation to nucleophilic catalysis</span></div><div class="casAuthors">Agten, Stijn M.; Dawson, Philip E.; Hackeng, Tilman M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">271-279</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Use of oxime forming reactions has become a widely applied strategy for peptide and protein bioconjugation.  The efficiency of the reaction and robust stability of the oxime product led to the development of a growing list of methods to introduce the required ketone or aldehyde functionality site specifically into proteins.  Early methods focused on site-specific oxidn. of an N-terminal serine or threonine and more recently transamination methods have been developed to convert a broader set of N-terminal amino acids into a ketone or aldehyde.  More recently, site-specific modification of protein has been attained through engineering enzymes involved in posttranslational modifications to accommodate aldehyde-contg. substrates.  Similarly, a growing list of unnatural amino acids can be introduced through development of selective amino-acyl tRNA synthetase/tRNA pairs combined with codon reassignment.  In the case of glycoproteins, glycans can be selectively modified chem. or enzymically to introduce aldehyde functional groups.  Finally, the total chem. synthesis of proteins complements these biol. and chemoenzymic approaches.  Once introduced, the oxime ligation of these aldehyde and ketone groups can be catalyzed by aniline or a variety of aniline derivs. to tune the activity, pH preference, stability and soly. of the catalyst.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowHo2_J0koqrVg90H21EOLACvtfcHk0lgI_c1kHb77NQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksFGjsrk%253D&md5=b616d6bf4a65fe8cbaa88d71dca3561b</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1002%2Fpsc.2874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.2874%26sid%3Dliteratum%253Aachs%26aulast%3DAgten%26aufirst%3DS.%2BM.%26aulast%3DDawson%26aufirst%3DP.%2BE.%26aulast%3DHackeng%26aufirst%3DT.%2BM.%26atitle%3DOxime%2520conjugation%2520in%2520protein%2520chemistry%253A%2520from%2520carbonyl%2520incorporation%2520to%2520nucleophilic%2520catalysis%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2016%26volume%3D22%26spage%3D271%26epage%3D279%26doi%3D10.1002%2Fpsc.2874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welborn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santos, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Voorhis, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pentelute, B. L.</span><span> </span><span class="NLM_article-title">Ï-Clamp-mediated cysteine conjugation</span> <span class="citation_source-journal">Nat. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">120</span><span class="NLM_x">â</span> <span class="NLM_lpage">128</span><span class="refDoi">Â DOI: 10.1038/nchem.2413</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnchem.2413" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26791894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVygurzE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=120-128&author=C.+Zhangauthor=M.+Welbornauthor=T.+Zhuauthor=N.+J.+Yangauthor=M.+S.+Santosauthor=T.+Van+Voorhisauthor=B.+L.+Pentelute&title=%CF%80-Clamp-mediated+cysteine+conjugation&doi=10.1038%2Fnchem.2413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Ï-Clamp-mediated cysteine conjugation</span></div><div class="casAuthors">Zhang, Chi; Welborn, Matthew; Zhu, Tianyu; Yang, Nicole J.; Santos, Michael S.; Van Voorhis, Troy; Pentelute, Bradley L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">120-128</span>CODEN:
                <span class="NLM_cas:coden">NCAHBB</span>;
        ISSN:<span class="NLM_cas:issn">1755-4330</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Site-selective functionalization of complex mols. is one of the most significant challenges in chem.  Typically, protecting groups or catalysts must be used to enable the selective modification of one site among many that are similarly reactive, and general strategies that selectively tune the local chem. environment around a target site are rare.  Here, the authors show a four-amino-acid sequence (Phe-Cys-Pro-Phe), which the authors call the Ï-clamp, that tunes the reactivity of its cysteine thiol for site-selective conjugation with perfluoroarom. reagents.  The authors use the Ï-clamp to selectively modify one cysteine site in proteins contg. multiple endogenous cysteine residues.  These examples include antibodies and cysteine-based enzymes that would be difficult to modify selectively using std. cysteine-based methods.  Antibodies modified using the Ï-clamp retained binding affinity to their targets, enabling the synthesis of site-specific antibody-drug conjugates for selective killing of HER2-pos. breast cancer cells.  The Ï-clamp is an unexpected approach to mediate site-selective chem. and provides new avenues to modify biomols. for research and therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN7ymIedFQd7Vg90H21EOLACvtfcHk0lgI_c1kHb77NQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVygurzE&md5=8c3c367f6fd7c64237bd0ba3e9bd40b4</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1038%2Fnchem.2413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchem.2413%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DWelborn%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DN.%2BJ.%26aulast%3DSantos%26aufirst%3DM.%2BS.%26aulast%3DVan%2BVoorhis%26aufirst%3DT.%26aulast%3DPentelute%26aufirst%3DB.%2BL.%26atitle%3D%25CF%2580-Clamp-mediated%2520cysteine%2520conjugation%26jtitle%3DNat.%2520Chem.%26date%3D2016%26volume%3D8%26spage%3D120%26epage%3D128%26doi%3D10.1038%2Fnchem.2413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group">Theile, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blom, A. E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kundrat, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ploegh, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guimaraes, C. P.</span><span> </span><span class="NLM_article-title">Site-specific N-terminal labeling of proteins using sortase-mediated reactions</span> <span class="citation_source-journal">Nat. Protoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1800</span><span class="NLM_x">â</span> <span class="NLM_lpage">1807</span><span class="refDoi">Â DOI: 10.1038/nprot.2013.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnprot.2013.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23989674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2hurrK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1800-1807&author=C.+S.+Theileauthor=M.+D.+Witteauthor=A.+E.+M.+Blomauthor=L.+Kundratauthor=H.+L.+Ploeghauthor=C.+P.+Guimaraes&title=Site-specific+N-terminal+labeling+of+proteins+using+sortase-mediated+reactions&doi=10.1038%2Fnprot.2013.102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Site-specific N-terminal labeling of proteins using sortase-mediated reactions</span></div><div class="casAuthors">Theile, Christopher S.; Witte, Martin D.; Blom, Annet E. M.; Kundrat, Lenka; Ploegh, Hidde L.; Guimaraes, Carla P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1800-1807, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This protocol describes the use of sortase-mediated reactions to label the N terminus of any given protein of interest.  The sortase recognition sequence, LPLPXTG (for Streptococcus aureus sortase A) or LPXTA (for Staphylococcus pyogenes sortase A), can be appended to a variety of probes such as fluorophores, biotin or even to other proteins.  The protein to be labeled acts as a nucleophile by attacking the intermediate formed between the probe contg. the LPXTG/A motif and the sortase enzyme.  If sortase, the protein of interest and a suitably functionalized label are available, the reactions usually require less than 3 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy2oSU1sYbKLVg90H21EOLACvtfcHk0lgI_c1kHb77NQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2hurrK&md5=3630095942671637c7b047ac2e69c85f</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2013.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2013.102%26sid%3Dliteratum%253Aachs%26aulast%3DTheile%26aufirst%3DC.%2BS.%26aulast%3DWitte%26aufirst%3DM.%2BD.%26aulast%3DBlom%26aufirst%3DA.%2BE.%2BM.%26aulast%3DKundrat%26aufirst%3DL.%26aulast%3DPloegh%26aufirst%3DH.%2BL.%26aulast%3DGuimaraes%26aufirst%3DC.%2BP.%26atitle%3DSite-specific%2520N-terminal%2520labeling%2520of%2520proteins%2520using%2520sortase-mediated%2520reactions%26jtitle%3DNat.%2520Protoc.%26date%3D2013%26volume%3D8%26spage%3D1800%26epage%3D1807%26doi%3D10.1038%2Fnprot.2013.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group">Wood, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camarero, J. A.</span><span> </span><span class="NLM_article-title">Intein applications: From protein purification and labeling to metabolic control methods</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">14512</span><span class="NLM_x">â</span> <span class="NLM_lpage">14519</span><span class="refDoi">Â DOI: 10.1074/jbc.R114.552653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1074%2Fjbc.R114.552653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24700459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXos1Cjurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=14512-14519&author=D.+W.+Woodauthor=J.+A.+Camarero&title=Intein+applications%3A+From+protein+purification+and+labeling+to+metabolic+control+methods&doi=10.1074%2Fjbc.R114.552653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Intein Applications: From Protein Purification and Labeling to Metabolic Control Methods</span></div><div class="casAuthors">Wood, David W.; Camarero, Julio A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">14512-14519</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review.  The discovery of inteins in the early 1990s opened the door to a wide variety of new technologies.  Early engineered inteins from various sources allowed the development of self-cleaving affinity tags and new methods for joining protein segments through expressed protein ligation.  Some applications were developed around native and engineered split inteins, which allow protein segments expressed sep. to be spliced together in vitro.  More recently, these early applications have been expanded and optimized through the discovery of highly efficient trans-splicing and trans-cleaving inteins.  These new inteins have enabled a wide variety of applications in metabolic engineering, protein labeling, biomaterials construction, protein cyclization, and protein purifn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZEPIbg2R7SbVg90H21EOLACvtfcHk0lgI_c1kHb77NQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXos1Cjurk%253D&md5=f14b096b63bb55957d0d5fe27a33a715</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1074%2Fjbc.R114.552653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.R114.552653%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DD.%2BW.%26aulast%3DCamarero%26aufirst%3DJ.%2BA.%26atitle%3DIntein%2520applications%253A%2520From%2520protein%2520purification%2520and%2520labeling%2520to%2520metabolic%2520control%2520methods%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D14512%26epage%3D14519%26doi%3D10.1074%2Fjbc.R114.552653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kim, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Axup, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, P. G.</span><span> </span><span class="NLM_article-title">Protein conjugation with genetically encoded unnatural amino acids</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">412</span><span class="NLM_x">â</span> <span class="NLM_lpage">419</span><span class="refDoi">Â DOI: 10.1016/j.cbpa.2013.04.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.cbpa.2013.04.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23664497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVGgsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=412-419&author=C.+H.+Kimauthor=J.+Y.+Axupauthor=P.+G.+Schultz&title=Protein+conjugation+with+genetically+encoded+unnatural+amino+acids&doi=10.1016%2Fj.cbpa.2013.04.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189aR"><div class="casContent"><span class="casTitleNuber">189a</span><div class="casTitle"><span class="NLM_cas:atitle">Protein conjugation with genetically encoded unnatural amino acids</span></div><div class="casAuthors">Kim, Chan Hyuk; Axup, Jun Y.; Schultz, Peter G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">412-419</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The site-specific incorporation of unnatural amino acids with orthogonal chem. reactivity into proteins enables the synthesis of structurally defined protein conjugates.  Amino acids contg. ketone, azide, alkyne, alkene, and tetrazine side chains can be genetically encoded in response to nonsense and frameshift codons.  These bio-orthogonal chem. handles allow precise control over the site and stoichiometry of conjugation, and have enabled medicinal chem.-like optimization of the phys. and biol. properties of protein conjugates, esp. the next-generation protein therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQfHma4vcPzLVg90H21EOLACvtfcHk0lih-KE4bljW4A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVGgsrs%253D&md5=2fded16f212df5db3f709bdd38e87887</span></div><a href="/servlet/linkout?suffix=cit189a&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2013.04.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2013.04.017%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DC.%2BH.%26aulast%3DAxup%26aufirst%3DJ.%2BY.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26atitle%3DProtein%2520conjugation%2520with%2520genetically%2520encoded%2520unnatural%2520amino%2520acids%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D17%26spage%3D412%26epage%3D419%26doi%3D10.1016%2Fj.cbpa.2013.04.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit189b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lim, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, I.</span><span> </span><span class="NLM_article-title">Bioconjugation of therapeutic proteins and enzymes using the expanded set of genetically encoded amino acids</span> <span class="citation_source-journal">Crit. Rev. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">803</span><span class="NLM_x">â</span> <span class="NLM_lpage">815</span><span class="refDoi">Â DOI: 10.3109/07388551.2015.1048504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3109%2F07388551.2015.1048504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26036278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ehtbbL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=803-815&author=S.+I.+Limauthor=I.+Kwon&title=Bioconjugation+of+therapeutic+proteins+and+enzymes+using+the+expanded+set+of+genetically+encoded+amino+acids&doi=10.3109%2F07388551.2015.1048504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189bR"><div class="casContent"><span class="casTitleNuber">189b</span><div class="casTitle"><span class="NLM_cas:atitle">Bioconjugation of therapeutic proteins and enzymes using the expanded set of genetically encoded amino acids</span></div><div class="casAuthors">Lim, Sung In; Kwon, Inchan</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Biotechnology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">803-815</span>CODEN:
                <span class="NLM_cas:coden">CRBTE5</span>;
        ISSN:<span class="NLM_cas:issn">0738-8551</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  The last decade has witnessed striking progress in the development of bioorthogonal reactions that are strictly directed towards intended sites in biomols. while avoiding interference by a no. of phys. and chem. factors in biol. environment.  Efforts to exploit bioorthogonal reactions in protein conjugation have led to the evolution of protein translational machineries and the expansion of genetic codes that systematically incorporate a range of non-natural amino acids contg. bioorthogonal groups into recombinant proteins in a site-specific manner.  Chemoselective conjugation of proteins has begun to find valuable applications to previously inaccessible problems.  In this review, we describe bioorthogonal reactions useful for protein conjugation, and biosynthetic methods that produce proteins amenable to those reactions through an expanded genetic code.  We then provide key examples in which novel protein conjugates, generated by the genetic incorporation of a non-natural amino acid and the chemoselective reactions, address unmet needs in protein therapeutics and enzyme engineering.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonOUvKYaG7bLVg90H21EOLACvtfcHk0lih-KE4bljW4A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ehtbbL&md5=fca815073051ed3ee3fc403f4d5cdfb6</span></div><a href="/servlet/linkout?suffix=cit189b&amp;dbid=16384&amp;doi=10.3109%2F07388551.2015.1048504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F07388551.2015.1048504%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DS.%2BI.%26aulast%3DKwon%26aufirst%3DI.%26atitle%3DBioconjugation%2520of%2520therapeutic%2520proteins%2520and%2520enzymes%2520using%2520the%2520expanded%2520set%2520of%2520genetically%2520encoded%2520amino%2520acids%26jtitle%3DCrit.%2520Rev.%2520Biotechnol.%26date%3D2016%26volume%3D36%26spage%3D803%26epage%3D815%26doi%3D10.3109%2F07388551.2015.1048504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group">Chirmule, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jawa, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meibohm, B.</span><span> </span><span class="NLM_article-title">Immunogenicity to therapeutic proteins: Impact on PK/PD and efficacy</span> <span class="citation_source-journal">AAPS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">296</span><span class="NLM_x">â</span> <span class="NLM_lpage">302</span><span class="refDoi">Â DOI: 10.1208/s12248-012-9340-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1208%2Fs12248-012-9340-y" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=296-302&author=N.+Chirmuleauthor=V.+Jawaauthor=B.+Meibohm&title=Immunogenicity+to+therapeutic+proteins%3A+Impact+on+PK%2FPD+and+efficacy&doi=10.1208%2Fs12248-012-9340-y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1208%2Fs12248-012-9340-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-012-9340-y%26sid%3Dliteratum%253Aachs%26aulast%3DChirmule%26aufirst%3DN.%26aulast%3DJawa%26aufirst%3DV.%26aulast%3DMeibohm%26aufirst%3DB.%26atitle%3DImmunogenicity%2520to%2520therapeutic%2520proteins%253A%2520Impact%2520on%2520PK%252FPD%2520and%2520efficacy%26jtitle%3DAAPS%2520J.%26date%3D2012%26volume%3D14%26spage%3D296%26epage%3D302%26doi%3D10.1208%2Fs12248-012-9340-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group">Jawa, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cousens, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awwad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakshull, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kropshofer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Groot, A. S.</span><span> </span><span class="NLM_article-title">T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation</span> <span class="citation_source-journal">Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">149</span><span class="NLM_x">, </span> <span class="NLM_fpage">534</span><span class="NLM_x">â</span> <span class="NLM_lpage">555</span><span class="refDoi">Â DOI: 10.1016/j.clim.2013.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.clim.2013.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24263283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFeks7%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2013&pages=534-555&author=V.+Jawaauthor=L.+P.+Cousensauthor=M.+Awwadauthor=E.+Wakshullauthor=H.+Kropshoferauthor=A.+S.+De+Groot&title=T-cell+dependent+immunogenicity+of+protein+therapeutics%3A+Preclinical+assessment+and+mitigation&doi=10.1016%2Fj.clim.2013.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation</span></div><div class="casAuthors">Jawa, Vibha; Cousens, Leslie P.; Awwad, Michel; Wakshull, Eric; Kropshofer, Harald; De Groot, Anne S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Immunology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">3PB</span>),
    <span class="NLM_cas:pages">534-555</span>CODEN:
                <span class="NLM_cas:coden">CLIIFY</span>;
        ISSN:<span class="NLM_cas:issn">1521-6616</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Protein therapeutics hold a prominent and rapidly expanding place among medicinal products.  Purified blood products, recombinant cytokines, growth factors, enzyme replacement factors, monoclonal antibodies, fusion proteins, and chimeric fusion proteins are all examples of therapeutic proteins that have been developed in the past few decades and approved for use in the treatment of human disease.  Despite early belief that the fully human nature of these proteins would represent a significant advantage, adverse effects assocd. with immune responses to some biol. therapies have become a topic of some concern.  As a result, drug developers are devising strategies to assess immune responses to protein therapeutics during both the preclin. and the clin. phases of development.  While there are many factors that contribute to protein immunogenicity, T cell- (thymus-) dependent (Td) responses appear to play a crit. role in the development of antibody responses to biol. therapeutics.  A range of methodologies to predict and measure Td immune responses to protein drugs has been developed.  This review will focus on the Td contribution to immunogenicity, summarizing current approaches for the prediction and measurement of T cell-dependent immune responses to protein biologics, discussing the advantages and limitations of these technologies, and suggesting a practical approach for assessing and mitigating Td immunogenicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdjcl9PB-KorVg90H21EOLACvtfcHk0lih-KE4bljW4A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFeks7%252FF&md5=f4f05e6e8d07d42407ca0d8b0654502f</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1016%2Fj.clim.2013.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clim.2013.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DJawa%26aufirst%3DV.%26aulast%3DCousens%26aufirst%3DL.%2BP.%26aulast%3DAwwad%26aufirst%3DM.%26aulast%3DWakshull%26aufirst%3DE.%26aulast%3DKropshofer%26aufirst%3DH.%26aulast%3DDe%2BGroot%26aufirst%3DA.%2BS.%26atitle%3DT-cell%2520dependent%2520immunogenicity%2520of%2520protein%2520therapeutics%253A%2520Preclinical%2520assessment%2520and%2520mitigation%26jtitle%3DClin.%2520Immunol.%26date%3D2013%26volume%3D149%26spage%3D534%26epage%3D555%26doi%3D10.1016%2Fj.clim.2013.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group">Baker, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lumicisi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryson, C. J.</span><span> </span><span class="NLM_article-title">Immunogenicity of protein therapeutics: The key causes, consequences and challenges</span> <span class="citation_source-journal">Self Nonself</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">â</span> <span class="NLM_lpage">322</span><span class="refDoi">Â DOI: 10.4161/self.1.4.13904</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.4161%2Fself.1.4.13904" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21487506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A280%3ADC%252BC2sbosl2ltA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=314-322&author=M.+P.+Bakerauthor=H.+M.+Reynoldsauthor=B.+Lumicisiauthor=C.+J.+Bryson&title=Immunogenicity+of+protein+therapeutics%3A+The+key+causes%2C+consequences+and+challenges&doi=10.4161%2Fself.1.4.13904"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Immunogenicity of protein therapeutics: The key causes, consequences and challenges</span></div><div class="casAuthors">Baker Matthew P; Reynolds Helen M; Lumicisi Brooke; Bryson Christine J</div><div class="citationInfo"><span class="NLM_cas:title">Self/nonself</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">314-322</span>
        ISSN:<span class="NLM_cas:issn">1938-2030</span>.
    </div><div class="casAbstract">The immunogenicity of protein therapeutics has so far proven to be difficult to predict in patients, with many biologics inducing undesirable immune responses directed towards the therapeutic resulting in reduced efficacy, anaphylaxis and occasionally life threatening autoimmunity.  The most common effect of administrating an immunogenic protein therapeutic is the development of a high affinity anti-therapeutic antibody response.  Furthermore, it is clear from clinical studies that protein therapeutics derived from endogenous human proteins are capable of stimulating undesirable immune responses in patients, and as a consequence, the prediction and reduction of immunogenicity has been the focus of intense research.  This review will outline the principle causes of the immunogenicity in protein therapeutics, and describe the development of pre-clinical models that can be used to aid in the prediction of the immunogenic potential of novel protein therapeutics prior to administration in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTP1ugBfdLNc36CEoQgWY10fW6udTcc2eYm_bwLZmjjD7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sbosl2ltA%253D%253D&md5=0fa913c65486289a38df1e06faa211b3</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.4161%2Fself.1.4.13904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fself.1.4.13904%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DM.%2BP.%26aulast%3DReynolds%26aufirst%3DH.%2BM.%26aulast%3DLumicisi%26aufirst%3DB.%26aulast%3DBryson%26aufirst%3DC.%2BJ.%26atitle%3DImmunogenicity%2520of%2520protein%2520therapeutics%253A%2520The%2520key%2520causes%252C%2520consequences%2520and%2520challenges%26jtitle%3DSelf%2520Nonself%26date%3D2010%26volume%3D1%26spage%3D314%26epage%3D322%26doi%3D10.4161%2Fself.1.4.13904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group">Rosenstock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charbonnel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolli, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boldrin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balena, R.</span><span> </span><span class="NLM_article-title">The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes</span> <span class="citation_source-journal">Diabetes Care</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">498</span><span class="NLM_x">â</span> <span class="NLM_lpage">504</span><span class="refDoi">Â DOI: 10.2337/dc12-0709</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.2337%2Fdc12-0709" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2013&pages=498-504&author=J.+Rosenstockauthor=B.+Balasauthor=B.+Charbonnelauthor=G.+B.+Bolliauthor=M.+Boldrinauthor=R.+Ratnerauthor=R.+Balena&title=The+fate+of+taspoglutide%2C+a+weekly+GLP-1+receptor+agonist%2C+versus+twice-daily+exenatide+for+type+2+diabetes&doi=10.2337%2Fdc12-0709"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.2337%2Fdc12-0709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdc12-0709%26sid%3Dliteratum%253Aachs%26aulast%3DRosenstock%26aufirst%3DJ.%26aulast%3DBalas%26aufirst%3DB.%26aulast%3DCharbonnel%26aufirst%3DB.%26aulast%3DBolli%26aufirst%3DG.%2BB.%26aulast%3DBoldrin%26aufirst%3DM.%26aulast%3DRatner%26aufirst%3DR.%26aulast%3DBalena%26aufirst%3DR.%26atitle%3DThe%2520fate%2520of%2520taspoglutide%252C%2520a%2520weekly%2520GLP-1%2520receptor%2520agonist%252C%2520versus%2520twice-daily%2520exenatide%2520for%2520type%25202%2520diabetes%26jtitle%3DDiabetes%2520Care%26date%3D2013%26volume%3D36%26spage%3D498%26epage%3D504%26doi%3D10.2337%2Fdc12-0709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Casadevall, N.</span><span> </span><span class="NLM_article-title">Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin</span> <span class="citation_source-journal">Nephrol., Dial., Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">viii37</span><span class="NLM_x">â</span> <span class="NLM_lpage">viii41</span><span class="refDoi">Â DOI: 10.1093/ndt/gfg1091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1093%2Fndt%2Fgfg1091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=14608000" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2003&pages=viii37-viii41&author=N.+Casadevall&title=Pure+red+cell+aplasia+and+anti-erythropoietin+antibodies+in+patients+treated+with+epoetin&doi=10.1093%2Fndt%2Fgfg1091"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit194a&amp;dbid=16384&amp;doi=10.1093%2Fndt%2Fgfg1091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fndt%252Fgfg1091%26sid%3Dliteratum%253Aachs%26aulast%3DCasadevall%26aufirst%3DN.%26atitle%3DPure%2520red%2520cell%2520aplasia%2520and%2520anti-erythropoietin%2520antibodies%2520in%2520patients%2520treated%2520with%2520epoetin%26jtitle%3DNephrol.%252C%2520Dial.%252C%2520Transplant.%26date%3D2003%26volume%3D18%26spage%3Dviii37%26epage%3Dviii41%26doi%3D10.1093%2Fndt%2Fgfg1091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit194b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Casadevall, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nataf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viron, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiladjian, J.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Dupont, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaud, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teyssandier, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varet, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayeux, P.</span><span> </span><span class="NLM_article-title">Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">346</span><span class="NLM_x">, </span> <span class="NLM_fpage">469</span><span class="NLM_x">â</span> <span class="NLM_lpage">475</span><span class="refDoi">Â DOI: 10.1056/NEJMoa011931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1056%2FNEJMoa011931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=11844847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtFCktr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2002&pages=469-475&author=N.+Casadevallauthor=J.+Natafauthor=B.+Vironauthor=A.+Koltaauthor=J.-J.+Kiladjianauthor=P.+Martin-Dupontauthor=P.+Michaudauthor=T.+Papoauthor=V.+Ugoauthor=I.+Teyssandierauthor=B.+Varetauthor=P.+Mayeux&title=Pure+Red-Cell+Aplasia+and+Antierythropoietin+Antibodies+in+Patients+Treated+with+Recombinant+Erythropoietin&doi=10.1056%2FNEJMoa011931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194bR"><div class="casContent"><span class="casTitleNuber">194b</span><div class="casTitle"><span class="NLM_cas:atitle">Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin</span></div><div class="casAuthors">Casadevall, Nicole; Nataf, Joelle; Viron, Beatrice; Kolta, Amir; Kiladjian, Jean-Jacques; Martin-Dupont, Philippe; Michaud, Patrick; Pap, Thomas; Ugo, Valerie; Teyssandier, Irene; Varet, Bruno; Mayeux, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">469-475</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Within a period of three years, we identified 13 patients in whom pure red-cell aplasia developed during treatment with recombinant human erythropoietin (epoetin).  We investigated whether there was an immunol. basis for the anemia in these patients.  Serum samples from the 13 patients with pure red-cell aplasia were tested for neutralizing antibodies that could inhibit erythroid-colony formation by normal bone marrow cells in vitro.  The presence of antierythropoietin antibodies was identified by means of binding assays with the use of radiolabeled intact, deglycosylated, or denatured epoetin.  Serum from all 13 patients blocked the formation of erythroid colonies by normal bone marrow cells.  The inhibition was reversed by epoetin.  Antibodies from 12 of the 13 patients bound only conformational epitopes in the protein moiety of epoetin; serum from the remaining patient bound to both conformational and linear epitopes in erythropoietin.  In all the patients, the antibody titer slowly decreased after the discontinuation of treatment with epoetin.  Neutralizing antierythropoietin antibodies and pure red-cell aplasia can develop in patients with the anemia of chronic renal failure during treatment with epoetin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaxcP6aygOU7Vg90H21EOLACvtfcHk0ljbOjztx7oMNQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtFCktr8%253D&md5=6b5fdf9fb67db136327e78e0400885c2</span></div><a href="/servlet/linkout?suffix=cit194b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa011931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa011931%26sid%3Dliteratum%253Aachs%26aulast%3DCasadevall%26aufirst%3DN.%26aulast%3DNataf%26aufirst%3DJ.%26aulast%3DViron%26aufirst%3DB.%26aulast%3DKolta%26aufirst%3DA.%26aulast%3DKiladjian%26aufirst%3DJ.-J.%26aulast%3DMartin-Dupont%26aufirst%3DP.%26aulast%3DMichaud%26aufirst%3DP.%26aulast%3DPapo%26aufirst%3DT.%26aulast%3DUgo%26aufirst%3DV.%26aulast%3DTeyssandier%26aufirst%3DI.%26aulast%3DVaret%26aufirst%3DB.%26aulast%3DMayeux%26aufirst%3DP.%26atitle%3DPure%2520Red-Cell%2520Aplasia%2520and%2520Antierythropoietin%2520Antibodies%2520in%2520Patients%2520Treated%2520with%2520Recombinant%2520Erythropoietin%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2002%26volume%3D346%26spage%3D469%26epage%3D475%26doi%3D10.1056%2FNEJMoa011931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Van Regenmortel, M. H. V.</span><span> </span><span class="NLM_article-title">Antigenicity and immunogenicity of synthetic peptides</span> <span class="citation_source-journal">Biologicals</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">â</span> <span class="NLM_lpage">213</span><span class="refDoi">Â DOI: 10.1006/biol.2001.0308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1006%2Fbiol.2001.0308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=11851317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD38Xht1Olu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2001&pages=209-213&author=M.+H.+V.+Van+Regenmortel&title=Antigenicity+and+immunogenicity+of+synthetic+peptides&doi=10.1006%2Fbiol.2001.0308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195aR"><div class="casContent"><span class="casTitleNuber">195a</span><div class="casTitle"><span class="NLM_cas:atitle">Antigenicity and immunogenicity of synthetic peptides</span></div><div class="casAuthors">Van Regenmortel, M. H. V.</div><div class="citationInfo"><span class="NLM_cas:title">Biologicals</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3/4</span>),
    <span class="NLM_cas:pages">209-213</span>CODEN:
                <span class="NLM_cas:coden">BILSEC</span>;
        ISSN:<span class="NLM_cas:issn">1045-1056</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review.  The ability of a peptide to react specifically with the functional binding site of a complementary antibody is known as its antigenic reactivity or antigenicity.  Our understanding of peptide antigenicity has improved considerably in recent years mainly through the x-ray crystallog. anal. of peptide-monoclonal antibody complexes.  This knowledge is obtained along reductionist lines by turning the biol. question of antigen recognition into the purely chem. phenomenon of protein-peptide interactions described in terms of at. forces and non-covalent bonds.  This makes it possible to improve the degree of steric complementarity between a peptide and a single monoclonal antibody and thus to improve the peptide's antigenicity following structure-based rational design principles.  The situation is quite different with immunogenicity which is the ability of the peptide to induce an immune response in a competent host.  Whereas antigenicity can be reduced to the level of chem., such a redn. is not achievable in the case of immunogenicity which depends on many complex interactions with various elements of the host immune system.  These cellular and regulatory mechanisms cannot be controlled by adjusting the structure of the peptide in a predetd. manner.  For this reason, it is not possible to develop a synthetic peptide vaccine using mol. design principles.  (c) 2001 The International Association of Biological Standardization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSUpBhbMtKJrVg90H21EOLACvtfcHk0ljbOjztx7oMNQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xht1Olu7g%253D&md5=c0e9d2c6985d5896024ce985420e0b6b</span></div><a href="/servlet/linkout?suffix=cit195a&amp;dbid=16384&amp;doi=10.1006%2Fbiol.2001.0308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbiol.2001.0308%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BRegenmortel%26aufirst%3DM.%2BH.%2BV.%26atitle%3DAntigenicity%2520and%2520immunogenicity%2520of%2520synthetic%2520peptides%26jtitle%3DBiologicals%26date%3D2001%26volume%3D29%26spage%3D209%26epage%3D213%26doi%3D10.1006%2Fbiol.2001.0308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit195b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Milton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milton, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, S. B.</span><span> </span><span class="NLM_article-title">Total chemical synthesis of a D-enzyme: the enantiomers of HIV-1 protease show reciprocal chiral substrate specificity</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">256</span><span class="NLM_x">, </span> <span class="NLM_fpage">1445</span><span class="NLM_x">â</span> <span class="NLM_lpage">1448</span><span class="refDoi">Â DOI: 10.1126/science.1604320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1126%2Fscience.1604320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1604320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADyaK38XltFajtbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=256&publication_year=1992&pages=1445-1448&author=R.+C.+Miltonauthor=S.+C.+Miltonauthor=S.+B.+Kent&title=Total+chemical+synthesis+of+a+D-enzyme%3A+the+enantiomers+of+HIV-1+protease+show+reciprocal+chiral+substrate+specificity&doi=10.1126%2Fscience.1604320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195bR"><div class="casContent"><span class="casTitleNuber">195b</span><div class="casTitle"><span class="NLM_cas:atitle">Total chemical synthesis of a D-enzyme:  the enantiomers of HIV-1 protease show demonstration of reciprocal chiral substrate specificity</span></div><div class="casAuthors">Milton, R. C. L.; Milton, S. C. F.; Kent, S. B. H.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">256</span>
        (<span class="NLM_cas:issue">5062</span>),
    <span class="NLM_cas:pages">1445-8</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The D and L forms of the enzyme HIV-1 protease have been prepd. by total chem. synthesis.  The two proteins had identical covalent structures.  However, the folded protein enzyme enantiomers showed reciprocal chiral specificity on peptide substrates.  I.e., each enzyme enantiomer cut only the corresponding substrate enantiomer.  Reciprocal chiral specificity was also evident in the effect of enantiomeric inhibitors.  These data imply that the folded forms of the chem. synthesized D- and L-enzyme mols. are mirror images of one another in all elements of the three-dimensional structure.  Enantiomeric proteins are expected to display reciprocal chiral specificity in all aspects of their biochem. interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_qxm_qTyi1rVg90H21EOLACvtfcHk0ljGwRjUa4kEhg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XltFajtbs%253D&md5=8f0148fa541fdaa97e043f31a99b184c</span></div><a href="/servlet/linkout?suffix=cit195b&amp;dbid=16384&amp;doi=10.1126%2Fscience.1604320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1604320%26sid%3Dliteratum%253Aachs%26aulast%3DMilton%26aufirst%3DR.%2BC.%26aulast%3DMilton%26aufirst%3DS.%2BC.%26aulast%3DKent%26aufirst%3DS.%2BB.%26atitle%3DTotal%2520chemical%2520synthesis%2520of%2520a%2520D-enzyme%253A%2520the%2520enantiomers%2520of%2520HIV-1%2520protease%2520show%2520reciprocal%2520chiral%2520substrate%2520specificity%26jtitle%3DScience%26date%3D1992%26volume%3D256%26spage%3D1445%26epage%3D1448%26doi%3D10.1126%2Fscience.1604320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Benkirane, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friede, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guichard, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briand, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Regenmortel, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, S.</span><span> </span><span class="NLM_article-title">Antigenicity and immunogenicity of modified synthetic peptides containing D-amino acid residues. Antibodies to a D-enantiomer do recognize the parent L-hexapeptide and reciprocally</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">268</span><span class="NLM_x">, </span> <span class="NLM_fpage">26279</span><span class="NLM_x">â</span> <span class="NLM_lpage">26285</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=26279-26285&author=N.+Benkiraneauthor=M.+Friedeauthor=G.+Guichardauthor=J.+P.+Briandauthor=M.+H.+Van+Regenmortelauthor=S.+Muller&title=Antigenicity+and+immunogenicity+of+modified+synthetic+peptides+containing+D-amino+acid+residues.+Antibodies+to+a+D-enantiomer+do+recognize+the+parent+L-hexapeptide+and+reciprocally"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit196a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBenkirane%26aufirst%3DN.%26aulast%3DFriede%26aufirst%3DM.%26aulast%3DGuichard%26aufirst%3DG.%26aulast%3DBriand%26aufirst%3DJ.%2BP.%26aulast%3DVan%2BRegenmortel%26aufirst%3DM.%2BH.%26aulast%3DMuller%26aufirst%3DS.%26atitle%3DAntigenicity%2520and%2520immunogenicity%2520of%2520modified%2520synthetic%2520peptides%2520containing%2520D-amino%2520acid%2520residues.%2520Antibodies%2520to%2520a%2520D-enantiomer%2520do%2520recognize%2520the%2520parent%2520L-hexapeptide%2520and%2520reciprocally%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D26279%26epage%3D26285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit196b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sela, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zisman, E.</span><span> </span><span class="NLM_article-title">Different roles of D-amino acids in immune phenomena</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">449</span><span class="NLM_x">â</span> <span class="NLM_lpage">456</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1997&pages=449-456&author=M.+Selaauthor=E.+Zisman&title=Different+roles+of+D-amino+acids+in+immune+phenomena"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit196b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSela%26aufirst%3DM.%26aulast%3DZisman%26aufirst%3DE.%26atitle%3DDifferent%2520roles%2520of%2520D-amino%2520acids%2520in%2520immune%2520phenomena%26jtitle%3DFASEB%2520J.%26date%3D1997%26volume%3D11%26spage%3D449%26epage%3D456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group">Perry, L. C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, M. P.</span><span> </span><span class="NLM_article-title">New approaches to prediction of immune responses to therapeutic proteins during preclinical development</span> <span class="citation_source-journal">Drugs R&amp;D</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">â</span> <span class="NLM_lpage">396</span><span class="refDoi">Â DOI: 10.2165/0126839-200809060-00004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.2165%2F0126839-200809060-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=18989990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsVaktQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=385-396&author=L.+C.+A.+Perryauthor=T.+D.+Jonesauthor=M.+P.+Baker&title=New+approaches+to+prediction+of+immune+responses+to+therapeutic+proteins+during+preclinical+development&doi=10.2165%2F0126839-200809060-00004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">New approaches to prediction of immune responses to therapeutic proteins during preclinical development</span></div><div class="casAuthors">Perry, Laura C. A.; Jones, Timothy D.; Baker, Matthew P.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs in R&D</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">385-396</span>CODEN:
                <span class="NLM_cas:coden">DRDDFD</span>;
        ISSN:<span class="NLM_cas:issn">1174-5886</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer Health</span>)
        </div><div class="casAbstract">A review.  Clin. studies show that immunogenicity obsd. against therapeutic proteins can limit efficacy and reduce the safety of the treatment.  It is therefore beneficial to be able to predict the immunogenicity of therapeutic proteins before they enter the clinic.  Studies using deimmunized proteins have highlighted the importance of T-cell epitopes in the generation of undesirable immunogenicity.  In silico, in vitro, ex vivo and in vivo methods have therefore been developed that focus on identification of CD4+ T-cell epitopes in the sequence of therapeutic proteins.  A case study of existing therapeutic proteins is presented to review these different approaches in order to assess their utility in predicting immunogenic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr24wFMMRGF0LVg90H21EOLACvtfcHk0ljGwRjUa4kEhg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsVaktQ%253D%253D&md5=9c4f75c046cf9a68410a1731c797030b</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.2165%2F0126839-200809060-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F0126839-200809060-00004%26sid%3Dliteratum%253Aachs%26aulast%3DPerry%26aufirst%3DL.%2BC.%2BA.%26aulast%3DJones%26aufirst%3DT.%2BD.%26aulast%3DBaker%26aufirst%3DM.%2BP.%26atitle%3DNew%2520approaches%2520to%2520prediction%2520of%2520immune%2520responses%2520to%2520therapeutic%2520proteins%2520during%2520preclinical%2520development%26jtitle%3DDrugs%2520R%2526amp%253BD%26date%3D2008%26volume%3D9%26spage%3D385%26epage%3D396%26doi%3D10.2165%2F0126839-200809060-00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span>EpiScreen Time Course T Cell Assay; <span class="NLM_publisher-name">Abenza</span>: <span class="NLM_publisher-loc">San Diego, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">; </span><a href="http://www.abzena.com/development-services/immunology/immunogenicity-assessment/episcreen-time-course-t-cell-assay/" class="extLink">http://www.abzena.com/development-services/immunology/immunogenicity-assessment/episcreen-time-course-t-cell-assay/</a> (accessed January 17, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=EpiScreen+Time+Course+T+Cell+Assay%3B+Abenza%3A+San+Diego%2C+CA%2C+2017%3B+http%3A%2F%2Fwww.abzena.com%2Fdevelopment-services%2Fimmunology%2Fimmunogenicity-assessment%2Fepiscreen-time-course-t-cell-assay%2F+%28accessed+January+17%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DEpiScreen%2520Time%2520Course%2520T%2520Cell%2520Assay%26pub%3DAbenza%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group">Baker, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, T. D.</span><span> </span><span class="NLM_article-title">Identification and removal of immunogenicity in therapeutic proteins</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">â</span> <span class="NLM_lpage">227</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2007&pages=219-227&author=M.+P.+Bakerauthor=T.+D.+Jones&title=Identification+and+removal+of+immunogenicity+in+therapeutic+proteins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DM.%2BP.%26aulast%3DJones%26aufirst%3DT.%2BD.%26atitle%3DIdentification%2520and%2520removal%2520of%2520immunogenicity%2520in%2520therapeutic%2520proteins%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2007%26volume%3D10%26spage%3D219%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group">Ho, C.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocchi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piek, T.</span><span> </span><span class="NLM_article-title">Comparison of the immunogenicity of wasp venom peptides with or without carbohydrate moieties</span> <span class="citation_source-journal">Toxicon</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">â</span> <span class="NLM_lpage">221</span><span class="refDoi">Â DOI: 10.1016/S0041-0101(97)00066-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2FS0041-0101%2897%2900066-4" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1998&pages=217-221&author=C.-L.+Hoauthor=Y.-L.+Linauthor=W.-C.+Chenauthor=R.+Rocchiauthor=T.+Piek&title=Comparison+of+the+immunogenicity+of+wasp+venom+peptides+with+or+without+carbohydrate+moieties&doi=10.1016%2FS0041-0101%2897%2900066-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1016%2FS0041-0101%2897%2900066-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0041-0101%252897%252900066-4%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DC.-L.%26aulast%3DLin%26aufirst%3DY.-L.%26aulast%3DChen%26aufirst%3DW.-C.%26aulast%3DRocchi%26aufirst%3DR.%26aulast%3DPiek%26aufirst%3DT.%26atitle%3DComparison%2520of%2520the%2520immunogenicity%2520of%2520wasp%2520venom%2520peptides%2520with%2520or%2520without%2520carbohydrate%2520moieties%26jtitle%3DToxicon%26date%3D1998%26volume%3D36%26spage%3D217%26epage%3D221%26doi%3D10.1016%2FS0041-0101%2897%2900066-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group">De Serres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillberger, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchins, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boytos, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weigl, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DePrince, R. B.</span><span> </span><span class="NLM_article-title">Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits: Evaluation of the potential for thrombopoietin neutralizing antibody production in man</span> <span class="citation_source-journal">Stem Cells</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">â</span> <span class="NLM_lpage">209</span><span class="refDoi">Â DOI: 10.1002/stem.170203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fstem.170203" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=203-209&author=M.+De+Serresauthor=B.+Ellisauthor=J.+E.+Dillbergerauthor=S.+K.+Rudolphauthor=J.+T.+Hutchinsauthor=C.+M.+Boytosauthor=D.+L.+Weiglauthor=R.+B.+DePrince&title=Immunogenicity+of+thrombopoietin+mimetic+peptide+GW395058+in+BALB%2Fc+mice+and+New+Zealand+white+rabbits%3A+Evaluation+of+the+potential+for+thrombopoietin+neutralizing+antibody+production+in+man&doi=10.1002%2Fstem.170203"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1002%2Fstem.170203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fstem.170203%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSerres%26aufirst%3DM.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DDillberger%26aufirst%3DJ.%2BE.%26aulast%3DRudolph%26aufirst%3DS.%2BK.%26aulast%3DHutchins%26aufirst%3DJ.%2BT.%26aulast%3DBoytos%26aufirst%3DC.%2BM.%26aulast%3DWeigl%26aufirst%3DD.%2BL.%26aulast%3DDePrince%26aufirst%3DR.%2BB.%26atitle%3DImmunogenicity%2520of%2520thrombopoietin%2520mimetic%2520peptide%2520GW395058%2520in%2520BALB%252Fc%2520mice%2520and%2520New%2520Zealand%2520white%2520rabbits%253A%2520Evaluation%2520of%2520the%2520potential%2520for%2520thrombopoietin%2520neutralizing%2520antibody%2520production%2520in%2520man%26jtitle%3DStem%2520Cells%26date%3D1999%26volume%3D17%26spage%3D203%26epage%3D209%26doi%3D10.1002%2Fstem.170203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group">Brinks, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiskoot, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellekens, H.</span><span> </span><span class="NLM_article-title">Immunogenicity of therapeutic proteins: The use of animal models</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">2379</span><span class="NLM_x">â</span> <span class="NLM_lpage">2385</span><span class="refDoi">Â DOI: 10.1007/s11095-011-0523-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1007%2Fs11095-011-0523-5" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2011&pages=2379-2385&author=V.+Brinksauthor=W.+Jiskootauthor=H.+Schellekens&title=Immunogenicity+of+therapeutic+proteins%3A+The+use+of+animal+models&doi=10.1007%2Fs11095-011-0523-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1007%2Fs11095-011-0523-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-011-0523-5%26sid%3Dliteratum%253Aachs%26aulast%3DBrinks%26aufirst%3DV.%26aulast%3DJiskoot%26aufirst%3DW.%26aulast%3DSchellekens%26aufirst%3DH.%26atitle%3DImmunogenicity%2520of%2520therapeutic%2520proteins%253A%2520The%2520use%2520of%2520animal%2520models%26jtitle%3DPharm.%2520Res.%26date%3D2011%26volume%3D28%26spage%3D2379%26epage%3D2385%26doi%3D10.1007%2Fs11095-011-0523-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bruno, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, C. S.</span><span> </span><span class="NLM_article-title">Basics and recent advances in peptide and protein drug delivery</span> <span class="citation_source-journal">Ther. Delivery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1443</span><span class="NLM_x">â</span> <span class="NLM_lpage">1467</span><span class="refDoi">Â DOI: 10.4155/tde.13.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.4155%2Ftde.13.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24228993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslOms7bP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1443-1467&author=B.+J.+Brunoauthor=G.+D.+Millerauthor=C.+S.+Lim&title=Basics+and+recent+advances+in+peptide+and+protein+drug+delivery&doi=10.4155%2Ftde.13.104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203aR"><div class="casContent"><span class="casTitleNuber">203a</span><div class="casTitle"><span class="NLM_cas:atitle">Basics and recent advances in peptide and protein drug delivery</span></div><div class="casAuthors">Bruno, Benjamin J.; Miller, Geoffrey D.; Lim, Carol S.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Delivery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1443-1467</span>CODEN:
                <span class="NLM_cas:coden">TDHEA7</span>;
        ISSN:<span class="NLM_cas:issn">2041-5990</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  While the peptide and protein therapeutic market has developed significantly in the past decades, delivery has limited their use.  Although oral delivery is preferred, most are currently delivered i.v. or s.c. due to degrdn. and limited absorption in the gastrointestinal tract.  Therefore, absorption enhancers, enzyme inhibitors, carrier systems and stability enhancers are being studied to facilitate oral peptide delivery.  Addnl., transdermal peptide delivery avoids the issues of the gastrointestinal tract, but also faces absorption limitations.  Due to proteases, opsonization and agglutination, free peptides are not systemically stable without modifications.  This review discusses oral and transdermal peptide drug delivery, focusing on barriers and solns. to absorption and stability issues.  Methods to increase systemic stability and site-specific delivery are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowxPeEyVr_AbVg90H21EOLACvtfcHk0lhwvBv9GL1KgA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslOms7bP&md5=89a01c120b11079cfe02f33d85248b5f</span></div><a href="/servlet/linkout?suffix=cit203a&amp;dbid=16384&amp;doi=10.4155%2Ftde.13.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ftde.13.104%26sid%3Dliteratum%253Aachs%26aulast%3DBruno%26aufirst%3DB.%2BJ.%26aulast%3DMiller%26aufirst%3DG.%2BD.%26aulast%3DLim%26aufirst%3DC.%2BS.%26atitle%3DBasics%2520and%2520recent%2520advances%2520in%2520peptide%2520and%2520protein%2520drug%2520delivery%26jtitle%3DTher.%2520Delivery%26date%3D2013%26volume%3D4%26spage%3D1443%26epage%3D1467%26doi%3D10.4155%2Ftde.13.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit203b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mitragotri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, R.</span><span> </span><span class="NLM_article-title">Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">655</span><span class="NLM_x">â</span> <span class="NLM_lpage">672</span><span class="refDoi">Â DOI: 10.1038/nrd4363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnrd4363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25103255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlWmu77J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=655-672&author=S.+Mitragotriauthor=P.+A.+Burkeauthor=R.+Langer&title=Overcoming+the+challenges+in+administering+biopharmaceuticals%3A+formulation+and+delivery+strategies&doi=10.1038%2Fnrd4363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203bR"><div class="casContent"><span class="casTitleNuber">203b</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies</span></div><div class="casAuthors">Mitragotri, Samir; Burke, Paul A.; Langer, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">655-672</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The formulation and delivery of biopharmaceutical drugs, such as monoclonal antibodies and recombinant proteins, poses substantial challenges owing to their large size and susceptibility to degrdn.  In this Review we highlight recent advances in formulation and delivery strategies - such as the use of microsphere-based controlled-release technologies, protein modification methods that make use of polyethylene glycol and other polymers, and genetic manipulation of biopharmaceutical drugs - and discuss their advantages and limitations.  We also highlight current and emerging delivery routes that provide an alternative to injection, including transdermal, oral and pulmonary delivery routes.  In addn., the potential of targeted and intracellular protein delivery is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb2Ov1x7gQYbVg90H21EOLACvtfcHk0lhwvBv9GL1KgA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlWmu77J&md5=c09c8b5cdbf60f13bd4c198caeada77d</span></div><a href="/servlet/linkout?suffix=cit203b&amp;dbid=16384&amp;doi=10.1038%2Fnrd4363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4363%26sid%3Dliteratum%253Aachs%26aulast%3DMitragotri%26aufirst%3DS.%26aulast%3DBurke%26aufirst%3DP.%2BA.%26aulast%3DLanger%26aufirst%3DR.%26atitle%3DOvercoming%2520the%2520challenges%2520in%2520administering%2520biopharmaceuticals%253A%2520formulation%2520and%2520delivery%2520strategies%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D655%26epage%3D672%26doi%3D10.1038%2Fnrd4363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group">Ginsberg, B. H.</span><span> </span><span class="NLM_article-title">Mixing pens and the future of diabetes drugs</span> <span class="citation_source-journal">J. Diabetes Sci. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">822</span><span class="NLM_x">â</span> <span class="NLM_lpage">823</span><span class="refDoi">Â DOI: 10.1177/1932296815585873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1177%2F1932296815585873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25944896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28Xkt1Oisbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=822-823&author=B.+H.+Ginsberg&title=Mixing+pens+and+the+future+of+diabetes+drugs&doi=10.1177%2F1932296815585873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Mixing pens and the future of diabetes drugs</span></div><div class="casAuthors">Ginsberg, Barry H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Diabetes Science and Technology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">822-823</span>CODEN:
                <span class="NLM_cas:coden">JDSTAV</span>;
        ISSN:<span class="NLM_cas:issn">1932-2968</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">With the availability of a smaller mixing pen, mass marketing of less stable medications is possible.  Bidureon is one such medication, and the properties of its pen are discussed along with the prospects for future mixing pens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX95Ins_-6R7Vg90H21EOLACvtfcHk0lhssLgSi1_8jQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xkt1Oisbs%253D&md5=acba42c02ca200657e0bb219e220df5e</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1177%2F1932296815585873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1932296815585873%26sid%3Dliteratum%253Aachs%26aulast%3DGinsberg%26aufirst%3DB.%2BH.%26atitle%3DMixing%2520pens%2520and%2520the%2520future%2520of%2520diabetes%2520drugs%26jtitle%3DJ.%2520Diabetes%2520Sci.%2520Technol.%26date%3D2015%26volume%3D9%26spage%3D822%26epage%3D823%26doi%3D10.1177%2F1932296815585873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group">Makadia, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, S. J.</span><span> </span><span class="NLM_article-title">Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier</span> <span class="citation_source-journal">Polymers</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1377</span><span class="NLM_x">â</span> <span class="NLM_lpage">1397</span><span class="refDoi">Â DOI: 10.3390/polym3031377</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3390%2Fpolym3031377" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=22577513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFOis7jJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=1377-1397&author=H.+K.+Makadiaauthor=S.+J.+Siegel&title=Poly+lactic-co-glycolic+acid+%28PLGA%29+as+biodegradable+controlled+drug+delivery+carrier&doi=10.3390%2Fpolym3031377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier</span></div><div class="casAuthors">Makadia, Hirenkumar K.; Siegel, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">Polymers (Basel, Switzerland)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1377-1397</span>CODEN:
                <span class="NLM_cas:coden">POLYCK</span>;
        ISSN:<span class="NLM_cas:issn">2073-4360</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  In past two decades poly lactic-co-glycolic acid (PLGA) has been among the most attractive polymeric candidates used to fabricate devices for drug delivery and tissue engineering applications.  PLGA is biocompatible and biodegradable, exhibits a wide range of erosion times, has tunable mech. properties and most importantly, is a FDA approved polymer.  In particular, PLGA has been extensively studied for the development of devices for controlled delivery of small mol. drugs, proteins and other macromols. in com. use and in research.  This manuscript describes the various fabrication techniques for these devices and the factors affecting their degrdn. and drug release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqKSnjbA3YlrVg90H21EOLACvtfcHk0lhssLgSi1_8jQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFOis7jJ&md5=dcc6e49beb083af56e0cc3213bb99f72</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.3390%2Fpolym3031377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fpolym3031377%26sid%3Dliteratum%253Aachs%26aulast%3DMakadia%26aufirst%3DH.%2BK.%26aulast%3DSiegel%26aufirst%3DS.%2BJ.%26atitle%3DPoly%2520lactic-co-glycolic%2520acid%2520%2528PLGA%2529%2520as%2520biodegradable%2520controlled%2520drug%2520delivery%2520carrier%26jtitle%3DPolymers%26date%3D2011%26volume%3D3%26spage%3D1377%26epage%3D1397%26doi%3D10.3390%2Fpolym3031377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group">Chan, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyrueix, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kravtzoff, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolas, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundstrom, K.</span><span> </span><span class="NLM_article-title">Review on MedusaÂ®: a polymer-based sustained release technology for protein and peptide drugs</span> <span class="citation_source-journal">Expert Opin. Drug Delivery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">â</span> <span class="NLM_lpage">451</span><span class="refDoi">Â DOI: 10.1517/17425247.4.4.441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1517%2F17425247.4.4.441" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=441-451&author=Y.+P.+Chanauthor=R.+Meyrueixauthor=R.+Kravtzoffauthor=F.+Nicolasauthor=K.+Lundstrom&title=Review+on+Medusa%C2%AE%3A+a+polymer-based+sustained+release+technology+for+protein+and+peptide+drugs&doi=10.1517%2F17425247.4.4.441"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1517%2F17425247.4.4.441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425247.4.4.441%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DY.%2BP.%26aulast%3DMeyrueix%26aufirst%3DR.%26aulast%3DKravtzoff%26aufirst%3DR.%26aulast%3DNicolas%26aufirst%3DF.%26aulast%3DLundstrom%26aufirst%3DK.%26atitle%3DReview%2520on%2520Medusa%25C2%25AE%253A%2520a%2520polymer-based%2520sustained%2520release%2520technology%2520for%2520protein%2520and%2520peptide%2520drugs%26jtitle%3DExpert%2520Opin.%2520Drug%2520Delivery%26date%3D2007%26volume%3D4%26spage%3D441%26epage%3D451%26doi%3D10.1517%2F17425247.4.4.441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group">Kopecek, J.</span><span> </span><span class="NLM_article-title">Polymer-drug conjugates: Origins, progress to date and future directions</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">â</span> <span class="NLM_lpage">59</span><span class="refDoi">Â DOI: 10.1016/j.addr.2012.10.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.addr.2012.10.014" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=49-59&author=J.+Kopecek&title=Polymer-drug+conjugates%3A+Origins%2C+progress+to+date+and+future+directions&doi=10.1016%2Fj.addr.2012.10.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2012.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2012.10.014%26sid%3Dliteratum%253Aachs%26aulast%3DKopecek%26aufirst%3DJ.%26atitle%3DPolymer-drug%2520conjugates%253A%2520Origins%252C%2520progress%2520to%2520date%2520and%2520future%2520directions%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2013%26volume%3D65%26spage%3D49%26epage%3D59%26doi%3D10.1016%2Fj.addr.2012.10.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Schneider, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henise, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashley, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santi, D. V.</span><span> </span><span class="NLM_article-title">Subcutaneously administered self-cleaving hydrogel octreotide conjugates provide very long-acting octreotide</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1638</span><span class="NLM_x">â</span> <span class="NLM_lpage">1644</span><span class="refDoi">Â DOI: 10.1021/acs.bioconjchem.6b00188</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.6b00188" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref208/cit208a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XptVelsbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=1638-1644&author=E.+L.+Schneiderauthor=J.+Heniseauthor=R.+Reidauthor=G.+W.+Ashleyauthor=D.+V.+Santi&title=Subcutaneously+administered+self-cleaving+hydrogel+octreotide+conjugates+provide+very+long-acting+octreotide&doi=10.1021%2Facs.bioconjchem.6b00188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208aR"><div class="casContent"><span class="casTitleNuber">208a</span><div class="casTitle"><span class="NLM_cas:atitle">Subcutaneously Administered Self-Cleaving Hydrogel-Octreotide Conjugates Provide Very Long-Acting Octreotide</span></div><div class="casAuthors">Schneider, Eric L.; Henise, Jeff; Reid, Ralph; Ashley, Gary W.; Santi, Daniel V.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1638-1644</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We developed a long-acting drug-delivery system that supports s.c. administration of the peptidic somatostatin agonist octreotide-a blockbuster drug used to treat acromegaly and neuroendocrine tumors.  The current once-a-month polymer-encapsulated octreotide, Sandostatin LAR, requires a painful intragluteal injection through a large needle by a health-care professional.  To overcome such shortcomings, Tetra-PEG hydrogel microspheres were covalently attached to the Î±-amine of D-Phe1 or the Îµ-amine of Lys5 of octreotide by a self-cleaving Î²-eliminative linker; upon s.c. injection in the rat using a small-bore needle, octreotide was slowly released.  The released drug from the Îµ-octreotide conjugate showed a remarkably long serum half-life that exceeded two months.  The Î±-octreotide conjugate had a half-life of â¼2 wk, and showed an excellent correlation of in vitro and in vivo drug release.  Pharmacokinetic models indicate these microspheres should support once-weekly to once-monthly self-administered s.c. dosing in humans.  The hydrogel-octreotide conjugate shows the favorable pharmacokinetics of Sandostatin LAR without its drawbacks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrB5E23rNfIerVg90H21EOLACvtfcHk0lhssLgSi1_8jQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptVelsbc%253D&md5=e268fe09b4ed119d78a0b4fbd7b11038</span></div><a href="/servlet/linkout?suffix=cit208a&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.6b00188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.6b00188%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DE.%2BL.%26aulast%3DHenise%26aufirst%3DJ.%26aulast%3DReid%26aufirst%3DR.%26aulast%3DAshley%26aufirst%3DG.%2BW.%26aulast%3DSanti%26aufirst%3DD.%2BV.%26atitle%3DSubcutaneously%2520administered%2520self-cleaving%2520hydrogel%2520octreotide%2520conjugates%2520provide%2520very%2520long-acting%2520octreotide%26jtitle%3DBioconjugate%2520Chem.%26date%3D2016%26volume%3D27%26spage%3D1638%26epage%3D1644%26doi%3D10.1021%2Facs.bioconjchem.6b00188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit208b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Henise, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hearn, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashley, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santi, D. V.</span><span> </span><span class="NLM_article-title">Biodegradable Tetra-PEG Hydrogels as Carriers for a Releasable Drug Delivery System</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">270</span><span class="NLM_x">â</span> <span class="NLM_lpage">278</span><span class="refDoi">Â DOI: 10.1021/bc5005476</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc5005476" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref208/cit208b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnvFGhtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=270-278&author=J.+Heniseauthor=B.+R.+Hearnauthor=G.+W.+Ashleyauthor=D.+V.+Santi&title=Biodegradable+Tetra-PEG+Hydrogels+as+Carriers+for+a+Releasable+Drug+Delivery+System&doi=10.1021%2Fbc5005476"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208bR"><div class="casContent"><span class="casTitleNuber">208b</span><div class="casTitle"><span class="NLM_cas:atitle">Biodegradable Tetra-PEG Hydrogels as Carriers for a Releasable Drug Delivery System</span></div><div class="casAuthors">Henise, Jeff; Hearn, Brian R.; Ashley, Gary W.; Santi, Daniel V.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">270-278</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have developed an approach to prep. drug-releasing Tetra-PEG hydrogels with exactly four crosslinks per monomer.  The gels contain two cleavable Î²-eliminative linkers: one for drug attachment that releases the drug at a predictable rate, and one with a longer half-life placed in each crosslink to control biodegrdn.  Thus, the system can be optimized to release the drug before significant gel degrdn. occurs.  The synthetic approach involves placing a heterobifunctional connector at each end of a four-arm PEG prepolymer; four unique end-groups of the resultant eight-arm prepolymer are used to tether a linker-drug, and the other four are used for polymn. with a second four-arm PEG.  Three different orthogonal reactions that form stable triazoles, diazines, or oximes have been used for tethering the drug to the PEG and for crosslinking the polymer.  Three formats for prepg. hydrogel-drug conjugates are described that either polymerize preformed PEG-drug conjugates or attach the drug postpolymn.  Degrdn. of drug-contg. hydrogels proceeds as expected for homogeneous tetra-PEG gels with minimal degrdn. occurring in early phases and sharp, predictable reverse gelation times.  The minimal early degrdn. allows design of gels that show almost complete drug release before significant gel-drug fragments are released.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrmt2jnIBZH7Vg90H21EOLACvtfcHk0lg6J16kx4rJFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnvFGhtQ%253D%253D&md5=451e725bebd4c7a7ec723979a7d65f62</span></div><a href="/servlet/linkout?suffix=cit208b&amp;dbid=16384&amp;doi=10.1021%2Fbc5005476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc5005476%26sid%3Dliteratum%253Aachs%26aulast%3DHenise%26aufirst%3DJ.%26aulast%3DHearn%26aufirst%3DB.%2BR.%26aulast%3DAshley%26aufirst%3DG.%2BW.%26aulast%3DSanti%26aufirst%3DD.%2BV.%26atitle%3DBiodegradable%2520Tetra-PEG%2520Hydrogels%2520as%2520Carriers%2520for%2520a%2520Releasable%2520Drug%2520Delivery%2520System%26jtitle%3DBioconjugate%2520Chem.%26date%3D2015%26volume%3D26%26spage%3D270%26epage%3D278%26doi%3D10.1021%2Fbc5005476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group">Frampton, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyseng-Williamson, K. A.</span><span> </span><span class="NLM_article-title">Degarelix</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">1967</span><span class="NLM_x">â</span> <span class="NLM_lpage">1976</span><span class="refDoi">Â DOI: 10.2165/10484080-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.2165%2F10484080-000000000-00000" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=1967-1976&author=J.+E.+Framptonauthor=K.+A.+Lyseng-Williamson&title=Degarelix&doi=10.2165%2F10484080-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.2165%2F10484080-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F10484080-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DFrampton%26aufirst%3DJ.%2BE.%26aulast%3DLyseng-Williamson%26aufirst%3DK.%2BA.%26atitle%3DDegarelix%26jtitle%3DDrugs%26date%3D2009%26volume%3D69%26spage%3D1967%26epage%3D1976%26doi%3D10.2165%2F10484080-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group">Antonijoan, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbanoj, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordero, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peraire, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VallÃ¨s, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">CheZÃ©rif-Cheikh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torres, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bismuth, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montes, M.</span><span> </span><span class="NLM_article-title">Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers</span> <span class="citation_source-journal">J. Pharm. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">471</span><span class="NLM_x">â</span> <span class="NLM_lpage">476</span><span class="refDoi">Â DOI: 10.1211/0022357023123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1211%2F0022357023123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=15099442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkt1erurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2004&pages=471-476&author=R.+M.+Antonijoanauthor=M.+J.+Barbanojauthor=J.+A.+Corderoauthor=C.+Peraireauthor=R.+Obachauthor=J.+Vall%C3%A8sauthor=R.+CheZ%C3%A9rif-Cheikhauthor=M.+L.+Torresauthor=F.+Bismuthauthor=M.+Montes&title=Pharmacokinetics+of+a+new+Autogel+formulation+of+the+somatostatin+analogue+lanreotide+after+a+single+subcutaneous+dose+in+healthy+volunteers&doi=10.1211%2F0022357023123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers</span></div><div class="casAuthors">Antonijoan, R. M.; Barbanoj, M. J.; Cordero, J. A.; Peraire, C.; Obach, R.; Valles, J.; Cherif-Cheikh, R.; Torres, M.-L.; Bismuth, F.; Montes, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">471-476</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Press</span>)
        </div><div class="casAbstract">The pharmacokinetics/tolerability of lanreotide Autogel have been evaluated.  Healthy volunteers (n = 24) first received immediate-release lanreotide as a single s.c. injection.  After two days, 40 or 60 mg lanreotide Autogel was injected s.c.  Blood was sampled at various intervals for 56 days.  Systemic/local adverse events and changes in biol. profile/vital signs were recorded.  Lanreotide Autogel produced a prolonged-release pharmacokinetic profile: mean area under the serum concn.-time curve from time 0 to infinity (AUC) was 53.73Â±8.99 and 79.48Â±13.06 ng mL-1 day for 40 and 60 mg, resp., mean peak serum concn. (Cmax) was 4.38Â±2.91 and 5.71Â±3.52 ng mL-1, resp., median time to reach Cmax (min.-max.) was 0.50 (0.083-18.0) and 0.38 (0.083-9.01) days, resp., mean apparent elimination half-life was 21.63Â±9.42 and 22.01Â±9.87 days, resp., and relative bioavailability was 0.93Â±0.12 and 0.82Â±0.15, resp.  Thus, lanreotide Autogel exhibited linear pharmacokinetics for the doses studied.  Pharmacokinetic profiles were similar in both genders, apart from statistically significant differences in Cmax and Cmax/AUC.  The Autogel formulation of lanreotide was well tolerated, with systemic adverse events being mild/moderate.  Erythema and a painless s.c. induration were the most common local adverse events.  Lanreotide Autogel provided a prolonged dosing interval and good tolerability for treating acromegaly and carcinoid syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5qRDwhNIpxLVg90H21EOLACvtfcHk0lg6J16kx4rJFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkt1erurk%253D&md5=50d53b840369220b33363f4b5c1ab170</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1211%2F0022357023123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1211%252F0022357023123%26sid%3Dliteratum%253Aachs%26aulast%3DAntonijoan%26aufirst%3DR.%2BM.%26aulast%3DBarbanoj%26aufirst%3DM.%2BJ.%26aulast%3DCordero%26aufirst%3DJ.%2BA.%26aulast%3DPeraire%26aufirst%3DC.%26aulast%3DObach%26aufirst%3DR.%26aulast%3DVall%25C3%25A8s%26aufirst%3DJ.%26aulast%3DCheZ%25C3%25A9rif-Cheikh%26aufirst%3DR.%26aulast%3DTorres%26aufirst%3DM.%2BL.%26aulast%3DBismuth%26aufirst%3DF.%26aulast%3DMontes%26aufirst%3DM.%26atitle%3DPharmacokinetics%2520of%2520a%2520new%2520Autogel%2520formulation%2520of%2520the%2520somatostatin%2520analogue%2520lanreotide%2520after%2520a%2520single%2520subcutaneous%2520dose%2520in%2520healthy%2520volunteers%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2004%26volume%3D56%26spage%3D471%26epage%3D476%26doi%3D10.1211%2F0022357023123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group">Amiram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luginbuhl, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feinglos, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chilkoti, A.</span><span> </span><span class="NLM_article-title">A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">172</span><span class="NLM_x">, </span> <span class="NLM_fpage">144</span><span class="NLM_x">â</span> <span class="NLM_lpage">151</span><span class="refDoi">Â DOI: 10.1016/j.jconrel.2013.07.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.jconrel.2013.07.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23928357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslOrsr7J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2013&pages=144-151&author=M.+Amiramauthor=K.+M.+Luginbuhlauthor=X.+Liauthor=M.+N.+Feinglosauthor=A.+Chilkoti&title=A+depot-forming+glucagon-like+peptide-1+fusion+protein+reduces+blood+glucose+for+five+days+with+a+single+injection&doi=10.1016%2Fj.jconrel.2013.07.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection</span></div><div class="casAuthors">Amiram, M.; Luginbuhl, K. M.; Li, X.; Feinglos, M. N.; Chilkoti, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">144-151</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Peptide drugs are an exciting class of pharmaceuticals for the treatment of a variety of diseases; however, their short half-life dictates multiple and frequent injections causing undesirable side effects.  Herein, we describe a novel peptide delivery system that seeks to combine the attractive features of prolonged circulation time with a prolonged release formulation.  This system consists of glucagon-like peptide-1, a type-2 diabetes drug fused to a thermally responsive, elastin-like-polypeptide (ELP) that undergoes a sol.-insol. phase transition between room temp. and body temp., thereby forming an injectable depot.  We synthesized a set of GLP-1-ELP fusions and verified their proteolytic stability and potency in vitro.  Significantly, a single injection of depot forming GLP-1-ELP fusions reduced blood glucose levels in mice for up to 5 days, 120 times longer than an injection of the native peptide.  These findings demonstrate the unique advantages of using ELPs to release peptide-ELP fusions from a depot combined with enhanced systemic circulation to create a tunable peptide delivery system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobECRp_3wmO7Vg90H21EOLACvtfcHk0lg6J16kx4rJFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslOrsr7J&md5=b06bf6a9e2fb8a2b759472a9eec7d60a</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2013.07.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2013.07.021%26sid%3Dliteratum%253Aachs%26aulast%3DAmiram%26aufirst%3DM.%26aulast%3DLuginbuhl%26aufirst%3DK.%2BM.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DFeinglos%26aufirst%3DM.%2BN.%26aulast%3DChilkoti%26aufirst%3DA.%26atitle%3DA%2520depot-forming%2520glucagon-like%2520peptide-1%2520fusion%2520protein%2520reduces%2520blood%2520glucose%2520for%2520five%2520days%2520with%2520a%2520single%2520injection%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2013%26volume%3D172%26spage%3D144%26epage%3D151%26doi%3D10.1016%2Fj.jconrel.2013.07.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yang, B.; Negulescu, C.; Eftimie, R. D. v. C.; Lautenbach, J. C. S.; Horwege, K.; Mercer, R.; Ford, D.; Alessi, T.</span><span> </span><span class="NLM_article-title">Stability of ITCA 650 for continuous subcutaneous delivery of exenatide at body temperature for 12 months</span>. In Diabetes Technology Meeting, November 5â7, 2009, San Francisco, CA,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=B.+Yang&author=C.+Negulescu&author=R.+D.+v.+C.+Eftimie&author=J.+C.+S.+Lautenbach&author=K.+Horwege&author=R.+Mercer&author=D.+Ford&author=T.+Alessi&title=Stability+of+ITCA+650+for+continuous+subcutaneous+delivery+of+exenatide+at+body+temperature+for+12+months"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit212a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DB.%26atitle%3DStability%2520of%2520ITCA%2520650%2520for%2520continuous%2520subcutaneous%2520delivery%2520of%2520exenatide%2520at%2520body%2520temperature%2520for%252012%2520months%26jtitle%3DDiabetes%2520Technology%2520Meeting%252C%2520November%25205%25E2%2580%25937%252C%25202009%252C%2520San%2520Francisco%252C%2520CA%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit212b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Henry, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenstock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logan, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alessi, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luskey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baron, M. A.</span><span> </span><span class="NLM_article-title">Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes</span> <span class="citation_source-journal">Diabetes Care</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">2559</span><span class="NLM_x">â</span> <span class="NLM_lpage">2565</span><span class="refDoi">Â DOI: 10.2337/dc12-2410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.2337%2Fdc12-2410" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2013&pages=2559-2565&author=R.+R.+Henryauthor=J.+Rosenstockauthor=D.+K.+Loganauthor=T.+R.+Alessiauthor=K.+Luskeyauthor=M.+A.+Baron&title=Randomized+trial+of+continuous+subcutaneous+delivery+of+exenatide+by+ITCA+650+versus+twice-daily+exenatide+injections+in+metformin-treated+type+2+diabetes&doi=10.2337%2Fdc12-2410"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit212b&amp;dbid=16384&amp;doi=10.2337%2Fdc12-2410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdc12-2410%26sid%3Dliteratum%253Aachs%26aulast%3DHenry%26aufirst%3DR.%2BR.%26aulast%3DRosenstock%26aufirst%3DJ.%26aulast%3DLogan%26aufirst%3DD.%2BK.%26aulast%3DAlessi%26aufirst%3DT.%2BR.%26aulast%3DLuskey%26aufirst%3DK.%26aulast%3DBaron%26aufirst%3DM.%2BA.%26atitle%3DRandomized%2520trial%2520of%2520continuous%2520subcutaneous%2520delivery%2520of%2520exenatide%2520by%2520ITCA%2520650%2520versus%2520twice-daily%2520exenatide%2520injections%2520in%2520metformin-treated%2520type%25202%2520diabetes%26jtitle%3DDiabetes%2520Care%26date%3D2013%26volume%3D36%26spage%3D2559%26epage%3D2565%26doi%3D10.2337%2Fdc12-2410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit212c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Henry, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenstock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alessi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luskey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baron, M. A.</span><span> </span><span class="NLM_article-title">Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes</span> <span class="citation_source-journal">J. Diabetes Complications</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">393</span><span class="NLM_x">â</span> <span class="NLM_lpage">398</span><span class="refDoi">Â DOI: 10.1016/j.jdiacomp.2013.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.jdiacomp.2013.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=24631129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A280%3ADC%252BC2crktVSkuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=393-398&author=R.+R.+Henryauthor=J.+Rosenstockauthor=D.+Loganauthor=T.+Alessiauthor=K.+Luskeyauthor=M.+A.+Baron&title=Continuous+subcutaneous+delivery+of+exenatide+via+ITCA+650+leads+to+sustained+glycemic+control+and+weight+loss+for+48+weeks+in+metformin-treated+subjects+with+type+2+diabetes&doi=10.1016%2Fj.jdiacomp.2013.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit212cR"><div class="casContent"><span class="casTitleNuber">212c</span><div class="casTitle"><span class="NLM_cas:atitle">Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes</span></div><div class="casAuthors">Henry Robert R; Rosenstock Julio; Logan Douglas; Alessi Thomas; Luskey Kenneth; Baron Michelle A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of diabetes and its complications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">393-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIMS:  Evaluate the efficacy and tolerability of ITCA 650 in subjects with type 2 diabetes treated for up to 48 weeks.  METHODS:  This was a 24-week extension to a randomized, 24-week, open-label, phase 2 study in subjects with type 2 diabetes inadequately controlled with metformin.  Subjects received ITCA 650 mg (20, 40, 60 or 80 Î¼g/day).  Mean changes for HbA1c, weight, and fasting plasma glucose (FPG) were evaluated.  RESULTS:  Mean changes in HbA1c from baseline to week 48 ranged from -0.85% to -1.51%.  At week 48, â¥64% of subjects with an HbA1c â¤7% at week 24 maintained an HbA1c â¤7%.  The incidence of adverse events (AEs) was dose-related and ranged from 13.3% with 20 Î¼g/day to 37.5% with 80 Î¼g/day.  Most AEs were mild and transient; the incidence of nausea declined from 12.9% to 9.5% over the 24-week extension.  One subject on ITCA 650 80 Î¼g/day experienced mild intermittent vomiting.  Three (3.5%) subjects experienced severe AEs, but none were considered related to study drug.  CONCLUSION:  Significant changes in HbA1c, body weight, and FPG attained with ITCA 650 were maintained to 48 weeks.  The incidence of AEs was lower in the 24-week extension than in the initial 24-week treatment phase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQWIrYtplHXGMuCWE5mhx1RfW6udTcc2eZEffj4fiX-rLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crktVSkuw%253D%253D&md5=cc2757106a5f572657f5541342d5626a</span></div><a href="/servlet/linkout?suffix=cit212c&amp;dbid=16384&amp;doi=10.1016%2Fj.jdiacomp.2013.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jdiacomp.2013.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DHenry%26aufirst%3DR.%2BR.%26aulast%3DRosenstock%26aufirst%3DJ.%26aulast%3DLogan%26aufirst%3DD.%26aulast%3DAlessi%26aufirst%3DT.%26aulast%3DLuskey%26aufirst%3DK.%26aulast%3DBaron%26aufirst%3DM.%2BA.%26atitle%3DContinuous%2520subcutaneous%2520delivery%2520of%2520exenatide%2520via%2520ITCA%2520650%2520leads%2520to%2520sustained%2520glycemic%2520control%2520and%2520weight%2520loss%2520for%252048%2520weeks%2520in%2520metformin-treated%2520subjects%2520with%2520type%25202%2520diabetes%26jtitle%3DJ.%2520Diabetes%2520Complications%26date%3D2014%26volume%3D28%26spage%3D393%26epage%3D398%26doi%3D10.1016%2Fj.jdiacomp.2013.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group">Schaepelynck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darmon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molines, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jannot-Lamotte, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treglia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raccah, D.</span><span> </span><span class="NLM_article-title">Advances in pump technology: insulin patch pumps, combined pumps and glucose sensors, and implanted pumps</span> <span class="citation_source-journal">Diabetes Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">S85</span><span class="NLM_x">â</span> <span class="NLM_lpage">S93</span><span class="refDoi">Â DOI: 10.1016/S1262-3636(11)70972-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2FS1262-3636%2811%2970972-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=22208717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFGitQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2011&pages=S85-S93&author=P.+Schaepelynckauthor=P.+Darmonauthor=L.+Molinesauthor=M.+F.+Jannot-Lamotteauthor=C.+Tregliaauthor=D.+Raccah&title=Advances+in+pump+technology%3A+insulin+patch+pumps%2C+combined+pumps+and+glucose+sensors%2C+and+implanted+pumps&doi=10.1016%2FS1262-3636%2811%2970972-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in pump technology: insulin patch pumps, combined pumps and glucose sensors, and implanted pumps</span></div><div class="casAuthors">Schaepelynck, P.; Darmon, P.; Molines, L.; Jannot-Lamotte, M. F.; Treglia, C.; Raccah, D.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes & Metabolism</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">Spec. Iss. 4</span>),
    <span class="NLM_cas:pages">S85-S93</span>CODEN:
                <span class="NLM_cas:coden">DIMEFW</span>;
        ISSN:<span class="NLM_cas:issn">1262-3636</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">This review discusses the most recent developments in insulin pump technol.  The benefits of the insulin pump to patients with type 1 diabetes are recognized both for its metabolic effectiveness and its pos. effects on quality of life.  The current pumps are reliable, small and light, and are becoming more and more sophisticated.  Nevertheless, there remain practical and psychol. constraints for the patient.  However, recent patch-pump advances should simplify the tech. aspects of pump treatment and enhance patient comfort.  Another advance combines the insulin pump with a glucose sensor.  Such a combination is logical for optimizing pump use and, to that end, developing an automated or closed-loop'system that permits the delivery of s.c. insulin adjusted according to measured levels of s.c. glucose.  Finally, implanted insulin pumps have proven their worth not only because of their simple use, but also for their contribution in the artificial pancreas project.  Indeed, the prompt response with i.p. administration of insulin makes it of interest for use in a closed-loop system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpigUU07f0kArVg90H21EOLACvtfcHk0lgZhHXMw7n2jw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFGitQ%253D%253D&md5=545dd974c9c8e1581d81600a4d2848db</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1016%2FS1262-3636%2811%2970972-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1262-3636%252811%252970972-7%26sid%3Dliteratum%253Aachs%26aulast%3DSchaepelynck%26aufirst%3DP.%26aulast%3DDarmon%26aufirst%3DP.%26aulast%3DMolines%26aufirst%3DL.%26aulast%3DJannot-Lamotte%26aufirst%3DM.%2BF.%26aulast%3DTreglia%26aufirst%3DC.%26aulast%3DRaccah%26aufirst%3DD.%26atitle%3DAdvances%2520in%2520pump%2520technology%253A%2520insulin%2520patch%2520pumps%252C%2520combined%2520pumps%2520and%2520glucose%2520sensors%252C%2520and%2520implanted%2520pumps%26jtitle%3DDiabetes%2520Metab.%26date%3D2011%26volume%3D37%26spage%3DS85%26epage%3DS93%26doi%3D10.1016%2FS1262-3636%2811%2970972-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group">Peyser, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dassau, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skyler, J. S.</span><span> </span><span class="NLM_article-title">The artificial pancreas: current status and future prospects in the management of diabetes</span> <span class="citation_source-journal">Ann. N. Y. Acad. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">1311</span><span class="NLM_x">, </span> <span class="NLM_fpage">102</span><span class="NLM_x">â</span> <span class="NLM_lpage">123</span><span class="refDoi">Â DOI: 10.1111/nyas.12431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1111%2Fnyas.12431" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1311&publication_year=2014&pages=102-123&author=T.+Peyserauthor=E.+Dassauauthor=M.+Bretonauthor=J.+S.+Skyler&title=The+artificial+pancreas%3A+current+status+and+future+prospects+in+the+management+of+diabetes&doi=10.1111%2Fnyas.12431"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1111%2Fnyas.12431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fnyas.12431%26sid%3Dliteratum%253Aachs%26aulast%3DPeyser%26aufirst%3DT.%26aulast%3DDassau%26aufirst%3DE.%26aulast%3DBreton%26aufirst%3DM.%26aulast%3DSkyler%26aufirst%3DJ.%2BS.%26atitle%3DThe%2520artificial%2520pancreas%253A%2520current%2520status%2520and%2520future%2520prospects%2520in%2520the%2520management%2520of%2520diabetes%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2014%26volume%3D1311%26spage%3D102%26epage%3D123%26doi%3D10.1111%2Fnyas.12431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yadav, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smart, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tajiri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basit, A. W.</span><span> </span><span class="NLM_article-title">Toward oral delivery of biopharmaceuticals: An assessment of the gastrointestinal stability of 17 peptide drugs</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">966</span><span class="NLM_x">â</span> <span class="NLM_lpage">973</span><span class="refDoi">Â DOI: 10.1021/mp500809f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp500809f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref215/cit215a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlyqsb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=966-973&author=J.+Wangauthor=V.+Yadavauthor=A.+L.+Smartauthor=S.+Tajiriauthor=A.+W.+Basit&title=Toward+oral+delivery+of+biopharmaceuticals%3A+An+assessment+of+the+gastrointestinal+stability+of+17+peptide+drugs&doi=10.1021%2Fmp500809f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit215aR"><div class="casContent"><span class="casTitleNuber">215a</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Oral Delivery of Biopharmaceuticals: An Assessment of the Gastrointestinal Stability of 17 Peptide Drugs</span></div><div class="casAuthors">Wang, Jie; Yadav, Vipul; Smart, Alice L.; Tajiri, Shinichiro; Basit, Abdul W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">966-973</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A major barrier to successful oral delivery of peptide and protein mols. is their inherent instability in the lumen of the gastrointestinal tract.  The aim of this study was to det. the stability of 17 disparate peptide drugs (insulin, calcitonin, glucagon, secretin, somatostatin, desmopressin, oxytocin, [Arg8]-vasopressin, octreotide, ciclosporin, leuprolide, nafarelin, buserelin, histrelin, [D-Ser]4-gonadorelin, deslorelin, and goserelin) in gastric and small intestinal fluids from both humans and pigs, and in simulated gastric and intestinal fluids.  In human gastric fluid, the larger peptides including somatostatin, calcitonin, secretin, glucagon, and insulin were metabolized rapidly, while the smaller peptides showed good stability.  In human small intestinal fluid, however, both small and large peptides degraded rapidly with the exception of the cyclic peptide ciclosporin and the disulfide-bridge contg. peptides octreotide and desmopressin, which showed good stability.  The stability of peptides in both simulated gastric fluid and pig gastric fluid correlated well with stability in human gastric fluid.  However, it was not possible to establish such a correlation with the small intestinal fluids because of the rapid rate of peptide degrdn.  This work has identified the mol. features in the structure of a wide range of peptides that influence their stability in the environment of the gastrointestinal tract, which in turn will allow for better selection of peptide candidates for oral delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraciXJLe-z4rVg90H21EOLACvtfcHk0lgJq-NYqtzeAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlyqsb8%253D&md5=a29abd913a44604892e879e735818ff9</span></div><a href="/servlet/linkout?suffix=cit215a&amp;dbid=16384&amp;doi=10.1021%2Fmp500809f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp500809f%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYadav%26aufirst%3DV.%26aulast%3DSmart%26aufirst%3DA.%2BL.%26aulast%3DTajiri%26aufirst%3DS.%26aulast%3DBasit%26aufirst%3DA.%2BW.%26atitle%3DToward%2520oral%2520delivery%2520of%2520biopharmaceuticals%253A%2520An%2520assessment%2520of%2520the%2520gastrointestinal%2520stability%2520of%252017%2520peptide%2520drugs%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2015%26volume%3D12%26spage%3D966%26epage%3D973%26doi%3D10.1021%2Fmp500809f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit215b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zhou, X. H.</span><span> </span><span class="NLM_article-title">Overcoming enzymatic and absorption barriers to non-parenterally administered protein and peptide drugs</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">239</span><span class="NLM_x">â</span> <span class="NLM_lpage">252</span><span class="refDoi">Â DOI: 10.1016/0168-3659(94)90071-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2F0168-3659%2894%2990071-X" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1994&pages=239-252&author=X.+H.+Zhou&title=Overcoming+enzymatic+and+absorption+barriers+to+non-parenterally+administered+protein+and+peptide+drugs&doi=10.1016%2F0168-3659%2894%2990071-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit215b&amp;dbid=16384&amp;doi=10.1016%2F0168-3659%2894%2990071-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0168-3659%252894%252990071-X%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DX.%2BH.%26atitle%3DOvercoming%2520enzymatic%2520and%2520absorption%2520barriers%2520to%2520non-parenterally%2520administered%2520protein%2520and%2520peptide%2520drugs%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D1994%26volume%3D29%26spage%3D239%26epage%3D252%26doi%3D10.1016%2F0168-3659%2894%2990071-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit215c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Karsdal, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riis, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stern, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arbit, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christiansen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henriksen, K.</span><span> </span><span class="NLM_article-title">Lessons learned from the clinical development of oral peptides</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">720</span><span class="NLM_x">â</span> <span class="NLM_lpage">732</span><span class="refDoi">Â DOI: 10.1111/bcp.12557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1111%2Fbcp.12557" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25408230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslOnu7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2015&pages=720-732&author=M.+A.+Karsdalauthor=B.+J.+Riisauthor=N.+Mehtaauthor=W.+Sternauthor=E.+Arbitauthor=C.+Christiansenauthor=K.+Henriksen&title=Lessons+learned+from+the+clinical+development+of+oral+peptides&doi=10.1111%2Fbcp.12557"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit215cR"><div class="casContent"><span class="casTitleNuber">215c</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons learned from the clinical development of oral peptides</span></div><div class="casAuthors">Karsdal, Morten Asser; Riis, Bente Juul; Mehta, Nozer; Stern, William; Arbit, Ehud; Christiansen, Claus; Henriksen, Kim</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">720-732</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The oral delivery of peptides and proteins has been hampered by an array of obstacles.  However, several promising novel oral delivery systems have been developed.  This paper reviews the most advanced oral formulation technologies, and highlights key lessons and implications from studies undertaken to date with these oral formulations.  Special interest is given to oral salmon calcitonin (CT), glucagon-like peptide-1 (GLP-1), insulin, PYY-(3-36), recombinant human parathyroid hormone (rhPTH(1-31)-NH2) and PTH(1-34), by different technologies.  The issues addressed include (i) interaction with water, (ii) interaction with food, (iii) diurnal variation, (iv) inter- and intra-subject variability, (v) correlation between efficacy and exposure and (vi) key deliverables of different technologies.  These key lessons may aid research in the development of other oral formulations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBun32dB2rgrVg90H21EOLACvtfcHk0lgJq-NYqtzeAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslOnu7Y%253D&md5=0f636db3549478f73bbc4ecb958e385d</span></div><a href="/servlet/linkout?suffix=cit215c&amp;dbid=16384&amp;doi=10.1111%2Fbcp.12557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.12557%26sid%3Dliteratum%253Aachs%26aulast%3DKarsdal%26aufirst%3DM.%2BA.%26aulast%3DRiis%26aufirst%3DB.%2BJ.%26aulast%3DMehta%26aufirst%3DN.%26aulast%3DStern%26aufirst%3DW.%26aulast%3DArbit%26aufirst%3DE.%26aulast%3DChristiansen%26aufirst%3DC.%26aulast%3DHenriksen%26aufirst%3DK.%26atitle%3DLessons%2520learned%2520from%2520the%2520clinical%2520development%2520of%2520oral%2520peptides%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2015%26volume%3D79%26spage%3D720%26epage%3D732%26doi%3D10.1111%2Fbcp.12557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216"><span><span class="NLM_contrib-group">Rembratt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graugaard-Jensen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senderovitz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norgaard, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Djurhuus, J. C.</span><span> </span><span class="NLM_article-title">Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55â70 years</span> <span class="citation_source-journal">Eur. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">397</span><span class="NLM_x">â</span> <span class="NLM_lpage">402</span><span class="refDoi">Â DOI: 10.1007/s00228-004-0781-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1007%2Fs00228-004-0781-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=15197520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslChsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=397-402&author=A.+Rembrattauthor=C.+Graugaard-Jensenauthor=T.+Senderovitzauthor=J.+P.+Norgaardauthor=J.+C.+Djurhuus&title=Pharmacokinetics+and+pharmacodynamics+of+desmopressin+administered+orally+versus+intravenously+at+daytime+versus+night-time+in+healthy+men+aged+55%E2%80%9370+years&doi=10.1007%2Fs00228-004-0781-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years</span></div><div class="casAuthors">Rembratt, Asa; Graugaard-Jensen, Charlotte; Senderovitz, Thomas; Norgaard, Jens Peter; Djurhuus, Jens Christian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">397-402</span>CODEN:
                <span class="NLM_cas:coden">EJCPAS</span>;
        ISSN:<span class="NLM_cas:issn">0031-6970</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">To investigate (1) the pharmacokinetic and pharmacodynamic profiles of desmopressin in men from an age group with a high incidence of nocturia; and (2) circadian variation in the pharmacokinetic parameters.  The study had an open, randomized, four-way cross-over design.  Desmopressin was administered orally (0.2 mg) and i.v. (2 Î¼g), daytime and night-time, yielding four in-hospital sessions, sepd. by at least 2 days.  Blood samples were taken before and at predetd. time points up to 12 h after dosing.  Pharmacokinetic parameters were derived using a two-compartmental model except for AUC(0 t), which was derived using non-compartmental anal.  Bioavailability was estd. using AUC(0 t) for the oral and the i.v. periods.  Urine, for measurements of vol. and osmolality, was collected in predetd. intervals before and until 12 h after dosing.  Fifteen healthy men aged 55-70 yr were included in the anal.  The concn.-time curve after 2 Î¼g i.v. desmopressin was best described using a biexponential term.  The mean (95% CI) AUC at night was 302 (272-335) pgÃh/mL and in the day was 281 (253-312) pgÃh/mL.  No statistically significant differences were detected between night and day except for terminal half-life, which was 3.1 h at night and 2.8 h in the daytime (P=0.02).  After oral desmopressin, concns. above the limit of quantification (2.5 pg/mL) were only detected in 51% of the samples.  Peak plasma concn. (Cmax) was 6.2 (5.1-7.5) pg/mL at night and 6.6 (5.5-7.9) pg/mL in the daytime.  Median time to reach Cmax (tmax) was 1.5 (range 1.0-4.1) h at night and 1.5 (range 0.5-3.0) h in the day.  The bioavailability was 0.08%.  The pharmacodynamic effects of oral and i.v. desmopressin given in the daytime were similar during the first 6 h after dosing.  The night-time dosing and daytime i.v. dose resulted in antidiuresis throughout the measuring period, while the effect of the daytime peroral dose receded after 6 h.  The pharmacokinetic profile of desmopressin is biexponential.  Terminal half-life was longer at night than in the daytime, but the difference is considered too small to be of clin. importance.  The plasma levels given by the i.v. dose resulted in a duration of action of 12 h or more.  Despite low bioavailability, the pharmacodynamic effects of oral desmopressin were similar in magnitude to those after i.v. dose at night and during the first 6 h after daytime administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-1FLSTS70pLVg90H21EOLACvtfcHk0lgJq-NYqtzeAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslChsrk%253D&md5=99383d45825422d50bdb42cc04e0cf18</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1007%2Fs00228-004-0781-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00228-004-0781-9%26sid%3Dliteratum%253Aachs%26aulast%3DRembratt%26aufirst%3DA.%26aulast%3DGraugaard-Jensen%26aufirst%3DC.%26aulast%3DSenderovitz%26aufirst%3DT.%26aulast%3DNorgaard%26aufirst%3DJ.%2BP.%26aulast%3DDjurhuus%26aufirst%3DJ.%2BC.%26atitle%3DPharmacokinetics%2520and%2520pharmacodynamics%2520of%2520desmopressin%2520administered%2520orally%2520versus%2520intravenously%2520at%2520daytime%2520versus%2520night-time%2520in%2520healthy%2520men%2520aged%252055%25E2%2580%259370%2520years%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2004%26volume%3D60%26spage%3D397%26epage%3D402%26doi%3D10.1007%2Fs00228-004-0781-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit217"><span><span class="NLM_contrib-group">Nielsen, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucke, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoermer, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairlie, D. P.</span><span> </span><span class="NLM_article-title">Orally Absorbed Cyclic Peptides</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">8094</span><span class="NLM_x">â</span> <span class="NLM_lpage">8128</span><span class="refDoi">Â DOI: 10.1021/acs.chemrev.6b00838</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.6b00838" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2sXot12lurY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2017&pages=8094-8128&author=D.+S.+Nielsenauthor=N.+E.+Shepherdauthor=W.+Xuauthor=A.+J.+Luckeauthor=M.+J.+Stoermerauthor=D.+P.+Fairlie&title=Orally+Absorbed+Cyclic+Peptides&doi=10.1021%2Facs.chemrev.6b00838"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Orally Absorbed Cyclic Peptides</span></div><div class="casAuthors">Nielsen, Daniel S.; Shepherd, Nicholas E.; Xu, Weijun; Lucke, Andrew J.; Stoermer, Martin J.; Fairlie, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">8094-8128</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Peptides and proteins are not orally bioavailable in mammals, although a few peptides are intestinally absorbed in small amts.  Polypeptides are generally too large and polar to passively diffuse through lipid membranes, while most known active transport mechanisms facilitate cell uptake of only very small peptides.  Systematic evaluations of peptides with mol. wts. above 500 Da are needed to identify parameters that influence oral bioavailability.  Here we describe 125 cyclic peptides contg. four to thirty-seven amino acids that are orally absorbed by mammals.  Cyclization minimizes degrdn. in the gut, blood and tissues by removing cleavable N- and C-termini and by shielding components from metabolic enzymes.  Cyclization also folds peptides into bioactive conformations that det. exposure of polar atoms to solvation by water and lipids, and therefore should influence oral bioavailability.  Key chem. properties thought to influence oral absorption and bioavailability are analyzed, including mol. wt., octanol-water partitioning, hydrogen bond donors/acceptors, rotatable bonds and polar surface area.  The cyclic peptides violated to different degrees all of the limits traditionally considered to be important for oral bioavailability of drug-like small mols., although fewer hydrogen bond donors and reduced flexibility generally favored oral absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprHf1YVkf7ErVg90H21EOLACvtfcHk0lh2w-CSU3RmIw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXot12lurY%253D&md5=38af1945471e5ddffd3ae630ebbe129b</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.6b00838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.6b00838%26sid%3Dliteratum%253Aachs%26aulast%3DNielsen%26aufirst%3DD.%2BS.%26aulast%3DShepherd%26aufirst%3DN.%2BE.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DLucke%26aufirst%3DA.%2BJ.%26aulast%3DStoermer%26aufirst%3DM.%2BJ.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26atitle%3DOrally%2520Absorbed%2520Cyclic%2520Peptides%26jtitle%3DChem.%2520Rev.%26date%3D2017%26volume%3D117%26spage%3D8094%26epage%3D8128%26doi%3D10.1021%2Facs.chemrev.6b00838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref218"><div class="reference"><strong class="refLabel"><a href="#ref218" class="rightTabRefNumLink">218</a></strong><div class="NLM_citation" id="rightTab-cit218a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springthorpe, B.</span><span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">â</span> <span class="NLM_lpage">890</span><span class="refDoi">Â DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit218aR"><div class="casContent"><span class="casTitleNuber">218a</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0lh2w-CSU3RmIw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit218a&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit218b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Arnott, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planey, S. L.</span><span> </span><span class="NLM_article-title">The influence of lipophilicity in drug discovery and design</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">863</span><span class="NLM_x">â</span> <span class="NLM_lpage">875</span><span class="refDoi">Â DOI: 10.1517/17460441.2012.714363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1517%2F17460441.2012.714363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=22992175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2lsbvJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=863-875&author=J.+A.+Arnottauthor=S.+L.+Planey&title=The+influence+of+lipophilicity+in+drug+discovery+and+design&doi=10.1517%2F17460441.2012.714363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit218bR"><div class="casContent"><span class="casTitleNuber">218b</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of lipophilicity in drug discovery and design</span></div><div class="casAuthors">Arnott, John A.; Planey, Sonia Lobo</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">863-875</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The role of lipophilicity in drug discovery and design is a crit. one.  Lipophilicity is a key physicochem. property that plays a crucial role in detg. ADMET (absorption, distribution, metab., excretion, and toxicity) properties and the overall suitability of drug candidates.  There is increasing evidence to suggest that control of physicochem. properties such as lipophilicity, within a defined optimal range, can improve compd. quality and the likelihood of therapeutic success.Areas covered: This review focuses on understanding lipophilicity, techniques used to measure lipophilicity, and summarizes the importance of lipophilicity in drug discovery and development, including a discussion of its impact on individual ADMET parameters as well as its overall influence on the drug discovery and design process, specifically within the past 15 years.Expert opinion: A current review of the literature reveals a continued reliance on the synthesis of novel structures with increased potency, rather than a focus on maintaining optimal physicochem. properties assocd. with ADMET throughout drug optimization.  Particular attention to the optimum region of lipophilicity, as well as monitoring of lipophilic efficiency indexes, may contribute significantly to the overall quality of candidate drugs at different stages of discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolWJgvv9yK87Vg90H21EOLACvtfcHk0lh2w-CSU3RmIw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2lsbvJ&md5=4dc5d7268216c9a59fcbd841fbf66735</span></div><a href="/servlet/linkout?suffix=cit218b&amp;dbid=16384&amp;doi=10.1517%2F17460441.2012.714363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2012.714363%26sid%3Dliteratum%253Aachs%26aulast%3DArnott%26aufirst%3DJ.%2BA.%26aulast%3DPlaney%26aufirst%3DS.%2BL.%26atitle%3DThe%2520influence%2520of%2520lipophilicity%2520in%2520drug%2520discovery%2520and%2520design%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2012%26volume%3D7%26spage%3D863%26epage%3D875%26doi%3D10.1517%2F17460441.2012.714363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref219"><div class="reference"><strong class="refLabel"><a href="#ref219" class="rightTabRefNumLink">219</a></strong><div class="NLM_citation" id="rightTab-cit219a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rafi, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hearn, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vedantham, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renslo, A. R.</span><span> </span><span class="NLM_article-title">Predicting and Improving the Membrane Permeability of Peptidic Small Molecules</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">3163</span><span class="NLM_x">â</span> <span class="NLM_lpage">3169</span><span class="refDoi">Â DOI: 10.1021/jm201634q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201634q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref219/cit219a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Ogtrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3163-3169&author=S.+B.+Rafiauthor=B.+R.+Hearnauthor=P.+Vedanthamauthor=M.+P.+Jacobsonauthor=A.+R.+Renslo&title=Predicting+and+Improving+the+Membrane+Permeability+of+Peptidic+Small+Molecules&doi=10.1021%2Fjm201634q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit219aR"><div class="casContent"><span class="casTitleNuber">219a</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting and Improving the Membrane Permeability of Peptidic Small Molecules</span></div><div class="casAuthors">Rafi, Salma B.; Hearn, Brian R.; Vedantham, Punitha; Jacobson, Matthew P.; Renslo, Adam R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3163-3169</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We evaluate exptl. and computationally the membrane permeability of matched sets of peptidic small mols. bearing natural or bioisosteric unnatural amino acids.  We find that the intentional introduction of hydrogen bond acceptor-donor pairs in such mols. can improve membrane permeability while retaining or improving other favorable drug-like properties.  We employ an all-atom force field based method to calc. changes in free energy assocd. with the transfer of the peptidic mols. from water to membrane.  This computational method correctly predicts rank order exptl. permeability trends within congeneric series and is much more predictive than calcns. (e.g., clogP) that do not consider three-dimensional conformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVAMuvF4vQFrVg90H21EOLACvtfcHk0lh496KlJJpwZw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Ogtrg%253D&md5=a517000b38fb76198d38beac165d2d99</span></div><a href="/servlet/linkout?suffix=cit219a&amp;dbid=16384&amp;doi=10.1021%2Fjm201634q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201634q%26sid%3Dliteratum%253Aachs%26aulast%3DRafi%26aufirst%3DS.%2BB.%26aulast%3DHearn%26aufirst%3DB.%2BR.%26aulast%3DVedantham%26aufirst%3DP.%26aulast%3DJacobson%26aufirst%3DM.%2BP.%26aulast%3DRenslo%26aufirst%3DA.%2BR.%26atitle%3DPredicting%2520and%2520Improving%2520the%2520Membrane%2520Permeability%2520of%2520Peptidic%2520Small%2520Molecules%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3163%26epage%3D3169%26doi%3D10.1021%2Fjm201634q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit219b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rezai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bock, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalyanaraman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lokey, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, M. P.</span><span> </span><span class="NLM_article-title">Conformational Flexibility, Internal Hydrogen Bonding, and Passive Membrane Permeability: Successful in Silico Prediction of the Relative Permeabilities of Cyclic Peptides</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x">, </span> <span class="NLM_fpage">14073</span><span class="NLM_x">â</span> <span class="NLM_lpage">14080</span><span class="refDoi">Â DOI: 10.1021/ja063076p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja063076p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref219/cit219b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVCmur3I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2006&pages=14073-14080&author=T.+Rezaiauthor=J.+E.+Bockauthor=M.+V.+Zhouauthor=C.+Kalyanaramanauthor=R.+S.+Lokeyauthor=M.+P.+Jacobson&title=Conformational+Flexibility%2C+Internal+Hydrogen+Bonding%2C+and+Passive+Membrane+Permeability%3A+Successful+in+Silico+Prediction+of+the+Relative+Permeabilities+of+Cyclic+Peptides&doi=10.1021%2Fja063076p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit219bR"><div class="casContent"><span class="casTitleNuber">219b</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational Flexibility, Internal Hydrogen Bonding, and Passive Membrane Permeability: Successful in Silico Prediction of the Relative Permeabilities of Cyclic Peptides</span></div><div class="casAuthors">Rezai, Taha; Bock, Jonathan E.; Zhou, Mai V.; Kalyanaraman, Chakrapani; Lokey, R. Scott; Jacobson, Matthew P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">14073-14080</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report an atomistic phys. model for the passive membrane permeability of cyclic peptides.  The computational modeling was performed in advance of the expts. and did not involve the use of "training data".  The model explicitly treats the conformational flexibility of the peptides by extensive conformational sampling in low (membrane) and high (water) dielec. environments.  The passive membrane permeabilities of 11 cyclic peptides were obtained exptl. using a parallel artificial membrane permeability assay (PAMPA) and showed a linear correlation with the computational results with R2 = 0.96.  In general, the results support the hypothesis, already well established in the literature, that the ability to form internal hydrogen bonds is crit. for passive membrane permeability and can be the distinguishing factor among closely related compds., such as those studied here.  However, we have found that the no. of internal hydrogen bonds that can form in the membrane and the solvent-exposed polar surface area correlate more poorly with PAMPA permeability than our model, which quant. ests. the solvation free energy losses upon moving from high-dielec. water to the low-dielec. interior of a membrane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofxfL018o86rVg90H21EOLACvtfcHk0lh496KlJJpwZw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVCmur3I&md5=78d4b4082e6a72b288d4b6dac933ca35</span></div><a href="/servlet/linkout?suffix=cit219b&amp;dbid=16384&amp;doi=10.1021%2Fja063076p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja063076p%26sid%3Dliteratum%253Aachs%26aulast%3DRezai%26aufirst%3DT.%26aulast%3DBock%26aufirst%3DJ.%2BE.%26aulast%3DZhou%26aufirst%3DM.%2BV.%26aulast%3DKalyanaraman%26aufirst%3DC.%26aulast%3DLokey%26aufirst%3DR.%2BS.%26aulast%3DJacobson%26aufirst%3DM.%2BP.%26atitle%3DConformational%2520Flexibility%252C%2520Internal%2520Hydrogen%2520Bonding%252C%2520and%2520Passive%2520Membrane%2520Permeability%253A%2520Successful%2520in%2520Silico%2520Prediction%2520of%2520the%2520Relative%2520Permeabilities%2520of%2520Cyclic%2520Peptides%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2006%26volume%3D128%26spage%3D14073%26epage%3D14080%26doi%3D10.1021%2Fja063076p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit219c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Wang, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Northfield, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colless, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaousis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamernig, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohman, R.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liras, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairlie, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craik, D. J.</span><span> </span><span class="NLM_article-title">Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">17504</span><span class="NLM_x">â</span> <span class="NLM_lpage">17509</span><span class="refDoi">Â DOI: 10.1073/pnas.1417611111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1073%2Fpnas.1417611111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25416591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKmu7vE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=17504-17509&author=C.+K.+Wangauthor=S.+E.+Northfieldauthor=B.+Collessauthor=S.+Chaousisauthor=I.+Hamernigauthor=R.-J.+Lohmanauthor=D.+S.+Nielsenauthor=C.+I.+Schroederauthor=S.+Lirasauthor=D.+A.+Priceauthor=D.+P.+Fairlieauthor=D.+J.+Craik&title=Rational+design+and+synthesis+of+an+orally+bioavailable+peptide+guided+by+NMR+amide+temperature+coefficients&doi=10.1073%2Fpnas.1417611111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit219cR"><div class="casContent"><span class="casTitleNuber">219c</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients</span></div><div class="casAuthors">Wang, Conan K.; Northfield, Susan E.; Colless, Barbara; Chaousis, Stephanie; Hamernig, Ingrid; Lohman, Rink-Jan; Nielsen, Daniel S.; Schroeder, Christina I.; Liras, Spiros; Price, David A.; Fairlie, David P.; Craik, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">17504-17509</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Enhancing the oral bioavailability of peptide drug leads is a major challenge in drug design.  As such, methods to address this challenge are highly sought after by the pharmaceutical industry.  Here, we propose a strategy to identify appropriate amides for N-methylation using temp. coeffs. measured by NMR to identify exposed amides in cyclic peptides.  N-methylation effectively caps these amides, modifying the overall solvation properties of the peptides and making them more membrane permeable.  The approach for identifying sites for N-methylation is a rapid alternative to the elucidation of 3D structures of peptide drug leads, which has been a commonly used structure-guided approach in the past.  Five leucine-rich peptide scaffolds are reported with selectively designed N-methylated derivs.  In vitro membrane permeability was assessed by parallel artificial membrane permeability assay and Caco-2 assay.  The most promising N-methylated peptide was then tested in vivo.  Here we report a novel peptide (15), which displayed an oral bioavailability of 33% in a rat model, thus validating the design approach.  We show that this approach can also be used to explain the notable increase in oral bioavailability of a somatostatin analog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ1pwUl6qUw7Vg90H21EOLACvtfcHk0lh496KlJJpwZw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKmu7vE&md5=02803e516bf514e3d941769b7bbf3607</span></div><a href="/servlet/linkout?suffix=cit219c&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1417611111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1417611111%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%2BK.%26aulast%3DNorthfield%26aufirst%3DS.%2BE.%26aulast%3DColless%26aufirst%3DB.%26aulast%3DChaousis%26aufirst%3DS.%26aulast%3DHamernig%26aufirst%3DI.%26aulast%3DLohman%26aufirst%3DR.-J.%26aulast%3DNielsen%26aufirst%3DD.%2BS.%26aulast%3DSchroeder%26aufirst%3DC.%2BI.%26aulast%3DLiras%26aufirst%3DS.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26aulast%3DCraik%26aufirst%3DD.%2BJ.%26atitle%3DRational%2520design%2520and%2520synthesis%2520of%2520an%2520orally%2520bioavailable%2520peptide%2520guided%2520by%2520NMR%2520amide%2520temperature%2520coefficients%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D17504%26epage%3D17509%26doi%3D10.1073%2Fpnas.1417611111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit219d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Ahlbach, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lexa, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bockus, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crews, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lokey, R. S.</span><span> </span><span class="NLM_article-title">Beyond cyclosporine A: conformation-dependent passive membrane permeabilities of cyclic peptide natural products</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2121</span><span class="NLM_x">â</span> <span class="NLM_lpage">2130</span><span class="refDoi">Â DOI: 10.4155/fmc.15.78</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.4155%2Ffmc.15.78" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26067057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVehs7%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=2121-2130&author=C.+L.+Ahlbachauthor=K.+W.+Lexaauthor=A.+T.+Bockusauthor=V.+Chenauthor=P.+Crewsauthor=M.+P.+Jacobsonauthor=R.+S.+Lokey&title=Beyond+cyclosporine+A%3A+conformation-dependent+passive+membrane+permeabilities+of+cyclic+peptide+natural+products&doi=10.4155%2Ffmc.15.78"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit219dR"><div class="casContent"><span class="casTitleNuber">219d</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond cyclosporine A: conformation-dependent passive membrane permeabilities of cyclic peptide natural products</span></div><div class="casAuthors">Ahlbach, Christopher L.; Lexa, Katrina W.; Bockus, Andrew T.; Chen, Valerie; Crews, Phillip; Jacobson, Matthew P.; Lokey, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2121-2130</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Many cyclic peptide natural products are larger and structurally more complex than conventional small mol. drugs.  Although some mols. in this class are known to possess favorable pharmacokinetic properties, there have been few reports on the membrane permeabilities of cyclic peptide natural products.  Here, we present the passive membrane permeabilities of 39 cyclic peptide natural products, and interpret the results using a computational permeability prediction algorithm based on their known or calcd. 3D conformations.  We found that the permeabilities of these compds., measured in a parallel artificial membrane permeability assay, spanned a wide range and demonstrated the important influence of conformation on membrane permeability.  These results will aid in the development of these compds. as a viable drug paradigm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4_Ar_CGW03bVg90H21EOLACvtfcHk0lgb83VE9cgd1A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVehs7%252FM&md5=69d8628920ebc6ad72b13162f3214f2d</span></div><a href="/servlet/linkout?suffix=cit219d&amp;dbid=16384&amp;doi=10.4155%2Ffmc.15.78&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.15.78%26sid%3Dliteratum%253Aachs%26aulast%3DAhlbach%26aufirst%3DC.%2BL.%26aulast%3DLexa%26aufirst%3DK.%2BW.%26aulast%3DBockus%26aufirst%3DA.%2BT.%26aulast%3DChen%26aufirst%3DV.%26aulast%3DCrews%26aufirst%3DP.%26aulast%3DJacobson%26aufirst%3DM.%2BP.%26aulast%3DLokey%26aufirst%3DR.%2BS.%26atitle%3DBeyond%2520cyclosporine%2520A%253A%2520conformation-dependent%2520passive%2520membrane%2520permeabilities%2520of%2520cyclic%2520peptide%2520natural%2520products%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D2121%26epage%3D2130%26doi%3D10.4155%2Ffmc.15.78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref220"><div class="reference"><strong class="refLabel"><a href="#ref220" class="rightTabRefNumLink">220</a></strong><div class="NLM_citation" id="rightTab-cit220"><span><span class="NLM_contrib-group">Busby, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartolini, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryant, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannig, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solinga, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobin, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakefield, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurtz, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, M. G.</span><span> </span><span class="NLM_article-title">Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">344</span><span class="NLM_x">, </span> <span class="NLM_fpage">196</span><span class="NLM_x">â</span> <span class="NLM_lpage">206</span><span class="refDoi">Â DOI: 10.1124/jpet.112.199430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1124%2Fjpet.112.199430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=23090647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1CrtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2013&pages=196-206&author=R.+W.+Busbyauthor=M.+M.+Kesslerauthor=W.+P.+Bartoliniauthor=A.+P.+Bryantauthor=G.+Hannigauthor=C.+S.+Higginsauthor=R.+M.+Solingaauthor=J.+V.+Tobinauthor=J.+D.+Wakefieldauthor=C.+B.+Kurtzauthor=M.+G.+Currie&title=Pharmacologic+properties%2C+metabolism%2C+and+disposition+of+linaclotide%2C+a+novel+therapeutic+peptide+approved+for+the+treatment+of+irritable+bowel+syndrome+with+constipation+and+chronic+idiopathic+constipation&doi=10.1124%2Fjpet.112.199430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation</span></div><div class="casAuthors">Busby, Robert W.; Kessler, Marco M.; Bartolini, Wilmin P.; Bryant, Alexander P.; Hannig, Gerhard; Higgins, Carolyn S.; Solinga, Robert M.; Tobin, Jenny V.; Wakefield, James D.; Kurtz, Caroline B.; Currie, Mark G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">196-206</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Linaclotide, a potent guanylate cyclase C agonist, is a therapeutic peptide approved in the United States for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.  We present for the first time the metab., degrdn., and disposition of linaclotide in animals and humans.  We examd. the metabolic stability of linaclotide in conditions that mimic the gastrointestinal tract and characterized the metabolite MM-419447 (CCEYCCNPACTGC), which contributes to the pharmacol. effects of linaclotide.  Systemic exposure to these active peptides is low in rats and humans, and the low systemic and portal vein concns. of linaclotide and MM-419447 obsd. in the rat confirmed both peptides are minimally absorbed after oral administration.  Linaclotide is stable in the acidic environment of the stomach and is converted to MM-419447 in the small intestine.  The disulfide bonds of both peptides are reduced in the small intestine, where they are subsequently proteolyzed and degraded.  After oral administration of linaclotide, <1% of the dose was excreted as active peptide in rat feces and a mean of 3-5% in human feces; in both cases MM-419447 was the predominant peptide recovered.  MM-419447 exhibits high-affinity binding in vitro to T84 cells, resulting in a significant, concn.-dependent accumulation of intracellular cyclic guanosine-3',5'-monophosphate (cGMP).  In rat models of gastrointestinal function, orally dosed MM-419447 significantly increased fluid secretion into small intestinal loops, increased intraluminal cGMP, and caused a dose-dependent acceleration in gastrointestinal transit.  These results demonstrate the importance of the active metabolite in contributing to linaclotide's pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0uVoDATTN-7Vg90H21EOLACvtfcHk0lgb83VE9cgd1A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1CrtQ%253D%253D&md5=dbe9f193a4cfb601e93dc3b92f3fee9f</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.199430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.199430%26sid%3Dliteratum%253Aachs%26aulast%3DBusby%26aufirst%3DR.%2BW.%26aulast%3DKessler%26aufirst%3DM.%2BM.%26aulast%3DBartolini%26aufirst%3DW.%2BP.%26aulast%3DBryant%26aufirst%3DA.%2BP.%26aulast%3DHannig%26aufirst%3DG.%26aulast%3DHiggins%26aufirst%3DC.%2BS.%26aulast%3DSolinga%26aufirst%3DR.%2BM.%26aulast%3DTobin%26aufirst%3DJ.%2BV.%26aulast%3DWakefield%26aufirst%3DJ.%2BD.%26aulast%3DKurtz%26aufirst%3DC.%2BB.%26aulast%3DCurrie%26aufirst%3DM.%2BG.%26atitle%3DPharmacologic%2520properties%252C%2520metabolism%252C%2520and%2520disposition%2520of%2520linaclotide%252C%2520a%2520novel%2520therapeutic%2520peptide%2520approved%2520for%2520the%2520treatment%2520of%2520irritable%2520bowel%2520syndrome%2520with%2520constipation%2520and%2520chronic%2520idiopathic%2520constipation%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D344%26spage%3D196%26epage%3D206%26doi%3D10.1124%2Fjpet.112.199430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref221"><div class="reference"><strong class="refLabel"><a href="#ref221" class="rightTabRefNumLink">221</a></strong><div class="NLM_citation" id="rightTab-cit221"><span><span class="NLM_contrib-group">Aguirre, T. A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teijeiro-Osorio, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coulter, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alonso, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brayden, D. J.</span><span> </span><span class="NLM_article-title">Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">â</span> <span class="NLM_lpage">241</span><span class="refDoi">Â DOI: 10.1016/j.addr.2016.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.addr.2016.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=26921819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1yitLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2016&pages=223-241&author=T.+A.+S.+Aguirreauthor=D.+Teijeiro-Osorioauthor=M.+Rosaauthor=I.+S.+Coulterauthor=M.+J.+Alonsoauthor=D.+J.+Brayden&title=Current+status+of+selected+oral+peptide+technologies+in+advanced+preclinical+development+and+in+clinical+trials&doi=10.1016%2Fj.addr.2016.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials</span></div><div class="casAuthors">Aguirre, T. A. S.; Teijeiro-Osorio, D.; Rosa, M.; Coulter, I. S.; Alonso, M. J.; Brayden, D. J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">Part_B</span>),
    <span class="NLM_cas:pages">223-241</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The development of oral dosage forms that allows absorption of therapeutic peptides to the systemic circulation is one of the greatest challenges for the pharmaceutical industry.  Currently, a no. of technologies including either mixts. of penetration enhancers or protease inhibitors and/or nanotechnol.-based products are under clin. development.  Typically, these formulations are presented in the form of enteric-coated tablets or capsules.  Systems undergoing preclin. investigation include further advances in nanotechnol., including intestinal microneedle patches, as well as their combination with regional delivery to the colon.  This review critically examines four selected promising oral peptide technologies at preclin. stage and the twelve that have progressed to clin. trials, as indicated in www.clinicaltrials.gov.  We examd. these technologies under the criteria of peptide selection, formulation design, system components and excipients, intestinal mechanism of action, efficacy in man, and safety issues.  The conclusion is that most of the technologies in clin. trials are incremental rather than paradigm-shifting and that even the more clin. advanced oral peptide drugs examples of oral bioavailability appear to yield oral bioavailability values of only 1-2% and are, therefore, only currently suitable for a limited range of peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNMwyZq973LLVg90H21EOLACvtfcHk0lgb83VE9cgd1A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1yitLo%253D&md5=6e1b2f3b75a6c75a1a4b34cf4ec2a370</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2016.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2016.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DAguirre%26aufirst%3DT.%2BA.%2BS.%26aulast%3DTeijeiro-Osorio%26aufirst%3DD.%26aulast%3DRosa%26aufirst%3DM.%26aulast%3DCoulter%26aufirst%3DI.%2BS.%26aulast%3DAlonso%26aufirst%3DM.%2BJ.%26aulast%3DBrayden%26aufirst%3DD.%2BJ.%26atitle%3DCurrent%2520status%2520of%2520selected%2520oral%2520peptide%2520technologies%2520in%2520advanced%2520preclinical%2520development%2520and%2520in%2520clinical%2520trials%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2016%26volume%3D106%26spage%3D223%26epage%3D241%26doi%3D10.1016%2Fj.addr.2016.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref222"><div class="reference"><strong class="refLabel"><a href="#ref222" class="rightTabRefNumLink">222</a></strong><div class="NLM_citation" id="rightTab-cit222"><span><span class="NLM_contrib-group">Mullard, A.</span><span> </span><span class="NLM_article-title">Oral GLP1 analogue rounds Phase II corner</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">227</span><span class="refDoi">Â DOI: 10.1038/nrd4607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnrd4607" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=227&author=A.+Mullard&title=Oral+GLP1+analogue+rounds+Phase+II+corner&doi=10.1038%2Fnrd4607"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1038%2Fnrd4607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4607%26sid%3Dliteratum%253Aachs%26aulast%3DMullard%26aufirst%3DA.%26atitle%3DOral%2520GLP1%2520analogue%2520rounds%2520Phase%2520II%2520corner%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D227%26doi%3D10.1038%2Fnrd4607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref223"><div class="reference"><strong class="refLabel"><a href="#ref223" class="rightTabRefNumLink">223</a></strong><div class="NLM_citation" id="rightTab-cit223"><span><span class="NLM_contrib-group">Maher, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mrsny, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brayden, D. J.</span><span> </span><span class="NLM_article-title">Intestinal permeation enhancers for oral peptide delivery</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">277</span><span class="NLM_x">â</span> <span class="NLM_lpage">319</span><span class="refDoi">Â DOI: 10.1016/j.addr.2016.06.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.addr.2016.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=27320643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVGisbbP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2016&pages=277-319&author=S.+Maherauthor=R.+J.+Mrsnyauthor=D.+J.+Brayden&title=Intestinal+permeation+enhancers+for+oral+peptide+delivery&doi=10.1016%2Fj.addr.2016.06.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal permeation enhancers for oral peptide delivery</span></div><div class="casAuthors">Maher, Sam; Mrsny, Randall J.; Brayden, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">Part_B</span>),
    <span class="NLM_cas:pages">277-319</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Intestinal permeation enhancers (PEs) are one of the most widely tested strategies to improve oral delivery of therapeutic peptides.  This article assesses the intestinal permeation enhancement action of over 250 PEs that have been tested in intestinal delivery models.  In depth anal. of pre-clin. data is presented for PEs as components of proprietary delivery systems that have progressed to clin. trials.  Given the importance of co-presentation of sufficiently high concns. of PE and peptide at the small intestinal epithelium, there is an emphasis on studies where PEs have been formulated with poorly permeable mols. in solid dosage forms and lipoidal dispersions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnl_3hMN_terVg90H21EOLACvtfcHk0ljRpjJVayyXeg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVGisbbP&md5=19fb9e5a30c6cd10009047f65d5329ad</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2016.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2016.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DMaher%26aufirst%3DS.%26aulast%3DMrsny%26aufirst%3DR.%2BJ.%26aulast%3DBrayden%26aufirst%3DD.%2BJ.%26atitle%3DIntestinal%2520permeation%2520enhancers%2520for%2520oral%2520peptide%2520delivery%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2016%26volume%3D106%26spage%3D277%26epage%3D319%26doi%3D10.1016%2Fj.addr.2016.06.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref224"><div class="reference"><strong class="refLabel"><a href="#ref224" class="rightTabRefNumLink">224</a></strong><div class="NLM_citation" id="rightTab-cit224a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">McCartney, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gleeson, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brayden, D. J.</span><span> </span><span class="NLM_article-title">Safety concerns over the use of intestinal permeation enhancers: A mini-review</span> <span class="citation_source-journal">Tissue Barriers</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1176822</span><span class="refDoi">Â DOI: 10.1080/21688370.2016.1176822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1080%2F21688370.2016.1176822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=27358756" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=e1176822&author=F.+McCartneyauthor=J.+P.+Gleesonauthor=D.+J.+Brayden&title=Safety+concerns+over+the+use+of+intestinal+permeation+enhancers%3A+A+mini-review&doi=10.1080%2F21688370.2016.1176822"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit224a&amp;dbid=16384&amp;doi=10.1080%2F21688370.2016.1176822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F21688370.2016.1176822%26sid%3Dliteratum%253Aachs%26aulast%3DMcCartney%26aufirst%3DF.%26aulast%3DGleeson%26aufirst%3DJ.%2BP.%26aulast%3DBrayden%26aufirst%3DD.%2BJ.%26atitle%3DSafety%2520concerns%2520over%2520the%2520use%2520of%2520intestinal%2520permeation%2520enhancers%253A%2520A%2520mini-review%26jtitle%3DTissue%2520Barriers%26date%3D2016%26volume%3D4%26spage%3De1176822%26doi%3D10.1080%2F21688370.2016.1176822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit224b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Castelli, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riley, M. G. I.</span><span> </span><span class="NLM_article-title">Pharmacokinetics of oral cyanocobalamin formulated with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC): An open-label, randomized, single-dose, parallel-group study in healthy male subjects</span> <span class="citation_source-journal">Clin. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">934</span><span class="NLM_x">â</span> <span class="NLM_lpage">945</span><span class="refDoi">Â DOI: 10.1016/j.clinthera.2011.05.088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1016%2Fj.clinthera.2011.05.088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=21722960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptVygsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2011&pages=934-945&author=M.+C.+Castelliauthor=D.+F.+Wongauthor=K.+Friedmanauthor=M.+G.+I.+Riley&title=Pharmacokinetics+of+oral+cyanocobalamin+formulated+with+sodium+N-%5B8-%282-hydroxybenzoyl%29amino%5Dcaprylate+%28SNAC%29%3A+An+open-label%2C+randomized%2C+single-dose%2C+parallel-group+study+in+healthy+male+subjects&doi=10.1016%2Fj.clinthera.2011.05.088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit224bR"><div class="casContent"><span class="casTitleNuber">224b</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of Oral Cyanocobalamin Formulated With Sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC): An Open-Label, Randomized, Single-Dose, Parallel-Group Study in Healthy Male Subjects</span></div><div class="casAuthors">Castelli, M. Cristina; Wong, Diane F.; Friedman, Kristen; Riley, M. Gary I.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">934-945</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Vitamin B12 (cobalamin) deficiency may be caused by inadequate dietary intake of B12 or by conditions that result in malabsorption of the vitamin.  Cryst. vitamin B12, usually in the form of cyanocobalamin, is administered parenterally (ie, i.m.) or orally for treating deficiency states.  I.m. administration is widely accepted as a treatment method.  Oral B12 supplementation is also used, but it is considered to be less reliable.  This study was conducted to compare the pharmacokinetics and tolerability of 2 oral formulations of cyanocobalamin-a marketed cyanocobalamin tablet (immediate-release B12 5 mg) and cyanocobalamin formulated with a proprietary carrier, sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC)-to establish the feasibility of using an absorption enhancer with B12 to improve uptake of the vitamin.  This was the first clin. study conducted with the cyanocobalamin/SNAC coformulation.  An open-label, randomized, single-dose, parallel-group study was conducted in healthy male subjects.  Subjects were randomly assigned to 1 of 4 treatment groups: treatment A subjects (n = 4) received 2 tablets of 5-mg cyanocobalamin formulated with 100-mg SNAC as part of a dose range-finding arm included to det. a dose to provide a measurable concn. of vitamin B12 at all time points when tested with the available vitamin B12 assay; treatment B subjects (n = 6) received 1 tablet of 5-mg cyanocobalamin formulated with 100-mg SNAC; treatment C subjects (n = 6) received 1 com. available 5-mg cyanocobalamin tablet; and treatment D subjects (n = 4) received com. available 1-mg cyanocobalamin IV.  Treatment A was completed 3 wk before treatments B, C, and D were studied.  Human serum B12 was analyzed by chemiluminescence assay method.  Validation procedures established that samples could be dild. up to 100 times without any effects on accuracy and precision.  The pharmacokinetic properties of vitamin B12 were characterized by noncompartmental anal.  Vitamin B12 abs. bioavailability ests. were calcd. between the oral (A, B, and C) and IV (D) treatments using non-baseline-adjusted vitamin B12 concns. as well as baseline-adjusted vitamin B12 concns., with or without body wt. adjustments.  Tolerability was evaluated through review or monitoring of medical history, phys. examn. findings, concomitant medications, vital signs, lab. tests (hematol., serum chem., and urinalysis values), electrocardiog., adverse events, and serious adverse events.  Twenty healthy male subjects, aged 20 to 45 years, participated in this study.  Based on data from treatment A, a 5-mg cyanocobalamin dose was selected for use with treatments B and C. The oral cyanocobalamin formulation contg. SNAC had greater mean abs. bioavailability than the com. oral formulation (5.09% vs 2.16%, resp.), calcd. on AUC0-last values uncorrected for baseline, wt., or body mass index.  It also had a reduced Tmax compared with the com. formulation (0.5 h vs 6.83 h, resp.).  The Ke was similar between treatments (0.028 1/h vs 0.025 1/h).  Comparable results were achieved using cor. values.  The cyanocobalamin/SNAC formulation was well tolerated, and there were no reported adverse events.  An oral formulation of 5-mg cyanocobalamin contg. 100-mg SNAC, an absorption enhancer, provided significantly improved bioavailability and a significant decrease in Tmax for B12 in a small study of normal healthy subjects compared with a com. available 5-mg cyanocobalamin oral formulation.  Both oral formulations and com. 1-mg cyanocobalamin IV were well tolerated.  ClinicalTrials.gov identifier: NCT01311739.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBbGPXAxLHQrVg90H21EOLACvtfcHk0ljRpjJVayyXeg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptVygsLw%253D&md5=a3bfd8f032bd54e560440a3019a7d161</span></div><a href="/servlet/linkout?suffix=cit224b&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2011.05.088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2011.05.088%26sid%3Dliteratum%253Aachs%26aulast%3DCastelli%26aufirst%3DM.%2BC.%26aulast%3DWong%26aufirst%3DD.%2BF.%26aulast%3DFriedman%26aufirst%3DK.%26aulast%3DRiley%26aufirst%3DM.%2BG.%2BI.%26atitle%3DPharmacokinetics%2520of%2520oral%2520cyanocobalamin%2520formulated%2520with%2520sodium%2520N-%255B8-%25282-hydroxybenzoyl%2529amino%255Dcaprylate%2520%2528SNAC%2529%253A%2520An%2520open-label%252C%2520randomized%252C%2520single-dose%252C%2520parallel-group%2520study%2520in%2520healthy%2520male%2520subjects%26jtitle%3DClin.%2520Ther.%26date%3D2011%26volume%3D33%26spage%3D934%26epage%3D945%26doi%3D10.1016%2Fj.clinthera.2011.05.088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref225"><div class="reference"><strong class="refLabel"><a href="#ref225" class="rightTabRefNumLink">225</a></strong><div class="NLM_citation" id="rightTab-cit225"><span><span class="NLM_contrib-group">Jabbour, S.; Pieber, R.; Rosenstock, J.</span><span> </span><span class="NLM_article-title">OR15â3: Robust dose-dependent glucose lowering and body weight reductions with the novel oral formulation of semaglutide in patients with early type 2 diabetes</span>. ENDO Endocrine Societyâs 98th Annual Meeting and Expo April 1â4, 2016, Boston, MA,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+Jabbour&author=R.+Pieber&author=J.+Rosenstock&title=OR15%E2%80%933%3A+Robust+dose-dependent+glucose+lowering+and+body+weight+reductions+with+the+novel+oral+formulation+of+semaglutide+in+patients+with+early+type+2+diabetes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DJabbour%26aufirst%3DS.%26atitle%3DOR15%25E2%2580%25933%253A%2520Robust%2520dose-dependent%2520glucose%2520lowering%2520and%2520body%2520weight%2520reductions%2520with%2520the%2520novel%2520oral%2520formulation%2520of%2520semaglutide%2520in%2520patients%2520with%2520early%2520type%25202%2520diabetes%26jtitle%3DENDO%2520Endocrine%2520Society%25E2%2580%2599s%252098th%2520Annual%2520Meeting%2520and%2520Expo%2520April%25201%25E2%2580%25934%252C%25202016%252C%2520Boston%252C%2520MA%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref226"><div class="reference"><strong class="refLabel"><a href="#ref226" class="rightTabRefNumLink">226</a></strong><div class="NLM_citation" id="rightTab-cit226"><span>Pre-clinical Data on Insulin and Adalimumab (Humira); <span class="NLM_publisher-name">Rani Therapeutics</span>: <span class="NLM_publisher-loc">San Jose, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">; </span><a href="http://www.ranitherapeutics.com/assets/rani_pre-clinical_data.pdf" class="extLink">http://www.ranitherapeutics.com/assets/rani_pre-clinical_data.pdf</a> (accessed January 17 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pre-clinical+Data+on+Insulin+and+Adalimumab+%28Humira%29%3B+Rani+Therapeutics%3A+San+Jose%2C+CA%2C+2017%3B+http%3A%2F%2Fwww.ranitherapeutics.com%2Fassets%2Frani_pre-clinical_data.pdf+%28accessed+January+17+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DPre-clinical%2520Data%2520on%2520Insulin%2520and%2520Adalimumab%2520%2528Humira%2529%26pub%3DRani%2520Therapeutics%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref227"><div class="reference"><strong class="refLabel"><a href="#ref227" class="rightTabRefNumLink">227</a></strong><div class="NLM_citation" id="rightTab-cit227"><span><span class="NLM_contrib-group">Traverso, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoellhammer, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauwers, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polat, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blankschtein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, R.</span><span> </span><span class="NLM_article-title">Microneedles for drug delivery via the gastrointestinal tract</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">362</span><span class="NLM_x">â</span> <span class="NLM_lpage">367</span><span class="refDoi">Â DOI: 10.1002/jps.24182</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1002%2Fjps.24182" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=25250829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVyntL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2015&pages=362-367&author=G.+Traversoauthor=C.+M.+Schoellhammerauthor=A.+Schroederauthor=R.+Maaauthor=G.+Y.+Lauwersauthor=B.+E.+Polatauthor=D.+G.+Andersonauthor=D.+Blankschteinauthor=R.+Langer&title=Microneedles+for+drug+delivery+via+the+gastrointestinal+tract&doi=10.1002%2Fjps.24182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Microneedles for Drug Delivery via the Gastrointestinal Tract</span></div><div class="casAuthors">Traverso, Giovanni; Schoellhammer, Carl M.; Schroeder, Avi; Maa, Ruby; Lauwers, Gregory Y.; Polat, Baris E.; Anderson, Daniel G.; Blankschtein, Daniel; Langer, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">362-367</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Both patients and physicians prefer the oral route of drug delivery.  The gastrointestinal (GI) tract, though, limits the bioavailability of certain therapeutics because of its protease and bacteria-rich environment as well as general pH variability from pH 1 to 7.  These extreme environments make oral delivery particularly challenging for the biol. class of therapeutics.  Here, we demonstrate proof-of-concept expts. in swine that microneedle-based delivery has the capacity for improved bioavailability of a biol. active macromol.  Moreover, we show that microneedle-contg. devices can be passed and excreted from the GI tract safely.  These findings strongly support the success of implementation of microneedle technol. for use in the GI tract. Â© 2014 Wiley Periodicals, Inc. and the American Pharmacists Assocn. J Pharm Sci 104:362-367, 2015.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMhdiZaPej2rVg90H21EOLACvtfcHk0lghP_AFWAMi1g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVyntL4%253D&md5=1381e40c98af31d4fb689c6c03a08cff</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1002%2Fjps.24182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.24182%26sid%3Dliteratum%253Aachs%26aulast%3DTraverso%26aufirst%3DG.%26aulast%3DSchoellhammer%26aufirst%3DC.%2BM.%26aulast%3DSchroeder%26aufirst%3DA.%26aulast%3DMaa%26aufirst%3DR.%26aulast%3DLauwers%26aufirst%3DG.%2BY.%26aulast%3DPolat%26aufirst%3DB.%2BE.%26aulast%3DAnderson%26aufirst%3DD.%2BG.%26aulast%3DBlankschtein%26aufirst%3DD.%26aulast%3DLanger%26aufirst%3DR.%26atitle%3DMicroneedles%2520for%2520drug%2520delivery%2520via%2520the%2520gastrointestinal%2520tract%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2015%26volume%3D104%26spage%3D362%26epage%3D367%26doi%3D10.1002%2Fjps.24182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref228"><div class="reference"><strong class="refLabel"><a href="#ref228" class="rightTabRefNumLink">228</a></strong><div class="NLM_citation" id="rightTab-cit228"><span><span class="NLM_contrib-group">Turker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onur, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozer, Y.</span><span> </span><span class="NLM_article-title">Nasal route and drug delivery systems</span> <span class="citation_source-journal">Pharm. World Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">137</span><span class="NLM_x">â</span> <span class="NLM_lpage">142</span><span class="refDoi">Â DOI: 10.1023/B:PHAR.0000026823.82950.ff</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1023%2FB%3APHAR.0000026823.82950.ff" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=15230360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A280%3ADC%252BD2czivVKhuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2004&pages=137-142&author=S.+Turkerauthor=E.+Onurauthor=Y.+Ozer&title=Nasal+route+and+drug+delivery+systems&doi=10.1023%2FB%3APHAR.0000026823.82950.ff"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Nasal route and drug delivery systems</span></div><div class="casAuthors">Turker Selcan; Onur Erten; Ozer Yekta</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacy world & science : PWS</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">137-42</span>
        ISSN:<span class="NLM_cas:issn">0928-1231</span>.
    </div><div class="casAbstract">Nasal drug administration has been used as an alternative route for the systemic availability of drugs restricted to intravenous administration.  This is due to the large surface area, porous endothelial membrane, high total blood flow, the avoidance of first-pass metabolism, and ready accessibility.  The nasal administration of drugs, including numerous compound, peptide and protein drugs, for systemic medication has been widely investigated in recent years.  Drugs are cleared rapidly from the nasal cavity after intranasal administration, resulting in rapid systemic drug absorption.  Several approaches are here discussed for increasing the residence time of drug formulations in the nasal cavity, resulting in improved nasal drug absorption.  The article highlights the importance and advantages of the drug delivery systems applied via the nasal route, which have bioadhesive properties.  Bioadhesive, or more appropriately, mucoadhesive systems have been prepared for both oral and peroral administration in the past.  The nasal mucosa presents an ideal site for bioadhesive drug delivery systems.  In this review we discuss the effects of microspheres and other bioadhesive drug delivery systems on nasal drug absorption.  Drug delivery systems, such as microspheres, liposomes and gels have been demonstrated to have good bioadhesive characteristics and that swell easily when in contact with the nasal mucosa.  These drug delivery systems have the ability to control the rate of drug clearance from the nasal cavity as well as protect the drug from enzymatic degradation in nasal secretions.  The mechanisms and effectiveness of these drug delivery systems are described in order to guide the development of specific and effective therapies for the future development of peptide preparations and other drugs that otherwise should be administered parenterally.  As a consequence, bioavailability and residence time of the drugs that are administered via the nasal route can be increased by bioadhesive drug delivery systems.  Although the majority of this work involving the use of microspheres, liposomes and gels is limited to the delivery of macromolecules (e.g., insulin and growth hormone), the general principles involved could be applied to other drug candidates.  It must be emphasized that many drugs can be absorbed well if the contact time between formulation and the nasal mucosa is optimized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTFPMMW718vtMKL0FlyGHDofW6udTcc2eakMPTfSyq5eLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2czivVKhuw%253D%253D&md5=8402f7717a50782df9331f6716fdb350</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1023%2FB%3APHAR.0000026823.82950.ff&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FB%253APHAR.0000026823.82950.ff%26sid%3Dliteratum%253Aachs%26aulast%3DTurker%26aufirst%3DS.%26aulast%3DOnur%26aufirst%3DE.%26aulast%3DOzer%26aufirst%3DY.%26atitle%3DNasal%2520route%2520and%2520drug%2520delivery%2520systems%26jtitle%3DPharm.%2520World%2520Sci.%26date%3D2004%26volume%3D26%26spage%3D137%26epage%3D142%26doi%3D10.1023%2FB%3APHAR.0000026823.82950.ff" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref229"><div class="reference"><strong class="refLabel"><a href="#ref229" class="rightTabRefNumLink">229</a></strong><div class="NLM_citation" id="rightTab-cit229"><span><span class="NLM_contrib-group">Thwala, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preat, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Csaba, N. S.</span><span> </span><span class="NLM_article-title">Emerging delivery platforms for mucosal administration of biopharmaceuticals: a critical update on nasal, pulmonary and oral routes</span> <span class="citation_source-journal">Expert Opin. Drug Delivery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">â</span> <span class="NLM_lpage">36</span><span class="refDoi">Â DOI: 10.1080/17425247.2016.1206074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1080%2F17425247.2016.1206074" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=23-36&author=L.+N.+Thwalaauthor=V.+Preatauthor=N.+S.+Csaba&title=Emerging+delivery+platforms+for+mucosal+administration+of+biopharmaceuticals%3A+a+critical+update+on+nasal%2C+pulmonary+and+oral+routes&doi=10.1080%2F17425247.2016.1206074"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1080%2F17425247.2016.1206074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17425247.2016.1206074%26sid%3Dliteratum%253Aachs%26aulast%3DThwala%26aufirst%3DL.%2BN.%26aulast%3DPreat%26aufirst%3DV.%26aulast%3DCsaba%26aufirst%3DN.%2BS.%26atitle%3DEmerging%2520delivery%2520platforms%2520for%2520mucosal%2520administration%2520of%2520biopharmaceuticals%253A%2520a%2520critical%2520update%2520on%2520nasal%252C%2520pulmonary%2520and%2520oral%2520routes%26jtitle%3DExpert%2520Opin.%2520Drug%2520Delivery%26date%3D2017%26volume%3D14%26spage%3D23%26epage%3D36%26doi%3D10.1080%2F17425247.2016.1206074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref230"><div class="reference"><strong class="refLabel"><a href="#ref230" class="rightTabRefNumLink">230</a></strong><div class="NLM_citation" id="rightTab-cit230"><span><span class="NLM_contrib-group">Ozsoy, Y. L. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gungor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cevher, E.</span><span> </span><span class="NLM_article-title">Nasal delivery of high molecular weight drugs</span> <span class="citation_source-journal">Molecules</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">3754</span><span class="NLM_x">â</span> <span class="NLM_lpage">3779</span><span class="refDoi">Â DOI: 10.3390/molecules14093754</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3390%2Fmolecules14093754" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=19783956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1egsbzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=3754-3779&author=Y.+L.+Z.+Ozsoyauthor=S.+Gungorauthor=E.+Cevher&title=Nasal+delivery+of+high+molecular+weight+drugs&doi=10.3390%2Fmolecules14093754"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">Nasal delivery of high molecular weight drugs</span></div><div class="casAuthors">Ozsoy, Yildiz; Gungor, Sevgi; Cevher, Erdal</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3754-3779</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">Molecular Diversity Preservation International</span>)
        </div><div class="casAbstract">A review.  Nasal drug delivery may be used for either local or systemic effects.  Low mol. wt. drugs with are rapidly absorbed through nasal mucosa.  The main reasons for this are the high permeability, fairly wide absorption area, porous and thin endothelial basement membrane of the nasal epithelium.  Despite the many advantages of the nasal route, limitations such as the high mol. wt. (HMW) of drugs may impede drug absorption through the nasal mucosa.  Recent studies have focused particularly on the nasal application of HMW therapeutic agents such as peptide-protein drugs and vaccines intended for systemic effects.  Due to their hydrophilic structure, the nasal bioavailability of peptide and protein drugs is normally less than 1%.  Besides their weak mucosal membrane permeability and enzymic degrdn. in nasal mucosa, these drugs are rapidly cleared from the nasal cavity after administration because of mucociliary clearance.  There are many approaches for increasing the residence time of drug formulations in the nasal cavity resulting in enhanced drug absorption.  In this review article, nasal route and transport mechanisms across the nasal mucosa will be briefly presented.  In the second part, current studies regarding the nasal application of macromol. drugs and vaccines with nano- and micro-particulate carrier systems will be summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWSOHRGWj0HrVg90H21EOLACvtfcHk0lghP_AFWAMi1g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1egsbzL&md5=b13f278926081cf6506bae4df275f607</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.3390%2Fmolecules14093754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules14093754%26sid%3Dliteratum%253Aachs%26aulast%3DOzsoy%26aufirst%3DY.%2BL.%2BZ.%26aulast%3DGungor%26aufirst%3DS.%26aulast%3DCevher%26aufirst%3DE.%26atitle%3DNasal%2520delivery%2520of%2520high%2520molecular%2520weight%2520drugs%26jtitle%3DMolecules%26date%3D2009%26volume%3D14%26spage%3D3754%26epage%3D3779%26doi%3D10.3390%2Fmolecules14093754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref231"><div class="reference"><strong class="refLabel"><a href="#ref231" class="rightTabRefNumLink">231</a></strong><div class="NLM_citation" id="rightTab-cit231"><span><span class="NLM_contrib-group">Black, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummins, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Royle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philip, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waugh, N.</span><span> </span><span class="NLM_article-title">The clinical and cost effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation</span> <span class="citation_source-journal">Health Technol. Assess.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">126</span><span class="refDoi">Â DOI: 10.3310/hta11330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.3310%2Fhta11330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=17767897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A280%3ADC%252BD2srhslamtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=1-126&author=C.+Blackauthor=E.+Cumminsauthor=P.+Royleauthor=S.+Philipauthor=N.+Waugh&title=The+clinical+and+cost+effectiveness+of+inhaled+insulin+in+diabetes+mellitus%3A+a+systematic+review+and+economic+evaluation&doi=10.3310%2Fhta11330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation</span></div><div class="casAuthors">Black C; Cummins E; Royle P; Philip S; Waugh N</div><div class="citationInfo"><span class="NLM_cas:title">Health technology assessment (Winchester, England)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">1-126</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  To review the clinical effectiveness and cost-effectiveness of a new technology, the inhaled insulin, Exubera (Pfizer and Sanofi-Aventis, in collaboration with Nektar Therapeutics), a short-acting insulin.  DATA SOURCES:  Electronic databases were searched up to November 2005.  REVIEW METHODS:  A systematic literature review was conducted and economic modelling carried out.  An industry model was used for modelling.  RESULTS:  Nine trials of inhaled insulins were found, but only seven used the Exubera form of inhaled insulin.  The other two used inhaled insulins that have not yet been licensed.  There were five trials in type 1 and two in type 2 diabetes.  Inhaled insulin is clinically effective, and is as good as short-acting soluble insulin in controlling blood glucose, plus it works slightly more quickly.  None of the published trials compared it with short-acting analogues.  Most patients in the trials were on combinations of short-acting, and either long- or intermediate-acting insulin, and both were changed, making it more difficult to assess the effects of only the change from soluble to inhaled insulin.  Patient preference was the only significant difference between inhaled and soluble insulin in the trials.  Most patients preferred inhaled to injected short-acting insulin, and this has some effect on quality of life measures.  However, the control groups mostly used syringes and needles, rather than pens.  As pens are more convenient, their use might have narrowed the patient satisfaction difference.  There were no trials of inhaled insulin against continuous subcutaneous insulin infusion (CSII).  No serious adverse experiences of inhaled insulin in the lung have been seen to date, but it is too soon yet to judge long-term effects.  The manufacturer's model appears to be a high-quality one, although the results depend more on the assumptions fed into the model than on the model itself.  The key assumptions are the size of the gain in quality of life utility from inhaling rather than injecting insulin, the effect of having an inhaled option on the willingness to start insulin among people with poor diabetic control on oral drugs, and the effect on glycaemic control.  We consider that these assumptions make the cost-effectiveness appear better than it really would be.  The manufacturer's submission assumed utility gains of 0.036-0.075 in patients with type 1 diabetes, and 0.027-0.067 in those with type 2, based on an unpublished utility elicitation study sponsored by the manufacturer.  We thought that these gains were optimistic and that gains of 0.02 or less were more likely, on average.  However, patients with particular problems with injection sites might have more to gain, although they might also be a group with much to gain from CSII.  A key factor is the cost of inhaled insulin.  Much more insulin has to be given by inhaler than by injection, and so the cost of inhaled insulin is much higher than injected.  The extra cost depends on dosage but ranges from around 600 pounds to over 1000 pounds per patient per year.  CONCLUSIONS:  The inhaled insulin, Exubera, appears to be as effective, but no better than injected short-acting insulin.  The additional cost is so much more that it is unlikely to be cost-effective.  The long-term safety is uncertain.  Additional research is recommended into the safety, efficacy and cost-effectiveness of inhaled insulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQcZKcAPknDOPtos8R3JUhXfW6udTcc2eZ2fe4S1kuNzrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2srhslamtQ%253D%253D&md5=dbec6e42e0bb804f6fd8bdb7dac0594a</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.3310%2Fhta11330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3310%252Fhta11330%26sid%3Dliteratum%253Aachs%26aulast%3DBlack%26aufirst%3DC.%26aulast%3DCummins%26aufirst%3DE.%26aulast%3DRoyle%26aufirst%3DP.%26aulast%3DPhilip%26aufirst%3DS.%26aulast%3DWaugh%26aufirst%3DN.%26atitle%3DThe%2520clinical%2520and%2520cost%2520effectiveness%2520of%2520inhaled%2520insulin%2520in%2520diabetes%2520mellitus%253A%2520a%2520systematic%2520review%2520and%2520economic%2520evaluation%26jtitle%3DHealth%2520Technol.%2520Assess.%26date%3D2007%26volume%3D11%26spage%3D1%26epage%3D126%26doi%3D10.3310%2Fhta11330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref232"><div class="reference"><strong class="refLabel"><a href="#ref232" class="rightTabRefNumLink">232</a></strong><div class="NLM_citation" id="rightTab-cit232"><span><span class="NLM_contrib-group">Hollander, P. A.</span><span> </span><span class="NLM_article-title">Evolution of a pulmonary insulin delivery system (Exubera) for patients with diabetes</span> <span class="citation_source-journal">MedGenMed</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">45</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2007&pages=45&author=P.+A.+Hollander&title=Evolution+of+a+pulmonary+insulin+delivery+system+%28Exubera%29+for+patients+with+diabetes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHollander%26aufirst%3DP.%2BA.%26atitle%3DEvolution%2520of%2520a%2520pulmonary%2520insulin%2520delivery%2520system%2520%2528Exubera%2529%2520for%2520patients%2520with%2520diabetes%26jtitle%3DMedGenMed%26date%3D2007%26volume%3D9%26spage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref233"><div class="reference"><strong class="refLabel"><a href="#ref233" class="rightTabRefNumLink">233</a></strong><div class="NLM_citation" id="rightTab-cit233"><span><span class="NLM_contrib-group">Heinemann, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baughman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boss, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hompesch, M.</span><span> </span><span class="NLM_article-title">Pharmacokinetic and pharmacodynamic properties of a novel inhaled insulin</span> <span class="citation_source-journal">J. Diabetes Sci. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">148</span><span class="NLM_x">â</span> <span class="NLM_lpage">156</span><span class="refDoi">Â DOI: 10.1177/1932296816658055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1177%2F1932296816658055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=27378794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVOgt7fN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=148-156&author=L.+Heinemannauthor=R.+Baughmanauthor=A.+Bossauthor=M.+Hompesch&title=Pharmacokinetic+and+pharmacodynamic+properties+of+a+novel+inhaled+insulin&doi=10.1177%2F1932296816658055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic and pharmacodynamic properties of a novel inhaled insulin</span></div><div class="casAuthors">Heinemann, Lutz; Baughman, Robert; Boss, Anders; Hompesch, Marcus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Diabetes Science and Technology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">148-156</span>CODEN:
                <span class="NLM_cas:coden">JDSTAV</span>;
        ISSN:<span class="NLM_cas:issn">1932-2968</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Advances in insulin treatment options over recent decades have markedly improved the management of diabetes.  Despite this, glycemic control remains suboptimal in many people with diabetes.  Although postprandial glucose control has been improved with the development of s.c. injected rapid-acting insulin analogs, currently available insulins are not able to fully mimic the physiol. time-action profile of endogenously secreted insulin after a meal.  The delayed onset of metabolic action and prolonged period of effect induce the risk of postprandial hyperglycemia and late postprandial hypoglycemia.  A no. of alternative routes of insulin administration have been investigated over time in an attempt to overcome the limitations assocd. with s.c. administration and to provide an improved time-action insulin profile more closely simulating physiol. prandial insulin release.  Among these, pulmonary insulin delivery has shown the most promise.  Technosphere Inhaled Insulin (TI) is a rapid-acting inhaled human insulin recently approved by the FDA for prandial insulin therapy.  In this article we discuss the pharmacokinetic and pharmacodynamic properties of TI, and, based on key studies performed during its clin. development, the implications for improved postprandial glucose control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWzEom0UsOibVg90H21EOLACvtfcHk0lif8EG4O3ph1g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVOgt7fN&md5=6e3482cecbad3052fe0a29d381c755f8</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1177%2F1932296816658055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1932296816658055%26sid%3Dliteratum%253Aachs%26aulast%3DHeinemann%26aufirst%3DL.%26aulast%3DBaughman%26aufirst%3DR.%26aulast%3DBoss%26aufirst%3DA.%26aulast%3DHompesch%26aufirst%3DM.%26atitle%3DPharmacokinetic%2520and%2520pharmacodynamic%2520properties%2520of%2520a%2520novel%2520inhaled%2520insulin%26jtitle%3DJ.%2520Diabetes%2520Sci.%2520Technol.%26date%3D2017%26volume%3D11%26spage%3D148%26epage%3D156%26doi%3D10.1177%2F1932296816658055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref234"><div class="reference"><strong class="refLabel"><a href="#ref234" class="rightTabRefNumLink">234</a></strong><div class="NLM_citation" id="rightTab-cit234"><span>Inhalable Insulin: A Losing Battle?; <span class="NLM_publisher-name">Pharmaceutical-technology.com</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">; </span><a href="http://www.pharmaceutical-technology.com/features/featureinhalable-insulin-a-losing-battle-4872250/" class="extLink">http://www.pharmaceutical-technology.com/features/featureinhalable-insulin-a-losing-battle-4872250/</a> (accessed January 17 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Inhalable+Insulin%3A+A+Losing+Battle%3F%3B+Pharmaceutical-technology.com%3A+New+York%2C+2017%3B+http%3A%2F%2Fwww.pharmaceutical-technology.com%2Ffeatures%2Ffeatureinhalable-insulin-a-losing-battle-4872250%2F+%28accessed+January+17+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DInhalable%2520Insulin%253A%2520A%2520Losing%2520Battle%253F%26pub%3DPharmaceutical-technology.com%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref235"><div class="reference"><strong class="refLabel"><a href="#ref235" class="rightTabRefNumLink">235</a></strong><div class="NLM_citation" id="rightTab-cit235"><span><span class="NLM_contrib-group">Smietana, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siatkowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">M?ller, M.</span><span> </span><span class="NLM_article-title">Trends in clinical success rates</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">379</span><span class="NLM_x">â</span> <span class="NLM_lpage">380</span><span class="refDoi">Â DOI: 10.1038/nrd.2016.85</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=10.1038%2Fnrd.2016.85" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=27199245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;key=1%3ACAS%3A528%3ADC%252BC28Xot1Smurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=379-380&author=K.+Smietanaauthor=M.+Siatkowskiauthor=M.+M%3Fller&title=Trends+in+clinical+success+rates&doi=10.1038%2Fnrd.2016.85"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">Trends in clinical success rates</span></div><div class="casAuthors">Smietana, Katarzyna; Siatkowski, Marcin; Moeller, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">379-380</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This anal. of the industry's clin.-stage portfolio in the past two decades reveals several trends, including a recent improvement in success rates in late-stage trials, an increase in overall portfolio size and higher success rates for biologics and partnered projects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQX2Lw9DBOLbVg90H21EOLACvtfcHk0lif8EG4O3ph1g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xot1Smurg%253D&md5=2654eccd09eda5f587d19af95b6b42b9</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.85&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.85%26sid%3Dliteratum%253Aachs%26aulast%3DSmietana%26aufirst%3DK.%26aulast%3DSiatkowski%26aufirst%3DM.%26aulast%3DM%253Fller%26aufirst%3DM.%26atitle%3DTrends%2520in%2520clinical%2520success%2520rates%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D379%26epage%3D380%26doi%3D10.1038%2Fnrd.2016.85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00318&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-4%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00318%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00318" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677b63778e563de9","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
